rp_entity_id,category,relevance,ess,rpna_date_utc
270305,merger-completed,100,66,1/1/2020
868808,private-placement,100,56,1/1/2020
C66B44,partnership,100,61,1/1/2020
FAE021,award,100,58,1/1/2020
03B431,conference-participant,100,50,1/2/2020
03B8CF,asset-sale,100,62,1/2/2020
06C826,acquisition-acquirer,100,49,1/2/2020
095A04,conference-participant,100,50,1/2/2020
0A6824,unit-acquisition-completed-acquiree,100,67,1/2/2020
0E439E,earnings,100,50,1/2/2020
105D00,conference-call,100,50,1/2/2020
10C19B,dividend-up,100,81,1/2/2020
12E454,earnings,100,50,1/2/2020
17EDA5,acquisition-acquiree,100,76,1/2/2020
17EDA5,acquisition-acquiree,100,76,1/2/2020
17EDA5,acquisition-acquiree,100,76,1/2/2020
1921DD,product-release,100,64,1/2/2020
1A5D5D,legal-issues-defendant,100,22,1/2/2020
1A5D5D,legal-issues-defendant,100,22,1/2/2020
1E9A6D,acquisition-completed-acquirer,100,49,1/2/2020
1EBF8D,conference-participant,100,50,1/2/2020
1F9D90,conference-participant,100,50,1/2/2020
1FAF22,legal-issues-defendant,100,22,1/2/2020
221AD7,earnings,100,50,1/2/2020
22C58E,earnings,100,50,1/2/2020
239106,business-contract,100,69,1/2/2020
24A89A,legal-issues-defendant,100,22,1/2/2020
25A6CC,legal-issues-defendant,100,22,1/2/2020
28F905,executive-appointment,100,54,1/2/2020
2AA6A8,conference-participant,100,50,1/2/2020
2C19A4,dividend,100,50,1/2/2020
2EB04E,earnings,100,50,1/2/2020
2F7474,conference-call,100,50,1/2/2020
30DFD3,business-contract,100,69,1/2/2020
3159AA,facility-open,100,65,1/2/2020
328250,acquisition-completed-acquirer,100,49,1/2/2020
33AD83,product-release,100,64,1/2/2020
33AD83,product-release,100,64,1/2/2020
34B411,merger-completed,100,66,1/2/2020
34B411,earnings,100,50,1/2/2020
384CD3,acquisition-completed-acquirer,100,49,1/2/2020
385DD4,business-contract,100,69,1/2/2020
39BFF6,conference-call,100,50,1/2/2020
3A3447,facility-open,100,65,1/2/2020
3A94DF,unit-acquisition-completed-acquirer,100,49,1/2/2020
3B50FE,conference-participant,100,50,1/2/2020
3DD5E2,conference-participant,100,50,1/2/2020
41785E,earnings,100,50,1/2/2020
41A93D,conference-participant,100,50,1/2/2020
41B53E,dividend,100,50,1/2/2020
41EC04,legal-issues-defendant,100,22,1/2/2020
449A26,acquisition-completed-acquiree,100,76,1/2/2020
45BC35,conference-participant,100,50,1/2/2020
4885C8,earnings,100,50,1/2/2020
514067,conference-participant,100,50,1/2/2020
520632,conference-call,100,50,1/2/2020
59C539,conference-call,100,50,1/2/2020
5B3415,executive-appointment,100,54,1/2/2020
5D43A7,conference-call,100,50,1/2/2020
5E9934,conference-call,100,50,1/2/2020
5F2FF7,earnings,100,50,1/2/2020
619882,conference-organizer,100,57,1/2/2020
619882,conference-organizer,100,57,1/2/2020
619882,conference-organizer,100,57,1/2/2020
619882,conference-organizer,100,57,1/2/2020
619882,conference-organizer,100,57,1/2/2020
619882,conference-organizer,100,57,1/2/2020
619882,conference-organizer,100,57,1/2/2020
619882,conference-organizer,100,57,1/2/2020
619882,conference-organizer,100,57,1/2/2020
619882,conference-organizer,100,57,1/2/2020
619882,conference-organizer,100,57,1/2/2020
619882,conference-organizer,100,57,1/2/2020
619882,conference-organizer,100,57,1/2/2020
619882,conference-organizer,100,57,1/2/2020
619882,conference-organizer,100,57,1/2/2020
619882,conference-organizer,100,57,1/2/2020
619882,conference-organizer,100,57,1/2/2020
619882,conference-organizer,100,57,1/2/2020
619882,conference-organizer,100,57,1/2/2020
619882,conference-organizer,100,57,1/2/2020
619882,conference-organizer,100,57,1/2/2020
61B81B,dividend,100,50,1/2/2020
63F892,earnings,100,50,1/2/2020
651C85,campaign-ad-release,100,59,1/2/2020
665618,dividend,100,50,1/2/2020
69CE71,dividend,100,50,1/2/2020
6A01DF,merger-failed,100,21,1/2/2020
6CC55E,clinical-trials,100,56,1/2/2020
6DDA15,legal-issues-defendant,100,22,1/2/2020
6E1E61,earnings,100,50,1/2/2020
71E2EF,facility-open,100,65,1/2/2020
723548,dividend,100,50,1/2/2020
72DF04,acquisition-acquirer,100,49,1/2/2020
741937,executive-appointment,100,54,1/2/2020
7520CC,acquisition-completed-acquirer,100,49,1/2/2020
763724,dividend,100,50,1/2/2020
76DD0C,conference-participant,100,50,1/2/2020
76E80F,hirings,100,65,1/2/2020
76F067,partnership,100,61,1/2/2020
78A1BB,acquisition-completed-acquirer,100,49,1/2/2020
7A0EC4,conference-participant,100,50,1/2/2020
7D85A9,executive-appointment,100,54,1/2/2020
810FAD,conference-call,100,50,1/2/2020
81EAD4,conference-participant,100,50,1/2/2020
84AB66,merger-completed,100,66,1/2/2020
855DF7,business-contract,100,69,1/2/2020
85DE00,conference-participant,100,50,1/2/2020
8665BA,conference-call,100,50,1/2/2020
88193E,executive-appointment,100,54,1/2/2020
8EF425,earnings,100,50,1/2/2020
8F3231,unit-acquisition-acquirer,100,49,1/2/2020
911AB8,ownership-decrease-owner,100,46,1/2/2020
911AB8,ownership-decrease-owner,100,46,1/2/2020
911AB8,ownership-decrease-owner,100,46,1/2/2020
911AB8,ownership-decrease-owner,100,46,1/2/2020
92D3A0,conference-call,100,50,1/2/2020
9.36E+10,business-contract,100,69,1/2/2020
94637C,conference-participant,100,50,1/2/2020
9978F1,conference-participant,100,50,1/2/2020
9C3D3C,unit-acquisition-acquirer,100,49,1/2/2020
9D5FA4,conference-participant,100,50,1/2/2020
9E0811,executive-appointment,100,54,1/2/2020
9F37C5,dividend,100,50,1/2/2020
9FA83B,conference-participant,100,50,1/2/2020
9FB4B7,clinical-trials,100,56,1/2/2020
A3230E,conference-participant,100,50,1/2/2020
A5B913,earnings,100,50,1/2/2020
A6828A,dividend,100,50,1/2/2020
A72FD9,conference-participant,100,50,1/2/2020
A80FE0,facility-close,100,47,1/2/2020
A868C9,conference-participant,100,50,1/2/2020
ABBAD1,earnings,100,50,1/2/2020
AEF2C3,executive-appointment,100,54,1/2/2020
AFDF2E,legal-issues-defendant,100,22,1/2/2020
B290A2,conference-participant,100,50,1/2/2020
B303A6,legal-issues-defendant,100,22,1/2/2020
B303A6,legal-issues-defendant,100,22,1/2/2020
B7BBFF,executive-appointment,100,54,1/2/2020
B83D67,conference-participant,100,50,1/2/2020
B8F71F,executive-appointment,100,54,1/2/2020
BA218A,conference-call,100,50,1/2/2020
BB88B6,earnings,100,50,1/2/2020
BBAE2A,conference-call,100,50,1/2/2020
BDEC1E,conference-participant,100,50,1/2/2020
BEB756,conference-call,100,50,1/2/2020
C03C8B,conference-call,100,50,1/2/2020
C22BE8,facility-open,100,65,1/2/2020
C7AE14,dividend,100,50,1/2/2020
C97B2D,conference-call,100,50,1/2/2020
C9E107,earnings,100,50,1/2/2020
CA212F,executive-appointment,100,54,1/2/2020
CAD7D9,earnings,100,50,1/2/2020
CB89EA,conference-participant,100,50,1/2/2020
D09938,conference-call,100,50,1/2/2020
D21D8A,conference-call,100,50,1/2/2020
D501DC,conference-call,100,50,1/2/2020
D54E62,conference-call,100,50,1/2/2020
D8DA3D,legal-issues-defendant,100,22,1/2/2020
D93A25,business-contract,100,69,1/2/2020
D9E036,acquisition-completed-acquirer,100,49,1/2/2020
DD682D,executive-appointment,100,54,1/2/2020
DF1F7A,conference-call,100,50,1/2/2020
DF5F14,unit-acquisition-completed-acquirer,100,49,1/2/2020
DF6FDD,conference-participant,100,50,1/2/2020
E05DC8,acquisition-completed-acquirer,100,49,1/2/2020
E21871,settlement,100,56,1/2/2020
E30B34,conference-participant,100,50,1/2/2020
E30B34,conference-participant,100,50,1/2/2020
E6D89E,merger-failed,100,21,1/2/2020
E829E8,conference-call,100,50,1/2/2020
EB7FBF,dividend,100,50,1/2/2020
EC8116,dividend,100,50,1/2/2020
ECA300,acquisition-completed-acquirer,100,49,1/2/2020
ED5171,earnings,100,50,1/2/2020
EDD234,reorganization-unit-complete,100,74,1/2/2020
EE04F0,executive-appointment,100,54,1/2/2020
F15E41,unit-acquisition-completed-acquirer,100,49,1/2/2020
F15E41,unit-acquisition-completed-acquirer,100,49,1/2/2020
F1CD47,conference-participant,100,50,1/2/2020
F30508,conference-participant,100,50,1/2/2020
F5349B,executive-appointment,100,54,1/2/2020
F5A214,acquisition-completed-acquirer,100,49,1/2/2020
F5D059,dividend,100,50,1/2/2020
F721A7,executive-appointment,100,54,1/2/2020
F721A7,executive-appointment,100,54,1/2/2020
F80389,conference-call,100,50,1/2/2020
FC9A88,acquisition-completed-acquirer,100,49,1/2/2020
FD6926,conference-participant,100,50,1/2/2020
FDC7E6,buybacks,100,74,1/2/2020
FE1A1D,executive-appointment,100,54,1/2/2020
FF227B,conference-participant,100,50,1/2/2020
01478A,conference-call,100,50,1/3/2020
0BC853,acquisition-interest-acquirer,100,46,1/3/2020
152E1D,legal-issues-defendant,100,22,1/3/2020
1A5D5D,legal-issues-defendant,100,22,1/3/2020
1EBF8D,conference-call,100,50,1/3/2020
250BEE,conference-call,100,50,1/3/2020
25A6CC,legal-issues-defendant,100,22,1/3/2020
29A4CC,conference-call,100,50,1/3/2020
2D643C,conference-call,100,50,1/3/2020
2F7A7E,conference-call,100,50,1/3/2020
30DFD3,conference-call,100,50,1/3/2020
31F25C,conference-call,100,50,1/3/2020
3301B7,acquisition-completed-acquirer,100,49,1/3/2020
338544,conference-call,100,50,1/3/2020
366A08,executive-appointment,100,54,1/3/2020
3.88E+02,dividend,100,50,1/3/2020
38C46F,dividend,100,50,1/3/2020
3A3447,facility-open,100,65,1/3/2020
3D7971,acquisition-completed-acquirer,100,49,1/3/2020
4.03E+05,award,100,58,1/3/2020
408089,earnings,100,50,1/3/2020
41EC04,legal-issues-defendant,100,22,1/3/2020
42AABD,partnership,100,61,1/3/2020
4A5C8D,earnings,100,50,1/3/2020
4D8313,unit-acquisition-acquirer,100,49,1/3/2020
4E4E75,conference-participant,100,50,1/3/2020
52BF94,conference-call,100,50,1/3/2020
5A0FF1,conference-participant,100,50,1/3/2020
5BC2F4,conference-call,100,50,1/3/2020
5CC29D,earnings,100,50,1/3/2020
5F9CE3,conference-participant,100,50,1/3/2020
619882,conference-organizer,100,57,1/3/2020
619882,conference-organizer,100,57,1/3/2020
619882,conference-organizer,100,57,1/3/2020
619882,conference-organizer,100,57,1/3/2020
619882,conference-organizer,100,57,1/3/2020
619882,conference-organizer,100,57,1/3/2020
619882,conference-organizer,100,57,1/3/2020
619882,conference-organizer,100,57,1/3/2020
619882,conference-organizer,100,57,1/3/2020
619882,conference-call,100,50,1/3/2020
619882,conference-organizer,100,57,1/3/2020
619882,conference-organizer,100,57,1/3/2020
619882,conference-organizer,100,57,1/3/2020
619882,conference-organizer,100,57,1/3/2020
665D7D,conference-participant,100,50,1/3/2020
67529E,conference-call,100,50,1/3/2020
68BA15,conference-call,100,50,1/3/2020
69E8E1,legal-issues-defendant,100,22,1/3/2020
7ACFD4,conference-participant,100,50,1/3/2020
7B9AFA,conference-participant,100,50,1/3/2020
7D85A9,conference-participant,100,50,1/3/2020
8665BA,conference-participant,100,50,1/3/2020
873DB9,conference-participant,100,50,1/3/2020
8A8E41,unit-acquisition-acquirer,100,49,1/3/2020
8BAA15,conference-participant,100,50,1/3/2020
8DCF18,conference-participant,100,50,1/3/2020
8E4250,conference-call,100,50,1/3/2020
9196A2,conference-call,100,50,1/3/2020
949625,conference-call,100,50,1/3/2020
97FE80,executive-appointment,100,54,1/3/2020
A49498,ipo-considered,100,60,1/3/2020
A5195E,conference-participant,100,50,1/3/2020
A79F7D,public-offering,100,43,1/3/2020
AFDF2E,legal-issues-defendant,100,22,1/3/2020
B13B68,acquisition-completed-acquirer,100,49,1/3/2020
B303A6,legal-issues-defendant,100,22,1/3/2020
B4703C,conference-call,100,50,1/3/2020
B762D3,earnings,100,50,1/3/2020
BA0442,conference-participant,100,50,1/3/2020
BB5142,conference-call,100,50,1/3/2020
BC5680,legal-issues-defendant,100,22,1/3/2020
BCC55F,conference-participant,100,50,1/3/2020
BE5935,conference-participant,100,50,1/3/2020
BE86A1,executive-appointment,100,54,1/3/2020
BE86A1,executive-appointment,100,54,1/3/2020
BFEA04,executive-appointment,100,54,1/3/2020
C27E19,earnings,100,50,1/3/2020
C5C0E9,conference-participant,100,50,1/3/2020
D5AF19,earnings,100,50,1/3/2020
D90F43,acquisition-completed-acquirer,100,49,1/3/2020
DB5CA5,dividend,100,50,1/3/2020
DC2F77,earnings,100,50,1/3/2020
DF42A0,acquisition-completed-acquirer,100,49,1/3/2020
EB5E78,conference-participant,100,50,1/3/2020
EC99D0,executive-appointment,100,54,1/3/2020
F4E882,legal-issues-defendant,100,22,1/3/2020
F4E992,conference-call,100,50,1/3/2020
FC4550,dividend,100,50,1/3/2020
FEC475,legal-issues-defendant,100,22,1/3/2020
2E1322,legal-issues-defendant,100,22,1/4/2020
5FF95F,earnings,100,50,1/4/2020
BC5680,legal-issues-defendant,100,22,1/4/2020
225CA2,business-contract-terminated,100,31,1/5/2020
4BEB48,product-release,100,64,1/5/2020
6D3F35,product-release,100,64,1/5/2020
6D3F35,product-release,100,64,1/5/2020
00067A,earnings,100,50,1/6/2020
002A99,executive-appointment,100,54,1/6/2020
00326D,conference-call,100,50,1/6/2020
0157B1,partnership,100,61,1/6/2020
0157B1,partnership,100,61,1/6/2020
31025,earnings,100,50,1/6/2020
033B58,partnership,100,61,1/6/2020
03CF95,acquisition-completed-acquirer,100,49,1/6/2020
04EB2F,conference-participant,100,50,1/6/2020
61366,settlement,100,56,1/6/2020
0919B1,executive-resignation,100,44,1/6/2020
099C88,business-contract,100,69,1/6/2020
0F0693,conference-participant,100,50,1/6/2020
0F2BC9,conference-call,100,50,1/6/2020
1080C0,executive-appointment,100,54,1/6/2020
1151F4,conference-call,100,50,1/6/2020
139303,merger-completed,100,66,1/6/2020
159AE4,facility-sale,100,52,1/6/2020
16FC89,earnings,100,50,1/6/2020
1.79E+10,conference-call,100,50,1/6/2020
17EDA5,product-release,100,64,1/6/2020
184866,clinical-trials-start,100,64,1/6/2020
1880C5,clinical-trials,100,56,1/6/2020
1A2D9F,earnings,100,50,1/6/2020
1A5D5D,legal-issues-defendant,100,22,1/6/2020
1BDB2A,conference-participant,100,50,1/6/2020
1D5C51,conference-participant,100,50,1/6/2020
1D943E,conference-participant,100,50,1/6/2020
1DB6A6,executive-resignation,100,44,1/6/2020
1E1125,conference-organizer,100,57,1/6/2020
1EBF8D,partnership,100,61,1/6/2020
20BEEA,conference-call,100,50,1/6/2020
225CA2,fundraising,100,64,1/6/2020
225CA2,fundraising,100,64,1/6/2020
227D48,acquisition-completed-acquirer,100,49,1/6/2020
228D42,partnership,100,61,1/6/2020
228D42,partnership,100,61,1/6/2020
2667B6,earnings,100,50,1/6/2020
28DCA8,earnings-guidance,100,50,1/6/2020
2A1009,conference-participant,100,50,1/6/2020
2A9C0A,conference-call,100,50,1/6/2020
2B8179,clinical-trials-start,100,64,1/6/2020
2F1299,executive-appointment,100,54,1/6/2020
2F5256,conference-call,100,50,1/6/2020
30DE64,clinical-trials-positive,100,87,1/6/2020
3.14E+47,earnings,100,50,1/6/2020
32F943,conference-participant,100,50,1/6/2020
367E1C,conference-participant,100,50,1/6/2020
3A3447,facility-open,100,65,1/6/2020
3AAEAE,executive-appointment,100,54,1/6/2020
3ACF46,business-contract,100,69,1/6/2020
3AF7FD,conference-call,100,50,1/6/2020
3C3B6B,conference-participant,100,50,1/6/2020
3EE65E,conference-participant,100,50,1/6/2020
401072,clinical-trials-start,100,64,1/6/2020
41EC04,legal-issues-defendant,100,22,1/6/2020
41EC04,legal-issues-defendant,100,22,1/6/2020
42DC93,earnings,100,50,1/6/2020
434F38,conference-participant,100,50,1/6/2020
43A060,conference-participant,100,50,1/6/2020
467F2C,conference-participant,100,50,1/6/2020
4A6F00,award,100,58,1/6/2020
4F9926,product-release,100,64,1/6/2020
4F9926,product-release,100,64,1/6/2020
513A86,executive-appointment,100,54,1/6/2020
52015A,dividend,100,50,1/6/2020
546A27,orphan-drug-designation,100,76,1/6/2020
546A9C,partnership,100,61,1/6/2020
55438C,business-contract,100,69,1/6/2020
5546DA,market-entry,100,57,1/6/2020
56EA2B,public-offering,100,43,1/6/2020
57A854,executive-appointment,100,54,1/6/2020
586BD7,conference-participant,100,50,1/6/2020
594402,conference-participant,100,50,1/6/2020
59B229,earnings,100,50,1/6/2020
59DB8C,conference-participant,100,50,1/6/2020
5B3FA2,conference-participant,100,50,1/6/2020
5C2A47,product-release,100,64,1/6/2020
5D41E4,partnership,100,61,1/6/2020
5D41E4,partnership,100,61,1/6/2020
5D41E4,partnership,100,61,1/6/2020
5EC388,earnings,100,50,1/6/2020
5F3D91,executive-appointment,100,54,1/6/2020
619882,conference-organizer,100,57,1/6/2020
619882,conference-organizer,100,57,1/6/2020
619882,conference-organizer,100,57,1/6/2020
619882,conference-organizer,100,57,1/6/2020
619882,conference-organizer,100,57,1/6/2020
619882,conference-organizer,100,57,1/6/2020
619882,conference-organizer,100,57,1/6/2020
619882,conference-organizer,100,57,1/6/2020
619882,conference-organizer,100,57,1/6/2020
619882,conference-organizer,100,57,1/6/2020
619882,conference-organizer,100,57,1/6/2020
619882,conference-organizer,100,57,1/6/2020
619882,conference-organizer,100,57,1/6/2020
619882,conference-organizer,100,57,1/6/2020
619882,conference-organizer,100,57,1/6/2020
619882,conference-organizer,100,57,1/6/2020
619882,conference-organizer,100,57,1/6/2020
619882,conference-organizer,100,57,1/6/2020
619882,conference-organizer,100,57,1/6/2020
619882,conference-organizer,100,57,1/6/2020
619882,conference-organizer,100,57,1/6/2020
619882,conference-organizer,100,57,1/6/2020
619882,conference-organizer,100,57,1/6/2020
619882,conference-organizer,100,57,1/6/2020
619882,conference-organizer,100,57,1/6/2020
619882,conference-organizer,100,57,1/6/2020
619882,conference-organizer,100,57,1/6/2020
619882,conference-organizer,100,57,1/6/2020
619882,conference-organizer,100,57,1/6/2020
619882,conference-organizer,100,57,1/6/2020
619882,conference-organizer,100,57,1/6/2020
619882,conference-organizer,100,57,1/6/2020
619882,conference-organizer,100,57,1/6/2020
619882,conference-organizer,100,57,1/6/2020
619882,conference-organizer,100,57,1/6/2020
619882,conference-organizer,100,57,1/6/2020
619882,conference-organizer,100,57,1/6/2020
619882,conference-organizer,100,57,1/6/2020
619882,conference-organizer,100,57,1/6/2020
619882,conference-organizer,100,57,1/6/2020
619882,conference-organizer,100,57,1/6/2020
619882,conference-organizer,100,57,1/6/2020
619882,conference-organizer,100,57,1/6/2020
619882,conference-organizer,100,57,1/6/2020
619882,conference-organizer,100,57,1/6/2020
619882,conference-organizer,100,57,1/6/2020
619882,conference-organizer,100,57,1/6/2020
619882,conference-organizer,100,57,1/6/2020
619882,conference-organizer,100,57,1/6/2020
619882,conference-organizer,100,57,1/6/2020
619882,conference-organizer,100,57,1/6/2020
620381,conference-participant,100,50,1/6/2020
622DBE,campaign-ad-release,100,59,1/6/2020
627186,conference-participant,100,50,1/6/2020
6474BA,earnings,100,50,1/6/2020
651C85,conference-participant,100,50,1/6/2020
66A667,award,100,58,1/6/2020
68E6E9,earnings,100,50,1/6/2020
69345C,product-release,100,64,1/6/2020
69345C,product-release,100,64,1/6/2020
69345C,product-release,100,64,1/6/2020
6CBF41,conference-participant,100,50,1/6/2020
6D0CAB,acquisition-acquirer,100,49,1/6/2020
6D9ECA,fast-track-designation,100,81,1/6/2020
6DDA15,legal-issues-defendant,100,22,1/6/2020
719477,conference-call,100,50,1/6/2020
71E2EF,unit-acquisition-acquiree,100,76,1/6/2020
7255D2,business-contract,100,69,1/6/2020
72FCA3,award,100,58,1/6/2020
7823A3,partnership,100,61,1/6/2020
787D14,executive-appointment,100,54,1/6/2020
787D14,executive-appointment,100,54,1/6/2020
789ADD,earnings,100,50,1/6/2020
78F9ED,supply-decrease,100,28,1/6/2020
790C34,partnership,100,61,1/6/2020
790C34,partnership,100,61,1/6/2020
79340A,earnings,100,50,1/6/2020
7AF907,patient-enrollment-complete,100,64,1/6/2020
7F3669,conference-participant,100,50,1/6/2020
804708,hirings,100,65,1/6/2020
819492,conference-participant,100,50,1/6/2020
82B57E,conference-participant,100,50,1/6/2020
83066C,conference-participant,100,50,1/6/2020
830BDB,conference-participant,100,50,1/6/2020
862941,conference-participant,100,50,1/6/2020
87486A,conference-call,100,50,1/6/2020
88193E,conference-participant,100,50,1/6/2020
8A8E41,partnership,100,61,1/6/2020
8A8E41,partnership,100,61,1/6/2020
8BAA15,earnings-guidance,100,50,1/6/2020
8E93A4,conference-call,100,50,1/6/2020
8E93A4,conference-call,100,50,1/6/2020
911AB8,dividend-guidance-up,100,83,1/6/2020
925759,conference-participant,100,50,1/6/2020
92D230,executive-appointment,100,54,1/6/2020
931AE7,conference-participant,100,50,1/6/2020
934029,conference-participant,100,50,1/6/2020
93AD2E,earnings,100,50,1/6/2020
94637C,conference-participant,100,50,1/6/2020
9592FB,asset-sale,100,62,1/6/2020
9.62E+76,earnings,100,50,1/6/2020
96F126,business-contract,100,69,1/6/2020
97644E,product-release,100,64,1/6/2020
9978F1,executive-appointment,100,54,1/6/2020
9A2760,conference-participant,100,50,1/6/2020
9AF3DC,conference-call,100,50,1/6/2020
9C5174,earnings,100,50,1/6/2020
9D3360,earnings,100,50,1/6/2020
9D5FA4,executive-appointment,100,54,1/6/2020
9E5C2C,conference-call,100,50,1/6/2020
9EED50,conference-call,100,50,1/6/2020
9F03CF,conference-call,100,50,1/6/2020
9F048E,conference-participant,100,50,1/6/2020
A204A7,conference-participant,100,50,1/6/2020
A26C26,conference-participant,100,50,1/6/2020
A5628C,earnings,100,50,1/6/2020
A5A4F5,partnership,100,61,1/6/2020
A6FE1C,unit-acquisition-acquirer,100,49,1/6/2020
A7A0C8,executive-appointment,100,54,1/6/2020
A99576,conference-call,100,50,1/6/2020
AADE0B,stake-acquirer,100,48,1/6/2020
AB4A7E,conference-participant,100,50,1/6/2020
AEBB80,conference-participant,100,50,1/6/2020
AEFC90,executive-appointment,100,54,1/6/2020
B0998E,index-listing,100,76,1/6/2020
B2DAF6,conference-participant,100,50,1/6/2020
B303A6,legal-issues-defendant,100,22,1/6/2020
B33E77,clinical-trials,100,56,1/6/2020
B33E77,clinical-trials,100,56,1/6/2020
B4C673,acquisition-acquirer,100,49,1/6/2020
B4C673,acquisition-acquirer,100,49,1/6/2020
B6082A,conference-call,100,50,1/6/2020
B83BCE,earnings,100,50,1/6/2020
B83D67,settlement,100,56,1/6/2020
B840EF,conference-participant,100,50,1/6/2020
BA218A,executive-appointment,100,54,1/6/2020
BBF349,product-release,100,64,1/6/2020
BC5680,legal-issues-defendant,100,22,1/6/2020
BD9668,conference-call,100,50,1/6/2020
BDEC1E,public-offering,100,43,1/6/2020
BFEA04,executive-appointment,100,54,1/6/2020
C01737,partnership,100,61,1/6/2020
C0BA36,award,100,58,1/6/2020
C188F8,product-release,100,64,1/6/2020
C230FE,earnings,100,50,1/6/2020
C4A241,conference-call,100,50,1/6/2020
C50B26,acquisition-acquirer,100,49,1/6/2020
C50B26,acquisition-acquirer,100,49,1/6/2020
C5D2AE,earnings,100,50,1/6/2020
C5E100,conference-participant,100,50,1/6/2020
C62AA4,unit-acquisition-acquirer,100,49,1/6/2020
C7859D,dividend,100,50,1/6/2020
C81E00,conference-call,100,50,1/6/2020
C81E00,conference-call,100,50,1/6/2020
CAB222,conference-participant,100,50,1/6/2020
CAD7D9,legal-issues-defendant,100,22,1/6/2020
CB89EA,product-release,100,64,1/6/2020
CC8F6E,conference-participant,100,50,1/6/2020
CDFCC9,conference-participant,100,50,1/6/2020
CE5664,earnings,100,50,1/6/2020
CF073E,conference-participant,100,50,1/6/2020
CF6A5A,executive-resignation,100,44,1/6/2020
CF9054,business-contract,100,69,1/6/2020
D0909F,earnings-guidance,100,50,1/6/2020
D1C26F,conference-participant,100,50,1/6/2020
D36B23,conference-participant,100,50,1/6/2020
D63B0F,investment-investor,100,55,1/6/2020
D721C6,facility-open,100,65,1/6/2020
D721C6,facility-open,100,65,1/6/2020
D77F7E,asset-sale,100,62,1/6/2020
D77F7E,asset-sale,100,62,1/6/2020
D8760C,conference-call,100,50,1/6/2020
D90F43,partnership,100,61,1/6/2020
D90F43,partnership,100,61,1/6/2020
D90F43,partnership,100,61,1/6/2020
DA0CB8,conference-call,100,50,1/6/2020
DBB28E,partnership,100,61,1/6/2020
DC2F77,note-sale,100,52,1/6/2020
DC5299,conference-call,100,50,1/6/2020
DD1BA1,unit-acquisition-acquiree,100,76,1/6/2020
DD1BA1,unit-acquisition-acquiree,100,76,1/6/2020
DD1BA1,facility-upgrade,100,65,1/6/2020
DD9E41,conference-participant,100,50,1/6/2020
E00373,partnership,100,61,1/6/2020
E06265,conference-participant,100,50,1/6/2020
E0D3BA,earnings,100,50,1/6/2020
E12A6E,earnings,100,50,1/6/2020
E28D9C,business-contract,100,69,1/6/2020
E592F0,conference-participant,100,50,1/6/2020
E598FB,executive-appointment,100,54,1/6/2020
E67C2C,conference-participant,100,50,1/6/2020
E68E62,conference-participant,100,50,1/6/2020
E7BF32,clinical-trials,100,56,1/6/2020
E8B315,conference-call,100,50,1/6/2020
E8E899,conference-participant,100,50,1/6/2020
EB1E1A,conference-participant,100,50,1/6/2020
EB7FBF,earnings,100,50,1/6/2020
ED2A5E,conference-participant,100,50,1/6/2020
EE6F1C,government-contract,100,69,1/6/2020
EEB5F9,conference-participant,100,50,1/6/2020
F18844,partnership,100,61,1/6/2020
F1CD47,earnings,100,50,1/6/2020
F5D410,conference-participant,100,50,1/6/2020
F6A945,earnings,100,50,1/6/2020
F6E248,partnership,100,61,1/6/2020
FAAFA2,conference-participant,100,50,1/6/2020
FC01C0,conference-participant,100,50,1/6/2020
FC1B7B,conference-call,100,50,1/6/2020
FC9A88,earnings,100,50,1/6/2020
FD0CA4,conference-call,100,50,1/6/2020
FD4588,acquisition-acquirer,100,49,1/6/2020
FDD3FC,conference-participant,100,50,1/6/2020
FEC475,executive-appointment,100,54,1/6/2020
FEE4B0,earnings,100,50,1/6/2020
9397,earnings,100,50,1/7/2020
00E601,earnings,100,50,1/7/2020
13528,partnership,100,61,1/7/2020
0157B1,partnership,100,61,1/7/2020
048B70,conference-call,100,50,1/7/2020
0624BE,conference-participant,100,50,1/7/2020
95294,executive-appointment,100,54,1/7/2020
0986B5,merger-completed,100,66,1/7/2020
0A9D0A,legal-verdict-disfavored,100,22,1/7/2020
0BC853,earnings,100,50,1/7/2020
0CE204,legal-issues-defendant,100,22,1/7/2020
0FC848,conference-participant,100,50,1/7/2020
12DE76,conference-organizer,100,57,1/7/2020
12F98C,product-release,100,64,1/7/2020
133644,executive-appointment,100,54,1/7/2020
14BA06,earnings,100,50,1/7/2020
15A388,business-contract,100,69,1/7/2020
15B10D,conference-participant,100,50,1/7/2020
17EDA5,partnership,100,61,1/7/2020
182BE7,conference-participant,100,50,1/7/2020
188394,conference-call,100,50,1/7/2020
19BF16,trading-listing,100,61,1/7/2020
1B9535,executive-appointment,100,54,1/7/2020
1CD09C,conference-participant,100,50,1/7/2020
1EBF8D,partnership,100,61,1/7/2020
1EC3E8,executive-appointment,100,54,1/7/2020
1F716B,conference-participant,100,50,1/7/2020
1FAF22,legal-issues-defendant,100,22,1/7/2020
2158DF,partnership,100,61,1/7/2020
2158DF,partnership,100,61,1/7/2020
223552,conference-participant,100,50,1/7/2020
228D42,partnership,100,61,1/7/2020
228D42,partnership,100,61,1/7/2020
22C58E,patent-infringement-plaintiff,100,47,1/7/2020
25A6CC,legal-issues-defendant,100,22,1/7/2020
25A6CC,legal-issues-defendant,100,22,1/7/2020
26D8ED,executive-resignation,100,44,1/7/2020
28F905,executive-appointment,100,54,1/7/2020
2950FF,earnings,100,50,1/7/2020
2950FF,earnings,100,50,1/7/2020
29B702,earnings,100,50,1/7/2020
2B5483,conference-participant,100,50,1/7/2020
2C35B5,executive-appointment,100,54,1/7/2020
30CBF9,partnership,100,61,1/7/2020
315EB0,executive-appointment,100,54,1/7/2020
326EDD,conference-call,100,50,1/7/2020
32DCB3,executive-appointment,100,54,1/7/2020
33E8C7,note-sale,100,52,1/7/2020
33E8C7,note-sale,100,52,1/7/2020
34B411,executive-appointment,100,54,1/7/2020
35AE32,unit-acquisition-acquirer,100,49,1/7/2020
35AE32,executive-resignation,100,44,1/7/2020
3.73E+87,partnership,100,61,1/7/2020
37727A,earnings,100,50,1/7/2020
3C6CCC,product-release,100,64,1/7/2020
3F868D,conference-participant,100,50,1/7/2020
4398A2,conference-participant,100,50,1/7/2020
44209A,earnings,100,50,1/7/2020
442769,business-contract,100,69,1/7/2020
44A4FC,unit-acquisition-acquirer,100,49,1/7/2020
44A4FC,conference-participant,100,50,1/7/2020
49A344,earnings,100,50,1/7/2020
4A2457,business-contract,100,69,1/7/2020
4A6F00,partnership,100,61,1/7/2020
4B3DC9,executive-appointment,100,54,1/7/2020
4B49CF,earnings,100,50,1/7/2020
4BAF2E,clinical-trials,100,56,1/7/2020
4C1FA1,note-sale,100,52,1/7/2020
4C6C63,product-release,100,64,1/7/2020
4D8313,business-contract,100,69,1/7/2020
4D8313,business-contract,100,69,1/7/2020
4F783B,partnership,100,61,1/7/2020
50070E,conference-organizer,100,57,1/7/2020
50070E,conference-organizer,100,57,1/7/2020
543900,executive-resignation,100,44,1/7/2020
54512F,conference-participant,100,50,1/7/2020
550D01,conference-call,100,50,1/7/2020
56EA2B,public-offering,100,43,1/7/2020
589846,conference-participant,100,50,1/7/2020
59872F,conference-participant,100,50,1/7/2020
5C2A47,partnership,100,61,1/7/2020
5D1956,earnings,100,50,1/7/2020
5F2FF7,partnership,100,61,1/7/2020
60DD84,conference-call,100,50,1/7/2020
619882,conference-organizer,100,57,1/7/2020
619882,conference-organizer,100,57,1/7/2020
619882,conference-organizer,100,57,1/7/2020
619882,conference-organizer,100,57,1/7/2020
619882,conference-organizer,100,57,1/7/2020
619882,conference-organizer,100,57,1/7/2020
619882,conference-organizer,100,57,1/7/2020
619882,conference-organizer,100,57,1/7/2020
619882,conference-organizer,100,57,1/7/2020
619882,conference-organizer,100,57,1/7/2020
619882,conference-organizer,100,57,1/7/2020
619882,conference-organizer,100,57,1/7/2020
619882,conference-organizer,100,57,1/7/2020
619882,conference-organizer,100,57,1/7/2020
619882,partnership,100,61,1/7/2020
619882,conference-organizer,100,57,1/7/2020
619882,conference-organizer,100,57,1/7/2020
619882,conference-organizer,100,57,1/7/2020
619882,conference-organizer,100,57,1/7/2020
619882,conference-organizer,100,57,1/7/2020
619882,conference-organizer,100,57,1/7/2020
619882,conference-organizer,100,57,1/7/2020
619882,conference-organizer,100,57,1/7/2020
619882,conference-organizer,100,57,1/7/2020
619882,conference-organizer,100,57,1/7/2020
619882,conference-organizer,100,57,1/7/2020
619882,conference-organizer,100,57,1/7/2020
619882,conference-organizer,100,57,1/7/2020
619882,conference-organizer,100,57,1/7/2020
619882,conference-organizer,100,57,1/7/2020
619882,conference-organizer,100,57,1/7/2020
619882,conference-organizer,100,57,1/7/2020
61A586,conference-participant,100,50,1/7/2020
627186,earnings,100,50,1/7/2020
636639,acquisition-acquirer,100,49,1/7/2020
636639,acquisition-acquirer,100,49,1/7/2020
636639,acquisition-acquirer,100,49,1/7/2020
639BD6,earnings,100,50,1/7/2020
665D7D,regulatory-product-approval-granted,100,81,1/7/2020
6830FE,executive-appointment,100,54,1/7/2020
693ECD,conference-participant,100,50,1/7/2020
69E8E1,legal-issues-defendant,100,22,1/7/2020
69E8E1,conference-call,100,50,1/7/2020
69E8E1,conference-call,100,50,1/7/2020
6ABCB8,patent-infringement-defendant,100,26,1/7/2020
6B0784,conference-call,100,50,1/7/2020
6B0784,conference-call,100,50,1/7/2020
6DDA15,legal-issues-defendant,100,22,1/7/2020
6DDA15,legal-issues-defendant,100,22,1/7/2020
6E8864,revenues,100,50,1/7/2020
704B78,earnings,100,50,1/7/2020
704B78,public-offering,100,43,1/7/2020
70CA28,business-contract,100,69,1/7/2020
71694D,conference-participant,100,50,1/7/2020
717DB4,conference-participant,100,50,1/7/2020
726DDF,executive-appointment,100,54,1/7/2020
72CB93,executive-appointment,100,54,1/7/2020
73C9E2,conference-call,100,50,1/7/2020
7.44E+09,conference-call,100,50,1/7/2020
7.45E+28,conference-participant,100,50,1/7/2020
763DBE,partnership,100,61,1/7/2020
76959C,conference-participant,100,50,1/7/2020
76CEFB,earnings,100,50,1/7/2020
76F067,conference-participant,100,50,1/7/2020
7999F3,executive-appointment,100,54,1/7/2020
7ACFD4,executive-appointment,100,54,1/7/2020
7B1E50,donation,100,54,1/7/2020
7CD98F,earnings,100,50,1/7/2020
7D35D8,product-release,100,64,1/7/2020
7D7716,earnings,100,50,1/7/2020
7DD584,conference-participant,100,50,1/7/2020
7E1D5D,product-release,100,64,1/7/2020
7E1D5D,unit-acquisition-acquirer,100,49,1/7/2020
7F2922,conference-participant,100,50,1/7/2020
8.10E+32,dividend,100,50,1/7/2020
83A065,public-offering,100,43,1/7/2020
84A6B9,earnings,100,50,1/7/2020
85CDC9,conference-participant,100,50,1/7/2020
89F693,unit-acquisition-acquiree,100,76,1/7/2020
89F693,business-contract,100,69,1/7/2020
8C84DF,earnings,100,50,1/7/2020
8D4486,campaign-ad-release,100,59,1/7/2020
8D5145,earnings,100,50,1/7/2020
8E10BF,patient-enrollment-start,100,58,1/7/2020
92B047,conference-call,100,50,1/7/2020
9.36E+10,business-contract,100,69,1/7/2020
93633B,conference-call,100,50,1/7/2020
94637C,partnership,100,61,1/7/2020
94637C,partnership,100,61,1/7/2020
94A326,clinical-trials-start,100,64,1/7/2020
95C392,earnings,100,50,1/7/2020
965360,earnings,100,50,1/7/2020
966ACE,conference-participant,100,50,1/7/2020
96A2D3,conference-participant,100,50,1/7/2020
96B4FF,conference-participant,100,50,1/7/2020
9.74E+08,conference-participant,100,50,1/7/2020
986AF6,conference-call,100,50,1/7/2020
990AD0,conference-organizer,100,57,1/7/2020
9CA4C6,conference-call,100,50,1/7/2020
9D65C1,earnings,100,50,1/7/2020
9E5C2C,conference-participant,100,50,1/7/2020
A23747,conference-participant,100,50,1/7/2020
A3800A,executive-appointment,100,54,1/7/2020
A6213D,partnership,100,61,1/7/2020
A63387,executive-resignation,100,44,1/7/2020
A75D43,conference-call,100,50,1/7/2020
A79D88,facility-open,100,65,1/7/2020
A79F7D,clinical-trials,100,56,1/7/2020
A80FE0,note-sale,100,52,1/7/2020
A868C9,business-contract,100,69,1/7/2020
A8AC4C,conference-participant,100,50,1/7/2020
ADF092,earnings,100,50,1/7/2020
AFF7B4,conference-call,100,50,1/7/2020
B1FC3B,business-contract,100,69,1/7/2020
B290A2,clinical-trials-positive,100,87,1/7/2020
B290A2,public-offering,100,43,1/7/2020
B303A6,legal-issues-defendant,100,22,1/7/2020
B446B8,earnings,100,50,1/7/2020
B642E8,facility-open,100,65,1/7/2020
B642E8,facility-open,100,65,1/7/2020
B7202A,earnings-guidance,100,50,1/7/2020
B9CD50,conference-participant,100,50,1/7/2020
BC5680,legal-issues-defendant,100,22,1/7/2020
BC5680,legal-issues-defendant,100,22,1/7/2020
BCC55F,partnership,100,61,1/7/2020
BCC55F,partnership,100,61,1/7/2020
BCC55F,partnership,100,61,1/7/2020
BCC55F,partnership,100,61,1/7/2020
BFE02C,conference-call,100,50,1/7/2020
C062D4,conference-call,100,50,1/7/2020
C11C46,conference-participant,100,50,1/7/2020
C15DB3,unit-acquisition-acquiree,100,76,1/7/2020
C230FE,executive-appointment,100,54,1/7/2020
C45C1F,conference-participant,100,50,1/7/2020
C45CE7,conference-participant,100,50,1/7/2020
C4A912,conference-participant,100,50,1/7/2020
C598D7,acquisition-completed-acquirer,100,49,1/7/2020
C6C702,acquisition-acquirer,100,49,1/7/2020
C6C702,conference-participant,100,50,1/7/2020
C951A2,earnings,100,50,1/7/2020
C9881C,executive-appointment,100,54,1/7/2020
CAD7D9,conference-participant,100,50,1/7/2020
CB88B3,executive-appointment,100,54,1/7/2020
CBA33B,earnings,100,50,1/7/2020
CD06A2,earnings,100,50,1/7/2020
CDC817,conference-participant,100,50,1/7/2020
CE5664,conference-participant,100,50,1/7/2020
CF351E,public-offering,100,43,1/7/2020
CF6A5A,earnings,100,50,1/7/2020
D1588D,conference-participant,100,50,1/7/2020
D697DE,conference-participant,100,50,1/7/2020
D6EAA3,note-sale,100,52,1/7/2020
D6EAA3,note-sale,100,52,1/7/2020
D76AEF,conference-participant,100,50,1/7/2020
D78CCD,conference-call,100,50,1/7/2020
DB5CA5,earnings,100,50,1/7/2020
DC1405,conference-participant,100,50,1/7/2020
DF11D9,conference-call,100,50,1/7/2020
DF532D,conference-call,100,50,1/7/2020
DF6FDD,product-release,100,64,1/7/2020
E00373,product-release,100,64,1/7/2020
E11C41,conference-call,100,50,1/7/2020
E124EB,conference-call,100,50,1/7/2020
E15736,conference-call,100,50,1/7/2020
E15736,conference-call,100,50,1/7/2020
E15736,conference-call,100,50,1/7/2020
E1BD05,conference-participant,100,50,1/7/2020
E1E093,business-contract,100,69,1/7/2020
E2F130,partnership,100,61,1/7/2020
E5A3B6,conference-participant,100,50,1/7/2020
E610CD,conference-participant,100,50,1/7/2020
E754F0,conference-participant,100,50,1/7/2020
EEBCEF,earnings,100,50,1/7/2020
EF5BED,executive-appointment,100,54,1/7/2020
EF5BED,executive-appointment,100,54,1/7/2020
F0B335,conference-participant,100,50,1/7/2020
F40EE2,patent-infringement-defendant,100,26,1/7/2020
F40EE2,partnership,100,61,1/7/2020
F40EE2,partnership,100,61,1/7/2020
F47871,conference-participant,100,50,1/7/2020
F4CDA3,unit-acquisition-acquirer,100,49,1/7/2020
F5D410,conference-call,100,50,1/7/2020
F6FF0D,earnings-guidance,100,50,1/7/2020
F7902B,partnership,100,61,1/7/2020
F8BA6C,partnership,100,61,1/7/2020
FA044A,conference-call,100,50,1/7/2020
FA35C6,conference-participant,100,50,1/7/2020
FC1F9D,conference-call,100,50,1/7/2020
FD9526,conference-call,100,50,1/7/2020
FF4343,executive-appointment,100,54,1/7/2020
00067A,conference-participant,100,50,1/8/2020
001F1B,revenues,100,50,1/8/2020
51332,conference-call,100,50,1/8/2020
081AB9,conference-call,100,50,1/8/2020
0B57D7,conference-call,100,50,1/8/2020
0B7375,conference-participant,100,50,1/8/2020
0BD199,clinical-trials,100,56,1/8/2020
0C2A0D,partnership,100,61,1/8/2020
0C2A0D,partnership,100,61,1/8/2020
0E499E,conference-participant,100,50,1/8/2020
0F04E5,partnership,100,61,1/8/2020
147C38,award,100,58,1/8/2020
147C38,award,100,58,1/8/2020
152FA5,executive-appointment,100,54,1/8/2020
1748B3,conference-call,100,50,1/8/2020
1782D5,note-sale,100,52,1/8/2020
19CAC7,conference-call,100,50,1/8/2020
1D1B07,earnings,100,50,1/8/2020
1D3A00,earnings-guidance-up,100,83,1/8/2020
1D5C51,partnership,100,61,1/8/2020
1EBF8D,regulatory-product-approval-granted,100,81,1/8/2020
1EBF8D,regulatory-product-approval-granted,100,81,1/8/2020
1EBF8D,regulatory-product-approval-granted,100,81,1/8/2020
1EBF8D,regulatory-product-approval-granted,100,81,1/8/2020
1EBF8D,regulatory-product-approval-granted,100,81,1/8/2020
1FAF22,legal-issues-defendant,100,22,1/8/2020
206852,conference-call,100,50,1/8/2020
21022F,executive-appointment,100,54,1/8/2020
25A6CC,legal-issues-defendant,100,22,1/8/2020
2CB4C9,partnership,100,61,1/8/2020
2CB4C9,partnership,100,61,1/8/2020
2D76CE,revenues,100,50,1/8/2020
2D76CE,earnings,100,50,1/8/2020
2FF046,conference-participant,100,50,1/8/2020
3390DE,conference-call,100,50,1/8/2020
39FB23,acquisition-acquirer,100,49,1/8/2020
3BCF24,earnings,100,50,1/8/2020
3C7F5F,business-contract,100,69,1/8/2020
3F1C69,conference-participant,100,50,1/8/2020
4017AD,executive-appointment,100,54,1/8/2020
4135F7,partnership,100,61,1/8/2020
414FFF,partnership,100,61,1/8/2020
416C55,acquisition-acquirer,100,49,1/8/2020
42EFC7,conference-participant,100,50,1/8/2020
479930,conference-participant,100,50,1/8/2020
4AE584,revenue-up,100,69,1/8/2020
4AE584,revenue-up,100,69,1/8/2020
4B3555,earnings,100,50,1/8/2020
4B3DC9,unit-acquisition-acquiree,100,76,1/8/2020
4BDCA7,business-contract,100,69,1/8/2020
4CDA2B,conference-participant,100,50,1/8/2020
4D8313,conference-call,100,50,1/8/2020
4EC4C1,earnings,100,50,1/8/2020
4EC4C1,earnings,100,50,1/8/2020
4EC4C1,earnings,100,50,1/8/2020
4EC4C1,earnings,100,50,1/8/2020
4F9926,campaign-ad-release,100,59,1/8/2020
51E682,conference-call,100,50,1/8/2020
543900,note-sale,100,52,1/8/2020
543900,note-sale,100,52,1/8/2020
55C289,conference-call,100,50,1/8/2020
56277A,executive-appointment,100,54,1/8/2020
57CAAB,conference-participant,100,50,1/8/2020
5B97B2,earnings,100,50,1/8/2020
5C2A47,conference-participant,100,50,1/8/2020
5C2A47,conference-call,100,50,1/8/2020
5E6959,conference-call,100,50,1/8/2020
5F2FF7,partnership,100,61,1/8/2020
5F2FF7,partnership,100,61,1/8/2020
5F2FF7,partnership,100,61,1/8/2020
5F9CE3,earnings,100,50,1/8/2020
601785,earnings,100,50,1/8/2020
60EA12,earnings,100,50,1/8/2020
6137BF,conference-participant,100,50,1/8/2020
619882,conference-organizer,100,57,1/8/2020
619882,conference-organizer,100,57,1/8/2020
619882,conference-organizer,100,57,1/8/2020
619882,conference-organizer,100,57,1/8/2020
619882,conference-organizer,100,57,1/8/2020
619882,conference-organizer,100,57,1/8/2020
619882,conference-organizer,100,57,1/8/2020
619882,conference-organizer,100,57,1/8/2020
619882,conference-organizer,100,57,1/8/2020
619882,conference-organizer,100,57,1/8/2020
619882,conference-organizer,100,57,1/8/2020
619882,conference-organizer,100,57,1/8/2020
619882,conference-organizer,100,57,1/8/2020
619882,conference-organizer,100,57,1/8/2020
619882,conference-organizer,100,57,1/8/2020
619882,conference-organizer,100,57,1/8/2020
619882,conference-organizer,100,57,1/8/2020
619882,conference-organizer,100,57,1/8/2020
619882,conference-organizer,100,57,1/8/2020
619882,conference-organizer,100,57,1/8/2020
619882,conference-organizer,100,57,1/8/2020
619882,conference-organizer,100,57,1/8/2020
619882,conference-organizer,100,57,1/8/2020
619882,conference-organizer,100,57,1/8/2020
619882,conference-organizer,100,57,1/8/2020
619882,conference-organizer,100,57,1/8/2020
619882,conference-organizer,100,57,1/8/2020
619882,conference-organizer,100,57,1/8/2020
619882,conference-organizer,100,57,1/8/2020
61BCA7,partnership,100,61,1/8/2020
61BCA7,earnings,100,50,1/8/2020
64E346,note-sale,100,52,1/8/2020
6559D8,executive-appointment,100,54,1/8/2020
66A667,dividend,100,50,1/8/2020
66A667,dividend,100,50,1/8/2020
66A667,executive-appointment,100,54,1/8/2020
66A667,executive-appointment,100,54,1/8/2020
6810DE,clinical-trials-start,100,64,1/8/2020
6830FE,partnership,100,61,1/8/2020
68AB62,conference-call,100,50,1/8/2020
6925EB,conference-participant,100,50,1/8/2020
69E8E1,legal-issues-defendant,100,22,1/8/2020
6B236C,executive-appointment,100,54,1/8/2020
6DDA15,legal-issues-defendant,100,22,1/8/2020
6-Dec-05,executive-appointment,100,54,1/8/2020
6.00E+19,product-release,100,64,1/8/2020
704B78,public-offering,100,43,1/8/2020
70CA28,conference-participant,100,50,1/8/2020
7122EB,executive-appointment,100,54,1/8/2020
71B0CF,partnership,100,61,1/8/2020
73A213,conference-participant,100,50,1/8/2020
7.40E+289,earnings,100,50,1/8/2020
7.40E+289,earnings,100,50,1/8/2020
7.40E+289,earnings,100,50,1/8/2020
75F982,business-contract,100,69,1/8/2020
76DD0C,executive-appointment,100,54,1/8/2020
76E80F,executive-appointment,100,54,1/8/2020
773A17,conference-participant,100,50,1/8/2020
7A975D,earnings,100,50,1/8/2020
7A975D,earnings,100,50,1/8/2020
7A975D,earnings,100,50,1/8/2020
7F7464,clinical-trials-start,100,64,1/8/2020
7FD8B9,conference-participant,100,50,1/8/2020
7FEEE1,conference-participant,100,50,1/8/2020
8.10E+32,earnings,100,50,1/8/2020
8.22E+27,conference-call,100,50,1/8/2020
83A065,public-offering,100,43,1/8/2020
83B1C8,conference-participant,100,50,1/8/2020
86478F,earnings,100,50,1/8/2020
8C5519,acquisition-completed-acquirer,100,49,1/8/2020
8D4486,partnership,100,61,1/8/2020
8D4486,partnership,100,61,1/8/2020
8D4486,partnership,100,61,1/8/2020
911AB8,earnings,100,50,1/8/2020
91C82E,earnings-per-share-positive,100,69,1/8/2020
91C82E,earnings-per-share-positive,100,69,1/8/2020
91C82E,earnings-per-share-positive,100,69,1/8/2020
91C82E,earnings-per-share-positive,100,69,1/8/2020
92D757,partnership,100,61,1/8/2020
9.31E+77,conference-participant,100,50,1/8/2020
945DE6,acquisition-acquirer,100,49,1/8/2020
94C0B5,conference-call,100,50,1/8/2020
97693A,executive-appointment,100,54,1/8/2020
977A1E,conference-call,100,50,1/8/2020
990AD0,earnings,100,50,1/8/2020
9978F1,public-offering,100,43,1/8/2020
99B61C,patient-enrollment-start,100,58,1/8/2020
9B71A7,earnings,100,50,1/8/2020
9B71A7,earnings,100,50,1/8/2020
9B71A7,earnings,100,50,1/8/2020
9C8BC3,award,100,58,1/8/2020
9CE4C7,earnings,100,50,1/8/2020
9E5C2C,note-sale,100,52,1/8/2020
9F71E5,partnership,100,61,1/8/2020
A1E3B3,product-release,100,64,1/8/2020
A1E3B3,product-release,100,64,1/8/2020
A48593,conference-participant,100,50,1/8/2020
A5DD24,conference-participant,100,50,1/8/2020
A60318,earnings,100,50,1/8/2020
A6213D,dividend,100,50,1/8/2020
A63387,conference-participant,100,50,1/8/2020
A6D095,conference-participant,100,50,1/8/2020
A6FC89,conference-participant,100,50,1/8/2020
A753BB,acquisition-acquirer,100,49,1/8/2020
A790A5,executive-appointment,100,54,1/8/2020
A8E72A,conference-participant,100,50,1/8/2020
AB7F05,partnership,100,61,1/8/2020
AB7F05,partnership,100,61,1/8/2020
AD23DE,partnership,100,61,1/8/2020
AD3C93,partnership,100,61,1/8/2020
AD3C93,partnership,100,61,1/8/2020
AE4125,executive-appointment,100,54,1/8/2020
B2E6B5,conference-call,100,50,1/8/2020
B303A6,legal-issues-defendant,100,22,1/8/2020
B80AD1,conference-participant,100,50,1/8/2020
B8EF97,revenues,100,50,1/8/2020
B9764A,conference-participant,100,50,1/8/2020
BC5680,legal-issues-defendant,100,22,1/8/2020
BDEC1E,public-offering,100,43,1/8/2020
BE14CF,joint-venture,100,62,1/8/2020
BFD0A7,conference-participant,100,50,1/8/2020
C0BA36,conference-participant,100,50,1/8/2020
C2609A,earnings,100,50,1/8/2020
C356AC,executive-appointment,100,54,1/8/2020
C41C25,earnings,100,50,1/8/2020
C4706C,dividend,100,50,1/8/2020
C4A432,partnership,100,61,1/8/2020
C5C137,earnings,100,50,1/8/2020
C5F463,business-contract,100,69,1/8/2020
C83B88,business-contract,100,69,1/8/2020
C83B88,executive-appointment,100,54,1/8/2020
C8A059,conference-participant,100,50,1/8/2020
C941DC,partnership,100,61,1/8/2020
C9A96E,partnership,100,61,1/8/2020
CA99D7,executive-appointment,100,54,1/8/2020
CBB77B,executive-appointment,100,54,1/8/2020
CCBBAD,executive-resignation,100,44,1/8/2020
CE5C6E,conference-participant,100,50,1/8/2020
CED4D0,investment-investor,100,55,1/8/2020
CFF15D,partnership,100,61,1/8/2020
CFF15D,partnership,100,61,1/8/2020
CFF15D,partnership,100,61,1/8/2020
D06755,earnings,100,50,1/8/2020
D17F7E,earnings,100,50,1/8/2020
D17F7E,executive-appointment,100,54,1/8/2020
D2C0B6,conference-participant,100,50,1/8/2020
D437C3,earnings,100,50,1/8/2020
D4C0CB,conference-participant,100,50,1/8/2020
D63B0F,conference-participant,100,50,1/8/2020
D6853F,conference-call,100,50,1/8/2020
D7A953,earnings,100,50,1/8/2020
D95385,conference-participant,100,50,1/8/2020
DA199F,earnings,100,50,1/8/2020
DA199F,earnings,100,50,1/8/2020
DA199F,earnings,100,50,1/8/2020
DA199F,earnings,100,50,1/8/2020
DA199F,earnings,100,50,1/8/2020
DA199F,earnings,100,50,1/8/2020
DB7FA7,conference-call,100,50,1/8/2020
DD0099,earnings,100,50,1/8/2020
DD1BA1,executive-appointment,100,54,1/8/2020
DD1BA1,executive-appointment,100,54,1/8/2020
DEF058,earnings,100,50,1/8/2020
DF6FDD,acquisition-acquiree,100,76,1/8/2020
E20392,conference-participant,100,50,1/8/2020
E30A8F,earnings,100,50,1/8/2020
E61888,dividend,100,50,1/8/2020
E68733,acquisition-acquirer,100,49,1/8/2020
E68733,acquisition-acquirer,100,49,1/8/2020
E8A49A,earnings,100,50,1/8/2020
E959F3,earnings,100,50,1/8/2020
E9E6FD,conference-call,100,50,1/8/2020
ED22DC,conference-participant,100,50,1/8/2020
ED9576,earnings,100,50,1/8/2020
F46EC9,facility-upgrade,100,65,1/8/2020
F4E882,legal-issues-defendant,100,22,1/8/2020
F58C23,conference-call,100,50,1/8/2020
F5D059,earnings,100,50,1/8/2020
F5D059,earnings,100,50,1/8/2020
F5D059,earnings,100,50,1/8/2020
F5D059,earnings,100,50,1/8/2020
F5D059,earnings,100,50,1/8/2020
F5D059,earnings,100,50,1/8/2020
F5D059,earnings,100,50,1/8/2020
F5D410,debt-extension-recipient,100,73,1/8/2020
F6E248,business-contract,100,69,1/8/2020
F7ADEB,conference-participant,100,50,1/8/2020
FACF19,earnings,100,50,1/8/2020
FCA54E,conference-participant,100,50,1/8/2020
FDC7E6,conference-call,100,50,1/8/2020
FEC475,partnership,100,61,1/8/2020
00067A,business-contract,100,69,1/9/2020
001F1B,operating-earnings,100,50,1/9/2020
00326D,earnings,100,50,1/9/2020
036C6F,revenue-up,100,60,1/9/2020
71860,earnings,100,50,1/9/2020
07EC43,award,100,58,1/9/2020
09062E,acquisition-acquirer,100,49,1/9/2020
0AAD90,conference-participant,100,50,1/9/2020
0BC853,acquisition-interest-acquirer,100,46,1/9/2020
0BC853,acquisition-acquirer,100,49,1/9/2020
0BD199,conference-participant,100,50,1/9/2020
0BF198,conference-participant,100,50,1/9/2020
0E499E,revenues,100,50,1/9/2020
0E499E,earnings,100,50,1/9/2020
0ED415,conference-call,100,50,1/9/2020
0F0440,revenues,100,50,1/9/2020
10100E,revenues,100,50,1/9/2020
1080C0,conference-participant,100,50,1/9/2020
119CB6,conference-call,100,50,1/9/2020
135B09,conference-call,100,50,1/9/2020
13C3E0,earnings,100,50,1/9/2020
152FA5,conference-participant,100,50,1/9/2020
165B86,acquisition-acquirer,100,49,1/9/2020
1782D5,note-sale,100,52,1/9/2020
17EDA5,executive-appointment,100,54,1/9/2020
1834C0,unit-acquisition-acquirer,100,49,1/9/2020
184988,reorganization,100,53,1/9/2020
1DE526,conference-call,100,50,1/9/2020
1E7785,conference-participant,100,50,1/9/2020
1F9D90,conference-call,100,50,1/9/2020
1FAF22,legal-issues-defendant,100,22,1/9/2020
228D42,investment-investor,100,55,1/9/2020
228D42,partnership,100,61,1/9/2020
228D42,partnership,100,61,1/9/2020
251988,facility-open,100,65,1/9/2020
25A6CC,legal-issues-defendant,100,22,1/9/2020
267718,business-contract,100,69,1/9/2020
27BFA1,conference-call,100,50,1/9/2020
2B9DBB,conference-call,100,50,1/9/2020
2C681C,conference-participant,100,50,1/9/2020
2C681C,conference-participant,100,50,1/9/2020
2DA92D,conference-call,100,50,1/9/2020
2E61CC,product-release,100,64,1/9/2020
30AB63,buybacks,100,74,1/9/2020
315EB0,acquisition-completed-acquirer,100,49,1/9/2020
315EB0,acquisition-completed-acquirer,100,49,1/9/2020
338544,legal-issues-defendant,100,22,1/9/2020
342218,conference-call,100,50,1/9/2020
3461CF,credit-rating-affirmation-rater,20,50,1/9/2020
3471C0,conference-call,100,50,1/9/2020
34B97A,conference-call,100,50,1/9/2020
353DBB,conference-call,100,50,1/9/2020
35557B,executive-appointment,100,54,1/9/2020
39D9DA,earnings,100,50,1/9/2020
3AAEAE,executive-appointment,100,54,1/9/2020
3B37F7,dividend,100,50,1/9/2020
3DE4D1,conference-call,100,50,1/9/2020
414FFF,executive-appointment,100,54,1/9/2020
414FFF,earnings,100,50,1/9/2020
434F38,earnings,100,50,1/9/2020
448215,public-offering,100,43,1/9/2020
4.91E+58,conference-call,100,50,1/9/2020
4.91E+58,partnership,100,61,1/9/2020
494EB9,earnings,100,50,1/9/2020
4B3DC9,executive-appointment,100,54,1/9/2020
4B5054,conference-call,100,50,1/9/2020
4BF3D6,conference-participant,100,50,1/9/2020
4D8124,earnings,100,50,1/9/2020
4F9926,executive-appointment,100,54,1/9/2020
53E575,conference-call,100,50,1/9/2020
546A9C,earnings,100,50,1/9/2020
55C9B5,partnership,100,61,1/9/2020
567F3D,conference-call,100,50,1/9/2020
56EA2B,public-offering,100,43,1/9/2020
589803,clinical-trials,100,56,1/9/2020
616E3B,conference-call,100,50,1/9/2020
619882,conference-organizer,100,57,1/9/2020
619882,conference-organizer,100,57,1/9/2020
619882,conference-organizer,100,57,1/9/2020
619882,conference-organizer,100,57,1/9/2020
619882,conference-organizer,100,57,1/9/2020
619882,conference-organizer,100,57,1/9/2020
619882,conference-organizer,100,57,1/9/2020
619882,conference-organizer,100,57,1/9/2020
619882,conference-organizer,100,57,1/9/2020
619882,conference-organizer,100,57,1/9/2020
619882,conference-organizer,100,57,1/9/2020
619882,conference-organizer,100,57,1/9/2020
619882,conference-organizer,100,57,1/9/2020
619882,conference-organizer,100,57,1/9/2020
619882,conference-organizer,100,57,1/9/2020
619882,conference-organizer,100,57,1/9/2020
619882,conference-organizer,100,57,1/9/2020
619882,conference-organizer,100,57,1/9/2020
619882,conference-organizer,100,57,1/9/2020
619882,conference-organizer,100,57,1/9/2020
619882,conference-organizer,100,57,1/9/2020
619882,conference-organizer,100,57,1/9/2020
619882,conference-organizer,100,57,1/9/2020
619882,conference-organizer,100,57,1/9/2020
619882,conference-organizer,100,57,1/9/2020
66A667,earnings,100,50,1/9/2020
6810DE,executive-appointment,100,54,1/9/2020
698FF9,executive-appointment,100,54,1/9/2020
69E8E1,legal-issues-defendant,100,22,1/9/2020
6DDA15,legal-issues-defendant,100,22,1/9/2020
6F39FC,dividend,100,50,1/9/2020
7239BB,earnings-guidance,100,50,1/9/2020
728737,dividend,100,50,1/9/2020
72CB93,conference-call,100,50,1/9/2020
72FCA3,earnings,100,50,1/9/2020
763DBE,clinical-trials-filed,100,60,1/9/2020
76F067,conference-participant,100,50,1/9/2020
7740DE,same-store-sales,100,50,1/9/2020
7B9212,revenues,100,50,1/9/2020
7BC92D,credit-extension-recipient,100,69,1/9/2020
7E1D5D,acquisition-acquirer,100,49,1/9/2020
7E2DE6,earnings,100,50,1/9/2020
80D744,conference-call,100,50,1/9/2020
82C202,earnings,100,50,1/9/2020
859281,earnings,100,50,1/9/2020
85DE00,conference-call,100,50,1/9/2020
873DB9,conference-call,100,50,1/9/2020
89F693,dividend,100,50,1/9/2020
8AB85C,public-offering,100,43,1/9/2020
8B6E7E,conference-call,100,50,1/9/2020
8B8656,product-release,100,64,1/9/2020
8BE916,earnings,100,50,1/9/2020
8C6C1B,executive-resignation,100,44,1/9/2020
8D4486,partnership,100,61,1/9/2020
8D4486,partnership,100,61,1/9/2020
91C82E,dividend-up,100,81,1/9/2020
922F0C,earnings,100,50,1/9/2020
925759,executive-appointment,100,54,1/9/2020
93965C,conference-participant,100,50,1/9/2020
958938,conference-participant,100,50,1/9/2020
9.74E+08,earnings,100,50,1/9/2020
9C8664,conference-call,100,50,1/9/2020
9E575E,conference-participant,100,50,1/9/2020
9EF4CF,business-contract,100,69,1/9/2020
A01664,earnings,100,50,1/9/2020
A15C71,note-sale,100,52,1/9/2020
A433A5,conference-participant,100,50,1/9/2020
A52533,conference-participant,100,50,1/9/2020
A60318,conference-participant,100,50,1/9/2020
A63387,partnership,100,61,1/9/2020
A6828A,partnership,100,61,1/9/2020
A790A5,conference-participant,100,50,1/9/2020
AA847A,conference-call,100,50,1/9/2020
AADE0B,conference-call,100,50,1/9/2020
ABB493,public-offering,100,43,1/9/2020
AC3584,revenues,100,50,1/9/2020
AE3113,executive-appointment,100,54,1/9/2020
AEF2C3,conference-participant,100,50,1/9/2020
AFDF2E,earnings,100,50,1/9/2020
AFDF2E,earnings,100,50,1/9/2020
B04426,conference-participant,100,50,1/9/2020
B2256A,conference-call,100,50,1/9/2020
B290A2,public-offering,100,43,1/9/2020
B303A6,legal-issues-defendant,100,22,1/9/2020
BBF349,earnings,100,50,1/9/2020
BC5680,legal-issues-defendant,100,22,1/9/2020
BC5680,legal-issues-defendant,100,22,1/9/2020
BCC13E,conference-participant,100,50,1/9/2020
BE14CF,conference-call,100,50,1/9/2020
C0BA36,award,100,58,1/9/2020
C0F70B,earnings,100,50,1/9/2020
C16A8F,conference-call,100,50,1/9/2020
C32A39,conference-call,100,50,1/9/2020
C3F99F,conference-participant,100,50,1/9/2020
C4C77F,dividend,100,50,1/9/2020
C62AA4,business-contract,100,69,1/9/2020
C659EB,conference-call,100,50,1/9/2020
C66B44,conference-call,100,50,1/9/2020
C9732E,legal-issues-defendant,100,22,1/9/2020
C9D866,conference-call,100,50,1/9/2020
CA3CB9,conference-call,100,50,1/9/2020
CC35BE,product-release,100,64,1/9/2020
CCB623,executive-appointment,100,54,1/9/2020
CD051C,conference-call,100,50,1/9/2020
CDD75E,executive-appointment,100,54,1/9/2020
CE96E7,earnings,100,50,1/9/2020
CFF97C,partnership,100,61,1/9/2020
D07B07,revenues,100,50,1/9/2020
D08D2C,dividend,100,50,1/9/2020
D1344A,facility-open,100,65,1/9/2020
D17C1B,earnings,100,50,1/9/2020
D3FA2C,conference-call,100,50,1/9/2020
D4070C,market-entry,100,57,1/9/2020
D4070C,market-entry,100,57,1/9/2020
D4AC65,acquisition-acquirer,100,49,1/9/2020
D7AC6E,earnings,100,50,1/9/2020
D82EF3,conference-call,100,50,1/9/2020
D8442A,revenue-volume-up,100,69,1/9/2020
D8DA3D,conference-call,100,50,1/9/2020
D90F43,conference-call,100,50,1/9/2020
DA199F,dividend-up,100,70,1/9/2020
DB06B0,earnings,100,50,1/9/2020
DC0998,executive-appointment,100,54,1/9/2020
DC0998,executive-appointment,100,54,1/9/2020
DF6FDD,earnings,100,50,1/9/2020
E074A0,earnings,100,50,1/9/2020
E124EB,conference-participant,100,50,1/9/2020
E12A6E,dividend,100,50,1/9/2020
E20BFE,revenue-up,100,69,1/9/2020
E28D9C,conference-participant,100,50,1/9/2020
E2CB7B,conference-participant,100,50,1/9/2020
E2F130,earnings,100,50,1/9/2020
E3E68E,executive-appointment,100,54,1/9/2020
E3E68E,executive-appointment,100,54,1/9/2020
EA79C7,merger-completed,100,66,1/9/2020
EB5E78,conference-call,100,50,1/9/2020
EB6965,dividend,100,50,1/9/2020
ED0402,executive-appointment,100,54,1/9/2020
EF1AD9,conference-call,100,50,1/9/2020
F209B4,earnings,100,50,1/9/2020
F209B4,earnings,100,50,1/9/2020
F30508,partnership,100,61,1/9/2020
F4E882,legal-issues-defendant,100,22,1/9/2020
F4E992,earnings-up,100,68,1/9/2020
F4E992,earnings,100,50,1/9/2020
F50BAB,conference-call,100,50,1/9/2020
F6A945,executive-appointment,100,54,1/9/2020
F6DCE4,dividend,100,50,1/9/2020
F6DE54,executive-appointment,100,54,1/9/2020
F6E248,stake-acquirer,100,48,1/9/2020
F6E248,stake-acquirer,100,48,1/9/2020
F8084B,conference-call,100,50,1/9/2020
F9AA02,executive-appointment,100,54,1/9/2020
FAAFA2,partnership,100,61,1/9/2020
FC1F9D,partnership,100,61,1/9/2020
FD4588,conference-participant,100,50,1/9/2020
FEC475,legal-issues-defendant,100,22,1/9/2020
FEC475,conference-call,100,50,1/9/2020
00326E,conference-call,100,50,1/10/2020
0490C6,business-contract,100,69,1/10/2020
078D52,dividend,100,50,1/10/2020
95294,joint-venture,100,62,1/10/2020
95294,joint-venture,100,62,1/10/2020
95294,joint-venture,100,62,1/10/2020
0A7650,conference-call,100,50,1/10/2020
0C4131,conference-call,100,50,1/10/2020
0CADBC,dividend,100,50,1/10/2020
106394,executive-appointment,100,54,1/10/2020
1DE526,conference-participant,100,50,1/10/2020
21022F,conference-call,100,50,1/10/2020
228D42,partnership,100,61,1/10/2020
267718,partnership,100,61,1/10/2020
26F99F,partnership,100,61,1/10/2020
279916,executive-appointment,100,54,1/10/2020
2.89E+11,dividend,100,50,1/10/2020
2B7A40,conference-call,100,50,1/10/2020
2BBE62,earnings,100,50,1/10/2020
2BF36E,conference-participant,100,50,1/10/2020
2CB4C9,earnings,100,50,1/10/2020
2DB344,earnings,100,50,1/10/2020
309922,conference-call,100,50,1/10/2020
328250,conference-call,100,50,1/10/2020
34B97A,acquisition-acquirer,100,49,1/10/2020
3.50E+27,conference-call,100,50,1/10/2020
36C09B,conference-participant,100,50,1/10/2020
370C50,conference-call,100,50,1/10/2020
39FB23,product-release,100,64,1/10/2020
3A1C46,earnings,100,50,1/10/2020
4.00E+163,conference-call,100,50,1/10/2020
43A74A,conference-participant,100,50,1/10/2020
44A4FC,partnership,100,61,1/10/2020
4A6F00,partnership,100,61,1/10/2020
4A6F00,partnership,100,61,1/10/2020
4A6F00,partnership,100,61,1/10/2020
4A6F00,business-contract,100,69,1/10/2020
4D971D,conference-call,100,50,1/10/2020
5088A5,acquisition-acquiree,100,76,1/10/2020
51B442,earnings,100,50,1/10/2020
51D876,earnings,100,50,1/10/2020
539F49,partnership,100,61,1/10/2020
539F49,clinical-trials-filed,100,60,1/10/2020
5546DA,conference-call,100,50,1/10/2020
5675EB,earnings,100,50,1/10/2020
589803,earnings,100,50,1/10/2020
59B229,partnership,100,61,1/10/2020
5D41E4,conference-participant,100,50,1/10/2020
619882,conference-organizer,100,57,1/10/2020
619882,conference-organizer,100,57,1/10/2020
619882,conference-organizer,100,57,1/10/2020
619882,conference-organizer,100,57,1/10/2020
619882,conference-organizer,100,57,1/10/2020
619882,conference-organizer,100,57,1/10/2020
619882,conference-organizer,100,57,1/10/2020
6D0CAB,dividend,100,50,1/10/2020
6F5DD2,conference-participant,100,50,1/10/2020
70FCEF,executive-appointment,100,54,1/10/2020
76959C,legal-issues-defendant,100,22,1/10/2020
7B0BA6,award,100,58,1/10/2020
7D5384,executive-appointment,100,54,1/10/2020
835C86,conference-participant,100,50,1/10/2020
88350F,conference-call,100,50,1/10/2020
8AB85C,public-offering,100,43,1/10/2020
8B2C4A,conference-call,100,50,1/10/2020
8E0E32,earnings,100,50,1/10/2020
8E4F9A,conference-participant,100,50,1/10/2020
91C82E,partnership,100,61,1/10/2020
925759,clinical-trials-start,100,64,1/10/2020
93F143,earnings,100,50,1/10/2020
94637C,partnership,100,61,1/10/2020
97AF94,dividend,100,50,1/10/2020
980C14,dividend,100,50,1/10/2020
9978F1,public-offering,100,43,1/10/2020
9CF9B1,earnings,100,50,1/10/2020
9E298A,conference-call,100,50,1/10/2020
9F5997,asset-sale,100,62,1/10/2020
A01983,dividend,100,50,1/10/2020
A02FB1,conference-call,100,50,1/10/2020
A072C4,business-contract,100,69,1/10/2020
A1A317,conference-call,100,50,1/10/2020
A1E3B3,conference-participant,100,50,1/10/2020
A1EAC8,executive-appointment,100,54,1/10/2020
A41450,dividend,100,50,1/10/2020
A4A612,earnings,100,50,1/10/2020
A65325,conference-call,100,50,1/10/2020
A6828A,fast-track-designation,100,81,1/10/2020
A6FE1C,acquisition-acquirer,100,49,1/10/2020
AADE0B,stake-acquirer,100,48,1/10/2020
AE0CCE,revenue-guidance,100,50,1/10/2020
B09B1F,executive-appointment,100,54,1/10/2020
B7BBFF,dividend,100,50,1/10/2020
B7EB38,earnings,100,50,1/10/2020
B9764A,earnings,100,50,1/10/2020
BAD9EA,merger-completed,100,66,1/10/2020
BB127B,revenue-up,100,58,1/10/2020
BBBB41,conference-call,100,50,1/10/2020
BD15E8,earnings,100,50,1/10/2020
BD8517,executive-appointment,100,54,1/10/2020
C36189,rights-issue,100,43,1/10/2020
C85A72,unit-acquisition-acquirer,100,49,1/10/2020
CC6FF5,earnings,100,50,1/10/2020
CFF97C,unit-acquisition-completed-acquirer,100,49,1/10/2020
CFF97C,acquisition-completed-acquirer,100,49,1/10/2020
D1173F,conference-call,100,50,1/10/2020
D501DC,dividend-up,100,54,1/10/2020
D6144F,conference-participant,100,50,1/10/2020
E35610,business-contract,100,69,1/10/2020
E4158B,earnings,100,50,1/10/2020
E592F0,earnings,100,50,1/10/2020
E6D89E,partnership,100,61,1/10/2020
E6D89E,patent-infringement-plaintiff,100,47,1/10/2020
F294DD,earnings,100,50,1/10/2020
F30508,acquisition-acquirer,100,49,1/10/2020
F30508,acquisition-acquirer,100,49,1/10/2020
F7902B,earnings,100,50,1/10/2020
FE609F,acquisition-completed-acquirer,100,49,1/10/2020
FF4343,conference-call,100,50,1/10/2020
FF5413,earnings,100,50,1/10/2020
0157B1,partnership,100,61,1/11/2020
0157B1,partnership,100,61,1/11/2020
0157B1,partnership,100,61,1/11/2020
25A6CC,legal-issues-defendant,100,22,1/11/2020
4A6F00,partnership,100,61,1/11/2020
4A6F00,partnership,100,61,1/11/2020
4A6F00,partnership,100,61,1/11/2020
6DDA15,legal-issues-defendant,100,22,1/11/2020
B303A6,legal-issues-defendant,100,22,1/11/2020
BC5680,legal-issues-defendant,100,22,1/11/2020
FEC475,legal-issues-defendant,100,22,1/11/2020
31025,partnership,100,61,1/12/2020
1FAF22,legal-issues-defendant,100,22,1/12/2020
1FAF22,revenue-guidance,100,50,1/12/2020
267718,business-contract,100,69,1/12/2020
4A6F00,partnership,100,61,1/12/2020
B604DF,merger,100,66,1/12/2020
B604DF,merger,100,66,1/12/2020
C951A2,earnings,100,50,1/12/2020
F179ED,partnership,100,61,1/12/2020
0142B5,conference-call,100,50,1/13/2020
01D03F,executive-appointment,100,54,1/13/2020
01D03F,partnership,100,61,1/13/2020
01D03F,partnership,100,61,1/13/2020
070B45,product-release,100,64,1/13/2020
71860,product-release,100,64,1/13/2020
07EC43,conference-call,100,50,1/13/2020
095A04,partnership,100,61,1/13/2020
0A0D9E,conference-call,100,50,1/13/2020
0B2071,acquisition-completed-acquirer,100,49,1/13/2020
0BC853,merger,100,66,1/13/2020
0BC853,merger,100,66,1/13/2020
0C355F,revenue-guidance-up,100,83,1/13/2020
0C466B,executive-appointment,100,54,1/13/2020
10AE08,earnings,100,50,1/13/2020
1A2D9F,executive-appointment,100,54,1/13/2020
1AB808,revenue-up,100,72,1/13/2020
1AD9CC,revenues,100,50,1/13/2020
1BDB2A,conference-call,100,50,1/13/2020
1F19C8,hirings,100,65,1/13/2020
1FAF22,legal-issues-defendant,100,22,1/13/2020
21D903,revenues,100,50,1/13/2020
228D42,partnership,100,61,1/13/2020
24A89A,clinical-trials-start,100,64,1/13/2020
24A89A,clinical-trials-start,100,64,1/13/2020
251988,product-release,100,64,1/13/2020
251988,partnership,100,61,1/13/2020
25A6CC,legal-issues-defendant,100,22,1/13/2020
267718,business-contract,100,69,1/13/2020
26F31D,executive-appointment,100,54,1/13/2020
26F99F,acquisition-acquirer,100,49,1/13/2020
284289,conference-call,100,50,1/13/2020
2A1009,earnings,100,50,1/13/2020
2AA6A8,partnership,100,61,1/13/2020
2CC60C,earnings-guidance-meet-expectations,100,59,1/13/2020
2EBA55,dividend,100,50,1/13/2020
2FEA66,dividend,100,50,1/13/2020
30DFD3,earnings-guidance-meet-expectations,100,59,1/13/2020
315EB0,conference-call,100,50,1/13/2020
32F943,executive-appointment,100,54,1/13/2020
338544,legal-issues-defendant,100,22,1/13/2020
35557B,note-sale,100,52,1/13/2020
3B20AB,executive-appointment,100,54,1/13/2020
3F4497,conference-call,100,50,1/13/2020
420168,earnings,100,50,1/13/2020
43A060,market-entry,100,57,1/13/2020
450ECB,conference-call,100,50,1/13/2020
4591D3,conference-call,100,50,1/13/2020
45BC35,earnings,100,50,1/13/2020
467F2C,earnings,100,50,1/13/2020
4.91E+58,executive-appointment,100,54,1/13/2020
49A344,conference-participant,100,50,1/13/2020
4A5C8D,conference-participant,100,50,1/13/2020
4A6F00,partnership,100,61,1/13/2020
504FE2,partnership,100,61,1/13/2020
504FE2,partnership,100,61,1/13/2020
5088A5,earnings,100,50,1/13/2020
510EA6,acquisition-acquirer,100,49,1/13/2020
514067,revenues,100,50,1/13/2020
5340D0,conference-organizer,100,57,1/13/2020
53F491,earnings,100,50,1/13/2020
5.43E+08,conference-participant,100,50,1/13/2020
54512F,award,100,58,1/13/2020
5.47E+28,clinical-trials,100,56,1/13/2020
564F3E,earnings,100,50,1/13/2020
59DB8C,executive-appointment,100,54,1/13/2020
5A423F,earnings,100,50,1/13/2020
5BE42C,conference-call,100,50,1/13/2020
5D0337,earnings,100,50,1/13/2020
610D47,conference-call,100,50,1/13/2020
619882,conference-organizer,100,57,1/13/2020
619882,conference-organizer,100,57,1/13/2020
619882,conference-organizer,100,57,1/13/2020
619882,conference-organizer,100,57,1/13/2020
619882,conference-organizer,100,57,1/13/2020
619882,conference-organizer,100,57,1/13/2020
619882,conference-organizer,100,57,1/13/2020
636BBF,executive-appointment,100,54,1/13/2020
665D7D,conference-call,100,50,1/13/2020
66667F,executive-appointment,100,54,1/13/2020
67B923,revenues,100,50,1/13/2020
698FF9,earnings,100,50,1/13/2020
69C99E,business-contract,100,69,1/13/2020
6B0E45,conference-call,100,50,1/13/2020
6CC55E,business-contract,100,69,1/13/2020
6CC55E,business-contract,100,69,1/13/2020
6D6B40,earnings,100,50,1/13/2020
6F22E7,executive-appointment,100,54,1/13/2020
7032D0,earnings,100,50,1/13/2020
71553E,revenues,100,50,1/13/2020
73C521,dividend,100,50,1/13/2020
76959C,executive-appointment,100,54,1/13/2020
76F067,partnership,100,61,1/13/2020
76F067,partnership,100,61,1/13/2020
7823A3,earnings,100,50,1/13/2020
78F776,revenues,100,50,1/13/2020
7AB859,executive-appointment,100,54,1/13/2020
7B0BA6,earnings,100,50,1/13/2020
7E1D5D,unit-acquisition-completed-acquirer,100,49,1/13/2020
7E62B5,conference-call,100,50,1/13/2020
7F3665,revenues,100,50,1/13/2020
7F3669,earnings,100,50,1/13/2020
81222C,earnings,100,50,1/13/2020
819492,regulatory-product-approval-granted,100,81,1/13/2020
82C202,business-contract,100,69,1/13/2020
859281,acquisition-completed-acquirer,100,49,1/13/2020
85DA04,executive-appointment,100,54,1/13/2020
862941,earnings-guidance,100,50,1/13/2020
862941,earnings-guidance,100,50,1/13/2020
8665BA,business-contract,100,69,1/13/2020
86A1B9,partnership,100,61,1/13/2020
89F693,unit-acquisition-acquiree,100,76,1/13/2020
8A8E41,award,100,58,1/13/2020
8A8E41,award,100,58,1/13/2020
8AC65D,conference-call,100,50,1/13/2020
8D0EEA,partnership,100,61,1/13/2020
8E9CD8,earnings,100,50,1/13/2020
931AE7,clinical-trials-filed,100,60,1/13/2020
93AD2E,facility-sale,100,52,1/13/2020
9470CC,executive-appointment,100,54,1/13/2020
957A07,revenues,100,50,1/13/2020
9592FB,revenues,100,50,1/13/2020
967D92,earnings,100,50,1/13/2020
97693A,earnings-guidance,100,50,1/13/2020
9A2760,business-contract,100,69,1/13/2020
9A2760,acquisition-acquirer,100,49,1/13/2020
9CA432,conference-call,100,50,1/13/2020
9D65C1,conference-participant,100,50,1/13/2020
9F6B1A,earnings,100,50,1/13/2020
A05C43,executive-appointment,100,54,1/13/2020
A26C26,earnings,100,50,1/13/2020
A3AAA5,dividend,100,50,1/13/2020
A4F67C,earnings,100,50,1/13/2020
A6828A,partnership,100,61,1/13/2020
A6828A,partnership,100,61,1/13/2020
A746F6,conference-call,100,50,1/13/2020
A87CD6,earnings,100,50,1/13/2020
AE7D16,business-contract,100,69,1/13/2020
AE7D16,business-contract,100,69,1/13/2020
AED61E,revenue-up,100,69,1/13/2020
B0D41A,clinical-trials,100,56,1/13/2020
B13B68,conference-participant,100,50,1/13/2020
B13B68,partnership,100,61,1/13/2020
B2206F,earnings,100,50,1/13/2020
B2256A,executive-resignation,100,44,1/13/2020
B290A2,public-offering,100,43,1/13/2020
B303A6,legal-issues-defendant,100,22,1/13/2020
B4B281,revenues,100,50,1/13/2020
B4C673,executive-appointment,100,54,1/13/2020
B5734D,exchange-compliance,100,76,1/13/2020
B840EF,partnership,100,61,1/13/2020
BC5680,legal-issues-defendant,100,22,1/13/2020
BDF85E,earnings-guidance-meet-expectations,100,59,1/13/2020
BE5935,earnings,100,50,1/13/2020
C0200F,earnings,100,50,1/13/2020
C06EB6,clinical-trials-positive,100,87,1/13/2020
C07E05,revenues,100,50,1/13/2020
C188F8,regulatory-product-approval-granted,100,81,1/13/2020
C2E39B,executive-appointment,100,54,1/13/2020
C3BAE7,earnings,100,50,1/13/2020
C564E4,clinical-trials-filed,100,60,1/13/2020
C564E4,revenues,100,50,1/13/2020
C564E4,revenues,100,50,1/13/2020
C5F463,award,100,58,1/13/2020
C65004,revenues,100,50,1/13/2020
C7AE14,conference-call,100,50,1/13/2020
C98CDB,partnership,100,61,1/13/2020
CB88B3,conference-participant,100,50,1/13/2020
CBDB4D,legal-issues-plaintiff,100,44,1/13/2020
CC176E,earnings,100,50,1/13/2020
CDAF5B,conference-call,100,50,1/13/2020
CDC817,earnings,100,50,1/13/2020
CDE118,earnings,100,50,1/13/2020
CDE51C,executive-appointment,100,54,1/13/2020
CDE51C,earnings,100,50,1/13/2020
CE4E6D,note-sale,100,52,1/13/2020
CE4FD9,conference-participant,100,50,1/13/2020
CE5C6E,executive-appointment,100,54,1/13/2020
CEC5B9,business-contract,100,69,1/13/2020
CEDFD5,unit-acquisition-acquirer,100,49,1/13/2020
CEDFD5,acquisition-acquirer,100,49,1/13/2020
CF6A5A,executive-appointment,100,54,1/13/2020
CF6A5A,earnings,100,50,1/13/2020
CFF97C,conference-call,100,50,1/13/2020
D17C1B,revenue-volume,100,50,1/13/2020
D29B44,earnings,100,50,1/13/2020
D42DBA,revenues,100,50,1/13/2020
D65A13,revenue-up,100,60,1/13/2020
DD682D,earnings,100,50,1/13/2020
E12A6E,public-offering,100,43,1/13/2020
E2F130,dividend,100,50,1/13/2020
E30B34,earnings,100,50,1/13/2020
E30B34,earnings,100,50,1/13/2020
E3E68E,conference-call,100,50,1/13/2020
E3E68E,conference-call,100,50,1/13/2020
E6D89E,partnership,100,61,1/13/2020
E6D89E,partnership,100,61,1/13/2020
E6D89E,product-release,100,64,1/13/2020
E6D89E,earnings,100,50,1/13/2020
E74B55,partnership,100,61,1/13/2020
EA62FC,conference-call,100,50,1/13/2020
EB1E1A,partnership,100,61,1/13/2020
ECA300,same-store-sales,100,50,1/13/2020
EF25A5,earnings,100,50,1/13/2020
EFA7B2,revenues,100,50,1/13/2020
F1EB39,conference-participant,100,50,1/13/2020
F3FCC3,earnings,100,50,1/13/2020
F48947,revenues,100,50,1/13/2020
F4E882,legal-issues-defendant,100,22,1/13/2020
F4E992,conference-participant,100,50,1/13/2020
F5349B,product-release,100,64,1/13/2020
F5C78B,earnings,100,50,1/13/2020
F93C8A,dividend,100,50,1/13/2020
F93C8A,unit-acquisition-completed-acquiree,100,67,1/13/2020
FACF19,conference-participant,100,50,1/13/2020
FDF799,legal-issues-defendant,100,22,1/13/2020
02870F,facility-open,100,65,1/14/2020
02ACBD,unit-acquisition-acquiree,100,76,1/14/2020
03B431,conference-call,100,50,1/14/2020
03FAA6,earnings,100,50,1/14/2020
06A456,reorganization,100,53,1/14/2020
07C69F,conference-call,100,50,1/14/2020
95294,executive-appointment,100,54,1/14/2020
09DE1F,partnership,100,61,1/14/2020
0A77DB,award,100,58,1/14/2020
0DE3D5,merger-completed,100,66,1/14/2020
0DE3D5,merger-completed,100,66,1/14/2020
10943B,conference-call,100,50,1/14/2020
1151F4,executive-appointment,100,54,1/14/2020
1220D2,unit-acquisition-acquirer,100,49,1/14/2020
1220D2,unit-acquisition-acquirer,100,49,1/14/2020
1220D2,earnings,100,50,1/14/2020
17EDA5,acquisition-acquirer,100,49,1/14/2020
190B91,earnings,100,50,1/14/2020
1D9E55,earnings,100,50,1/14/2020
1DA44F,conference-call,100,50,1/14/2020
1DF15D,conference-call,100,50,1/14/2020
1E1125,executive-appointment,100,54,1/14/2020
1EBF8D,partnership,100,61,1/14/2020
1EBF8D,partnership,100,61,1/14/2020
1FAF22,legal-issues-defendant,100,22,1/14/2020
228D42,partnership,100,61,1/14/2020
228D42,partnership,100,61,1/14/2020
232053,earnings,100,50,1/14/2020
25A6CC,legal-issues-defendant,100,22,1/14/2020
267718,partnership,100,61,1/14/2020
26CC63,board-meeting,100,51,1/14/2020
292388,partnership,100,61,1/14/2020
2950FF,conference-call,100,50,1/14/2020
2950FF,conference-call,100,50,1/14/2020
2E61CC,dividend,100,50,1/14/2020
2F1299,conference-call,100,50,1/14/2020
315EB0,partnership,100,61,1/14/2020
3461CF,business-contract,100,69,1/14/2020
387541,dividend-up,100,62,1/14/2020
39FB23,revenue-guidance-up,100,83,1/14/2020
3A113F,revenues,100,50,1/14/2020
3B20AB,dividend,100,50,1/14/2020
3CBA2A,conference-call,100,50,1/14/2020
3ED92D,earnings-guidance,100,50,1/14/2020
3F6A9C,executive-appointment,100,54,1/14/2020
4.03E+05,conference-call,100,50,1/14/2020
442587,business-contract,100,69,1/14/2020
448215,public-offering,100,43,1/14/2020
458D2C,legal-issues-defendant,100,22,1/14/2020
46A16E,conference-call,100,50,1/14/2020
47BA98,earnings,100,50,1/14/2020
49A344,business-contract,100,69,1/14/2020
4A6F00,partnership,100,61,1/14/2020
4A6F00,partnership,100,61,1/14/2020
50070E,product-release,100,64,1/14/2020
5225A4,conference-call,100,50,1/14/2020
525A1C,earnings,100,50,1/14/2020
58CA9A,earnings,100,50,1/14/2020
5AA3B1,revenue-guidance,100,50,1/14/2020
5E9934,earnings,100,50,1/14/2020
6.18E+08,earnings,100,50,1/14/2020
619882,earnings,100,50,1/14/2020
66E04A,earnings,100,50,1/14/2020
6B494E,dividend-up,100,81,1/14/2020
6BF593,earnings,100,50,1/14/2020
6C4D2F,conference-call,100,50,1/14/2020
6C6D73,patent-awarded,100,72,1/14/2020
6DDA15,legal-issues-defendant,100,22,1/14/2020
6DDA15,legal-issues-defendant,100,22,1/14/2020
71E2EF,facility-open,100,65,1/14/2020
73BCBA,product-release,100,64,1/14/2020
762A3E,conference-call,100,50,1/14/2020
773A17,earnings,100,50,1/14/2020
7A975D,dividend,100,50,1/14/2020
7ACD98,award,100,58,1/14/2020
7F3FBC,acquisition-acquirer,100,49,1/14/2020
810FAD,executive-appointment,100,54,1/14/2020
837C04,conference-call,100,50,1/14/2020
8AB85C,public-offering,100,43,1/14/2020
8CF6DD,executive-appointment,100,54,1/14/2020
8DBBE6,conference-call,100,50,1/14/2020
8E0E32,dividend,100,50,1/14/2020
8FE7A5,earnings,100,50,1/14/2020
8FE7A5,business-contract,100,69,1/14/2020
8FE7A5,business-contract,100,69,1/14/2020
8FE7A5,business-contract,100,69,1/14/2020
915E7B,conference-call,100,50,1/14/2020
950AB7,earnings,100,50,1/14/2020
98CEBB,partnership,100,61,1/14/2020
9978F1,public-offering,100,43,1/14/2020
99ACAD,executive-appointment,100,54,1/14/2020
9A602D,conference-call,100,50,1/14/2020
9E0811,earnings,100,50,1/14/2020
9EBAFA,dividend-up,100,81,1/14/2020
A350C1,conference-call,100,50,1/14/2020
A4386C,conference-call,100,50,1/14/2020
A43906,conference-call,100,50,1/14/2020
A47F2E,earnings,100,50,1/14/2020
A5628C,executive-appointment,100,54,1/14/2020
A6213D,earnings,100,50,1/14/2020
A74F6F,conference-call,100,50,1/14/2020
A868C9,conference-call,100,50,1/14/2020
AA98ED,conference-call,100,50,1/14/2020
ABB493,executive-appointment,100,54,1/14/2020
B1B10C,conference-call,100,50,1/14/2020
B1DF3C,earnings,100,50,1/14/2020
B1FC3B,business-contract,100,69,1/14/2020
B303A6,legal-issues-defendant,100,22,1/14/2020
B54A74,earnings,100,50,1/14/2020
B8DD94,conference-call,100,50,1/14/2020
B98EFA,earnings,100,50,1/14/2020
BB0587,conference-call,100,50,1/14/2020
BC5680,legal-issues-defendant,100,22,1/14/2020
BFCACF,conference-call,100,50,1/14/2020
BFEA04,partnership,100,61,1/14/2020
C0030A,earnings,100,50,1/14/2020
C3BAE7,acquisition-completed-acquirer,100,49,1/14/2020
C66B44,product-release,100,64,1/14/2020
C6C702,partnership,100,61,1/14/2020
C6C702,partnership,100,61,1/14/2020
C7859D,earnings-up,100,68,1/14/2020
C7859D,earnings-up,100,68,1/14/2020
C7859D,earnings-up,100,68,1/14/2020
C7859D,earnings-up,100,68,1/14/2020
C7859D,earnings-up,100,68,1/14/2020
C7859D,earnings-up,100,68,1/14/2020
C7859D,public-offering,100,43,1/14/2020
C8257F,executive-appointment,100,54,1/14/2020
C97B2D,revenues,100,50,1/14/2020
CC339B,earnings,100,50,1/14/2020
CC6FF5,partnership,100,61,1/14/2020
CC8F6E,executive-appointment,100,54,1/14/2020
D70365,earnings,100,50,1/14/2020
D7918D,conference-call,100,50,1/14/2020
DCD97F,conference-call,100,50,1/14/2020
DD682D,dividend,100,50,1/14/2020
E10D31,facility-close,100,47,1/14/2020
E35610,conference-call,100,50,1/14/2020
E592F0,partnership,100,61,1/14/2020
E6E012,earnings,100,50,1/14/2020
E6E012,earnings,100,50,1/14/2020
E70531,partnership,100,61,1/14/2020
E8846E,earnings,100,50,1/14/2020
EAA0A7,earnings,100,50,1/14/2020
ECDEB2,earnings,100,50,1/14/2020
EEA6B3,earnings,100,50,1/14/2020
EEA6B3,executive-resignation,100,44,1/14/2020
F02D0A,earnings,100,50,1/14/2020
F32F88,conference-call,100,50,1/14/2020
F4E882,legal-issues-defendant,100,22,1/14/2020
F4E882,legal-issues-defendant,100,22,1/14/2020
F5D410,debt-extension-recipient,100,73,1/14/2020
FC1B7B,executive-resignation,100,44,1/14/2020
FD1312,earnings,100,50,1/14/2020
FDF28E,earnings,100,50,1/14/2020
FEC475,legal-issues-defendant,100,22,1/14/2020
003B70,dividend-up,100,81,1/15/2020
034B61,partnership,100,61,1/15/2020
03FAA6,partnership,100,61,1/15/2020
48590,earnings,100,50,1/15/2020
083F72,conference-call,100,50,1/15/2020
09F623,dividend-up,100,81,1/15/2020
0C2A0D,earnings,100,50,1/15/2020
0C6293,executive-appointment,100,54,1/15/2020
0C6293,executive-appointment,100,54,1/15/2020
0C6293,executive-appointment,100,54,1/15/2020
0C6861,dividend,100,50,1/15/2020
0FDE97,conference-call,100,50,1/15/2020
11074E,conference-call,100,50,1/15/2020
12A3A3,partnership,100,61,1/15/2020
1CD708,executive-appointment,100,54,1/15/2020
1FAF22,conference-participant,100,50,1/15/2020
1FAF22,legal-issues-defendant,100,22,1/15/2020
1FE3CB,earnings,100,50,1/15/2020
205AD5,earnings,100,50,1/15/2020
205AD5,earnings,100,50,1/15/2020
205AD5,earnings,100,50,1/15/2020
205AD5,earnings,100,50,1/15/2020
20D00A,earnings,100,50,1/15/2020
2.45E+15,earnings,100,50,1/15/2020
24A89A,patent-awarded,100,72,1/15/2020
250BEE,dividend,100,50,1/15/2020
2720AB,conference-call,100,50,1/15/2020
27B191,conference-call,100,50,1/15/2020
28DCA8,executive-appointment,100,54,1/15/2020
2.90E+62,earnings,100,50,1/15/2020
2E1322,partnership,100,61,1/15/2020
2F960F,conference-participant,100,50,1/15/2020
315EB0,partnership,100,61,1/15/2020
31666F,dividend,100,50,1/15/2020
3.30E+34,earnings-up,100,68,1/15/2020
3.30E+34,earnings-up,100,68,1/15/2020
3.30E+34,earnings-up,100,68,1/15/2020
35F4B5,conference-call,100,50,1/15/2020
366A08,note-sale,100,52,1/15/2020
3696BF,conference-call,100,50,1/15/2020
37020C,conference-call,100,50,1/15/2020
3C11C4,product-release,100,64,1/15/2020
3CCC90,executive-appointment,100,54,1/15/2020
3DDE54,note-sale,100,52,1/15/2020
416291,dividend,100,50,1/15/2020
435ACE,conference-call,100,50,1/15/2020
444CC8,conference-call,100,50,1/15/2020
447FC6,conference-call,100,50,1/15/2020
44A4FC,earnings,100,50,1/15/2020
44ED36,earnings,100,50,1/15/2020
458D2C,revenue-volume,100,50,1/15/2020
4649D5,executive-appointment,100,54,1/15/2020
4A6F00,partnership,100,61,1/15/2020
4B3676,earnings,100,50,1/15/2020
4BBA23,conference-call,100,50,1/15/2020
4C7DB5,earnings,100,50,1/15/2020
4E3D15,facility-sale,100,52,1/15/2020
4FCC78,dividend,100,50,1/15/2020
504FE2,partnership,100,61,1/15/2020
53C421,conference-call,100,50,1/15/2020
589F5A,dividend,100,50,1/15/2020
58CA9A,dividend,100,50,1/15/2020
59DB8C,partnership,100,61,1/15/2020
5C8D61,earnings,100,50,1/15/2020
5F1B7B,earnings,100,50,1/15/2020
605F40,conference-call,100,50,1/15/2020
6166D1,earnings,100,50,1/15/2020
619882,dividend,100,50,1/15/2020
61B81B,earnings-positive,100,69,1/15/2020
61B81B,earnings-positive,100,69,1/15/2020
61B81B,earnings-positive,100,69,1/15/2020
61B81B,earnings-positive,100,69,1/15/2020
61B81B,earnings-positive,100,69,1/15/2020
61B81B,earnings-positive,100,69,1/15/2020
61B81B,earnings-positive,100,69,1/15/2020
622DBE,conference-call,100,50,1/15/2020
657097,unit-acquisition-acquirer,100,49,1/15/2020
66ECFD,dividend,100,50,1/15/2020
69345C,earnings,100,50,1/15/2020
69FDFC,executive-appointment,100,54,1/15/2020
6BD606,executive-appointment,100,54,1/15/2020
6BD606,executive-appointment,100,54,1/15/2020
6D0CAB,operating-earnings,100,50,1/15/2020
6DDA15,legal-issues-defendant,100,22,1/15/2020
746373,conference-call,100,50,1/15/2020
75F982,partnership,100,61,1/15/2020
75F982,partnership,100,61,1/15/2020
75F982,partnership,100,61,1/15/2020
75F982,partnership,100,61,1/15/2020
75F982,partnership,100,61,1/15/2020
767F86,executive-resignation,100,44,1/15/2020
775439,dividend,100,50,1/15/2020
7B0BA6,partnership,100,61,1/15/2020
7B8CB5,business-contract,100,69,1/15/2020
7C62A3,conference-call,100,50,1/15/2020
7CBC40,executive-appointment,100,54,1/15/2020
7CBC40,executive-appointment,100,54,1/15/2020
7E1542,earnings,100,50,1/15/2020
804708,partnership,100,61,1/15/2020
850779,earnings-per-share-positive,100,69,1/15/2020
850779,earnings-per-share,100,50,1/15/2020
850779,earnings-per-share,100,50,1/15/2020
850779,earnings-per-share,100,50,1/15/2020
860AB6,dividend,100,50,1/15/2020
860AB6,dividend,100,50,1/15/2020
8CF6DD,executive-appointment,100,54,1/15/2020
8D4486,business-contract,100,69,1/15/2020
9043FE,earnings,100,50,1/15/2020
9043FE,earnings,100,50,1/15/2020
90D6A5,executive-resignation,100,44,1/15/2020
911CA9,executive-appointment,100,54,1/15/2020
911CA9,executive-appointment,100,54,1/15/2020
93D207,earnings,100,50,1/15/2020
96F126,business-contract,100,69,1/15/2020
9810C0,conference-call,100,50,1/15/2020
990AD0,earnings,100,50,1/15/2020
99B61C,executive-appointment,100,54,1/15/2020
9A02C4,conference-call,100,50,1/15/2020
9B5968,dividend,100,50,1/15/2020
9B5968,dividend,100,50,1/15/2020
9F5CBB,public-offering,100,43,1/15/2020
9FF5F1,earnings,100,50,1/15/2020
A5195E,campaign-ad-release,100,59,1/15/2020
A666C8,dividend,100,50,1/15/2020
AA5C8E,earnings,100,50,1/15/2020
AD375D,business-contract,100,69,1/15/2020
AD9F1D,earnings,100,50,1/15/2020
AE3113,earnings,100,50,1/15/2020
B1A85D,business-contract,100,69,1/15/2020
B303A6,legal-issues-defendant,100,22,1/15/2020
B54A74,executive-appointment,100,54,1/15/2020
B5766D,merger,100,66,1/15/2020
B604DF,conference-call,100,50,1/15/2020
B80AD1,patient-enrollment-complete,100,64,1/15/2020
BA218A,earnings-positive,100,69,1/15/2020
BA218A,earnings-positive,100,69,1/15/2020
BA218A,earnings-positive,100,69,1/15/2020
BA218A,earnings-positive,100,69,1/15/2020
BA218A,earnings-positive,100,69,1/15/2020
BA218A,earnings-positive,100,69,1/15/2020
BAAA60,conference-call,100,50,1/15/2020
BC4876,dividend,100,50,1/15/2020
BC5680,legal-issues-defendant,100,22,1/15/2020
BD8517,earnings,100,50,1/15/2020
C3EE99,earnings,100,50,1/15/2020
C7859D,public-offering,100,43,1/15/2020
C9A96E,partnership,100,61,1/15/2020
C9D866,public-offering,100,43,1/15/2020
C9D866,public-offering,100,43,1/15/2020
CAD7D9,legal-issues-defendant,100,22,1/15/2020
CB7AB2,earnings,100,50,1/15/2020
CC6FF5,acquisition-completed-acquirer,100,49,1/15/2020
CD4DA8,executive-appointment,100,54,1/15/2020
CDD75E,business-contract,100,69,1/15/2020
CEC5B9,conference-call,100,50,1/15/2020
CF6A5A,product-release,100,64,1/15/2020
D2B9E5,partnership,100,61,1/15/2020
D56D6D,product-release,100,64,1/15/2020
D58A11,executive-appointment,100,54,1/15/2020
D58A11,earnings,100,50,1/15/2020
D5AF19,earnings,100,50,1/15/2020
D6EAA3,executive-appointment,100,54,1/15/2020
D93A25,earnings,100,50,1/15/2020
E1E36F,acquisition-acquirer,100,49,1/15/2020
E1E36F,acquisition-acquirer,100,49,1/15/2020
E1E36F,acquisition-acquirer,100,49,1/15/2020
E5752F,earnings,100,50,1/15/2020
E6A53A,earnings,100,50,1/15/2020
E6A53A,earnings,100,50,1/15/2020
EB36DE,conference-call,100,50,1/15/2020
EDF5CA,conference-call,100,50,1/15/2020
EE967B,earnings,100,50,1/15/2020
EF7163,conference-call,100,50,1/15/2020
EF77A3,dividend-up,100,57,1/15/2020
F0B877,conference-call,100,50,1/15/2020
F179ED,earnings,100,50,1/15/2020
F721A7,earnings,100,50,1/15/2020
F721A7,earnings,100,50,1/15/2020
FAEABE,earnings-per-share-positive,100,69,1/15/2020
FAEABE,earnings,100,50,1/15/2020
FAEABE,earnings,100,50,1/15/2020
FD4BBE,earnings,100,50,1/15/2020
FD9A97,earnings,100,50,1/15/2020
FDC08C,dividend,100,50,1/15/2020
00326E,executive-appointment,100,54,1/16/2020
00698D,dividend,100,50,1/16/2020
0157B1,conference-call,100,50,1/16/2020
03FB17,earnings,100,50,1/16/2020
04EB2F,earnings,100,50,1/16/2020
68396,note-sale,100,52,1/16/2020
06A456,conference-organizer,100,57,1/16/2020
070B45,award,100,58,1/16/2020
07CA6A,conference-call,100,50,1/16/2020
07CA6A,conference-call,100,50,1/16/2020
083F72,dividend,100,50,1/16/2020
0BC17A,earnings,100,50,1/16/2020
0F2BC9,business-contract,100,69,1/16/2020
10C19B,earnings,100,50,1/16/2020
1490F3,conference-call,100,50,1/16/2020
15B10D,product-release,100,64,1/16/2020
182B8C,conference-call,100,50,1/16/2020
1A6A94,dividend,100,50,1/16/2020
1E5786,earnings-above-expectations,100,88,1/16/2020
1E5786,earnings-above-expectations,100,88,1/16/2020
1E5786,earnings-above-expectations,100,88,1/16/2020
1E5786,earnings-above-expectations,100,88,1/16/2020
1E5786,earnings-above-expectations,100,88,1/16/2020
1E5786,earnings-above-expectations,100,88,1/16/2020
1EBF8D,acquisition-completed-acquirer,100,49,1/16/2020
1FAF22,legal-issues-defendant,100,22,1/16/2020
20BEEA,conference-call,100,50,1/16/2020
21022F,revenues,100,50,1/16/2020
21245F,conference-call,100,50,1/16/2020
219B21,earnings,100,50,1/16/2020
222BF9,conference-call,100,50,1/16/2020
228D42,partnership,100,61,1/16/2020
24CB56,dividend,100,50,1/16/2020
25A6CC,legal-issues-defendant,100,22,1/16/2020
25A6CC,legal-issues-defendant,100,22,1/16/2020
292388,partnership,100,61,1/16/2020
2A17B1,conference-call,100,50,1/16/2020
2BA977,conference-call,100,50,1/16/2020
2D981A,merger,100,66,1/16/2020
2DC88B,earnings,100,50,1/16/2020
2E1322,facility-open,100,65,1/16/2020
2EB88B,earnings,100,50,1/16/2020
2F7A7E,executive-appointment,100,54,1/16/2020
31666F,earnings,100,50,1/16/2020
31666F,earnings,100,50,1/16/2020
31F25C,executive-appointment,100,54,1/16/2020
32CB22,conference-call,100,50,1/16/2020
343996,dividend-up,100,81,1/16/2020
343996,dividend,100,50,1/16/2020
35AE32,executive-resignation,100,44,1/16/2020
35AE32,executive-resignation,100,44,1/16/2020
35AE32,legal-issues-defendant,100,22,1/16/2020
3696BF,partnership,100,61,1/16/2020
37727A,award,100,58,1/16/2020
39D9DA,executive-resignation,100,44,1/16/2020
39FB23,earnings,100,50,1/16/2020
39FB23,dividend,100,50,1/16/2020
3C8A04,earnings,100,50,1/16/2020
3D6933,business-contract,100,69,1/16/2020
3D6933,business-contract,100,69,1/16/2020
3DC887,earnings,100,50,1/16/2020
3DDE54,note-sale,100,52,1/16/2020
3E15F6,conference-call,100,50,1/16/2020
3FBC9B,earnings,100,50,1/16/2020
416C55,earnings,100,50,1/16/2020
449A26,earnings-positive,100,69,1/16/2020
449A26,dividend,100,50,1/16/2020
4591D3,partnership,100,61,1/16/2020
47BA98,dividend,100,50,1/16/2020
4806CE,donation,100,54,1/16/2020
4A6F00,executive-appointment,100,54,1/16/2020
4A6F00,executive-appointment,100,54,1/16/2020
4AC91D,dividend,100,50,1/16/2020
4B49CF,dividend,100,50,1/16/2020
4C6C63,product-release,100,64,1/16/2020
4D203E,earnings,100,50,1/16/2020
4D203E,earnings,100,50,1/16/2020
524CE4,conference-call,100,50,1/16/2020
53A226,earnings,100,50,1/16/2020
583A75,conference-call,100,50,1/16/2020
5A9F54,earnings,100,50,1/16/2020
5D43A7,dividend,100,50,1/16/2020
5EAA43,conference-call,100,50,1/16/2020
6137BF,conference-call,100,50,1/16/2020
622037,earnings,100,50,1/16/2020
6284B5,conference-call,100,50,1/16/2020
62EFEE,earnings,100,50,1/16/2020
6634D9,business-contract,100,69,1/16/2020
6BD606,executive-appointment,100,54,1/16/2020
6BD606,executive-appointment,100,54,1/16/2020
6D6B40,earnings-negative,100,33,1/16/2020
6DBBBC,executive-appointment,100,54,1/16/2020
6E7060,executive-appointment,100,54,1/16/2020
752A70,unit-acquisition-acquirer,100,49,1/16/2020
75F982,partnership,100,61,1/16/2020
762B8D,dividend,100,50,1/16/2020
771985,earnings,100,50,1/16/2020
78F9ED,conference-call,100,50,1/16/2020
790C34,earnings,100,50,1/16/2020
7A10FF,earnings,100,50,1/16/2020
7ACFD4,product-release,100,64,1/16/2020
7BAAE7,dividend-up,100,81,1/16/2020
7BAAE7,earnings,100,50,1/16/2020
7DC1C4,earnings,100,50,1/16/2020
82E58A,conference-call,100,50,1/16/2020
838ADD,dividend,100,50,1/16/2020
838ADD,earnings,100,50,1/16/2020
855DF7,dividend,100,50,1/16/2020
8665BA,partnership,100,61,1/16/2020
86A1B9,earnings,100,50,1/16/2020
88923D,conference-call,100,50,1/16/2020
88923D,conference-call,100,50,1/16/2020
8E8E6E,earnings,100,50,1/16/2020
92D3A0,dividend,100,50,1/16/2020
9.36E+10,business-contract,100,69,1/16/2020
96F126,product-release,100,64,1/16/2020
97644E,note-sale,100,52,1/16/2020
97644E,note-sale,100,52,1/16/2020
97AAF6,dividend,100,50,1/16/2020
98CEBB,award,100,58,1/16/2020
98CEBB,earnings,100,50,1/16/2020
99028D,conference-call,100,50,1/16/2020
9.92E+94,executive-appointment,100,54,1/16/2020
9D2790,product-release,100,64,1/16/2020
9E5C2C,conference-participant,100,50,1/16/2020
9EBAFA,acquisition-completed-acquirer,100,49,1/16/2020
9F5CBB,public-offering,100,43,1/16/2020
9FB4B7,trading-halt,100,43,1/16/2020
A1EAC8,conference-call,100,50,1/16/2020
A28C54,executive-appointment,100,54,1/16/2020
A3AAA5,conference-call,100,50,1/16/2020
A5151E,earnings,100,50,1/16/2020
A5628C,earnings-positive,100,69,1/16/2020
A5A4F5,dividend,100,50,1/16/2020
A5A4F5,dividend,100,50,1/16/2020
A5A4F5,award,100,58,1/16/2020
A70BF5,earnings,100,50,1/16/2020
A7F0A5,executive-appointment,100,54,1/16/2020
AB7726,investment-investor,100,55,1/16/2020
AECCA9,award,100,58,1/16/2020
AFF7B4,executive-appointment,100,54,1/16/2020
B13B68,partnership,100,61,1/16/2020
B2206F,executive-appointment,100,54,1/16/2020
B2DAF6,earnings,100,50,1/16/2020
B303A6,legal-issues-defendant,100,22,1/16/2020
B37FB4,executive-resignation,100,44,1/16/2020
B72BE9,conference-call,100,50,1/16/2020
BC5680,legal-issues-defendant,100,22,1/16/2020
BCC55F,partnership,100,61,1/16/2020
BF5959,patent-awarded,100,72,1/16/2020
C3BAE7,conference-participant,100,50,1/16/2020
C48574,public-offering,100,43,1/16/2020
C54140,earnings,100,50,1/16/2020
C83B88,product-release,100,64,1/16/2020
C83B88,product-release,100,64,1/16/2020
CA212F,earnings,100,50,1/16/2020
CD4DA8,executive-appointment,100,54,1/16/2020
CE4E6D,note-sale,100,52,1/16/2020
CE5C6E,fast-track-designation,100,81,1/16/2020
CEC5B9,product-release,100,64,1/16/2020
CF9054,earnings,100,50,1/16/2020
D1C0B9,earnings,100,50,1/16/2020
D2B9E5,earnings,100,50,1/16/2020
D33D8C,earnings-per-share-positive,100,69,1/16/2020
D33D8C,earnings-per-share-positive,100,69,1/16/2020
D33D8C,earnings-per-share-positive,100,69,1/16/2020
D33D8C,earnings-per-share-positive,100,69,1/16/2020
D33D8C,earnings-per-share-positive,100,69,1/16/2020
D33D8C,earnings-per-share-positive,100,69,1/16/2020
D6489C,partnership,100,61,1/16/2020
D6489C,partnership,100,61,1/16/2020
DC0998,conference-call,100,50,1/16/2020
DD7A96,conference-call,100,50,1/16/2020
E0207A,earnings,100,50,1/16/2020
E26FC3,earnings,100,50,1/16/2020
E4CE73,product-release,100,64,1/16/2020
E8846E,donation,100,54,1/16/2020
E8B315,earnings-positive,100,69,1/16/2020
EAEBF3,dividend,100,50,1/16/2020
EB61C4,conference-call,100,50,1/16/2020
EBD89A,conference-call,100,50,1/16/2020
EE74E1,earnings,100,50,1/16/2020
EF5BED,dividend,100,50,1/16/2020
EF5BED,earnings-positive,100,69,1/16/2020
EF5BED,earnings,100,50,1/16/2020
EF5BED,earnings,100,50,1/16/2020
EF5BED,earnings,100,50,1/16/2020
F24FF0,conference-call,100,50,1/16/2020
F30508,conference-call,100,50,1/16/2020
F46EC9,partnership,100,61,1/16/2020
F4F46F,executive-appointment,100,54,1/16/2020
F509E2,conference-call,100,50,1/16/2020
F88A04,earnings,100,50,1/16/2020
F8BDCE,earnings,100,50,1/16/2020
F8BDCE,earnings,100,50,1/16/2020
F8BDCE,earnings,100,50,1/16/2020
FA36A4,dividend,100,50,1/16/2020
FA918D,conference-call,100,50,1/16/2020
FB728F,dividend,100,50,1/16/2020
FEC475,legal-issues-defendant,100,22,1/16/2020
FEC475,legal-issues-defendant,100,22,1/16/2020
FF6644,legal-issues-defendant,100,22,1/16/2020
03596A,earnings,100,50,1/17/2020
95294,earnings,100,50,1/17/2020
0BB9E5,earnings,100,50,1/17/2020
0CBC4D,earnings,100,50,1/17/2020
0DE3D5,note-sale,100,52,1/17/2020
0F65C9,conference-call,100,50,1/17/2020
13C3E0,legal-issues-defendant,100,22,1/17/2020
147C38,dividend,100,50,1/17/2020
19C105,conference-call,100,50,1/17/2020
1F19C8,conference-call,100,50,1/17/2020
1FAF22,legal-issues-defendant,100,22,1/17/2020
21245F,award,100,58,1/17/2020
24C48B,conference-call,100,50,1/17/2020
25A6CC,legal-issues-defendant,100,22,1/17/2020
263216,conference-participant,100,50,1/17/2020
2F98A5,dividend,100,50,1/17/2020
3461CF,award,100,58,1/17/2020
355B19,dividend,100,50,1/17/2020
35AE32,legal-issues-defendant,100,22,1/17/2020
3BE00F,earnings,100,50,1/17/2020
3C3B6B,earnings,100,50,1/17/2020
442587,business-contract,100,69,1/17/2020
4595EF,conference-call,100,50,1/17/2020
4FCC78,executive-appointment,100,54,1/17/2020
51527B,conference-call,100,50,1/17/2020
55C9B5,partnership,100,61,1/17/2020
562853,earnings,100,50,1/17/2020
5BC2F4,earnings,100,50,1/17/2020
5D87DF,earnings,100,50,1/17/2020
647143,dividend,100,50,1/17/2020
66CB62,dividend,100,50,1/17/2020
68BA15,dividend,100,50,1/17/2020
6CDFC6,conference-call,100,50,1/17/2020
6F6559,dividend,100,50,1/17/2020
73C521,earnings,100,50,1/17/2020
73C521,earnings,100,50,1/17/2020
73C521,earnings,100,50,1/17/2020
73C521,earnings,100,50,1/17/2020
73C521,earnings,100,50,1/17/2020
741937,executive-appointment,100,54,1/17/2020
767F86,earnings,100,50,1/17/2020
7A5097,conference-call,100,50,1/17/2020
7AB859,conference-call,100,50,1/17/2020
7D5384,conference-call,100,50,1/17/2020
881190,executive-appointment,100,54,1/17/2020
900356,conference-call,100,50,1/17/2020
911ACB,earnings,100,50,1/17/2020
92D3A0,earnings,100,50,1/17/2020
9.36E+10,business-contract,100,69,1/17/2020
990AD0,dividend,100,50,1/17/2020
9981C6,earnings,100,50,1/17/2020
9D30A8,earnings,100,50,1/17/2020
9D5D35,earnings,100,50,1/17/2020
A16DEA,earnings,100,50,1/17/2020
A3BFAA,merger,100,66,1/17/2020
A3BFAA,merger,100,66,1/17/2020
A7A0BD,merger-completed,100,66,1/17/2020
A9ED24,dividend,100,50,1/17/2020
AA09AD,stake-acquiree,100,62,1/17/2020
AD23DE,business-contract,100,69,1/17/2020
AFD1CA,conference-participant,100,50,1/17/2020
AFDF2E,dividend,100,50,1/17/2020
AFEC35,public-offering,100,43,1/17/2020
AFF7B4,dividend,100,50,1/17/2020
B303A6,legal-issues-defendant,100,22,1/17/2020
B4703C,dividend,100,50,1/17/2020
BC5680,legal-issues-defendant,100,22,1/17/2020
BDD12C,market-entry,100,57,1/17/2020
BFE02C,earnings-positive,100,69,1/17/2020
C48574,public-offering,100,43,1/17/2020
CD06A2,earnings,100,50,1/17/2020
CFF15D,dividend,100,50,1/17/2020
DD3BB1,earnings,100,50,1/17/2020
E8D221,dividend,100,50,1/17/2020
EB6965,conference-call,100,50,1/17/2020
F5C8AB,earnings-guidance,100,50,1/17/2020
F82D37,earnings,100,50,1/17/2020
FEC475,legal-issues-defendant,100,22,1/17/2020
FF6644,earnings,100,50,1/17/2020
73C9E2,name-change,100,49,1/18/2020
B303A6,legal-issues-defendant,100,22,1/18/2020
BC5680,legal-issues-defendant,100,22,1/18/2020
F4E882,legal-issues-defendant,100,22,1/18/2020
16F4D8,earnings,100,50,1/20/2020
1CDD1C,conference-call,100,50,1/20/2020
2096DE,executive-appointment,100,54,1/20/2020
25A6CC,legal-issues-defendant,100,22,1/20/2020
309922,earnings,100,50,1/20/2020
34B411,fundraising,100,64,1/20/2020
367E1C,conference-call,100,50,1/20/2020
39FB23,facility-upgrade,100,65,1/20/2020
3A3447,earnings,100,50,1/20/2020
422A82,dividend,100,50,1/20/2020
442587,business-contract,100,69,1/20/2020
447FC6,product-release,100,64,1/20/2020
4A6F00,business-contract,100,69,1/20/2020
4E7C1F,executive-appointment,100,54,1/20/2020
5EC388,earnings,100,50,1/20/2020
5EC388,merger-regulatory-approval,100,81,1/20/2020
797C20,conference-call,100,50,1/20/2020
94C0B5,dividend,100,50,1/20/2020
9D2790,earnings,100,50,1/20/2020
9D4EC7,conference-call,100,50,1/20/2020
9D4EC7,conference-call,100,50,1/20/2020
A7CCF0,conference-call,100,50,1/20/2020
AA09AD,stake-acquiree,100,62,1/20/2020
BB58FF,conference-organizer,100,57,1/20/2020
BC5680,legal-issues-defendant,100,22,1/20/2020
BC5680,legal-issues-defendant,100,22,1/20/2020
BDD12C,earnings,100,50,1/20/2020
C5C0E9,conference-call,100,50,1/20/2020
D33270,acquisition-acquirer,100,49,1/20/2020
D8442A,award,100,58,1/20/2020
E124EB,partnership,100,61,1/20/2020
E90C84,conference-call,100,50,1/20/2020
EBC84C,earnings,100,50,1/20/2020
F02D0A,settlement,100,56,1/20/2020
F04E05,dividend-up,100,61,1/20/2020
F18844,executive-appointment,100,54,1/20/2020
F50BAB,dividend,100,50,1/20/2020
FAE021,earnings,100,50,1/20/2020
FAE021,earnings,100,50,1/20/2020
00067A,partnership,100,61,1/21/2020
00FC70,conference-call,100,50,1/21/2020
01D03F,regulatory-product-approval-granted,100,81,1/21/2020
55018,earnings-positive,100,69,1/21/2020
08A40F,earnings-per-share-positive,100,69,1/21/2020
08A40F,earnings-per-share-positive,100,69,1/21/2020
08A40F,earnings-per-share-positive,100,69,1/21/2020
08A40F,earnings-per-share-positive,100,69,1/21/2020
08A40F,earnings-per-share-positive,100,69,1/21/2020
08A40F,earnings-per-share-positive,100,69,1/21/2020
08A40F,earnings-per-share-positive,100,69,1/21/2020
09F623,conference-call,100,50,1/21/2020
0BA8CE,executive-appointment,100,54,1/21/2020
0C136E,earnings,100,50,1/21/2020
0C4131,earnings,100,50,1/21/2020
0CC01F,earnings,100,50,1/21/2020
0CC62B,business-contract,100,69,1/21/2020
0D26E0,dividend,100,50,1/21/2020
0DC050,earnings,100,50,1/21/2020
10100E,public-offering,100,43,1/21/2020
106394,note-sale,100,52,1/21/2020
108FDA,executive-appointment,100,54,1/21/2020
1151F4,award,100,58,1/21/2020
129DC8,executive-resignation,100,44,1/21/2020
147C38,award,100,58,1/21/2020
16FC89,dividend,100,50,1/21/2020
1748B3,earnings,100,50,1/21/2020
1748B3,earnings,100,50,1/21/2020
1748B3,earnings,100,50,1/21/2020
1748B3,earnings,100,50,1/21/2020
1748B3,earnings,100,50,1/21/2020
1748B3,earnings,100,50,1/21/2020
190B91,award,100,58,1/21/2020
1921DD,partnership,100,61,1/21/2020
1A6A94,dividend,100,50,1/21/2020
1B6F77,public-offering,100,43,1/21/2020
1E9A6D,earnings,100,50,1/21/2020
1F08A6,conference-call,100,50,1/21/2020
1F19C8,partnership,100,61,1/21/2020
1FA8F7,earnings,100,50,1/21/2020
1FAF22,legal-issues-defendant,100,22,1/21/2020
20BEEA,award,100,58,1/21/2020
214051,earnings,100,50,1/21/2020
21F9CA,earnings,100,50,1/21/2020
225CA2,conference-call,100,50,1/21/2020
228D42,partnership,100,61,1/21/2020
22C58E,partnership,100,61,1/21/2020
24C48B,business-contract,100,69,1/21/2020
24C48B,business-contract,100,69,1/21/2020
26F31D,earnings,100,50,1/21/2020
272704,earnings-positive,100,69,1/21/2020
272704,earnings,100,50,1/21/2020
272704,earnings,100,50,1/21/2020
272704,earnings,100,50,1/21/2020
272704,earnings,100,50,1/21/2020
272704,earnings,100,50,1/21/2020
272704,earnings,100,50,1/21/2020
272704,earnings,100,50,1/21/2020
282C18,earnings,100,50,1/21/2020
282C18,earnings,100,50,1/21/2020
28AF37,award,100,58,1/21/2020
2B49F4,earnings,100,50,1/21/2020
2B49F4,earnings,100,50,1/21/2020
2B49F4,earnings,100,50,1/21/2020
2B49F4,earnings,100,50,1/21/2020
2B5483,earnings,100,50,1/21/2020
2EBA55,conference-call,100,50,1/21/2020
3.14E+47,earnings,100,50,1/21/2020
326EDD,dividend,100,50,1/21/2020
33E8C7,earnings,100,50,1/21/2020
36529A,executive-appointment,100,54,1/21/2020
371B0A,conference-call,100,50,1/21/2020
373B06,earnings,100,50,1/21/2020
3.73E+87,patent-infringement-plaintiff,100,47,1/21/2020
3B37F7,conference-organizer,100,57,1/21/2020
3C7F5F,earnings,100,50,1/21/2020
3CCC90,dividend,100,50,1/21/2020
3ED92D,partnership,100,61,1/21/2020
401072,public-offering,100,43,1/21/2020
415188,conference-call,100,50,1/21/2020
41785E,earnings,100,50,1/21/2020
41B53E,investment-investor,100,55,1/21/2020
43A74A,executive-appointment,100,54,1/21/2020
467F2C,conference-call,100,50,1/21/2020
4A6F00,partnership,100,61,1/21/2020
4A6F00,partnership,100,61,1/21/2020
4BEB48,earnings,100,50,1/21/2020
4D371E,earnings,100,50,1/21/2020
4DD09F,conference-participant,100,50,1/21/2020
50070E,credit-extension-provider,100,57,1/21/2020
50070E,credit-extension-provider,100,57,1/21/2020
50070E,credit-extension-provider,100,57,1/21/2020
5225A4,earnings,100,50,1/21/2020
545272,conference-call,100,50,1/21/2020
5487B1,conference-call,100,50,1/21/2020
55CD6F,note-sale,100,52,1/21/2020
56EFC7,award,100,58,1/21/2020
57CAAB,earnings,100,50,1/21/2020
586FFD,conference-call,100,50,1/21/2020
5876DC,dividend,100,50,1/21/2020
5876DC,dividend,100,50,1/21/2020
58B46F,conference-call,100,50,1/21/2020
59B229,partnership,100,61,1/21/2020
5B226B,business-contract,100,69,1/21/2020
5B3415,conference-call,100,50,1/21/2020
5B35C7,earnings-up,100,68,1/21/2020
5B35C7,earnings-up,100,68,1/21/2020
5B35C7,earnings-up,100,68,1/21/2020
5F9CE3,award,100,58,1/21/2020
619882,conference-organizer,100,57,1/21/2020
619882,partnership,100,61,1/21/2020
61BCA7,partnership,100,61,1/21/2020
647143,earnings,100,50,1/21/2020
647143,earnings,100,50,1/21/2020
647143,earnings,100,50,1/21/2020
647143,earnings,100,50,1/21/2020
66667F,private-placement,100,56,1/21/2020
66749D,earnings,100,50,1/21/2020
66E04A,market-entry,100,57,1/21/2020
66E04A,facility-open,100,65,1/21/2020
67B923,conference-call,100,50,1/21/2020
6A01DF,earnings,100,50,1/21/2020
6A01DF,earnings,100,50,1/21/2020
6A961B,conference-call,100,50,1/21/2020
6ABCB8,earnings,100,50,1/21/2020
6B236C,conference-call,100,50,1/21/2020
6B494E,facility-upgrade,100,65,1/21/2020
6B5379,earnings,100,50,1/21/2020
6C4D2F,earnings,100,50,1/21/2020
6C4D2F,earnings,100,50,1/21/2020
6C4D2F,earnings,100,50,1/21/2020
6C4D2F,earnings,100,50,1/21/2020
6C4D2F,earnings,100,50,1/21/2020
6C4D2F,earnings,100,50,1/21/2020
6C4D2F,earnings,100,50,1/21/2020
6C4D2F,earnings,100,50,1/21/2020
6C987C,earnings-positive,100,69,1/21/2020
6CDFC6,business-contract,100,69,1/21/2020
6D1ADF,conference-call,100,50,1/21/2020
6D3B7B,earnings,100,50,1/21/2020
6D4636,conference-call,100,50,1/21/2020
6D9B53,fast-track-designation,100,81,1/21/2020
6F39FC,public-offering,100,43,1/21/2020
7255D2,conference-call,100,50,1/21/2020
72C2CE,conference-call,100,50,1/21/2020
741937,earnings,100,50,1/21/2020
756045,executive-appointment,100,54,1/21/2020
756BB4,partnership,100,61,1/21/2020
75F665,dividend,100,50,1/21/2020
75F665,earnings,100,50,1/21/2020
789A7D,conference-call,100,50,1/21/2020
7A51FE,conference-call,100,50,1/21/2020
7B6C88,conference-call,100,50,1/21/2020
7B6EB1,earnings,100,50,1/21/2020
7C4168,note-sale,100,52,1/21/2020
7C4168,note-sale,100,52,1/21/2020
7E3F8F,award,100,58,1/21/2020
804708,executive-appointment,100,54,1/21/2020
82E58A,dividend,100,50,1/21/2020
82FD6D,conference-call,100,50,1/21/2020
8303CD,conference-call,100,50,1/21/2020
855DF7,dividend,100,50,1/21/2020
87B81A,executive-appointment,100,54,1/21/2020
8802B4,dividend-up,100,81,1/21/2020
8802B4,earnings-guidance,100,50,1/21/2020
8802B4,earnings-guidance,100,50,1/21/2020
8CF6DD,earnings,100,50,1/21/2020
8D4486,earnings,100,50,1/21/2020
8D9993,conference-call,100,50,1/21/2020
8D9993,dividend,100,50,1/21/2020
8DAAB9,dividend,100,50,1/21/2020
8DDA23,dividend,100,50,1/21/2020
8E0E32,award,100,58,1/21/2020
902670,conference-call,100,50,1/21/2020
90D6A5,conference-call,100,50,1/21/2020
9196A2,executive-appointment,100,54,1/21/2020
934029,conference-call,100,50,1/21/2020
94563D,partnership,100,61,1/21/2020
95DC1F,award,100,58,1/21/2020
95DC1F,executive-appointment,100,54,1/21/2020
965360,earnings,100,50,1/21/2020
96A2D3,earnings,100,50,1/21/2020
96F126,business-contract,100,69,1/21/2020
96F126,earnings,100,50,1/21/2020
977A1E,donation,100,54,1/21/2020
979451,earnings,100,50,1/21/2020
98CAED,earnings,100,50,1/21/2020
99ACAD,business-contract,100,69,1/21/2020
99ACAD,earnings,100,50,1/21/2020
9C8664,earnings,100,50,1/21/2020
9CA4C6,dividend-up,100,81,1/21/2020
9D56F2,executive-appointment,100,54,1/21/2020
9D6A24,award,100,58,1/21/2020
9E91C6,award,100,58,1/21/2020
9E98F2,earnings,100,50,1/21/2020
9F5CBB,public-offering,100,43,1/21/2020
9F71E5,executive-resignation,100,44,1/21/2020
A0F146,conference-call,100,50,1/21/2020
A1EAC8,executive-appointment,100,54,1/21/2020
A21649,conference-call,100,50,1/21/2020
A247F5,earnings,100,50,1/21/2020
A403CF,earnings,100,50,1/21/2020
A48593,conference-call,100,50,1/21/2020
A631A3,acquisition-interest-acquirer,100,46,1/21/2020
A63387,business-contract,100,69,1/21/2020
A63387,earnings,100,50,1/21/2020
A65325,legal-issues-defendant,100,22,1/21/2020
A70BF5,conference-call,100,50,1/21/2020
A746F6,earnings-per-share-positive,100,69,1/21/2020
A746F6,earnings-per-share-positive,100,69,1/21/2020
A746F6,earnings-per-share-positive,100,69,1/21/2020
A746F6,earnings-per-share-positive,100,69,1/21/2020
A746F6,earnings-per-share-positive,100,69,1/21/2020
A746F6,earnings-per-share-positive,100,69,1/21/2020
A746F6,earnings-per-share-positive,100,69,1/21/2020
A746F6,earnings-per-share-positive,100,69,1/21/2020
A746F6,earnings-per-share-positive,100,69,1/21/2020
A746F6,earnings-per-share-positive,100,69,1/21/2020
A806FA,conference-call,100,50,1/21/2020
A8CBDA,dividend,100,50,1/21/2020
AC7C4F,award,100,58,1/21/2020
AFDF2E,buybacks,100,74,1/21/2020
B13B68,conference-call,100,50,1/21/2020
B1FC3B,business-contract,100,69,1/21/2020
B642E8,award,100,58,1/21/2020
B77F14,business-contract,100,69,1/21/2020
B7BDA3,earnings,100,50,1/21/2020
B840EF,conference-call,100,50,1/21/2020
B85DCE,executive-appointment,100,54,1/21/2020
B9CD50,earnings,100,50,1/21/2020
BC5680,legal-issues-defendant,100,22,1/21/2020
BD9668,earnings,100,50,1/21/2020
BDD12C,partnership,100,61,1/21/2020
BF5959,patent-awarded,100,72,1/21/2020
C037A8,conference-call,100,50,1/21/2020
C0F4D0,earnings,100,50,1/21/2020
C11C46,executive-appointment,100,54,1/21/2020
C2609A,award,100,58,1/21/2020
C32A39,earnings-up,100,68,1/21/2020
C32A39,earnings-up,100,68,1/21/2020
C32A39,earnings-up,100,68,1/21/2020
C32A39,earnings-up,100,68,1/21/2020
C32A39,earnings-up,100,68,1/21/2020
C32A39,earnings-up,100,68,1/21/2020
C32A39,earnings-up,100,68,1/21/2020
C32A39,earnings-up,100,68,1/21/2020
C32A39,dividend,100,50,1/21/2020
C72B8F,conference-call,100,50,1/21/2020
C98CDB,earnings,100,50,1/21/2020
C9B932,award,100,58,1/21/2020
CBCC6A,partnership,100,61,1/21/2020
CE8251,product-release,100,64,1/21/2020
CE8251,product-release,100,64,1/21/2020
CE8251,product-release,100,64,1/21/2020
CE8251,product-release,100,64,1/21/2020
D04D9F,earnings,100,50,1/21/2020
D08D2C,index-listing,100,76,1/21/2020
D1CFC8,award,100,58,1/21/2020
D33D8C,award,100,58,1/21/2020
D393DF,earnings,100,50,1/21/2020
D8760C,earnings,100,50,1/21/2020
D8760C,earnings,100,50,1/21/2020
D8760C,earnings,100,50,1/21/2020
D8760C,earnings,100,50,1/21/2020
D8760C,earnings,100,50,1/21/2020
D8760C,earnings,100,50,1/21/2020
D90F43,unit-acquisition-acquiree,100,76,1/21/2020
D9B1C9,award,100,58,1/21/2020
D9B1C9,dividend,100,50,1/21/2020
DB5CA5,award,100,58,1/21/2020
DBB28E,partnership,100,61,1/21/2020
DBCA3F,facility-relocation,100,50,1/21/2020
DD1BA1,earnings,100,50,1/21/2020
DF532D,earnings,100,50,1/21/2020
DF532D,earnings,100,50,1/21/2020
E05026,partnership,100,61,1/21/2020
E4CE73,product-release,100,64,1/21/2020
E592F0,settlement,100,56,1/21/2020
E68733,award,100,58,1/21/2020
E68733,award,100,58,1/21/2020
E68C3D,patent-infringement-defendant,100,26,1/21/2020
E70531,partnership,100,61,1/21/2020
EB7D6C,acquisition-completed-acquirer,100,49,1/21/2020
ECD263,earnings,100,50,1/21/2020
EE6F1C,business-contract,100,69,1/21/2020
EE967B,executive-appointment,100,54,1/21/2020
EF25A5,business-contract,100,69,1/21/2020
F4E882,legal-issues-defendant,100,22,1/21/2020
F57F6F,earnings,100,50,1/21/2020
F5C78B,merger,100,66,1/21/2020
F5C78B,merger,100,66,1/21/2020
F5C78B,earnings-positive,100,69,1/21/2020
F5C78B,earnings,100,50,1/21/2020
F5C78B,earnings,100,50,1/21/2020
F5C78B,earnings,100,50,1/21/2020
F5C78B,earnings,100,50,1/21/2020
F5C78B,earnings,100,50,1/21/2020
F5D499,stake-acquirer,100,48,1/21/2020
F5D499,acquisition-completed-acquirer,100,49,1/21/2020
F6E248,earnings,100,50,1/21/2020
F85CC0,executive-appointment,100,54,1/21/2020
F9CAF8,conference-call,100,50,1/21/2020
FA35C6,earnings,100,50,1/21/2020
FA36A4,dividend,100,50,1/21/2020
FA840E,earnings,100,50,1/21/2020
FADF1A,conference-call,100,50,1/21/2020
FB728F,dividend,100,50,1/21/2020
FD1312,earnings,100,50,1/21/2020
FD39EB,dividend,100,50,1/21/2020
FE1A1D,executive-appointment,100,54,1/21/2020
0142B5,dividend,100,50,1/22/2020
018C11,conference-call,100,50,1/22/2020
03D5F9,earnings,100,50,1/22/2020
43862,public-offering,100,43,1/22/2020
58828,operating-earnings,100,50,1/22/2020
06A456,earnings-guidance-down,100,19,1/22/2020
06A456,earnings-guidance-down,100,19,1/22/2020
71860,earnings,100,50,1/22/2020
07CA6A,executive-appointment,100,54,1/22/2020
07CA6A,executive-appointment,100,54,1/22/2020
0AB700,earnings,100,50,1/22/2020
0E6027,earnings-positive,100,69,1/22/2020
0E6027,earnings,100,50,1/22/2020
0ED415,investment-investor,100,55,1/22/2020
106394,note-sale,100,52,1/22/2020
1065BC,unit-acquisition-acquiree,100,76,1/22/2020
1151F4,business-contract,100,69,1/22/2020
1216D1,executive-appointment,100,54,1/22/2020
12DE76,award,100,58,1/22/2020
1348C9,conference-call,100,50,1/22/2020
159AE4,dividend,100,50,1/22/2020
159AE4,dividend,100,50,1/22/2020
165B3A,earnings-positive,100,69,1/22/2020
165B3A,earnings-positive,100,69,1/22/2020
165B3A,earnings-positive,100,69,1/22/2020
165B3A,earnings-positive,100,69,1/22/2020
16F4D8,executive-appointment,100,54,1/22/2020
1782D5,conference-call,100,50,1/22/2020
1A2D9F,earnings,100,50,1/22/2020
1A9DE1,earnings-up,100,68,1/22/2020
1A9DE1,earnings-up,100,68,1/22/2020
1A9DE1,earnings-up,100,68,1/22/2020
1B16C1,conference-call,100,50,1/22/2020
1E5786,dividend,100,50,1/22/2020
1E9A6D,dividend,100,50,1/22/2020
1FAF22,legal-issues-defendant,100,22,1/22/2020
20BEEA,earnings,100,50,1/22/2020
2.45E+15,earnings,100,50,1/22/2020
26D8ED,conference-call,100,50,1/22/2020
27C10F,earnings,100,50,1/22/2020
28DCF3,earnings-up,100,86,1/22/2020
2AE625,conference-call,100,50,1/22/2020
2CBB58,conference-call,100,50,1/22/2020
2DB344,earnings,100,50,1/22/2020
2E1322,earnings,100,50,1/22/2020
2E902B,conference-call,100,50,1/22/2020
31A7CC,earnings-up,100,68,1/22/2020
34B411,earnings,100,50,1/22/2020
34B411,earnings,100,50,1/22/2020
34B411,earnings,100,50,1/22/2020
34B411,earnings,100,50,1/22/2020
34B411,earnings,100,50,1/22/2020
34B411,earnings,100,50,1/22/2020
34B411,earnings,100,50,1/22/2020
34B411,earnings,100,50,1/22/2020
34B411,earnings,100,50,1/22/2020
34B411,earnings,100,50,1/22/2020
34B411,earnings,100,50,1/22/2020
34B411,earnings,100,50,1/22/2020
384CD3,executive-appointment,100,54,1/22/2020
39BFF6,earnings,100,50,1/22/2020
39BFF6,earnings,100,50,1/22/2020
39BFF6,earnings,100,50,1/22/2020
3ACF46,business-contract,100,69,1/22/2020
3B20AB,earnings,100,50,1/22/2020
3B37F7,earnings-guidance,100,50,1/22/2020
3CCC90,earnings,100,50,1/22/2020
423279,earnings-per-share-positive,100,69,1/22/2020
490D4B,conference-call,100,50,1/22/2020
4B49CF,earnings,100,50,1/22/2020
4C2F17,conference-participant,100,50,1/22/2020
4D971D,dividend,100,50,1/22/2020
4D971D,earnings,100,50,1/22/2020
4D971D,earnings,100,50,1/22/2020
4D971D,earnings,100,50,1/22/2020
4D971D,earnings,100,50,1/22/2020
4D971D,earnings,100,50,1/22/2020
4FB770,conference-call,100,50,1/22/2020
50070E,conference-call,100,50,1/22/2020
504FE2,conference-call,100,50,1/22/2020
520632,earnings,100,50,1/22/2020
520632,earnings,100,50,1/22/2020
520632,earnings,100,50,1/22/2020
520632,earnings,100,50,1/22/2020
520632,earnings,100,50,1/22/2020
54F1D2,executive-appointment,100,54,1/22/2020
553949,partnership,100,61,1/22/2020
55C289,earnings,100,50,1/22/2020
5675EB,dividend,100,50,1/22/2020
5675EB,operating-earnings,100,50,1/22/2020
56765E,earnings,100,50,1/22/2020
56AFF4,operating-earnings,100,50,1/22/2020
5B7739,conference-call,100,50,1/22/2020
5B97B2,earnings,100,50,1/22/2020
5C7601,business-contract,100,69,1/22/2020
5D41E4,business-contract,100,69,1/22/2020
5DA8B3,earnings,100,50,1/22/2020
5DA8B3,merger,100,66,1/22/2020
5F6D73,earnings,100,50,1/22/2020
5F6D73,earnings,100,50,1/22/2020
5F6D73,earnings,100,50,1/22/2020
5F6D73,earnings,100,50,1/22/2020
5F6D73,earnings,100,50,1/22/2020
5F9CE3,acquisition-acquirer,100,49,1/22/2020
605F40,facility-sale,100,52,1/22/2020
62B20A,conference-call,100,50,1/22/2020
66A667,legal-issues-defendant,100,22,1/22/2020
67529E,earnings,100,50,1/22/2020
67529E,earnings,100,50,1/22/2020
67529E,earnings,100,50,1/22/2020
67529E,earnings,100,50,1/22/2020
67529E,earnings,100,50,1/22/2020
67529E,earnings,100,50,1/22/2020
67529E,earnings,100,50,1/22/2020
69C99E,clinical-trials-complete,100,56,1/22/2020
69FDFC,executive-appointment,100,54,1/22/2020
6D3B7B,earnings,100,50,1/22/2020
6F0A63,conference-call,100,50,1/22/2020
6F39FC,public-offering,100,43,1/22/2020
7262F2,earnings,100,50,1/22/2020
752A70,earnings,100,50,1/22/2020
7.83E+79,earnings-up,100,68,1/22/2020
791D59,award,100,58,1/22/2020
7AC86E,earnings,100,50,1/22/2020
7B492C,conference-call,100,50,1/22/2020
7B4B91,conference-call,100,50,1/22/2020
7B4B91,dividend-up,100,81,1/22/2020
7E1D5D,partnership,100,61,1/22/2020
7F9984,index-listing,100,76,1/22/2020
8.10E+32,award,100,58,1/22/2020
8.10E+32,auditor-appointment,100,50,1/22/2020
8275FE,earnings,100,50,1/22/2020
8377DB,earnings,100,50,1/22/2020
8377DB,earnings,100,50,1/22/2020
8377DB,earnings,100,50,1/22/2020
8377DB,earnings,100,50,1/22/2020
8377DB,earnings,100,50,1/22/2020
845655,conference-call,100,50,1/22/2020
845655,conference-call,100,50,1/22/2020
85AD00,earnings,100,50,1/22/2020
85DA04,earnings,100,50,1/22/2020
8BE916,earnings-up,100,68,1/22/2020
8BE916,earnings-up,100,68,1/22/2020
8BE916,earnings-up,100,68,1/22/2020
8BE916,earnings-up,100,68,1/22/2020
8BE916,earnings-up,100,68,1/22/2020
8BE916,earnings-up,100,68,1/22/2020
8BE916,earnings-up,100,68,1/22/2020
8C1238,conference-call,100,50,1/22/2020
8C5519,earnings,100,50,1/22/2020
8CF6DD,executive-appointment,100,54,1/22/2020
8D4486,earnings,100,50,1/22/2020
8D4486,partnership,100,61,1/22/2020
8D4486,partnership,100,61,1/22/2020
8E82A6,earnings,100,50,1/22/2020
8E8E6E,award,100,58,1/22/2020
925759,clinical-trials-positive,100,87,1/22/2020
93633B,earnings,100,50,1/22/2020
93965C,conference-call,100,50,1/22/2020
93F143,earnings,100,50,1/22/2020
954A47,earnings-positive,100,69,1/22/2020
9.54E+32,product-release,100,64,1/22/2020
9.62E+76,earnings,100,50,1/22/2020
966DBE,trading-listing,100,61,1/22/2020
968103,earnings,100,50,1/22/2020
968B00,earnings,100,50,1/22/2020
97AAF6,executive-appointment,100,54,1/22/2020
97AAF6,earnings,100,50,1/22/2020
989E2F,unit-acquisition-acquirer,100,49,1/22/2020
9.92E+94,earnings,100,50,1/22/2020
99DC8D,conference-call,100,50,1/22/2020
9BB35A,conference-call,100,50,1/22/2020
9CE4C7,earnings,100,50,1/22/2020
9D30A8,earnings,100,50,1/22/2020
9F62D1,earnings-per-share-up,100,67,1/22/2020
9FA83B,conference-call,100,50,1/22/2020
A2CAF7,earnings,100,50,1/22/2020
A3F598,conference-call,100,50,1/22/2020
A6828A,earnings,100,50,1/22/2020
AA5C8E,dividend,100,50,1/22/2020
AA5C8E,dividend,100,50,1/22/2020
AA5C8E,dividend,100,50,1/22/2020
AA5C8E,dividend,100,50,1/22/2020
AA5C8E,dividend,100,50,1/22/2020
AA5C8E,dividend,100,50,1/22/2020
AA5C8E,dividend,100,50,1/22/2020
AABEA0,dividend,100,50,1/22/2020
AB7F05,earnings,100,50,1/22/2020
AC775C,conference-call,100,50,1/22/2020
AFF43F,earnings,100,50,1/22/2020
AFF43F,dividend,100,50,1/22/2020
B0998E,earnings,100,50,1/22/2020
B0FE08,dividend,100,50,1/22/2020
B303A6,legal-issues-defendant,100,22,1/22/2020
B5734D,earnings,100,50,1/22/2020
B8DD94,facility-sale,100,52,1/22/2020
B9CD50,executive-appointment,100,54,1/22/2020
BB5271,conference-call,100,50,1/22/2020
BE14CF,partnership,100,61,1/22/2020
BE645B,conference-participant,100,50,1/22/2020
BE7BA4,conference-call,100,50,1/22/2020
C36189,rights-issue,100,43,1/22/2020
C48574,public-offering,100,43,1/22/2020
C598D7,dividend,100,50,1/22/2020
C5D2AE,award,100,58,1/22/2020
C65004,public-offering,100,43,1/22/2020
C951A2,executive-appointment,100,54,1/22/2020
C99CC8,conference-call,100,50,1/22/2020
C9B932,earnings,100,50,1/22/2020
C9F39B,earnings,100,50,1/22/2020
C9F39B,earnings,100,50,1/22/2020
C9F39B,earnings,100,50,1/22/2020
C9F39B,earnings,100,50,1/22/2020
C9F39B,earnings,100,50,1/22/2020
C9F39B,earnings,100,50,1/22/2020
C9F39B,earnings,100,50,1/22/2020
CA1620,award,100,58,1/22/2020
CB9E13,conference-call,100,50,1/22/2020
CDC217,executive-appointment,100,54,1/22/2020
D15833,supply-increase,100,95,1/22/2020
D21D8A,earnings,100,50,1/22/2020
D21D8A,earnings,100,50,1/22/2020
D21D8A,earnings,100,50,1/22/2020
D21D8A,earnings,100,50,1/22/2020
D21D8A,earnings,100,50,1/22/2020
D21D8A,earnings,100,50,1/22/2020
D21D8A,earnings,100,50,1/22/2020
D437C3,earnings,100,50,1/22/2020
D437C3,earnings,100,50,1/22/2020
D437C3,earnings,100,50,1/22/2020
D437C3,earnings,100,50,1/22/2020
D63B0F,asset-sale,100,62,1/22/2020
D6853F,government-contract,100,69,1/22/2020
D77F7E,earnings,100,50,1/22/2020
D7918D,dividend,100,50,1/22/2020
D7A953,earnings,100,50,1/22/2020
DA90E1,dividend,100,50,1/22/2020
E07573,dividend,100,50,1/22/2020
E124EB,patent-awarded,100,72,1/22/2020
E16133,earnings,100,50,1/22/2020
E1E36F,earnings,100,50,1/22/2020
E3E68E,award,100,58,1/22/2020
E3E68E,award,100,58,1/22/2020
E4CE73,award,100,58,1/22/2020
E68C3D,partnership,100,61,1/22/2020
ED79D9,award,100,58,1/22/2020
F294DD,earnings,100,50,1/22/2020
F58C23,conference-call,100,50,1/22/2020
F5D410,acquisition-acquirer,100,49,1/22/2020
F702CA,award,100,58,1/22/2020
F88A04,dividend,100,50,1/22/2020
FAEABE,dividend-up,100,55,1/22/2020
FC9A88,dividend-up,100,61,1/22/2020
FD4588,earnings,100,50,1/22/2020
FD6926,regulatory-product-approval-granted,100,81,1/22/2020
FF4343,earnings-up,100,63,1/22/2020
FF4343,earnings,100,50,1/22/2020
FF4343,earnings,100,50,1/22/2020
FF4343,earnings,100,50,1/22/2020
FF4343,earnings,100,50,1/22/2020
FF4343,earnings,100,50,1/22/2020
FF4343,earnings,100,50,1/22/2020
FF4343,earnings,100,50,1/22/2020
FF4343,earnings,100,50,1/22/2020
FF4343,earnings,100,50,1/22/2020
FF4343,earnings,100,50,1/22/2020
FF4343,earnings,100,50,1/22/2020
FF4343,earnings,100,50,1/22/2020
003B70,earnings,100,50,1/23/2020
0157B1,donation,100,54,1/23/2020
03F5A4,earnings-positive,100,69,1/23/2020
43862,public-offering,100,43,1/23/2020
51332,dividend,100,50,1/23/2020
0560D8,dividend,100,50,1/23/2020
07C907,earnings,100,50,1/23/2020
099A92,conference-call,100,50,1/23/2020
0A7650,earnings-up,100,68,1/23/2020
0A7650,earnings,100,50,1/23/2020
0B2071,dividend,100,50,1/23/2020
0B9E6F,earnings,100,50,1/23/2020
0F65C9,dividend,100,50,1/23/2020
10100E,public-offering,100,43,1/23/2020
105D00,earnings,100,50,1/23/2020
105D00,earnings,100,50,1/23/2020
105D00,earnings,100,50,1/23/2020
105D00,earnings,100,50,1/23/2020
105D00,earnings,100,50,1/23/2020
105D00,earnings,100,50,1/23/2020
105D00,earnings,100,50,1/23/2020
105D00,earnings,100,50,1/23/2020
10673F,earnings-up,100,68,1/23/2020
10673F,earnings-up,100,68,1/23/2020
129DC8,conference-call,100,50,1/23/2020
149301,conference-call,100,50,1/23/2020
16B183,conference-call,100,50,1/23/2020
182B8C,earnings,100,50,1/23/2020
18EC17,earnings,100,50,1/23/2020
18EC17,earnings,100,50,1/23/2020
18EC17,earnings,100,50,1/23/2020
19BF16,business-contract,100,69,1/23/2020
1A6A94,conference-call,100,50,1/23/2020
1B637E,dividend,100,50,1/23/2020
1B9535,conference-call,100,50,1/23/2020
1DDEDA,conference-call,100,50,1/23/2020
2093B1,executive-appointment,100,54,1/23/2020
20BEEA,conference-call,100,50,1/23/2020
20DC4E,earnings,100,50,1/23/2020
21022F,earnings,100,50,1/23/2020
225CA2,executive-appointment,100,54,1/23/2020
225CA2,executive-appointment,100,54,1/23/2020
2262BD,executive-appointment,100,54,1/23/2020
228D42,partnership,100,61,1/23/2020
238302,dividend,100,50,1/23/2020
24CB56,earnings-positive,100,69,1/23/2020
24CB56,earnings,100,50,1/23/2020
24CB56,earnings,100,50,1/23/2020
24CB56,earnings,100,50,1/23/2020
24CB56,earnings,100,50,1/23/2020
24CB56,earnings,100,50,1/23/2020
24CB56,earnings,100,50,1/23/2020
24CB56,earnings,100,50,1/23/2020
24CB56,earnings,100,50,1/23/2020
24CB56,earnings,100,50,1/23/2020
25102A,business-contract,100,69,1/23/2020
25102A,business-contract,100,69,1/23/2020
25529C,earnings,100,50,1/23/2020
267718,product-release,100,64,1/23/2020
26CC63,dividend,100,50,1/23/2020
272472,earnings-up,100,78,1/23/2020
272472,earnings-up,100,78,1/23/2020
272472,earnings-up,100,78,1/23/2020
272472,earnings-up,100,78,1/23/2020
272472,earnings-up,100,78,1/23/2020
272472,earnings-up,100,78,1/23/2020
272472,earnings-up,100,78,1/23/2020
272704,dividend,100,50,1/23/2020
29B702,earnings,100,50,1/23/2020
29B702,earnings,100,50,1/23/2020
29B702,earnings,100,50,1/23/2020
29B702,earnings,100,50,1/23/2020
29B702,earnings,100,50,1/23/2020
29B702,earnings,100,50,1/23/2020
29B702,earnings,100,50,1/23/2020
29B702,earnings,100,50,1/23/2020
29B702,earnings,100,50,1/23/2020
29B702,earnings,100,50,1/23/2020
2B9DBB,earnings,100,50,1/23/2020
2DA92D,earnings,100,50,1/23/2020
2E61CC,earnings,100,50,1/23/2020
2E6514,earnings-positive,100,69,1/23/2020
2EB88B,executive-appointment,100,54,1/23/2020
2F7474,earnings,100,50,1/23/2020
2F9304,executive-appointment,100,54,1/23/2020
3159AA,conference-call,100,50,1/23/2020
31F25C,earnings,100,50,1/23/2020
328250,earnings,100,50,1/23/2020
32F24A,conference-call,100,50,1/23/2020
343996,earnings,100,50,1/23/2020
34B411,executive-appointment,100,54,1/23/2020
384CD3,earnings,100,50,1/23/2020
39FB23,earnings-up,100,68,1/23/2020
3A6D90,dividend,100,50,1/23/2020
3AAEAE,executive-appointment,100,54,1/23/2020
3DE4D1,earnings,100,50,1/23/2020
3DE4D1,earnings,100,50,1/23/2020
3DE4D1,earnings,100,50,1/23/2020
3DE4D1,earnings,100,50,1/23/2020
3E39A5,dividend,100,50,1/23/2020
401072,public-offering,100,43,1/23/2020
42AABD,conference-call,100,50,1/23/2020
4455C4,earnings-guidance-up,100,83,1/23/2020
453282,earnings-per-share-positive,100,69,1/23/2020
453282,earnings,100,50,1/23/2020
45444E,conference-call,100,50,1/23/2020
46CF27,earnings-up,100,68,1/23/2020
46CF27,earnings,100,50,1/23/2020
46CF27,earnings,100,50,1/23/2020
46CF27,earnings,100,50,1/23/2020
46CF27,earnings,100,50,1/23/2020
46CF27,earnings,100,50,1/23/2020
46CF27,earnings,100,50,1/23/2020
46CF27,earnings,100,50,1/23/2020
46CF27,earnings,100,50,1/23/2020
4B3555,earnings,100,50,1/23/2020
4B3555,earnings,100,50,1/23/2020
4B3555,earnings,100,50,1/23/2020
4B3555,earnings,100,50,1/23/2020
4B3555,earnings,100,50,1/23/2020
4B3555,earnings,100,50,1/23/2020
4BD6DB,earnings,100,50,1/23/2020
4EE14A,executive-appointment,100,54,1/23/2020
4EE14A,executive-appointment,100,54,1/23/2020
4EE167,earnings,100,50,1/23/2020
4EEE7E,earnings,100,50,1/23/2020
4F9487,earnings-up,100,68,1/23/2020
4F9487,earnings-up,100,68,1/23/2020
4F9487,earnings,100,50,1/23/2020
4F9487,earnings,100,50,1/23/2020
4F9487,earnings,100,50,1/23/2020
4F9487,earnings,100,50,1/23/2020
4F9487,earnings,100,50,1/23/2020
4F9487,earnings,100,50,1/23/2020
50070E,partnership,100,61,1/23/2020
50070E,partnership,100,61,1/23/2020
504FE2,executive-appointment,100,54,1/23/2020
532D47,conference-call,100,50,1/23/2020
545272,dividend,100,50,1/23/2020
553949,conference-call,100,50,1/23/2020
5546DA,earnings-per-share-positive,100,69,1/23/2020
5546DA,earnings-per-share-positive,100,69,1/23/2020
5546DA,earnings-per-share-positive,100,69,1/23/2020
5546DA,earnings-per-share-positive,100,69,1/23/2020
5546DA,earnings-per-share-positive,100,69,1/23/2020
556A57,dividend-up,100,81,1/23/2020
55C9B5,facility-open,100,65,1/23/2020
55C9B5,facility-open,100,65,1/23/2020
57634F,earnings,100,50,1/23/2020
58CA9A,acquisition-interest-acquirer,100,46,1/23/2020
59DB8C,earnings,100,50,1/23/2020
5A64D5,conference-call,100,50,1/23/2020
5A64D5,dividend,100,50,1/23/2020
5AF08A,earnings,100,50,1/23/2020
5B6C11,earnings,100,50,1/23/2020
5BE42C,dividend-up,100,61,1/23/2020
5D1956,earnings,100,50,1/23/2020
5FF95F,earnings-positive,100,69,1/23/2020
622037,dividend,100,50,1/23/2020
62B1C6,dividend,100,50,1/23/2020
636931,earnings,100,50,1/23/2020
641F17,dividend-up,100,59,1/23/2020
6474BA,earnings-positive,100,69,1/23/2020
6474BA,earnings,100,50,1/23/2020
6474BA,earnings,100,50,1/23/2020
6474BA,earnings,100,50,1/23/2020
6474BA,earnings,100,50,1/23/2020
6474BA,earnings,100,50,1/23/2020
6474BA,earnings,100,50,1/23/2020
6474BA,earnings,100,50,1/23/2020
6474BA,earnings,100,50,1/23/2020
6474BA,earnings,100,50,1/23/2020
6474BA,earnings,100,50,1/23/2020
657097,public-offering,100,43,1/23/2020
665440,executive-appointment,100,54,1/23/2020
6B5379,dividend,100,50,1/23/2020
6CC55E,earnings,100,50,1/23/2020
6DDA15,legal-issues-defendant,100,22,1/23/2020
713810,business-contract,100,69,1/23/2020
72DF04,award,100,58,1/23/2020
72FCA3,dividend,100,50,1/23/2020
731675,conference-call,100,50,1/23/2020
7520CC,earnings,100,50,1/23/2020
75F665,earnings,100,50,1/23/2020
75F665,earnings,100,50,1/23/2020
75F665,earnings,100,50,1/23/2020
762B8D,earnings,100,50,1/23/2020
765913,earnings,100,50,1/23/2020
767F86,donation,100,54,1/23/2020
76E80F,partnership,100,61,1/23/2020
78F776,earnings,100,50,1/23/2020
791D59,earnings,100,50,1/23/2020
7A5D58,earnings,100,50,1/23/2020
7AB859,acquisition-completed-acquirer,100,49,1/23/2020
7ACD98,business-contract,100,69,1/23/2020
7B1156,conference-call,100,50,1/23/2020
7C75FD,dividend,100,50,1/23/2020
7E3F8F,partnership,100,61,1/23/2020
7E3F8F,partnership,100,61,1/23/2020
7F3A5F,business-contract,100,69,1/23/2020
7F3A5F,earnings,100,50,1/23/2020
7F9984,earnings,100,50,1/23/2020
80D744,dividend-up,100,81,1/23/2020
81A88D,earnings,100,50,1/23/2020
8.10E+205,conference-call,100,50,1/23/2020
8.22E+27,earnings,100,50,1/23/2020
83598E,dividend,100,50,1/23/2020
835C86,dividend,100,50,1/23/2020
859281,dividend,100,50,1/23/2020
86478F,earnings,100,50,1/23/2020
87B81A,earnings,100,50,1/23/2020
8802B4,conference-call,100,50,1/23/2020
8817D5,earnings-up,100,68,1/23/2020
88923D,award,100,58,1/23/2020
88923D,award,100,58,1/23/2020
8A8E41,product-release,100,64,1/23/2020
8B2C4A,earnings,100,50,1/23/2020
8C84DF,revenue-up,100,69,1/23/2020
8D4486,partnership,100,61,1/23/2020
8D4486,partnership,100,61,1/23/2020
8D5145,earnings,100,50,1/23/2020
8DAAB9,earnings,100,50,1/23/2020
8DDA23,earnings,100,50,1/23/2020
8DE56F,earnings,100,50,1/23/2020
8DE56F,earnings,100,50,1/23/2020
8E8E6E,executive-appointment,100,54,1/23/2020
8E8E6E,executive-appointment,100,54,1/23/2020
8F3BCC,earnings-per-share-positive,100,69,1/23/2020
901327,earnings,100,50,1/23/2020
911AB8,executive-resignation,100,44,1/23/2020
9196A2,product-release,100,64,1/23/2020
9196A2,product-release,100,64,1/23/2020
91E5EE,earnings,100,50,1/23/2020
92D6A5,dividend,100,50,1/23/2020
940C3D,dividend,100,50,1/23/2020
9548BB,executive-appointment,100,54,1/23/2020
9548BB,earnings,100,50,1/23/2020
95A92E,executive-appointment,100,54,1/23/2020
965360,dividend,100,50,1/23/2020
989E2F,earnings,100,50,1/23/2020
989E2F,earnings,100,50,1/23/2020
989E2F,earnings,100,50,1/23/2020
9A602D,executive-appointment,100,54,1/23/2020
9E298A,dividend,100,50,1/23/2020
9F37C5,public-offering,100,43,1/23/2020
9F37C5,public-offering,100,43,1/23/2020
9F5997,earnings,100,50,1/23/2020
A1EAC8,government-contract,100,69,1/23/2020
A4D173,conference-call,100,50,1/23/2020
A4D173,conference-call,100,50,1/23/2020
A868C9,executive-appointment,100,54,1/23/2020
A8CBDA,earnings-positive,100,69,1/23/2020
A94718,note-sale,100,52,1/23/2020
AA247D,earnings,100,50,1/23/2020
AD3008,earnings,100,50,1/23/2020
AE7D16,product-release,100,64,1/23/2020
AEF2C3,note-sale,100,52,1/23/2020
AEF2C3,note-sale,100,52,1/23/2020
AEF2C3,note-sale,100,52,1/23/2020
B04426,executive-appointment,100,54,1/23/2020
B1FC3B,business-contract,100,69,1/23/2020
B33E77,business-contract,100,69,1/23/2020
B5766D,earnings-per-share-positive,100,69,1/23/2020
B5766D,earnings,100,50,1/23/2020
B5766D,earnings,100,50,1/23/2020
B5766D,earnings,100,50,1/23/2020
B5766D,earnings,100,50,1/23/2020
B5766D,earnings,100,50,1/23/2020
B6CD92,earnings-positive,100,69,1/23/2020
B6CD92,earnings-positive,100,69,1/23/2020
B6CD92,earnings-positive,100,69,1/23/2020
B6CD92,earnings-positive,100,69,1/23/2020
B73395,executive-appointment,100,54,1/23/2020
B8EF97,dividend,100,50,1/23/2020
BBBB41,dividend,100,50,1/23/2020
BC3AD2,earnings,100,50,1/23/2020
BC3AD2,earnings,100,50,1/23/2020
BC3AD2,earnings,100,50,1/23/2020
BC3AD2,earnings,100,50,1/23/2020
BC3AD2,earnings,100,50,1/23/2020
BC3AD2,earnings,100,50,1/23/2020
BC3AD2,earnings,100,50,1/23/2020
BC3AD2,earnings,100,50,1/23/2020
BC5680,product-release,100,64,1/23/2020
BC5680,earnings,100,50,1/23/2020
BEB756,earnings,100,50,1/23/2020
C062D4,dividend,100,50,1/23/2020
C1CBA4,earnings-positive,100,69,1/23/2020
C1CBA4,earnings-positive,100,69,1/23/2020
C1CBA4,earnings-positive,100,69,1/23/2020
C1CBA4,earnings-positive,100,69,1/23/2020
C1CBA4,earnings-positive,100,69,1/23/2020
C1CBA4,earnings-positive,100,69,1/23/2020
C1CBA4,earnings-positive,100,69,1/23/2020
C1CBA4,earnings-positive,100,69,1/23/2020
C2F597,earnings,100,50,1/23/2020
C41C25,earnings,100,50,1/23/2020
C4706C,conference-call,100,50,1/23/2020
C65004,public-offering,100,43,1/23/2020
C66A8C,earnings,100,50,1/23/2020
C83B88,earnings,100,50,1/23/2020
C83B88,dividend-up,100,60,1/23/2020
C9E107,earnings,100,50,1/23/2020
C9E107,dividend,100,50,1/23/2020
CDAA0E,earnings,100,50,1/23/2020
CFE5BE,earnings,100,50,1/23/2020
CFE5BE,earnings,100,50,1/23/2020
CFE5BE,earnings,100,50,1/23/2020
CFE5BE,earnings,100,50,1/23/2020
CFE5BE,earnings,100,50,1/23/2020
CFE5BE,earnings,100,50,1/23/2020
CFE5BE,earnings,100,50,1/23/2020
CFE5BE,earnings,100,50,1/23/2020
D0DFE5,earnings,100,50,1/23/2020
D17C1B,earnings,100,50,1/23/2020
D17C1B,earnings,100,50,1/23/2020
D17C1B,earnings,100,50,1/23/2020
D17C1B,earnings,100,50,1/23/2020
D1AE3B,earnings,100,50,1/23/2020
D4463B,earnings,100,50,1/23/2020
D78CCD,earnings,100,50,1/23/2020
D78CCD,earnings,100,50,1/23/2020
D78CCD,earnings,100,50,1/23/2020
D78CCD,earnings,100,50,1/23/2020
D78CCD,earnings,100,50,1/23/2020
D78CCD,earnings,100,50,1/23/2020
D78CCD,earnings,100,50,1/23/2020
D78CCD,earnings,100,50,1/23/2020
D8F347,earnings,100,50,1/23/2020
DA48E4,dividend,100,50,1/23/2020
DBCA3F,earnings,100,50,1/23/2020
DE4924,conference-call,100,50,1/23/2020
DF6FDD,earnings,100,50,1/23/2020
E114F4,conference-call,100,50,1/23/2020
E124EB,conference-call,100,50,1/23/2020
E1BD05,earnings,100,50,1/23/2020
E3656D,conference-call,100,50,1/23/2020
E393B0,earnings,100,50,1/23/2020
E393B0,earnings,100,50,1/23/2020
E393B0,earnings,100,50,1/23/2020
E393B0,earnings,100,50,1/23/2020
E393B0,earnings,100,50,1/23/2020
E393B0,earnings,100,50,1/23/2020
E49AA3,earnings,100,50,1/23/2020
E68733,product-release,100,64,1/23/2020
E68733,product-release,100,64,1/23/2020
E6A53A,note-sale,100,52,1/23/2020
E6A53A,note-sale,100,52,1/23/2020
E94704,conference-call,100,50,1/23/2020
E9C7C0,product-release,100,64,1/23/2020
EA4E68,earnings,100,50,1/23/2020
EA4E68,earnings,100,50,1/23/2020
EA4E68,earnings,100,50,1/23/2020
EB2F14,earnings,100,50,1/23/2020
EB6965,unit-acquisition-acquirer,100,49,1/23/2020
EDF5CA,dividend,100,50,1/23/2020
F04E05,earnings,100,50,1/23/2020
F1EB39,executive-appointment,100,54,1/23/2020
F24FF0,earnings,100,50,1/23/2020
F4E882,conference-call,100,50,1/23/2020
F4E882,legal-issues-defendant,100,22,1/23/2020
F5D410,acquisition-completed-acquirer,100,49,1/23/2020
F5D410,acquisition-completed-acquirer,100,49,1/23/2020
FC9A88,earnings,100,50,1/23/2020
FD0CA4,earnings,100,50,1/23/2020
FEC475,legal-issues-defendant,100,22,1/23/2020
48590,partnership,100,61,1/24/2020
75172,conference-call,100,50,1/24/2020
07EC43,executive-appointment,100,54,1/24/2020
099A02,earnings,100,50,1/24/2020
099A02,earnings,100,50,1/24/2020
0A748B,earnings,100,50,1/24/2020
0C6861,conference-call,100,50,1/24/2020
0DE3D5,conference-call,100,50,1/24/2020
106394,acquisition-completed-acquirer,100,49,1/24/2020
156A99,earnings,100,50,1/24/2020
19BF16,business-contract,100,69,1/24/2020
19C105,earnings,100,50,1/24/2020
19C105,earnings,100,50,1/24/2020
19C105,earnings,100,50,1/24/2020
19C105,dividend,100,50,1/24/2020
1A6A94,conference-call,100,50,1/24/2020
1CF3A8,conference-call,100,50,1/24/2020
1FAF22,legal-issues-defendant,100,22,1/24/2020
25DD05,dividend,100,50,1/24/2020
272472,dividend-up,100,60,1/24/2020
28AF37,earnings,100,50,1/24/2020
2ABF77,conference-call,100,50,1/24/2020
2B0AF4,executive-resignation,100,44,1/24/2020
314D88,revenue-guidance-up,100,83,1/24/2020
3A94DF,earnings,100,50,1/24/2020
3D9999,earnings-positive,100,69,1/24/2020
460C93,dividend-up,100,81,1/24/2020
460C93,dividend-up,100,81,1/24/2020
460C93,dividend-up,100,81,1/24/2020
460C93,dividend-up,100,81,1/24/2020
47BA98,earnings,100,50,1/24/2020
4A6F00,partnership,100,61,1/24/2020
4C37C5,earnings-per-share-positive,100,69,1/24/2020
4C37C5,earnings,100,50,1/24/2020
4C37C5,earnings,100,50,1/24/2020
51888A,acquisition-acquirer,100,49,1/24/2020
519FE0,acquisition-completed-acquirer,100,49,1/24/2020
5480A7,earnings,100,50,1/24/2020
5480A7,earnings,100,50,1/24/2020
5480A7,earnings,100,50,1/24/2020
5480A7,earnings,100,50,1/24/2020
5487B1,legal-issues-defendant,100,22,1/24/2020
55CD6F,note-sale,100,52,1/24/2020
5A64D5,dividend,100,50,1/24/2020
5BFE94,dividend,100,50,1/24/2020
62B1C6,dividend,100,50,1/24/2020
641F17,executive-appointment,100,54,1/24/2020
657097,public-offering,100,43,1/24/2020
713810,business-contract,100,69,1/24/2020
72EF75,earnings,100,50,1/24/2020
73A71F,conference-call,100,50,1/24/2020
741937,executive-appointment,100,54,1/24/2020
762A3E,dividend,100,50,1/24/2020
78A1BB,earnings,100,50,1/24/2020
7B4B91,earnings,100,50,1/24/2020
7DD8CC,dividend,100,50,1/24/2020
803FED,dividend-guidance,100,50,1/24/2020
804708,conference-call,100,50,1/24/2020
8377DB,investment-investor,100,55,1/24/2020
877C0C,earnings,100,50,1/24/2020
8A8E41,partnership,100,61,1/24/2020
8CF6DD,award,100,58,1/24/2020
95DC1F,dividend,100,50,1/24/2020
96F126,dividend,100,50,1/24/2020
96F126,executive-appointment,100,54,1/24/2020
977A1E,dividend,100,50,1/24/2020
97B027,dividend,100,50,1/24/2020
980C14,conference-call,100,50,1/24/2020
A05C43,merger,100,66,1/24/2020
A05C43,merger,100,66,1/24/2020
A05C43,merger,100,66,1/24/2020
A05C43,merger,100,66,1/24/2020
A05C43,merger,100,66,1/24/2020
A58224,conference-call,100,50,1/24/2020
A6FE1C,unit-acquisition-acquirer,100,49,1/24/2020
A94718,note-sale,100,52,1/24/2020
AA1EAA,conference-call,100,50,1/24/2020
AA3AB8,dividend,100,50,1/24/2020
AABEA0,earnings-up,100,68,1/24/2020
AE7D16,executive-appointment,100,54,1/24/2020
B0B969,conference-call,100,50,1/24/2020
B303A6,legal-issues-defendant,100,22,1/24/2020
B4C673,dividend-up,100,62,1/24/2020
B5DE80,executive-resignation,100,44,1/24/2020
B614F8,public-offering,100,43,1/24/2020
B803B1,conference-call,100,50,1/24/2020
BC948D,conference-call,100,50,1/24/2020
C0030A,stake-acquirer,100,48,1/24/2020
C16A8F,dividend,100,50,1/24/2020
C1CBA4,dividend,100,50,1/24/2020
C356AC,earnings,100,50,1/24/2020
C38440,acquisition-completed-acquirer,100,49,1/24/2020
C83B88,partnership,100,61,1/24/2020
C9F39B,earnings,100,50,1/24/2020
C9F39B,earnings,100,50,1/24/2020
C9F39B,earnings,100,50,1/24/2020
C9F39B,earnings,100,50,1/24/2020
C9F39B,earnings,100,50,1/24/2020
C9F39B,earnings,100,50,1/24/2020
C9F39B,earnings,100,50,1/24/2020
CDAB24,earnings,100,50,1/24/2020
CFF15D,conference-call,100,50,1/24/2020
CFF97C,credit-rating-outlook-revision-rater,20,50,1/24/2020
CFF97C,credit-rating-outlook-revision-rater,20,50,1/24/2020
D08D2C,conference-call,100,50,1/24/2020
D25249,facility-open,100,65,1/24/2020
D56E4C,reorganization-complete,100,74,1/24/2020
D56E4C,reorganization-complete,100,74,1/24/2020
D598E7,government-contract,100,69,1/24/2020
D721C6,earnings-up,100,80,1/24/2020
D7F569,dividend,100,50,1/24/2020
D8442A,legal-verdict-disfavored,100,22,1/24/2020
D8442A,legal-verdict-disfavored,100,22,1/24/2020
D854DD,conference-call,100,50,1/24/2020
D854F3,earnings,100,50,1/24/2020
DA48E4,earnings-per-share,100,50,1/24/2020
DBFB51,earnings,100,50,1/24/2020
DC0D18,earnings,100,50,1/24/2020
DD0F15,legal-issues-defendant,100,22,1/24/2020
DD0F15,legal-issues-defendant,100,22,1/24/2020
DD0F15,legal-issues-defendant,100,22,1/24/2020
DF42A0,conference-call,100,50,1/24/2020
E0A84E,legal-issues-defendant,100,22,1/24/2020
E40FB6,earnings,100,50,1/24/2020
E40FB6,earnings,100,50,1/24/2020
E40FB6,earnings,100,50,1/24/2020
E40FB6,earnings,100,50,1/24/2020
E40FB6,earnings,100,50,1/24/2020
E68C3D,earnings,100,50,1/24/2020
E70531,partnership,100,61,1/24/2020
E99180,earnings,100,50,1/24/2020
ED1A74,executive-appointment,100,54,1/24/2020
ED8676,earnings-positive,100,69,1/24/2020
ED8676,earnings-positive,100,69,1/24/2020
ED8676,earnings-positive,100,69,1/24/2020
ED8676,earnings-positive,100,69,1/24/2020
ED8676,earnings-positive,100,69,1/24/2020
ED8676,earnings-positive,100,69,1/24/2020
ED8676,earnings-positive,100,69,1/24/2020
ED8676,earnings-positive,100,69,1/24/2020
ED8676,earnings-positive,100,69,1/24/2020
ED8676,earnings-positive,100,69,1/24/2020
ED8676,dividend-up,100,58,1/24/2020
EEEA9F,earnings,100,50,1/24/2020
F0B877,executive-appointment,100,54,1/24/2020
F30508,executive-appointment,100,54,1/24/2020
F31B13,earnings,100,50,1/24/2020
F31B13,earnings,100,50,1/24/2020
F31B13,earnings,100,50,1/24/2020
F31B13,earnings,100,50,1/24/2020
F31B13,dividend,100,50,1/24/2020
F7FCA4,dividend,100,50,1/24/2020
FC01C0,conference-participant,100,50,1/24/2020
FD39EB,earnings,100,50,1/24/2020
FDC08C,earnings,100,50,1/24/2020
FDC08C,earnings,100,50,1/24/2020
FDC08C,earnings,100,50,1/24/2020
FDC08C,earnings,100,50,1/24/2020
FDC08C,earnings,100,50,1/24/2020
FE7A63,earnings,100,50,1/24/2020
FE7A63,earnings,100,50,1/24/2020
FE7A63,earnings,100,50,1/24/2020
FE7A63,earnings,100,50,1/24/2020
FE7A63,earnings,100,50,1/24/2020
FE7A63,earnings,100,50,1/24/2020
FE7A63,earnings,100,50,1/24/2020
FE7A63,earnings,100,50,1/24/2020
FEC475,legal-issues-defendant,100,22,1/24/2020
76F067,executive-appointment,100,54,1/25/2020
DD0F15,legal-issues-defendant,100,22,1/25/2020
DD0F15,legal-issues-defendant,100,22,1/25/2020
01D03F,regulatory-product-application,100,69,1/27/2020
01D03F,regulatory-product-application,100,69,1/27/2020
01D03F,clinical-trials-filed,100,60,1/27/2020
01D03F,clinical-trials-filed,100,60,1/27/2020
03596A,legal-issues-defendant,100,22,1/27/2020
43862,public-offering,100,43,1/27/2020
0A59F8,earnings,100,50,1/27/2020
0A6824,executive-appointment,100,54,1/27/2020
0A6824,dividend,100,50,1/27/2020
0CC62B,conference-call,100,50,1/27/2020
0CE7F6,executive-appointment,100,54,1/27/2020
0E439E,unit-acquisition-interest-acquirer,100,47,1/27/2020
0F04E5,earnings,100,50,1/27/2020
108FDA,earnings,100,50,1/27/2020
1201B5,acquisition-interest-acquirer,100,46,1/27/2020
12DE76,executive-appointment,100,54,1/27/2020
147C38,donation,100,54,1/27/2020
1EBF8D,regulatory-product-approval-granted,100,81,1/27/2020
1EBF8D,regulatory-product-approval-granted,100,81,1/27/2020
1F2B5D,earnings-up,100,68,1/27/2020
1F2B5D,earnings-up,100,68,1/27/2020
1F2B5D,earnings-up,100,68,1/27/2020
1F2B5D,earnings-up,100,68,1/27/2020
1F2B5D,earnings-up,100,68,1/27/2020
206852,earnings,100,50,1/27/2020
206852,earnings,100,50,1/27/2020
206852,earnings,100,50,1/27/2020
206852,earnings,100,50,1/27/2020
206852,earnings,100,50,1/27/2020
206852,earnings,100,50,1/27/2020
206852,earnings,100,50,1/27/2020
206852,earnings,100,50,1/27/2020
206852,earnings,100,50,1/27/2020
206852,earnings,100,50,1/27/2020
206852,earnings,100,50,1/27/2020
20DC4E,dividend,100,50,1/27/2020
2158DF,earnings,100,50,1/27/2020
25A6CC,legal-issues-defendant,100,22,1/27/2020
25A6CC,legal-issues-defendant,100,22,1/27/2020
25DD05,earnings,100,50,1/27/2020
29A4CC,earnings,100,50,1/27/2020
29B702,conference-participant,100,50,1/27/2020
2D2D43,dividend-up,100,81,1/27/2020
2EC172,conference-call,100,50,1/27/2020
315EB0,award,100,58,1/27/2020
332F87,earnings-per-share-up,100,68,1/27/2020
34A959,earnings,100,50,1/27/2020
38FB49,earnings,100,50,1/27/2020
38FB49,earnings,100,50,1/27/2020
38FB49,earnings,100,50,1/27/2020
38FB49,earnings,100,50,1/27/2020
38FB49,earnings,100,50,1/27/2020
38FB49,earnings,100,50,1/27/2020
38FB49,earnings,100,50,1/27/2020
38FB49,earnings,100,50,1/27/2020
3A4BDB,earnings-up,100,68,1/27/2020
3A4BDB,earnings-up,100,68,1/27/2020
3A4BDB,earnings-up,100,68,1/27/2020
3A4BDB,earnings-up,100,68,1/27/2020
3A4BDB,earnings-up,100,68,1/27/2020
3BBD10,earnings,100,50,1/27/2020
3DCECC,conference-call,100,50,1/27/2020
41B0E2,earnings,100,50,1/27/2020
448215,executive-appointment,100,54,1/27/2020
4591D3,acquisition-acquirer,100,49,1/27/2020
4591D3,revenues,100,50,1/27/2020
45BC35,conference-call,100,50,1/27/2020
467F2C,partnership,100,61,1/27/2020
4806CE,facility-open,100,65,1/27/2020
49914B,executive-appointment,100,54,1/27/2020
4B3DC9,earnings,100,50,1/27/2020
4B3DC9,earnings,100,50,1/27/2020
4B3DC9,earnings,100,50,1/27/2020
4B3DC9,earnings,100,50,1/27/2020
4B3DC9,earnings,100,50,1/27/2020
4B3DC9,earnings,100,50,1/27/2020
4B3DC9,earnings,100,50,1/27/2020
4B3DC9,earnings,100,50,1/27/2020
4B3DC9,earnings,100,50,1/27/2020
4B3DC9,earnings,100,50,1/27/2020
4B3DC9,earnings,100,50,1/27/2020
4B3DC9,earnings,100,50,1/27/2020
4B6EF9,earnings,100,50,1/27/2020
4B6EF9,dividend,100,50,1/27/2020
4CDA2B,public-offering,100,43,1/27/2020
4D72C8,conference-call,100,50,1/27/2020
4D72C8,conference-call,100,50,1/27/2020
4D8313,earnings,100,50,1/27/2020
4D8313,earnings,100,50,1/27/2020
4D8313,earnings,100,50,1/27/2020
4D8E5E,earnings,100,50,1/27/2020
519FE0,partnership,100,61,1/27/2020
548AC0,conference-call,100,50,1/27/2020
56B7C1,earnings,100,50,1/27/2020
589846,product-release,100,64,1/27/2020
59DB8C,public-offering,100,43,1/27/2020
5BE42C,earnings,100,50,1/27/2020
5D0337,executive-appointment,100,54,1/27/2020
5FE4B6,earnings,100,50,1/27/2020
633043,earnings,100,50,1/27/2020
657097,unit-acquisition-acquirer,100,49,1/27/2020
65D0AA,clinical-trials,100,56,1/27/2020
65D0AA,acquisition-bid-rejected-acquiree,100,18,1/27/2020
665D7D,business-contract,100,69,1/27/2020
665D7D,business-contract,100,69,1/27/2020
665D7D,debt-extension-recipient,100,73,1/27/2020
6844D2,executive-appointment,100,54,1/27/2020
6B236C,dividend,100,50,1/27/2020
6CC55E,clinical-trials,100,56,1/27/2020
6CDFC6,earnings,100,50,1/27/2020
6D4636,earnings,100,50,1/27/2020
6D4636,earnings,100,50,1/27/2020
6D4636,earnings,100,50,1/27/2020
6DBBBC,partnership,100,61,1/27/2020
6DDA15,legal-issues-defendant,100,22,1/27/2020
6F39FC,conference-call,100,50,1/27/2020
6F3FA8,conference-call,100,50,1/27/2020
6F6559,award,100,58,1/27/2020
719477,business-contract,100,69,1/27/2020
726EEA,earnings,100,50,1/27/2020
735388,dividend,100,50,1/27/2020
76D79A,conference-call,100,50,1/27/2020
76D79A,dividend,100,50,1/27/2020
76F067,earnings,100,50,1/27/2020
7712CB,earnings,100,50,1/27/2020
771985,business-contract,100,69,1/27/2020
782B46,earnings,100,50,1/27/2020
78A1BB,executive-appointment,100,54,1/27/2020
791D59,partnership,100,61,1/27/2020
791EC1,conference-call,100,50,1/27/2020
7AF5B8,public-offering,100,43,1/27/2020
7D97DE,conference-call,100,50,1/27/2020
7DD8CC,conference-call,100,50,1/27/2020
7F3669,earnings,100,50,1/27/2020
84A6B9,earnings-up,100,68,1/27/2020
84A6B9,earnings,100,50,1/27/2020
84A6B9,earnings,100,50,1/27/2020
84A6B9,earnings,100,50,1/27/2020
84A6B9,earnings,100,50,1/27/2020
84A6B9,earnings,100,50,1/27/2020
84A6B9,earnings,100,50,1/27/2020
850779,dividend,100,50,1/27/2020
859281,earnings,100,50,1/27/2020
85DA04,partnership,100,61,1/27/2020
873DB9,dividend,100,50,1/27/2020
880C0C,conference-call,100,50,1/27/2020
89FBB1,dividend,100,50,1/27/2020
8AC740,conference-call,100,50,1/27/2020
8BAA15,earnings,100,50,1/27/2020
8C1238,earnings,100,50,1/27/2020
8C1238,earnings,100,50,1/27/2020
8C1238,earnings,100,50,1/27/2020
8C1238,earnings,100,50,1/27/2020
8C1238,earnings,100,50,1/27/2020
8E93A4,earnings,100,50,1/27/2020
8F3231,earnings,100,50,1/27/2020
905356,conference-call,100,50,1/27/2020
9368BE,conference-call,100,50,1/27/2020
95DE39,earnings-up,100,74,1/27/2020
968103,dividend,100,50,1/27/2020
971F7B,earnings,100,50,1/27/2020
986AF6,conference-call,100,50,1/27/2020
9A602D,executive-appointment,100,54,1/27/2020
9C5BA5,conference-call,100,50,1/27/2020
9EF4CF,partnership,100,61,1/27/2020
9F18FA,earnings,100,50,1/27/2020
9F18FA,earnings,100,50,1/27/2020
9F37C5,dividend,100,50,1/27/2020
A3230E,clinical-trials-start,100,64,1/27/2020
A3800A,earnings,100,50,1/27/2020
A3BFAA,dividend,100,50,1/27/2020
A429A5,operating-earnings,100,50,1/27/2020
A6828A,regulatory-product-approval-granted,100,81,1/27/2020
A96867,buybacks,100,74,1/27/2020
AAEE21,conference-call,100,50,1/27/2020
AB7726,earnings,100,50,1/27/2020
AC7C4F,executive-appointment,100,54,1/27/2020
AE79CD,clinical-trials-filed,100,60,1/27/2020
AED6CF,dividend,100,50,1/27/2020
AFDF2E,revenues,100,50,1/27/2020
B1FC3B,business-contract,100,69,1/27/2020
B2F431,earnings-up,100,68,1/27/2020
B2F431,earnings-up,100,68,1/27/2020
B2F431,earnings-up,100,68,1/27/2020
B2F431,earnings-up,100,68,1/27/2020
B2F431,earnings-up,100,68,1/27/2020
B303A6,legal-issues-defendant,100,22,1/27/2020
B303A6,legal-issues-defendant,100,22,1/27/2020
B5BA39,earnings,100,50,1/27/2020
B72BE9,revenues,100,50,1/27/2020
B72BE9,revenues,100,50,1/27/2020
B72BE9,revenues,100,50,1/27/2020
BB02FB,conference-call,100,50,1/27/2020
BB88B6,product-release,100,64,1/27/2020
BDD12C,earnings,100,50,1/27/2020
C062D4,earnings,100,50,1/27/2020
C062D4,earnings,100,50,1/27/2020
C062D4,earnings,100,50,1/27/2020
C062D4,earnings,100,50,1/27/2020
C062D4,earnings,100,50,1/27/2020
C062D4,earnings,100,50,1/27/2020
C062D4,earnings,100,50,1/27/2020
C062D4,earnings,100,50,1/27/2020
C0BA36,conference-call,100,50,1/27/2020
C11C46,earnings,100,50,1/27/2020
C4A432,conference-call,100,50,1/27/2020
C598D7,revenue-up,100,64,1/27/2020
C598D7,revenues,100,50,1/27/2020
C598D7,revenues,100,50,1/27/2020
C62AA4,conference-call,100,50,1/27/2020
C65004,earnings,100,50,1/27/2020
C7863D,conference-call,100,50,1/27/2020
CBDB4D,patent-infringement-plaintiff,100,47,1/27/2020
CFD4B6,executive-appointment,100,54,1/27/2020
CFE5BE,dividend,100,50,1/27/2020
D06755,executive-appointment,100,54,1/27/2020
D08D2C,earnings,100,50,1/27/2020
D0909F,resource-discovery,100,88,1/27/2020
D15833,dividend,100,50,1/27/2020
D25249,conference-call,100,50,1/27/2020
D57D99,unit-acquisition-completed-acquirer,100,49,1/27/2020
D6EAA3,conference-call,100,50,1/27/2020
D76AEF,executive-appointment,100,54,1/27/2020
D8442A,legal-verdict-disfavored,100,22,1/27/2020
D8442A,legal-verdict-disfavored,100,22,1/27/2020
DD0F15,legal-issues-defendant,100,22,1/27/2020
DD0F15,legal-issues-defendant,100,22,1/27/2020
DDC415,earnings,100,50,1/27/2020
DDEA6A,revenue-guidance,100,50,1/27/2020
DF18E6,headquarters-change,100,50,1/27/2020
DF46C5,dividend,100,50,1/27/2020
DF46C5,earnings,100,50,1/27/2020
DF46C5,earnings,100,50,1/27/2020
DF46C5,earnings,100,50,1/27/2020
DF46C5,earnings,100,50,1/27/2020
DF46C5,earnings,100,50,1/27/2020
E1E093,stake-acquirer,100,48,1/27/2020
E6A53A,earnings,100,50,1/27/2020
E6A53A,earnings,100,50,1/27/2020
E6A53A,earnings,100,50,1/27/2020
E70531,earnings,100,50,1/27/2020
E87676,dividend-up,100,81,1/27/2020
E9FF33,executive-appointment,100,54,1/27/2020
EA62FC,dividend,100,50,1/27/2020
EC99D0,earnings,100,50,1/27/2020
ECDEB2,earnings,100,50,1/27/2020
F0027C,public-offering,100,43,1/27/2020
F2526D,earnings,100,50,1/27/2020
F3FCC3,dividend,100,50,1/27/2020
F46EC9,earnings,100,50,1/27/2020
F4E882,legal-issues-defendant,100,22,1/27/2020
F5349B,earnings,100,50,1/27/2020
F6A945,earnings,100,50,1/27/2020
F6A945,business-combination,100,54,1/27/2020
F6A945,business-combination,100,54,1/27/2020
F6FA6A,regulatory-investigation,100,22,1/27/2020
F6FA6A,regulatory-investigation,100,22,1/27/2020
F7D8AE,ipo,100,71,1/27/2020
F80389,business-contract,100,69,1/27/2020
F80389,business-contract,100,69,1/27/2020
F80FF9,conference-call,100,50,1/27/2020
F95726,earnings,100,50,1/27/2020
FD9526,unit-acquisition-completed-acquirer,100,49,1/27/2020
FD9526,acquisition-completed-acquirer,100,49,1/27/2020
FEC475,legal-issues-defendant,100,22,1/27/2020
FFCD0E,revenues,100,50,1/27/2020
003B70,dividend,100,50,1/28/2020
0157B1,executive-appointment,100,54,1/28/2020
03B8CF,earnings,100,50,1/28/2020
08A40F,partnership,100,61,1/28/2020
0B2071,earnings-up,100,68,1/28/2020
0B2071,earnings,100,50,1/28/2020
0BC29E,conference-call,100,50,1/28/2020
0C6861,note-sale,100,52,1/28/2020
0C8D82,conference-call,100,50,1/28/2020
0CCCB7,conference-call,100,50,1/28/2020
0E439E,earnings-guidance,100,50,1/28/2020
0E439E,earnings-guidance,100,50,1/28/2020
0E439E,earnings-guidance,100,50,1/28/2020
0E439E,earnings-guidance,100,50,1/28/2020
0EC508,investment-investor,100,55,1/28/2020
0F2BC9,conference-call,100,50,1/28/2020
102727,earnings,100,50,1/28/2020
125212,patient-enrollment-complete,100,64,1/28/2020
12DE76,product-release,100,64,1/28/2020
12DE76,product-release,100,64,1/28/2020
12DE76,product-release,100,64,1/28/2020
139303,executive-appointment,100,54,1/28/2020
16C544,dividend,100,50,1/28/2020
1.79E+10,acquisition-acquirer,100,49,1/28/2020
1.79E+10,acquisition-acquirer,100,49,1/28/2020
1.79E+10,acquisition-acquirer,100,49,1/28/2020
1.79E+10,earnings,100,50,1/28/2020
1A5D5D,asset-sale,100,62,1/28/2020
1B6F77,public-offering,100,43,1/28/2020
1BDB2A,earnings,100,50,1/28/2020
1E68B3,earnings,100,50,1/28/2020
1E9A6D,earnings,100,50,1/28/2020
1EBF8D,dividend,100,50,1/28/2020
1FA886,business-contract,100,69,1/28/2020
1FE3CB,dividend,100,50,1/28/2020
1FE3CB,earnings,100,50,1/28/2020
222BF9,conference-call,100,50,1/28/2020
225CA2,earnings-per-share-above-expectations,100,83,1/28/2020
225CA2,earnings-per-share-above-expectations,100,83,1/28/2020
225CA2,earnings-per-share-above-expectations,100,83,1/28/2020
225CA2,earnings-per-share-above-expectations,100,83,1/28/2020
225CA2,earnings-per-share-above-expectations,100,83,1/28/2020
225CA2,earnings-per-share-above-expectations,100,83,1/28/2020
225CA2,earnings-per-share-above-expectations,100,83,1/28/2020
225CA2,earnings-per-share-above-expectations,100,83,1/28/2020
225CA2,earnings-per-share-above-expectations,100,83,1/28/2020
225CA2,earnings-per-share-above-expectations,100,83,1/28/2020
225CA2,earnings-per-share-above-expectations,100,83,1/28/2020
225CA2,earnings-per-share-above-expectations,100,83,1/28/2020
225CA2,earnings-per-share-above-expectations,100,83,1/28/2020
228D42,conference-organizer,100,57,1/28/2020
22C58E,earnings,100,50,1/28/2020
2491BC,legal-issues-defendant,100,22,1/28/2020
249B39,earnings-positive,100,69,1/28/2020
25A6CC,legal-issues-defendant,100,22,1/28/2020
2667B6,earnings,100,50,1/28/2020
2667B6,earnings,100,50,1/28/2020
2667B6,earnings,100,50,1/28/2020
2667B6,earnings,100,50,1/28/2020
2667B6,earnings,100,50,1/28/2020
267718,earnings,100,50,1/28/2020
270305,dividend,100,50,1/28/2020
270305,earnings,100,50,1/28/2020
270305,earnings,100,50,1/28/2020
270305,earnings,100,50,1/28/2020
270305,earnings,100,50,1/28/2020
272704,executive-appointment,100,54,1/28/2020
2B0AF4,conference-call,100,50,1/28/2020
2CF9D3,executive-appointment,100,54,1/28/2020
2D643C,dividend,100,50,1/28/2020
2DC88B,credit-extension-recipient,100,69,1/28/2020
2E0496,earnings,100,50,1/28/2020
2E0496,earnings,100,50,1/28/2020
2E2E6E,earnings,100,50,1/28/2020
2F5256,earnings,100,50,1/28/2020
30E01D,earnings,100,50,1/28/2020
32C8CD,executive-appointment,100,54,1/28/2020
32F24A,executive-appointment,100,54,1/28/2020
34B97A,earnings,100,50,1/28/2020
34B97A,earnings,100,50,1/28/2020
34B97A,earnings,100,50,1/28/2020
34B97A,earnings,100,50,1/28/2020
37020C,earnings,100,50,1/28/2020
37020C,earnings,100,50,1/28/2020
37020C,earnings,100,50,1/28/2020
37020C,earnings,100,50,1/28/2020
37020C,earnings,100,50,1/28/2020
37020C,earnings,100,50,1/28/2020
37020C,earnings,100,50,1/28/2020
37020C,earnings,100,50,1/28/2020
37020C,earnings,100,50,1/28/2020
3.73E+87,earnings,100,50,1/28/2020
3.73E+87,earnings,100,50,1/28/2020
3.73E+87,earnings,100,50,1/28/2020
3BB616,conference-call,100,50,1/28/2020
3BCF24,earnings,100,50,1/28/2020
3C6CCC,earnings,100,50,1/28/2020
3CBA2A,earnings,100,50,1/28/2020
3CBA2A,earnings,100,50,1/28/2020
3CBA2A,earnings,100,50,1/28/2020
3CBA2A,earnings,100,50,1/28/2020
3CBA2A,earnings,100,50,1/28/2020
3CBA2A,earnings,100,50,1/28/2020
3D9999,dividend,100,50,1/28/2020
4135F7,conference-call,100,50,1/28/2020
41EC04,conference-call,100,50,1/28/2020
420168,earnings,100,50,1/28/2020
442769,conference-call,100,50,1/28/2020
449217,earnings,100,50,1/28/2020
449217,earnings,100,50,1/28/2020
449217,earnings,100,50,1/28/2020
449217,earnings,100,50,1/28/2020
449217,earnings,100,50,1/28/2020
449217,earnings,100,50,1/28/2020
449A26,executive-appointment,100,54,1/28/2020
485445,earnings,100,50,1/28/2020
4A6F00,partnership,100,61,1/28/2020
4B3676,executive-appointment,100,54,1/28/2020
4CDA2B,clinical-trials-start,100,64,1/28/2020
50070E,conference-organizer,100,57,1/28/2020
51B442,earnings,100,50,1/28/2020
5340D0,earnings,100,50,1/28/2020
54A646,earnings-up,100,68,1/28/2020
54A646,earnings-up,100,68,1/28/2020
54A646,earnings-up,100,68,1/28/2020
54A646,earnings-up,100,68,1/28/2020
54F1D2,executive-appointment,100,54,1/28/2020
567F3D,dividend,100,50,1/28/2020
56AFF4,dividend,100,50,1/28/2020
5704AC,earnings,100,50,1/28/2020
59A832,conference-call,100,50,1/28/2020
59B229,earnings,100,50,1/28/2020
59C539,dividend,100,50,1/28/2020
5A423F,earnings,100,50,1/28/2020
5F1B7B,earnings,100,50,1/28/2020
6.18E+08,earnings,100,50,1/28/2020
6.18E+08,earnings,100,50,1/28/2020
6.18E+08,earnings,100,50,1/28/2020
622DBE,executive-appointment,100,54,1/28/2020
64854A,conference-call,100,50,1/28/2020
676FFD,legal-issues-defendant,100,22,1/28/2020
676FFD,legal-issues-defendant,100,22,1/28/2020
69345C,earnings,100,50,1/28/2020
69494C,conference-call,100,50,1/28/2020
69FDFC,partnership,100,61,1/28/2020
6BC6F9,earnings,100,50,1/28/2020
6CD55A,earnings,100,50,1/28/2020
6DDA15,legal-issues-defendant,100,22,1/28/2020
6E705B,partnership,100,61,1/28/2020
722D55,earnings,100,50,1/28/2020
76CEFB,earnings,100,50,1/28/2020
76E80F,executive-appointment,100,54,1/28/2020
76E80F,executive-appointment,100,54,1/28/2020
773A17,revenue-up,100,67,1/28/2020
773A17,revenue-up,100,69,1/28/2020
773A17,revenue-up,100,69,1/28/2020
782B46,dividend,100,50,1/28/2020
7C4F43,clinical-trials-start,100,64,1/28/2020
7D5FD6,earnings,100,50,1/28/2020
7DD584,earnings,100,50,1/28/2020
7F3A5F,shareholder-rights-plan,100,43,1/28/2020
81F4BE,earnings,100,50,1/28/2020
81F4BE,earnings,100,50,1/28/2020
8377DB,earnings,100,50,1/28/2020
8377DB,earnings,100,50,1/28/2020
837C04,dividend,100,50,1/28/2020
837C04,earnings-positive,100,69,1/28/2020
837C04,earnings,100,50,1/28/2020
837C04,earnings,100,50,1/28/2020
837C04,earnings,100,50,1/28/2020
837C04,earnings,100,50,1/28/2020
859D62,dividend,100,50,1/28/2020
86A1B9,partnership,100,61,1/28/2020
86A1B9,partnership,100,61,1/28/2020
881190,conference-call,100,50,1/28/2020
8A8E41,award,100,58,1/28/2020
8C311A,earnings,100,50,1/28/2020
8CF6DD,executive-appointment,100,54,1/28/2020
8CF6DD,dividend-up,100,81,1/28/2020
8D4486,dividend,100,50,1/28/2020
8D4486,dividend,100,50,1/28/2020
8E82A6,index-listing,100,76,1/28/2020
8F6995,conference-call,100,50,1/28/2020
925759,clinical-trials-positive,100,87,1/28/2020
92D6A5,revenues,100,50,1/28/2020
92D757,partnership,100,61,1/28/2020
92D757,earnings,100,50,1/28/2020
9.36E+10,executive-appointment,100,54,1/28/2020
95F59E,earnings,100,50,1/28/2020
9673BD,conference-participant,100,50,1/28/2020
96F126,earnings,100,50,1/28/2020
972356,earnings,100,50,1/28/2020
986AF6,earnings,100,50,1/28/2020
986AF6,earnings,100,50,1/28/2020
986AF6,earnings,100,50,1/28/2020
98CEBB,partnership,100,61,1/28/2020
990AD0,executive-appointment,100,54,1/28/2020
997348,earnings,100,50,1/28/2020
997348,earnings,100,50,1/28/2020
9C8BC3,conference-call,100,50,1/28/2020
9CA619,executive-appointment,100,54,1/28/2020
9D2790,product-release,100,64,1/28/2020
9D56F2,earnings,100,50,1/28/2020
9D56F2,earnings,100,50,1/28/2020
9D56F2,earnings,100,50,1/28/2020
9D56F2,earnings,100,50,1/28/2020
9D56F2,earnings,100,50,1/28/2020
9DDE1B,dividend,100,50,1/28/2020
9EA947,conference-call,100,50,1/28/2020
9F5997,legal-issues-defendant,100,22,1/28/2020
A01200,conference-participant,100,50,1/28/2020
A15C71,earnings,100,50,1/28/2020
A1A317,earnings,100,50,1/28/2020
A1A317,earnings,100,50,1/28/2020
A1A317,earnings,100,50,1/28/2020
A1A317,earnings,100,50,1/28/2020
A5A4F5,executive-resignation,100,44,1/28/2020
A5A4F5,executive-resignation,100,44,1/28/2020
A60354,conference-call,100,50,1/28/2020
A65325,dividend-up,100,81,1/28/2020
A65325,earnings-positive,100,69,1/28/2020
A80FE0,conference-call,100,50,1/28/2020
A8CBDA,executive-appointment,100,54,1/28/2020
A99576,earnings,100,50,1/28/2020
AD3C93,earnings,100,50,1/28/2020
AE4EEB,earnings,100,50,1/28/2020
AE4EEB,earnings,100,50,1/28/2020
AE4EEB,earnings,100,50,1/28/2020
AE4EEB,earnings,100,50,1/28/2020
AE4EEB,earnings,100,50,1/28/2020
AE4EEB,earnings,100,50,1/28/2020
AE4EEB,earnings,100,50,1/28/2020
AE4EEB,earnings,100,50,1/28/2020
AE4EEB,earnings,100,50,1/28/2020
AE4EEB,earnings,100,50,1/28/2020
AE4EEB,earnings,100,50,1/28/2020
AE4EEB,earnings,100,50,1/28/2020
AFF7B4,executive-appointment,100,54,1/28/2020
B1B10C,earnings,100,50,1/28/2020
B1B10C,public-offering,100,43,1/28/2020
B2DAF6,earnings,100,50,1/28/2020
B303A6,dividend,100,50,1/28/2020
B303A6,legal-issues-defendant,100,22,1/28/2020
B3ED62,conference-call,100,50,1/28/2020
B4703C,earnings-per-share-positive,100,69,1/28/2020
B4703C,earnings-positive,100,69,1/28/2020
B4703C,earnings-positive,100,69,1/28/2020
B5766D,dividend,100,50,1/28/2020
B614F8,public-offering,100,43,1/28/2020
B8F71F,earnings,100,50,1/28/2020
BB88B6,acquisition-acquirer,100,49,1/28/2020
BCE9DA,earnings,100,50,1/28/2020
BCE9DA,earnings,100,50,1/28/2020
BDEF34,earnings,100,50,1/28/2020
BDEF34,earnings,100,50,1/28/2020
BDEF34,earnings,100,50,1/28/2020
BDEF34,earnings,100,50,1/28/2020
BDEF34,earnings,100,50,1/28/2020
BDEF34,earnings,100,50,1/28/2020
BDEF34,earnings,100,50,1/28/2020
BDEF34,earnings,100,50,1/28/2020
BFCACF,earnings,100,50,1/28/2020
BFEA04,conference-call,100,50,1/28/2020
C29715,earnings,100,50,1/28/2020
C41C25,dividend,100,50,1/28/2020
C659EB,unit-acquisition-acquirer,100,49,1/28/2020
C659EB,earnings,100,50,1/28/2020
C659EB,earnings,100,50,1/28/2020
C659EB,earnings,100,50,1/28/2020
C659EB,earnings,100,50,1/28/2020
C72B8F,earnings,100,50,1/28/2020
C81E00,earnings,100,50,1/28/2020
C81E00,earnings,100,50,1/28/2020
C81E00,earnings,100,50,1/28/2020
C81E00,earnings,100,50,1/28/2020
C81E00,earnings,100,50,1/28/2020
C81E00,earnings,100,50,1/28/2020
C81E00,earnings,100,50,1/28/2020
C81E00,earnings,100,50,1/28/2020
C81E00,earnings,100,50,1/28/2020
C8923A,public-offering,100,43,1/28/2020
C9C62A,earnings,100,50,1/28/2020
CBA33B,dividend,100,50,1/28/2020
CD06A2,dividend-up,100,81,1/28/2020
CDC217,conference-participant,100,50,1/28/2020
CE2791,conference-call,100,50,1/28/2020
CF6A5A,earnings,100,50,1/28/2020
D0DFE5,earnings,100,50,1/28/2020
D1344A,earnings,100,50,1/28/2020
D33270,business-contract,100,69,1/28/2020
D3CEDF,conference-call,100,50,1/28/2020
D63B0F,conference-call,100,50,1/28/2020
D75910,award,100,58,1/28/2020
D8442A,earnings-up,100,68,1/28/2020
D8442A,earnings-up,100,68,1/28/2020
D9CAF0,earnings,100,50,1/28/2020
DA0CB8,dividend,100,50,1/28/2020
DAC66A,earnings,100,50,1/28/2020
DAFED3,earnings,100,50,1/28/2020
DB396B,legal-issues-defendant,100,22,1/28/2020
DB7FA7,earnings-positive,100,69,1/28/2020
DB7FA7,earnings-up,100,68,1/28/2020
DB7FA7,earnings-up,100,68,1/28/2020
DB7FA7,earnings-up,100,68,1/28/2020
DB7FA7,earnings-up,100,68,1/28/2020
DB7FA7,earnings-up,100,68,1/28/2020
DB7FA7,earnings-up,100,68,1/28/2020
DC1405,earnings,100,50,1/28/2020
DC2F77,dividend-up,100,81,1/28/2020
DC486E,earnings,100,50,1/28/2020
DD0F15,legal-issues-defendant,100,22,1/28/2020
DD3BB1,executive-appointment,100,54,1/28/2020
DD3BB1,executive-appointment,100,54,1/28/2020
DF11D9,earnings,100,50,1/28/2020
DF11D9,earnings,100,50,1/28/2020
DF11D9,earnings,100,50,1/28/2020
DF11D9,earnings,100,50,1/28/2020
DF11D9,earnings,100,50,1/28/2020
DF11D9,earnings,100,50,1/28/2020
DF18E6,clinical-trials,100,56,1/28/2020
DF8855,earnings,100,50,1/28/2020
E10D31,conference-call,100,50,1/28/2020
E10D31,conference-call,100,50,1/28/2020
E124EB,award,100,58,1/28/2020
E21871,dividend,100,50,1/28/2020
E5F0A8,earnings,100,50,1/28/2020
E8846E,dividend,100,50,1/28/2020
E9C7C0,partnership,100,61,1/28/2020
E9E6FD,earnings,100,50,1/28/2020
E9FF33,earnings,100,50,1/28/2020
EAEBF3,conference-call,100,50,1/28/2020
EBD89A,earnings,100,50,1/28/2020
ED79D9,conference-call,100,50,1/28/2020
EDF5CA,earnings,100,50,1/28/2020
EDF5CA,earnings,100,50,1/28/2020
EDF5CA,earnings,100,50,1/28/2020
EDF5CA,earnings,100,50,1/28/2020
EDF5CA,earnings,100,50,1/28/2020
EDF5CA,earnings,100,50,1/28/2020
EDF5CA,earnings,100,50,1/28/2020
EEEA9F,legal-issues-defendant,100,22,1/28/2020
EF76C8,dividend,100,50,1/28/2020
F0027C,public-offering,100,43,1/28/2020
F0B877,facility-open,100,65,1/28/2020
F294DD,earnings,100,50,1/28/2020
F294DD,earnings,100,50,1/28/2020
F294DD,earnings,100,50,1/28/2020
F294DD,earnings,100,50,1/28/2020
F294DD,earnings,100,50,1/28/2020
F294DD,earnings,100,50,1/28/2020
F294DD,earnings,100,50,1/28/2020
F294DD,earnings,100,50,1/28/2020
F294DD,earnings,100,50,1/28/2020
F294DD,earnings,100,50,1/28/2020
F294DD,earnings,100,50,1/28/2020
F294DD,earnings,100,50,1/28/2020
F294DD,earnings,100,50,1/28/2020
F294DD,earnings,100,50,1/28/2020
F294DD,earnings,100,50,1/28/2020
F294DD,earnings,100,50,1/28/2020
F57F6F,executive-appointment,100,54,1/28/2020
F57F6F,executive-appointment,100,54,1/28/2020
F57F6F,conference-participant,100,50,1/28/2020
F6E248,regulatory-product-approval-granted,100,81,1/28/2020
F793FA,earnings,100,50,1/28/2020
F85CC0,earnings,100,50,1/28/2020
F85CC0,earnings,100,50,1/28/2020
FB7724,earnings,100,50,1/28/2020
FC01C0,conference-call,100,50,1/28/2020
FC4550,earnings,100,50,1/28/2020
FD9A97,dividend,100,50,1/28/2020
003B70,executive-appointment,100,54,1/29/2020
20751,public-offering,100,43,1/29/2020
03CF95,earnings,100,50,1/29/2020
55018,dividend,100,50,1/29/2020
58828,earnings-per-share-up,100,82,1/29/2020
06C826,index-listing,100,76,1/29/2020
081AB9,earnings,100,50,1/29/2020
0986B5,earnings,100,50,1/29/2020
0A7650,buybacks,100,74,1/29/2020
0B4D10,earnings,100,50,1/29/2020
0B57D7,earnings,100,50,1/29/2020
0E2992,earnings-per-share-positive,100,69,1/29/2020
10AE08,partnership,100,61,1/29/2020
1216D1,earnings-up,100,68,1/29/2020
1216D1,earnings-up,100,68,1/29/2020
1216D1,earnings-up,100,68,1/29/2020
1216D1,earnings-up,100,68,1/29/2020
1216D1,earnings-up,100,68,1/29/2020
1216D1,earnings-up,100,68,1/29/2020
1216D1,earnings-up,100,68,1/29/2020
126F95,earnings,100,50,1/29/2020
126F95,earnings,100,50,1/29/2020
126F95,earnings,100,50,1/29/2020
126F95,earnings,100,50,1/29/2020
12DE76,conference-call,100,50,1/29/2020
12E454,earnings,100,50,1/29/2020
157D9F,executive-appointment,100,54,1/29/2020
168A5D,unit-acquisition-acquiree,100,76,1/29/2020
168A5D,acquisition-acquiree,100,76,1/29/2020
1782D5,business-contract,100,69,1/29/2020
197019,dividend-up,100,81,1/29/2020
19BF16,earnings,100,50,1/29/2020
1DB833,fundraising,100,64,1/29/2020
1DDEDA,executive-appointment,100,54,1/29/2020
1E8A99,earnings,100,50,1/29/2020
1EC3E8,earnings-up,100,68,1/29/2020
200D8B,earnings,100,50,1/29/2020
2031CE,earnings,100,50,1/29/2020
2031CE,earnings,100,50,1/29/2020
2031CE,earnings,100,50,1/29/2020
2031CE,earnings,100,50,1/29/2020
2031CE,earnings,100,50,1/29/2020
2031CE,earnings,100,50,1/29/2020
221AD7,earnings,100,50,1/29/2020
228D42,product-release,100,64,1/29/2020
250BEE,dividend,100,50,1/29/2020
25102A,dividend,100,50,1/29/2020
25102A,earnings,100,50,1/29/2020
251988,earnings,100,50,1/29/2020
251988,earnings,100,50,1/29/2020
251988,earnings,100,50,1/29/2020
251988,earnings,100,50,1/29/2020
251988,earnings,100,50,1/29/2020
251988,earnings,100,50,1/29/2020
25A6CC,legal-issues-defendant,100,22,1/29/2020
264EB3,earnings,100,50,1/29/2020
264EB3,earnings,100,50,1/29/2020
2720AB,earnings,100,50,1/29/2020
27BFA1,earnings-per-share-positive,100,69,1/29/2020
27BFA1,earnings-per-share-positive,100,69,1/29/2020
27BFA1,earnings-per-share-positive,100,69,1/29/2020
27BFA1,earnings-per-share-positive,100,69,1/29/2020
27BFA1,earnings-per-share-positive,100,69,1/29/2020
27BFA1,earnings-per-share-positive,100,69,1/29/2020
27BFA1,earnings-per-share-positive,100,69,1/29/2020
2A9C0A,earnings-positive,100,69,1/29/2020
2A9C0A,earnings,100,50,1/29/2020
2A9C0A,earnings,100,50,1/29/2020
2A9C0A,earnings,100,50,1/29/2020
2A9C0A,earnings,100,50,1/29/2020
2A9C0A,earnings,100,50,1/29/2020
2B7A40,earnings-per-share-positive,100,69,1/29/2020
2B7A40,earnings-positive,100,69,1/29/2020
2B7A40,earnings-positive,100,69,1/29/2020
2B7A40,earnings-positive,100,69,1/29/2020
2D2D43,earnings,100,50,1/29/2020
2D2D43,earnings,100,50,1/29/2020
2D2D43,earnings,100,50,1/29/2020
2D2D43,earnings,100,50,1/29/2020
2D2D43,earnings,100,50,1/29/2020
2D2D43,earnings,100,50,1/29/2020
2D485F,earnings,100,50,1/29/2020
2D5011,earnings,100,50,1/29/2020
2D643C,earnings,100,50,1/29/2020
2EB04E,partnership,100,61,1/29/2020
2F1299,dividend,100,50,1/29/2020
2F94A5,earnings,100,50,1/29/2020
31553A,earnings,100,50,1/29/2020
32CB22,earnings,100,50,1/29/2020
3696BF,earnings,100,50,1/29/2020
3798B9,earnings,100,50,1/29/2020
3A3447,dividend,100,50,1/29/2020
3DE4D1,executive-appointment,100,54,1/29/2020
3E149C,partnership,100,61,1/29/2020
416C55,earnings,100,50,1/29/2020
422A82,earnings,100,50,1/29/2020
422A82,earnings,100,50,1/29/2020
422A82,earnings,100,50,1/29/2020
43A74A,earnings,100,50,1/29/2020
447FC6,earnings,100,50,1/29/2020
447FC6,earnings,100,50,1/29/2020
45ABCC,earnings,100,50,1/29/2020
47752F,earnings,100,50,1/29/2020
4885C8,earnings,100,50,1/29/2020
494EB9,earnings,100,50,1/29/2020
49A344,executive-appointment,100,54,1/29/2020
4A5C8D,dividend,100,50,1/29/2020
4A6F00,partnership,100,61,1/29/2020
4A6F00,partnership,100,61,1/29/2020
4A6F00,partnership,100,61,1/29/2020
4C37C5,dividend,100,50,1/29/2020
4C37C5,executive-appointment,100,54,1/29/2020
4D7BD8,earnings,100,50,1/29/2020
4D7BD8,earnings,100,50,1/29/2020
4D7BD8,earnings,100,50,1/29/2020
4D7BD8,earnings,100,50,1/29/2020
4D7BD8,earnings,100,50,1/29/2020
4D7BD8,earnings,100,50,1/29/2020
4D7BD8,earnings,100,50,1/29/2020
4D7BD8,earnings,100,50,1/29/2020
4D7BD8,earnings,100,50,1/29/2020
4E7C1F,earnings,100,50,1/29/2020
4E7C1F,earnings,100,50,1/29/2020
4E7C1F,earnings,100,50,1/29/2020
50070E,conference-organizer,100,57,1/29/2020
53E575,partnership,100,61,1/29/2020
54A646,dividend,100,50,1/29/2020
55438C,earnings,100,50,1/29/2020
55438C,earnings,100,50,1/29/2020
55438C,earnings,100,50,1/29/2020
55438C,earnings,100,50,1/29/2020
55ACCB,product-release,100,64,1/29/2020
56632F,conference-call,100,50,1/29/2020
587EDF,earnings,100,50,1/29/2020
589F5A,earnings,100,50,1/29/2020
5D63F1,earnings,100,50,1/29/2020
5F2FF7,business-contract,100,69,1/29/2020
5F3E74,conference-call,100,50,1/29/2020
601785,executive-appointment,100,54,1/29/2020
60DD84,revenues,100,50,1/29/2020
60DD84,revenues,100,50,1/29/2020
60DD84,revenues,100,50,1/29/2020
62EFEE,dividend,100,50,1/29/2020
62EFEE,earnings-guidance,100,50,1/29/2020
62F41C,legal-issues-defendant,100,22,1/29/2020
63E8D5,earnings,100,50,1/29/2020
65CF8E,dividend,100,50,1/29/2020
65CF8E,dividend,100,50,1/29/2020
662682,earnings,100,50,1/29/2020
662682,dividend,100,50,1/29/2020
66ECFD,earnings,100,50,1/29/2020
673C9A,conference-call,100,50,1/29/2020
6ACFBF,earnings,100,50,1/29/2020
6CB7F9,conference-call,100,50,1/29/2020
6DDA15,legal-issues-defendant,100,22,1/29/2020
6EB9DA,dividend,100,50,1/29/2020
71B0CF,public-offering,100,43,1/29/2020
71E2EF,earnings,100,50,1/29/2020
722DE3,earnings-up,100,68,1/29/2020
722DE3,earnings,100,50,1/29/2020
728737,earnings,100,50,1/29/2020
732449,earnings,100,50,1/29/2020
735388,earnings,100,50,1/29/2020
73A213,earnings,100,50,1/29/2020
7.44E+09,dividend,100,50,1/29/2020
791EC1,business-contract,100,69,1/29/2020
7A10FF,earnings,100,50,1/29/2020
7A2A49,conference-call,100,50,1/29/2020
7A2A49,conference-call,100,50,1/29/2020
7A3633,earnings,100,50,1/29/2020
7A3633,partnership,100,61,1/29/2020
7A3633,partnership,100,61,1/29/2020
7AB859,earnings,100,50,1/29/2020
7AF5B8,public-offering,100,43,1/29/2020
7B6C88,earnings,100,50,1/29/2020
7B9AFA,earnings,100,50,1/29/2020
7C4F43,clinical-trials,100,56,1/29/2020
7C62A3,earnings,100,50,1/29/2020
7E1542,earnings,100,50,1/29/2020
7E3F8F,earnings,100,50,1/29/2020
7E62B5,earnings,100,50,1/29/2020
830BDB,conference-call,100,50,1/29/2020
83B1C8,patient-enrollment-complete,100,64,1/29/2020
83B1C8,patient-enrollment-complete,100,64,1/29/2020
84920B,earnings,100,50,1/29/2020
858942,earnings,100,50,1/29/2020
860AB6,conference-call,100,50,1/29/2020
860AB6,earnings,100,50,1/29/2020
8A8E41,earnings,100,50,1/29/2020
8A8E41,partnership,100,61,1/29/2020
8DCBBB,earnings,100,50,1/29/2020
8E93A4,dividend,100,50,1/29/2020
8EF425,earnings,100,50,1/29/2020
8EF425,earnings,100,50,1/29/2020
8EF425,earnings,100,50,1/29/2020
8EF425,earnings,100,50,1/29/2020
8EF425,earnings,100,50,1/29/2020
8EF425,earnings,100,50,1/29/2020
8FE7A5,earnings,100,50,1/29/2020
8FF2EF,earnings,100,50,1/29/2020
902255,earnings,100,50,1/29/2020
902670,dividend,100,50,1/29/2020
907ED2,earnings,100,50,1/29/2020
92D9C9,conference-call,100,50,1/29/2020
942165,dividend,100,50,1/29/2020
9.54E+32,earnings,100,50,1/29/2020
95C575,earnings,100,50,1/29/2020
96BFF4,executive-appointment,100,54,1/29/2020
977A1E,partnership,100,61,1/29/2020
98CEBB,partnership,100,61,1/29/2020
990AD0,dividend,100,50,1/29/2020
990AD0,conference-organizer,100,57,1/29/2020
9.92E+94,earnings,100,50,1/29/2020
9.92E+94,earnings,100,50,1/29/2020
9.92E+94,earnings,100,50,1/29/2020
9A02C4,earnings,100,50,1/29/2020
9A02C4,dividend,100,50,1/29/2020
9A602D,executive-appointment,100,54,1/29/2020
9BB35A,conference-call,100,50,1/29/2020
9D2790,partnership,100,61,1/29/2020
9E3224,earnings,100,50,1/29/2020
9EED50,earnings-up,100,68,1/29/2020
A6213D,partnership,100,61,1/29/2020
A6ABE9,earnings,100,50,1/29/2020
A6FE1C,unit-acquisition-acquirer,100,49,1/29/2020
A7102F,business-contract,100,69,1/29/2020
A7102F,business-contract,100,69,1/29/2020
A7A0C8,orphan-drug-designation,100,76,1/29/2020
AA7FE0,partnership,100,61,1/29/2020
AADE0B,dividend-up,100,81,1/29/2020
AE0CCE,executive-appointment,100,54,1/29/2020
AED6CF,conference-call,100,50,1/29/2020
B08954,earnings,100,50,1/29/2020
B1FC3B,executive-appointment,100,54,1/29/2020
B1FC3B,acquisition-acquirer,100,49,1/29/2020
B1FC3B,acquisition-acquirer,100,49,1/29/2020
B1FC3B,acquisition-acquirer,100,49,1/29/2020
B1FC3B,acquisition-acquirer,100,49,1/29/2020
B1FC3B,acquisition-acquirer,100,49,1/29/2020
B303A6,legal-issues-defendant,100,22,1/29/2020
B6082A,earnings,100,50,1/29/2020
B8F71F,executive-appointment,100,54,1/29/2020
BB88B6,earnings,100,50,1/29/2020
BBAE2A,dividend-up,100,60,1/29/2020
BCC55F,conference-call,100,50,1/29/2020
BD8517,earnings,100,50,1/29/2020
BDD12C,award,100,58,1/29/2020
C2E120,earnings,100,50,1/29/2020
C4A912,conference-call,100,50,1/29/2020
C66B44,earnings,100,50,1/29/2020
C7AE14,conference-participant,100,50,1/29/2020
C8923A,public-offering,100,43,1/29/2020
C8A248,earnings,100,50,1/29/2020
C951A2,earnings,100,50,1/29/2020
C951A2,earnings,100,50,1/29/2020
C951A2,earnings,100,50,1/29/2020
C951A2,earnings,100,50,1/29/2020
C951A2,earnings,100,50,1/29/2020
C951A2,earnings,100,50,1/29/2020
C99CC8,partnership,100,61,1/29/2020
C9B932,earnings,100,50,1/29/2020
C9F39B,earnings,100,50,1/29/2020
C9F39B,earnings,100,50,1/29/2020
C9F39B,earnings,100,50,1/29/2020
C9F39B,earnings,100,50,1/29/2020
C9F39B,earnings,100,50,1/29/2020
C9F39B,earnings,100,50,1/29/2020
C9F39B,earnings,100,50,1/29/2020
C9F39B,earnings,100,50,1/29/2020
C9F39B,earnings,100,50,1/29/2020
C9F39B,earnings,100,50,1/29/2020
C9F39B,earnings,100,50,1/29/2020
C9F39B,earnings,100,50,1/29/2020
C9F39B,earnings,100,50,1/29/2020
C9F39B,earnings,100,50,1/29/2020
CA1620,business-contract,100,69,1/29/2020
CA99D7,conference-call,100,50,1/29/2020
CA99D7,conference-call,100,50,1/29/2020
CBA33B,earnings,100,50,1/29/2020
CD4DA8,earnings,100,50,1/29/2020
CD4DA8,earnings,100,50,1/29/2020
CD4DA8,earnings,100,50,1/29/2020
CD4DA8,earnings,100,50,1/29/2020
CD4DA8,earnings,100,50,1/29/2020
CD4DA8,earnings,100,50,1/29/2020
CD4DA8,earnings,100,50,1/29/2020
CD4DA8,earnings,100,50,1/29/2020
CD4DA8,earnings,100,50,1/29/2020
CD4DA8,earnings,100,50,1/29/2020
CD4DA8,earnings,100,50,1/29/2020
CDEDFE,buybacks,100,74,1/29/2020
CE1002,earnings,100,50,1/29/2020
CE1002,earnings,100,50,1/29/2020
CE1002,earnings,100,50,1/29/2020
CE1002,earnings,100,50,1/29/2020
CE1002,earnings,100,50,1/29/2020
CE1002,acquisition-acquirer,100,49,1/29/2020
CE1002,acquisition-acquirer,100,49,1/29/2020
CE1002,acquisition-acquirer,100,49,1/29/2020
CFF97C,product-release,100,64,1/29/2020
CFF97C,dividend-up,100,67,1/29/2020
D06755,earnings,100,50,1/29/2020
D0909F,earnings,100,50,1/29/2020
D33D8C,dividend,100,50,1/29/2020
D437C3,note-sale,100,52,1/29/2020
D48275,earnings,100,50,1/29/2020
D501DC,earnings,100,50,1/29/2020
D54E62,dividend-up,100,81,1/29/2020
D57D99,award,100,58,1/29/2020
D58A11,earnings,100,50,1/29/2020
D58A11,earnings,100,50,1/29/2020
D58A11,earnings,100,50,1/29/2020
D5A350,earnings,100,50,1/29/2020
D5AF19,dividend,100,50,1/29/2020
D721C6,earnings-up,100,68,1/29/2020
D721C6,earnings-up,100,68,1/29/2020
D9164D,earnings,100,50,1/29/2020
DA90E1,earnings,100,50,1/29/2020
DCD97F,earnings,100,50,1/29/2020
DD0F15,legal-issues-defendant,100,22,1/29/2020
DD0F15,legal-issues-defendant,100,22,1/29/2020
DD3BB1,earnings,100,50,1/29/2020
DEF058,earnings,100,50,1/29/2020
DF01B1,conference-call,100,50,1/29/2020
E00373,earnings,100,50,1/29/2020
E0339F,earnings,100,50,1/29/2020
E0339F,earnings,100,50,1/29/2020
E0339F,earnings,100,50,1/29/2020
E0339F,earnings,100,50,1/29/2020
E6D89E,earnings,100,50,1/29/2020
E6D89E,earnings,100,50,1/29/2020
E6D89E,earnings,100,50,1/29/2020
E6D89E,earnings,100,50,1/29/2020
E70531,dividend,100,50,1/29/2020
E74B55,conference-call,100,50,1/29/2020
E829E8,earnings,100,50,1/29/2020
E866D2,dividend,100,50,1/29/2020
E8A49A,earnings,100,50,1/29/2020
EB5E78,conference-participant,100,50,1/29/2020
ED2EFD,dividend,100,50,1/29/2020
ED9576,earnings,100,50,1/29/2020
EDF5CA,earnings,100,50,1/29/2020
EE1E44,earnings-up,100,68,1/29/2020
EE1E44,earnings-up,100,68,1/29/2020
EE1E44,earnings-up,100,68,1/29/2020
EE1E44,earnings-up,100,68,1/29/2020
EE1E44,earnings-up,100,68,1/29/2020
EE1E44,earnings-up,100,68,1/29/2020
EE74E1,earnings,100,50,1/29/2020
EE74E1,earnings,100,50,1/29/2020
EE74E1,earnings,100,50,1/29/2020
EFD406,conference-call,100,50,1/29/2020
F0B2B5,conference-call,100,50,1/29/2020
F1CD47,earnings,100,50,1/29/2020
F2E253,dividend,100,50,1/29/2020
F3FCC3,earnings-up,100,68,1/29/2020
F40EE2,earnings,100,50,1/29/2020
F40EE2,earnings,100,50,1/29/2020
F50BAB,earnings,100,50,1/29/2020
F51DB0,conference-call,100,50,1/29/2020
F6FA6A,conference-call,100,50,1/29/2020
F7902B,earnings,100,50,1/29/2020
F7902B,earnings,100,50,1/29/2020
F90EE5,conference-organizer,100,57,1/29/2020
F93C8A,conference-call,100,50,1/29/2020
FAE021,partnership,100,61,1/29/2020
FAE021,partnership,100,61,1/29/2020
FAE021,partnership,100,61,1/29/2020
FAE021,business-contract,100,69,1/29/2020
FAE021,partnership,100,61,1/29/2020
FAE021,business-contract,100,69,1/29/2020
FC1736,partnership,100,61,1/29/2020
FD4BBE,earnings,100,50,1/29/2020
FD4E8D,revenues,100,50,1/29/2020
FD4E8D,revenues,100,50,1/29/2020
FD4E8D,revenues,100,50,1/29/2020
FD9A97,earnings,100,50,1/29/2020
FDC7E6,dividend,100,50,1/29/2020
FDC7E6,earnings,100,50,1/29/2020
FEE4B0,dividend,100,50,1/29/2020
FF4BA4,partnership,100,61,1/29/2020
00326E,earnings,100,50,1/30/2020
9397,earnings,100,50,1/30/2020
0142B5,earnings-per-share-positive,100,69,1/30/2020
01478A,earnings,100,50,1/30/2020
0157B1,partnership,100,61,1/30/2020
0157B1,revenue-up,100,70,1/30/2020
0157B1,revenue-up,100,70,1/30/2020
0157B1,revenue-up,100,70,1/30/2020
0157B1,revenue-up,100,70,1/30/2020
0157B1,revenue-up,100,70,1/30/2020
0157B1,revenue-up,100,70,1/30/2020
0157B1,revenue-up,100,70,1/30/2020
20751,public-offering,100,43,1/30/2020
03542C,earnings-guidance,100,50,1/30/2020
43862,conference-call,100,50,1/30/2020
070B45,earnings,100,50,1/30/2020
07CA6A,earnings,100,50,1/30/2020
07CA6A,earnings,100,50,1/30/2020
95294,executive-appointment,100,54,1/30/2020
0BC853,earnings,100,50,1/30/2020
0BF198,executive-appointment,100,54,1/30/2020
0BF198,executive-appointment,100,54,1/30/2020
0ED415,earnings,100,50,1/30/2020
0F2BC9,business-contract,100,69,1/30/2020
0F91FC,conference-call,100,50,1/30/2020
0FDE97,partnership,100,61,1/30/2020
105D00,dividend,100,50,1/30/2020
10AE08,earnings,100,50,1/30/2020
1151F4,earnings,100,50,1/30/2020
1151F4,earnings,100,50,1/30/2020
1151F4,earnings,100,50,1/30/2020
1151F4,earnings,100,50,1/30/2020
1151F4,earnings,100,50,1/30/2020
1151F4,earnings,100,50,1/30/2020
159AE4,earnings,100,50,1/30/2020
168A5D,executive-appointment,100,54,1/30/2020
1D943E,earnings,100,50,1/30/2020
1DB6A6,earnings,100,50,1/30/2020
1DB6A6,earnings,100,50,1/30/2020
1DB6A6,earnings,100,50,1/30/2020
1DB6A6,earnings,100,50,1/30/2020
1DB6A6,earnings,100,50,1/30/2020
1DB6A6,earnings,100,50,1/30/2020
1DDEDA,earnings,100,50,1/30/2020
1DF15D,earnings,100,50,1/30/2020
1F19C8,acquisition-acquirer,100,49,1/30/2020
1FC422,earnings,100,50,1/30/2020
2093B1,earnings-up,100,68,1/30/2020
2093B1,earnings,100,50,1/30/2020
2093B1,earnings,100,50,1/30/2020
2093B1,earnings,100,50,1/30/2020
219B21,earnings,100,50,1/30/2020
239106,conference-call,100,50,1/30/2020
24CB56,earnings,100,50,1/30/2020
250BEE,earnings,100,50,1/30/2020
250BEE,earnings,100,50,1/30/2020
250BEE,earnings,100,50,1/30/2020
250BEE,earnings,100,50,1/30/2020
250BEE,earnings,100,50,1/30/2020
28DCA8,earnings,100,50,1/30/2020
28DCA8,earnings,100,50,1/30/2020
28DCA8,earnings,100,50,1/30/2020
2A17B1,earnings,100,50,1/30/2020
2A17B1,earnings,100,50,1/30/2020
2A17B1,earnings,100,50,1/30/2020
2A17B1,earnings,100,50,1/30/2020
2BA977,earnings,100,50,1/30/2020
343996,earnings-up,100,68,1/30/2020
343996,earnings-up,100,68,1/30/2020
3461CF,executive-appointment,100,54,1/30/2020
34E9F9,conference-call,100,50,1/30/2020
35AE32,executive-appointment,100,54,1/30/2020
36E479,earnings,100,50,1/30/2020
370C50,acquisition-acquirer,100,49,1/30/2020
370C50,earnings,100,50,1/30/2020
370C50,earnings,100,50,1/30/2020
370C50,earnings,100,50,1/30/2020
370C50,earnings,100,50,1/30/2020
370C50,earnings,100,50,1/30/2020
370C50,earnings,100,50,1/30/2020
370C50,earnings,100,50,1/30/2020
370C50,earnings,100,50,1/30/2020
370C50,earnings,100,50,1/30/2020
370C50,earnings,100,50,1/30/2020
370C50,earnings,100,50,1/30/2020
370C50,earnings,100,50,1/30/2020
372037,product-release,100,64,1/30/2020
3A1C46,executive-appointment,100,54,1/30/2020
3A4BDB,dividend,100,50,1/30/2020
3BC360,dividend,100,50,1/30/2020
3ED92D,earnings,100,50,1/30/2020
3ED92D,earnings,100,50,1/30/2020
3ED92D,earnings,100,50,1/30/2020
3ED92D,earnings,100,50,1/30/2020
3ED92D,earnings,100,50,1/30/2020
3ED92D,earnings,100,50,1/30/2020
3ED92D,earnings,100,50,1/30/2020
3ED92D,earnings,100,50,1/30/2020
3ED92D,executive-appointment,100,54,1/30/2020
408089,earnings,100,50,1/30/2020
41A93D,partnership,100,61,1/30/2020
41A93D,earnings,100,50,1/30/2020
41D61C,earnings,100,50,1/30/2020
434F38,earnings,100,50,1/30/2020
448BF3,product-release,100,64,1/30/2020
451D61,conference-call,100,50,1/30/2020
4595EF,earnings,100,50,1/30/2020
479930,earnings,100,50,1/30/2020
49F4D0,earnings,100,50,1/30/2020
4B5054,partnership,100,61,1/30/2020
4C6C63,dividend,100,50,1/30/2020
4D8313,private-placement,100,56,1/30/2020
4E2D94,earnings,100,50,1/30/2020
4E2D94,dividend,100,50,1/30/2020
50070E,conference-organizer,100,57,1/30/2020
50070E,conference-organizer,100,57,1/30/2020
50070E,conference-organizer,100,57,1/30/2020
525A1C,earnings,100,50,1/30/2020
52D936,executive-appointment,100,54,1/30/2020
53A226,earnings,100,50,1/30/2020
543C77,ipo-pricing,100,50,1/30/2020
5.47E+28,rights-issue,100,43,1/30/2020
54F271,earnings,100,50,1/30/2020
553949,earnings-up,100,68,1/30/2020
553949,earnings,100,50,1/30/2020
553949,earnings,100,50,1/30/2020
553949,earnings,100,50,1/30/2020
553949,earnings,100,50,1/30/2020
553949,earnings,100,50,1/30/2020
55438C,business-contract,100,69,1/30/2020
56EFC7,partnership,100,61,1/30/2020
57634F,earnings,100,50,1/30/2020
57CAAB,earnings,100,50,1/30/2020
57CAAB,earnings,100,50,1/30/2020
57CAAB,earnings,100,50,1/30/2020
57CAAB,earnings,100,50,1/30/2020
583A75,earnings,100,50,1/30/2020
59C539,earnings,100,50,1/30/2020
5A64D5,earnings,100,50,1/30/2020
5B6C11,earnings,100,50,1/30/2020
5D16CF,conference-call,100,50,1/30/2020
5E6959,earnings-up,100,68,1/30/2020
5F9CE3,revenue-up,100,69,1/30/2020
5F9CE3,earnings,100,50,1/30/2020
5F9CE3,earnings,100,50,1/30/2020
5F9CE3,earnings,100,50,1/30/2020
6137BF,earnings,100,50,1/30/2020
636639,operating-earnings-positive,100,69,1/30/2020
636639,earnings,100,50,1/30/2020
636639,earnings,100,50,1/30/2020
636639,earnings,100,50,1/30/2020
636639,earnings,100,50,1/30/2020
636639,earnings,100,50,1/30/2020
641F17,earnings,100,50,1/30/2020
6634D9,earnings,100,50,1/30/2020
69494C,earnings,100,50,1/30/2020
6A6BDC,facility-open,100,65,1/30/2020
6B5379,earnings,100,50,1/30/2020
6B5379,earnings,100,50,1/30/2020
6B5379,earnings,100,50,1/30/2020
6CC55E,clinical-trials-positive,100,87,1/30/2020
6CDFC6,earnings,100,50,1/30/2020
6DBBBC,acquisition-completed-acquirer,100,49,1/30/2020
6EB9DA,earnings,100,50,1/30/2020
6EB9DA,earnings,100,50,1/30/2020
6EB9DA,earnings,100,50,1/30/2020
6F92A9,earnings,100,50,1/30/2020
7273FF,earnings,100,50,1/30/2020
731675,merger-completed,100,66,1/30/2020
731675,merger-completed,100,66,1/30/2020
73529F,conference-call,100,50,1/30/2020
73C9E2,earnings,100,50,1/30/2020
7448A3,dividend,100,50,1/30/2020
76CEFB,earnings,100,50,1/30/2020
76DD0C,clinical-trials-start,100,64,1/30/2020
76F067,earnings,100,50,1/30/2020
7734AC,earnings,100,50,1/30/2020
79167B,acquisition-acquirer,100,49,1/30/2020
7AC86E,dividend,100,50,1/30/2020
7B0BA6,dividend,100,50,1/30/2020
7BAAE7,earnings,100,50,1/30/2020
7BAAE7,earnings,100,50,1/30/2020
7CBC40,earnings,100,50,1/30/2020
7D5384,earnings,100,50,1/30/2020
7D5384,earnings,100,50,1/30/2020
7D5384,earnings,100,50,1/30/2020
7D5384,earnings,100,50,1/30/2020
7D5384,earnings,100,50,1/30/2020
7D7716,earnings,100,50,1/30/2020
7D85A9,earnings,100,50,1/30/2020
7DC1C4,earnings,100,50,1/30/2020
8377DB,revenues,100,50,1/30/2020
84AB66,earnings-positive,100,69,1/30/2020
8665BA,earnings,100,50,1/30/2020
86BAC7,earnings,100,50,1/30/2020
86BAC7,earnings,100,50,1/30/2020
8B1F37,earnings,100,50,1/30/2020
8B1F37,earnings,100,50,1/30/2020
8B1F37,earnings,100,50,1/30/2020
8B1F37,earnings,100,50,1/30/2020
8B1F37,earnings,100,50,1/30/2020
8B1F37,earnings,100,50,1/30/2020
8B1F37,earnings,100,50,1/30/2020
8B1F37,earnings,100,50,1/30/2020
8B3B0E,conference-call,100,50,1/30/2020
8B6E7E,earnings,100,50,1/30/2020
8C5519,merger-regulatory-approval,100,81,1/30/2020
8DBE73,conference-call,100,50,1/30/2020
8DE56F,earnings,100,50,1/30/2020
8DE56F,earnings,100,50,1/30/2020
8DE74B,conference-call,100,50,1/30/2020
8E0E32,earnings,100,50,1/30/2020
8E0E32,earnings,100,50,1/30/2020
8E0E32,earnings,100,50,1/30/2020
8E0E32,earnings,100,50,1/30/2020
8E0E32,earnings,100,50,1/30/2020
8E0E32,earnings,100,50,1/30/2020
922F0C,earnings,100,50,1/30/2020
922F0C,earnings,100,50,1/30/2020
93C130,earnings,100,50,1/30/2020
93C130,earnings,100,50,1/30/2020
93C130,earnings,100,50,1/30/2020
93C130,dividend,100,50,1/30/2020
93D207,earnings,100,50,1/30/2020
943239,earnings,100,50,1/30/2020
94563D,earnings,100,50,1/30/2020
949625,earnings,100,50,1/30/2020
950AB7,earnings,100,50,1/30/2020
950AB7,dividend,100,50,1/30/2020
9.97E+09,earnings,100,50,1/30/2020
99ACAD,product-release,100,64,1/30/2020
99ACAD,product-release,100,64,1/30/2020
9B5968,earnings,100,50,1/30/2020
9B5968,earnings,100,50,1/30/2020
9CE4C7,dividend,100,50,1/30/2020
9CF9B1,earnings,100,50,1/30/2020
9D6A24,earnings,100,50,1/30/2020
9D6A24,earnings,100,50,1/30/2020
9E298A,earnings,100,50,1/30/2020
9E298A,earnings,100,50,1/30/2020
9E298A,earnings,100,50,1/30/2020
9EA947,product-release,100,64,1/30/2020
9EF4CF,legal-issues-defendant,100,22,1/30/2020
9EF4CF,legal-issues-defendant,100,22,1/30/2020
9F03CF,earnings,100,50,1/30/2020
9F03CF,dividend,100,50,1/30/2020
A02FB1,earnings,100,50,1/30/2020
A23747,earnings,100,50,1/30/2020
A247F5,earnings-per-share-positive,100,69,1/30/2020
A247F5,earnings-per-share-positive,100,69,1/30/2020
A4386C,dividend,100,50,1/30/2020
A4D173,earnings,100,50,1/30/2020
A4D173,earnings,100,50,1/30/2020
A5E715,earnings-per-share-positive,100,69,1/30/2020
A666C8,revenues,100,50,1/30/2020
A666C8,earnings,100,50,1/30/2020
A75D43,earnings,100,50,1/30/2020
A7F0A5,conference-call,100,50,1/30/2020
A94718,conference-call,100,50,1/30/2020
A9ED24,conference-call,100,50,1/30/2020
AADE0B,earnings,100,50,1/30/2020
ABBAD1,earnings,100,50,1/30/2020
AF93DE,executive-appointment,100,54,1/30/2020
AFEC35,earnings,100,50,1/30/2020
B0B969,earnings,100,50,1/30/2020
B1B10C,public-offering,100,43,1/30/2020
B303A6,legal-issues-defendant,100,22,1/30/2020
B381D8,earnings,100,50,1/30/2020
B619CB,earnings-positive,100,69,1/30/2020
B934BF,conference-call,100,50,1/30/2020
B96637,product-release,100,64,1/30/2020
BB07E4,dividend,100,50,1/30/2020
BDF2BD,conference-call,100,50,1/30/2020
BE86A1,earnings,100,50,1/30/2020
BF79F5,conference-call,100,50,1/30/2020
C1114B,conference-call,100,50,1/30/2020
C188F8,earnings,100,50,1/30/2020
C2609A,dividend,100,50,1/30/2020
C4452A,executive-appointment,100,54,1/30/2020
C4F567,revenues,100,50,1/30/2020
C4F567,earnings,100,50,1/30/2020
C4F567,earnings,100,50,1/30/2020
C4F567,earnings,100,50,1/30/2020
C4F567,earnings,100,50,1/30/2020
C5D2AE,earnings,100,50,1/30/2020
C6C702,conference-call,100,50,1/30/2020
C72B8F,partnership,100,61,1/30/2020
C8A248,earnings,100,50,1/30/2020
C9881C,executive-appointment,100,54,1/30/2020
C9F39B,executive-appointment,100,54,1/30/2020
CA1620,conference-call,100,50,1/30/2020
CA3CB9,partnership,100,61,1/30/2020
CB22CD,conference-call,100,50,1/30/2020
CBBFBF,legal-issues-defendant,100,22,1/30/2020
CC8F6E,earnings,100,50,1/30/2020
CDEDFE,earnings,100,50,1/30/2020
CDFCC9,partnership,100,61,1/30/2020
CE96E7,earnings,100,50,1/30/2020
CE96E7,earnings,100,50,1/30/2020
CE96E7,earnings,100,50,1/30/2020
CE96E7,earnings,100,50,1/30/2020
CFF57D,executive-appointment,100,54,1/30/2020
D2E553,facility-open,100,65,1/30/2020
D3FA2C,dividend,100,50,1/30/2020
D4070C,earnings,100,50,1/30/2020
D4070C,earnings,100,50,1/30/2020
D437C3,note-sale,100,52,1/30/2020
D56D6D,earnings,100,50,1/30/2020
D8C09D,conference-call,100,50,1/30/2020
D8DBA3,operating-earnings,100,50,1/30/2020
DB06B0,earnings,100,50,1/30/2020
DB06B0,earnings,100,50,1/30/2020
DB06B0,earnings,100,50,1/30/2020
DB06B0,earnings,100,50,1/30/2020
DB06B0,earnings,100,50,1/30/2020
DB2E4E,legal-issues-dismissed-plaintiff,100,44,1/30/2020
DC2F77,earnings,100,50,1/30/2020
DC5299,operating-earnings,100,50,1/30/2020
DD0F15,legal-issues-defendant,100,22,1/30/2020
DE4924,dividend,100,50,1/30/2020
DE4924,credit-extension-recipient,100,69,1/30/2020
DE4924,earnings,100,50,1/30/2020
DE5611,dividend,100,50,1/30/2020
E09E2B,conference-call,100,50,1/30/2020
E124EB,earnings,100,50,1/30/2020
E1BD05,revenue-up,100,72,1/30/2020
E1BD05,revenue-up,100,72,1/30/2020
E21871,earnings,100,50,1/30/2020
E2CFD2,partnership,100,61,1/30/2020
E30B34,award,100,58,1/30/2020
E82A2D,dividend,100,50,1/30/2020
E866D2,legal-issues-defendant,100,22,1/30/2020
E8846E,donation,100,54,1/30/2020
E959F3,dividend,100,50,1/30/2020
EC70EC,earnings,100,50,1/30/2020
ED0D7C,conference-call,100,50,1/30/2020
ED3CA8,earnings,100,50,1/30/2020
ED79D9,partnership,100,61,1/30/2020
ED9C04,earnings,100,50,1/30/2020
EDF5CA,legal-issues-defendant,100,22,1/30/2020
EDF5CA,legal-issues-defendant,100,22,1/30/2020
EEA6B3,earnings-up,100,68,1/30/2020
EEA6B3,earnings-up,100,68,1/30/2020
EEA6B3,earnings-up,100,68,1/30/2020
EF1AD9,dividend,100,50,1/30/2020
EF1AD9,earnings,100,50,1/30/2020
EF1AD9,earnings,100,50,1/30/2020
EF1AD9,earnings,100,50,1/30/2020
EF76C8,earnings,100,50,1/30/2020
F0027C,public-offering,100,43,1/30/2020
F0A9DE,earnings,100,50,1/30/2020
F30508,earnings-positive,100,69,1/30/2020
F30508,earnings,100,50,1/30/2020
F30508,earnings,100,50,1/30/2020
F30508,earnings,100,50,1/30/2020
F30508,earnings,100,50,1/30/2020
F30508,earnings,100,50,1/30/2020
F30508,earnings,100,50,1/30/2020
F30508,earnings,100,50,1/30/2020
F4F46F,partnership,100,61,1/30/2020
F4F46F,conference-call,100,50,1/30/2020
F569FD,public-offering,100,43,1/30/2020
F6E248,executive-appointment,100,54,1/30/2020
F82D37,dividend,100,50,1/30/2020
FA918D,earnings,100,50,1/30/2020
FA918D,earnings,100,50,1/30/2020
FACF19,dividend,100,50,1/30/2020
FAE021,earnings,100,50,1/30/2020
FAE021,earnings,100,50,1/30/2020
FAE021,earnings,100,50,1/30/2020
FAE021,earnings,100,50,1/30/2020
FBDA0F,earnings,100,50,1/30/2020
FC1B7B,earnings,100,50,1/30/2020
FC1F9D,earnings,100,50,1/30/2020
FF5413,earnings-positive,100,69,1/30/2020
FF5413,earnings-positive,100,69,1/30/2020
FF5413,business-contract,100,69,1/30/2020
FFE543,earnings,100,50,1/30/2020
003B70,index-listing,100,76,1/31/2020
13528,partnership,100,61,1/31/2020
02870F,conference-call,100,50,1/31/2020
71860,buybacks,100,74,1/31/2020
07EC43,conference-participant,100,50,1/31/2020
95294,award,100,58,1/31/2020
0CE204,earnings,100,50,1/31/2020
0FDE97,earnings,100,50,1/31/2020
0FDE97,earnings,100,50,1/31/2020
0FDE97,earnings,100,50,1/31/2020
0FDE97,earnings,100,50,1/31/2020
0FDE97,earnings,100,50,1/31/2020
0FDE97,earnings,100,50,1/31/2020
0FDE97,earnings,100,50,1/31/2020
108BD2,earnings-positive,100,69,1/31/2020
108BD2,earnings,100,50,1/31/2020
108BD2,earnings,100,50,1/31/2020
108BD2,earnings,100,50,1/31/2020
108BD2,earnings,100,50,1/31/2020
139303,earnings,100,50,1/31/2020
1EBF8D,business-contract,100,69,1/31/2020
1EBF8D,executive-appointment,100,54,1/31/2020
1FA886,government-contract,100,69,1/31/2020
222BF9,earnings,100,50,1/31/2020
2262BD,earnings,100,50,1/31/2020
24C48B,earnings,100,50,1/31/2020
25102A,executive-appointment,100,54,1/31/2020
25102A,executive-appointment,100,54,1/31/2020
25A6CC,legal-issues-defendant,100,22,1/31/2020
25AB8E,executive-appointment,100,54,1/31/2020
278C18,earnings,100,50,1/31/2020
28DCF3,operating-earnings,100,50,1/31/2020
2D485F,dividend,100,50,1/31/2020
31A7CC,dividend,100,50,1/31/2020
3224CC,earnings,100,50,1/31/2020
338544,earnings,100,50,1/31/2020
339F20,executive-appointment,100,54,1/31/2020
33E9D5,trading-halt,100,43,1/31/2020
3461CF,donation,100,54,1/31/2020
353DBB,earnings,100,50,1/31/2020
353DBB,earnings,100,50,1/31/2020
353DBB,earnings,100,50,1/31/2020
3B318A,executive-appointment,100,54,1/31/2020
3F6A9C,conference-call,100,50,1/31/2020
3FACA7,earnings-positive,100,69,1/31/2020
3FACA7,earnings,100,50,1/31/2020
3FACA7,earnings,100,50,1/31/2020
3FACA7,earnings,100,50,1/31/2020
416291,conference-call,100,50,1/31/2020
435ACE,dividend,100,50,1/31/2020
4885C8,dividend,100,50,1/31/2020
4D371E,dividend,100,50,1/31/2020
4F71DC,executive-appointment,100,54,1/31/2020
50070E,conference-organizer,100,57,1/31/2020
50070E,conference-organizer,100,57,1/31/2020
504FE2,unit-acquisition-completed-acquirer,100,49,1/31/2020
51E682,dividend-up,100,81,1/31/2020
562853,earnings,100,50,1/31/2020
57DDB9,conference-call,100,50,1/31/2020
57EF50,dividend,100,50,1/31/2020
59DB8C,public-offering,100,43,1/31/2020
5BFE94,conference-call,100,50,1/31/2020
5C7601,conference-participant,100,50,1/31/2020
61E975,conference-call,100,50,1/31/2020
61E975,dividend,100,50,1/31/2020
622037,executive-appointment,100,54,1/31/2020
62F41C,legal-issues-defendant,100,22,1/31/2020
62F41C,legal-issues-defendant,100,22,1/31/2020
62F41C,legal-issues-defendant,100,22,1/31/2020
62F41C,legal-issues-defendant,100,22,1/31/2020
6B236C,dividend-up,100,65,1/31/2020
6E7060,dividend,100,50,1/31/2020
6ED519,dividend,100,50,1/31/2020
7032D0,earnings,100,50,1/31/2020
726DDF,conference-call,100,50,1/31/2020
72F0FC,dividend,100,50,1/31/2020
72F0FC,buybacks,100,74,1/31/2020
731675,index-listing,100,76,1/31/2020
742AAB,conference-call,100,50,1/31/2020
743C70,earnings,100,50,1/31/2020
767F86,earnings,100,50,1/31/2020
767F86,earnings,100,50,1/31/2020
767F86,earnings,100,50,1/31/2020
76BD96,dividend,100,50,1/31/2020
789ADD,earnings,100,50,1/31/2020
789ADD,earnings,100,50,1/31/2020
789ADD,earnings,100,50,1/31/2020
789ADD,earnings,100,50,1/31/2020
7B492C,partnership,100,61,1/31/2020
80C400,dividend-up,100,81,1/31/2020
824CCA,earnings,100,50,1/31/2020
855DF7,conference-call,100,50,1/31/2020
86AA9C,conference-call,100,50,1/31/2020
86BAC7,dividend,100,50,1/31/2020
902255,dividend,100,50,1/31/2020
94637C,product-recall,100,29,1/31/2020
990AD0,conference-organizer,100,57,1/31/2020
9981C6,earnings,100,50,1/31/2020
99B61C,ipo-pricing,100,50,1/31/2020
9D6A24,dividend,100,50,1/31/2020
9EF4CF,legal-issues-defendant,100,22,1/31/2020
9EF4CF,fraud,100,44,1/31/2020
9EF4CF,legal-issues-defendant,100,22,1/31/2020
9EF4CF,legal-issues-defendant,100,22,1/31/2020
9EF4CF,fraud-defendant,100,20,1/31/2020
9F048E,earnings,100,50,1/31/2020
9F5CBB,dividend,100,50,1/31/2020
A2CA3F,dividend,100,50,1/31/2020
A2CA3F,buybacks,100,74,1/31/2020
A41450,earnings,100,50,1/31/2020
A49498,ipo-pricing,100,50,1/31/2020
A4BCDE,earnings,100,50,1/31/2020
A5151E,executive-appointment,100,54,1/31/2020
A746F6,earnings,100,50,1/31/2020
A806FA,dividend,100,50,1/31/2020
A8B137,dividend-up,100,81,1/31/2020
AC7AAE,public-offering,100,43,1/31/2020
B303A6,legal-issues-defendant,100,22,1/31/2020
B4B281,conference-call,100,50,1/31/2020
B53C12,conference-call,100,50,1/31/2020
B7EB38,earnings,100,50,1/31/2020
C0200F,product-release,100,64,1/31/2020
C0200F,earnings,100,50,1/31/2020
C7FC95,business-contract,100,69,1/31/2020
C8923A,public-offering,100,43,1/31/2020
CA3CB9,earnings-positive,100,69,1/31/2020
CA3CB9,supply-increase,100,74,1/31/2020
CB88B3,earnings,100,50,1/31/2020
CBA33B,acquisition-acquirer,100,49,1/31/2020
CBBFBF,executive-resignation,100,44,1/31/2020
CBCC6A,earnings,100,50,1/31/2020
CBCC6A,earnings,100,50,1/31/2020
CBFFDD,business-contract,100,69,1/31/2020
CC339B,earnings,100,50,1/31/2020
CCBBAD,earnings,100,50,1/31/2020
D54E62,earnings,100,50,1/31/2020
D54E62,earnings,100,50,1/31/2020
D54E62,earnings,100,50,1/31/2020
D54E62,earnings,100,50,1/31/2020
D54E62,earnings,100,50,1/31/2020
D598E7,earnings,100,50,1/31/2020
D8760C,executive-appointment,100,54,1/31/2020
D88EF3,earnings,100,50,1/31/2020
D88EF3,earnings,100,50,1/31/2020
D88EF3,earnings,100,50,1/31/2020
D88EF3,earnings,100,50,1/31/2020
D88EF3,earnings,100,50,1/31/2020
D88EF3,earnings,100,50,1/31/2020
D88EF3,earnings,100,50,1/31/2020
DA199F,buybacks,100,74,1/31/2020
DD0F15,legal-issues-defendant,100,22,1/31/2020
DF01B1,conference-participant,100,50,1/31/2020
E259C7,dividend,100,50,1/31/2020
E5F0A8,earnings,100,50,1/31/2020
E6A53A,dividend,100,50,1/31/2020
E6A53A,dividend,100,50,1/31/2020
E6E012,dividend,100,50,1/31/2020
E6E012,dividend,100,50,1/31/2020
E70531,earnings,100,50,1/31/2020
E70531,earnings,100,50,1/31/2020
E70531,earnings,100,50,1/31/2020
E70531,earnings,100,50,1/31/2020
E70531,earnings,100,50,1/31/2020
E90C84,conference-call,100,50,1/31/2020
EB6965,earnings,100,50,1/31/2020
EB6965,earnings,100,50,1/31/2020
EB6965,earnings,100,50,1/31/2020
EB6965,earnings,100,50,1/31/2020
EB6965,earnings,100,50,1/31/2020
EB6965,earnings,100,50,1/31/2020
EB6965,earnings,100,50,1/31/2020
EDF5CA,legal-issues-defendant,100,22,1/31/2020
EEBCEF,dividend,100,50,1/31/2020
F0B335,business-contract,100,69,1/31/2020
F11638,earnings,100,50,1/31/2020
F30508,regulatory-product-approval-granted,100,81,1/31/2020
F30508,regulatory-product-approval-granted,100,81,1/31/2020
F4F46F,conference-participant,100,50,1/31/2020
F5C78B,dividend,100,50,1/31/2020
F769E9,conference-call,100,50,1/31/2020
FD0CA4,dividend-up,100,81,1/31/2020
FD554E,merger-regulatory-approval,100,81,1/31/2020
FF4BA4,earnings,100,50,1/31/2020
FF5413,legal-issues-defendant,100,22,1/31/2020
25A6CC,legal-issues-defendant,100,22,2/1/2020
3DDE54,acquisition-completed-acquirer,100,49,2/1/2020
62F41C,legal-issues-defendant,100,22,2/1/2020
7AF5B8,public-offering,100,43,2/1/2020
835C86,earnings,100,50,2/1/2020
9EF4CF,legal-issues-defendant,100,22,2/1/2020
F4E882,legal-issues-defendant,100,22,2/1/2020
20751,public-offering,100,43,2/3/2020
03596A,earnings,100,50,2/3/2020
099C88,business-contract,100,69,2/3/2020
0AB700,dividend,100,60,2/3/2020
0BF198,clinical-trials-positive,100,87,2/3/2020
0BF528,conference-call,100,50,2/3/2020
0F0440,executive-appointment,100,54,2/3/2020
105D00,acquisition-completed-acquirer,100,49,2/3/2020
135B09,stake-acquirer,100,48,2/3/2020
138DDE,public-offering,100,43,2/3/2020
152AB9,reverse-stock-splits,100,51,2/3/2020
168A5D,partnership,100,61,2/3/2020
18EC17,executive-resignation,100,44,2/3/2020
1BC12C,dividend,100,50,2/3/2020
1DE526,earnings,100,50,2/3/2020
1E83DE,acquisition-completed-acquirer,100,49,2/3/2020
1F19C8,market-entry,100,57,2/3/2020
1F3CFB,business-contract,100,69,2/3/2020
1FA886,legal-issues-defendant,100,22,2/3/2020
2082EA,executive-appointment,100,54,2/3/2020
21245F,unit-acquisition-acquirer,100,49,2/3/2020
21245F,unit-acquisition-acquirer,100,49,2/3/2020
214051,business-contract,100,69,2/3/2020
214051,operating-earnings,100,50,2/3/2020
221AD7,donation,100,54,2/3/2020
225CA2,market-entry,100,57,2/3/2020
225CA2,executive-appointment,100,54,2/3/2020
227D48,earnings,100,50,2/3/2020
228D42,partnership,100,61,2/3/2020
228D42,partnership,100,61,2/3/2020
23207A,conference-call,100,50,2/3/2020
25102A,acquisition-acquirer,100,49,2/3/2020
25A6CC,legal-issues-defendant,100,22,2/3/2020
25A6CC,legal-issues-defendant,100,22,2/3/2020
25A6CC,legal-issues-defendant,100,22,2/3/2020
2667B6,dividend,100,50,2/3/2020
270305,merger-completed,100,66,2/3/2020
2A1009,earnings,100,50,2/3/2020
306623,conference-call,100,50,2/3/2020
326EDD,earnings,100,50,2/3/2020
338544,legal-issues-defendant,100,22,2/3/2020
33E9D5,trading-resumed,100,58,2/3/2020
34E9F9,dividend,100,50,2/3/2020
367E1C,executive-appointment,100,54,2/3/2020
36E479,fast-track-designation,100,81,2/3/2020
370C50,product-price-raise,100,57,2/3/2020
382EAE,conference-call,100,50,2/3/2020
385DD4,market-entry,100,57,2/3/2020
396D7C,executive-appointment,100,54,2/3/2020
39FB23,acquisition-completed-acquirer,100,49,2/3/2020
3A113F,note-sale,100,52,2/3/2020
3A3447,earnings,100,50,2/3/2020
3A3447,earnings,100,50,2/3/2020
3A3447,earnings,100,50,2/3/2020
3A3447,earnings,100,50,2/3/2020
3AF7FD,earnings,100,50,2/3/2020
3AF7FD,dividend,100,50,2/3/2020
4017AD,earnings,100,50,2/3/2020
43E8F5,clinical-trials,100,56,2/3/2020
448215,earnings,100,50,2/3/2020
44A4FC,acquisition-acquirer,100,49,2/3/2020
44A4FC,acquisition-acquirer,100,49,2/3/2020
44A4FC,earnings,100,50,2/3/2020
44A4FC,public-offering,100,43,2/3/2020
44A4FC,public-offering,100,43,2/3/2020
4649D5,asset-sale,100,62,2/3/2020
47FCF2,earnings,100,50,2/3/2020
492117,earnings,100,50,2/3/2020
492117,note-sale,100,52,2/3/2020
4AC91D,partnership,100,61,2/3/2020
4CDA2B,public-offering,100,43,2/3/2020
4FCC78,conference-call,100,50,2/3/2020
50070E,conference-organizer,100,57,2/3/2020
514067,earnings,100,50,2/3/2020
543C77,ipo-completed,100,76,2/3/2020
546A27,business-contract,100,69,2/3/2020
546A9C,acquisition-acquirer,100,49,2/3/2020
56EA2B,revenue-up,100,65,2/3/2020
587EDF,earnings,100,50,2/3/2020
58B46F,dividend,100,50,2/3/2020
5968F9,clinical-trials-filed,100,60,2/3/2020
5A423F,conference-participant,100,50,2/3/2020
5AF08A,earnings,100,50,2/3/2020
5EC388,merger-completed,100,66,2/3/2020
5EF130,conference-call,100,50,2/3/2020
62F41C,legal-issues-defendant,100,22,2/3/2020
62F41C,legal-issues-defendant,100,22,2/3/2020
62F41C,legal-issues-defendant,100,22,2/3/2020
64854A,executive-appointment,100,54,2/3/2020
657097,unit-acquisition-acquirer,100,49,2/3/2020
66A667,executive-appointment,100,54,2/3/2020
66A667,executive-appointment,100,54,2/3/2020
676FFD,legal-issues-defendant,100,22,2/3/2020
68B03F,earnings,100,50,2/3/2020
69CE71,conference-call,100,50,2/3/2020
69FDFC,product-release,100,64,2/3/2020
69FDFC,product-release,100,64,2/3/2020
6CF43C,dividend-up,100,81,2/3/2020
6D0CAB,earnings,100,50,2/3/2020
6D3B7B,dividend,100,50,2/3/2020
6D3F35,conference-call,100,50,2/3/2020
6D9B53,conference-participant,100,50,2/3/2020
70CA28,earnings,100,50,2/3/2020
70CA28,earnings,100,50,2/3/2020
71B0CF,public-offering,100,43,2/3/2020
724F84,earnings,100,50,2/3/2020
729368,earnings,100,50,2/3/2020
73A213,earnings,100,50,2/3/2020
73A213,earnings,100,50,2/3/2020
73BCBA,executive-appointment,100,54,2/3/2020
765913,acquisition-acquirer,100,49,2/3/2020
765913,acquisition-acquirer,100,49,2/3/2020
766047,earnings,100,50,2/3/2020
769F40,executive-appointment,100,54,2/3/2020
769F40,executive-appointment,100,54,2/3/2020
790C34,earnings,100,50,2/3/2020
79340A,earnings,100,50,2/3/2020
7B6EB1,conference-participant,100,50,2/3/2020
7D5FD6,market-entry,100,57,2/3/2020
7DA412,earnings,100,50,2/3/2020
7DA412,earnings,100,50,2/3/2020
7E3F8F,product-release,100,64,2/3/2020
7F3FBC,acquisition-acquirer,100,49,2/3/2020
7FEEE1,partnership,100,61,2/3/2020
83598E,earnings,100,50,2/3/2020
8377DB,partnership,100,61,2/3/2020
85DA04,product-release,100,64,2/3/2020
85DA04,product-release,100,64,2/3/2020
86F123,acquisition-acquirer,100,49,2/3/2020
8A8E41,partnership,100,61,2/3/2020
8BFAA4,executive-appointment,100,54,2/3/2020
8D0EEA,executive-appointment,100,54,2/3/2020
8D4AE6,earnings,100,50,2/3/2020
8F6995,earnings,100,50,2/3/2020
9087B9,dividend,100,50,2/3/2020
92D757,dividend-up,100,81,2/3/2020
93965C,earnings,100,50,2/3/2020
940C3D,partnership,100,61,2/3/2020
9.86E+03,earnings,100,50,2/3/2020
990AD0,conference-organizer,100,57,2/3/2020
990AD0,conference-organizer,100,57,2/3/2020
9934AD,executive-appointment,100,54,2/3/2020
9A2760,executive-appointment,100,54,2/3/2020
9D2790,earnings,100,50,2/3/2020
9D2790,earnings,100,50,2/3/2020
9D2790,earnings,100,50,2/3/2020
9D2790,earnings,100,50,2/3/2020
9D2790,earnings,100,50,2/3/2020
9D2790,earnings,100,50,2/3/2020
9D2790,earnings,100,50,2/3/2020
9D4EC7,earnings,100,50,2/3/2020
9EF4CF,legal-issues-defendant,100,22,2/3/2020
9EF4CF,legal-issues-defendant,100,22,2/3/2020
9EF4CF,legal-issues-defendant,100,22,2/3/2020
9EF4CF,legal-issues-defendant,100,22,2/3/2020
A15C71,acquisition-completed-acquirer,100,49,2/3/2020
A1E3B3,earnings,100,50,2/3/2020
A29DBD,earnings,100,50,2/3/2020
A47A7D,product-release,100,64,2/3/2020
A5195E,clinical-trials-filed,100,60,2/3/2020
A666C8,product-release,100,64,2/3/2020
A79D88,patent-awarded,100,72,2/3/2020
AB7726,executive-appointment,100,54,2/3/2020
AD3008,acquisition-acquirer,100,49,2/3/2020
AD9F1D,market-entry,100,57,2/3/2020
B1FC3B,business-contract,100,69,2/3/2020
B2D492,earnings,100,50,2/3/2020
B33E77,clinical-trials,100,56,2/3/2020
B3CB74,conference-organizer,100,57,2/3/2020
B604DF,earnings,100,50,2/3/2020
B604DF,dividend,100,50,2/3/2020
B7FA9B,conference-call,100,50,2/3/2020
B934BF,executive-appointment,100,54,2/3/2020
BAAA60,earnings,100,50,2/3/2020
BB58FF,earnings,100,50,2/3/2020
BD682F,earnings,100,50,2/3/2020
BFE02C,note-sale,100,52,2/3/2020
C230FE,earnings,100,50,2/3/2020
C230FE,earnings,100,50,2/3/2020
C38440,acquisition-completed-acquirer,100,49,2/3/2020
C66A8C,executive-appointment,100,54,2/3/2020
C7AE14,earnings,100,50,2/3/2020
CAB222,conference-call,100,50,2/3/2020
CBBFBF,regulatory-investigation,100,22,2/3/2020
CDD75E,public-offering,100,43,2/3/2020
CE4E6D,executive-appointment,100,54,2/3/2020
CE96E7,unit-acquisition-acquiree,100,76,2/3/2020
CE96E7,unit-acquisition-acquiree,100,76,2/3/2020
D139BC,conference-call,100,50,2/3/2020
D1AE3B,executive-appointment,100,54,2/3/2020
D33270,award,100,58,2/3/2020
D6534D,conference-call,100,50,2/3/2020
D78BF1,award,100,58,2/3/2020
D8F347,legal-issues-defendant,100,22,2/3/2020
D93A25,asset-sale,100,62,2/3/2020
DA91AE,earnings,100,50,2/3/2020
DC2F77,facility-relocation,100,50,2/3/2020
DD9E41,earnings,100,50,2/3/2020
E4CE73,conference-call,100,50,2/3/2020
E4CE73,executive-appointment,100,54,2/3/2020
E90C84,conference-participant,100,50,2/3/2020
EA62FC,earnings,100,50,2/3/2020
EB61C4,conference-participant,100,50,2/3/2020
EC4E82,acquisition-completed-acquirer,100,49,2/3/2020
ED2EFD,facility-upgrade,100,65,2/3/2020
F02D0A,executive-appointment,100,54,2/3/2020
F05B1B,merger-completed,100,66,2/3/2020
F05B1B,merger-completed,100,66,2/3/2020
F2BC3D,acquisition-acquirer,100,49,2/3/2020
F3EDB4,executive-appointment,100,54,2/3/2020
F3FCC3,conference-participant,100,50,2/3/2020
F4CDA3,conference-call,100,50,2/3/2020
F5D410,executive-appointment,100,54,2/3/2020
F5D410,executive-appointment,100,54,2/3/2020
F702CA,executive-appointment,100,54,2/3/2020
FC4550,dividend,100,50,2/3/2020
13528,product-release,100,64,2/4/2020
0157B1,market-entry,100,57,2/4/2020
0157B1,partnership,100,61,2/4/2020
31025,revenue-up,100,69,2/4/2020
03B8CF,dividend-up,100,81,2/4/2020
03FB17,revenue-up,100,54,2/4/2020
03FB17,revenue-up,100,54,2/4/2020
03FB17,revenue-up,100,54,2/4/2020
03FB17,revenue-up,100,54,2/4/2020
03FB17,revenue-up,100,54,2/4/2020
03FB17,revenue-up,100,54,2/4/2020
03FB17,revenue-up,100,54,2/4/2020
03FB17,revenue-up,100,54,2/4/2020
0560D8,conference-participant,100,50,2/4/2020
06EE79,earnings,100,50,2/4/2020
0A77DB,partnership,100,61,2/4/2020
0C2A0D,executive-appointment,100,54,2/4/2020
0DC050,earnings,100,50,2/4/2020
0E439E,acquisition-acquirer,100,49,2/4/2020
108A2B,conference-call,100,50,2/4/2020
1216D1,earnings,100,50,2/4/2020
131443,earnings,100,50,2/4/2020
135B09,earnings-up,100,68,2/4/2020
135B09,earnings-up,100,68,2/4/2020
135B09,earnings-up,100,68,2/4/2020
135B09,earnings-up,100,68,2/4/2020
135B09,earnings-up,100,68,2/4/2020
138DDE,public-offering,100,43,2/4/2020
13C3E0,business-contract,100,69,2/4/2020
17EDA5,product-release,100,64,2/4/2020
1834C0,conference-call,100,50,2/4/2020
1880C5,executive-appointment,100,54,2/4/2020
190B91,earnings,100,50,2/4/2020
1921DD,partnership,100,61,2/4/2020
1F9D90,earnings,100,50,2/4/2020
1FAF22,partnership,100,61,2/4/2020
1FAF22,partnership,100,61,2/4/2020
21F9CA,revenues,100,50,2/4/2020
249674,conference-call,100,50,2/4/2020
24C48B,dividend,100,50,2/4/2020
2571FA,earnings,100,50,2/4/2020
267718,business-contract,100,69,2/4/2020
26DC29,award,100,58,2/4/2020
28AF37,earnings,100,50,2/4/2020
28AF37,earnings,100,50,2/4/2020
28AF37,earnings,100,50,2/4/2020
28AF37,earnings,100,50,2/4/2020
28AF37,earnings,100,50,2/4/2020
292388,earnings,100,50,2/4/2020
2950FF,earnings,100,50,2/4/2020
2950FF,earnings,100,50,2/4/2020
2.90E+62,earnings,100,50,2/4/2020
2.90E+62,dividend-up,100,81,2/4/2020
2BF36E,conference-call,100,50,2/4/2020
2CBB58,revenue-up,100,69,2/4/2020
2CBB58,revenues,100,50,2/4/2020
2CBB58,revenues,100,50,2/4/2020
2CBB58,revenues,100,50,2/4/2020
2DC88B,executive-appointment,100,54,2/4/2020
2DC88B,conference-participant,100,50,2/4/2020
2E902B,earnings,100,50,2/4/2020
2F1299,earnings,100,50,2/4/2020
2F1299,earnings,100,50,2/4/2020
2F1299,earnings,100,50,2/4/2020
2F1299,earnings,100,50,2/4/2020
2F1299,earnings,100,50,2/4/2020
2F1299,earnings,100,50,2/4/2020
2F24A5,earnings,100,50,2/4/2020
2F9304,earnings,100,50,2/4/2020
31F25C,dividend,100,50,2/4/2020
32C8CD,partnership,100,61,2/4/2020
34A959,acquisition-regulatory-approval-acquirer,100,54,2/4/2020
366A08,dividend,100,50,2/4/2020
367E1C,earnings,100,50,2/4/2020
370C50,legal-issues-defendant,100,22,2/4/2020
373B06,earnings,100,50,2/4/2020
384CD3,dividend,100,50,2/4/2020
387541,conference-call,100,50,2/4/2020
38C46F,dividend,100,50,2/4/2020
39FB23,partnership,100,61,2/4/2020
3B318A,conference-participant,100,50,2/4/2020
3BC360,earnings,100,50,2/4/2020
3DB18B,credit-extension-recipient,100,69,2/4/2020
4.03E+05,earnings,100,50,2/4/2020
4.03E+05,earnings,100,50,2/4/2020
4.03E+05,earnings,100,50,2/4/2020
4.03E+05,earnings,100,50,2/4/2020
4.03E+05,dividend,100,50,2/4/2020
4.00E+163,earnings,100,50,2/4/2020
40F7DE,conference-call,100,50,2/4/2020
435ACE,earnings,100,50,2/4/2020
43A060,partnership,100,61,2/4/2020
442587,credit-extension-recipient,100,69,2/4/2020
448215,dividend,100,50,2/4/2020
448BF3,public-offering,100,43,2/4/2020
453282,dividend,100,50,2/4/2020
46017C,conference-call,100,50,2/4/2020
4A5C8D,earnings,100,50,2/4/2020
4A5C8D,earnings,100,50,2/4/2020
4C6C63,earnings,100,50,2/4/2020
50070E,conference-organizer,100,57,2/4/2020
50070E,conference-organizer,100,57,2/4/2020
504FE2,business-contract,100,69,2/4/2020
504FE2,unit-acquisition-acquirer,100,49,2/4/2020
504FE2,business-contract,100,69,2/4/2020
507AE7,earnings,100,50,2/4/2020
51B442,earnings,100,50,2/4/2020
51F541,conference-call,100,50,2/4/2020
54F1D2,earnings,100,50,2/4/2020
55C9B5,dividend,100,50,2/4/2020
56277A,earnings,100,50,2/4/2020
57DDB9,partnership,100,61,2/4/2020
57F3DA,earnings,100,50,2/4/2020
586FFD,revenues,100,50,2/4/2020
586FFD,revenues,100,50,2/4/2020
589803,partnership,100,61,2/4/2020
5B3FA2,executive-appointment,100,54,2/4/2020
5B7739,conference-participant,100,50,2/4/2020
5FE4B6,earnings,100,50,2/4/2020
601785,dividend,100,50,2/4/2020
622DBE,earnings,100,50,2/4/2020
629F0F,buybacks,100,74,2/4/2020
62B20A,earnings,100,50,2/4/2020
62F41C,legal-issues-defendant,100,22,2/4/2020
633054,product-release,100,64,2/4/2020
65CF8E,earnings,100,50,2/4/2020
65CF8E,earnings,100,50,2/4/2020
665618,conference-call,100,50,2/4/2020
67B923,earnings,100,50,2/4/2020
69FDFC,partnership,100,61,2/4/2020
69FDFC,partnership,100,61,2/4/2020
6BDA0C,dividend,100,50,2/4/2020
6DBBBC,unit-acquisition-acquirer,100,49,2/4/2020
6DD6BA,earnings,100,50,2/4/2020
6DDA15,legal-issues-defendant,100,22,2/4/2020
717DB4,earnings,100,50,2/4/2020
719477,earnings,100,50,2/4/2020
719477,earnings,100,50,2/4/2020
719477,earnings,100,50,2/4/2020
728737,earnings,100,50,2/4/2020
728737,public-offering,100,43,2/4/2020
75F982,acquisition-acquirer,100,49,2/4/2020
75F982,merger-regulatory-approval,100,81,2/4/2020
762A3E,conference-organizer,100,57,2/4/2020
762A3E,conference-organizer,100,57,2/4/2020
7823A3,conference-participant,100,50,2/4/2020
790C34,product-release,100,64,2/4/2020
797C20,dividend-up,100,81,2/4/2020
7A51FE,conference-participant,100,50,2/4/2020
7B492C,earnings,100,50,2/4/2020
804708,executive-appointment,100,54,2/4/2020
82FD6D,earnings,100,50,2/4/2020
85DE00,dividend,100,50,2/4/2020
85DE00,earnings,100,50,2/4/2020
88193E,conference-call,100,50,2/4/2020
8AC65D,executive-appointment,100,54,2/4/2020
8AC65D,earnings,100,50,2/4/2020
8BAA15,executive-appointment,100,54,2/4/2020
8C5519,acquisition-completed-acquirer,100,49,2/4/2020
8D0EEA,reverse-stock-splits,100,51,2/4/2020
8D5145,dividend-up,100,60,2/4/2020
8DA42F,conference-call,100,50,2/4/2020
8DE74B,executive-appointment,100,54,2/4/2020
8F6995,dividend,100,50,2/4/2020
900356,earnings,100,50,2/4/2020
901327,unit-acquisition-acquiree,100,76,2/4/2020
901327,earnings,100,50,2/4/2020
901327,earnings,100,50,2/4/2020
901327,earnings,100,50,2/4/2020
901327,earnings,100,50,2/4/2020
901327,earnings,100,50,2/4/2020
92B047,earnings,100,50,2/4/2020
934CC3,executive-appointment,100,54,2/4/2020
93AD2E,conference-call,100,50,2/4/2020
93F143,investment-investor,100,55,2/4/2020
9548BB,executive-appointment,100,54,2/4/2020
9548BB,dividend,100,50,2/4/2020
968966,earnings,100,50,2/4/2020
968966,dividend,100,50,2/4/2020
9.74E+08,earnings,100,50,2/4/2020
99B61C,ipo-completed,100,76,2/4/2020
99DC8D,dividend,100,50,2/4/2020
99DC8D,earnings,100,50,2/4/2020
9D56F2,conference-participant,100,50,2/4/2020
9D5FA4,earnings,100,50,2/4/2020
9E0811,earnings,100,50,2/4/2020
9E0811,earnings,100,50,2/4/2020
9EF4CF,legal-issues-defendant,100,22,2/4/2020
9F18FA,earnings,100,50,2/4/2020
9F18FA,earnings,100,50,2/4/2020
A398B9,earnings,100,50,2/4/2020
A49498,ipo-completed,100,76,2/4/2020
A4B899,earnings,100,50,2/4/2020
A52B6B,earnings,100,50,2/4/2020
A6213D,earnings,100,50,2/4/2020
A63387,award,100,58,2/4/2020
A63820,earnings,100,50,2/4/2020
A70BF5,earnings,100,50,2/4/2020
A70BF5,earnings,100,50,2/4/2020
A70BF5,earnings,100,50,2/4/2020
A70BF5,earnings,100,50,2/4/2020
A70BF5,earnings,100,50,2/4/2020
A70BF5,earnings,100,50,2/4/2020
A868C9,revenue-up,100,71,2/4/2020
A868C9,revenue-up,100,71,2/4/2020
A868C9,revenue-up,100,71,2/4/2020
A868C9,revenue-up,100,71,2/4/2020
A94718,earnings,100,50,2/4/2020
ACD9A4,earnings,100,50,2/4/2020
AD3C93,earnings,100,50,2/4/2020
AED61E,conference-call,100,50,2/4/2020
AED6CF,index-listing,100,76,2/4/2020
AFF7B4,earnings,100,50,2/4/2020
AFF7B4,earnings,100,50,2/4/2020
AFF7B4,earnings,100,50,2/4/2020
AFF7B4,earnings,100,50,2/4/2020
B05118,earnings,100,50,2/4/2020
B0998E,earnings,100,50,2/4/2020
B1FC3B,business-contract,100,69,2/4/2020
B2206F,earnings,100,50,2/4/2020
B2E6B5,dividend,100,50,2/4/2020
B2E6B5,earnings,100,50,2/4/2020
B2E6B5,earnings,100,50,2/4/2020
B303A6,legal-issues-defendant,100,22,2/4/2020
B4C673,facility-open,100,65,2/4/2020
B54A74,earnings,100,50,2/4/2020
B66928,dividend,100,50,2/4/2020
B7BBFF,earnings,100,50,2/4/2020
B8F71F,executive-appointment,100,54,2/4/2020
B9764A,earnings,100,50,2/4/2020
B9764A,unit-acquisition-acquirer,100,49,2/4/2020
BB127B,conference-call,100,50,2/4/2020
BB5142,earnings,100,50,2/4/2020
BD8517,executive-appointment,100,54,2/4/2020
BFAEB4,legal-issues-defendant,100,22,2/4/2020
C0F70B,conference-participant,100,50,2/4/2020
C15F8F,earnings,100,50,2/4/2020
C16A8F,earnings,100,50,2/4/2020
C16A8F,earnings,100,50,2/4/2020
C16A8F,earnings,100,50,2/4/2020
C16A8F,earnings,100,50,2/4/2020
C4A432,partnership,100,61,2/4/2020
C659EB,conference-participant,100,50,2/4/2020
C7FC95,partnership,100,61,2/4/2020
C8257F,conference-call,100,50,2/4/2020
C9C62A,earnings,100,50,2/4/2020
CA99D7,executive-appointment,100,54,2/4/2020
CAC8D0,executive-appointment,100,54,2/4/2020
CBFFDD,business-contract,100,69,2/4/2020
CDFCC9,dividend,100,50,2/4/2020
CDFCC9,earnings,100,50,2/4/2020
CDFCC9,earnings,100,50,2/4/2020
CDFCC9,earnings,100,50,2/4/2020
CDFCC9,earnings,100,50,2/4/2020
CDFCC9,earnings,100,50,2/4/2020
CE1002,note-sale,100,52,2/4/2020
CE5664,earnings,100,50,2/4/2020
CE5664,earnings,100,50,2/4/2020
CE5664,earnings,100,50,2/4/2020
CE96E7,conference-participant,100,50,2/4/2020
D1173F,earnings,100,50,2/4/2020
D4AC65,partnership,100,61,2/4/2020
D518D8,award,100,58,2/4/2020
D60BB2,earnings,100,50,2/4/2020
D6144F,note-sale,100,52,2/4/2020
D64EDF,earnings,100,50,2/4/2020
D69D42,earnings,100,50,2/4/2020
D78CCD,legal-issues-defendant,100,22,2/4/2020
D8442A,product-release,100,64,2/4/2020
D8442A,product-release,100,64,2/4/2020
D88EF3,note-sale,100,52,2/4/2020
DA199F,partnership,100,61,2/4/2020
DD0F15,legal-issues-defendant,100,22,2/4/2020
DD0F15,legal-issues-defendant,100,22,2/4/2020
DE4924,note-sale,100,52,2/4/2020
DE4924,note-sale,100,52,2/4/2020
DE5611,product-release,100,64,2/4/2020
DF204B,facility-open,100,65,2/4/2020
DF42A0,dividend,100,50,2/4/2020
DF42A0,earnings,100,50,2/4/2020
DF42A0,earnings,100,50,2/4/2020
DF42A0,earnings,100,50,2/4/2020
DF42A0,earnings,100,50,2/4/2020
DF42A0,executive-appointment,100,54,2/4/2020
E074A0,earnings,100,50,2/4/2020
E114F4,earnings,100,50,2/4/2020
E114F4,earnings,100,50,2/4/2020
E114F4,earnings,100,50,2/4/2020
E114F4,earnings,100,50,2/4/2020
E393B0,buybacks,100,74,2/4/2020
E4CE73,partnership,100,61,2/4/2020
E592F0,earnings,100,50,2/4/2020
E592F0,earnings,100,50,2/4/2020
E5A3B6,public-offering,100,43,2/4/2020
E67C2C,earnings,100,50,2/4/2020
E68733,earnings,100,50,2/4/2020
E68733,earnings,100,50,2/4/2020
E6E012,earnings,100,50,2/4/2020
E6E012,earnings,100,50,2/4/2020
E87676,conference-call,100,50,2/4/2020
E90C84,earnings,100,50,2/4/2020
EAA0A7,executive-appointment,100,54,2/4/2020
EB36DE,earnings,100,50,2/4/2020
ED5171,executive-appointment,100,54,2/4/2020
EDF5CA,legal-issues-defendant,100,22,2/4/2020
EE6F1C,business-contract,100,69,2/4/2020
EE6F1C,unit-acquisition-acquiree,100,76,2/4/2020
EE6F1C,earnings,100,50,2/4/2020
EE6F1C,earnings,100,50,2/4/2020
EE6F1C,earnings,100,50,2/4/2020
EE6F1C,earnings,100,50,2/4/2020
EF5BED,executive-appointment,100,54,2/4/2020
EF5BED,executive-appointment,100,54,2/4/2020
F0B2B5,earnings,100,50,2/4/2020
F0B2B5,earnings,100,50,2/4/2020
F0B2B5,earnings,100,50,2/4/2020
F0B2B5,earnings,100,50,2/4/2020
F0B2B5,earnings,100,50,2/4/2020
F0B2B5,earnings,100,50,2/4/2020
F1529C,acquisition-acquirer,100,49,2/4/2020
F3016C,earnings,100,50,2/4/2020
F39E1E,earnings,100,50,2/4/2020
F569FD,public-offering,100,43,2/4/2020
F57F6F,earnings,100,50,2/4/2020
F5D410,earnings,100,50,2/4/2020
F5D410,earnings,100,50,2/4/2020
F5D410,earnings,100,50,2/4/2020
F5D410,earnings,100,50,2/4/2020
F5D410,earnings,100,50,2/4/2020
F5D410,earnings,100,50,2/4/2020
F5D499,conference-call,100,50,2/4/2020
F6E248,earnings,100,50,2/4/2020
F6E248,dividend-up,100,58,2/4/2020
F8084B,earnings-per-share-positive,100,69,2/4/2020
F8084B,earnings,100,50,2/4/2020
F8084B,earnings,100,50,2/4/2020
F80FF9,earnings,100,50,2/4/2020
F85CC0,conference-participant,100,50,2/4/2020
F85CC0,conference-participant,100,50,2/4/2020
F9CAF8,earnings,100,50,2/4/2020
F9CAF8,earnings,100,50,2/4/2020
F9CAF8,earnings,100,50,2/4/2020
F9CAF8,earnings,100,50,2/4/2020
FA36A4,conference-call,100,50,2/4/2020
FE89E0,earnings,100,50,2/4/2020
FEC475,earnings,100,50,2/4/2020
FEC475,earnings,100,50,2/4/2020
FEC475,earnings,100,50,2/4/2020
FEC475,earnings,100,50,2/4/2020
FEC475,earnings,100,50,2/4/2020
FF5413,dividend-up,100,81,2/4/2020
FF6644,product-release,100,64,2/4/2020
00067A,earnings,100,50,2/5/2020
00D6B5,conference-call,100,50,2/5/2020
03B431,earnings,100,50,2/5/2020
03B431,earnings,100,50,2/5/2020
048B70,earnings,100,50,2/5/2020
048B70,earnings,100,50,2/5/2020
048B70,earnings,100,50,2/5/2020
0624BE,earnings,100,50,2/5/2020
075CF7,dividend-up,100,72,2/5/2020
07EC43,earnings,100,50,2/5/2020
07EC43,executive-appointment,100,54,2/5/2020
099C88,conference-call,100,50,2/5/2020
0A6824,earnings,100,50,2/5/2020
0CBC4D,earnings,100,50,2/5/2020
0E5223,conference-call,100,50,2/5/2020
0EC508,earnings,100,50,2/5/2020
106394,note-sale,100,52,2/5/2020
1065BC,earnings,100,50,2/5/2020
11074E,earnings,100,50,2/5/2020
1201B5,clinical-trials,100,56,2/5/2020
152AB9,earnings,100,50,2/5/2020
152FA5,executive-appointment,100,54,2/5/2020
15789A,earnings,100,50,2/5/2020
15A388,conference-participant,100,50,2/5/2020
1866B2,business-contract,100,69,2/5/2020
1866B2,business-contract,100,69,2/5/2020
1866B2,business-contract,100,69,2/5/2020
1921DD,partnership,100,61,2/5/2020
19CAC7,earnings,100,50,2/5/2020
1AB808,earnings,100,50,2/5/2020
1B5FEA,conference-participant,100,50,2/5/2020
1BC12C,earnings,100,50,2/5/2020
1CD09C,conference-call,100,50,2/5/2020
1DA44F,earnings,100,50,2/5/2020
1E7785,conference-participant,100,50,2/5/2020
1EBF8D,earnings,100,50,2/5/2020
200D8B,earnings,100,50,2/5/2020
21D903,earnings,100,50,2/5/2020
227F04,earnings,100,50,2/5/2020
228D42,conference-organizer,100,57,2/5/2020
228D42,partnership,100,61,2/5/2020
24C48B,executive-appointment,100,54,2/5/2020
253604,clinical-trials,100,56,2/5/2020
263216,earnings,100,50,2/5/2020
263216,earnings,100,50,2/5/2020
263216,earnings,100,50,2/5/2020
263216,earnings,100,50,2/5/2020
263216,earnings,100,50,2/5/2020
263216,earnings,100,50,2/5/2020
27B191,earnings,100,50,2/5/2020
27B191,earnings,100,50,2/5/2020
27B191,earnings,100,50,2/5/2020
27B191,earnings,100,50,2/5/2020
27B191,dividend,100,50,2/5/2020
27BFA1,dividend,100,50,2/5/2020
27BFA1,public-offering,100,43,2/5/2020
284289,earnings,100,50,2/5/2020
2BAE5F,dividend-up,100,56,2/5/2020
2D981A,clinical-trials,100,56,2/5/2020
2F94A5,executive-resignation,100,44,2/5/2020
2FEA66,operating-earnings,100,50,2/5/2020
301493,earnings,100,50,2/5/2020
3159AA,facility-open,100,65,2/5/2020
31643A,earnings,100,50,2/5/2020
339F20,earnings,100,50,2/5/2020
339F20,earnings,100,50,2/5/2020
33E8C7,earnings,100,50,2/5/2020
33FD66,product-release,100,64,2/5/2020
33FD66,earnings,100,50,2/5/2020
356B21,ipo-pricing,100,50,2/5/2020
35F4B5,earnings-up,100,68,2/5/2020
370C50,dividend,100,50,2/5/2020
3A113F,note-sale,100,52,2/5/2020
3A113F,conference-call,100,50,2/5/2020
3A3447,conference-participant,100,50,2/5/2020
3AF7FD,conference-participant,100,50,2/5/2020
3B2311,earnings,100,50,2/5/2020
3FACA7,dividend,100,50,2/5/2020
416C55,dividend,100,50,2/5/2020
43F4A8,partnership,100,61,2/5/2020
442587,earnings,100,50,2/5/2020
442587,earnings,100,50,2/5/2020
444CC8,earnings-up,100,68,2/5/2020
448BF3,public-offering,100,43,2/5/2020
44ED36,earnings,100,50,2/5/2020
468DD4,earnings,100,50,2/5/2020
485445,conference-participant,100,50,2/5/2020
492117,note-sale,100,52,2/5/2020
50070E,conference-organizer,100,57,2/5/2020
504FE2,conference-participant,100,50,2/5/2020
50D1EC,partnership,100,61,2/5/2020
510EA6,partnership,100,61,2/5/2020
510EA6,partnership,100,61,2/5/2020
514067,conference-participant,100,50,2/5/2020
51E682,earnings,100,50,2/5/2020
5403F8,earnings,100,50,2/5/2020
545272,earnings,100,50,2/5/2020
54F271,revenues,100,50,2/5/2020
55ACCB,earnings,100,50,2/5/2020
57B174,conference-call,100,50,2/5/2020
57F3DA,unit-acquisition-acquirer,100,49,2/5/2020
583223,earnings,100,50,2/5/2020
5B15E1,earnings,100,50,2/5/2020
5C7601,earnings,100,50,2/5/2020
5DD486,dividend-up,100,63,2/5/2020
5DD48B,earnings,100,50,2/5/2020
605F40,earnings,100,50,2/5/2020
61A586,conference-participant,100,50,2/5/2020
62F41C,legal-issues-defendant,100,22,2/5/2020
639BD6,revenues,100,50,2/5/2020
639BD6,revenues,100,50,2/5/2020
639BD6,revenues,100,50,2/5/2020
64854A,earnings,100,50,2/5/2020
66749D,earnings,100,50,2/5/2020
66E3C0,revenue-up,100,63,2/5/2020
698FF9,dividend,100,50,2/5/2020
6A961B,earnings,100,50,2/5/2020
6ABCB8,earnings,100,50,2/5/2020
6B6375,executive-appointment,100,54,2/5/2020
6CDFC6,partnership,100,61,2/5/2020
6DC1D7,executive-appointment,100,54,2/5/2020
6E1E61,earnings,100,50,2/5/2020
6E705B,partnership,100,61,2/5/2020
6F0096,conference-call,100,50,2/5/2020
7262F2,earnings,100,50,2/5/2020
731675,demand-increase,100,94,2/5/2020
731675,earnings,100,50,2/5/2020
731675,earnings,100,50,2/5/2020
731675,earnings,100,50,2/5/2020
747219,note-sale,100,52,2/5/2020
76BD96,conference-call,100,50,2/5/2020
79167B,conference-call,100,50,2/5/2020
7AC86E,earnings,100,50,2/5/2020
7AC86E,earnings,100,50,2/5/2020
7AC86E,earnings,100,50,2/5/2020
7BFF81,revenues,100,50,2/5/2020
7BFF81,revenues,100,50,2/5/2020
7BFF81,revenues,100,50,2/5/2020
7C75FD,earnings,100,50,2/5/2020
7D35D8,executive-appointment,100,54,2/5/2020
7D35D8,earnings,100,50,2/5/2020
7E1D5D,earnings,100,50,2/5/2020
7F9984,earnings,100,50,2/5/2020
8.10E+32,earnings,100,50,2/5/2020
810FAD,dividend,100,50,2/5/2020
810FAD,revenue-up,100,69,2/5/2020
810FAD,revenue-up,100,69,2/5/2020
810FAD,revenue-up,100,69,2/5/2020
810FAD,revenue-up,100,69,2/5/2020
810FAD,revenue-up,100,69,2/5/2020
810FAD,revenue-up,100,69,2/5/2020
810FAD,revenue-up,100,69,2/5/2020
8665BA,product-release,100,64,2/5/2020
87486A,dividend,100,50,2/5/2020
88923D,partnership,100,61,2/5/2020
88923D,partnership,100,61,2/5/2020
890FF4,conference-call,100,50,2/5/2020
8A0368,conference-call,100,50,2/5/2020
8DE74B,dividend,100,50,2/5/2020
8E10BF,regulatory-product-approval-granted,100,81,2/5/2020
8E82A6,executive-resignation,100,44,2/5/2020
922F0C,dividend,100,50,2/5/2020
92B73F,dividend,100,50,2/5/2020
93D207,product-release,100,64,2/5/2020
949625,dividend,100,50,2/5/2020
957A07,earnings,100,50,2/5/2020
95A92E,partnership,100,61,2/5/2020
9673BD,dividend,100,50,2/5/2020
96A2D3,earnings,100,50,2/5/2020
9.74E+08,unit-acquisition-acquiree,100,76,2/5/2020
977A1E,conference-call,100,50,2/5/2020
979451,earnings,100,50,2/5/2020
990AD0,conference-organizer,100,57,2/5/2020
9B0C9C,earnings,100,50,2/5/2020
9BB35A,earnings,100,50,2/5/2020
9D5D35,earnings,100,50,2/5/2020
9EF4CF,legal-issues-defendant,100,22,2/5/2020
9EF4CF,legal-issues-defendant,100,22,2/5/2020
9F71E5,acquisition-acquirer,100,49,2/5/2020
9FA83B,earnings,100,50,2/5/2020
A4A612,earnings,100,50,2/5/2020
A4CD53,earnings,100,50,2/5/2020
A60318,facility-open,100,65,2/5/2020
A63387,earnings,100,50,2/5/2020
A6FC89,conference-call,100,50,2/5/2020
A753BB,unit-acquisition-acquirer,100,49,2/5/2020
A753BB,unit-acquisition-acquirer,100,49,2/5/2020
A753BB,acquisition-acquirer,100,49,2/5/2020
A790A5,conference-call,100,50,2/5/2020
A79F7D,merger-completed,100,66,2/5/2020
AA847A,earnings,100,50,2/5/2020
AAC8B6,conference-call,100,50,2/5/2020
AAC8B6,conference-call,100,50,2/5/2020
ABBAD1,conference-participant,100,50,2/5/2020
AC7C4F,executive-appointment,100,54,2/5/2020
AD22F2,executive-appointment,100,54,2/5/2020
AD23DE,conference-call,100,50,2/5/2020
AD6141,earnings,100,50,2/5/2020
AEF2C3,conference-call,100,50,2/5/2020
AEFC90,earnings,100,50,2/5/2020
B0FE08,earnings,100,50,2/5/2020
B0FE08,earnings,100,50,2/5/2020
B0FE08,earnings,100,50,2/5/2020
B1A85D,product-release,100,64,2/5/2020
B1FC3B,business-contract,100,69,2/5/2020
B48FC9,earnings,100,50,2/5/2020
B83BCE,earnings,100,50,2/5/2020
B8DD94,earnings,100,50,2/5/2020
B8EF97,revenues,100,50,2/5/2020
B9CD50,executive-appointment,100,54,2/5/2020
BB5142,buybacks,100,74,2/5/2020
BB88B6,conference-participant,100,50,2/5/2020
BC5680,earnings,100,50,2/5/2020
BDF2BD,debt-extension-recipient,100,73,2/5/2020
BF79F5,product-release,100,64,2/5/2020
BFAEB4,legal-issues-defendant,100,22,2/5/2020
C037A8,earnings,100,50,2/5/2020
C06EB6,earnings,100,50,2/5/2020
C1114B,conference-participant,100,50,2/5/2020
C188F8,earnings,100,50,2/5/2020
C2F597,earnings,100,50,2/5/2020
C3BCD5,dividend,100,50,2/5/2020
C425AE,earnings,100,50,2/5/2020
C50B26,earnings,100,50,2/5/2020
C5D2AE,conference-participant,100,50,2/5/2020
C5E100,executive-appointment,100,54,2/5/2020
C65004,revenue-up,100,69,2/5/2020
C65004,revenue-up,100,69,2/5/2020
C65004,revenue-up,100,69,2/5/2020
C951A2,product-release,100,64,2/5/2020
C97B2D,earnings,100,50,2/5/2020
CA99D7,earnings,100,50,2/5/2020
CB9E13,earnings,100,50,2/5/2020
CBBFBF,legal-issues-defendant,100,22,2/5/2020
CDAB24,earnings,100,50,2/5/2020
CFF15D,earnings,100,50,2/5/2020
CFF15D,earnings,100,50,2/5/2020
D17F7E,earnings,100,50,2/5/2020
D17F7E,earnings,100,50,2/5/2020
D17F7E,earnings,100,50,2/5/2020
D17F7E,earnings,100,50,2/5/2020
D17F7E,earnings,100,50,2/5/2020
D17F7E,business-contract,100,69,2/5/2020
D20C8F,earnings,100,50,2/5/2020
D437C3,executive-appointment,100,54,2/5/2020
D5A350,dividend,100,50,2/5/2020
D76AEF,conference-call,100,50,2/5/2020
D78BF1,earnings,100,50,2/5/2020
D7918D,earnings,100,50,2/5/2020
D854DD,earnings,100,50,2/5/2020
D854DD,earnings,100,50,2/5/2020
D854DD,earnings,100,50,2/5/2020
DC437D,earnings,100,50,2/5/2020
DCD97F,executive-appointment,100,54,2/5/2020
E1E36F,earnings,100,50,2/5/2020
E1E36F,earnings,100,50,2/5/2020
E1E36F,earnings,100,50,2/5/2020
E1E36F,earnings,100,50,2/5/2020
E1E36F,earnings,100,50,2/5/2020
E2CB7B,conference-participant,100,50,2/5/2020
E30A8F,earnings,100,50,2/5/2020
E30A8F,earnings,100,50,2/5/2020
E30A8F,earnings,100,50,2/5/2020
E30A8F,earnings,100,50,2/5/2020
E30A8F,earnings,100,50,2/5/2020
E5752F,earnings,100,50,2/5/2020
E5752F,earnings,100,50,2/5/2020
E5752F,earnings,100,50,2/5/2020
E5752F,earnings,100,50,2/5/2020
E5D914,earnings,100,50,2/5/2020
E5F0A8,acquisition-completed-acquirer,100,49,2/5/2020
E72599,conference-call,100,50,2/5/2020
E7BF32,patient-enrollment-complete,100,64,2/5/2020
E7BF32,patient-enrollment-complete,100,64,2/5/2020
E9C7C0,earnings-up,100,68,2/5/2020
E9C7C0,earnings-up,100,68,2/5/2020
E9C7C0,earnings-up,100,68,2/5/2020
E9C7C0,earnings-up,100,68,2/5/2020
E9C7C0,earnings-up,100,68,2/5/2020
E9C7C0,earnings-up,100,68,2/5/2020
E9C7C0,earnings-up,100,68,2/5/2020
EC1AF3,conference-call,100,50,2/5/2020
ECE814,earnings,100,50,2/5/2020
ED0402,earnings,100,50,2/5/2020
ED2A5E,conference-call,100,50,2/5/2020
ED7F13,earnings,100,50,2/5/2020
EE967B,conference-participant,100,50,2/5/2020
EF45B6,earnings,100,50,2/5/2020
F179ED,earnings,100,50,2/5/2020
F18844,dividend,100,50,2/5/2020
F18844,earnings,100,50,2/5/2020
F40EE2,dividend-up,100,81,2/5/2020
F40EE2,dividend-up,100,81,2/5/2020
F48947,earnings,100,50,2/5/2020
F48947,conference-participant,100,50,2/5/2020
F4CDA3,earnings,100,50,2/5/2020
F4E882,legal-issues-defendant,100,22,2/5/2020
F58C23,public-offering,100,43,2/5/2020
F5D410,note-sale,100,52,2/5/2020
F5D410,note-sale,100,52,2/5/2020
F5D410,public-offering,100,43,2/5/2020
F5D499,business-contract,100,69,2/5/2020
F6FA6A,executive-appointment,100,54,2/5/2020
F7ADEB,conference-call,100,50,2/5/2020
F8BA6C,earnings,100,50,2/5/2020
FA35C6,earnings,100,50,2/5/2020
FACF19,executive-appointment,100,54,2/5/2020
FC1B7B,executive-appointment,100,54,2/5/2020
FFE543,award,100,58,2/5/2020
0358AF,revenue-up,100,69,2/6/2020
48590,earnings,100,50,2/6/2020
61366,earnings,100,50,2/6/2020
061A3B,earnings,100,50,2/6/2020
71860,conference-participant,100,50,2/6/2020
75172,earnings,100,50,2/6/2020
083F72,earnings,100,50,2/6/2020
95294,executive-appointment,100,54,2/6/2020
95294,earnings,100,50,2/6/2020
0A59F8,partnership,100,61,2/6/2020
0B2071,executive-resignation,100,44,2/6/2020
0BC17A,dividend-up,100,69,2/6/2020
0BC17A,earnings,100,50,2/6/2020
0BD4E8,executive-appointment,100,54,2/6/2020
0CE204,business-contract,100,69,2/6/2020
102F04,earnings,100,50,2/6/2020
10943B,earnings,100,50,2/6/2020
119CB6,earnings-per-share-positive,100,69,2/6/2020
1201B5,earnings,100,50,2/6/2020
133644,conference-participant,100,50,2/6/2020
14ED2B,dividend,100,50,2/6/2020
152B9E,conference-call,100,50,2/6/2020
15789A,award,100,58,2/6/2020
1.79E+10,conference-call,100,50,2/6/2020
182BE7,conference-call,100,50,2/6/2020
1880C5,conference-participant,100,50,2/6/2020
1AB023,partnership,100,61,2/6/2020
1AB023,partnership,100,61,2/6/2020
1AB023,partnership,100,61,2/6/2020
1E1125,conference-organizer,100,57,2/6/2020
1F08A6,dividend,100,50,2/6/2020
1F464F,earnings,100,50,2/6/2020
222BF9,dividend,100,50,2/6/2020
2262BD,earnings,100,50,2/6/2020
228D42,business-contract,100,69,2/6/2020
228D42,partnership,100,61,2/6/2020
2491BC,earnings,100,50,2/6/2020
26D8ED,earnings,100,50,2/6/2020
28B730,earnings,100,50,2/6/2020
2ABF77,earnings,100,50,2/6/2020
2ABF77,earnings,100,50,2/6/2020
2B5483,earnings,100,50,2/6/2020
2C7505,earnings,100,50,2/6/2020
2CA60F,earnings,100,50,2/6/2020
2CA60F,earnings,100,50,2/6/2020
2CA60F,earnings,100,50,2/6/2020
2CA60F,earnings,100,50,2/6/2020
2DC88B,earnings,100,50,2/6/2020
2EB88B,revenues,100,50,2/6/2020
2FF046,earnings,100,50,2/6/2020
2FF046,earnings,100,50,2/6/2020
2FF046,earnings,100,50,2/6/2020
301493,legal-issues-defendant,100,22,2/6/2020
301493,legal-issues-defendant,100,22,2/6/2020
30DFD3,earnings,100,50,2/6/2020
3159AA,earnings,100,50,2/6/2020
3159AA,dividend,100,50,2/6/2020
3390DE,earnings,100,50,2/6/2020
3587B4,earnings,100,50,2/6/2020
3587B4,earnings,100,50,2/6/2020
3587B4,earnings,100,50,2/6/2020
3587B4,earnings,100,50,2/6/2020
3587B4,earnings,100,50,2/6/2020
366A08,conference-call,100,50,2/6/2020
36E479,earnings,100,50,2/6/2020
370C50,legal-issues-defendant,100,22,2/6/2020
3BE00F,earnings,100,50,2/6/2020
401072,earnings,100,50,2/6/2020
408089,facility-open,100,65,2/6/2020
41C528,acquisition-completed-acquirer,100,49,2/6/2020
43A060,earnings,100,50,2/6/2020
4649D5,executive-appointment,100,54,2/6/2020
47752F,dividend,100,50,2/6/2020
49BBBC,product-release,100,64,2/6/2020
49F4D0,earnings,100,50,2/6/2020
4A6F00,investment-investor,100,55,2/6/2020
4B7006,earnings,100,50,2/6/2020
4BDCA7,conference-participant,100,50,2/6/2020
4C1FA1,earnings,100,50,2/6/2020
4EEE7E,earnings,100,50,2/6/2020
4F9926,partnership,100,61,2/6/2020
513A86,earnings,100,50,2/6/2020
52015A,conference-call,100,50,2/6/2020
52FB2F,earnings,100,50,2/6/2020
53C421,earnings,100,50,2/6/2020
5403F8,executive-appointment,100,54,2/6/2020
5487B1,legal-issues-defendant,100,22,2/6/2020
548AC0,earnings,100,50,2/6/2020
54A713,earnings,100,50,2/6/2020
54B889,conference-call,100,50,2/6/2020
562853,dividend,100,50,2/6/2020
567F3D,earnings,100,50,2/6/2020
567F3D,earnings,100,50,2/6/2020
567F3D,earnings,100,50,2/6/2020
567F3D,earnings,100,50,2/6/2020
567F3D,earnings,100,50,2/6/2020
567F3D,earnings,100,50,2/6/2020
56FB7C,dividend-up,100,81,2/6/2020
57356F,earnings,100,50,2/6/2020
57356F,earnings,100,50,2/6/2020
57356F,earnings,100,50,2/6/2020
583A75,revenue-volume,100,50,2/6/2020
589803,earnings,100,50,2/6/2020
59872F,conference-call,100,50,2/6/2020
59DB8C,settlement,100,56,2/6/2020
59DB8C,earnings,100,50,2/6/2020
59DB8C,settlement,100,56,2/6/2020
5D02B7,earnings,100,50,2/6/2020
5D0337,earnings,100,50,2/6/2020
5D41E4,public-offering,100,43,2/6/2020
5DD486,executive-appointment,100,54,2/6/2020
5DD486,executive-resignation,100,44,2/6/2020
5EAA43,earnings,100,50,2/6/2020
5EF130,earnings,100,50,2/6/2020
5EF130,earnings,100,50,2/6/2020
5EF130,earnings,100,50,2/6/2020
5F2FF7,dividend,100,50,2/6/2020
5FE4B6,dividend,100,50,2/6/2020
622DBE,note-sale,100,52,2/6/2020
622DBE,note-sale,100,52,2/6/2020
627186,executive-appointment,100,54,2/6/2020
62F41C,legal-issues-defendant,100,22,2/6/2020
63F892,earnings,100,50,2/6/2020
641F17,conference-participant,100,50,2/6/2020
67B052,earnings,100,50,2/6/2020
68BA15,earnings,100,50,2/6/2020
69345C,partnership,100,61,2/6/2020
69FDFC,partnership,100,61,2/6/2020
69FDFC,partnership,100,61,2/6/2020
6A01DF,earnings,100,50,2/6/2020
6A171E,earnings,100,50,2/6/2020
6A961B,earnings,100,50,2/6/2020
6B0784,earnings,100,50,2/6/2020
6BBCBA,ipo-pricing,100,50,2/6/2020
6BDA0C,conference-call,100,50,2/6/2020
6CF43C,earnings,100,50,2/6/2020
6DDA15,legal-issues-defendant,100,22,2/6/2020
6DDA15,earnings,100,50,2/6/2020
6F5DD2,conference-participant,100,50,2/6/2020
6F92A9,earnings,100,50,2/6/2020
72CB93,earnings,100,50,2/6/2020
731675,acquisition-completed-acquirer,100,49,2/6/2020
73C521,dividend,100,50,2/6/2020
73F70F,conference-call,100,50,2/6/2020
7410C3,earnings-guidance,100,50,2/6/2020
742AAB,earnings,100,50,2/6/2020
7.44E+09,earnings,100,50,2/6/2020
76959C,earnings,100,50,2/6/2020
76B926,conference-call,100,50,2/6/2020
7740DE,same-store-sales-up,100,51,2/6/2020
7823A3,earnings,100,50,2/6/2020
791D59,earnings,100,50,2/6/2020
793C11,earnings,100,50,2/6/2020
7A10FF,dividend,100,50,2/6/2020
7B1156,earnings,100,50,2/6/2020
7B9212,revenues,100,50,2/6/2020
7B9AFA,earnings,100,50,2/6/2020
7C790D,conference-call,100,50,2/6/2020
7CD98F,earnings,100,50,2/6/2020
7D5FD6,dividend,100,50,2/6/2020
7DD584,partnership,100,61,2/6/2020
7DD584,partnership,100,61,2/6/2020
81A88D,earnings,100,50,2/6/2020
8.10E+205,earnings,100,50,2/6/2020
82C202,earnings,100,50,2/6/2020
82E58A,earnings,100,50,2/6/2020
82F088,earnings,100,50,2/6/2020
838ADD,buybacks,100,74,2/6/2020
838ADD,earnings-up,100,68,2/6/2020
838ADD,earnings-up,100,68,2/6/2020
838ADD,earnings-up,100,68,2/6/2020
838ADD,earnings-up,100,68,2/6/2020
838ADD,earnings-up,100,68,2/6/2020
838ADD,earnings-up,100,68,2/6/2020
838ADD,earnings-up,100,68,2/6/2020
8614A2,earnings,100,50,2/6/2020
86A1B9,earnings-positive,100,69,2/6/2020
86A1B9,earnings-positive,100,69,2/6/2020
86A1B9,earnings-positive,100,69,2/6/2020
86A1B9,earnings-positive,100,69,2/6/2020
8.73E+09,stake-acquirer,100,48,2/6/2020
873DB9,earnings,100,50,2/6/2020
873DB9,earnings,100,50,2/6/2020
873DB9,earnings,100,50,2/6/2020
873DB9,legal-issues-defendant,100,22,2/6/2020
873DB9,legal-issues-defendant,100,22,2/6/2020
87B81A,revenue-up,100,69,2/6/2020
87B81A,earnings,100,50,2/6/2020
87B81A,earnings,100,50,2/6/2020
87B81A,earnings,100,50,2/6/2020
87B81A,dividend,100,50,2/6/2020
88350F,donation,100,54,2/6/2020
895D56,earnings,100,50,2/6/2020
896771,executive-appointment,100,54,2/6/2020
89F693,earnings-above-expectations,100,88,2/6/2020
8B9B3B,clinical-trials-positive,100,87,2/6/2020
8BFE9A,conference-call,100,50,2/6/2020
8D4AE6,dividend,100,50,2/6/2020
9043FE,earnings,100,50,2/6/2020
9043FE,earnings,100,50,2/6/2020
918D6D,executive-appointment,100,54,2/6/2020
92D757,earnings,100,50,2/6/2020
92D757,earnings,100,50,2/6/2020
92D757,earnings,100,50,2/6/2020
92D757,earnings,100,50,2/6/2020
92D757,earnings,100,50,2/6/2020
92D9C9,earnings,100,50,2/6/2020
934029,earnings,100,50,2/6/2020
9.36E+10,earnings,100,50,2/6/2020
9.36E+10,earnings,100,50,2/6/2020
94563D,earnings,100,50,2/6/2020
94637C,earnings,100,50,2/6/2020
94756D,earnings,100,50,2/6/2020
9548BB,earnings-per-share-up,100,68,2/6/2020
9548BB,earnings,100,50,2/6/2020
9548BB,earnings,100,50,2/6/2020
9548BB,earnings,100,50,2/6/2020
9673BD,conference-call,100,50,2/6/2020
96B4FF,conference-participant,100,50,2/6/2020
9810C0,earnings,100,50,2/6/2020
98D33E,dividend,100,50,2/6/2020
99028D,earnings-up,100,68,2/6/2020
990AD0,conference-organizer,100,57,2/6/2020
990AD0,conference-organizer,100,57,2/6/2020
990AD0,conference-organizer,100,57,2/6/2020
9ABD30,earnings,100,50,2/6/2020
9AF3DC,earnings,100,50,2/6/2020
9B4066,dividend,100,50,2/6/2020
9E575E,regulatory-product-approval-granted,100,81,2/6/2020
9E91C6,earnings,100,50,2/6/2020
9E98F2,earnings,100,50,2/6/2020
9E98F2,earnings,100,50,2/6/2020
9E98F2,earnings,100,50,2/6/2020
9EBAFA,conference-call,100,50,2/6/2020
9EF4CF,legal-issues-defendant,100,22,2/6/2020
9F71E5,dividend-up,100,59,2/6/2020
9F71E5,conference-call,100,50,2/6/2020
9FA83B,conference-participant,100,50,2/6/2020
9FD2D9,conference-call,100,50,2/6/2020
A01200,conference-call,100,50,2/6/2020
A01664,earnings,100,50,2/6/2020
A1EAC8,dividend,100,50,2/6/2020
A3AAA5,earnings,100,50,2/6/2020
A403CF,earnings,100,50,2/6/2020
A403CF,dividend,100,50,2/6/2020
A5B913,earnings,100,50,2/6/2020
A6213D,executive-appointment,100,54,2/6/2020
A6828A,acquisition-acquiree,100,76,2/6/2020
A6828A,acquisition-acquiree,100,76,2/6/2020
A70BF5,conference-participant,100,50,2/6/2020
A7102F,conference-call,100,50,2/6/2020
A7CCF0,earnings,100,50,2/6/2020
A806FA,earnings,100,50,2/6/2020
A806FA,earnings,100,50,2/6/2020
A806FA,earnings,100,50,2/6/2020
A806FA,earnings,100,50,2/6/2020
AB4A7E,conference-call,100,50,2/6/2020
AD1ACF,earnings,100,50,2/6/2020
AD1ACF,earnings,100,50,2/6/2020
AD1ACF,earnings,100,50,2/6/2020
AD1ACF,earnings,100,50,2/6/2020
AD1ACF,dividend,100,50,2/6/2020
AE4125,conference-call,100,50,2/6/2020
AECCA9,conference-call,100,50,2/6/2020
AFD1CA,earnings,100,50,2/6/2020
B04426,product-release,100,64,2/6/2020
B1FC3B,business-contract,100,69,2/6/2020
B1FC3B,business-contract,100,69,2/6/2020
B2256A,note-sale,100,52,2/6/2020
B2256A,note-sale,100,52,2/6/2020
B303A6,legal-issues-defendant,100,22,2/6/2020
B303A6,legal-issues-defendant,100,22,2/6/2020
B4C673,earnings-positive,100,69,2/6/2020
B4C673,earnings-positive,100,69,2/6/2020
B4C673,earnings-positive,100,69,2/6/2020
B4C673,earnings-positive,100,69,2/6/2020
B4C673,earnings-positive,100,69,2/6/2020
B4C673,earnings-positive,100,69,2/6/2020
B4C673,earnings-positive,100,69,2/6/2020
B4C673,earnings-positive,100,69,2/6/2020
B66928,executive-appointment,100,54,2/6/2020
B6843B,earnings,100,50,2/6/2020
B7202A,acquisition-acquirer,100,49,2/6/2020
B7202A,acquisition-acquirer,100,49,2/6/2020
B7202A,unit-acquisition-acquirer,100,49,2/6/2020
B72D2E,acquisition-interest-acquirer,100,46,2/6/2020
B72D2E,acquisition-interest-acquirer,100,46,2/6/2020
B80AD1,earnings,100,50,2/6/2020
B96637,conference-call,100,50,2/6/2020
BB0787,earnings,100,50,2/6/2020
BBBB41,earnings,100,50,2/6/2020
BBBB41,earnings,100,50,2/6/2020
BBBB41,earnings,100,50,2/6/2020
BBBB41,earnings,100,50,2/6/2020
BBBB41,earnings,100,50,2/6/2020
BBBB41,earnings,100,50,2/6/2020
BBBB41,earnings,100,50,2/6/2020
BBF349,earnings,100,50,2/6/2020
BBF349,earnings,100,50,2/6/2020
BBF349,earnings,100,50,2/6/2020
BBF349,earnings,100,50,2/6/2020
BCC55F,partnership,100,61,2/6/2020
BD9668,dividend,100,50,2/6/2020
BE14CF,earnings,100,50,2/6/2020
BFAEB4,legal-issues-defendant,100,22,2/6/2020
C0200F,business-contract,100,69,2/6/2020
C2609A,conference-participant,100,50,2/6/2020
C38440,earnings,100,50,2/6/2020
C38440,earnings,100,50,2/6/2020
C4706C,earnings,100,50,2/6/2020
C4A241,earnings-up,100,68,2/6/2020
C4A241,earnings,100,50,2/6/2020
C4A241,earnings,100,50,2/6/2020
C4A241,earnings,100,50,2/6/2020
C4A241,earnings,100,50,2/6/2020
C4FBDC,executive-appointment,100,54,2/6/2020
C564E4,conference-call,100,50,2/6/2020
C5C0E9,earnings,100,50,2/6/2020
C659EB,dividend,100,50,2/6/2020
C66B44,buybacks,100,74,2/6/2020
C941DC,earnings,100,50,2/6/2020
C98CDB,earnings,100,50,2/6/2020
C99CC8,unit-acquisition-acquiree,100,76,2/6/2020
C99CC8,acquisition-acquiree,100,76,2/6/2020
C9E4EC,earnings,100,50,2/6/2020
CA1620,earnings,100,50,2/6/2020
CC8F6E,earnings,100,50,2/6/2020
CDD75E,conference-participant,100,50,2/6/2020
CEC5B9,earnings,100,50,2/6/2020
CEC5B9,earnings,100,50,2/6/2020
CFF97C,earnings,100,50,2/6/2020
D04D9F,earnings,100,50,2/6/2020
D04D9F,earnings,100,50,2/6/2020
D04D9F,earnings,100,50,2/6/2020
D04D9F,earnings,100,50,2/6/2020
D29B44,earnings,100,50,2/6/2020
D3F64D,earnings,100,50,2/6/2020
D4070C,executive-appointment,100,54,2/6/2020
D4070C,executive-appointment,100,54,2/6/2020
D4C0CB,private-placement,100,56,2/6/2020
D5938F,earnings,100,50,2/6/2020
D65A13,revenues,100,50,2/6/2020
D65A13,revenues,100,50,2/6/2020
D6853F,dividend,100,50,2/6/2020
D8F347,dividend,100,50,2/6/2020
D90F43,earnings,100,50,2/6/2020
D90F43,earnings,100,50,2/6/2020
D90F43,earnings,100,50,2/6/2020
D90F43,earnings,100,50,2/6/2020
D90F43,earnings,100,50,2/6/2020
D90F43,earnings,100,50,2/6/2020
D90F43,earnings,100,50,2/6/2020
DAFED3,buybacks,100,74,2/6/2020
DB396B,conference-call,100,50,2/6/2020
DC437D,dividend,100,50,2/6/2020
DD1BA1,earnings,100,50,2/6/2020
DD1BA1,earnings,100,50,2/6/2020
DD1BA1,earnings,100,50,2/6/2020
DD1BA1,earnings,100,50,2/6/2020
DD1BA1,earnings,100,50,2/6/2020
DD1BA1,earnings,100,50,2/6/2020
DD1BA1,earnings,100,50,2/6/2020
DDC415,earnings,100,50,2/6/2020
DF204B,conference-call,100,50,2/6/2020
E00373,business-contract,100,69,2/6/2020
E05DC8,earnings,100,50,2/6/2020
E0D3BA,earnings,100,50,2/6/2020
E19A99,earnings,100,50,2/6/2020
E1C16B,conference-participant,100,50,2/6/2020
E2CB7B,earnings,100,50,2/6/2020
E2CFD2,conference-call,100,50,2/6/2020
E49AA3,earnings,100,50,2/6/2020
E6EDED,earnings,100,50,2/6/2020
E71AE6,public-offering,100,43,2/6/2020
E74B55,executive-resignation,100,44,2/6/2020
E94704,earnings,100,50,2/6/2020
E9FF33,executive-appointment,100,54,2/6/2020
ECDEB2,earnings,100,50,2/6/2020
ECDEB2,earnings,100,50,2/6/2020
ED1A74,ipo-pricing,100,50,2/6/2020
ED79D9,settlement,100,56,2/6/2020
F294DD,dividend,100,50,2/6/2020
F32F88,dividend,100,50,2/6/2020
F3FCC3,buybacks,100,74,2/6/2020
F44EA2,earnings,100,50,2/6/2020
F46EC9,earnings,100,50,2/6/2020
F47871,earnings,100,50,2/6/2020
F4E882,legal-issues-defendant,100,22,2/6/2020
F4E882,legal-issues-defendant,100,22,2/6/2020
F4F46F,earnings,100,50,2/6/2020
F5349B,executive-appointment,100,54,2/6/2020
F769E9,earnings,100,50,2/6/2020
F7935D,earnings,100,50,2/6/2020
F88A04,earnings,100,50,2/6/2020
F88A04,earnings,100,50,2/6/2020
F88A04,earnings,100,50,2/6/2020
F88A04,earnings,100,50,2/6/2020
F8C5D7,conference-call,100,50,2/6/2020
FC1F9D,dividend,100,50,2/6/2020
FC80E6,conference-call,100,50,2/6/2020
FD6926,conference-call,100,50,2/6/2020
FEE4B0,earnings-up,100,68,2/6/2020
FEE4B0,earnings-up,100,68,2/6/2020
FEE4B0,earnings-up,100,68,2/6/2020
FEE4B0,earnings-up,100,68,2/6/2020
FEE4B0,earnings-up,100,68,2/6/2020
FFE543,revenue-up,100,69,2/6/2020
FFE543,revenues,100,50,2/6/2020
FFE543,revenues,100,50,2/6/2020
FFE543,revenues,100,50,2/6/2020
001F1B,revenues,100,50,2/7/2020
001F1B,earnings,100,50,2/7/2020
20751,public-offering,100,43,2/7/2020
31025,revenue-up,100,69,2/7/2020
03FB17,revenue-up,100,54,2/7/2020
03FB17,revenue-up,100,54,2/7/2020
03FB17,revenue-up,100,54,2/7/2020
03FB17,revenue-up,100,54,2/7/2020
03FB17,revenue-up,100,54,2/7/2020
03FB17,revenue-up,100,54,2/7/2020
03FB17,revenue-up,100,54,2/7/2020
03FB17,revenue-up,100,54,2/7/2020
05D148,reverse-stock-splits,100,51,2/7/2020
065D38,ipo-pricing,100,50,2/7/2020
065D38,ipo-pricing,100,50,2/7/2020
06EE79,earnings,100,50,2/7/2020
0FABBD,conference-call,100,50,2/7/2020
105D00,acquisition-completed-acquirer,100,49,2/7/2020
1272B3,earnings,100,50,2/7/2020
152AB9,reverse-stock-splits,100,51,2/7/2020
16B183,dividend,100,50,2/7/2020
182546,earnings,100,50,2/7/2020
1880C5,executive-appointment,100,54,2/7/2020
18EC17,executive-resignation,100,44,2/7/2020
1A3E1B,earnings,100,50,2/7/2020
1E1125,conference-organizer,100,57,2/7/2020
1F43A1,earnings,100,50,2/7/2020
1FA886,legal-issues-defendant,100,22,2/7/2020
1FAF22,partnership,100,61,2/7/2020
1FE7F0,earnings,100,50,2/7/2020
21F9CA,revenues,100,50,2/7/2020
221783,earnings,100,50,2/7/2020
221AD7,donation,100,54,2/7/2020
249674,conference-call,100,50,2/7/2020
25102A,acquisition-acquirer,100,49,2/7/2020
26008A,conference-call,100,50,2/7/2020
267718,business-contract,100,69,2/7/2020
26CC63,conference-participant,100,50,2/7/2020
26DC29,award,100,58,2/7/2020
270305,merger-completed,100,66,2/7/2020
270B78,index-listing,100,76,2/7/2020
28AC4E,conference-participant,100,50,2/7/2020
292388,earnings,100,50,2/7/2020
2950FF,earnings,100,50,2/7/2020
2.90E+62,earnings,100,50,2/7/2020
2.90E+62,dividend-up,100,81,2/7/2020
2A1009,earnings,100,50,2/7/2020
2BA977,conference-call,100,50,2/7/2020
2BF36E,conference-call,100,50,2/7/2020
2EB88B,partnership,100,61,2/7/2020
301493,legal-issues-defendant,100,22,2/7/2020
306623,conference-call,100,50,2/7/2020
32C8CD,partnership,100,61,2/7/2020
35AE32,earnings,100,50,2/7/2020
36E479,fast-track-designation,100,81,2/7/2020
370C50,legal-issues-defendant,100,22,2/7/2020
371C01,conference-call,100,50,2/7/2020
373B06,earnings,100,50,2/7/2020
382EAE,conference-call,100,50,2/7/2020
387541,conference-call,100,50,2/7/2020
396D7C,executive-appointment,100,54,2/7/2020
3A113F,note-sale,100,52,2/7/2020
3A113F,note-sale,100,52,2/7/2020
3B318A,conference-participant,100,50,2/7/2020
3F6A9C,earnings,100,50,2/7/2020
3F6A9C,earnings,100,50,2/7/2020
3F6A9C,earnings,100,50,2/7/2020
3F6A9C,earnings,100,50,2/7/2020
3F6A9C,earnings,100,50,2/7/2020
3F6A9C,earnings,100,50,2/7/2020
3F6A9C,earnings,100,50,2/7/2020
3F6A9C,earnings,100,50,2/7/2020
423279,dividend,100,50,2/7/2020
435ACE,earnings,100,50,2/7/2020
442587,credit-extension-recipient,100,69,2/7/2020
448BF3,public-offering,100,43,2/7/2020
49BBBC,earnings,100,50,2/7/2020
4A6F00,partnership,100,61,2/7/2020
4B3676,conference-participant,100,50,2/7/2020
4BBA23,operating-earnings,100,50,2/7/2020
4C37C5,executive-appointment,100,54,2/7/2020
4CDA2B,public-offering,100,43,2/7/2020
4EE167,earnings,100,50,2/7/2020
4FCC78,conference-call,100,50,2/7/2020
50070E,conference-organizer,100,57,2/7/2020
50070E,conference-organizer,100,57,2/7/2020
50070E,conference-organizer,100,57,2/7/2020
50702E,earnings,100,50,2/7/2020
50702E,earnings,100,50,2/7/2020
514067,earnings,100,50,2/7/2020
543C77,ipo-completed,100,76,2/7/2020
5B7739,conference-participant,100,50,2/7/2020
5D41E4,public-offering,100,43,2/7/2020
5FE4B6,earnings,100,50,2/7/2020
601785,dividend,100,50,2/7/2020
62B20A,earnings,100,50,2/7/2020
62F41C,legal-issues-defendant,100,22,2/7/2020
62F41C,legal-issues-defendant,100,22,2/7/2020
636931,merger,100,66,2/7/2020
636931,buybacks,100,74,2/7/2020
6.52E+64,executive-appointment,100,54,2/7/2020
65CF8E,earnings,100,50,2/7/2020
665618,conference-call,100,50,2/7/2020
665D7D,earnings,100,50,2/7/2020
665D7D,earnings,100,50,2/7/2020
665D7D,earnings,100,50,2/7/2020
665D7D,earnings,100,50,2/7/2020
665D7D,earnings,100,50,2/7/2020
66749D,conference-participant,100,50,2/7/2020
66749D,dividend,100,50,2/7/2020
66A667,executive-appointment,100,54,2/7/2020
676FFD,legal-issues-defendant,100,22,2/7/2020
68B03F,business-contract,100,69,2/7/2020
6A01DF,executive-resignation,100,44,2/7/2020
6A6BDC,earnings,100,50,2/7/2020
6D3B7B,dividend,100,50,2/7/2020
6DBBBC,conference-call,100,50,2/7/2020
6DDA15,legal-issues-defendant,100,22,2/7/2020
6F39FC,dividend,100,50,2/7/2020
70CA28,earnings,100,50,2/7/2020
70CA28,earnings,100,50,2/7/2020
72EF75,dividend,100,50,2/7/2020
762A3E,conference-organizer,100,57,2/7/2020
78F9ED,legal-issues-defendant,100,22,2/7/2020
7B1E50,earnings,100,50,2/7/2020
7B1E50,earnings,100,50,2/7/2020
7BAAE7,dividend,100,50,2/7/2020
7DA412,earnings,100,50,2/7/2020
7F3FBC,acquisition-acquirer,100,49,2/7/2020
81EAD4,product-release,100,64,2/7/2020
8377DB,partnership,100,61,2/7/2020
838ADD,stake-acquirer,100,48,2/7/2020
86F123,acquisition-acquirer,100,49,2/7/2020
88350F,executive-appointment,100,54,2/7/2020
883D82,earnings,100,50,2/7/2020
8AC65D,executive-appointment,100,54,2/7/2020
8AC65D,earnings,100,50,2/7/2020
8BAA15,executive-appointment,100,54,2/7/2020
8BAA15,business-contract,100,69,2/7/2020
8D0EEA,executive-appointment,100,54,2/7/2020
8D0EEA,reverse-stock-splits,100,51,2/7/2020
8D4AE6,earnings,100,50,2/7/2020
8D5145,dividend-up,100,60,2/7/2020
8DA42F,conference-call,100,50,2/7/2020
8E0E32,conference-participant,100,50,2/7/2020
8E10BF,conference-participant,100,50,2/7/2020
8F6995,earnings,100,50,2/7/2020
8F6995,dividend,100,50,2/7/2020
905356,index-listing,100,76,2/7/2020
9087B9,dividend,100,50,2/7/2020
9196A2,conference-organizer,100,57,2/7/2020
93965C,earnings,100,50,2/7/2020
966DBE,earnings,100,50,2/7/2020
9.74E+08,earnings,100,50,2/7/2020
990AD0,conference-organizer,100,57,2/7/2020
99B61C,ipo-completed,100,76,2/7/2020
9A2760,executive-appointment,100,54,2/7/2020
9D2790,earnings,100,50,2/7/2020
9D2790,earnings,100,50,2/7/2020
9D2790,earnings,100,50,2/7/2020
9D2790,earnings,100,50,2/7/2020
9D2790,earnings,100,50,2/7/2020
9D2790,earnings,100,50,2/7/2020
9D2790,earnings,100,50,2/7/2020
9D30A8,conference-participant,100,50,2/7/2020
9D65C1,executive-resignation,100,44,2/7/2020
9E0811,earnings,100,50,2/7/2020
9E0811,earnings,100,50,2/7/2020
9EF4CF,legal-issues-defendant,100,22,2/7/2020
9EF4CF,legal-issues-defendant,100,22,2/7/2020
9F5997,unit-acquisition-acquirer,100,49,2/7/2020
A01664,conference-participant,100,50,2/7/2020
A16DEA,conference-participant,100,50,2/7/2020
A29DBD,earnings,100,50,2/7/2020
A47A7D,product-release,100,64,2/7/2020
A49498,ipo-completed,100,76,2/7/2020
A5195E,clinical-trials-filed,100,60,2/7/2020
A8CBDA,conference-participant,100,50,2/7/2020
AB7726,executive-appointment,100,54,2/7/2020
AB7726,dividend,100,50,2/7/2020
AD3008,acquisition-acquirer,100,49,2/7/2020
AD9F1D,dividend,100,50,2/7/2020
AE7D16,stake-acquiree,100,62,2/7/2020
AED61E,conference-call,100,50,2/7/2020
B05118,earnings,100,50,2/7/2020
B076A1,conference-call,100,50,2/7/2020
B08C51,business-contract,100,69,2/7/2020
B0D41A,conference-participant,100,50,2/7/2020
B303A6,legal-issues-defendant,100,22,2/7/2020
B3CB74,conference-organizer,100,57,2/7/2020
B4528F,conference-call,100,50,2/7/2020
B7BBFF,earnings,100,50,2/7/2020
B7FA9B,conference-call,100,50,2/7/2020
B934BF,executive-appointment,100,54,2/7/2020
BD682F,earnings,100,50,2/7/2020
BFAEB4,legal-issues-defendant,100,22,2/7/2020
C03C8B,unit-acquisition-acquirer,100,49,2/7/2020
C07E05,executive-appointment,100,54,2/7/2020
C0F70B,conference-participant,100,50,2/7/2020
C230FE,earnings,100,50,2/7/2020
C230FE,earnings,100,50,2/7/2020
C38440,acquisition-completed-acquirer,100,49,2/7/2020
C3DE7D,earnings,100,50,2/7/2020
C425AE,legal-issues-defendant,100,22,2/7/2020
C425AE,legal-issues-defendant,100,22,2/7/2020
C7FC95,partnership,100,61,2/7/2020
C94CFC,hirings,100,65,2/7/2020
C9A96E,unit-acquisition-acquiree,100,76,2/7/2020
C9A96E,unit-acquisition-acquiree,100,76,2/7/2020
C9C62A,earnings,100,50,2/7/2020
CBBFBF,dividend-down,100,19,2/7/2020
CDD75E,public-offering,100,43,2/7/2020
CDE118,earnings,100,50,2/7/2020
CDFCC9,dividend,100,50,2/7/2020
CDFCC9,earnings,100,50,2/7/2020
CDFCC9,earnings,100,50,2/7/2020
CDFCC9,earnings,100,50,2/7/2020
CDFCC9,earnings,100,50,2/7/2020
CDFCC9,earnings,100,50,2/7/2020
CE5664,earnings,100,50,2/7/2020
CE5664,earnings,100,50,2/7/2020
CE5664,earnings,100,50,2/7/2020
CF351E,earnings,100,50,2/7/2020
D15833,board-meeting,100,51,2/7/2020
D1C26F,earnings,100,50,2/7/2020
D29B44,conference-participant,100,50,2/7/2020
D3FD6D,conference-call,100,50,2/7/2020
D518D8,award,100,58,2/7/2020
D518D8,conference-call,100,50,2/7/2020
D6534D,conference-call,100,50,2/7/2020
D78BF1,award,100,58,2/7/2020
D78CCD,legal-issues-defendant,100,22,2/7/2020
D7F569,earnings,100,50,2/7/2020
DA9443,clinical-trials,100,56,2/7/2020
DAFED3,conference-participant,100,50,2/7/2020
DBB7ED,exchange-noncompliance,100,24,2/7/2020
DBEF02,earnings,100,50,2/7/2020
DF6FDD,dividend,100,50,2/7/2020
E074A0,earnings,100,50,2/7/2020
E09997,dividend,100,50,2/7/2020
E3656D,earnings,100,50,2/7/2020
E5A3B6,public-offering,100,43,2/7/2020
E68733,earnings,100,50,2/7/2020
E6E012,earnings,100,50,2/7/2020
E71AE6,public-offering,100,43,2/7/2020
E87676,conference-call,100,50,2/7/2020
EAA0A7,executive-appointment,100,54,2/7/2020
EB61C4,conference-participant,100,50,2/7/2020
ED2EFD,facility-upgrade,100,65,2/7/2020
ED9576,dividend-up,100,81,2/7/2020
EDF5CA,legal-issues-defendant,100,22,2/7/2020
F05B1B,merger-completed,100,66,2/7/2020
F05B1B,merger-completed,100,66,2/7/2020
F1529C,earnings,100,50,2/7/2020
F1529C,earnings,100,50,2/7/2020
F1C04C,dividend,100,50,2/7/2020
F2BC3D,acquisition-acquirer,100,49,2/7/2020
F3016C,earnings,100,50,2/7/2020
F3FCC3,conference-participant,100,50,2/7/2020
F4CDA3,conference-call,100,50,2/7/2020
F4E882,legal-issues-defendant,100,22,2/7/2020
F569FD,public-offering,100,43,2/7/2020
F5D499,conference-call,100,50,2/7/2020
F6DA75,earnings,100,50,2/7/2020
F6DA75,earnings,100,50,2/7/2020
F702CA,executive-appointment,100,54,2/7/2020
F7D8AE,ipo-pricing,100,50,2/7/2020
F80FF9,earnings,100,50,2/7/2020
F85CC0,conference-participant,100,50,2/7/2020
FEC475,conference-participant,100,50,2/7/2020
168A5D,hirings,100,65,2/8/2020
E1BD05,executive-appointment,100,54,2/8/2020
BFAEB4,legal-issues-defendant,100,22,2/9/2020
13528,conference-participant,100,50,2/10/2020
13528,dividend,100,50,2/10/2020
03596A,executive-appointment,100,54,2/10/2020
053EFF,product-release,100,64,2/10/2020
078D52,earnings,100,50,2/10/2020
078D52,earnings,100,50,2/10/2020
099C88,conference-participant,100,50,2/10/2020
0A0D9E,executive-appointment,100,54,2/10/2020
0B13E8,conference-call,100,50,2/10/2020
0BD4E8,executive-appointment,100,54,2/10/2020
0BF198,conference-call,100,50,2/10/2020
0F2BC9,business-contract,100,69,2/10/2020
138DDE,earnings,100,50,2/10/2020
15A388,earnings,100,50,2/10/2020
15B10D,executive-appointment,100,54,2/10/2020
16F4D8,business-contract,100,69,2/10/2020
18EC17,acquisition-acquirer,100,49,2/10/2020
1A5D5D,acquisition-acquirer,100,49,2/10/2020
1AE482,earnings,100,50,2/10/2020
1AF7E2,conference-call,100,50,2/10/2020
1CF3A8,earnings,100,50,2/10/2020
1DB6A6,dividend,100,50,2/10/2020
1E1125,conference-organizer,100,57,2/10/2020
1F716B,earnings,100,50,2/10/2020
1FA886,legal-issues-defendant,100,22,2/10/2020
23207A,earnings,100,50,2/10/2020
23207A,earnings,100,50,2/10/2020
25102A,note-sale,100,52,2/10/2020
25102A,note-sale,100,52,2/10/2020
25102A,note-sale,100,52,2/10/2020
25102A,note-sale,100,52,2/10/2020
25102A,note-sale,100,52,2/10/2020
25102A,note-sale,100,52,2/10/2020
26DC29,conference-participant,100,50,2/10/2020
26F31D,earnings,100,50,2/10/2020
2B9DBB,dividend,100,50,2/10/2020
306623,earnings,100,50,2/10/2020
30AB63,earnings,100,50,2/10/2020
30DE64,public-offering,100,43,2/10/2020
31803E,earnings,100,50,2/10/2020
32CB22,note-sale,100,52,2/10/2020
32CB22,note-sale,100,52,2/10/2020
346BF2,trading-listing,100,61,2/10/2020
3A3447,note-sale,100,52,2/10/2020
3B37F7,note-sale,100,52,2/10/2020
3CBA2A,partnership,100,61,2/10/2020
3DB18B,earnings,100,50,2/10/2020
3DD5E2,earnings,100,50,2/10/2020
3E70FC,earnings,100,50,2/10/2020
408380,executive-appointment,100,54,2/10/2020
40F7DE,earnings,100,50,2/10/2020
41785E,conference-participant,100,50,2/10/2020
41ED98,asset-sale,100,62,2/10/2020
425BDC,conference-call,100,50,2/10/2020
429BFB,executive-appointment,100,54,2/10/2020
429BFB,conference-call,100,50,2/10/2020
43A74A,settlement,100,56,2/10/2020
442769,conference-participant,100,50,2/10/2020
44A4FC,acquisition-completed-acquirer,100,49,2/10/2020
490D4B,earnings,100,50,2/10/2020
49CC59,conference-call,100,50,2/10/2020
4D8124,product-release,100,64,2/10/2020
50070E,conference-call,100,50,2/10/2020
5.43E+08,conference-participant,100,50,2/10/2020
567F3D,conference-participant,100,50,2/10/2020
567F3D,conference-participant,100,50,2/10/2020
5968F9,earnings,100,50,2/10/2020
5AF08A,conference-participant,100,50,2/10/2020
5C8D61,earnings,100,50,2/10/2020
5C8D61,earnings,100,50,2/10/2020
5C8D61,earnings,100,50,2/10/2020
5D1956,acquisition-acquirer,100,49,2/10/2020
5FDBD0,conference-call,100,50,2/10/2020
615B6D,conference-participant,100,50,2/10/2020
629F0F,earnings,100,50,2/10/2020
62F41C,legal-issues-defendant,100,22,2/10/2020
64E615,conference-call,100,50,2/10/2020
657097,earnings,100,50,2/10/2020
665440,conference-call,100,50,2/10/2020
68E3E0,conference-call,100,50,2/10/2020
693ECD,earnings,100,50,2/10/2020
69FDFC,earnings,100,50,2/10/2020
6B494E,facility-upgrade,100,65,2/10/2020
6BBCBA,ipo-completed,100,76,2/10/2020
6BD606,dividend,100,50,2/10/2020
6D156D,earnings,100,50,2/10/2020
6D6B40,earnings,100,50,2/10/2020
6DDA15,legal-issues-defendant,100,22,2/10/2020
6F3FA8,earnings,100,50,2/10/2020
6F3FA8,earnings,100,50,2/10/2020
6F3FA8,earnings,100,50,2/10/2020
6F3FA8,earnings,100,50,2/10/2020
6F3FA8,earnings,100,50,2/10/2020
6F3FA8,earnings,100,50,2/10/2020
6F5DD2,earnings,100,50,2/10/2020
701531,earnings,100,50,2/10/2020
73BCBA,conference-call,100,50,2/10/2020
7448A3,earnings,100,50,2/10/2020
747219,note-sale,100,52,2/10/2020
762B8D,earnings,100,50,2/10/2020
7A10FF,conference-participant,100,50,2/10/2020
7A2A49,earnings,100,50,2/10/2020
7A51FE,buybacks,100,74,2/10/2020
7A51FE,earnings,100,50,2/10/2020
7ACD98,conference-call,100,50,2/10/2020
7ACD98,acquisition-acquirer,100,49,2/10/2020
7F0372,earnings,100,50,2/10/2020
7F2922,earnings,100,50,2/10/2020
7F3A5F,executive-appointment,100,54,2/10/2020
83066C,conference-call,100,50,2/10/2020
83A065,public-offering,100,43,2/10/2020
85DA04,earnings,100,50,2/10/2020
85DA04,earnings,100,50,2/10/2020
85DA04,earnings,100,50,2/10/2020
85DA04,earnings,100,50,2/10/2020
8AC740,earnings,100,50,2/10/2020
8B4A45,facility-open,100,65,2/10/2020
8BAA15,product-recall,100,29,2/10/2020
8C6C1B,facility-open,100,65,2/10/2020
8DCF18,conference-call,100,50,2/10/2020
900356,acquisition-acquirer,100,49,2/10/2020
900356,acquisition-acquirer,100,49,2/10/2020
91E5EE,earnings,100,50,2/10/2020
9548BB,credit-extension-recipient,100,69,2/10/2020
95DC1F,executive-appointment,100,54,2/10/2020
9.62E+76,partnership,100,61,2/10/2020
968B00,earnings-positive,100,69,2/10/2020
968B00,earnings-positive,100,69,2/10/2020
96F126,product-release,100,64,2/10/2020
97644E,partnership,100,61,2/10/2020
980C14,dividend,100,50,2/10/2020
9E575E,note-sale,100,52,2/10/2020
9EF4CF,legal-issues-defendant,100,22,2/10/2020
A1EAC8,conference-call,100,50,2/10/2020
A47A7D,business-contract,100,69,2/10/2020
A48593,conference-participant,100,50,2/10/2020
A495F7,earnings,100,50,2/10/2020
A7102F,conference-participant,100,50,2/10/2020
AAEE21,earnings,100,50,2/10/2020
B1B10C,dividend,100,50,2/10/2020
B1DF3C,earnings,100,50,2/10/2020
B303A6,legal-issues-defendant,100,22,2/10/2020
B33E77,clinical-trials-start,100,64,2/10/2020
B3ED62,executive-appointment,100,54,2/10/2020
B614F8,revenues,100,50,2/10/2020
B7202A,note-sale,100,52,2/10/2020
B8A51F,regulatory-product-approval-granted,100,81,2/10/2020
BA0442,acquisition-acquirer,100,49,2/10/2020
BB0587,earnings,100,50,2/10/2020
BB127B,acquisition-acquiree,100,76,2/10/2020
BFAEB4,legal-issues-defendant,100,22,2/10/2020
C0BA36,earnings,100,50,2/10/2020
C0F70B,earnings,100,50,2/10/2020
C2609A,earnings,100,50,2/10/2020
C3BAE7,earnings,100,50,2/10/2020
C5C137,product-release,100,64,2/10/2020
C9C62A,executive-appointment,100,54,2/10/2020
CB6A9C,conference-call,100,50,2/10/2020
CBBFBF,legal-issues-defendant,100,22,2/10/2020
CBBFBF,legal-issues-defendant,100,22,2/10/2020
CDAB24,award,100,58,2/10/2020
D13F1C,executive-appointment,100,54,2/10/2020
D29F43,conference-call,100,50,2/10/2020
D57D99,earnings,100,50,2/10/2020
D60BB2,dividend-up,100,81,2/10/2020
DA91AE,dividend,100,50,2/10/2020
DB7014,operating-earnings,100,50,2/10/2020
DD0F15,legal-issues-defendant,100,22,2/10/2020
DD0F15,legal-issues-defendant,100,22,2/10/2020
DE5611,conference-call,100,50,2/10/2020
DF18E6,public-offering,100,43,2/10/2020
DF204B,facility-upgrade,100,65,2/10/2020
E0207A,business-contract,100,69,2/10/2020
E05026,earnings,100,50,2/10/2020
E0647D,earnings,100,50,2/10/2020
E0647D,earnings,100,50,2/10/2020
E259C7,revenue-up,100,69,2/10/2020
E3A829,acquisition-completed-acquirer,100,49,2/10/2020
E3A829,acquisition-completed-acquirer,100,49,2/10/2020
E3E68E,executive-appointment,100,54,2/10/2020
E3E68E,executive-appointment,100,54,2/10/2020
E3E68E,earnings,100,50,2/10/2020
E3E68E,earnings,100,50,2/10/2020
E754F0,earnings,100,50,2/10/2020
E802CE,conference-call,100,50,2/10/2020
E93A40,earnings,100,50,2/10/2020
ECA300,facility-open,100,65,2/10/2020
ECD263,partnership,100,61,2/10/2020
EE967B,earnings,100,50,2/10/2020
EFD406,earnings,100,50,2/10/2020
EFD406,earnings,100,50,2/10/2020
EFD406,earnings,100,50,2/10/2020
EFD406,earnings,100,50,2/10/2020
EFD406,earnings,100,50,2/10/2020
EFD406,earnings,100,50,2/10/2020
EFD406,earnings,100,50,2/10/2020
F1EB39,conference-participant,100,50,2/10/2020
F24FF0,buybacks,100,74,2/10/2020
F3FCC3,debt-extension-recipient,100,73,2/10/2020
F509E2,earnings,100,50,2/10/2020
F9CAF8,dividend,100,50,2/10/2020
FAB97A,earnings,100,50,2/10/2020
FADF1A,earnings,100,50,2/10/2020
FAE021,business-contract,100,69,2/10/2020
FAE021,union-pact,100,61,2/10/2020
FAE021,union-pact,100,61,2/10/2020
FD0CA4,unit-acquisition-acquiree,100,76,2/10/2020
FD0CA4,unit-acquisition-acquiree,100,76,2/10/2020
FD0CA4,unit-acquisition-acquiree,100,76,2/10/2020
FD9526,dividend,100,50,2/10/2020
FF6644,conference-participant,100,50,2/10/2020
002A99,conference-participant,100,50,2/11/2020
002A99,regulatory-product-approval-granted,100,81,2/11/2020
00698D,conference-call,100,50,2/11/2020
0157B1,partnership,100,61,2/11/2020
02870F,earnings,100,50,2/11/2020
040DBB,conference-call,100,50,2/11/2020
04EB2F,earnings,100,50,2/11/2020
0560D8,earnings,100,50,2/11/2020
0919B1,earnings,100,50,2/11/2020
0968A5,conference-call,100,50,2/11/2020
0BD4E8,award,100,58,2/11/2020
0C2A0D,dividend,100,50,2/11/2020
125212,clinical-trials,100,56,2/11/2020
125212,clinical-trials,100,56,2/11/2020
12A3A3,executive-appointment,100,54,2/11/2020
12A3A3,executive-appointment,100,54,2/11/2020
12DE76,executive-appointment,100,54,2/11/2020
12F98C,executive-resignation,100,44,2/11/2020
131443,dividend,100,50,2/11/2020
136B26,conference-participant,100,50,2/11/2020
149301,dividend,100,50,2/11/2020
157D9F,earnings,100,50,2/11/2020
16C544,earnings,100,50,2/11/2020
1B16C1,earnings,100,50,2/11/2020
1BDB2A,dividend,100,50,2/11/2020
1CF3A8,note-sale,100,52,2/11/2020
1D3A00,conference-call,100,50,2/11/2020
1EA923,executive-resignation,100,44,2/11/2020
221445,dividend,100,50,2/11/2020
241AF7,conference-call,100,50,2/11/2020
25AB8E,earnings,100,50,2/11/2020
263216,trading-halt,100,43,2/11/2020
292388,earnings,100,50,2/11/2020
292388,earnings,100,50,2/11/2020
292388,earnings,100,50,2/11/2020
2E902B,conference-participant,100,50,2/11/2020
2EB04E,earnings-up,100,68,2/11/2020
2EC172,earnings,100,50,2/11/2020
2F6782,conference-call,100,50,2/11/2020
2F7A7E,conference-call,100,50,2/11/2020
3.14E+47,business-contract,100,69,2/11/2020
315EB0,business-contract,100,69,2/11/2020
315EB0,executive-appointment,100,54,2/11/2020
31DB20,earnings,100,50,2/11/2020
338544,legal-issues-defendant,100,22,2/11/2020
3461CF,award,100,58,2/11/2020
346BF2,conference-call,100,50,2/11/2020
34B97A,public-offering,100,43,2/11/2020
3587B4,dividend,100,50,2/11/2020
35AE32,legal-issues-defendant,100,22,2/11/2020
370C50,legal-issues-defendant,100,22,2/11/2020
372037,executive-resignation,100,44,2/11/2020
37727A,earnings,100,50,2/11/2020
37E18B,conference-call,100,50,2/11/2020
389CFB,conference-call,100,50,2/11/2020
3A3948,conference-call,100,50,2/11/2020
3BBD10,product-release,100,64,2/11/2020
3C8A04,dividend,100,50,2/11/2020
3F4497,earnings,100,50,2/11/2020
41EC04,earnings,100,50,2/11/2020
42AABD,business-contract,100,69,2/11/2020
43A060,partnership,100,61,2/11/2020
43F4A8,conference-call,100,50,2/11/2020
44209A,earnings,100,50,2/11/2020
442769,business-contract,100,69,2/11/2020
44740A,conference-call,100,50,2/11/2020
44A4FC,partnership,100,61,2/11/2020
451D61,conference-participant,100,50,2/11/2020
45BC35,earnings,100,50,2/11/2020
4649D5,earnings,100,50,2/11/2020
467F2C,earnings,100,50,2/11/2020
4.91E+58,earnings-up,100,68,2/11/2020
4.91E+58,earnings,100,50,2/11/2020
4.91E+58,earnings,100,50,2/11/2020
4.91E+58,earnings,100,50,2/11/2020
4.91E+58,earnings,100,50,2/11/2020
4.91E+58,earnings,100,50,2/11/2020
4.91E+58,earnings,100,50,2/11/2020
494EB9,dividend,100,50,2/11/2020
494EB9,legal-issues-defendant,100,22,2/11/2020
49CC59,executive-appointment,100,54,2/11/2020
4AC91D,earnings,100,50,2/11/2020
4B3676,acquisition-completed-acquirer,100,49,2/11/2020
4C2F17,business-contract,100,69,2/11/2020
4C2F17,business-contract,100,69,2/11/2020
4E7C1F,regulatory-product-approval-granted,100,81,2/11/2020
4EEB00,clinical-trials,100,56,2/11/2020
50070E,conference-organizer,100,57,2/11/2020
507AE7,dividend,100,50,2/11/2020
51D876,partnership,100,61,2/11/2020
539F49,legal-issues-defendant,100,22,2/11/2020
5.47E+28,rights-issue,100,43,2/11/2020
5480A7,dividend,100,50,2/11/2020
54DF47,conference-call,100,50,2/11/2020
56632F,dividend,100,50,2/11/2020
57DDB9,merger-completed,100,66,2/11/2020
57DDB9,merger-completed,100,66,2/11/2020
59A832,earnings,100,50,2/11/2020
5A0FF1,earnings,100,50,2/11/2020
5B6C11,dividend,100,50,2/11/2020
5CCDAD,earnings,100,50,2/11/2020
5DE5A5,conference-participant,100,50,2/11/2020
619882,conference-organizer,100,57,2/11/2020
61BCA7,earnings,100,50,2/11/2020
629F0F,conference-participant,100,50,2/11/2020
62CDDE,conference-call,100,50,2/11/2020
633054,merger,100,66,2/11/2020
64FF65,conference-call,100,50,2/11/2020
665D7D,conference-participant,100,50,2/11/2020
66667F,asset-sale,100,62,2/11/2020
66E04A,earnings,100,50,2/11/2020
673C9A,earnings,100,50,2/11/2020
68E3E0,dividend,100,50,2/11/2020
69CE71,investment-investor,100,55,2/11/2020
69CE71,facility-open,100,65,2/11/2020
6BD606,conference-call,100,50,2/11/2020
6BD606,conference-call,100,50,2/11/2020
6CC55E,conference-participant,100,50,2/11/2020
6CC55E,clinical-trials-positive,100,87,2/11/2020
6D9B53,business-contract,100,69,2/11/2020
6E8864,conference-participant,100,50,2/11/2020
705636,dividend,100,50,2/11/2020
722D55,earnings,100,50,2/11/2020
741937,dividend,100,50,2/11/2020
742AAB,legal-issues-defendant,100,22,2/11/2020
742AAB,legal-issues-defendant,100,22,2/11/2020
762A3E,conference-organizer,100,57,2/11/2020
76BD96,conference-call,100,50,2/11/2020
79340A,conference-participant,100,50,2/11/2020
7F3665,earnings,100,50,2/11/2020
7F9BE2,dividend,100,50,2/11/2020
82C202,unit-acquisition-acquirer,100,49,2/11/2020
82C202,unit-acquisition-acquirer,100,49,2/11/2020
8303CD,earnings,100,50,2/11/2020
8377DB,conference-participant,100,50,2/11/2020
837C04,executive-appointment,100,54,2/11/2020
83A065,public-offering,100,43,2/11/2020
896771,conference-call,100,50,2/11/2020
8A8E41,partnership,100,61,2/11/2020
8C6C1B,facility-open,100,65,2/11/2020
8E9CD8,earnings-up,100,68,2/11/2020
8E9CD8,earnings,100,50,2/11/2020
8E9CD8,earnings,100,50,2/11/2020
8E9CD8,earnings,100,50,2/11/2020
8E9CD8,earnings,100,50,2/11/2020
8E9CD8,earnings,100,50,2/11/2020
902255,executive-resignation,100,44,2/11/2020
925759,orphan-drug-designation,100,76,2/11/2020
92D9C9,public-offering,100,43,2/11/2020
92D9C9,public-offering,100,43,2/11/2020
9.31E+77,conference-call,100,50,2/11/2020
944B2E,executive-appointment,100,54,2/11/2020
95C575,dividend,100,50,2/11/2020
968B00,dividend,100,50,2/11/2020
977A1E,earnings,100,50,2/11/2020
97AF94,earnings,100,50,2/11/2020
98CEBB,conference-participant,100,50,2/11/2020
990AD0,conference-organizer,100,57,2/11/2020
9BB35A,partnership,100,61,2/11/2020
9EF4CF,legal-issues-defendant,100,22,2/11/2020
9F5997,legal-issues-defendant,100,22,2/11/2020
9F62D1,dividend,100,50,2/11/2020
A16DEA,earnings,100,50,2/11/2020
A2C979,clinical-trials-start,100,64,2/11/2020
A41450,earnings,100,50,2/11/2020
A47A7D,executive-appointment,100,54,2/11/2020
A4F67C,earnings,100,50,2/11/2020
A60354,earnings,100,50,2/11/2020
A666C8,earnings,100,50,2/11/2020
A6828A,partnership,100,61,2/11/2020
A868C9,conference-participant,100,50,2/11/2020
A87CD6,revenue-up,100,51,2/11/2020
A87CD6,revenues,100,50,2/11/2020
A87CD6,revenues,100,50,2/11/2020
A87CD6,revenues,100,50,2/11/2020
A87CD6,revenues,100,50,2/11/2020
A87CD6,revenues,100,50,2/11/2020
A87CD6,revenues,100,50,2/11/2020
AA09AD,earnings,100,50,2/11/2020
AA09AD,earnings,100,50,2/11/2020
AA98ED,operating-earnings-up,100,68,2/11/2020
ACDF88,hirings,100,65,2/11/2020
ACDF88,conference-call,100,50,2/11/2020
AFDF2E,asset-sale,100,62,2/11/2020
B01111,earnings,100,50,2/11/2020
B13B68,earnings,100,50,2/11/2020
B1A85D,earnings,100,50,2/11/2020
B1FC3B,conference-participant,100,50,2/11/2020
B303A6,earnings,100,50,2/11/2020
B303A6,legal-issues-defendant,100,22,2/11/2020
B614F8,public-offering,100,43,2/11/2020
B7202A,note-sale,100,52,2/11/2020
BB5271,earnings,100,50,2/11/2020
BBC05B,earnings,100,50,2/11/2020
BCC13E,earnings,100,50,2/11/2020
BD682F,public-offering,100,43,2/11/2020
BD8517,note-sale,100,52,2/11/2020
BFEA04,earnings,100,50,2/11/2020
C03C8B,dividend,100,50,2/11/2020
C425AE,legal-issues-defendant,100,22,2/11/2020
C4A912,executive-appointment,100,54,2/11/2020
C8257F,earnings,100,50,2/11/2020
C8257F,dividend,100,50,2/11/2020
C99CC8,business-contract,100,69,2/11/2020
CBBFBF,legal-issues-defendant,100,22,2/11/2020
CBBFBF,legal-issues-defendant,100,22,2/11/2020
CBBFBF,legal-issues-defendant,100,22,2/11/2020
CBBFBF,legal-issues-defendant,100,22,2/11/2020
CBBFBF,fraud-defendant,100,20,2/11/2020
CBBFBF,legal-issues-defendant,100,22,2/11/2020
CBDB4D,partnership,100,61,2/11/2020
CBDB4D,partnership,100,61,2/11/2020
CDAA0E,conference-participant,100,50,2/11/2020
CDFCC9,conference-participant,100,50,2/11/2020
CEC5B9,note-sale,100,52,2/11/2020
CEC5B9,note-sale,100,52,2/11/2020
CEC5B9,note-sale,100,52,2/11/2020
CEC5B9,note-sale,100,52,2/11/2020
CED4D0,earnings,100,50,2/11/2020
D07B07,award,100,58,2/11/2020
D139BC,earnings,100,50,2/11/2020
D1C26F,conference-participant,100,50,2/11/2020
D56D6D,dividend,100,50,2/11/2020
D6489C,business-contract,100,69,2/11/2020
D6534D,earnings,100,50,2/11/2020
D697DE,earnings,100,50,2/11/2020
D6EAA3,earnings,100,50,2/11/2020
D6EAA3,earnings,100,50,2/11/2020
D6EAA3,earnings,100,50,2/11/2020
D6EAA3,earnings,100,50,2/11/2020
D6EAA3,earnings,100,50,2/11/2020
D6EAA3,earnings,100,50,2/11/2020
D8DA3D,earnings,100,50,2/11/2020
D8DA3D,earnings,100,50,2/11/2020
DA0CB8,earnings,100,50,2/11/2020
DA91AE,partnership,100,61,2/11/2020
DB5CA5,dividend,100,50,2/11/2020
DBB28E,conference-call,100,50,2/11/2020
DD0F15,legal-issues-defendant,100,22,2/11/2020
DD682D,earnings,100,50,2/11/2020
DF8855,earnings,100,50,2/11/2020
DF8855,earnings,100,50,2/11/2020
DF8855,earnings,100,50,2/11/2020
DF8855,earnings,100,50,2/11/2020
DF8855,earnings,100,50,2/11/2020
E00373,earnings,100,50,2/11/2020
E074A0,dividend,100,50,2/11/2020
E15736,earnings,100,50,2/11/2020
E20BFE,revenues,100,50,2/11/2020
E28D9C,conference-call,100,50,2/11/2020
E71AE6,public-offering,100,43,2/11/2020
E829E8,dividend,100,50,2/11/2020
E96E0B,conference-call,100,50,2/11/2020
EA79C7,executive-appointment,100,54,2/11/2020
EB43F4,executive-appointment,100,54,2/11/2020
EBD89A,conference-participant,100,50,2/11/2020
ECF4F8,earnings,100,50,2/11/2020
ED0D7C,dividend,100,50,2/11/2020
ED1A74,ipo-pricing,100,50,2/11/2020
ED1A74,ipo-completed,100,76,2/11/2020
ED2A5E,conference-participant,100,50,2/11/2020
EDD234,conference-call,100,50,2/11/2020
F1529C,dividend,100,50,2/11/2020
F1EB39,business-contract,100,69,2/11/2020
F5349B,executive-appointment,100,54,2/11/2020
F6A987,earnings-up,100,68,2/11/2020
F85CC0,earnings,100,50,2/11/2020
F85CC0,earnings,100,50,2/11/2020
F8DE55,earnings,100,50,2/11/2020
F90EE5,earnings,100,50,2/11/2020
FB728F,conference-call,100,50,2/11/2020
FC01C0,acquisition-acquirer,100,49,2/11/2020
FC1A6E,earnings,100,50,2/11/2020
FC1B7B,dividend,100,50,2/11/2020
FD9526,executive-appointment,100,54,2/11/2020
FDF28E,earnings,100,50,2/11/2020
FF5413,stake-acquirer,100,48,2/11/2020
FF6644,partnership,100,61,2/11/2020
FFAB4A,earnings,100,50,2/11/2020
02870F,legal-issues-defendant,100,22,2/12/2020
03CF95,partnership,100,61,2/12/2020
054E7E,conference-participant,100,50,2/12/2020
065D38,ipo-completed,100,76,2/12/2020
07C69F,earnings,100,50,2/12/2020
07C69F,earnings,100,50,2/12/2020
07C69F,earnings,100,50,2/12/2020
07C69F,earnings,100,50,2/12/2020
07C69F,earnings,100,50,2/12/2020
09DE1F,earnings,100,50,2/12/2020
0B4D10,earnings,100,50,2/12/2020
0CE7F6,earnings,100,50,2/12/2020
0E64D4,partnership,100,61,2/12/2020
0E64D4,partnership,100,61,2/12/2020
1220D2,earnings,100,50,2/12/2020
12731D,conference-call,100,50,2/12/2020
12731D,conference-call,100,50,2/12/2020
12DE76,earnings,100,50,2/12/2020
12DE76,earnings,100,50,2/12/2020
12DE76,earnings,100,50,2/12/2020
12DE76,earnings,100,50,2/12/2020
1490F3,product-release,100,64,2/12/2020
1490F3,stake-acquirer,100,48,2/12/2020
149301,earnings,100,50,2/12/2020
1866B2,conference-call,100,50,2/12/2020
1A5957,earnings,100,50,2/12/2020
1BDB2A,conference-participant,100,50,2/12/2020
1C599A,earnings,100,50,2/12/2020
1D5C51,conference-call,100,50,2/12/2020
1D9E55,earnings,100,50,2/12/2020
1DA44F,dividend-up,100,81,2/12/2020
20D00A,earnings,100,50,2/12/2020
228D42,campaign-ad-release,100,59,2/12/2020
263216,trading-resumed,100,58,2/12/2020
270B78,earnings,100,50,2/12/2020
28AC4E,partnership,100,61,2/12/2020
2B5483,legal-issues-defendant,100,22,2/12/2020
2B5483,legal-issues-defendant,100,22,2/12/2020
2BC05E,legal-issues-defendant,100,22,2/12/2020
2C19A4,earnings,100,50,2/12/2020
2DDB22,earnings-guidance,100,50,2/12/2020
2F94A5,dividend,100,50,2/12/2020
30DE64,public-offering,100,43,2/12/2020
315EB0,earnings,100,50,2/12/2020
315EB0,dividend,100,50,2/12/2020
326EDD,dividend,100,50,2/12/2020
32CB22,conference-participant,100,50,2/12/2020
33AD83,partnership,100,61,2/12/2020
3461CF,earnings,100,50,2/12/2020
3461CF,product-release,100,64,2/12/2020
34E9F9,earnings,100,50,2/12/2020
3.50E+27,earnings,100,50,2/12/2020
35F4B5,dividend-up,100,81,2/12/2020
366A08,note-sale,100,52,2/12/2020
367434,patent-awarded,100,72,2/12/2020
36A1CB,conference-call,100,50,2/12/2020
372037,conference-call,100,50,2/12/2020
387375,public-offering,100,43,2/12/2020
38FB49,dividend,100,50,2/12/2020
3A6D90,executive-resignation,100,44,2/12/2020
3B37F7,note-sale,100,52,2/12/2020
3C3B6B,earnings,100,50,2/12/2020
3C3B6B,partnership,100,61,2/12/2020
3C7F5F,dividend,100,50,2/12/2020
40B903,earnings,100,50,2/12/2020
442769,earnings,100,50,2/12/2020
442769,earnings,100,50,2/12/2020
442769,earnings,100,50,2/12/2020
442769,earnings,100,50,2/12/2020
44A4FC,executive-appointment,100,54,2/12/2020
45ABCC,revenue-up,100,89,2/12/2020
45ABCC,revenue-up,100,89,2/12/2020
45ABCC,revenue-up,100,89,2/12/2020
4.60E+06,earnings,100,50,2/12/2020
47FCF2,earnings,100,50,2/12/2020
485445,earnings,100,50,2/12/2020
490D4B,executive-appointment,100,54,2/12/2020
4A2457,conference-call,100,50,2/12/2020
4B5054,dividend,100,50,2/12/2020
4F9926,product-release,100,64,2/12/2020
504FE2,partnership,100,61,2/12/2020
51888A,earnings-per-share-positive,100,69,2/12/2020
51888A,earnings,100,50,2/12/2020
51888A,earnings,100,50,2/12/2020
51888A,dividend,100,50,2/12/2020
532D47,earnings,100,50,2/12/2020
53EF9E,conference-call,100,50,2/12/2020
58CA9A,conference-organizer,100,57,2/12/2020
59872F,product-release,100,64,2/12/2020
5A9F54,revenue-up,100,69,2/12/2020
5A9F54,revenue-up,100,69,2/12/2020
5A9F54,revenue-up,100,69,2/12/2020
5A9F54,revenue-up,100,69,2/12/2020
5A9F54,revenue-up,100,69,2/12/2020
5BC2F4,dividend,100,50,2/12/2020
5DD486,earnings,100,50,2/12/2020
5E6959,conference-participant,100,50,2/12/2020
5EAA43,dividend,100,50,2/12/2020
5F3D91,clinical-trials,100,56,2/12/2020
60EA12,dividend-up,100,81,2/12/2020
60EA12,earnings,100,50,2/12/2020
619882,investment-investor,100,55,2/12/2020
619882,investment-investor,100,55,2/12/2020
619882,investment-investor,100,55,2/12/2020
619882,investment-investor,100,55,2/12/2020
61E975,earnings-positive,100,69,2/12/2020
61E975,earnings,100,50,2/12/2020
61E975,earnings,100,50,2/12/2020
61E975,earnings,100,50,2/12/2020
61E975,earnings,100,50,2/12/2020
61E975,earnings,100,50,2/12/2020
61E975,earnings,100,50,2/12/2020
62F41C,legal-issues-defendant,100,22,2/12/2020
62F41C,legal-issues-defendant,100,22,2/12/2020
66E3C0,business-contract,100,69,2/12/2020
68E6E9,dividend,100,50,2/12/2020
698FF9,earnings,100,50,2/12/2020
69CE71,earnings,100,50,2/12/2020
6B494E,earnings,100,50,2/12/2020
6CB7F9,earnings,100,50,2/12/2020
6E7060,conference-call,100,50,2/12/2020
6ED519,conference-call,100,50,2/12/2020
6F22E7,conference-call,100,50,2/12/2020
6F39FC,earnings,100,50,2/12/2020
704B78,earnings,100,50,2/12/2020
719477,dividend,100,50,2/12/2020
73A71F,dividend,100,50,2/12/2020
7410C3,earnings,100,50,2/12/2020
748EB6,conference-participant,100,50,2/12/2020
762A3E,earnings,100,50,2/12/2020
762A3E,partnership,100,61,2/12/2020
76F067,regulatory-product-approval-granted,100,81,2/12/2020
78F9ED,earnings,100,50,2/12/2020
790D0D,earnings,100,50,2/12/2020
7A0EC4,conference-participant,100,50,2/12/2020
7B0BA6,partnership,100,61,2/12/2020
7E3F8F,earnings,100,50,2/12/2020
7F3A5F,acquisition-acquiree,100,76,2/12/2020
7F9BE2,earnings,100,50,2/12/2020
7FDE1C,conference-call,100,50,2/12/2020
824CCA,buybacks,100,74,2/12/2020
824CCA,earnings,100,50,2/12/2020
824CCA,earnings,100,50,2/12/2020
824CCA,earnings,100,50,2/12/2020
83A065,conference-call,100,50,2/12/2020
84920B,earnings-positive,100,69,2/12/2020
85CDC9,earnings,100,50,2/12/2020
8665BA,partnership,100,61,2/12/2020
8665BA,partnership,100,61,2/12/2020
8665BA,partnership,100,61,2/12/2020
873DB9,partnership,100,61,2/12/2020
881190,dividend,100,50,2/12/2020
881190,executive-appointment,100,54,2/12/2020
893904,earnings,100,50,2/12/2020
8A8E41,board-meeting,100,51,2/12/2020
8C6C1B,facility-open,100,65,2/12/2020
8CF6DD,executive-appointment,100,54,2/12/2020
8E8E6E,earnings,100,50,2/12/2020
901327,dividend,100,50,2/12/2020
905356,index-listing,100,76,2/12/2020
934CC3,earnings,100,50,2/12/2020
9.39E+69,public-offering,100,43,2/12/2020
93D207,partnership,100,61,2/12/2020
94983E,earnings-delayed,100,26,2/12/2020
958938,executive-appointment,100,54,2/12/2020
9B71A7,legal-issues-defendant,100,22,2/12/2020
9B71A7,legal-issues-defendant,100,22,2/12/2020
9E4A5F,executive-appointment,100,54,2/12/2020
9E575E,note-sale,100,52,2/12/2020
9FF5F1,earnings,100,50,2/12/2020
A1E3B3,business-contract,100,69,2/12/2020
A1EAC8,partnership,100,61,2/12/2020
A29DBD,product-recall,100,29,2/12/2020
A398F8,earnings,100,50,2/12/2020
A4BCDE,earnings,100,50,2/12/2020
A4D173,dividend,100,50,2/12/2020
A4D173,dividend,100,50,2/12/2020
A6828A,conference-participant,100,50,2/12/2020
A8CBDA,conference-participant,100,50,2/12/2020
AA1EAA,earnings,100,50,2/12/2020
AADE0B,acquisition-acquirer,100,49,2/12/2020
AD1ACF,executive-appointment,100,54,2/12/2020
AD23DE,earnings,100,50,2/12/2020
AD23DE,earnings,100,50,2/12/2020
AD23DE,earnings,100,50,2/12/2020
AD23DE,earnings,100,50,2/12/2020
AD23DE,earnings,100,50,2/12/2020
AD23DE,earnings,100,50,2/12/2020
AD23DE,earnings,100,50,2/12/2020
AD23DE,earnings,100,50,2/12/2020
AD23DE,earnings,100,50,2/12/2020
AD3008,earnings,100,50,2/12/2020
ADF1B0,conference-call,100,50,2/12/2020
AE7D16,earnings,100,50,2/12/2020
B076A1,earnings,100,50,2/12/2020
B5766D,executive-appointment,100,54,2/12/2020
B5DE80,earnings,100,50,2/12/2020
B642E8,earnings,100,50,2/12/2020
B66928,earnings,100,50,2/12/2020
B7EB38,buybacks,100,74,2/12/2020
B80AD1,earnings,100,50,2/12/2020
BCE9DA,earnings,100,50,2/12/2020
BCE9DA,earnings,100,50,2/12/2020
BD682F,dividend,100,50,2/12/2020
BDCC11,earnings,100,50,2/12/2020
BF5959,patent-awarded,100,72,2/12/2020
C06EB6,revenue-up,100,84,2/12/2020
C07E05,earnings,100,50,2/12/2020
C15F8F,conference-participant,100,50,2/12/2020
C27E19,earnings,100,50,2/12/2020
C29715,buybacks,100,74,2/12/2020
C2E39B,conference-participant,100,50,2/12/2020
C36189,rights-issue,100,43,2/12/2020
C38440,executive-appointment,100,54,2/12/2020
C3EE99,conference-call,100,50,2/12/2020
C4FBDC,conference-call,100,50,2/12/2020
C62AA4,earnings,100,50,2/12/2020
C659EB,executive-resignation,100,44,2/12/2020
C8923A,earnings,100,50,2/12/2020
C9739A,orphan-drug-designation,100,76,2/12/2020
CBBFBF,legal-issues-defendant,100,22,2/12/2020
CBBFBF,legal-issues-defendant,100,22,2/12/2020
CBBFBF,legal-issues-defendant,100,22,2/12/2020
CBBFBF,legal-issues-defendant,100,22,2/12/2020
CBBFBF,legal-issues-defendant,100,22,2/12/2020
CBBFBF,legal-issues-defendant,100,22,2/12/2020
CC35BE,earnings,100,50,2/12/2020
CC6FF5,earnings,100,50,2/12/2020
CC8F6E,conference-participant,100,50,2/12/2020
CCB623,government-contract,100,69,2/12/2020
CD2A4D,earnings,100,50,2/12/2020
CDAF5B,dividend,100,50,2/12/2020
CDE51C,earnings,100,50,2/12/2020
CE4FD9,earnings,100,50,2/12/2020
CE4FD9,earnings,100,50,2/12/2020
CE4FD9,earnings,100,50,2/12/2020
CE4FD9,earnings,100,50,2/12/2020
CE4FD9,earnings,100,50,2/12/2020
CF9054,executive-appointment,100,54,2/12/2020
D04D9F,buybacks,100,74,2/12/2020
D2B9E5,facility-open,100,65,2/12/2020
D2B9E5,facility-open,100,65,2/12/2020
D2C0B6,earnings,100,50,2/12/2020
D4070C,dividend,100,50,2/12/2020
D4070C,dividend,100,50,2/12/2020
D45285,conference-call,100,50,2/12/2020
D4AC65,earnings-up,100,68,2/12/2020
D4AC65,earnings-up,100,68,2/12/2020
D4AC65,earnings-up,100,68,2/12/2020
D4AC65,earnings-up,100,68,2/12/2020
D4AC65,earnings-up,100,68,2/12/2020
D4AC65,earnings-up,100,68,2/12/2020
D650A7,credit-extension-recipient,100,69,2/12/2020
D9B1C9,conference-call,100,50,2/12/2020
DA48E4,executive-appointment,100,54,2/12/2020
DA48E4,conference-participant,100,50,2/12/2020
DA9443,public-offering,100,43,2/12/2020
DC1405,conference-participant,100,50,2/12/2020
DCD97F,conference-participant,100,50,2/12/2020
DD0F15,legal-issues-defendant,100,22,2/12/2020
DF18E6,public-offering,100,43,2/12/2020
DF532D,product-release,100,64,2/12/2020
DF6FDD,business-contract,100,69,2/12/2020
E0207A,earnings,100,50,2/12/2020
E06265,dividend,100,50,2/12/2020
E12A6E,earnings,100,50,2/12/2020
E26FC3,dividend-up,100,81,2/12/2020
E30B34,earnings,100,50,2/12/2020
E30B34,earnings,100,50,2/12/2020
E49AA3,product-release,100,64,2/12/2020
E9C7C0,executive-appointment,100,54,2/12/2020
ECF709,earnings,100,50,2/12/2020
ED0402,acquisition-acquirer,100,49,2/12/2020
ED0402,acquisition-acquirer,100,49,2/12/2020
EE6F1C,business-contract,100,69,2/12/2020
F1CD47,conference-participant,100,50,2/12/2020
F3EDB4,government-contract,100,69,2/12/2020
F4E882,legal-issues-defendant,100,22,2/12/2020
F4E882,legal-issues-defendant,100,22,2/12/2020
F5D499,earnings,100,50,2/12/2020
F702CA,dividend,100,50,2/12/2020
FA044A,earnings,100,50,2/12/2020
FA044A,earnings,100,50,2/12/2020
FA044A,earnings,100,50,2/12/2020
FA044A,earnings,100,50,2/12/2020
FAB97A,conference-participant,100,50,2/12/2020
FDD3FC,regulatory-product-approval-granted,100,81,2/12/2020
FDD3FC,public-offering,100,43,2/12/2020
FF9FF6,acquisition-acquirer,100,49,2/12/2020
FF9FF6,acquisition-acquirer,100,49,2/12/2020
9397,conference-participant,100,50,2/13/2020
00E601,dividend,100,50,2/13/2020
01D03F,partnership,100,61,2/13/2020
01D03F,acquisition-completed-acquirer,100,49,2/13/2020
02870F,legal-issues-defendant,100,22,2/13/2020
034B61,partnership,100,61,2/13/2020
03FB17,partnership,100,61,2/13/2020
04996E,earnings,100,50,2/13/2020
51332,credit-rating-affirmation,100,51,2/13/2020
053EFF,dividend,100,50,2/13/2020
070B45,earnings,100,50,2/13/2020
07CA6A,dividend,100,50,2/13/2020
07CA6A,dividend,100,50,2/13/2020
0A0D9E,earnings,100,50,2/13/2020
0A9D0A,earnings,100,50,2/13/2020
0AAD90,executive-appointment,100,54,2/13/2020
0BC29E,earnings,100,50,2/13/2020
0C2A0D,earnings,100,50,2/13/2020
0C2A0D,earnings,100,50,2/13/2020
0C2A0D,earnings,100,50,2/13/2020
0C2A0D,earnings,100,50,2/13/2020
0C2A0D,earnings,100,50,2/13/2020
0C355F,conference-call,100,50,2/13/2020
0C8D82,earnings,100,50,2/13/2020
0E3436,partnership,100,61,2/13/2020
0E499E,earnings,100,50,2/13/2020
0F91FC,earnings,100,50,2/13/2020
1096C6,earnings,100,50,2/13/2020
1096C6,earnings,100,50,2/13/2020
1201B5,revenue-up,100,86,2/13/2020
1201B5,revenue-up,100,86,2/13/2020
1201B5,revenue-up,100,86,2/13/2020
12A3A3,conference-participant,100,50,2/13/2020
135B09,dividend,100,50,2/13/2020
1490F3,earnings,100,50,2/13/2020
1490F3,earnings,100,50,2/13/2020
157CC1,conference-participant,100,50,2/13/2020
1.79E+10,dividend,100,50,2/13/2020
1.79E+10,earnings,100,50,2/13/2020
180DA0,conference-call,100,50,2/13/2020
1B4F31,earnings,100,50,2/13/2020
1BC12C,reorganization-considered,100,56,2/13/2020
1CF3A8,note-sale,100,52,2/13/2020
1DEBBE,earnings,100,50,2/13/2020
1E1125,earnings,100,50,2/13/2020
1E1125,conference-organizer,100,57,2/13/2020
1E1125,conference-organizer,100,57,2/13/2020
1E1125,conference-organizer,100,57,2/13/2020
1FA886,earnings,100,50,2/13/2020
1FA886,earnings,100,50,2/13/2020
1FA886,earnings,100,50,2/13/2020
202E5A,conference-call,100,50,2/13/2020
2082EA,earnings,100,50,2/13/2020
2096DE,earnings,100,50,2/13/2020
21153F,earnings,100,50,2/13/2020
21153F,earnings,100,50,2/13/2020
21153F,earnings,100,50,2/13/2020
21153F,earnings,100,50,2/13/2020
21153F,earnings,100,50,2/13/2020
21153F,earnings,100,50,2/13/2020
21153F,earnings,100,50,2/13/2020
21153F,earnings,100,50,2/13/2020
21153F,earnings,100,50,2/13/2020
21153F,earnings,100,50,2/13/2020
21153F,earnings,100,50,2/13/2020
21153F,earnings,100,50,2/13/2020
21153F,earnings,100,50,2/13/2020
21153F,earnings,100,50,2/13/2020
21153F,earnings,100,50,2/13/2020
21153F,earnings,100,50,2/13/2020
21153F,earnings,100,50,2/13/2020
21153F,earnings,100,50,2/13/2020
21153F,unit-acquisition-acquirer,100,49,2/13/2020
21268E,conference-call,100,50,2/13/2020
221445,conference-call,100,50,2/13/2020
227F04,conference-participant,100,50,2/13/2020
228D42,partnership,100,61,2/13/2020
228D42,partnership,100,61,2/13/2020
25A6CC,earnings,100,50,2/13/2020
25DD05,board-meeting,100,51,2/13/2020
25DD05,earnings,100,50,2/13/2020
26F99F,executive-appointment,100,54,2/13/2020
275300,executive-appointment,100,54,2/13/2020
27C10F,legal-issues-defendant,100,22,2/13/2020
27C10F,legal-issues-defendant,100,22,2/13/2020
28F905,conference-call,100,50,2/13/2020
297DA8,conference-call,100,50,2/13/2020
29CEBF,conference-call,100,50,2/13/2020
2BC05E,legal-issues-defendant,100,22,2/13/2020
2BC05E,legal-issues-defendant,100,22,2/13/2020
2CB4C9,executive-appointment,100,54,2/13/2020
2E1322,earnings,100,50,2/13/2020
2EBA55,earnings,100,50,2/13/2020
2F960F,earnings,100,50,2/13/2020
33AD83,conference-call,100,50,2/13/2020
3461CF,acquisition-completed-acquirer,100,49,2/13/2020
349DA4,earnings,100,50,2/13/2020
383ADA,dividend-up,100,81,2/13/2020
387375,public-offering,100,43,2/13/2020
39692D,earnings,100,50,2/13/2020
3D6933,note-sale,100,52,2/13/2020
3D6933,note-sale,100,52,2/13/2020
3DC887,earnings,100,50,2/13/2020
3DDE54,earnings,100,50,2/13/2020
3DDE54,earnings,100,50,2/13/2020
3DDE54,earnings,100,50,2/13/2020
3DDE54,earnings,100,50,2/13/2020
3DDE54,earnings,100,50,2/13/2020
3DDE54,earnings,100,50,2/13/2020
3FACA7,earnings,100,50,2/13/2020
401072,earnings,100,50,2/13/2020
42AABD,buybacks,100,74,2/13/2020
42AABD,earnings,100,50,2/13/2020
4455C4,conference-call,100,50,2/13/2020
451D61,earnings,100,50,2/13/2020
479930,earnings,100,50,2/13/2020
48F795,earnings,100,50,2/13/2020
4A3438,conference-call,100,50,2/13/2020
4A6F00,business-contract,100,69,2/13/2020
4BAF2E,ipo-pricing,100,50,2/13/2020
4C5CC9,conference-call,100,50,2/13/2020
4E4E75,conference-call,100,50,2/13/2020
4FB770,dividend,100,50,2/13/2020
507AE7,executive-appointment,100,54,2/13/2020
52BF94,earnings,100,50,2/13/2020
53F491,conference-participant,100,50,2/13/2020
5.43E+08,conference-call,100,50,2/13/2020
564F3E,earnings,100,50,2/13/2020
56632F,earnings,100,50,2/13/2020
5B3415,earnings,100,50,2/13/2020
5B3FA2,earnings,100,50,2/13/2020
5B3FA2,conference-call,100,50,2/13/2020
5D16CF,earnings,100,50,2/13/2020
5DD48B,facility-open,100,65,2/13/2020
5DE5A5,earnings-up,100,68,2/13/2020
5DE5A5,earnings-up,100,68,2/13/2020
5DE5A5,earnings-up,100,68,2/13/2020
616E3B,earnings,100,50,2/13/2020
619882,conference-organizer,100,57,2/13/2020
6284B5,earnings,100,50,2/13/2020
6284B5,earnings,100,50,2/13/2020
62F41C,legal-issues-defendant,100,22,2/13/2020
633054,business-contract,100,69,2/13/2020
665618,dividend-up,100,61,2/13/2020
665618,earnings-up,100,68,2/13/2020
665618,earnings-up,100,68,2/13/2020
665618,earnings-up,100,68,2/13/2020
67B052,earnings,100,50,2/13/2020
694749,earnings,100,50,2/13/2020
69E8E1,earnings,100,50,2/13/2020
69E8E1,earnings,100,50,2/13/2020
69E8E1,earnings,100,50,2/13/2020
69E8E1,earnings,100,50,2/13/2020
69E8E1,earnings,100,50,2/13/2020
6A3C35,earnings,100,50,2/13/2020
6CC55E,earnings,100,50,2/13/2020
6.00E+19,earnings,100,50,2/13/2020
6E8864,earnings,100,50,2/13/2020
709AED,earnings,100,50,2/13/2020
709AED,dividend,100,50,2/13/2020
709AED,executive-appointment,100,54,2/13/2020
717DB4,earnings,100,50,2/13/2020
72609A,conference-call,100,50,2/13/2020
728737,dividend,100,50,2/13/2020
72C2CE,earnings,100,50,2/13/2020
73A71F,earnings,100,50,2/13/2020
73F70F,dividend,100,50,2/13/2020
74404C,conference-call,100,50,2/13/2020
7.49E+07,product-release,100,64,2/13/2020
7710F3,conference-call,100,50,2/13/2020
7734AC,dividend,100,50,2/13/2020
7ADE57,expenses-down,100,61,2/13/2020
7B0BA6,earnings,100,50,2/13/2020
7B8CB5,executive-appointment,100,54,2/13/2020
7C4F43,loan-recipient,100,59,2/13/2020
7CBC40,earnings,100,50,2/13/2020
7E1D5D,product-release,100,64,2/13/2020
7E1D5D,unit-acquisition-completed-acquirer,100,49,2/13/2020
7E3F8F,buybacks,100,74,2/13/2020
803FED,dividend,100,50,2/13/2020
80D744,earnings,100,50,2/13/2020
81222C,earnings,100,50,2/13/2020
845533,earnings,100,50,2/13/2020
859D62,earnings,100,50,2/13/2020
862941,conference-participant,100,50,2/13/2020
862941,earnings,100,50,2/13/2020
8665BA,partnership,100,61,2/13/2020
86AA9C,note-sale,100,52,2/13/2020
893904,conference-participant,100,50,2/13/2020
89B2E7,earnings,100,50,2/13/2020
8BE916,dividend,100,50,2/13/2020
8C6C1B,facility-open,100,65,2/13/2020
8DBBE6,earnings,100,50,2/13/2020
8DE74B,earnings,100,50,2/13/2020
8DE74B,earnings,100,50,2/13/2020
8DE74B,earnings,100,50,2/13/2020
8DE74B,earnings,100,50,2/13/2020
8E4250,earnings,100,50,2/13/2020
8EEA28,dividend,100,50,2/13/2020
8F8F2F,conference-call,100,50,2/13/2020
8FCA78,earnings,100,50,2/13/2020
8FCA78,earnings,100,50,2/13/2020
8FCA78,earnings,100,50,2/13/2020
8FCA78,earnings,100,50,2/13/2020
9196A2,conference-organizer,100,57,2/13/2020
92D757,conference-participant,100,50,2/13/2020
9.39E+69,public-offering,100,43,2/13/2020
93AD2E,earnings,100,50,2/13/2020
93AD2E,executive-appointment,100,54,2/13/2020
943239,earnings,100,50,2/13/2020
943239,executive-appointment,100,54,2/13/2020
945DE6,executive-resignation,100,44,2/13/2020
9507FF,earnings,100,50,2/13/2020
9548BB,note-sale,100,52,2/13/2020
95C392,earnings,100,50,2/13/2020
9.62E+76,dividend,100,50,2/13/2020
96B4FF,earnings,100,50,2/13/2020
971F7B,earnings,100,50,2/13/2020
972356,sanctions-target,100,19,2/13/2020
972356,acquisition-completed-acquiree,100,76,2/13/2020
972356,unit-acquisition-completed-acquiree,100,67,2/13/2020
972356,unit-acquisition-completed-acquiree,100,67,2/13/2020
9.86E+03,earnings,100,50,2/13/2020
990AD0,conference-organizer,100,57,2/13/2020
99B61C,patient-enrollment-start,100,58,2/13/2020
9BB35A,earnings-per-share-positive,100,69,2/13/2020
9BB35A,earnings-per-share,100,50,2/13/2020
9BB35A,earnings-per-share,100,50,2/13/2020
9BB35A,earnings-per-share,100,50,2/13/2020
9BB35A,dividend,100,50,2/13/2020
9C25FF,earnings,100,50,2/13/2020
9D5FA4,earnings,100,50,2/13/2020
9D5FA4,earnings,100,50,2/13/2020
9F5CBB,conference-call,100,50,2/13/2020
9F6B1A,earnings,100,50,2/13/2020
A1EAC8,earnings,100,50,2/13/2020
A23747,earnings,100,50,2/13/2020
A3AAA5,public-offering,100,43,2/13/2020
A3AAA5,public-offering,100,43,2/13/2020
A433A5,unit-acquisition-acquirer,100,49,2/13/2020
A52533,earnings,100,50,2/13/2020
A631A3,earnings,100,50,2/13/2020
A6FE1C,unit-acquisition-acquirer,100,49,2/13/2020
AD375D,earnings,100,50,2/13/2020
AD9F1D,revenue-up,100,69,2/13/2020
AD9F1D,revenue-up,100,69,2/13/2020
AD9F1D,revenue-up,100,69,2/13/2020
AD9F1D,revenue-up,100,69,2/13/2020
AD9F1D,revenue-up,100,69,2/13/2020
AD9F1D,revenue-up,100,69,2/13/2020
AD9F1D,revenue-up,100,69,2/13/2020
AD9F1D,revenue-up,100,69,2/13/2020
AD9F1D,revenue-up,100,69,2/13/2020
AD9F1D,revenue-up,100,69,2/13/2020
AD9F1D,revenue-up,100,69,2/13/2020
AEBB80,earnings,100,50,2/13/2020
B05118,conference-participant,100,50,2/13/2020
B09B1F,conference-call,100,50,2/13/2020
B1FC3B,business-contract,100,69,2/13/2020
B2206F,partnership,100,61,2/13/2020
B303A6,legal-issues-defendant,100,22,2/13/2020
B381D8,earnings,100,50,2/13/2020
B54A74,conference-participant,100,50,2/13/2020
B5734D,fundraising,100,64,2/13/2020
B614F8,public-offering,100,43,2/13/2020
B7202A,acquisition-completed-acquirer,100,49,2/13/2020
B72BE9,dividend,100,50,2/13/2020
B83D67,earnings,100,50,2/13/2020
B840EF,earnings,100,50,2/13/2020
B8F71F,conference-participant,100,50,2/13/2020
BB07E4,note-sale,100,52,2/13/2020
BB58FF,conference-participant,100,50,2/13/2020
BF79F5,earnings,100,50,2/13/2020
BFE02C,conference-participant,100,50,2/13/2020
C0030A,earnings-up,100,68,2/13/2020
C0030A,earnings,100,50,2/13/2020
C0030A,earnings,100,50,2/13/2020
C0030A,earnings,100,50,2/13/2020
C0030A,earnings,100,50,2/13/2020
C0030A,earnings,100,50,2/13/2020
C03C8B,earnings,100,50,2/13/2020
C1114B,earnings,100,50,2/13/2020
C11C46,conference-participant,100,50,2/13/2020
C2609A,business-contract,100,69,2/13/2020
C2E39B,earnings,100,50,2/13/2020
C2E39B,earnings,100,50,2/13/2020
C356AC,earnings,100,50,2/13/2020
C356AC,dividend,100,50,2/13/2020
C3BAE7,conference-participant,100,50,2/13/2020
C4A912,earnings,100,50,2/13/2020
C564E4,earnings,100,50,2/13/2020
C66A8C,earnings,100,50,2/13/2020
C8A059,earnings,100,50,2/13/2020
C8A248,dividend,100,50,2/13/2020
C941DC,conference-participant,100,50,2/13/2020
C9A96E,award,100,58,2/13/2020
CA212F,dividend,100,50,2/13/2020
CBBFBF,legal-issues-defendant,100,22,2/13/2020
CC0C78,earnings,100,50,2/13/2020
CC176E,executive-appointment,100,54,2/13/2020
CC176E,earnings,100,50,2/13/2020
CDAA0E,earnings,100,50,2/13/2020
CDAF5B,earnings,100,50,2/13/2020
CE5664,dividend,100,50,2/13/2020
CE96E7,dividend,100,50,2/13/2020
CFB6CA,executive-appointment,100,54,2/13/2020
D03C7A,dividend,100,50,2/13/2020
D296C6,dividend,100,50,2/13/2020
D296C6,earnings,100,50,2/13/2020
D437C3,executive-appointment,100,54,2/13/2020
D45285,executive-resignation,100,44,2/13/2020
D6489C,product-release,100,64,2/13/2020
D64C6D,dividend,100,50,2/13/2020
D75910,acquisition-acquirer,100,49,2/13/2020
D854DD,dividend,100,50,2/13/2020
D8DA3D,dividend,100,50,2/13/2020
D9164D,dividend,100,50,2/13/2020
D9164D,earnings,100,50,2/13/2020
D96202,earnings,100,50,2/13/2020
DA9443,public-offering,100,43,2/13/2020
DB5CA5,earnings,100,50,2/13/2020
DB9829,earnings,100,50,2/13/2020
DC0D18,earnings,100,50,2/13/2020
DD3BB1,public-offering,100,43,2/13/2020
E09E2B,earnings,100,50,2/13/2020
E09E2B,earnings,100,50,2/13/2020
E09E2B,earnings,100,50,2/13/2020
E22FDE,executive-appointment,100,54,2/13/2020
E49AA3,dividend,100,50,2/13/2020
E4CE73,partnership,100,61,2/13/2020
E5C910,clinical-trials-start,100,64,2/13/2020
E802CE,executive-appointment,100,54,2/13/2020
E8846E,conference-participant,100,50,2/13/2020
E94704,dividend,100,50,2/13/2020
EA62FC,conference-participant,100,50,2/13/2020
EAA0A7,earnings,100,50,2/13/2020
EB61C4,earnings,100,50,2/13/2020
ED0D7C,earnings,100,50,2/13/2020
ED0D7C,earnings,100,50,2/13/2020
ED0D7C,earnings,100,50,2/13/2020
ED0D7C,earnings,100,50,2/13/2020
ED0D7C,earnings,100,50,2/13/2020
ED9C04,award,100,58,2/13/2020
EF25A5,earnings,100,50,2/13/2020
F02D0A,earnings-per-share-positive,100,69,2/13/2020
F02D0A,earnings-positive,100,69,2/13/2020
F1C04C,conference-call,100,50,2/13/2020
F2BC3D,executive-appointment,100,54,2/13/2020
F47871,earnings,100,50,2/13/2020
F4E882,earnings,100,50,2/13/2020
F4E882,earnings,100,50,2/13/2020
F4E882,earnings,100,50,2/13/2020
F4E882,earnings,100,50,2/13/2020
F4E882,earnings,100,50,2/13/2020
F4E882,earnings,100,50,2/13/2020
F4E882,earnings,100,50,2/13/2020
F5D410,conference-call,100,50,2/13/2020
F702CA,earnings,100,50,2/13/2020
F721A7,earnings,100,50,2/13/2020
F721A7,earnings,100,50,2/13/2020
F7D8AE,ipo-completed,100,76,2/13/2020
F82D37,executive-appointment,100,54,2/13/2020
F93C8A,dividend,100,50,2/13/2020
FA840E,earnings,100,50,2/13/2020
FAE021,dividend-up,100,81,2/13/2020
FAE021,dividend-up,100,81,2/13/2020
FC1B7B,conference-participant,100,50,2/13/2020
FD6926,conference-participant,100,50,2/13/2020
FD9526,earnings,100,50,2/13/2020
FDF799,earnings,100,50,2/13/2020
FF4343,dividend,100,50,2/13/2020
FF6644,dividend,100,50,2/13/2020
03FAA6,earnings,100,50,2/14/2020
43862,earnings,100,50,2/14/2020
054B55,acquisition-completed-acquirer,100,49,2/14/2020
07CA6A,award,100,58,2/14/2020
07CA6A,award,100,58,2/14/2020
84625,dividend,100,50,2/14/2020
0B4D10,dividend,100,50,2/14/2020
0E64D4,earnings,100,50,2/14/2020
0E64D4,earnings,100,50,2/14/2020
0E64D4,earnings,100,50,2/14/2020
0E64D4,earnings,100,50,2/14/2020
0E64D4,earnings,100,50,2/14/2020
0E64D4,earnings,100,50,2/14/2020
1065BC,executive-resignation,100,44,2/14/2020
12DE76,partnership,100,61,2/14/2020
14391F,earnings,100,50,2/14/2020
152E1D,conference-call,100,50,2/14/2020
1921DD,dividend,100,50,2/14/2020
1921DD,dividend,100,50,2/14/2020
19CAC7,dividend,100,50,2/14/2020
1BC12C,acquisition-acquirer,100,49,2/14/2020
1FA886,legal-issues-defendant,100,22,2/14/2020
223216,ebitda-up,100,68,2/14/2020
225CA2,executive-appointment,100,54,2/14/2020
228D42,partnership,100,61,2/14/2020
253B2F,conference-call,100,50,2/14/2020
27A791,conference-call,100,50,2/14/2020
2.89E+11,dividend,100,50,2/14/2020
2B5483,legal-issues-defendant,100,22,2/14/2020
2BC05E,legal-issues-defendant,100,22,2/14/2020
2BC05E,legal-issues-defendant,100,22,2/14/2020
2BC05E,legal-issues-defendant,100,22,2/14/2020
2BC05E,legal-issues-defendant,100,22,2/14/2020
2BC05E,legal-issues-defendant,100,22,2/14/2020
2BC05E,legal-issues-defendant,100,22,2/14/2020
2CB4C9,dividend,100,50,2/14/2020
2CB4C9,dividend,100,50,2/14/2020
2F1299,executive-appointment,100,54,2/14/2020
301493,stake-acquiree,100,62,2/14/2020
31666F,executive-appointment,100,54,2/14/2020
3224CC,executive-appointment,100,54,2/14/2020
3461CF,credit-rating-confirmation-rater,20,50,2/14/2020
353DBB,dividend,100,50,2/14/2020
385DD4,dividend,100,50,2/14/2020
387375,conference-call,100,50,2/14/2020
3AF7FD,conference-participant,100,50,2/14/2020
416291,dividend,100,50,2/14/2020
453282,acquisition-completed-acquirer,100,49,2/14/2020
49F4D0,dividend,100,50,2/14/2020
4B5054,earnings,100,50,2/14/2020
4D8313,dividend,100,50,2/14/2020
504FE2,conference-participant,100,50,2/14/2020
504FE2,dividend,100,50,2/14/2020
5065B1,earnings,100,50,2/14/2020
53A226,dividend,100,50,2/14/2020
57B174,dividend-up,100,81,2/14/2020
5A53BF,regulatory-product-approval-granted,100,81,2/14/2020
5A9A82,earnings,100,50,2/14/2020
5A9A82,earnings,100,50,2/14/2020
5A9A82,earnings,100,50,2/14/2020
5A9A82,earnings,100,50,2/14/2020
5BFE94,earnings,100,50,2/14/2020
5C2A47,conference-call,100,50,2/14/2020
615B6D,earnings,100,50,2/14/2020
619882,dividend,100,50,2/14/2020
61E975,conference-participant,100,50,2/14/2020
636639,dividend,100,50,2/14/2020
651C85,regulatory-product-approval-granted,100,81,2/14/2020
651C85,regulatory-product-approval-granted,100,81,2/14/2020
6844D2,dividend,100,50,2/14/2020
6B0E45,dividend,100,50,2/14/2020
6DDA15,legal-issues-defendant,100,22,2/14/2020
6E8349,earnings,100,50,2/14/2020
713810,price-target-upgrade,100,74,2/14/2020
72CB93,conference-participant,100,50,2/14/2020
72CB93,award,100,58,2/14/2020
76BD96,earnings,100,50,2/14/2020
789A7D,dividend,100,50,2/14/2020
7A51FE,dividend,100,50,2/14/2020
7D5384,executive-appointment,100,54,2/14/2020
7F3665,executive-appointment,100,54,2/14/2020
80C400,conference-call,100,50,2/14/2020
81EAD4,conference-call,100,50,2/14/2020
885758,legal-issues-defendant,100,22,2/14/2020
8C6C1B,facility-open,100,65,2/14/2020
9.97E+09,dividend-up,100,54,2/14/2020
9E575E,earnings,100,50,2/14/2020
9E5C2C,earnings,100,50,2/14/2020
9EF4CF,legal-issues-defendant,100,22,2/14/2020
A1EAC8,executive-appointment,100,54,2/14/2020
A21649,dividend,100,50,2/14/2020
A3AAA5,dividend,100,50,2/14/2020
A4B899,dividend,100,50,2/14/2020
A666C8,campaign-ad-release,100,59,2/14/2020
A9ED24,dividend,100,50,2/14/2020
AAC8B6,executive-appointment,100,54,2/14/2020
AAC8B6,executive-appointment,100,54,2/14/2020
AD22F2,revenues,100,50,2/14/2020
AD23DE,partnership,100,61,2/14/2020
AD23DE,partnership,100,61,2/14/2020
B1A85D,partnership,100,61,2/14/2020
B303A6,legal-issues-defendant,100,22,2/14/2020
B508E5,earnings,100,50,2/14/2020
B7EB38,conference-participant,100,50,2/14/2020
BDE867,operating-earnings,100,50,2/14/2020
C3BCD5,earnings,100,50,2/14/2020
C3BCD5,conference-participant,100,50,2/14/2020
C8257F,business-contract,100,69,2/14/2020
CA14CC,dividend,100,50,2/14/2020
CA99D7,dividend,100,50,2/14/2020
CD2A4D,conference-participant,100,50,2/14/2020
CDE118,unit-acquisition-acquirer,100,49,2/14/2020
D25249,dividend,100,50,2/14/2020
D2B9E5,dividend-up,100,81,2/14/2020
D95385,clinical-trials,100,56,2/14/2020
DA0A9E,dividend,100,50,2/14/2020
DB23C8,earnings,100,50,2/14/2020
DD0F15,legal-issues-defendant,100,22,2/14/2020
DD0F15,legal-issues-defendant,100,22,2/14/2020
DD0F15,legal-issues-defendant,100,22,2/14/2020
DF18E6,public-offering,100,43,2/14/2020
E0207A,dividend,100,50,2/14/2020
E0F4E5,business-contract,100,69,2/14/2020
E0F4E5,business-contract,100,69,2/14/2020
E0F4E5,business-contract,100,69,2/14/2020
E0F4E5,business-contract,100,69,2/14/2020
E49AA3,legal-verdict-favored,100,78,2/14/2020
E70531,executive-appointment,100,54,2/14/2020
E8846E,dividend,100,50,2/14/2020
EAA0A7,earnings,100,50,2/14/2020
EF5BED,earnings,100,50,2/14/2020
F2E253,conference-call,100,50,2/14/2020
F4E882,legal-issues-defendant,100,22,2/14/2020
FC80E6,dividend,100,50,2/14/2020
FDD3FC,public-offering,100,43,2/14/2020
FF4BA4,dividend,100,50,2/14/2020
2BC05E,legal-issues-defendant,100,22,2/15/2020
2BC05E,legal-issues-defendant,100,22,2/15/2020
370C50,legal-issues-defendant,100,22,2/15/2020
12731D,conference-call,100,50,2/17/2020
12731D,conference-call,100,50,2/17/2020
1E1125,conference-organizer,100,57,2/17/2020
2920D5,conference-participant,100,50,2/17/2020
2920D5,conference-participant,100,50,2/17/2020
2BC05E,legal-issues-defendant,100,22,2/17/2020
2E1322,product-release,100,64,2/17/2020
4017AD,earnings,100,50,2/17/2020
416C55,conference-participant,100,50,2/17/2020
458D2C,revenue-volume,100,50,2/17/2020
504FE2,executive-appointment,100,54,2/17/2020
51F541,earnings,100,50,2/17/2020
550D01,facility-open,100,65,2/17/2020
693ECD,conference-participant,100,50,2/17/2020
6BDA0C,executive-appointment,100,54,2/17/2020
77B8E9,patent-awarded,100,72,2/17/2020
797C20,earnings-per-share-up,100,55,2/17/2020
7B492C,executive-resignation,100,44,2/17/2020
810FAD,conference-participant,100,50,2/17/2020
85DE00,conference-participant,100,50,2/17/2020
8C6C1B,facility-open,100,65,2/17/2020
918D6D,ipo,100,71,2/17/2020
918D6D,ipo,100,71,2/17/2020
918D6D,ipo,100,71,2/17/2020
918D6D,ipo,100,71,2/17/2020
9.65E+07,conference-call,100,50,2/17/2020
9EA947,partnership,100,61,2/17/2020
A63387,dividend,100,50,2/17/2020
A79D88,unit-acquisition-acquirer,100,49,2/17/2020
A8AC4C,conference-call,100,50,2/17/2020
B3CB74,conference-organizer,100,57,2/17/2020
B3CB74,conference-organizer,100,57,2/17/2020
BF79F5,executive-appointment,100,54,2/17/2020
C3CF29,earnings,100,50,2/17/2020
C45CE7,dividend,100,50,2/17/2020
CAB222,conference-call,100,50,2/17/2020
CBBFBF,legal-issues-defendant,100,22,2/17/2020
CDAF5B,stake-acquirer,100,48,2/17/2020
CFD4B6,conference-call,100,50,2/17/2020
D33270,business-contract,100,69,2/17/2020
D6853F,business-contract,100,69,2/17/2020
D9E036,business-contract,100,69,2/17/2020
DB23C8,conference-participant,100,50,2/17/2020
DD9E41,conference-participant,100,50,2/17/2020
EEEA9F,earnings,100,50,2/17/2020
F2E253,executive-appointment,100,54,2/17/2020
F39E1E,dividend-up,100,81,2/17/2020
F4E882,legal-issues-defendant,100,22,2/17/2020
FA40E2,earnings-guidance,100,50,2/17/2020
FA40E2,earnings-guidance,100,50,2/17/2020
002A99,earnings,100,50,2/18/2020
00326E,award,100,58,2/18/2020
00E601,operating-earnings,100,50,2/18/2020
00E601,earnings,100,50,2/18/2020
00E601,earnings,100,50,2/18/2020
00E601,earnings,100,50,2/18/2020
01D03F,partnership,100,61,2/18/2020
02FC1A,conference-participant,100,50,2/18/2020
033B58,conference-participant,100,50,2/18/2020
03FAA6,partnership,100,61,2/18/2020
03FB17,dividend,100,50,2/18/2020
06EE79,earnings,100,50,2/18/2020
09062E,conference-participant,100,50,2/18/2020
091B6C,conference-participant,100,50,2/18/2020
091B6C,conference-participant,100,50,2/18/2020
099C88,award,100,58,2/18/2020
0A9D0A,dividend-up,100,57,2/18/2020
0CE204,earnings,100,50,2/18/2020
0E3436,executive-appointment,100,54,2/18/2020
0F0440,donation,100,54,2/18/2020
0F65C9,earnings,100,50,2/18/2020
0F65C9,dividend,100,50,2/18/2020
0FABBD,executive-appointment,100,54,2/18/2020
1080C0,earnings,100,50,2/18/2020
1201B5,acquisition-completed-acquirer,100,49,2/18/2020
126F95,dividend,100,50,2/18/2020
12A3A3,dividend,100,50,2/18/2020
14833D,earnings,100,50,2/18/2020
14BA06,earnings,100,50,2/18/2020
14BA06,dividend-up,100,71,2/18/2020
184866,earnings,100,50,2/18/2020
190B91,business-contract,100,69,2/18/2020
1A5D5D,earnings,100,50,2/18/2020
1A6A94,executive-appointment,100,54,2/18/2020
1CDD1C,earnings,100,50,2/18/2020
1CDD1C,earnings,100,50,2/18/2020
1CF3A8,note-sale,100,52,2/18/2020
1D943E,earnings,100,50,2/18/2020
1D943E,conference-participant,100,50,2/18/2020
1E04A5,earnings,100,50,2/18/2020
1FA886,business-contract,100,69,2/18/2020
1FAF22,acquisition-completed-acquirer,100,49,2/18/2020
1FAF22,dividend,100,50,2/18/2020
202E5A,clinical-trials,100,56,2/18/2020
2082EA,executive-appointment,100,54,2/18/2020
225CA2,executive-appointment,100,54,2/18/2020
25A6CC,conference-participant,100,50,2/18/2020
25AB8E,earnings,100,50,2/18/2020
25AB8E,executive-appointment,100,54,2/18/2020
26DC29,award,100,58,2/18/2020
284289,buybacks,100,74,2/18/2020
2.89E+11,note-sale,100,52,2/18/2020
28B730,earnings,100,50,2/18/2020
2A17B1,earnings,100,50,2/18/2020
2BC05E,partnership,100,61,2/18/2020
2BC05E,legal-issues-defendant,100,22,2/18/2020
2C7505,patient-enrollment-complete,100,64,2/18/2020
2C7505,patient-enrollment-complete,100,64,2/18/2020
2CC60C,earnings,100,50,2/18/2020
2E0496,earnings,100,50,2/18/2020
2E0496,earnings,100,50,2/18/2020
2E902B,conference-participant,100,50,2/18/2020
319BE2,conference-call,100,50,2/18/2020
31AA84,note-sale,100,52,2/18/2020
31F25C,buybacks,100,74,2/18/2020
3224CC,earnings,100,50,2/18/2020
326EDD,public-offering,100,43,2/18/2020
33AD83,business-contract,100,69,2/18/2020
35AE32,legal-issues-defendant,100,22,2/18/2020
37E18B,earnings,100,50,2/18/2020
37E18B,earnings,100,50,2/18/2020
37E18B,earnings,100,50,2/18/2020
385DD4,executive-appointment,100,54,2/18/2020
385DD4,market-entry,100,57,2/18/2020
39FB23,executive-appointment,100,54,2/18/2020
3AAEAE,conference-participant,100,50,2/18/2020
3B20AB,acquisition-acquiree,100,76,2/18/2020
3B318A,conference-call,100,50,2/18/2020
3B50FE,conference-call,100,50,2/18/2020
3D7971,dividend,100,50,2/18/2020
3DD5E2,conference-participant,100,50,2/18/2020
41785E,dividend,100,50,2/18/2020
427F32,conference-call,100,50,2/18/2020
43E8F5,conference-call,100,50,2/18/2020
43E8F5,conference-participant,100,50,2/18/2020
44A4FC,conference-participant,100,50,2/18/2020
451D61,conference-participant,100,50,2/18/2020
490D4B,executive-resignation,100,44,2/18/2020
49CC59,executive-resignation,100,44,2/18/2020
4BAF2E,ipo-completed,100,76,2/18/2020
4BDCA7,conference-call,100,50,2/18/2020
4C2F17,conference-participant,100,50,2/18/2020
4C2F17,conference-participant,100,50,2/18/2020
4C7DB5,dividend,100,50,2/18/2020
4E5784,earnings,100,50,2/18/2020
4EEB00,conference-participant,100,50,2/18/2020
4F0A80,earnings,100,50,2/18/2020
4F9926,partnership,100,61,2/18/2020
4FB770,earnings,100,50,2/18/2020
504FE2,earnings,100,50,2/18/2020
520632,product-release,100,64,2/18/2020
523039,conference-participant,100,50,2/18/2020
53EF9E,earnings,100,50,2/18/2020
53EF9E,executive-resignation,100,44,2/18/2020
556F08,conference-participant,100,50,2/18/2020
56EFC7,earnings,100,50,2/18/2020
5704AC,executive-appointment,100,54,2/18/2020
57B174,earnings,100,50,2/18/2020
583223,conference-participant,100,50,2/18/2020
58C2D4,earnings,100,50,2/18/2020
596116,earnings,100,50,2/18/2020
59DB8C,public-offering,100,43,2/18/2020
5A423F,earnings,100,50,2/18/2020
5B6C11,acquisition-acquirer,100,49,2/18/2020
5B6C11,acquisition-acquirer,100,49,2/18/2020
5B6C11,acquisition-acquirer,100,49,2/18/2020
5C2A47,earnings,100,50,2/18/2020
616E3B,dividend,100,50,2/18/2020
649CBD,earnings,100,50,2/18/2020
6.52E+64,earnings,100,50,2/18/2020
6.52E+64,earnings,100,50,2/18/2020
6.52E+64,earnings,100,50,2/18/2020
6.52E+64,earnings,100,50,2/18/2020
67303E,earnings,100,50,2/18/2020
693ECD,earnings,100,50,2/18/2020
6B236C,earnings,100,50,2/18/2020
6DBBBC,earnings-up,100,68,2/18/2020
6DBBBC,earnings-up,100,68,2/18/2020
6DBBBC,earnings-up,100,68,2/18/2020
6DBBBC,earnings-up,100,68,2/18/2020
6DBBBC,earnings-up,100,68,2/18/2020
6DDA15,legal-issues-defendant,100,22,2/18/2020
705636,trading-listing,100,61,2/18/2020
713810,same-store-sales-up,100,52,2/18/2020
713810,dividend-up,100,81,2/18/2020
722D55,conference-participant,100,50,2/18/2020
752A70,earnings,100,50,2/18/2020
762A3E,conference-organizer,100,57,2/18/2020
762A3E,conference-organizer,100,57,2/18/2020
762A3E,conference-organizer,100,57,2/18/2020
762A3E,conference-organizer,100,57,2/18/2020
762A3E,conference-organizer,100,57,2/18/2020
767F86,executive-appointment,100,54,2/18/2020
79167B,business-contract,100,69,2/18/2020
7ACD98,partnership,100,61,2/18/2020
7ACD98,partnership,100,61,2/18/2020
7B9AFA,conference-participant,100,50,2/18/2020
803FED,executive-appointment,100,54,2/18/2020
8.10E+32,dividend,100,50,2/18/2020
83B1C8,earnings,100,50,2/18/2020
845533,executive-appointment,100,54,2/18/2020
860AB6,earnings,100,50,2/18/2020
87486A,conference-participant,100,50,2/18/2020
880C0C,earnings,100,50,2/18/2020
88611B,earnings,100,50,2/18/2020
890FF4,earnings,100,50,2/18/2020
895D56,business-contract,100,69,2/18/2020
896771,investment-investor,100,55,2/18/2020
8A0368,conference-participant,100,50,2/18/2020
8BE916,buybacks,100,74,2/18/2020
8BFAA4,executive-appointment,100,54,2/18/2020
8C6C1B,facility-open,100,65,2/18/2020
8C6C1B,conference-call,100,50,2/18/2020
8DAAB9,executive-resignation,100,44,2/18/2020
8E10BF,clinical-trials-start,100,64,2/18/2020
8EEA28,earnings,100,50,2/18/2020
902255,earnings,100,50,2/18/2020
9087B9,conference-participant,100,50,2/18/2020
911AB8,dividend,100,50,2/18/2020
915E7B,executive-appointment,100,54,2/18/2020
915E7B,earnings,100,50,2/18/2020
9196A2,conference-organizer,100,57,2/18/2020
91E5EE,dividend,100,50,2/18/2020
92B625,conference-call,100,50,2/18/2020
9.39E+69,public-offering,100,43,2/18/2020
93D207,partnership,100,61,2/18/2020
93D207,partnership,100,61,2/18/2020
93D207,business-contract,100,69,2/18/2020
944B2E,executive-appointment,100,54,2/18/2020
945DE6,buybacks,100,74,2/18/2020
945DE6,earnings,100,50,2/18/2020
945DE6,earnings,100,50,2/18/2020
945DE6,earnings,100,50,2/18/2020
945DE6,earnings,100,50,2/18/2020
945DE6,earnings,100,50,2/18/2020
945DE6,earnings,100,50,2/18/2020
9470CC,earnings,100,50,2/18/2020
94C0B5,earnings,100,50,2/18/2020
9592FB,earnings,100,50,2/18/2020
95C575,executive-appointment,100,54,2/18/2020
9.65E+09,conference-call,100,50,2/18/2020
96A6CD,earnings,100,50,2/18/2020
9.74E+08,business-contract,100,69,2/18/2020
986AF6,dividend,100,50,2/18/2020
98CEBB,partnership,100,61,2/18/2020
98CEBB,conference-participant,100,50,2/18/2020
990AD0,conference-organizer,100,57,2/18/2020
990AD0,conference-organizer,100,57,2/18/2020
9934AD,earnings,100,50,2/18/2020
9A602D,earnings-per-share-positive,100,69,2/18/2020
9A602D,earnings-per-share-positive,100,69,2/18/2020
9A602D,earnings-per-share-positive,100,69,2/18/2020
9A602D,earnings-per-share-positive,100,69,2/18/2020
9A602D,earnings-per-share-positive,100,69,2/18/2020
9A602D,earnings-per-share-positive,100,69,2/18/2020
9A602D,earnings-per-share-positive,100,69,2/18/2020
9B71A7,conference-call,100,50,2/18/2020
9CA619,earnings-guidance-meet-expectations,100,59,2/18/2020
9CDA4F,earnings,100,50,2/18/2020
9F37C5,conference-call,100,50,2/18/2020
A01983,dividend,100,50,2/18/2020
A11CF4,conference-participant,100,50,2/18/2020
A1BB98,earnings,100,50,2/18/2020
A29DBD,partnership,100,61,2/18/2020
A29DBD,partnership,100,61,2/18/2020
A2CA3F,earnings,100,50,2/18/2020
A350C1,earnings,100,50,2/18/2020
A350C1,dividend,100,50,2/18/2020
A398B9,conference-participant,100,50,2/18/2020
A48593,earnings,100,50,2/18/2020
A4B899,earnings,100,50,2/18/2020
A4B899,executive-appointment,100,54,2/18/2020
A4CD53,conference-participant,100,50,2/18/2020
A5195E,regulatory-product-approval-granted,100,81,2/18/2020
A6828A,partnership,100,61,2/18/2020
A790A5,earnings,100,50,2/18/2020
A790A5,earnings,100,50,2/18/2020
A87CD6,dividend,100,50,2/18/2020
AAC8B6,dividend,100,50,2/18/2020
AAC8B6,dividend,100,50,2/18/2020
AC642C,earnings,100,50,2/18/2020
AC642C,earnings,100,50,2/18/2020
ACDF88,executive-appointment,100,54,2/18/2020
ACF0B4,conference-call,100,50,2/18/2020
ADF1B0,earnings,100,50,2/18/2020
AED61E,revenues,100,50,2/18/2020
AED61E,revenues,100,50,2/18/2020
AEEB76,conference-participant,100,50,2/18/2020
B1A85D,earnings,100,50,2/18/2020
B1FC3B,business-contract,100,69,2/18/2020
B37FB4,earnings-up,100,68,2/18/2020
B3CB74,conference-organizer,100,57,2/18/2020
B3CB74,conference-organizer,100,57,2/18/2020
B3CB74,conference-organizer,100,57,2/18/2020
B3CB74,conference-organizer,100,57,2/18/2020
B3CB74,conference-organizer,100,57,2/18/2020
B508E5,acquisition-acquirer,100,49,2/18/2020
B96637,conference-call,100,50,2/18/2020
B9BDE8,facility-open,100,65,2/18/2020
B9CD50,earnings-positive,100,69,2/18/2020
BA0442,earnings,100,50,2/18/2020
BB02FB,earnings-per-share,100,50,2/18/2020
BB02FB,earnings-per-share,100,50,2/18/2020
BB02FB,earnings-per-share,100,50,2/18/2020
BB02FB,earnings-per-share,100,50,2/18/2020
BB02FB,earnings-per-share,100,50,2/18/2020
BB02FB,earnings-per-share,100,50,2/18/2020
BC4876,earnings,100,50,2/18/2020
BCC55F,earnings,100,50,2/18/2020
BDD12C,executive-appointment,100,54,2/18/2020
BDD12C,dividend,100,50,2/18/2020
BDEC1E,conference-participant,100,50,2/18/2020
C0BA36,partnership,100,61,2/18/2020
C15DB3,executive-appointment,100,54,2/18/2020
C2609A,business-contract,100,69,2/18/2020
C356AC,partnership,100,61,2/18/2020
C36189,conference-participant,100,50,2/18/2020
C45CE7,earnings,100,50,2/18/2020
C4A432,executive-appointment,100,54,2/18/2020
C65004,conference-participant,100,50,2/18/2020
C66A8C,public-offering,100,43,2/18/2020
C7FC95,business-contract,100,69,2/18/2020
C83B88,conference-participant,100,50,2/18/2020
C98CDB,partnership,100,61,2/18/2020
CA1620,conference-participant,100,50,2/18/2020
CBA33B,acquisition-acquirer,100,49,2/18/2020
CBBFBF,legal-issues-defendant,100,22,2/18/2020
CDAA0E,fundraising,100,64,2/18/2020
CDC817,conference-call,100,50,2/18/2020
CFF15D,partnership,100,61,2/18/2020
CFF15D,executive-appointment,100,54,2/18/2020
CFF97C,credit-rating-upgrade-rater,20,50,2/18/2020
D06996,conference-call,100,50,2/18/2020
D17C1B,executive-appointment,100,54,2/18/2020
D1C0B9,acquisition-acquirer,100,49,2/18/2020
D296C6,earnings,100,50,2/18/2020
D36B23,conference-participant,100,50,2/18/2020
D3CEDF,earnings,100,50,2/18/2020
D3CEDF,acquisition-acquirer,100,49,2/18/2020
D3CEDF,acquisition-acquirer,100,49,2/18/2020
D6853F,legal-issues-defendant,100,22,2/18/2020
D6853F,legal-issues-defendant,100,22,2/18/2020
D6EAA3,executive-appointment,100,54,2/18/2020
D75910,conference-call,100,50,2/18/2020
D78CCD,note-sale,100,52,2/18/2020
DA0A9E,executive-appointment,100,54,2/18/2020
DA9443,public-offering,100,43,2/18/2020
DB396B,legal-issues-defendant,100,22,2/18/2020
DD0F15,legal-issues-defendant,100,22,2/18/2020
DDCB34,conference-call,100,50,2/18/2020
DF01B1,earnings,100,50,2/18/2020
E06265,earnings,100,50,2/18/2020
E0A84E,partnership,100,61,2/18/2020
E12A6E,executive-appointment,100,54,2/18/2020
E15736,earnings,100,50,2/18/2020
E15736,earnings,100,50,2/18/2020
E68733,earnings,100,50,2/18/2020
E68733,earnings,100,50,2/18/2020
E68733,earnings,100,50,2/18/2020
E68C3D,dividend-up,100,65,2/18/2020
E87676,revenues,100,50,2/18/2020
EB1E1A,conference-participant,100,50,2/18/2020
EB2F14,dividend,100,50,2/18/2020
EBC84C,earnings,100,50,2/18/2020
EBC84C,earnings,100,50,2/18/2020
EBC84C,earnings,100,50,2/18/2020
EBC84C,earnings,100,50,2/18/2020
EBC84C,earnings,100,50,2/18/2020
EBC84C,earnings,100,50,2/18/2020
EC1AF3,earnings,100,50,2/18/2020
ECE19E,executive-appointment,100,54,2/18/2020
ED79D9,earnings,100,50,2/18/2020
EF25A5,executive-appointment,100,54,2/18/2020
F0B877,earnings,100,50,2/18/2020
F1529C,conference-participant,100,50,2/18/2020
F1EB39,conference-call,100,50,2/18/2020
F3816D,conference-participant,100,50,2/18/2020
F39E1E,earnings,100,50,2/18/2020
F3FCC3,debt-extension-recipient,100,73,2/18/2020
F47871,conference-participant,100,50,2/18/2020
F4F46F,conference-participant,100,50,2/18/2020
F5349B,executive-appointment,100,54,2/18/2020
F5C78B,acquisition-completed-acquirer,100,49,2/18/2020
F5C8AB,earnings-per-share-positive,100,69,2/18/2020
F5C8AB,earnings-per-share,100,50,2/18/2020
F5C8AB,earnings-per-share,100,50,2/18/2020
F5D499,conference-participant,100,50,2/18/2020
F6FA6A,credit-extension-recipient,100,69,2/18/2020
FD2565,conference-participant,100,50,2/18/2020
FD6926,conference-participant,100,50,2/18/2020
FE609F,conference-call,100,50,2/18/2020
FF227B,conference-participant,100,50,2/18/2020
003B70,operating-earnings,100,50,2/19/2020
00FC70,dividend,100,50,2/19/2020
018C11,earnings,100,50,2/19/2020
018C11,executive-appointment,100,54,2/19/2020
01B8D6,earnings,100,50,2/19/2020
01D03F,partnership,100,61,2/19/2020
01D03F,partnership,100,61,2/19/2020
03D5F9,earnings,100,50,2/19/2020
0490C6,earnings,100,50,2/19/2020
095A04,earnings,100,50,2/19/2020
98977,earnings,100,50,2/19/2020
98977,executive-appointment,100,54,2/19/2020
099C88,business-contract,100,69,2/19/2020
0A1D77,partnership,100,61,2/19/2020
0B7375,conference-participant,100,50,2/19/2020
0BD199,conference-participant,100,50,2/19/2020
0BF198,conference-participant,100,50,2/19/2020
0E439E,note-sale,100,52,2/19/2020
0E439E,note-sale,100,52,2/19/2020
10100E,earnings,100,50,2/19/2020
10673F,dividend,100,50,2/19/2020
108A2B,operating-earnings,100,50,2/19/2020
1151F4,dividend-up,100,56,2/19/2020
1151F4,executive-appointment,100,54,2/19/2020
11A49E,conference-participant,100,50,2/19/2020
1220D2,earnings,100,50,2/19/2020
129DC8,earnings,100,50,2/19/2020
12E454,product-release,100,64,2/19/2020
1348C9,dividend,100,50,2/19/2020
138DDE,earnings,100,50,2/19/2020
143C52,conference-call,100,50,2/19/2020
152B9E,earnings,100,50,2/19/2020
159739,earnings,100,50,2/19/2020
159739,earnings,100,50,2/19/2020
1834C0,dividend,100,50,2/19/2020
184988,conference-participant,100,50,2/19/2020
190B91,ownership-decrease-owner,100,46,2/19/2020
19BF16,executive-resignation,100,44,2/19/2020
19BF16,earnings,100,50,2/19/2020
1A5957,earnings,100,50,2/19/2020
1AC649,conference-participant,100,50,2/19/2020
1E1125,conference-organizer,100,57,2/19/2020
1E83DE,earnings,100,50,2/19/2020
1EBF8D,business-contract,100,69,2/19/2020
1F3CFB,earnings,100,50,2/19/2020
1FAF22,conference-participant,100,50,2/19/2020
2031CE,dividend,100,50,2/19/2020
21022F,earnings,100,50,2/19/2020
2158DF,executive-appointment,100,54,2/19/2020
228D42,partnership,100,61,2/19/2020
24FA23,earnings,100,50,2/19/2020
25AB8E,legal-issues-defendant,100,22,2/19/2020
25AB8E,legal-issues-defendant,100,22,2/19/2020
267718,partnership,100,61,2/19/2020
279916,earnings,100,50,2/19/2020
2920D5,dividend-up,100,81,2/19/2020
2920D5,earnings,100,50,2/19/2020
2A17B1,dividend-up,100,62,2/19/2020
2AA6A8,conference-call,100,50,2/19/2020
2B49F4,note-sale,100,52,2/19/2020
2B8179,conference-participant,100,50,2/19/2020
2BAE5F,earnings,100,50,2/19/2020
2BAE5F,earnings,100,50,2/19/2020
2BAE5F,earnings,100,50,2/19/2020
2BC05E,legal-issues-defendant,100,22,2/19/2020
2CB4C9,unit-acquisition-acquiree,100,76,2/19/2020
2CB4C9,unit-acquisition-acquiree,100,76,2/19/2020
2F6782,dividend-up,100,54,2/19/2020
326EDD,public-offering,100,43,2/19/2020
326EDD,public-offering,100,43,2/19/2020
32F943,earnings,100,50,2/19/2020
33AD83,conference-participant,100,50,2/19/2020
343996,ownership-increase-owner,100,56,2/19/2020
3461CF,conference-participant,100,50,2/19/2020
35AE32,earnings,100,50,2/19/2020
3.50E+27,dividend,100,50,2/19/2020
373B06,public-offering,100,43,2/19/2020
37426C,conference-call,100,50,2/19/2020
387541,earnings,100,50,2/19/2020
3A113F,earnings,100,50,2/19/2020
3A1C46,earnings,100,50,2/19/2020
3DCECC,earnings,100,50,2/19/2020
3DDE54,conference-participant,100,50,2/19/2020
3E15F6,dividend,100,50,2/19/2020
3ED92D,note-sale,100,52,2/19/2020
3ED92D,note-sale,100,52,2/19/2020
401072,conference-participant,100,50,2/19/2020
408089,dividend,100,50,2/19/2020
416C55,acquisition-acquirer,100,49,2/19/2020
416C55,acquisition-acquirer,100,49,2/19/2020
4455C4,earnings,100,50,2/19/2020
4455C4,earnings,100,50,2/19/2020
4455C4,earnings,100,50,2/19/2020
4455C4,earnings,100,50,2/19/2020
44A4FC,note-sale,100,52,2/19/2020
46017C,conference-participant,100,50,2/19/2020
47752F,earnings,100,50,2/19/2020
47752F,earnings,100,50,2/19/2020
47752F,earnings,100,50,2/19/2020
47752F,earnings,100,50,2/19/2020
47752F,earnings,100,50,2/19/2020
49A344,earnings,100,50,2/19/2020
49A344,earnings,100,50,2/19/2020
49A344,earnings,100,50,2/19/2020
4B3555,dividend-up,100,60,2/19/2020
4BBA23,unit-acquisition-acquirer,100,49,2/19/2020
4C1FA1,earnings,100,50,2/19/2020
4C350A,earnings,100,50,2/19/2020
4C3FE9,conference-participant,100,50,2/19/2020
4C5CC9,dividend,100,50,2/19/2020
4D8124,dividend-up,100,81,2/19/2020
4DD09F,earnings,100,50,2/19/2020
4E6F5A,conference-participant,100,50,2/19/2020
507AE7,note-sale,100,52,2/19/2020
50D1EC,patent-awarded,100,72,2/19/2020
520632,partnership,100,61,2/19/2020
56765E,dividend-up,100,81,2/19/2020
56B7C1,earnings,100,50,2/19/2020
58CA9A,conference-organizer,100,57,2/19/2020
594402,earnings,100,50,2/19/2020
59872F,partnership,100,61,2/19/2020
59872F,partnership,100,61,2/19/2020
5B226B,dividend,100,50,2/19/2020
5B3FA2,executive-appointment,100,54,2/19/2020
5B6C11,acquisition-acquirer,100,49,2/19/2020
5B6C11,acquisition-acquirer,100,49,2/19/2020
5B6C11,acquisition-acquirer,100,49,2/19/2020
5B6C11,acquisition-acquirer,100,49,2/19/2020
5D87DF,dividend,100,50,2/19/2020
5E6959,executive-appointment,100,54,2/19/2020
5E6959,executive-appointment,100,54,2/19/2020
5F3D91,reverse-stock-splits,100,51,2/19/2020
5FC507,conference-participant,100,50,2/19/2020
605F40,award,100,58,2/19/2020
619882,conference-organizer,100,57,2/19/2020
619882,conference-organizer,100,57,2/19/2020
62F41C,legal-issues-defendant,100,22,2/19/2020
62F41C,legal-issues-defendant,100,22,2/19/2020
6559D8,conference-participant,100,50,2/19/2020
665D7D,conference-participant,100,50,2/19/2020
66667F,partnership,100,61,2/19/2020
66749D,conference-participant,100,50,2/19/2020
676FFD,legal-issues-defendant,100,22,2/19/2020
676FFD,earnings,100,50,2/19/2020
69C99E,conference-participant,100,50,2/19/2020
6A3C35,earnings,100,50,2/19/2020
6A3C35,earnings,100,50,2/19/2020
6A3C35,earnings,100,50,2/19/2020
6A3C35,earnings,100,50,2/19/2020
6A3C35,earnings,100,50,2/19/2020
6A3C35,earnings,100,50,2/19/2020
6A3C35,earnings,100,50,2/19/2020
6B0E45,earnings,100,50,2/19/2020
6B6375,earnings,100,50,2/19/2020
6BC6F9,earnings,100,50,2/19/2020
6BF593,earnings,100,50,2/19/2020
6BF593,earnings,100,50,2/19/2020
6BF593,earnings,100,50,2/19/2020
6CC55E,clinical-trials-positive,100,87,2/19/2020
6D1ADF,earnings,100,50,2/19/2020
6DC1D7,conference-call,100,50,2/19/2020
6DDA15,earnings,100,50,2/19/2020
6DDA15,earnings,100,50,2/19/2020
6DDA15,earnings,100,50,2/19/2020
6DDA15,earnings,100,50,2/19/2020
6DDA15,earnings,100,50,2/19/2020
6DDA15,earnings,100,50,2/19/2020
6-Dec-05,conference-participant,100,50,2/19/2020
6E7060,earnings,100,50,2/19/2020
6EB9DA,executive-appointment,100,54,2/19/2020
6F0096,earnings,100,50,2/19/2020
6F22E7,earnings,100,50,2/19/2020
701531,conference-participant,100,50,2/19/2020
7273FF,earnings,100,50,2/19/2020
729368,earnings,100,50,2/19/2020
73BCBA,earnings,100,50,2/19/2020
73BCBA,earnings,100,50,2/19/2020
73BCBA,earnings,100,50,2/19/2020
73BCBA,earnings,100,50,2/19/2020
74404C,dividend,100,50,2/19/2020
7.45E+28,earnings,100,50,2/19/2020
746373,earnings,100,50,2/19/2020
746373,dividend-up,100,58,2/19/2020
747219,conference-participant,100,50,2/19/2020
762A3E,conference-organizer,100,57,2/19/2020
762A3E,conference-organizer,100,57,2/19/2020
762A3E,conference-organizer,100,57,2/19/2020
762A3E,conference-organizer,100,57,2/19/2020
762A3E,conference-organizer,100,57,2/19/2020
762A3E,conference-organizer,100,57,2/19/2020
762A3E,conference-organizer,100,57,2/19/2020
769F40,dividend,100,50,2/19/2020
76B926,dividend,100,50,2/19/2020
76BD96,note-sale,100,52,2/19/2020
76BECC,conference-call,100,50,2/19/2020
76E80F,conference-call,100,50,2/19/2020
771985,earnings,100,50,2/19/2020
7AC86E,unit-acquisition-acquirer,100,49,2/19/2020
7B6EB1,earnings,100,50,2/19/2020
7C75FD,earnings,100,50,2/19/2020
7C75FD,earnings,100,50,2/19/2020
7C75FD,earnings,100,50,2/19/2020
7C75FD,earnings,100,50,2/19/2020
7C75FD,earnings,100,50,2/19/2020
7C75FD,earnings,100,50,2/19/2020
7C75FD,earnings,100,50,2/19/2020
7C75FD,earnings,100,50,2/19/2020
7DD584,conference-participant,100,50,2/19/2020
7E0EB0,conference-call,100,50,2/19/2020
7E1D5D,earnings,100,50,2/19/2020
7E1D5D,earnings,100,50,2/19/2020
7E1D5D,earnings,100,50,2/19/2020
7E1D5D,earnings,100,50,2/19/2020
7F3FBC,acquisition-acquirer,100,49,2/19/2020
7FDE1C,earnings,100,50,2/19/2020
80C400,earnings,100,50,2/19/2020
818A2F,dividend,100,50,2/19/2020
818A2F,dividend,100,50,2/19/2020
8802B4,earnings,100,50,2/19/2020
881190,earnings-positive,100,69,2/19/2020
881190,earnings-positive,100,69,2/19/2020
881190,earnings-positive,100,69,2/19/2020
881190,earnings-positive,100,69,2/19/2020
881190,earnings-positive,100,69,2/19/2020
8AB37F,conference-call,100,50,2/19/2020
8AB85C,conference-participant,100,50,2/19/2020
8B4A45,earnings,100,50,2/19/2020
8C6C1B,facility-open,100,65,2/19/2020
8E0E32,executive-appointment,100,54,2/19/2020
8E10BF,public-offering,100,43,2/19/2020
8EDACA,conference-call,100,50,2/19/2020
8F8F2F,earnings,100,50,2/19/2020
8F8F2F,earnings,100,50,2/19/2020
8F8F2F,earnings,100,50,2/19/2020
8F8F2F,earnings,100,50,2/19/2020
8FF2EF,dividend,100,50,2/19/2020
905356,earnings-per-share-positive,100,69,2/19/2020
905356,earnings,100,50,2/19/2020
905356,earnings,100,50,2/19/2020
90D6A5,earnings,100,50,2/19/2020
90D6A5,dividend,100,50,2/19/2020
9196A2,conference-organizer,100,57,2/19/2020
9196A2,conference-organizer,100,57,2/19/2020
9368BE,conference-call,100,50,2/19/2020
93D207,conference-participant,100,50,2/19/2020
94A326,conference-participant,100,50,2/19/2020
99B61C,conference-participant,100,50,2/19/2020
9B5968,executive-appointment,100,54,2/19/2020
9B5968,executive-appointment,100,54,2/19/2020
9B730A,conference-call,100,50,2/19/2020
9BF177,earnings,100,50,2/19/2020
9C5174,partnership,100,61,2/19/2020
9C5174,business-contract,100,69,2/19/2020
9D4EC7,dividend,100,50,2/19/2020
9DDE1B,earnings,100,50,2/19/2020
9EA947,earnings,100,50,2/19/2020
9EBAFA,earnings,100,50,2/19/2020
9F37C5,dividend,100,50,2/19/2020
9F37C5,earnings,100,50,2/19/2020
A23747,conference-participant,100,50,2/19/2020
A3AAA5,dividend,100,50,2/19/2020
A47A7D,earnings,100,50,2/19/2020
A52B6B,conference-participant,100,50,2/19/2020
A631A3,conference-participant,100,50,2/19/2020
A631A3,conference-participant,100,50,2/19/2020
A6FC89,conference-participant,100,50,2/19/2020
AA1EAA,public-offering,100,43,2/19/2020
AA3AB8,earnings,100,50,2/19/2020
AAC8B6,facility-sale,100,52,2/19/2020
AAC8B6,facility-sale,100,52,2/19/2020
AB7F05,earnings,100,50,2/19/2020
AC775C,earnings,100,50,2/19/2020
ACDF88,conference-participant,100,50,2/19/2020
AEF2C3,earnings,100,50,2/19/2020
AFD7DD,conference-call,100,50,2/19/2020
B3CB74,conference-organizer,100,57,2/19/2020
B3CB74,conference-organizer,100,57,2/19/2020
B3CB74,conference-organizer,100,57,2/19/2020
B48FC9,revenues,100,50,2/19/2020
B48FC9,revenues,100,50,2/19/2020
B48FC9,revenues,100,50,2/19/2020
B4B281,dividend,100,50,2/19/2020
B614F8,product-release,100,64,2/19/2020
B76C82,debt,100,50,2/19/2020
B83D67,conference-participant,100,50,2/19/2020
B840EF,business-contract,100,69,2/19/2020
B840EF,partnership,100,61,2/19/2020
B96637,earnings,100,50,2/19/2020
B96637,earnings,100,50,2/19/2020
B98EFA,business-contract,100,69,2/19/2020
B98EFA,business-contract,100,69,2/19/2020
BB0587,dividend,100,50,2/19/2020
BBAE2A,dividend,100,50,2/19/2020
BBBB41,conference-participant,100,50,2/19/2020
BCC13E,conference-participant,100,50,2/19/2020
BCC55F,conference-participant,100,50,2/19/2020
BDE867,conference-participant,100,50,2/19/2020
C05839,earnings,100,50,2/19/2020
C15DB3,earnings,100,50,2/19/2020
C2609A,conference-participant,100,50,2/19/2020
C2E426,earnings,100,50,2/19/2020
C4C77F,conference-call,100,50,2/19/2020
C74887,conference-participant,100,50,2/19/2020
C7859D,conference-participant,100,50,2/19/2020
C7FC95,business-contract,100,69,2/19/2020
C8257F,note-sale,100,52,2/19/2020
C9D866,earnings,100,50,2/19/2020
CB22CD,dividend-up,100,81,2/19/2020
CB88B3,earnings,100,50,2/19/2020
CBBFBF,legal-issues-defendant,100,22,2/19/2020
CBBFBF,legal-issues-defendant,100,22,2/19/2020
CBFFDD,dividend,100,50,2/19/2020
CCBBAD,dividend,100,50,2/19/2020
CDE118,dividend,100,50,2/19/2020
CE5C6E,earnings,100,50,2/19/2020
D1AE3B,dividend,100,50,2/19/2020
D1C26F,executive-appointment,100,54,2/19/2020
D21D8A,executive-appointment,100,54,2/19/2020
D27FAB,conference-call,100,50,2/19/2020
D29F43,dividend,100,50,2/19/2020
D2B9E5,earnings,100,50,2/19/2020
D2B9E5,earnings,100,50,2/19/2020
D2B9E5,earnings,100,50,2/19/2020
D4070C,executive-appointment,100,54,2/19/2020
D4070C,executive-appointment,100,54,2/19/2020
D4463B,note-sale,100,52,2/19/2020
D4463B,note-acquisition,100,66,2/19/2020
D4463B,acquisition-interest-acquirer,100,46,2/19/2020
D56D6D,earnings,100,50,2/19/2020
D63B0F,dividend-up,100,81,2/19/2020
D63B0F,earnings,100,50,2/19/2020
D63B0F,earnings,100,50,2/19/2020
D63B0F,earnings,100,50,2/19/2020
D6853F,legal-issues-defendant,100,22,2/19/2020
D6EAA3,dividend,100,50,2/19/2020
D6EAA3,executive-appointment,100,54,2/19/2020
D70365,earnings,100,50,2/19/2020
D76AEF,earnings,100,50,2/19/2020
D8DBA3,dividend-up,100,81,2/19/2020
D8ECA1,executive-appointment,100,54,2/19/2020
D90441,dividend,100,50,2/19/2020
D90441,dividend,100,50,2/19/2020
D9FC89,earnings,100,50,2/19/2020
DBB28E,product-release,100,64,2/19/2020
DC0066,clinical-trials-start,100,64,2/19/2020
DC486E,dividend-up,100,81,2/19/2020
DC486E,dividend-up,100,81,2/19/2020
DD0F15,legal-issues-defendant,100,22,2/19/2020
DD7A96,earnings,100,50,2/19/2020
DE4924,note-sale,100,52,2/19/2020
DF18E6,conference-participant,100,50,2/19/2020
E07573,earnings-guidance,100,50,2/19/2020
E13782,executive-appointment,100,54,2/19/2020
E1E093,acquisition-acquiree,100,76,2/19/2020
E1E36F,conference-participant,100,50,2/19/2020
E20392,earnings,100,50,2/19/2020
E21871,earnings,100,50,2/19/2020
E2F66E,conference-call,100,50,2/19/2020
E35610,partnership,100,61,2/19/2020
E5D914,earnings,100,50,2/19/2020
E5D914,earnings,100,50,2/19/2020
E5D914,earnings,100,50,2/19/2020
E5D914,earnings,100,50,2/19/2020
E5D914,earnings,100,50,2/19/2020
E610CD,earnings,100,50,2/19/2020
E68C3D,earnings,100,50,2/19/2020
E69BA5,earnings,100,50,2/19/2020
E69BA5,dividend,100,50,2/19/2020
E6E012,conference-organizer,100,57,2/19/2020
E6E012,conference-organizer,100,57,2/19/2020
E74FED,product-release,100,64,2/19/2020
E74FED,product-release,100,64,2/19/2020
E8A49A,award,100,58,2/19/2020
E9C7C0,conference-participant,100,50,2/19/2020
EB61C4,dividend,100,50,2/19/2020
EB7FBF,conference-call,100,50,2/19/2020
ED2A5E,earnings,100,50,2/19/2020
ED7F13,earnings,100,50,2/19/2020
EF1AD9,conference-participant,100,50,2/19/2020
F15E41,earnings,100,50,2/19/2020
F15E41,earnings,100,50,2/19/2020
F47871,regulatory-product-approval-granted,100,81,2/19/2020
F4D241,earnings,100,50,2/19/2020
F58C23,patient-enrollment-complete,100,64,2/19/2020
F6E248,conference-participant,100,50,2/19/2020
F88A04,executive-appointment,100,54,2/19/2020
F90EE5,dividend,100,50,2/19/2020
FD554E,executive-appointment,100,54,2/19/2020
FDD3FC,public-offering,100,43,2/19/2020
FFAB4A,dividend,100,50,2/19/2020
00067A,executive-appointment,100,54,2/20/2020
00FC70,earnings,100,50,2/20/2020
0157B1,partnership,100,61,2/20/2020
01B8D6,conference-participant,100,50,2/20/2020
02870F,dividend-up,100,74,2/20/2020
036C6F,dividend-up,100,81,2/20/2020
03B8CF,settlement,100,56,2/20/2020
61366,earnings,100,50,2/20/2020
61366,earnings-guidance,100,50,2/20/2020
061A3B,earnings,100,50,2/20/2020
68396,earnings,100,50,2/20/2020
06C826,conference-call,100,50,2/20/2020
84625,earnings,100,50,2/20/2020
84625,earnings,100,50,2/20/2020
099C88,dividend,100,50,2/20/2020
099C88,earnings,100,50,2/20/2020
0A7650,dividend-up,100,77,2/20/2020
0C136E,earnings,100,50,2/20/2020
0E499E,revenue-up,100,69,2/20/2020
0E499E,earnings,100,50,2/20/2020
0E499E,earnings,100,50,2/20/2020
0F04E5,earnings,100,50,2/20/2020
0F2BC9,executive-appointment,100,54,2/20/2020
0FDE97,unit-acquisition-completed-acquiree,100,67,2/20/2020
0FDE97,unit-acquisition-completed-acquiree,100,67,2/20/2020
0FDE97,unit-acquisition-completed-acquiree,100,67,2/20/2020
102F04,earnings,100,50,2/20/2020
106394,earnings,100,50,2/20/2020
1096C6,earnings,100,50,2/20/2020
1151F4,executive-appointment,100,54,2/20/2020
12731D,earnings,100,50,2/20/2020
12731D,earnings,100,50,2/20/2020
12DE76,partnership,100,61,2/20/2020
131443,executive-resignation,100,44,2/20/2020
13C3E0,note-sale,100,52,2/20/2020
147C38,earnings,100,50,2/20/2020
154272,conference-participant,100,50,2/20/2020
165B86,conference-call,100,50,2/20/2020
16C544,earnings,100,50,2/20/2020
184866,clinical-trials,100,56,2/20/2020
184866,clinical-trials,100,56,2/20/2020
197612,earnings-up,100,91,2/20/2020
197612,dividend,100,50,2/20/2020
19BF16,legal-issues-defendant,100,22,2/20/2020
19BF16,legal-issues-defendant,100,22,2/20/2020
1A6A94,earnings,100,50,2/20/2020
1AF7E2,earnings,100,50,2/20/2020
1B4F31,earnings,100,50,2/20/2020
1B9535,earnings,100,50,2/20/2020
1C2593,conference-call,100,50,2/20/2020
1CB9D3,conference-call,100,50,2/20/2020
1CD09C,earnings,100,50,2/20/2020
1E1125,conference-organizer,100,57,2/20/2020
1E1125,conference-organizer,100,57,2/20/2020
1E1125,conference-organizer,100,57,2/20/2020
1E1125,conference-organizer,100,57,2/20/2020
1F08A6,earnings,100,50,2/20/2020
1F9258,conference-participant,100,50,2/20/2020
2082EA,earnings,100,50,2/20/2020
2093B1,dividend-up,100,64,2/20/2020
228D42,partnership,100,61,2/20/2020
228D42,partnership,100,61,2/20/2020
228D42,partnership,100,61,2/20/2020
238302,conference-call,100,50,2/20/2020
239106,earnings,100,50,2/20/2020
239106,earnings,100,50,2/20/2020
239106,earnings,100,50,2/20/2020
2.45E+15,dividend,100,50,2/20/2020
249674,earnings,100,50,2/20/2020
249674,earnings,100,50,2/20/2020
249674,earnings,100,50,2/20/2020
249674,earnings,100,50,2/20/2020
249B39,dividend,100,50,2/20/2020
25102A,executive-appointment,100,54,2/20/2020
275300,dividend,100,50,2/20/2020
2A1009,earnings,100,50,2/20/2020
2A1009,earnings,100,50,2/20/2020
2A1009,earnings,100,50,2/20/2020
2A1009,earnings,100,50,2/20/2020
2A1009,earnings,100,50,2/20/2020
2BC05E,earnings,100,50,2/20/2020
2BC05E,legal-issues-defendant,100,22,2/20/2020
2C3348,earnings,100,50,2/20/2020
2DB344,dividend,100,50,2/20/2020
2DDB22,earnings,100,50,2/20/2020
2E0445,conference-participant,100,50,2/20/2020
2EB88B,stake-acquirer,100,48,2/20/2020
2F5256,dividend,100,50,2/20/2020
30AB63,conference-participant,100,50,2/20/2020
314D88,earnings,100,50,2/20/2020
31AA84,note-sale,100,52,2/20/2020
3.20E+263,earnings,100,50,2/20/2020
34A959,acquisition-regulatory-approval-acquirer,100,54,2/20/2020
3798B9,earnings,100,50,2/20/2020
387375,earnings,100,50,2/20/2020
3.88E+02,earnings,100,50,2/20/2020
396D7C,earnings,100,50,2/20/2020
39BFF6,executive-appointment,100,54,2/20/2020
3AAEAE,executive-appointment,100,54,2/20/2020
3B8484,earnings,100,50,2/20/2020
3BB616,earnings,100,50,2/20/2020
3C7F5F,earnings,100,50,2/20/2020
3C7F5F,earnings,100,50,2/20/2020
3C7F5F,earnings,100,50,2/20/2020
3C7F5F,earnings,100,50,2/20/2020
3C7F5F,earnings,100,50,2/20/2020
3C7F5F,earnings,100,50,2/20/2020
3DCECC,earnings,100,50,2/20/2020
3E15F6,earnings,100,50,2/20/2020
3E15F6,earnings,100,50,2/20/2020
3E15F6,earnings,100,50,2/20/2020
3E15F6,earnings,100,50,2/20/2020
3E39A5,product-release,100,64,2/20/2020
3E39A5,earnings,100,50,2/20/2020
3ED92D,conference-participant,100,50,2/20/2020
3F1C69,earnings,100,50,2/20/2020
3F868D,earnings,100,50,2/20/2020
3F96D5,earnings,100,50,2/20/2020
415188,dividend-up,100,81,2/20/2020
415188,earnings,100,50,2/20/2020
41B53E,earnings,100,50,2/20/2020
41B53E,earnings,100,50,2/20/2020
41B53E,earnings,100,50,2/20/2020
4290EF,dividend,100,50,2/20/2020
44A4FC,conference-organizer,100,57,2/20/2020
44A4FC,note-sale,100,52,2/20/2020
45ABCC,product-release,100,64,2/20/2020
47B4CC,conference-call,100,50,2/20/2020
4AC91D,legal-issues-defendant,100,22,2/20/2020
4AC91D,legal-issues-defendant,100,22,2/20/2020
4AC91D,shareholder-rights-plan,100,43,2/20/2020
4AC91D,shareholder-rights-plan,100,43,2/20/2020
4C350A,conference-call,100,50,2/20/2020
4C6C63,partnership,100,61,2/20/2020
4C7DB5,earnings,100,50,2/20/2020
4D8124,earnings,100,50,2/20/2020
4EE167,earnings,100,50,2/20/2020
4F9487,investment-investor,100,55,2/20/2020
50070E,earnings,100,50,2/20/2020
507AE7,note-sale,100,52,2/20/2020
5088A5,earnings,100,50,2/20/2020
51F541,dividend-up,100,81,2/20/2020
524CE4,earnings,100,50,2/20/2020
5487B1,acquisition-acquirer,100,49,2/20/2020
5487B1,earnings,100,50,2/20/2020
5487B1,earnings,100,50,2/20/2020
5487B1,earnings,100,50,2/20/2020
5487B1,earnings,100,50,2/20/2020
5487B1,earnings,100,50,2/20/2020
5487B1,earnings,100,50,2/20/2020
5487B1,acquisition-acquirer,100,49,2/20/2020
5487B1,acquisition-acquirer,100,49,2/20/2020
54A713,dividend-up,100,81,2/20/2020
550D01,facility-open,100,65,2/20/2020
55C9B5,conference-participant,100,50,2/20/2020
55CD6F,earnings,100,50,2/20/2020
5704AC,earnings,100,50,2/20/2020
57A854,earnings,100,50,2/20/2020
57DDB9,business-contract,100,69,2/20/2020
57F3DA,earnings,100,50,2/20/2020
5968F9,earnings,100,50,2/20/2020
5A9A82,regulatory-investigation,100,22,2/20/2020
5BC2F4,dividend,100,50,2/20/2020
5C7601,dividend,100,50,2/20/2020
5D1329,conference-call,100,50,2/20/2020
5D43A7,earnings,100,50,2/20/2020
5D43A7,earnings,100,50,2/20/2020
5D43A7,earnings,100,50,2/20/2020
5D43A7,earnings,100,50,2/20/2020
5D43A7,earnings,100,50,2/20/2020
62F41C,legal-issues-defendant,100,22,2/20/2020
651C85,earnings,100,50,2/20/2020
651C85,public-offering,100,43,2/20/2020
665D7D,dividend,100,50,2/20/2020
66E04A,partnership,100,61,2/20/2020
66E04A,partnership,100,61,2/20/2020
66E04A,partnership,100,61,2/20/2020
67A658,earnings,100,50,2/20/2020
67A658,executive-appointment,100,54,2/20/2020
68586A,conference-call,100,50,2/20/2020
68E6E9,earnings,100,50,2/20/2020
69C99E,patient-enrollment-complete,100,64,2/20/2020
6A171E,earnings,100,50,2/20/2020
6B494E,public-offering,100,43,2/20/2020
6C4D2F,dividend,100,50,2/20/2020
6C6D73,public-offering,100,43,2/20/2020
6CDFC6,partnership,100,61,2/20/2020
6F0A63,earnings,100,50,2/20/2020
6F3FA8,dividend,100,50,2/20/2020
71553E,conference-participant,100,50,2/20/2020
71694D,conference-call,100,50,2/20/2020
71E2EF,dividend,100,50,2/20/2020
7255D2,partnership,100,61,2/20/2020
73F70F,earnings,100,50,2/20/2020
73F7F9,conference-call,100,50,2/20/2020
756045,dividend,100,50,2/20/2020
762A3E,conference-organizer,100,57,2/20/2020
763724,conference-call,100,50,2/20/2020
766047,executive-appointment,100,54,2/20/2020
766047,dividend,100,50,2/20/2020
76B926,earnings,100,50,2/20/2020
78A1BB,dividend,100,50,2/20/2020
791EC1,dividend,100,50,2/20/2020
7999F3,executive-appointment,100,54,2/20/2020
7999F3,earnings,100,50,2/20/2020
7A0EC4,conference-call,100,50,2/20/2020
7B8CB5,dividend,100,50,2/20/2020
7C4168,earnings,100,50,2/20/2020
7DA412,earnings,100,50,2/20/2020
7DD8CC,earnings,100,50,2/20/2020
805CD8,earnings,100,50,2/20/2020
8.10E+205,public-offering,100,43,2/20/2020
81EAD4,earnings,100,50,2/20/2020
8377DB,facility-open,100,65,2/20/2020
83E0AC,conference-call,100,50,2/20/2020
88193E,earnings,100,50,2/20/2020
88923D,earnings,100,50,2/20/2020
88923D,earnings,100,50,2/20/2020
88923D,earnings,100,50,2/20/2020
88923D,earnings,100,50,2/20/2020
88923D,earnings,100,50,2/20/2020
88923D,earnings,100,50,2/20/2020
896771,partnership,100,61,2/20/2020
8A8E41,partnership,100,61,2/20/2020
8B3B0E,earnings,100,50,2/20/2020
8BAA15,earnings,100,50,2/20/2020
8C6C1B,facility-open,100,65,2/20/2020
8D4486,unit-acquisition-acquiree,100,76,2/20/2020
8D4486,unit-acquisition-acquiree,100,76,2/20/2020
8E10BF,public-offering,100,43,2/20/2020
8E3F58,earnings,100,50,2/20/2020
8FCA78,acquisition-completed-acquirer,100,49,2/20/2020
90DD65,fundraising,100,64,2/20/2020
911AB8,earnings,100,50,2/20/2020
9196A2,conference-organizer,100,57,2/20/2020
9196A2,acquisition-acquirer,100,49,2/20/2020
9196A2,acquisition-acquirer,100,49,2/20/2020
9196A2,conference-organizer,100,57,2/20/2020
947B0B,conference-call,100,50,2/20/2020
94983E,dividend,100,50,2/20/2020
949D62,earnings,100,50,2/20/2020
954A47,dividend,100,50,2/20/2020
95DC1F,conference-call,100,50,2/20/2020
9.65E+07,earnings,100,50,2/20/2020
9.65E+07,earnings,100,50,2/20/2020
9.65E+07,earnings,100,50,2/20/2020
9673BD,settlement,100,56,2/20/2020
96F126,partnership,100,61,2/20/2020
971334,dividend,100,50,2/20/2020
971334,earnings,100,50,2/20/2020
97AAF6,earnings,100,50,2/20/2020
97AAF6,earnings,100,50,2/20/2020
97AAF6,earnings,100,50,2/20/2020
97AAF6,earnings,100,50,2/20/2020
97AAF6,earnings,100,50,2/20/2020
98CAED,earnings,100,50,2/20/2020
98CAED,dividend,100,50,2/20/2020
990AD0,conference-organizer,100,57,2/20/2020
9CA432,conference-participant,100,50,2/20/2020
9CA432,conference-participant,100,50,2/20/2020
9EBAFA,public-offering,100,43,2/20/2020
9F048E,earnings,100,50,2/20/2020
A01200,executive-appointment,100,54,2/20/2020
A072C4,conference-call,100,50,2/20/2020
A1E3B3,conference-participant,100,50,2/20/2020
A21649,earnings,100,50,2/20/2020
A4CD53,earnings,100,50,2/20/2020
A5151E,earnings,100,50,2/20/2020
A5195E,earnings,100,50,2/20/2020
A63387,conference-participant,100,50,2/20/2020
A666C8,conference-participant,100,50,2/20/2020
A7102F,earnings-up,100,68,2/20/2020
A7102F,earnings,100,50,2/20/2020
A7102F,earnings,100,50,2/20/2020
A7102F,earnings,100,50,2/20/2020
A7102F,earnings,100,50,2/20/2020
A72AB6,conference-call,100,50,2/20/2020
A7A0C8,conference-participant,100,50,2/20/2020
A94637,conference-call,100,50,2/20/2020
AA1EAA,public-offering,100,43,2/20/2020
AB4A7E,earnings,100,50,2/20/2020
AD23DE,dividend,100,50,2/20/2020
AD3C93,conference-participant,100,50,2/20/2020
AFD1CA,earnings,100,50,2/20/2020
B05118,earnings,100,50,2/20/2020
B1A85D,partnership,100,61,2/20/2020
B1DF3C,award,100,58,2/20/2020
B1DF3C,award,100,58,2/20/2020
B2256A,earnings,100,50,2/20/2020
B381D8,earnings,100,50,2/20/2020
B3CB74,conference-organizer,100,57,2/20/2020
B3CB74,conference-organizer,100,57,2/20/2020
B3CB74,conference-organizer,100,57,2/20/2020
B3CB74,conference-organizer,100,57,2/20/2020
B3CB74,conference-organizer,100,57,2/20/2020
B3CB74,conference-organizer,100,57,2/20/2020
B48FC9,conference-participant,100,50,2/20/2020
B619CB,executive-appointment,100,54,2/20/2020
B8A51F,earnings,100,50,2/20/2020
B8F71F,dividend,100,50,2/20/2020
B934BF,dividend,100,50,2/20/2020
BA0442,conference-participant,100,50,2/20/2020
BB0787,dividend,100,50,2/20/2020
BD682F,earnings,100,50,2/20/2020
BDF2BD,earnings,100,50,2/20/2020
BE14CF,dividend,100,50,2/20/2020
BE7BA4,earnings,100,50,2/20/2020
C15DB3,executive-appointment,100,54,2/20/2020
C2609A,conference-participant,100,50,2/20/2020
C32A39,note-sale,100,52,2/20/2020
C38440,earnings,100,50,2/20/2020
C3F99F,conference-call,100,50,2/20/2020
C4A432,earnings,100,50,2/20/2020
C4A432,earnings,100,50,2/20/2020
C4A432,earnings,100,50,2/20/2020
C4A432,unit-acquisition-acquirer,100,49,2/20/2020
C5E100,partnership,100,61,2/20/2020
C624A1,earnings,100,50,2/20/2020
C624A1,earnings,100,50,2/20/2020
C62AA4,dividend,100,50,2/20/2020
C6C702,earnings,100,50,2/20/2020
C83B88,executive-appointment,100,54,2/20/2020
C8923A,earnings,100,50,2/20/2020
C93C44,executive-appointment,100,54,2/20/2020
C9A96E,conference-participant,100,50,2/20/2020
C9D866,executive-appointment,100,54,2/20/2020
C9E04B,earnings,100,50,2/20/2020
C9E4EC,earnings,100,50,2/20/2020
CA212F,legal-issues-defendant,100,22,2/20/2020
CA212F,legal-issues-defendant,100,22,2/20/2020
CB22CD,earnings,100,50,2/20/2020
CB7AB2,earnings,100,50,2/20/2020
CB89EA,executive-appointment,100,54,2/20/2020
CBDB4D,conference-call,100,50,2/20/2020
CC35BE,earnings,100,50,2/20/2020
CE1002,dividend,100,50,2/20/2020
CE1002,executive-appointment,100,54,2/20/2020
CE5C6E,conference-participant,100,50,2/20/2020
CFF57D,conference-call,100,50,2/20/2020
D03C7A,earnings,100,50,2/20/2020
D03C7A,earnings,100,50,2/20/2020
D03C7A,earnings,100,50,2/20/2020
D09938,earnings,100,50,2/20/2020
D11C1C,earnings,100,50,2/20/2020
D29F43,earnings,100,50,2/20/2020
D518D8,revenues,100,50,2/20/2020
D518D8,revenues,100,50,2/20/2020
D518D8,revenues,100,50,2/20/2020
D518D8,revenues,100,50,2/20/2020
D518D8,revenues,100,50,2/20/2020
D57D99,dividend,100,50,2/20/2020
D598E7,government-contract,100,69,2/20/2020
D5B13D,conference-participant,100,50,2/20/2020
D650A7,conference-call,100,50,2/20/2020
D6534D,dividend,100,50,2/20/2020
D6EAA3,executive-appointment,100,54,2/20/2020
D9B1C9,earnings,100,50,2/20/2020
D9B1C9,earnings,100,50,2/20/2020
D9B1C9,earnings,100,50,2/20/2020
DA9443,earnings,100,50,2/20/2020
DAFED3,note-sale,100,52,2/20/2020
DAFED3,note-sale,100,52,2/20/2020
DBFB51,conference-call,100,50,2/20/2020
DC2B00,conference-call,100,50,2/20/2020
DC5299,executive-appointment,100,54,2/20/2020
DD0F15,legal-issues-defendant,100,22,2/20/2020
DF01B1,legal-issues-defendant,100,22,2/20/2020
DF01B1,legal-issues-defendant,100,22,2/20/2020
DF01B1,legal-issues-defendant,100,22,2/20/2020
DF01B1,legal-issues-defendant,100,22,2/20/2020
DF01B1,legal-issues-defendant,100,22,2/20/2020
DF01B1,legal-issues-defendant,100,22,2/20/2020
DF1F7A,earnings,100,50,2/20/2020
E05DC8,earnings,100,50,2/20/2020
E11C41,earnings,100,50,2/20/2020
E124EB,dividend,100,50,2/20/2020
E5752F,conference-participant,100,50,2/20/2020
E74FED,earnings,100,50,2/20/2020
E82A2D,conference-call,100,50,2/20/2020
E866D2,legal-issues-defendant,100,22,2/20/2020
E866D2,legal-issues-defendant,100,22,2/20/2020
E866D2,legal-issues-defendant,100,22,2/20/2020
EAEBF3,earnings,100,50,2/20/2020
EB36DE,legal-issues-defendant,100,22,2/20/2020
ED4560,conference-participant,100,50,2/20/2020
ED9C04,earnings,100,50,2/20/2020
EEA6B3,dividend,100,50,2/20/2020
EFD406,executive-appointment,100,54,2/20/2020
F0027C,earnings,100,50,2/20/2020
F0EEFB,earnings,100,50,2/20/2020
F1C04C,operating-earnings,100,50,2/20/2020
F30508,acquisition-completed-acquirer,100,49,2/20/2020
F4E882,business-contract,100,69,2/20/2020
F51DB0,earnings,100,50,2/20/2020
F66B58,conference-call,100,50,2/20/2020
F6FA6A,earnings,100,50,2/20/2020
F6FF0D,earnings,100,50,2/20/2020
F7902B,sponsorship,100,57,2/20/2020
F7FCA4,earnings,100,50,2/20/2020
F80389,earnings,100,50,2/20/2020
F80389,earnings,100,50,2/20/2020
F80389,earnings,100,50,2/20/2020
F80389,earnings,100,50,2/20/2020
F80389,earnings,100,50,2/20/2020
F80389,earnings,100,50,2/20/2020
F80389,earnings,100,50,2/20/2020
F80389,earnings,100,50,2/20/2020
F80389,earnings,100,50,2/20/2020
F80389,earnings,100,50,2/20/2020
F93C8A,earnings,100,50,2/20/2020
F93C8A,earnings,100,50,2/20/2020
F93C8A,earnings,100,50,2/20/2020
F93C8A,earnings,100,50,2/20/2020
FC80E6,earnings,100,50,2/20/2020
FD6926,earnings,100,50,2/20/2020
FD6926,dividend,100,50,2/20/2020
FDD3FC,conference-participant,100,50,2/20/2020
FDE409,earnings,100,50,2/20/2020
FE609F,earnings,100,50,2/20/2020
FEE4B0,conference-participant,100,50,2/20/2020
0358AF,board-meeting,100,51,2/21/2020
083F72,conference-participant,100,50,2/21/2020
0B57D7,dividend,100,50,2/21/2020
0E2992,dividend,100,50,2/21/2020
1065BC,executive-appointment,100,54,2/21/2020
1096C6,conference-participant,100,50,2/21/2020
119CB6,stock-splits,100,49,2/21/2020
138DDE,board-meeting,100,51,2/21/2020
139303,acquisition-acquirer,100,49,2/21/2020
14391F,earnings,100,50,2/21/2020
14391F,earnings,100,50,2/21/2020
14391F,earnings,100,50,2/21/2020
14391F,earnings,100,50,2/21/2020
14391F,earnings,100,50,2/21/2020
14391F,earnings,100,50,2/21/2020
14391F,earnings,100,50,2/21/2020
19BF16,executive-resignation,100,44,2/21/2020
1E1125,conference-organizer,100,57,2/21/2020
1E1125,conference-organizer,100,57,2/21/2020
1E1125,conference-organizer,100,57,2/21/2020
1F43A1,earnings,100,50,2/21/2020
25102A,conference-participant,100,50,2/21/2020
251988,earnings,100,50,2/21/2020
251988,earnings,100,50,2/21/2020
251988,earnings,100,50,2/21/2020
251988,earnings,100,50,2/21/2020
251988,earnings,100,50,2/21/2020
251988,earnings,100,50,2/21/2020
251988,earnings,100,50,2/21/2020
251988,earnings,100,50,2/21/2020
251988,earnings,100,50,2/21/2020
251988,earnings,100,50,2/21/2020
251988,earnings,100,50,2/21/2020
251988,earnings,100,50,2/21/2020
251988,earnings,100,50,2/21/2020
251988,earnings,100,50,2/21/2020
251988,earnings,100,50,2/21/2020
251988,earnings,100,50,2/21/2020
251988,earnings,100,50,2/21/2020
251988,earnings,100,50,2/21/2020
251988,earnings,100,50,2/21/2020
251988,earnings,100,50,2/21/2020
251988,earnings,100,50,2/21/2020
251988,earnings,100,50,2/21/2020
251988,earnings,100,50,2/21/2020
251988,earnings,100,50,2/21/2020
251988,earnings,100,50,2/21/2020
251988,earnings,100,50,2/21/2020
251988,earnings,100,50,2/21/2020
251988,earnings,100,50,2/21/2020
251988,earnings,100,50,2/21/2020
251988,earnings,100,50,2/21/2020
251988,earnings,100,50,2/21/2020
251988,earnings,100,50,2/21/2020
251988,earnings,100,50,2/21/2020
251988,earnings,100,50,2/21/2020
251988,earnings,100,50,2/21/2020
251988,earnings,100,50,2/21/2020
251988,earnings,100,50,2/21/2020
251988,earnings,100,50,2/21/2020
251988,earnings,100,50,2/21/2020
251988,earnings,100,50,2/21/2020
251988,earnings,100,50,2/21/2020
251988,earnings,100,50,2/21/2020
251988,earnings,100,50,2/21/2020
251988,earnings,100,50,2/21/2020
251988,earnings,100,50,2/21/2020
251988,earnings,100,50,2/21/2020
251988,earnings,100,50,2/21/2020
251988,earnings,100,50,2/21/2020
251988,earnings,100,50,2/21/2020
251988,earnings,100,50,2/21/2020
251988,earnings,100,50,2/21/2020
251988,earnings,100,50,2/21/2020
251988,earnings,100,50,2/21/2020
251988,earnings,100,50,2/21/2020
251988,earnings,100,50,2/21/2020
251988,earnings,100,50,2/21/2020
251988,earnings,100,50,2/21/2020
2AE625,earnings,100,50,2/21/2020
2BC05E,legal-issues-defendant,100,22,2/21/2020
2F5256,note-sale,100,52,2/21/2020
2F5256,note-sale,100,52,2/21/2020
342218,earnings,100,50,2/21/2020
36529A,conference-participant,100,50,2/21/2020
3798B9,conference-participant,100,50,2/21/2020
3B20AB,conference-participant,100,50,2/21/2020
3BE00F,executive-appointment,100,54,2/21/2020
3BE00F,dividend,100,50,2/21/2020
4.00E+163,executive-appointment,100,54,2/21/2020
41C528,executive-appointment,100,54,2/21/2020
41ED98,conference-call,100,50,2/21/2020
43A060,business-contract,100,69,2/21/2020
4AC91D,legal-issues-defendant,100,22,2/21/2020
4AC91D,legal-issues-defendant,100,22,2/21/2020
4AC91D,legal-issues-defendant,100,22,2/21/2020
4C37C5,facility-open,100,65,2/21/2020
4C7DB5,acquisition-acquirer,100,49,2/21/2020
4C92B9,conference-call,100,50,2/21/2020
51888A,unit-acquisition-acquirer,100,49,2/21/2020
520632,dividend,100,50,2/21/2020
57DDB9,business-contract,100,69,2/21/2020
5876DC,earnings,100,50,2/21/2020
58CA9A,conference-organizer,100,57,2/21/2020
58CA9A,conference-organizer,100,57,2/21/2020
5B35C7,dividend,100,50,2/21/2020
61BCA7,award,100,58,2/21/2020
6391C2,conference-participant,100,50,2/21/2020
6C6D73,public-offering,100,43,2/21/2020
6C987C,earnings,100,50,2/21/2020
6D9B53,fundraising,100,64,2/21/2020
6F0096,earnings,100,50,2/21/2020
6F0A63,dividend,100,50,2/21/2020
726EEA,earnings,100,50,2/21/2020
726EEA,earnings,100,50,2/21/2020
726EEA,earnings,100,50,2/21/2020
726EEA,earnings,100,50,2/21/2020
726EEA,earnings,100,50,2/21/2020
726EEA,earnings,100,50,2/21/2020
726EEA,dividend-up,100,65,2/21/2020
741937,earnings,100,50,2/21/2020
75F665,dividend,100,50,2/21/2020
771985,conference-participant,100,50,2/21/2020
78F776,conference-participant,100,50,2/21/2020
790D0D,dividend,100,50,2/21/2020
7A10FF,partnership,100,61,2/21/2020
7F2922,earnings,100,50,2/21/2020
819492,earnings,100,50,2/21/2020
85AD00,dividend,100,50,2/21/2020
86AA9C,dividend,100,50,2/21/2020
88611B,dividend,100,50,2/21/2020
8C6C1B,facility-open,100,65,2/21/2020
8E4F9A,earnings,100,50,2/21/2020
911AB8,conference-participant,100,50,2/21/2020
911ACB,buybacks,100,74,2/21/2020
95F59E,earnings,100,50,2/21/2020
967D92,dividend,100,50,2/21/2020
97644E,earnings,100,50,2/21/2020
9AF3DC,dividend,100,50,2/21/2020
9F5997,earnings,100,50,2/21/2020
9FD2D9,earnings,100,50,2/21/2020
9FD2D9,earnings,100,50,2/21/2020
9FD2D9,earnings,100,50,2/21/2020
A350C1,board-meeting,100,51,2/21/2020
AA98ED,partnership,100,61,2/21/2020
ACD9A4,dividend,100,50,2/21/2020
AD1ACF,executive-appointment,100,54,2/21/2020
B04426,earnings,100,50,2/21/2020
B1DF3C,conference-participant,100,50,2/21/2020
B3CB74,conference-organizer,100,57,2/21/2020
B3CB74,conference-organizer,100,57,2/21/2020
B3CB74,conference-organizer,100,57,2/21/2020
B4B281,executive-appointment,100,54,2/21/2020
B560AF,executive-appointment,100,54,2/21/2020
BBAE2A,executive-appointment,100,54,2/21/2020
BDF2BD,conference-participant,100,50,2/21/2020
C03C8B,conference-participant,100,50,2/21/2020
C2DD02,conference-call,100,50,2/21/2020
C32A39,dividend,100,50,2/21/2020
C564E4,conference-participant,100,50,2/21/2020
C94CFC,conference-participant,100,50,2/21/2020
C9739A,conference-participant,100,50,2/21/2020
C9C62A,unit-acquisition-acquirer,100,49,2/21/2020
CA212F,legal-issues-defendant,100,22,2/21/2020
CBBFBF,legal-issues-defendant,100,22,2/21/2020
CBBFBF,earnings,100,50,2/21/2020
CBBFBF,legal-issues-defendant,100,22,2/21/2020
CBBFBF,legal-issues-defendant,100,22,2/21/2020
CE4E6D,conference-call,100,50,2/21/2020
CFF97C,conference-participant,100,50,2/21/2020
D139BC,conference-participant,100,50,2/21/2020
D3FD6D,revenue-up,100,69,2/21/2020
D3FD6D,earnings,100,50,2/21/2020
D3FD6D,earnings,100,50,2/21/2020
D3FD6D,earnings,100,50,2/21/2020
D518D8,business-contract,100,69,2/21/2020
D63B0F,conference-participant,100,50,2/21/2020
D697DE,conference-participant,100,50,2/21/2020
D82EF3,partnership,100,61,2/21/2020
DA0A9E,earnings,100,50,2/21/2020
DB23C8,conference-participant,100,50,2/21/2020
DB7EC3,earnings,100,50,2/21/2020
DD0F15,legal-issues-defendant,100,22,2/21/2020
DF01B1,legal-issues-defendant,100,22,2/21/2020
DF01B1,legal-issues-defendant,100,22,2/21/2020
E1C16B,conference-participant,100,50,2/21/2020
E1E36F,dividend,100,50,2/21/2020
E866D2,legal-issues-defendant,100,22,2/21/2020
E866D2,legal-issues-defendant,100,22,2/21/2020
E866D2,legal-issues-defendant,100,22,2/21/2020
E866D2,legal-issues-defendant,100,22,2/21/2020
EB61C4,executive-resignation,100,44,2/21/2020
EBC84C,dividend,100,50,2/21/2020
EE967B,dividend,100,50,2/21/2020
EEA6B3,earnings-guidance-meet-expectations,100,59,2/21/2020
F1529C,conference-participant,100,50,2/21/2020
F5D410,conference-participant,100,50,2/21/2020
F67165,conference-participant,100,50,2/21/2020
FF227B,conference-call,100,50,2/21/2020
2BC05E,legal-issues-defendant,100,22,2/22/2020
4AC91D,legal-issues-defendant,100,22,2/22/2020
4AC91D,legal-issues-defendant,100,22,2/22/2020
CA212F,legal-issues-defendant,100,22,2/22/2020
CBBFBF,legal-issues-defendant,100,22,2/22/2020
DF01B1,legal-issues-defendant,100,22,2/22/2020
E866D2,legal-issues-defendant,100,22,2/22/2020
F4E882,award,100,58,2/22/2020
834152,clinical-trials,100,56,2/23/2020
A2C979,conference-call,100,50,2/23/2020
00E601,conference-participant,100,50,2/24/2020
20751,earnings,100,50,2/24/2020
02ACBD,conference-call,100,50,2/24/2020
040DBB,earnings,100,50,2/24/2020
04996E,earnings,100,50,2/24/2020
0624BE,dividend,100,50,2/24/2020
091B6C,conference-participant,100,50,2/24/2020
091B6C,conference-participant,100,50,2/24/2020
099A92,earnings,100,50,2/24/2020
099A92,dividend,100,50,2/24/2020
09F623,earnings-up,100,61,2/24/2020
09F623,earnings-up,100,61,2/24/2020
09F623,earnings-up,100,61,2/24/2020
09F623,earnings-up,100,61,2/24/2020
0A9D0A,unit-acquisition-acquirer,100,49,2/24/2020
0C136E,earnings,100,50,2/24/2020
0DC050,buybacks,100,74,2/24/2020
0E5223,earnings,100,50,2/24/2020
0F0693,earnings,100,50,2/24/2020
1220D2,conference-participant,100,50,2/24/2020
15789A,revenue-volume-up,100,54,2/24/2020
15B10D,conference-call,100,50,2/24/2020
168A5D,executive-appointment,100,54,2/24/2020
16F4D8,earnings,100,50,2/24/2020
16FC89,earnings,100,50,2/24/2020
1834C0,executive-appointment,100,54,2/24/2020
184988,conference-participant,100,50,2/24/2020
19BF16,legal-issues-defendant,100,22,2/24/2020
1E1125,credit-extension-provider,100,57,2/24/2020
1E1125,conference-organizer,100,57,2/24/2020
1E4FB9,earnings,100,50,2/24/2020
1E5786,conference-participant,100,50,2/24/2020
1E7785,earnings,100,50,2/24/2020
1E7785,earnings,100,50,2/24/2020
1E7785,earnings,100,50,2/24/2020
1E7785,earnings,100,50,2/24/2020
1E7785,earnings,100,50,2/24/2020
1E7785,earnings,100,50,2/24/2020
1F464F,conference-participant,100,50,2/24/2020
206852,executive-appointment,100,54,2/24/2020
2082EA,conference-participant,100,50,2/24/2020
225CA2,executive-appointment,100,54,2/24/2020
228D42,partnership,100,61,2/24/2020
23207A,partnership,100,61,2/24/2020
241AF7,earnings,100,50,2/24/2020
24CB56,conference-participant,100,50,2/24/2020
24FA23,conference-participant,100,50,2/24/2020
25A6CC,earnings,100,50,2/24/2020
25A6CC,earnings,100,50,2/24/2020
25A6CC,earnings,100,50,2/24/2020
25A6CC,earnings,100,50,2/24/2020
25A6CC,earnings,100,50,2/24/2020
26DC29,conference-call,100,50,2/24/2020
272704,conference-participant,100,50,2/24/2020
27A791,earnings,100,50,2/24/2020
28AC4E,earnings,100,50,2/24/2020
28AF37,business-contract,100,69,2/24/2020
295F9F,conference-call,100,50,2/24/2020
2BC05E,legal-issues-defendant,100,22,2/24/2020
2BC05E,legal-issues-defendant,100,22,2/24/2020
2BC05E,legal-issues-defendant,100,22,2/24/2020
2CBB58,acquisition-acquirer,100,49,2/24/2020
2D643C,executive-appointment,100,54,2/24/2020
2E61CC,product-release,100,64,2/24/2020
2F24A5,executive-appointment,100,54,2/24/2020
2F9304,award,100,58,2/24/2020
314D88,conference-participant,100,50,2/24/2020
3.14E+47,note-sale,100,52,2/24/2020
315EB0,facility-open,100,65,2/24/2020
315EB0,facility-open,100,65,2/24/2020
31803E,conference-participant,100,50,2/24/2020
3471C0,revenue-up,100,69,2/24/2020
3C7F5F,partnership,100,61,2/24/2020
3D7971,earnings,100,50,2/24/2020
4017AD,dividend,100,50,2/24/2020
414FFF,conference-call,100,50,2/24/2020
422A82,business-contract,100,69,2/24/2020
43A74A,earnings,100,50,2/24/2020
43A74A,earnings,100,50,2/24/2020
43A74A,earnings,100,50,2/24/2020
43A74A,earnings,100,50,2/24/2020
43A74A,earnings,100,50,2/24/2020
43A74A,earnings,100,50,2/24/2020
43A74A,earnings,100,50,2/24/2020
43A74A,earnings,100,50,2/24/2020
43F4A8,earnings,100,50,2/24/2020
442587,partnership,100,61,2/24/2020
448BF3,conference-call,100,50,2/24/2020
45BC35,note-sale,100,52,2/24/2020
4A2457,earnings,100,50,2/24/2020
4A6F00,partnership,100,61,2/24/2020
4AC91D,legal-issues-defendant,100,22,2/24/2020
4AC91D,earnings,100,50,2/24/2020
4AC91D,earnings,100,50,2/24/2020
4AC91D,earnings,100,50,2/24/2020
4AC91D,earnings,100,50,2/24/2020
4BDCA7,earnings,100,50,2/24/2020
4CDA2B,conference-participant,100,50,2/24/2020
4ECD1A,earnings,100,50,2/24/2020
4F0A80,dividend,100,50,2/24/2020
5065B1,asset-up,100,72,2/24/2020
507AE7,product-release,100,64,2/24/2020
50D1EC,earnings,100,50,2/24/2020
514067,earnings,100,50,2/24/2020
51D876,partnership,100,61,2/24/2020
51D876,conference-participant,100,50,2/24/2020
51D876,conference-participant,100,50,2/24/2020
524CE4,conference-participant,100,50,2/24/2020
543C77,conference-participant,100,50,2/24/2020
546A27,earnings,100,50,2/24/2020
54DF47,trading-listing,100,61,2/24/2020
55438C,executive-appointment,100,54,2/24/2020
55C9B5,revenues,100,50,2/24/2020
587EDF,executive-appointment,100,54,2/24/2020
58B46F,unit-acquisition-acquiree,100,76,2/24/2020
58CA9A,conference-organizer,100,57,2/24/2020
58CA9A,conference-organizer,100,57,2/24/2020
59872F,executive-appointment,100,54,2/24/2020
59DB8C,partnership,100,61,2/24/2020
59DB8C,product-release,100,64,2/24/2020
59DB8C,product-release,100,64,2/24/2020
59DB8C,public-offering,100,43,2/24/2020
5DD486,conference-participant,100,50,2/24/2020
6137BF,conference-participant,100,50,2/24/2020
620381,clinical-trials,100,56,2/24/2020
64E615,earnings,100,50,2/24/2020
665D7D,debt-extension-recipient,100,73,2/24/2020
6830FE,earnings,100,50,2/24/2020
68B03F,earnings,100,50,2/24/2020
68E3E0,dividend,100,50,2/24/2020
698FF9,conference-participant,100,50,2/24/2020
6B236C,executive-appointment,100,54,2/24/2020
6BD606,supply-decrease,100,28,2/24/2020
6BD606,supply-decrease,100,28,2/24/2020
6BD606,earnings,100,50,2/24/2020
6D3F35,earnings,100,50,2/24/2020
6D9ECA,executive-appointment,100,54,2/24/2020
6DBBBC,investment-investor,100,55,2/24/2020
6DBBBC,award,100,58,2/24/2020
6DD6BA,earnings,100,50,2/24/2020
6-Dec-05,earnings,100,50,2/24/2020
6E705B,partnership,100,61,2/24/2020
6E8349,earnings,100,50,2/24/2020
6E8864,operating-earnings,100,50,2/24/2020
6E8864,operating-earnings,100,50,2/24/2020
6E8864,operating-earnings,100,50,2/24/2020
701531,earnings,100,50,2/24/2020
7262F2,acquisition-acquirer,100,49,2/24/2020
7.45E+28,conference-participant,100,50,2/24/2020
762A3E,conference-organizer,100,57,2/24/2020
762A3E,conference-organizer,100,57,2/24/2020
762A3E,conference-organizer,100,57,2/24/2020
762A3E,conference-organizer,100,57,2/24/2020
762A3E,conference-organizer,100,57,2/24/2020
762A3E,conference-organizer,100,57,2/24/2020
762A3E,conference-organizer,100,57,2/24/2020
762A3E,conference-organizer,100,57,2/24/2020
762A3E,conference-organizer,100,57,2/24/2020
762A3E,conference-organizer,100,57,2/24/2020
762A3E,conference-organizer,100,57,2/24/2020
762A3E,conference-organizer,100,57,2/24/2020
762A3E,conference-organizer,100,57,2/24/2020
7712CB,executive-appointment,100,54,2/24/2020
7712CB,earnings,100,50,2/24/2020
7712CB,executive-appointment,100,54,2/24/2020
7712CB,dividend,100,50,2/24/2020
7712CB,dividend,100,50,2/24/2020
791EC1,earnings,100,50,2/24/2020
7B8CB5,executive-appointment,100,54,2/24/2020
7B8CB5,earnings,100,50,2/24/2020
7C4F43,conference-participant,100,50,2/24/2020
7CD98F,executive-resignation,100,44,2/24/2020
7F3A5F,business-contract,100,69,2/24/2020
7F9E16,conference-call,100,50,2/24/2020
7FD8B9,conference-call,100,50,2/24/2020
8303CD,buybacks,100,74,2/24/2020
83066C,earnings,100,50,2/24/2020
8377DB,dividend-up,100,81,2/24/2020
83A065,earnings,100,50,2/24/2020
845533,executive-appointment,100,54,2/24/2020
84A6B9,executive-appointment,100,54,2/24/2020
85DE00,conference-participant,100,50,2/24/2020
8665BA,conference-participant,100,50,2/24/2020
8B9B3B,earnings,100,50,2/24/2020
8C6C1B,facility-open,100,65,2/24/2020
8C84DF,earnings-revision,100,29,2/24/2020
8DCF18,executive-appointment,100,54,2/24/2020
8DCF18,earnings,100,50,2/24/2020
8FCA78,dividend,100,50,2/24/2020
9196A2,conference-organizer,100,57,2/24/2020
9196A2,conference-organizer,100,57,2/24/2020
9196A2,conference-organizer,100,57,2/24/2020
9196A2,conference-organizer,100,57,2/24/2020
92005C,conference-participant,100,50,2/24/2020
92B625,conference-participant,100,50,2/24/2020
931AE7,earnings,100,50,2/24/2020
9.39E+69,conference-participant,100,50,2/24/2020
967D92,earnings,100,50,2/24/2020
96A2D3,conference-participant,100,50,2/24/2020
96A6CD,executive-appointment,100,54,2/24/2020
9810C0,conference-participant,100,50,2/24/2020
98CEBB,earnings,100,50,2/24/2020
9C5174,conference-participant,100,50,2/24/2020
9E575E,earnings,100,50,2/24/2020
9E98F2,product-release,100,64,2/24/2020
9F6B1A,business-contract,100,69,2/24/2020
A01983,conference-call,100,50,2/24/2020
A398F8,conference-participant,100,50,2/24/2020
A47F2E,earnings,100,50,2/24/2020
A52B6B,earnings,100,50,2/24/2020
A5DD24,conference-participant,100,50,2/24/2020
A790A5,conference-participant,100,50,2/24/2020
A8CBDA,business-contract,100,69,2/24/2020
A94A7B,conference-participant,100,50,2/24/2020
A9ED24,earnings,100,50,2/24/2020
AA1EAA,public-offering,100,43,2/24/2020
AA3AB8,executive-appointment,100,54,2/24/2020
AFD1CA,facility-open,100,65,2/24/2020
B1DF3C,partnership,100,61,2/24/2020
B2206F,conference-participant,100,50,2/24/2020
B3CB74,conference-organizer,100,57,2/24/2020
B3CB74,conference-organizer,100,57,2/24/2020
B3CB74,conference-organizer,100,57,2/24/2020
B3CB74,conference-organizer,100,57,2/24/2020
B3CB74,conference-organizer,100,57,2/24/2020
B3CB74,conference-organizer,100,57,2/24/2020
B3CB74,conference-organizer,100,57,2/24/2020
B3CB74,conference-organizer,100,57,2/24/2020
B3CB74,conference-organizer,100,57,2/24/2020
B3CB74,conference-organizer,100,57,2/24/2020
B3CB74,conference-organizer,100,57,2/24/2020
B3CB74,conference-organizer,100,57,2/24/2020
B508E5,conference-participant,100,50,2/24/2020
B53C12,earnings,100,50,2/24/2020
B840EF,conference-participant,100,50,2/24/2020
B934BF,earnings,100,50,2/24/2020
BB127B,partnership,100,61,2/24/2020
BCC13E,conference-participant,100,50,2/24/2020
BCE9DA,dividend,100,50,2/24/2020
BCE9DA,dividend,100,50,2/24/2020
BDD12C,conference-participant,100,50,2/24/2020
BDEC1E,conference-call,100,50,2/24/2020
BDF85E,executive-appointment,100,54,2/24/2020
BFE02C,executive-appointment,100,54,2/24/2020
C11C46,earnings,100,50,2/24/2020
C29715,executive-appointment,100,54,2/24/2020
C45C1F,conference-participant,100,50,2/24/2020
C4F9C6,conference-participant,100,50,2/24/2020
C4FBDC,earnings-up,100,68,2/24/2020
C4FBDC,earnings,100,50,2/24/2020
C4FBDC,earnings,100,50,2/24/2020
C4FBDC,earnings,100,50,2/24/2020
C4FBDC,earnings,100,50,2/24/2020
C6C702,conference-participant,100,50,2/24/2020
C83B88,partnership,100,61,2/24/2020
C99CC8,product-release,100,64,2/24/2020
CA1620,conference-participant,100,50,2/24/2020
CBBFBF,legal-issues-defendant,100,22,2/24/2020
CBBFBF,legal-issues-defendant,100,22,2/24/2020
CDAF5B,conference-participant,100,50,2/24/2020
CE4E6D,executive-resignation,100,44,2/24/2020
CFF97C,product-release,100,64,2/24/2020
D1588D,conference-participant,100,50,2/24/2020
D17C1B,partnership,100,61,2/24/2020
D48275,conference-participant,100,50,2/24/2020
D57D99,earnings,100,50,2/24/2020
D598E7,government-contract,100,69,2/24/2020
D8442A,legal-issues-dismissed-defendant,100,79,2/24/2020
D9E036,earnings-up,100,68,2/24/2020
D9E036,earnings,100,50,2/24/2020
D9E036,earnings,100,50,2/24/2020
DA9443,conference-participant,100,50,2/24/2020
DB2E4E,earnings,100,50,2/24/2020
DB396B,legal-issues-defendant,100,22,2/24/2020
DB9F70,conference-participant,100,50,2/24/2020
DD0F15,legal-issues-defendant,100,22,2/24/2020
DD0F15,legal-issues-defendant,100,22,2/24/2020
DD7A96,conference-participant,100,50,2/24/2020
DF01B1,fraud-defendant,100,20,2/24/2020
DF01B1,legal-issues-defendant,100,22,2/24/2020
E0E4B7,earnings,100,50,2/24/2020
E0E4B7,conference-participant,100,50,2/24/2020
E2CB7B,executive-appointment,100,54,2/24/2020
E30A8F,product-release,100,64,2/24/2020
E41190,earnings,100,50,2/24/2020
E4CE73,earnings,100,50,2/24/2020
E5C910,conference-participant,100,50,2/24/2020
E610CD,conference-participant,100,50,2/24/2020
E67C2C,earnings,100,50,2/24/2020
E68733,executive-appointment,100,54,2/24/2020
E68733,executive-appointment,100,54,2/24/2020
E829E8,earnings,100,50,2/24/2020
E84500,earnings,100,50,2/24/2020
E8E899,award,100,58,2/24/2020
E93A40,earnings,100,50,2/24/2020
E93A40,legal-issues-defendant,100,22,2/24/2020
EAA0A7,conference-participant,100,50,2/24/2020
EB43F4,earnings,100,50,2/24/2020
ED2A5E,conference-participant,100,50,2/24/2020
ED7F13,conference-participant,100,50,2/24/2020
EEBCEF,board-meeting,100,51,2/24/2020
F02170,conference-participant,100,50,2/24/2020
F11638,acquisition-acquirer,100,49,2/24/2020
F11638,acquisition-acquirer,100,49,2/24/2020
F2BC3D,conference-participant,100,50,2/24/2020
F3EDB4,business-contract,100,69,2/24/2020
F44EA2,earnings,100,50,2/24/2020
F48947,earnings,100,50,2/24/2020
F4E882,legal-issues-defendant,100,22,2/24/2020
F4E882,legal-issues-defendant,100,22,2/24/2020
F88A04,partnership,100,61,2/24/2020
FA36A4,earnings,100,50,2/24/2020
FA36A4,executive-appointment,100,54,2/24/2020
FACCF6,earnings,100,50,2/24/2020
FD2565,earnings,100,50,2/24/2020
FD554E,conference-call,100,50,2/24/2020
FF6644,product-release,100,64,2/24/2020
FFAB4A,earnings,100,50,2/24/2020
00326E,award,100,58,2/25/2020
00D6B5,earnings,100,50,2/25/2020
00E601,executive-appointment,100,54,2/25/2020
018C11,conference-participant,100,50,2/25/2020
01D03F,regulatory-product-approval-granted,100,81,2/25/2020
01D03F,regulatory-product-approval-granted,100,81,2/25/2020
01D03F,partnership,100,61,2/25/2020
02FC1A,conference-participant,100,50,2/25/2020
03596A,executive-appointment,100,54,2/25/2020
036C6F,conference-call,100,50,2/25/2020
053EFF,earnings,100,50,2/25/2020
0560D8,earnings,100,50,2/25/2020
06C826,earnings,100,50,2/25/2020
075CF7,executive-appointment,100,54,2/25/2020
08A40F,partnership,100,61,2/25/2020
08A40F,partnership,100,61,2/25/2020
09062E,earnings,100,50,2/25/2020
09062E,earnings,100,50,2/25/2020
0968A5,earnings,100,50,2/25/2020
0986B5,dividend,100,50,2/25/2020
98977,earnings,100,50,2/25/2020
0BC29E,buybacks,100,74,2/25/2020
0BD4E8,award,100,58,2/25/2020
0BF198,earnings,100,50,2/25/2020
0C136E,dividend,100,50,2/25/2020
0C6861,earnings,100,50,2/25/2020
0CC62B,earnings,100,50,2/25/2020
0CC62B,earnings,100,50,2/25/2020
0CC62B,earnings,100,50,2/25/2020
0CC62B,earnings,100,50,2/25/2020
0CC62B,earnings,100,50,2/25/2020
0CC62B,earnings,100,50,2/25/2020
0D03C8,conference-participant,100,50,2/25/2020
0DBB81,conference-participant,100,50,2/25/2020
0F0440,award,100,58,2/25/2020
0FABBD,earnings,100,50,2/25/2020
1065BC,investment-investor,100,55,2/25/2020
1080C0,earnings,100,50,2/25/2020
11B8A4,acquisition-acquirer,100,49,2/25/2020
1220D2,partnership,100,61,2/25/2020
1348C9,earnings,100,50,2/25/2020
14BA33,earnings,100,50,2/25/2020
152E1D,operating-earnings,100,50,2/25/2020
152E1D,operating-earnings,100,50,2/25/2020
152E1D,operating-earnings,100,50,2/25/2020
152E1D,operating-earnings,100,50,2/25/2020
152E1D,operating-earnings,100,50,2/25/2020
152E1D,operating-earnings,100,50,2/25/2020
152E1D,operating-earnings,100,50,2/25/2020
16F4D8,conference-participant,100,50,2/25/2020
17EDA5,executive-appointment,100,54,2/25/2020
1834C0,earnings,100,50,2/25/2020
1866B2,buybacks,100,74,2/25/2020
190B91,campaign-ad-release,100,59,2/25/2020
19BF16,business-contract,100,69,2/25/2020
19BF16,legal-issues-defendant,100,22,2/25/2020
1B5FEA,partnership,100,61,2/25/2020
1B637E,dividend,100,50,2/25/2020
1E1125,conference-organizer,100,57,2/25/2020
1FA886,partnership,100,61,2/25/2020
202E5A,conference-participant,100,50,2/25/2020
223552,conference-participant,100,50,2/25/2020
223552,partnership,100,61,2/25/2020
223552,partnership,100,61,2/25/2020
228D42,partnership,100,61,2/25/2020
228D42,partnership,100,61,2/25/2020
228D42,partnership,100,61,2/25/2020
228D42,partnership,100,61,2/25/2020
24C48B,conference-participant,100,50,2/25/2020
24CB56,conference-organizer,100,57,2/25/2020
25A6CC,legal-issues-defendant,100,22,2/25/2020
26008A,earnings-up,100,68,2/25/2020
26008A,earnings-up,100,68,2/25/2020
26008A,earnings-up,100,68,2/25/2020
26DC29,conference-participant,100,50,2/25/2020
270B78,dividend,100,50,2/25/2020
295F9F,business-contract,100,69,2/25/2020
2AE625,executive-appointment,100,54,2/25/2020
2B0AF4,earnings,100,50,2/25/2020
2B0AF4,earnings,100,50,2/25/2020
2B0AF4,legal-issues-defendant,100,22,2/25/2020
2B0AF4,legal-issues-defendant,100,22,2/25/2020
2B0AF4,legal-issues-defendant,100,22,2/25/2020
2B0AF4,legal-issues-defendant,100,22,2/25/2020
2B0AF4,stock-loss,100,40,2/25/2020
2B0AF4,legal-issues-defendant,100,22,2/25/2020
2B49F4,government-contract,100,69,2/25/2020
2B7A40,award,100,58,2/25/2020
2BC05E,legal-issues-defendant,100,22,2/25/2020
2CC71C,conference-call,100,50,2/25/2020
2CC71C,conference-participant,100,50,2/25/2020
2E6514,executive-appointment,100,54,2/25/2020
2E89AE,earnings,100,50,2/25/2020
2EB04E,partnership,100,61,2/25/2020
2F6782,earnings,100,50,2/25/2020
32C8CD,earnings,100,50,2/25/2020
32CB22,conference-participant,100,50,2/25/2020
33E9D5,executive-appointment,100,54,2/25/2020
346BF2,earnings,100,50,2/25/2020
35557B,earnings,100,50,2/25/2020
367434,conference-participant,100,50,2/25/2020
367E1C,conference-participant,100,50,2/25/2020
36A1CB,earnings,100,50,2/25/2020
3798B9,note-sale,100,52,2/25/2020
37B618,unit-acquisition-acquirer,100,49,2/25/2020
396D7C,conference-participant,100,50,2/25/2020
3A3948,earnings,100,50,2/25/2020
3B50FE,earnings,100,50,2/25/2020
3C3B6B,conference-participant,100,50,2/25/2020
414FFF,partnership,100,61,2/25/2020
416C55,award,100,58,2/25/2020
42AABD,conference-participant,100,50,2/25/2020
43E8F5,earnings,100,50,2/25/2020
45444E,earnings,100,50,2/25/2020
46A16E,earnings,100,50,2/25/2020
47752F,award,100,58,2/25/2020
49BBBC,partnership,100,61,2/25/2020
4A6F00,partnership,100,61,2/25/2020
4BEB48,earnings,100,50,2/25/2020
4BF3D6,conference-participant,100,50,2/25/2020
4DD203,executive-death,100,31,2/25/2020
4ECD1A,earnings,100,50,2/25/2020
4F783B,earnings,100,50,2/25/2020
4F783B,earnings,100,50,2/25/2020
4F783B,earnings,100,50,2/25/2020
4F783B,earnings,100,50,2/25/2020
4F783B,earnings,100,50,2/25/2020
504FE2,award,100,58,2/25/2020
513A86,earnings,100,50,2/25/2020
519FE0,dividend,100,50,2/25/2020
51D876,award,100,58,2/25/2020
550D01,earnings,100,50,2/25/2020
55C289,dividend,100,50,2/25/2020
564F3E,dividend,100,50,2/25/2020
56EA2B,conference-call,100,50,2/25/2020
56FB7C,earnings,100,50,2/25/2020
57CAAB,conference-participant,100,50,2/25/2020
58CA9A,conference-organizer,100,57,2/25/2020
594402,conference-participant,100,50,2/25/2020
596116,earnings,100,50,2/25/2020
59B229,buybacks,100,74,2/25/2020
59F0B0,earnings,100,50,2/25/2020
59F0B0,earnings,100,50,2/25/2020
59F0B0,earnings,100,50,2/25/2020
59F0B0,earnings,100,50,2/25/2020
5CCDAD,earnings,100,50,2/25/2020
5CCDAD,executive-appointment,100,54,2/25/2020
605F40,facility-open,100,65,2/25/2020
6166D1,award,100,58,2/25/2020
619882,conference-organizer,100,57,2/25/2020
61A586,earnings,100,50,2/25/2020
61A586,public-offering,100,43,2/25/2020
61BCA7,stake-acquirer,100,48,2/25/2020
62CDDE,earnings,100,50,2/25/2020
64E615,award,100,58,2/25/2020
651C85,trading-listing,100,61,2/25/2020
66749D,award,100,58,2/25/2020
67B052,conference-participant,100,50,2/25/2020
68E3E0,earnings,100,50,2/25/2020
68E3E0,earnings,100,50,2/25/2020
68E3E0,earnings,100,50,2/25/2020
68E3E0,earnings,100,50,2/25/2020
68E3E0,earnings,100,50,2/25/2020
68E3E0,earnings,100,50,2/25/2020
6925EB,conference-participant,100,50,2/25/2020
6C6D73,public-offering,100,43,2/25/2020
6CD55A,dividend,100,50,2/25/2020
6E7060,business-contract,100,69,2/25/2020
6F0096,dividend-up,100,70,2/25/2020
71B0CF,earnings,100,50,2/25/2020
722DE3,acquisition-acquirer,100,49,2/25/2020
72CB93,conference-participant,100,50,2/25/2020
7410C3,earnings,100,50,2/25/2020
748EB6,earnings,100,50,2/25/2020
752A70,conference-participant,100,50,2/25/2020
762A3E,conference-organizer,100,57,2/25/2020
762A3E,conference-organizer,100,57,2/25/2020
762A3E,conference-organizer,100,57,2/25/2020
762A3E,conference-organizer,100,57,2/25/2020
762A3E,conference-organizer,100,57,2/25/2020
762A3E,conference-organizer,100,57,2/25/2020
762A3E,conference-organizer,100,57,2/25/2020
762A3E,conference-organizer,100,57,2/25/2020
762A3E,conference-organizer,100,57,2/25/2020
762A3E,conference-organizer,100,57,2/25/2020
762A3E,conference-organizer,100,57,2/25/2020
762A3E,conference-organizer,100,57,2/25/2020
762A3E,conference-organizer,100,57,2/25/2020
762A3E,conference-organizer,100,57,2/25/2020
762A3E,conference-organizer,100,57,2/25/2020
762A3E,conference-organizer,100,57,2/25/2020
762A3E,conference-organizer,100,57,2/25/2020
762A3E,conference-organizer,100,57,2/25/2020
762A3E,conference-organizer,100,57,2/25/2020
762A3E,conference-organizer,100,57,2/25/2020
762A3E,conference-organizer,100,57,2/25/2020
766047,award,100,58,2/25/2020
769F40,earnings,100,50,2/25/2020
76D79A,earnings,100,50,2/25/2020
790C34,award,100,58,2/25/2020
7A10FF,unit-acquisition-acquirer,100,49,2/25/2020
7F3665,earnings,100,50,2/25/2020
7FEEE1,conference-participant,100,50,2/25/2020
817ED9,campaign-ad-release,100,59,2/25/2020
82F088,earnings,100,50,2/25/2020
83B1C8,earnings,100,50,2/25/2020
85CDC9,earnings,100,50,2/25/2020
8665BA,dividend-up,100,81,2/25/2020
86F123,conference-call,100,50,2/25/2020
87B81A,conference-participant,100,50,2/25/2020
893904,earnings,100,50,2/25/2020
8C6C1B,facility-open,100,65,2/25/2020
8CF6DD,executive-appointment,100,54,2/25/2020
8DA42F,earnings,100,50,2/25/2020
8E0E32,award,100,58,2/25/2020
8FF2EF,conference-call,100,50,2/25/2020
903AB4,dividend,100,50,2/25/2020
90D6A5,dividend,100,50,2/25/2020
9196A2,conference-organizer,100,57,2/25/2020
9196A2,conference-organizer,100,57,2/25/2020
9196A2,conference-organizer,100,57,2/25/2020
9196A2,conference-organizer,100,57,2/25/2020
9196A2,conference-organizer,100,57,2/25/2020
9196A2,conference-organizer,100,57,2/25/2020
92B625,earnings,100,50,2/25/2020
92D757,insider-buy,100,61,2/25/2020
9.31E+77,earnings,100,50,2/25/2020
958938,conference-call,100,50,2/25/2020
95C392,executive-appointment,100,54,2/25/2020
966ACE,patient-enrollment-complete,100,64,2/25/2020
9673BD,earnings,100,50,2/25/2020
9673BD,earnings,100,50,2/25/2020
9673BD,earnings,100,50,2/25/2020
9673BD,earnings,100,50,2/25/2020
96A6CD,earnings,100,50,2/25/2020
97AF94,earnings,100,50,2/25/2020
97B027,conference-call,100,50,2/25/2020
994468,dividend,100,50,2/25/2020
9978F1,earnings,100,50,2/25/2020
99ACAD,dividend,100,50,2/25/2020
99ACAD,earnings,100,50,2/25/2020
9A2760,earnings,100,50,2/25/2020
9A602D,award,100,58,2/25/2020
9AF3DC,award,100,58,2/25/2020
9BBFA5,conference-call,100,50,2/25/2020
9C5174,revenues,100,50,2/25/2020
9C5174,revenues,100,50,2/25/2020
9CA432,earnings,100,50,2/25/2020
9D307D,product-release,100,64,2/25/2020
9D5FA4,conference-participant,100,50,2/25/2020
9E575E,conference-participant,100,50,2/25/2020
A072C4,conference-participant,100,50,2/25/2020
A11CF4,conference-participant,100,50,2/25/2020
A15C71,earnings,100,50,2/25/2020
A1BB98,earnings,100,50,2/25/2020
A1BB98,earnings,100,50,2/25/2020
A1BB98,earnings,100,50,2/25/2020
A1BB98,earnings,100,50,2/25/2020
A1BB98,earnings,100,50,2/25/2020
A1BB98,earnings,100,50,2/25/2020
A21649,public-offering,100,43,2/25/2020
A26EF7,conference-participant,100,50,2/25/2020
A29A46,earnings,100,50,2/25/2020
A29DBD,earnings,100,50,2/25/2020
A2C979,conference-participant,100,50,2/25/2020
A350C1,conference-participant,100,50,2/25/2020
A3F598,award,100,58,2/25/2020
A5195E,executive-appointment,100,54,2/25/2020
A5DD24,earnings,100,50,2/25/2020
A5E715,dividend,100,50,2/25/2020
A60354,dividend,100,50,2/25/2020
A70BF5,dividend,100,50,2/25/2020
A7102F,award,100,58,2/25/2020
A79D88,regulatory-product-approval-granted,100,81,2/25/2020
A7A0C8,conference-call,100,50,2/25/2020
A80FE0,earnings,100,50,2/25/2020
A80FE0,conference-participant,100,50,2/25/2020
A80FE0,conference-participant,100,50,2/25/2020
A80FE0,conference-participant,100,50,2/25/2020
A8E2FE,conference-participant,100,50,2/25/2020
AA98ED,award,100,58,2/25/2020
AC7AAE,earnings,100,50,2/25/2020
ACDF88,earnings,100,50,2/25/2020
ACDF88,earnings,100,50,2/25/2020
ADFB3A,conference-participant,100,50,2/25/2020
AE7D16,earnings,100,50,2/25/2020
AECCA9,dividend,100,50,2/25/2020
AFEC35,earnings,100,50,2/25/2020
B2D492,earnings,100,50,2/25/2020
B37FB4,partnership,100,61,2/25/2020
B3CB74,conference-organizer,100,57,2/25/2020
B3CB74,conference-organizer,100,57,2/25/2020
B3CB74,conference-organizer,100,57,2/25/2020
B3CB74,conference-organizer,100,57,2/25/2020
B3CB74,conference-organizer,100,57,2/25/2020
B3CB74,conference-organizer,100,57,2/25/2020
B48FC9,conference-participant,100,50,2/25/2020
B5BA39,earnings,100,50,2/25/2020
B5BA39,award,100,58,2/25/2020
B5DE80,conference-participant,100,50,2/25/2020
B6082A,dividend,100,50,2/25/2020
B7BDA3,earnings,100,50,2/25/2020
B7FA9B,earnings-up,100,68,2/25/2020
B83D67,conference-participant,100,50,2/25/2020
B9764A,award,100,58,2/25/2020
BB127B,executive-resignation,100,44,2/25/2020
BB127B,earnings,100,50,2/25/2020
BBC05B,earnings,100,50,2/25/2020
BCC13E,earnings,100,50,2/25/2020
BD8517,award,100,58,2/25/2020
BF5959,partnership,100,61,2/25/2020
BF79F5,dividend,100,50,2/25/2020
C01737,conference-participant,100,50,2/25/2020
C0200F,award,100,58,2/25/2020
C037A8,conference-participant,100,50,2/25/2020
C07E05,earnings,100,50,2/25/2020
C2F597,executive-appointment,100,54,2/25/2020
C3CF29,earnings,100,50,2/25/2020
C3CF29,earnings,100,50,2/25/2020
C3CF29,earnings,100,50,2/25/2020
C3CF29,earnings,100,50,2/25/2020
C45CE7,earnings,100,50,2/25/2020
C54140,business-contract,100,69,2/25/2020
C5C137,earnings,100,50,2/25/2020
C5D2AE,product-release,100,64,2/25/2020
C81E00,executive-appointment,100,54,2/25/2020
C81E00,executive-appointment,100,54,2/25/2020
C81E00,conference-participant,100,50,2/25/2020
C81E00,conference-participant,100,50,2/25/2020
C8923A,conference-participant,100,50,2/25/2020
C8FAC7,business-contract,100,69,2/25/2020
C941DC,earnings,100,50,2/25/2020
C9732E,earnings,100,50,2/25/2020
C99CC8,earnings,100,50,2/25/2020
C99CC8,earnings,100,50,2/25/2020
C99CC8,earnings,100,50,2/25/2020
C99CC8,earnings,100,50,2/25/2020
C99CC8,earnings,100,50,2/25/2020
CAB222,conference-participant,100,50,2/25/2020
CBBFBF,legal-issues-defendant,100,22,2/25/2020
CC0C78,revenues,100,50,2/25/2020
CD4DA8,conference-organizer,100,57,2/25/2020
CE2791,earnings,100,50,2/25/2020
CE96E7,award,100,58,2/25/2020
CFF15D,partnership,100,61,2/25/2020
CFF15D,partnership,100,61,2/25/2020
CFF15D,partnership,100,61,2/25/2020
CFF97C,analyst-ratings-change-negative-rater,20,50,2/25/2020
D15833,dividend,100,50,2/25/2020
D20C8F,earnings,100,50,2/25/2020
D36B23,conference-participant,100,50,2/25/2020
D3FA2C,earnings,100,50,2/25/2020
D4070C,award,100,58,2/25/2020
D4070C,award,100,58,2/25/2020
D518D8,conference-participant,100,50,2/25/2020
D518D8,dividend,100,50,2/25/2020
D58A11,conference-participant,100,50,2/25/2020
D598E7,partnership,100,61,2/25/2020
D64C6D,conference-call,100,50,2/25/2020
D64EDF,dividend-up,100,58,2/25/2020
D75910,earnings,100,50,2/25/2020
D75910,earnings,100,50,2/25/2020
D75910,earnings,100,50,2/25/2020
D75910,earnings,100,50,2/25/2020
D77F7E,earnings,100,50,2/25/2020
D77F7E,earnings,100,50,2/25/2020
D77F7E,earnings,100,50,2/25/2020
D77F7E,earnings,100,50,2/25/2020
D77F7E,earnings,100,50,2/25/2020
D77F7E,earnings,100,50,2/25/2020
D78CCD,award,100,58,2/25/2020
D854F3,conference-participant,100,50,2/25/2020
D8ECA1,executive-appointment,100,54,2/25/2020
D96202,award,100,58,2/25/2020
D9C07E,earnings,100,50,2/25/2020
D9C07E,earnings,100,50,2/25/2020
D9C07E,earnings,100,50,2/25/2020
D9C07E,earnings,100,50,2/25/2020
D9C07E,earnings,100,50,2/25/2020
D9C07E,earnings,100,50,2/25/2020
D9C07E,earnings,100,50,2/25/2020
D9C07E,earnings,100,50,2/25/2020
D9C07E,earnings,100,50,2/25/2020
D9C07E,earnings,100,50,2/25/2020
D9C07E,earnings,100,50,2/25/2020
D9C07E,earnings,100,50,2/25/2020
DA0CB8,conference-participant,100,50,2/25/2020
DB396B,legal-issues-defendant,100,22,2/25/2020
DB9F70,executive-appointment,100,54,2/25/2020
DC1405,earnings,100,50,2/25/2020
DD0F15,legal-issues-defendant,100,22,2/25/2020
DDEA6A,earnings,100,50,2/25/2020
DF01B1,legal-issues-defendant,100,22,2/25/2020
DF18E6,executive-appointment,100,54,2/25/2020
DF18E6,legal-issues-defendant,100,22,2/25/2020
DF6FDD,award,100,58,2/25/2020
E35610,conference-participant,100,50,2/25/2020
E3656D,conference-participant,100,50,2/25/2020
E3A829,conference-call,100,50,2/25/2020
E598FB,conference-participant,100,50,2/25/2020
E68C3D,partnership,100,61,2/25/2020
E68C3D,partnership,100,61,2/25/2020
E69BA5,earnings,100,50,2/25/2020
E8C557,conference-participant,100,50,2/25/2020
E93A40,legal-issues-defendant,100,22,2/25/2020
E959F3,award,100,58,2/25/2020
E96E0B,earnings,100,50,2/25/2020
ECE19E,conference-participant,100,50,2/25/2020
ED0402,earnings-up,100,74,2/25/2020
ED0402,earnings-up,100,74,2/25/2020
ED0402,earnings-up,100,74,2/25/2020
ED0402,earnings-up,100,74,2/25/2020
ED3CA8,conference-participant,100,50,2/25/2020
ED9C04,conference-participant,100,50,2/25/2020
EE04F0,partnership,100,61,2/25/2020
EE1E44,dividend,100,50,2/25/2020
EEA734,earnings,100,50,2/25/2020
EEBCEF,earnings,100,50,2/25/2020
EF1AD9,business-contract,100,69,2/25/2020
F11638,partnership,100,61,2/25/2020
F1CD47,dividend,100,50,2/25/2020
F3016C,earnings,100,50,2/25/2020
F39E1E,legal-issues-defendant,100,22,2/25/2020
F3D2EB,dividend,100,50,2/25/2020
F3FCC3,debt-extension-recipient,100,73,2/25/2020
F4E882,legal-issues-defendant,100,22,2/25/2020
F6DE54,earnings,100,50,2/25/2020
F6E1B5,earnings,100,50,2/25/2020
F85CC0,award,100,58,2/25/2020
F85CC0,award,100,58,2/25/2020
F8C5D7,earnings,100,50,2/25/2020
F9AA02,conference-participant,100,50,2/25/2020
FB7724,earnings,100,50,2/25/2020
FCA54E,partnership,100,61,2/25/2020
FD4588,earnings,100,50,2/25/2020
FD6926,conference-participant,100,50,2/25/2020
00698D,conference-participant,100,50,2/26/2020
9397,conference-participant,100,50,2/26/2020
13528,earnings,100,50,2/26/2020
20751,conference-participant,100,50,2/26/2020
06A456,conference-call,100,50,2/26/2020
099A92,conference-participant,100,50,2/26/2020
0A59F8,partnership,100,61,2/26/2020
0B13E8,earnings,100,50,2/26/2020
0BD199,patient-enrollment-complete,100,64,2/26/2020
0BF198,conference-participant,100,50,2/26/2020
0C6293,conference-call,100,50,2/26/2020
0C6861,conference-participant,100,50,2/26/2020
0CCCB7,dividend,100,50,2/26/2020
0CCCB7,earnings-up,100,68,2/26/2020
0DE3D5,operating-earnings,100,50,2/26/2020
0F2BC9,earnings,100,50,2/26/2020
0F65C9,conference-participant,100,50,2/26/2020
108A2B,conference-participant,100,50,2/26/2020
10C19B,conference-participant,100,50,2/26/2020
13A782,earnings,100,50,2/26/2020
147098,dividend,100,50,2/26/2020
147098,earnings,100,50,2/26/2020
159AE4,conference-call,100,50,2/26/2020
16B183,earnings,100,50,2/26/2020
1866B2,earnings,100,50,2/26/2020
1880C5,conference-participant,100,50,2/26/2020
19BF16,legal-issues-defendant,100,22,2/26/2020
19BF16,legal-issues-defendant,100,22,2/26/2020
19BF16,legal-issues-defendant,100,22,2/26/2020
19BF16,legal-issues-defendant,100,22,2/26/2020
19BF16,legal-issues-defendant,100,22,2/26/2020
19CAC7,executive-appointment,100,54,2/26/2020
1AB808,earnings,100,50,2/26/2020
1AC649,fast-track-designation,100,81,2/26/2020
1B637E,earnings,100,50,2/26/2020
1B6F77,conference-participant,100,50,2/26/2020
1C599A,earnings,100,50,2/26/2020
1CD09C,regulatory-product-approval-granted,100,81,2/26/2020
1CD4B5,conference-participant,100,50,2/26/2020
1D5C51,earnings,100,50,2/26/2020
1D943E,conference-participant,100,50,2/26/2020
1E1125,conference-organizer,100,57,2/26/2020
1E1125,conference-organizer,100,57,2/26/2020
1F08A6,conference-participant,100,50,2/26/2020
20BEEA,dividend-up,100,81,2/26/2020
2158DF,earnings,100,50,2/26/2020
221783,executive-appointment,100,54,2/26/2020
225CA2,executive-appointment,100,54,2/26/2020
227D48,earnings,100,50,2/26/2020
228D42,earnings-guidance,100,50,2/26/2020
24A89A,conference-participant,100,50,2/26/2020
24FA23,earnings,100,50,2/26/2020
251988,legal-issues-defendant,100,22,2/26/2020
25DD05,conference-participant,100,50,2/26/2020
26D8ED,executive-resignation,100,44,2/26/2020
26F99F,conference-participant,100,50,2/26/2020
270B78,earnings,100,50,2/26/2020
275300,earnings,100,50,2/26/2020
275300,earnings,100,50,2/26/2020
275300,earnings,100,50,2/26/2020
275300,earnings,100,50,2/26/2020
275300,earnings,100,50,2/26/2020
275300,earnings,100,50,2/26/2020
275300,earnings,100,50,2/26/2020
275300,earnings,100,50,2/26/2020
275300,earnings,100,50,2/26/2020
275300,earnings,100,50,2/26/2020
275300,earnings,100,50,2/26/2020
275300,earnings,100,50,2/26/2020
275300,earnings,100,50,2/26/2020
275300,earnings,100,50,2/26/2020
275300,earnings,100,50,2/26/2020
275300,earnings,100,50,2/26/2020
275300,earnings,100,50,2/26/2020
28F905,earnings,100,50,2/26/2020
297DA8,earnings,100,50,2/26/2020
2AA6A8,earnings,100,50,2/26/2020
2B0AF4,fraud,100,44,2/26/2020
2B0AF4,legal-issues-defendant,100,22,2/26/2020
2B0AF4,legal-issues-defendant,100,22,2/26/2020
2B0AF4,legal-issues-defendant,100,22,2/26/2020
2B0AF4,legal-issues-defendant,100,22,2/26/2020
2BAE5F,unit-acquisition-acquirer,100,49,2/26/2020
2BC05E,legal-issues-defendant,100,22,2/26/2020
2BC05E,legal-issues-defendant,100,22,2/26/2020
2C19A4,earnings,100,50,2/26/2020
2C3348,earnings,100,50,2/26/2020
2CBB58,conference-participant,100,50,2/26/2020
2D981A,conference-call,100,50,2/26/2020
2D981A,clinical-trials,100,56,2/26/2020
2DA92D,dividend,100,50,2/26/2020
2F7A7E,earnings,100,50,2/26/2020
2F98A5,earnings,100,50,2/26/2020
306623,conference-participant,100,50,2/26/2020
3.14E+47,note-sale,100,52,2/26/2020
319BE2,earnings,100,50,2/26/2020
319BE2,dividend-up,100,81,2/26/2020
31DB20,earnings,100,50,2/26/2020
32F24A,earnings,100,50,2/26/2020
32F943,earnings,100,50,2/26/2020
337024,earnings,100,50,2/26/2020
337024,earnings,100,50,2/26/2020
337024,earnings,100,50,2/26/2020
3471C0,partnership,100,61,2/26/2020
34A959,revenues,100,50,2/26/2020
372037,dividend,100,50,2/26/2020
372037,earnings,100,50,2/26/2020
384CD3,earnings,100,50,2/26/2020
385DD4,earnings,100,50,2/26/2020
3DD5E2,earnings,100,50,2/26/2020
408380,earnings,100,50,2/26/2020
41C36B,earnings,100,50,2/26/2020
425BDC,earnings,100,50,2/26/2020
4290EF,product-release,100,64,2/26/2020
4290EF,earnings,100,50,2/26/2020
431B74,dividend,100,50,2/26/2020
431B74,dividend,100,50,2/26/2020
4455C4,conference-participant,100,50,2/26/2020
44740A,earnings,100,50,2/26/2020
44740A,earnings,100,50,2/26/2020
45BC35,conference-participant,100,50,2/26/2020
467F2C,conference-participant,100,50,2/26/2020
468DD4,earnings,100,50,2/26/2020
4885C8,facility-open,100,65,2/26/2020
4.91E+58,conference-participant,100,50,2/26/2020
49A344,award,100,58,2/26/2020
4B6EF9,dividend,100,50,2/26/2020
4B6EF9,earnings,100,50,2/26/2020
4BEB48,conference-participant,100,50,2/26/2020
4C2F17,conference-participant,100,50,2/26/2020
4D72C8,earnings,100,50,2/26/2020
4D72C8,earnings,100,50,2/26/2020
4D8313,executive-appointment,100,54,2/26/2020
4E6F5A,conference-participant,100,50,2/26/2020
4F9926,partnership,100,61,2/26/2020
53EF9E,dividend,100,50,2/26/2020
5403F8,earnings,100,50,2/26/2020
5.47E+28,conference-participant,100,50,2/26/2020
54B889,earnings,100,50,2/26/2020
55438C,executive-appointment,100,54,2/26/2020
55C9B5,product-release,100,64,2/26/2020
583223,earnings,100,50,2/26/2020
589846,conference-call,100,50,2/26/2020
58CA9A,conference-organizer,100,57,2/26/2020
58CA9A,conference-organizer,100,57,2/26/2020
58EA22,conference-participant,100,50,2/26/2020
594402,earnings,100,50,2/26/2020
59872F,earnings,100,50,2/26/2020
59B229,executive-appointment,100,54,2/26/2020
59DB8C,conference-participant,100,50,2/26/2020
59DB8C,partnership,100,61,2/26/2020
5A0FF1,earnings,100,50,2/26/2020
5A9A82,executive-resignation,100,44,2/26/2020
5AAE17,conference-call,100,50,2/26/2020
5B3FA2,earnings,100,50,2/26/2020
5D02B7,conference-call,100,50,2/26/2020
5D16CF,dividend,100,50,2/26/2020
5D41E4,conference-call,100,50,2/26/2020
5E9934,conference-call,100,50,2/26/2020
609208,partnership,100,61,2/26/2020
60DD84,conference-participant,100,50,2/26/2020
633054,partnership,100,61,2/26/2020
64FF65,earnings,100,50,2/26/2020
66CB62,earnings,100,50,2/26/2020
694749,earnings,100,50,2/26/2020
6D2BF6,earnings,100,50,2/26/2020
6D2BF6,conference-participant,100,50,2/26/2020
6D3F35,conference-participant,100,50,2/26/2020
6F30F9,earnings,100,50,2/26/2020
6F6559,award,100,58,2/26/2020
704B78,earnings,100,50,2/26/2020
713810,conference-participant,100,50,2/26/2020
71553E,earnings,100,50,2/26/2020
71E2EF,earnings,100,50,2/26/2020
723548,earnings,100,50,2/26/2020
7448A3,earnings,100,50,2/26/2020
747219,conference-participant,100,50,2/26/2020
756BB4,partnership,100,61,2/26/2020
762A3E,conference-organizer,100,57,2/26/2020
762A3E,conference-organizer,100,57,2/26/2020
762A3E,conference-organizer,100,57,2/26/2020
762A3E,conference-organizer,100,57,2/26/2020
762A3E,conference-organizer,100,57,2/26/2020
762A3E,conference-organizer,100,57,2/26/2020
762A3E,conference-organizer,100,57,2/26/2020
762A3E,conference-organizer,100,57,2/26/2020
762A3E,conference-organizer,100,57,2/26/2020
762A3E,conference-organizer,100,57,2/26/2020
762A3E,conference-organizer,100,57,2/26/2020
762A3E,conference-organizer,100,57,2/26/2020
762A3E,conference-organizer,100,57,2/26/2020
762A3E,conference-organizer,100,57,2/26/2020
762A3E,conference-organizer,100,57,2/26/2020
762A3E,conference-organizer,100,57,2/26/2020
762A3E,conference-organizer,100,57,2/26/2020
762A3E,conference-organizer,100,57,2/26/2020
762A3E,conference-organizer,100,57,2/26/2020
762A3E,conference-organizer,100,57,2/26/2020
76BECC,earnings,100,50,2/26/2020
76E80F,revenues,100,50,2/26/2020
76E80F,revenues,100,50,2/26/2020
76E80F,revenues,100,50,2/26/2020
76E80F,revenues,100,50,2/26/2020
789A7D,earnings-guidance,100,50,2/26/2020
789A7D,earnings,100,50,2/26/2020
789A7D,earnings,100,50,2/26/2020
789A7D,earnings,100,50,2/26/2020
79340A,conference-participant,100,50,2/26/2020
7A3633,earnings,100,50,2/26/2020
7AD81E,executive-appointment,100,54,2/26/2020
7ADE57,conference-call,100,50,2/26/2020
7B0BA6,conference-participant,100,50,2/26/2020
7CD98F,dividend-up,100,81,2/26/2020
7E3F8F,antitrust-suit-defendant,100,21,2/26/2020
7E3F8F,antitrust-suit-defendant,100,21,2/26/2020
7FC386,earnings,100,50,2/26/2020
803FED,conference-call,100,50,2/26/2020
805CD8,conference-participant,100,50,2/26/2020
81222C,earnings,100,50,2/26/2020
82F088,conference-participant,100,50,2/26/2020
830BDB,earnings,100,50,2/26/2020
838ADD,unit-acquisition-acquirer,100,49,2/26/2020
838ADD,stake-acquirer,100,48,2/26/2020
83E0AC,earnings,100,50,2/26/2020
858942,earnings,100,50,2/26/2020
863350,executive-appointment,100,54,2/26/2020
86A1B9,executive-appointment,100,54,2/26/2020
86A1B9,dividend,100,50,2/26/2020
877C0C,earnings,100,50,2/26/2020
88193E,note-sale,100,52,2/26/2020
890FF4,executive-appointment,100,54,2/26/2020
896771,executive-appointment,100,54,2/26/2020
896771,earnings,100,50,2/26/2020
89E771,earnings,100,50,2/26/2020
89E771,dividend,100,50,2/26/2020
89F693,executive-appointment,100,54,2/26/2020
8A0368,earnings,100,50,2/26/2020
8A8E41,partnership,100,61,2/26/2020
8B1E11,earnings,100,50,2/26/2020
8C6C1B,facility-open,100,65,2/26/2020
8DAAB9,buybacks,100,74,2/26/2020
8DCF18,conference-participant,100,50,2/26/2020
8E10BF,conference-participant,100,50,2/26/2020
8EDACA,earnings,100,50,2/26/2020
8EEA28,conference-participant,100,50,2/26/2020
9087B9,earnings,100,50,2/26/2020
9196A2,investment-investor,100,55,2/26/2020
9196A2,investment-investor,100,55,2/26/2020
9196A2,conference-organizer,100,57,2/26/2020
9196A2,conference-organizer,100,57,2/26/2020
9196A2,conference-organizer,100,57,2/26/2020
9196A2,conference-organizer,100,57,2/26/2020
9196A2,conference-organizer,100,57,2/26/2020
9.31E+77,conference-participant,100,50,2/26/2020
934029,conference-participant,100,50,2/26/2020
93AD2E,reorganization-unit,100,53,2/26/2020
93AD2E,executive-appointment,100,54,2/26/2020
942165,earnings,100,50,2/26/2020
9507FF,earnings,100,50,2/26/2020
957A07,earnings,100,50,2/26/2020
95DC1F,partnership,100,61,2/26/2020
968103,earnings,100,50,2/26/2020
96A6CD,conference-participant,100,50,2/26/2020
971F7B,executive-resignation,100,44,2/26/2020
980C14,earnings,100,50,2/26/2020
9.86E+03,conference-participant,100,50,2/26/2020
9A602D,legal-issues-defendant,100,22,2/26/2020
9B730A,earnings,100,50,2/26/2020
9C5BA5,revenues,100,50,2/26/2020
9D65C1,conference-participant,100,50,2/26/2020
9EA947,dividend-up,100,81,2/26/2020
9FB4B7,earnings,100,50,2/26/2020
A1E3B3,antitrust-suit-plaintiff,100,44,2/26/2020
A1E3B3,antitrust-suit-plaintiff,100,44,2/26/2020
A1EAC8,executive-resignation,100,44,2/26/2020
A26C26,earnings,100,50,2/26/2020
A37D68,earnings,100,50,2/26/2020
A398F8,earnings,100,50,2/26/2020
A3F598,earnings,100,50,2/26/2020
A3F598,earnings,100,50,2/26/2020
A3F598,earnings,100,50,2/26/2020
A3F598,earnings,100,50,2/26/2020
A58224,conference-participant,100,50,2/26/2020
A631A3,partnership,100,61,2/26/2020
A631A3,partnership,100,61,2/26/2020
A666C8,partnership,100,61,2/26/2020
A666C8,partnership,100,61,2/26/2020
A6828A,conference-participant,100,50,2/26/2020
A6FE1C,unit-acquisition-acquirer,100,49,2/26/2020
A790A5,dividend,100,50,2/26/2020
A7A0C8,patient-enrollment-complete,100,64,2/26/2020
ACF0B4,earnings,100,50,2/26/2020
AD6141,earnings,100,50,2/26/2020
AD6141,earnings,100,50,2/26/2020
AD6141,earnings,100,50,2/26/2020
AD6141,earnings,100,50,2/26/2020
AD6141,earnings,100,50,2/26/2020
AD6141,dividend,100,50,2/26/2020
AD6141,buybacks,100,74,2/26/2020
AE3113,earnings,100,50,2/26/2020
AE4EEB,conference-participant,100,50,2/26/2020
AE79CD,earnings,100,50,2/26/2020
AE79CD,conference-participant,100,50,2/26/2020
AEBB80,earnings,100,50,2/26/2020
AECCA9,earnings,100,50,2/26/2020
AECCA9,earnings,100,50,2/26/2020
AECCA9,earnings,100,50,2/26/2020
AECCA9,earnings,100,50,2/26/2020
AECCA9,earnings,100,50,2/26/2020
B04426,conference-participant,100,50,2/26/2020
B09B1F,award,100,58,2/26/2020
B09B1F,earnings,100,50,2/26/2020
B09B1F,earnings,100,50,2/26/2020
B09B1F,earnings,100,50,2/26/2020
B09B1F,earnings,100,50,2/26/2020
B09B1F,earnings,100,50,2/26/2020
B106FA,earnings,100,50,2/26/2020
B290A2,conference-participant,100,50,2/26/2020
B3CB74,conference-organizer,100,57,2/26/2020
B3CB74,conference-organizer,100,57,2/26/2020
B3CB74,conference-organizer,100,57,2/26/2020
B3CB74,conference-organizer,100,57,2/26/2020
B3CB74,conference-organizer,100,57,2/26/2020
B3CB74,conference-organizer,100,57,2/26/2020
B3CB74,conference-organizer,100,57,2/26/2020
B3CB74,conference-organizer,100,57,2/26/2020
B3CB74,conference-organizer,100,57,2/26/2020
B3CB74,conference-organizer,100,57,2/26/2020
B3CB74,conference-organizer,100,57,2/26/2020
B3CB74,conference-organizer,100,57,2/26/2020
B3CB74,conference-organizer,100,57,2/26/2020
B3CB74,conference-organizer,100,57,2/26/2020
B560AF,earnings,100,50,2/26/2020
B560AF,earnings,100,50,2/26/2020
B560AF,earnings,100,50,2/26/2020
B560AF,earnings,100,50,2/26/2020
B560AF,earnings,100,50,2/26/2020
B642E8,dividend,100,50,2/26/2020
B66928,earnings,100,50,2/26/2020
B7202A,conference-call,100,50,2/26/2020
B76C82,capex,100,50,2/26/2020
B77F14,conference-call,100,50,2/26/2020
B803B1,earnings,100,50,2/26/2020
B803B1,conference-participant,100,50,2/26/2020
B9764A,conference-participant,100,50,2/26/2020
B9CD50,conference-participant,100,50,2/26/2020
BAD655,earnings,100,50,2/26/2020
BC948D,conference-participant,100,50,2/26/2020
BCC55F,partnership,100,61,2/26/2020
BD15E8,buybacks,100,74,2/26/2020
BDE867,dividend,100,50,2/26/2020
BFE02C,dividend,100,50,2/26/2020
C06EB6,clinical-trials-start,100,64,2/26/2020
C06EB6,clinical-trials-start,100,64,2/26/2020
C407A0,earnings,100,50,2/26/2020
C54140,earnings,100,50,2/26/2020
C54140,earnings,100,50,2/26/2020
C54140,earnings,100,50,2/26/2020
C54140,earnings,100,50,2/26/2020
C72B8F,conference-participant,100,50,2/26/2020
C9E04B,earnings,100,50,2/26/2020
CA14CC,earnings,100,50,2/26/2020
CB6A9C,earnings,100,50,2/26/2020
CB89EA,earnings,100,50,2/26/2020
CBBFBF,legal-issues-defendant,100,22,2/26/2020
CBDB4D,earnings,100,50,2/26/2020
CC0C78,conference-participant,100,50,2/26/2020
CD4DA8,conference-organizer,100,57,2/26/2020
CE1002,conference-participant,100,50,2/26/2020
D08D2C,conference-participant,100,50,2/26/2020
D0DE27,dividend,100,50,2/26/2020
D17F7E,joint-venture,100,62,2/26/2020
D17F7E,joint-venture,100,62,2/26/2020
D25249,earnings,100,50,2/26/2020
D3CEDF,executive-appointment,100,54,2/26/2020
D4AC65,partnership,100,61,2/26/2020
D518D8,legal-issues-defendant,100,22,2/26/2020
D5B13D,conference-participant,100,50,2/26/2020
D81463,earnings,100,50,2/26/2020
D81463,earnings,100,50,2/26/2020
D81463,dividend-up,100,81,2/26/2020
D81463,dividend-up,100,81,2/26/2020
D854F3,dividend-up,100,81,2/26/2020
D9FC89,conference-participant,100,50,2/26/2020
DB396B,earnings,100,50,2/26/2020
DB7014,conference-participant,100,50,2/26/2020
DD0099,dividend,100,50,2/26/2020
DD0F15,legal-issues-defendant,100,22,2/26/2020
DDC415,joint-venture,100,62,2/26/2020
DDC415,joint-venture,100,62,2/26/2020
DDEA6A,conference-participant,100,50,2/26/2020
DF01B1,legal-issues-defendant,100,22,2/26/2020
DF18E6,legal-issues-defendant,100,22,2/26/2020
E0339F,dividend,100,50,2/26/2020
E06265,earnings,100,50,2/26/2020
E07573,earnings,100,50,2/26/2020
E09997,conference-call,100,50,2/26/2020
E20392,conference-participant,100,50,2/26/2020
E21871,conference-participant,100,50,2/26/2020
E22FDE,conference-participant,100,50,2/26/2020
E28D9C,earnings,100,50,2/26/2020
E38906,executive-appointment,100,54,2/26/2020
E74B55,earnings,100,50,2/26/2020
E754F0,earnings,100,50,2/26/2020
E802CE,earnings,100,50,2/26/2020
E829E8,earnings,100,50,2/26/2020
E93A40,legal-issues-defendant,100,22,2/26/2020
E93A40,legal-issues-defendant,100,22,2/26/2020
EC8116,earnings,100,50,2/26/2020
ECE814,earnings,100,50,2/26/2020
ECF4F8,earnings,100,50,2/26/2020
ED4560,earnings,100,50,2/26/2020
EEA734,conference-participant,100,50,2/26/2020
EEB5F9,conference-participant,100,50,2/26/2020
EF45B6,dividend,100,50,2/26/2020
EF5914,earnings,100,50,2/26/2020
EF7163,earnings,100,50,2/26/2020
F02170,revenue-up,100,64,2/26/2020
F02170,revenues,100,50,2/26/2020
F02170,revenues,100,50,2/26/2020
F02170,revenues,100,50,2/26/2020
F02170,revenues,100,50,2/26/2020
F1529C,conference-participant,100,50,2/26/2020
F179ED,conference-participant,100,50,2/26/2020
F1CD47,conference-participant,100,50,2/26/2020
F2E253,earnings,100,50,2/26/2020
F2E253,earnings,100,50,2/26/2020
F2E253,earnings,100,50,2/26/2020
F2E253,earnings,100,50,2/26/2020
F2E253,earnings,100,50,2/26/2020
F2E253,earnings,100,50,2/26/2020
F4D241,conference-participant,100,50,2/26/2020
F5349B,earnings,100,50,2/26/2020
F5349B,dividend,100,50,2/26/2020
F569FD,conference-participant,100,50,2/26/2020
F6E248,clinical-trials-start,100,64,2/26/2020
F83279,dividend,100,50,2/26/2020
FAB97A,acquisition-completed-acquirer,100,49,2/26/2020
FE1A1D,earnings,100,50,2/26/2020
FE7A63,conference-participant,100,50,2/26/2020
FF6644,product-release,100,64,2/26/2020
FFE543,partnership,100,61,2/26/2020
FFE543,partnership,100,61,2/26/2020
00698D,earnings,100,50,2/27/2020
13528,partnership,100,61,2/27/2020
01478A,dividend-up,100,81,2/27/2020
036C6F,earnings,100,50,2/27/2020
036C6F,earnings,100,50,2/27/2020
036C6F,earnings,100,50,2/27/2020
03B431,conference-participant,100,50,2/27/2020
03CF95,revenue-guidance,100,50,2/27/2020
68396,earnings,100,50,2/27/2020
06C826,earnings,100,50,2/27/2020
070B45,conference-participant,100,50,2/27/2020
07C69F,conference-participant,100,50,2/27/2020
091B6C,clinical-trials-start,100,64,2/27/2020
091B6C,clinical-trials-start,100,64,2/27/2020
091B6C,clinical-trials-start,100,64,2/27/2020
095A04,earnings,100,50,2/27/2020
0A59F8,earnings,100,50,2/27/2020
0A59F8,earnings,100,50,2/27/2020
0A59F8,earnings,100,50,2/27/2020
0A59F8,earnings,100,50,2/27/2020
0A59F8,earnings,100,50,2/27/2020
0A59F8,earnings,100,50,2/27/2020
0A59F8,earnings,100,50,2/27/2020
0A77DB,earnings,100,50,2/27/2020
0A9D0A,earnings,100,50,2/27/2020
0BA8CE,earnings,100,50,2/27/2020
0BC29E,executive-appointment,100,54,2/27/2020
0C355F,revenue-up,100,69,2/27/2020
0C355F,revenue-up,100,69,2/27/2020
0C355F,revenue-up,100,69,2/27/2020
0C355F,revenue-up,100,69,2/27/2020
0C355F,revenue-up,100,69,2/27/2020
0C355F,revenue-up,100,69,2/27/2020
0E439E,dividend-up,100,81,2/27/2020
0E5619,regulatory-product-approval-granted,100,81,2/27/2020
1279ED,earnings,100,50,2/27/2020
129DC8,conference-participant,100,50,2/27/2020
12A3A3,conference-call,100,50,2/27/2020
12E454,partnership,100,61,2/27/2020
12E454,partnership,100,61,2/27/2020
12E454,partnership,100,61,2/27/2020
1490F3,dividend-up,100,81,2/27/2020
152FA5,conference-participant,100,50,2/27/2020
157CC1,earnings,100,50,2/27/2020
159AE4,credit-extension-recipient,100,69,2/27/2020
165B86,earnings,100,50,2/27/2020
165B86,earnings,100,50,2/27/2020
165B86,earnings,100,50,2/27/2020
165B86,earnings,100,50,2/27/2020
1782D5,earnings,100,50,2/27/2020
180DA0,earnings,100,50,2/27/2020
182BE7,earnings,100,50,2/27/2020
197019,earnings,100,50,2/27/2020
19BF16,legal-issues-defendant,100,22,2/27/2020
19BF16,legal-issues-defendant,100,22,2/27/2020
19BF16,legal-issues-defendant,100,22,2/27/2020
19BF16,legal-issues-defendant,100,22,2/27/2020
1CB9D3,earnings,100,50,2/27/2020
1D3A00,dividend,100,50,2/27/2020
1D3A00,earnings,100,50,2/27/2020
1DE526,conference-participant,100,50,2/27/2020
1DEBBE,earnings,100,50,2/27/2020
1DEBBE,earnings,100,50,2/27/2020
1DEBBE,earnings,100,50,2/27/2020
1DEBBE,earnings,100,50,2/27/2020
1DEBBE,earnings,100,50,2/27/2020
1DEBBE,earnings,100,50,2/27/2020
1DEBBE,earnings,100,50,2/27/2020
1DEBBE,earnings,100,50,2/27/2020
1E1125,conference-organizer,100,57,2/27/2020
1EBF8D,conference-participant,100,50,2/27/2020
1F464F,earnings,100,50,2/27/2020
1FC422,earnings,100,50,2/27/2020
1FCC00,dividend,100,50,2/27/2020
1FCC00,earnings,100,50,2/27/2020
1FCC00,earnings,100,50,2/27/2020
1FCC00,earnings,100,50,2/27/2020
1FE7F0,earnings,100,50,2/27/2020
200D8B,product-release,100,64,2/27/2020
202E5A,earnings,100,50,2/27/2020
2096DE,earnings,100,50,2/27/2020
221783,earnings,100,50,2/27/2020
225CA2,reorganization-unit,100,53,2/27/2020
225CA2,dividend,100,50,2/27/2020
232053,earnings,100,50,2/27/2020
253B2F,earnings,100,50,2/27/2020
2571FA,earnings,100,50,2/27/2020
2571FA,executive-appointment,100,54,2/27/2020
267718,executive-appointment,100,54,2/27/2020
267718,executive-appointment,100,54,2/27/2020
267718,executive-appointment,100,54,2/27/2020
270305,award,100,58,2/27/2020
272704,conference-participant,100,50,2/27/2020
275300,legal-issues-defendant,100,22,2/27/2020
275300,legal-issues-defendant,100,22,2/27/2020
275300,legal-issues-defendant,100,22,2/27/2020
275300,legal-issues-defendant,100,22,2/27/2020
275300,legal-issues-defendant,100,22,2/27/2020
275300,legal-issues-defendant,100,22,2/27/2020
275300,legal-issues-defendant,100,22,2/27/2020
275300,legal-issues-defendant,100,22,2/27/2020
27C10F,legal-issues-defendant,100,22,2/27/2020
28AF37,conference-participant,100,50,2/27/2020
28F905,earnings,100,50,2/27/2020
28F905,earnings,100,50,2/27/2020
2950FF,executive-appointment,100,54,2/27/2020
2950FF,executive-appointment,100,54,2/27/2020
29A4CC,dividend-up,100,81,2/27/2020
2A6DBE,public-offering,100,43,2/27/2020
2B0AF4,legal-issues-defendant,100,22,2/27/2020
2B0AF4,legal-issues-defendant,100,22,2/27/2020
2B0AF4,legal-issues-defendant,100,22,2/27/2020
2B0AF4,legal-issues-defendant,100,22,2/27/2020
2B0AF4,legal-issues-defendant,100,22,2/27/2020
2BA977,dividend,100,50,2/27/2020
2BBE62,earnings,100,50,2/27/2020
2BBE62,earnings,100,50,2/27/2020
2BBE62,earnings,100,50,2/27/2020
2BBE62,earnings,100,50,2/27/2020
2BC05E,legal-issues-defendant,100,22,2/27/2020
2C7505,executive-appointment,100,54,2/27/2020
2D5011,dividend,100,50,2/27/2020
2E2E6E,dividend,100,50,2/27/2020
2EC172,executive-appointment,100,54,2/27/2020
2F5256,business-contract,100,69,2/27/2020
2FDEE3,earnings,100,50,2/27/2020
30DE64,earnings,100,50,2/27/2020
31803E,earnings,100,50,2/27/2020
33AD83,earnings,100,50,2/27/2020
3471C0,earnings,100,50,2/27/2020
34A959,acquisition-regulatory-approval-acquirer,100,54,2/27/2020
355B19,earnings,100,50,2/27/2020
35AE32,executive-appointment,100,54,2/27/2020
366A08,earnings,100,50,2/27/2020
367434,earnings,100,50,2/27/2020
371B0A,earnings-up,100,68,2/27/2020
371B0A,earnings-up,100,68,2/27/2020
371B0A,earnings-up,100,68,2/27/2020
371B0A,earnings-up,100,68,2/27/2020
371B0A,earnings-up,100,68,2/27/2020
371C01,earnings,100,50,2/27/2020
371C01,earnings,100,50,2/27/2020
384CD3,unit-acquisition-acquirer,100,49,2/27/2020
389CFB,earnings,100,50,2/27/2020
396D7C,earnings,100,50,2/27/2020
3A94DF,dividend-up,100,63,2/27/2020
3B2311,earnings,100,50,2/27/2020
3B8484,earnings-up,100,68,2/27/2020
3BC360,earnings,100,50,2/27/2020
3F1C69,earnings,100,50,2/27/2020
3F4668,revenues,100,50,2/27/2020
3F4668,revenues,100,50,2/27/2020
3F4668,revenues,100,50,2/27/2020
3F4668,revenues,100,50,2/27/2020
3F4668,revenues,100,50,2/27/2020
416291,earnings,100,50,2/27/2020
41A93D,buybacks,100,74,2/27/2020
41ED98,buybacks,100,74,2/27/2020
422CE3,dividend,100,50,2/27/2020
43A060,earnings,100,50,2/27/2020
43A74A,conference-participant,100,50,2/27/2020
45444E,board-meeting,100,51,2/27/2020
46017C,earnings,100,50,2/27/2020
47B4CC,earnings,100,50,2/27/2020
47B4CC,earnings,100,50,2/27/2020
47B4CC,earnings,100,50,2/27/2020
4806CE,earnings,100,50,2/27/2020
48F795,earnings,100,50,2/27/2020
494EB9,legal-issues-defendant,100,22,2/27/2020
49CC59,earnings,100,50,2/27/2020
4A2457,business-contract,100,69,2/27/2020
4A2457,conference-participant,100,50,2/27/2020
4AC91D,executive-appointment,100,54,2/27/2020
4AC91D,executive-appointment,100,54,2/27/2020
4B3DC9,conference-participant,100,50,2/27/2020
4B7006,earnings,100,50,2/27/2020
4C92B9,earnings,100,50,2/27/2020
4D371E,conference-participant,100,50,2/27/2020
4D8124,conference-organizer,100,57,2/27/2020
4E4E75,operating-earnings,100,50,2/27/2020
4E7C1F,conference-participant,100,50,2/27/2020
4ECD1A,dividend,100,50,2/27/2020
51D876,earnings,100,50,2/27/2020
51D876,earnings,100,50,2/27/2020
51D876,earnings,100,50,2/27/2020
51D876,earnings,100,50,2/27/2020
51D876,earnings,100,50,2/27/2020
51D876,earnings,100,50,2/27/2020
51D876,earnings,100,50,2/27/2020
52015A,earnings,100,50,2/27/2020
52FB2F,earnings,100,50,2/27/2020
5.43E+08,conference-participant,100,50,2/27/2020
545272,board-meeting,100,51,2/27/2020
54DF47,earnings,100,50,2/27/2020
55CD6F,dividend,100,50,2/27/2020
56765E,earnings,100,50,2/27/2020
56765E,earnings,100,50,2/27/2020
56765E,earnings,100,50,2/27/2020
56765E,earnings,100,50,2/27/2020
56765E,earnings,100,50,2/27/2020
56765E,earnings,100,50,2/27/2020
56765E,earnings,100,50,2/27/2020
5704AC,conference-participant,100,50,2/27/2020
577033,earnings,100,50,2/27/2020
57A854,clinical-trials,100,56,2/27/2020
587EDF,conference-call,100,50,2/27/2020
58B46F,earnings-per-share-positive,100,69,2/27/2020
58B46F,earnings,100,50,2/27/2020
58B46F,earnings,100,50,2/27/2020
58B46F,earnings,100,50,2/27/2020
58B46F,earnings,100,50,2/27/2020
58B46F,earnings,100,50,2/27/2020
58B46F,earnings,100,50,2/27/2020
58C2D4,conference-participant,100,50,2/27/2020
58CA9A,conference-organizer,100,57,2/27/2020
59872F,conference-participant,100,50,2/27/2020
59F0B0,conference-participant,100,50,2/27/2020
5B7739,earnings,100,50,2/27/2020
5CEE02,earnings,100,50,2/27/2020
5D02B7,dividend,100,50,2/27/2020
5D1329,earnings,100,50,2/27/2020
5D63F1,award,100,58,2/27/2020
5E7E82,earnings-above-expectations,100,88,2/27/2020
601785,conference-participant,100,50,2/27/2020
619882,conference-organizer,100,57,2/27/2020
61A586,public-offering,100,43,2/27/2020
627186,conference-participant,100,50,2/27/2020
62F41C,legal-issues-defendant,100,22,2/27/2020
62F41C,legal-issues-defendant,100,22,2/27/2020
63F892,executive-appointment,100,54,2/27/2020
649CBD,earnings,100,50,2/27/2020
64E346,earnings,100,50,2/27/2020
657097,earnings,100,50,2/27/2020
676FFD,legal-issues-defendant,100,22,2/27/2020
6B236C,conference-participant,100,50,2/27/2020
6B6375,earnings,100,50,2/27/2020
6BDA0C,earnings,100,50,2/27/2020
6C987C,dividend,100,50,2/27/2020
6D156D,earnings,100,50,2/27/2020
6DC1D7,earnings,100,50,2/27/2020
6EA292,earnings,100,50,2/27/2020
6ED519,asset-sale,100,62,2/27/2020
6ED519,earnings,100,50,2/27/2020
6ED519,earnings,100,50,2/27/2020
6ED519,earnings,100,50,2/27/2020
7032D0,dividend,100,50,2/27/2020
71E2EF,product-release,100,64,2/27/2020
72609A,earnings,100,50,2/27/2020
73529F,earnings,100,50,2/27/2020
7.45E+28,earnings,100,50,2/27/2020
762A3E,conference-organizer,100,57,2/27/2020
762A3E,conference-organizer,100,57,2/27/2020
762A3E,conference-organizer,100,57,2/27/2020
762A3E,conference-organizer,100,57,2/27/2020
762A3E,conference-organizer,100,57,2/27/2020
762A3E,conference-organizer,100,57,2/27/2020
763724,earnings,100,50,2/27/2020
76BECC,business-contract,100,69,2/27/2020
78F9ED,shooting,100,7,2/27/2020
79167B,earnings,100,50,2/27/2020
7AF5B8,earnings,100,50,2/27/2020
7AF5B8,earnings,100,50,2/27/2020
7C4F43,earnings,100,50,2/27/2020
7C790D,earnings-delayed,100,26,2/27/2020
7E0EB0,earnings,100,50,2/27/2020
805CD8,earnings,100,50,2/27/2020
82C202,earnings-guidance-up,100,83,2/27/2020
8303CD,conference-participant,100,50,2/27/2020
83E0AC,conference-call,100,50,2/27/2020
845533,earnings,100,50,2/27/2020
855DF7,reorganization-unit,100,53,2/27/2020
85DA04,note-sale,100,52,2/27/2020
85DA04,partnership,100,61,2/27/2020
85DE00,conference-participant,100,50,2/27/2020
862941,earnings,100,50,2/27/2020
873DB9,legal-issues-defendant,100,22,2/27/2020
873DB9,legal-issues-defendant,100,22,2/27/2020
88193E,note-sale,100,52,2/27/2020
88193E,conference-participant,100,50,2/27/2020
895D56,earnings,100,50,2/27/2020
8AB37F,earnings,100,50,2/27/2020
8AC65D,conference-participant,100,50,2/27/2020
8C6C1B,facility-open,100,65,2/27/2020
8CF6DD,conference-participant,100,50,2/27/2020
8D4486,partnership,100,61,2/27/2020
8D4486,partnership,100,61,2/27/2020
8D4486,partnership,100,61,2/27/2020
8E82A6,conference-participant,100,50,2/27/2020
900356,conference-participant,100,50,2/27/2020
9196A2,conference-organizer,100,57,2/27/2020
9196A2,conference-organizer,100,57,2/27/2020
9196A2,conference-organizer,100,57,2/27/2020
9196A2,conference-organizer,100,57,2/27/2020
9196A2,conference-organizer,100,57,2/27/2020
925759,conference-participant,100,50,2/27/2020
92D757,executive-appointment,100,54,2/27/2020
942165,executive-appointment,100,54,2/27/2020
94756D,earnings,100,50,2/27/2020
947B0B,earnings,100,50,2/27/2020
958938,partnership,100,61,2/27/2020
958938,partnership,100,61,2/27/2020
958938,partnership,100,61,2/27/2020
958938,partnership,100,61,2/27/2020
9A602D,dividend,100,50,2/27/2020
9ABD30,earnings,100,50,2/27/2020
9B71A7,reorganization,100,53,2/27/2020
9C25FF,earnings,100,50,2/27/2020
9C3D3C,earnings,100,50,2/27/2020
9CA432,conference-participant,100,50,2/27/2020
9CA619,conference-call,100,50,2/27/2020
9CDA4F,earnings,100,50,2/27/2020
9D2790,dividend,100,50,2/27/2020
9D307D,conference-call,100,50,2/27/2020
9DDE1B,dividend-up,100,81,2/27/2020
9DDE1B,earnings,100,50,2/27/2020
9EED50,buybacks,100,74,2/27/2020
9F048E,conference-participant,100,50,2/27/2020
9F6B1A,partnership,100,61,2/27/2020
A05C43,earnings,100,50,2/27/2020
A072C4,earnings,100,50,2/27/2020
A0F146,earnings,100,50,2/27/2020
A3800A,dividend,100,50,2/27/2020
A3800A,earnings,100,50,2/27/2020
A38F30,earnings,100,50,2/27/2020
A433A5,conference-call,100,50,2/27/2020
A631A3,partnership,100,61,2/27/2020
A631A3,partnership,100,61,2/27/2020
A631A3,earnings,100,50,2/27/2020
A63387,government-contract,100,69,2/27/2020
A70BF5,executive-appointment,100,54,2/27/2020
A79D88,earnings,100,50,2/27/2020
A8B137,conference-participant,100,50,2/27/2020
A8E72A,conference-participant,100,50,2/27/2020
A8FDE8,earnings,100,50,2/27/2020
A8FDE8,dividend,100,50,2/27/2020
AAC8B6,earnings,100,50,2/27/2020
AAC8B6,earnings,100,50,2/27/2020
AAC8B6,earnings,100,50,2/27/2020
AAC8B6,earnings,100,50,2/27/2020
AAC8B6,earnings,100,50,2/27/2020
AAC8B6,earnings,100,50,2/27/2020
AAC8B6,earnings,100,50,2/27/2020
AAC8B6,earnings,100,50,2/27/2020
AAC8B6,earnings,100,50,2/27/2020
AAC8B6,earnings,100,50,2/27/2020
AAC8B6,earnings,100,50,2/27/2020
AAC8B6,earnings,100,50,2/27/2020
AC3584,earnings,100,50,2/27/2020
ADF092,earnings,100,50,2/27/2020
AE4EEB,executive-resignation,100,44,2/27/2020
AECCA9,business-contract,100,69,2/27/2020
B04426,earnings,100,50,2/27/2020
B290A2,earnings,100,50,2/27/2020
B3CB74,conference-organizer,100,57,2/27/2020
B3CB74,conference-organizer,100,57,2/27/2020
B3CB74,conference-organizer,100,57,2/27/2020
B3CB74,conference-organizer,100,57,2/27/2020
B3CB74,conference-organizer,100,57,2/27/2020
B3CB74,conference-organizer,100,57,2/27/2020
B3CB74,conference-organizer,100,57,2/27/2020
B3CB74,conference-organizer,100,57,2/27/2020
B3CB74,conference-organizer,100,57,2/27/2020
B4528F,conference-participant,100,50,2/27/2020
B508E5,earnings,100,50,2/27/2020
B614F8,public-offering,100,43,2/27/2020
B642E8,operating-earnings-positive,100,69,2/27/2020
B642E8,earnings,100,50,2/27/2020
B642E8,earnings,100,50,2/27/2020
B642E8,earnings,100,50,2/27/2020
B642E8,earnings,100,50,2/27/2020
B642E8,earnings,100,50,2/27/2020
B6843B,revenue-up,100,69,2/27/2020
B6843B,revenue-up,100,69,2/27/2020
B6843B,revenue-up,100,69,2/27/2020
B6843B,revenue-up,100,69,2/27/2020
B6843B,revenue-up,100,69,2/27/2020
B6843B,revenue-up,100,69,2/27/2020
B6CD92,buybacks,100,74,2/27/2020
B7202A,revenues,100,50,2/27/2020
B7202A,revenues,100,50,2/27/2020
B73395,earnings,100,50,2/27/2020
B98EFA,operating-earnings,100,50,2/27/2020
BAAA60,dividend,100,50,2/27/2020
BB5271,unit-acquisition-acquirer,100,49,2/27/2020
BC3AD2,dividend,100,50,2/27/2020
BD15E8,dividend,100,50,2/27/2020
BD8517,award,100,58,2/27/2020
BDA775,dividend,100,50,2/27/2020
BDCC11,earnings,100,50,2/27/2020
BE5935,earnings,100,50,2/27/2020
C03C8B,regulatory-product-approval-granted,100,81,2/27/2020
C27E19,dividend,100,50,2/27/2020
C2DD02,earnings,100,50,2/27/2020
C2E39B,earnings,100,50,2/27/2020
C3DE7D,earnings,100,50,2/27/2020
C3F99F,earnings,100,50,2/27/2020
C4A912,conference-participant,100,50,2/27/2020
C50B26,acquisition-acquirer,100,49,2/27/2020
C564E4,regulatory-product-application,100,69,2/27/2020
C7FC95,partnership,100,61,2/27/2020
C83B88,conference-participant,100,50,2/27/2020
C85A72,revenue-up,100,77,2/27/2020
C85A72,revenue-up,100,77,2/27/2020
C85A72,revenue-up,100,77,2/27/2020
C85A72,revenue-up,100,77,2/27/2020
C85A72,revenue-up,100,77,2/27/2020
C85A72,revenue-up,100,77,2/27/2020
C8FAC7,earnings,100,50,2/27/2020
C9A96E,earnings,100,50,2/27/2020
CA212F,earnings,100,50,2/27/2020
CB7AB2,executive-appointment,100,54,2/27/2020
CBBFBF,legal-issues-defendant,100,22,2/27/2020
CC35BE,executive-appointment,100,54,2/27/2020
CC3EC4,earnings,100,50,2/27/2020
CEC08B,earnings,100,50,2/27/2020
CEC5B9,partnership,100,61,2/27/2020
CEDFD5,partnership,100,61,2/27/2020
CEDFD5,partnership,100,61,2/27/2020
CEDFD5,partnership,100,61,2/27/2020
CEDFD5,partnership,100,61,2/27/2020
CEDFD5,partnership,100,61,2/27/2020
CF7292,conference-call,100,50,2/27/2020
D09938,earnings,100,50,2/27/2020
D13F1C,earnings,100,50,2/27/2020
D29B44,conference-participant,100,50,2/27/2020
D3F64D,dividend,100,50,2/27/2020
D48275,conference-call,100,50,2/27/2020
D64EDF,executive-appointment,100,54,2/27/2020
D76AEF,dividend-up,100,81,2/27/2020
D95385,earnings,100,50,2/27/2020
DD0F15,legal-issues-defendant,100,22,2/27/2020
DDB002,conference-call,100,50,2/27/2020
DDCB34,dividend,100,50,2/27/2020
DDCB34,earnings,100,50,2/27/2020
DDCB34,executive-appointment,100,54,2/27/2020
DE20DF,earnings,100,50,2/27/2020
E0647D,earnings,100,50,2/27/2020
E0647D,earnings,100,50,2/27/2020
E0E4B7,earnings,100,50,2/27/2020
E10D31,earnings,100,50,2/27/2020
E10D31,dividend,100,50,2/27/2020
E13782,earnings,100,50,2/27/2020
E16133,earnings,100,50,2/27/2020
E19A99,earnings,100,50,2/27/2020
E2CB7B,earnings,100,50,2/27/2020
E2F66E,earnings-positive,100,69,2/27/2020
E30B34,executive-appointment,100,54,2/27/2020
E30B34,conference-participant,100,50,2/27/2020
E30B34,conference-participant,100,50,2/27/2020
E41190,earnings,100,50,2/27/2020
E6D89E,patent-infringement-plaintiff,100,47,2/27/2020
E72599,earnings,100,50,2/27/2020
E72599,executive-appointment,100,54,2/27/2020
E866D2,legal-issues-defendant,100,22,2/27/2020
E866D2,legal-issues-defendant,100,22,2/27/2020
E8846E,regulatory-investigation,100,22,2/27/2020
E8E899,award,100,58,2/27/2020
E8E899,conference-participant,100,50,2/27/2020
E93A40,legal-issues-defendant,100,22,2/27/2020
E93A40,legal-issues-defendant,100,22,2/27/2020
EB1E1A,clinical-trials-start,100,64,2/27/2020
ECA300,conference-call,100,50,2/27/2020
ED2EFD,earnings,100,50,2/27/2020
ED3CA8,earnings,100,50,2/27/2020
ED3CA8,executive-appointment,100,54,2/27/2020
EDD234,executive-appointment,100,54,2/27/2020
EEEA9F,index-listing,100,76,2/27/2020
EF25A5,earnings,100,50,2/27/2020
EF25A5,earnings,100,50,2/27/2020
EF25A5,earnings,100,50,2/27/2020
EF25A5,earnings,100,50,2/27/2020
F0027C,earnings,100,50,2/27/2020
F0A9DE,dividend,100,50,2/27/2020
F30508,regulatory-product-approval-granted,100,81,2/27/2020
F43A11,partnership,100,61,2/27/2020
F73DD1,dividend,100,50,2/27/2020
F7935D,earnings,100,50,2/27/2020
F7ADEB,conference-participant,100,50,2/27/2020
F7D8AE,earnings,100,50,2/27/2020
F83279,earnings-guidance,100,50,2/27/2020
F83279,earnings,100,50,2/27/2020
F92DBC,product-release,100,64,2/27/2020
F92DBC,product-release,100,64,2/27/2020
FC1A6E,conference-participant,100,50,2/27/2020
FC1A6E,earnings,100,50,2/27/2020
FC4550,conference-participant,100,50,2/27/2020
FD39EB,earnings,100,50,2/27/2020
FD39EB,earnings,100,50,2/27/2020
FD39EB,earnings,100,50,2/27/2020
FD39EB,earnings,100,50,2/27/2020
FD39EB,earnings,100,50,2/27/2020
FD39EB,earnings,100,50,2/27/2020
FD39EB,earnings,100,50,2/27/2020
FD39EB,earnings,100,50,2/27/2020
FDF1C0,dividend,100,50,2/27/2020
FDF799,earnings,100,50,2/27/2020
FF4343,partnership,100,61,2/27/2020
02ACBD,earnings,100,50,2/28/2020
0325B7,conference-call,100,50,2/28/2020
0358AF,conference-participant,100,50,2/28/2020
099C88,executive-appointment,100,54,2/28/2020
09F623,conference-participant,100,50,2/28/2020
0A59F8,partnership,100,61,2/28/2020
0BC853,conference-call,100,50,2/28/2020
0BD970,earnings,100,50,2/28/2020
0C136E,facility-open,100,65,2/28/2020
0CC62B,conference-participant,100,50,2/28/2020
0CE7F6,earnings,100,50,2/28/2020
0E5223,conference-participant,100,50,2/28/2020
1065BC,product-release,100,64,2/28/2020
1490F3,business-combination,100,54,2/28/2020
16B882,earnings,100,50,2/28/2020
1748F6,earnings,100,50,2/28/2020
182BE7,conference-participant,100,50,2/28/2020
188394,dividend,100,50,2/28/2020
19BF16,legal-issues-defendant,100,22,2/28/2020
1CD09C,conference-participant,100,50,2/28/2020
1E1125,conference-organizer,100,57,2/28/2020
1E1125,conference-organizer,100,57,2/28/2020
1E1125,conference-organizer,100,57,2/28/2020
1E1125,conference-organizer,100,57,2/28/2020
238302,board-meeting,100,51,2/28/2020
250BEE,conference-participant,100,50,2/28/2020
275300,legal-issues-defendant,100,22,2/28/2020
275300,legal-issues-defendant,100,22,2/28/2020
275300,legal-issues-defendant,100,22,2/28/2020
275300,legal-issues-defendant,100,22,2/28/2020
275300,legal-issues-defendant,100,22,2/28/2020
29A4CC,executive-appointment,100,54,2/28/2020
2.90E+62,buybacks,100,74,2/28/2020
2BC05E,legal-issues-defendant,100,22,2/28/2020
2BDC1C,clinical-trials,100,56,2/28/2020
2CF9D3,ipo-pricing,100,50,2/28/2020
2E0496,product-release,100,64,2/28/2020
2E0496,product-release,100,64,2/28/2020
2E1322,merger,100,66,2/28/2020
2E89AE,settlement,100,56,2/28/2020
2E89AE,settlement,100,56,2/28/2020
2E89AE,patent-infringement-plaintiff,100,47,2/28/2020
2FDEE3,conference-participant,100,50,2/28/2020
3587B4,regulatory-investigation,100,22,2/28/2020
36A1CB,dividend,100,50,2/28/2020
36C09B,conference-call,100,50,2/28/2020
372037,legal-issues-defendant,100,22,2/28/2020
372037,legal-issues-defendant,100,22,2/28/2020
383ADA,earnings,100,50,2/28/2020
3A94DF,buybacks,100,74,2/28/2020
3B20AB,conference-participant,100,50,2/28/2020
3B37F7,conference-call,100,50,2/28/2020
3BA1BF,conference-call,100,50,2/28/2020
3FACA7,joint-venture,100,62,2/28/2020
4135F7,earnings,100,50,2/28/2020
420168,conference-participant,100,50,2/28/2020
44209A,award,100,58,2/28/2020
448BF3,conference-participant,100,50,2/28/2020
44DDBD,conference-call,100,50,2/28/2020
494EB9,legal-issues-defendant,100,22,2/28/2020
494EB9,legal-issues-defendant,100,22,2/28/2020
494EB9,legal-issues-defendant,100,22,2/28/2020
494EB9,legal-issues-defendant,100,22,2/28/2020
4DAF5F,buybacks,100,74,2/28/2020
4DAF5F,buybacks,100,74,2/28/2020
4FB770,conference-participant,100,50,2/28/2020
54DF47,dividend,100,50,2/28/2020
556A57,buybacks,100,74,2/28/2020
56277A,conference-participant,100,50,2/28/2020
5675EB,buybacks,100,74,2/28/2020
58CA9A,conference-organizer,100,57,2/28/2020
58CA9A,conference-organizer,100,57,2/28/2020
58CA9A,conference-organizer,100,57,2/28/2020
58CA9A,conference-organizer,100,57,2/28/2020
5CEE02,conference-organizer,100,57,2/28/2020
5D63F1,dividend,100,50,2/28/2020
5DD486,conference-participant,100,50,2/28/2020
5DE5A5,dividend,100,50,2/28/2020
5E7E82,dividend,100,50,2/28/2020
619882,conference-organizer,100,57,2/28/2020
62F41C,legal-issues-defendant,100,22,2/28/2020
64E346,conference-participant,100,50,2/28/2020
665D7D,clinical-trials,100,56,2/28/2020
665D7D,clinical-trials,100,56,2/28/2020
705636,revenue-up,100,70,2/28/2020
705636,revenues,100,50,2/28/2020
713810,unit-acquisition-acquiree,100,76,2/28/2020
71694D,earnings-guidance,100,50,2/28/2020
7255D2,earnings,100,50,2/28/2020
726DDF,earnings,100,50,2/28/2020
72EF75,buybacks,100,74,2/28/2020
731675,buybacks,100,74,2/28/2020
75F665,buybacks,100,74,2/28/2020
762A3E,conference-organizer,100,57,2/28/2020
762A3E,award,100,58,2/28/2020
762A3E,conference-organizer,100,57,2/28/2020
762A3E,conference-organizer,100,57,2/28/2020
762A3E,conference-organizer,100,57,2/28/2020
76F067,conference-participant,100,50,2/28/2020
7740DE,dividend,100,50,2/28/2020
7A0EC4,award,100,58,2/28/2020
7ACFD4,earnings,100,50,2/28/2020
7F2922,conference-participant,100,50,2/28/2020
7F3FBC,unit-acquisition-acquirer,100,49,2/28/2020
804708,dividend,100,50,2/28/2020
83B1C8,conference-participant,100,50,2/28/2020
855DF7,executive-appointment,100,54,2/28/2020
855DF7,earnings,100,50,2/28/2020
873DB9,legal-issues-defendant,100,22,2/28/2020
873DB9,legal-issues-defendant,100,22,2/28/2020
873DB9,legal-issues-defendant,100,22,2/28/2020
873DB9,legal-issues-defendant,100,22,2/28/2020
873DB9,legal-issues-defendant,100,22,2/28/2020
8C6C1B,facility-open,100,65,2/28/2020
8E82A6,dividend,100,50,2/28/2020
8EF425,conference-participant,100,50,2/28/2020
8F8F2F,dividend,100,50,2/28/2020
9196A2,conference-organizer,100,57,2/28/2020
9196A2,conference-organizer,100,57,2/28/2020
92B047,facility-open,100,65,2/28/2020
958938,earnings,100,50,2/28/2020
99028D,conference-participant,100,50,2/28/2020
990AD0,conference-organizer,100,57,2/28/2020
9934AD,earnings,100,50,2/28/2020
9934AD,earnings,100,50,2/28/2020
9934AD,earnings,100,50,2/28/2020
9934AD,earnings,100,50,2/28/2020
9981C6,dividend,100,50,2/28/2020
9F5CBB,dividend,100,50,2/28/2020
A16DEA,conference-participant,100,50,2/28/2020
A6213D,business-contract,100,69,2/28/2020
A6213D,partnership,100,61,2/28/2020
A96867,dividend-up,100,81,2/28/2020
B2AA0A,earnings,100,50,2/28/2020
B37FB4,dividend,100,50,2/28/2020
B3CB74,conference-organizer,100,57,2/28/2020
B3CB74,conference-organizer,100,57,2/28/2020
B3CB74,conference-organizer,100,57,2/28/2020
B3CB74,conference-organizer,100,57,2/28/2020
B3CB74,conference-organizer,100,57,2/28/2020
B3CB74,conference-organizer,100,57,2/28/2020
B3CB74,conference-organizer,100,57,2/28/2020
B3CB74,conference-organizer,100,57,2/28/2020
B3CB74,conference-organizer,100,57,2/28/2020
B3CB74,conference-organizer,100,57,2/28/2020
B77F14,earnings,100,50,2/28/2020
BAD655,earnings,100,50,2/28/2020
BDE867,earnings,100,50,2/28/2020
BDE867,earnings,100,50,2/28/2020
BDE867,earnings,100,50,2/28/2020
BDE867,earnings,100,50,2/28/2020
BE14CF,unit-acquisition-acquirer,100,49,2/28/2020
C0030A,conference-participant,100,50,2/28/2020
C01737,earnings,100,50,2/28/2020
C50B26,acquisition-acquirer,100,49,2/28/2020
C5C137,dividend,100,50,2/28/2020
C85A72,conference-participant,100,50,2/28/2020
C9D866,conference-participant,100,50,2/28/2020
C9E107,conference-participant,100,50,2/28/2020
CBBFBF,facility-open,100,65,2/28/2020
CBBFBF,facility-open,100,65,2/28/2020
CBBFBF,earnings,100,50,2/28/2020
CBBFBF,earnings,100,50,2/28/2020
CBBFBF,earnings,100,50,2/28/2020
CBBFBF,earnings,100,50,2/28/2020
CBBFBF,earnings,100,50,2/28/2020
CBBFBF,legal-issues-defendant,100,22,2/28/2020
CE4FD9,conference-participant,100,50,2/28/2020
CF211D,conference-participant,100,50,2/28/2020
CF351E,earnings,100,50,2/28/2020
D15833,conference-call,100,50,2/28/2020
D518D8,legal-issues-defendant,100,22,2/28/2020
D64EDF,earnings-above-expectations,100,88,2/28/2020
D64EDF,earnings-above-expectations,100,88,2/28/2020
D64EDF,earnings-above-expectations,100,88,2/28/2020
D64EDF,earnings-above-expectations,100,88,2/28/2020
D64EDF,earnings-above-expectations,100,88,2/28/2020
DC0066,conference-participant,100,50,2/28/2020
DC2F77,conference-participant,100,50,2/28/2020
DD0F15,legal-issues-defendant,100,22,2/28/2020
DD7A96,dividend,100,50,2/28/2020
DF01B1,legal-issues-defendant,100,22,2/28/2020
DF204B,executive-appointment,100,54,2/28/2020
E10D31,executive-appointment,100,54,2/28/2020
E35610,earnings,100,50,2/28/2020
E61888,earnings,100,50,2/28/2020
E866D2,legal-issues-defendant,100,22,2/28/2020
E8B21D,acquisition-completed-acquirer,100,49,2/28/2020
E8C557,business-contract,100,69,2/28/2020
ECD263,conference-participant,100,50,2/28/2020
EE1E44,conference-participant,100,50,2/28/2020
EE6F1C,dividend-up,100,63,2/28/2020
F00285,earnings,100,50,2/28/2020
F0B335,conference-participant,100,50,2/28/2020
F47871,executive-appointment,100,54,2/28/2020
F47871,executive-appointment,100,54,2/28/2020
F57F6F,conference-participant,100,50,2/28/2020
F6DCE4,executive-appointment,100,54,2/28/2020
F72E4B,earnings,100,50,2/28/2020
F72E4B,earnings,100,50,2/28/2020
F72E4B,earnings,100,50,2/28/2020
F72E4B,earnings,100,50,2/28/2020
F7D8AE,conference-participant,100,50,2/28/2020
F92DBC,earnings,100,50,2/28/2020
F92DBC,earnings,100,50,2/28/2020
F92DBC,earnings,100,50,2/28/2020
F92DBC,earnings,100,50,2/28/2020
F92DBC,earnings,100,50,2/28/2020
F92DBC,earnings,100,50,2/28/2020
F92DBC,earnings,100,50,2/28/2020
F92DBC,earnings,100,50,2/28/2020
F92DBC,earnings,100,50,2/28/2020
F92DBC,earnings,100,50,2/28/2020
F92DBC,earnings,100,50,2/28/2020
F92DBC,earnings,100,50,2/28/2020
F92DBC,earnings,100,50,2/28/2020
F92DBC,earnings,100,50,2/28/2020
F92DBC,earnings,100,50,2/28/2020
FC4550,dividend,100,50,2/28/2020
FC8733,conference-participant,100,50,2/28/2020
FD554E,earnings,100,50,2/28/2020
FD554E,earnings,100,50,2/28/2020
FDF799,conference-participant,100,50,2/28/2020
FF227B,earnings,100,50,2/28/2020
FF6644,conference-participant,100,50,2/28/2020
0CE204,legal-issues-defendant,100,22,2/29/2020
19BF16,legal-issues-defendant,100,22,2/29/2020
275300,legal-issues-defendant,100,22,2/29/2020
2B0AF4,legal-issues-defendant,100,22,2/29/2020
2BC05E,legal-issues-defendant,100,22,2/29/2020
2BF36E,dividend,100,50,2/29/2020
494EB9,legal-issues-defendant,100,22,2/29/2020
873DB9,legal-issues-defendant,100,22,2/29/2020
CBBFBF,legal-issues-defendant,100,22,2/29/2020
DD0F15,legal-issues-defendant,100,22,2/29/2020
DF01B1,legal-issues-defendant,100,22,2/29/2020
E866D2,legal-issues-defendant,100,22,2/29/2020
873DB9,legal-issues-defendant,100,22,3/1/2020
873DB9,legal-issues-defendant,100,22,3/1/2020
873DB9,legal-issues-defendant,100,22,3/1/2020
DF01B1,legal-issues-defendant,100,22,3/1/2020
EEEA9F,merger-completed,100,66,3/1/2020
002A99,earnings,100,50,3/2/2020
01B8D6,earnings,100,50,3/2/2020
20751,earnings,100,50,3/2/2020
02FC1A,earnings,100,50,3/2/2020
02FC1A,earnings,100,50,3/2/2020
03FAA6,earnings,100,50,3/2/2020
03FAA6,earnings,100,50,3/2/2020
03FAA6,earnings,100,50,3/2/2020
03FAA6,earnings,100,50,3/2/2020
03FAA6,earnings,100,50,3/2/2020
03FAA6,earnings,100,50,3/2/2020
48590,partnership,100,61,3/2/2020
48590,partnership,100,61,3/2/2020
06EF42,earnings,100,50,3/2/2020
075CF7,executive-appointment,100,54,3/2/2020
07C69F,conference-participant,100,50,3/2/2020
0C4131,acquisition-completed-acquirer,100,49,3/2/2020
0C6861,legal-issues-defendant,100,22,3/2/2020
0DBB81,earnings,100,50,3/2/2020
0EF1AF,conference-call,100,50,3/2/2020
1272B3,earnings,100,50,3/2/2020
136B26,private-placement,100,56,3/2/2020
14833D,earnings,100,50,3/2/2020
168A5D,legal-issues-plaintiff,100,44,3/2/2020
1834C0,conference-participant,100,50,3/2/2020
190B91,conference-participant,100,50,3/2/2020
19BF16,award,100,58,3/2/2020
1E04A5,earnings,100,50,3/2/2020
1FA886,buybacks,100,74,3/2/2020
221445,earnings,100,50,3/2/2020
221AD7,legal-issues-defendant,100,22,3/2/2020
221AD7,legal-issues-defendant,100,22,3/2/2020
225CA2,acquisition-interest-acquirer,100,46,3/2/2020
238302,earnings,100,50,3/2/2020
24C48B,acquisition-completed-acquirer,100,49,3/2/2020
24C48B,acquisition-completed-acquirer,100,49,3/2/2020
25A6CC,conference-participant,100,50,3/2/2020
2720AB,acquisition-completed-acquirer,100,49,3/2/2020
274B8A,conference-call,100,50,3/2/2020
275300,legal-issues-defendant,100,22,3/2/2020
275300,legal-issues-defendant,100,22,3/2/2020
275300,legal-issues-defendant,100,22,3/2/2020
2B0AF4,legal-issues-defendant,100,22,3/2/2020
2B49F4,conference-call,100,50,3/2/2020
2B8179,earnings,100,50,3/2/2020
2BF36E,earnings,100,50,3/2/2020
2CC71C,earnings,100,50,3/2/2020
2E36AD,partnership,100,61,3/2/2020
2EB04E,partnership,100,61,3/2/2020
2F7474,acquisition-completed-acquirer,100,49,3/2/2020
32DCB3,earnings,100,50,3/2/2020
372037,legal-issues-defendant,100,22,3/2/2020
372037,legal-issues-defendant,100,22,3/2/2020
372037,legal-issues-defendant,100,22,3/2/2020
372037,legal-issues-defendant,100,22,3/2/2020
372037,legal-issues-defendant,100,22,3/2/2020
372037,legal-issues-defendant,100,22,3/2/2020
38FB49,conference-participant,100,50,3/2/2020
3AAEAE,conference-call,100,50,3/2/2020
3B8484,unit-acquisition-acquirer,100,49,3/2/2020
3BBD10,acquisition-completed-acquirer,100,49,3/2/2020
3C6CCC,earnings,100,50,3/2/2020
3C6CCC,earnings,100,50,3/2/2020
3C6CCC,earnings,100,50,3/2/2020
3C6CCC,earnings,100,50,3/2/2020
3C6CCC,earnings,100,50,3/2/2020
3C6CCC,earnings,100,50,3/2/2020
3F96D5,earnings,100,50,3/2/2020
40F7DE,award,100,58,3/2/2020
429BFB,earnings,100,50,3/2/2020
42AABD,business-contract,100,69,3/2/2020
431B74,executive-resignation,100,44,3/2/2020
431B74,executive-resignation,100,44,3/2/2020
448215,earnings,100,50,3/2/2020
448BF3,earnings,100,50,3/2/2020
448BF3,earnings,100,50,3/2/2020
4649D5,earnings,100,50,3/2/2020
4.60E+06,patent-awarded,100,72,3/2/2020
485445,dividend,100,50,3/2/2020
494EB9,legal-issues-defendant,100,22,3/2/2020
494EB9,legal-issues-defendant,100,22,3/2/2020
4A3438,earnings,100,50,3/2/2020
4A6F00,business-contract,100,69,3/2/2020
4AC91D,acquisition-interest-acquiree,100,82,3/2/2020
4C7DB5,note-sale,100,52,3/2/2020
4DAF5F,buybacks,100,74,3/2/2020
4DAF5F,buybacks,100,74,3/2/2020
4E3D15,operating-earnings,100,50,3/2/2020
4EE14A,acquisition-completed-acquirer,100,49,3/2/2020
4EE14A,acquisition-completed-acquirer,100,49,3/2/2020
4EE167,public-offering,100,43,3/2/2020
4EEB00,business-contract,100,69,3/2/2020
510EA1,earnings,100,50,3/2/2020
510EA6,unit-acquisition-acquirer,100,49,3/2/2020
514067,conference-participant,100,50,3/2/2020
524CE4,executive-resignation,100,44,3/2/2020
52FB2F,conference-participant,100,50,3/2/2020
543900,executive-appointment,100,54,3/2/2020
546A27,earnings,100,50,3/2/2020
55C9B5,partnership,100,61,3/2/2020
56EA2B,dividend,100,50,3/2/2020
57EF50,conference-call,100,50,3/2/2020
587D25,executive-appointment,100,54,3/2/2020
587D25,conference-call,100,50,3/2/2020
58CA9A,conference-organizer,100,57,3/2/2020
58CA9A,conference-organizer,100,57,3/2/2020
58CA9A,conference-organizer,100,57,3/2/2020
596116,executive-appointment,100,54,3/2/2020
5AF08A,buybacks,100,74,3/2/2020
5B226B,revenue-up,100,67,3/2/2020
5B226B,revenue-up,100,67,3/2/2020
5B226B,revenue-up,100,67,3/2/2020
5B226B,conference-call,100,50,3/2/2020
5B6C11,acquisition-completed-acquirer,100,49,3/2/2020
633054,partnership,100,61,3/2/2020
662682,unit-acquisition-completed-acquirer,100,49,3/2/2020
6925EB,earnings,100,50,3/2/2020
69E8E1,legal-issues-defendant,100,22,3/2/2020
6BBCBA,business-contract,100,69,3/2/2020
6BF593,earnings-guidance-meet-expectations,100,59,3/2/2020
6D9ECA,earnings,100,50,3/2/2020
70CA28,conference-participant,100,50,3/2/2020
71E2EF,product-release,100,64,3/2/2020
747219,business-contract,100,69,3/2/2020
747219,business-contract,100,69,3/2/2020
747219,business-contract,100,69,3/2/2020
747219,dividend,100,50,3/2/2020
762A3E,conference-organizer,100,57,3/2/2020
763DBE,earnings,100,50,3/2/2020
79167B,acquisition-completed-acquirer,100,49,3/2/2020
7A3633,note-sale,100,52,3/2/2020
7AB859,acquisition-completed-acquirer,100,49,3/2/2020
7B6EB1,acquisition-acquirer,100,49,3/2/2020
7BFF81,business-contract,100,69,3/2/2020
7BFF81,acquisition-completed-acquirer,100,49,3/2/2020
82B57E,executive-appointment,100,54,3/2/2020
83066C,trading-halt,100,43,3/2/2020
83066C,trading-resumed,100,58,3/2/2020
8377DB,stock-loss,100,40,3/2/2020
85CDC9,executive-resignation,100,44,3/2/2020
86F123,earnings-positive,100,69,3/2/2020
873DB9,legal-issues-defendant,100,22,3/2/2020
873DB9,conference-participant,100,50,3/2/2020
8A8E41,conference-participant,100,50,3/2/2020
8AB37F,executive-appointment,100,54,3/2/2020
8BAA15,partnership,100,61,3/2/2020
8C5519,conference-participant,100,50,3/2/2020
8C6C1B,facility-open,100,65,3/2/2020
8D4486,partnership,100,61,3/2/2020
8D4486,partnership,100,61,3/2/2020
8E10BF,conference-call,100,50,3/2/2020
8EF425,dividend,100,50,3/2/2020
8FCA78,board-meeting,100,51,3/2/2020
9196A2,conference-organizer,100,57,3/2/2020
9196A2,conference-organizer,100,57,3/2/2020
92005C,executive-appointment,100,54,3/2/2020
934CC3,executive-appointment,100,54,3/2/2020
94637C,dividend-up,100,81,3/2/2020
9546A5,conference-call,100,50,3/2/2020
95A92E,earnings,100,50,3/2/2020
966DBE,earnings,100,50,3/2/2020
966DBE,earnings,100,50,3/2/2020
966DBE,earnings,100,50,3/2/2020
966DBE,earnings,100,50,3/2/2020
966DBE,earnings,100,50,3/2/2020
9.86E+03,award,100,58,3/2/2020
9CA432,conference-participant,100,50,3/2/2020
9D65C1,earnings,100,50,3/2/2020
A29A46,earnings,100,50,3/2/2020
A2CAF7,earnings-guidance,100,50,3/2/2020
A3230E,executive-appointment,100,54,3/2/2020
A350C1,board-meeting,100,51,3/2/2020
A631A3,legal-issues-defendant,100,22,3/2/2020
A631A3,legal-issues-defendant,100,22,3/2/2020
A8AC4C,earnings,100,50,3/2/2020
A9ED24,conference-participant,100,50,3/2/2020
AC642C,business-combination,100,54,3/2/2020
AC642C,business-combination,100,54,3/2/2020
AC642C,business-combination,100,54,3/2/2020
AC642C,business-combination,100,54,3/2/2020
AC642C,earnings,100,50,3/2/2020
AC642C,earnings,100,50,3/2/2020
AEFC90,conference-participant,100,50,3/2/2020
AFD7DD,earnings,100,50,3/2/2020
AFD7DD,earnings,100,50,3/2/2020
AFD7DD,earnings,100,50,3/2/2020
AFD7DD,business-contract,100,69,3/2/2020
AFD7DD,business-contract,100,69,3/2/2020
B0D41A,earnings,100,50,3/2/2020
B1FC3B,earnings,100,50,3/2/2020
B2F431,executive-resignation,100,44,3/2/2020
B33E77,earnings,100,50,3/2/2020
B3CB74,conference-organizer,100,57,3/2/2020
B3CB74,conference-organizer,100,57,3/2/2020
B3CB74,conference-organizer,100,57,3/2/2020
B48D6A,conference-participant,100,50,3/2/2020
B5734D,conference-call,100,50,3/2/2020
B614F8,public-offering,100,43,3/2/2020
B72D2E,executive-resignation,100,44,3/2/2020
B8F71F,executive-appointment,100,54,3/2/2020
BDEC1E,earnings,100,50,3/2/2020
C062D4,executive-appointment,100,54,3/2/2020
C16A8F,executive-appointment,100,54,3/2/2020
C2609A,executive-appointment,100,54,3/2/2020
C27E19,conference-participant,100,50,3/2/2020
C45CE7,buybacks,100,74,3/2/2020
C4A432,acquisition-completed-acquirer,100,49,3/2/2020
C584BE,earnings,100,50,3/2/2020
C5E100,conference-call,100,50,3/2/2020
C659EB,unit-acquisition-acquirer,100,49,3/2/2020
C7859D,dividend,100,50,3/2/2020
C81E00,executive-appointment,100,54,3/2/2020
C81E00,executive-appointment,100,54,3/2/2020
C8257F,executive-appointment,100,54,3/2/2020
C8FAC7,partnership,100,61,3/2/2020
CA1620,executive-appointment,100,54,3/2/2020
CAB222,earnings,100,50,3/2/2020
CBFFDD,earnings,100,50,3/2/2020
CBFFDD,earnings,100,50,3/2/2020
CBFFDD,earnings,100,50,3/2/2020
CBFFDD,earnings,100,50,3/2/2020
CBFFDD,earnings,100,50,3/2/2020
CBFFDD,trading-halt,100,43,3/2/2020
CD4DA8,executive-appointment,100,54,3/2/2020
CD4DA8,conference-organizer,100,57,3/2/2020
CDC217,earnings,100,50,3/2/2020
CE4E6D,earnings-up,100,68,3/2/2020
CE4E6D,earnings-up,100,68,3/2/2020
CE4E6D,earnings-up,100,68,3/2/2020
CE4E6D,earnings-up,100,68,3/2/2020
CE4E6D,earnings-up,100,68,3/2/2020
CF3FF9,legal-issues-defendant,100,22,3/2/2020
D06996,earnings,100,50,3/2/2020
D15833,supply-increase,100,74,3/2/2020
D1C26F,conference-participant,100,50,3/2/2020
D2B9E5,earnings-guidance,100,50,3/2/2020
D2B9E5,earnings-guidance,100,50,3/2/2020
D33270,business-contract,100,69,3/2/2020
D3DE34,earnings,100,50,3/2/2020
D3DE34,earnings,100,50,3/2/2020
D518D8,legal-issues-defendant,100,22,3/2/2020
D518D8,legal-issues-defendant,100,22,3/2/2020
D518D8,legal-issues-defendant,100,22,3/2/2020
D518D8,legal-issues-defendant,100,22,3/2/2020
D518D8,legal-issues-defendant,100,22,3/2/2020
D6144F,conference-call,100,50,3/2/2020
D6853F,legal-issues-defendant,100,22,3/2/2020
DB9829,acquisition-completed-acquirer,100,49,3/2/2020
DD0F15,legal-issues-defendant,100,22,3/2/2020
DF01B1,legal-issues-defendant,100,22,3/2/2020
E0D3BA,buybacks,100,74,3/2/2020
E16133,business-contract,100,69,3/2/2020
E1C16B,award,100,58,3/2/2020
E259C7,executive-appointment,100,54,3/2/2020
E4CE73,product-release,100,64,3/2/2020
E4CE73,product-release,100,64,3/2/2020
E5752F,partnership,100,61,3/2/2020
E7BF32,earnings,100,50,3/2/2020
E7BF32,earnings,100,50,3/2/2020
EB36DE,business-contract,100,69,3/2/2020
EB43F4,clinical-trials,100,56,3/2/2020
EB43F4,earnings,100,50,3/2/2020
EDD234,earnings,100,50,3/2/2020
EE04F0,conference-call,100,50,3/2/2020
F44EA2,award,100,58,3/2/2020
F47871,public-offering,100,43,3/2/2020
F4D241,earnings,100,50,3/2/2020
F5349B,earnings-guidance,100,50,3/2/2020
F5349B,earnings-guidance,100,50,3/2/2020
F6E248,acquisition-acquirer,100,49,3/2/2020
F6E248,acquisition-acquirer,100,49,3/2/2020
F7ADEB,business-contract,100,69,3/2/2020
F7ADEB,business-contract,100,69,3/2/2020
FAAFA2,earnings,100,50,3/2/2020
FAE021,legal-issues-defendant,100,22,3/2/2020
FB728F,earnings,100,50,3/2/2020
FBD92D,earnings,100,50,3/2/2020
FD2565,partnership,100,61,3/2/2020
FD2565,partnership,100,61,3/2/2020
FDD3FC,earnings,100,50,3/2/2020
FFCD0E,earnings,100,50,3/2/2020
0325B7,earnings,100,50,3/3/2020
03D5F9,merger-completed,100,66,3/3/2020
03D5F9,merger-completed,100,66,3/3/2020
07C907,dividend-up,100,81,3/3/2020
0B13E8,partnership,100,61,3/3/2020
0B400D,legal-issues-defendant,100,22,3/3/2020
0B7375,conference-call,100,50,3/3/2020
0C136E,acquisition-acquirer,100,49,3/3/2020
0C136E,acquisition-acquirer,100,49,3/3/2020
0C6861,conference-participant,100,50,3/3/2020
0D03C8,earnings,100,50,3/3/2020
0E2992,conference-participant,100,50,3/3/2020
0E3436,earnings,100,50,3/3/2020
0F0440,earnings,100,50,3/3/2020
0F0440,earnings,100,50,3/3/2020
1080C0,fast-track-designation,100,81,3/3/2020
12E454,acquisition-completed-acquiree,100,76,3/3/2020
136B26,conference-participant,100,50,3/3/2020
147C38,product-release,100,64,3/3/2020
157D9F,conference-call,100,50,3/3/2020
184866,clinical-trials,100,56,3/3/2020
184866,clinical-trials,100,56,3/3/2020
184866,earnings,100,50,3/3/2020
1921DD,partnership,100,61,3/3/2020
1921DD,partnership,100,61,3/3/2020
19BF16,legal-issues-defendant,100,22,3/3/2020
1AE9D5,conference-call,100,50,3/3/2020
1B6F77,executive-appointment,100,54,3/3/2020
1E5786,conference-participant,100,50,3/3/2020
21153F,product-release,100,64,3/3/2020
221AD7,legal-issues-defendant,100,22,3/3/2020
221AD7,legal-issues-defendant,100,22,3/3/2020
221AD7,legal-issues-defendant,100,22,3/3/2020
228D42,partnership,100,61,3/3/2020
228D42,partnership,100,61,3/3/2020
228D42,partnership,100,61,3/3/2020
249674,business-contract,100,69,3/3/2020
275300,legal-issues-defendant,100,22,3/3/2020
29A4CC,executive-appointment,100,54,3/3/2020
2A4131,earnings,100,50,3/3/2020
2B0AF4,legal-issues-defendant,100,22,3/3/2020
2BC05E,legal-issues-defendant,100,22,3/3/2020
2D643C,conference-participant,100,50,3/3/2020
2D981A,earnings,100,50,3/3/2020
2FF046,conference-participant,100,50,3/3/2020
315EB0,acquisition-completed-acquirer,100,49,3/3/2020
32DCB3,clinical-trials,100,56,3/3/2020
3461CF,credit-rating-upgrade-rater,20,50,3/3/2020
372037,legal-issues-defendant,100,22,3/3/2020
372037,acquisition-acquirer,100,49,3/3/2020
372037,legal-issues-defendant,100,22,3/3/2020
372037,legal-issues-defendant,100,22,3/3/2020
372037,legal-issues-defendant,100,22,3/3/2020
372037,legal-issues-defendant,100,22,3/3/2020
372037,legal-issues-defendant,100,22,3/3/2020
3.73E+87,product-release,100,64,3/3/2020
38C46F,dividend,100,50,3/3/2020
39FB23,acquisition-completed-acquirer,100,49,3/3/2020
3B37F7,earnings,100,50,3/3/2020
3B50FE,dividend,100,50,3/3/2020
422CE3,earnings,100,50,3/3/2020
427F32,earnings,100,50,3/3/2020
42978B,dividend,100,50,3/3/2020
42AABD,business-contract,100,69,3/3/2020
45BC35,acquisition-acquirer,100,49,3/3/2020
468DD4,conference-participant,100,50,3/3/2020
494EB9,legal-issues-defendant,100,22,3/3/2020
49914B,executive-resignation,100,44,3/3/2020
4A2457,business-contract,100,69,3/3/2020
4A6F00,partnership,100,61,3/3/2020
4AC91D,legal-issues-defendant,100,22,3/3/2020
4D229C,earnings,100,50,3/3/2020
4DAF5F,buybacks,100,74,3/3/2020
4DAF5F,buybacks,100,74,3/3/2020
4DD09F,earnings,100,50,3/3/2020
4DD203,earnings,100,50,3/3/2020
5065B1,conference-participant,100,50,3/3/2020
519FE0,earnings,100,50,3/3/2020
51E682,product-release,100,64,3/3/2020
52015A,buybacks,100,74,3/3/2020
543900,executive-appointment,100,54,3/3/2020
556F08,earnings,100,50,3/3/2020
55D0F3,earnings,100,50,3/3/2020
56EFC7,dividend,100,50,3/3/2020
579E8F,fundraising,100,64,3/3/2020
58CA9A,conference-participant,100,50,3/3/2020
5B3FA2,executive-appointment,100,54,3/3/2020
5BC2F4,executive-appointment,100,54,3/3/2020
5CEE02,unit-acquisition-acquirer,100,49,3/3/2020
5E1DF3,earnings-up,100,68,3/3/2020
609208,conference-call,100,50,3/3/2020
619882,credit-extension-provider,100,57,3/3/2020
619882,conference-organizer,100,57,3/3/2020
619882,conference-organizer,100,57,3/3/2020
619882,conference-organizer,100,57,3/3/2020
620381,earnings,100,50,3/3/2020
62CDDE,conference-participant,100,50,3/3/2020
633054,partnership,100,61,3/3/2020
66E04A,buybacks,100,74,3/3/2020
6810DE,earnings,100,50,3/3/2020
6830FE,earnings,100,50,3/3/2020
68586A,credit-extension-recipient,100,69,3/3/2020
6CC55E,business-contract,100,69,3/3/2020
6CC55E,business-contract,100,69,3/3/2020
6D9B53,conference-participant,100,50,3/3/2020
6E8864,conference-participant,100,50,3/3/2020
70FCEF,earnings,100,50,3/3/2020
7122EB,fundraising,100,64,3/3/2020
72FCA3,executive-appointment,100,54,3/3/2020
747219,earnings,100,50,3/3/2020
76D79A,dividend,100,50,3/3/2020
76DD0C,earnings,100,50,3/3/2020
775439,earnings,100,50,3/3/2020
7A2A49,acquisition-completed-acquirer,100,49,3/3/2020
7A3633,note-sale,100,52,3/3/2020
7AB859,business-contract,100,69,3/3/2020
7ACD98,award,100,58,3/3/2020
7ACFD4,executive-appointment,100,54,3/3/2020
7ACFD4,executive-appointment,100,54,3/3/2020
7ACFD4,executive-appointment,100,54,3/3/2020
7ACFD4,executive-appointment,100,54,3/3/2020
7ACFD4,executive-appointment,100,54,3/3/2020
7ACFD4,executive-appointment,100,54,3/3/2020
7BC92D,earnings,100,50,3/3/2020
7C62A3,earnings-guidance,100,50,3/3/2020
80D744,acquisition-completed-acquirer,100,49,3/3/2020
8.10E+32,executive-appointment,100,54,3/3/2020
862941,conference-participant,100,50,3/3/2020
8665BA,business-contract,100,69,3/3/2020
8665BA,acquisition-acquirer,100,49,3/3/2020
8665BA,acquisition-acquirer,100,49,3/3/2020
8665BA,acquisition-acquirer,100,49,3/3/2020
8665BA,acquisition-acquirer,100,49,3/3/2020
8665BA,acquisition-acquirer,100,49,3/3/2020
8665BA,acquisition-acquirer,100,49,3/3/2020
873DB9,legal-issues-defendant,100,22,3/3/2020
873DB9,legal-issues-defendant,100,22,3/3/2020
873DB9,legal-issues-defendant,100,22,3/3/2020
873DB9,legal-issues-defendant,100,22,3/3/2020
893904,conference-participant,100,50,3/3/2020
8B9B3B,public-offering,100,43,3/3/2020
8C6C1B,facility-open,100,65,3/3/2020
8C6C1B,earnings,100,50,3/3/2020
902255,business-contract,100,69,3/3/2020
9196A2,conference-organizer,100,57,3/3/2020
92005C,earnings,100,50,3/3/2020
93F143,product-release,100,64,3/3/2020
94637C,dividend,100,50,3/3/2020
9470CC,earnings,100,50,3/3/2020
947B0B,conference-participant,100,50,3/3/2020
954004,conference-call,100,50,3/3/2020
9.65E+09,earnings,100,50,3/3/2020
96F126,product-release,100,64,3/3/2020
979451,legal-issues-defendant,100,22,3/3/2020
98CEBB,business-contract,100,69,3/3/2020
990AD0,conference-organizer,100,57,3/3/2020
99B61C,clinical-trials,100,56,3/3/2020
9D56F2,conference-call,100,50,3/3/2020
9E575E,conference-participant,100,50,3/3/2020
9FB4B7,earnings,100,50,3/3/2020
A1E3B3,earnings,100,50,3/3/2020
A26C26,conference-participant,100,50,3/3/2020
A5195E,conference-participant,100,50,3/3/2020
A58224,conference-participant,100,50,3/3/2020
A631A3,legal-issues-defendant,100,22,3/3/2020
A631A3,partnership,100,61,3/3/2020
A63387,conference-participant,100,50,3/3/2020
A63820,earnings,100,50,3/3/2020
A6FE1C,acquisition-acquirer,100,49,3/3/2020
A868C9,campaign-ad-release,100,59,3/3/2020
A871B0,earnings,100,50,3/3/2020
AAEE21,buybacks,100,74,3/3/2020
AC642C,merger,100,66,3/3/2020
AC7AAE,earnings,100,50,3/3/2020
ADD9DC,earnings,100,50,3/3/2020
AEFC90,clinical-trials-start,100,64,3/3/2020
AF93DE,conference-call,100,50,3/3/2020
B05118,product-release,100,64,3/3/2020
B076A1,dividend,100,50,3/3/2020
B3CB74,conference-organizer,100,57,3/3/2020
B446B8,earnings,100,50,3/3/2020
B446B8,earnings,100,50,3/3/2020
B446B8,earnings,100,50,3/3/2020
B48D6A,earnings,100,50,3/3/2020
B48D6A,earnings,100,50,3/3/2020
B48FC9,conference-participant,100,50,3/3/2020
B803B1,conference-participant,100,50,3/3/2020
B83BCE,conference-participant,100,50,3/3/2020
B8EF97,partnership,100,61,3/3/2020
B8F71F,conference-participant,100,50,3/3/2020
BC948D,executive-appointment,100,54,3/3/2020
BC948D,conference-participant,100,50,3/3/2020
BD9668,executive-appointment,100,54,3/3/2020
BDA775,earnings,100,50,3/3/2020
BDEF34,dividend,100,50,3/3/2020
C03C8B,executive-appointment,100,54,3/3/2020
C1114B,conference-participant,100,50,3/3/2020
C2609A,business-contract,100,69,3/3/2020
C4452A,dividend,100,50,3/3/2020
C97B2D,partnership,100,61,3/3/2020
CBB77B,earnings,100,50,3/3/2020
CBBFBF,legal-issues-defendant,100,22,3/3/2020
CBBFBF,legal-issues-defendant,100,22,3/3/2020
CBCC6A,conference-organizer,100,57,3/3/2020
CBDB4D,conference-participant,100,50,3/3/2020
CBFFDD,trading-resumed,100,58,3/3/2020
CC176E,executive-appointment,100,54,3/3/2020
CC6F6E,earnings,100,50,3/3/2020
CCB623,earnings,100,50,3/3/2020
CDAF5B,dividend,100,50,3/3/2020
CDC817,earnings,100,50,3/3/2020
CFF15D,partnership,100,61,3/3/2020
CFF97C,partnership,100,61,3/3/2020
D518D8,legal-issues-defendant,100,22,3/3/2020
D518D8,legal-issues-defendant,100,22,3/3/2020
D518D8,legal-issues-defendant,100,22,3/3/2020
D518D8,legal-issues-defendant,100,22,3/3/2020
D518D8,legal-issues-defendant,100,22,3/3/2020
D518D8,legal-issues-defendant,100,22,3/3/2020
D6EAA3,conference-participant,100,50,3/3/2020
D78BF1,dividend,100,50,3/3/2020
DBB28E,earnings,100,50,3/3/2020
DBB28E,earnings,100,50,3/3/2020
DBB28E,earnings,100,50,3/3/2020
DBB28E,earnings,100,50,3/3/2020
DBB28E,earnings,100,50,3/3/2020
DBB28E,earnings,100,50,3/3/2020
DC486E,partnership,100,61,3/3/2020
DDEA6A,earnings,100,50,3/3/2020
DF01B1,legal-issues-defendant,100,22,3/3/2020
E05026,earnings,100,50,3/3/2020
E09556,conference-call,100,50,3/3/2020
E20BFE,earnings,100,50,3/3/2020
E20BFE,earnings,100,50,3/3/2020
E20BFE,earnings,100,50,3/3/2020
E38906,earnings,100,50,3/3/2020
E592F0,conference-participant,100,50,3/3/2020
E866D2,conference-participant,100,50,3/3/2020
EAA0A7,conference-participant,100,50,3/3/2020
EC4E82,unit-acquisition-completed-acquirer,100,49,3/3/2020
ECF709,earnings-per-share-up,100,58,3/3/2020
ECF709,earnings-per-share-up,100,58,3/3/2020
ECF709,earnings-per-share-up,100,58,3/3/2020
EEA734,earnings,100,50,3/3/2020
F1EB39,earnings,100,50,3/3/2020
F47871,public-offering,100,43,3/3/2020
F4CDA3,unit-acquisition-acquirer,100,49,3/3/2020
F4FBD8,executive-appointment,100,54,3/3/2020
F6DCE4,earnings,100,50,3/3/2020
FA40E2,earnings,100,50,3/3/2020
FE609F,conference-participant,100,50,3/3/2020
FE7A63,dividend,100,50,3/3/2020
FE89E0,executive-appointment,100,54,3/3/2020
FF4BA4,executive-appointment,100,54,3/3/2020
0157B1,partnership,100,61,3/4/2020
01D03F,executive-appointment,100,54,3/4/2020
0358AF,dividend-up,100,81,3/4/2020
053EFF,earnings,100,50,3/4/2020
0624BE,earnings,100,50,3/4/2020
71860,executive-appointment,100,54,3/4/2020
0919B1,dividend-up,100,81,3/4/2020
0A77DB,conference-participant,100,50,3/4/2020
0AD2E3,earnings-up,100,68,3/4/2020
0AD2E3,earnings-up,100,68,3/4/2020
0C6861,legal-issues-defendant,100,22,3/4/2020
0F2BC9,business-contract,100,69,3/4/2020
0FE3A6,earnings,100,50,3/4/2020
10AE08,executive-resignation,100,44,3/4/2020
11A49E,earnings,100,50,3/4/2020
1220D2,conference-participant,100,50,3/4/2020
12DE76,partnership,100,61,3/4/2020
133644,conference-participant,100,50,3/4/2020
143C52,earnings,100,50,3/4/2020
16B183,executive-appointment,100,54,3/4/2020
1921DD,executive-appointment,100,54,3/4/2020
1921DD,partnership,100,61,3/4/2020
1921DD,partnership,100,61,3/4/2020
19BF16,legal-issues-defendant,100,22,3/4/2020
1A3E1B,earnings,100,50,3/4/2020
1D1B07,earnings,100,50,3/4/2020
1D1B07,earnings,100,50,3/4/2020
1E83DE,earnings,100,50,3/4/2020
2003A5,earnings,100,50,3/4/2020
221AD7,acquisition-acquirer,100,49,3/4/2020
221AD7,acquisition-acquirer,100,49,3/4/2020
223552,partnership,100,61,3/4/2020
228D42,partnership,100,61,3/4/2020
2667B6,executive-appointment,100,54,3/4/2020
2667B6,executive-appointment,100,54,3/4/2020
267718,executive-appointment,100,54,3/4/2020
275300,legal-issues-defendant,100,22,3/4/2020
275300,legal-issues-defendant,100,22,3/4/2020
275300,legal-issues-defendant,100,22,3/4/2020
275300,legal-issues-defendant,100,22,3/4/2020
279916,earnings,100,50,3/4/2020
27C10F,earnings,100,50,3/4/2020
29CEBF,earnings,100,50,3/4/2020
2AA6A8,clinical-trials-start,100,64,3/4/2020
2BC05E,legal-issues-defendant,100,22,3/4/2020
2C7505,partnership,100,61,3/4/2020
2C7505,partnership,100,61,3/4/2020
2CC60C,revenue-up,100,69,3/4/2020
2D2D43,earnings,100,50,3/4/2020
2E1322,merger,100,66,3/4/2020
2F9304,earnings,100,50,3/4/2020
2F960F,earnings,100,50,3/4/2020
2F98A5,note-sale,100,52,3/4/2020
30AB63,earnings-guidance,100,50,3/4/2020
34B411,award,100,58,3/4/2020
372037,legal-issues-defendant,100,22,3/4/2020
372037,legal-issues-defendant,100,22,3/4/2020
372037,legal-issues-defendant,100,22,3/4/2020
372037,legal-issues-defendant,100,22,3/4/2020
3A1C46,earnings,100,50,3/4/2020
3A3447,facility-open,100,65,3/4/2020
3DD5E2,note-sale,100,52,3/4/2020
3ED92D,note-sale,100,52,3/4/2020
4.00E+163,public-offering,100,43,3/4/2020
422CE3,legal-issues-defendant,100,22,3/4/2020
43A060,conference-participant,100,50,3/4/2020
494EB9,legal-issues-defendant,100,22,3/4/2020
49A344,executive-appointment,100,54,3/4/2020
4A6F00,partnership,100,61,3/4/2020
4C3FE9,earnings,100,50,3/4/2020
4DAF5F,buybacks,100,74,3/4/2020
4DAF5F,buybacks,100,74,3/4/2020
4EE167,public-offering,100,43,3/4/2020
5.43E+08,executive-resignation,100,44,3/4/2020
543900,earnings,100,50,3/4/2020
543900,earnings,100,50,3/4/2020
543900,earnings,100,50,3/4/2020
543900,earnings,100,50,3/4/2020
543900,earnings,100,50,3/4/2020
543900,earnings,100,50,3/4/2020
543900,earnings,100,50,3/4/2020
543900,earnings,100,50,3/4/2020
543900,earnings,100,50,3/4/2020
543900,earnings,100,50,3/4/2020
54512F,earnings,100,50,3/4/2020
5487B1,dividend,100,50,3/4/2020
5AAE17,earnings,100,50,3/4/2020
5B35C7,earnings,100,50,3/4/2020
5B35C7,earnings,100,50,3/4/2020
5B3FA2,conference-participant,100,50,3/4/2020
619882,conference-organizer,100,57,3/4/2020
619882,conference-organizer,100,57,3/4/2020
619882,conference-organizer,100,57,3/4/2020
62B1C6,earnings,100,50,3/4/2020
633043,earnings,100,50,3/4/2020
6474BA,buybacks,100,74,3/4/2020
66A667,executive-appointment,100,54,3/4/2020
66A667,executive-appointment,100,54,3/4/2020
673C9A,executive-appointment,100,54,3/4/2020
6830FE,executive-appointment,100,54,3/4/2020
68586A,conference-participant,100,50,3/4/2020
69C99E,earnings,100,50,3/4/2020
6C6D73,executive-appointment,100,54,3/4/2020
6D9B53,conference-participant,100,50,3/4/2020
6D9ECA,note-sale,100,52,3/4/2020
6DBBBC,partnership,100,61,3/4/2020
6DC1D7,acquisition-completed-acquirer,100,49,3/4/2020
6-Dec-05,partnership,100,61,3/4/2020
6E705B,conference-participant,100,50,3/4/2020
73C9E2,conference-participant,100,50,3/4/2020
747219,conference-participant,100,50,3/4/2020
769F40,earnings,100,50,3/4/2020
76BD96,note-sale,100,52,3/4/2020
76F067,dividend,100,50,3/4/2020
787D14,earnings,100,50,3/4/2020
790D0D,buybacks,100,74,3/4/2020
791EC1,executive-resignation,100,44,3/4/2020
7ACD98,earnings,100,50,3/4/2020
7ADE57,earnings,100,50,3/4/2020
7ADE57,earnings,100,50,3/4/2020
7ADE57,earnings,100,50,3/4/2020
7ADE57,earnings,100,50,3/4/2020
7ADE57,earnings,100,50,3/4/2020
7B1156,conference-participant,100,50,3/4/2020
7B9AFA,conference-participant,100,50,3/4/2020
7F9BE2,note-sale,100,52,3/4/2020
7FC386,dividend,100,50,3/4/2020
7FD8B9,earnings,100,50,3/4/2020
817ED9,dividend,100,50,3/4/2020
8.10E+205,executive-appointment,100,54,3/4/2020
82B57E,earnings,100,50,3/4/2020
859D62,earnings,100,50,3/4/2020
859D62,earnings,100,50,3/4/2020
859D62,earnings,100,50,3/4/2020
859D62,earnings,100,50,3/4/2020
859D62,earnings,100,50,3/4/2020
859D62,earnings,100,50,3/4/2020
873DB9,legal-issues-defendant,100,22,3/4/2020
873DB9,legal-issues-defendant,100,22,3/4/2020
873DB9,legal-issues-defendant,100,22,3/4/2020
880C0C,dividend,100,50,3/4/2020
8AC740,dividend,100,50,3/4/2020
8B9B3B,public-offering,100,43,3/4/2020
8BFE9A,executive-appointment,100,54,3/4/2020
8C6C1B,facility-open,100,65,3/4/2020
8D0EEA,trading-listing,100,61,3/4/2020
8D4486,partnership,100,61,3/4/2020
8D4486,partnership,100,61,3/4/2020
8DA42F,facility-open,100,65,3/4/2020
9004C4,conference-call,100,50,3/4/2020
911AB8,note-sale,100,52,3/4/2020
9196A2,conference-organizer,100,57,3/4/2020
91C82E,conference-call,100,50,3/4/2020
9592FB,earnings,100,50,3/4/2020
967D92,facility-sale,100,52,3/4/2020
972356,note-sale,100,52,3/4/2020
990AD0,conference-organizer,100,57,3/4/2020
9B71A7,executive-appointment,100,54,3/4/2020
9BF177,earnings,100,50,3/4/2020
9C3D3C,earnings,100,50,3/4/2020
9D307D,conference-participant,100,50,3/4/2020
9F71E5,earnings,100,50,3/4/2020
A01200,earnings,100,50,3/4/2020
A02FB1,buybacks,100,74,3/4/2020
A29DBD,note-sale,100,52,3/4/2020
A47F2E,business-contract,100,69,3/4/2020
A49498,conference-call,100,50,3/4/2020
A63387,business-contract,100,69,3/4/2020
B13B68,executive-appointment,100,54,3/4/2020
B1FC3B,executive-appointment,100,54,3/4/2020
B1FC3B,dividend,100,50,3/4/2020
B3A166,earnings,100,50,3/4/2020
B4F5F4,conference-call,100,50,3/4/2020
B5DE80,executive-resignation,100,44,3/4/2020
B76C82,earnings,100,50,3/4/2020
BB127B,conference-participant,100,50,3/4/2020
C2F597,conference-participant,100,50,3/4/2020
C38440,executive-appointment,100,54,3/4/2020
C3BCD5,legal-issues-defendant,100,22,3/4/2020
C4A432,facility-open,100,65,3/4/2020
C4F9C6,earnings,100,50,3/4/2020
C50B26,executive-appointment,100,54,3/4/2020
C584BE,earnings,100,50,3/4/2020
C584BE,earnings,100,50,3/4/2020
C584BE,earnings,100,50,3/4/2020
C98CDB,conference-participant,100,50,3/4/2020
CBB77B,dividend,100,50,3/4/2020
CD2A4D,earnings,100,50,3/4/2020
CF3FF9,legal-issues-defendant,100,22,3/4/2020
D0909F,dividend,100,50,3/4/2020
D1C26F,conference-participant,100,50,3/4/2020
D1CFC8,conference-call,100,50,3/4/2020
D2C0B6,earnings,100,50,3/4/2020
D4463B,note-sale,100,52,3/4/2020
D518D8,legal-issues-defendant,100,22,3/4/2020
D518D8,legal-issues-defendant,100,22,3/4/2020
D518D8,legal-issues-defendant,100,22,3/4/2020
D58A11,executive-appointment,100,54,3/4/2020
DA48E4,conference-participant,100,50,3/4/2020
DCD97F,dividend-up,100,81,3/4/2020
DDB002,earnings,100,50,3/4/2020
DF01B1,legal-issues-defendant,100,22,3/4/2020
DF01B1,legal-issues-defendant,100,22,3/4/2020
DF5F14,conference-call,100,50,3/4/2020
E3E68E,partnership,100,61,3/4/2020
E3E68E,partnership,100,61,3/4/2020
E5A3B6,executive-appointment,100,54,3/4/2020
E8C557,earnings,100,50,3/4/2020
E8F0E2,fundraising,100,64,3/4/2020
E94704,conference-participant,100,50,3/4/2020
ED0402,executive-appointment,100,54,3/4/2020
F0EEFB,earnings,100,50,3/4/2020
F179ED,executive-appointment,100,54,3/4/2020
F72E4B,earnings,100,50,3/4/2020
F7ADEB,earnings,100,50,3/4/2020
F7ADEB,earnings,100,50,3/4/2020
F7ADEB,earnings,100,50,3/4/2020
F7ADEB,earnings,100,50,3/4/2020
FC4550,dividend,100,50,3/4/2020
054E7E,earnings,100,50,3/5/2020
95294,acquisition-acquirer,100,49,3/5/2020
09F623,note-sale,100,52,3/5/2020
0BF528,earnings-positive,100,69,3/5/2020
0E5619,conference-call,100,50,3/5/2020
1279ED,executive-resignation,100,44,3/5/2020
1490F3,facility-open,100,65,3/5/2020
152AB9,earnings,100,50,3/5/2020
152AB9,earnings,100,50,3/5/2020
157CC1,earnings,100,50,3/5/2020
15901B,conference-call,100,50,3/5/2020
16FC89,dividend,100,50,3/5/2020
17EDA5,partnership,100,61,3/5/2020
1C2593,earnings,100,50,3/5/2020
1E1125,executive-appointment,100,54,3/5/2020
1F9258,earnings,100,50,3/5/2020
205AD5,donation,100,54,3/5/2020
205AD5,donation,100,54,3/5/2020
21268E,earnings,100,50,3/5/2020
227D48,dividend,100,50,3/5/2020
251988,partnership,100,61,3/5/2020
275300,legal-issues-defendant,100,22,3/5/2020
2BC05E,legal-issues-defendant,100,22,3/5/2020
2C681C,conference-call,100,50,3/5/2020
2C681C,conference-call,100,50,3/5/2020
2CF9D3,executive-appointment,100,54,3/5/2020
2E1322,merger,100,66,3/5/2020
2E36AD,earnings,100,50,3/5/2020
2E36AD,earnings,100,50,3/5/2020
2EB04E,partnership,100,61,3/5/2020
301493,earnings,100,50,3/5/2020
3461CF,credit-rating-upgrade-rater,20,50,3/5/2020
3461CF,credit-rating-upgrade-rater,20,50,3/5/2020
36A1CB,executive-appointment,100,54,3/5/2020
36C09B,orphan-drug-designation,100,76,3/5/2020
372037,legal-issues-defendant,100,22,3/5/2020
372037,legal-issues-defendant,100,22,3/5/2020
383ADA,earnings,100,50,3/5/2020
3ACF46,earnings,100,50,3/5/2020
3C75D6,earnings,100,50,3/5/2020
3C75D6,earnings,100,50,3/5/2020
3C75D6,earnings,100,50,3/5/2020
3C7F5F,executive-appointment,100,54,3/5/2020
3CBA2A,partnership,100,61,3/5/2020
3DD5E2,note-sale,100,52,3/5/2020
3E39A5,earnings,100,50,3/5/2020
3EE65E,earnings,100,50,3/5/2020
407878,earnings,100,50,3/5/2020
4.00E+163,public-offering,100,43,3/5/2020
416C55,conference-participant,100,50,3/5/2020
427F32,dividend,100,50,3/5/2020
4398A2,earnings,100,50,3/5/2020
442587,credit-extension-recipient,100,69,3/5/2020
44DDBD,earnings,100,50,3/5/2020
4649D5,legal-issues-defendant,100,22,3/5/2020
4649D5,legal-issues-defendant,100,22,3/5/2020
494EB9,legal-issues-defendant,100,22,3/5/2020
494EB9,legal-issues-defendant,100,22,3/5/2020
49914B,buybacks,100,74,3/5/2020
4A6F00,partnership,100,61,3/5/2020
4A6F00,partnership,100,61,3/5/2020
4A6F00,partnership,100,61,3/5/2020
4A6F00,partnership,100,61,3/5/2020
4DAF5F,buybacks,100,74,3/5/2020
4DAF5F,buybacks,100,74,3/5/2020
4EE167,conference-participant,100,50,3/5/2020
4FCC78,earnings,100,50,3/5/2020
4FCC78,earnings,100,50,3/5/2020
523039,executive-appointment,100,54,3/5/2020
5.47E+28,rights-issue,100,43,3/5/2020
56EFC7,earnings,100,50,3/5/2020
586BD7,conference-call,100,50,3/5/2020
5876DC,earnings,100,50,3/5/2020
58C2D4,earnings,100,50,3/5/2020
5CC29D,conference-call,100,50,3/5/2020
5CEE02,conference-organizer,100,57,3/5/2020
5E1DF3,conference-participant,100,50,3/5/2020
5F2FF7,conference-participant,100,50,3/5/2020
6166D1,partnership,100,61,3/5/2020
619882,conference-organizer,100,57,3/5/2020
619882,conference-organizer,100,57,3/5/2020
619882,conference-organizer,100,57,3/5/2020
62F41C,legal-issues-defendant,100,22,3/5/2020
633054,partnership,100,61,3/5/2020
6559D8,earnings,100,50,3/5/2020
662682,note-sale,100,52,3/5/2020
665440,earnings,100,50,3/5/2020
665440,earnings,100,50,3/5/2020
665440,earnings,100,50,3/5/2020
665440,earnings,100,50,3/5/2020
66A667,earnings,100,50,3/5/2020
66A667,earnings,100,50,3/5/2020
67B052,patent-awarded,100,72,3/5/2020
68586A,earnings,100,50,3/5/2020
69C99E,executive-appointment,100,54,3/5/2020
6A01DF,executive-appointment,100,54,3/5/2020
6CBF41,earnings,100,50,3/5/2020
6.00E+19,earnings,100,50,3/5/2020
6.00E+19,business-contract,100,69,3/5/2020
722DE3,business-contract,100,69,3/5/2020
7255D2,earnings,100,50,3/5/2020
73F7F9,earnings,100,50,3/5/2020
74404C,earnings,100,50,3/5/2020
748EB6,patent-awarded,100,72,3/5/2020
756045,earnings,100,50,3/5/2020
76959C,earnings,100,50,3/5/2020
7740DE,same-store-sales-down,100,47,3/5/2020
77F01E,executive-appointment,100,54,3/5/2020
787D14,earnings,100,50,3/5/2020
790C34,executive-appointment,100,54,3/5/2020
7B9212,earnings,100,50,3/5/2020
7BEA98,earnings,100,50,3/5/2020
7C4F43,earnings,100,50,3/5/2020
7C790D,legal-issues-defendant,100,22,3/5/2020
8.10E+32,dividend,100,50,3/5/2020
817ED9,executive-appointment,100,54,3/5/2020
826FD6,earnings,100,50,3/5/2020
873DB9,legal-issues-defendant,100,22,3/5/2020
873DB9,legal-issues-defendant,100,22,3/5/2020
89FBB1,earnings,100,50,3/5/2020
8A8E41,dividend,100,50,3/5/2020
8B4A45,facility-open,100,65,3/5/2020
8BFAA4,conference-call,100,50,3/5/2020
8BFE9A,earnings,100,50,3/5/2020
8C6C1B,facility-open,100,65,3/5/2020
8DE56F,award,100,58,3/5/2020
8DE56F,award,100,58,3/5/2020
8EDACA,conference-participant,100,50,3/5/2020
8F8F2F,executive-appointment,100,54,3/5/2020
92B047,credit-extension-provider,100,57,3/5/2020
93D207,partnership,100,61,3/5/2020
942633,dividend,100,50,3/5/2020
94983E,legal-issues-defendant,100,22,3/5/2020
968966,award,100,58,3/5/2020
97644E,earnings,100,50,3/5/2020
9810C0,dividend,100,50,3/5/2020
98CEBB,product-release,100,64,3/5/2020
990AD0,conference-organizer,100,57,3/5/2020
997348,dividend,100,50,3/5/2020
99B61C,executive-appointment,100,54,3/5/2020
9EA947,facility-open,100,65,3/5/2020
A05C43,earnings,100,50,3/5/2020
A204A7,earnings,100,50,3/5/2020
A23747,product-release,100,64,3/5/2020
A29DBD,note-sale,100,52,3/5/2020
A37D68,earnings,100,50,3/5/2020
A433A5,earnings,100,50,3/5/2020
A4BCDE,award,100,58,3/5/2020
A5195E,earnings,100,50,3/5/2020
A52533,facility-open,100,65,3/5/2020
A52533,earnings,100,50,3/5/2020
A63387,business-contract,100,69,3/5/2020
A63387,executive-appointment,100,54,3/5/2020
A72AB6,earnings,100,50,3/5/2020
A790A5,business-contract,100,69,3/5/2020
A7A0C8,earnings,100,50,3/5/2020
AC3584,revenue-up,100,69,3/5/2020
AC3584,revenue-up,100,69,3/5/2020
AC3584,revenue-up,100,69,3/5/2020
ACC7D3,earnings,100,50,3/5/2020
ADD9DC,facility-open,100,65,3/5/2020
AE7D16,product-release,100,64,3/5/2020
AEBB80,executive-appointment,100,54,3/5/2020
B37FB4,conference-participant,100,50,3/5/2020
B3ED62,earnings,100,50,3/5/2020
B5766D,executive-appointment,100,54,3/5/2020
B8EF97,earnings,100,50,3/5/2020
B98EFA,operating-earnings,100,50,3/5/2020
C22BE8,dividend,100,50,3/5/2020
C3BCD5,legal-issues-defendant,100,22,3/5/2020
C3BCD5,legal-issues-defendant,100,22,3/5/2020
C5F463,business-contract,100,69,3/5/2020
C8A059,earnings,100,50,3/5/2020
C9881C,conference-call,100,50,3/5/2020
CA1620,dividend,100,50,3/5/2020
CB89EA,conference-participant,100,50,3/5/2020
CBA33B,award,100,58,3/5/2020
CBBFBF,legal-issues-defendant,100,22,3/5/2020
CC6FF5,partnership,100,61,3/5/2020
CE96E7,executive-appointment,100,54,3/5/2020
CF3FF9,earnings,100,50,3/5/2020
CFF57D,earnings,100,50,3/5/2020
CFF57D,earnings,100,50,3/5/2020
CFF57D,earnings,100,50,3/5/2020
CFF57D,earnings,100,50,3/5/2020
D07B07,earnings,100,50,3/5/2020
D33D8C,executive-appointment,100,54,3/5/2020
D518D8,legal-issues-defendant,100,22,3/5/2020
D622D5,executive-death,100,31,3/5/2020
D8760C,conference-participant,100,50,3/5/2020
D88EF3,note-sale,100,52,3/5/2020
D8C09D,earnings,100,50,3/5/2020
D8C09D,executive-appointment,100,54,3/5/2020
D8ECA1,executive-appointment,100,54,3/5/2020
DA0CB8,dividend,100,50,3/5/2020
DB7FA7,investment-investor,100,55,3/5/2020
DB9829,earnings,100,50,3/5/2020
DB9F70,conference-call,100,50,3/5/2020
DBFB51,earnings,100,50,3/5/2020
DD0F15,earnings,100,50,3/5/2020
DD0F15,legal-issues-defendant,100,22,3/5/2020
DE5611,earnings,100,50,3/5/2020
DF01B1,legal-issues-defendant,100,22,3/5/2020
DF01B1,legal-issues-defendant,100,22,3/5/2020
DF16DE,earnings,100,50,3/5/2020
DF18E6,conference-call,100,50,3/5/2020
E09556,earnings,100,50,3/5/2020
E09556,earnings,100,50,3/5/2020
E13782,earnings,100,50,3/5/2020
E1E093,business-contract,100,69,3/5/2020
E22FDE,earnings,100,50,3/5/2020
E68E62,earnings,100,50,3/5/2020
E68E62,earnings,100,50,3/5/2020
E6EDED,dividend,100,50,3/5/2020
E71AE6,earnings,100,50,3/5/2020
E8E899,revenue-guidance,100,50,3/5/2020
E90C84,dividend,100,50,3/5/2020
EF5BED,product-release,100,64,3/5/2020
F3816D,conference-call,100,50,3/5/2020
F3FCC3,debt-extension-recipient,100,73,3/5/2020
F46EC9,executive-appointment,100,54,3/5/2020
F4D241,facility-open,100,65,3/5/2020
F5D499,conference-participant,100,50,3/5/2020
F66B58,earnings,100,50,3/5/2020
FD554E,dividend,100,50,3/5/2020
FDE409,earnings,100,50,3/5/2020
FE89E0,asset-sale,100,62,3/5/2020
FEBFE1,earnings,100,50,3/5/2020
001F1B,revenues,100,50,3/6/2020
03542C,earnings,100,50,3/6/2020
065D38,buybacks,100,74,3/6/2020
06CB5B,earnings,100,50,3/6/2020
06CB5B,earnings,100,50,3/6/2020
95294,executive-appointment,100,54,3/6/2020
0BA8CE,award,100,58,3/6/2020
0C6861,legal-issues-defendant,100,22,3/6/2020
0C6861,legal-issues-defendant,100,22,3/6/2020
0C6861,conference-participant,100,50,3/6/2020
0E64D4,partnership,100,61,3/6/2020
0E64D4,partnership,100,61,3/6/2020
1151F4,executive-appointment,100,54,3/6/2020
13C3E0,executive-appointment,100,54,3/6/2020
159739,dividend,100,50,3/6/2020
159739,dividend,100,50,3/6/2020
159739,conference-call,100,50,3/6/2020
159739,conference-call,100,50,3/6/2020
19BF16,fraud-defendant,100,20,3/6/2020
1A3E1B,donation,100,54,3/6/2020
21153F,award,100,58,3/6/2020
221AD7,legal-issues-defendant,100,22,3/6/2020
2.45E+15,award,100,58,3/6/2020
26D8ED,conference-participant,100,50,3/6/2020
2B0AF4,fraud-defendant,100,20,3/6/2020
2BC05E,legal-issues-defendant,100,22,3/6/2020
33AD83,partnership,100,61,3/6/2020
372037,legal-issues-defendant,100,22,3/6/2020
372037,legal-issues-defendant,100,22,3/6/2020
3B9886,conference-call,100,50,3/6/2020
3DED49,conference-call,100,50,3/6/2020
41C528,earnings,100,50,3/6/2020
425BDC,unit-acquisition-completed-acquiree,100,67,3/6/2020
4649D5,legal-issues-defendant,100,22,3/6/2020
494EB9,legal-issues-defendant,100,22,3/6/2020
49914B,executive-appointment,100,54,3/6/2020
4DAF5F,buybacks,100,74,3/6/2020
4DAF5F,buybacks,100,74,3/6/2020
4E6F5A,earnings,100,50,3/6/2020
4EE167,public-offering,100,43,3/6/2020
52BF94,conference-call,100,50,3/6/2020
5AA3B1,conference-call,100,50,3/6/2020
619882,conference-organizer,100,57,3/6/2020
62F41C,legal-issues-defendant,100,22,3/6/2020
636639,unit-acquisition-acquiree,100,76,3/6/2020
693ECD,fundraising,100,64,3/6/2020
6F39FC,dividend,100,50,3/6/2020
75768D,conference-call,100,50,3/6/2020
787D14,conference-participant,100,50,3/6/2020
790C34,revenue-guidance,100,50,3/6/2020
7A10FF,partnership,100,61,3/6/2020
7ACBA4,earnings,100,50,3/6/2020
7C790D,legal-issues-defendant,100,22,3/6/2020
80C400,buybacks,100,74,3/6/2020
8303CD,conference-participant,100,50,3/6/2020
873DB9,legal-issues-defendant,100,22,3/6/2020
873DB9,legal-issues-defendant,100,22,3/6/2020
8A8E41,conference-call,100,50,3/6/2020
8B9B3B,public-offering,100,43,3/6/2020
8C6C1B,facility-open,100,65,3/6/2020
8CF6DD,executive-appointment,100,54,3/6/2020
8D9993,executive-appointment,100,54,3/6/2020
94983E,legal-issues-defendant,100,22,3/6/2020
94983E,legal-issues-defendant,100,22,3/6/2020
950CDB,dividend,100,50,3/6/2020
980C14,executive-resignation,100,44,3/6/2020
990AD0,conference-organizer,100,57,3/6/2020
A28675,earnings,100,50,3/6/2020
AD9F1D,conference-participant,100,50,3/6/2020
B72D2E,earnings,100,50,3/6/2020
B762D3,earnings,100,50,3/6/2020
B762D3,earnings,100,50,3/6/2020
B762D3,earnings,100,50,3/6/2020
BDD12C,facility-open,100,65,3/6/2020
BDE867,executive-appointment,100,54,3/6/2020
BE86A1,dividend,100,50,3/6/2020
C1114B,award,100,58,3/6/2020
C3BCD5,legal-issues-defendant,100,22,3/6/2020
C5F463,partnership,100,61,3/6/2020
C9E4EC,conference-participant,100,50,3/6/2020
CA212F,legal-issues-defendant,100,22,3/6/2020
CBBFBF,legal-issues-defendant,100,22,3/6/2020
CBBFBF,legal-issues-defendant,100,22,3/6/2020
CFD4B6,conference-call,100,50,3/6/2020
D518D8,legal-issues-defendant,100,22,3/6/2020
D518D8,legal-issues-defendant,100,22,3/6/2020
DD0F15,legal-issues-defendant,100,22,3/6/2020
DD0F15,legal-issues-defendant,100,22,3/6/2020
DF01B1,legal-issues-defendant,100,22,3/6/2020
DF1F7A,executive-appointment,100,54,3/6/2020
DF6FDD,earnings-guidance,100,50,3/6/2020
E866D2,legal-issues-defendant,100,22,3/6/2020
EDF5CA,legal-issues-defendant,100,22,3/6/2020
EE04F0,legal-issues-defendant,100,22,3/6/2020
EEB5F9,conference-call,100,50,3/6/2020
F05B1B,executive-appointment,100,54,3/6/2020
F47871,public-offering,100,43,3/6/2020
F88147,earnings,100,50,3/6/2020
FCA54E,earnings,100,50,3/6/2020
E8846E,donation,100,54,3/8/2020
00067A,conference-participant,100,50,3/9/2020
034B61,earnings-guidance-suspended,100,29,3/9/2020
03542C,dividend,100,50,3/9/2020
03542C,earnings,100,50,3/9/2020
040DBB,dividend,100,50,3/9/2020
07EC43,executive-appointment,100,54,3/9/2020
0A59F8,partnership,100,61,3/9/2020
0A59F8,partnership,100,61,3/9/2020
0B73A7,earnings,100,50,3/9/2020
0B73A7,earnings,100,50,3/9/2020
0C6861,legal-issues-defendant,100,22,3/9/2020
0E499E,conference-participant,100,50,3/9/2020
0FC848,earnings,100,50,3/9/2020
10100E,earnings,100,50,3/9/2020
129DC8,executive-appointment,100,54,3/9/2020
12E454,executive-appointment,100,54,3/9/2020
143C9C,executive-appointment,100,54,3/9/2020
143C9C,executive-appointment,100,54,3/9/2020
15901B,conference-participant,100,50,3/9/2020
15B10D,earnings,100,50,3/9/2020
1AB023,earnings,100,50,3/9/2020
1AB023,earnings,100,50,3/9/2020
1AB023,earnings,100,50,3/9/2020
1D9E55,conference-participant,100,50,3/9/2020
221AD7,legal-issues-defendant,100,22,3/9/2020
228D42,partnership,100,61,3/9/2020
228D42,dividend,100,50,3/9/2020
2491BC,partnership,100,61,3/9/2020
2491BC,partnership,100,61,3/9/2020
26CC63,executive-appointment,100,54,3/9/2020
26CC63,earnings,100,50,3/9/2020
26DC29,conference-call,100,50,3/9/2020
275300,legal-issues-defendant,100,22,3/9/2020
275300,legal-issues-defendant,100,22,3/9/2020
295F9F,earnings,100,50,3/9/2020
295F9F,earnings,100,50,3/9/2020
2BC05E,executive-appointment,100,54,3/9/2020
2BC05E,legal-issues-defendant,100,22,3/9/2020
2D981A,merger-completed,100,66,3/9/2020
2D981A,merger-completed,100,66,3/9/2020
2F7A7E,earnings-guidance-suspended,100,29,3/9/2020
2F98A5,executive-appointment,100,54,3/9/2020
32C8CD,earnings,100,50,3/9/2020
32DCB3,business-contract,100,69,3/9/2020
34B97A,conference-participant,100,50,3/9/2020
372037,legal-issues-defendant,100,22,3/9/2020
3B318A,earnings,100,50,3/9/2020
3C6CCC,executive-appointment,100,54,3/9/2020
40F7DE,conference-participant,100,50,3/9/2020
42EFC7,earnings,100,50,3/9/2020
44A4FC,conference-participant,100,50,3/9/2020
450ECB,earnings,100,50,3/9/2020
450ECB,earnings,100,50,3/9/2020
458D2C,revenue-volume,100,50,3/9/2020
4A6F00,partnership,100,61,3/9/2020
4A6F00,partnership,100,61,3/9/2020
4C37C5,dividend,100,50,3/9/2020
4DAF5F,buybacks,100,74,3/9/2020
4DAF5F,buybacks,100,74,3/9/2020
54F1D2,public-offering,100,43,3/9/2020
57A854,executive-appointment,100,54,3/9/2020
583A75,revenue-volume,100,50,3/9/2020
583A75,revenue-volume,100,50,3/9/2020
59A832,dividend,100,50,3/9/2020
59F0B0,conference-call,100,50,3/9/2020
5F3E74,conference-participant,100,50,3/9/2020
5FDBD0,unit-acquisition-acquiree,100,76,3/9/2020
5FDBD0,unit-acquisition-acquiree,100,76,3/9/2020
5FDBD0,unit-acquisition-acquiree,100,76,3/9/2020
619882,conference-organizer,100,57,3/9/2020
61B81B,conference-call,100,50,3/9/2020
62B1C6,earnings,100,50,3/9/2020
657097,unit-acquisition-acquirer,100,49,3/9/2020
665D7D,partnership,100,61,3/9/2020
665D7D,debt-extension-recipient,100,73,3/9/2020
6844D2,executive-appointment,100,54,3/9/2020
6D4636,business-contract,100,69,3/9/2020
6F3FA8,unit-acquisition-acquiree,100,76,3/9/2020
726DDF,facility-upgrade,100,65,3/9/2020
7273FF,buybacks,100,74,3/9/2020
7.45E+28,executive-appointment,100,54,3/9/2020
78F776,earnings,100,50,3/9/2020
7BC92D,business-contract,100,69,3/9/2020
7BFF81,award,100,58,3/9/2020
7C62A3,award,100,58,3/9/2020
7FD8B9,conference-participant,100,50,3/9/2020
803FED,earnings,100,50,3/9/2020
810A4B,business-contract,100,69,3/9/2020
873DB9,legal-issues-defendant,100,22,3/9/2020
877734,conference-call,100,50,3/9/2020
881190,partnership,100,61,3/9/2020
896771,partnership,100,61,3/9/2020
8A8E41,product-release,100,64,3/9/2020
8C6C1B,facility-open,100,65,3/9/2020
8E10BF,earnings,100,50,3/9/2020
8E4F9A,operating-earnings,100,50,3/9/2020
9087B9,conference-participant,100,50,3/9/2020
913437,partnership,100,61,3/9/2020
92D230,conference-call,100,50,3/9/2020
9.39E+69,orphan-drug-designation,100,76,3/9/2020
944B2E,earnings,100,50,3/9/2020
9592FB,product-release,100,64,3/9/2020
97B027,earnings,100,50,3/9/2020
98D33E,earnings,100,50,3/9/2020
9.92E+94,executive-appointment,100,54,3/9/2020
9.92E+94,executive-appointment,100,54,3/9/2020
9B730A,conference-participant,100,50,3/9/2020
9F5997,legal-issues-defendant,100,22,3/9/2020
A26EF7,business-contract,100,69,3/9/2020
A2C979,executive-resignation,100,44,3/9/2020
A3800A,executive-appointment,100,54,3/9/2020
A6213D,partnership,100,61,3/9/2020
A631A3,legal-issues-defendant,100,22,3/9/2020
ACDCFA,executive-appointment,100,54,3/9/2020
AE4125,earnings,100,50,3/9/2020
AEEB76,partnership,100,61,3/9/2020
B01215,conference-call,100,50,3/9/2020
B1FC3B,product-release,100,64,3/9/2020
B9BDE8,earnings,100,50,3/9/2020
BB88B6,award,100,58,3/9/2020
BE379D,conference-call,100,50,3/9/2020
BFD0A7,conference-call,100,50,3/9/2020
C0BA36,product-release,100,64,3/9/2020
C188F8,conference-participant,100,50,3/9/2020
C564E4,conference-participant,100,50,3/9/2020
C58D71,earnings,100,50,3/9/2020
C6C702,partnership,100,61,3/9/2020
C6C702,partnership,100,61,3/9/2020
CBBFBF,legal-issues-defendant,100,22,3/9/2020
CC339B,dividend-up,100,54,3/9/2020
CC6FF5,partnership,100,61,3/9/2020
CD4DA8,executive-appointment,100,54,3/9/2020
CF351E,dividend,100,50,3/9/2020
CF3FF9,legal-issues-defendant,100,22,3/9/2020
D2E553,revenues,100,50,3/9/2020
D2E553,revenues,100,50,3/9/2020
D2E553,revenues,100,50,3/9/2020
D42DBA,executive-appointment,100,54,3/9/2020
D518D8,legal-issues-defendant,100,22,3/9/2020
D518D8,legal-issues-defendant,100,22,3/9/2020
D622D5,operating-earnings,100,50,3/9/2020
D650A7,unit-acquisition-acquirer,100,49,3/9/2020
D8ECA1,earnings,100,50,3/9/2020
DA48E4,executive-appointment,100,54,3/9/2020
DD0F15,legal-issues-defendant,100,22,3/9/2020
DF01B1,legal-issues-defendant,100,22,3/9/2020
E19A99,index-listing,100,76,3/9/2020
E30B34,conference-participant,100,50,3/9/2020
E30B34,conference-participant,100,50,3/9/2020
E68733,dividend,100,50,3/9/2020
E68733,dividend,100,50,3/9/2020
E7BF32,earnings,100,50,3/9/2020
E866D2,legal-issues-defendant,100,22,3/9/2020
E8846E,executive-resignation,100,44,3/9/2020
E8C557,executive-appointment,100,54,3/9/2020
EE04F0,legal-issues-defendant,100,22,3/9/2020
EEA6B3,partnership,100,61,3/9/2020
F30508,conference-participant,100,50,3/9/2020
F5349B,partnership,100,61,3/9/2020
F6A987,dividend,100,50,3/9/2020
F6DE54,settlement,100,56,3/9/2020
FACF19,partnership,100,61,3/9/2020
FCA54E,earnings,100,50,3/9/2020
FDD3FC,earnings,100,50,3/9/2020
FE89E0,conference-call,100,50,3/9/2020
00326D,dividend,100,50,3/10/2020
20751,patient-enrollment-complete,100,64,3/10/2020
033B58,earnings,100,50,3/10/2020
03B8CF,partnership,100,61,3/10/2020
05D148,business-contract,100,69,3/10/2020
07C69F,buybacks,100,74,3/10/2020
95294,unit-acquisition-acquiree,100,76,3/10/2020
95294,dividend,100,50,3/10/2020
0B7375,earnings,100,50,3/10/2020
0C2A0D,product-release,100,64,3/10/2020
0CE204,settlement,100,56,3/10/2020
0CE204,earnings-guidance-up,100,83,3/10/2020
0CE204,legal-issues-defendant,100,22,3/10/2020
0F0693,earnings,100,50,3/10/2020
12E454,award,100,58,3/10/2020
12E454,award,100,58,3/10/2020
136B26,earnings,100,50,3/10/2020
15901B,earnings,100,50,3/10/2020
15A388,partnership,100,61,3/10/2020
1880C5,conference-call,100,50,3/10/2020
18D9FA,earnings,100,50,3/10/2020
1B6F77,conference-participant,100,50,3/10/2020
1EBF8D,product-release,100,64,3/10/2020
1F08A6,dividend,100,50,3/10/2020
228D42,executive-appointment,100,54,3/10/2020
249B39,executive-appointment,100,54,3/10/2020
263216,dividend,100,50,3/10/2020
26DC29,earnings,100,50,3/10/2020
27BFA1,conference-call,100,50,3/10/2020
2A1009,business-contract,100,69,3/10/2020
2B8179,earnings,100,50,3/10/2020
2BC05E,legal-issues-defendant,100,22,3/10/2020
2BF36E,conference-participant,100,50,3/10/2020
2C681C,business-contract,100,69,3/10/2020
2EBC0B,dividend,100,50,3/10/2020
36529A,earnings,100,50,3/10/2020
36529A,earnings,100,50,3/10/2020
372037,legal-issues-defendant,100,22,3/10/2020
3E39A5,buybacks,100,74,3/10/2020
4806CE,investment-investor,100,55,3/10/2020
4885C8,award,100,58,3/10/2020
4A5C8D,spin-off,100,58,3/10/2020
4A6F00,partnership,100,61,3/10/2020
4A6F00,partnership,100,61,3/10/2020
4C31F3,conference-call,100,50,3/10/2020
4C7DB5,business-contract,100,69,3/10/2020
4DAF5F,buybacks,100,74,3/10/2020
4DAF5F,buybacks,100,74,3/10/2020
50070E,joint-venture,100,62,3/10/2020
523039,earnings,100,50,3/10/2020
54512F,earnings,100,50,3/10/2020
5546DA,buybacks,100,74,3/10/2020
56277A,dividend,100,50,3/10/2020
5D41E4,earnings,100,50,3/10/2020
5DD486,conference-call,100,50,3/10/2020
5FDBD0,earnings,100,50,3/10/2020
619882,conference-organizer,100,57,3/10/2020
627186,earnings,100,50,3/10/2020
636BBF,earnings,100,50,3/10/2020
641F17,earnings,100,50,3/10/2020
66667F,earnings,100,50,3/10/2020
66E04A,earnings-guidance-suspended,100,29,3/10/2020
68AB62,earnings,100,50,3/10/2020
69CE71,business-contract,100,69,3/10/2020
6D2BF6,earnings,100,50,3/10/2020
6D4636,facility-upgrade,100,65,3/10/2020
6ED519,executive-appointment,100,54,3/10/2020
70FCEF,earnings,100,50,3/10/2020
71B0CF,earnings,100,50,3/10/2020
735388,debt-restructuring,100,59,3/10/2020
748EB6,earnings,100,50,3/10/2020
766047,product-release,100,64,3/10/2020
766047,product-release,100,64,3/10/2020
7A10FF,executive-appointment,100,54,3/10/2020
7A975D,earnings,100,50,3/10/2020
80D744,acquisition-acquirer,100,49,3/10/2020
819492,earnings,100,50,3/10/2020
82C202,conference-participant,100,50,3/10/2020
8377DB,legal-issues-defendant,100,22,3/10/2020
848C0B,earnings,100,50,3/10/2020
863350,earnings,100,50,3/10/2020
8665BA,executive-appointment,100,54,3/10/2020
873DB9,legal-issues-defendant,100,22,3/10/2020
8E3F58,executive-appointment,100,54,3/10/2020
8E3F58,earnings,100,50,3/10/2020
9087B9,buybacks,100,74,3/10/2020
92B047,buybacks,100,74,3/10/2020
94A326,earnings,100,50,3/10/2020
95C575,buybacks,100,74,3/10/2020
9673BD,partnership,100,61,3/10/2020
9.86E+03,award,100,58,3/10/2020
990AD0,conference-organizer,100,57,3/10/2020
990AD0,dividend,100,50,3/10/2020
9A2760,earnings,100,50,3/10/2020
9A2760,earnings,100,50,3/10/2020
9A2760,earnings,100,50,3/10/2020
9A2760,earnings,100,50,3/10/2020
9A2760,earnings,100,50,3/10/2020
9C009A,earnings,100,50,3/10/2020
9F048E,executive-appointment,100,54,3/10/2020
A1EAC8,executive-appointment,100,54,3/10/2020
A26EF7,earnings,100,50,3/10/2020
A3AAA5,dividend,100,50,3/10/2020
A495F7,earnings,100,50,3/10/2020
A5628C,executive-appointment,100,54,3/10/2020
A7102F,joint-venture,100,62,3/10/2020
A74F6F,earnings,100,50,3/10/2020
A871B0,dividend,100,50,3/10/2020
A871B0,earnings,100,50,3/10/2020
B01111,earnings,100,50,3/10/2020
B13B68,conference-participant,100,50,3/10/2020
B2206F,product-release,100,64,3/10/2020
B37FB4,executive-appointment,100,54,3/10/2020
B614F8,analyst-ratings-change-neutral,100,78,3/10/2020
B66928,conference-participant,100,50,3/10/2020
B80AD1,public-offering,100,43,3/10/2020
BD15E8,acquisition-completed-acquirer,100,49,3/10/2020
BD8517,executive-appointment,100,54,3/10/2020
C037A8,executive-appointment,100,54,3/10/2020
C22BE8,conference-call,100,50,3/10/2020
C407A0,business-contract,100,69,3/10/2020
C407A0,business-contract,100,69,3/10/2020
C48574,revenue-up,100,79,3/10/2020
C48574,revenue-up,100,69,3/10/2020
C48574,revenue-up,100,69,3/10/2020
C48574,revenue-up,100,69,3/10/2020
C598D7,acquisition-acquirer,100,49,3/10/2020
C6C702,partnership,100,61,3/10/2020
C6C702,partnership,100,61,3/10/2020
C74887,earnings,100,50,3/10/2020
C8A248,conference-participant,100,50,3/10/2020
C9732E,legal-issues-defendant,100,22,3/10/2020
CAD7D9,conference-call,100,50,3/10/2020
CB89EA,investment-recipient,100,73,3/10/2020
CBB77B,earnings,100,50,3/10/2020
CBB77B,earnings,100,50,3/10/2020
CBBFBF,legal-issues-defendant,100,22,3/10/2020
CDE51C,award,100,58,3/10/2020
CFF15D,dividend-up,100,55,3/10/2020
D064D5,earnings,100,50,3/10/2020
D06755,product-release,100,64,3/10/2020
D13F1C,earnings,100,50,3/10/2020
D13F1C,earnings,100,50,3/10/2020
D13F1C,earnings,100,50,3/10/2020
D13F1C,earnings,100,50,3/10/2020
D13F1C,earnings,100,50,3/10/2020
D13F1C,earnings,100,50,3/10/2020
D13F1C,earnings,100,50,3/10/2020
D437C3,conference-participant,100,50,3/10/2020
D47D56,business-contract,100,69,3/10/2020
D4AC65,product-release,100,64,3/10/2020
D518D8,legal-issues-defendant,100,22,3/10/2020
D518D8,legal-issues-defendant,100,22,3/10/2020
D75910,executive-appointment,100,54,3/10/2020
D75910,dividend,100,50,3/10/2020
D76AEF,executive-appointment,100,54,3/10/2020
DB396B,dividend,100,50,3/10/2020
DC486E,trading-halt,100,43,3/10/2020
DC486E,trading-resumed,100,58,3/10/2020
DD0F15,legal-issues-defendant,100,22,3/10/2020
DF01B1,legal-issues-defendant,100,22,3/10/2020
DF1F7A,dividend,100,50,3/10/2020
E1BD05,conference-participant,100,50,3/10/2020
E22FDE,conference-participant,100,50,3/10/2020
E71AE6,executive-appointment,100,54,3/10/2020
E829E8,executive-appointment,100,54,3/10/2020
E8846E,investment-investor,100,55,3/10/2020
E8E899,executive-appointment,100,54,3/10/2020
E99180,buybacks,100,74,3/10/2020
EEB5F9,earnings,100,50,3/10/2020
EF7163,buybacks,100,74,3/10/2020
EFA7B2,earnings,100,50,3/10/2020
F2BC3D,earnings,100,50,3/10/2020
F6DCE4,partnership,100,61,3/10/2020
F6E1B5,earnings,100,50,3/10/2020
F6FA6A,executive-appointment,100,54,3/10/2020
FAAFA2,conference-participant,100,50,3/10/2020
FBD92D,earnings,100,50,3/10/2020
FC1736,earnings,100,50,3/10/2020
FC9A88,buybacks,100,74,3/10/2020
0157B1,partnership,100,61,3/11/2020
0157B1,product-release,100,64,3/11/2020
0157B1,executive-appointment,100,54,3/11/2020
48590,executive-appointment,100,54,3/11/2020
06A456,earnings,100,50,3/11/2020
083F72,earnings,100,50,3/11/2020
09F623,capex-down,100,35,3/11/2020
0A77DB,earnings,100,50,3/11/2020
0A77DB,executive-appointment,100,54,3/11/2020
0C8D82,buybacks,100,74,3/11/2020
0CADBC,earnings,100,50,3/11/2020
1201B5,public-offering,100,43,3/11/2020
154272,credit-extension-recipient,100,69,3/11/2020
1748F6,earnings,100,50,3/11/2020
1E9A6D,award,100,58,3/11/2020
1FAF22,conference-call,100,50,3/11/2020
223552,conference-participant,100,50,3/11/2020
223552,partnership,100,61,3/11/2020
2262BD,credit-extension-recipient,100,69,3/11/2020
26FA41,revenue-up,100,69,3/11/2020
292A70,earnings,100,50,3/11/2020
2BC05E,legal-issues-defendant,100,22,3/11/2020
2C681C,earnings,100,50,3/11/2020
2C681C,earnings,100,50,3/11/2020
2EB04E,partnership,100,61,3/11/2020
301493,legal-issues-defendant,100,22,3/11/2020
301493,legal-issues-defendant,100,22,3/11/2020
301493,legal-issues-defendant,100,22,3/11/2020
301493,legal-issues-defendant,100,22,3/11/2020
301493,legal-issues-defendant,100,22,3/11/2020
301493,legal-issues-defendant,100,22,3/11/2020
30DE64,earnings,100,50,3/11/2020
3461CF,earnings-guidance-up,100,83,3/11/2020
372037,legal-issues-defendant,100,22,3/11/2020
37B120,earnings,100,50,3/11/2020
3CCC90,conference-call,100,50,3/11/2020
3D6933,pretax-earnings-positive,100,69,3/11/2020
3D6933,pretax-earnings-positive,100,69,3/11/2020
3F4497,buybacks,100,74,3/11/2020
408380,earnings,100,50,3/11/2020
45BC35,product-release,100,64,3/11/2020
4.60E+06,earnings,100,50,3/11/2020
494EB9,legal-issues-defendant,100,22,3/11/2020
4B49CF,earnings,100,50,3/11/2020
4C2F17,earnings,100,50,3/11/2020
4C3FE9,earnings,100,50,3/11/2020
4D8313,executive-appointment,100,54,3/11/2020
4DAF5F,buybacks,100,74,3/11/2020
4DAF5F,buybacks,100,74,3/11/2020
4DD203,earnings,100,50,3/11/2020
4EE14A,earnings,100,50,3/11/2020
4EE14A,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
52D936,earnings,100,50,3/11/2020
5.47E+28,orphan-drug-designation,100,76,3/11/2020
55D0F3,earnings,100,50,3/11/2020
57B174,executive-appointment,100,54,3/11/2020
57EF50,earnings,100,50,3/11/2020
57EF50,earnings,100,50,3/11/2020
57EF50,earnings,100,50,3/11/2020
587D25,conference-participant,100,50,3/11/2020
589846,earnings,100,50,3/11/2020
5CEE02,conference-organizer,100,57,3/11/2020
5E9934,earnings-up,100,68,3/11/2020
60FE03,earnings,100,50,3/11/2020
60FE03,earnings,100,50,3/11/2020
619882,conference-organizer,100,57,3/11/2020
61E975,executive-appointment,100,54,3/11/2020
657097,unit-acquisition-acquirer,100,49,3/11/2020
69CE71,dividend,100,50,3/11/2020
6DD6BA,credit-extension-recipient,100,69,3/11/2020
6-Dec-05,earnings,100,50,3/11/2020
6F3936,conference-call,100,50,3/11/2020
6F6559,earnings,100,50,3/11/2020
71553E,earnings,100,50,3/11/2020
71694D,earnings,100,50,3/11/2020
72EF75,earnings-revision,100,29,3/11/2020
7448A3,conference-participant,100,50,3/11/2020
7AF907,conference-participant,100,50,3/11/2020
7FEEE1,earnings,100,50,3/11/2020
818A2F,earnings,100,50,3/11/2020
818A2F,earnings,100,50,3/11/2020
8377DB,legal-issues-defendant,100,22,3/11/2020
8377DB,legal-issues-defendant,100,22,3/11/2020
873DB9,legal-issues-defendant,100,22,3/11/2020
877C0C,executive-appointment,100,54,3/11/2020
8B1F37,dividend,100,50,3/11/2020
8B3B0E,dividend,100,50,3/11/2020
8B8656,earnings,100,50,3/11/2020
8D5145,buybacks,100,74,3/11/2020
8FF57A,earnings,100,50,3/11/2020
9004C4,earnings,100,50,3/11/2020
9004C4,earnings-up,100,68,3/11/2020
92005C,earnings,100,50,3/11/2020
947B0B,clinical-trials,100,56,3/11/2020
95C392,award,100,58,3/11/2020
967D92,earnings-guidance-suspended,100,29,3/11/2020
979451,legal-issues-defendant,100,22,3/11/2020
9B5968,dividend,100,50,3/11/2020
9B5968,dividend,100,50,3/11/2020
A01983,dividend,100,50,3/11/2020
A21649,dividend,100,50,3/11/2020
A26C26,earnings,100,50,3/11/2020
A26C26,earnings,100,50,3/11/2020
A350C1,acquisition-completed-acquirer,100,49,3/11/2020
ACDCFA,earnings,100,50,3/11/2020
ADFB3A,earnings,100,50,3/11/2020
AE0CCE,earnings,100,50,3/11/2020
AE79CD,earnings,100,50,3/11/2020
AED6CF,investment-investor,100,55,3/11/2020
AEEB76,earnings,100,50,3/11/2020
AF93DE,earnings,100,50,3/11/2020
B33E77,legal-issues-defendant,100,22,3/11/2020
B33E77,legal-issues-defendant,100,22,3/11/2020
B37FB4,award,100,58,3/11/2020
B3A166,earnings,100,50,3/11/2020
B604DF,legal-issues-defendant,100,22,3/11/2020
B73395,earnings,100,50,3/11/2020
B73395,earnings,100,50,3/11/2020
B73395,earnings,100,50,3/11/2020
B73395,earnings,100,50,3/11/2020
B73395,earnings,100,50,3/11/2020
B80AD1,public-offering,100,43,3/11/2020
B840EF,partnership,100,61,3/11/2020
B8A51F,earnings,100,50,3/11/2020
C4F9C6,executive-appointment,100,54,3/11/2020
C9732E,legal-issues-defendant,100,22,3/11/2020
C9732E,legal-issues-defendant,100,22,3/11/2020
C9732E,legal-issues-defendant,100,22,3/11/2020
C9732E,legal-issues-defendant,100,22,3/11/2020
C9732E,legal-issues-defendant,100,22,3/11/2020
CB89EA,earnings,100,50,3/11/2020
CBBFBF,legal-issues-defendant,100,22,3/11/2020
CD051C,earnings,100,50,3/11/2020
CD051C,earnings,100,50,3/11/2020
CD051C,earnings,100,50,3/11/2020
CD051C,earnings,100,50,3/11/2020
CD051C,earnings,100,50,3/11/2020
CE2791,buybacks,100,74,3/11/2020
CF6A5A,executive-appointment,100,54,3/11/2020
CFB6CA,earnings,100,50,3/11/2020
CFB6CA,earnings,100,50,3/11/2020
CFB6CA,earnings,100,50,3/11/2020
CFF15D,partnership,100,61,3/11/2020
D3FA2C,earnings-guidance-suspended,100,29,3/11/2020
D650A7,dividend,100,50,3/11/2020
D90441,earnings,100,50,3/11/2020
D90441,earnings,100,50,3/11/2020
D90441,earnings,100,50,3/11/2020
DD0F15,legal-issues-defendant,100,22,3/11/2020
DF01B1,legal-issues-defendant,100,22,3/11/2020
DF5F14,earnings,100,50,3/11/2020
E124EB,partnership,100,61,3/11/2020
E124EB,award,100,58,3/11/2020
E3A829,earnings,100,50,3/11/2020
E4CE73,clinical-trials,100,56,3/11/2020
E5C910,earnings,100,50,3/11/2020
E68E62,partnership,100,61,3/11/2020
E866D2,legal-issues-defendant,100,22,3/11/2020
E8C557,earnings,100,50,3/11/2020
EB6965,executive-appointment,100,54,3/11/2020
EB6965,dividend-up,100,81,3/11/2020
EFD406,executive-appointment,100,54,3/11/2020
F05B1B,earnings,100,50,3/11/2020
F05B1B,earnings,100,50,3/11/2020
F3EDB4,earnings,100,50,3/11/2020
F73DD1,earnings,100,50,3/11/2020
FD2565,earnings,100,50,3/11/2020
02ACBD,executive-appointment,100,54,3/12/2020
0490C6,earnings,100,50,3/12/2020
0490C6,earnings,100,50,3/12/2020
0490C6,earnings,100,50,3/12/2020
0490C6,earnings,100,50,3/12/2020
0919B1,earnings,100,50,3/12/2020
09DE1F,earnings,100,50,3/12/2020
0C6293,earnings-up,100,68,3/12/2020
0C6293,earnings,100,50,3/12/2020
0C6293,earnings,100,50,3/12/2020
0E5619,earnings,100,50,3/12/2020
0EF1AF,earnings,100,50,3/12/2020
0FC848,earnings,100,50,3/12/2020
106394,dividend,100,50,3/12/2020
106394,dividend,100,50,3/12/2020
1201B5,public-offering,100,43,3/12/2020
12E454,partnership,100,61,3/12/2020
14BA06,capex-down,100,35,3/12/2020
15789A,earnings,100,50,3/12/2020
16B882,revenue-volume,100,50,3/12/2020
1748F6,partnership,100,61,3/12/2020
17EDA5,dividend,100,50,3/12/2020
190BE6,earnings,100,50,3/12/2020
196D18,earnings,100,50,3/12/2020
196D18,earnings,100,50,3/12/2020
19BF16,legal-issues-defendant,100,22,3/12/2020
1AC649,earnings,100,50,3/12/2020
1AD9CC,earnings,100,50,3/12/2020
1CD4B5,earnings,100,50,3/12/2020
1CD4B5,earnings,100,50,3/12/2020
1CD708,dividend,100,50,3/12/2020
1F43A1,dividend-up,100,81,3/12/2020
1F464F,executive-appointment,100,54,3/12/2020
20403D,earnings,100,50,3/12/2020
2158DF,partnership,100,61,3/12/2020
223552,partnership,100,61,3/12/2020
232053,earnings,100,50,3/12/2020
26D8ED,executive-appointment,100,54,3/12/2020
275300,legal-issues-defendant,100,22,3/12/2020
2B0AF4,executive-appointment,100,54,3/12/2020
2BC05E,legal-issues-defendant,100,22,3/12/2020
2D981A,earnings,100,50,3/12/2020
2D981A,earnings,100,50,3/12/2020
2E1322,legal-issues-defendant,100,22,3/12/2020
2EB04E,partnership,100,61,3/12/2020
301493,legal-issues-defendant,100,22,3/12/2020
301493,legal-issues-defendant,100,22,3/12/2020
301493,legal-issues-defendant,100,22,3/12/2020
31666F,buybacks,100,74,3/12/2020
338544,merger,100,66,3/12/2020
341759,earnings,100,50,3/12/2020
3461CF,award,100,58,3/12/2020
372037,legal-issues-defendant,100,22,3/12/2020
372037,legal-issues-defendant,100,22,3/12/2020
3B9886,executive-resignation,100,44,3/12/2020
41B53E,buybacks,100,74,3/12/2020
4398A2,earnings,100,50,3/12/2020
4398A2,earnings,100,50,3/12/2020
43A060,partnership,100,61,3/12/2020
449447,earnings,100,50,3/12/2020
4AC91D,legal-issues-defendant,100,22,3/12/2020
4D229C,earnings,100,50,3/12/2020
4DAF5F,buybacks,100,74,3/12/2020
4DAF5F,buybacks,100,74,3/12/2020
4EEB00,operating-earnings,100,50,3/12/2020
4EEB00,earnings,100,50,3/12/2020
4F783B,buybacks,100,74,3/12/2020
5065B1,dividend,100,50,3/12/2020
510EA6,supply-increase,100,74,3/12/2020
54B889,executive-appointment,100,54,3/12/2020
55C9B5,partnership,100,61,3/12/2020
57A854,earnings,100,50,3/12/2020
586BD7,earnings,100,50,3/12/2020
5876DC,executive-appointment,100,54,3/12/2020
587D25,earnings,100,50,3/12/2020
5AA3B1,earnings,100,50,3/12/2020
5AA3B1,partnership,100,61,3/12/2020
5AA3B1,partnership,100,61,3/12/2020
5F9CE3,executive-appointment,100,54,3/12/2020
619882,executive-appointment,100,54,3/12/2020
6559D8,clinical-trials-positive,100,87,3/12/2020
6559D8,earnings,100,50,3/12/2020
6810DE,earnings,100,50,3/12/2020
6810DE,fast-track-designation,100,81,3/12/2020
69C99E,earnings,100,50,3/12/2020
69CE71,partnership,100,61,3/12/2020
6EA292,dividend,100,50,3/12/2020
709AED,buybacks,100,74,3/12/2020
72FCA3,earnings,100,50,3/12/2020
73A213,buybacks,100,74,3/12/2020
73C521,award,100,58,3/12/2020
747219,earnings,100,50,3/12/2020
756BB4,earnings,100,50,3/12/2020
76DD0C,earnings,100,50,3/12/2020
7710F3,earnings,100,50,3/12/2020
79167B,buybacks,100,74,3/12/2020
7A0EC4,earnings,100,50,3/12/2020
7ADE57,acquisition-acquirer,100,49,3/12/2020
7BC92D,earnings,100,50,3/12/2020
7BEA98,earnings,100,50,3/12/2020
7F9984,buybacks,100,74,3/12/2020
817ED9,earnings,100,50,3/12/2020
82E58A,executive-appointment,100,54,3/12/2020
8665BA,business-contract,100,69,3/12/2020
873DB9,legal-issues-defendant,100,22,3/12/2020
877734,earnings,100,50,3/12/2020
8.79E+06,earnings,100,50,3/12/2020
885758,earnings,100,50,3/12/2020
8A8E41,partnership,100,61,3/12/2020
8BFAA4,earnings,100,50,3/12/2020
8C6C1B,executive-appointment,100,54,3/12/2020
8E4250,conference-call,100,50,3/12/2020
8E82A6,conference-participant,100,50,3/12/2020
8EEA28,earnings,100,50,3/12/2020
918D6D,ipo-pricing,100,50,3/12/2020
918D6D,ipo-pricing,100,50,3/12/2020
918D6D,ipo-pricing,100,50,3/12/2020
92D6A5,buybacks,100,74,3/12/2020
9546A5,earnings,100,50,3/12/2020
95DC1F,dividend,100,50,3/12/2020
97693A,conference-call,100,50,3/12/2020
989E2F,dividend,100,50,3/12/2020
9D307D,earnings,100,50,3/12/2020
A017F4,earnings,100,50,3/12/2020
A01983,earnings,100,50,3/12/2020
A204A7,earnings,100,50,3/12/2020
A26C26,buybacks,100,74,3/12/2020
A28675,earnings,100,50,3/12/2020
A6828A,business-contract,100,69,3/12/2020
A6FC89,earnings,100,50,3/12/2020
A6FE1C,unit-acquisition-acquirer,100,49,3/12/2020
AA3AB8,earnings,100,50,3/12/2020
AADE0B,executive-appointment,100,54,3/12/2020
ABB493,earnings,100,50,3/12/2020
AD22F2,earnings,100,50,3/12/2020
AE4EEB,dividend-up,100,81,3/12/2020
AE7D16,product-release,100,64,3/12/2020
B01215,earnings,100,50,3/12/2020
B05000,earnings,100,50,3/12/2020
B08C51,executive-appointment,100,54,3/12/2020
B08C51,earnings,100,50,3/12/2020
B106FA,earnings,100,50,3/12/2020
B33E77,earnings,100,50,3/12/2020
B381D8,executive-appointment,100,54,3/12/2020
B3ED62,business-contract,100,69,3/12/2020
BA218A,executive-appointment,100,54,3/12/2020
BDF2BD,buybacks,100,74,3/12/2020
BEB756,buybacks,100,74,3/12/2020
BFAEB4,conference-call,100,50,3/12/2020
BFD0A7,earnings,100,50,3/12/2020
C11C46,partnership,100,61,3/12/2020
C2DD02,dividend,100,50,3/12/2020
C45C1F,executive-appointment,100,54,3/12/2020
C4F9C6,earnings,100,50,3/12/2020
C598D7,acquisition-acquirer,100,49,3/12/2020
C5E100,earnings,100,50,3/12/2020
C9732E,legal-issues-defendant,100,22,3/12/2020
C9881C,revenue-up,100,69,3/12/2020
C9881C,revenue-up,100,69,3/12/2020
C9881C,revenue-up,100,69,3/12/2020
CB7AB2,award,100,58,3/12/2020
CCB623,earnings,100,50,3/12/2020
CCB623,executive-appointment,100,54,3/12/2020
CDC217,earnings,100,50,3/12/2020
CDD75E,earnings,100,50,3/12/2020
CEDFD5,partnership,100,61,3/12/2020
CF3FF9,earnings,100,50,3/12/2020
CF7292,earnings,100,50,3/12/2020
CFD4B6,earnings,100,50,3/12/2020
D07B07,earnings,100,50,3/12/2020
D11C1C,dividend-up,100,81,3/12/2020
D36B23,earnings,100,50,3/12/2020
D42DBA,earnings,100,50,3/12/2020
D518D8,legal-issues-defendant,100,22,3/12/2020
D6144F,earnings,100,50,3/12/2020
D6489C,earnings,100,50,3/12/2020
D6853F,legal-issues-defendant,100,22,3/12/2020
D697DE,earnings,100,50,3/12/2020
D7918D,executive-salary,100,52,3/12/2020
DB9F70,earnings,100,50,3/12/2020
DC0066,earnings,100,50,3/12/2020
DC2B00,earnings,100,50,3/12/2020
DD0F15,legal-issues-defendant,100,22,3/12/2020
DD0F15,earnings,100,50,3/12/2020
DF01B1,legal-issues-defendant,100,22,3/12/2020
DF01B1,legal-issues-defendant,100,22,3/12/2020
DF16DE,earnings,100,50,3/12/2020
DF18E6,earnings,100,50,3/12/2020
E38906,earnings,100,50,3/12/2020
E71AE6,earnings,100,50,3/12/2020
E82A2D,earnings,100,50,3/12/2020
E866D2,legal-issues-defendant,100,22,3/12/2020
E8D221,earnings,100,50,3/12/2020
EB1E1A,earnings,100,50,3/12/2020
ECA300,earnings,100,50,3/12/2020
ECF4F8,earnings-guidance,100,50,3/12/2020
EE6F1C,partnership,100,61,3/12/2020
EF5914,earnings,100,50,3/12/2020
F30508,fast-track-designation,100,81,3/12/2020
F3816D,earnings,100,50,3/12/2020
F47871,executive-appointment,100,54,3/12/2020
F569FD,earnings,100,50,3/12/2020
F6A945,earnings,100,50,3/12/2020
F6DCE4,dividend,100,50,3/12/2020
F6FA6A,product-release,100,64,3/12/2020
F7902B,acquisition-acquirer,100,49,3/12/2020
FAE021,executive-appointment,100,54,3/12/2020
FAE021,executive-appointment,100,54,3/12/2020
FC1736,revenue-up,100,69,3/12/2020
FC1736,earnings,100,50,3/12/2020
FC1736,earnings,100,50,3/12/2020
FEE4B0,acquisition-acquirer,100,49,3/12/2020
07CA6A,award,100,58,3/13/2020
07CA6A,award,100,58,3/13/2020
149301,buybacks,100,74,3/13/2020
154272,earnings,100,50,3/13/2020
16B882,earnings,100,50,3/13/2020
19BF16,legal-issues-defendant,100,22,3/13/2020
1AB023,earnings,100,50,3/13/2020
1AB023,earnings,100,50,3/13/2020
1AB023,earnings,100,50,3/13/2020
1B6F77,earnings,100,50,3/13/2020
228D42,partnership,100,61,3/13/2020
228D42,executive-appointment,100,54,3/13/2020
26CC63,earnings,100,50,3/13/2020
26CC63,earnings,100,50,3/13/2020
26CC63,earnings,100,50,3/13/2020
275300,legal-issues-defendant,100,22,3/13/2020
275300,dividend,100,50,3/13/2020
29B702,dividend,100,50,3/13/2020
2BC05E,legal-issues-defendant,100,22,3/13/2020
2C35B5,earnings,100,50,3/13/2020
2E1322,acquisition-acquiree,100,76,3/13/2020
2E1322,acquisition-acquiree,100,76,3/13/2020
2EBA55,dividend,100,50,3/13/2020
301493,legal-issues-defendant,100,22,3/13/2020
301493,legal-issues-defendant,100,22,3/13/2020
372037,legal-issues-defendant,100,22,3/13/2020
372037,legal-issues-defendant,100,22,3/13/2020
372037,legal-issues-defendant,100,22,3/13/2020
37B618,dividend,100,50,3/13/2020
37B618,earnings,100,50,3/13/2020
39692D,earnings-guidance-suspended,100,29,3/13/2020
4649D5,executive-appointment,100,54,3/13/2020
46CF27,acquisition-completed-acquirer,100,49,3/13/2020
46CF27,acquisition-completed-acquirer,100,49,3/13/2020
4.91E+58,loan-recipient,100,59,3/13/2020
494EB9,legal-issues-defendant,100,22,3/13/2020
4C7DB5,acquisition-completed-acquirer,100,49,3/13/2020
4DAF5F,buybacks,100,74,3/13/2020
4DAF5F,buybacks,100,74,3/13/2020
562853,buybacks,100,74,3/13/2020
57CAAB,donation,100,54,3/13/2020
5AA3B1,partnership,100,61,3/13/2020
6166D1,conference-call,100,50,3/13/2020
619882,dividend,100,50,3/13/2020
657097,dividend,100,50,3/13/2020
6634D9,earnings,100,50,3/13/2020
6D3B7B,dividend,100,50,3/13/2020
6FCEF9,earnings,100,50,3/13/2020
726EEA,stock-gain,100,63,3/13/2020
728737,dividend,100,50,3/13/2020
728737,dividend,100,50,3/13/2020
7B9212,earnings,100,50,3/13/2020
826FD6,dividend,100,50,3/13/2020
83598E,business-contract,100,69,3/13/2020
89FBB1,buybacks,100,74,3/13/2020
97B027,executive-appointment,100,54,3/13/2020
9B4066,acquisition-acquirer,100,49,3/13/2020
9C5BA5,revenues,100,50,3/13/2020
A47A7D,buybacks,100,74,3/13/2020
A4BCDE,dividend-up,100,81,3/13/2020
A6828A,partnership,100,61,3/13/2020
A94637,buybacks,100,74,3/13/2020
AC7C4F,earnings,100,50,3/13/2020
ADF1B0,buybacks,100,74,3/13/2020
B33E77,legal-issues-defendant,100,22,3/13/2020
B33E77,legal-issues-defendant,100,22,3/13/2020
B33E77,legal-issues-defendant,100,22,3/13/2020
B33E77,legal-issues-defendant,100,22,3/13/2020
B4B281,earnings,100,50,3/13/2020
B4F5F4,earnings,100,50,3/13/2020
B762D3,dividend,100,50,3/13/2020
BD44C9,earnings,100,50,3/13/2020
C9732E,legal-issues-defendant,100,22,3/13/2020
C9F39B,dividend,100,50,3/13/2020
CA212F,shareholder-rights-plan,100,43,3/13/2020
D09938,buybacks,100,74,3/13/2020
D139BC,dividend,100,50,3/13/2020
D518D8,legal-issues-defendant,100,22,3/13/2020
D7918D,legal-issues-defendant,100,22,3/13/2020
D8ECA1,earnings,100,50,3/13/2020
D8ECA1,earnings,100,50,3/13/2020
D8ECA1,earnings,100,50,3/13/2020
D8ECA1,earnings,100,50,3/13/2020
D8ECA1,earnings,100,50,3/13/2020
D96202,conference-call,100,50,3/13/2020
DC6EF3,earnings,100,50,3/13/2020
DD0F15,legal-issues-defendant,100,22,3/13/2020
DD0F15,legal-issues-defendant,100,22,3/13/2020
DF01B1,legal-issues-defendant,100,22,3/13/2020
E866D2,legal-issues-defendant,100,22,3/13/2020
E8846E,executive-appointment,100,54,3/13/2020
EA4E68,dividend,100,50,3/13/2020
F294DD,dividend,100,50,3/13/2020
FACF19,partnership,100,61,3/13/2020
221AD7,legal-issues-defendant,100,22,3/14/2020
275300,legal-issues-defendant,100,22,3/14/2020
275300,legal-issues-defendant,100,22,3/14/2020
2BC05E,legal-issues-defendant,100,22,3/14/2020
301493,legal-issues-defendant,100,22,3/14/2020
372037,legal-issues-defendant,100,22,3/14/2020
494EB9,legal-issues-defendant,100,22,3/14/2020
62F41C,legal-issues-defendant,100,22,3/14/2020
873DB9,legal-issues-defendant,100,22,3/14/2020
B33E77,legal-issues-defendant,100,22,3/14/2020
B33E77,legal-issues-defendant,100,22,3/14/2020
C9732E,legal-issues-defendant,100,22,3/14/2020
CBBFBF,legal-issues-defendant,100,22,3/14/2020
D518D8,legal-issues-defendant,100,22,3/14/2020
D7918D,legal-issues-defendant,100,22,3/14/2020
D7918D,legal-issues-defendant,100,22,3/14/2020
DD0F15,legal-issues-defendant,100,22,3/14/2020
00326E,business-contract-terminated,100,31,3/16/2020
0157B1,revenue-up,100,92,3/16/2020
075CF7,executive-appointment,100,54,3/16/2020
07C69F,facility-sale,100,52,3/16/2020
95294,executive-appointment,100,54,3/16/2020
09DE1F,executive-appointment,100,54,3/16/2020
0B13E8,executive-appointment,100,54,3/16/2020
0B400D,executive-appointment,100,54,3/16/2020
0B4D10,executive-appointment,100,54,3/16/2020
0B4D10,dividend,100,50,3/16/2020
0B9E6F,buybacks,100,74,3/16/2020
0CC01F,dividend,100,50,3/16/2020
0F0440,partnership,100,61,3/16/2020
152FA5,earnings,100,50,3/16/2020
152FA5,earnings,100,50,3/16/2020
168A5D,unit-acquisition-completed-acquiree,100,67,3/16/2020
1880C5,earnings,100,50,3/16/2020
19BF16,executive-appointment,100,54,3/16/2020
1AE9D5,revenue-up,100,69,3/16/2020
1AE9D5,revenue-up,100,69,3/16/2020
1B5FEA,earnings,100,50,3/16/2020
1EBF8D,regulatory-product-approval-granted,100,81,3/16/2020
20403D,dividend-up,100,60,3/16/2020
21D903,earnings,100,50,3/16/2020
225CA2,trading-halt,100,43,3/16/2020
225CA2,trading-resumed,100,58,3/16/2020
2262BD,executive-appointment,100,54,3/16/2020
24A89A,earnings,100,50,3/16/2020
24A89A,earnings,100,50,3/16/2020
25D3CE,earnings,100,50,3/16/2020
25D3CE,earnings,100,50,3/16/2020
25D3CE,earnings,100,50,3/16/2020
25D3CE,earnings,100,50,3/16/2020
25DD05,dividend,100,50,3/16/2020
26E3BA,earnings,100,50,3/16/2020
275300,legal-issues-defendant,100,22,3/16/2020
282C18,dividend,100,50,3/16/2020
2920D5,capex,100,50,3/16/2020
2B0AF4,stock-loss,100,40,3/16/2020
2BC05E,legal-issues-defendant,100,22,3/16/2020
2BC05E,legal-issues-defendant,100,22,3/16/2020
301493,legal-issues-defendant,100,22,3/16/2020
356B21,conference-call,100,50,3/16/2020
35AE32,executive-appointment,100,54,3/16/2020
366A08,capex-guidance-down,100,35,3/16/2020
366A08,capex-guidance-down,100,35,3/16/2020
372037,legal-issues-defendant,100,22,3/16/2020
372037,legal-issues-defendant,100,22,3/16/2020
37B120,merger,100,66,3/16/2020
37B120,acquisition-acquirer,100,49,3/16/2020
37B120,acquisition-acquirer,100,49,3/16/2020
37B120,earnings,100,50,3/16/2020
3C8A04,conference-call,100,50,3/16/2020
3CCC90,buybacks,100,74,3/16/2020
416291,dividend,100,50,3/16/2020
427F32,executive-appointment,100,54,3/16/2020
494EB9,legal-issues-defendant,100,22,3/16/2020
4A7C1F,fraud-defendant,100,20,3/16/2020
4A7C1F,legal-issues-defendant,100,22,3/16/2020
4A7C1F,legal-issues-defendant,100,22,3/16/2020
4B7006,board-meeting,100,51,3/16/2020
4C31F3,earnings-delayed,100,26,3/16/2020
4C5CC9,buybacks,100,74,3/16/2020
4DAF5F,buybacks,100,74,3/16/2020
4DAF5F,buybacks,100,74,3/16/2020
4E6F5A,executive-appointment,100,54,3/16/2020
4EE14A,legal-issues-defendant,100,22,3/16/2020
539F49,executive-appointment,100,54,3/16/2020
539F49,earnings,100,50,3/16/2020
539F49,earnings,100,50,3/16/2020
5.47E+28,earnings,100,50,3/16/2020
54A713,asset-sale,100,62,3/16/2020
54DF47,dividend,100,50,3/16/2020
5675EB,dividend,100,50,3/16/2020
5704AC,dividend,100,50,3/16/2020
58CA9A,earnings,100,50,3/16/2020
5BC2F4,buybacks,100,74,3/16/2020
5CEE02,spin-off,100,58,3/16/2020
5D16CF,acquisition-completed-acquirer,100,49,3/16/2020
5E6959,dividend,100,50,3/16/2020
5F3D91,earnings,100,50,3/16/2020
5F3D91,earnings,100,50,3/16/2020
5F3D91,earnings,100,50,3/16/2020
629F0F,credit-extension-recipient,100,69,3/16/2020
62A48D,conference-call,100,50,3/16/2020
62F41C,legal-issues-defendant,100,22,3/16/2020
64636E,earnings,100,50,3/16/2020
66ECFD,earnings,100,50,3/16/2020
693ECD,conference-call,100,50,3/16/2020
6CF43C,dividend,100,50,3/16/2020
6DC1D7,buybacks,100,74,3/16/2020
6E7060,dividend,100,50,3/16/2020
732A9B,earnings,100,50,3/16/2020
7DD8CC,dividend,100,50,3/16/2020
845533,buybacks,100,74,3/16/2020
85AD00,executive-resignation,100,44,3/16/2020
873DB9,legal-issues-defendant,100,22,3/16/2020
873DB9,legal-issues-defendant,100,22,3/16/2020
885758,earnings,100,50,3/16/2020
8E82A6,executive-appointment,100,54,3/16/2020
8FCA78,acquisition-acquirer,100,49,3/16/2020
911CA9,earnings,100,50,3/16/2020
911CA9,earnings,100,50,3/16/2020
911CA9,earnings,100,50,3/16/2020
9196A2,dividend,100,50,3/16/2020
9.39E+69,earnings,100,50,3/16/2020
944B2E,earnings,100,50,3/16/2020
954004,partnership,100,61,3/16/2020
95C392,executive-appointment,100,54,3/16/2020
96A2D3,index-listing,100,76,3/16/2020
96F126,executive-appointment,100,54,3/16/2020
97FE80,earnings,100,50,3/16/2020
9B4066,unit-acquisition-acquirer,100,49,3/16/2020
9BB35A,executive-appointment,100,54,3/16/2020
A58224,investment-investor,100,55,3/16/2020
A806FA,dividend,100,50,3/16/2020
A80FE0,executive-appointment,100,54,3/16/2020
A8E72A,earnings,100,50,3/16/2020
AA1EAA,dividend,100,50,3/16/2020
AADE0B,unit-acquisition-acquirer,100,49,3/16/2020
AC7C4F,business-contract,100,69,3/16/2020
ACDCFA,operating-earnings,100,50,3/16/2020
AED61E,earnings,100,50,3/16/2020
B2D799,earnings,100,50,3/16/2020
B303A6,executive-appointment,100,54,3/16/2020
B33E77,legal-issues-defendant,100,22,3/16/2020
B33E77,legal-issues-defendant,100,22,3/16/2020
B33E77,legal-issues-defendant,100,22,3/16/2020
B33E77,legal-issues-defendant,100,22,3/16/2020
B5734D,earnings,100,50,3/16/2020
B5734D,earnings,100,50,3/16/2020
B5734D,earnings,100,50,3/16/2020
BA0442,earnings,100,50,3/16/2020
BB127B,partnership,100,61,3/16/2020
BE379D,earnings,100,50,3/16/2020
BE645B,earnings,100,50,3/16/2020
BE645B,earnings,100,50,3/16/2020
C564E4,clinical-trials-start,100,64,3/16/2020
C58D71,earnings,100,50,3/16/2020
C93C44,earnings,100,50,3/16/2020
C9732E,legal-issues-defendant,100,22,3/16/2020
C99CC8,acquisition-completed-acquiree,100,76,3/16/2020
C99CC8,unit-acquisition-completed-acquiree,100,67,3/16/2020
C99CC8,unit-acquisition-completed-acquiree,100,67,3/16/2020
C99CC8,unit-acquisition-completed-acquiree,100,67,3/16/2020
CAB222,executive-appointment,100,54,3/16/2020
CC6FF5,executive-appointment,100,54,3/16/2020
D03C7A,executive-appointment,100,54,3/16/2020
D518D8,legal-issues-defendant,100,22,3/16/2020
D6853F,legal-issues-defendant,100,22,3/16/2020
D69D42,dividend,100,50,3/16/2020
D7918D,legal-issues-defendant,100,22,3/16/2020
D9B1C9,business-contract,100,69,3/16/2020
DD0F15,legal-issues-defendant,100,22,3/16/2020
DD0F15,legal-issues-defendant,100,22,3/16/2020
DF01B1,legal-issues-defendant,100,22,3/16/2020
E09997,earnings,100,50,3/16/2020
E2F130,business-contract,100,69,3/16/2020
E866D2,legal-issues-defendant,100,22,3/16/2020
E866D2,legal-issues-defendant,100,22,3/16/2020
EB36DE,business-contract,100,69,3/16/2020
EB7D6C,earnings,100,50,3/16/2020
EB7D6C,earnings,100,50,3/16/2020
ED22DC,earnings,100,50,3/16/2020
ED79D9,product-release,100,64,3/16/2020
ED7F13,dividend,100,50,3/16/2020
F58C23,patient-enrollment-complete,100,64,3/16/2020
F73DD1,earnings,100,50,3/16/2020
F80389,dividend,100,50,3/16/2020
F88147,earnings,100,50,3/16/2020
FA918D,executive-resignation,100,44,3/16/2020
55018,buyback-suspended,100,24,3/17/2020
06A456,facility-close,100,47,3/17/2020
0B73A7,facility-close,100,47,3/17/2020
0B73A7,facility-close,100,47,3/17/2020
0E3436,earnings,100,50,3/17/2020
0E3436,earnings,100,50,3/17/2020
138DDE,dividend,100,50,3/17/2020
1AF7E2,dividend,100,50,3/17/2020
1BC12C,partnership,100,61,3/17/2020
1EBF8D,clinical-trials,100,56,3/17/2020
1FAF22,earnings,100,50,3/17/2020
21245F,unit-acquisition-completed-acquirer,100,49,3/17/2020
228D42,award,100,58,3/17/2020
22C58E,product-release,100,64,3/17/2020
24A89A,clinical-trials-start,100,64,3/17/2020
24A89A,clinical-trials-start,100,64,3/17/2020
267718,product-release,100,64,3/17/2020
275300,legal-issues-defendant,100,22,3/17/2020
292A70,dividend,100,50,3/17/2020
2BC05E,legal-issues-defendant,100,22,3/17/2020
2BC05E,legal-issues-defendant,100,22,3/17/2020
2C3348,partnership,100,61,3/17/2020
2F24A5,earnings,100,50,3/17/2020
301493,legal-issues-defendant,100,22,3/17/2020
301493,legal-issues-defendant,100,22,3/17/2020
3.14E+47,dividend,100,50,3/17/2020
372037,legal-issues-defendant,100,22,3/17/2020
372037,legal-issues-defendant,100,22,3/17/2020
397A8F,earnings,100,50,3/17/2020
397A8F,conference-call,100,50,3/17/2020
3C8A04,unit-acquisition-acquirer,100,49,3/17/2020
41A93D,executive-appointment,100,54,3/17/2020
42978B,conference-call,100,50,3/17/2020
448215,executive-appointment,100,54,3/17/2020
44A4FC,partnership,100,61,3/17/2020
499C75,legal-issues-defendant,100,22,3/17/2020
499C75,fraud-defendant,100,20,3/17/2020
499C75,legal-issues-defendant,100,22,3/17/2020
499C75,legal-issues-defendant,100,22,3/17/2020
4A5C8D,earnings-guidance-up,100,83,3/17/2020
4A7C1F,legal-issues-defendant,100,22,3/17/2020
4AE584,earnings,100,50,3/17/2020
4DAF5F,buybacks,100,74,3/17/2020
4DAF5F,buybacks,100,74,3/17/2020
4E4E75,dividend,100,50,3/17/2020
53E575,product-release,100,64,3/17/2020
5487B1,legal-issues-defendant,100,22,3/17/2020
564F3E,earnings-guidance-suspended,100,29,3/17/2020
58EA22,earnings,100,50,3/17/2020
5B97B2,dividend,100,50,3/17/2020
5C2A47,partnership,100,61,3/17/2020
5D63F1,earnings-guidance,100,50,3/17/2020
5E6959,partnership,100,61,3/17/2020
6166D1,dividend,100,50,3/17/2020
619882,dividend,100,50,3/17/2020
62F41C,legal-issues-defendant,100,22,3/17/2020
665D7D,business-contract,100,69,3/17/2020
665D7D,business-contract,100,69,3/17/2020
6844D2,earnings,100,50,3/17/2020
6844D2,earnings,100,50,3/17/2020
6ED519,dividend,100,50,3/17/2020
719477,donation,100,54,3/17/2020
7239BB,unit-acquisition-acquirer,100,49,3/17/2020
76BD96,buybacks,100,74,3/17/2020
790C34,business-contract,100,69,3/17/2020
790C34,business-contract,100,69,3/17/2020
7B1E50,dividend,100,50,3/17/2020
8.10E+32,donation,100,54,3/17/2020
873DB9,legal-issues-defendant,100,22,3/17/2020
895D56,executive-appointment,100,54,3/17/2020
8FF2EF,earnings,100,50,3/17/2020
8FF2EF,note-sale,100,52,3/17/2020
9004C4,earnings,100,50,3/17/2020
911AB8,acquisition-acquiree,100,76,3/17/2020
911AB8,acquisition-acquiree,100,76,3/17/2020
923D93,business-contract,100,69,3/17/2020
923D93,business-contract,100,69,3/17/2020
9.39E+69,legal-issues-defendant,100,22,3/17/2020
954004,earnings,100,50,3/17/2020
96BFF4,earnings,100,50,3/17/2020
96BFF4,earnings,100,50,3/17/2020
96BFF4,earnings,100,50,3/17/2020
9CF9B1,executive-appointment,100,54,3/17/2020
A247F5,legal-issues-defendant,100,22,3/17/2020
A2C979,earnings,100,50,3/17/2020
A3800A,facility-close,100,47,3/17/2020
A631A3,partnership,100,61,3/17/2020
A6828A,partnership,100,61,3/17/2020
A6828A,conference-call,100,50,3/17/2020
A70BF5,earnings,100,50,3/17/2020
A72FD9,conference-call,100,50,3/17/2020
AC7C4F,award,100,58,3/17/2020
AD375D,public-offering,100,43,3/17/2020
B33E77,legal-issues-defendant,100,22,3/17/2020
B33E77,legal-issues-defendant,100,22,3/17/2020
B33E77,legal-issues-defendant,100,22,3/17/2020
B3ED62,conference-call,100,50,3/17/2020
B46E12,dividend,100,50,3/17/2020
B72D2E,buybacks,100,74,3/17/2020
B8EF97,unit-acquisition-acquirer,100,49,3/17/2020
BB5142,government-contract,100,69,3/17/2020
C05839,dividend,100,50,3/17/2020
C9732E,legal-issues-defendant,100,22,3/17/2020
CBBFBF,legal-issues-defendant,100,22,3/17/2020
CC3EC4,executive-appointment,100,54,3/17/2020
CDD75E,note-sale,100,52,3/17/2020
D4C0CB,earnings,100,50,3/17/2020
D7AC6E,dividend,100,50,3/17/2020
D8ECA1,executive-appointment,100,54,3/17/2020
D95385,executive-appointment,100,54,3/17/2020
DB9829,dividend,100,50,3/17/2020
DC2B00,executive-appointment,100,54,3/17/2020
DD0F15,legal-issues-defendant,100,22,3/17/2020
DDB002,earnings,100,50,3/17/2020
DF01B1,legal-issues-defendant,100,22,3/17/2020
DF204B,facility-close,100,47,3/17/2020
E0207A,product-release,100,64,3/17/2020
E6D89E,product-release,100,64,3/17/2020
EB7D6C,earnings,100,50,3/17/2020
F1529C,conference-call,100,50,3/17/2020
F1EB39,partnership,100,61,3/17/2020
F3EDB4,dividend,100,50,3/17/2020
F3EDB4,executive-appointment,100,54,3/17/2020
0A0CF0,dividend,100,50,3/18/2020
0DBB81,orphan-drug-designation,100,76,3/18/2020
108A2B,dividend,100,50,3/18/2020
18A98C,patient-enrollment-suspended,100,36,3/18/2020
190B91,acquisition-acquirer,100,49,3/18/2020
1AB023,facility-close,100,47,3/18/2020
1AB023,facility-close,100,47,3/18/2020
1AB023,facility-close,100,47,3/18/2020
1DF15D,dividend,100,50,3/18/2020
20BEEA,earnings-guidance,100,50,3/18/2020
21D903,legal-issues-defendant,100,22,3/18/2020
228D42,partnership,100,61,3/18/2020
267718,partnership,100,61,3/18/2020
267718,clinical-trials-positive,100,87,3/18/2020
267718,clinical-trials,100,56,3/18/2020
275300,legal-issues-defendant,100,22,3/18/2020
2A1009,business-contract,100,69,3/18/2020
2A6DBE,business-contract,100,69,3/18/2020
2B0AF4,legal-issues-defendant,100,22,3/18/2020
2BC05E,legal-issues-defendant,100,22,3/18/2020
2D2D43,executive-appointment,100,54,3/18/2020
301493,legal-issues-defendant,100,22,3/18/2020
372037,legal-issues-defendant,100,22,3/18/2020
3FACA7,earnings,100,50,3/18/2020
448215,dividend,100,50,3/18/2020
449447,earnings,100,50,3/18/2020
494EB9,legal-issues-defendant,100,22,3/18/2020
4A7C1F,legal-issues-defendant,100,22,3/18/2020
4BAF2E,patent-awarded,100,72,3/18/2020
4DAF5F,buybacks,100,74,3/18/2020
4DAF5F,buybacks,100,74,3/18/2020
609208,earnings,100,50,3/18/2020
6391C2,earnings,100,50,3/18/2020
63E8D5,dividend,100,50,3/18/2020
665D7D,business-contract,100,69,3/18/2020
665D7D,business-contract,100,69,3/18/2020
6844D2,partnership,100,61,3/18/2020
6F3936,earnings,100,50,3/18/2020
6F3936,earnings,100,50,3/18/2020
6F3936,earnings,100,50,3/18/2020
6F3936,earnings,100,50,3/18/2020
6F3936,earnings,100,50,3/18/2020
6F3936,earnings,100,50,3/18/2020
6F3936,earnings,100,50,3/18/2020
7239BB,conference-call,100,50,3/18/2020
775439,dividend,100,50,3/18/2020
7A0EC4,partnership,100,61,3/18/2020
7A5097,earnings,100,50,3/18/2020
817ED9,facility-close,100,47,3/18/2020
817ED9,facility-close,100,47,3/18/2020
873DB9,legal-issues-defendant,100,22,3/18/2020
8AB85C,earnings,100,50,3/18/2020
8D0EEA,earnings,100,50,3/18/2020
911AB8,note-sale,100,52,3/18/2020
911ACB,dividend,100,50,3/18/2020
94637C,executive-appointment,100,54,3/18/2020
98A286,earnings,100,50,3/18/2020
9.92E+94,buybacks,100,74,3/18/2020
9A602D,earnings-guidance-meet-expectations,100,59,3/18/2020
9CA619,earnings,100,50,3/18/2020
9D5FA4,partnership,100,61,3/18/2020
A247F5,legal-issues-defendant,100,22,3/18/2020
A247F5,legal-issues-defendant,100,22,3/18/2020
A49498,earnings,100,50,3/18/2020
A49498,earnings,100,50,3/18/2020
A49498,earnings,100,50,3/18/2020
A49498,earnings,100,50,3/18/2020
A63820,partnership,100,61,3/18/2020
A6828A,clinical-trials-filed,100,60,3/18/2020
A72FD9,business-contract,100,69,3/18/2020
A79F7D,earnings,100,50,3/18/2020
A87CD6,conference-participant,100,50,3/18/2020
AD3008,earnings-guidance-suspended,100,29,3/18/2020
AD6141,executive-appointment,100,54,3/18/2020
B33E77,fraud-defendant,100,20,3/18/2020
B33E77,legal-issues-defendant,100,22,3/18/2020
B33E77,legal-issues-defendant,100,22,3/18/2020
B33E77,legal-issues-defendant,100,22,3/18/2020
B4C673,merger-regulatory-approval,100,81,3/18/2020
B4C673,unit-acquisition-completed-acquirer,100,49,3/18/2020
B4C673,acquisition-completed-acquirer,100,49,3/18/2020
B8DD94,asset-sale,100,62,3/18/2020
BB5271,executive-appointment,100,54,3/18/2020
BD682F,dividend,100,50,3/18/2020
C598D7,executive-appointment,100,54,3/18/2020
C9732E,legal-issues-defendant,100,22,3/18/2020
CAC8D0,product-release,100,64,3/18/2020
CBBFBF,legal-issues-defendant,100,22,3/18/2020
CF073E,partnership,100,61,3/18/2020
D25249,earnings-guidance,100,50,3/18/2020
D3FA2C,dividend,100,50,3/18/2020
D518D8,legal-issues-defendant,100,22,3/18/2020
D82EF3,earnings-guidance-suspended,100,29,3/18/2020
D8442A,product-release,100,64,3/18/2020
D8442A,product-release,100,64,3/18/2020
D8442A,product-release,100,64,3/18/2020
D90F43,partnership,100,61,3/18/2020
DA0A9E,conference-call,100,50,3/18/2020
DD0F15,legal-issues-defendant,100,22,3/18/2020
DF01B1,legal-issues-defendant,100,22,3/18/2020
DFADDB,orphan-drug-designation,100,76,3/18/2020
DFADDB,orphan-drug-designation,100,76,3/18/2020
E8B21D,buybacks,100,74,3/18/2020
E959F3,conference-call,100,50,3/18/2020
EB7FBF,dividend,100,50,3/18/2020
ED79D9,dividend,100,50,3/18/2020
F5D059,conference-call,100,50,3/18/2020
F748C7,earnings,100,50,3/18/2020
F748C7,dividend,100,50,3/18/2020
F85CC0,dividend,100,50,3/18/2020
F85CC0,dividend,100,50,3/18/2020
FC9869,earnings,100,50,3/18/2020
01D03F,clinical-trials-start,100,64,3/19/2020
01D03F,clinical-trials-start,100,64,3/19/2020
033B58,earnings,100,50,3/19/2020
04996E,executive-appointment,100,54,3/19/2020
0A0CF0,earnings,100,50,3/19/2020
1201B5,public-offering,100,43,3/19/2020
133644,earnings,100,50,3/19/2020
1348C9,executive-resignation,100,44,3/19/2020
1921DD,business-contract,100,69,3/19/2020
1B5FEA,conference-participant,100,50,3/19/2020
1EBF8D,partnership,100,61,3/19/2020
1EBF8D,partnership,100,61,3/19/2020
221AD7,legal-issues-defendant,100,22,3/19/2020
228D42,partnership,100,61,3/19/2020
24D81E,hirings,100,65,3/19/2020
28F905,executive-appointment,100,54,3/19/2020
297DA8,product-release,100,64,3/19/2020
2A6DBE,earnings,100,50,3/19/2020
2BC05E,legal-issues-defendant,100,22,3/19/2020
2BC05E,legal-issues-defendant,100,22,3/19/2020
301493,legal-issues-defendant,100,22,3/19/2020
356B21,earnings,100,50,3/19/2020
3587B4,executive-appointment,100,54,3/19/2020
372037,legal-issues-defendant,100,22,3/19/2020
372037,legal-issues-defendant,100,22,3/19/2020
37727A,dividend-up,100,81,3/19/2020
39D9DA,conference-call,100,50,3/19/2020
408089,earnings-guidance-meet-expectations,100,59,3/19/2020
420168,dividend,100,50,3/19/2020
494EB9,legal-issues-defendant,100,22,3/19/2020
499C75,legal-issues-defendant,100,22,3/19/2020
4A6F00,partnership,100,61,3/19/2020
4A7C1F,legal-issues-defendant,100,22,3/19/2020
520632,conference-call,100,50,3/19/2020
52B567,earnings,100,50,3/19/2020
539F49,legal-issues-defendant,100,22,3/19/2020
539F49,legal-issues-defendant,100,22,3/19/2020
539F49,legal-issues-defendant,100,22,3/19/2020
5C7601,donation,100,54,3/19/2020
5CC29D,dividend,100,50,3/19/2020
62F41C,legal-issues-defendant,100,22,3/19/2020
69CE71,facility-open,100,65,3/19/2020
6F30F9,dividend,100,50,3/19/2020
75768D,earnings,100,50,3/19/2020
76B926,executive-appointment,100,54,3/19/2020
7740DE,earnings,100,50,3/19/2020
7771D7,earnings,100,50,3/19/2020
791EC1,business-contract,100,69,3/19/2020
7999F3,dividend,100,50,3/19/2020
7ACBA4,dividend,100,50,3/19/2020
84AB66,dividend,100,50,3/19/2020
8EF425,dividend,100,50,3/19/2020
911CA9,executive-appointment,100,54,3/19/2020
91C82E,earnings-per-share-positive,100,69,3/19/2020
91C82E,earnings-per-share-positive,100,69,3/19/2020
91C82E,earnings-per-share-positive,100,69,3/19/2020
966ACE,executive-appointment,100,54,3/19/2020
9.82E+06,earnings,100,50,3/19/2020
986AF6,earnings-guidance,100,50,3/19/2020
9BBFA5,earnings,100,50,3/19/2020
A3AAA5,dividend,100,50,3/19/2020
A6828A,clinical-trials-filed,100,60,3/19/2020
AA7FE0,conference-call,100,50,3/19/2020
AD3C93,acquisition-acquirer,100,49,3/19/2020
ADD9DC,earnings,100,50,3/19/2020
AEBB80,dividend,100,50,3/19/2020
B08C51,earnings,100,50,3/19/2020
B1B10C,conference-call,100,50,3/19/2020
B33E77,legal-issues-defendant,100,22,3/19/2020
B33E77,legal-issues-defendant,100,22,3/19/2020
B3ED62,executive-resignation,100,44,3/19/2020
BDF85E,shareholder-rights-plan,100,43,3/19/2020
BFAEB4,earnings,100,50,3/19/2020
C0200F,earnings-guidance-suspended,100,29,3/19/2020
CBBFBF,legal-issues-defendant,100,22,3/19/2020
CCBBAD,buyback-suspended,100,24,3/19/2020
D03C7A,executive-appointment,100,54,3/19/2020
D2E553,dividend,100,50,3/19/2020
D518D8,legal-issues-defendant,100,22,3/19/2020
D622D5,dividend,100,50,3/19/2020
D6853F,legal-issues-defendant,100,22,3/19/2020
DD0F15,legal-issues-defendant,100,22,3/19/2020
DD0F15,legal-issues-defendant,100,22,3/19/2020
DDCB34,executive-appointment,100,54,3/19/2020
DF01B1,legal-issues-defendant,100,22,3/19/2020
E124EB,business-contract,100,69,3/19/2020
E1C16B,dividend,100,50,3/19/2020
E2F66E,buybacks,100,74,3/19/2020
E598FB,earnings,100,50,3/19/2020
E61888,legal-issues-defendant,100,22,3/19/2020
E68733,supply-increase,100,74,3/19/2020
E68733,supply-increase,100,74,3/19/2020
E866D2,legal-issues-defendant,100,22,3/19/2020
E8B315,dividend-up,100,55,3/19/2020
EAEBF3,dividend-down,100,19,3/19/2020
EB7FBF,earnings,100,50,3/19/2020
ECDEB2,dividend,100,50,3/19/2020
F6FA6A,executive-appointment,100,54,3/19/2020
F6FA6A,executive-appointment,100,54,3/19/2020
FC01C0,legal-issues-defendant,100,22,3/19/2020
FC1B7B,note-sale,100,52,3/19/2020
FE1A1D,executive-appointment,100,54,3/19/2020
143C52,executive-appointment,100,54,3/20/2020
205AD5,earnings,100,50,3/20/2020
21D903,legal-issues-defendant,100,22,3/20/2020
221AD7,legal-issues-defendant,100,22,3/20/2020
228D42,partnership,100,61,3/20/2020
2B0AF4,legal-issues-defendant,100,22,3/20/2020
2BC05E,legal-issues-defendant,100,22,3/20/2020
2BC05E,legal-issues-defendant,100,22,3/20/2020
2BC05E,legal-issues-defendant,100,22,3/20/2020
2E61CC,donation,100,54,3/20/2020
2E902B,dividend,100,50,3/20/2020
301493,legal-issues-defendant,100,22,3/20/2020
339F20,dividend,100,50,3/20/2020
33FD66,earnings,100,50,3/20/2020
372037,legal-issues-defendant,100,22,3/20/2020
3B9886,earnings,100,50,3/20/2020
3D9999,earnings,100,50,3/20/2020
3F4497,dividend,100,50,3/20/2020
4A7C1F,legal-issues-defendant,100,22,3/20/2020
4A7C1F,legal-issues-defendant,100,22,3/20/2020
4A7C1F,legal-issues-defendant,100,22,3/20/2020
4AC91D,legal-issues-defendant,100,22,3/20/2020
4CDA2B,partnership,100,61,3/20/2020
4E2D94,earnings-guidance,100,50,3/20/2020
539F49,legal-issues-defendant,100,22,3/20/2020
539F49,legal-issues-defendant,100,22,3/20/2020
58CA9A,award,100,58,3/20/2020
5A53BF,executive-appointment,100,54,3/20/2020
62A48D,earnings,100,50,3/20/2020
62F41C,legal-issues-defendant,100,22,3/20/2020
68B03F,conference-participant,100,50,3/20/2020
726DDF,partnership,100,61,3/20/2020
726DDF,partnership,100,61,3/20/2020
76E80F,dividend,100,50,3/20/2020
7ADE57,dividend,100,50,3/20/2020
7D5FD6,earnings,100,50,3/20/2020
868808,dividend,100,50,3/20/2020
873DB9,legal-issues-defendant,100,22,3/20/2020
873DB9,legal-issues-defendant,100,22,3/20/2020
8817D5,conference-call,100,50,3/20/2020
88923D,acquisition-acquirer,100,49,3/20/2020
8E9CD8,credit-extension-recipient,100,69,3/20/2020
965360,buyback-suspended,100,24,3/20/2020
9.74E+08,dividend,100,50,3/20/2020
97FE80,partnership,100,61,3/20/2020
990AD0,award,100,58,3/20/2020
9D5FA4,partnership,100,61,3/20/2020
B33E77,legal-issues-defendant,100,22,3/20/2020
B33E77,legal-issues-defendant,100,22,3/20/2020
C5F463,partnership,100,61,3/20/2020
CBBFBF,legal-issues-defendant,100,22,3/20/2020
CBFFDD,partnership,100,61,3/20/2020
CCB623,business-contract,100,69,3/20/2020
D11C1C,buybacks,100,74,3/20/2020
D7918D,legal-issues-defendant,100,22,3/20/2020
DD0F15,legal-issues-defendant,100,22,3/20/2020
DF01B1,legal-issues-defendant,100,22,3/20/2020
DF01B1,legal-issues-defendant,100,22,3/20/2020
E00373,earnings-guidance-suspended,100,29,3/20/2020
E866D2,legal-issues-defendant,100,22,3/20/2020
ECD263,earnings,100,50,3/20/2020
F30508,executive-appointment,100,54,3/20/2020
F5D059,earnings,100,50,3/20/2020
F6DCE4,investment-investor,100,55,3/20/2020
F82D37,conference-call,100,50,3/20/2020
FF227B,clinical-trials,100,56,3/20/2020
2BC05E,legal-issues-defendant,100,22,3/21/2020
301493,legal-issues-defendant,100,22,3/21/2020
494EB9,legal-issues-defendant,100,22,3/21/2020
4A7C1F,legal-issues-defendant,100,22,3/21/2020
62F41C,legal-issues-defendant,100,22,3/21/2020
6830FE,partnership,100,61,3/21/2020
873DB9,legal-issues-defendant,100,22,3/21/2020
B33E77,legal-issues-defendant,100,22,3/21/2020
B33E77,fraud-defendant,100,20,3/21/2020
C9732E,legal-issues-defendant,100,22,3/21/2020
CBBFBF,legal-issues-defendant,100,22,3/21/2020
DD0F15,legal-issues-defendant,100,22,3/21/2020
DF01B1,legal-issues-defendant,100,22,3/21/2020
8E8E6E,executive-appointment,100,54,3/22/2020
9.54E+32,facility-close,100,47,3/22/2020
07EC43,acquisition-acquirer,100,49,3/23/2020
09DE1F,partnership,100,61,3/23/2020
0BD199,earnings,100,50,3/23/2020
0E439E,earnings,100,50,3/23/2020
1748F6,executive-appointment,100,54,3/23/2020
21D903,legal-issues-defendant,100,22,3/23/2020
2491BC,earnings-guidance-suspended,100,29,3/23/2020
25102A,conference-call,100,50,3/23/2020
251988,earnings,100,50,3/23/2020
2B0AF4,executive-appointment,100,54,3/23/2020
2BBE62,executive-appointment,100,54,3/23/2020
2BC05E,legal-issues-defendant,100,22,3/23/2020
2CC71C,executive-appointment,100,54,3/23/2020
2FDEE3,dividend,100,50,3/23/2020
301493,legal-issues-defendant,100,22,3/23/2020
30E01D,partnership,100,61,3/23/2020
32DCB3,clinical-trials,100,56,3/23/2020
338544,legal-issues-defendant,100,22,3/23/2020
35B907,dividend,100,50,3/23/2020
372037,legal-issues-defendant,100,22,3/23/2020
396D7C,executive-appointment,100,54,3/23/2020
44740A,product-release,100,64,3/23/2020
44ED36,buybacks,100,74,3/23/2020
451D61,regulatory-product-approval-granted,100,81,3/23/2020
453282,conference-call,100,50,3/23/2020
4.91E+58,fundraising,100,64,3/23/2020
499C75,legal-issues-defendant,100,22,3/23/2020
49A344,earnings,100,50,3/23/2020
4A5C8D,executive-resignation,100,44,3/23/2020
4A6F00,partnership,100,61,3/23/2020
4A6F00,partnership,100,61,3/23/2020
4A7C1F,legal-issues-defendant,100,22,3/23/2020
4C37C5,conference-call,100,50,3/23/2020
56EA2B,note-sale,100,52,3/23/2020
56EA2B,note-sale,100,52,3/23/2020
57DDB9,partnership,100,61,3/23/2020
59872F,executive-appointment,100,54,3/23/2020
65D0AA,partnership,100,61,3/23/2020
665D7D,clinical-trials-positive,100,87,3/23/2020
665D7D,debt-extension-recipient,100,73,3/23/2020
6BBCBA,partnership,100,61,3/23/2020
7122EB,clinical-trials-start,100,64,3/23/2020
7A3633,conference-call,100,50,3/23/2020
805CD8,executive-appointment,100,54,3/23/2020
8665BA,note-sale,100,52,3/23/2020
873DB9,legal-issues-defendant,100,22,3/23/2020
913437,earnings,100,50,3/23/2020
94C0B5,conference-call,100,50,3/23/2020
97FE80,partnership,100,61,3/23/2020
99B61C,executive-appointment,100,54,3/23/2020
A072C4,business-contract,100,69,3/23/2020
A2CAF7,earnings-guidance,100,50,3/23/2020
A52533,partnership,100,61,3/23/2020
A761FE,conference-call,100,50,3/23/2020
AD375D,dividend,100,50,3/23/2020
B33E77,legal-issues-defendant,100,22,3/23/2020
B604DF,legal-issues-defendant,100,22,3/23/2020
B83BCE,executive-appointment,100,54,3/23/2020
BB127B,conference-participant,100,50,3/23/2020
BC5680,partnership,100,61,3/23/2020
C22BE8,earnings,100,50,3/23/2020
C2E39B,product-release,100,64,3/23/2020
C4706C,executive-appointment,100,54,3/23/2020
C4A432,dividend,100,50,3/23/2020
C4C77F,executive-appointment,100,54,3/23/2020
C83B88,partnership,100,61,3/23/2020
CFF97C,product-release,100,64,3/23/2020
D1588D,earnings,100,50,3/23/2020
D1588D,earnings,100,50,3/23/2020
D4463B,dividend-suspended,100,13,3/23/2020
D518D8,legal-issues-defendant,100,22,3/23/2020
D57D99,facility-close,100,47,3/23/2020
DC2B00,hirings,100,65,3/23/2020
DD0F15,legal-issues-defendant,100,22,3/23/2020
DD0F15,legal-issues-defendant,100,22,3/23/2020
DF01B1,legal-issues-defendant,100,22,3/23/2020
E0339F,earnings,100,50,3/23/2020
E07573,buybacks,100,74,3/23/2020
E3656D,acquisition-completed-acquirer,100,49,3/23/2020
E866D2,legal-issues-defendant,100,22,3/23/2020
EB7D6C,executive-appointment,100,54,3/23/2020
EB7D6C,legal-issues-defendant,100,22,3/23/2020
EB7D6C,legal-issues-defendant,100,22,3/23/2020
EB7D6C,legal-issues-defendant,100,22,3/23/2020
F02170,business-contract,100,69,3/23/2020
F0B335,clinical-trials,100,56,3/23/2020
F2E253,hirings,100,65,3/23/2020
F30508,clinical-trials,100,56,3/23/2020
F4CDA3,dividend,100,50,3/23/2020
F769E9,executive-appointment,100,54,3/23/2020
FD4588,acquisition-acquirer,100,49,3/23/2020
FD9A97,conference-call,100,50,3/23/2020
00067A,note-sale,100,52,3/24/2020
00067A,note-sale,100,52,3/24/2020
0157B1,product-release,100,64,3/24/2020
03B8CF,partnership,100,61,3/24/2020
095A04,business-contract,100,69,3/24/2020
095A04,business-contract,100,69,3/24/2020
09DE1F,partnership,100,61,3/24/2020
09DE1F,partnership,100,61,3/24/2020
1096C6,partnership,100,61,3/24/2020
12F98C,business-contract,100,69,3/24/2020
131443,ownership-increase-owner,100,56,3/24/2020
131443,ownership-increase-owner,100,56,3/24/2020
152E1D,executive-appointment,100,54,3/24/2020
15A388,executive-appointment,100,54,3/24/2020
1E83DE,executive-appointment,100,54,3/24/2020
228D42,award,100,58,3/24/2020
26DC29,stock-gain,100,63,3/24/2020
2B0AF4,legal-issues-defendant,100,22,3/24/2020
2BC05E,legal-issues-defendant,100,22,3/24/2020
2D643C,executive-appointment,100,54,3/24/2020
2D981A,executive-appointment,100,54,3/24/2020
301493,legal-issues-defendant,100,22,3/24/2020
34E9F9,business-contract,100,69,3/24/2020
372037,legal-issues-defendant,100,22,3/24/2020
396D7C,partnership,100,61,3/24/2020
417BF9,conference-call,100,50,3/24/2020
494EB9,legal-issues-defendant,100,22,3/24/2020
494EB9,legal-issues-defendant,100,22,3/24/2020
499C75,legal-issues-defendant,100,22,3/24/2020
499C75,legal-issues-defendant,100,22,3/24/2020
499C75,legal-issues-defendant,100,22,3/24/2020
499C75,legal-issues-defendant,100,22,3/24/2020
499C75,legal-issues-defendant,100,22,3/24/2020
4A6F00,partnership,100,61,3/24/2020
4BF3D6,earnings,100,50,3/24/2020
4C31F3,conference-call,100,50,3/24/2020
4CDA2B,earnings,100,50,3/24/2020
510EA6,earnings,100,50,3/24/2020
510EA6,earnings,100,50,3/24/2020
543C77,earnings,100,50,3/24/2020
55C9B5,revenues,100,50,3/24/2020
55C9B5,revenues,100,50,3/24/2020
58CA9A,executive-appointment,100,54,3/24/2020
62F41C,legal-issues-defendant,100,22,3/24/2020
65D0AA,partnership,100,61,3/24/2020
665440,product-release,100,64,3/24/2020
6F5DD2,bought-deal,100,43,3/24/2020
723548,dividend,100,50,3/24/2020
76E80F,note-sale,100,52,3/24/2020
7823A3,partnership,100,61,3/24/2020
790D0D,executive-appointment,100,54,3/24/2020
7A3633,revenues,100,50,3/24/2020
7AC86E,executive-appointment,100,54,3/24/2020
7AC86E,executive-appointment,100,54,3/24/2020
7ACD98,earnings-guidance,100,50,3/24/2020
7D35D8,stock-gain,100,63,3/24/2020
7E2DE6,earnings,100,50,3/24/2020
863350,earnings,100,50,3/24/2020
86A1B9,partnership,100,61,3/24/2020
873DB9,legal-issues-defendant,100,22,3/24/2020
8D9993,dividend,100,50,3/24/2020
8F3231,conference-call,100,50,3/24/2020
91E5EE,resource-discovery,100,88,3/24/2020
92B625,executive-appointment,100,54,3/24/2020
938D89,earnings,100,50,3/24/2020
9A602D,conference-call,100,50,3/24/2020
9EF4CF,legal-issues-defendant,100,22,3/24/2020
A16DEA,executive-appointment,100,54,3/24/2020
A26C26,dividend,100,50,3/24/2020
A6213D,partnership,100,61,3/24/2020
A631A3,partnership,100,61,3/24/2020
A7A0C8,clinical-trials,100,56,3/24/2020
A8E2FE,executive-appointment,100,54,3/24/2020
AEEB76,executive-appointment,100,54,3/24/2020
B33E77,partnership,100,61,3/24/2020
B33E77,legal-issues-defendant,100,22,3/24/2020
B33E77,partnership,100,61,3/24/2020
B33E77,partnership,100,61,3/24/2020
B33E77,legal-issues-defendant,100,22,3/24/2020
B33E77,legal-issues-defendant,100,22,3/24/2020
B9BDE8,earnings,100,50,3/24/2020
BF5959,conference-participant,100,50,3/24/2020
C81E00,board-meeting,100,51,3/24/2020
C81E00,board-meeting,100,51,3/24/2020
C9732E,clinical-trials-positive,100,87,3/24/2020
C9739A,fast-track-designation,100,81,3/24/2020
CA212F,executive-appointment,100,54,3/24/2020
CBBFBF,legal-issues-defendant,100,22,3/24/2020
CBBFBF,legal-issues-defendant,100,22,3/24/2020
CBBFBF,legal-issues-defendant,100,22,3/24/2020
CBBFBF,legal-issues-defendant,100,22,3/24/2020
CF073E,earnings,100,50,3/24/2020
D1CFC8,earnings,100,50,3/24/2020
D518D8,donation,100,54,3/24/2020
D5B13D,earnings,100,50,3/24/2020
D64C6D,earnings,100,50,3/24/2020
D6EAA3,executive-appointment,100,54,3/24/2020
D854F3,supply-increase,100,74,3/24/2020
DA48E4,business-contract,100,69,3/24/2020
DB88A1,earnings,100,50,3/24/2020
DCD97F,campaign-ad-release,100,59,3/24/2020
DF11D9,conference-call,100,50,3/24/2020
E21871,conference-call,100,50,3/24/2020
EB36DE,business-contract,100,69,3/24/2020
EC8116,dividend,100,50,3/24/2020
EC99D0,product-release,100,64,3/24/2020
ED2EFD,investment-investor,100,55,3/24/2020
EE6F1C,business-contract,100,69,3/24/2020
F11638,executive-appointment,100,54,3/24/2020
F2BC3D,earnings,100,50,3/24/2020
F3D2EB,dividend,100,50,3/24/2020
F3EDB4,earnings-up,100,68,3/24/2020
F3EDB4,earnings,100,50,3/24/2020
F3EDB4,earnings,100,50,3/24/2020
F4F46F,business-contract,100,69,3/24/2020
F5D499,revenue-up,100,91,3/24/2020
F9AA02,clinical-trials-start,100,64,3/24/2020
FD2565,partnership,100,61,3/24/2020
FD2565,partnership,100,61,3/24/2020
FD2565,partnership,100,61,3/24/2020
01D03F,partnership,100,61,3/25/2020
05AF14,dividend,100,50,3/25/2020
09062E,board-meeting,100,51,3/25/2020
0E2992,conference-call,100,50,3/25/2020
1.79E+10,conference-call,100,50,3/25/2020
223552,clinical-trials-start,100,64,3/25/2020
223552,business-contract,100,69,3/25/2020
25AB8E,executive-appointment,100,54,3/25/2020
275300,legal-issues-defendant,100,22,3/25/2020
275300,legal-issues-defendant,100,22,3/25/2020
292A70,earnings,100,50,3/25/2020
2B0AF4,legal-issues-defendant,100,22,3/25/2020
2BC05E,legal-issues-defendant,100,22,3/25/2020
2C7505,business-contract,100,69,3/25/2020
2F7474,dividend,100,50,3/25/2020
301493,legal-issues-defendant,100,22,3/25/2020
3BB616,dividend-suspended,100,13,3/25/2020
41B53E,buyback-suspended,100,24,3/25/2020
485445,business-contract,100,69,3/25/2020
494EB9,legal-issues-defendant,100,22,3/25/2020
499C75,legal-issues-defendant,100,22,3/25/2020
49BBBC,earnings,100,50,3/25/2020
49F4D0,dividend,100,50,3/25/2020
4B49CF,earnings,100,50,3/25/2020
4BDCA7,business-contract,100,69,3/25/2020
4C2F17,earnings,100,50,3/25/2020
4C31F3,earnings,100,50,3/25/2020
4CDA2B,business-contract,100,69,3/25/2020
4CDA2B,partnership,100,61,3/25/2020
4F71DC,earnings,100,50,3/25/2020
4F9487,dividend,100,50,3/25/2020
53F491,dividend,100,50,3/25/2020
543900,dividend,100,50,3/25/2020
545272,unit-acquisition-acquiree,100,76,3/25/2020
62F41C,legal-issues-defendant,100,22,3/25/2020
6391C2,executive-appointment,100,54,3/25/2020
641F17,earnings,100,50,3/25/2020
6925EB,legal-issues-defendant,100,22,3/25/2020
6DDA15,executive-appointment,100,54,3/25/2020
6F6559,earnings,100,50,3/25/2020
6F6559,earnings,100,50,3/25/2020
6F6559,earnings,100,50,3/25/2020
6F6559,earnings,100,50,3/25/2020
6FCEF9,earnings,100,50,3/25/2020
71B0CF,conference-participant,100,50,3/25/2020
7273FF,acquisition-acquirer,100,49,3/25/2020
7EA323,conference-call,100,50,3/25/2020
82BB33,earnings,100,50,3/25/2020
873DB9,legal-issues-defendant,100,22,3/25/2020
94983E,business-contract,100,69,3/25/2020
94983E,business-contract,100,69,3/25/2020
9BB35A,executive-appointment,100,54,3/25/2020
A753BB,dividend,100,50,3/25/2020
AECCA9,executive-appointment,100,54,3/25/2020
AEEB76,earnings,100,50,3/25/2020
B2E6B5,executive-appointment,100,54,3/25/2020
B4528F,executive-appointment,100,54,3/25/2020
B604DF,legal-issues-defendant,100,22,3/25/2020
B6082A,conference-call,100,50,3/25/2020
C4706C,earnings-guidance-suspended,100,29,3/25/2020
C4706C,earnings-guidance-suspended,100,29,3/25/2020
C9732E,legal-issues-defendant,100,22,3/25/2020
C9732E,legal-issues-defendant,100,22,3/25/2020
CA212F,business-contract,100,69,3/25/2020
CAD7D9,credit-extension-recipient,100,69,3/25/2020
CBA33B,product-release,100,64,3/25/2020
CBBFBF,legal-issues-defendant,100,22,3/25/2020
CE5664,board-meeting,100,51,3/25/2020
CFF97C,credit-rating-outlook-negative-rater,20,50,3/25/2020
D518D8,legal-issues-defendant,100,22,3/25/2020
D9E036,credit-extension-recipient,100,69,3/25/2020
DF01B1,legal-issues-defendant,100,22,3/25/2020
E10D31,donation,100,54,3/25/2020
E2F130,conference-call,100,50,3/25/2020
E8E899,executive-resignation,100,44,3/25/2020
E99180,dividend,100,50,3/25/2020
EB7D6C,legal-issues-defendant,100,22,3/25/2020
EF7163,dividend,100,50,3/25/2020
EF77A3,earnings,100,50,3/25/2020
F88A04,earnings,100,50,3/25/2020
FD9526,conference-call,100,50,3/25/2020
FF4BA4,earnings,100,50,3/25/2020
0157B1,partnership,100,61,3/26/2020
0157B1,partnership,100,61,3/26/2020
03F5A4,dividend,100,50,3/26/2020
55018,conference-call,100,50,3/26/2020
05AF14,earnings,100,50,3/26/2020
0A59F8,earnings-guidance-suspended,100,29,3/26/2020
0AAD90,earnings,100,50,3/26/2020
0BD4E8,dividend,100,50,3/26/2020
0D03C8,earnings,100,50,3/26/2020
125212,earnings,100,50,3/26/2020
12A3A3,revenue-up,100,69,3/26/2020
12A3A3,revenue-up,100,69,3/26/2020
12A3A3,revenue-up,100,69,3/26/2020
12A3A3,revenue-up,100,69,3/26/2020
12E454,partnership,100,61,3/26/2020
12E454,executive-appointment,100,54,3/26/2020
133644,earnings,100,50,3/26/2020
1748B3,executive-appointment,100,54,3/26/2020
1A3E1B,executive-resignation,100,44,3/26/2020
1A9DE1,dividend,100,50,3/26/2020
1A9DE1,dividend,100,50,3/26/2020
1BC12C,executive-appointment,100,54,3/26/2020
1D1B07,conference-call,100,50,3/26/2020
1D1B07,conference-call,100,50,3/26/2020
253B2F,dividend,100,50,3/26/2020
27A791,acquisition-completed-acquirer,100,49,3/26/2020
2ABF77,clinical-trials,100,56,3/26/2020
2B0AF4,legal-issues-defendant,100,22,3/26/2020
2BC05E,legal-issues-defendant,100,22,3/26/2020
2CC60C,dividend,100,50,3/26/2020
2F98A5,executive-appointment,100,54,3/26/2020
301493,legal-issues-defendant,100,22,3/26/2020
34B97A,executive-appointment,100,54,3/26/2020
372037,legal-issues-defendant,100,22,3/26/2020
416291,executive-appointment,100,54,3/26/2020
4649D5,legal-issues-defendant,100,22,3/26/2020
4885C8,earnings,100,50,3/26/2020
499C75,legal-issues-defendant,100,22,3/26/2020
4A7C1F,legal-issues-defendant,100,22,3/26/2020
4BF3D6,conference-participant,100,50,3/26/2020
513A86,executive-appointment,100,54,3/26/2020
59DB8C,partnership,100,61,3/26/2020
5FC507,orphan-drug-designation,100,76,3/26/2020
616E3B,conference-call,100,50,3/26/2020
68E6E9,earnings,100,50,3/26/2020
6925EB,legal-issues-defendant,100,22,3/26/2020
6925EB,legal-issues-defendant,100,22,3/26/2020
6925EB,legal-issues-defendant,100,22,3/26/2020
6925EB,legal-issues-defendant,100,22,3/26/2020
6925EB,legal-issues-defendant,100,22,3/26/2020
6925EB,legal-issues-defendant,100,22,3/26/2020
6925EB,legal-issues-defendant,100,22,3/26/2020
6CC55E,executive-appointment,100,54,3/26/2020
6F5DD2,bought-deal,100,43,3/26/2020
7239BB,earnings,100,50,3/26/2020
726DDF,executive-appointment,100,54,3/26/2020
72FCA3,earnings,100,50,3/26/2020
72FCA3,earnings,100,50,3/26/2020
72FCA3,earnings,100,50,3/26/2020
72FCA3,earnings,100,50,3/26/2020
873DB9,legal-issues-defendant,100,22,3/26/2020
8BAA15,revenue-guidance-up,100,83,3/26/2020
9.39E+69,conference-participant,100,50,3/26/2020
94637C,earnings,100,50,3/26/2020
94983E,legal-issues-defendant,100,22,3/26/2020
97693A,earnings,100,50,3/26/2020
98A286,earnings-per-share-positive,100,69,3/26/2020
9CE4C7,donation,100,54,3/26/2020
9CE4C7,donation,100,54,3/26/2020
9CE4C7,donation,100,54,3/26/2020
9CE4C7,donation,100,54,3/26/2020
9CE4C7,donation,100,54,3/26/2020
9CE4C7,donation,100,54,3/26/2020
9D30A8,award,100,58,3/26/2020
9FA83B,partnership,100,61,3/26/2020
A1EAC8,note-sale,100,52,3/26/2020
A1EAC8,acquisition-completed-acquirer,100,49,3/26/2020
A6828A,partnership,100,61,3/26/2020
A6FB29,earnings,100,50,3/26/2020
A761FE,earnings,100,50,3/26/2020
B0FE08,business-contract,100,69,3/26/2020
B2D492,executive-appointment,100,54,3/26/2020
B33E77,legal-issues-defendant,100,22,3/26/2020
BA0442,partnership,100,61,3/26/2020
BA218A,dividend,100,50,3/26/2020
C2E120,dividend,100,50,3/26/2020
C7AE14,note-sale,100,52,3/26/2020
C9732E,legal-issues-defendant,100,22,3/26/2020
C9732E,legal-issues-defendant,100,22,3/26/2020
C9739A,earnings,100,50,3/26/2020
C9739A,earnings,100,50,3/26/2020
CBA33B,product-release,100,64,3/26/2020
CBB77B,award,100,58,3/26/2020
CC35BE,partnership,100,61,3/26/2020
CC6F6E,earnings,100,50,3/26/2020
CC6F6E,earnings,100,50,3/26/2020
CC6F6E,earnings,100,50,3/26/2020
CDAF5B,earnings-guidance-suspended,100,29,3/26/2020
D15833,dividend,100,50,3/26/2020
D21D8A,dividend,100,50,3/26/2020
D42DBA,earnings,100,50,3/26/2020
D64EDF,donation,100,54,3/26/2020
DA199F,earnings,100,50,3/26/2020
DF01B1,legal-issues-defendant,100,22,3/26/2020
E124EB,note-sale,100,52,3/26/2020
E30B34,note-sale,100,52,3/26/2020
E30B34,note-sale,100,52,3/26/2020
EB7D6C,legal-issues-defendant,100,22,3/26/2020
EC99D0,conference-call,100,50,3/26/2020
EDF5CA,legal-issues-defendant,100,22,3/26/2020
F209B4,earnings,100,50,3/26/2020
F24FF0,buyback-suspended,100,24,3/26/2020
F3FCC3,revenues,100,50,3/26/2020
FCA54E,earnings-guidance-suspended,100,29,3/26/2020
FD2565,partnership,100,61,3/26/2020
FD2565,partnership,100,61,3/26/2020
00698D,conference-call,100,50,3/27/2020
01D03F,regulatory-product-approval-granted,100,81,3/27/2020
01D03F,regulatory-product-approval-granted,100,81,3/27/2020
065D38,merger-completed,100,66,3/27/2020
0A59F8,partnership,100,61,3/27/2020
0A59F8,partnership,100,61,3/27/2020
0A59F8,partnership,100,61,3/27/2020
0C136E,earnings,100,50,3/27/2020
157CC1,acquisition-acquirer,100,49,3/27/2020
157CC1,acquisition-acquirer,100,49,3/27/2020
19BF16,fraud,100,44,3/27/2020
1AC649,partnership,100,61,3/27/2020
1AC649,partnership,100,61,3/27/2020
1AC649,partnership,100,61,3/27/2020
1AC649,partnership,100,61,3/27/2020
1BC12C,partnership,100,61,3/27/2020
251988,dividend,100,50,3/27/2020
251988,dividend,100,50,3/27/2020
267718,partnership,100,61,3/27/2020
2A9C0A,earnings-positive,100,69,3/27/2020
2E61CC,partnership,100,61,3/27/2020
2EB88B,business-contract,100,69,3/27/2020
372037,fraud,100,44,3/27/2020
39FB23,earnings,100,50,3/27/2020
3C7F5F,note-sale,100,52,3/27/2020
4AE584,revenue-up,100,69,3/27/2020
4AE584,earnings,100,50,3/27/2020
4AE584,revenue-up,100,69,3/27/2020
4AE584,earnings,100,50,3/27/2020
4F9487,conference-call,100,50,3/27/2020
56EA2B,executive-appointment,100,54,3/27/2020
66A667,dividend,100,50,3/27/2020
66A667,dividend,100,50,3/27/2020
68BA15,conference-call,100,50,3/27/2020
6925EB,legal-issues-defendant,100,22,3/27/2020
6925EB,legal-issues-defendant,100,22,3/27/2020
6F0A63,business-contract,100,69,3/27/2020
73C521,earnings,100,50,3/27/2020
756BB4,earnings,100,50,3/27/2020
7F7C87,earnings,100,50,3/27/2020
838ADD,fundraising,100,64,3/27/2020
8C84DF,earnings,100,50,3/27/2020
92D3A0,conference-call,100,50,3/27/2020
94983E,earnings,100,50,3/27/2020
98CAED,unit-acquisition-completed-acquirer,100,49,3/27/2020
9D2790,partnership,100,61,3/27/2020
A38F30,shareholder-rights-plan,100,43,3/27/2020
AE0CCE,earnings,100,50,3/27/2020
B303A6,donation,100,54,3/27/2020
B6CD92,dividend,100,50,3/27/2020
BE14CF,board-meeting,100,51,3/27/2020
C0030A,shareholder-rights-plan,100,43,3/27/2020
C07E05,executive-appointment,100,54,3/27/2020
C8257F,note-sale,100,52,3/27/2020
C9A96E,executive-appointment,100,54,3/27/2020
CDD75E,regulatory-product-approval-granted,100,81,3/27/2020
CE69E9,executive-firing,100,36,3/27/2020
D1AE3B,conference-call,100,50,3/27/2020
E38906,conference-participant,100,50,3/27/2020
E68733,product-release,100,64,3/27/2020
E68733,product-release,100,64,3/27/2020
EB7D6C,legal-issues-defendant,100,22,3/27/2020
ECF4F8,executive-appointment,100,54,3/27/2020
EDF5CA,legal-issues-defendant,100,22,3/27/2020
EDF5CA,legal-issues-defendant,100,22,3/27/2020
EDF5CA,legal-issues-defendant,100,22,3/27/2020
EDF5CA,legal-issues-defendant,100,22,3/27/2020
F509E2,legal-issues-defendant,100,22,3/27/2020
F509E2,legal-issues-defendant,100,22,3/27/2020
F7ADEB,award,100,58,3/27/2020
F90EE5,board-meeting,100,51,3/27/2020
F9AA02,earnings,100,50,3/27/2020
4A7C1F,legal-issues-defendant,100,22,3/28/2020
76F067,clinical-trials-positive,100,87,3/28/2020
EDF5CA,legal-issues-defendant,100,22,3/28/2020
CDFCC9,settlement,100,56,3/29/2020
EB7D6C,legal-issues-defendant,100,22,3/29/2020
F509E2,legal-issues-defendant,100,22,3/29/2020
04CCCD,dividend,100,50,3/30/2020
04EB2F,acquisition-regulatory-approval-acquirer,100,54,3/30/2020
05D148,public-offering,100,43,3/30/2020
09F623,conference-participant,100,50,3/30/2020
0AB700,dividend,100,50,3/30/2020
0B400D,trading-halt,100,43,3/30/2020
0B73A7,donation,100,54,3/30/2020
0B73A7,donation,100,54,3/30/2020
0C6861,dividend,100,50,3/30/2020
0CC62B,conference-call,100,50,3/30/2020
0F91FC,executive-appointment,100,54,3/30/2020
11A49E,executive-appointment,100,54,3/30/2020
12E454,business-contract,100,69,3/30/2020
159AE4,conference-call,100,50,3/30/2020
1921DD,partnership,100,61,3/30/2020
1B5FEA,earnings,100,50,3/30/2020
1B5FEA,earnings,100,50,3/30/2020
1B5FEA,earnings,100,50,3/30/2020
1E7785,executive-appointment,100,54,3/30/2020
1FA886,business-contract-terminated,100,31,3/30/2020
223552,partnership,100,61,3/30/2020
26F99F,earnings,100,50,3/30/2020
2CC71C,patient-enrollment-complete,100,64,3/30/2020
2DA92D,acquisition-completed-acquirer,100,49,3/30/2020
2E0445,earnings,100,50,3/30/2020
2FDEE3,board-meeting,100,51,3/30/2020
2FDEE3,board-meeting,100,51,3/30/2020
389CFB,executive-appointment,100,54,3/30/2020
3B9886,executive-appointment,100,54,3/30/2020
42DC93,earnings,100,50,3/30/2020
451D61,regulatory-product-review-positive,100,73,3/30/2020
45ABCC,stake-acquiree,100,62,3/30/2020
494EB9,legal-issues-defendant,100,22,3/30/2020
4A7C1F,legal-issues-defendant,100,22,3/30/2020
52B567,earnings,100,50,3/30/2020
5AA3B1,executive-appointment,100,54,3/30/2020
615B6D,clinical-trials-positive,100,87,3/30/2020
619882,credit-extension-provider,100,57,3/30/2020
62F41C,legal-issues-defendant,100,22,3/30/2020
68BA15,acquisition-acquirer,100,49,3/30/2020
69C99E,clinical-trials,100,56,3/30/2020
6F0096,executive-appointment,100,54,3/30/2020
722D55,asset-sale,100,62,3/30/2020
723548,dividend,100,50,3/30/2020
7.49E+07,earnings,100,50,3/30/2020
7.49E+07,earnings,100,50,3/30/2020
756045,executive-appointment,100,54,3/30/2020
7999F3,note-sale,100,52,3/30/2020
7999F3,note-sale,100,52,3/30/2020
7F7C87,earnings,100,50,3/30/2020
8665BA,note-sale,100,52,3/30/2020
885758,executive-appointment,100,54,3/30/2020
8AB85C,earnings,100,50,3/30/2020
8E0E32,asset-sale,100,62,3/30/2020
8F3BCC,executive-appointment,100,54,3/30/2020
903AB4,public-offering,100,43,3/30/2020
911CA9,ownership-increase-held,100,67,3/30/2020
913437,earnings,100,50,3/30/2020
92B047,conference-call,100,50,3/30/2020
94208D,product-release,100,64,3/30/2020
A6FB29,earnings-up,100,68,3/30/2020
A6FB29,earnings-up,100,68,3/30/2020
A6FB29,earnings-up,100,68,3/30/2020
A6FB29,earnings-up,100,68,3/30/2020
A6FB29,earnings-up,100,68,3/30/2020
A6FB29,earnings-up,100,68,3/30/2020
A6FB29,earnings-up,100,68,3/30/2020
A6FB29,earnings-up,100,68,3/30/2020
A6FB29,earnings-up,100,68,3/30/2020
A79D88,executive-appointment,100,54,3/30/2020
B13B68,partnership,100,61,3/30/2020
B4C673,note-sale,100,52,3/30/2020
BAD9EA,earnings,100,50,3/30/2020
BDF85E,earnings,100,50,3/30/2020
BF5959,conference-call,100,50,3/30/2020
BFEA04,product-release,100,64,3/30/2020
BFEA04,product-release,100,64,3/30/2020
C0030A,partnership,100,61,3/30/2020
C22BE8,acquisition-acquirer,100,49,3/30/2020
C5C0E9,conference-call,100,50,3/30/2020
CE5C6E,executive-appointment,100,54,3/30/2020
CE8A7B,earnings,100,50,3/30/2020
CFF15D,executive-appointment,100,54,3/30/2020
D36B23,executive-appointment,100,54,3/30/2020
D3F64D,dividend,100,50,3/30/2020
D6489C,partnership,100,61,3/30/2020
D78BF1,earnings,100,50,3/30/2020
D854DD,asset-sale,100,62,3/30/2020
D93A25,conference-call,100,50,3/30/2020
DA48E4,acquisition-acquirer,100,49,3/30/2020
DAFED3,supply-increase,100,74,3/30/2020
DB7EC3,executive-appointment,100,54,3/30/2020
E0E4B7,patient-enrollment-complete,100,64,3/30/2020
E261E9,earnings,100,50,3/30/2020
E5A3B6,earnings,100,50,3/30/2020
E829E8,conference-call,100,50,3/30/2020
E8E899,credit-extension-recipient,100,69,3/30/2020
EB7D6C,legal-issues-defendant,100,22,3/30/2020
EB7D6C,legal-issues-defendant,100,22,3/30/2020
EB7D6C,legal-issues-defendant,100,22,3/30/2020
EB7D6C,legal-issues-defendant,100,22,3/30/2020
EB7D6C,legal-issues-defendant,100,22,3/30/2020
EC8116,dividend,100,50,3/30/2020
ED1A74,earnings,100,50,3/30/2020
ED22DC,earnings,100,50,3/30/2020
EDF5CA,legal-issues-defendant,100,22,3/30/2020
EF5BED,executive-appointment,100,54,3/30/2020
EFA7B2,earnings,100,50,3/30/2020
F30508,regulatory-product-approval-granted,100,81,3/30/2020
F3EDB4,shareholder-rights-plan,100,43,3/30/2020
F509E2,legal-issues-defendant,100,22,3/30/2020
F5349B,partnership,100,61,3/30/2020
F6581D,conference-call,100,50,3/30/2020
F6581D,earnings,100,50,3/30/2020
F6A392,earnings,100,50,3/30/2020
F748C7,settlement,100,56,3/30/2020
F93C8A,note-sale,100,52,3/30/2020
FBD92D,partnership,100,61,3/30/2020
FF227B,clinical-trials,100,56,3/30/2020
0CC01F,earnings,100,50,3/31/2020
1921DD,partnership,100,61,3/31/2020
1921DD,unit-acquisition-acquiree,100,76,3/31/2020
1A2D9F,board-meeting,100,51,3/31/2020
1BC12C,partnership,100,61,3/31/2020
1DE526,conference-call,100,50,3/31/2020
1E7785,credit-rating-affirmation,100,54,3/31/2020
2158DF,award,100,58,3/31/2020
228D42,campaign-ad-release,100,59,3/31/2020
275300,note-sale,100,52,3/31/2020
275300,note-sale,100,52,3/31/2020
2A1009,business-contract,100,69,3/31/2020
2BC05E,shareholder-rights-plan,100,43,3/31/2020
2C681C,business-contract,100,69,3/31/2020
2D2D43,executive-appointment,100,54,3/31/2020
2D643C,conference-call,100,50,3/31/2020
2EC172,conference-call,100,50,3/31/2020
36E479,clinical-trials,100,56,3/31/2020
3BCF24,dividend,100,50,3/31/2020
4.03E+05,award,100,58,3/31/2020
408089,earnings,100,50,3/31/2020
4A6F00,partnership,100,61,3/31/2020
4C2F17,conference-participant,100,50,3/31/2020
50D1EC,partnership,100,61,3/31/2020
510EA6,acquisition-acquirer,100,49,3/31/2020
59872F,partnership,100,61,3/31/2020
5B6C11,executive-appointment,100,54,3/31/2020
5D1329,partnership,100,61,3/31/2020
5F3D91,clinical-trials-filed,100,60,3/31/2020
665D7D,donation,100,54,3/31/2020
67303E,clinical-trials-filed,100,60,3/31/2020
6925EB,legal-issues-defendant,100,22,3/31/2020
693ECD,executive-appointment,100,54,3/31/2020
72C2CE,partnership,100,61,3/31/2020
742AAB,executive-appointment,100,54,3/31/2020
7.40E+289,dividend,100,50,3/31/2020
765913,earnings,100,50,3/31/2020
789A7D,note-sale,100,52,3/31/2020
79340A,earnings,100,50,3/31/2020
7BFF81,note-sale,100,52,3/31/2020
7EA323,earnings,100,50,3/31/2020
8802B4,conference-call,100,50,3/31/2020
8876D6,buyback-suspended,100,24,3/31/2020
88D80A,earnings,100,50,3/31/2020
8F3BCC,earnings,100,50,3/31/2020
903AB4,public-offering,100,43,3/31/2020
91E5EE,government-contract,100,69,3/31/2020
92005C,patient-enrollment-complete,100,64,3/31/2020
92D9C9,dividend,100,50,3/31/2020
92D9C9,dividend,100,50,3/31/2020
93AD2E,earnings,100,50,3/31/2020
94637C,clinical-trials-filed,100,60,3/31/2020
97FE80,partnership,100,61,3/31/2020
9B730A,business-contract,100,69,3/31/2020
9B730A,business-contract,100,69,3/31/2020
9E3224,dividend,100,50,3/31/2020
9F5CBB,dividend,100,50,3/31/2020
A52B6B,acquisition-interest-acquirer,100,46,3/31/2020
A63387,partnership,100,61,3/31/2020
A753BB,partnership,100,61,3/31/2020
A80FE0,index-listing,100,76,3/31/2020
AE3113,partnership,100,61,3/31/2020
B1A85D,business-contract,100,69,3/31/2020
B3CB74,executive-appointment,100,54,3/31/2020
B508E5,product-release,100,64,3/31/2020
B614F8,earnings,100,50,3/31/2020
B803B1,dividend,100,50,3/31/2020
BE14CF,conference-call,100,50,3/31/2020
C188F8,product-release,100,64,3/31/2020
C2E39B,credit-extension-recipient,100,69,3/31/2020
C564E4,business-contract,100,69,3/31/2020
C564E4,business-contract,100,69,3/31/2020
C598D7,conference-call,100,50,3/31/2020
C83B88,product-release,100,64,3/31/2020
C83B88,conference-call,100,50,3/31/2020
C8A248,revenue-up,100,69,3/31/2020
C8FAC7,note-sale,100,52,3/31/2020
CAD7D9,earnings,100,50,3/31/2020
CD06A2,donation,100,54,3/31/2020
CDAA0E,product-release,100,64,3/31/2020
CDD75E,executive-appointment,100,54,3/31/2020
CE4E6D,government-contract,100,69,3/31/2020
CF7292,conference-participant,100,50,3/31/2020
CFF97C,credit-rating-confirmation-rater,20,50,3/31/2020
D5938F,fast-track-designation,100,81,3/31/2020
D9E036,business-contract,100,69,3/31/2020
DB88A1,earnings,100,50,3/31/2020
DB88A1,earnings,100,50,3/31/2020
DB88A1,earnings,100,50,3/31/2020
DB88A1,earnings,100,50,3/31/2020
DB88A1,earnings,100,50,3/31/2020
DB88A1,earnings,100,50,3/31/2020
DB88A1,earnings,100,50,3/31/2020
DB88A1,earnings,100,50,3/31/2020
DB88A1,earnings,100,50,3/31/2020
DB88A1,earnings,100,50,3/31/2020
DD1BA1,asset-sale,100,62,3/31/2020
DDCB34,executive-appointment,100,54,3/31/2020
DF42A0,executive-appointment,100,54,3/31/2020
E0207A,product-release,100,64,3/31/2020
E124EB,unit-acquisition-acquirer,100,49,3/31/2020
E15736,earnings-guidance,100,50,3/31/2020
E8846E,partnership,100,61,3/31/2020
EAEA91,earnings,100,50,3/31/2020
EAEA91,dividend,100,50,3/31/2020
EB6965,award,100,58,3/31/2020
EB7D6C,legal-issues-defendant,100,22,3/31/2020
EB7D6C,legal-issues-defendant,100,22,3/31/2020
F209B4,clinical-trials,100,56,3/31/2020
F30508,partnership,100,61,3/31/2020
F3EDB4,joint-venture,100,62,3/31/2020
F40EE2,award,100,58,3/31/2020
F40EE2,award,100,58,3/31/2020
F46EC9,earnings-guidance-suspended,100,29,3/31/2020
FA40E2,earnings,100,50,3/31/2020
FA40E2,earnings,100,50,3/31/2020
FA40E2,earnings,100,50,3/31/2020
FA40E2,earnings,100,50,3/31/2020
FA40E2,earnings,100,50,3/31/2020
FA40E2,earnings,100,50,3/31/2020
FA40E2,earnings,100,50,3/31/2020
FA40E2,earnings,100,50,3/31/2020
FD9526,facility-sale,100,52,3/31/2020
FDF28E,donation,100,54,3/31/2020
00067A,earnings,100,50,4/1/2020
05D148,public-offering,100,43,4/1/2020
078D52,dividend,100,50,4/1/2020
07C69F,conference-call,100,50,4/1/2020
083F72,award,100,58,4/1/2020
09062E,unit-acquisition-acquirer,100,49,4/1/2020
09062E,acquisition-completed-acquirer,100,49,4/1/2020
09062E,acquisition-completed-acquirer,100,49,4/1/2020
09062E,acquisition-completed-acquirer,100,49,4/1/2020
09062E,acquisition-completed-acquirer,100,49,4/1/2020
091B6C,fundraising,100,64,4/1/2020
091B6C,fundraising,100,64,4/1/2020
0E64D4,earnings,100,50,4/1/2020
105D00,acquisition-completed-acquirer,100,49,4/1/2020
108FDA,board-meeting,100,51,4/1/2020
10C19B,dividend-up,100,81,4/1/2020
12DE76,partnership,100,61,4/1/2020
1348C9,conference-call,100,50,4/1/2020
1490F3,award,100,58,4/1/2020
19CAC7,conference-call,100,50,4/1/2020
1A3E1B,trading-halt,100,43,4/1/2020
1A3E1B,trading-resumed,100,58,4/1/2020
1AF7E2,layoffs,100,43,4/1/2020
1BC12C,revenue-volume,100,50,4/1/2020
1BC12C,conference-call,100,50,4/1/2020
1C2593,executive-appointment,100,54,4/1/2020
1F716B,conference-call,100,50,4/1/2020
228D42,partnership,100,61,4/1/2020
251988,executive-appointment,100,54,4/1/2020
2571FA,government-contract,100,69,4/1/2020
274B8A,conference-call,100,50,4/1/2020
275300,legal-issues-defendant,100,22,4/1/2020
2C35B5,clinical-trials,100,56,4/1/2020
2E89AE,public-offering,100,43,4/1/2020
2E89AE,public-offering,100,43,4/1/2020
2F5256,unit-acquisition-completed-acquirer,100,49,4/1/2020
31553A,earnings,100,50,4/1/2020
34B411,earnings,100,50,4/1/2020
370C50,acquisition-completed-acquirer,100,49,4/1/2020
414FFF,earnings,100,50,4/1/2020
41B53E,dividend,100,50,4/1/2020
4398A2,clinical-trials-filed,100,60,4/1/2020
494EB9,legal-issues-defendant,100,22,4/1/2020
4A7C1F,fraud,100,44,4/1/2020
4D8313,conference-call,100,50,4/1/2020
4EC4C1,conference-call,100,50,4/1/2020
56632F,executive-appointment,100,54,4/1/2020
57DDB9,merger-completed,100,66,4/1/2020
57DDB9,merger-completed,100,66,4/1/2020
57DDB9,note-sale,100,52,4/1/2020
58B46F,conference-call,100,50,4/1/2020
59F0B0,conference-call,100,50,4/1/2020
5A0FF1,merger-completed,100,66,4/1/2020
5AF08A,earnings,100,50,4/1/2020
5BC2F4,earnings,100,50,4/1/2020
5CC29D,earnings,100,50,4/1/2020
63F892,earnings,100,50,4/1/2020
665618,dividend-up,100,61,4/1/2020
66ECFD,layoffs,100,43,4/1/2020
68BA15,dividend,100,50,4/1/2020
693ECD,executive-appointment,100,54,4/1/2020
69FDFC,demand-increase,100,83,4/1/2020
6D0CAB,acquisition-completed-acquirer,100,49,4/1/2020
6E1E61,conference-call,100,50,4/1/2020
719477,conference-call,100,50,4/1/2020
723548,dividend,100,50,4/1/2020
75F665,conference-call,100,50,4/1/2020
763724,dividend,100,50,4/1/2020
7710F3,partnership,100,61,4/1/2020
791EC1,unit-acquisition-acquirer,100,49,4/1/2020
7A10FF,acquisition-completed-acquirer,100,49,4/1/2020
7A975D,earnings,100,50,4/1/2020
7A975D,earnings,100,50,4/1/2020
7A975D,earnings,100,50,4/1/2020
7ACFD4,unit-acquisition-acquiree,100,76,4/1/2020
7B6EB1,ownership-increase-owner,100,56,4/1/2020
7B6EB1,acquisition-acquirer,100,49,4/1/2020
7F7C87,credit-extension-recipient,100,69,4/1/2020
810FAD,conference-call,100,50,4/1/2020
8.10E+205,executive-appointment,100,54,4/1/2020
83598E,acquisition-interest-acquirer,100,46,4/1/2020
86F123,executive-appointment,100,54,4/1/2020
89B2E7,dividend,100,50,4/1/2020
93F143,settlement,100,56,4/1/2020
9592FB,acquisition-acquirer,100,49,4/1/2020
9.62E+76,earnings,100,50,4/1/2020
96F126,earnings,100,50,4/1/2020
9CA4C6,conference-call,100,50,4/1/2020
9D56F2,dividend,100,50,4/1/2020
A0F146,exchange-noncompliance,100,24,4/1/2020
A49498,product-release,100,64,4/1/2020
A5B913,earnings,100,50,4/1/2020
A631A3,fraud,100,44,4/1/2020
A631A3,legal-issues-defendant,100,22,4/1/2020
A631A3,legal-issues-defendant,100,22,4/1/2020
A631A3,legal-issues-defendant,100,22,4/1/2020
A631A3,legal-issues-defendant,100,22,4/1/2020
A70BF5,executive-appointment,100,54,4/1/2020
A8CBDA,earnings,100,50,4/1/2020
AD9F1D,conference-call,100,50,4/1/2020
AECCA9,unit-acquisition-completed-acquiree,100,67,4/1/2020
B09B1F,executive-appointment,100,54,4/1/2020
B2AA0A,earnings-guidance-suspended,100,29,4/1/2020
B48FC9,public-offering,100,43,4/1/2020
BAAA60,conference-call,100,50,4/1/2020
BB5142,conference-call,100,50,4/1/2020
BB88B6,earnings,100,50,4/1/2020
BE7BA4,conference-call,100,50,4/1/2020
BFEA04,board-meeting,100,51,4/1/2020
C03C8B,conference-call,100,50,4/1/2020
C32A39,note-sale,100,52,4/1/2020
C3EE99,earnings,100,50,4/1/2020
C4F9C6,business-contract,100,69,4/1/2020
C564E4,partnership,100,61,4/1/2020
C62AA4,earnings-guidance-suspended,100,29,4/1/2020
C7AE14,dividend,100,50,4/1/2020
C9E107,earnings,100,50,4/1/2020
CC176E,earnings,100,50,4/1/2020
CF211D,earnings,100,50,4/1/2020
CF211D,earnings,100,50,4/1/2020
CFF97C,credit-rating-outlook-stable-rater,20,50,4/1/2020
D77F7E,partnership,100,61,4/1/2020
D77F7E,partnership,100,61,4/1/2020
DC2B00,note-sale,100,52,4/1/2020
DC2F77,dividend,100,50,4/1/2020
DEF058,earnings,100,50,4/1/2020
DF16DE,executive-appointment,100,54,4/1/2020
DF1F7A,conference-call,100,50,4/1/2020
E09997,executive-appointment,100,54,4/1/2020
E12A6E,earnings,100,50,4/1/2020
EC8116,dividend,100,50,4/1/2020
EE6F1C,business-contract,100,69,4/1/2020
EF1AD9,conference-call,100,50,4/1/2020
F2BC3D,unit-acquisition-acquirer,100,49,4/1/2020
F509E2,legal-issues-defendant,100,22,4/1/2020
F509E2,legal-issues-defendant,100,22,4/1/2020
F509E2,legal-issues-defendant,100,22,4/1/2020
F748C7,settlement,100,56,4/1/2020
FA044A,conference-call,100,50,4/1/2020
FBDA0F,acquisition-completed-acquirer,100,49,4/1/2020
FC9A88,acquisition-completed-acquirer,100,49,4/1/2020
FFAB4A,acquisition-completed-acquiree,100,76,4/1/2020
31025,earnings,100,50,4/2/2020
09DE1F,partnership,100,61,4/2/2020
0A9D0A,unit-acquisition-completed-acquirer,100,49,4/2/2020
0B400D,trading-resumed,100,58,4/2/2020
0BF198,executive-appointment,100,54,4/2/2020
0BF198,executive-appointment,100,54,4/2/2020
0C8D82,conference-call,100,50,4/2/2020
0CCCB7,donation,100,54,4/2/2020
0FC848,acquisition-acquirer,100,49,4/2/2020
105D00,conference-call,100,50,4/2/2020
10C19B,conference-call,100,50,4/2/2020
119CB6,conference-call,100,50,4/2/2020
16B183,resource-discovery,100,88,4/2/2020
188394,earnings,100,50,4/2/2020
1A3E1B,investment-investor,100,55,4/2/2020
1EBF8D,conference-call,100,50,4/2/2020
206852,conference-call,100,50,4/2/2020
20D00A,executive-appointment,100,54,4/2/2020
221AD7,acquisition-completed-acquirer,100,49,4/2/2020
221AD7,acquisition-completed-acquirer,100,49,4/2/2020
221AD7,earnings,100,50,4/2/2020
223552,partnership,100,61,4/2/2020
223552,partnership,100,61,4/2/2020
228D42,product-release,100,64,4/2/2020
228D42,partnership,100,61,4/2/2020
22C58E,earnings,100,50,4/2/2020
267718,executive-appointment,100,54,4/2/2020
2.90E+62,earnings,100,50,4/2/2020
2A1009,partnership,100,61,4/2/2020
2B0AF4,conference-call,100,50,4/2/2020
2C7505,partnership,100,61,4/2/2020
2C7505,partnership,100,61,4/2/2020
2D981A,settlement,100,56,4/2/2020
2F7474,conference-call,100,50,4/2/2020
33E9D5,earnings,100,50,4/2/2020
342218,conference-call,100,50,4/2/2020
370C50,award,100,58,4/2/2020
38C46F,dividend,100,50,4/2/2020
3E70FC,credit-extension-recipient,100,69,4/2/2020
3F4668,legal-issues-defendant,100,22,4/2/2020
43A74A,note-sale,100,52,4/2/2020
449A26,conference-call,100,50,4/2/2020
4A6F00,partnership,100,61,4/2/2020
4A7C1F,legal-issues-defendant,100,22,4/2/2020
4B49CF,dividend-up,100,81,4/2/2020
4D371E,earnings,100,50,4/2/2020
4FCC78,dividend,100,50,4/2/2020
53F491,earnings,100,50,4/2/2020
55CD6F,earnings-guidance-suspended,100,29,4/2/2020
56B7C1,dividend,100,50,4/2/2020
58B46F,executive-appointment,100,54,4/2/2020
58CA9A,business-contract,100,69,4/2/2020
59B229,earnings,100,50,4/2/2020
5C7601,earnings,100,50,4/2/2020
5EAA43,executive-appointment,100,54,4/2/2020
61B81B,dividend,100,50,4/2/2020
62F41C,executive-appointment,100,54,4/2/2020
657097,unit-acquisition-acquirer,100,49,4/2/2020
665D7D,conference-call,100,50,4/2/2020
66A667,earnings,100,50,4/2/2020
67529E,conference-call,100,50,4/2/2020
67A658,public-offering,100,43,4/2/2020
68AB62,conference-call,100,50,4/2/2020
68E6E9,executive-appointment,100,54,4/2/2020
6B494E,fundraising,100,64,4/2/2020
6CC55E,clinical-trials,100,56,4/2/2020
73C9E2,board-meeting,100,51,4/2/2020
746373,conference-call,100,50,4/2/2020
748EB6,executive-appointment,100,54,4/2/2020
76F067,partnership,100,61,4/2/2020
7771D7,earnings,100,50,4/2/2020
7771D7,earnings,100,50,4/2/2020
7771D7,earnings,100,50,4/2/2020
7771D7,earnings,100,50,4/2/2020
7ADE57,unit-acquisition-acquirer,100,49,4/2/2020
7BEA98,business-contract,100,69,4/2/2020
7BEA98,business-contract,100,69,4/2/2020
7E1D5D,partnership,100,61,4/2/2020
82C202,unit-acquisition-completed-acquirer,100,49,4/2/2020
83598E,merger-failed,100,21,4/2/2020
885758,debt-extension-recipient,100,73,4/2/2020
88611B,business-contract,100,69,4/2/2020
88923D,partnership,100,61,4/2/2020
88923D,partnership,100,61,4/2/2020
88923D,partnership,100,61,4/2/2020
8F3231,conference-call,100,50,4/2/2020
922F0C,earnings,100,50,4/2/2020
944B2E,executive-appointment,100,54,4/2/2020
945DE6,business-contract,100,69,4/2/2020
94A326,executive-appointment,100,54,4/2/2020
96B4FF,executive-appointment,100,54,4/2/2020
9A602D,conference-call,100,50,4/2/2020
9C8664,conference-call,100,50,4/2/2020
9E5C2C,conference-call,100,50,4/2/2020
9F18FA,note-sale,100,52,4/2/2020
9F18FA,note-sale,100,52,4/2/2020
9F18FA,note-sale,100,52,4/2/2020
A1EAC8,business-contract,100,69,4/2/2020
A3230E,executive-appointment,100,54,4/2/2020
A350C1,conference-call,100,50,4/2/2020
A5195E,executive-appointment,100,54,4/2/2020
A6213D,revenue-volume-down,100,37,4/2/2020
A6828A,partnership,100,61,4/2/2020
A72FD9,business-contract,100,69,4/2/2020
A8E72A,executive-appointment,100,54,4/2/2020
A99576,earnings,100,50,4/2/2020
AA7FE0,earnings,100,50,4/2/2020
AA7FE0,earnings,100,50,4/2/2020
AA7FE0,earnings,100,50,4/2/2020
AA7FE0,earnings,100,50,4/2/2020
AA7FE0,earnings,100,50,4/2/2020
ABBAD1,acquisition-completed-acquirer,100,49,4/2/2020
B0D41A,partnership,100,61,4/2/2020
B48FC9,public-offering,100,43,4/2/2020
B840EF,earnings,100,50,4/2/2020
BB127B,conference-participant,100,50,4/2/2020
BDF85E,earnings,100,50,4/2/2020
C4452A,earnings,100,50,4/2/2020
C4452A,executive-appointment,100,54,4/2/2020
C4F567,revenues,100,50,4/2/2020
C65004,revenues,100,50,4/2/2020
C8FAC7,note-sale,100,52,4/2/2020
C99CC8,award,100,58,4/2/2020
CB7AB2,earnings,100,50,4/2/2020
CE8251,stake-acquirer,100,48,4/2/2020
D437C3,earnings,100,50,4/2/2020
D54E62,conference-call,100,50,4/2/2020
D56E4C,trading-halt,100,43,4/2/2020
D56E4C,trading-resumed,100,58,4/2/2020
D88EF3,conference-call,100,50,4/2/2020
DC2F77,conference-call,100,50,4/2/2020
E8846E,business-contract,100,69,4/2/2020
E8E899,executive-appointment,100,54,4/2/2020
E959F3,earnings,100,50,4/2/2020
ED5171,earnings,100,50,4/2/2020
EF77A3,earnings,100,50,4/2/2020
F0B877,conference-call,100,50,4/2/2020
F4E992,conference-call,100,50,4/2/2020
F509E2,legal-issues-defendant,100,22,4/2/2020
F5349B,business-contract,100,69,4/2/2020
F5D059,dividend,100,50,4/2/2020
F5D410,conference-call,100,50,4/2/2020
FA918D,donation,100,54,4/2/2020
FACF19,earnings,100,50,4/2/2020
FB728F,asset-sale,100,62,4/2/2020
FC1B7B,conference-call,100,50,4/2/2020
FC4550,dividend,100,50,4/2/2020
1151F4,conference-call,100,50,4/3/2020
12DE76,partnership,100,61,4/3/2020
139303,acquisition-completed-acquirer,100,49,4/3/2020
139303,acquisition-completed-acquirer,100,49,4/3/2020
168A5D,partnership,100,61,4/3/2020
16C7F0,conference-call,100,50,4/3/2020
1D1B07,earnings,100,50,4/3/2020
1D3A00,shareholder-rights-plan,100,43,4/3/2020
2667B6,merger-completed,100,66,4/3/2020
2667B6,merger-completed,100,66,4/3/2020
267718,business-contract,100,69,4/3/2020
28DCA8,earnings-guidance,100,50,4/3/2020
28DCF3,acquisition-completed-acquirer,100,49,4/3/2020
2CB4C9,earnings,100,50,4/3/2020
2EC172,partnership,100,61,4/3/2020
30DFD3,conference-call,100,50,4/3/2020
33AD83,note-sale,100,52,4/3/2020
33AD83,note-sale,100,52,4/3/2020
370C50,conference-call,100,50,4/3/2020
3C7F5F,business-contract,100,69,4/3/2020
422CE3,executive-appointment,100,54,4/3/2020
423279,earnings-delayed,100,26,4/3/2020
46CF27,earnings,100,50,4/3/2020
4A7C1F,earnings,100,50,4/3/2020
4A7C1F,earnings,100,50,4/3/2020
550D01,conference-call,100,50,4/3/2020
59B229,executive-appointment,100,54,4/3/2020
59C539,conference-call,100,50,4/3/2020
5EC388,earnings,100,50,4/3/2020
60EA12,earnings,100,50,4/3/2020
713810,board-meeting,100,51,4/3/2020
762A3E,conference-call,100,50,4/3/2020
765913,acquisition-regulatory-approval-acquirer,100,54,4/3/2020
76E80F,conference-participant,100,50,4/3/2020
7B0BA6,partnership,100,61,4/3/2020
7E3F8F,earnings,100,50,4/3/2020
850779,earnings,100,50,4/3/2020
85AD00,conference-call,100,50,4/3/2020
86A1B9,partnership,100,61,4/3/2020
8AA108,ipo-pricing,100,50,4/3/2020
938D89,legal-issues-defendant,100,22,4/3/2020
938D89,legal-issues-defendant,100,22,4/3/2020
938D89,legal-issues-defendant,100,22,4/3/2020
957A07,earnings,100,50,4/3/2020
98CAED,earnings,100,50,4/3/2020
9F71E5,earnings,100,50,4/3/2020
A1EAC8,business-contract,100,69,4/3/2020
A41450,dividend,100,50,4/3/2020
A47F2E,earnings,100,50,4/3/2020
A5A4F5,earnings,100,50,4/3/2020
A5A4F5,earnings,100,50,4/3/2020
A5A4F5,earnings,100,50,4/3/2020
A5A4F5,earnings,100,50,4/3/2020
A5A4F5,earnings,100,50,4/3/2020
A5A4F5,earnings,100,50,4/3/2020
A5A4F5,earnings,100,50,4/3/2020
A5A4F5,earnings,100,50,4/3/2020
A5A4F5,earnings,100,50,4/3/2020
A5A4F5,earnings,100,50,4/3/2020
A5A4F5,earnings,100,50,4/3/2020
A5A4F5,earnings,100,50,4/3/2020
A5A4F5,earnings,100,50,4/3/2020
A5A4F5,earnings,100,50,4/3/2020
A5A4F5,earnings,100,50,4/3/2020
A5A4F5,earnings,100,50,4/3/2020
A5A4F5,earnings,100,50,4/3/2020
A5A4F5,earnings,100,50,4/3/2020
A631A3,legal-issues-defendant,100,22,4/3/2020
B08954,acquisition-completed-acquirer,100,49,4/3/2020
B5DE80,conference-call,100,50,4/3/2020
BFE02C,conference-call,100,50,4/3/2020
C0200F,earnings,100,50,4/3/2020
C4706C,executive-appointment,100,54,4/3/2020
CC6FF5,earnings,100,50,4/3/2020
CDFCC9,legal-issues-defendant,100,22,4/3/2020
D5AF19,earnings,100,50,4/3/2020
D6EAA3,ownership-increase-held,100,67,4/3/2020
DC486E,earnings,100,50,4/3/2020
DC486E,earnings,100,50,4/3/2020
E0207A,executive-appointment,100,54,4/3/2020
E6EDED,conference-call,100,50,4/3/2020
E8A49A,shareholder-rights-plan,100,43,4/3/2020
EB7D6C,legal-issues-defendant,100,22,4/3/2020
F2BC3D,partnership,100,61,4/3/2020
F43A11,conference-call,100,50,4/3/2020
F509E2,legal-issues-defendant,100,22,4/3/2020
FAAFA2,executive-appointment,100,54,4/3/2020
FDF28E,partnership,100,61,4/3/2020
249B39,earnings,100,50,4/4/2020
990AD0,legal-issues-defendant,100,22,4/4/2020
BDA775,private-placement,100,56,4/4/2020
D7918D,legal-issues-defendant,100,22,4/4/2020
F509E2,legal-issues-defendant,100,22,4/4/2020
990AD0,legal-issues-defendant,100,22,4/5/2020
9397,executive-appointment,100,54,4/6/2020
0358AF,earnings,100,50,4/6/2020
05D148,clinical-trials,100,56,4/6/2020
05D148,clinical-trials,100,56,4/6/2020
0968A5,executive-appointment,100,54,4/6/2020
09DE1F,note-sale,100,52,4/6/2020
09DE1F,note-sale,100,52,4/6/2020
09F623,conference-call,100,50,4/6/2020
0A0D9E,unit-acquisition-acquirer,100,49,4/6/2020
0A0D9E,unit-acquisition-acquirer,100,49,4/6/2020
0AAD90,product-release,100,64,4/6/2020
0CBC4D,earnings,100,50,4/6/2020
1151F4,facility-sale,100,52,4/6/2020
131443,partnership,100,61,4/6/2020
149301,note-sale,100,52,4/6/2020
15789A,executive-appointment,100,54,4/6/2020
17EDA5,unit-acquisition-acquiree,100,76,4/6/2020
1834C0,unit-acquisition-acquirer,100,49,4/6/2020
19BF16,executive-appointment,100,54,4/6/2020
1F716B,donation,100,54,4/6/2020
20BEEA,conference-call,100,50,4/6/2020
21245F,earnings-guidance,100,50,4/6/2020
223552,partnership,100,61,4/6/2020
223552,partnership,100,61,4/6/2020
225CA2,partnership,100,61,4/6/2020
29A4CC,conference-call,100,50,4/6/2020
2A1009,executive-appointment,100,54,4/6/2020
2C3348,partnership,100,61,4/6/2020
2CC71C,executive-appointment,100,54,4/6/2020
2CD1E0,donation,100,54,4/6/2020
2D981A,clinical-trials,100,56,4/6/2020
301493,legal-issues-defendant,100,22,4/6/2020
30DFD3,revenues,100,50,4/6/2020
30E01D,donation,100,54,4/6/2020
315EB0,conference-call,100,50,4/6/2020
326EDD,award,100,58,4/6/2020
326EDD,conference-call,100,50,4/6/2020
3461CF,credit-rating-downgrade-rater,20,50,4/6/2020
34B97A,partnership,100,61,4/6/2020
34E9F9,dividend,100,50,4/6/2020
372037,legal-issues-defendant,100,22,4/6/2020
39BFF6,conference-call,100,50,4/6/2020
3BBD10,earnings,100,50,4/6/2020
3C7F5F,earnings,100,50,4/6/2020
3DD5E2,conference-call,100,50,4/6/2020
414FFF,unit-acquisition-completed-acquiree,100,67,4/6/2020
42EFC7,clinical-trials-positive,100,87,4/6/2020
44740A,executive-appointment,100,54,4/6/2020
4591D3,executive-appointment,100,54,4/6/2020
4A3438,executive-appointment,100,54,4/6/2020
4A6F00,partnership,100,61,4/6/2020
4FCC78,conference-call,100,50,4/6/2020
504FE2,conference-call,100,50,4/6/2020
52015A,dividend,100,50,4/6/2020
545272,dividend,100,50,4/6/2020
5487B1,conference-call,100,50,4/6/2020
564F3E,earnings,100,50,4/6/2020
589803,reorganization,100,53,4/6/2020
5BFE94,board-meeting,100,51,4/6/2020
5E6959,conference-call,100,50,4/6/2020
5EAA43,business-contract,100,69,4/6/2020
5FC507,executive-appointment,100,54,4/6/2020
601785,earnings,100,50,4/6/2020
619882,earnings,100,50,4/6/2020
665D7D,debt-extension-recipient,100,73,4/6/2020
69CE71,facility-open,100,65,4/6/2020
6D6B40,earnings,100,50,4/6/2020
6E705B,legal-issues-defendant,100,22,4/6/2020
6F3FA8,conference-participant,100,50,4/6/2020
71E2EF,earnings,100,50,4/6/2020
73BCBA,product-release,100,64,4/6/2020
748EB6,conference-participant,100,50,4/6/2020
7E1D5D,business-contract,100,69,4/6/2020
7E2DE6,earnings,100,50,4/6/2020
7E3F8F,product-release,100,64,4/6/2020
7F3669,earnings,100,50,4/6/2020
7FEEE1,executive-appointment,100,54,4/6/2020
8.10E+32,conference-call,100,50,4/6/2020
8377DB,hirings,100,65,4/6/2020
8377DB,hirings,100,65,4/6/2020
873DB9,conference-call,100,50,4/6/2020
8BFAA4,earnings-guidance-suspended,100,29,4/6/2020
8D4486,executive-appointment,100,54,4/6/2020
8DCBBB,conference-call,100,50,4/6/2020
8E93A4,conference-call,100,50,4/6/2020
911AB8,conference-call,100,50,4/6/2020
91E5EE,regulatory-investigation-completed,100,50,4/6/2020
938D89,legal-issues-defendant,100,22,4/6/2020
938D89,legal-issues-defendant,100,22,4/6/2020
957A07,revenues,100,50,4/6/2020
95F59E,earnings,100,50,4/6/2020
9934AD,executive-appointment,100,54,4/6/2020
9AF3DC,conference-call,100,50,4/6/2020
9C5174,earnings,100,50,4/6/2020
9D30A8,earnings,100,50,4/6/2020
9D6A24,conference-call,100,50,4/6/2020
9F03CF,conference-call,100,50,4/6/2020
9F5997,acquisition-completed-acquirer,100,49,4/6/2020
9F6B1A,earnings,100,50,4/6/2020
A2CAF7,executive-appointment,100,54,4/6/2020
A5628C,earnings,100,50,4/6/2020
A72FD9,earnings,100,50,4/6/2020
AC7C4F,executive-appointment,100,54,4/6/2020
AD1ACF,conference-call,100,50,4/6/2020
B1FC3B,business-contract,100,69,4/6/2020
B290A2,executive-appointment,100,54,4/6/2020
B33E77,clinical-trials-start,100,64,4/6/2020
B33E77,clinical-trials-start,100,64,4/6/2020
B446B8,earnings,100,50,4/6/2020
B604DF,business-contract,100,69,4/6/2020
B614F8,regulatory-product-approval-granted,100,81,4/6/2020
B83BCE,unit-acquisition-acquirer,100,49,4/6/2020
B83BCE,revenue-guidance,100,50,4/6/2020
B96637,conference-call,100,50,4/6/2020
BDA775,private-placement,100,56,4/6/2020
BEB756,conference-call,100,50,4/6/2020
C0F70B,earnings,100,50,4/6/2020
C41C25,earnings,100,50,4/6/2020
C5D2AE,earnings,100,50,4/6/2020
C7859D,dividend,100,50,4/6/2020
C8257F,executive-appointment,100,54,4/6/2020
C8257F,executive-resignation,100,44,4/6/2020
C8A248,partnership,100,61,4/6/2020
C9881C,executive-resignation,100,44,4/6/2020
C98CDB,partnership,100,61,4/6/2020
C9D866,conference-call,100,50,4/6/2020
CAC8D0,earnings,100,50,4/6/2020
CAC8D0,executive-appointment,100,54,4/6/2020
CE1002,executive-appointment,100,54,4/6/2020
CEC08B,executive-appointment,100,54,4/6/2020
D4C0CB,conference-participant,100,50,4/6/2020
D501DC,dividend,100,50,4/6/2020
D518D8,partnership,100,61,4/6/2020
D7918D,legal-issues-defendant,100,22,4/6/2020
D7918D,legal-issues-defendant,100,22,4/6/2020
D854F3,conference-call,100,50,4/6/2020
DC5299,conference-call,100,50,4/6/2020
E20392,government-contract,100,69,4/6/2020
E2F130,dividend-up,100,81,4/6/2020
E30A8F,earnings,100,50,4/6/2020
E35610,conference-call,100,50,4/6/2020
E8B315,conference-call,100,50,4/6/2020
E94704,conference-call,100,50,4/6/2020
EB61C4,conference-call,100,50,4/6/2020
EB7D6C,legal-issues-defendant,100,22,4/6/2020
ECE814,earnings,100,50,4/6/2020
ED9576,earnings,100,50,4/6/2020
EEB5F9,executive-appointment,100,54,4/6/2020
F509E2,fraud,100,44,4/6/2020
F509E2,legal-issues-defendant,100,22,4/6/2020
F50BAB,conference-call,100,50,4/6/2020
F5349B,executive-appointment,100,54,4/6/2020
F5D499,partnership,100,61,4/6/2020
F6E248,partnership,100,61,4/6/2020
FA840E,patient-enrollment-complete,100,64,4/6/2020
FC01C0,executive-appointment,100,54,4/6/2020
FD9526,earnings,100,50,4/6/2020
FF6644,business-contract,100,69,4/6/2020
001F1B,revenues,100,50,4/7/2020
0157B1,executive-appointment,100,54,4/7/2020
0157B1,executive-appointment,100,54,4/7/2020
20751,conference-participant,100,50,4/7/2020
0A9D0A,revenues,100,50,4/7/2020
0BD199,patent-awarded,100,72,4/7/2020
0CCCB7,conference-participant,100,50,4/7/2020
0F0693,executive-appointment,100,54,4/7/2020
15A388,earnings,100,50,4/7/2020
1A3E1B,conference-organizer,100,57,4/7/2020
1CDD1C,conference-call,100,50,4/7/2020
1D1B07,executive-appointment,100,54,4/7/2020
2082EA,conference-participant,100,50,4/7/2020
21153F,settlement,100,56,4/7/2020
21245F,reorganization-unit,100,53,4/7/2020
21D903,earnings,100,50,4/7/2020
228D42,partnership,100,61,4/7/2020
24FA23,conference-participant,100,50,4/7/2020
250BEE,conference-call,100,50,4/7/2020
26D8ED,earnings-guidance-suspended,100,29,4/7/2020
26E3BA,conference-participant,100,50,4/7/2020
275300,legal-issues-defendant,100,22,4/7/2020
2EC172,note-sale,100,52,4/7/2020
2EC172,note-sale,100,52,4/7/2020
2F5256,conference-call,100,50,4/7/2020
31803E,reorganization,100,53,4/7/2020
31803E,reorganization,100,53,4/7/2020
37426C,earnings,100,50,4/7/2020
3798B9,facility-open,100,65,4/7/2020
387375,earnings,100,50,4/7/2020
3A113F,revenues,100,50,4/7/2020
3DC887,earnings,100,50,4/7/2020
416C55,dividend,100,50,4/7/2020
41785E,earnings,100,50,4/7/2020
442769,conference-call,100,50,4/7/2020
45ABCC,product-discontinued,100,48,4/7/2020
4649D5,executive-appointment,100,54,4/7/2020
4C1FA1,legal-issues-defendant,100,22,4/7/2020
4C1FA1,legal-issues-defendant,100,22,4/7/2020
4C1FA1,legal-issues-defendant,100,22,4/7/2020
4D72C8,conference-call,100,50,4/7/2020
4D72C8,conference-call,100,50,4/7/2020
4EC4C1,earnings,100,50,4/7/2020
51E682,conference-call,100,50,4/7/2020
56765E,earnings,100,50,4/7/2020
58CA9A,market-entry,100,57,4/7/2020
5A0FF1,earnings,100,50,4/7/2020
5C2A47,conference-call,100,50,4/7/2020
5D1956,earnings,100,50,4/7/2020
5F9CE3,earnings,100,50,4/7/2020
627186,earnings,100,50,4/7/2020
62B20A,conference-call,100,50,4/7/2020
6810DE,fast-track-designation,100,81,4/7/2020
6BDA0C,donation,100,54,4/7/2020
73A213,earnings,100,50,4/7/2020
77F01E,executive-appointment,100,54,4/7/2020
789A7D,business-contract,100,69,4/7/2020
7A975D,dividend,100,50,4/7/2020
7E1D5D,product-release,100,64,4/7/2020
80D744,conference-call,100,50,4/7/2020
819492,clinical-trials-start,100,64,4/7/2020
81A88D,earnings,100,50,4/7/2020
8377DB,legal-issues-defendant,100,22,4/7/2020
8AA108,ipo-completed,100,76,4/7/2020
8D4486,partnership,100,61,4/7/2020
90D6A5,conference-call,100,50,4/7/2020
91C82E,dividend,100,50,4/7/2020
925759,conference-participant,100,50,4/7/2020
95DC1F,facility-open,100,65,4/7/2020
965360,earnings,100,50,4/7/2020
9673BD,conference-call,100,50,4/7/2020
968103,dividend-suspended,100,13,4/7/2020
977A1E,conference-call,100,50,4/7/2020
9.86E+03,product-release,100,64,4/7/2020
990AD0,dividend,100,50,4/7/2020
9B71A7,earnings,100,50,4/7/2020
9C8BC3,conference-call,100,50,4/7/2020
9E575E,conference-participant,100,50,4/7/2020
9E91C6,note-sale,100,52,4/7/2020
9F5997,earnings-above-expectations,100,88,4/7/2020
A398B9,earnings,100,50,4/7/2020
A631A3,executive-appointment,100,54,4/7/2020
A631A3,legal-issues-defendant,100,22,4/7/2020
A63820,product-release,100,64,4/7/2020
A6FC89,product-release,100,64,4/7/2020
A75D43,conference-call,100,50,4/7/2020
A79F7D,conference-participant,100,50,4/7/2020
A8CBDA,board-meeting,100,51,4/7/2020
AADE0B,conference-call,100,50,4/7/2020
AFF7B4,conference-call,100,50,4/7/2020
B05118,earnings,100,50,4/7/2020
B1A85D,government-contract,100,69,4/7/2020
B1B10C,conference-call,100,50,4/7/2020
B1FC3B,government-contract,100,69,4/7/2020
B2256A,conference-call,100,50,4/7/2020
B4528F,business-contract,100,69,4/7/2020
B4703C,conference-call,100,50,4/7/2020
B48D6A,executive-appointment,100,54,4/7/2020
B5766D,conference-call,100,50,4/7/2020
B7202A,conference-participant,100,50,4/7/2020
B8F71F,executive-appointment,100,54,4/7/2020
B8F71F,earnings,100,50,4/7/2020
BB127B,revenue-down,100,30,4/7/2020
BB127B,conference-participant,100,50,4/7/2020
BB5271,conference-call,100,50,4/7/2020
BCC55F,award,100,58,4/7/2020
C01737,executive-appointment,100,54,4/7/2020
C36189,conference-participant,100,50,4/7/2020
C3BAE7,acquisition-completed-acquirer,100,49,4/7/2020
C45C1F,conference-participant,100,50,4/7/2020
C4706C,dividend,100,50,4/7/2020
C4F9C6,conference-participant,100,50,4/7/2020
C5C137,executive-appointment,100,54,4/7/2020
C7859D,conference-call,100,50,4/7/2020
C7FC95,partnership,100,61,4/7/2020
C941DC,executive-appointment,100,54,4/7/2020
C951A2,revenues,100,50,4/7/2020
C951A2,earnings,100,50,4/7/2020
C98CDB,partnership,100,61,4/7/2020
C98CDB,earnings,100,50,4/7/2020
C9F39B,conference-call,100,50,4/7/2020
CAC8D0,donation,100,54,4/7/2020
CBBFBF,legal-issues-defendant,100,22,4/7/2020
CEC08B,shareholder-rights-plan,100,43,4/7/2020
D501DC,conference-call,100,50,4/7/2020
D5AF19,partnership,100,61,4/7/2020
D7918D,legal-issues-defendant,100,22,4/7/2020
D8760C,conference-call,100,50,4/7/2020
D90F43,partnership,100,61,4/7/2020
D95385,executive-appointment,100,54,4/7/2020
DB5CA5,earnings,100,50,4/7/2020
DC0998,conference-call,100,50,4/7/2020
DD7A96,conference-call,100,50,4/7/2020
DF532D,conference-call,100,50,4/7/2020
E2F130,earnings,100,50,4/7/2020
E70531,capex-down,100,7,4/7/2020
E8846E,earnings,100,50,4/7/2020
EB7D6C,legal-issues-defendant,100,22,4/7/2020
ED0D7C,conference-call,100,50,4/7/2020
F179ED,executive-appointment,100,54,4/7/2020
F1CD47,earnings,100,50,4/7/2020
F1EB39,business-contract,100,69,4/7/2020
F3816D,conference-participant,100,50,4/7/2020
F6E248,acquisition-completed-acquirer,100,49,4/7/2020
F72E4B,executive-appointment,100,54,4/7/2020
F83279,earnings,100,50,4/7/2020
FEE4B0,earnings,100,50,4/7/2020
001F1B,operating-earnings,100,50,4/8/2020
02870F,executive-resignation,100,44,4/8/2020
034B61,note-sale,100,52,4/8/2020
034B61,note-sale,100,52,4/8/2020
05D148,clinical-trials-filed,100,60,4/8/2020
06A456,unit-acquisition-acquirer,100,49,4/8/2020
07CA6A,conference-call,100,50,4/8/2020
07CA6A,conference-call,100,50,4/8/2020
98977,partnership,100,61,4/8/2020
1096C6,product-release,100,64,4/8/2020
129DC8,conference-call,100,50,4/8/2020
129DC8,executive-resignation,100,44,4/8/2020
12E454,patent-infringement-defendant,100,26,4/8/2020
135B09,conference-call,100,50,4/8/2020
147C38,earnings,100,50,4/8/2020
1490F3,conference-call,100,50,4/8/2020
149301,public-offering,100,43,4/8/2020
14ED2B,note-sale,100,52,4/8/2020
15A388,business-contract,100,69,4/8/2020
16C544,donation,100,54,4/8/2020
1748B3,conference-call,100,50,4/8/2020
184866,conference-participant,100,50,4/8/2020
1866B2,merger,100,66,4/8/2020
1866B2,merger,100,66,4/8/2020
18EC17,earnings,100,50,4/8/2020
1B9535,conference-call,100,50,4/8/2020
1FCC00,business-contract,100,69,4/8/2020
2571FA,conference-call,100,50,4/8/2020
2BC05E,credit-extension-recipient,100,69,4/8/2020
2CB4C9,earnings,100,50,4/8/2020
2CF9D3,conference-participant,100,50,4/8/2020
2EB04E,settlement,100,56,4/8/2020
3.14E+47,earnings,100,50,4/8/2020
32DCB3,patent-awarded,100,72,4/8/2020
36A1CB,executive-appointment,100,54,4/8/2020
384CD3,earnings,100,50,4/8/2020
385DD4,partnership,100,61,4/8/2020
3BCF24,earnings,100,50,4/8/2020
3DB18B,revenues,100,50,4/8/2020
3DCECC,partnership,100,61,4/8/2020
3DE4D1,conference-call,100,50,4/8/2020
3ED92D,earnings-guidance,100,50,4/8/2020
3EE65E,product-release,100,64,4/8/2020
3F1C69,conference-participant,100,50,4/8/2020
4.03E+05,award,100,58,4/8/2020
415188,conference-call,100,50,4/8/2020
422CE3,note-sale,100,52,4/8/2020
4591D3,executive-appointment,100,54,4/8/2020
45BC35,conference-call,100,50,4/8/2020
47752F,earnings,100,50,4/8/2020
4.91E+58,conference-call,100,50,4/8/2020
4B3555,executive-appointment,100,54,4/8/2020
4C1FA1,legal-issues-defendant,100,22,4/8/2020
4C6C63,earnings,100,50,4/8/2020
4EE167,legal-issues-defendant,100,22,4/8/2020
4EE167,legal-issues-defendant,100,22,4/8/2020
4EE167,legal-issues-defendant,100,22,4/8/2020
589803,partnership,100,61,4/8/2020
589803,partnership,100,61,4/8/2020
59872F,business-contract,100,69,4/8/2020
5B3415,conference-call,100,50,4/8/2020
605F40,conference-call,100,50,4/8/2020
61BCA7,earnings,100,50,4/8/2020
6.52E+64,facility-close,100,47,4/8/2020
6.52E+64,facility-close,100,47,4/8/2020
662682,conference-call,100,50,4/8/2020
66667F,joint-venture,100,62,4/8/2020
66ECFD,dividend,100,50,4/8/2020
66ECFD,executive-appointment,100,54,4/8/2020
68B03F,executive-appointment,100,54,4/8/2020
6B0E45,conference-call,100,50,4/8/2020
6B494E,fundraising,100,64,4/8/2020
6CB7F9,conference-call,100,50,4/8/2020
6E7060,dividend,100,50,4/8/2020
728737,dividend,100,50,4/8/2020
73C9E2,conference-call,100,50,4/8/2020
741937,earnings,100,50,4/8/2020
7.40E+289,earnings,100,50,4/8/2020
7.40E+289,earnings,100,50,4/8/2020
7.40E+289,earnings,100,50,4/8/2020
752A70,earnings,100,50,4/8/2020
762A3E,conference-call,100,50,4/8/2020
767F86,dividend,100,50,4/8/2020
771985,conference-call,100,50,4/8/2020
78F776,revenues,100,50,4/8/2020
7A3633,earnings,100,50,4/8/2020
7A5097,dividend,100,50,4/8/2020
8303CD,conference-call,100,50,4/8/2020
8377DB,fraud,100,44,4/8/2020
8377DB,legal-issues-defendant,100,22,4/8/2020
85DE00,conference-call,100,50,4/8/2020
8D4486,partnership,100,61,4/8/2020
8EF425,conference-call,100,50,4/8/2020
8FE7A5,earnings,100,50,4/8/2020
990AD0,earnings,100,50,4/8/2020
9BB35A,conference-call,100,50,4/8/2020
9C8BC3,note-sale,100,52,4/8/2020
9D65C1,earnings,100,50,4/8/2020
9F18FA,note-sale,100,52,4/8/2020
9F18FA,note-sale,100,52,4/8/2020
A3AAA5,dividend,100,50,4/8/2020
A43906,conference-call,100,50,4/8/2020
A4A612,conference-call,100,50,4/8/2020
A5195E,conference-participant,100,50,4/8/2020
A60318,earnings,100,50,4/8/2020
A746F6,conference-call,100,50,4/8/2020
A7CCF0,executive-appointment,100,54,4/8/2020
AA5C8E,earnings,100,50,4/8/2020
AA98ED,conference-call,100,50,4/8/2020
ADF092,earnings,100,50,4/8/2020
AE79CD,regulatory-product-approval-granted,100,81,4/8/2020
B1FC3B,business-contract,100,69,4/8/2020
B508E5,note-sale,100,52,4/8/2020
B83BCE,earnings,100,50,4/8/2020
B8DD94,conference-call,100,50,4/8/2020
B8EF97,revenues,100,50,4/8/2020
BA0442,partnership,100,61,4/8/2020
BA218A,conference-call,100,50,4/8/2020
BC5680,partnership,100,61,4/8/2020
BCC13E,conference-participant,100,50,4/8/2020
BF5959,public-offering,100,43,4/8/2020
C3BAE7,earnings,100,50,4/8/2020
CB7AB2,product-release,100,64,4/8/2020
CBBFBF,legal-issues-defendant,100,22,4/8/2020
CBFFDD,trading-halt,100,43,4/8/2020
CC8F6E,earnings-guidance-suspended,100,29,4/8/2020
CCB623,business-contract,100,69,4/8/2020
CFF97C,conference-call,100,50,4/8/2020
D06755,earnings,100,50,4/8/2020
D36B23,conference-participant,100,50,4/8/2020
D5938F,conference-participant,100,50,4/8/2020
D7A953,earnings,100,50,4/8/2020
DD0F15,conference-participant,100,50,4/8/2020
DF01B1,conference-call,100,50,4/8/2020
E0207A,partnership,100,61,4/8/2020
E20392,executive-appointment,100,54,4/8/2020
E74B55,conference-call,100,50,4/8/2020
E845D9,earnings,100,50,4/8/2020
E8F0E2,ipo-pricing,100,50,4/8/2020
EB7D6C,legal-issues-defendant,100,22,4/8/2020
EB7D6C,legal-issues-defendant,100,22,4/8/2020
EE74E1,earnings,100,50,4/8/2020
EEA6B3,earnings,100,50,4/8/2020
F30508,conference-call,100,50,4/8/2020
F47871,partnership,100,61,4/8/2020
F509E2,legal-issues-defendant,100,22,4/8/2020
F509E2,legal-issues-defendant,100,22,4/8/2020
F5D059,earnings,100,50,4/8/2020
F5D059,earnings,100,50,4/8/2020
F5D059,earnings,100,50,4/8/2020
F5D059,earnings,100,50,4/8/2020
F5D059,earnings,100,50,4/8/2020
F5D059,earnings,100,50,4/8/2020
F5D499,acquisition-acquirer,100,49,4/8/2020
F8084B,earnings,100,50,4/8/2020
FC01C0,conference-participant,100,50,4/8/2020
FC1B7B,conference-call,100,50,4/8/2020
FDF799,revenues,100,50,4/8/2020
FEC475,conference-call,100,50,4/8/2020
FF227B,fundraising,100,64,4/8/2020
02FC1A,conference-participant,100,50,4/9/2020
034B61,note-sale,100,52,4/9/2020
034B61,note-sale,100,52,4/9/2020
03D5F9,partnership,100,61,4/9/2020
03D5F9,partnership,100,61,4/9/2020
070B45,executive-appointment,100,54,4/9/2020
71860,earnings,100,50,4/9/2020
081AB9,conference-call,100,50,4/9/2020
95294,acquisition-completed-acquirer,100,49,4/9/2020
0B400D,executive-salary,100,52,4/9/2020
0BA2EF,dividend,100,50,4/9/2020
0BC17A,conference-call,100,50,4/9/2020
0BC853,merger-regulatory-approval,100,81,4/9/2020
0E5619,conference-participant,100,50,4/9/2020
12E454,partnership,100,61,4/9/2020
12E454,earnings,100,50,4/9/2020
154272,conference-participant,100,50,4/9/2020
1921DD,earnings-guidance,100,50,4/9/2020
1A2D9F,earnings,100,50,4/9/2020
1CD4B5,patent-awarded,100,72,4/9/2020
1DF15D,conference-call,100,50,4/9/2020
1E1125,dividend,100,50,4/9/2020
267718,partnership,100,61,4/9/2020
267718,partnership,100,61,4/9/2020
267718,partnership,100,61,4/9/2020
27A791,earnings,100,50,4/9/2020
2950FF,earnings,100,50,4/9/2020
2950FF,earnings,100,50,4/9/2020
2BC05E,legal-issues-defendant,100,22,4/9/2020
2BC05E,legal-issues-defendant,100,22,4/9/2020
2D76CE,revenues,100,50,4/9/2020
2DA92D,conference-call,100,50,4/9/2020
2E902B,conference-call,100,50,4/9/2020
301493,fraud-defendant,100,20,4/9/2020
314D88,earnings,100,50,4/9/2020
31F25C,conference-call,100,50,4/9/2020
32F24A,executive-appointment,100,54,4/9/2020
35AE32,business-contract,100,69,4/9/2020
3.73E+87,executive-appointment,100,54,4/9/2020
37727A,conference-call,100,50,4/9/2020
3798B9,earnings,100,50,4/9/2020
382EAE,conference-call,100,50,4/9/2020
3.88E+02,conference-call,100,50,4/9/2020
3A3948,conference-call,100,50,4/9/2020
3AF7FD,conference-call,100,50,4/9/2020
3BE00F,earnings,100,50,4/9/2020
3C75D6,executive-resignation,100,44,4/9/2020
3C7F5F,business-contract,100,69,4/9/2020
4.03E+05,conference-call,100,50,4/9/2020
4135F7,conference-call,100,50,4/9/2020
417BF9,earnings,100,50,4/9/2020
434F38,earnings,100,50,4/9/2020
43E8F5,revenues,100,50,4/9/2020
4806CE,conference-call,100,50,4/9/2020
4C1FA1,legal-issues-defendant,100,22,4/9/2020
4C1FA1,legal-issues-defendant,100,22,4/9/2020
4EE167,legal-issues-defendant,100,22,4/9/2020
4EE167,legal-issues-defendant,100,22,4/9/2020
4EE167,legal-issues-defendant,100,22,4/9/2020
4EE167,legal-issues-defendant,100,22,4/9/2020
4EE167,earnings,100,50,4/9/2020
4EE167,legal-issues-defendant,100,22,4/9/2020
4F9926,investment-investor,100,55,4/9/2020
4FB770,conference-call,100,50,4/9/2020
52D936,note-sale,100,52,4/9/2020
5675EB,earnings,100,50,4/9/2020
567F3D,dividend,100,50,4/9/2020
57356F,conference-call,100,50,4/9/2020
58B46F,unit-acquisition-acquiree,100,76,4/9/2020
594402,partnership,100,61,4/9/2020
5A423F,earnings,100,50,4/9/2020
5F3E74,conference-call,100,50,4/9/2020
6137BF,conference-call,100,50,4/9/2020
66749D,earnings,100,50,4/9/2020
6830FE,partnership,100,61,4/9/2020
6A3C35,dividend,100,50,4/9/2020
6DDA15,executive-appointment,100,54,4/9/2020
6F0A63,conference-call,100,50,4/9/2020
701531,executive-appointment,100,54,4/9/2020
723548,shareholder-rights-plan,100,43,4/9/2020
72CB93,earnings,100,50,4/9/2020
72FCA3,dividend,100,50,4/9/2020
73529F,conference-call,100,50,4/9/2020
7.45E+28,conference-participant,100,50,4/9/2020
7710F3,conference-call,100,50,4/9/2020
791D59,earnings,100,50,4/9/2020
7B9212,revenues,100,50,4/9/2020
8.22E+27,executive-appointment,100,54,4/9/2020
8377DB,legal-issues-defendant,100,22,4/9/2020
8377DB,legal-issues-defendant,100,22,4/9/2020
837C04,conference-call,100,50,4/9/2020
86A1B9,partnership,100,61,4/9/2020
8B6E7E,conference-call,100,50,4/9/2020
8BAA15,earnings,100,50,4/9/2020
8BE916,earnings,100,50,4/9/2020
8E0E32,earnings,100,50,4/9/2020
8E3F58,earnings,100,50,4/9/2020
8E4F9A,conference-participant,100,50,4/9/2020
8E82A6,earnings,100,50,4/9/2020
945DE6,partnership,100,61,4/9/2020
94637C,partnership,100,61,4/9/2020
94756D,earnings,100,50,4/9/2020
95C392,conference-call,100,50,4/9/2020
95DE39,product-release,100,64,4/9/2020
96A2D3,earnings,100,50,4/9/2020
971F7B,earnings,100,50,4/9/2020
97AF94,dividend,100,50,4/9/2020
9810C0,conference-call,100,50,4/9/2020
9A02C4,board-meeting,100,51,4/9/2020
9C8BC3,note-sale,100,52,4/9/2020
9F6B1A,partnership,100,61,4/9/2020
A01200,conference-call,100,50,4/9/2020
A1EAC8,conference-call,100,50,4/9/2020
A495F7,earnings,100,50,4/9/2020
A5195E,clinical-trials-start,100,64,4/9/2020
A666C8,product-release,100,64,4/9/2020
A6FC89,conference-participant,100,50,4/9/2020
AD23DE,executive-appointment,100,54,4/9/2020
AD23DE,conference-call,100,50,4/9/2020
AE79CD,conference-participant,100,50,4/9/2020
B1DF3C,earnings,100,50,4/9/2020
B77F14,executive-appointment,100,54,4/9/2020
B7BBFF,dividend,100,50,4/9/2020
B7BDA3,conference-call,100,50,4/9/2020
BDE867,business-contract,100,69,4/9/2020
BF79F5,conference-call,100,50,4/9/2020
C16A8F,conference-call,100,50,4/9/2020
C230FE,earnings,100,50,4/9/2020
C27E19,earnings,100,50,4/9/2020
C74887,conference-participant,100,50,4/9/2020
C81E00,conference-call,100,50,4/9/2020
C81E00,conference-call,100,50,4/9/2020
C8FAC7,partnership,100,61,4/9/2020
C9B932,market-entry,100,57,4/9/2020
CA1620,conference-call,100,50,4/9/2020
CB88B3,earnings,100,50,4/9/2020
CBBFBF,legal-issues-defendant,100,22,4/9/2020
CBBFBF,legal-issues-defendant,100,22,4/9/2020
CBFFDD,trading-resumed,100,58,4/9/2020
CCB623,partnership,100,61,4/9/2020
CD4DA8,conference-call,100,50,4/9/2020
CEDFD5,partnership,100,61,4/9/2020
D0909F,earnings-guidance,100,50,4/9/2020
D77F7E,earnings,100,50,4/9/2020
D7AC6E,earnings,100,50,4/9/2020
DC0D18,executive-appointment,100,54,4/9/2020
DCD97F,conference-call,100,50,4/9/2020
DDC415,earnings,100,50,4/9/2020
DEF058,partnership,100,61,4/9/2020
DF532D,donation,100,54,4/9/2020
E05DC8,earnings,100,50,4/9/2020
E12A6E,dividend,100,50,4/9/2020
E1E36F,earnings,100,50,4/9/2020
E598FB,conference-participant,100,50,4/9/2020
E845D9,earnings,100,50,4/9/2020
E8A49A,executive-appointment,100,54,4/9/2020
ED3CA8,conference-call,100,50,4/9/2020
F02D0A,earnings,100,50,4/9/2020
F0B335,conference-participant,100,50,4/9/2020
F4E992,revenue-up,100,69,4/9/2020
F4E992,earnings,100,50,4/9/2020
F51DB0,conference-call,100,50,4/9/2020
F5D499,business-contract,100,69,4/9/2020
F85CC0,acquisition-interest-acquirer,100,46,4/9/2020
F85CC0,acquisition-interest-acquirer,100,46,4/9/2020
F85CC0,acquisition-interest-acquirer,100,46,4/9/2020
F85CC0,acquisition-interest-acquirer,100,46,4/9/2020
F85CC0,acquisition-interest-acquirer,100,46,4/9/2020
F85CC0,acquisition-interest-acquirer,100,46,4/9/2020
F85CC0,acquisition-interest-acquirer,100,46,4/9/2020
F85CC0,acquisition-interest-acquirer,100,46,4/9/2020
F85CC0,acquisition-interest-acquirer,100,46,4/9/2020
F85CC0,acquisition-interest-acquirer,100,46,4/9/2020
F85CC0,acquisition-interest-acquirer,100,46,4/9/2020
F85CC0,acquisition-interest-acquirer,100,46,4/9/2020
F85CC0,acquisition-interest-acquirer,100,46,4/9/2020
F85CC0,acquisition-interest-acquirer,100,46,4/9/2020
F85CC0,acquisition-interest-acquirer,100,46,4/9/2020
F85CC0,acquisition-interest-acquirer,100,46,4/9/2020
F85CC0,acquisition-interest-acquirer,100,46,4/9/2020
F85CC0,acquisition-interest-acquirer,100,46,4/9/2020
F85CC0,acquisition-interest-acquirer,100,46,4/9/2020
F85CC0,acquisition-interest-acquirer,100,46,4/9/2020
F85CC0,acquisition-interest-acquirer,100,46,4/9/2020
F85CC0,acquisition-interest-acquirer,100,46,4/9/2020
F85CC0,acquisition-interest-acquirer,100,46,4/9/2020
F85CC0,acquisition-interest-acquirer,100,46,4/9/2020
F85CC0,acquisition-interest-acquirer,100,46,4/9/2020
F85CC0,acquisition-interest-acquirer,100,46,4/9/2020
F85CC0,acquisition-interest-acquirer,100,46,4/9/2020
F85CC0,stake-acquirer,100,48,4/9/2020
F93C8A,dividend,100,50,4/9/2020
FD4588,conference-call,100,50,4/9/2020
FDC7E6,conference-call,100,50,4/9/2020
0C2A0D,board-meeting,100,51,4/10/2020
10AE08,earnings,100,50,4/10/2020
223552,business-contract,100,69,4/10/2020
2BC05E,legal-issues-defendant,100,22,4/10/2020
338544,conference-call,100,50,4/10/2020
3696BF,conference-call,100,50,4/10/2020
3C7F5F,partnership,100,61,4/10/2020
3E15F6,conference-call,100,50,4/10/2020
4D971D,conference-call,100,50,4/10/2020
510EA6,executive-resignation,100,44,4/10/2020
6C4D2F,dividend,100,50,4/10/2020
719477,executive-appointment,100,54,4/10/2020
762B8D,dividend,100,50,4/10/2020
76CEFB,earnings,100,50,4/10/2020
76D79A,conference-call,100,50,4/10/2020
7A10FF,earnings,100,50,4/10/2020
7A5097,business-contract,100,69,4/10/2020
8.10E+32,business-contract,100,69,4/10/2020
8.22E+27,conference-call,100,50,4/10/2020
8377DB,legal-issues-defendant,100,22,4/10/2020
93F143,earnings,100,50,4/10/2020
9548BB,earnings,100,50,4/10/2020
9EED50,conference-call,100,50,4/10/2020
A02FB1,conference-call,100,50,4/10/2020
A1A317,conference-call,100,50,4/10/2020
A3F598,conference-call,100,50,4/10/2020
A6828A,regulatory-investigation-completed,100,50,4/10/2020
AFEC35,earnings,100,50,4/10/2020
C97B2D,board-meeting,100,51,4/10/2020
C9E107,earnings,100,50,4/10/2020
CB7AB2,executive-resignation,100,44,4/10/2020
CE5C6E,conference-participant,100,50,4/10/2020
D65A13,conference-call,100,50,4/10/2020
E0339F,earnings-revision,100,29,4/10/2020
F30508,clinical-trials-start,100,64,4/10/2020
F30508,clinical-trials-start,100,64,4/10/2020
F85CC0,stake-acquirer,100,48,4/10/2020
F85CC0,stake-acquirer,100,48,4/10/2020
FAE021,board-meeting,100,51,4/10/2020
FAE021,board-meeting,100,51,4/10/2020
FE7A63,earnings,100,50,4/10/2020
FEC475,unit-acquisition-acquiree,100,76,4/10/2020
0B400D,legal-issues-defendant,100,22,4/11/2020
3F4668,legal-issues-defendant,100,22,4/11/2020
B840EF,index-listing,100,76,4/11/2020
C83B88,partnership,100,61,4/11/2020
2BC05E,legal-issues-defendant,100,22,4/12/2020
0142B5,conference-call,100,50,4/13/2020
04EB2F,board-meeting,100,51,4/13/2020
0BD4E8,business-contract,100,69,4/13/2020
0DC050,earnings,100,50,4/13/2020
152FA5,clinical-trials,100,56,4/13/2020
180DA0,business-contract,100,69,4/13/2020
1921DD,note-sale,100,52,4/13/2020
1921DD,note-sale,100,52,4/13/2020
1921DD,note-sale,100,52,4/13/2020
1921DD,note-sale,100,52,4/13/2020
1F9D90,conference-call,100,50,4/13/2020
1FE3CB,conference-call,100,50,4/13/2020
2158DF,earnings,100,50,4/13/2020
227D48,conference-call,100,50,4/13/2020
22C58E,supply-increase,100,74,4/13/2020
25AB8E,shareholder-rights-plan,100,43,4/13/2020
2BC05E,legal-issues-defendant,100,22,4/13/2020
2C7505,partnership,100,61,4/13/2020
30E01D,earnings,100,50,4/13/2020
34B97A,conference-call,100,50,4/13/2020
3A1C46,earnings,100,50,4/13/2020
3B37F7,dividend,100,50,4/13/2020
3F4668,legal-issues-defendant,100,22,4/13/2020
3F4668,legal-issues-defendant,100,22,4/13/2020
3F4668,legal-issues-defendant,100,22,4/13/2020
3F4668,legal-issues-defendant,100,22,4/13/2020
3F4668,legal-issues-defendant,100,22,4/13/2020
44ED36,dividend,100,50,4/13/2020
4591D3,conference-call,100,50,4/13/2020
499C75,legal-issues-defendant,100,22,4/13/2020
4A7C1F,legal-issues-defendant,100,22,4/13/2020
4B5054,conference-call,100,50,4/13/2020
4D8124,campaign-ad-release,100,59,4/13/2020
51527B,conference-call,100,50,4/13/2020
567F3D,conference-call,100,50,4/13/2020
58CA9A,partnership,100,61,4/13/2020
5A423F,clinical-trials,100,56,4/13/2020
5A9F54,earnings,100,50,4/13/2020
5B3415,executive-appointment,100,54,4/13/2020
5BE42C,conference-call,100,50,4/13/2020
66667F,unit-acquisition-acquirer,100,49,4/13/2020
66CB62,reverse-stock-splits,100,51,4/13/2020
676FFD,insider-buy,100,61,4/13/2020
68B03F,earnings,100,50,4/13/2020
6A6BDC,partnership,100,61,4/13/2020
6B236C,conference-call,100,50,4/13/2020
6-Dec-05,regulatory-product-approval-granted,100,81,4/13/2020
7032D0,earnings,100,50,4/13/2020
729368,earnings,100,50,4/13/2020
7823A3,earnings,100,50,4/13/2020
787D14,product-release,100,64,4/13/2020
79167B,conference-call,100,50,4/13/2020
7B0BA6,earnings-guidance-up,100,83,4/13/2020
7B0BA6,earnings-guidance-up,100,83,4/13/2020
7B6EB1,board-meeting,100,51,4/13/2020
7B6EB1,donation,100,54,4/13/2020
7B9AFA,earnings-guidance-suspended,100,29,4/13/2020
7BAAE7,earnings,100,50,4/13/2020
7DA412,earnings,100,50,4/13/2020
7E62B5,conference-call,100,50,4/13/2020
83066C,conference-call,100,50,4/13/2020
8DBBE6,conference-call,100,50,4/13/2020
901327,earnings,100,50,4/13/2020
911CA9,clinical-trials-start,100,64,4/13/2020
9196A2,conference-call,100,50,4/13/2020
92D3A0,dividend,100,50,4/13/2020
934029,conference-call,100,50,4/13/2020
9368BE,conference-call,100,50,4/13/2020
949625,conference-call,100,50,4/13/2020
972356,executive-appointment,100,54,4/13/2020
9.86E+03,award,100,58,4/13/2020
9F048E,earnings,100,50,4/13/2020
9F18FA,note-sale,100,52,4/13/2020
9F18FA,note-sale,100,52,4/13/2020
9F18FA,note-sale,100,52,4/13/2020
9F18FA,note-sale,100,52,4/13/2020
9FA83B,partnership,100,61,4/13/2020
A01983,dividend,100,50,4/13/2020
A4386C,earnings,100,50,4/13/2020
A72AB6,note-sale,100,52,4/13/2020
A72AB6,note-sale,100,52,4/13/2020
A72AB6,note-sale,100,52,4/13/2020
A80FE0,conference-call,100,50,4/13/2020
AAEE21,conference-call,100,50,4/13/2020
AC775C,conference-call,100,50,4/13/2020
ACC7D3,earnings,100,50,4/13/2020
AF210D,earnings,100,50,4/13/2020
AFF7B4,dividend,100,50,4/13/2020
B1A85D,partnership,100,61,4/13/2020
B2206F,earnings,100,50,4/13/2020
B2E6B5,conference-call,100,50,4/13/2020
BBAE2A,conference-call,100,50,4/13/2020
BDE867,executive-salary-cut,100,53,4/13/2020
C062D4,conference-call,100,50,4/13/2020
C11C46,earnings,100,50,4/13/2020
C2E39B,partnership,100,61,4/13/2020
C2E39B,partnership,100,61,4/13/2020
C32A39,conference-call,100,50,4/13/2020
C4A912,conference-call,100,50,4/13/2020
C659EB,conference-call,100,50,4/13/2020
C9D866,donation,100,54,4/13/2020
CA212F,earnings,100,50,4/13/2020
CBB77B,executive-appointment,100,54,4/13/2020
CBDB4D,earnings,100,50,4/13/2020
CBDB4D,note-sale,100,52,4/13/2020
CE5664,earnings,100,50,4/13/2020
CF351E,earnings,100,50,4/13/2020
CF351E,earnings,100,50,4/13/2020
CF351E,earnings,100,50,4/13/2020
D2B9E5,earnings,100,50,4/13/2020
D36B23,clinical-trials,100,56,4/13/2020
D3C794,earnings,100,50,4/13/2020
D64EDF,earnings,100,50,4/13/2020
D6EAA3,conference-call,100,50,4/13/2020
D8DA3D,conference-call,100,50,4/13/2020
D9FC89,earnings,100,50,4/13/2020
DC0D18,earnings,100,50,4/13/2020
DC1405,public-offering,100,43,4/13/2020
DF204B,note-sale,100,52,4/13/2020
DF204B,conference-call,100,50,4/13/2020
E124EB,conference-call,100,50,4/13/2020
E16133,conference-call,100,50,4/13/2020
E28D9C,index-listing,100,76,4/13/2020
E3E68E,conference-call,100,50,4/13/2020
E3E68E,conference-call,100,50,4/13/2020
E8F0E2,ipo-completed,100,76,4/13/2020
EB6965,conference-call,100,50,4/13/2020
EB7D6C,donation,100,54,4/13/2020
EC8116,shareholder-rights-plan,100,43,4/13/2020
ECDEB2,board-meeting,100,51,4/13/2020
ED0402,earnings,100,50,4/13/2020
EE967B,earnings,100,50,4/13/2020
EF77A3,debt-extension-recipient,100,73,4/13/2020
EFD406,conference-call,100,50,4/13/2020
F39E1E,note-sale,100,52,4/13/2020
F39E1E,note-sale,100,52,4/13/2020
F48947,revenue-guidance,100,50,4/13/2020
F509E2,legal-issues-defendant,100,22,4/13/2020
F702CA,investment-investor,100,55,4/13/2020
F8BDCE,earnings,100,50,4/13/2020
FA840E,patient-enrollment-complete,100,64,4/13/2020
FF5413,earnings,100,50,4/13/2020
00326E,conference-call,100,50,4/14/2020
00E601,earnings,100,50,4/14/2020
03B431,earnings-above-expectations,100,88,4/14/2020
03B8CF,partnership,100,61,4/14/2020
03FAA6,partnership,100,61,4/14/2020
48590,earnings,100,50,4/14/2020
070B45,earnings,100,50,4/14/2020
95294,note-sale,100,52,4/14/2020
0A59F8,savings,100,74,4/14/2020
0A59F8,savings,100,74,4/14/2020
0B400D,shareholder-rights-plan,100,43,4/14/2020
0BA2EF,earnings,100,50,4/14/2020
131443,partnership,100,61,4/14/2020
152AB9,partnership,100,61,4/14/2020
17EDA5,partnership,100,61,4/14/2020
1834C0,conference-call,100,50,4/14/2020
1866B2,conference-call,100,50,4/14/2020
1AF7E2,conference-call,100,50,4/14/2020
1B9535,executive-appointment,100,54,4/14/2020
1E9A6D,earnings,100,50,4/14/2020
1F08A6,conference-call,100,50,4/14/2020
1F9258,partnership,100,61,4/14/2020
202E5A,executive-appointment,100,54,4/14/2020
21245F,executive-appointment,100,54,4/14/2020
221445,conference-call,100,50,4/14/2020
25A6CC,earnings,100,50,4/14/2020
29B702,earnings,100,50,4/14/2020
2C7505,fast-track-designation,100,81,4/14/2020
2C7505,fast-track-designation,100,81,4/14/2020
2E0496,earnings,100,50,4/14/2020
2E0496,earnings,100,50,4/14/2020
2E1322,legal-issues-defendant,100,22,4/14/2020
2E61CC,dividend-up,100,81,4/14/2020
31666F,dividend,100,50,4/14/2020
3390DE,conference-call,100,50,4/14/2020
33E8C7,earnings,100,50,4/14/2020
373B06,earnings,100,50,4/14/2020
385DD4,credit-extension-recipient,100,69,4/14/2020
387541,dividend,100,50,4/14/2020
3CBA2A,conference-call,100,50,4/14/2020
3F4668,legal-issues-defendant,100,22,4/14/2020
41ED98,executive-appointment,100,54,4/14/2020
425BDC,conference-call,100,50,4/14/2020
42EFC7,public-offering,100,43,4/14/2020
43A74A,earnings,100,50,4/14/2020
458D2C,revenue-volume,100,50,4/14/2020
46017C,conference-call,100,50,4/14/2020
4C37C5,dividend,100,50,4/14/2020
50070E,executive-appointment,100,54,4/14/2020
5225A4,conference-organizer,100,57,4/14/2020
524CE4,earnings,100,50,4/14/2020
548AC0,conference-call,100,50,4/14/2020
55438C,earnings,100,50,4/14/2020
59872F,executive-appointment,100,54,4/14/2020
5B35C7,earnings-up,100,68,4/14/2020
5C2A47,award,100,58,4/14/2020
619882,earnings,100,50,4/14/2020
62F41C,earnings,100,50,4/14/2020
641F17,note-sale,100,52,4/14/2020
64E346,investment-investor,100,55,4/14/2020
64E346,investment-investor,100,55,4/14/2020
665440,conference-call,100,50,4/14/2020
6B494E,dividend,100,50,4/14/2020
6C4D2F,conference-call,100,50,4/14/2020
747219,earnings,100,50,4/14/2020
767F86,earnings,100,50,4/14/2020
76B926,conference-call,100,50,4/14/2020
7AC86E,earnings,100,50,4/14/2020
7BC92D,conference-participant,100,50,4/14/2020
7CBC40,earnings,100,50,4/14/2020
7D7716,earnings,100,50,4/14/2020
830BDB,conference-call,100,50,4/14/2020
86A1B9,earnings,100,50,4/14/2020
87486A,conference-call,100,50,4/14/2020
88923D,conference-call,100,50,4/14/2020
88923D,conference-call,100,50,4/14/2020
89F693,earnings,100,50,4/14/2020
8A8E41,partnership,100,61,4/14/2020
8AC65D,conference-call,100,50,4/14/2020
8DA42F,earnings,100,50,4/14/2020
8DE74B,conference-call,100,50,4/14/2020
92D3A0,earnings,100,50,4/14/2020
93633B,conference-call,100,50,4/14/2020
942165,earnings,100,50,4/14/2020
96F126,earnings,100,50,4/14/2020
986AF6,conference-call,100,50,4/14/2020
98CEBB,earnings,100,50,4/14/2020
9ABD30,note-sale,100,52,4/14/2020
9B71A7,fraud-defendant,100,20,4/14/2020
9EBAFA,dividend-up,100,81,4/14/2020
9F5997,conference-call,100,50,4/14/2020
A29DBD,executive-appointment,100,54,4/14/2020
A6828A,dividend-up,100,81,4/14/2020
A6828A,earnings,100,50,4/14/2020
A6828A,business-contract,100,69,4/14/2020
A6828A,business-contract,100,69,4/14/2020
A70BF5,executive-appointment,100,54,4/14/2020
AA847A,conference-call,100,50,4/14/2020
AC7C4F,business-contract,100,69,4/14/2020
AD3C93,donation,100,54,4/14/2020
AEF2C3,conference-call,100,50,4/14/2020
AFF43F,earnings,100,50,4/14/2020
B01111,note-sale,100,52,4/14/2020
B1FC3B,business-contract,100,69,4/14/2020
B37FB4,earnings,100,50,4/14/2020
B4703C,dividend,100,50,4/14/2020
B508E5,partnership,100,61,4/14/2020
B54A74,earnings,100,50,4/14/2020
B614F8,business-contract,100,69,4/14/2020
B7EB38,earnings,100,50,4/14/2020
BAD9EA,public-offering,100,43,4/14/2020
BB0587,conference-call,100,50,4/14/2020
BB0787,executive-appointment,100,54,4/14/2020
BBF349,earnings,100,50,4/14/2020
BD9668,conference-call,100,50,4/14/2020
BFCACF,conference-call,100,50,4/14/2020
C4FBDC,donation,100,54,4/14/2020
C66B44,executive-appointment,100,54,4/14/2020
C7859D,earnings,100,50,4/14/2020
C7859D,earnings,100,50,4/14/2020
C7859D,earnings,100,50,4/14/2020
C7859D,earnings,100,50,4/14/2020
C7859D,earnings,100,50,4/14/2020
C7859D,earnings,100,50,4/14/2020
C83B88,executive-appointment,100,54,4/14/2020
CA3CB9,conference-call,100,50,4/14/2020
CBBFBF,note-sale,100,52,4/14/2020
CBDB4D,note-sale,100,52,4/14/2020
CD051C,conference-call,100,50,4/14/2020
CD06A2,earnings,100,50,4/14/2020
CD2A4D,partnership,100,61,4/14/2020
CDE51C,earnings,100,50,4/14/2020
CE2791,conference-call,100,50,4/14/2020
D1173F,conference-call,100,50,4/14/2020
D17C1B,partnership,100,61,4/14/2020
D5938F,business-contract,100,69,4/14/2020
D5938F,business-contract,100,69,4/14/2020
D5938F,executive-appointment,100,54,4/14/2020
D598E7,conference-call,100,50,4/14/2020
D64C6D,executive-appointment,100,54,4/14/2020
D70365,conference-call,100,50,4/14/2020
D7918D,legal-issues-defendant,100,22,4/14/2020
DB06B0,earnings,100,50,4/14/2020
DD682D,earnings,100,50,4/14/2020
E21871,earnings,100,50,4/14/2020
E4CE73,business-contract,100,69,4/14/2020
E6C8DC,executive-appointment,100,54,4/14/2020
E6D89E,revenue-guidance,100,50,4/14/2020
E87676,conference-call,100,50,4/14/2020
E8846E,earnings,100,50,4/14/2020
EA62FC,conference-call,100,50,4/14/2020
ED7F13,earnings,100,50,4/14/2020
EF7163,conference-call,100,50,4/14/2020
F1EB39,business-contract,100,69,4/14/2020
F3016C,earnings,100,50,4/14/2020
F43A11,earnings,100,50,4/14/2020
F5D410,business-contract,100,69,4/14/2020
F85CC0,earnings,100,50,4/14/2020
F85CC0,earnings,100,50,4/14/2020
FAE021,partnership,100,61,4/14/2020
FC9A88,conference-call,100,50,4/14/2020
FD4BBE,earnings,100,50,4/14/2020
FDF28E,earnings,100,50,4/14/2020
FFAB4A,earnings,100,50,4/14/2020
9397,board-meeting,100,51,4/15/2020
03F5A4,earnings-positive,100,69,4/15/2020
51332,earnings,100,50,4/15/2020
0919B1,conference-call,100,50,4/15/2020
0A6824,earnings,100,50,4/15/2020
0B4D10,earnings,100,50,4/15/2020
0B57D7,conference-call,100,50,4/15/2020
0C4131,conference-call,100,50,4/15/2020
0CADBC,dividend,100,50,4/15/2020
0E3436,partnership,100,61,4/15/2020
12E454,partnership,100,61,4/15/2020
135B09,donation,100,54,4/15/2020
14BA06,earnings,100,50,4/15/2020
16C544,note-sale,100,52,4/15/2020
1A5957,earnings,100,50,4/15/2020
1AB808,earnings,100,50,4/15/2020
1AF7E2,executive-resignation,100,44,4/15/2020
1C2593,executive-appointment,100,54,4/15/2020
1D5C51,conference-call,100,50,4/15/2020
1FA886,partnership,100,61,4/15/2020
20403D,acquisition-acquirer,100,49,4/15/2020
2.45E+15,earnings,100,50,4/15/2020
251988,partnership,100,61,4/15/2020
26CC63,dividend,100,50,4/15/2020
26DC29,award,100,58,4/15/2020
273BA3,partnership,100,61,4/15/2020
275300,legal-issues-defendant,100,22,4/15/2020
29B702,executive-death,100,31,4/15/2020
2A17B1,conference-call,100,50,4/15/2020
2C19A4,conference-call,100,50,4/15/2020
2C7505,investment-recipient,100,73,4/15/2020
2E1322,earnings,100,50,4/15/2020
309922,conference-call,100,50,4/15/2020
32CB22,conference-call,100,50,4/15/2020
3.30E+34,earnings,100,50,4/15/2020
3.30E+34,earnings,100,50,4/15/2020
3.30E+34,earnings,100,50,4/15/2020
367E1C,earnings,100,50,4/15/2020
370C50,dividend,100,50,4/15/2020
387541,conference-call,100,50,4/15/2020
3C3B6B,earnings,100,50,4/15/2020
3DDE54,earnings,100,50,4/15/2020
3F4668,legal-issues-defendant,100,22,4/15/2020
41EC04,executive-appointment,100,54,4/15/2020
423279,dividend,100,50,4/15/2020
42EFC7,public-offering,100,43,4/15/2020
442769,board-meeting,100,51,4/15/2020
44A4FC,earnings,100,50,4/15/2020
49914B,conference-call,100,50,4/15/2020
4A2457,business-contract,100,69,4/15/2020
4B3676,earnings,100,50,4/15/2020
4B7006,partnership,100,61,4/15/2020
4C1FA1,legal-issues-defendant,100,22,4/15/2020
4C1FA1,legal-issues-defendant,100,22,4/15/2020
4C3FE9,public-offering,100,43,4/15/2020
4C7DB5,note-sale,100,52,4/15/2020
4C7DB5,note-sale,100,52,4/15/2020
4EE167,legal-issues-defendant,100,22,4/15/2020
514067,conference-call,100,50,4/15/2020
520632,product-release,100,64,4/15/2020
53C421,conference-call,100,50,4/15/2020
53EF9E,conference-call,100,50,4/15/2020
56B7C1,conference-call,100,50,4/15/2020
56EFC7,product-release,100,64,4/15/2020
589F5A,dividend,100,50,4/15/2020
58CA9A,earnings,100,50,4/15/2020
5A423F,earnings,100,50,4/15/2020
5B97B2,earnings,100,50,4/15/2020
5BFE94,conference-call,100,50,4/15/2020
5C8D61,earnings,100,50,4/15/2020
5D43A7,dividend,100,50,4/15/2020
5F2FF7,earnings,100,50,4/15/2020
5F6D73,earnings,100,50,4/15/2020
5F6D73,earnings,100,50,4/15/2020
5F6D73,earnings,100,50,4/15/2020
5F6D73,earnings,100,50,4/15/2020
5F6D73,earnings,100,50,4/15/2020
5FE4B6,conference-call,100,50,4/15/2020
5FF95F,earnings,100,50,4/15/2020
60DD84,conference-call,100,50,4/15/2020
6166D1,earnings,100,50,4/15/2020
6.18E+08,earnings,100,50,4/15/2020
619882,dividend,100,50,4/15/2020
61B81B,earnings-positive,100,69,4/15/2020
61B81B,earnings-positive,100,69,4/15/2020
61B81B,earnings-positive,100,69,4/15/2020
61B81B,earnings-positive,100,69,4/15/2020
61B81B,earnings-positive,100,69,4/15/2020
61B81B,earnings-positive,100,69,4/15/2020
61B81B,earnings-positive,100,69,4/15/2020
61B81B,earnings-positive,100,69,4/15/2020
622DBE,conference-call,100,50,4/15/2020
665618,conference-call,100,50,4/15/2020
69345C,earnings,100,50,4/15/2020
698FF9,earnings,100,50,4/15/2020
69E8E1,executive-appointment,100,54,4/15/2020
69E8E1,executive-appointment,100,54,4/15/2020
6D0CAB,operating-earnings,100,50,4/15/2020
6-Dec-05,public-offering,100,43,4/15/2020
6F0096,conference-call,100,50,4/15/2020
73A71F,conference-call,100,50,4/15/2020
73BCBA,conference-call,100,50,4/15/2020
7448A3,conference-call,100,50,4/15/2020
78F9ED,partnership,100,61,4/15/2020
797C20,conference-call,100,50,4/15/2020
7A5097,conference-call,100,50,4/15/2020
7AB859,conference-call,100,50,4/15/2020
7D35D8,earnings,100,50,4/15/2020
804708,conference-call,100,50,4/15/2020
819492,executive-appointment,100,54,4/15/2020
8377DB,legal-issues-defendant,100,22,4/15/2020
8377DB,legal-issues-defendant,100,22,4/15/2020
859281,earnings,100,50,4/15/2020
860AB6,conference-call,100,50,4/15/2020
86478F,earnings,100,50,4/15/2020
89FBB1,dividend,100,50,4/15/2020
8A8E41,business-contract,100,69,4/15/2020
8B2C4A,conference-call,100,50,4/15/2020
8B9B3B,conference-call,100,50,4/15/2020
8D4AE6,earnings,100,50,4/15/2020
8D5145,earnings,100,50,4/15/2020
8DBE73,conference-call,100,50,4/15/2020
8FF2EF,earnings,100,50,4/15/2020
911CA9,public-offering,100,43,4/15/2020
950AB7,earnings,100,50,4/15/2020
9.74E+08,earnings,100,50,4/15/2020
990AD0,earnings,100,50,4/15/2020
9A602D,business-contract,100,69,4/15/2020
9ABD30,note-sale,100,52,4/15/2020
9B71A7,legal-issues-defendant,100,22,4/15/2020
9B71A7,legal-issues-defendant,100,22,4/15/2020
9B71A7,legal-issues-defendant,100,22,4/15/2020
9B71A7,legal-issues-defendant,100,22,4/15/2020
9B71A7,earnings,100,50,4/15/2020
9B71A7,earnings,100,50,4/15/2020
9B71A7,earnings,100,50,4/15/2020
9B71A7,earnings,100,50,4/15/2020
9C8BC3,dividend,100,50,4/15/2020
9F048E,product-release,100,64,4/15/2020
9FA83B,public-offering,100,43,4/15/2020
9FF5F1,earnings,100,50,4/15/2020
A1DBF0,business-contract,100,69,4/15/2020
A398F8,earnings,100,50,4/15/2020
A631A3,partnership,100,61,4/15/2020
A9ED24,dividend,100,50,4/15/2020
AAC8B6,conference-call,100,50,4/15/2020
AAC8B6,conference-call,100,50,4/15/2020
AE3113,earnings,100,50,4/15/2020
B01111,note-sale,100,52,4/15/2020
B0998E,earnings,100,50,4/15/2020
B37FB4,partnership,100,61,4/15/2020
B4703C,executive-resignation,100,44,4/15/2020
B48FC9,partnership,100,61,4/15/2020
B8EF97,dividend-up,100,81,4/15/2020
BCC55F,board-meeting,100,51,4/15/2020
BD8517,earnings,100,50,4/15/2020
BDE867,operating-earnings,100,50,4/15/2020
BE5935,earnings,100,50,4/15/2020
C0030A,earnings,100,50,4/15/2020
C1114B,conference-call,100,50,4/15/2020
C4A241,conference-call,100,50,4/15/2020
C4C77F,dividend,100,50,4/15/2020
C62AA4,executive-appointment,100,54,4/15/2020
C9B932,earnings,100,50,4/15/2020
CAC8D0,facility-open,100,65,4/15/2020
CCB623,regulatory-product-approval-granted,100,81,4/15/2020
CE96E7,earnings,100,50,4/15/2020
CEC5B9,conference-call,100,50,4/15/2020
CF211D,earnings,100,50,4/15/2020
CFF15D,partnership,100,61,4/15/2020
D33D8C,earnings-per-share-positive,100,69,4/15/2020
D33D8C,earnings-per-share-positive,100,69,4/15/2020
D33D8C,earnings-per-share-positive,100,69,4/15/2020
D33D8C,earnings-per-share-positive,100,69,4/15/2020
D33D8C,earnings-per-share-positive,100,69,4/15/2020
D33D8C,earnings-per-share-positive,100,69,4/15/2020
D5AF19,fundraising,100,64,4/15/2020
D5AF19,fundraising,100,64,4/15/2020
D7918D,legal-issues-defendant,100,22,4/15/2020
D88EF3,note-sale,100,52,4/15/2020
D88EF3,partnership,100,61,4/15/2020
DA199F,executive-appointment,100,54,4/15/2020
DB7FA7,conference-call,100,50,4/15/2020
DD3BB1,earnings,100,50,4/15/2020
E15736,conference-call,100,50,4/15/2020
E15736,conference-call,100,50,4/15/2020
E15736,conference-call,100,50,4/15/2020
E30A8F,product-release,100,64,4/15/2020
E5752F,earnings,100,50,4/15/2020
E5D914,earnings,100,50,4/15/2020
E5D914,earnings,100,50,4/15/2020
E6E012,earnings,100,50,4/15/2020
E6E012,earnings,100,50,4/15/2020
E70531,supply-increase,100,74,4/15/2020
E84500,dividend,100,50,4/15/2020
E9E6FD,conference-call,100,50,4/15/2020
ED2A5E,conference-call,100,50,4/15/2020
EF5BED,product-release,100,64,4/15/2020
EFA7B2,earnings,100,50,4/15/2020
F179ED,earnings,100,50,4/15/2020
F294DD,earnings,100,50,4/15/2020
F4E882,earnings,100,50,4/15/2020
F4F46F,product-release,100,64,4/15/2020
F5C78B,conference-call,100,50,4/15/2020
F6A945,earnings,100,50,4/15/2020
F702CA,dividend,100,50,4/15/2020
F9CAF8,executive-appointment,100,54,4/15/2020
FD39EB,dividend,100,50,4/15/2020
FDC08C,dividend,100,50,4/15/2020
FF227B,executive-appointment,100,54,4/15/2020
FF6644,conference-call,100,50,4/15/2020
00698D,dividend,100,50,4/16/2020
13528,board-meeting,100,51,4/16/2020
0157B1,conference-call,100,50,4/16/2020
03FAA6,product-release,100,64,4/16/2020
43862,conference-call,100,50,4/16/2020
04EB2F,earnings,100,50,4/16/2020
71860,executive-resignation,100,44,4/16/2020
07C907,earnings,100,50,4/16/2020
07C907,earnings,100,50,4/16/2020
083F72,dividend,100,50,4/16/2020
083F72,dividend,100,50,4/16/2020
09062E,earnings,100,50,4/16/2020
099C88,acquisition-completed-acquirer,100,49,4/16/2020
09F623,dividend,100,50,4/16/2020
0A6824,note-sale,100,52,4/16/2020
0A9D0A,earnings,100,50,4/16/2020
0C6861,conference-call,100,50,4/16/2020
0ED415,conference-call,100,50,4/16/2020
0F04E5,earnings,100,50,4/16/2020
0F2BC9,conference-call,100,50,4/16/2020
0FDE97,conference-call,100,50,4/16/2020
10943B,conference-call,100,50,4/16/2020
1096C6,business-contract,100,69,4/16/2020
1201B5,clinical-trials-positive,100,87,4/16/2020
1220D2,partnership,100,61,4/16/2020
1220D2,partnership,100,61,4/16/2020
1272B3,earnings,100,50,4/16/2020
12E454,partnership,100,61,4/16/2020
12E454,business-contract,100,69,4/16/2020
152AB9,earnings,100,50,4/16/2020
165B3A,earnings-positive,100,69,4/16/2020
165B3A,earnings-positive,100,69,4/16/2020
165B3A,earnings-positive,100,69,4/16/2020
165B3A,earnings-positive,100,69,4/16/2020
165B3A,earnings-positive,100,69,4/16/2020
180DA0,conference-call,100,50,4/16/2020
18EC17,earnings,100,50,4/16/2020
18EC17,earnings,100,50,4/16/2020
18EC17,earnings,100,50,4/16/2020
19C105,earnings,100,50,4/16/2020
19CAC7,earnings,100,50,4/16/2020
19CAC7,earnings,100,50,4/16/2020
1BDB2A,conference-call,100,50,4/16/2020
1DEBBE,shareholder-rights-plan,100,43,4/16/2020
1DEBBE,earnings,100,50,4/16/2020
1E9A6D,dividend,100,50,4/16/2020
1F716B,donation,100,54,4/16/2020
221445,dividend,100,50,4/16/2020
222BF9,conference-call,100,50,4/16/2020
228D42,partnership,100,61,4/16/2020
24CB56,earnings-positive,100,69,4/16/2020
24CB56,earnings,100,50,4/16/2020
24CB56,earnings,100,50,4/16/2020
24CB56,earnings,100,50,4/16/2020
24CB56,earnings,100,50,4/16/2020
24CB56,earnings,100,50,4/16/2020
24CB56,earnings,100,50,4/16/2020
24CB56,earnings,100,50,4/16/2020
24CB56,earnings,100,50,4/16/2020
26D8ED,conference-call,100,50,4/16/2020
2720AB,conference-call,100,50,4/16/2020
272704,earnings,100,50,4/16/2020
275300,conference-call,100,50,4/16/2020
2A1009,conference-call,100,50,4/16/2020
2B7A40,conference-call,100,50,4/16/2020
2B9DBB,conference-call,100,50,4/16/2020
2BBE62,earnings,100,50,4/16/2020
2C681C,clinical-trials-start,100,64,4/16/2020
2DB344,earnings,100,50,4/16/2020
2DC88B,earnings,100,50,4/16/2020
31803E,earnings,100,50,4/16/2020
338544,executive-appointment,100,54,4/16/2020
3.30E+34,dividend,100,50,4/16/2020
33E9D5,earnings,100,50,4/16/2020
341759,executive-appointment,100,54,4/16/2020
343996,dividend,100,50,4/16/2020
343996,dividend,100,50,4/16/2020
3461CF,donation,100,54,4/16/2020
349DA4,earnings,100,50,4/16/2020
372037,conference-call,100,50,4/16/2020
3.73E+87,partnership,100,61,4/16/2020
37E18B,conference-participant,100,50,4/16/2020
39FB23,dividend,100,50,4/16/2020
39FB23,executive-appointment,100,54,4/16/2020
3B20AB,dividend,100,50,4/16/2020
3C3B6B,award,100,58,4/16/2020
3C8A04,earnings,100,50,4/16/2020
3DCECC,conference-call,100,50,4/16/2020
3F4668,legal-issues-defendant,100,22,4/16/2020
3FBC9B,earnings,100,50,4/16/2020
4.03E+05,business-contract,100,69,4/16/2020
43E8F5,conference-call,100,50,4/16/2020
44209A,earnings,100,50,4/16/2020
444CC8,conference-call,100,50,4/16/2020
451D61,conference-call,100,50,4/16/2020
45444E,earnings,100,50,4/16/2020
46A16E,conference-call,100,50,4/16/2020
479930,earnings,100,50,4/16/2020
47BA98,dividend,100,50,4/16/2020
4B3555,earnings,100,50,4/16/2020
4B6EF9,earnings,100,50,4/16/2020
4BBA23,conference-call,100,50,4/16/2020
4C3FE9,public-offering,100,43,4/16/2020
4C5CC9,conference-call,100,50,4/16/2020
4EEE7E,earnings,100,50,4/16/2020
50702E,clinical-trials-start,100,64,4/16/2020
50702E,clinical-trials-start,100,64,4/16/2020
520632,earnings,100,50,4/16/2020
520632,earnings,100,50,4/16/2020
520632,earnings,100,50,4/16/2020
545272,conference-call,100,50,4/16/2020
5.47E+28,executive-appointment,100,54,4/16/2020
55438C,campaign-ad-release,100,59,4/16/2020
56277A,conference-call,100,50,4/16/2020
58C2D4,earnings,100,50,4/16/2020
59C539,earnings,100,50,4/16/2020
59C539,earnings,100,50,4/16/2020
5B6C11,earnings,100,50,4/16/2020
5CCDAD,earnings,100,50,4/16/2020
5D16CF,conference-call,100,50,4/16/2020
615B6D,public-offering,100,43,4/16/2020
6166D1,dividend,100,50,4/16/2020
622037,earnings,100,50,4/16/2020
62A48D,earnings,100,50,4/16/2020
6474BA,earnings,100,50,4/16/2020
66E04A,note-sale,100,52,4/16/2020
6BD606,conference-call,100,50,4/16/2020
6BD606,conference-call,100,50,4/16/2020
6CC55E,earnings,100,50,4/16/2020
6ED519,conference-call,100,50,4/16/2020
724F84,executive-appointment,100,54,4/16/2020
72C2CE,conference-call,100,50,4/16/2020
74404C,conference-call,100,50,4/16/2020
762B8D,earnings,100,50,4/16/2020
7710F3,executive-appointment,100,54,4/16/2020
790C34,earnings,100,50,4/16/2020
7B0BA6,earnings,100,50,4/16/2020
7CD98F,earnings,100,50,4/16/2020
7D5384,conference-call,100,50,4/16/2020
7DD8CC,conference-call,100,50,4/16/2020
7E1542,earnings,100,50,4/16/2020
810FAD,product-release,100,64,4/16/2020
810FAD,business-contract,100,69,4/16/2020
81222C,public-offering,100,43,4/16/2020
8377DB,fraud,100,44,4/16/2020
85DA04,earnings,100,50,4/16/2020
877C0C,product-release,100,64,4/16/2020
87B81A,note-sale,100,52,4/16/2020
87B81A,note-sale,100,52,4/16/2020
881190,conference-call,100,50,4/16/2020
89B2E7,earnings,100,50,4/16/2020
8A8E41,product-release,100,64,4/16/2020
8A8E41,acquisition-acquirer,100,49,4/16/2020
8AB37F,conference-call,100,50,4/16/2020
8BFAA4,shareholder-rights-plan,100,43,4/16/2020
8E9CD8,earnings,100,50,4/16/2020
902670,conference-call,100,50,4/16/2020
9087B9,conference-call,100,50,4/16/2020
911CA9,public-offering,100,43,4/16/2020
9196A2,revenues,100,50,4/16/2020
9196A2,revenues,100,50,4/16/2020
9196A2,revenues,100,50,4/16/2020
9196A2,revenues,100,50,4/16/2020
9196A2,revenues,100,50,4/16/2020
93D207,earnings,100,50,4/16/2020
97693A,executive-resignation,100,44,4/16/2020
979451,earnings,100,50,4/16/2020
97AAF6,dividend,100,50,4/16/2020
97FE80,earnings,100,50,4/16/2020
986AF6,executive-resignation,100,44,4/16/2020
99028D,conference-call,100,50,4/16/2020
990AD0,earnings,100,50,4/16/2020
9.92E+94,earnings,100,50,4/16/2020
99ACAD,earnings,100,50,4/16/2020
9B71A7,legal-issues-defendant,100,22,4/16/2020
9B71A7,legal-issues-defendant,100,22,4/16/2020
9CE4C7,earnings,100,50,4/16/2020
9D30A8,earnings,100,50,4/16/2020
9E298A,conference-call,100,50,4/16/2020
9E98F2,earnings,100,50,4/16/2020
A1EAC8,business-contract,100,69,4/16/2020
A3800A,note-sale,100,52,4/16/2020
A4D173,conference-call,100,50,4/16/2020
A4D173,conference-call,100,50,4/16/2020
A5151E,earnings,100,50,4/16/2020
AA247D,earnings,100,50,4/16/2020
AC7C4F,award,100,58,4/16/2020
ADF092,product-release,100,64,4/16/2020
AFD7DD,conference-call,100,50,4/16/2020
B13B68,conference-call,100,50,4/16/2020
B1B10C,partnership,100,61,4/16/2020
B2DAF6,earnings,100,50,4/16/2020
B7FA9B,conference-call,100,50,4/16/2020
B803B1,conference-call,100,50,4/16/2020
B85DCE,executive-appointment,100,54,4/16/2020
B8EF97,product-release,100,64,4/16/2020
B8EF97,note-sale,100,52,4/16/2020
B934BF,conference-call,100,50,4/16/2020
BAD9EA,public-offering,100,43,4/16/2020
BBF349,business-contract,100,69,4/16/2020
BC948D,conference-call,100,50,4/16/2020
BCC55F,conference-call,100,50,4/16/2020
BD682F,earnings,100,50,4/16/2020
BF79F5,investment-investor,100,55,4/16/2020
C32A39,dividend,100,50,4/16/2020
C66A8C,earnings,100,50,4/16/2020
C941DC,earnings,100,50,4/16/2020
CAB222,conference-call,100,50,4/16/2020
CAC8D0,earnings,100,50,4/16/2020
CAC8D0,facility-open,100,65,4/16/2020
CB6A9C,conference-call,100,50,4/16/2020
CDAA0E,earnings,100,50,4/16/2020
CDE118,earnings,100,50,4/16/2020
D08D2C,conference-call,100,50,4/16/2020
D139BC,conference-call,100,50,4/16/2020
D1C0B9,earnings,100,50,4/16/2020
D33D8C,business-contract,100,69,4/16/2020
D3DE34,conference-call,100,50,4/16/2020
D3DE34,conference-call,100,50,4/16/2020
D54E62,asset-sale,100,62,4/16/2020
D56E4C,conference-call,100,50,4/16/2020
D56E4C,conference-call,100,50,4/16/2020
D5AF19,earnings,100,50,4/16/2020
D7918D,earnings,100,50,4/16/2020
D90F43,partnership,100,61,4/16/2020
D90F43,conference-call,100,50,4/16/2020
DB5CA5,donation,100,54,4/16/2020
DB7EC3,earnings,100,50,4/16/2020
DB7EC3,earnings,100,50,4/16/2020
DB88A1,business-contract,100,69,4/16/2020
DC1405,public-offering,100,43,4/16/2020
DC5299,note-sale,100,52,4/16/2020
DDCB34,conference-call,100,50,4/16/2020
E0207A,earnings,100,50,4/16/2020
E0647D,earnings,100,50,4/16/2020
E0647D,earnings,100,50,4/16/2020
E074A0,earnings,100,50,4/16/2020
E15736,conference-call,100,50,4/16/2020
E28D9C,conference-call,100,50,4/16/2020
E4CE73,partnership,100,61,4/16/2020
E8E899,conference-call,100,50,4/16/2020
E90C84,conference-call,100,50,4/16/2020
E9C7C0,executive-appointment,100,54,4/16/2020
EAEBF3,dividend,100,50,4/16/2020
EB7D6C,fraud,100,44,4/16/2020
EBC84C,earnings,100,50,4/16/2020
EBD89A,business-contract,100,69,4/16/2020
ED9C04,earnings,100,50,4/16/2020
EF5BED,earnings-positive,100,69,4/16/2020
EF5BED,earnings,100,50,4/16/2020
EF5BED,earnings,100,50,4/16/2020
EF5BED,earnings,100,50,4/16/2020
EF5BED,dividend,100,50,4/16/2020
F39E1E,note-sale,100,52,4/16/2020
F43A11,legal-issues-defendant,100,22,4/16/2020
F509E2,fraud,100,44,4/16/2020
F5349B,earnings,100,50,4/16/2020
F6E248,earnings,100,50,4/16/2020
F6FA6A,shareholder-rights-plan,100,43,4/16/2020
F702CA,earnings,100,50,4/16/2020
F702CA,earnings,100,50,4/16/2020
F702CA,earnings,100,50,4/16/2020
F702CA,earnings,100,50,4/16/2020
F702CA,earnings,100,50,4/16/2020
F7ADEB,conference-call,100,50,4/16/2020
FA36A4,conference-call,100,50,4/16/2020
FA40E2,dividend,100,50,4/16/2020
FA918D,conference-call,100,50,4/16/2020
FD2565,partnership,100,61,4/16/2020
FD2565,partnership,100,61,4/16/2020
00D6B5,earnings,100,50,4/17/2020
048B70,conference-call,100,50,4/17/2020
0A7650,conference-call,100,50,4/17/2020
0C355F,conference-call,100,50,4/17/2020
0CC62B,conference-call,100,50,4/17/2020
0F65C9,conference-call,100,50,4/17/2020
1216D1,conference-call,100,50,4/17/2020
139303,executive-appointment,100,54,4/17/2020
1782D5,conference-call,100,50,4/17/2020
182B8C,conference-call,100,50,4/17/2020
1A6A94,conference-call,100,50,4/17/2020
1FAF22,conference-call,100,50,4/17/2020
20403D,buybacks,100,74,4/17/2020
2.45E+15,award,100,58,4/17/2020
24C48B,conference-call,100,50,4/17/2020
25DD05,conference-call,100,50,4/17/2020
264EB3,board-meeting,100,51,4/17/2020
270305,unit-acquisition-completed-acquiree,100,67,4/17/2020
2BA977,conference-call,100,50,4/17/2020
2E61CC,earnings,100,50,4/17/2020
2EC172,conference-call,100,50,4/17/2020
3471C0,conference-call,100,50,4/17/2020
3BB616,earnings,100,50,4/17/2020
3BC360,conference-call,100,50,4/17/2020
3E39A5,earnings,100,50,4/17/2020
42EFC7,public-offering,100,43,4/17/2020
435ACE,conference-call,100,50,4/17/2020
492117,executive-appointment,100,54,4/17/2020
4D8124,executive-appointment,100,54,4/17/2020
52FB2F,earnings,100,50,4/17/2020
5546DA,conference-call,100,50,4/17/2020
55C9B5,conference-call,100,50,4/17/2020
56632F,earnings,100,50,4/17/2020
5704AC,earnings,100,50,4/17/2020
5B7739,conference-call,100,50,4/17/2020
5BC2F4,earnings,100,50,4/17/2020
5D0337,earnings,100,50,4/17/2020
5D87DF,earnings,100,50,4/17/2020
61E975,conference-call,100,50,4/17/2020
64636E,executive-appointment,100,54,4/17/2020
64636E,executive-appointment,100,54,4/17/2020
647143,dividend,100,50,4/17/2020
67A658,dividend,100,50,4/17/2020
67A658,dividend,100,50,4/17/2020
69E8E1,conference-call,100,50,4/17/2020
6C987C,earnings-positive,100,69,4/17/2020
6CDFC6,conference-call,100,50,4/17/2020
6D3B7B,earnings,100,50,4/17/2020
713810,executive-appointment,100,54,4/17/2020
72609A,conference-call,100,50,4/17/2020
73C521,earnings-positive,100,69,4/17/2020
73C521,earnings,100,50,4/17/2020
73C521,earnings,100,50,4/17/2020
73C521,earnings,100,50,4/17/2020
73C521,earnings,100,50,4/17/2020
73C521,earnings,100,50,4/17/2020
789A7D,conference-call,100,50,4/17/2020
791EC1,conference-call,100,50,4/17/2020
7AB859,board-meeting,100,51,4/17/2020
7BC92D,loan-recipient,100,59,4/17/2020
7E62B5,conference-call,100,50,4/17/2020
81222C,public-offering,100,43,4/17/2020
8C1238,conference-call,100,50,4/17/2020
8D4486,partnership,100,61,4/17/2020
8D4486,partnership,100,61,4/17/2020
8DCBBB,earnings,100,50,4/17/2020
8DCBBB,earnings,100,50,4/17/2020
911ACB,earnings,100,50,4/17/2020
9196A2,partnership,100,61,4/17/2020
958938,executive-appointment,100,54,4/17/2020
966DBE,earnings,100,50,4/17/2020
9C5BA5,earnings,100,50,4/17/2020
9F18FA,note-sale,100,52,4/17/2020
9F18FA,note-sale,100,52,4/17/2020
9F5CBB,conference-call,100,50,4/17/2020
A247F5,earnings,100,50,4/17/2020
A3800A,note-sale,100,52,4/17/2020
A65325,conference-call,100,50,4/17/2020
B72BE9,conference-call,100,50,4/17/2020
BEB756,dividend,100,50,4/17/2020
BFE02C,earnings-positive,100,69,4/17/2020
C0200F,board-meeting,100,51,4/17/2020
C4452A,dividend,100,50,4/17/2020
CB9E13,conference-call,100,50,4/17/2020
CBBFBF,note-sale,100,52,4/17/2020
CBBFBF,earnings,100,50,4/17/2020
CDAF5B,conference-call,100,50,4/17/2020
CE1002,dividend,100,50,4/17/2020
CFF15D,conference-call,100,50,4/17/2020
D3CEDF,conference-call,100,50,4/17/2020
D3FD6D,conference-call,100,50,4/17/2020
D58A11,earnings,100,50,4/17/2020
D64EDF,donation,100,54,4/17/2020
D77F7E,partnership,100,61,4/17/2020
D96202,conference-call,100,50,4/17/2020
DB396B,conference-call,100,50,4/17/2020
DDB002,conference-call,100,50,4/17/2020
DF6FDD,earnings,100,50,4/17/2020
E3656D,conference-call,100,50,4/17/2020
E592F0,earnings,100,50,4/17/2020
E70531,partnership,100,61,4/17/2020
E82A2D,conference-call,100,50,4/17/2020
E866D2,legal-issues-defendant,100,22,4/17/2020
E8D221,dividend-up,100,55,4/17/2020
EC99D0,board-meeting,100,51,4/17/2020
F1C04C,conference-call,100,50,4/17/2020
F46EC9,earnings,100,50,4/17/2020
F721A7,earnings,100,50,4/17/2020
F721A7,earnings,100,50,4/17/2020
F748C7,executive-resignation,100,44,4/17/2020
F7ADEB,loan-recipient,100,59,4/17/2020
F82D37,earnings-up,100,68,4/17/2020
F82D37,earnings,100,50,4/17/2020
F82D37,earnings,100,50,4/17/2020
F9CAF8,asset-sale,100,62,4/17/2020
FAE021,product-release,100,64,4/17/2020
FAE021,product-release,100,64,4/17/2020
FAE021,earnings,100,50,4/17/2020
FAE021,earnings,100,50,4/17/2020
FD6926,board-meeting,100,51,4/17/2020
FFE543,earnings,100,50,4/17/2020
01D03F,regulatory-product-approval-granted,100,81,4/18/2020
0A59F8,partnership,100,61,4/18/2020
4AC91D,legal-issues-defendant,100,22,4/19/2020
9B71A7,legal-issues-defendant,100,22,4/19/2020
CA212F,legal-issues-defendant,100,22,4/19/2020
DF01B1,legal-issues-defendant,100,22,4/19/2020
E866D2,legal-issues-defendant,100,22,4/19/2020
018C11,investment-investor,100,55,4/20/2020
099A92,conference-call,100,50,4/20/2020
0A1D77,earnings-positive,100,69,4/20/2020
0BC29E,earnings,100,50,4/20/2020
0BF198,conference-call,100,50,4/20/2020
0CC01F,earnings,100,50,4/20/2020
1065BC,conference-call,100,50,4/20/2020
126F95,earnings,100,50,4/20/2020
126F95,earnings,100,50,4/20/2020
126F95,earnings,100,50,4/20/2020
139303,conference-call,100,50,4/20/2020
147C38,dividend-up,100,81,4/20/2020
152E1D,credit-extension-recipient,100,69,4/20/2020
152FA5,conference-call,100,50,4/20/2020
15789A,earnings,100,50,4/20/2020
15901B,conference-call,100,50,4/20/2020
15901B,conference-call,100,50,4/20/2020
15901B,conference-call,100,50,4/20/2020
168A5D,partnership,100,61,4/20/2020
16B183,conference-call,100,50,4/20/2020
1748B3,earnings-negative,100,33,4/20/2020
1748B3,earnings-negative,100,33,4/20/2020
1748B3,earnings-negative,100,33,4/20/2020
1748B3,earnings-negative,100,33,4/20/2020
1748B3,earnings-negative,100,33,4/20/2020
182BE7,earnings,100,50,4/20/2020
190B91,earnings,100,50,4/20/2020
190B91,product-release,100,64,4/20/2020
19BF16,earnings,100,50,4/20/2020
1A3E1B,earnings,100,50,4/20/2020
1A3E1B,earnings,100,50,4/20/2020
1A3E1B,earnings,100,50,4/20/2020
1A3E1B,earnings,100,50,4/20/2020
1A3E1B,earnings,100,50,4/20/2020
1A3E1B,earnings,100,50,4/20/2020
1A3E1B,earnings,100,50,4/20/2020
1A3E1B,earnings,100,50,4/20/2020
1A3E1B,earnings,100,50,4/20/2020
1A3E1B,earnings,100,50,4/20/2020
1A3E1B,earnings,100,50,4/20/2020
1A3E1B,earnings,100,50,4/20/2020
1A3E1B,earnings,100,50,4/20/2020
1A3E1B,earnings,100,50,4/20/2020
1A3E1B,earnings,100,50,4/20/2020
1C599A,earnings,100,50,4/20/2020
1D9E55,earnings,100,50,4/20/2020
1F43A1,earnings,100,50,4/20/2020
206852,earnings,100,50,4/20/2020
20BEEA,earnings,100,50,4/20/2020
20BEEA,earnings,100,50,4/20/2020
20BEEA,earnings,100,50,4/20/2020
249674,earnings,100,50,4/20/2020
249B39,board-meeting,100,51,4/20/2020
24CB56,board-meeting,100,51,4/20/2020
2667B6,earnings,100,50,4/20/2020
267718,investment-investor,100,55,4/20/2020
27BFA1,earnings,100,50,4/20/2020
27BFA1,earnings,100,50,4/20/2020
27BFA1,earnings,100,50,4/20/2020
27BFA1,earnings,100,50,4/20/2020
27BFA1,earnings,100,50,4/20/2020
27BFA1,earnings,100,50,4/20/2020
27C10F,earnings,100,50,4/20/2020
282C18,earnings,100,50,4/20/2020
2B49F4,earnings,100,50,4/20/2020
2B49F4,earnings,100,50,4/20/2020
2B49F4,earnings,100,50,4/20/2020
2B49F4,earnings,100,50,4/20/2020
2BDC1C,conference-call,100,50,4/20/2020
2CA60F,earnings,100,50,4/20/2020
2CA60F,earnings,100,50,4/20/2020
2CA60F,note-sale,100,52,4/20/2020
2E902B,earnings,100,50,4/20/2020
2EBA55,conference-call,100,50,4/20/2020
309922,earnings,100,50,4/20/2020
328250,conference-call,100,50,4/20/2020
32C8CD,earnings,100,50,4/20/2020
346BF2,conference-call,100,50,4/20/2020
34B411,earnings,100,50,4/20/2020
34E9F9,conference-call,100,50,4/20/2020
353DBB,conference-call,100,50,4/20/2020
35AE32,reorganization,100,53,4/20/2020
35B907,earnings,100,50,4/20/2020
35B907,earnings,100,50,4/20/2020
387541,earnings,100,50,4/20/2020
389CFB,conference-call,100,50,4/20/2020
38FB49,earnings,100,50,4/20/2020
38FB49,earnings,100,50,4/20/2020
38FB49,earnings,100,50,4/20/2020
38FB49,earnings,100,50,4/20/2020
38FB49,earnings,100,50,4/20/2020
38FB49,earnings,100,50,4/20/2020
38FB49,earnings,100,50,4/20/2020
3AF7FD,conference-participant,100,50,4/20/2020
3B20AB,earnings,100,50,4/20/2020
3DDE54,unit-acquisition-acquiree,100,76,4/20/2020
416C55,earnings,100,50,4/20/2020
41EC04,conference-call,100,50,4/20/2020
499C75,legal-issues-defendant,100,22,4/20/2020
4A2457,award,100,58,4/20/2020
4A5C8D,earnings,100,50,4/20/2020
4A7C1F,legal-issues-defendant,100,22,4/20/2020
4AC91D,legal-issues-defendant,100,22,4/20/2020
4BEB48,earnings,100,50,4/20/2020
4C3FE9,public-offering,100,43,4/20/2020
4D371E,earnings,100,50,4/20/2020
4EE167,legal-issues-defendant,100,22,4/20/2020
4EE167,legal-issues-defendant,100,22,4/20/2020
4F71DC,partnership,100,61,4/20/2020
50070E,conference-call,100,50,4/20/2020
51D876,earnings,100,50,4/20/2020
532D47,conference-call,100,50,4/20/2020
56765E,unit-acquisition-acquirer,100,49,4/20/2020
57CAAB,earnings,100,50,4/20/2020
596116,product-release,100,64,4/20/2020
59872F,executive-appointment,100,54,4/20/2020
5BC2F4,partnership,100,61,4/20/2020
5D41E4,conference-call,100,50,4/20/2020
5F1B7B,earnings,100,50,4/20/2020
61A586,earnings,100,50,4/20/2020
61A586,credit-extension-recipient,100,69,4/20/2020
647143,earnings,100,50,4/20/2020
647143,earnings,100,50,4/20/2020
647143,earnings,100,50,4/20/2020
647143,earnings,100,50,4/20/2020
647143,earnings,100,50,4/20/2020
665D7D,debt-extension-recipient,100,73,4/20/2020
6DC1D7,conference-call,100,50,4/20/2020
6F0A63,acquisition-completed-acquirer,100,49,4/20/2020
722DE3,business-contract,100,69,4/20/2020
726EEA,earnings,100,50,4/20/2020
742AAB,note-sale,100,52,4/20/2020
752A70,executive-appointment,100,54,4/20/2020
75F665,earnings,100,50,4/20/2020
75F665,earnings,100,50,4/20/2020
75F665,earnings,100,50,4/20/2020
775439,earnings,100,50,4/20/2020
77B8E9,patent-awarded,100,72,4/20/2020
7ACD98,conference-call,100,50,4/20/2020
7BAAE7,business-contract,100,69,4/20/2020
7BFF81,acquisition-completed-acquirer,100,49,4/20/2020
7D97DE,conference-call,100,50,4/20/2020
81EAD4,stock-gain,100,63,4/20/2020
81EAD4,donation,100,54,4/20/2020
859281,earnings,100,50,4/20/2020
859281,earnings,100,50,4/20/2020
859281,earnings,100,50,4/20/2020
859281,earnings,100,50,4/20/2020
859281,earnings,100,50,4/20/2020
859281,dividend,100,50,4/20/2020
85AD00,earnings,100,50,4/20/2020
862941,earnings,100,50,4/20/2020
88611B,earnings,100,50,4/20/2020
896771,conference-call,100,50,4/20/2020
8A0368,conference-call,100,50,4/20/2020
8B9B3B,executive-appointment,100,54,4/20/2020
8D4486,earnings,100,50,4/20/2020
8D4486,earnings,100,50,4/20/2020
8D4486,earnings,100,50,4/20/2020
8D4486,earnings,100,50,4/20/2020
8DDA23,board-meeting,100,51,4/20/2020
903AB4,earnings,100,50,4/20/2020
9043FE,earnings,100,50,4/20/2020
9043FE,earnings,100,50,4/20/2020
911CA9,public-offering,100,43,4/20/2020
92B047,earnings,100,50,4/20/2020
93965C,earnings,100,50,4/20/2020
93D207,partnership,100,61,4/20/2020
93D207,partnership,100,61,4/20/2020
94637C,clinical-trials-positive,100,87,4/20/2020
94C0B5,earnings,100,50,4/20/2020
9.86E+03,earnings,100,50,4/20/2020
9981C6,earnings,100,50,4/20/2020
9A02C4,conference-call,100,50,4/20/2020
9B4066,unit-acquisition-acquirer,100,49,4/20/2020
9B71A7,legal-issues-defendant,100,22,4/20/2020
9BBFA5,public-offering,100,43,4/20/2020
9CF9B1,earnings,100,50,4/20/2020
9D2790,product-release,100,64,4/20/2020
9D4EC7,conference-call,100,50,4/20/2020
9D4EC7,conference-call,100,50,4/20/2020
9D5D35,earnings,100,50,4/20/2020
9EA947,conference-call,100,50,4/20/2020
9F62D1,earnings-per-share-down,100,42,4/20/2020
A05C43,earnings,100,50,4/20/2020
A05C43,earnings,100,50,4/20/2020
A38F30,exchange-noncompliance,100,24,4/20/2020
A4B899,conference-call,100,50,4/20/2020
A5628C,earnings,100,50,4/20/2020
A746F6,earnings-per-share-positive,100,69,4/20/2020
A746F6,earnings-per-share-positive,100,69,4/20/2020
A746F6,earnings-per-share-positive,100,69,4/20/2020
A746F6,earnings-per-share-positive,100,69,4/20/2020
A746F6,earnings-per-share-positive,100,69,4/20/2020
A746F6,earnings-per-share-positive,100,69,4/20/2020
A746F6,earnings-per-share-positive,100,69,4/20/2020
A746F6,earnings-per-share-positive,100,69,4/20/2020
A746F6,earnings-per-share-positive,100,69,4/20/2020
A7CCF0,conference-call,100,50,4/20/2020
ACF77B,dividend,100,50,4/20/2020
AD23DE,earnings,100,50,4/20/2020
AD23DE,earnings,100,50,4/20/2020
AD23DE,earnings,100,50,4/20/2020
AD23DE,earnings,100,50,4/20/2020
AD23DE,earnings,100,50,4/20/2020
AD23DE,earnings,100,50,4/20/2020
AE4125,conference-call,100,50,4/20/2020
AFD1CA,conference-call,100,50,4/20/2020
B1A85D,business-contract,100,69,4/20/2020
B2206F,partnership,100,61,4/20/2020
B2F431,earnings-positive,100,69,4/20/2020
B37FB4,partnership,100,61,4/20/2020
B604DF,earnings,100,50,4/20/2020
B604DF,earnings,100,50,4/20/2020
B604DF,earnings,100,50,4/20/2020
B604DF,earnings,100,50,4/20/2020
B642E8,earnings,100,50,4/20/2020
BB58FF,conference-organizer,100,57,4/20/2020
BBC05B,operating-earnings,100,50,4/20/2020
BD15E8,conference-call,100,50,4/20/2020
C062D4,product-release,100,64,4/20/2020
C41C25,earnings,100,50,4/20/2020
C4FBDC,conference-call,100,50,4/20/2020
C54140,earnings,100,50,4/20/2020
C62AA4,conference-call,100,50,4/20/2020
C83B88,partnership,100,61,4/20/2020
C9881C,executive-appointment,100,54,4/20/2020
C99CC8,earnings,100,50,4/20/2020
CA212F,legal-issues-defendant,100,22,4/20/2020
CC6FF5,earnings,100,50,4/20/2020
CDD75E,executive-appointment,100,54,4/20/2020
D04D9F,conference-call,100,50,4/20/2020
D17F7E,earnings,100,50,4/20/2020
D1AE3B,earnings,100,50,4/20/2020
D45285,earnings,100,50,4/20/2020
D697DE,earnings,100,50,4/20/2020
D6EAA3,board-meeting,100,51,4/20/2020
D8760C,earnings,100,50,4/20/2020
D8760C,earnings,100,50,4/20/2020
D8760C,earnings,100,50,4/20/2020
D8760C,earnings,100,50,4/20/2020
D8760C,earnings,100,50,4/20/2020
D9E036,executive-appointment,100,54,4/20/2020
DA0CB8,conference-call,100,50,4/20/2020
DA48E4,unit-acquisition-acquirer,100,49,4/20/2020
DA48E4,unit-acquisition-completed-acquirer,100,49,4/20/2020
DC2B00,facility-open,100,65,4/20/2020
DD7A96,conference-call,100,50,4/20/2020
DE4924,conference-call,100,50,4/20/2020
DF01B1,legal-issues-defendant,100,22,4/20/2020
DF18E6,executive-appointment,100,54,4/20/2020
E21871,executive-appointment,100,54,4/20/2020
E30B34,earnings,100,50,4/20/2020
E30B34,earnings,100,50,4/20/2020
E35610,executive-appointment,100,54,4/20/2020
E68C3D,donation,100,54,4/20/2020
E72599,conference-call,100,50,4/20/2020
E866D2,legal-issues-defendant,100,22,4/20/2020
EE6F1C,business-contract,100,69,4/20/2020
EEA6B3,executive-appointment,100,54,4/20/2020
F0B335,business-contract,100,69,4/20/2020
F1CD47,credit-extension-recipient,100,69,4/20/2020
F24FF0,facility-close,100,47,4/20/2020
F32F88,conference-call,100,50,4/20/2020
F44EA2,earnings,100,50,4/20/2020
F47871,clinical-trials-start,100,64,4/20/2020
F82D37,note-sale,100,52,4/20/2020
F88A04,product-release,100,64,4/20/2020
F93C8A,conference-call,100,50,4/20/2020
FAB97A,earnings,100,50,4/20/2020
FD6926,conference-call,100,50,4/20/2020
0142B5,board-meeting,100,51,4/21/2020
01D03F,regulatory-product-approval-granted,100,81,4/21/2020
31025,revenue-up,100,69,4/21/2020
31025,earnings,100,50,4/21/2020
31025,earnings,100,50,4/21/2020
31025,earnings,100,50,4/21/2020
033B58,clinical-trials,100,56,4/21/2020
03596A,earnings,100,50,4/21/2020
03FB17,earnings,100,50,4/21/2020
040DBB,earnings,100,50,4/21/2020
0560D8,earnings,100,50,4/21/2020
06A456,shareholder-rights-plan,100,43,4/21/2020
06EE79,earnings,100,50,4/21/2020
0A0D9E,partnership,100,61,4/21/2020
0A0D9E,conference-call,100,50,4/21/2020
0AB700,earnings,100,50,4/21/2020
0BB9E5,earnings,100,50,4/21/2020
0C136E,acquisition-acquirer,100,49,4/21/2020
0C136E,acquisition-acquirer,100,49,4/21/2020
0C2A0D,earnings,100,50,4/21/2020
0FABBD,conference-call,100,50,4/21/2020
11074E,conference-call,100,50,4/21/2020
1201B5,legal-issues-defendant,100,22,4/21/2020
1201B5,legal-issues-defendant,100,22,4/21/2020
152B9E,conference-call,100,50,4/21/2020
15A388,executive-appointment,100,54,4/21/2020
1E04A5,earnings,100,50,4/21/2020
1E9A6D,earnings,100,50,4/21/2020
1FA8F7,earnings-per-share-positive,100,69,4/21/2020
205AD5,donation,100,54,4/21/2020
20BEEA,conference-call,100,50,4/21/2020
21245F,executive-appointment,100,54,4/21/2020
225CA2,conference-call,100,50,4/21/2020
228D42,partnership,100,61,4/21/2020
239106,conference-call,100,50,4/21/2020
24A89A,executive-appointment,100,54,4/21/2020
25102A,product-release,100,64,4/21/2020
25102A,product-release,100,64,4/21/2020
26F31D,product-release,100,64,4/21/2020
272704,earnings-positive,100,69,4/21/2020
275300,legal-issues-defendant,100,22,4/21/2020
2A1009,executive-appointment,100,54,4/21/2020
2CF9D3,orphan-drug-designation,100,76,4/21/2020
2E2E6E,earnings,100,50,4/21/2020
2E89AE,earnings,100,50,4/21/2020
2EB04E,conference-call,100,50,4/21/2020
2F1299,conference-call,100,50,4/21/2020
2F5256,earnings,100,50,4/21/2020
2F9304,partnership,100,61,4/21/2020
32F24A,conference-call,100,50,4/21/2020
3461CF,business-contract,100,69,4/21/2020
34B97A,earnings,100,50,4/21/2020
34B97A,earnings,100,50,4/21/2020
34B97A,earnings,100,50,4/21/2020
34B97A,earnings,100,50,4/21/2020
387541,note-sale,100,52,4/21/2020
39BFF6,earnings,100,50,4/21/2020
39BFF6,earnings,100,50,4/21/2020
39BFF6,earnings,100,50,4/21/2020
3A1C46,earnings,100,50,4/21/2020
3CCC90,earnings,100,50,4/21/2020
3CCC90,dividend,100,50,4/21/2020
3D9999,earnings-positive,100,69,4/21/2020
3F4668,legal-issues-defendant,100,22,4/21/2020
3F868D,conference-call,100,50,4/21/2020
3F96D5,earnings,100,50,4/21/2020
4.03E+05,earnings,100,50,4/21/2020
4.03E+05,earnings,100,50,4/21/2020
4.03E+05,earnings,100,50,4/21/2020
4.03E+05,earnings,100,50,4/21/2020
414FFF,note-sale,100,52,4/21/2020
416C55,loan-recipient,100,59,4/21/2020
41785E,earnings,100,50,4/21/2020
42AABD,conference-call,100,50,4/21/2020
447FC6,executive-appointment,100,54,4/21/2020
44ED36,earnings,100,50,4/21/2020
458D2C,business-contract,100,69,4/21/2020
45ABCC,earnings,100,50,4/21/2020
47BA98,conference-call,100,50,4/21/2020
485445,board-meeting,100,51,4/21/2020
4.91E+58,executive-appointment,100,54,4/21/2020
49BBBC,note-sale,100,52,4/21/2020
4A6F00,partnership,100,61,4/21/2020
4BEB48,award,100,58,4/21/2020
4C2F17,partnership,100,61,4/21/2020
4C2F17,partnership,100,61,4/21/2020
4C5CC9,dividend,100,50,4/21/2020
4C6C63,dividend,100,50,4/21/2020
4EE167,legal-issues-defendant,100,22,4/21/2020
5088A5,earnings,100,50,4/21/2020
513A86,executive-appointment,100,54,4/21/2020
51F541,conference-call,100,50,4/21/2020
52015A,earnings,100,50,4/21/2020
54B889,conference-call,100,50,4/21/2020
55C9B5,partnership,100,61,4/21/2020
562853,conference-call,100,50,4/21/2020
57DDB9,business-contract,100,69,4/21/2020
57F3DA,earnings,100,50,4/21/2020
586FFD,conference-call,100,50,4/21/2020
5876DC,dividend,100,50,4/21/2020
58CA9A,dividend,100,50,4/21/2020
59A832,conference-call,100,50,4/21/2020
5D41E4,conference-call,100,50,4/21/2020
5D43A7,partnership,100,61,4/21/2020
5FDBD0,conference-call,100,50,4/21/2020
62B20A,earnings,100,50,4/21/2020
636639,earnings-per-share-positive,100,69,4/21/2020
636639,earnings-per-share,100,50,4/21/2020
636639,earnings-per-share,100,50,4/21/2020
636639,earnings-per-share,100,50,4/21/2020
64854A,conference-call,100,50,4/21/2020
6A961B,conference-call,100,50,4/21/2020
6ABCB8,earnings,100,50,4/21/2020
6D3B7B,earnings,100,50,4/21/2020
6D4636,conference-call,100,50,4/21/2020
6D9B53,executive-appointment,100,54,4/21/2020
6-Dec-05,public-offering,100,43,4/21/2020
6E705B,public-offering,100,43,4/21/2020
6E8864,conference-call,100,50,4/21/2020
722D55,earnings,100,50,4/21/2020
73F7F9,legal-verdict-disfavored,100,22,4/21/2020
742AAB,note-sale,100,52,4/21/2020
75F665,earnings-negative,100,33,4/21/2020
75F665,earnings-negative,100,33,4/21/2020
75F665,earnings-negative,100,33,4/21/2020
75F665,earnings-negative,100,33,4/21/2020
75F665,earnings-negative,100,33,4/21/2020
75F665,earnings-negative,100,33,4/21/2020
75F665,earnings-negative,100,33,4/21/2020
75F665,earnings-negative,100,33,4/21/2020
75F665,earnings-negative,100,33,4/21/2020
75F665,earnings-negative,100,33,4/21/2020
75F665,dividend,100,50,4/21/2020
766047,executive-appointment,100,54,4/21/2020
76BD96,note-sale,100,52,4/21/2020
78F9ED,conference-call,100,50,4/21/2020
790C34,product-release,100,64,4/21/2020
7A51FE,conference-call,100,50,4/21/2020
7AC86E,product-release,100,64,4/21/2020
7B492C,conference-call,100,50,4/21/2020
7B4B91,conference-call,100,50,4/21/2020
7B6EB1,earnings,100,50,4/21/2020
7C62A3,conference-call,100,50,4/21/2020
81222C,public-offering,100,43,4/21/2020
83066C,partnership,100,61,4/21/2020
8377DB,earnings,100,50,4/21/2020
8377DB,earnings,100,50,4/21/2020
8377DB,earnings,100,50,4/21/2020
8377DB,earnings,100,50,4/21/2020
8377DB,earnings,100,50,4/21/2020
8377DB,legal-issues-defendant,100,22,4/21/2020
858942,note-sale,100,52,4/21/2020
858942,credit-extension-recipient,100,69,4/21/2020
858942,credit-extension-recipient,100,69,4/21/2020
858942,note-sale,100,52,4/21/2020
85CDC9,earnings,100,50,4/21/2020
890FF4,conference-call,100,50,4/21/2020
8A8E41,product-release,100,64,4/21/2020
8A8E41,product-release,100,64,4/21/2020
8C5519,earnings,100,50,4/21/2020
8C5519,earnings,100,50,4/21/2020
8C5519,earnings,100,50,4/21/2020
8C5519,earnings,100,50,4/21/2020
8C5519,earnings,100,50,4/21/2020
8C5519,earnings,100,50,4/21/2020
8CF6DD,earnings,100,50,4/21/2020
8D4486,earnings,100,50,4/21/2020
8D4486,partnership,100,61,4/21/2020
8D4486,partnership,100,61,4/21/2020
8DAAB9,earnings,100,50,4/21/2020
905356,earnings,100,50,4/21/2020
911AB8,dividend-up,100,87,4/21/2020
93F143,earnings,100,50,4/21/2020
93F143,earnings,100,50,4/21/2020
93F143,earnings,100,50,4/21/2020
93F143,earnings,100,50,4/21/2020
947B0B,clinical-trials,100,56,4/21/2020
9507FF,earnings,100,50,4/21/2020
9548BB,earnings-per-share-positive,100,69,4/21/2020
958938,partnership,100,61,4/21/2020
958938,partnership,100,61,4/21/2020
9592FB,earnings,100,50,4/21/2020
9.62E+76,earnings,100,50,4/21/2020
9.62E+76,earnings,100,50,4/21/2020
967D92,executive-resignation,100,44,4/21/2020
96F126,earnings,100,50,4/21/2020
96F126,earnings,100,50,4/21/2020
97AF94,earnings,100,50,4/21/2020
98CAED,earnings,100,50,4/21/2020
98CAED,earnings,100,50,4/21/2020
98CAED,earnings,100,50,4/21/2020
98CAED,dividend,100,50,4/21/2020
990AD0,conference-organizer,100,57,4/21/2020
99B61C,patient-enrollment-start,100,58,4/21/2020
99DC8D,conference-call,100,50,4/21/2020
9B71A7,executive-appointment,100,54,4/21/2020
9CA4C6,dividend,100,50,4/21/2020
9CA4C6,earnings-up,100,68,4/21/2020
9CDA4F,executive-resignation,100,44,4/21/2020
9D2790,earnings,100,50,4/21/2020
9E4A5F,earnings,100,50,4/21/2020
9EF4CF,earnings,100,50,4/21/2020
9F6B1A,regulatory-product-approval-granted,100,81,4/21/2020
9FA83B,note-sale,100,52,4/21/2020
A0F146,conference-call,100,50,4/21/2020
A15C71,conference-call,100,50,4/21/2020
A16DEA,earnings,100,50,4/21/2020
A23747,earnings,100,50,4/21/2020
A2CA3F,earnings,100,50,4/21/2020
A2CA3F,dividend,100,50,4/21/2020
A3AAA5,conference-call,100,50,4/21/2020
A4CD53,earnings,100,50,4/21/2020
A52B6B,acquisition-completed-acquirer,100,49,4/21/2020
A60354,conference-call,100,50,4/21/2020
A6213D,earnings,100,50,4/21/2020
A63387,executive-appointment,100,54,4/21/2020
A63820,earnings,100,50,4/21/2020
A63820,earnings,100,50,4/21/2020
A63820,earnings,100,50,4/21/2020
A63820,earnings,100,50,4/21/2020
A7102F,conference-call,100,50,4/21/2020
A746F6,dividend,100,50,4/21/2020
A75D43,product-release,100,64,4/21/2020
A8AC4C,conference-call,100,50,4/21/2020
A8CBDA,dividend,100,50,4/21/2020
AB7726,earnings,100,50,4/21/2020
ACD9A4,earnings,100,50,4/21/2020
ADF1B0,conference-call,100,50,4/21/2020
AEBB80,earnings,100,50,4/21/2020
B1A85D,executive-appointment,100,54,4/21/2020
B1B10C,earnings,100,50,4/21/2020
B1B10C,earnings,100,50,4/21/2020
B1B10C,earnings,100,50,4/21/2020
B1FC3B,business-contract,100,69,4/21/2020
B2256A,note-sale,100,52,4/21/2020
B2256A,note-sale,100,52,4/21/2020
B4528F,conference-call,100,50,4/21/2020
B48FC9,earnings,100,50,4/21/2020
B560AF,dividend,100,50,4/21/2020
B5766D,earnings-per-share-positive,100,69,4/21/2020
B5766D,earnings,100,50,4/21/2020
B5766D,earnings,100,50,4/21/2020
B5766D,earnings,100,50,4/21/2020
B5766D,earnings,100,50,4/21/2020
B5766D,earnings,100,50,4/21/2020
B5766D,dividend,100,50,4/21/2020
B8A51F,earnings,100,50,4/21/2020
B8F71F,earnings,100,50,4/21/2020
B96DF5,earnings,100,50,4/21/2020
B9764A,partnership,100,61,4/21/2020
B9CD50,earnings,100,50,4/21/2020
BAD9EA,patent-awarded,100,72,4/21/2020
BB5142,earnings,100,50,4/21/2020
BBBB41,conference-call,100,50,4/21/2020
BCC55F,partnership,100,61,4/21/2020
BCE9DA,earnings,100,50,4/21/2020
BCE9DA,earnings,100,50,4/21/2020
BD9668,earnings,100,50,4/21/2020
BDD12C,dividend,100,50,4/21/2020
BE14CF,conference-participant,100,50,4/21/2020
BFEA04,conference-call,100,50,4/21/2020
C0200F,earnings,100,50,4/21/2020
C0200F,earnings,100,50,4/21/2020
C1114B,product-release,100,64,4/21/2020
C2F597,earnings,100,50,4/21/2020
C6C702,partnership,100,61,4/21/2020
C6C702,conference-call,100,50,4/21/2020
C72B8F,conference-call,100,50,4/21/2020
C9881C,acquisition-interest-acquiree,100,82,4/21/2020
CA1620,earnings-per-share-up,100,75,4/21/2020
CAC8D0,facility-open,100,65,4/21/2020
CB22CD,conference-call,100,50,4/21/2020
CD06A2,earnings,100,50,4/21/2020
CD06A2,earnings,100,50,4/21/2020
CFE5BE,earnings,100,50,4/21/2020
CFE5BE,earnings,100,50,4/21/2020
CFE5BE,earnings,100,50,4/21/2020
CFE5BE,earnings,100,50,4/21/2020
CFE5BE,earnings,100,50,4/21/2020
CFE5BE,earnings,100,50,4/21/2020
CFE5BE,earnings,100,50,4/21/2020
CFE5BE,earnings,100,50,4/21/2020
CFF15D,dividend,100,50,4/21/2020
D2B9E5,note-sale,100,52,4/21/2020
D518D8,conference-call,100,50,4/21/2020
D518D8,product-release,100,64,4/21/2020
D64EDF,donation,100,54,4/21/2020
D78CCD,note-sale,100,52,4/21/2020
D78CCD,note-sale,100,52,4/21/2020
D854DD,conference-call,100,50,4/21/2020
D9164D,earnings,100,50,4/21/2020
D9B1C9,dividend,100,50,4/21/2020
DA9443,clinical-trials-complete,100,56,4/21/2020
DAFED3,conference-call,100,50,4/21/2020
DBFB51,conference-call,100,50,4/21/2020
DD0099,earnings,100,50,4/21/2020
DF532D,earnings,100,50,4/21/2020
DF532D,earnings,100,50,4/21/2020
E0207A,unit-acquisition-acquirer,100,49,4/21/2020
E19A99,earnings,100,50,4/21/2020
E68733,executive-appointment,100,54,4/21/2020
E8A49A,patent-infringement-plaintiff,100,47,4/21/2020
E90C84,conference-call,100,50,4/21/2020
E94704,earnings,100,50,4/21/2020
E94704,earnings,100,50,4/21/2020
E94704,earnings,100,50,4/21/2020
E94704,earnings,100,50,4/21/2020
E94704,earnings,100,50,4/21/2020
E9FF33,earnings,100,50,4/21/2020
EB36DE,conference-call,100,50,4/21/2020
EB61C4,dividend,100,50,4/21/2020
EC1AF3,conference-call,100,50,4/21/2020
ECD263,earnings,100,50,4/21/2020
ECDEB2,earnings,100,50,4/21/2020
ECF4F8,conference-call,100,50,4/21/2020
EE6F1C,earnings,100,50,4/21/2020
EEA6B3,earnings,100,50,4/21/2020
EEA6B3,earnings,100,50,4/21/2020
EEA6B3,earnings,100,50,4/21/2020
EF76C8,dividend,100,50,4/21/2020
F04E05,dividend,100,50,4/21/2020
F4F46F,conference-call,100,50,4/21/2020
F6E248,partnership,100,61,4/21/2020
F748C7,product-release,100,64,4/21/2020
F8DE55,earnings,100,50,4/21/2020
FA35C6,earnings,100,50,4/21/2020
FA840E,earnings,100,50,4/21/2020
FAEABE,earnings-per-share-positive,100,69,4/21/2020
FAEABE,earnings,100,50,4/21/2020
FAEABE,earnings,100,50,4/21/2020
FB7724,earnings,100,50,4/21/2020
FC4550,conference-call,100,50,4/21/2020
FD39EB,earnings,100,50,4/21/2020
FDF799,earnings,100,50,4/21/2020
01478A,conference-call,100,50,4/22/2020
018C11,conference-call,100,50,4/22/2020
03FB17,asset-sale,100,62,4/22/2020
58828,operating-earnings,100,50,4/22/2020
099A02,earnings,100,50,4/22/2020
099A02,earnings,100,50,4/22/2020
099C88,business-contract,100,69,4/22/2020
0A77DB,earnings,100,50,4/22/2020
0B57D7,earnings,100,50,4/22/2020
0C466B,revenue-up,100,69,4/22/2020
0C466B,revenue-up,100,69,4/22/2020
0C466B,revenue-up,100,69,4/22/2020
0CBC4D,earnings,100,50,4/22/2020
0CCCB7,conference-call,100,50,4/22/2020
0CE204,earnings,100,50,4/22/2020
0E439E,earnings,100,50,4/22/2020
0E439E,earnings,100,50,4/22/2020
0E439E,earnings,100,50,4/22/2020
0E6027,earnings-positive,100,69,4/22/2020
0E6027,earnings,100,50,4/22/2020
10100E,earnings,100,50,4/22/2020
1279ED,conference-call,100,50,4/22/2020
131443,partnership,100,61,4/22/2020
149301,earnings,100,50,4/22/2020
159739,earnings,100,50,4/22/2020
159739,earnings,100,50,4/22/2020
184866,earnings,100,50,4/22/2020
19BF16,legal-issues-defendant,100,22,4/22/2020
1A9DE1,earnings-positive,100,69,4/22/2020
1D943E,earnings,100,50,4/22/2020
1DA44F,conference-organizer,100,57,4/22/2020
1E4FB9,unit-acquisition-acquirer,100,49,4/22/2020
1E5786,dividend,100,50,4/22/2020
1E68B3,conference-call,100,50,4/22/2020
2031CE,earnings-positive,100,69,4/22/2020
23207A,product-release,100,64,4/22/2020
241AF7,conference-call,100,50,4/22/2020
2.45E+15,earnings,100,50,4/22/2020
25102A,earnings,100,50,4/22/2020
25102A,earnings,100,50,4/22/2020
25102A,earnings,100,50,4/22/2020
25102A,earnings,100,50,4/22/2020
25102A,earnings,100,50,4/22/2020
25102A,earnings,100,50,4/22/2020
25102A,dividend-up,100,54,4/22/2020
251988,earnings,100,50,4/22/2020
251988,earnings,100,50,4/22/2020
251988,earnings,100,50,4/22/2020
251988,earnings,100,50,4/22/2020
251988,earnings,100,50,4/22/2020
26FA41,earnings,100,50,4/22/2020
270B78,earnings,100,50,4/22/2020
275300,fraud,100,44,4/22/2020
275300,legal-issues-defendant,100,22,4/22/2020
2920D5,earnings,100,50,4/22/2020
29CEBF,conference-call,100,50,4/22/2020
2A9C0A,conference-call,100,50,4/22/2020
2B0AF4,legal-issues-defendant,100,22,4/22/2020
2CB4C9,earnings,100,50,4/22/2020
2CC60C,note-sale,100,52,4/22/2020
2EB88B,earnings,100,50,4/22/2020
2F1299,note-sale,100,52,4/22/2020
2F1299,note-sale,100,52,4/22/2020
2F6782,conference-call,100,50,4/22/2020
31A7CC,earnings,100,50,4/22/2020
31A7CC,earnings,100,50,4/22/2020
31A7CC,earnings,100,50,4/22/2020
31A7CC,earnings,100,50,4/22/2020
31A7CC,earnings,100,50,4/22/2020
31DB20,earnings,100,50,4/22/2020
342218,dividend,100,50,4/22/2020
3461CF,dividend,100,50,4/22/2020
34B411,dividend,100,50,4/22/2020
3696BF,earnings,100,50,4/22/2020
36A1CB,conference-call,100,50,4/22/2020
3.73E+87,earnings,100,50,4/22/2020
3A3447,dividend,100,50,4/22/2020
3BE00F,product-release,100,64,4/22/2020
3DC887,product-release,100,64,4/22/2020
3DE4D1,earnings,100,50,4/22/2020
3DE4D1,donation,100,54,4/22/2020
3F4668,earnings,100,50,4/22/2020
408089,dividend,100,50,4/22/2020
420168,earnings,100,50,4/22/2020
425BDC,product-release,100,64,4/22/2020
427F32,conference-call,100,50,4/22/2020
429BFB,earnings,100,50,4/22/2020
448215,earnings,100,50,4/22/2020
485445,earnings,100,50,4/22/2020
494EB9,legal-issues-defendant,100,22,4/22/2020
49BBBC,note-sale,100,52,4/22/2020
4B5054,dividend,100,50,4/22/2020
4D7BD8,revenues,100,50,4/22/2020
4D7BD8,revenues,100,50,4/22/2020
4D7BD8,revenues,100,50,4/22/2020
4D7BD8,revenues,100,50,4/22/2020
4D7BD8,revenues,100,50,4/22/2020
4D7BD8,revenues,100,50,4/22/2020
4D7BD8,revenues,100,50,4/22/2020
4D8313,earnings,100,50,4/22/2020
4D8313,earnings,100,50,4/22/2020
4D971D,dividend,100,50,4/22/2020
4D971D,earnings,100,50,4/22/2020
4D971D,earnings,100,50,4/22/2020
4D971D,earnings,100,50,4/22/2020
4D971D,earnings,100,50,4/22/2020
4D971D,earnings,100,50,4/22/2020
4D971D,earnings,100,50,4/22/2020
4EE14A,earnings,100,50,4/22/2020
4EE14A,earnings,100,50,4/22/2020
4F71DC,earnings,100,50,4/22/2020
4F71DC,earnings,100,50,4/22/2020
4F71DC,earnings,100,50,4/22/2020
4F71DC,earnings,100,50,4/22/2020
513A86,earnings,100,50,4/22/2020
53F491,earnings-per-share-positive,100,69,4/22/2020
53F491,earnings-per-share-positive,100,69,4/22/2020
53F491,earnings-per-share-positive,100,69,4/22/2020
53F491,earnings-per-share-positive,100,69,4/22/2020
53F491,earnings-per-share-positive,100,69,4/22/2020
5546DA,dividend,100,50,4/22/2020
55ACCB,earnings,100,50,4/22/2020
55C289,earnings,100,50,4/22/2020
56AFF4,operating-earnings,100,50,4/22/2020
57DDB9,merger,100,66,4/22/2020
586BD7,conference-call,100,50,4/22/2020
5876DC,earnings,100,50,4/22/2020
594402,earnings,100,50,4/22/2020
596116,earnings,100,50,4/22/2020
59872F,business-contract,100,69,4/22/2020
5A9F54,earnings,100,50,4/22/2020
5A9F54,earnings,100,50,4/22/2020
5A9F54,earnings,100,50,4/22/2020
5A9F54,earnings,100,50,4/22/2020
5AAE17,conference-call,100,50,4/22/2020
5B97B2,earnings,100,50,4/22/2020
5D63F1,earnings,100,50,4/22/2020
5F2FF7,earnings,100,50,4/22/2020
5F2FF7,note-sale,100,52,4/22/2020
5F60CE,earnings,100,50,4/22/2020
5F9CE3,earnings,100,50,4/22/2020
62B1C6,dividend-suspended,100,13,4/22/2020
63E8D5,earnings,100,50,4/22/2020
651C85,executive-appointment,100,54,4/22/2020
6.52E+64,executive-resignation,100,44,4/22/2020
657097,unit-acquisition-acquirer,100,49,4/22/2020
67529E,earnings-positive,100,69,4/22/2020
67529E,earnings-positive,100,69,4/22/2020
67529E,earnings-positive,100,69,4/22/2020
67529E,earnings-positive,100,69,4/22/2020
67529E,earnings-positive,100,69,4/22/2020
67529E,earnings-positive,100,69,4/22/2020
67529E,earnings-positive,100,69,4/22/2020
67529E,earnings-positive,100,69,4/22/2020
6B5379,dividend,100,50,4/22/2020
6CB7F9,earnings,100,50,4/22/2020
6D1ADF,conference-call,100,50,4/22/2020
6DD6BA,earnings,100,50,4/22/2020
6DD6BA,earnings,100,50,4/22/2020
6DD6BA,earnings,100,50,4/22/2020
6E1E61,earnings,100,50,4/22/2020
6E705B,public-offering,100,43,4/22/2020
6F0096,earnings,100,50,4/22/2020
6F0096,earnings,100,50,4/22/2020
6F0096,earnings,100,50,4/22/2020
6F3FA8,conference-call,100,50,4/22/2020
722DE3,business-contract,100,69,4/22/2020
73C521,dividend,100,50,4/22/2020
7410C3,executive-appointment,100,54,4/22/2020
771985,earnings,100,50,4/22/2020
771985,earnings,100,50,4/22/2020
771985,earnings,100,50,4/22/2020
771985,earnings,100,50,4/22/2020
771985,earnings,100,50,4/22/2020
771985,earnings,100,50,4/22/2020
771985,earnings,100,50,4/22/2020
771985,earnings,100,50,4/22/2020
771985,earnings,100,50,4/22/2020
771985,earnings,100,50,4/22/2020
7.83E+79,earnings,100,50,4/22/2020
7B492C,conference-call,100,50,4/22/2020
7F0372,earnings,100,50,4/22/2020
7FD8B9,conference-call,100,50,4/22/2020
8.10E+32,award,100,58,4/22/2020
8275FE,dividend,100,50,4/22/2020
82C202,earnings,100,50,4/22/2020
82E58A,conference-call,100,50,4/22/2020
830BDB,earnings,100,50,4/22/2020
83598E,dividend,100,50,4/22/2020
8377DB,partnership,100,61,4/22/2020
837C04,executive-appointment,100,54,4/22/2020
845533,earnings,100,50,4/22/2020
845655,conference-call,100,50,4/22/2020
845655,conference-call,100,50,4/22/2020
8665BA,earnings,100,50,4/22/2020
873DB9,legal-issues-defendant,100,22,4/22/2020
87B81A,earnings,100,50,4/22/2020
88350F,executive-appointment,100,54,4/22/2020
8A8E41,business-contract,100,69,4/22/2020
8B3B0E,conference-call,100,50,4/22/2020
8C1238,earnings,100,50,4/22/2020
8C1238,earnings,100,50,4/22/2020
8C1238,earnings,100,50,4/22/2020
8C1238,earnings,100,50,4/22/2020
8C1238,earnings,100,50,4/22/2020
8E4250,earnings,100,50,4/22/2020
9196A2,analyst-ratings-set-positive-rater,20,50,4/22/2020
91E5EE,earnings,100,50,4/22/2020
93633B,earnings,100,50,4/22/2020
93633B,earnings,100,50,4/22/2020
93633B,earnings,100,50,4/22/2020
93633B,earnings,100,50,4/22/2020
93D207,dividend,100,50,4/22/2020
940C3D,earnings,100,50,4/22/2020
94208D,conference-call,100,50,4/22/2020
9.65E+09,conference-call,100,50,4/22/2020
9673BD,earnings,100,50,4/22/2020
9673BD,earnings,100,50,4/22/2020
9673BD,earnings,100,50,4/22/2020
96F126,dividend,100,50,4/22/2020
97AAF6,earnings,100,50,4/22/2020
990AD0,dividend,100,50,4/22/2020
9ABD30,earnings,100,50,4/22/2020
9BB35A,earnings-per-share,100,50,4/22/2020
9BB35A,earnings-per-share,100,50,4/22/2020
9BB35A,earnings-per-share,100,50,4/22/2020
9BB35A,dividend,100,50,4/22/2020
9CE4C7,earnings,100,50,4/22/2020
9D30A8,earnings,100,50,4/22/2020
9D5FA4,earnings,100,50,4/22/2020
9E298A,dividend,100,50,4/22/2020
A1E3B3,product-release,100,64,4/22/2020
A1E3B3,product-release,100,64,4/22/2020
A2CAF7,earnings,100,50,4/22/2020
A433A5,conference-call,100,50,4/22/2020
A4A612,earnings,100,50,4/22/2020
A5195E,earnings,100,50,4/22/2020
A63387,earnings,100,50,4/22/2020
A63387,partnership,100,61,4/22/2020
A63820,sanctions-target,100,19,4/22/2020
A8CBDA,earnings-negative,100,33,4/22/2020
A99576,earnings,100,50,4/22/2020
AA5C8E,dividend-up,100,55,4/22/2020
AA5C8E,dividend-up,100,55,4/22/2020
AA5C8E,dividend-up,100,55,4/22/2020
AA5C8E,dividend-up,100,55,4/22/2020
AA5C8E,dividend-up,100,55,4/22/2020
AA5C8E,dividend-up,100,55,4/22/2020
AA5C8E,dividend-up,100,55,4/22/2020
AB7F05,earnings,100,50,4/22/2020
AB7F05,earnings,100,50,4/22/2020
AB7F05,earnings,100,50,4/22/2020
ABEE43,earnings,100,50,4/22/2020
AC642C,conference-call,100,50,4/22/2020
AC642C,conference-call,100,50,4/22/2020
AD3C93,earnings,100,50,4/22/2020
AE7D16,earnings,100,50,4/22/2020
AED6CF,conference-call,100,50,4/22/2020
AFDF2E,dividend,100,50,4/22/2020
B0FE08,dividend-up,100,81,4/22/2020
B0FE08,executive-appointment,100,54,4/22/2020
B4F5F4,conference-call,100,50,4/22/2020
B66928,earnings,100,50,4/22/2020
B96637,conference-call,100,50,4/22/2020
BA218A,earnings-positive,100,69,4/22/2020
BA218A,earnings,100,50,4/22/2020
BA218A,earnings,100,50,4/22/2020
BA218A,earnings,100,50,4/22/2020
BA218A,earnings,100,50,4/22/2020
BA218A,earnings,100,50,4/22/2020
BAAA60,earnings,100,50,4/22/2020
BCC13E,earnings,100,50,4/22/2020
C32A39,dividend,100,50,4/22/2020
C45CE7,earnings,100,50,4/22/2020
C58D71,executive-appointment,100,54,4/22/2020
C9B932,earnings,100,50,4/22/2020
C9B932,earnings,100,50,4/22/2020
C9F39B,earnings,100,50,4/22/2020
C9F39B,earnings,100,50,4/22/2020
C9F39B,earnings,100,50,4/22/2020
C9F39B,earnings,100,50,4/22/2020
C9F39B,earnings,100,50,4/22/2020
C9F39B,earnings,100,50,4/22/2020
CB88B3,earnings,100,50,4/22/2020
CB89EA,earnings,100,50,4/22/2020
CBBFBF,dividend,100,50,4/22/2020
CD4DA8,earnings,100,50,4/22/2020
CD4DA8,earnings,100,50,4/22/2020
CD4DA8,earnings,100,50,4/22/2020
CD4DA8,earnings,100,50,4/22/2020
CD4DA8,earnings,100,50,4/22/2020
CD4DA8,earnings,100,50,4/22/2020
CD4DA8,earnings,100,50,4/22/2020
CD4DA8,earnings,100,50,4/22/2020
CD4DA8,earnings,100,50,4/22/2020
CD4DA8,earnings,100,50,4/22/2020
CDAB24,earnings,100,50,4/22/2020
CE4FD9,award,100,58,4/22/2020
CEC08B,earnings,100,50,4/22/2020
CF3FF9,partnership,100,61,4/22/2020
CF6A5A,earnings,100,50,4/22/2020
CF9054,earnings,100,50,4/22/2020
D21D8A,earnings,100,50,4/22/2020
D21D8A,earnings,100,50,4/22/2020
D21D8A,earnings,100,50,4/22/2020
D21D8A,earnings,100,50,4/22/2020
D21D8A,earnings,100,50,4/22/2020
D21D8A,earnings,100,50,4/22/2020
D21D8A,earnings,100,50,4/22/2020
D29F43,conference-call,100,50,4/22/2020
D33D8C,dividend,100,50,4/22/2020
D393DF,earnings,100,50,4/22/2020
D393DF,earnings,100,50,4/22/2020
D48275,earnings,100,50,4/22/2020
D63B0F,executive-appointment,100,54,4/22/2020
D7A953,earnings,100,50,4/22/2020
D93A25,earnings,100,50,4/22/2020
DA90E1,dividend,100,50,4/22/2020
DC0998,earnings,100,50,4/22/2020
DC0998,earnings,100,50,4/22/2020
DC0998,earnings,100,50,4/22/2020
DC0998,earnings,100,50,4/22/2020
DD7A96,earnings,100,50,4/22/2020
DF11D9,earnings,100,50,4/22/2020
E10D31,conference-call,100,50,4/22/2020
E26FC3,earnings,100,50,4/22/2020
E30B34,earnings,100,50,4/22/2020
E30B34,earnings,100,50,4/22/2020
E30B34,earnings,100,50,4/22/2020
E30B34,earnings,100,50,4/22/2020
E68E62,executive-appointment,100,54,4/22/2020
E90C84,earnings,100,50,4/22/2020
E90C84,earnings,100,50,4/22/2020
EC1AF3,partnership,100,61,4/22/2020
EC1AF3,partnership,100,61,4/22/2020
ED79D9,business-contract,100,69,4/22/2020
ED9576,earnings,100,50,4/22/2020
EDD234,conference-call,100,50,4/22/2020
EEA6B3,dividend,100,50,4/22/2020
F3FCC3,earnings,100,50,4/22/2020
F47871,clinical-trials-start,100,64,4/22/2020
F47871,clinical-trials-start,100,64,4/22/2020
F7902B,earnings,100,50,4/22/2020
FA044A,earnings,100,50,4/22/2020
FACF19,dividend,100,50,4/22/2020
FADF1A,conference-call,100,50,4/22/2020
FB728F,conference-call,100,50,4/22/2020
FD2565,partnership,100,61,4/22/2020
FD2565,partnership,100,61,4/22/2020
FD4E8D,earnings,100,50,4/22/2020
FDF28E,note-sale,100,52,4/22/2020
FF4343,conference-call,100,50,4/22/2020
FF6644,conference-call,100,50,4/22/2020
FFAB4A,dividend,100,50,4/22/2020
FFCD0E,revenues,100,50,4/22/2020
00D6B5,note-sale,100,52,4/23/2020
00FC70,conference-call,100,50,4/23/2020
01B8D6,earnings,100,50,4/23/2020
03D5F9,earnings,100,50,4/23/2020
040DBB,executive-appointment,100,54,4/23/2020
51332,dividend,100,50,4/23/2020
55018,earnings-negative,100,33,4/23/2020
55018,earnings-negative,100,33,4/23/2020
55018,earnings-negative,100,33,4/23/2020
55018,earnings-negative,100,33,4/23/2020
55018,earnings-negative,100,33,4/23/2020
55018,earnings-negative,100,33,4/23/2020
55018,earnings-negative,100,33,4/23/2020
55018,earnings-negative,100,33,4/23/2020
0560D8,dividend,100,50,4/23/2020
061A3B,earnings,100,50,4/23/2020
71860,earnings,100,50,4/23/2020
75172,conference-call,100,50,4/23/2020
0A0CF0,partnership,100,61,4/23/2020
0A59F8,partnership,100,61,4/23/2020
0A59F8,earnings,100,50,4/23/2020
0B2071,dividend,100,50,4/23/2020
0B9E6F,earnings,100,50,4/23/2020
0C355F,earnings,100,50,4/23/2020
0C8D82,earnings,100,50,4/23/2020
105D00,earnings,100,50,4/23/2020
105D00,earnings,100,50,4/23/2020
105D00,earnings,100,50,4/23/2020
105D00,earnings,100,50,4/23/2020
105D00,earnings,100,50,4/23/2020
105D00,earnings,100,50,4/23/2020
1096C6,earnings,100,50,4/23/2020
10C19B,earnings,100,50,4/23/2020
10C19B,earnings,100,50,4/23/2020
10C19B,earnings,100,50,4/23/2020
10C19B,earnings,100,50,4/23/2020
10C19B,earnings,100,50,4/23/2020
10C19B,earnings,100,50,4/23/2020
119CB6,earnings-per-share-positive,100,69,4/23/2020
1201B5,business-contract,100,69,4/23/2020
12DE76,partnership,100,61,4/23/2020
12E454,partnership,100,61,4/23/2020
12E454,partnership,100,61,4/23/2020
13C3E0,earnings,100,50,4/23/2020
14833D,earnings,100,50,4/23/2020
152B9E,dividend,100,50,4/23/2020
15789A,earnings,100,50,4/23/2020
15B10D,partnership,100,61,4/23/2020
17EDA5,business-contract,100,69,4/23/2020
182B8C,earnings,100,50,4/23/2020
18D9FA,conference-call,100,50,4/23/2020
19BF16,legal-issues-defendant,100,22,4/23/2020
19BF16,legal-issues-defendant,100,22,4/23/2020
1AF7E2,earnings,100,50,4/23/2020
1AF7E2,earnings,100,50,4/23/2020
1CD09C,conference-call,100,50,4/23/2020
1CF3A8,conference-call,100,50,4/23/2020
1D1B07,note-sale,100,52,4/23/2020
1D1B07,note-sale,100,52,4/23/2020
1E1125,earnings,100,50,4/23/2020
1EBF8D,clinical-trials-filed,100,60,4/23/2020
1F464F,earnings-guidance-suspended,100,29,4/23/2020
1FAF22,conference-participant,100,50,4/23/2020
1FCC00,executive-appointment,100,54,4/23/2020
1FCC00,executive-appointment,100,54,4/23/2020
2093B1,earnings,100,50,4/23/2020
2096DE,earnings,100,50,4/23/2020
20DC4E,earnings,100,50,4/23/2020
21268E,conference-call,100,50,4/23/2020
219B21,conference-call,100,50,4/23/2020
223216,ebitda-up,100,56,4/23/2020
228D42,partnership,100,61,4/23/2020
24D81E,earnings,100,50,4/23/2020
24FA23,earnings,100,50,4/23/2020
25102A,note-sale,100,52,4/23/2020
25102A,note-sale,100,52,4/23/2020
25A6CC,earnings,100,50,4/23/2020
25A6CC,earnings,100,50,4/23/2020
25A6CC,earnings,100,50,4/23/2020
25A6CC,earnings,100,50,4/23/2020
272472,earnings,100,50,4/23/2020
272704,dividend,100,50,4/23/2020
275300,legal-issues-defendant,100,22,4/23/2020
284289,earnings,100,50,4/23/2020
28AF37,earnings,100,50,4/23/2020
2A1009,business-contract,100,69,4/23/2020
2A4131,earnings,100,50,4/23/2020
2B0AF4,legal-issues-defendant,100,22,4/23/2020
2B0AF4,legal-issues-defendant,100,22,4/23/2020
2B5483,earnings,100,50,4/23/2020
2CC60C,note-sale,100,52,4/23/2020
2D2D43,note-sale,100,52,4/23/2020
2D981A,business-contract,100,69,4/23/2020
2DA92D,earnings,100,50,4/23/2020
2F7474,earnings,100,50,4/23/2020
2F960F,earnings,100,50,4/23/2020
2F98A5,dividend,100,50,4/23/2020
31553A,earnings,100,50,4/23/2020
31553A,earnings,100,50,4/23/2020
31553A,earnings,100,50,4/23/2020
3159AA,conference-call,100,50,4/23/2020
31666F,earnings,100,50,4/23/2020
319BE2,conference-call,100,50,4/23/2020
31F25C,board-meeting,100,51,4/23/2020
3471C0,earnings,100,50,4/23/2020
3471C0,earnings,100,50,4/23/2020
3471C0,earnings,100,50,4/23/2020
3471C0,earnings,100,50,4/23/2020
34A959,earnings,100,50,4/23/2020
366A08,note-sale,100,52,4/23/2020
367434,earnings,100,50,4/23/2020
372037,legal-issues-defendant,100,22,4/23/2020
39692D,note-sale,100,52,4/23/2020
3A3447,earnings,100,50,4/23/2020
3A3948,earnings,100,50,4/23/2020
3E39A5,dividend,100,50,4/23/2020
3F6A9C,conference-call,100,50,4/23/2020
4290EF,dividend,100,50,4/23/2020
435ACE,dividend,100,50,4/23/2020
44740A,conference-call,100,50,4/23/2020
449A26,earnings-positive,100,69,4/23/2020
449A26,dividend,100,50,4/23/2020
453282,earnings-per-share-positive,100,69,4/23/2020
45ABCC,product-release,100,64,4/23/2020
47B4CC,conference-call,100,50,4/23/2020
47FCF2,earnings,100,50,4/23/2020
487B7A,dividend,100,50,4/23/2020
48F795,earnings,100,50,4/23/2020
494EB9,legal-issues-defendant,100,22,4/23/2020
4AC91D,partnership,100,61,4/23/2020
4C1FA1,earnings,100,50,4/23/2020
4C1FA1,legal-issues-defendant,100,22,4/23/2020
4C2F17,earnings,100,50,4/23/2020
4C7DB5,earnings,100,50,4/23/2020
4E913D,earnings,100,50,4/23/2020
4EE167,earnings,100,50,4/23/2020
4EE167,earnings,100,50,4/23/2020
514067,revenue-guidance,100,50,4/23/2020
5225A4,earnings,100,50,4/23/2020
5225A4,earnings,100,50,4/23/2020
5225A4,earnings,100,50,4/23/2020
5225A4,earnings,100,50,4/23/2020
5225A4,earnings,100,50,4/23/2020
53F491,product-release,100,64,4/23/2020
53F491,award,100,58,4/23/2020
556A57,dividend,100,50,4/23/2020
556F08,earnings,100,50,4/23/2020
57356F,earnings,100,50,4/23/2020
57356F,earnings,100,50,4/23/2020
57356F,earnings,100,50,4/23/2020
57DDB9,conference-call,100,50,4/23/2020
59872F,partnership,100,61,4/23/2020
5A64D5,dividend,100,50,4/23/2020
5B3FA2,earnings,100,50,4/23/2020
5B7739,executive-appointment,100,54,4/23/2020
5BE42C,dividend,100,50,4/23/2020
5BFE94,dividend,100,50,4/23/2020
5DE5A5,dividend-up,100,81,4/23/2020
5E6959,partnership,100,61,4/23/2020
5FE4B6,earnings,100,50,4/23/2020
5FE4B6,earnings,100,50,4/23/2020
6137BF,earnings,100,50,4/23/2020
6137BF,earnings,100,50,4/23/2020
622037,dividend,100,50,4/23/2020
62B1C6,dividend-suspended,100,13,4/23/2020
636931,earnings,100,50,4/23/2020
6474BA,earnings-positive,100,69,4/23/2020
6474BA,earnings,100,50,4/23/2020
6474BA,earnings,100,50,4/23/2020
6474BA,earnings,100,50,4/23/2020
6474BA,earnings,100,50,4/23/2020
6474BA,earnings,100,50,4/23/2020
6474BA,earnings,100,50,4/23/2020
6474BA,earnings,100,50,4/23/2020
651C85,conference-call,100,50,4/23/2020
662682,dividend,100,50,4/23/2020
66CB62,shareholder-rights-plan,100,43,4/23/2020
694749,earnings,100,50,4/23/2020
6A3C35,earnings,100,50,4/23/2020
6B5379,earnings,100,50,4/23/2020
6BF593,conference-call,100,50,4/23/2020
6C987C,dividend,100,50,4/23/2020
6CD55A,earnings,100,50,4/23/2020
6CF43C,earnings,100,50,4/23/2020
6D6B40,partnership,100,61,4/23/2020
6D6B40,partnership,100,61,4/23/2020
6DBBBC,conference-call,100,50,4/23/2020
6.00E+19,conference-call,100,50,4/23/2020
6EB9DA,earnings,100,50,4/23/2020
6EB9DA,earnings,100,50,4/23/2020
6EB9DA,earnings,100,50,4/23/2020
713810,product-release,100,64,4/23/2020
7520CC,earnings,100,50,4/23/2020
7712CB,exchange-noncompliance,100,24,4/23/2020
7712CB,earnings,100,50,4/23/2020
7734AC,earnings,100,50,4/23/2020
78A1BB,earnings,100,50,4/23/2020
78A1BB,earnings,100,50,4/23/2020
78A1BB,earnings,100,50,4/23/2020
78A1BB,earnings,100,50,4/23/2020
78A1BB,earnings,100,50,4/23/2020
791D59,earnings,100,50,4/23/2020
7A0EC4,partnership,100,61,4/23/2020
7B1E50,earnings,100,50,4/23/2020
7D5FD6,earnings,100,50,4/23/2020
7F3665,earnings,100,50,4/23/2020
7F9E16,conference-call,100,50,4/23/2020
803FED,conference-call,100,50,4/23/2020
80D744,earnings,100,50,4/23/2020
817ED9,note-sale,100,52,4/23/2020
82B57E,earnings,100,50,4/23/2020
82F088,conference-call,100,50,4/23/2020
838ADD,earnings,100,50,4/23/2020
8614A2,earnings,100,50,4/23/2020
86A1B9,business-contract,100,69,4/23/2020
873DB9,legal-issues-defendant,100,22,4/23/2020
8817D5,earnings,100,50,4/23/2020
8817D5,earnings,100,50,4/23/2020
895D56,operating-earnings,100,50,4/23/2020
8A8E41,earnings,100,50,4/23/2020
8B2C4A,earnings,100,50,4/23/2020
8B2C4A,earnings,100,50,4/23/2020
8B2C4A,earnings,100,50,4/23/2020
8B2C4A,earnings,100,50,4/23/2020
8B2C4A,earnings,100,50,4/23/2020
8B2C4A,earnings,100,50,4/23/2020
8B2C4A,earnings,100,50,4/23/2020
8C84DF,earnings,100,50,4/23/2020
8D5145,earnings,100,50,4/23/2020
8DBBE6,partnership,100,61,4/23/2020
8DBBE6,partnership,100,61,4/23/2020
8DE56F,earnings,100,50,4/23/2020
8DE56F,earnings,100,50,4/23/2020
8DE74B,earnings,100,50,4/23/2020
8E8E6E,note-sale,100,52,4/23/2020
8E8E6E,note-sale,100,52,4/23/2020
8F3BCC,earnings-per-share-positive,100,69,4/23/2020
8F8F2F,conference-call,100,50,4/23/2020
922F0C,earnings-per-share,100,50,4/23/2020
92D6A5,dividend,100,50,4/23/2020
943239,earnings,100,50,4/23/2020
947B0B,executive-appointment,100,54,4/23/2020
966ACE,earnings,100,50,4/23/2020
97644E,earnings,100,50,4/23/2020
990AD0,conference-organizer,100,57,4/23/2020
9.92E+94,earnings,100,50,4/23/2020
9.92E+94,earnings,100,50,4/23/2020
9.92E+94,earnings,100,50,4/23/2020
9.97E+09,earnings,100,50,4/23/2020
9A2760,earnings,100,50,4/23/2020
9B71A7,legal-issues-defendant,100,22,4/23/2020
9CA432,conference-call,100,50,4/23/2020
9CDA4F,earnings,100,50,4/23/2020
9D307D,earnings,100,50,4/23/2020
9E98F2,partnership,100,61,4/23/2020
9F03CF,earnings,100,50,4/23/2020
9F03CF,dividend,100,50,4/23/2020
9F71E5,executive-appointment,100,54,4/23/2020
9FD2D9,conference-call,100,50,4/23/2020
A02FB1,earnings,100,50,4/23/2020
A29DBD,executive-appointment,100,54,4/23/2020
A41450,earnings,100,50,4/23/2020
A48593,conference-call,100,50,4/23/2020
A4D173,earnings,100,50,4/23/2020
A4D173,earnings,100,50,4/23/2020
A5B913,earnings,100,50,4/23/2020
A5B913,earnings,100,50,4/23/2020
A666C8,earnings,100,50,4/23/2020
A6828A,partnership,100,61,4/23/2020
A79F7D,business-contract,100,69,4/23/2020
A7CCF0,executive-resignation,100,44,4/23/2020
AABEA0,dividend,100,50,4/23/2020
AB4A7E,conference-call,100,50,4/23/2020
AD3008,earnings,100,50,4/23/2020
AD375D,earnings,100,50,4/23/2020
ADF092,business-contract,100,69,4/23/2020
AE0CCE,executive-appointment,100,54,4/23/2020
B076A1,conference-call,100,50,4/23/2020
B09B1F,conference-call,100,50,4/23/2020
B6843B,earnings,100,50,4/23/2020
B7202A,conference-call,100,50,4/23/2020
B8DD94,earnings,100,50,4/23/2020
B96637,earnings-up,100,68,4/23/2020
B96637,earnings-up,100,68,4/23/2020
BA0442,earnings,100,50,4/23/2020
BAAA60,dividend,100,50,4/23/2020
BF79F5,earnings,100,50,4/23/2020
BF79F5,earnings,100,50,4/23/2020
C037A8,conference-call,100,50,4/23/2020
C16A8F,dividend,100,50,4/23/2020
C29715,earnings,100,50,4/23/2020
C29715,earnings,100,50,4/23/2020
C32A39,earnings,100,50,4/23/2020
C38440,earnings,100,50,4/23/2020
C598D7,dividend,100,50,4/23/2020
C7859D,business-contract,100,69,4/23/2020
C9E107,earnings,100,50,4/23/2020
C9E107,dividend,100,50,4/23/2020
C9E4EC,earnings,100,50,4/23/2020
CFD4B6,conference-call,100,50,4/23/2020
D13F1C,executive-appointment,100,54,4/23/2020
D17C1B,earnings,100,50,4/23/2020
D4AC65,conference-call,100,50,4/23/2020
D518D8,legal-issues-defendant,100,22,4/23/2020
D57D99,earnings,100,50,4/23/2020
D57D99,facility-open,100,65,4/23/2020
D63B0F,conference-call,100,50,4/23/2020
D721C6,earnings-positive,100,69,4/23/2020
D7F569,earnings,100,50,4/23/2020
D8F347,earnings-up,100,68,4/23/2020
D8F347,earnings,100,50,4/23/2020
D8F347,earnings,100,50,4/23/2020
D90F43,partnership,100,61,4/23/2020
DA48E4,earnings-per-share,100,50,4/23/2020
DA90E1,earnings,100,50,4/23/2020
DBCA3F,earnings,100,50,4/23/2020
DD7A96,executive-appointment,100,54,4/23/2020
DDC415,earnings,100,50,4/23/2020
DDC415,earnings,100,50,4/23/2020
E05DC8,earnings,100,50,4/23/2020
E09556,product-release,100,64,4/23/2020
E10D31,dividend,100,50,4/23/2020
E1BD05,earnings,100,50,4/23/2020
E2CFD2,conference-call,100,50,4/23/2020
E2F66E,conference-call,100,50,4/23/2020
E393B0,earnings,100,50,4/23/2020
E3A829,earnings,100,50,4/23/2020
E3E68E,product-release,100,64,4/23/2020
E3E68E,product-release,100,64,4/23/2020
E3E68E,note-sale,100,52,4/23/2020
E3E68E,note-sale,100,52,4/23/2020
E3E68E,note-sale,100,52,4/23/2020
E3E68E,note-sale,100,52,4/23/2020
E49AA3,earnings,100,50,4/23/2020
E5752F,conference-participant,100,50,4/23/2020
E68C3D,earnings,100,50,4/23/2020
E829E8,board-meeting,100,51,4/23/2020
E8B21D,earnings,100,50,4/23/2020
E8B21D,earnings,100,50,4/23/2020
E8B21D,earnings,100,50,4/23/2020
E8B21D,earnings,100,50,4/23/2020
E8B315,earnings-positive,100,69,4/23/2020
E94704,dividend,100,50,4/23/2020
E96E0B,earnings,100,50,4/23/2020
E99180,earnings,100,50,4/23/2020
EA4E68,earnings,100,50,4/23/2020
EAA0A7,earnings,100,50,4/23/2020
EB2F14,earnings,100,50,4/23/2020
EBD89A,business-contract,100,69,4/23/2020
ECD263,note-sale,100,52,4/23/2020
ED2EFD,dividend,100,50,4/23/2020
ED8676,earnings-positive,100,69,4/23/2020
ED8676,earnings-positive,100,69,4/23/2020
ED8676,earnings-positive,100,69,4/23/2020
ED8676,earnings-positive,100,69,4/23/2020
ED8676,earnings-positive,100,69,4/23/2020
ED8676,earnings-positive,100,69,4/23/2020
ED8676,earnings-positive,100,69,4/23/2020
ED8676,earnings-positive,100,69,4/23/2020
ED8676,earnings-positive,100,69,4/23/2020
ED8676,dividend,100,50,4/23/2020
EF1AD9,dividend,100,50,4/23/2020
EF1AD9,earnings,100,50,4/23/2020
EF1AD9,earnings,100,50,4/23/2020
EF1AD9,earnings,100,50,4/23/2020
EF25A5,earnings,100,50,4/23/2020
F0027C,earnings,100,50,4/23/2020
F0A9DE,earnings,100,50,4/23/2020
F0B877,earnings,100,50,4/23/2020
F30508,earnings,100,50,4/23/2020
F30508,earnings,100,50,4/23/2020
F30508,earnings,100,50,4/23/2020
F30508,earnings,100,50,4/23/2020
F30508,earnings,100,50,4/23/2020
F30508,regulatory-product-application,100,69,4/23/2020
F5349B,partnership,100,61,4/23/2020
F57F6F,earnings,100,50,4/23/2020
F6A945,earnings,100,50,4/23/2020
F7935D,earnings,100,50,4/23/2020
F8C5D7,conference-call,100,50,4/23/2020
FBD92D,earnings,100,50,4/23/2020
FC1F9D,earnings,100,50,4/23/2020
FD2565,conference-call,100,50,4/23/2020
FDF28E,note-sale,100,52,4/23/2020
FFE543,earnings,100,50,4/23/2020
002A99,earnings,100,50,4/24/2020
0157B1,product-release,100,64,4/24/2020
02870F,conference-call,100,50,4/24/2020
099C88,conference-call,100,50,4/24/2020
0A59F8,partnership,100,61,4/24/2020
0F91FC,conference-call,100,50,4/24/2020
106394,asset-sale,100,62,4/24/2020
106394,asset-sale,100,62,4/24/2020
1201B5,earnings,100,50,4/24/2020
156A99,earnings,100,50,4/24/2020
16B882,earnings,100,50,4/24/2020
19BF16,legal-issues-defendant,100,22,4/24/2020
19C105,earnings,100,50,4/24/2020
19C105,earnings,100,50,4/24/2020
19C105,earnings,100,50,4/24/2020
19CAC7,dividend,100,50,4/24/2020
1FC422,earnings,100,50,4/24/2020
20403D,buybacks,100,74,4/24/2020
221783,earnings,100,50,4/24/2020
2262BD,earnings,100,50,4/24/2020
251988,executive-resignation,100,44,4/24/2020
26F31D,earnings,100,50,4/24/2020
272472,dividend,100,50,4/24/2020
275300,legal-issues-defendant,100,22,4/24/2020
28DCF3,earnings,100,50,4/24/2020
2B0AF4,legal-issues-defendant,100,22,4/24/2020
30AB63,earnings-revision,100,29,4/24/2020
339F20,earnings-up,100,68,4/24/2020
34A959,unit-acquisition-acquiree,100,76,4/24/2020
366A08,note-sale,100,52,4/24/2020
372037,legal-issues-defendant,100,22,4/24/2020
383ADA,earnings,100,50,4/24/2020
3A94DF,acquisition-completed-acquirer,100,49,4/24/2020
3D9999,dividend,100,50,4/24/2020
3F4668,fraud-defendant,100,20,4/24/2020
3F4668,legal-issues-defendant,100,22,4/24/2020
4017AD,earnings,100,50,4/24/2020
408380,earnings,100,50,4/24/2020
414FFF,note-sale,100,52,4/24/2020
416291,conference-call,100,50,4/24/2020
4398A2,executive-appointment,100,54,4/24/2020
449217,earnings-positive,100,69,4/24/2020
449217,earnings,100,50,4/24/2020
449217,earnings,100,50,4/24/2020
449217,earnings,100,50,4/24/2020
449217,earnings,100,50,4/24/2020
45ABCC,executive-appointment,100,54,4/24/2020
494EB9,legal-issues-defendant,100,22,4/24/2020
4A3438,conference-call,100,50,4/24/2020
4B5054,earnings,100,50,4/24/2020
4C37C5,revenues,100,50,4/24/2020
4C37C5,revenues,100,50,4/24/2020
4C37C5,revenues,100,50,4/24/2020
4D203E,earnings,100,50,4/24/2020
4D203E,earnings,100,50,4/24/2020
4EE167,legal-issues-defendant,100,22,4/24/2020
519FE0,unit-acquisition-acquirer,100,49,4/24/2020
53F491,dividend,100,50,4/24/2020
543900,revenue-up,100,94,4/24/2020
54A646,earnings-positive,100,69,4/24/2020
54A646,earnings-positive,100,69,4/24/2020
54A646,earnings-positive,100,69,4/24/2020
54A646,earnings-positive,100,69,4/24/2020
54DF47,conference-call,100,50,4/24/2020
553949,conference-call,100,50,4/24/2020
58B46F,dividend,100,50,4/24/2020
58B46F,board-meeting,100,51,4/24/2020
5B35C7,earnings,100,50,4/24/2020
5B35C7,earnings,100,50,4/24/2020
5D41E4,conference-call,100,50,4/24/2020
619882,credit-extension-provider,100,57,4/24/2020
619882,credit-extension-provider,100,57,4/24/2020
633043,earnings,100,50,4/24/2020
641F17,dividend,100,50,4/24/2020
69CE71,conference-call,100,50,4/24/2020
6B0E45,dividend,100,50,4/24/2020
6C6D73,regulatory-product-application,100,69,4/24/2020
6C6D73,conference-call,100,50,4/24/2020
6CC55E,executive-appointment,100,54,4/24/2020
6E705B,conference-call,100,50,4/24/2020
72EF75,dividend,100,50,4/24/2020
72EF75,earnings,100,50,4/24/2020
7520CC,executive-appointment,100,54,4/24/2020
76B926,earnings,100,50,4/24/2020
76CEFB,earnings,100,50,4/24/2020
77B8E9,partnership,100,61,4/24/2020
7B0BA6,dividend,100,50,4/24/2020
7B1156,conference-call,100,50,4/24/2020
7B4B91,earnings,100,50,4/24/2020
7B6EB1,board-meeting,100,51,4/24/2020
81EAD4,conference-call,100,50,4/24/2020
86DFBD,earnings,100,50,4/24/2020
873DB9,legal-issues-defendant,100,22,4/24/2020
877C0C,earnings,100,50,4/24/2020
8C6C1B,donation,100,54,4/24/2020
8F3231,earnings,100,50,4/24/2020
9004C4,conference-call,100,50,4/24/2020
9004C4,conference-call,100,50,4/24/2020
9.31E+77,conference-organizer,100,57,4/24/2020
997348,earnings,100,50,4/24/2020
997348,earnings,100,50,4/24/2020
9AF3DC,dividend,100,50,4/24/2020
9B5968,board-meeting,100,51,4/24/2020
9B5968,board-meeting,100,51,4/24/2020
9CA432,conference-call,100,50,4/24/2020
9EED50,executive-appointment,100,54,4/24/2020
A3230E,ipo-pricing,100,50,4/24/2020
A38F30,business-contract,100,69,4/24/2020
A79F7D,public-offering,100,43,4/24/2020
A871B0,earnings,100,50,4/24/2020
AABEA0,earnings,100,50,4/24/2020
AAC8B6,executive-appointment,100,54,4/24/2020
AAC8B6,executive-appointment,100,54,4/24/2020
AEF2C3,board-meeting,100,51,4/24/2020
B9764A,earnings,100,50,4/24/2020
BDD12C,earnings,100,50,4/24/2020
BDF2BD,conference-call,100,50,4/24/2020
BFE02C,executive-appointment,100,54,4/24/2020
C01737,earnings,100,50,4/24/2020
C41C25,note-sale,100,52,4/24/2020
C4706C,conference-call,100,50,4/24/2020
C8257F,conference-call,100,50,4/24/2020
C8923A,earnings,100,50,4/24/2020
C98CDB,earnings,100,50,4/24/2020
CC339B,earnings,100,50,4/24/2020
CD06A2,merger-regulatory-approval,100,81,4/24/2020
CFF97C,credit-rating-downgrade-rater,20,50,4/24/2020
CFF97C,credit-rating-downgrade-rater,20,50,4/24/2020
D13F1C,earnings,100,50,4/24/2020
D1C26F,partnership,100,61,4/24/2020
D29B44,earnings,100,50,4/24/2020
D3DE34,executive-appointment,100,54,4/24/2020
D3DE34,executive-appointment,100,54,4/24/2020
D518D8,legal-issues-defendant,100,22,4/24/2020
D7F569,dividend,100,50,4/24/2020
D7F569,executive-appointment,100,54,4/24/2020
D8ECA1,earnings,100,50,4/24/2020
DA0A9E,earnings,100,50,4/24/2020
DBEF02,earnings,100,50,4/24/2020
E5F0A8,earnings-positive,100,69,4/24/2020
E5F0A8,earnings,100,50,4/24/2020
E5F0A8,earnings,100,50,4/24/2020
E5F0A8,earnings,100,50,4/24/2020
E5F0A8,earnings,100,50,4/24/2020
E6E012,dividend,100,50,4/24/2020
E6E012,dividend,100,50,4/24/2020
EDF5CA,conference-call,100,50,4/24/2020
EE6F1C,dividend,100,50,4/24/2020
EF77A3,dividend,100,50,4/24/2020
F02170,executive-appointment,100,54,4/24/2020
F05B1B,executive-appointment,100,54,4/24/2020
F294DD,dividend,100,50,4/24/2020
F4D241,earnings,100,50,4/24/2020
F6DE54,board-meeting,100,51,4/24/2020
F6FA6A,earnings,100,50,4/24/2020
F80389,conference-call,100,50,4/24/2020
F95726,merger-completed,100,66,4/24/2020
FC1B7B,award,100,58,4/24/2020
FD0CA4,dividend,100,50,4/24/2020
FDC08C,earnings,100,50,4/24/2020
FDC08C,earnings,100,50,4/24/2020
FDC08C,earnings,100,50,4/24/2020
FDC08C,earnings,100,50,4/24/2020
FDC08C,earnings,100,50,4/24/2020
FDF28E,unit-acquisition-completed-acquirer,100,49,4/24/2020
FE7A63,earnings,100,50,4/24/2020
FE7A63,earnings,100,50,4/24/2020
FE7A63,earnings,100,50,4/24/2020
FE7A63,earnings,100,50,4/24/2020
FE7A63,earnings,100,50,4/24/2020
FE7A63,earnings,100,50,4/24/2020
FE7A63,earnings,100,50,4/24/2020
414FFF,note-sale,100,52,4/25/2020
55438C,joint-venture-terminated,100,38,4/25/2020
AA98ED,partnership,100,61,4/25/2020
D518D8,legal-issues-defendant,100,22,4/26/2020
03FAA6,earnings,100,50,4/27/2020
0490C6,earnings,100,50,4/27/2020
083F72,conference-call,100,50,4/27/2020
08A40F,earnings-per-share-positive,100,69,4/27/2020
08A40F,earnings-per-share-positive,100,69,4/27/2020
08A40F,earnings-per-share-positive,100,69,4/27/2020
08A40F,earnings-per-share-positive,100,69,4/27/2020
08A40F,earnings-per-share-positive,100,69,4/27/2020
08A40F,earnings-per-share-positive,100,69,4/27/2020
08A40F,earnings-per-share-positive,100,69,4/27/2020
095A04,earnings,100,50,4/27/2020
099A02,executive-resignation,100,44,4/27/2020
0A59F8,product-release,100,64,4/27/2020
0A6824,dividend,100,50,4/27/2020
0A7650,earnings,100,50,4/27/2020
0BA8CE,earnings,100,50,4/27/2020
0CC62B,earnings,100,50,4/27/2020
0CC62B,earnings,100,50,4/27/2020
0CC62B,earnings,100,50,4/27/2020
0CC62B,earnings,100,50,4/27/2020
0CC62B,earnings,100,50,4/27/2020
0D26E0,earnings-positive,100,69,4/27/2020
0E5619,regulatory-product-approval-granted,100,81,4/27/2020
10673F,earnings,100,50,4/27/2020
10673F,earnings,100,50,4/27/2020
108FDA,earnings,100,50,4/27/2020
1201B5,business-contract,100,69,4/27/2020
139303,board-meeting,100,51,4/27/2020
152FA5,clinical-trials-positive,100,87,4/27/2020
182546,dividend,100,50,4/27/2020
18EC17,executive-appointment,100,54,4/27/2020
19BF16,legal-issues-defendant,100,22,4/27/2020
19BF16,legal-issues-defendant,100,22,4/27/2020
1E7785,conference-call,100,50,4/27/2020
1EBF8D,partnership,100,61,4/27/2020
1FAF22,conference-participant,100,50,4/27/2020
20DC4E,dividend,100,50,4/27/2020
221445,earnings,100,50,4/27/2020
221AD7,legal-issues-defendant,100,22,4/27/2020
228D42,partnership,100,61,4/27/2020
25102A,product-release,100,64,4/27/2020
25102A,product-release,100,64,4/27/2020
25102A,board-meeting,100,51,4/27/2020
2667B6,dividend,100,50,4/27/2020
26DC29,award,100,58,4/27/2020
275300,legal-issues-defendant,100,22,4/27/2020
278C18,earnings,100,50,4/27/2020
28DCF3,earnings,100,50,4/27/2020
295F9F,conference-call,100,50,4/27/2020
29A4CC,earnings,100,50,4/27/2020
2A9C0A,earnings-positive,100,69,4/27/2020
2A9C0A,earnings,100,50,4/27/2020
2A9C0A,earnings,100,50,4/27/2020
2A9C0A,earnings,100,50,4/27/2020
2A9C0A,earnings,100,50,4/27/2020
2B0AF4,legal-issues-defendant,100,22,4/27/2020
2B0AF4,legal-issues-defendant,100,22,4/27/2020
2B0AF4,board-meeting,100,51,4/27/2020
2D2D43,credit-extension-recipient,100,69,4/27/2020
2DB344,earnings,100,50,4/27/2020
2F1299,note-sale,100,52,4/27/2020
306623,conference-call,100,50,4/27/2020
319BE2,dividend,100,50,4/27/2020
319BE2,earnings,100,50,4/27/2020
339F20,earnings,100,50,4/27/2020
343996,earnings,100,50,4/27/2020
370C50,earnings,100,50,4/27/2020
396D7C,earnings,100,50,4/27/2020
39FB23,earnings,100,50,4/27/2020
39FB23,earnings,100,50,4/27/2020
39FB23,earnings,100,50,4/27/2020
3A4BDB,earnings-positive,100,69,4/27/2020
3B50FE,partnership,100,61,4/27/2020
3CCC90,executive-appointment,100,54,4/27/2020
3EE65E,award,100,58,4/27/2020
3F4668,legal-issues-defendant,100,22,4/27/2020
3FBC9B,executive-appointment,100,54,4/27/2020
407878,conference-call,100,50,4/27/2020
41A93D,earnings,100,50,4/27/2020
43A060,earnings,100,50,4/27/2020
4455C4,conference-call,100,50,4/27/2020
448BF3,earnings,100,50,4/27/2020
450ECB,conference-call,100,50,4/27/2020
4591D3,revenues,100,50,4/27/2020
460C93,earnings,100,50,4/27/2020
49914B,earnings,100,50,4/27/2020
4A6F00,partnership,100,61,4/27/2020
4B3DC9,earnings,100,50,4/27/2020
4B3DC9,earnings,100,50,4/27/2020
4B3DC9,earnings,100,50,4/27/2020
4B3DC9,earnings,100,50,4/27/2020
4B3DC9,earnings,100,50,4/27/2020
4B3DC9,earnings,100,50,4/27/2020
4B3DC9,earnings,100,50,4/27/2020
4B3DC9,earnings,100,50,4/27/2020
4B3DC9,earnings,100,50,4/27/2020
4B3DC9,earnings,100,50,4/27/2020
4B3DC9,earnings,100,50,4/27/2020
4B3DC9,earnings,100,50,4/27/2020
4F9487,earnings-positive,100,69,4/27/2020
4F9487,earnings,100,50,4/27/2020
4F9487,earnings,100,50,4/27/2020
4F9487,earnings,100,50,4/27/2020
4F9487,earnings,100,50,4/27/2020
4F9487,earnings,100,50,4/27/2020
4F9487,earnings,100,50,4/27/2020
4F9487,earnings,100,50,4/27/2020
51E682,earnings,100,50,4/27/2020
5480A7,earnings,100,50,4/27/2020
5546DA,earnings,100,50,4/27/2020
5675EB,dividend,100,50,4/27/2020
5675EB,earnings,100,50,4/27/2020
56EA2B,revenue-up,100,71,4/27/2020
57CAAB,partnership,100,61,4/27/2020
586BD7,earnings,100,50,4/27/2020
589F5A,earnings,100,50,4/27/2020
58CA9A,product-release,100,64,4/27/2020
59B229,earnings,100,50,4/27/2020
59B229,earnings,100,50,4/27/2020
59B229,earnings,100,50,4/27/2020
59B229,earnings,100,50,4/27/2020
5A423F,conference-participant,100,50,4/27/2020
5A53BF,earnings,100,50,4/27/2020
5A64D5,conference-call,100,50,4/27/2020
5AAE17,executive-appointment,100,54,4/27/2020
5BE42C,earnings,100,50,4/27/2020
5C8D61,earnings,100,50,4/27/2020
5C8D61,earnings,100,50,4/27/2020
5C8D61,earnings,100,50,4/27/2020
5D02B7,earnings,100,50,4/27/2020
5F2FF7,facility-open,100,65,4/27/2020
610D47,earnings,100,50,4/27/2020
619882,partnership,100,61,4/27/2020
619882,conference-organizer,100,57,4/27/2020
62CDDE,conference-call,100,50,4/27/2020
657097,earnings,100,50,4/27/2020
665D7D,debt-extension-recipient,100,73,4/27/2020
66667F,unit-acquisition-completed-acquirer,100,49,4/27/2020
66A667,conference-participant,100,50,4/27/2020
66A667,conference-participant,100,50,4/27/2020
68B03F,earnings,100,50,4/27/2020
69CE71,product-release,100,64,4/27/2020
69CE71,product-release,100,64,4/27/2020
6A01DF,earnings,100,50,4/27/2020
6BC6F9,earnings,100,50,4/27/2020
6BDA0C,conference-call,100,50,4/27/2020
6D4636,earnings,100,50,4/27/2020
6D4636,earnings,100,50,4/27/2020
6D4636,earnings,100,50,4/27/2020
6DDA15,earnings,100,50,4/27/2020
6-Dec-05,clinical-trials,100,56,4/27/2020
701531,earnings,100,50,4/27/2020
709AED,dividend,100,50,4/27/2020
709AED,earnings,100,50,4/27/2020
709AED,earnings,100,50,4/27/2020
709AED,earnings,100,50,4/27/2020
717DB4,earnings,100,50,4/27/2020
7.44E+09,earnings,100,50,4/27/2020
7448A3,earnings,100,50,4/27/2020
748EB6,conference-call,100,50,4/27/2020
762A3E,executive-appointment,100,54,4/27/2020
762A3E,dividend,100,50,4/27/2020
76BD96,note-sale,100,52,4/27/2020
76F067,earnings,100,50,4/27/2020
79340A,earnings,100,50,4/27/2020
7B492C,unit-acquisition-completed-acquiree,100,67,4/27/2020
7BAAE7,earnings-per-share-positive,100,69,4/27/2020
7BAAE7,earnings,100,50,4/27/2020
7C75FD,dividend,100,50,4/27/2020
7F3FBC,operating-earnings,100,50,4/27/2020
7FC386,earnings,100,50,4/27/2020
80C400,conference-call,100,50,4/27/2020
824CCA,earnings,100,50,4/27/2020
83066C,earnings,100,50,4/27/2020
83066C,earnings,100,50,4/27/2020
8377DB,earnings,100,50,4/27/2020
83B1C8,earnings,100,50,4/27/2020
855DF7,conference-call,100,50,4/27/2020
85AD00,earnings-per-share-positive,100,69,4/27/2020
86AA9C,conference-call,100,50,4/27/2020
873DB9,legal-issues-defendant,100,22,4/27/2020
8802B4,earnings,100,50,4/27/2020
880C0C,conference-call,100,50,4/27/2020
885758,earnings,100,50,4/27/2020
89FBB1,conference-call,100,50,4/27/2020
8D4AE6,earnings,100,50,4/27/2020
8D4AE6,earnings,100,50,4/27/2020
8D4AE6,earnings,100,50,4/27/2020
8D4AE6,earnings,100,50,4/27/2020
8D4AE6,earnings,100,50,4/27/2020
8D4AE6,dividend,100,50,4/27/2020
8DDA23,dividend,100,50,4/27/2020
8E93A4,earnings,100,50,4/27/2020
8F6995,dividend,100,50,4/27/2020
8FE7A5,earnings,100,50,4/27/2020
902255,earnings,100,50,4/27/2020
915E7B,conference-call,100,50,4/27/2020
92D757,index-listing,100,76,4/27/2020
931AE7,public-offering,100,43,4/27/2020
95DE39,earnings-positive,100,69,4/27/2020
95DE39,earnings-positive,100,69,4/27/2020
95DE39,earnings-positive,100,69,4/27/2020
95DE39,earnings-positive,100,69,4/27/2020
968103,earnings,100,50,4/27/2020
97B027,conference-call,100,50,4/27/2020
986AF6,conference-call,100,50,4/27/2020
990AD0,conference-organizer,100,57,4/27/2020
9934AD,conference-call,100,50,4/27/2020
9B71A7,fraud-defendant,100,20,4/27/2020
9B71A7,legal-issues-defendant,100,22,4/27/2020
9D307D,partnership,100,61,4/27/2020
9D65C1,earnings,100,50,4/27/2020
9F18FA,earnings,100,50,4/27/2020
9F18FA,earnings,100,50,4/27/2020
9FA83B,conference-call,100,50,4/27/2020
A15C71,hirings,100,65,4/27/2020
A204A7,earnings,100,50,4/27/2020
A3230E,clinical-trials,100,56,4/27/2020
A350C1,operating-earnings,100,50,4/27/2020
A350C1,operating-earnings,100,50,4/27/2020
A350C1,operating-earnings,100,50,4/27/2020
A350C1,operating-earnings,100,50,4/27/2020
A350C1,operating-earnings,100,50,4/27/2020
A350C1,operating-earnings,100,50,4/27/2020
A495F7,product-release,100,64,4/27/2020
A6828A,clinical-trials-filed,100,60,4/27/2020
A7F0A5,earnings,100,50,4/27/2020
A96867,earnings-positive,100,69,4/27/2020
A96867,earnings-positive,100,69,4/27/2020
A96867,earnings-positive,100,69,4/27/2020
A96867,earnings-positive,100,69,4/27/2020
A96867,earnings-positive,100,69,4/27/2020
A96867,earnings-positive,100,69,4/27/2020
A96867,earnings-positive,100,69,4/27/2020
AAC8B6,dividend,100,50,4/27/2020
AAC8B6,dividend,100,50,4/27/2020
AAEE21,earnings,100,50,4/27/2020
AC7C4F,business-contract,100,69,4/27/2020
AD6141,earnings,100,50,4/27/2020
ADF1B0,earnings,100,50,4/27/2020
ADF1B0,earnings,100,50,4/27/2020
ADF1B0,earnings,100,50,4/27/2020
AEEB76,earnings,100,50,4/27/2020
B33E77,earnings,100,50,4/27/2020
B381D8,earnings,100,50,4/27/2020
B5BA39,legal-issues-plaintiff,100,44,4/27/2020
B6082A,earnings,100,50,4/27/2020
B72BE9,revenues,100,50,4/27/2020
B72BE9,revenues,100,50,4/27/2020
B72BE9,revenues,100,50,4/27/2020
B840EF,product-release,100,64,4/27/2020
B98EFA,executive-appointment,100,54,4/27/2020
BC3AD2,earnings,100,50,4/27/2020
BC3AD2,earnings,100,50,4/27/2020
BC3AD2,earnings,100,50,4/27/2020
BC3AD2,earnings,100,50,4/27/2020
BC3AD2,earnings,100,50,4/27/2020
BC3AD2,earnings,100,50,4/27/2020
BC3AD2,earnings,100,50,4/27/2020
C2E426,earnings,100,50,4/27/2020
C38440,executive-appointment,100,54,4/27/2020
C3F99F,earnings,100,50,4/27/2020
C4F9C6,clinical-trials,100,56,4/27/2020
C598D7,revenue-up,100,63,4/27/2020
C598D7,revenues,100,50,4/27/2020
C598D7,revenues,100,50,4/27/2020
C5F463,partnership,100,61,4/27/2020
C83B88,conference-participant,100,50,4/27/2020
C83B88,conference-participant,100,50,4/27/2020
CC3EC4,earnings,100,50,4/27/2020
CCB623,earnings,100,50,4/27/2020
CD4DA8,executive-appointment,100,54,4/27/2020
CDAA0E,partnership,100,61,4/27/2020
CDC817,earnings,100,50,4/27/2020
CE4E6D,conference-call,100,50,4/27/2020
CEDFD5,note-sale,100,52,4/27/2020
CEDFD5,note-sale,100,52,4/27/2020
CF351E,fundraising,100,64,4/27/2020
CFE5BE,dividend,100,50,4/27/2020
D06996,earnings,100,50,4/27/2020
D0DFE5,earnings,100,50,4/27/2020
D15833,dividend,100,50,4/27/2020
D3C794,earnings,100,50,4/27/2020
D518D8,legal-issues-defendant,100,22,4/27/2020
D518D8,legal-issues-defendant,100,22,4/27/2020
D56D6D,conference-participant,100,50,4/27/2020
D60BB2,partnership,100,61,4/27/2020
D6534D,conference-call,100,50,4/27/2020
DA48E4,note-sale,100,52,4/27/2020
DAC66A,earnings,100,50,4/27/2020
DD9E41,earnings,100,50,4/27/2020
DD9E41,earnings,100,50,4/27/2020
DD9E41,earnings,100,50,4/27/2020
DD9E41,earnings,100,50,4/27/2020
DF01B1,earnings,100,50,4/27/2020
DF01B1,note-sale,100,52,4/27/2020
DF01B1,note-sale,100,52,4/27/2020
DF18E6,clinical-trials-start,100,64,4/27/2020
DF18E6,conference-call,100,50,4/27/2020
DF46C5,dividend,100,50,4/27/2020
DF46C5,earnings,100,50,4/27/2020
DF46C5,earnings,100,50,4/27/2020
DF46C5,earnings,100,50,4/27/2020
DF46C5,earnings,100,50,4/27/2020
DF6FDD,earnings,100,50,4/27/2020
DF8855,earnings,100,50,4/27/2020
E09997,conference-call,100,50,4/27/2020
E09E2B,acquisition-completed-acquirer,100,49,4/27/2020
E0D3BA,earnings,100,50,4/27/2020
E124EB,business-contract,100,69,4/27/2020
E1E093,business-contract,100,69,4/27/2020
E259C7,earnings,100,50,4/27/2020
E6A53A,conference-call,100,50,4/27/2020
E6A53A,conference-call,100,50,4/27/2020
E70531,earnings,100,50,4/27/2020
E7BF32,earnings,100,50,4/27/2020
E7BF32,earnings,100,50,4/27/2020
E802CE,conference-call,100,50,4/27/2020
E87676,dividend,100,50,4/27/2020
E8846E,executive-appointment,100,54,4/27/2020
E8846E,conference-organizer,100,57,4/27/2020
E8846E,conference-organizer,100,57,4/27/2020
E8846E,conference-organizer,100,57,4/27/2020
E8B21D,public-offering,100,43,4/27/2020
E93A40,earnings,100,50,4/27/2020
EB61C4,earnings,100,50,4/27/2020
EBD89A,conference-call,100,50,4/27/2020
EC70EC,earnings,100,50,4/27/2020
EC70EC,earnings,100,50,4/27/2020
EC70EC,earnings,100,50,4/27/2020
EC70EC,earnings,100,50,4/27/2020
EC70EC,earnings,100,50,4/27/2020
EC70EC,earnings,100,50,4/27/2020
ECDEB2,earnings,100,50,4/27/2020
ED7F13,conference-call,100,50,4/27/2020
EE74E1,earnings,100,50,4/27/2020
EE74E1,earnings,100,50,4/27/2020
EE74E1,earnings,100,50,4/27/2020
EEA6B3,partnership,100,61,4/27/2020
F0B2B5,conference-call,100,50,4/27/2020
F209B4,public-offering,100,43,4/27/2020
F2526D,earnings,100,50,4/27/2020
F31B13,earnings,100,50,4/27/2020
F3FCC3,dividend,100,50,4/27/2020
F5C78B,earnings,100,50,4/27/2020
F793FA,earnings,100,50,4/27/2020
F7FCA4,dividend,100,50,4/27/2020
F95726,earnings,100,50,4/27/2020
FC80E6,conference-call,100,50,4/27/2020
FC9A88,dividend,100,50,4/27/2020
FC9A88,earnings,100,50,4/27/2020
FC9A88,earnings,100,50,4/27/2020
FD1312,earnings,100,50,4/27/2020
FF4343,dividend,100,50,4/27/2020
FF6644,dividend,100,50,4/27/2020
FFAB4A,earnings,100,50,4/27/2020
0157B1,product-release,100,64,4/28/2020
0157B1,donation,100,54,4/28/2020
01D03F,product-release,100,64,4/28/2020
01D03F,product-release,100,64,4/28/2020
01D03F,merger-regulatory-approval,100,81,4/28/2020
03542C,credit-extension-recipient,100,69,4/28/2020
03542C,earnings,100,50,4/28/2020
03B8CF,earnings,100,50,4/28/2020
03B8CF,earnings,100,50,4/28/2020
03B8CF,earnings,100,50,4/28/2020
03B8CF,earnings,100,50,4/28/2020
03B8CF,earnings,100,50,4/28/2020
03B8CF,earnings,100,50,4/28/2020
68396,earnings,100,50,4/28/2020
070B45,earnings,100,50,4/28/2020
081AB9,executive-salary,100,52,4/28/2020
081AB9,earnings,100,50,4/28/2020
099A92,board-meeting,100,51,4/28/2020
09DE1F,product-release,100,64,4/28/2020
09F623,earnings,100,50,4/28/2020
09F623,earnings,100,50,4/28/2020
09F623,earnings,100,50,4/28/2020
0BF528,executive-appointment,100,54,4/28/2020
0C4131,earnings,100,50,4/28/2020
0F0693,earnings,100,50,4/28/2020
0FABBD,earnings,100,50,4/28/2020
0FABBD,earnings,100,50,4/28/2020
0FABBD,earnings,100,50,4/28/2020
0FABBD,earnings,100,50,4/28/2020
102727,earnings,100,50,4/28/2020
10AE08,earnings,100,50,4/28/2020
1151F4,executive-appointment,100,54,4/28/2020
1220D2,earnings,100,50,4/28/2020
12731D,conference-call,100,50,4/28/2020
12731D,conference-call,100,50,4/28/2020
131443,earnings,100,50,4/28/2020
131443,earnings,100,50,4/28/2020
131443,earnings,100,50,4/28/2020
131443,earnings,100,50,4/28/2020
131443,earnings,100,50,4/28/2020
1348C9,earnings,100,50,4/28/2020
1348C9,earnings,100,50,4/28/2020
1348C9,earnings,100,50,4/28/2020
159739,public-offering,100,43,4/28/2020
159739,public-offering,100,43,4/28/2020
168A5D,executive-appointment,100,54,4/28/2020
16FC89,earnings,100,50,4/28/2020
1866B2,earnings,100,50,4/28/2020
188394,dividend,100,50,4/28/2020
197612,earnings,100,50,4/28/2020
19BF16,legal-issues-defendant,100,22,4/28/2020
1A3E1B,dividend,100,50,4/28/2020
1B16C1,conference-call,100,50,4/28/2020
1BDB2A,earnings,100,50,4/28/2020
1E9A6D,partnership,100,61,4/28/2020
1EBF8D,earnings,100,50,4/28/2020
1EBF8D,regulatory-product-approval-granted,100,81,4/28/2020
1EBF8D,regulatory-product-approval-granted,100,81,4/28/2020
1EBF8D,regulatory-product-approval-granted,100,81,4/28/2020
1EBF8D,regulatory-product-approval-granted,100,81,4/28/2020
1F9D90,earnings,100,50,4/28/2020
1FE3CB,operating-earnings,100,50,4/28/2020
1FE3CB,dividend,100,50,4/28/2020
1FE7F0,board-meeting,100,51,4/28/2020
221AD7,legal-issues-defendant,100,22,4/28/2020
221AD7,legal-issues-defendant,100,22,4/28/2020
223552,earnings,100,50,4/28/2020
225CA2,earnings,100,50,4/28/2020
225CA2,earnings,100,50,4/28/2020
225CA2,earnings,100,50,4/28/2020
225CA2,earnings,100,50,4/28/2020
225CA2,earnings,100,50,4/28/2020
225CA2,earnings,100,50,4/28/2020
225CA2,earnings,100,50,4/28/2020
225CA2,earnings,100,50,4/28/2020
225CA2,earnings,100,50,4/28/2020
225CA2,earnings,100,50,4/28/2020
225CA2,earnings,100,50,4/28/2020
227D48,earnings,100,50,4/28/2020
227D48,earnings,100,50,4/28/2020
227D48,earnings,100,50,4/28/2020
227D48,earnings,100,50,4/28/2020
22C58E,earnings,100,50,4/28/2020
23207A,product-release,100,64,4/28/2020
249B39,earnings-positive,100,69,4/28/2020
24FA23,conference-participant,100,50,4/28/2020
253B2F,conference-call,100,50,4/28/2020
267718,earnings,100,50,4/28/2020
267718,earnings,100,50,4/28/2020
267718,earnings,100,50,4/28/2020
267718,earnings,100,50,4/28/2020
267718,earnings,100,50,4/28/2020
267718,earnings,100,50,4/28/2020
267718,earnings,100,50,4/28/2020
267718,earnings,100,50,4/28/2020
267718,earnings,100,50,4/28/2020
267718,earnings,100,50,4/28/2020
270305,earnings,100,50,4/28/2020
270305,earnings,100,50,4/28/2020
270305,earnings,100,50,4/28/2020
270305,earnings,100,50,4/28/2020
270305,dividend,100,50,4/28/2020
2ABF77,conference-call,100,50,4/28/2020
2D643C,dividend,100,50,4/28/2020
2F24A5,earnings,100,50,4/28/2020
2F94A5,earnings,100,50,4/28/2020
30E01D,executive-appointment,100,54,4/28/2020
32F943,business-contract,100,69,4/28/2020
332F87,earnings,100,50,4/28/2020
33AD83,executive-appointment,100,54,4/28/2020
33FD66,earnings,100,50,4/28/2020
33FD66,earnings,100,50,4/28/2020
33FD66,earnings,100,50,4/28/2020
33FD66,earnings,100,50,4/28/2020
33FD66,earnings,100,50,4/28/2020
3461CF,product-release,100,64,4/28/2020
37020C,conference-call,100,50,4/28/2020
373B06,earnings,100,50,4/28/2020
396D7C,executive-appointment,100,54,4/28/2020
3BB616,earnings,100,50,4/28/2020
3BCF24,earnings,100,50,4/28/2020
3CBA2A,earnings,100,50,4/28/2020
3CBA2A,earnings,100,50,4/28/2020
3CBA2A,earnings,100,50,4/28/2020
3CBA2A,earnings,100,50,4/28/2020
3CBA2A,earnings,100,50,4/28/2020
3CBA2A,earnings,100,50,4/28/2020
3CBA2A,earnings,100,50,4/28/2020
3ED92D,earnings,100,50,4/28/2020
3ED92D,earnings,100,50,4/28/2020
3ED92D,earnings,100,50,4/28/2020
3ED92D,earnings,100,50,4/28/2020
3ED92D,earnings,100,50,4/28/2020
3ED92D,earnings,100,50,4/28/2020
416C55,earnings,100,50,4/28/2020
420168,earnings,100,50,4/28/2020
423279,earnings-per-share-positive,100,69,4/28/2020
425BDC,conference-call,100,50,4/28/2020
43F4A8,earnings,100,50,4/28/2020
46CF27,earnings,100,50,4/28/2020
46CF27,earnings,100,50,4/28/2020
46CF27,earnings,100,50,4/28/2020
46CF27,earnings,100,50,4/28/2020
46CF27,earnings,100,50,4/28/2020
46CF27,earnings,100,50,4/28/2020
46CF27,earnings,100,50,4/28/2020
46CF27,earnings,100,50,4/28/2020
490D4B,conference-call,100,50,4/28/2020
4A2457,conference-call,100,50,4/28/2020
4A6F00,partnership,100,61,4/28/2020
4B49CF,conference-participant,100,50,4/28/2020
4BF3D6,executive-appointment,100,54,4/28/2020
4C6C63,earnings,100,50,4/28/2020
4C6C63,earnings,100,50,4/28/2020
4C6C63,earnings,100,50,4/28/2020
4C6C63,earnings,100,50,4/28/2020
4C6C63,earnings,100,50,4/28/2020
4C6C63,earnings,100,50,4/28/2020
4C6C63,earnings,100,50,4/28/2020
4C6C63,earnings,100,50,4/28/2020
51888A,earnings,100,50,4/28/2020
52BF94,earnings,100,50,4/28/2020
52BF94,earnings,100,50,4/28/2020
52BF94,earnings,100,50,4/28/2020
52BF94,earnings,100,50,4/28/2020
53EF9E,earnings,100,50,4/28/2020
53EF9E,earnings,100,50,4/28/2020
5.43E+08,earnings,100,50,4/28/2020
562853,executive-appointment,100,54,4/28/2020
57A854,earnings,100,50,4/28/2020
583A75,conference-call,100,50,4/28/2020
596116,earnings,100,50,4/28/2020
5968F9,earnings,100,50,4/28/2020
59C539,earnings,100,50,4/28/2020
59C539,earnings,100,50,4/28/2020
5AA3B1,earnings,100,50,4/28/2020
5D1329,clinical-trials,100,56,4/28/2020
5DA8B3,earnings,100,50,4/28/2020
5E6959,earnings-up,100,68,4/28/2020
5EAA43,business-contract,100,69,4/28/2020
5EC388,earnings-positive,100,69,4/28/2020
601785,dividend,100,50,4/28/2020
61E975,dividend,100,50,4/28/2020
649CBD,earnings,100,50,4/28/2020
6810DE,earnings,100,50,4/28/2020
6844D2,partnership,100,61,4/28/2020
6844D2,product-release,100,64,4/28/2020
69345C,earnings,100,50,4/28/2020
69345C,earnings,100,50,4/28/2020
69345C,earnings,100,50,4/28/2020
69345C,earnings,100,50,4/28/2020
69494C,conference-call,100,50,4/28/2020
6ABCB8,earnings,100,50,4/28/2020
6B494E,earnings,100,50,4/28/2020
6B67BD,clinical-trials,100,56,4/28/2020
6BC6F9,product-release,100,64,4/28/2020
6C4D2F,earnings,100,50,4/28/2020
6C4D2F,earnings,100,50,4/28/2020
6C4D2F,earnings,100,50,4/28/2020
6C4D2F,earnings,100,50,4/28/2020
6C4D2F,earnings,100,50,4/28/2020
6C4D2F,earnings,100,50,4/28/2020
6C4D2F,earnings,100,50,4/28/2020
6C4D2F,earnings,100,50,4/28/2020
6D3F35,partnership,100,61,4/28/2020
6D3F35,partnership,100,61,4/28/2020
6D3F35,conference-call,100,50,4/28/2020
704B78,earnings,100,50,4/28/2020
71B0CF,earnings,100,50,4/28/2020
726DDF,conference-call,100,50,4/28/2020
731675,conference-call,100,50,4/28/2020
732A9B,earnings,100,50,4/28/2020
73A71F,dividend,100,50,4/28/2020
765913,dividend,100,50,4/28/2020
767F86,earnings,100,50,4/28/2020
767F86,earnings,100,50,4/28/2020
767F86,earnings,100,50,4/28/2020
767F86,earnings,100,50,4/28/2020
767F86,earnings,100,50,4/28/2020
767F86,earnings,100,50,4/28/2020
767F86,earnings,100,50,4/28/2020
767F86,earnings,100,50,4/28/2020
767F86,earnings,100,50,4/28/2020
767F86,earnings,100,50,4/28/2020
782B46,earnings,100,50,4/28/2020
791D59,conference-participant,100,50,4/28/2020
7A10FF,earnings,100,50,4/28/2020
7AC86E,earnings,100,50,4/28/2020
7AC86E,earnings,100,50,4/28/2020
7CBC40,earnings,100,50,4/28/2020
7CBC40,earnings,100,50,4/28/2020
7CBC40,earnings,100,50,4/28/2020
7CBC40,earnings,100,50,4/28/2020
7D35D8,earnings,100,50,4/28/2020
7DD584,earnings,100,50,4/28/2020
7E0EB0,conference-call,100,50,4/28/2020
7E3F8F,earnings,100,50,4/28/2020
7E3F8F,earnings,100,50,4/28/2020
7E3F8F,earnings,100,50,4/28/2020
7E3F8F,earnings,100,50,4/28/2020
7F9984,earnings,100,50,4/28/2020
805CD8,conference-call,100,50,4/28/2020
8303CD,earnings,100,50,4/28/2020
850779,earnings,100,50,4/28/2020
850779,earnings,100,50,4/28/2020
873DB9,dividend,100,50,4/28/2020
87B81A,board-meeting,100,51,4/28/2020
8AC65D,earnings,100,50,4/28/2020
8B9B3B,earnings,100,50,4/28/2020
8BAA15,business-contract,100,69,4/28/2020
8BE916,earnings,100,50,4/28/2020
8C311A,earnings,100,50,4/28/2020
8CF6DD,dividend,100,50,4/28/2020
8D4486,partnership,100,61,4/28/2020
8D4486,partnership,100,61,4/28/2020
8D4486,dividend-up,100,81,4/28/2020
8D4486,dividend-up,100,81,4/28/2020
8DCF18,conference-call,100,50,4/28/2020
8E10BF,clinical-trials-start,100,64,4/28/2020
8E4F9A,conference-call,100,50,4/28/2020
907ED2,earnings-up,100,68,4/28/2020
92D9C9,conference-call,100,50,4/28/2020
9.31E+77,unit-acquisition-acquirer,100,49,4/28/2020
9.31E+77,unit-acquisition-acquirer,100,49,4/28/2020
94563D,earnings,100,50,4/28/2020
945DE6,dividend,100,50,4/28/2020
949D62,earnings,100,50,4/28/2020
965360,earnings,100,50,4/28/2020
967D92,conference-call,100,50,4/28/2020
968B00,earnings,100,50,4/28/2020
96A6CD,regulatory-product-approval-granted,100,81,4/28/2020
9.74E+08,earnings,100,50,4/28/2020
9.74E+08,earnings,100,50,4/28/2020
9.74E+08,earnings,100,50,4/28/2020
9.74E+08,earnings,100,50,4/28/2020
97FE80,executive-appointment,100,54,4/28/2020
986AF6,earnings,100,50,4/28/2020
986AF6,earnings,100,50,4/28/2020
986AF6,earnings,100,50,4/28/2020
9A602D,earnings-per-share-positive,100,69,4/28/2020
9A602D,earnings-per-share-positive,100,69,4/28/2020
9A602D,earnings-per-share-positive,100,69,4/28/2020
9A602D,earnings-per-share-positive,100,69,4/28/2020
9A602D,earnings-per-share-positive,100,69,4/28/2020
9A602D,earnings-per-share-positive,100,69,4/28/2020
9C25FF,conference-call,100,50,4/28/2020
A1EAC8,dividend,100,50,4/28/2020
A3230E,ipo-completed,100,76,4/28/2020
A398B9,earnings,100,50,4/28/2020
A398B9,earnings,100,50,4/28/2020
A398B9,earnings,100,50,4/28/2020
A47A7D,earnings,100,50,4/28/2020
A47F2E,earnings,100,50,4/28/2020
A4F67C,earnings,100,50,4/28/2020
A58224,conference-call,100,50,4/28/2020
A5E715,earnings,100,50,4/28/2020
A62FD6,earnings,100,50,4/28/2020
A62FD6,earnings,100,50,4/28/2020
A62FD6,earnings,100,50,4/28/2020
A62FD6,earnings,100,50,4/28/2020
A65325,dividend,100,50,4/28/2020
A65325,earnings-positive,100,69,4/28/2020
A6ABE9,earnings,100,50,4/28/2020
A6ABE9,conference-call,100,50,4/28/2020
A70BF5,earnings,100,50,4/28/2020
A70BF5,earnings,100,50,4/28/2020
A70BF5,earnings,100,50,4/28/2020
A70BF5,earnings,100,50,4/28/2020
A70BF5,earnings,100,50,4/28/2020
A79D88,earnings,100,50,4/28/2020
A79D88,earnings,100,50,4/28/2020
A8B137,earnings,100,50,4/28/2020
A8B137,earnings,100,50,4/28/2020
A8B137,earnings,100,50,4/28/2020
A8B137,earnings,100,50,4/28/2020
A8B137,earnings,100,50,4/28/2020
A8E2FE,executive-appointment,100,54,4/28/2020
A94A7B,partnership,100,61,4/28/2020
ABB493,executive-appointment,100,54,4/28/2020
AE0CCE,conference-call,100,50,4/28/2020
AEF2C3,earnings,100,50,4/28/2020
AFF43F,earnings,100,50,4/28/2020
AFF43F,dividend,100,50,4/28/2020
B09B1F,award,100,58,4/28/2020
B0D41A,clinical-trials,100,56,4/28/2020
B0D41A,clinical-trials,100,56,4/28/2020
B1DF3C,acquisition-interest-acquirer,100,46,4/28/2020
B1DF3C,acquisition-interest-acquirer,100,46,4/28/2020
B1DF3C,acquisition-interest-acquirer,100,46,4/28/2020
B1DF3C,note-sale,100,52,4/28/2020
B2DAF6,earnings,100,50,4/28/2020
B303A6,dividend,100,50,4/28/2020
B33E77,patient-enrollment-complete,100,64,4/28/2020
B33E77,patient-enrollment-complete,100,64,4/28/2020
B37FB4,earnings,100,50,4/28/2020
B37FB4,earnings,100,50,4/28/2020
B37FB4,earnings,100,50,4/28/2020
B37FB4,earnings,100,50,4/28/2020
B37FB4,earnings,100,50,4/28/2020
B37FB4,earnings,100,50,4/28/2020
B508E5,conference-call,100,50,4/28/2020
B619CB,earnings-positive,100,69,4/28/2020
B840EF,earnings,100,50,4/28/2020
B98EFA,operating-earnings,100,50,4/28/2020
BB07E4,note-sale,100,52,4/28/2020
BB5271,earnings,100,50,4/28/2020
BE14CF,earnings,100,50,4/28/2020
BFCACF,earnings,100,50,4/28/2020
C0BA36,conference-call,100,50,4/28/2020
C41C25,dividend,100,50,4/28/2020
C45CE7,earnings,100,50,4/28/2020
C624A1,earnings,100,50,4/28/2020
C624A1,earnings,100,50,4/28/2020
C659EB,earnings,100,50,4/28/2020
C659EB,earnings,100,50,4/28/2020
C659EB,earnings,100,50,4/28/2020
C72B8F,earnings,100,50,4/28/2020
C8257F,earnings,100,50,4/28/2020
C8257F,earnings,100,50,4/28/2020
C85A72,revenue-up,100,61,4/28/2020
C85A72,revenue-up,100,61,4/28/2020
C85A72,revenue-up,100,61,4/28/2020
C8A248,partnership,100,61,4/28/2020
C99CC8,earnings,100,50,4/28/2020
C99CC8,earnings,100,50,4/28/2020
C99CC8,earnings,100,50,4/28/2020
C99CC8,earnings,100,50,4/28/2020
CC176E,earnings,100,50,4/28/2020
CC8F6E,earnings,100,50,4/28/2020
CD06A2,executive-appointment,100,54,4/28/2020
CD06A2,executive-appointment,100,54,4/28/2020
CD2A4D,partnership,100,61,4/28/2020
CDE118,acquisition-completed-acquirer,100,49,4/28/2020
CFF97C,revenue-up,100,64,4/28/2020
CFF97C,revenue-up,100,64,4/28/2020
CFF97C,revenue-up,100,64,4/28/2020
CFF97C,revenue-up,100,64,4/28/2020
CFF97C,revenue-up,100,64,4/28/2020
D04D9F,earnings,100,50,4/28/2020
D139BC,earnings,100,50,4/28/2020
D4AC65,partnership,100,61,4/28/2020
D518D8,legal-issues-defendant,100,22,4/28/2020
D6144F,conference-call,100,50,4/28/2020
D78BF1,earnings,100,50,4/28/2020
D7918D,operating-earnings,100,50,4/28/2020
D9CAF0,earnings,100,50,4/28/2020
DA9443,patent-awarded,100,72,4/28/2020
DAFED3,award,100,58,4/28/2020
DB06B0,partnership,100,61,4/28/2020
DB2E4E,business-contract,100,69,4/28/2020
DB7FA7,earnings,100,50,4/28/2020
DC1405,earnings,100,50,4/28/2020
DC486E,earnings,100,50,4/28/2020
DCD97F,executive-appointment,100,54,4/28/2020
DD1BA1,earnings,100,50,4/28/2020
DDEA6A,operating-earnings,100,50,4/28/2020
DE4924,dividend,100,50,4/28/2020
DE4924,earnings,100,50,4/28/2020
DF11D9,dividend,100,50,4/28/2020
DF46C5,executive-resignation,100,44,4/28/2020
E074A0,dividend,100,50,4/28/2020
E07573,dividend,100,50,4/28/2020
E11C41,conference-call,100,50,4/28/2020
E21871,dividend,100,50,4/28/2020
E2CB7B,earnings,100,50,4/28/2020
E30A8F,earnings,100,50,4/28/2020
E30A8F,earnings,100,50,4/28/2020
E30A8F,earnings,100,50,4/28/2020
E30A8F,earnings,100,50,4/28/2020
E38906,earnings,100,50,4/28/2020
E4CE73,product-release,100,64,4/28/2020
E5D914,earnings,100,50,4/28/2020
E5D914,earnings,100,50,4/28/2020
E5D914,earnings,100,50,4/28/2020
E829E8,earnings-per-share-positive,100,69,4/28/2020
E84500,earnings,100,50,4/28/2020
E866D2,earnings,100,50,4/28/2020
E866D2,earnings,100,50,4/28/2020
E866D2,earnings,100,50,4/28/2020
E866D2,earnings,100,50,4/28/2020
E866D2,earnings,100,50,4/28/2020
E866D2,earnings,100,50,4/28/2020
E866D2,earnings,100,50,4/28/2020
E866D2,public-offering,100,43,4/28/2020
E87676,revenues,100,50,4/28/2020
E8846E,conference-organizer,100,57,4/28/2020
E8846E,executive-appointment,100,54,4/28/2020
E8846E,dividend,100,50,4/28/2020
E9E6FD,earnings,100,50,4/28/2020
E9FF33,earnings,100,50,4/28/2020
EA62FC,dividend,100,50,4/28/2020
EAEBF3,earnings,100,50,4/28/2020
EBC84C,earnings,100,50,4/28/2020
EBC84C,earnings,100,50,4/28/2020
EBC84C,earnings,100,50,4/28/2020
EBC84C,earnings,100,50,4/28/2020
EBC84C,earnings,100,50,4/28/2020
EC70EC,note-sale,100,52,4/28/2020
EC99D0,earnings,100,50,4/28/2020
ECF709,earnings,100,50,4/28/2020
ED0402,revenue-up,100,69,4/28/2020
ED0402,revenue-up,100,69,4/28/2020
ED0402,revenue-up,100,69,4/28/2020
ED0402,revenue-up,100,69,4/28/2020
ED7F13,earnings,100,50,4/28/2020
ED9C04,patent-awarded,100,72,4/28/2020
EE04F0,conference-call,100,50,4/28/2020
EE6F1C,business-contract,100,69,4/28/2020
EEB5F9,conference-call,100,50,4/28/2020
F0B2B5,earnings,100,50,4/28/2020
F294DD,earnings,100,50,4/28/2020
F294DD,earnings,100,50,4/28/2020
F294DD,earnings,100,50,4/28/2020
F294DD,earnings,100,50,4/28/2020
F3816D,executive-appointment,100,54,4/28/2020
F40EE2,earnings,100,50,4/28/2020
F40EE2,earnings,100,50,4/28/2020
F40EE2,earnings,100,50,4/28/2020
F47871,earnings,100,50,4/28/2020
F48947,earnings,100,50,4/28/2020
F5C78B,earnings,100,50,4/28/2020
F5D410,earnings,100,50,4/28/2020
F6FA6A,award,100,58,4/28/2020
F721A7,executive-salary-cut,100,53,4/28/2020
F721A7,executive-salary-cut,100,53,4/28/2020
F72E4B,earnings,100,50,4/28/2020
F7902B,unit-acquisition-completed-acquirer,100,49,4/28/2020
F80FF9,conference-call,100,50,4/28/2020
FAE021,earnings,100,50,4/28/2020
FAE021,earnings,100,50,4/28/2020
FAE021,earnings,100,50,4/28/2020
FAE021,earnings,100,50,4/28/2020
FAEABE,dividend,100,50,4/28/2020
FC9A88,product-outage,100,36,4/28/2020
FC9A88,earnings,100,50,4/28/2020
FD2565,clinical-trials,100,56,4/28/2020
FD4BBE,earnings,100,50,4/28/2020
FD4BBE,earnings,100,50,4/28/2020
FD4BBE,earnings,100,50,4/28/2020
FDD3FC,earnings,100,50,4/28/2020
00067A,earnings,100,50,4/29/2020
0157B1,partnership,100,61,4/29/2020
033B58,conference-participant,100,50,4/29/2020
03B8CF,earnings,100,50,4/29/2020
03B8CF,earnings,100,50,4/29/2020
03B8CF,earnings,100,50,4/29/2020
03B8CF,earnings,100,50,4/29/2020
03B8CF,earnings,100,50,4/29/2020
03B8CF,earnings,100,50,4/29/2020
03B8CF,earnings,100,50,4/29/2020
03B8CF,earnings,100,50,4/29/2020
03B8CF,earnings,100,50,4/29/2020
03B8CF,earnings,100,50,4/29/2020
03B8CF,earnings,100,50,4/29/2020
03B8CF,earnings,100,50,4/29/2020
03B8CF,earnings,100,50,4/29/2020
03B8CF,earnings,100,50,4/29/2020
03B8CF,earnings,100,50,4/29/2020
03B8CF,earnings,100,50,4/29/2020
03B8CF,earnings,100,50,4/29/2020
03B8CF,earnings,100,50,4/29/2020
03B8CF,earnings,100,50,4/29/2020
03B8CF,earnings,100,50,4/29/2020
03B8CF,earnings,100,50,4/29/2020
03B8CF,earnings,100,50,4/29/2020
03B8CF,earnings,100,50,4/29/2020
03B8CF,earnings,100,50,4/29/2020
03B8CF,earnings,100,50,4/29/2020
03B8CF,earnings,100,50,4/29/2020
03B8CF,earnings,100,50,4/29/2020
03B8CF,earnings,100,50,4/29/2020
03B8CF,earnings,100,50,4/29/2020
03B8CF,earnings,100,50,4/29/2020
03B8CF,earnings,100,50,4/29/2020
03B8CF,earnings,100,50,4/29/2020
03B8CF,earnings,100,50,4/29/2020
03B8CF,earnings,100,50,4/29/2020
03B8CF,earnings,100,50,4/29/2020
03B8CF,earnings,100,50,4/29/2020
03B8CF,earnings,100,50,4/29/2020
053EFF,conference-call,100,50,4/29/2020
55018,dividend,100,50,4/29/2020
58828,earnings-per-share-up,100,73,4/29/2020
58828,dividend,100,50,4/29/2020
065D38,earnings,100,50,4/29/2020
075CF7,executive-appointment,100,54,4/29/2020
08A40F,executive-appointment,100,54,4/29/2020
08A40F,executive-appointment,100,54,4/29/2020
095A04,partnership,100,61,4/29/2020
0986B5,earnings,100,50,4/29/2020
98977,earnings,100,50,4/29/2020
099A92,earnings,100,50,4/29/2020
099C88,earnings,100,50,4/29/2020
099C88,earnings,100,50,4/29/2020
099C88,earnings,100,50,4/29/2020
099C88,earnings,100,50,4/29/2020
0A748B,earnings,100,50,4/29/2020
0A748B,earnings,100,50,4/29/2020
0B2071,earnings,100,50,4/29/2020
0B4D10,earnings,100,50,4/29/2020
0B73A7,note-sale,100,52,4/29/2020
0B73A7,note-sale,100,52,4/29/2020
0B73A7,note-sale,100,52,4/29/2020
0B73A7,note-sale,100,52,4/29/2020
0C136E,earnings,100,50,4/29/2020
0E2992,earnings-per-share-positive,100,69,4/29/2020
0E64D4,analyst-ratings-change-neutral-rater,20,50,4/29/2020
0EC508,earnings,100,50,4/29/2020
1080C0,earnings,100,50,4/29/2020
1216D1,earnings,100,50,4/29/2020
12DE76,conference-call,100,50,4/29/2020
12E454,earnings,100,50,4/29/2020
12E454,earnings,100,50,4/29/2020
12E454,earnings,100,50,4/29/2020
133644,partnership,100,61,4/29/2020
14BA33,earnings,100,50,4/29/2020
152AB9,conference-participant,100,50,4/29/2020
152E1D,conference-call,100,50,4/29/2020
15901B,earnings,100,50,4/29/2020
1.79E+10,conference-call,100,50,4/29/2020
19BF16,partnership,100,61,4/29/2020
1A2D9F,earnings,100,50,4/29/2020
1A2D9F,earnings,100,50,4/29/2020
1A2D9F,earnings,100,50,4/29/2020
1A2D9F,earnings,100,50,4/29/2020
1A2D9F,earnings,100,50,4/29/2020
1A2D9F,earnings,100,50,4/29/2020
1A2D9F,earnings,100,50,4/29/2020
1A2D9F,earnings,100,50,4/29/2020
1A3E1B,executive-appointment,100,54,4/29/2020
1B4F31,earnings,100,50,4/29/2020
1BC12C,partnership,100,61,4/29/2020
1CD708,earnings,100,50,4/29/2020
1D5C51,earnings,100,50,4/29/2020
1E8A99,earnings,100,50,4/29/2020
1EC3E8,dividend,100,50,4/29/2020
1F19C8,earnings,100,50,4/29/2020
2003A5,earnings,100,50,4/29/2020
2082EA,conference-call,100,50,4/29/2020
20D00A,earnings,100,50,4/29/2020
221AD7,legal-issues-defendant,100,22,4/29/2020
221AD7,earnings,100,50,4/29/2020
222BF9,dividend,100,50,4/29/2020
22C58E,conference-organizer,100,57,4/29/2020
2.45E+15,investment-investor,100,55,4/29/2020
250BEE,dividend,100,50,4/29/2020
25AB8E,fraud-defendant,100,20,4/29/2020
25AB8E,legal-issues-defendant,100,22,4/29/2020
25AB8E,legal-issues-defendant,100,22,4/29/2020
25AB8E,legal-issues-defendant,100,22,4/29/2020
264EB3,earnings,100,50,4/29/2020
264EB3,earnings,100,50,4/29/2020
264EB3,earnings,100,50,4/29/2020
264EB3,earnings,100,50,4/29/2020
264EB3,earnings,100,50,4/29/2020
267718,earnings,100,50,4/29/2020
2720AB,earnings,100,50,4/29/2020
275300,earnings,100,50,4/29/2020
275300,earnings,100,50,4/29/2020
275300,earnings,100,50,4/29/2020
275300,earnings,100,50,4/29/2020
275300,earnings,100,50,4/29/2020
275300,earnings,100,50,4/29/2020
275300,earnings,100,50,4/29/2020
275300,earnings,100,50,4/29/2020
292388,earnings,100,50,4/29/2020
2950FF,earnings,100,50,4/29/2020
2950FF,earnings,100,50,4/29/2020
2A17B1,earnings,100,50,4/29/2020
2A17B1,earnings,100,50,4/29/2020
2A17B1,earnings,100,50,4/29/2020
2B0AF4,earnings,100,50,4/29/2020
2B7A40,earnings-per-share-positive,100,69,4/29/2020
2B7A40,earnings-positive,100,69,4/29/2020
2B7A40,earnings-positive,100,69,4/29/2020
2B7A40,earnings-positive,100,69,4/29/2020
2B9DBB,earnings,100,50,4/29/2020
2D2D43,dividend,100,50,4/29/2020
2D5011,earnings,100,50,4/29/2020
2D643C,earnings,100,50,4/29/2020
2F24A5,executive-resignation,100,44,4/29/2020
2F6782,dividend,100,50,4/29/2020
301493,legal-issues-defendant,100,22,4/29/2020
31F25C,earnings,100,50,4/29/2020
3224CC,earnings,100,50,4/29/2020
326EDD,earnings,100,50,4/29/2020
32F943,earnings,100,50,4/29/2020
33E8C7,earnings,100,50,4/29/2020
33E8C7,earnings,100,50,4/29/2020
371C01,conference-call,100,50,4/29/2020
37426C,executive-appointment,100,54,4/29/2020
387541,note-sale,100,52,4/29/2020
3B2311,earnings,100,50,4/29/2020
3BC360,earnings,100,50,4/29/2020
3BC360,earnings,100,50,4/29/2020
3BC360,earnings,100,50,4/29/2020
3BC360,earnings,100,50,4/29/2020
3DE4D1,dividend,100,50,4/29/2020
3F4497,earnings,100,50,4/29/2020
3F4668,legal-issues-defendant,100,22,4/29/2020
401072,earnings,100,50,4/29/2020
408089,earnings,100,50,4/29/2020
4135F7,earnings-up,100,68,4/29/2020
41D61C,earnings,100,50,4/29/2020
425BDC,earnings,100,50,4/29/2020
442769,earnings,100,50,4/29/2020
442769,earnings,100,50,4/29/2020
442769,earnings,100,50,4/29/2020
442769,earnings,100,50,4/29/2020
4455C4,earnings,100,50,4/29/2020
4455C4,earnings,100,50,4/29/2020
4455C4,earnings,100,50,4/29/2020
4455C4,earnings,100,50,4/29/2020
447FC6,conference-call,100,50,4/29/2020
44A4FC,business-contract,100,69,4/29/2020
46017C,conference-participant,100,50,4/29/2020
47752F,earnings,100,50,4/29/2020
47752F,earnings,100,50,4/29/2020
47752F,earnings,100,50,4/29/2020
47752F,earnings,100,50,4/29/2020
4806CE,dividend,100,50,4/29/2020
4885C8,dividend,100,50,4/29/2020
499C75,legal-issues-defendant,100,22,4/29/2020
49A344,earnings,100,50,4/29/2020
49A344,earnings,100,50,4/29/2020
49A344,earnings,100,50,4/29/2020
4A5C8D,dividend,100,50,4/29/2020
4A6F00,partnership,100,61,4/29/2020
4A6F00,partnership,100,61,4/29/2020
4A6F00,earnings,100,50,4/29/2020
4A7C1F,legal-issues-defendant,100,22,4/29/2020
4B3555,earnings,100,50,4/29/2020
4C2F17,conference-participant,100,50,4/29/2020
4DD09F,earnings,100,50,4/29/2020
4EEB00,orphan-drug-designation,100,76,4/29/2020
51888A,dividend,100,50,4/29/2020
51F541,earnings,100,50,4/29/2020
52D936,dividend,100,50,4/29/2020
539F49,legal-issues-defendant,100,22,4/29/2020
546A27,earnings,100,50,4/29/2020
54F271,earnings,100,50,4/29/2020
55438C,earnings,100,50,4/29/2020
55438C,earnings,100,50,4/29/2020
55438C,earnings,100,50,4/29/2020
55438C,earnings,100,50,4/29/2020
55438C,earnings,100,50,4/29/2020
55438C,earnings,100,50,4/29/2020
55438C,earnings,100,50,4/29/2020
55438C,earnings,100,50,4/29/2020
55438C,earnings,100,50,4/29/2020
55438C,earnings,100,50,4/29/2020
55438C,earnings,100,50,4/29/2020
55438C,earnings,100,50,4/29/2020
55C9B5,earnings,100,50,4/29/2020
57634F,legal-issues-defendant,100,22,4/29/2020
57B174,conference-call,100,50,4/29/2020
57CAAB,earnings,100,50,4/29/2020
57EF50,conference-call,100,50,4/29/2020
594402,earnings,100,50,4/29/2020
59872F,partnership,100,61,4/29/2020
59872F,partnership,100,61,4/29/2020
59872F,partnership,100,61,4/29/2020
5A423F,earnings,100,50,4/29/2020
5AAE17,earnings,100,50,4/29/2020
5AF08A,earnings,100,50,4/29/2020
5BFE94,earnings,100,50,4/29/2020
5D63F1,earnings,100,50,4/29/2020
5DD486,earnings,100,50,4/29/2020
5F1B7B,earnings,100,50,4/29/2020
5F9CE3,partnership,100,61,4/29/2020
5F9CE3,partnership,100,61,4/29/2020
5FF95F,earnings-positive,100,69,4/29/2020
605F40,earnings,100,50,4/29/2020
60DD84,revenue-up,100,69,4/29/2020
6284B5,conference-call,100,50,4/29/2020
62EFEE,earnings,100,50,4/29/2020
633054,partnership,100,61,4/29/2020
641F17,earnings,100,50,4/29/2020
641F17,earnings,100,50,4/29/2020
641F17,earnings,100,50,4/29/2020
641F17,earnings,100,50,4/29/2020
641F17,earnings,100,50,4/29/2020
641F17,earnings,100,50,4/29/2020
64854A,earnings,100,50,4/29/2020
662682,earnings,100,50,4/29/2020
66E3C0,revenue-up,100,62,4/29/2020
66ECFD,earnings,100,50,4/29/2020
67303E,conference-call,100,50,4/29/2020
673C9A,conference-call,100,50,4/29/2020
6925EB,legal-issues-defendant,100,22,4/29/2020
693ECD,earnings,100,50,4/29/2020
6A3C35,earnings,100,50,4/29/2020
6A3C35,earnings,100,50,4/29/2020
6A3C35,earnings,100,50,4/29/2020
6A3C35,earnings,100,50,4/29/2020
6ACFBF,earnings,100,50,4/29/2020
6B0E45,earnings,100,50,4/29/2020
6CC55E,conference-participant,100,50,4/29/2020
6D156D,earnings,100,50,4/29/2020
6D3F35,executive-appointment,100,54,4/29/2020
6DBBBC,dividend,100,50,4/29/2020
6E8864,conference-participant,100,50,4/29/2020
6EB9DA,dividend,100,50,4/29/2020
6EB9DA,executive-appointment,100,54,4/29/2020
705636,revenue-up,100,57,4/29/2020
722DE3,earnings,100,50,4/29/2020
722DE3,earnings,100,50,4/29/2020
7255D2,earnings,100,50,4/29/2020
728737,earnings,100,50,4/29/2020
729368,earnings,100,50,4/29/2020
72CB93,executive-appointment,100,54,4/29/2020
735388,earnings,100,50,4/29/2020
73A213,earnings,100,50,4/29/2020
73BCBA,earnings,100,50,4/29/2020
73BCBA,earnings,100,50,4/29/2020
73BCBA,earnings,100,50,4/29/2020
746373,earnings,100,50,4/29/2020
746373,earnings,100,50,4/29/2020
748EB6,clinical-trials,100,56,4/29/2020
752A70,earnings,100,50,4/29/2020
762A3E,earnings,100,50,4/29/2020
763724,conference-call,100,50,4/29/2020
766047,earnings,100,50,4/29/2020
76B926,dividend,100,50,4/29/2020
76BECC,conference-call,100,50,4/29/2020
76DD0C,clinical-trials,100,56,4/29/2020
790D0D,earnings,100,50,4/29/2020
7B492C,executive-appointment,100,54,4/29/2020
7B4B91,dividend,100,50,4/29/2020
7B6C88,conference-call,100,50,4/29/2020
7C790D,conference-call,100,50,4/29/2020
7E1542,earnings,100,50,4/29/2020
7E62B5,earnings,100,50,4/29/2020
82F088,conference-participant,100,50,4/29/2020
830BDB,revenue-up,100,72,4/29/2020
860AB6,dividend,100,50,4/29/2020
860AB6,dividend,100,50,4/29/2020
88350F,executive-appointment,100,54,4/29/2020
896771,earnings,100,50,4/29/2020
8B1E11,earnings,100,50,4/29/2020
8C5519,dividend,100,50,4/29/2020
8DA42F,conference-call,100,50,4/29/2020
8DBE73,revenues,100,50,4/29/2020
8DBE73,revenues,100,50,4/29/2020
8DBE73,revenues,100,50,4/29/2020
8E93A4,dividend,100,50,4/29/2020
8F6995,conference-call,100,50,4/29/2020
8F8F2F,earnings,100,50,4/29/2020
8F8F2F,earnings,100,50,4/29/2020
8FF2EF,conference-call,100,50,4/29/2020
901327,earnings,100,50,4/29/2020
901327,earnings,100,50,4/29/2020
901327,earnings,100,50,4/29/2020
901327,earnings,100,50,4/29/2020
9087B9,dividend,100,50,4/29/2020
911CA9,conference-participant,100,50,4/29/2020
92B625,conference-call,100,50,4/29/2020
942165,dividend,100,50,4/29/2020
94C0B5,dividend,100,50,4/29/2020
9507FF,conference-participant,100,50,4/29/2020
954A47,facility-open,100,65,4/29/2020
9592FB,conference-participant,100,50,4/29/2020
9673BD,dividend,100,50,4/29/2020
96A6CD,clinical-trials-start,100,64,4/29/2020
972356,earnings,100,50,4/29/2020
972356,earnings,100,50,4/29/2020
972356,earnings,100,50,4/29/2020
972356,earnings,100,50,4/29/2020
972356,earnings,100,50,4/29/2020
990AD0,conference-organizer,100,57,4/29/2020
990AD0,conference-organizer,100,57,4/29/2020
990AD0,conference-organizer,100,57,4/29/2020
990AD0,conference-organizer,100,57,4/29/2020
990AD0,conference-organizer,100,57,4/29/2020
990AD0,conference-organizer,100,57,4/29/2020
990AD0,conference-organizer,100,57,4/29/2020
990AD0,conference-organizer,100,57,4/29/2020
990AD0,conference-organizer,100,57,4/29/2020
9.97E+09,earnings,100,50,4/29/2020
9C8664,earnings,100,50,4/29/2020
9D307D,board-meeting,100,51,4/29/2020
9E91C6,partnership,100,61,4/29/2020
9EA947,business-contract,100,69,4/29/2020
9F37C5,conference-call,100,50,4/29/2020
9F6B1A,earnings,100,50,4/29/2020
9F6B1A,earnings,100,50,4/29/2020
9F6B1A,earnings,100,50,4/29/2020
9F6B1A,earnings,100,50,4/29/2020
A05C43,earnings,100,50,4/29/2020
A1E3B3,product-release,100,64,4/29/2020
A1E3B3,product-release,100,64,4/29/2020
A247F5,earnings-per-share-positive,100,69,4/29/2020
A247F5,earnings-per-share-positive,100,69,4/29/2020
A398F8,earnings,100,50,4/29/2020
A3BFAA,dividend,100,50,4/29/2020
A429A5,operating-earnings,100,50,4/29/2020
A48593,business-contract,100,69,4/29/2020
A4CD53,conference-participant,100,50,4/29/2020
A6213D,partnership,100,61,4/29/2020
A666C8,executive-appointment,100,54,4/29/2020
A6828A,business-contract,100,69,4/29/2020
A74F6F,conference-call,100,50,4/29/2020
A80FE0,earnings,100,50,4/29/2020
A8AC4C,earnings-up,100,68,4/29/2020
AA847A,earnings,100,50,4/29/2020
AA98ED,earnings,100,50,4/29/2020
AADE0B,dividend,100,50,4/29/2020
AC7AAE,public-offering,100,43,4/29/2020
AD3C93,earnings,100,50,4/29/2020
AD9F1D,earnings,100,50,4/29/2020
AD9F1D,earnings,100,50,4/29/2020
AD9F1D,earnings,100,50,4/29/2020
AD9F1D,earnings,100,50,4/29/2020
AD9F1D,earnings,100,50,4/29/2020
AD9F1D,earnings,100,50,4/29/2020
AD9F1D,earnings,100,50,4/29/2020
AD9F1D,earnings,100,50,4/29/2020
AD9F1D,earnings,100,50,4/29/2020
AF93DE,conference-call,100,50,4/29/2020
AFDF2E,earnings,100,50,4/29/2020
AFDF2E,earnings,100,50,4/29/2020
AFDF2E,earnings,100,50,4/29/2020
B04426,conference-call,100,50,4/29/2020
B076A1,earnings,100,50,4/29/2020
B076A1,earnings,100,50,4/29/2020
B076A1,earnings,100,50,4/29/2020
B08954,earnings,100,50,4/29/2020
B0998E,earnings,100,50,4/29/2020
B0B969,conference-call,100,50,4/29/2020
B106FA,earnings,100,50,4/29/2020
B1B10C,note-sale,100,52,4/29/2020
B1DF3C,note-sale,100,52,4/29/2020
B290A2,earnings,100,50,4/29/2020
B2D492,earnings,100,50,4/29/2020
B33E77,legal-issues-defendant,100,22,4/29/2020
B4C673,revenues,100,50,4/29/2020
B4C673,revenues,100,50,4/29/2020
B4C673,revenues,100,50,4/29/2020
B4C673,revenues,100,50,4/29/2020
B4C673,revenues,100,50,4/29/2020
B4C673,revenues,100,50,4/29/2020
B53C12,conference-call,100,50,4/29/2020
B77F14,conference-call,100,50,4/29/2020
B83BCE,earnings,100,50,4/29/2020
B98EFA,fundraising,100,64,4/29/2020
BB5142,partnership,100,61,4/29/2020
BB88B6,earnings,100,50,4/29/2020
BC4876,dividend,100,50,4/29/2020
BD8517,earnings,100,50,4/29/2020
BDCC11,earnings,100,50,4/29/2020
BDEC1E,conference-call,100,50,4/29/2020
BDEF34,earnings,100,50,4/29/2020
BDEF34,earnings,100,50,4/29/2020
BDEF34,earnings,100,50,4/29/2020
BDEF34,earnings,100,50,4/29/2020
BDEF34,earnings,100,50,4/29/2020
BDEF34,earnings,100,50,4/29/2020
BDEF34,earnings,100,50,4/29/2020
BDEF34,earnings,100,50,4/29/2020
BE379D,conference-call,100,50,4/29/2020
BF5959,conference-call,100,50,4/29/2020
C05839,earnings,100,50,4/29/2020
C05839,earnings,100,50,4/29/2020
C05839,earnings,100,50,4/29/2020
C05839,earnings,100,50,4/29/2020
C0BA36,award,100,58,4/29/2020
C11C46,executive-appointment,100,54,4/29/2020
C16A8F,earnings,100,50,4/29/2020
C16A8F,earnings,100,50,4/29/2020
C16A8F,earnings,100,50,4/29/2020
C188F8,earnings,100,50,4/29/2020
C230FE,earnings,100,50,4/29/2020
C230FE,earnings,100,50,4/29/2020
C2E120,earnings,100,50,4/29/2020
C4A241,earnings-up,100,68,4/29/2020
C4A241,earnings,100,50,4/29/2020
C4A241,earnings,100,50,4/29/2020
C4A241,earnings,100,50,4/29/2020
C8A248,dividend,100,50,4/29/2020
C951A2,earnings,100,50,4/29/2020
C951A2,earnings,100,50,4/29/2020
C951A2,earnings,100,50,4/29/2020
C951A2,earnings,100,50,4/29/2020
C951A2,earnings,100,50,4/29/2020
C951A2,earnings,100,50,4/29/2020
C9732E,legal-issues-defendant,100,22,4/29/2020
C97B2D,earnings,100,50,4/29/2020
C99CC8,earnings,100,50,4/29/2020
C99CC8,earnings,100,50,4/29/2020
C99CC8,earnings,100,50,4/29/2020
C99CC8,earnings,100,50,4/29/2020
C99CC8,earnings,100,50,4/29/2020
C99CC8,earnings,100,50,4/29/2020
C99CC8,earnings,100,50,4/29/2020
C99CC8,earnings,100,50,4/29/2020
C99CC8,earnings,100,50,4/29/2020
C99CC8,earnings,100,50,4/29/2020
C99CC8,business-contract,100,69,4/29/2020
C9D866,earnings,100,50,4/29/2020
C9D866,earnings,100,50,4/29/2020
C9D866,earnings,100,50,4/29/2020
C9D866,earnings,100,50,4/29/2020
C9D866,earnings,100,50,4/29/2020
C9D866,earnings,100,50,4/29/2020
C9D866,earnings,100,50,4/29/2020
C9D866,earnings,100,50,4/29/2020
C9D866,earnings,100,50,4/29/2020
C9D866,earnings,100,50,4/29/2020
C9D866,earnings,100,50,4/29/2020
C9D866,earnings,100,50,4/29/2020
C9D866,earnings,100,50,4/29/2020
CA1620,conference-call,100,50,4/29/2020
CB7AB2,product-release,100,64,4/29/2020
CB9E13,earnings,100,50,4/29/2020
CBA33B,dividend,100,50,4/29/2020
CBA33B,earnings,100,50,4/29/2020
CBDB4D,conference-call,100,50,4/29/2020
CC339B,award,100,58,4/29/2020
CD06A2,dividend,100,50,4/29/2020
CFF15D,earnings,100,50,4/29/2020
CFF15D,earnings,100,50,4/29/2020
D06755,earnings,100,50,4/29/2020
D06755,earnings,100,50,4/29/2020
D06755,earnings,100,50,4/29/2020
D07B07,earnings,100,50,4/29/2020
D09938,earnings,100,50,4/29/2020
D0DFE5,earnings,100,50,4/29/2020
D17F7E,earnings,100,50,4/29/2020
D17F7E,earnings,100,50,4/29/2020
D17F7E,earnings,100,50,4/29/2020
D17F7E,earnings,100,50,4/29/2020
D17F7E,earnings,100,50,4/29/2020
D20C8F,earnings,100,50,4/29/2020
D437C3,earnings,100,50,4/29/2020
D437C3,earnings,100,50,4/29/2020
D437C3,earnings,100,50,4/29/2020
D437C3,earnings,100,50,4/29/2020
D501DC,earnings,100,50,4/29/2020
D518D8,product-release,100,64,4/29/2020
D54E62,dividend,100,50,4/29/2020
D5A350,earnings,100,50,4/29/2020
D650A7,earnings,100,50,4/29/2020
D65A13,acquisition-acquirer,100,49,4/29/2020
D65A13,reorganization-unit,100,53,4/29/2020
D6EAA3,dividend,100,50,4/29/2020
D78CCD,conference-call,100,50,4/29/2020
D8DBA3,operating-earnings,100,50,4/29/2020
D9E036,business-contract,100,69,4/29/2020
DB23C8,award,100,58,4/29/2020
DB88A1,product-release,100,64,4/29/2020
DCD97F,earnings,100,50,4/29/2020
DD3BB1,earnings,100,50,4/29/2020
DE5611,conference-call,100,50,4/29/2020
DEF058,earnings,100,50,4/29/2020
DEF058,earnings,100,50,4/29/2020
DEF058,earnings,100,50,4/29/2020
DEF058,earnings,100,50,4/29/2020
E00373,earnings,100,50,4/29/2020
E0339F,dividend,100,50,4/29/2020
E0647D,earnings,100,50,4/29/2020
E0647D,earnings,100,50,4/29/2020
E0647D,earnings,100,50,4/29/2020
E0647D,earnings,100,50,4/29/2020
E0647D,earnings,100,50,4/29/2020
E1E36F,earnings,100,50,4/29/2020
E1E36F,earnings,100,50,4/29/2020
E1E36F,earnings,100,50,4/29/2020
E1E36F,earnings,100,50,4/29/2020
E1E36F,earnings,100,50,4/29/2020
E1E36F,earnings,100,50,4/29/2020
E1E36F,earnings,100,50,4/29/2020
E259C7,note-sale,100,52,4/29/2020
E4CE73,product-release,100,64,4/29/2020
E6C8DC,conference-call,100,50,4/29/2020
E70531,dividend,100,50,4/29/2020
E866D2,note-sale,100,52,4/29/2020
E96E0B,conference-participant,100,50,4/29/2020
EC70EC,note-sale,100,52,4/29/2020
ECDEB2,earnings,100,50,4/29/2020
ED2A5E,earnings,100,50,4/29/2020
ED2A5E,earnings,100,50,4/29/2020
ED2A5E,earnings,100,50,4/29/2020
ED2A5E,earnings,100,50,4/29/2020
ED2A5E,earnings,100,50,4/29/2020
ED2A5E,earnings,100,50,4/29/2020
ED2A5E,earnings,100,50,4/29/2020
EE967B,earnings,100,50,4/29/2020
EF45B6,earnings,100,50,4/29/2020
EF76C8,earnings,100,50,4/29/2020
F15E41,earnings,100,50,4/29/2020
F15E41,earnings,100,50,4/29/2020
F15E41,earnings,100,50,4/29/2020
F15E41,earnings,100,50,4/29/2020
F1CD47,earnings,100,50,4/29/2020
F2BC3D,earnings,100,50,4/29/2020
F31B13,dividend,100,50,4/29/2020
F43A11,legal-issues-defendant,100,22,4/29/2020
F50BAB,earnings,100,50,4/29/2020
F50BAB,earnings,100,50,4/29/2020
F50BAB,earnings,100,50,4/29/2020
F50BAB,earnings,100,50,4/29/2020
F51DB0,conference-participant,100,50,4/29/2020
F5349B,executive-appointment,100,54,4/29/2020
F5D410,partnership,100,61,4/29/2020
F5D410,partnership,100,61,4/29/2020
F6E248,clinical-trials,100,56,4/29/2020
F6E248,clinical-trials,100,56,4/29/2020
F7902B,earnings,100,50,4/29/2020
F7902B,earnings,100,50,4/29/2020
F88A04,dividend,100,50,4/29/2020
FA918D,executive-appointment,100,54,4/29/2020
FA918D,dividend,100,50,4/29/2020
FBDA0F,earnings,100,50,4/29/2020
FC1B7B,earnings,100,50,4/29/2020
FD6926,conference-participant,100,50,4/29/2020
FD6926,business-contract,100,69,4/29/2020
FDC7E6,dividend-down,100,19,4/29/2020
FDC7E6,earnings,100,50,4/29/2020
FE1A1D,operating-earnings,100,50,4/29/2020
FEE4B0,dividend,100,50,4/29/2020
FF227B,earnings,100,50,4/29/2020
FFE543,market-entry,100,57,4/29/2020
00067A,conference-participant,100,50,4/30/2020
00326E,earnings,100,50,4/30/2020
9397,earnings,100,50,4/30/2020
9397,earnings,100,50,4/30/2020
0142B5,earnings-per-share-positive,100,69,4/30/2020
01478A,earnings,100,50,4/30/2020
0157B1,earnings,100,50,4/30/2020
0157B1,earnings,100,50,4/30/2020
0157B1,earnings,100,50,4/30/2020
0157B1,earnings,100,50,4/30/2020
0157B1,earnings,100,50,4/30/2020
0157B1,earnings,100,50,4/30/2020
0157B1,earnings,100,50,4/30/2020
0157B1,business-contract,100,69,4/30/2020
0157B1,business-contract,100,69,4/30/2020
20751,earnings,100,50,4/30/2020
04996E,executive-appointment,100,54,4/30/2020
61366,earnings,100,50,4/30/2020
07CA6A,earnings,100,50,4/30/2020
07CA6A,earnings,100,50,4/30/2020
07CA6A,dividend,100,50,4/30/2020
07CA6A,dividend,100,50,4/30/2020
09DE1F,unit-acquisition-completed-acquiree,100,67,4/30/2020
0A7650,earnings,100,50,4/30/2020
0A9D0A,earnings,100,50,4/30/2020
0BC17A,dividend,100,50,4/30/2020
0BC17A,earnings,100,50,4/30/2020
0BC853,earnings,100,50,4/30/2020
0BC853,acquisition-interest-acquirer,100,46,4/30/2020
0BC853,acquisition-interest-acquirer,100,46,4/30/2020
0BF198,earnings,100,50,4/30/2020
0C2A0D,earnings,100,50,4/30/2020
0D03C8,earnings,100,50,4/30/2020
0DE3D5,conference-call,100,50,4/30/2020
0E499E,earnings,100,50,4/30/2020
0ED415,earnings,100,50,4/30/2020
0ED415,earnings,100,50,4/30/2020
0ED415,earnings,100,50,4/30/2020
0F04E5,earnings,100,50,4/30/2020
0F04E5,earnings,100,50,4/30/2020
0F04E5,earnings,100,50,4/30/2020
105D00,dividend,100,50,4/30/2020
106394,earnings,100,50,4/30/2020
10943B,earnings,100,50,4/30/2020
11A49E,conference-call,100,50,4/30/2020
13C3E0,earnings,100,50,4/30/2020
147C38,earnings,100,50,4/30/2020
165B86,conference-call,100,50,4/30/2020
1748F6,executive-appointment,100,54,4/30/2020
1782D5,earnings,100,50,4/30/2020
1.79E+10,dividend,100,50,4/30/2020
17EDA5,product-release,100,64,4/30/2020
17EDA5,product-release,100,64,4/30/2020
17EDA5,conference-call,100,50,4/30/2020
180DA0,earnings,100,50,4/30/2020
1834C0,dividend,100,50,4/30/2020
197019,dividend,100,50,4/30/2020
1B5FEA,earnings,100,50,4/30/2020
1B637E,partnership,100,61,4/30/2020
1CD09C,business-contract,100,69,4/30/2020
1DB6A6,earnings,100,50,4/30/2020
1DE526,earnings,100,50,4/30/2020
1DEBBE,earnings,100,50,4/30/2020
1DF15D,earnings,100,50,4/30/2020
1DF15D,earnings,100,50,4/30/2020
1DF15D,earnings,100,50,4/30/2020
1F716B,acquisition-acquirer,100,49,4/30/2020
1F716B,earnings,100,50,4/30/2020
1F716B,business-contract,100,69,4/30/2020
1FAF22,earnings,100,50,4/30/2020
1FAF22,earnings,100,50,4/30/2020
1FAF22,earnings,100,50,4/30/2020
1FAF22,earnings,100,50,4/30/2020
202E5A,conference-call,100,50,4/30/2020
219B21,earnings,100,50,4/30/2020
219B21,earnings,100,50,4/30/2020
219B21,earnings,100,50,4/30/2020
219B21,earnings,100,50,4/30/2020
219B21,earnings,100,50,4/30/2020
219B21,earnings,100,50,4/30/2020
221AD7,legal-issues-defendant,100,22,4/30/2020
222BF9,earnings,100,50,4/30/2020
228D42,partnership,100,61,4/30/2020
238302,conference-call,100,50,4/30/2020
2491BC,earnings,100,50,4/30/2020
2491BC,earnings,100,50,4/30/2020
2491BC,earnings,100,50,4/30/2020
2491BC,earnings,100,50,4/30/2020
249674,earnings,100,50,4/30/2020
24FA23,earnings,100,50,4/30/2020
25529C,earnings,100,50,4/30/2020
25AB8E,legal-issues-defendant,100,22,4/30/2020
25AB8E,legal-issues-defendant,100,22,4/30/2020
25AB8E,legal-issues-defendant,100,22,4/30/2020
25AB8E,legal-issues-defendant,100,22,4/30/2020
267718,partnership,100,61,4/30/2020
267718,partnership,100,61,4/30/2020
267718,partnership,100,61,4/30/2020
26D8ED,earnings,100,50,4/30/2020
270B78,earnings,100,50,4/30/2020
27A791,earnings,100,50,4/30/2020
28B730,earnings,100,50,4/30/2020
28DCF3,earnings,100,50,4/30/2020
28F905,conference-call,100,50,4/30/2020
29B702,earnings,100,50,4/30/2020
2.90E+62,earnings,100,50,4/30/2020
2.90E+62,earnings,100,50,4/30/2020
2.90E+62,earnings,100,50,4/30/2020
2.90E+62,earnings,100,50,4/30/2020
2.90E+62,earnings,100,50,4/30/2020
2.90E+62,dividend,100,50,4/30/2020
2A1009,earnings,100,50,4/30/2020
2A1009,earnings,100,50,4/30/2020
2A1009,earnings,100,50,4/30/2020
2A1009,earnings,100,50,4/30/2020
2AA6A8,conference-call,100,50,4/30/2020
2BA977,earnings,100,50,4/30/2020
2BA977,earnings,100,50,4/30/2020
2BA977,earnings,100,50,4/30/2020
2BA977,earnings,100,50,4/30/2020
2BA977,earnings,100,50,4/30/2020
2BA977,earnings,100,50,4/30/2020
2BA977,earnings,100,50,4/30/2020
2BA977,earnings,100,50,4/30/2020
2BA977,earnings,100,50,4/30/2020
2BC05E,earnings,100,50,4/30/2020
2BC05E,earnings,100,50,4/30/2020
2BC05E,earnings,100,50,4/30/2020
2BC05E,earnings,100,50,4/30/2020
2C3348,earnings,100,50,4/30/2020
2CA60F,earnings,100,50,4/30/2020
2CA60F,earnings,100,50,4/30/2020
2CA60F,earnings,100,50,4/30/2020
2CC71C,conference-call,100,50,4/30/2020
2D2D43,executive-appointment,100,54,4/30/2020
2DC88B,earnings,100,50,4/30/2020
2E6514,earnings-positive,100,69,4/30/2020
2EC172,earnings,100,50,4/30/2020
2EC172,earnings,100,50,4/30/2020
2EC172,earnings,100,50,4/30/2020
2EC172,earnings,100,50,4/30/2020
2EC172,earnings,100,50,4/30/2020
2EC172,earnings,100,50,4/30/2020
301493,conference-call,100,50,4/30/2020
30DE64,conference-call,100,50,4/30/2020
30DFD3,earnings,100,50,4/30/2020
314D88,earnings,100,50,4/30/2020
31A7CC,dividend,100,50,4/30/2020
328250,earnings,100,50,4/30/2020
32C8CD,earnings,100,50,4/30/2020
338544,earnings,100,50,4/30/2020
3461CF,earnings,100,50,4/30/2020
349DA4,earnings,100,50,4/30/2020
34B97A,conference-participant,100,50,4/30/2020
34E9F9,earnings,100,50,4/30/2020
34E9F9,earnings,100,50,4/30/2020
34E9F9,earnings,100,50,4/30/2020
34E9F9,earnings,100,50,4/30/2020
34E9F9,earnings,100,50,4/30/2020
35557B,earnings,100,50,4/30/2020
371B0A,conference-call,100,50,4/30/2020
372037,dividend,100,50,4/30/2020
372037,earnings,100,50,4/30/2020
372037,earnings,100,50,4/30/2020
3798B9,earnings,100,50,4/30/2020
383ADA,earnings,100,50,4/30/2020
387375,earnings,100,50,4/30/2020
3.88E+02,earnings,100,50,4/30/2020
3.88E+02,dividend,100,50,4/30/2020
389CFB,earnings,100,50,4/30/2020
3A94DF,earnings,100,50,4/30/2020
3F4668,legal-issues-defendant,100,22,4/30/2020
3F6A9C,earnings,100,50,4/30/2020
3F6A9C,note-sale,100,52,4/30/2020
3F868D,earnings,100,50,4/30/2020
434F38,earnings,100,50,4/30/2020
4398A2,earnings,100,50,4/30/2020
4398A2,earnings,100,50,4/30/2020
43E8F5,earnings,100,50,4/30/2020
447FC6,earnings,100,50,4/30/2020
447FC6,earnings,100,50,4/30/2020
447FC6,earnings,100,50,4/30/2020
44DDBD,conference-call,100,50,4/30/2020
451D61,earnings,100,50,4/30/2020
468DD4,earnings,100,50,4/30/2020
479930,earnings,100,50,4/30/2020
47B4CC,earnings,100,50,4/30/2020
47B4CC,earnings,100,50,4/30/2020
47BA98,earnings,100,50,4/30/2020
4806CE,earnings,100,50,4/30/2020
4885C8,earnings,100,50,4/30/2020
4BD6DB,earnings,100,50,4/30/2020
4BDCA7,conference-call,100,50,4/30/2020
4C1FA1,legal-issues-defendant,100,22,4/30/2020
4C37C5,conference-participant,100,50,4/30/2020
4E2D94,earnings,100,50,4/30/2020
4E2D94,dividend,100,50,4/30/2020
4ECD1A,credit-extension-recipient,100,69,4/30/2020
4ECD1A,facility-open,100,65,4/30/2020
4EEE7E,earnings,100,50,4/30/2020
4F783B,executive-appointment,100,54,4/30/2020
4F783B,dividend,100,50,4/30/2020
50070E,conference-organizer,100,57,4/30/2020
519FE0,fundraising,100,64,4/30/2020
52015A,earnings,100,50,4/30/2020
532D47,earnings,100,50,4/30/2020
54A646,dividend,100,50,4/30/2020
54A713,earnings,100,50,4/30/2020
54A713,dividend,100,50,4/30/2020
553949,earnings,100,50,4/30/2020
553949,earnings,100,50,4/30/2020
553949,earnings,100,50,4/30/2020
553949,earnings,100,50,4/30/2020
553949,earnings,100,50,4/30/2020
55438C,partnership,100,61,4/30/2020
56277A,conference-participant,100,50,4/30/2020
56632F,earnings,100,50,4/30/2020
56632F,earnings,100,50,4/30/2020
56632F,earnings,100,50,4/30/2020
567F3D,earnings,100,50,4/30/2020
567F3D,earnings,100,50,4/30/2020
567F3D,earnings,100,50,4/30/2020
567F3D,earnings,100,50,4/30/2020
57634F,legal-issues-defendant,100,22,4/30/2020
583223,earnings,100,50,4/30/2020
583223,executive-resignation,100,44,4/30/2020
587D25,conference-call,100,50,4/30/2020
58C2D4,earnings,100,50,4/30/2020
59C539,earnings,100,50,4/30/2020
59DB8C,earnings,100,50,4/30/2020
5A64D5,earnings,100,50,4/30/2020
5B6C11,earnings,100,50,4/30/2020
5CCDAD,earnings,100,50,4/30/2020
5D0337,earnings,100,50,4/30/2020
5D1329,conference-call,100,50,4/30/2020
5D1329,executive-appointment,100,54,4/30/2020
5D16CF,earnings,100,50,4/30/2020
5D1956,earnings,100,50,4/30/2020
5D43A7,earnings,100,50,4/30/2020
5D43A7,earnings,100,50,4/30/2020
5D43A7,earnings,100,50,4/30/2020
5D43A7,earnings,100,50,4/30/2020
5F3D91,earnings,100,50,4/30/2020
5F3E74,earnings,100,50,4/30/2020
5F3E74,earnings,100,50,4/30/2020
619882,conference-organizer,100,57,4/30/2020
61A586,partnership,100,61,4/30/2020
63E8D5,earnings,100,50,4/30/2020
63E8D5,earnings,100,50,4/30/2020
64E615,earnings,100,50,4/30/2020
64FF65,conference-call,100,50,4/30/2020
6.52E+64,donation,100,54,4/30/2020
6559D8,conference-call,100,50,4/30/2020
665440,product-release,100,64,4/30/2020
68BA15,board-meeting,100,51,4/30/2020
69345C,partnership,100,61,4/30/2020
69494C,earnings,100,50,4/30/2020
69C99E,earnings,100,50,4/30/2020
6B0784,conference-call,100,50,4/30/2020
6B0784,conference-call,100,50,4/30/2020
6B5379,earnings,100,50,4/30/2020
6B5379,earnings,100,50,4/30/2020
6B5379,earnings,100,50,4/30/2020
6B6375,executive-appointment,100,54,4/30/2020
6B6375,earnings,100,50,4/30/2020
6B67BD,earnings,100,50,4/30/2020
6CDFC6,earnings,100,50,4/30/2020
6D2BF6,earnings,100,50,4/30/2020
6DC1D7,earnings,100,50,4/30/2020
6E705B,earnings,100,50,4/30/2020
6EB9DA,executive-appointment,100,54,4/30/2020
6F0A63,earnings,100,50,4/30/2020
713810,executive-appointment,100,54,4/30/2020
73529F,earnings,100,50,4/30/2020
73C9E2,earnings,100,50,4/30/2020
742AAB,conference-call,100,50,4/30/2020
7.45E+28,earnings,100,50,4/30/2020
747219,conference-participant,100,50,4/30/2020
76D79A,conference-call,100,50,4/30/2020
76F067,earnings,100,50,4/30/2020
76F067,earnings,100,50,4/30/2020
7710F3,earnings,100,50,4/30/2020
7710F3,earnings,100,50,4/30/2020
7710F3,executive-appointment,100,54,4/30/2020
7823A3,earnings,100,50,4/30/2020
7823A3,earnings,100,50,4/30/2020
7823A3,earnings,100,50,4/30/2020
7823A3,earnings,100,50,4/30/2020
7823A3,earnings,100,50,4/30/2020
782B46,dividend,100,50,4/30/2020
782B46,buybacks,100,74,4/30/2020
789ADD,earnings,100,50,4/30/2020
789ADD,earnings,100,50,4/30/2020
789ADD,earnings,100,50,4/30/2020
789ADD,earnings,100,50,4/30/2020
78F9ED,earnings,100,50,4/30/2020
78F9ED,earnings,100,50,4/30/2020
78F9ED,earnings,100,50,4/30/2020
78F9ED,earnings,100,50,4/30/2020
78F9ED,earnings,100,50,4/30/2020
78F9ED,earnings,100,50,4/30/2020
78F9ED,earnings,100,50,4/30/2020
79167B,earnings,100,50,4/30/2020
79167B,earnings,100,50,4/30/2020
79167B,earnings,100,50,4/30/2020
79167B,earnings,100,50,4/30/2020
7A5D58,earnings,100,50,4/30/2020
7B8CB5,earnings,100,50,4/30/2020
7B9AFA,earnings,100,50,4/30/2020
7BAAE7,dividend,100,50,4/30/2020
7BAAE7,dividend,100,50,4/30/2020
7BEA98,earnings,100,50,4/30/2020
7C4F43,earnings,100,50,4/30/2020
7D5384,earnings,100,50,4/30/2020
7D5384,earnings,100,50,4/30/2020
7D5384,earnings,100,50,4/30/2020
7D5384,earnings,100,50,4/30/2020
7D5384,earnings,100,50,4/30/2020
7DA412,earnings,100,50,4/30/2020
81222C,earnings,100,50,4/30/2020
81A88D,earnings,100,50,4/30/2020
81EAD4,business-contract,100,69,4/30/2020
81EAD4,business-contract,100,69,4/30/2020
81EAD4,earnings,100,50,4/30/2020
81EAD4,earnings,100,50,4/30/2020
81EAD4,earnings,100,50,4/30/2020
8.22E+27,earnings,100,50,4/30/2020
837C04,dividend,100,50,4/30/2020
837C04,earnings,100,50,4/30/2020
837C04,earnings,100,50,4/30/2020
837C04,earnings,100,50,4/30/2020
837C04,earnings,100,50,4/30/2020
837C04,earnings,100,50,4/30/2020
837C04,earnings,100,50,4/30/2020
837C04,earnings,100,50,4/30/2020
84A6B9,earnings,100,50,4/30/2020
84AB66,earnings-positive,100,69,4/30/2020
8.40E+120,clinical-trials,100,56,4/30/2020
85DE00,dividend,100,50,4/30/2020
85DE00,earnings,100,50,4/30/2020
86478F,earnings,100,50,4/30/2020
86BAC7,earnings,100,50,4/30/2020
86F123,earnings,100,50,4/30/2020
8802B4,earnings,100,50,4/30/2020
880C0C,earnings,100,50,4/30/2020
8A0368,earnings,100,50,4/30/2020
8A0368,earnings,100,50,4/30/2020
8A0368,earnings,100,50,4/30/2020
8A0368,earnings,100,50,4/30/2020
8AA108,regulatory-product-approval-granted,100,81,4/30/2020
8AB85C,earnings,100,50,4/30/2020
8B1F37,earnings,100,50,4/30/2020
8B1F37,earnings,100,50,4/30/2020
8B1F37,earnings,100,50,4/30/2020
8B1F37,earnings,100,50,4/30/2020
8B1F37,earnings,100,50,4/30/2020
8B1F37,earnings,100,50,4/30/2020
8B1F37,earnings,100,50,4/30/2020
8B1F37,earnings,100,50,4/30/2020
8B1F37,earnings,100,50,4/30/2020
8B1F37,earnings,100,50,4/30/2020
8B6E7E,earnings,100,50,4/30/2020
8E0E32,earnings,100,50,4/30/2020
8E8E6E,earnings,100,50,4/30/2020
8F3231,note-sale,100,52,4/30/2020
913437,earnings,100,50,4/30/2020
92D6A5,earnings,100,50,4/30/2020
931AE7,public-offering,100,43,4/30/2020
934029,earnings,100,50,4/30/2020
934CC3,conference-call,100,50,4/30/2020
93C130,earnings,100,50,4/30/2020
93C130,dividend,100,50,4/30/2020
93D207,earnings,100,50,4/30/2020
94756D,earnings,100,50,4/30/2020
9507FF,earnings,100,50,4/30/2020
950AB7,earnings,100,50,4/30/2020
9.54E+32,earnings,100,50,4/30/2020
9.54E+32,earnings,100,50,4/30/2020
95C392,earnings,100,50,4/30/2020
95F59E,board-meeting,100,51,4/30/2020
96F126,dividend,100,50,4/30/2020
96F126,government-contract,100,69,4/30/2020
971334,earnings,100,50,4/30/2020
971334,earnings,100,50,4/30/2020
971334,earnings,100,50,4/30/2020
971334,earnings,100,50,4/30/2020
971F7B,earnings,100,50,4/30/2020
971F7B,earnings,100,50,4/30/2020
971F7B,earnings,100,50,4/30/2020
971F7B,earnings,100,50,4/30/2020
979451,earnings,100,50,4/30/2020
9810C0,earnings,100,50,4/30/2020
98D33E,dividend,100,50,4/30/2020
990AD0,conference-organizer,100,57,4/30/2020
990AD0,conference-organizer,100,57,4/30/2020
990AD0,conference-organizer,100,57,4/30/2020
990AD0,conference-organizer,100,57,4/30/2020
9934AD,acquisition-acquiree,100,76,4/30/2020
9934AD,business-contract,100,69,4/30/2020
9AF3DC,earnings,100,50,4/30/2020
9B5968,earnings-up,100,68,4/30/2020
9B5968,earnings-up,100,68,4/30/2020
9B71A7,executive-appointment,100,54,4/30/2020
9B730A,conference-call,100,50,4/30/2020
9CA432,board-meeting,100,51,4/30/2020
9CDA4F,earnings,100,50,4/30/2020
9CE4C7,dividend,100,50,4/30/2020
9E3224,earnings,100,50,4/30/2020
9E575E,earnings,100,50,4/30/2020
9EED50,earnings,100,50,4/30/2020
9F37C5,dividend,100,50,4/30/2020
9F5CBB,dividend,100,50,4/30/2020
9F71E5,earnings,100,50,4/30/2020
9F71E5,dividend,100,50,4/30/2020
A01664,earnings,100,50,4/30/2020
A072C4,conference-call,100,50,4/30/2020
A204A7,earnings,100,50,4/30/2020
A29DBD,earnings,100,50,4/30/2020
A41450,earnings,100,50,4/30/2020
A4386C,dividend,100,50,4/30/2020
A4D173,dividend,100,50,4/30/2020
A4D173,dividend,100,50,4/30/2020
A5151E,earnings,100,50,4/30/2020
A52533,earnings,100,50,4/30/2020
A666C8,earnings,100,50,4/30/2020
A666C8,earnings,100,50,4/30/2020
A666C8,earnings,100,50,4/30/2020
A6828A,partnership,100,61,4/30/2020
A7A0BD,conference-call,100,50,4/30/2020
A7CCF0,earnings,100,50,4/30/2020
A7CCF0,earnings,100,50,4/30/2020
A94637,revenues,100,50,4/30/2020
AADE0B,earnings,100,50,4/30/2020
AC1952,earnings,100,50,4/30/2020
AC3584,earnings,100,50,4/30/2020
AC7AAE,earnings,100,50,4/30/2020
AC7AAE,public-offering,100,43,4/30/2020
AC7AAE,public-offering,100,43,4/30/2020
AD1ACF,partnership,100,61,4/30/2020
AE79CD,product-release,100,64,4/30/2020
AFEC35,earnings,100,50,4/30/2020
B05118,earnings,100,50,4/30/2020
B2256A,earnings,100,50,4/30/2020
B2AA0A,earnings-positive,100,69,4/30/2020
B3ED62,earnings,100,50,4/30/2020
B4C673,product-release,100,64,4/30/2020
B7BDA3,earnings,100,50,4/30/2020
B7EB38,earnings,100,50,4/30/2020
B7EB38,earnings,100,50,4/30/2020
B80AD1,earnings,100,50,4/30/2020
BA0442,executive-appointment,100,54,4/30/2020
BB0787,earnings,100,50,4/30/2020
BB07E4,dividend,100,50,4/30/2020
BBAE2A,earnings,100,50,4/30/2020
BBBB41,dividend,100,50,4/30/2020
BBBB41,executive-appointment,100,54,4/30/2020
BD15E8,earnings,100,50,4/30/2020
BD682F,earnings,100,50,4/30/2020
BDD12C,earnings,100,50,4/30/2020
BDE867,award,100,58,4/30/2020
BE14CF,conference-participant,100,50,4/30/2020
BE86A1,earnings,100,50,4/30/2020
BEB756,earnings,100,50,4/30/2020
BFD0A7,conference-call,100,50,4/30/2020
C0030A,earnings-up,100,68,4/30/2020
C0030A,earnings,100,50,4/30/2020
C0030A,earnings,100,50,4/30/2020
C0030A,earnings,100,50,4/30/2020
C0030A,earnings,100,50,4/30/2020
C062D4,dividend,100,50,4/30/2020
C11C46,executive-appointment,100,54,4/30/2020
C1CBA4,earnings-positive,100,69,4/30/2020
C1CBA4,earnings-positive,100,69,4/30/2020
C1CBA4,earnings-positive,100,69,4/30/2020
C1CBA4,earnings-positive,100,69,4/30/2020
C1CBA4,earnings-positive,100,69,4/30/2020
C1CBA4,earnings-positive,100,69,4/30/2020
C1CBA4,earnings-positive,100,69,4/30/2020
C1CBA4,dividend,100,50,4/30/2020
C2609A,dividend,100,50,4/30/2020
C29715,note-sale,100,52,4/30/2020
C32A39,earnings,100,50,4/30/2020
C356AC,dividend,100,50,4/30/2020
C356AC,earnings,100,50,4/30/2020
C356AC,earnings,100,50,4/30/2020
C356AC,earnings,100,50,4/30/2020
C356AC,earnings,100,50,4/30/2020
C356AC,earnings,100,50,4/30/2020
C4A912,earnings,100,50,4/30/2020
C4A912,earnings,100,50,4/30/2020
C4A912,earnings,100,50,4/30/2020
C4F567,revenues,100,50,4/30/2020
C4F567,revenues,100,50,4/30/2020
C4F567,revenues,100,50,4/30/2020
C4F567,revenues,100,50,4/30/2020
C4F9C6,earnings,100,50,4/30/2020
C564E4,conference-call,100,50,4/30/2020
C58D71,earnings,100,50,4/30/2020
C81E00,operating-earnings,100,50,4/30/2020
C81E00,operating-earnings,100,50,4/30/2020
C83B88,earnings,100,50,4/30/2020
C83B88,earnings,100,50,4/30/2020
C83B88,earnings,100,50,4/30/2020
C83B88,earnings,100,50,4/30/2020
C83B88,earnings,100,50,4/30/2020
C98CDB,earnings,100,50,4/30/2020
C9C62A,earnings,100,50,4/30/2020
CAB222,earnings,100,50,4/30/2020
CB22CD,credit-extension-recipient,100,69,4/30/2020
CB7AB2,earnings,100,50,4/30/2020
CC0C78,earnings,100,50,4/30/2020
CC35BE,earnings,100,50,4/30/2020
CDAF5B,operating-earnings,100,50,4/30/2020
CDC217,earnings,100,50,4/30/2020
CDEDFE,earnings,100,50,4/30/2020
CE1002,earnings,100,50,4/30/2020
CE1002,earnings,100,50,4/30/2020
CE1002,earnings,100,50,4/30/2020
CE1002,earnings,100,50,4/30/2020
CE5C6E,earnings,100,50,4/30/2020
CE96E7,earnings,100,50,4/30/2020
D03C7A,earnings,100,50,4/30/2020
D1344A,earnings,100,50,4/30/2020
D1C0B9,revenue-up,100,69,4/30/2020
D1C0B9,revenue-up,100,69,4/30/2020
D1C0B9,revenue-up,100,69,4/30/2020
D1C0B9,revenue-up,100,69,4/30/2020
D1C0B9,revenue-up,100,69,4/30/2020
D4070C,earnings,100,50,4/30/2020
D4070C,earnings,100,50,4/30/2020
D4C0CB,executive-appointment,100,54,4/30/2020
D64C6D,acquisition-acquiree,100,76,4/30/2020
D64EDF,donation,100,54,4/30/2020
D64EDF,dividend,100,50,4/30/2020
D65A13,revenues,100,50,4/30/2020
D65A13,revenues,100,50,4/30/2020
D65A13,revenues,100,50,4/30/2020
D8442A,earnings,100,50,4/30/2020
D8442A,earnings,100,50,4/30/2020
D8442A,earnings,100,50,4/30/2020
D8760C,dividend,100,50,4/30/2020
D8ECA1,earnings,100,50,4/30/2020
D8ECA1,earnings,100,50,4/30/2020
D8ECA1,earnings,100,50,4/30/2020
D8ECA1,earnings,100,50,4/30/2020
DC1405,conference-participant,100,50,4/30/2020
DD0099,earnings,100,50,4/30/2020
DDCB34,dividend,100,50,4/30/2020
DDCB34,earnings,100,50,4/30/2020
DFADDB,earnings,100,50,4/30/2020
E0207A,earnings,100,50,4/30/2020
E0207A,earnings,100,50,4/30/2020
E0207A,earnings,100,50,4/30/2020
E0207A,earnings,100,50,4/30/2020
E0339F,earnings,100,50,4/30/2020
E0339F,earnings,100,50,4/30/2020
E0339F,earnings,100,50,4/30/2020
E05026,earnings,100,50,4/30/2020
E09E2B,conference-call,100,50,4/30/2020
E10D31,earnings,100,50,4/30/2020
E124EB,unit-acquisition-completed-acquiree,100,67,4/30/2020
E124EB,unit-acquisition-completed-acquiree,100,67,4/30/2020
E124EB,unit-acquisition-completed-acquiree,100,67,4/30/2020
E12A6E,earnings,100,50,4/30/2020
E13782,earnings,100,50,4/30/2020
E1BD05,earnings,100,50,4/30/2020
E1BD05,earnings,100,50,4/30/2020
E259C7,note-sale,100,52,4/30/2020
E2F66E,earnings-above-expectations,100,88,4/30/2020
E40FB6,earnings,100,50,4/30/2020
E40FB6,earnings,100,50,4/30/2020
E40FB6,earnings,100,50,4/30/2020
E40FB6,earnings,100,50,4/30/2020
E6D89E,earnings,100,50,4/30/2020
E6D89E,earnings,100,50,4/30/2020
E6D89E,earnings,100,50,4/30/2020
E6E012,earnings,100,50,4/30/2020
E6E012,earnings,100,50,4/30/2020
E6E012,earnings,100,50,4/30/2020
E6E012,earnings,100,50,4/30/2020
E6E012,earnings,100,50,4/30/2020
E6EDED,earnings,100,50,4/30/2020
E74FED,earnings,100,50,4/30/2020
E8C557,earnings,100,50,4/30/2020
E8E899,partnership,100,61,4/30/2020
E959F3,dividend,100,50,4/30/2020
EBD89A,earnings,100,50,4/30/2020
ED0D7C,dividend,100,50,4/30/2020
ED0D7C,earnings,100,50,4/30/2020
ED0D7C,earnings,100,50,4/30/2020
ED0D7C,earnings,100,50,4/30/2020
ED0D7C,earnings,100,50,4/30/2020
ED0D7C,earnings,100,50,4/30/2020
ED4560,earnings,100,50,4/30/2020
EDF5CA,earnings,100,50,4/30/2020
EDF5CA,earnings,100,50,4/30/2020
EDF5CA,earnings,100,50,4/30/2020
EDF5CA,earnings,100,50,4/30/2020
EDF5CA,earnings,100,50,4/30/2020
EDF5CA,earnings,100,50,4/30/2020
EE1E44,earnings,100,50,4/30/2020
EE1E44,earnings,100,50,4/30/2020
EE1E44,earnings,100,50,4/30/2020
EE1E44,earnings,100,50,4/30/2020
EE1E44,earnings,100,50,4/30/2020
F0027C,earnings,100,50,4/30/2020
F02D0A,dividend,100,50,4/30/2020
F04E05,earnings,100,50,4/30/2020
F0B335,earnings,100,50,4/30/2020
F11638,earnings,100,50,4/30/2020
F1C04C,operating-earnings,100,50,4/30/2020
F209B4,public-offering,100,43,4/30/2020
F294DD,earnings,100,50,4/30/2020
F294DD,earnings,100,50,4/30/2020
F294DD,earnings,100,50,4/30/2020
F294DD,earnings,100,50,4/30/2020
F294DD,earnings,100,50,4/30/2020
F294DD,earnings,100,50,4/30/2020
F294DD,earnings,100,50,4/30/2020
F294DD,earnings,100,50,4/30/2020
F294DD,earnings,100,50,4/30/2020
F294DD,earnings,100,50,4/30/2020
F294DD,earnings,100,50,4/30/2020
F294DD,earnings,100,50,4/30/2020
F294DD,earnings,100,50,4/30/2020
F294DD,earnings,100,50,4/30/2020
F294DD,earnings,100,50,4/30/2020
F294DD,earnings,100,50,4/30/2020
F294DD,earnings,100,50,4/30/2020
F2E253,conference-call,100,50,4/30/2020
F2E253,dividend,100,50,4/30/2020
F3816D,conference-call,100,50,4/30/2020
F47871,partnership,100,61,4/30/2020
F4F46F,earnings,100,50,4/30/2020
F51DB0,earnings,100,50,4/30/2020
F5C78B,dividend,100,50,4/30/2020
F6E248,earnings,100,50,4/30/2020
F6E248,dividend,100,50,4/30/2020
F8084B,earnings,100,50,4/30/2020
F8084B,earnings,100,50,4/30/2020
F9AA02,partnership,100,61,4/30/2020
F9AA02,partnership,100,61,4/30/2020
FA36A4,earnings,100,50,4/30/2020
FA840E,conference-participant,100,50,4/30/2020
FA918D,earnings,100,50,4/30/2020
FA918D,earnings,100,50,4/30/2020
FACF19,product-price-cut,100,49,4/30/2020
FC4550,earnings,100,50,4/30/2020
FD6926,earnings,100,50,4/30/2020
FD6926,earnings,100,50,4/30/2020
FD6926,earnings,100,50,4/30/2020
FD6926,earnings,100,50,4/30/2020
FD9526,earnings,100,50,4/30/2020
FDF799,earnings,100,50,4/30/2020
FDF799,earnings,100,50,4/30/2020
FE89E0,earnings,100,50,4/30/2020
FFCD0E,conference-call,100,50,4/30/2020
0157B1,earnings,100,50,5/1/2020
03B8CF,asset-sale,100,62,5/1/2020
43862,earnings,100,50,5/1/2020
0624BE,earnings,100,50,5/1/2020
0BF528,conference-call,100,50,5/1/2020
0E5223,conference-call,100,50,5/1/2020
0ED415,earnings,100,50,5/1/2020
0ED415,earnings,100,50,5/1/2020
0ED415,earnings,100,50,5/1/2020
0FDE97,earnings,100,50,5/1/2020
0FDE97,earnings,100,50,5/1/2020
0FDE97,earnings,100,50,5/1/2020
0FDE97,earnings,100,50,5/1/2020
0FDE97,earnings,100,50,5/1/2020
0FDE97,earnings,100,50,5/1/2020
102F04,earnings,100,50,5/1/2020
108BD2,earnings,100,50,5/1/2020
119CB6,buybacks,100,74,5/1/2020
139303,earnings,100,50,5/1/2020
14ED2B,earnings,100,50,5/1/2020
16F4D8,conference-call,100,50,5/1/2020
1A3E1B,earnings,100,50,5/1/2020
1A3E1B,conference-organizer,100,57,5/1/2020
1A6A94,earnings,100,50,5/1/2020
1DB833,ipo-pricing,100,50,5/1/2020
1F43A1,earnings,100,50,5/1/2020
221AD7,legal-issues-defendant,100,22,5/1/2020
25AB8E,legal-issues-defendant,100,22,5/1/2020
25AB8E,legal-issues-defendant,100,22,5/1/2020
25AB8E,legal-issues-defendant,100,22,5/1/2020
27BFA1,dividend,100,50,5/1/2020
2A17B1,acquisition-completed-acquirer,100,49,5/1/2020
2A4131,executive-appointment,100,54,5/1/2020
2AE625,earnings,100,50,5/1/2020
2BF36E,conference-call,100,50,5/1/2020
2BF36E,conference-call,100,50,5/1/2020
2DDB22,earnings-guidance,100,50,5/1/2020
2EBC0B,conference-call,100,50,5/1/2020
32F24A,executive-appointment,100,54,5/1/2020
35AE32,earnings,100,50,5/1/2020
36C09B,clinical-trials,100,56,5/1/2020
3B8484,earnings,100,50,5/1/2020
3FACA7,earnings,100,50,5/1/2020
41ED98,conference-call,100,50,5/1/2020
420168,note-sale,100,52,5/1/2020
4.60E+06,revenues,100,50,5/1/2020
4C3FE9,earnings,100,50,5/1/2020
4D371E,dividend,100,50,5/1/2020
4E3D15,operating-earnings,100,50,5/1/2020
504FE2,dividend,100,50,5/1/2020
57634F,legal-issues-defendant,100,22,5/1/2020
5B6C11,acquisition-completed-acquirer,100,49,5/1/2020
5DA8B3,acquisition-completed-acquirer,100,49,5/1/2020
6.52E+64,earnings,100,50,5/1/2020
6634D9,earnings,100,50,5/1/2020
665D7D,earnings,100,50,5/1/2020
66749D,earnings,100,50,5/1/2020
66749D,earnings,100,50,5/1/2020
66749D,earnings,100,50,5/1/2020
66749D,earnings,100,50,5/1/2020
6B236C,dividend,100,50,5/1/2020
6D3B7B,dividend,100,50,5/1/2020
6E8349,earnings,100,50,5/1/2020
6F39FC,conference-call,100,50,5/1/2020
6F6559,dividend,100,50,5/1/2020
7032D0,earnings,100,50,5/1/2020
704B78,conference-participant,100,50,5/1/2020
704B78,conference-call,100,50,5/1/2020
705636,dividend,100,50,5/1/2020
719477,earnings,100,50,5/1/2020
719477,earnings,100,50,5/1/2020
719477,earnings,100,50,5/1/2020
726EEA,earnings,100,50,5/1/2020
726EEA,earnings,100,50,5/1/2020
726EEA,earnings,100,50,5/1/2020
726EEA,earnings,100,50,5/1/2020
726EEA,earnings,100,50,5/1/2020
7273FF,earnings,100,50,5/1/2020
72F0FC,dividend,100,50,5/1/2020
72F0FC,earnings,100,50,5/1/2020
741937,earnings,100,50,5/1/2020
741937,earnings,100,50,5/1/2020
741937,earnings,100,50,5/1/2020
76BD96,dividend,100,50,5/1/2020
791EC1,unit-acquisition-completed-acquirer,100,49,5/1/2020
7A0EC4,acquisition-completed-acquirer,100,49,5/1/2020
7ACBA4,earnings,100,50,5/1/2020
7BC92D,earnings,100,50,5/1/2020
7E1D5D,award,100,58,5/1/2020
7FEEE1,executive-appointment,100,54,5/1/2020
82FD6D,conference-call,100,50,5/1/2020
83E0AC,conference-call,100,50,5/1/2020
84920B,executive-appointment,100,54,5/1/2020
8AC740,conference-call,100,50,5/1/2020
8BFAA4,conference-call,100,50,5/1/2020
8FCA78,earnings,100,50,5/1/2020
8FCA78,earnings,100,50,5/1/2020
8FCA78,earnings,100,50,5/1/2020
8FCA78,earnings,100,50,5/1/2020
900356,conference-call,100,50,5/1/2020
902255,dividend,100,50,5/1/2020
902670,executive-appointment,100,54,5/1/2020
947B0B,earnings,100,50,5/1/2020
990AD0,conference-organizer,100,57,5/1/2020
990AD0,conference-organizer,100,57,5/1/2020
990AD0,conference-organizer,100,57,5/1/2020
9B71A7,legal-issues-defendant,100,22,5/1/2020
9B730A,conference-call,100,50,5/1/2020
9D2790,product-release,100,64,5/1/2020
A47A7D,government-contract,100,69,5/1/2020
A49498,conference-call,100,50,5/1/2020
A4BCDE,earnings,100,50,5/1/2020
AA09AD,executive-appointment,100,54,5/1/2020
AADE0B,board-meeting,100,51,5/1/2020
AB4A7E,award,100,58,5/1/2020
AC642C,earnings,100,50,5/1/2020
AC642C,earnings,100,50,5/1/2020
AD9F1D,dividend,100,50,5/1/2020
AE7D16,earnings,100,50,5/1/2020
AEFC90,executive-resignation,100,44,5/1/2020
AEFC90,conference-participant,100,50,5/1/2020
AFD1CA,investment-investor,100,55,5/1/2020
AFD1CA,investment-investor,100,55,5/1/2020
B2206F,product-release,100,64,5/1/2020
B2D492,earnings,100,50,5/1/2020
B5BA39,earnings,100,50,5/1/2020
B77F14,earnings,100,50,5/1/2020
B77F14,earnings,100,50,5/1/2020
B77F14,earnings,100,50,5/1/2020
BAD655,earnings,100,50,5/1/2020
BFE02C,conference-participant,100,50,5/1/2020
C01737,earnings,100,50,5/1/2020
C062D4,conference-participant,100,50,5/1/2020
C3BCD5,earnings,100,50,5/1/2020
C3BCD5,earnings,100,50,5/1/2020
C3BCD5,expenses-charge,100,28,5/1/2020
C5E100,conference-call,100,50,5/1/2020
CA3CB9,earnings-up,100,68,5/1/2020
CBCC6A,earnings,100,50,5/1/2020
CBCC6A,earnings,100,50,5/1/2020
D0DE27,earnings,100,50,5/1/2020
D11C1C,conference-call,100,50,5/1/2020
D3FD6D,revenues,100,50,5/1/2020
D3FD6D,revenues,100,50,5/1/2020
D3FD6D,revenues,100,50,5/1/2020
D3FD6D,revenues,100,50,5/1/2020
D54E62,earnings,100,50,5/1/2020
D54E62,earnings,100,50,5/1/2020
D54E62,earnings,100,50,5/1/2020
D54E62,earnings,100,50,5/1/2020
D56D6D,earnings,100,50,5/1/2020
D5A350,acquisition-completed-acquirer,100,49,5/1/2020
D854F3,earnings,100,50,5/1/2020
D854F3,earnings,100,50,5/1/2020
D854F3,earnings,100,50,5/1/2020
D854F3,earnings,100,50,5/1/2020
D88EF3,earnings,100,50,5/1/2020
D88EF3,earnings,100,50,5/1/2020
D88EF3,earnings,100,50,5/1/2020
D88EF3,earnings,100,50,5/1/2020
D88EF3,earnings,100,50,5/1/2020
D88EF3,earnings,100,50,5/1/2020
D88EF3,earnings,100,50,5/1/2020
D9B1C9,conference-call,100,50,5/1/2020
DDC415,name-change,100,49,5/1/2020
DDC415,name-change,100,49,5/1/2020
E38906,facility-open,100,65,5/1/2020
E70531,earnings,100,50,5/1/2020
E70531,earnings,100,50,5/1/2020
E70531,earnings,100,50,5/1/2020
E70531,earnings,100,50,5/1/2020
E70531,earnings,100,50,5/1/2020
EB6965,earnings,100,50,5/1/2020
EB6965,earnings,100,50,5/1/2020
EB6965,earnings,100,50,5/1/2020
EB6965,earnings,100,50,5/1/2020
EB6965,earnings,100,50,5/1/2020
ED0402,donation,100,54,5/1/2020
EDF5CA,dividend,100,50,5/1/2020
EE1E44,acquisition-completed-acquirer,100,49,5/1/2020
EF5914,earnings,100,50,5/1/2020
F1529C,earnings-up,100,68,5/1/2020
F1529C,earnings-up,100,68,5/1/2020
F1529C,earnings-up,100,68,5/1/2020
F1529C,earnings-up,100,68,5/1/2020
F1529C,earnings-up,100,68,5/1/2020
F1529C,earnings-up,100,68,5/1/2020
F1529C,earnings-up,100,68,5/1/2020
F1529C,earnings-up,100,68,5/1/2020
F1529C,earnings-up,100,68,5/1/2020
F1529C,earnings-up,100,68,5/1/2020
F1529C,earnings-up,100,68,5/1/2020
F2BC3D,acquisition-acquirer,100,49,5/1/2020
F2BC3D,acquisition-acquirer,100,49,5/1/2020
F40EE2,dividend,100,50,5/1/2020
F40EE2,dividend,100,50,5/1/2020
F40EE2,dividend,100,50,5/1/2020
F40EE2,dividend,100,50,5/1/2020
F4E882,partnership,100,61,5/1/2020
F5D410,conference-participant,100,50,5/1/2020
F6DE54,earnings,100,50,5/1/2020
F6E1B5,earnings,100,50,5/1/2020
F6E248,regulatory-product-approval-granted,100,81,5/1/2020
F80FF9,earnings,100,50,5/1/2020
FF4BA4,earnings,100,50,5/1/2020
FF4BA4,earnings,100,50,5/1/2020
FF4BA4,earnings,100,50,5/1/2020
FF4BA4,earnings,100,50,5/1/2020
FF4BA4,earnings,100,50,5/1/2020
FF4BA4,earnings,100,50,5/1/2020
03B8CF,acquisition-acquiree,100,76,5/2/2020
0BD970,earnings,100,50,5/2/2020
835C86,earnings,100,50,5/2/2020
EB7D6C,legal-issues-defendant,100,22,5/2/2020
01D03F,regulatory-product-approval-granted,100,81,5/3/2020
301493,legal-issues-defendant,100,22,5/3/2020
00067A,conference-participant,100,50,5/4/2020
003B70,operating-earnings,100,50,5/4/2020
02870F,earnings,100,50,5/4/2020
02870F,earnings,100,50,5/4/2020
02870F,earnings,100,50,5/4/2020
02870F,earnings,100,50,5/4/2020
02ACBD,conference-call,100,50,5/4/2020
033B58,earnings,100,50,5/4/2020
040DBB,earnings,100,50,5/4/2020
05D148,conference-participant,100,50,5/4/2020
06C826,conference-call,100,50,5/4/2020
07C69F,earnings,100,50,5/4/2020
09DE1F,earnings,100,50,5/4/2020
09F623,note-sale,100,52,5/4/2020
0A0D9E,conference-participant,100,50,5/4/2020
0B13E8,conference-call,100,50,5/4/2020
0B7375,conference-call,100,50,5/4/2020
0BC29E,regulatory-product-approval-granted,100,81,5/4/2020
0BC29E,dividend,100,50,5/4/2020
0BC29E,earnings,100,50,5/4/2020
0BC29E,earnings,100,50,5/4/2020
0BC29E,earnings,100,50,5/4/2020
0BC29E,earnings,100,50,5/4/2020
0BC29E,earnings,100,50,5/4/2020
0BC29E,earnings,100,50,5/4/2020
0BC29E,earnings,100,50,5/4/2020
0BC29E,earnings,100,50,5/4/2020
0BF198,public-offering,100,43,5/4/2020
0BF198,public-offering,100,43,5/4/2020
0C6861,executive-appointment,100,54,5/4/2020
0CC62B,merger,100,66,5/4/2020
0DBB81,earnings,100,50,5/4/2020
0DC050,earnings,100,50,5/4/2020
0DC050,earnings,100,50,5/4/2020
0DC050,earnings,100,50,5/4/2020
0E499E,executive-appointment,100,54,5/4/2020
0E5223,earnings,100,50,5/4/2020
0E5619,conference-call,100,50,5/4/2020
0EF1AF,conference-call,100,50,5/4/2020
10100E,earnings,100,50,5/4/2020
1080C0,earnings,100,50,5/4/2020
108A2B,earnings-guidance,100,50,5/4/2020
1272B3,earnings,100,50,5/4/2020
12731D,conference-call,100,50,5/4/2020
12731D,conference-call,100,50,5/4/2020
12F98C,partnership,100,61,5/4/2020
13A782,earnings,100,50,5/4/2020
157CC1,executive-appointment,100,54,5/4/2020
157D9F,executive-appointment,100,54,5/4/2020
16F4D8,executive-salary,100,52,5/4/2020
17EDA5,acquisition-acquirer,100,49,5/4/2020
1834C0,unit-acquisition-acquirer,100,49,5/4/2020
184988,earnings,100,50,5/4/2020
1880C5,conference-call,100,50,5/4/2020
18D9FA,executive-appointment,100,54,5/4/2020
197019,earnings,100,50,5/4/2020
1A3E1B,conference-organizer,100,57,5/4/2020
1BC12C,partnership,100,61,5/4/2020
1CD708,dividend,100,50,5/4/2020
241AF7,earnings,100,50,5/4/2020
251988,unit-acquisition-acquirer,100,49,5/4/2020
297DA8,earnings,100,50,5/4/2020
297DA8,earnings,100,50,5/4/2020
2B8179,earnings,100,50,5/4/2020
2CF9D3,earnings,100,50,5/4/2020
2E89AE,conference-participant,100,50,5/4/2020
2F9304,earnings,100,50,5/4/2020
301493,legal-issues-defendant,100,22,5/4/2020
306623,earnings,100,50,5/4/2020
343996,earnings,100,50,5/4/2020
343996,earnings,100,50,5/4/2020
346BF2,earnings,100,50,5/4/2020
36529A,earnings,100,50,5/4/2020
38C46F,dividend,100,50,5/4/2020
3AAEAE,conference-call,100,50,5/4/2020
3AF7FD,dividend,100,50,5/4/2020
3C8A04,executive-appointment,100,54,5/4/2020
3F1C69,earnings,100,50,5/4/2020
408380,earnings,100,50,5/4/2020
41B53E,earnings,100,50,5/4/2020
41B53E,earnings,100,50,5/4/2020
41B53E,earnings,100,50,5/4/2020
429BFB,earnings,100,50,5/4/2020
435ACE,earnings,100,50,5/4/2020
43A74A,earnings,100,50,5/4/2020
43A74A,earnings,100,50,5/4/2020
43A74A,earnings,100,50,5/4/2020
43A74A,earnings,100,50,5/4/2020
43A74A,earnings,100,50,5/4/2020
43A74A,earnings,100,50,5/4/2020
43A74A,earnings,100,50,5/4/2020
44A4FC,partnership,100,61,5/4/2020
44A4FC,partnership,100,61,5/4/2020
44ED36,earnings,100,50,5/4/2020
44ED36,earnings,100,50,5/4/2020
44ED36,earnings,100,50,5/4/2020
44ED36,earnings,100,50,5/4/2020
44ED36,earnings,100,50,5/4/2020
458D2C,conference-call,100,50,5/4/2020
45BC35,conference-participant,100,50,5/4/2020
467F2C,conference-call,100,50,5/4/2020
490D4B,earnings,100,50,5/4/2020
490D4B,earnings,100,50,5/4/2020
4A2457,business-contract,100,69,5/4/2020
4A6F00,business-contract,100,69,5/4/2020
4DD203,conference-call,100,50,5/4/2020
4E5784,earnings,100,50,5/4/2020
4E7C1F,earnings,100,50,5/4/2020
4E7C1F,earnings,100,50,5/4/2020
4E7C1F,earnings,100,50,5/4/2020
4EEB00,conference-call,100,50,5/4/2020
504FE2,unit-acquisition-completed-acquirer,100,49,5/4/2020
504FE2,unit-acquisition-completed-acquirer,100,49,5/4/2020
5088A5,earnings,100,50,5/4/2020
510EA1,earnings,100,50,5/4/2020
51D876,executive-appointment,100,54,5/4/2020
51E682,dividend,100,50,5/4/2020
5403F8,earnings,100,50,5/4/2020
5.47E+28,earnings,100,50,5/4/2020
5546DA,executive-appointment,100,54,5/4/2020
55C9B5,executive-appointment,100,54,5/4/2020
55C9B5,conference-participant,100,50,5/4/2020
564F3E,earnings,100,50,5/4/2020
56FB7C,dividend-up,100,81,5/4/2020
57634F,legal-issues-defendant,100,22,5/4/2020
57DDB9,conference-participant,100,50,5/4/2020
57DDB9,conference-participant,100,50,5/4/2020
57DDB9,earnings,100,50,5/4/2020
5A53BF,earnings,100,50,5/4/2020
619882,conference-organizer,100,57,5/4/2020
619882,conference-organizer,100,57,5/4/2020
619882,conference-organizer,100,57,5/4/2020
61A586,earnings,100,50,5/4/2020
61BCA7,earnings,100,50,5/4/2020
67B052,earnings,100,50,5/4/2020
69E8E1,earnings,100,50,5/4/2020
69E8E1,earnings,100,50,5/4/2020
69E8E1,earnings,100,50,5/4/2020
69E8E1,earnings,100,50,5/4/2020
69E8E1,earnings,100,50,5/4/2020
6D6B40,earnings,100,50,5/4/2020
6D6B40,partnership,100,61,5/4/2020
6-Dec-05,partnership,100,61,5/4/2020
6-Dec-05,partnership,100,61,5/4/2020
6-Dec-05,earnings,100,50,5/4/2020
70CA28,conference-participant,100,50,5/4/2020
70CA28,earnings,100,50,5/4/2020
70CA28,earnings,100,50,5/4/2020
71553E,earnings,100,50,5/4/2020
73A213,earnings,100,50,5/4/2020
73A213,earnings,100,50,5/4/2020
73A213,earnings,100,50,5/4/2020
7.44E+09,earnings,100,50,5/4/2020
743C70,earnings,100,50,5/4/2020
743C70,earnings,100,50,5/4/2020
76BD96,conference-call,100,50,5/4/2020
76DD0C,earnings,100,50,5/4/2020
76F067,conference-participant,100,50,5/4/2020
787D14,conference-call,100,50,5/4/2020
7AB859,partnership,100,61,5/4/2020
7ACD98,earnings,100,50,5/4/2020
7B6C88,earnings,100,50,5/4/2020
7C790D,earnings,100,50,5/4/2020
7F3669,earnings,100,50,5/4/2020
7F3A5F,note-sale,100,52,5/4/2020
7F3A5F,earnings,100,50,5/4/2020
7FDE1C,conference-call,100,50,5/4/2020
81222C,award,100,58,5/4/2020
84A6B9,earnings,100,50,5/4/2020
84A6B9,earnings,100,50,5/4/2020
84A6B9,earnings,100,50,5/4/2020
84A6B9,earnings,100,50,5/4/2020
84A6B9,earnings,100,50,5/4/2020
84A6B9,earnings,100,50,5/4/2020
84A6B9,earnings,100,50,5/4/2020
860AB6,earnings,100,50,5/4/2020
88193E,conference-participant,100,50,5/4/2020
88350F,conference-call,100,50,5/4/2020
895D56,partnership,100,61,5/4/2020
8AB37F,revenue-up,100,79,5/4/2020
8AB37F,earnings,100,50,5/4/2020
8AB37F,earnings,100,50,5/4/2020
8B1F37,unit-acquisition-acquirer,100,49,5/4/2020
8B1F37,acquisition-acquirer,100,49,5/4/2020
8B1F37,unit-acquisition-acquirer,100,49,5/4/2020
8B1F37,unit-acquisition-acquirer,100,49,5/4/2020
8B1F37,unit-acquisition-acquirer,100,49,5/4/2020
8BFE9A,conference-call,100,50,5/4/2020
8E3F58,earnings,100,50,5/4/2020
8E8E6E,note-sale,100,52,5/4/2020
8EDACA,legal-issues-defendant,100,22,5/4/2020
8F6995,earnings,100,50,5/4/2020
918D6D,executive-appointment,100,54,5/4/2020
91E5EE,earnings,100,50,5/4/2020
92005C,earnings,100,50,5/4/2020
934CC3,partnership,100,61,5/4/2020
93965C,earnings,100,50,5/4/2020
93965C,earnings,100,50,5/4/2020
9.39E+69,partnership,100,61,5/4/2020
944B2E,earnings,100,50,5/4/2020
945DE6,earnings,100,50,5/4/2020
945DE6,earnings,100,50,5/4/2020
945DE6,earnings,100,50,5/4/2020
945DE6,earnings,100,50,5/4/2020
954A47,earnings-positive,100,69,5/4/2020
957A07,earnings,100,50,5/4/2020
958938,conference-call,100,50,5/4/2020
9.65E+07,conference-call,100,50,5/4/2020
966ACE,earnings,100,50,5/4/2020
968966,earnings,100,50,5/4/2020
968966,dividend,100,50,5/4/2020
968B00,earnings-negative,100,33,5/4/2020
968B00,earnings-negative,100,33,5/4/2020
980C14,conference-call,100,50,5/4/2020
98CEBB,earnings,100,50,5/4/2020
98D33E,earnings,100,50,5/4/2020
990AD0,earnings,100,50,5/4/2020
990AD0,conference-organizer,100,57,5/4/2020
990AD0,conference-organizer,100,57,5/4/2020
990AD0,conference-organizer,100,57,5/4/2020
9A602D,executive-salary-increase,100,44,5/4/2020
9B5968,note-sale,100,52,5/4/2020
9C009A,earnings,100,50,5/4/2020
9C5BA5,earnings,100,50,5/4/2020
9D4EC7,earnings,100,50,5/4/2020
9D4EC7,earnings,100,50,5/4/2020
9D4EC7,earnings,100,50,5/4/2020
9D5D35,earnings,100,50,5/4/2020
9D5D35,earnings,100,50,5/4/2020
9D5D35,earnings,100,50,5/4/2020
9D5FA4,regulatory-product-approval-granted,100,81,5/4/2020
9E98F2,business-contract,100,69,5/4/2020
9EA947,earnings,100,50,5/4/2020
9FB4B7,earnings,100,50,5/4/2020
A01983,conference-call,100,50,5/4/2020
A1A317,earnings,100,50,5/4/2020
A1A317,earnings,100,50,5/4/2020
A1A317,earnings,100,50,5/4/2020
A1A317,earnings,100,50,5/4/2020
A1E3B3,earnings,100,50,5/4/2020
A28675,earnings,100,50,5/4/2020
A29A46,conference-call,100,50,5/4/2020
A47A7D,executive-appointment,100,54,5/4/2020
A495F7,partnership,100,61,5/4/2020
A4B899,earnings,100,50,5/4/2020
A4CD53,executive-appointment,100,54,5/4/2020
A52B6B,earnings,100,50,5/4/2020
A7F0A5,earnings,100,50,5/4/2020
A806FA,conference-call,100,50,5/4/2020
A868C9,earnings,100,50,5/4/2020
A87CD6,dividend,100,50,5/4/2020
A87CD6,earnings-per-share-positive,100,69,5/4/2020
A87CD6,earnings-per-share-positive,100,69,5/4/2020
A87CD6,earnings-per-share-positive,100,69,5/4/2020
A87CD6,earnings-per-share-positive,100,69,5/4/2020
A87CD6,earnings-per-share-positive,100,69,5/4/2020
A87CD6,earnings-per-share-positive,100,69,5/4/2020
A8CBDA,conference-participant,100,50,5/4/2020
A8CBDA,executive-appointment,100,54,5/4/2020
A8FDE8,earnings,100,50,5/4/2020
A8FDE8,earnings,100,50,5/4/2020
A8FDE8,dividend,100,50,5/4/2020
AADE0B,partnership,100,61,5/4/2020
AC7C4F,government-contract,100,69,5/4/2020
ACDCFA,earnings,100,50,5/4/2020
ACF0B4,conference-call,100,50,5/4/2020
AD1ACF,earnings,100,50,5/4/2020
AD1ACF,earnings,100,50,5/4/2020
AD1ACF,earnings,100,50,5/4/2020
AD1ACF,earnings,100,50,5/4/2020
AD1ACF,earnings,100,50,5/4/2020
AD23DE,product-release,100,64,5/4/2020
AFDF2E,executive-resignation,100,44,5/4/2020
AFF7B4,earnings,100,50,5/4/2020
AFF7B4,earnings,100,50,5/4/2020
AFF7B4,earnings,100,50,5/4/2020
B01215,conference-call,100,50,5/4/2020
B0D41A,earnings,100,50,5/4/2020
B33E77,legal-issues-defendant,100,22,5/4/2020
B33E77,legal-issues-defendant,100,22,5/4/2020
B381D8,earnings,100,50,5/4/2020
B3A166,conference-call,100,50,5/4/2020
B560AF,earnings,100,50,5/4/2020
B560AF,earnings,100,50,5/4/2020
B560AF,earnings,100,50,5/4/2020
B560AF,earnings,100,50,5/4/2020
B642E8,earnings,100,50,5/4/2020
B642E8,earnings,100,50,5/4/2020
B642E8,earnings,100,50,5/4/2020
B642E8,earnings,100,50,5/4/2020
B642E8,earnings,100,50,5/4/2020
B72BE9,executive-appointment,100,54,5/4/2020
B80AD1,clinical-trials-filed,100,60,5/4/2020
B98EFA,executive-appointment,100,54,5/4/2020
BB58FF,earnings,100,50,5/4/2020
BC4876,earnings,100,50,5/4/2020
BDF85E,public-offering,100,43,5/4/2020
BFCACF,executive-appointment,100,54,5/4/2020
C0F70B,earnings,100,50,5/4/2020
C1114B,earnings,100,50,5/4/2020
C1114B,earnings,100,50,5/4/2020
C1114B,earnings,100,50,5/4/2020
C11C46,earnings,100,50,5/4/2020
C2DD02,conference-call,100,50,5/4/2020
C3CF29,earnings,100,50,5/4/2020
C598D7,unit-acquisition-completed-acquirer,100,49,5/4/2020
C66B44,conference-call,100,50,5/4/2020
C9732E,legal-issues-defendant,100,22,5/4/2020
CBBFBF,partnership,100,61,5/4/2020
CCB623,earnings,100,50,5/4/2020
CCBBAD,earnings,100,50,5/4/2020
CDAB24,earnings,100,50,5/4/2020
CE2791,earnings,100,50,5/4/2020
CEC08B,award,100,58,5/4/2020
CF3FF9,earnings,100,50,5/4/2020
CFF15D,executive-appointment,100,54,5/4/2020
CFF97C,merger-failed,100,21,5/4/2020
CFF97C,executive-appointment,100,54,5/4/2020
D06996,earnings,100,50,5/4/2020
D15833,conference-call,100,50,5/4/2020
D15833,conference-call,100,50,5/4/2020
D33270,acquisition-completed-acquirer,100,49,5/4/2020
D33270,unit-acquisition-completed-acquirer,100,49,5/4/2020
D36686,executive-appointment,100,54,5/4/2020
D3FA2C,conference-call,100,50,5/4/2020
D60BB2,earnings,100,50,5/4/2020
D82EF3,conference-call,100,50,5/4/2020
D854DD,dividend,100,50,5/4/2020
D8C09D,conference-call,100,50,5/4/2020
D90F43,partnership,100,61,5/4/2020
D9B1C9,executive-appointment,100,54,5/4/2020
D9E036,earnings-up,100,68,5/4/2020
D9E036,earnings,100,50,5/4/2020
DA91AE,earnings,100,50,5/4/2020
DB2E4E,earnings,100,50,5/4/2020
DBEF02,buybacks,100,74,5/4/2020
DC0D18,earnings,100,50,5/4/2020
DC0D18,earnings,100,50,5/4/2020
DC0D18,earnings,100,50,5/4/2020
DC0D18,earnings,100,50,5/4/2020
DC0D18,earnings,100,50,5/4/2020
DD1BA1,partnership,100,61,5/4/2020
DD1BA1,executive-appointment,100,54,5/4/2020
DF5F14,earnings,100,50,5/4/2020
E0E4B7,earnings,100,50,5/4/2020
E15736,earnings,100,50,5/4/2020
E15736,earnings,100,50,5/4/2020
E21871,earnings,100,50,5/4/2020
E22FDE,conference-call,100,50,5/4/2020
E261E9,executive-appointment,100,54,5/4/2020
E3E68E,earnings,100,50,5/4/2020
E3E68E,earnings,100,50,5/4/2020
E3E68E,earnings,100,50,5/4/2020
E61888,business-contract-terminated,100,31,5/4/2020
E67C2C,earnings,100,50,5/4/2020
E69BA5,conference-call,100,50,5/4/2020
E6D89E,executive-appointment,100,54,5/4/2020
E71AE6,earnings,100,50,5/4/2020
E7BF32,earnings,100,50,5/4/2020
E7BF32,earnings,100,50,5/4/2020
E8846E,partnership,100,61,5/4/2020
E8A49A,earnings,100,50,5/4/2020
EA62FC,earnings,100,50,5/4/2020
EB5E78,earnings,100,50,5/4/2020
EB5E78,earnings,100,50,5/4/2020
EB5E78,earnings,100,50,5/4/2020
EB5E78,earnings,100,50,5/4/2020
EB7D6C,executive-appointment,100,54,5/4/2020
ED0D7C,conference-participant,100,50,5/4/2020
EE04F0,earnings,100,50,5/4/2020
EE04F0,earnings,100,50,5/4/2020
EE04F0,earnings,100,50,5/4/2020
EE6F1C,unit-acquisition-completed-acquiree,100,67,5/4/2020
EE6F1C,unit-acquisition-completed-acquiree,100,67,5/4/2020
F1C04C,donation,100,54,5/4/2020
F1CD47,conference-participant,100,50,5/4/2020
F30508,dividend,100,50,5/4/2020
F32F88,dividend,100,50,5/4/2020
F39E1E,earnings,100,50,5/4/2020
F44EA2,earnings,100,50,5/4/2020
F769E9,conference-call,100,50,5/4/2020
F7FCA4,earnings,100,50,5/4/2020
F7FCA4,earnings,100,50,5/4/2020
F7FCA4,earnings,100,50,5/4/2020
F7FCA4,earnings,100,50,5/4/2020
F88147,earnings,100,50,5/4/2020
F9CAF8,conference-call,100,50,5/4/2020
FC1A6E,earnings,100,50,5/4/2020
FC4550,dividend,100,50,5/4/2020
FCA54E,earnings,100,50,5/4/2020
FD0CA4,earnings,100,50,5/4/2020
FD1312,earnings,100,50,5/4/2020
FD6926,conference-participant,100,50,5/4/2020
FD6926,dividend,100,50,5/4/2020
FF4343,earnings-positive,100,69,5/4/2020
13528,dividend,100,50,5/5/2020
018C11,earnings,100,50,5/5/2020
0325B7,conference-call,100,50,5/5/2020
03596A,earnings,100,50,5/5/2020
03B431,earnings,100,50,5/5/2020
03FB17,earnings,100,50,5/5/2020
48590,earnings,100,50,5/5/2020
054E7E,earnings,100,50,5/5/2020
0560D8,earnings,100,50,5/5/2020
0560D8,earnings,100,50,5/5/2020
0560D8,earnings,100,50,5/5/2020
68396,earnings,100,50,5/5/2020
06EE79,earnings,100,50,5/5/2020
070B45,conference-participant,100,50,5/5/2020
71860,conference-participant,100,50,5/5/2020
07C907,dividend,100,50,5/5/2020
081AB9,earnings,100,50,5/5/2020
09DE1F,note-sale,100,52,5/5/2020
09DE1F,note-sale,100,52,5/5/2020
0A9D0A,conference-participant,100,50,5/5/2020
0A9D0A,dividend,100,50,5/5/2020
0AD2E3,earnings,100,50,5/5/2020
0BF198,public-offering,100,43,5/5/2020
0BF198,public-offering,100,43,5/5/2020
0FC848,earnings,100,50,5/5/2020
0FE3A6,conference-call,100,50,5/5/2020
10100E,conference-participant,100,50,5/5/2020
1080C0,public-offering,100,43,5/5/2020
11074E,earnings,100,50,5/5/2020
12A3A3,dividend-up,100,81,5/5/2020
12A3A3,dividend-up,100,81,5/5/2020
14BA06,operating-earnings,100,50,5/5/2020
152E1D,operating-earnings,100,50,5/5/2020
152E1D,operating-earnings,100,50,5/5/2020
152E1D,operating-earnings,100,50,5/5/2020
152E1D,operating-earnings,100,50,5/5/2020
152E1D,operating-earnings,100,50,5/5/2020
152E1D,operating-earnings,100,50,5/5/2020
1748F6,executive-appointment,100,54,5/5/2020
1748F6,executive-appointment,100,54,5/5/2020
1834C0,earnings,100,50,5/5/2020
1A5D5D,earnings,100,50,5/5/2020
1A5D5D,earnings,100,50,5/5/2020
1A5D5D,earnings,100,50,5/5/2020
1A5D5D,earnings,100,50,5/5/2020
1A5D5D,earnings,100,50,5/5/2020
1A5D5D,earnings,100,50,5/5/2020
1AE9D5,conference-call,100,50,5/5/2020
1B16C1,earnings,100,50,5/5/2020
1B637E,earnings,100,50,5/5/2020
1B9535,earnings,100,50,5/5/2020
1CB9D3,conference-call,100,50,5/5/2020
1CDD1C,earnings,100,50,5/5/2020
1DB833,ipo-completed,100,76,5/5/2020
1E04A5,earnings,100,50,5/5/2020
1E68B3,earnings,100,50,5/5/2020
1EC3E8,earnings,100,50,5/5/2020
1EC3E8,earnings,100,50,5/5/2020
1F08A6,earnings,100,50,5/5/2020
1F9258,earnings,100,50,5/5/2020
1FAF22,dividend-up,100,81,5/5/2020
2082EA,conference-participant,100,50,5/5/2020
227D48,dividend,100,50,5/5/2020
23207A,conference-call,100,50,5/5/2020
24C48B,dividend,100,50,5/5/2020
2571FA,earnings,100,50,5/5/2020
2571FA,earnings,100,50,5/5/2020
2571FA,earnings,100,50,5/5/2020
2571FA,earnings,100,50,5/5/2020
26008A,conference-call,100,50,5/5/2020
26F31D,earnings,100,50,5/5/2020
26F31D,earnings,100,50,5/5/2020
26F31D,earnings,100,50,5/5/2020
284289,earnings,100,50,5/5/2020
28DCA8,earnings-positive,100,69,5/5/2020
28DCA8,earnings,100,50,5/5/2020
28DCA8,earnings,100,50,5/5/2020
28DCA8,earnings,100,50,5/5/2020
28F905,executive-appointment,100,54,5/5/2020
295F9F,earnings,100,50,5/5/2020
2D2D43,earnings,100,50,5/5/2020
2D643C,executive-appointment,100,54,5/5/2020
2D981A,earnings,100,50,5/5/2020
2E0496,earnings,100,50,5/5/2020
2E0496,earnings,100,50,5/5/2020
2E1322,earnings,100,50,5/5/2020
2E1322,earnings,100,50,5/5/2020
2E89AE,earnings,100,50,5/5/2020
2E89AE,earnings,100,50,5/5/2020
2F1299,earnings,100,50,5/5/2020
2F1299,earnings,100,50,5/5/2020
2F1299,earnings,100,50,5/5/2020
2F1299,earnings,100,50,5/5/2020
2F1299,earnings,100,50,5/5/2020
2F1299,earnings,100,50,5/5/2020
2F1299,earnings,100,50,5/5/2020
2F6782,earnings,100,50,5/5/2020
2F9304,partnership,100,61,5/5/2020
301493,fraud-defendant,100,20,5/5/2020
301493,legal-issues-defendant,100,22,5/5/2020
32F24A,earnings,100,50,5/5/2020
3390DE,earnings,100,50,5/5/2020
3461CF,credit-rating-set-rater,20,50,5/5/2020
353DBB,earnings,100,50,5/5/2020
353DBB,earnings,100,50,5/5/2020
35F4B5,earnings,100,50,5/5/2020
35F4B5,earnings,100,50,5/5/2020
367E1C,conference-participant,100,50,5/5/2020
36A1CB,earnings,100,50,5/5/2020
36A1CB,earnings,100,50,5/5/2020
36C09B,clinical-trials-positive,100,87,5/5/2020
36E479,earnings,100,50,5/5/2020
37020C,dividend,100,50,5/5/2020
37426C,earnings,100,50,5/5/2020
37426C,earnings,100,50,5/5/2020
384CD3,conference-participant,100,50,5/5/2020
385DD4,fundraising,100,64,5/5/2020
396D7C,conference-participant,100,50,5/5/2020
3A1C46,earnings,100,50,5/5/2020
3B37F7,conference-call,100,50,5/5/2020
3BA1BF,conference-call,100,50,5/5/2020
3BE00F,earnings,100,50,5/5/2020
3BE00F,earnings,100,50,5/5/2020
3BE00F,earnings,100,50,5/5/2020
3C7F5F,partnership,100,61,5/5/2020
3D6933,pretax-earnings-positive,100,69,5/5/2020
3D6933,pretax-earnings-positive,100,69,5/5/2020
3DC887,earnings,100,50,5/5/2020
3ED92D,conference-participant,100,50,5/5/2020
3F4668,legal-issues-defendant,100,22,5/5/2020
3F6A9C,dividend,100,50,5/5/2020
4.03E+05,dividend,100,50,5/5/2020
4290EF,earnings,100,50,5/5/2020
42AABD,earnings,100,50,5/5/2020
43E8F5,conference-participant,100,50,5/5/2020
442587,earnings-above-expectations,100,88,5/5/2020
44740A,earnings,100,50,5/5/2020
44A4FC,earnings,100,50,5/5/2020
44DDBD,earnings,100,50,5/5/2020
46A16E,earnings,100,50,5/5/2020
47BA98,board-meeting,100,51,5/5/2020
47FCF2,fundraising,100,64,5/5/2020
47FCF2,partnership,100,61,5/5/2020
4.91E+58,earnings-positive,100,69,5/5/2020
4.91E+58,earnings-positive,100,69,5/5/2020
4.91E+58,earnings-positive,100,69,5/5/2020
4.91E+58,earnings-positive,100,69,5/5/2020
4.91E+58,earnings-positive,100,69,5/5/2020
4.91E+58,earnings-positive,100,69,5/5/2020
492117,earnings,100,50,5/5/2020
4A5C8D,executive-appointment,100,54,5/5/2020
4A6F00,partnership,100,61,5/5/2020
4C2F17,executive-appointment,100,54,5/5/2020
4C37C5,partnership,100,61,5/5/2020
4D8124,dividend,100,50,5/5/2020
4F783B,earnings,100,50,5/5/2020
4F783B,earnings,100,50,5/5/2020
4F783B,earnings,100,50,5/5/2020
4F783B,earnings,100,50,5/5/2020
4F783B,earnings,100,50,5/5/2020
50070E,conference-organizer,100,57,5/5/2020
504FE2,earnings,100,50,5/5/2020
507AE7,earnings,100,50,5/5/2020
54512F,earnings,100,50,5/5/2020
5.47E+28,patient-enrollment-complete,100,64,5/5/2020
54B889,earnings,100,50,5/5/2020
550D01,earnings-up,100,68,5/5/2020
550D01,earnings,100,50,5/5/2020
553949,executive-appointment,100,54,5/5/2020
56277A,conference-participant,100,50,5/5/2020
562853,earnings,100,50,5/5/2020
56FB7C,earnings,100,50,5/5/2020
5704AC,operating-earnings,100,50,5/5/2020
57DDB9,conference-participant,100,50,5/5/2020
583A75,earnings,100,50,5/5/2020
586FFD,revenues,100,50,5/5/2020
586FFD,revenues,100,50,5/5/2020
5876DC,earnings,100,50,5/5/2020
589803,earnings,100,50,5/5/2020
58C2D4,conference-participant,100,50,5/5/2020
59872F,conference-call,100,50,5/5/2020
59A832,earnings,100,50,5/5/2020
5D41E4,conference-participant,100,50,5/5/2020
5FDBD0,operating-earnings,100,50,5/5/2020
6.18E+08,earnings,100,50,5/5/2020
6.18E+08,earnings,100,50,5/5/2020
6.18E+08,earnings,100,50,5/5/2020
619882,conference-organizer,100,57,5/5/2020
619882,conference-organizer,100,57,5/5/2020
619882,conference-organizer,100,57,5/5/2020
619882,conference-organizer,100,57,5/5/2020
619882,conference-organizer,100,57,5/5/2020
622DBE,earnings,100,50,5/5/2020
62B1C6,earnings,100,50,5/5/2020
62CDDE,earnings,100,50,5/5/2020
651C85,earnings,100,50,5/5/2020
665D7D,acquisition-regulatory-approval-acquiree,100,81,5/5/2020
66E04A,partnership,100,61,5/5/2020
68E3E0,revenue-up,100,69,5/5/2020
68E3E0,revenue-up,100,69,5/5/2020
68E3E0,revenue-up,100,69,5/5/2020
68E3E0,revenue-up,100,69,5/5/2020
6925EB,legal-issues-defendant,100,22,5/5/2020
698FF9,dividend,100,50,5/5/2020
6A171E,earnings,100,50,5/5/2020
6C987C,executive-appointment,100,54,5/5/2020
6CBF41,conference-participant,100,50,5/5/2020
6CC55E,earnings,100,50,5/5/2020
6D2BF6,earnings,100,50,5/5/2020
6E7060,earnings,100,50,5/5/2020
6E8349,earnings,100,50,5/5/2020
6E8864,operating-earnings,100,50,5/5/2020
717DB4,earnings,100,50,5/5/2020
717DB4,earnings,100,50,5/5/2020
717DB4,earnings,100,50,5/5/2020
717DB4,earnings,100,50,5/5/2020
719477,executive-appointment,100,54,5/5/2020
72CB93,earnings,100,50,5/5/2020
73A71F,earnings,100,50,5/5/2020
747219,earnings,100,50,5/5/2020
762B8D,earnings,100,50,5/5/2020
76D79A,earnings,100,50,5/5/2020
7AD81E,fundraising,100,64,5/5/2020
7B492C,earnings,100,50,5/5/2020
7B6EB1,earnings,100,50,5/5/2020
7BFF81,partnership,100,61,5/5/2020
7C4168,earnings,100,50,5/5/2020
7D7716,earnings,100,50,5/5/2020
7D7716,earnings,100,50,5/5/2020
7D7716,earnings,100,50,5/5/2020
7D7716,earnings,100,50,5/5/2020
7D7716,earnings,100,50,5/5/2020
7E0EB0,award,100,58,5/5/2020
7F3A5F,note-sale,100,52,5/5/2020
7F9BE2,dividend,100,50,5/5/2020
80D744,dividend,100,50,5/5/2020
82E58A,dividend,100,50,5/5/2020
838ADD,earnings,100,50,5/5/2020
838ADD,earnings,100,50,5/5/2020
838ADD,earnings,100,50,5/5/2020
838ADD,earnings,100,50,5/5/2020
838ADD,earnings,100,50,5/5/2020
848C0B,earnings,100,50,5/5/2020
85CDC9,earnings,100,50,5/5/2020
85DE00,conference-participant,100,50,5/5/2020
873DB9,conference-participant,100,50,5/5/2020
8.79E+06,earnings,100,50,5/5/2020
881190,dividend,100,50,5/5/2020
890FF4,earnings,100,50,5/5/2020
890FF4,earnings,100,50,5/5/2020
890FF4,earnings,100,50,5/5/2020
890FF4,earnings,100,50,5/5/2020
890FF4,earnings,100,50,5/5/2020
890FF4,earnings,100,50,5/5/2020
890FF4,earnings,100,50,5/5/2020
8AC740,earnings,100,50,5/5/2020
8B9B3B,earnings,100,50,5/5/2020
8D4486,product-release,100,64,5/5/2020
8D4486,product-release,100,64,5/5/2020
8D4486,product-release,100,64,5/5/2020
8D5145,dividend,100,50,5/5/2020
8DAAB9,dividend,100,50,5/5/2020
8E10BF,conference-call,100,50,5/5/2020
8E4F9A,operating-earnings,100,50,5/5/2020
8E82A6,dividend,100,50,5/5/2020
8EDACA,note-sale,100,52,5/5/2020
8EEA28,earnings,100,50,5/5/2020
8FCA78,dividend,100,50,5/5/2020
9043FE,earnings,100,50,5/5/2020
9043FE,earnings,100,50,5/5/2020
9087B9,earnings,100,50,5/5/2020
911AB8,earnings-positive,100,69,5/5/2020
911AB8,earnings-positive,100,69,5/5/2020
911CA9,clinical-trials-start,100,64,5/5/2020
92D3A0,conference-call,100,50,5/5/2020
92D9C9,earnings,100,50,5/5/2020
9.31E+77,earnings,100,50,5/5/2020
934029,conference-participant,100,50,5/5/2020
93D207,conference-participant,100,50,5/5/2020
94A326,conference-participant,100,50,5/5/2020
9507FF,public-offering,100,43,5/5/2020
9592FB,earnings,100,50,5/5/2020
965360,dividend,100,50,5/5/2020
977A1E,earnings,100,50,5/5/2020
977A1E,earnings,100,50,5/5/2020
977A1E,earnings,100,50,5/5/2020
97AF94,earnings,100,50,5/5/2020
9.86E+03,earnings,100,50,5/5/2020
990AD0,conference-organizer,100,57,5/5/2020
990AD0,conference-organizer,100,57,5/5/2020
990AD0,conference-organizer,100,57,5/5/2020
990AD0,conference-organizer,100,57,5/5/2020
990AD0,conference-organizer,100,57,5/5/2020
990AD0,conference-organizer,100,57,5/5/2020
990AD0,conference-organizer,100,57,5/5/2020
990AD0,conference-organizer,100,57,5/5/2020
990AD0,conference-organizer,100,57,5/5/2020
990AD0,conference-organizer,100,57,5/5/2020
990AD0,conference-organizer,100,57,5/5/2020
990AD0,conference-organizer,100,57,5/5/2020
990AD0,conference-organizer,100,57,5/5/2020
990AD0,conference-organizer,100,57,5/5/2020
990AD0,conference-organizer,100,57,5/5/2020
990AD0,conference-organizer,100,57,5/5/2020
9981C6,earnings,100,50,5/5/2020
99DC8D,dividend,100,50,5/5/2020
99DC8D,earnings,100,50,5/5/2020
9B5968,note-sale,100,52,5/5/2020
9D2790,earnings,100,50,5/5/2020
9D2790,earnings,100,50,5/5/2020
9D2790,earnings,100,50,5/5/2020
9D2790,earnings,100,50,5/5/2020
9D2790,earnings,100,50,5/5/2020
9D2790,earnings,100,50,5/5/2020
9D2790,earnings,100,50,5/5/2020
9D2790,earnings,100,50,5/5/2020
9D6A24,earnings,100,50,5/5/2020
9EF4CF,earnings,100,50,5/5/2020
9F18FA,earnings,100,50,5/5/2020
9F18FA,earnings,100,50,5/5/2020
9FF5F1,earnings,100,50,5/5/2020
A05C43,earnings,100,50,5/5/2020
A05C43,earnings,100,50,5/5/2020
A05C43,earnings,100,50,5/5/2020
A05C43,earnings,100,50,5/5/2020
A05C43,earnings,100,50,5/5/2020
A16DEA,earnings,100,50,5/5/2020
A16DEA,earnings,100,50,5/5/2020
A16DEA,earnings,100,50,5/5/2020
A16DEA,earnings,100,50,5/5/2020
A16DEA,earnings,100,50,5/5/2020
A16DEA,earnings,100,50,5/5/2020
A16DEA,earnings,100,50,5/5/2020
A16DEA,earnings,100,50,5/5/2020
A1EAC8,business-contract,100,69,5/5/2020
A23747,earnings,100,50,5/5/2020
A26EF7,earnings,100,50,5/5/2020
A26EF7,earnings,100,50,5/5/2020
A4386C,earnings,100,50,5/5/2020
A4CD53,earnings,100,50,5/5/2020
A4CD53,earnings,100,50,5/5/2020
A60354,earnings,100,50,5/5/2020
A60354,earnings,100,50,5/5/2020
A60354,earnings,100,50,5/5/2020
A60354,earnings,100,50,5/5/2020
A631A3,legal-issues-defendant,100,22,5/5/2020
A7102F,earnings,100,50,5/5/2020
A74F6F,revenues,100,50,5/5/2020
A74F6F,revenues,100,50,5/5/2020
A79F7D,earnings,100,50,5/5/2020
A80FE0,conference-participant,100,50,5/5/2020
AA09AD,earnings,100,50,5/5/2020
ABBAD1,earnings,100,50,5/5/2020
AC775C,earnings,100,50,5/5/2020
AC775C,earnings,100,50,5/5/2020
AC775C,earnings,100,50,5/5/2020
ACDF88,conference-call,100,50,5/5/2020
AE4EEB,earnings,100,50,5/5/2020
AEBB80,earnings,100,50,5/5/2020
B01111,earnings,100,50,5/5/2020
B05000,earnings,100,50,5/5/2020
B0D41A,executive-appointment,100,54,5/5/2020
B33E77,legal-issues-defendant,100,22,5/5/2020
B33E77,legal-issues-defendant,100,22,5/5/2020
B37FB4,partnership,100,61,5/5/2020
B446B8,earnings,100,50,5/5/2020
B446B8,earnings,100,50,5/5/2020
B446B8,earnings,100,50,5/5/2020
B4703C,earnings,100,50,5/5/2020
B53C12,earnings,100,50,5/5/2020
B54A74,earnings,100,50,5/5/2020
B6082A,dividend,100,50,5/5/2020
B83BCE,conference-participant,100,50,5/5/2020
B8A51F,earnings,100,50,5/5/2020
B8F71F,note-sale,100,52,5/5/2020
B9764A,earnings,100,50,5/5/2020
B98EFA,operating-earnings,100,50,5/5/2020
B9CD50,earnings,100,50,5/5/2020
BB02FB,note-sale,100,52,5/5/2020
BB0587,earnings-up,100,68,5/5/2020
BB0587,earnings,100,50,5/5/2020
BB0587,earnings,100,50,5/5/2020
BB0587,earnings,100,50,5/5/2020
BB0587,earnings,100,50,5/5/2020
BBBB41,earnings,100,50,5/5/2020
BBBB41,earnings,100,50,5/5/2020
BBBB41,earnings,100,50,5/5/2020
BBBB41,earnings,100,50,5/5/2020
BBBB41,earnings,100,50,5/5/2020
BBC05B,operating-earnings,100,50,5/5/2020
BCC13E,earnings,100,50,5/5/2020
BCE9DA,earnings,100,50,5/5/2020
BCE9DA,earnings,100,50,5/5/2020
BCE9DA,earnings,100,50,5/5/2020
BCE9DA,earnings,100,50,5/5/2020
BDA775,earnings,100,50,5/5/2020
BDF2BD,earnings-positive,100,69,5/5/2020
BDF2BD,earnings,100,50,5/5/2020
BDF2BD,earnings,100,50,5/5/2020
BDF2BD,earnings,100,50,5/5/2020
BDF2BD,earnings,100,50,5/5/2020
BFCACF,conference-participant,100,50,5/5/2020
BFEA04,earnings,100,50,5/5/2020
BFEA04,earnings,100,50,5/5/2020
BFEA04,earnings,100,50,5/5/2020
BFEA04,earnings,100,50,5/5/2020
BFEA04,earnings,100,50,5/5/2020
C062D4,earnings,100,50,5/5/2020
C062D4,earnings,100,50,5/5/2020
C062D4,earnings,100,50,5/5/2020
C062D4,earnings,100,50,5/5/2020
C062D4,earnings,100,50,5/5/2020
C062D4,earnings,100,50,5/5/2020
C06EB6,clinical-trials-positive,100,87,5/5/2020
C06EB6,clinical-trials-positive,100,87,5/5/2020
C15F8F,earnings,100,50,5/5/2020
C2609A,earnings,100,50,5/5/2020
C27E19,operating-earnings,100,50,5/5/2020
C2E39B,earnings,100,50,5/5/2020
C3BAE7,conference-participant,100,50,5/5/2020
C3EE99,award,100,58,5/5/2020
C3F99F,earnings,100,50,5/5/2020
C54140,earnings,100,50,5/5/2020
C5C0E9,earnings,100,50,5/5/2020
C5C0E9,earnings,100,50,5/5/2020
C85A72,partnership,100,61,5/5/2020
C8923A,earnings,100,50,5/5/2020
C8A248,earnings,100,50,5/5/2020
C8A248,earnings,100,50,5/5/2020
C8A248,earnings,100,50,5/5/2020
C8A248,earnings,100,50,5/5/2020
C8A248,earnings,100,50,5/5/2020
C8A248,earnings,100,50,5/5/2020
C8A248,earnings,100,50,5/5/2020
C9739A,conference-participant,100,50,5/5/2020
C9C62A,earnings,100,50,5/5/2020
CA212F,earnings,100,50,5/5/2020
CAB222,conference-participant,100,50,5/5/2020
CB22CD,earnings,100,50,5/5/2020
CC8F6E,earnings,100,50,5/5/2020
CE4E6D,earnings-up,100,68,5/5/2020
CE4E6D,earnings-up,100,68,5/5/2020
CE4E6D,earnings-up,100,68,5/5/2020
CE4E6D,earnings-up,100,68,5/5/2020
CEC08B,partnership,100,61,5/5/2020
CF6A5A,earnings,100,50,5/5/2020
CF6A5A,earnings,100,50,5/5/2020
D1173F,earnings,100,50,5/5/2020
D1173F,earnings,100,50,5/5/2020
D1173F,earnings,100,50,5/5/2020
D1173F,earnings,100,50,5/5/2020
D15833,earnings,100,50,5/5/2020
D15833,earnings,100,50,5/5/2020
D29F43,dividend,100,50,5/5/2020
D3CEDF,earnings,100,50,5/5/2020
D3CEDF,earnings,100,50,5/5/2020
D3CEDF,earnings,100,50,5/5/2020
D3CEDF,earnings,100,50,5/5/2020
D3CEDF,earnings,100,50,5/5/2020
D3CEDF,earnings,100,50,5/5/2020
D45285,earnings,100,50,5/5/2020
D45285,earnings,100,50,5/5/2020
D64EDF,earnings-above-expectations,100,88,5/5/2020
D64EDF,earnings,100,50,5/5/2020
D64EDF,earnings,100,50,5/5/2020
D64EDF,earnings,100,50,5/5/2020
D6534D,earnings,100,50,5/5/2020
D6534D,earnings,100,50,5/5/2020
D6853F,business-contract,100,69,5/5/2020
D721C6,executive-appointment,100,54,5/5/2020
D81463,earnings,100,50,5/5/2020
D81463,earnings,100,50,5/5/2020
D854F3,conference-participant,100,50,5/5/2020
D8DA3D,earnings,100,50,5/5/2020
D8DA3D,earnings,100,50,5/5/2020
D8DA3D,earnings,100,50,5/5/2020
D8DA3D,earnings,100,50,5/5/2020
D8DA3D,earnings,100,50,5/5/2020
D9164D,dividend,100,50,5/5/2020
D9164D,earnings-up,100,68,5/5/2020
D96202,earnings-up,100,68,5/5/2020
DB06B0,earnings,100,50,5/5/2020
DB5CA5,donation,100,54,5/5/2020
DB7014,conference-call,100,50,5/5/2020
DBFB51,earnings,100,50,5/5/2020
DC1405,earnings,100,50,5/5/2020
DC2F77,earnings,100,50,5/5/2020
DD682D,earnings,100,50,5/5/2020
DD682D,unit-acquisition-acquirer,100,49,5/5/2020
DDEA6A,operating-earnings,100,50,5/5/2020
DF01B1,earnings,100,50,5/5/2020
DF01B1,earnings,100,50,5/5/2020
DF01B1,earnings,100,50,5/5/2020
DF01B1,earnings,100,50,5/5/2020
DF6FDD,product-release,100,64,5/5/2020
E074A0,earnings,100,50,5/5/2020
E124EB,dividend,100,50,5/5/2020
E30A8F,partnership,100,61,5/5/2020
E35610,earnings,100,50,5/5/2020
E35610,earnings,100,50,5/5/2020
E35610,earnings,100,50,5/5/2020
E35610,earnings,100,50,5/5/2020
E4CE73,product-release,100,64,5/5/2020
E69BA5,earnings,100,50,5/5/2020
E6A53A,earnings,100,50,5/5/2020
E6A53A,earnings,100,50,5/5/2020
E6A53A,earnings,100,50,5/5/2020
E6C8DC,earnings,100,50,5/5/2020
E8A49A,partnership,100,61,5/5/2020
E8C557,dividend,100,50,5/5/2020
E8E899,earnings,100,50,5/5/2020
EB36DE,earnings,100,50,5/5/2020
EB43F4,earnings,100,50,5/5/2020
EBC84C,conference-participant,100,50,5/5/2020
EC1AF3,earnings,100,50,5/5/2020
ED2EFD,earnings,100,50,5/5/2020
ED9C04,conference-participant,100,50,5/5/2020
EE6F1C,earnings,100,50,5/5/2020
EE6F1C,earnings,100,50,5/5/2020
EE6F1C,earnings,100,50,5/5/2020
EE6F1C,earnings,100,50,5/5/2020
EEB5F9,conference-participant,100,50,5/5/2020
EF5BED,partnership,100,61,5/5/2020
EF5BED,executive-appointment,100,54,5/5/2020
EF5BED,partnership,100,61,5/5/2020
EF5BED,partnership,100,61,5/5/2020
EF5BED,partnership,100,61,5/5/2020
EF5BED,partnership,100,61,5/5/2020
F3016C,earnings,100,50,5/5/2020
F3016C,earnings,100,50,5/5/2020
F3016C,earnings,100,50,5/5/2020
F3816D,conference-participant,100,50,5/5/2020
F46EC9,earnings,100,50,5/5/2020
F46EC9,earnings,100,50,5/5/2020
F46EC9,earnings,100,50,5/5/2020
F46EC9,earnings,100,50,5/5/2020
F47871,earnings,100,50,5/5/2020
F47871,partnership,100,61,5/5/2020
F4CDA3,conference-call,100,50,5/5/2020
F4E882,earnings,100,50,5/5/2020
F5C8AB,earnings-per-share-positive,100,69,5/5/2020
F5C8AB,earnings-per-share-positive,100,69,5/5/2020
F5C8AB,earnings-per-share,100,50,5/5/2020
F5D059,revenue-guidance,100,50,5/5/2020
F6A987,earnings,100,50,5/5/2020
F85CC0,earnings,100,50,5/5/2020
F85CC0,earnings,100,50,5/5/2020
F8C5D7,operating-earnings,100,50,5/5/2020
F90EE5,earnings,100,50,5/5/2020
FB7724,earnings,100,50,5/5/2020
FD554E,conference-call,100,50,5/5/2020
FDD3FC,earnings,100,50,5/5/2020
FDF28E,earnings,100,50,5/5/2020
FDF799,partnership,100,61,5/5/2020
FE609F,conference-call,100,50,5/5/2020
FEC475,earnings,100,50,5/5/2020
00D6B5,earnings,100,50,5/6/2020
0157B1,partnership,100,61,5/6/2020
01D03F,regulatory-product-approval-granted,100,81,5/6/2020
02FC1A,earnings,100,50,5/6/2020
02FC1A,earnings,100,50,5/6/2020
03542C,conference-call,100,50,5/6/2020
03CF95,earnings,100,50,5/6/2020
03D5F9,earnings,100,50,5/6/2020
55018,partnership,100,61,5/6/2020
58828,partnership,100,61,5/6/2020
06C826,earnings,100,50,5/6/2020
06CB5B,earnings,100,50,5/6/2020
081AB9,earnings,100,50,5/6/2020
0919B1,earnings,100,50,5/6/2020
98977,earnings,100,50,5/6/2020
0A0D9E,earnings,100,50,5/6/2020
0A0D9E,earnings,100,50,5/6/2020
0A0D9E,earnings,100,50,5/6/2020
0A59F8,shareholder-rights-plan,100,43,5/6/2020
0A77DB,earnings,100,50,5/6/2020
0C6861,earnings,100,50,5/6/2020
0CCCB7,earnings,100,50,5/6/2020
0CE204,earnings,100,50,5/6/2020
0CE7F6,earnings,100,50,5/6/2020
0E439E,dividend,100,50,5/6/2020
0E64D4,earnings,100,50,5/6/2020
1065BC,earnings,100,50,5/6/2020
12731D,earnings,100,50,5/6/2020
149301,earnings,100,50,5/6/2020
15A388,revenue-up,100,69,5/6/2020
1.79E+10,earnings,100,50,5/6/2020
1.79E+10,business-contract,100,69,5/6/2020
188394,unit-acquisition-acquirer,100,49,5/6/2020
18D9FA,earnings,100,50,5/6/2020
18D9FA,earnings,100,50,5/6/2020
1921DD,note-sale,100,52,5/6/2020
1921DD,note-sale,100,52,5/6/2020
1921DD,note-sale,100,52,5/6/2020
1921DD,note-sale,100,52,5/6/2020
19BF16,earnings,100,50,5/6/2020
19BF16,earnings,100,50,5/6/2020
19BF16,earnings,100,50,5/6/2020
19BF16,earnings,100,50,5/6/2020
1AB808,earnings,100,50,5/6/2020
1AB808,earnings,100,50,5/6/2020
1AB808,earnings,100,50,5/6/2020
1C2593,conference-call,100,50,5/6/2020
1CD09C,conference-participant,100,50,5/6/2020
1D943E,earnings,100,50,5/6/2020
1D9E55,earnings,100,50,5/6/2020
1D9E55,earnings,100,50,5/6/2020
1DA44F,earnings,100,50,5/6/2020
1DB6A6,dividend,100,50,5/6/2020
1E7785,earnings,100,50,5/6/2020
1E7785,earnings,100,50,5/6/2020
1E7785,earnings,100,50,5/6/2020
1E7785,earnings,100,50,5/6/2020
1E7785,earnings,100,50,5/6/2020
1E7785,earnings,100,50,5/6/2020
1FAF22,clinical-trials,100,56,5/6/2020
2003A5,earnings,100,50,5/6/2020
2082EA,earnings,100,50,5/6/2020
227F04,earnings,100,50,5/6/2020
227F04,partnership,100,61,5/6/2020
24A89A,earnings,100,50,5/6/2020
24D81E,index-listing,100,76,5/6/2020
25AB8E,legal-issues-defendant,100,22,5/6/2020
263216,earnings,100,50,5/6/2020
263216,earnings,100,50,5/6/2020
263216,earnings,100,50,5/6/2020
263216,earnings,100,50,5/6/2020
263216,earnings,100,50,5/6/2020
263216,earnings,100,50,5/6/2020
263216,earnings,100,50,5/6/2020
263216,conference-participant,100,50,5/6/2020
28F905,earnings,100,50,5/6/2020
2920D5,earnings,100,50,5/6/2020
297DA8,earnings,100,50,5/6/2020
29CEBF,earnings,100,50,5/6/2020
29CEBF,earnings,100,50,5/6/2020
29CEBF,earnings,100,50,5/6/2020
29CEBF,earnings,100,50,5/6/2020
2ABF77,earnings,100,50,5/6/2020
2ABF77,earnings,100,50,5/6/2020
2B7A40,dividend,100,50,5/6/2020
2BAE5F,earnings,100,50,5/6/2020
2C681C,conference-call,100,50,5/6/2020
2C7505,earnings,100,50,5/6/2020
2CBB58,conference-call,100,50,5/6/2020
2D485F,earnings,100,50,5/6/2020
2D485F,earnings,100,50,5/6/2020
2D485F,earnings,100,50,5/6/2020
2D485F,earnings,100,50,5/6/2020
2E0445,fast-track-designation,100,81,5/6/2020
2F960F,earnings,100,50,5/6/2020
2FDEE3,earnings,100,50,5/6/2020
2FEA66,operating-earnings,100,50,5/6/2020
301493,legal-issues-defendant,100,22,5/6/2020
315EB0,earnings,100,50,5/6/2020
315EB0,earnings,100,50,5/6/2020
315EB0,earnings,100,50,5/6/2020
315EB0,earnings,100,50,5/6/2020
315EB0,earnings,100,50,5/6/2020
315EB0,earnings,100,50,5/6/2020
315EB0,dividend,100,50,5/6/2020
3461CF,executive-appointment,100,54,5/6/2020
367E1C,earnings,100,50,5/6/2020
37727A,earnings,100,50,5/6/2020
37727A,earnings,100,50,5/6/2020
37727A,earnings,100,50,5/6/2020
37727A,earnings,100,50,5/6/2020
37727A,earnings,100,50,5/6/2020
37727A,earnings,100,50,5/6/2020
37727A,earnings,100,50,5/6/2020
37727A,earnings,100,50,5/6/2020
384CD3,earnings,100,50,5/6/2020
3A1C46,public-offering,100,43,5/6/2020
3A3447,earnings,100,50,5/6/2020
3A3447,earnings,100,50,5/6/2020
3A3447,earnings,100,50,5/6/2020
3A3447,earnings,100,50,5/6/2020
3A3447,earnings,100,50,5/6/2020
3B2311,earnings,100,50,5/6/2020
3DCECC,earnings,100,50,5/6/2020
3FACA7,dividend,100,50,5/6/2020
401072,earnings,100,50,5/6/2020
4.00E+163,earnings,100,50,5/6/2020
427F32,earnings,100,50,5/6/2020
444CC8,earnings,100,50,5/6/2020
45BC35,earnings,100,50,5/6/2020
485445,dividend,100,50,5/6/2020
4B6EF9,dividend,100,50,5/6/2020
4B6EF9,earnings,100,50,5/6/2020
4C1FA1,legal-issues-defendant,100,22,5/6/2020
4C350A,earnings,100,50,5/6/2020
4C350A,earnings,100,50,5/6/2020
4C6C63,partnership,100,61,5/6/2020
4C6C63,partnership,100,61,5/6/2020
4D72C8,earnings,100,50,5/6/2020
4D8124,earnings,100,50,5/6/2020
4EE14A,operating-earnings,100,50,5/6/2020
4EE14A,operating-earnings,100,50,5/6/2020
4EE167,legal-issues-defendant,100,22,5/6/2020
4FB770,earnings,100,50,5/6/2020
50070E,conference-organizer,100,57,5/6/2020
513A86,earnings,100,50,5/6/2020
519FE0,earnings,100,50,5/6/2020
52FB2F,credit-extension-recipient,100,69,5/6/2020
5340D0,earnings,100,50,5/6/2020
545272,earnings,100,50,5/6/2020
546A27,earnings,100,50,5/6/2020
54F271,earnings,100,50,5/6/2020
54F271,earnings,100,50,5/6/2020
54F271,earnings,100,50,5/6/2020
54F271,earnings,100,50,5/6/2020
57B174,earnings,100,50,5/6/2020
57B174,earnings,100,50,5/6/2020
57B174,earnings,100,50,5/6/2020
57B174,earnings,100,50,5/6/2020
57DDB9,earnings,100,50,5/6/2020
57EF50,earnings,100,50,5/6/2020
57EF50,earnings,100,50,5/6/2020
57EF50,earnings,100,50,5/6/2020
57F3DA,earnings,100,50,5/6/2020
57F3DA,earnings,100,50,5/6/2020
594402,conference-participant,100,50,5/6/2020
5968F9,earnings,100,50,5/6/2020
5A0FF1,earnings,100,50,5/6/2020
5A0FF1,earnings,100,50,5/6/2020
5C7601,earnings,100,50,5/6/2020
5CEE02,earnings,100,50,5/6/2020
5DD486,dividend,100,50,5/6/2020
60EA12,dividend,100,50,5/6/2020
60EA12,earnings,100,50,5/6/2020
616E3B,earnings,100,50,5/6/2020
616E3B,earnings,100,50,5/6/2020
616E3B,earnings,100,50,5/6/2020
616E3B,earnings,100,50,5/6/2020
616E3B,earnings,100,50,5/6/2020
619882,conference-organizer,100,57,5/6/2020
619882,conference-organizer,100,57,5/6/2020
619882,conference-organizer,100,57,5/6/2020
619882,conference-organizer,100,57,5/6/2020
61E975,earnings-positive,100,69,5/6/2020
620381,partnership,100,61,5/6/2020
620381,partnership,100,61,5/6/2020
64E615,executive-appointment,100,54,5/6/2020
657097,earnings,100,50,5/6/2020
665D7D,debt-extension-recipient,100,73,5/6/2020
67A658,executive-resignation,100,44,5/6/2020
6925EB,legal-issues-defendant,100,22,5/6/2020
694749,earnings,100,50,5/6/2020
694749,earnings,100,50,5/6/2020
694749,earnings,100,50,5/6/2020
694749,earnings,100,50,5/6/2020
698FF9,earnings,100,50,5/6/2020
698FF9,earnings,100,50,5/6/2020
69CE71,earnings,100,50,5/6/2020
69CE71,earnings,100,50,5/6/2020
69CE71,earnings,100,50,5/6/2020
69CE71,earnings,100,50,5/6/2020
69CE71,earnings,100,50,5/6/2020
69CE71,earnings,100,50,5/6/2020
69CE71,earnings,100,50,5/6/2020
6A3C35,credit-extension-recipient,100,69,5/6/2020
6A961B,earnings,100,50,5/6/2020
6B236C,earnings,100,50,5/6/2020
6B6375,earnings,100,50,5/6/2020
6BBCBA,conference-call,100,50,5/6/2020
6DBBBC,earnings,100,50,5/6/2020
6DBBBC,earnings,100,50,5/6/2020
6DBBBC,earnings,100,50,5/6/2020
6DBBBC,earnings,100,50,5/6/2020
6DBBBC,earnings,100,50,5/6/2020
6E705B,note-sale,100,52,5/6/2020
6E8349,note-sale,100,52,5/6/2020
6E8349,board-meeting,100,51,5/6/2020
6EA292,earnings,100,50,5/6/2020
6ED519,earnings,100,50,5/6/2020
6ED519,earnings,100,50,5/6/2020
6ED519,earnings,100,50,5/6/2020
6F22E7,conference-call,100,50,5/6/2020
6F3FA8,earnings,100,50,5/6/2020
6F3FA8,earnings,100,50,5/6/2020
6F3FA8,earnings,100,50,5/6/2020
6F3FA8,earnings,100,50,5/6/2020
71E2EF,earnings,100,50,5/6/2020
723548,earnings,100,50,5/6/2020
7262F2,earnings,100,50,5/6/2020
72C2CE,earnings,100,50,5/6/2020
731675,earnings,100,50,5/6/2020
732449,public-offering,100,43,5/6/2020
742AAB,earnings,100,50,5/6/2020
763724,earnings,100,50,5/6/2020
763724,earnings,100,50,5/6/2020
763724,earnings,100,50,5/6/2020
76B926,earnings,100,50,5/6/2020
76B926,earnings,100,50,5/6/2020
76BECC,earnings,100,50,5/6/2020
76BECC,earnings,100,50,5/6/2020
76BECC,earnings,100,50,5/6/2020
790C34,partnership,100,61,5/6/2020
790C34,partnership,100,61,5/6/2020
797C20,earnings,100,50,5/6/2020
7A3633,earnings,100,50,5/6/2020
7B1E50,product-release,100,64,5/6/2020
7BFF81,revenues,100,50,5/6/2020
7BFF81,revenues,100,50,5/6/2020
7BFF81,revenues,100,50,5/6/2020
7BFF81,revenues,100,50,5/6/2020
7E1D5D,earnings,100,50,5/6/2020
7FD8B9,earnings,100,50,5/6/2020
805CD8,earnings,100,50,5/6/2020
8.10E+32,earnings,100,50,5/6/2020
8.10E+32,earnings,100,50,5/6/2020
8.10E+32,earnings,100,50,5/6/2020
8.10E+32,earnings,100,50,5/6/2020
8.10E+32,earnings,100,50,5/6/2020
8.10E+32,earnings,100,50,5/6/2020
8.10E+32,earnings,100,50,5/6/2020
8.10E+32,earnings,100,50,5/6/2020
8.10E+32,earnings,100,50,5/6/2020
8.10E+32,earnings,100,50,5/6/2020
810FAD,earnings,100,50,5/6/2020
818A2F,earnings,100,50,5/6/2020
81EAD4,conference-participant,100,50,5/6/2020
82B57E,earnings,100,50,5/6/2020
82C202,earnings,100,50,5/6/2020
83E0AC,dividend,100,50,5/6/2020
845533,earnings,100,50,5/6/2020
845655,earnings,100,50,5/6/2020
85DA04,earnings,100,50,5/6/2020
85DA04,earnings,100,50,5/6/2020
85DA04,earnings,100,50,5/6/2020
85DA04,earnings,100,50,5/6/2020
8665BA,conference-participant,100,50,5/6/2020
87486A,dividend,100,50,5/6/2020
87486A,earnings,100,50,5/6/2020
87486A,earnings,100,50,5/6/2020
87486A,earnings,100,50,5/6/2020
87486A,earnings,100,50,5/6/2020
88193E,earnings,100,50,5/6/2020
8DE56F,earnings,100,50,5/6/2020
8E82A6,earnings,100,50,5/6/2020
8E82A6,earnings,100,50,5/6/2020
8E82A6,earnings,100,50,5/6/2020
8E82A6,earnings,100,50,5/6/2020
8EF425,earnings,100,50,5/6/2020
8EF425,earnings,100,50,5/6/2020
8EF425,earnings,100,50,5/6/2020
8EF425,earnings,100,50,5/6/2020
8EF425,earnings,100,50,5/6/2020
8EF425,earnings,100,50,5/6/2020
902670,earnings,100,50,5/6/2020
902670,earnings,100,50,5/6/2020
902670,earnings,100,50,5/6/2020
902670,earnings,100,50,5/6/2020
90D6A5,earnings,100,50,5/6/2020
90D6A5,earnings,100,50,5/6/2020
90D6A5,earnings,100,50,5/6/2020
90D6A5,earnings,100,50,5/6/2020
90DD65,executive-appointment,100,54,5/6/2020
925759,earnings,100,50,5/6/2020
9.39E+69,partnership,100,61,5/6/2020
9.39E+69,partnership,100,61,5/6/2020
949625,operating-earnings,100,50,5/6/2020
94983E,earnings,100,50,5/6/2020
9507FF,public-offering,100,43,5/6/2020
9548BB,dividend,100,50,5/6/2020
9548BB,executive-resignation,100,44,5/6/2020
96BFF4,conference-call,100,50,5/6/2020
977A1E,dividend,100,50,5/6/2020
9810C0,note-sale,100,52,5/6/2020
9.86E+03,conference-participant,100,50,5/6/2020
990AD0,conference-organizer,100,57,5/6/2020
990AD0,conference-organizer,100,57,5/6/2020
990AD0,conference-organizer,100,57,5/6/2020
990AD0,conference-organizer,100,57,5/6/2020
990AD0,conference-organizer,100,57,5/6/2020
990AD0,conference-organizer,100,57,5/6/2020
990AD0,conference-organizer,100,57,5/6/2020
990AD0,conference-organizer,100,57,5/6/2020
990AD0,conference-organizer,100,57,5/6/2020
990AD0,conference-organizer,100,57,5/6/2020
990AD0,conference-organizer,100,57,5/6/2020
990AD0,conference-organizer,100,57,5/6/2020
9A02C4,earnings,100,50,5/6/2020
9A02C4,dividend-up,100,81,5/6/2020
9B0C9C,earnings,100,50,5/6/2020
9D3360,conference-call,100,50,5/6/2020
9D5FA4,earnings,100,50,5/6/2020
9DDE1B,earnings,100,50,5/6/2020
9E91C6,earnings,100,50,5/6/2020
9F048E,earnings,100,50,5/6/2020
9F048E,earnings,100,50,5/6/2020
9F048E,earnings,100,50,5/6/2020
9F048E,earnings,100,50,5/6/2020
9F048E,earnings,100,50,5/6/2020
A01200,earnings,100,50,5/6/2020
A01200,earnings,100,50,5/6/2020
A01200,earnings,100,50,5/6/2020
A01200,earnings,100,50,5/6/2020
A350C1,dividend,100,50,5/6/2020
A3AAA5,earnings,100,50,5/6/2020
A433A5,earnings,100,50,5/6/2020
A5DD24,earnings,100,50,5/6/2020
A62FD6,note-sale,100,52,5/6/2020
A63387,earnings,100,50,5/6/2020
A6FC89,conference-call,100,50,5/6/2020
A871B0,earnings,100,50,5/6/2020
A9ED24,earnings,100,50,5/6/2020
A9ED24,earnings,100,50,5/6/2020
A9ED24,earnings,100,50,5/6/2020
A9ED24,earnings,100,50,5/6/2020
A9ED24,earnings,100,50,5/6/2020
AA1EAA,earnings,100,50,5/6/2020
AAC8B6,earnings,100,50,5/6/2020
ADF092,earnings,100,50,5/6/2020
ADF092,earnings,100,50,5/6/2020
AE4125,revenue-up,100,69,5/6/2020
AE4125,revenue-up,100,69,5/6/2020
AE4125,revenue-up,100,69,5/6/2020
AF93DE,earnings,100,50,5/6/2020
AFD7DD,earnings,100,50,5/6/2020
AFD7DD,earnings,100,50,5/6/2020
B09B1F,earnings,100,50,5/6/2020
B09B1F,earnings,100,50,5/6/2020
B09B1F,earnings,100,50,5/6/2020
B09B1F,earnings,100,50,5/6/2020
B0FE08,earnings,100,50,5/6/2020
B0FE08,earnings,100,50,5/6/2020
B0FE08,earnings,100,50,5/6/2020
B0FE08,earnings,100,50,5/6/2020
B2E6B5,dividend,100,50,5/6/2020
B2E6B5,earnings,100,50,5/6/2020
B2E6B5,earnings,100,50,5/6/2020
B2E6B5,earnings,100,50,5/6/2020
B33E77,legal-issues-defendant,100,22,5/6/2020
B66928,earnings,100,50,5/6/2020
B66928,earnings,100,50,5/6/2020
B66928,earnings,100,50,5/6/2020
B66928,earnings,100,50,5/6/2020
B66928,earnings,100,50,5/6/2020
B66928,earnings,100,50,5/6/2020
B66928,shareholder-rights-plan,100,43,5/6/2020
B80AD1,conference-participant,100,50,5/6/2020
B83D67,earnings,100,50,5/6/2020
B840EF,index-listing,100,76,5/6/2020
B9BDE8,earnings,100,50,5/6/2020
BAD655,earnings,100,50,5/6/2020
BB02FB,note-sale,100,52,5/6/2020
BC5680,earnings,100,50,5/6/2020
BC5680,earnings,100,50,5/6/2020
BCC55F,business-contract,100,69,5/6/2020
BE14CF,dividend,100,50,5/6/2020
C03C8B,earnings,100,50,5/6/2020
C03C8B,earnings,100,50,5/6/2020
C03C8B,earnings,100,50,5/6/2020
C03C8B,earnings,100,50,5/6/2020
C03C8B,earnings,100,50,5/6/2020
C15DB3,earnings,100,50,5/6/2020
C188F8,earnings,100,50,5/6/2020
C2F597,earnings,100,50,5/6/2020
C3DE7D,earnings,100,50,5/6/2020
C3EE99,conference-call,100,50,5/6/2020
C4FBDC,earnings-up,100,68,5/6/2020
C4FBDC,earnings,100,50,5/6/2020
C4FBDC,earnings,100,50,5/6/2020
C4FBDC,earnings,100,50,5/6/2020
C83B88,partnership,100,61,5/6/2020
C941DC,earnings,100,50,5/6/2020
C9732E,legal-issues-defendant,100,22,5/6/2020
CA14CC,earnings,100,50,5/6/2020
CA14CC,earnings,100,50,5/6/2020
CA14CC,earnings,100,50,5/6/2020
CA99D7,conference-call,100,50,5/6/2020
CAB222,acquisition-acquirer,100,49,5/6/2020
CB89EA,earnings,100,50,5/6/2020
CBBFBF,earnings,100,50,5/6/2020
CBDB4D,earnings,100,50,5/6/2020
CDE51C,product-release,100,64,5/6/2020
CE4FD9,earnings,100,50,5/6/2020
CE4FD9,earnings,100,50,5/6/2020
CE4FD9,earnings,100,50,5/6/2020
CE4FD9,earnings,100,50,5/6/2020
CE5C6E,conference-participant,100,50,5/6/2020
D25249,note-sale,100,52,5/6/2020
D25249,note-sale,100,52,5/6/2020
D29F43,earnings,100,50,5/6/2020
D2B9E5,earnings,100,50,5/6/2020
D2B9E5,earnings,100,50,5/6/2020
D2B9E5,earnings,100,50,5/6/2020
D4AC65,unit-acquisition-acquiree,100,76,5/6/2020
D4AC65,earnings,100,50,5/6/2020
D4AC65,earnings,100,50,5/6/2020
D4AC65,earnings,100,50,5/6/2020
D4AC65,earnings,100,50,5/6/2020
D4AC65,earnings,100,50,5/6/2020
D58A11,earnings,100,50,5/6/2020
D58A11,earnings,100,50,5/6/2020
D58A11,earnings,100,50,5/6/2020
D650A7,dividend,100,50,5/6/2020
D650A7,earnings,100,50,5/6/2020
D650A7,earnings,100,50,5/6/2020
D650A7,earnings,100,50,5/6/2020
D650A7,earnings,100,50,5/6/2020
D7918D,legal-issues-defendant,100,22,5/6/2020
D854DD,earnings,100,50,5/6/2020
D90441,earnings,100,50,5/6/2020
D9B1C9,earnings,100,50,5/6/2020
D9B1C9,earnings,100,50,5/6/2020
DB5CA5,donation,100,54,5/6/2020
DB7014,operating-earnings,100,50,5/6/2020
DF1F7A,earnings,100,50,5/6/2020
E124EB,earnings,100,50,5/6/2020
E124EB,earnings,100,50,5/6/2020
E124EB,earnings,100,50,5/6/2020
E124EB,executive-appointment,100,54,5/6/2020
E38906,earnings,100,50,5/6/2020
E592F0,earnings,100,50,5/6/2020
E592F0,earnings,100,50,5/6/2020
E592F0,earnings,100,50,5/6/2020
E592F0,earnings,100,50,5/6/2020
E610CD,earnings,100,50,5/6/2020
E610CD,earnings,100,50,5/6/2020
E610CD,earnings,100,50,5/6/2020
E61888,conference-call,100,50,5/6/2020
E68E62,earnings,100,50,5/6/2020
EB5E78,conference-participant,100,50,5/6/2020
EC8116,earnings,100,50,5/6/2020
EE967B,conference-participant,100,50,5/6/2020
F02170,earnings,100,50,5/6/2020
F02D0A,earnings-per-share-positive,100,69,5/6/2020
F02D0A,earnings,100,50,5/6/2020
F179ED,earnings,100,50,5/6/2020
F179ED,earnings,100,50,5/6/2020
F179ED,earnings,100,50,5/6/2020
F179ED,earnings,100,50,5/6/2020
F2E253,earnings,100,50,5/6/2020
F2E253,earnings,100,50,5/6/2020
F2E253,earnings,100,50,5/6/2020
F2E253,earnings,100,50,5/6/2020
F2E253,earnings,100,50,5/6/2020
F2E253,earnings,100,50,5/6/2020
F32F88,earnings,100,50,5/6/2020
F509E2,legal-issues-defendant,100,22,5/6/2020
F5349B,earnings,100,50,5/6/2020
F5349B,dividend,100,50,5/6/2020
F5C8AB,dividend,100,50,5/6/2020
F5D410,donation,100,54,5/6/2020
001F1B,revenues,100,50,5/7/2020
0157B1,partnership,100,61,5/7/2020
02ACBD,earnings,100,50,5/7/2020
03B8CF,business-contract,100,69,5/7/2020
03D5F9,executive-appointment,100,54,5/7/2020
03D5F9,executive-appointment,100,54,5/7/2020
03FAA6,earnings,100,50,5/7/2020
03FAA6,earnings,100,50,5/7/2020
03FAA6,earnings,100,50,5/7/2020
03FAA6,earnings,100,50,5/7/2020
03FAA6,earnings,100,50,5/7/2020
053EFF,earnings,100,50,5/7/2020
061A3B,earnings,100,50,5/7/2020
061A3B,earnings,100,50,5/7/2020
061A3B,earnings,100,50,5/7/2020
061A3B,earnings,100,50,5/7/2020
06C826,earnings,100,50,5/7/2020
75172,earnings,100,50,5/7/2020
07EC43,earnings,100,50,5/7/2020
07EC43,earnings,100,50,5/7/2020
07EC43,earnings,100,50,5/7/2020
07EC43,earnings,100,50,5/7/2020
09062E,earnings,100,50,5/7/2020
0A59F8,partnership,100,61,5/7/2020
0A59F8,earnings,100,50,5/7/2020
0A59F8,earnings,100,50,5/7/2020
0A59F8,earnings,100,50,5/7/2020
0A59F8,earnings,100,50,5/7/2020
0A59F8,earnings,100,50,5/7/2020
0A6824,earnings,100,50,5/7/2020
0B13E8,earnings,100,50,5/7/2020
0B13E8,note-sale,100,52,5/7/2020
0B13E8,earnings,100,50,5/7/2020
0B13E8,note-sale,100,52,5/7/2020
0BF198,public-offering,100,43,5/7/2020
0BF198,public-offering,100,43,5/7/2020
0CCCB7,dividend-up,100,59,5/7/2020
0EF1AF,earnings,100,50,5/7/2020
0F65C9,earnings,100,50,5/7/2020
0F65C9,dividend,100,50,5/7/2020
0F91FC,earnings,100,50,5/7/2020
102F04,earnings,100,50,5/7/2020
1096C6,earnings,100,50,5/7/2020
1151F4,earnings,100,50,5/7/2020
1151F4,earnings,100,50,5/7/2020
1151F4,earnings,100,50,5/7/2020
1151F4,earnings,100,50,5/7/2020
1151F4,earnings,100,50,5/7/2020
1151F4,earnings,100,50,5/7/2020
1151F4,earnings,100,50,5/7/2020
1201B5,earnings,100,50,5/7/2020
135B09,earnings-up,100,68,5/7/2020
135B09,earnings,100,50,5/7/2020
135B09,earnings,100,50,5/7/2020
135B09,earnings,100,50,5/7/2020
135B09,earnings,100,50,5/7/2020
14391F,earnings,100,50,5/7/2020
14391F,earnings,100,50,5/7/2020
14391F,earnings,100,50,5/7/2020
14391F,earnings,100,50,5/7/2020
1490F3,earnings,100,50,5/7/2020
1490F3,earnings,100,50,5/7/2020
1490F3,earnings,100,50,5/7/2020
1490F3,earnings,100,50,5/7/2020
1490F3,earnings,100,50,5/7/2020
1490F3,earnings,100,50,5/7/2020
15A388,conference-participant,100,50,5/7/2020
165B86,earnings,100,50,5/7/2020
16C544,earnings,100,50,5/7/2020
17EDA5,partnership,100,61,5/7/2020
17EDA5,partnership,100,61,5/7/2020
180DA0,dividend,100,50,5/7/2020
18D9FA,executive-appointment,100,54,5/7/2020
190B91,earnings,100,50,5/7/2020
190B91,earnings,100,50,5/7/2020
190B91,earnings,100,50,5/7/2020
190B91,earnings,100,50,5/7/2020
190B91,earnings,100,50,5/7/2020
190B91,earnings,100,50,5/7/2020
1A5957,earnings,100,50,5/7/2020
1A5957,earnings,100,50,5/7/2020
1A5957,earnings,100,50,5/7/2020
1A5957,earnings,100,50,5/7/2020
1A5957,earnings,100,50,5/7/2020
1B637E,dividend,100,50,5/7/2020
1BC12C,note-sale,100,52,5/7/2020
1CD09C,earnings,100,50,5/7/2020
1CD4B5,earnings,100,50,5/7/2020
1CF3A8,earnings,100,50,5/7/2020
1D943E,conference-participant,100,50,5/7/2020
1EBF8D,conference-participant,100,50,5/7/2020
1F3CFB,earnings,100,50,5/7/2020
202E5A,earnings,100,50,5/7/2020
2096DE,earnings,100,50,5/7/2020
21268E,earnings,100,50,5/7/2020
239106,earnings,100,50,5/7/2020
239106,earnings,100,50,5/7/2020
239106,earnings,100,50,5/7/2020
2.45E+15,dividend,100,50,5/7/2020
250BEE,earnings,100,50,5/7/2020
250BEE,earnings,100,50,5/7/2020
250BEE,earnings,100,50,5/7/2020
250BEE,earnings,100,50,5/7/2020
253B2F,earnings,100,50,5/7/2020
253B2F,earnings,100,50,5/7/2020
2667B6,earnings,100,50,5/7/2020
270305,earnings,100,50,5/7/2020
27A791,conference-participant,100,50,5/7/2020
27C10F,earnings,100,50,5/7/2020
27C10F,earnings,100,50,5/7/2020
27C10F,earnings,100,50,5/7/2020
27C10F,earnings,100,50,5/7/2020
28B730,earnings,100,50,5/7/2020
28F905,earnings,100,50,5/7/2020
28F905,earnings,100,50,5/7/2020
28F905,earnings,100,50,5/7/2020
28F905,earnings,100,50,5/7/2020
28F905,earnings,100,50,5/7/2020
28F905,earnings,100,50,5/7/2020
28F905,earnings,100,50,5/7/2020
28F905,earnings,100,50,5/7/2020
2B5483,earnings,100,50,5/7/2020
2B7A40,conference-participant,100,50,5/7/2020
2B8179,clinical-trials,100,56,5/7/2020
2B8179,earnings,100,50,5/7/2020
2BA977,conference-call,100,50,5/7/2020
2BBE62,earnings,100,50,5/7/2020
2BBE62,earnings,100,50,5/7/2020
2BBE62,earnings,100,50,5/7/2020
2BBE62,earnings,100,50,5/7/2020
2BDC1C,earnings,100,50,5/7/2020
2C35B5,earnings,100,50,5/7/2020
2CC71C,earnings,100,50,5/7/2020
2DA92D,dividend,100,50,5/7/2020
2F7A7E,conference-call,100,50,5/7/2020
301493,legal-issues-defendant,100,22,5/7/2020
301493,earnings,100,50,5/7/2020
301493,earnings,100,50,5/7/2020
30AB63,earnings,100,50,5/7/2020
30DE64,earnings,100,50,5/7/2020
3159AA,earnings,100,50,5/7/2020
3159AA,dividend,100,50,5/7/2020
31803E,earnings,100,50,5/7/2020
32DCB3,earnings,100,50,5/7/2020
3461CF,conference-participant,100,50,5/7/2020
349DA4,patient-enrollment-start,100,58,5/7/2020
355B19,earnings,100,50,5/7/2020
35F4B5,dividend,100,50,5/7/2020
366A08,earnings,100,50,5/7/2020
366A08,earnings,100,50,5/7/2020
366A08,earnings,100,50,5/7/2020
366A08,earnings,100,50,5/7/2020
366A08,earnings,100,50,5/7/2020
371C01,earnings,100,50,5/7/2020
371C01,earnings,100,50,5/7/2020
384CD3,executive-resignation,100,44,5/7/2020
3A1C46,public-offering,100,43,5/7/2020
3ACF46,earnings,100,50,5/7/2020
3ACF46,earnings,100,50,5/7/2020
3ACF46,earnings,100,50,5/7/2020
3ACF46,earnings,100,50,5/7/2020
3AF7FD,earnings,100,50,5/7/2020
3C75D6,earnings-up,100,68,5/7/2020
3C75D6,earnings,100,50,5/7/2020
3C75D6,earnings,100,50,5/7/2020
3C7F5F,earnings,100,50,5/7/2020
3C7F5F,earnings,100,50,5/7/2020
3C7F5F,earnings,100,50,5/7/2020
3C7F5F,earnings,100,50,5/7/2020
3C7F5F,earnings,100,50,5/7/2020
3C7F5F,partnership,100,61,5/7/2020
3C7F5F,earnings,100,50,5/7/2020
3DD5E2,operating-earnings,100,50,5/7/2020
3DDE54,note-sale,100,52,5/7/2020
3DDE54,note-sale,100,52,5/7/2020
3E39A5,earnings,100,50,5/7/2020
3E39A5,earnings,100,50,5/7/2020
3E39A5,earnings,100,50,5/7/2020
3E70FC,earnings,100,50,5/7/2020
3F4668,revenues,100,50,5/7/2020
3F4668,revenues,100,50,5/7/2020
3F4668,revenues,100,50,5/7/2020
3F4668,revenues,100,50,5/7/2020
3F4668,revenues,100,50,5/7/2020
3F4668,legal-issues-defendant,100,22,5/7/2020
4017AD,earnings,100,50,5/7/2020
40B903,earnings,100,50,5/7/2020
415188,dividend,100,50,5/7/2020
415188,earnings,100,50,5/7/2020
416291,earnings,100,50,5/7/2020
41A93D,earnings,100,50,5/7/2020
43A060,earnings,100,50,5/7/2020
43A060,earnings,100,50,5/7/2020
43A060,earnings,100,50,5/7/2020
43A74A,conference-participant,100,50,5/7/2020
43F4A8,executive-appointment,100,54,5/7/2020
44209A,earnings,100,50,5/7/2020
44A4FC,partnership,100,61,5/7/2020
45ABCC,revenue-up,100,86,5/7/2020
45ABCC,revenue-up,100,86,5/7/2020
45ABCC,revenue-up,100,86,5/7/2020
46017C,earnings,100,50,5/7/2020
47752F,note-sale,100,52,5/7/2020
47FCF2,earnings,100,50,5/7/2020
47FCF2,earnings,100,50,5/7/2020
47FCF2,earnings,100,50,5/7/2020
47FCF2,earnings,100,50,5/7/2020
47FCF2,earnings,100,50,5/7/2020
47FCF2,earnings,100,50,5/7/2020
47FCF2,earnings,100,50,5/7/2020
47FCF2,earnings,100,50,5/7/2020
49CC59,earnings,100,50,5/7/2020
49F4D0,earnings,100,50,5/7/2020
4A6F00,partnership,100,61,5/7/2020
4A7C1F,earnings,100,50,5/7/2020
4AE584,earnings,100,50,5/7/2020
4BDCA7,earnings,100,50,5/7/2020
4BEB48,earnings,100,50,5/7/2020
4BEB48,earnings,100,50,5/7/2020
4BEB48,earnings,100,50,5/7/2020
4BEB48,earnings,100,50,5/7/2020
4BEB48,earnings,100,50,5/7/2020
4BF3D6,earnings,100,50,5/7/2020
4C2F17,earnings,100,50,5/7/2020
4C350A,conference-call,100,50,5/7/2020
4C37C5,dividend,100,50,5/7/2020
4C92B9,earnings,100,50,5/7/2020
4D8124,executive-appointment,100,54,5/7/2020
4E6F5A,earnings,100,50,5/7/2020
4EE167,conference-participant,100,50,5/7/2020
50070E,conference-organizer,100,57,5/7/2020
504FE2,note-sale,100,52,5/7/2020
504FE2,note-sale,100,52,5/7/2020
507AE7,dividend,100,50,5/7/2020
50D1EC,earnings,100,50,5/7/2020
51D876,earnings,100,50,5/7/2020
51D876,earnings,100,50,5/7/2020
51D876,earnings,100,50,5/7/2020
51D876,earnings,100,50,5/7/2020
51D876,earnings,100,50,5/7/2020
51D876,earnings,100,50,5/7/2020
51D876,earnings,100,50,5/7/2020
525A1C,earnings,100,50,5/7/2020
525A1C,earnings,100,50,5/7/2020
525A1C,earnings,100,50,5/7/2020
525A1C,earnings,100,50,5/7/2020
525A1C,earnings,100,50,5/7/2020
52FB2F,earnings,100,50,5/7/2020
52FB2F,earnings,100,50,5/7/2020
52FB2F,earnings,100,50,5/7/2020
52FB2F,earnings,100,50,5/7/2020
5403F8,earnings,100,50,5/7/2020
5487B1,earnings,100,50,5/7/2020
5487B1,earnings,100,50,5/7/2020
5487B1,earnings,100,50,5/7/2020
5487B1,earnings,100,50,5/7/2020
5487B1,earnings,100,50,5/7/2020
5487B1,earnings,100,50,5/7/2020
556F08,earnings,100,50,5/7/2020
55ACCB,earnings,100,50,5/7/2020
55ACCB,earnings,100,50,5/7/2020
55ACCB,earnings,100,50,5/7/2020
56B7C1,earnings,100,50,5/7/2020
56B7C1,earnings,100,50,5/7/2020
56B7C1,earnings,100,50,5/7/2020
56B7C1,earnings,100,50,5/7/2020
587D25,earnings,100,50,5/7/2020
58B46F,earnings-negative,100,33,5/7/2020
59DB8C,earnings,100,50,5/7/2020
59F0B0,earnings,100,50,5/7/2020
59F0B0,earnings,100,50,5/7/2020
59F0B0,earnings,100,50,5/7/2020
59F0B0,earnings,100,50,5/7/2020
5B3FA2,earnings,100,50,5/7/2020
5CC29D,note-sale,100,52,5/7/2020
5CC29D,note-sale,100,52,5/7/2020
619882,conference-organizer,100,57,5/7/2020
619882,conference-participant,100,50,5/7/2020
619882,conference-participant,100,50,5/7/2020
619882,conference-participant,100,50,5/7/2020
620381,earnings,100,50,5/7/2020
622DBE,conference-participant,100,50,5/7/2020
627186,conference-participant,100,50,5/7/2020
6284B5,earnings,100,50,5/7/2020
6284B5,earnings,100,50,5/7/2020
6284B5,earnings,100,50,5/7/2020
6284B5,earnings,100,50,5/7/2020
6284B5,earnings,100,50,5/7/2020
62EFEE,dividend,100,50,5/7/2020
633043,earnings,100,50,5/7/2020
636639,dividend,100,50,5/7/2020
649CBD,earnings,100,50,5/7/2020
6559D8,earnings,100,50,5/7/2020
665440,earnings,100,50,5/7/2020
66E04A,earnings,100,50,5/7/2020
66E04A,earnings,100,50,5/7/2020
66E04A,earnings,100,50,5/7/2020
66E04A,earnings,100,50,5/7/2020
66E04A,earnings,100,50,5/7/2020
66E04A,earnings,100,50,5/7/2020
66E04A,earnings,100,50,5/7/2020
676FFD,earnings,100,50,5/7/2020
6810DE,earnings,100,50,5/7/2020
68E6E9,earnings,100,50,5/7/2020
6B0784,earnings,100,50,5/7/2020
6BC6F9,earnings,100,50,5/7/2020
6BD606,dividend,100,50,5/7/2020
6BD606,earnings,100,50,5/7/2020
6D1ADF,earnings,100,50,5/7/2020
6DDA15,executive-appointment,100,54,5/7/2020
6.00E+19,earnings,100,50,5/7/2020
6F30F9,earnings,100,50,5/7/2020
6F39FC,earnings,100,50,5/7/2020
6F92A9,earnings,100,50,5/7/2020
6FCEF9,earnings,100,50,5/7/2020
7255D2,earnings,100,50,5/7/2020
732449,public-offering,100,43,5/7/2020
74404C,earnings,100,50,5/7/2020
7.45E+28,earnings,100,50,5/7/2020
756045,earnings,100,50,5/7/2020
75F982,partnership,100,61,5/7/2020
7734AC,dividend,100,50,5/7/2020
773A17,earnings,100,50,5/7/2020
787D14,earnings,100,50,5/7/2020
793C11,earnings,100,50,5/7/2020
7B0BA6,earnings,100,50,5/7/2020
7B0BA6,earnings,100,50,5/7/2020
7B0BA6,earnings,100,50,5/7/2020
7B0BA6,earnings,100,50,5/7/2020
7B0BA6,earnings,100,50,5/7/2020
7B0BA6,conference-participant,100,50,5/7/2020
7B1156,earnings,100,50,5/7/2020
7B9212,revenues,100,50,5/7/2020
7BEA98,earnings,100,50,5/7/2020
7C4F43,earnings,100,50,5/7/2020
7CD98F,earnings,100,50,5/7/2020
7D85A9,earnings,100,50,5/7/2020
7F2922,earnings,100,50,5/7/2020
7F3665,earnings,100,50,5/7/2020
7FDE1C,earnings,100,50,5/7/2020
803FED,earnings,100,50,5/7/2020
81222C,earnings,100,50,5/7/2020
817ED9,note-sale,100,52,5/7/2020
8.10E+205,earnings,100,50,5/7/2020
81EAD4,product-release,100,64,5/7/2020
82F088,earnings,100,50,5/7/2020
8303CD,partnership,100,61,5/7/2020
834152,earnings,100,50,5/7/2020
83598E,earnings,100,50,5/7/2020
83E0AC,earnings,100,50,5/7/2020
84920B,earnings,100,50,5/7/2020
8614A2,earnings,100,50,5/7/2020
86F123,earnings,100,50,5/7/2020
873DB9,earnings,100,50,5/7/2020
873DB9,earnings,100,50,5/7/2020
873DB9,earnings,100,50,5/7/2020
873DB9,earnings,100,50,5/7/2020
873DB9,earnings,100,50,5/7/2020
88923D,earnings,100,50,5/7/2020
88923D,earnings,100,50,5/7/2020
88923D,earnings,100,50,5/7/2020
88923D,earnings,100,50,5/7/2020
88923D,earnings,100,50,5/7/2020
88923D,earnings,100,50,5/7/2020
8B3B0E,earnings,100,50,5/7/2020
8BFAA4,earnings,100,50,5/7/2020
8BFAA4,earnings,100,50,5/7/2020
8BFAA4,earnings,100,50,5/7/2020
8BFAA4,earnings,100,50,5/7/2020
8DCF18,conference-participant,100,50,5/7/2020
902255,executive-resignation,100,44,5/7/2020
903AB4,dividend-up,100,81,5/7/2020
90D6A5,dividend,100,50,5/7/2020
911AB8,donation,100,54,5/7/2020
911CA9,earnings,100,50,5/7/2020
911CA9,earnings,100,50,5/7/2020
9196A2,conference-organizer,100,57,5/7/2020
9.39E+69,earnings,100,50,5/7/2020
9.39E+69,earnings,100,50,5/7/2020
93AD2E,earnings-above-expectations,100,88,5/7/2020
93D207,partnership,100,61,5/7/2020
943239,earnings,100,50,5/7/2020
943239,earnings,100,50,5/7/2020
94563D,earnings,100,50,5/7/2020
94563D,earnings,100,50,5/7/2020
94563D,earnings,100,50,5/7/2020
94563D,earnings,100,50,5/7/2020
94637C,earnings,100,50,5/7/2020
94637C,earnings,100,50,5/7/2020
94637C,earnings,100,50,5/7/2020
94637C,earnings,100,50,5/7/2020
94637C,earnings,100,50,5/7/2020
94637C,earnings,100,50,5/7/2020
94756D,conference-participant,100,50,5/7/2020
947B0B,earnings,100,50,5/7/2020
9.62E+76,dividend-up,100,81,5/7/2020
9.65E+07,earnings,100,50,5/7/2020
9.65E+07,earnings,100,50,5/7/2020
9.65E+07,earnings,100,50,5/7/2020
97FE80,earnings,100,50,5/7/2020
97FE80,earnings,100,50,5/7/2020
97FE80,earnings,100,50,5/7/2020
990AD0,conference-organizer,100,57,5/7/2020
990AD0,conference-organizer,100,57,5/7/2020
990AD0,conference-organizer,100,57,5/7/2020
990AD0,conference-organizer,100,57,5/7/2020
990AD0,conference-organizer,100,57,5/7/2020
990AD0,conference-organizer,100,57,5/7/2020
9978F1,earnings,100,50,5/7/2020
9A602D,partnership,100,61,5/7/2020
9A602D,dividend,100,50,5/7/2020
9B71A7,legal-issues-defendant,100,22,5/7/2020
9B730A,earnings,100,50,5/7/2020
9C25FF,earnings,100,50,5/7/2020
9C5174,revenue-up,100,71,5/7/2020
9C5174,revenues,100,50,5/7/2020
9C5174,revenues,100,50,5/7/2020
9CF9B1,earnings,100,50,5/7/2020
9D307D,earnings,100,50,5/7/2020
9DDE1B,earnings,100,50,5/7/2020
9E575E,earnings,100,50,5/7/2020
9E5C2C,earnings,100,50,5/7/2020
9E98F2,earnings,100,50,5/7/2020
9E98F2,earnings,100,50,5/7/2020
9E98F2,earnings,100,50,5/7/2020
9EA947,dividend,100,50,5/7/2020
A01664,conference-participant,100,50,5/7/2020
A247F5,conference-participant,100,50,5/7/2020
A403CF,earnings,100,50,5/7/2020
A43906,earnings,100,50,5/7/2020
A43906,earnings,100,50,5/7/2020
A43906,earnings,100,50,5/7/2020
A43906,earnings,100,50,5/7/2020
A43906,earnings,100,50,5/7/2020
A43906,earnings,100,50,5/7/2020
A43906,earnings,100,50,5/7/2020
A43906,earnings,100,50,5/7/2020
A43906,earnings,100,50,5/7/2020
A43906,earnings,100,50,5/7/2020
A43906,earnings,100,50,5/7/2020
A43906,earnings,100,50,5/7/2020
A43906,earnings,100,50,5/7/2020
A75D43,earnings,100,50,5/7/2020
A7A0BD,earnings,100,50,5/7/2020
AB4A7E,earnings,100,50,5/7/2020
ABB493,earnings,100,50,5/7/2020
AC3584,revenue-up,100,79,5/7/2020
AC3584,revenue-up,100,79,5/7/2020
AC3584,revenue-up,100,79,5/7/2020
AC7AAE,earnings,100,50,5/7/2020
AC7C4F,business-contract,100,69,5/7/2020
ACD9A4,dividend,100,50,5/7/2020
ACF0B4,earnings,100,50,5/7/2020
AD23DE,dividend,100,50,5/7/2020
AD6141,earnings,100,50,5/7/2020
ADF092,note-sale,100,52,5/7/2020
ADF092,note-sale,100,52,5/7/2020
AE4125,conference-call,100,50,5/7/2020
AEFC90,earnings,100,50,5/7/2020
B0B969,earnings,100,50,5/7/2020
B106FA,earnings,100,50,5/7/2020
B13B68,earnings,100,50,5/7/2020
B33E77,legal-issues-defendant,100,22,5/7/2020
B3A166,earnings,100,50,5/7/2020
B3ED62,executive-appointment,100,54,5/7/2020
B5BA39,earnings,100,50,5/7/2020
B73395,earnings,100,50,5/7/2020
B73395,earnings,100,50,5/7/2020
B73395,earnings,100,50,5/7/2020
B73395,earnings,100,50,5/7/2020
B803B1,earnings,100,50,5/7/2020
B80AD1,earnings,100,50,5/7/2020
B9CD50,conference-participant,100,50,5/7/2020
BB127B,conference-call,100,50,5/7/2020
BB88B6,conference-participant,100,50,5/7/2020
BD44C9,earnings,100,50,5/7/2020
BDA775,private-placement,100,56,5/7/2020
BDE867,dividend,100,50,5/7/2020
BE5935,earnings,100,50,5/7/2020
BF79F5,conference-participant,100,50,5/7/2020
C22BE8,conference-call,100,50,5/7/2020
C4706C,earnings,100,50,5/7/2020
C659EB,dividend,100,50,5/7/2020
C66A8C,earnings,100,50,5/7/2020
C66A8C,earnings,100,50,5/7/2020
C66A8C,earnings,100,50,5/7/2020
C66A8C,earnings,100,50,5/7/2020
C83B88,partnership,100,61,5/7/2020
C941DC,conference-participant,100,50,5/7/2020
C9732E,legal-issues-defendant,100,22,5/7/2020
C9D866,conference-participant,100,50,5/7/2020
C9E4EC,earnings,100,50,5/7/2020
CB6A9C,earnings,100,50,5/7/2020
CB6A9C,earnings,100,50,5/7/2020
CB6A9C,earnings,100,50,5/7/2020
CB6A9C,earnings,100,50,5/7/2020
CB6A9C,earnings,100,50,5/7/2020
CB6A9C,earnings,100,50,5/7/2020
CB6A9C,earnings,100,50,5/7/2020
CB89EA,public-offering,100,43,5/7/2020
CBA33B,product-release,100,64,5/7/2020
CD051C,earnings,100,50,5/7/2020
CD2A4D,earnings,100,50,5/7/2020
CDE51C,earnings,100,50,5/7/2020
CE5C6E,earnings,100,50,5/7/2020
CEC08B,earnings,100,50,5/7/2020
CEC08B,earnings,100,50,5/7/2020
CEC08B,earnings,100,50,5/7/2020
CEC08B,earnings,100,50,5/7/2020
CEC08B,earnings,100,50,5/7/2020
CEC5B9,earnings,100,50,5/7/2020
CEC5B9,earnings,100,50,5/7/2020
CF9054,executive-resignation,100,44,5/7/2020
CFB6CA,earnings,100,50,5/7/2020
CFB6CA,earnings,100,50,5/7/2020
CFD4B6,earnings-up,100,68,5/7/2020
CFD4B6,earnings-up,100,68,5/7/2020
CFD4B6,earnings-up,100,68,5/7/2020
D0909F,earnings,100,50,5/7/2020
D17C1B,earnings,100,50,5/7/2020
D17C1B,earnings,100,50,5/7/2020
D17C1B,earnings,100,50,5/7/2020
D1C26F,conference-participant,100,50,5/7/2020
D1C26F,partnership,100,61,5/7/2020
D296C6,earnings,100,50,5/7/2020
D29B44,earnings,100,50,5/7/2020
D4070C,dividend,100,50,5/7/2020
D437C3,conference-participant,100,50,5/7/2020
D4C0CB,conference-participant,100,50,5/7/2020
D518D8,revenues,100,50,5/7/2020
D518D8,revenues,100,50,5/7/2020
D518D8,revenues,100,50,5/7/2020
D518D8,revenues,100,50,5/7/2020
D518D8,revenues,100,50,5/7/2020
D56E4C,earnings,100,50,5/7/2020
D56E4C,earnings,100,50,5/7/2020
D57D99,earnings,100,50,5/7/2020
D58A11,conference-participant,100,50,5/7/2020
D5938F,earnings,100,50,5/7/2020
D6144F,earnings,100,50,5/7/2020
D64C6D,dividend,100,50,5/7/2020
D697DE,earnings,100,50,5/7/2020
D6EAA3,earnings,100,50,5/7/2020
D6EAA3,earnings,100,50,5/7/2020
D6EAA3,earnings,100,50,5/7/2020
D6EAA3,earnings,100,50,5/7/2020
D77F7E,executive-appointment,100,54,5/7/2020
D854F3,conference-participant,100,50,5/7/2020
D854F3,dividend,100,50,5/7/2020
D90F43,legal-issues-defendant,100,22,5/7/2020
D90F43,earnings,100,50,5/7/2020
D90F43,earnings,100,50,5/7/2020
D90F43,earnings,100,50,5/7/2020
D90F43,earnings,100,50,5/7/2020
D90F43,earnings,100,50,5/7/2020
D90F43,earnings,100,50,5/7/2020
D90F43,earnings,100,50,5/7/2020
D93A25,conference-participant,100,50,5/7/2020
DA0CB8,earnings,100,50,5/7/2020
DB5CA5,dividend,100,50,5/7/2020
DBB28E,conference-call,100,50,5/7/2020
DC2B00,conference-call,100,50,5/7/2020
DC486E,executive-appointment,100,54,5/7/2020
DC5299,operating-earnings,100,50,5/7/2020
DD1BA1,earnings,100,50,5/7/2020
DD1BA1,earnings,100,50,5/7/2020
DD1BA1,earnings,100,50,5/7/2020
DD1BA1,earnings,100,50,5/7/2020
DD1BA1,earnings,100,50,5/7/2020
DD1BA1,earnings,100,50,5/7/2020
DD1BA1,earnings,100,50,5/7/2020
DD682D,dividend,100,50,5/7/2020
DE20DF,operating-earnings,100,50,5/7/2020
DFADDB,executive-appointment,100,54,5/7/2020
DFADDB,earnings,100,50,5/7/2020
E124EB,public-offering,100,43,5/7/2020
E19A99,earnings,100,50,5/7/2020
E22FDE,conference-participant,100,50,5/7/2020
E259C7,earnings,100,50,5/7/2020
E2CFD2,earnings,100,50,5/7/2020
E49AA3,earnings,100,50,5/7/2020
E4CE73,conference-call,100,50,5/7/2020
E5752F,earnings,100,50,5/7/2020
E5752F,earnings,100,50,5/7/2020
E5752F,earnings,100,50,5/7/2020
E5752F,earnings,100,50,5/7/2020
E68733,earnings,100,50,5/7/2020
E82A2D,earnings,100,50,5/7/2020
E8B21D,dividend,100,50,5/7/2020
E8C557,earnings,100,50,5/7/2020
E96E0B,earnings,100,50,5/7/2020
ED3CA8,earnings,100,50,5/7/2020
ED9576,dividend,100,50,5/7/2020
ED9C04,earnings,100,50,5/7/2020
ED9C04,earnings,100,50,5/7/2020
ED9C04,earnings,100,50,5/7/2020
ED9C04,earnings,100,50,5/7/2020
ED9C04,earnings,100,50,5/7/2020
ED9C04,earnings,100,50,5/7/2020
EDD234,earnings,100,50,5/7/2020
EDD234,earnings,100,50,5/7/2020
EEBCEF,dividend,100,50,5/7/2020
EF25A5,earnings,100,50,5/7/2020
EF25A5,earnings,100,50,5/7/2020
EF25A5,earnings,100,50,5/7/2020
EF25A5,earnings,100,50,5/7/2020
EF5914,earnings,100,50,5/7/2020
EF5BED,executive-appointment,100,54,5/7/2020
EF7163,earnings,100,50,5/7/2020
F48947,conference-participant,100,50,5/7/2020
F4FBD8,product-release,100,64,5/7/2020
F57F6F,earnings,100,50,5/7/2020
F721A7,earnings,100,50,5/7/2020
F721A7,earnings,100,50,5/7/2020
F80389,earnings,100,50,5/7/2020
F83279,earnings,100,50,5/7/2020
F83279,earnings,100,50,5/7/2020
F88A04,earnings,100,50,5/7/2020
F88A04,earnings,100,50,5/7/2020
F88A04,earnings,100,50,5/7/2020
F88A04,earnings,100,50,5/7/2020
FB728F,earnings,100,50,5/7/2020
FB728F,earnings,100,50,5/7/2020
FBD92D,earnings-up,100,68,5/7/2020
FBD92D,earnings,100,50,5/7/2020
FBD92D,earnings,100,50,5/7/2020
FD39EB,earnings,100,50,5/7/2020
FD4588,earnings,100,50,5/7/2020
FD4588,earnings,100,50,5/7/2020
FD4588,earnings,100,50,5/7/2020
FDF28E,conference-participant,100,50,5/7/2020
FE609F,earnings,100,50,5/7/2020
FEE4B0,earnings,100,50,5/7/2020
FEE4B0,earnings,100,50,5/7/2020
FEE4B0,earnings,100,50,5/7/2020
FEE4B0,earnings,100,50,5/7/2020
FEE4B0,earnings,100,50,5/7/2020
FF5413,earnings-positive,100,69,5/7/2020
FF5413,earnings-positive,100,69,5/7/2020
FF6644,conference-participant,100,50,5/7/2020
002A99,earnings,100,50,5/8/2020
002A99,conference-participant,100,50,5/8/2020
00E601,operating-earnings,100,50,5/8/2020
01B8D6,earnings,100,50,5/8/2020
20751,earnings,100,50,5/8/2020
20751,earnings,100,50,5/8/2020
0358AF,revenue-up,100,69,5/8/2020
048B70,earnings,100,50,5/8/2020
048B70,earnings,100,50,5/8/2020
048B70,earnings,100,50,5/8/2020
048B70,earnings,100,50,5/8/2020
61366,earnings,100,50,5/8/2020
84625,earnings,100,50,5/8/2020
84625,earnings,100,50,5/8/2020
095A04,earnings,100,50,5/8/2020
0A9D0A,conference-participant,100,50,5/8/2020
0CADBC,earnings,100,50,5/8/2020
0DE3D5,earnings,100,50,5/8/2020
0DE3D5,earnings,100,50,5/8/2020
0DE3D5,earnings,100,50,5/8/2020
0DE3D5,earnings,100,50,5/8/2020
0DE3D5,earnings,100,50,5/8/2020
0E499E,earnings,100,50,5/8/2020
0E5619,earnings,100,50,5/8/2020
0F0693,conference-participant,100,50,5/8/2020
0F2BC9,earnings-up,100,68,5/8/2020
0F2BC9,earnings-up,100,68,5/8/2020
0FE3A6,earnings,100,50,5/8/2020
1080C0,public-offering,100,43,5/8/2020
1080C0,conference-participant,100,50,5/8/2020
125212,earnings,100,50,5/8/2020
12731D,earnings,100,50,5/8/2020
12731D,earnings,100,50,5/8/2020
12731D,earnings,100,50,5/8/2020
12731D,earnings,100,50,5/8/2020
12731D,earnings,100,50,5/8/2020
1279ED,earnings,100,50,5/8/2020
129DC8,earnings,100,50,5/8/2020
129DC8,earnings,100,50,5/8/2020
129DC8,earnings,100,50,5/8/2020
129DC8,earnings,100,50,5/8/2020
133644,earnings,100,50,5/8/2020
147098,earnings,100,50,5/8/2020
152AB9,earnings,100,50,5/8/2020
152AB9,earnings,100,50,5/8/2020
154272,conference-participant,100,50,5/8/2020
154272,earnings,100,50,5/8/2020
15789A,earnings,100,50,5/8/2020
15789A,earnings,100,50,5/8/2020
15789A,earnings,100,50,5/8/2020
15789A,earnings,100,50,5/8/2020
157CC1,earnings,100,50,5/8/2020
157D9F,earnings,100,50,5/8/2020
157D9F,earnings,100,50,5/8/2020
157D9F,earnings,100,50,5/8/2020
157D9F,earnings,100,50,5/8/2020
159AE4,earnings,100,50,5/8/2020
159AE4,earnings,100,50,5/8/2020
159AE4,earnings,100,50,5/8/2020
15B10D,earnings,100,50,5/8/2020
15B10D,earnings,100,50,5/8/2020
15B10D,earnings,100,50,5/8/2020
16B183,operating-earnings,100,50,5/8/2020
16B882,earnings,100,50,5/8/2020
16FC89,earnings,100,50,5/8/2020
17EDA5,earnings,100,50,5/8/2020
182BE7,product-recall,100,29,5/8/2020
182BE7,earnings,100,50,5/8/2020
184866,earnings,100,50,5/8/2020
184866,fast-track-designation,100,81,5/8/2020
1AC649,earnings,100,50,5/8/2020
1B4F31,earnings,100,50,5/8/2020
1E83DE,asset-sale,100,62,5/8/2020
1F464F,earnings,100,50,5/8/2020
1FC422,earnings,100,50,5/8/2020
1FE7F0,earnings,100,50,5/8/2020
1FE7F0,earnings,100,50,5/8/2020
1FE7F0,earnings,100,50,5/8/2020
1FE7F0,earnings,100,50,5/8/2020
1FE7F0,earnings,100,50,5/8/2020
21022F,earnings,100,50,5/8/2020
2158DF,earnings,100,50,5/8/2020
2158DF,earnings,100,50,5/8/2020
2158DF,earnings,100,50,5/8/2020
2158DF,earnings,100,50,5/8/2020
221783,earnings,100,50,5/8/2020
221783,earnings,100,50,5/8/2020
221783,earnings,100,50,5/8/2020
221783,earnings,100,50,5/8/2020
221783,earnings,100,50,5/8/2020
221AD7,product-release,100,64,5/8/2020
223552,conference-participant,100,50,5/8/2020
228D42,executive-appointment,100,54,5/8/2020
228D42,partnership,100,61,5/8/2020
228D42,partnership,100,61,5/8/2020
22C58E,conference-participant,100,50,5/8/2020
24A89A,earnings,100,50,5/8/2020
24C48B,earnings,100,50,5/8/2020
25102A,business-contract-terminated,100,31,5/8/2020
25AB8E,legal-issues-defendant,100,22,5/8/2020
25D3CE,business-contract,100,69,5/8/2020
25DD05,earnings,100,50,5/8/2020
25DD05,earnings,100,50,5/8/2020
27A791,earnings,100,50,5/8/2020
27A791,earnings,100,50,5/8/2020
27A791,earnings,100,50,5/8/2020
27A791,earnings,100,50,5/8/2020
292388,earnings,100,50,5/8/2020
292388,earnings,100,50,5/8/2020
292388,earnings,100,50,5/8/2020
292388,earnings,100,50,5/8/2020
2.90E+62,conference-participant,100,50,5/8/2020
2A1009,board-meeting,100,51,5/8/2020
2AA6A8,earnings,100,50,5/8/2020
2BD89C,dividend,100,50,5/8/2020
2BF36E,earnings,100,50,5/8/2020
2C19A4,earnings,100,50,5/8/2020
2C19A4,earnings,100,50,5/8/2020
2C19A4,earnings,100,50,5/8/2020
2C19A4,earnings,100,50,5/8/2020
2C3348,earnings,100,50,5/8/2020
2C681C,conference-call,100,50,5/8/2020
2CB4C9,facility-open,100,65,5/8/2020
2D643C,conference-participant,100,50,5/8/2020
2DDB22,earnings,100,50,5/8/2020
2E36AD,earnings,100,50,5/8/2020
2E36AD,earnings,100,50,5/8/2020
2EB04E,earnings,100,50,5/8/2020
2EB04E,earnings,100,50,5/8/2020
2EB04E,earnings,100,50,5/8/2020
301493,legal-issues-defendant,100,22,5/8/2020
306623,conference-participant,100,50,5/8/2020
30DFD3,conference-participant,100,50,5/8/2020
31803E,conference-participant,100,50,5/8/2020
3.20E+263,earnings,100,50,5/8/2020
32F943,earnings,100,50,5/8/2020
3301B7,buybacks,100,74,5/8/2020
337024,revenue-up,100,79,5/8/2020
337024,revenue-up,100,79,5/8/2020
337024,revenue-up,100,79,5/8/2020
342218,earnings,100,50,5/8/2020
342218,earnings,100,50,5/8/2020
353DBB,dividend,100,50,5/8/2020
35AE32,earnings,100,50,5/8/2020
35AE32,earnings,100,50,5/8/2020
35AE32,earnings,100,50,5/8/2020
35AE32,earnings,100,50,5/8/2020
36E479,earnings,100,50,5/8/2020
370C50,business-contract,100,69,5/8/2020
37B618,earnings,100,50,5/8/2020
37E18B,conference-call,100,50,5/8/2020
382EAE,operating-earnings,100,50,5/8/2020
382EAE,operating-earnings,100,50,5/8/2020
382EAE,operating-earnings,100,50,5/8/2020
396D7C,earnings,100,50,5/8/2020
3A113F,earnings,100,50,5/8/2020
3A3447,note-sale,100,52,5/8/2020
3A94DF,conference-participant,100,50,5/8/2020
3B2311,conference-participant,100,50,5/8/2020
3B8484,earnings-up,100,68,5/8/2020
3BE00F,dividend-up,100,54,5/8/2020
3C3B6B,earnings,100,50,5/8/2020
3C3B6B,executive-appointment,100,54,5/8/2020
3DDE54,board-meeting,100,51,5/8/2020
3E15F6,earnings,100,50,5/8/2020
3E15F6,earnings,100,50,5/8/2020
3E15F6,earnings,100,50,5/8/2020
3E15F6,earnings,100,50,5/8/2020
3EE65E,earnings,100,50,5/8/2020
3F1C69,conference-participant,100,50,5/8/2020
407878,earnings,100,50,5/8/2020
4.00E+163,legal-issues-defendant,100,22,5/8/2020
416C55,conference-participant,100,50,5/8/2020
41C36B,earnings,100,50,5/8/2020
41C528,earnings,100,50,5/8/2020
41C528,earnings,100,50,5/8/2020
429BFB,public-offering,100,43,5/8/2020
429BFB,public-offering,100,43,5/8/2020
42EFC7,earnings,100,50,5/8/2020
42EFC7,earnings,100,50,5/8/2020
4398A2,earnings,100,50,5/8/2020
448BF3,conference-participant,100,50,5/8/2020
448BF3,earnings,100,50,5/8/2020
448BF3,conference-participant,100,50,5/8/2020
44A4FC,conference-participant,100,50,5/8/2020
468DD4,earnings,100,50,5/8/2020
46A16E,facility-close,100,47,5/8/2020
479930,board-meeting,100,51,5/8/2020
48F795,earnings,100,50,5/8/2020
494EB9,executive-appointment,100,54,5/8/2020
4A2457,earnings,100,50,5/8/2020
4A3438,earnings,100,50,5/8/2020
4A3438,earnings,100,50,5/8/2020
4A3438,earnings,100,50,5/8/2020
4A7C1F,legal-issues-defendant,100,22,5/8/2020
4A7C1F,legal-issues-defendant,100,22,5/8/2020
4AC91D,earnings,100,50,5/8/2020
4B7006,earnings,100,50,5/8/2020
4BBA23,operating-earnings,100,50,5/8/2020
4C1FA1,earnings,100,50,5/8/2020
4C1FA1,earnings,100,50,5/8/2020
4C1FA1,earnings,100,50,5/8/2020
4C1FA1,earnings,100,50,5/8/2020
4C1FA1,earnings,100,50,5/8/2020
4C3FE9,earnings,100,50,5/8/2020
4CDA2B,conference-participant,100,50,5/8/2020
4D229C,earnings,100,50,5/8/2020
4D72C8,earnings,100,50,5/8/2020
4D8E5E,earnings,100,50,5/8/2020
4F0A80,earnings,100,50,5/8/2020
4FCC78,earnings,100,50,5/8/2020
50070E,conference-organizer,100,57,5/8/2020
50070E,conference-organizer,100,57,5/8/2020
514067,earnings,100,50,5/8/2020
524CE4,earnings,100,50,5/8/2020
53C421,earnings,100,50,5/8/2020
543C77,conference-participant,100,50,5/8/2020
5.47E+28,operating-earnings,100,50,5/8/2020
548AC0,earnings,100,50,5/8/2020
54DF47,earnings,100,50,5/8/2020
54F1D2,earnings,100,50,5/8/2020
553949,dividend,100,50,5/8/2020
562853,dividend,100,50,5/8/2020
56765E,earnings,100,50,5/8/2020
577033,earnings,100,50,5/8/2020
57A854,earnings-up,100,68,5/8/2020
57A854,earnings,100,50,5/8/2020
57B174,dividend,100,50,5/8/2020
5A423F,clinical-trials,100,56,5/8/2020
5A9A82,earnings,100,50,5/8/2020
5AA3B1,earnings,100,50,5/8/2020
5B3415,earnings,100,50,5/8/2020
5B7739,earnings,100,50,5/8/2020
5C2A47,earnings,100,50,5/8/2020
5D1329,earnings,100,50,5/8/2020
5D41E4,earnings,100,50,5/8/2020
5DD48B,earnings,100,50,5/8/2020
5DD48B,public-offering,100,43,5/8/2020
5F9CE3,partnership,100,61,5/8/2020
60FE03,earnings,100,50,5/8/2020
619882,conference-organizer,100,57,5/8/2020
619882,conference-organizer,100,57,5/8/2020
619882,conference-organizer,100,57,5/8/2020
619882,conference-organizer,100,57,5/8/2020
619882,conference-organizer,100,57,5/8/2020
619882,conference-organizer,100,57,5/8/2020
619882,conference-organizer,100,57,5/8/2020
61E975,conference-participant,100,50,5/8/2020
62A48D,conference-call,100,50,5/8/2020
62A48D,conference-call,100,50,5/8/2020
62EFEE,earnings,100,50,5/8/2020
6391C2,conference-participant,100,50,5/8/2020
639BD6,revenues,100,50,5/8/2020
639BD6,revenues,100,50,5/8/2020
639BD6,revenues,100,50,5/8/2020
63F892,business-contract,100,69,5/8/2020
63F892,earnings,100,50,5/8/2020
64636E,earnings,100,50,5/8/2020
665D7D,acquisition-completed-acquirer,100,49,5/8/2020
665D7D,acquisition-completed-acquirer,100,49,5/8/2020
66749D,dividend,100,50,5/8/2020
68BA15,earnings,100,50,5/8/2020
6925EB,earnings,100,50,5/8/2020
693ECD,earnings,100,50,5/8/2020
693ECD,earnings,100,50,5/8/2020
69C99E,earnings,100,50,5/8/2020
6A01DF,earnings,100,50,5/8/2020
6B67BD,earnings,100,50,5/8/2020
6BF593,earnings,100,50,5/8/2020
6D0CAB,dividend,100,50,5/8/2020
6D156D,earnings,100,50,5/8/2020
6D9ECA,conference-participant,100,50,5/8/2020
6-Dec-05,earnings,100,50,5/8/2020
6F39FC,dividend,100,50,5/8/2020
704B78,earnings,100,50,5/8/2020
7255D2,earnings,100,50,5/8/2020
726DDF,earnings,100,50,5/8/2020
7273FF,earnings,100,50,5/8/2020
7448A3,conference-participant,100,50,5/8/2020
76BD96,earnings,100,50,5/8/2020
76DD0C,clinical-trials-start,100,64,5/8/2020
76F067,fast-track-designation,100,81,5/8/2020
789A7D,dividend,100,50,5/8/2020
7999F3,business-contract,100,69,5/8/2020
7999F3,business-contract,100,69,5/8/2020
7999F3,earnings,100,50,5/8/2020
7999F3,earnings,100,50,5/8/2020
7999F3,earnings,100,50,5/8/2020
7999F3,earnings,100,50,5/8/2020
7999F3,earnings,100,50,5/8/2020
7999F3,earnings,100,50,5/8/2020
7999F3,earnings,100,50,5/8/2020
7999F3,earnings,100,50,5/8/2020
7999F3,earnings,100,50,5/8/2020
7AC86E,dividend,100,50,5/8/2020
7AF5B8,earnings,100,50,5/8/2020
7B1E50,executive-appointment,100,54,5/8/2020
7C62A3,earnings,100,50,5/8/2020
7D5384,note-sale,100,52,5/8/2020
7D5FD6,dividend,100,50,5/8/2020
7DC1C4,earnings,100,50,5/8/2020
7DD8CC,earnings,100,50,5/8/2020
7E0EB0,earnings,100,50,5/8/2020
7EA323,earnings,100,50,5/8/2020
7F9BE2,earnings,100,50,5/8/2020
7FEEE1,earnings,100,50,5/8/2020
80D744,note-sale,100,52,5/8/2020
818A2F,earnings,100,50,5/8/2020
819492,earnings,100,50,5/8/2020
824CCA,earnings,100,50,5/8/2020
824CCA,earnings,100,50,5/8/2020
824CCA,earnings,100,50,5/8/2020
82E58A,earnings,100,50,5/8/2020
835C86,operating-earnings,100,50,5/8/2020
8377DB,executive-resignation,100,44,5/8/2020
838ADD,dividend,100,50,5/8/2020
83B1C8,conference-participant,100,50,5/8/2020
83E0AC,conference-call,100,50,5/8/2020
845655,earnings,100,50,5/8/2020
845655,earnings,100,50,5/8/2020
845655,earnings,100,50,5/8/2020
845655,earnings,100,50,5/8/2020
84920B,credit-extension-recipient,100,69,5/8/2020
858942,earnings,100,50,5/8/2020
862941,operating-earnings,100,50,5/8/2020
86BAC7,dividend,100,50,5/8/2020
87B81A,earnings,100,50,5/8/2020
87B81A,earnings,100,50,5/8/2020
87B81A,earnings,100,50,5/8/2020
87B81A,dividend,100,50,5/8/2020
883D82,earnings,100,50,5/8/2020
88611B,earnings,100,50,5/8/2020
893904,earnings,100,50,5/8/2020
895D56,earnings,100,50,5/8/2020
89FBB1,earnings,100,50,5/8/2020
89FBB1,earnings,100,50,5/8/2020
8A8E41,donation,100,54,5/8/2020
8AC65D,conference-participant,100,50,5/8/2020
8AC65D,conference-participant,100,50,5/8/2020
8B9B3B,conference-participant,100,50,5/8/2020
8BAA15,earnings,100,50,5/8/2020
8BAA15,earnings,100,50,5/8/2020
8C6C1B,conference-call,100,50,5/8/2020
8DA42F,earnings,100,50,5/8/2020
8DA42F,earnings,100,50,5/8/2020
8DA42F,earnings,100,50,5/8/2020
8DE56F,earnings,100,50,5/8/2020
8E10BF,conference-participant,100,50,5/8/2020
8E9CD8,earnings,100,50,5/8/2020
8FF2EF,dividend,100,50,5/8/2020
902255,earnings,100,50,5/8/2020
902255,earnings,100,50,5/8/2020
902255,earnings,100,50,5/8/2020
90D6A5,dividend,100,50,5/8/2020
915E7B,earnings,100,50,5/8/2020
918D6D,earnings,100,50,5/8/2020
91E5EE,note-sale,100,52,5/8/2020
92005C,earnings,100,50,5/8/2020
92B625,earnings,100,50,5/8/2020
92B73F,dividend,100,50,5/8/2020
931AE7,earnings,100,50,5/8/2020
938D89,earnings,100,50,5/8/2020
93F143,dividend,100,50,5/8/2020
94208D,earnings,100,50,5/8/2020
94208D,earnings,100,50,5/8/2020
94208D,earnings,100,50,5/8/2020
94208D,earnings,100,50,5/8/2020
94208D,earnings,100,50,5/8/2020
9470CC,conference-participant,100,50,5/8/2020
9470CC,earnings,100,50,5/8/2020
9507FF,public-offering,100,43,5/8/2020
95A92E,earnings,100,50,5/8/2020
95C575,earnings,100,50,5/8/2020
95F59E,earnings,100,50,5/8/2020
95F59E,earnings,100,50,5/8/2020
95F59E,earnings,100,50,5/8/2020
95F59E,earnings,100,50,5/8/2020
9.65E+09,earnings,100,50,5/8/2020
9673BD,note-sale,100,52,5/8/2020
9673BD,note-sale,100,52,5/8/2020
96A2D3,earnings,100,50,5/8/2020
96A6CD,earnings,100,50,5/8/2020
97644E,earnings,100,50,5/8/2020
97644E,earnings,100,50,5/8/2020
97644E,earnings,100,50,5/8/2020
97644E,earnings,100,50,5/8/2020
97644E,earnings,100,50,5/8/2020
979451,legal-issues-defendant,100,22,5/8/2020
97AAF6,earnings,100,50,5/8/2020
97AAF6,earnings,100,50,5/8/2020
97AAF6,earnings,100,50,5/8/2020
989E2F,earnings,100,50,5/8/2020
989E2F,earnings,100,50,5/8/2020
989E2F,earnings,100,50,5/8/2020
99028D,earnings,100,50,5/8/2020
990AD0,conference-organizer,100,57,5/8/2020
990AD0,conference-organizer,100,57,5/8/2020
990AD0,conference-organizer,100,57,5/8/2020
990AD0,conference-organizer,100,57,5/8/2020
990AD0,conference-organizer,100,57,5/8/2020
990AD0,conference-organizer,100,57,5/8/2020
990AD0,conference-organizer,100,57,5/8/2020
990AD0,conference-organizer,100,57,5/8/2020
990AD0,conference-organizer,100,57,5/8/2020
990AD0,conference-organizer,100,57,5/8/2020
990AD0,conference-organizer,100,57,5/8/2020
990AD0,conference-organizer,100,57,5/8/2020
990AD0,conference-organizer,100,57,5/8/2020
990AD0,conference-organizer,100,57,5/8/2020
990AD0,conference-organizer,100,57,5/8/2020
990AD0,conference-organizer,100,57,5/8/2020
990AD0,conference-organizer,100,57,5/8/2020
990AD0,conference-organizer,100,57,5/8/2020
990AD0,conference-organizer,100,57,5/8/2020
990AD0,conference-organizer,100,57,5/8/2020
994468,dividend,100,50,5/8/2020
99ACAD,earnings,100,50,5/8/2020
99ACAD,earnings,100,50,5/8/2020
99ACAD,earnings,100,50,5/8/2020
99ACAD,earnings,100,50,5/8/2020
99ACAD,earnings,100,50,5/8/2020
9A2760,earnings-up,100,68,5/8/2020
9A2760,earnings,100,50,5/8/2020
9A2760,earnings,100,50,5/8/2020
9A2760,earnings,100,50,5/8/2020
9ABD30,earnings,100,50,5/8/2020
9C3D3C,earnings,100,50,5/8/2020
9C3D3C,conference-participant,100,50,5/8/2020
9C5174,conference-participant,100,50,5/8/2020
9CA432,earnings,100,50,5/8/2020
9E0811,earnings,100,50,5/8/2020
9E298A,earnings,100,50,5/8/2020
9E298A,earnings,100,50,5/8/2020
9E298A,earnings,100,50,5/8/2020
9E298A,earnings,100,50,5/8/2020
9E4A5F,earnings,100,50,5/8/2020
9EBAFA,earnings,100,50,5/8/2020
9EBAFA,acquisition-completed-acquirer,100,49,5/8/2020
9F5997,earnings,100,50,5/8/2020
9F5CBB,earnings,100,50,5/8/2020
9FD2D9,earnings,100,50,5/8/2020
9FD2D9,earnings,100,50,5/8/2020
9FD2D9,earnings,100,50,5/8/2020
A017F4,earnings,100,50,5/8/2020
A01983,dividend,100,50,5/8/2020
A072C4,earnings,100,50,5/8/2020
A16DEA,conference-participant,100,50,5/8/2020
A1EAC8,earnings,100,50,5/8/2020
A350C1,conference-participant,100,50,5/8/2020
A3BFAA,merger-regulatory-approval,100,81,5/8/2020
A3F598,earnings,100,50,5/8/2020
A3F598,earnings,100,50,5/8/2020
A3F598,earnings,100,50,5/8/2020
A3F598,earnings,100,50,5/8/2020
A48593,earnings,100,50,5/8/2020
A5195E,earnings,100,50,5/8/2020
A5195E,conference-participant,100,50,5/8/2020
A62FD6,note-sale,100,52,5/8/2020
A631A3,legal-issues-defendant,100,22,5/8/2020
A6828A,unit-acquisition-acquiree,100,76,5/8/2020
A6828A,unit-acquisition-acquiree,100,76,5/8/2020
A746F6,earnings,100,50,5/8/2020
A7A0C8,conference-call,100,50,5/8/2020
A94637,revenue-up,100,69,5/8/2020
A94637,revenue-up,100,69,5/8/2020
AAC8B6,earnings,100,50,5/8/2020
AAC8B6,earnings,100,50,5/8/2020
AAC8B6,earnings,100,50,5/8/2020
AAC8B6,earnings,100,50,5/8/2020
AAC8B6,earnings,100,50,5/8/2020
ACC7D3,earnings,100,50,5/8/2020
AD1ACF,dividend,100,50,5/8/2020
AD1ACF,partnership,100,61,5/8/2020
AD3008,earnings,100,50,5/8/2020
ADFB3A,earnings,100,50,5/8/2020
AE3113,earnings,100,50,5/8/2020
AE79CD,earnings,100,50,5/8/2020
B01215,earnings,100,50,5/8/2020
B04426,earnings,100,50,5/8/2020
B05000,executive-appointment,100,54,5/8/2020
B08C51,earnings,100,50,5/8/2020
B1A85D,earnings,100,50,5/8/2020
B1DF3C,earnings,100,50,5/8/2020
B290A2,note-sale,100,52,5/8/2020
B290A2,conference-participant,100,50,5/8/2020
B2D799,executive-appointment,100,54,5/8/2020
B303A6,earnings,100,50,5/8/2020
B303A6,earnings,100,50,5/8/2020
B303A6,earnings,100,50,5/8/2020
B303A6,earnings,100,50,5/8/2020
B33E77,legal-issues-defendant,100,22,5/8/2020
B33E77,legal-issues-defendant,100,22,5/8/2020
B37FB4,partnership,100,61,5/8/2020
B4528F,conference-participant,100,50,5/8/2020
B5DE80,earnings,100,50,5/8/2020
B619CB,board-meeting,100,51,5/8/2020
B6CD92,earnings,100,50,5/8/2020
B7202A,earnings-positive,100,69,5/8/2020
B7FA9B,earnings,100,50,5/8/2020
B8A51F,conference-participant,100,50,5/8/2020
B8EF97,revenues,100,50,5/8/2020
BB02FB,earnings,100,50,5/8/2020
BCC55F,conference-participant,100,50,5/8/2020
BCC55F,earnings,100,50,5/8/2020
BD8517,executive-appointment,100,54,5/8/2020
BD9668,dividend,100,50,5/8/2020
BDE867,earnings,100,50,5/8/2020
BDE867,earnings,100,50,5/8/2020
BDE867,earnings,100,50,5/8/2020
BDEC1E,earnings,100,50,5/8/2020
BDF85E,public-offering,100,43,5/8/2020
BE7BA4,earnings,100,50,5/8/2020
BFD0A7,earnings,100,50,5/8/2020
BFD0A7,earnings,100,50,5/8/2020
BFD0A7,earnings,100,50,5/8/2020
C037A8,earnings,100,50,5/8/2020
C03C8B,note-sale,100,52,5/8/2020
C06EB6,earnings,100,50,5/8/2020
C0F70B,note-sale,100,52,5/8/2020
C0F70B,conference-participant,100,50,5/8/2020
C11C46,conference-participant,100,50,5/8/2020
C38440,earnings,100,50,5/8/2020
C407A0,earnings,100,50,5/8/2020
C425AE,earnings,100,50,5/8/2020
C4A432,conference-call,100,50,5/8/2020
C4F9C6,earnings,100,50,5/8/2020
C50B26,earnings,100,50,5/8/2020
C564E4,earnings,100,50,5/8/2020
C584BE,earnings,100,50,5/8/2020
C58D71,earnings,100,50,5/8/2020
C5D2AE,earnings,100,50,5/8/2020
C5F463,donation,100,54,5/8/2020
C62AA4,earnings,100,50,5/8/2020
C65004,earnings,100,50,5/8/2020
C6C702,earnings,100,50,5/8/2020
C9732E,legal-issues-defendant,100,22,5/8/2020
C9732E,legal-issues-defendant,100,22,5/8/2020
C9A96E,earnings,100,50,5/8/2020
CA99D7,conference-call,100,50,5/8/2020
CB89EA,public-offering,100,43,5/8/2020
CC35BE,earnings,100,50,5/8/2020
CC35BE,earnings,100,50,5/8/2020
CC35BE,earnings,100,50,5/8/2020
CC35BE,earnings,100,50,5/8/2020
CC35BE,earnings,100,50,5/8/2020
CCB623,public-offering,100,43,5/8/2020
CCB623,public-offering,100,43,5/8/2020
CDAA0E,conference-participant,100,50,5/8/2020
CDAA0E,earnings,100,50,5/8/2020
CDAA0E,conference-participant,100,50,5/8/2020
CDE118,earnings,100,50,5/8/2020
CDFCC9,dividend,100,50,5/8/2020
CDFCC9,earnings,100,50,5/8/2020
CDFCC9,earnings,100,50,5/8/2020
CDFCC9,earnings,100,50,5/8/2020
CDFCC9,earnings,100,50,5/8/2020
CDFCC9,earnings,100,50,5/8/2020
CE4FD9,conference-call,100,50,5/8/2020
CEC5B9,earnings,100,50,5/8/2020
CFB6CA,earnings,100,50,5/8/2020
CFB6CA,earnings,100,50,5/8/2020
CFD4B6,dividend,100,50,5/8/2020
D07B07,earnings,100,50,5/8/2020
D09938,earnings,100,50,5/8/2020
D11C1C,operating-earnings,100,50,5/8/2020
D13F1C,earnings,100,50,5/8/2020
D13F1C,earnings,100,50,5/8/2020
D13F1C,earnings,100,50,5/8/2020
D13F1C,earnings,100,50,5/8/2020
D13F1C,earnings,100,50,5/8/2020
D36B23,conference-participant,100,50,5/8/2020
D36B23,earnings,100,50,5/8/2020
D4070C,dividend,100,50,5/8/2020
D56D6D,executive-appointment,100,54,5/8/2020
D57D99,dividend,100,50,5/8/2020
D5A350,dividend,100,50,5/8/2020
D75910,conference-call,100,50,5/8/2020
D8442A,legal-issues-defendant,100,22,5/8/2020
D90441,earnings,100,50,5/8/2020
D90441,earnings,100,50,5/8/2020
D95385,earnings,100,50,5/8/2020
DA0A9E,dividend,100,50,5/8/2020
DAFED3,earnings,100,50,5/8/2020
DAFED3,earnings,100,50,5/8/2020
DAFED3,earnings,100,50,5/8/2020
DB23C8,earnings,100,50,5/8/2020
DB23C8,earnings,100,50,5/8/2020
DB23C8,earnings,100,50,5/8/2020
DB396B,earnings,100,50,5/8/2020
DB396B,earnings,100,50,5/8/2020
DB396B,earnings,100,50,5/8/2020
DB9F70,earnings,100,50,5/8/2020
DB9F70,conference-participant,100,50,5/8/2020
DC1405,conference-participant,100,50,5/8/2020
DC486E,executive-appointment,100,54,5/8/2020
DC6EF3,earnings,100,50,5/8/2020
DDB002,earnings,100,50,5/8/2020
DF16DE,earnings,100,50,5/8/2020
DF1F7A,dividend,100,50,5/8/2020
E0207A,conference-participant,100,50,5/8/2020
E0D3BA,earnings,100,50,5/8/2020
E124EB,public-offering,100,43,5/8/2020
E13782,earnings,100,50,5/8/2020
E15736,earnings,100,50,5/8/2020
E16133,earnings,100,50,5/8/2020
E1E36F,acquisition-completed-acquirer,100,49,5/8/2020
E20392,earnings,100,50,5/8/2020
E22FDE,earnings,100,50,5/8/2020
E22FDE,earnings,100,50,5/8/2020
E22FDE,earnings,100,50,5/8/2020
E26FC3,dividend,100,50,5/8/2020
E28D9C,earnings,100,50,5/8/2020
E3656D,earnings,100,50,5/8/2020
E3A829,earnings,100,50,5/8/2020
E3A829,earnings,100,50,5/8/2020
E3A829,earnings,100,50,5/8/2020
E3A829,earnings,100,50,5/8/2020
E41190,earnings,100,50,5/8/2020
E41190,earnings,100,50,5/8/2020
E41190,earnings,100,50,5/8/2020
E41190,earnings,100,50,5/8/2020
E68733,earnings,100,50,5/8/2020
E74B55,earnings,100,50,5/8/2020
E754F0,earnings,100,50,5/8/2020
E802CE,earnings,100,50,5/8/2020
E8846E,executive-appointment,100,54,5/8/2020
E8846E,legal-issues-defendant,100,22,5/8/2020
EAA0A7,earnings,100,50,5/8/2020
EAA0A7,earnings,100,50,5/8/2020
EAA0A7,earnings,100,50,5/8/2020
EAA0A7,earnings,100,50,5/8/2020
EAA0A7,earnings,100,50,5/8/2020
EAEBF3,earnings,100,50,5/8/2020
ECE814,earnings,100,50,5/8/2020
ECF4F8,earnings,100,50,5/8/2020
ED2EFD,executive-appointment,100,54,5/8/2020
EEA734,earnings,100,50,5/8/2020
EEB5F9,earnings,100,50,5/8/2020
F05B1B,earnings,100,50,5/8/2020
F05B1B,earnings,100,50,5/8/2020
F0B335,earnings,100,50,5/8/2020
F0B335,conference-participant,100,50,5/8/2020
F2526D,board-meeting,100,51,5/8/2020
F3816D,earnings,100,50,5/8/2020
F3FCC3,earnings,100,50,5/8/2020
F48947,conference-call,100,50,5/8/2020
F4D241,earnings,100,50,5/8/2020
F4E882,legal-issues-defendant,100,22,5/8/2020
F509E2,conference-call,100,50,5/8/2020
F569FD,earnings,100,50,5/8/2020
F58C23,conference-organizer,100,57,5/8/2020
F5D499,conference-call,100,50,5/8/2020
F6DE54,dividend-suspended,100,13,5/8/2020
F6FA6A,earnings,100,50,5/8/2020
F6FA6A,earnings,100,50,5/8/2020
F6FA6A,earnings,100,50,5/8/2020
F6FA6A,earnings,100,50,5/8/2020
F6FA6A,earnings,100,50,5/8/2020
F6FA6A,earnings,100,50,5/8/2020
F6FA6A,earnings,100,50,5/8/2020
F7935D,earnings,100,50,5/8/2020
F7D8AE,earnings,100,50,5/8/2020
F82D37,executive-appointment,100,54,5/8/2020
F85CC0,note-sale,100,52,5/8/2020
F85CC0,conference-participant,100,50,5/8/2020
F90EE5,dividend-up,100,81,5/8/2020
F93C8A,earnings,100,50,5/8/2020
F9AA02,earnings,100,50,5/8/2020
FA35C6,earnings,100,50,5/8/2020
FAB97A,earnings,100,50,5/8/2020
FC1A6E,conference-participant,100,50,5/8/2020
FC1F9D,dividend,100,50,5/8/2020
FC80E6,earnings,100,50,5/8/2020
FD2565,earnings,100,50,5/8/2020
FD554E,earnings,100,50,5/8/2020
FD554E,earnings,100,50,5/8/2020
FF227B,earnings,100,50,5/8/2020
1DB833,conference-participant,100,50,5/9/2020
301493,legal-issues-defendant,100,22,5/9/2020
790C34,earnings,100,50,5/9/2020
92D230,conference-call,100,50,5/9/2020
990AD0,conference-organizer,100,57,5/9/2020
B33E77,legal-issues-defendant,100,22,5/9/2020
C9732E,legal-issues-defendant,100,22,5/9/2020
F30508,regulatory-product-approval-granted,100,81,5/9/2020
F30508,regulatory-product-approval-granted,100,81,5/9/2020
F30508,regulatory-product-approval-granted,100,81,5/9/2020
301493,legal-issues-defendant,100,22,5/10/2020
C9732E,legal-issues-defendant,100,22,5/10/2020
00326D,conference-call,100,50,5/11/2020
13528,product-release,100,64,5/11/2020
01D03F,executive-death,100,31,5/11/2020
0325B7,earnings,100,50,5/11/2020
03542C,earnings,100,50,5/11/2020
036C6F,earnings,100,50,5/11/2020
036C6F,earnings,100,50,5/11/2020
036C6F,earnings,100,50,5/11/2020
036C6F,earnings,100,50,5/11/2020
0490C6,earnings,100,50,5/11/2020
0490C6,earnings,100,50,5/11/2020
0490C6,earnings,100,50,5/11/2020
0490C6,earnings,100,50,5/11/2020
04996E,earnings,100,50,5/11/2020
04EB2F,earnings,100,50,5/11/2020
05D148,clinical-trials,100,56,5/11/2020
05D148,clinical-trials,100,56,5/11/2020
06C826,conference-participant,100,50,5/11/2020
083F72,earnings,100,50,5/11/2020
84625,dividend,100,50,5/11/2020
95294,earnings,100,50,5/11/2020
0B400D,earnings,100,50,5/11/2020
0B7375,earnings,100,50,5/11/2020
0BD199,earnings,100,50,5/11/2020
0BD199,earnings,100,50,5/11/2020
0F0693,public-offering,100,43,5/11/2020
0FC848,earnings,100,50,5/11/2020
108A2B,operating-earnings,100,50,5/11/2020
1220D2,conference-participant,100,50,5/11/2020
12F98C,product-release,100,64,5/11/2020
138DDE,dividend,100,50,5/11/2020
14833D,earnings,100,50,5/11/2020
152FA5,public-offering,100,43,5/11/2020
152FA5,earnings,100,50,5/11/2020
1880C5,earnings,100,50,5/11/2020
196D18,earnings,100,50,5/11/2020
19BF16,board-meeting,100,51,5/11/2020
1A3E1B,conference-participant,100,50,5/11/2020
1A3E1B,earnings,100,50,5/11/2020
1B6F77,earnings,100,50,5/11/2020
1C599A,earnings,100,50,5/11/2020
1CB9D3,earnings,100,50,5/11/2020
1E4FB9,earnings,100,50,5/11/2020
21022F,executive-appointment,100,54,5/11/2020
21D903,earnings,100,50,5/11/2020
227F04,conference-participant,100,50,5/11/2020
227F04,conference-participant,100,50,5/11/2020
228D42,partnership,100,61,5/11/2020
232053,earnings,100,50,5/11/2020
23207A,earnings,100,50,5/11/2020
23207A,earnings,100,50,5/11/2020
238302,earnings,100,50,5/11/2020
2491BC,executive-appointment,100,54,5/11/2020
25D3CE,earnings-up,100,68,5/11/2020
25D3CE,earnings,100,50,5/11/2020
25D3CE,earnings,100,50,5/11/2020
25D3CE,earnings,100,50,5/11/2020
26D8ED,patent-awarded,100,72,5/11/2020
26E3BA,earnings,100,50,5/11/2020
27BFA1,capital-increase,100,43,5/11/2020
28AF37,executive-appointment,100,54,5/11/2020
28AF37,earnings,100,50,5/11/2020
28AF37,earnings,100,50,5/11/2020
28AF37,earnings,100,50,5/11/2020
28AF37,earnings,100,50,5/11/2020
28AF37,earnings,100,50,5/11/2020
2920D5,note-sale,100,52,5/11/2020
2B8179,public-offering,100,43,5/11/2020
2BAE5F,executive-appointment,100,54,5/11/2020
2C681C,earnings,100,50,5/11/2020
2C681C,earnings,100,50,5/11/2020
2CD1E0,partnership,100,61,5/11/2020
2CF9D3,earnings,100,50,5/11/2020
2D981A,earnings,100,50,5/11/2020
2EB88B,public-offering,100,43,5/11/2020
2EB88B,public-offering,100,43,5/11/2020
2EBA55,earnings,100,50,5/11/2020
2EBA55,dividend,100,50,5/11/2020
2F7A7E,earnings,100,50,5/11/2020
2FF046,earnings,100,50,5/11/2020
2FF046,earnings,100,50,5/11/2020
2FF046,earnings,100,50,5/11/2020
2FF046,earnings,100,50,5/11/2020
301493,legal-issues-defendant,100,22,5/11/2020
315EB0,public-offering,100,43,5/11/2020
33E8C7,debt-extension-recipient,100,73,5/11/2020
34A959,earnings,100,50,5/11/2020
3587B4,earnings,100,50,5/11/2020
3587B4,earnings,100,50,5/11/2020
3587B4,earnings,100,50,5/11/2020
3587B4,earnings,100,50,5/11/2020
3587B4,earnings,100,50,5/11/2020
36C09B,earnings,100,50,5/11/2020
37B120,earnings,100,50,5/11/2020
382EAE,executive-appointment,100,54,5/11/2020
385DD4,earnings,100,50,5/11/2020
3A1C46,conference-participant,100,50,5/11/2020
3B37F7,dividend,100,50,5/11/2020
3BA1BF,earnings,100,50,5/11/2020
3BA1BF,earnings,100,50,5/11/2020
3BA1BF,earnings,100,50,5/11/2020
3BA1BF,earnings,100,50,5/11/2020
3BA1BF,earnings,100,50,5/11/2020
3BA1BF,earnings,100,50,5/11/2020
3BA1BF,earnings,100,50,5/11/2020
3BA1BF,earnings,100,50,5/11/2020
3BA1BF,earnings,100,50,5/11/2020
3D7971,earnings,100,50,5/11/2020
3D7971,earnings,100,50,5/11/2020
3D7971,earnings,100,50,5/11/2020
3D7971,earnings,100,50,5/11/2020
3D7971,earnings,100,50,5/11/2020
3D7971,earnings,100,50,5/11/2020
3DCECC,public-offering,100,43,5/11/2020
3DD5E2,conference-participant,100,50,5/11/2020
3DED49,conference-call,100,50,5/11/2020
3F1C69,earnings,100,50,5/11/2020
3F96D5,earnings,100,50,5/11/2020
417BF9,conference-call,100,50,5/11/2020
41EC04,earnings,100,50,5/11/2020
41EC04,earnings,100,50,5/11/2020
41EC04,earnings,100,50,5/11/2020
41EC04,earnings,100,50,5/11/2020
41ED98,earnings,100,50,5/11/2020
429BFB,public-offering,100,43,5/11/2020
43F4A8,earnings,100,50,5/11/2020
43F4A8,earnings,100,50,5/11/2020
43F4A8,earnings,100,50,5/11/2020
43F4A8,earnings,100,50,5/11/2020
448215,earnings,100,50,5/11/2020
450ECB,earnings,100,50,5/11/2020
45444E,earnings,100,50,5/11/2020
4595EF,conference-call,100,50,5/11/2020
45ABCC,patent-infringement-plaintiff,100,47,5/11/2020
46017C,executive-appointment,100,54,5/11/2020
4.60E+06,earnings,100,50,5/11/2020
485445,earnings,100,50,5/11/2020
485445,earnings,100,50,5/11/2020
485445,earnings,100,50,5/11/2020
485445,earnings,100,50,5/11/2020
485445,earnings,100,50,5/11/2020
4A2457,business-contract,100,69,5/11/2020
4A2457,conference-participant,100,50,5/11/2020
4B3DC9,partnership,100,61,5/11/2020
4C6C63,partnership,100,61,5/11/2020
4C6C63,partnership,100,61,5/11/2020
4C7DB5,earnings,100,50,5/11/2020
4D229C,earnings,100,50,5/11/2020
4D8313,fundraising,100,64,5/11/2020
4DD203,earnings,100,50,5/11/2020
4EEB00,operating-earnings,100,50,5/11/2020
50070E,conference-organizer,100,57,5/11/2020
50070E,conference-organizer,100,57,5/11/2020
50070E,conference-organizer,100,57,5/11/2020
50070E,earnings,100,50,5/11/2020
51888A,name-change,100,49,5/11/2020
520632,regulatory-product-approval-granted,100,81,5/11/2020
539F49,earnings,100,50,5/11/2020
54512F,earnings,100,50,5/11/2020
55CD6F,note-sale,100,52,5/11/2020
55CD6F,note-sale,100,52,5/11/2020
55D0F3,earnings,100,50,5/11/2020
56277A,earnings,100,50,5/11/2020
57A854,executive-appointment,100,54,5/11/2020
587EDF,earnings,100,50,5/11/2020
587EDF,earnings,100,50,5/11/2020
5A423F,public-offering,100,43,5/11/2020
5B226B,earnings,100,50,5/11/2020
5C2A47,earnings,100,50,5/11/2020
5D63F1,earnings,100,50,5/11/2020
5E1DF3,earnings-up,100,68,5/11/2020
5E9934,earnings,100,50,5/11/2020
5F9CE3,note-sale,100,52,5/11/2020
619882,conference-organizer,100,57,5/11/2020
619882,conference-organizer,100,57,5/11/2020
619882,conference-organizer,100,57,5/11/2020
619882,conference-organizer,100,57,5/11/2020
619882,conference-organizer,100,57,5/11/2020
619882,conference-organizer,100,57,5/11/2020
619882,conference-organizer,100,57,5/11/2020
619882,conference-organizer,100,57,5/11/2020
61B81B,buybacks,100,74,5/11/2020
6284B5,executive-appointment,100,54,5/11/2020
629F0F,earnings,100,50,5/11/2020
62B1C6,earnings,100,50,5/11/2020
64E615,earnings,100,50,5/11/2020
64E615,earnings,100,50,5/11/2020
64E615,earnings,100,50,5/11/2020
64E615,earnings,100,50,5/11/2020
64FF65,earnings,100,50,5/11/2020
6634D9,earnings,100,50,5/11/2020
66667F,revenue-up,100,93,5/11/2020
67303E,business-contract,100,69,5/11/2020
67303E,earnings,100,50,5/11/2020
67B052,earnings,100,50,5/11/2020
67B052,earnings,100,50,5/11/2020
68AB62,earnings,100,50,5/11/2020
69FDFC,earnings,100,50,5/11/2020
69FDFC,partnership,100,61,5/11/2020
6B6375,executive-appointment,100,54,5/11/2020
6BDA0C,earnings,100,50,5/11/2020
6BDA0C,earnings,100,50,5/11/2020
6BDA0C,earnings,100,50,5/11/2020
6BDA0C,earnings,100,50,5/11/2020
6D0CAB,earnings,100,50,5/11/2020
6D3F35,earnings,100,50,5/11/2020
6D3F35,earnings,100,50,5/11/2020
6D3F35,earnings,100,50,5/11/2020
6D3F35,earnings,100,50,5/11/2020
6D3F35,earnings,100,50,5/11/2020
6D9ECA,clinical-trials,100,56,5/11/2020
6DDA15,earnings,100,50,5/11/2020
6DDA15,earnings,100,50,5/11/2020
6DDA15,earnings,100,50,5/11/2020
6DDA15,earnings,100,50,5/11/2020
6DDA15,earnings,100,50,5/11/2020
6E705B,executive-appointment,100,54,5/11/2020
6E705B,executive-appointment,100,54,5/11/2020
6E7060,earnings,100,50,5/11/2020
6E7060,earnings,100,50,5/11/2020
6E7060,earnings,100,50,5/11/2020
6E7060,earnings,100,50,5/11/2020
6E7060,earnings,100,50,5/11/2020
6E7060,earnings,100,50,5/11/2020
6E7060,earnings,100,50,5/11/2020
6F5DD2,earnings,100,50,5/11/2020
701531,earnings,100,50,5/11/2020
713810,conference-call,100,50,5/11/2020
71553E,earnings,100,50,5/11/2020
71694D,conference-call,100,50,5/11/2020
72F0FC,executive-appointment,100,54,5/11/2020
747219,dividend,100,50,5/11/2020
747219,earnings,100,50,5/11/2020
748EB6,earnings,100,50,5/11/2020
7.49E+07,earnings,100,50,5/11/2020
75F982,executive-appointment,100,54,5/11/2020
763DBE,earnings,100,50,5/11/2020
76959C,earnings,100,50,5/11/2020
76DD0C,earnings,100,50,5/11/2020
7712CB,earnings,100,50,5/11/2020
7712CB,earnings,100,50,5/11/2020
7712CB,earnings,100,50,5/11/2020
7712CB,earnings,100,50,5/11/2020
7712CB,earnings,100,50,5/11/2020
7712CB,earnings,100,50,5/11/2020
789A7D,earnings,100,50,5/11/2020
789A7D,earnings,100,50,5/11/2020
789A7D,earnings,100,50,5/11/2020
789A7D,earnings,100,50,5/11/2020
78F776,earnings,100,50,5/11/2020
791EC1,earnings,100,50,5/11/2020
7A51FE,earnings,100,50,5/11/2020
7BC92D,earnings,100,50,5/11/2020
7C75FD,conference-call,100,50,5/11/2020
7DD8CC,public-offering,100,43,5/11/2020
80C400,product-release,100,64,5/11/2020
830BDB,note-sale,100,52,5/11/2020
83B1C8,earnings,100,50,5/11/2020
855DF7,credit-extension-recipient,100,69,5/11/2020
855DF7,earnings,100,50,5/11/2020
877C0C,earnings,100,50,5/11/2020
8.79E+06,earnings,100,50,5/11/2020
88350F,earnings,100,50,5/11/2020
88350F,earnings,100,50,5/11/2020
88350F,earnings,100,50,5/11/2020
88350F,earnings,100,50,5/11/2020
885758,earnings,100,50,5/11/2020
893904,earnings,100,50,5/11/2020
893904,earnings,100,50,5/11/2020
895D56,business-contract,100,69,5/11/2020
8A8E41,conference-participant,100,50,5/11/2020
8A8E41,partnership,100,61,5/11/2020
8A8E41,partnership,100,61,5/11/2020
8BFE9A,earnings,100,50,5/11/2020
8DBBE6,earnings,100,50,5/11/2020
8DCF18,earnings,100,50,5/11/2020
8DCF18,earnings,100,50,5/11/2020
8E10BF,conference-participant,100,50,5/11/2020
900356,earnings,100,50,5/11/2020
9196A2,conference-organizer,100,57,5/11/2020
92D230,earnings,100,50,5/11/2020
92D230,earnings,100,50,5/11/2020
92D230,earnings,100,50,5/11/2020
92D230,earnings,100,50,5/11/2020
92D230,earnings,100,50,5/11/2020
92D230,earnings,100,50,5/11/2020
92D757,earnings,100,50,5/11/2020
9368BE,earnings,100,50,5/11/2020
944B2E,earnings,100,50,5/11/2020
944B2E,earnings,100,50,5/11/2020
944B2E,earnings,100,50,5/11/2020
944B2E,earnings,100,50,5/11/2020
944B2E,earnings,100,50,5/11/2020
9546A5,conference-call,100,50,5/11/2020
958938,earnings,100,50,5/11/2020
95F59E,conference-participant,100,50,5/11/2020
966DBE,earnings,100,50,5/11/2020
966DBE,earnings,100,50,5/11/2020
966DBE,earnings,100,50,5/11/2020
966DBE,earnings,100,50,5/11/2020
966DBE,earnings,100,50,5/11/2020
967D92,earnings,100,50,5/11/2020
968103,earnings,100,50,5/11/2020
97693A,legal-issues-defendant,100,22,5/11/2020
97B027,earnings,100,50,5/11/2020
97B027,earnings,100,50,5/11/2020
97B027,earnings,100,50,5/11/2020
980C14,earnings,100,50,5/11/2020
9810C0,product-release,100,64,5/11/2020
990AD0,conference-organizer,100,57,5/11/2020
990AD0,conference-organizer,100,57,5/11/2020
990AD0,conference-organizer,100,57,5/11/2020
990AD0,conference-organizer,100,57,5/11/2020
990AD0,conference-organizer,100,57,5/11/2020
990AD0,conference-organizer,100,57,5/11/2020
990AD0,conference-organizer,100,57,5/11/2020
990AD0,conference-organizer,100,57,5/11/2020
990AD0,conference-organizer,100,57,5/11/2020
990AD0,conference-organizer,100,57,5/11/2020
9934AD,earnings,100,50,5/11/2020
9C5BA5,conference-participant,100,50,5/11/2020
9C5BA5,revenues,100,50,5/11/2020
9FB4B7,earnings,100,50,5/11/2020
A01200,public-offering,100,43,5/11/2020
A01983,earnings,100,50,5/11/2020
A072C4,conference-participant,100,50,5/11/2020
A1BB98,earnings,100,50,5/11/2020
A1BB98,earnings,100,50,5/11/2020
A1BB98,earnings,100,50,5/11/2020
A1BB98,earnings,100,50,5/11/2020
A1BB98,earnings,100,50,5/11/2020
A28675,earnings,100,50,5/11/2020
A29A46,earnings,100,50,5/11/2020
A49498,conference-participant,100,50,5/11/2020
A495F7,earnings,100,50,5/11/2020
A6828A,legal-issues-defendant,100,22,5/11/2020
A7A0C8,conference-participant,100,50,5/11/2020
A8E72A,earnings,100,50,5/11/2020
A8E72A,conference-participant,100,50,5/11/2020
A94718,conference-call,100,50,5/11/2020
AAC8B6,executive-appointment,100,54,5/11/2020
AAC8B6,executive-appointment,100,54,5/11/2020
AB7726,executive-appointment,100,54,5/11/2020
AB7726,dividend,100,50,5/11/2020
ACDCFA,operating-earnings,100,50,5/11/2020
AD3008,public-offering,100,43,5/11/2020
AE79CD,earnings,100,50,5/11/2020
AED6CF,earnings,100,50,5/11/2020
AEEB76,earnings,100,50,5/11/2020
AEEB76,earnings,100,50,5/11/2020
AFBEB4,earnings,100,50,5/11/2020
B0D41A,earnings,100,50,5/11/2020
B1A85D,earnings,100,50,5/11/2020
B2D799,earnings,100,50,5/11/2020
B33E77,earnings,100,50,5/11/2020
B33E77,legal-issues-defendant,100,22,5/11/2020
B33E77,legal-issues-defendant,100,22,5/11/2020
B4F5F4,earnings,100,50,5/11/2020
B54A74,conference-participant,100,50,5/11/2020
B5DE80,note-sale,100,52,5/11/2020
B803B1,rights-issue,100,43,5/11/2020
B840EF,note-sale,100,52,5/11/2020
B934BF,earnings,100,50,5/11/2020
BA0442,earnings,100,50,5/11/2020
BA0442,earnings,100,50,5/11/2020
BBAE2A,note-sale,100,52,5/11/2020
BDCC11,earnings,100,50,5/11/2020
BE379D,earnings,100,50,5/11/2020
BE645B,earnings,100,50,5/11/2020
BFE02C,conference-participant,100,50,5/11/2020
C0BA36,earnings,100,50,5/11/2020
C2DD02,earnings,100,50,5/11/2020
C2E39B,earnings,100,50,5/11/2020
C2E39B,earnings,100,50,5/11/2020
C2E39B,earnings,100,50,5/11/2020
C3BAE7,earnings,100,50,5/11/2020
C3BAE7,earnings,100,50,5/11/2020
C3BAE7,earnings,100,50,5/11/2020
C3BAE7,earnings,100,50,5/11/2020
C3BAE7,earnings,100,50,5/11/2020
C3BAE7,earnings,100,50,5/11/2020
C3BCD5,dividend,100,50,5/11/2020
C3CF29,earnings,100,50,5/11/2020
C3CF29,earnings,100,50,5/11/2020
C3CF29,earnings,100,50,5/11/2020
C3CF29,earnings,100,50,5/11/2020
C564E4,conference-participant,100,50,5/11/2020
C584BE,earnings,100,50,5/11/2020
C65004,revenue-up,100,69,5/11/2020
C65004,revenue-up,100,69,5/11/2020
C65004,revenue-up,100,69,5/11/2020
C66A8C,public-offering,100,43,5/11/2020
C66A8C,public-offering,100,43,5/11/2020
C66B44,earnings,100,50,5/11/2020
C7AE14,earnings,100,50,5/11/2020
C93C44,earnings,100,50,5/11/2020
C93C44,earnings,100,50,5/11/2020
C9732E,earnings,100,50,5/11/2020
C9732E,legal-issues-defendant,100,22,5/11/2020
C98CDB,conference-participant,100,50,5/11/2020
CBFFDD,earnings,100,50,5/11/2020
CBFFDD,trading-halt,100,43,5/11/2020
CC0C78,revenues,100,50,5/11/2020
CC0C78,conference-participant,100,50,5/11/2020
CCB623,public-offering,100,43,5/11/2020
CDAA0E,conference-organizer,100,57,5/11/2020
CDC817,earnings,100,50,5/11/2020
CDFCC9,conference-participant,100,50,5/11/2020
CED4D0,earnings,100,50,5/11/2020
CF3FF9,earnings,100,50,5/11/2020
CFF97C,conference-participant,100,50,5/11/2020
CFF97C,operating-earnings,100,50,5/11/2020
D064D5,executive-appointment,100,54,5/11/2020
D08D2C,earnings,100,50,5/11/2020
D08D2C,earnings,100,50,5/11/2020
D08D2C,earnings,100,50,5/11/2020
D08D2C,earnings,100,50,5/11/2020
D08D2C,earnings,100,50,5/11/2020
D0DE27,earnings,100,50,5/11/2020
D1AE3B,executive-appointment,100,54,5/11/2020
D296C6,earnings,100,50,5/11/2020
D29B44,conference-participant,100,50,5/11/2020
D3F64D,conference-call,100,50,5/11/2020
D5A350,executive-resignation,100,44,5/11/2020
D63B0F,earnings,100,50,5/11/2020
D70365,earnings,100,50,5/11/2020
D77F7E,earnings,100,50,5/11/2020
D77F7E,earnings,100,50,5/11/2020
D77F7E,earnings,100,50,5/11/2020
D77F7E,earnings,100,50,5/11/2020
D77F7E,earnings,100,50,5/11/2020
D8C09D,earnings,100,50,5/11/2020
D9FC89,earnings,100,50,5/11/2020
D9FC89,earnings,100,50,5/11/2020
D9FC89,earnings,100,50,5/11/2020
D9FC89,earnings,100,50,5/11/2020
D9FC89,earnings,100,50,5/11/2020
DA9443,earnings,100,50,5/11/2020
DBCA3F,executive-appointment,100,54,5/11/2020
DC0066,earnings,100,50,5/11/2020
DF5F14,earnings,100,50,5/11/2020
DF8855,earnings,100,50,5/11/2020
DF8855,earnings,100,50,5/11/2020
DF8855,earnings,100,50,5/11/2020
DF8855,earnings,100,50,5/11/2020
DF8855,earnings,100,50,5/11/2020
DF8855,earnings,100,50,5/11/2020
E09997,earnings,100,50,5/11/2020
E0E4B7,earnings,100,50,5/11/2020
E0E4B7,clinical-trials-positive,100,87,5/11/2020
E11C41,earnings,100,50,5/11/2020
E12A6E,executive-appointment,100,54,5/11/2020
E1E093,patent-awarded,100,72,5/11/2020
E28D9C,conference-participant,100,50,5/11/2020
E30B34,conference-participant,100,50,5/11/2020
E30B34,conference-participant,100,50,5/11/2020
E49AA3,dividend,100,50,5/11/2020
E4CE73,product-release,100,64,5/11/2020
E61888,earnings,100,50,5/11/2020
E6C8DC,conference-participant,100,50,5/11/2020
E6D89E,partnership,100,61,5/11/2020
E71AE6,earnings,100,50,5/11/2020
EA62FC,conference-participant,100,50,5/11/2020
EA79C7,name-change,100,49,5/11/2020
EB43F4,earnings,100,50,5/11/2020
EEBCEF,earnings,100,50,5/11/2020
F00285,earnings,100,50,5/11/2020
F18844,partnership,100,61,5/11/2020
F18844,partnership,100,61,5/11/2020
F18844,partnership,100,61,5/11/2020
F18844,partnership,100,61,5/11/2020
F18844,partnership,100,61,5/11/2020
F18844,partnership,100,61,5/11/2020
F18844,partnership,100,61,5/11/2020
F18844,partnership,100,61,5/11/2020
F18844,partnership,100,61,5/11/2020
F18844,partnership,100,61,5/11/2020
F18844,partnership,100,61,5/11/2020
F209B4,conference-participant,100,50,5/11/2020
F48947,earnings,100,50,5/11/2020
F48947,earnings,100,50,5/11/2020
F4CDA3,earnings,100,50,5/11/2020
F4CDA3,earnings,100,50,5/11/2020
F4CDA3,earnings,100,50,5/11/2020
F4CDA3,earnings,100,50,5/11/2020
F4CDA3,earnings,100,50,5/11/2020
F4CDA3,earnings,100,50,5/11/2020
F509E2,earnings,100,50,5/11/2020
F5D499,product-release,100,64,5/11/2020
F6DA75,earnings,100,50,5/11/2020
F6E1B5,earnings,100,50,5/11/2020
F6FF0D,earnings,100,50,5/11/2020
F6FF0D,earnings,100,50,5/11/2020
F6FF0D,earnings,100,50,5/11/2020
F72E4B,earnings,100,50,5/11/2020
F72E4B,earnings,100,50,5/11/2020
F73DD1,earnings,100,50,5/11/2020
F73DD1,earnings,100,50,5/11/2020
F73DD1,earnings,100,50,5/11/2020
F73DD1,earnings,100,50,5/11/2020
F73DD1,earnings,100,50,5/11/2020
F73DD1,earnings,100,50,5/11/2020
F73DD1,earnings,100,50,5/11/2020
F7ADEB,earnings,100,50,5/11/2020
F7ADEB,earnings,100,50,5/11/2020
F7ADEB,earnings,100,50,5/11/2020
F7ADEB,earnings,100,50,5/11/2020
F88147,executive-appointment,100,54,5/11/2020
F88147,earnings,100,50,5/11/2020
F88A04,partnership,100,61,5/11/2020
FADF1A,earnings,100,50,5/11/2020
FCA54E,earnings-up,100,68,5/11/2020
FCA54E,earnings,100,50,5/11/2020
FCA54E,earnings,100,50,5/11/2020
FFCD0E,earnings,100,50,5/11/2020
0142B5,dividend,100,50,5/12/2020
0157B1,revenue-up,100,92,5/12/2020
03596A,product-release,100,64,5/12/2020
036C6F,earnings,100,50,5/12/2020
036C6F,earnings,100,50,5/12/2020
036C6F,earnings,100,50,5/12/2020
036C6F,earnings,100,50,5/12/2020
03B8CF,dividend,100,50,5/12/2020
03CF95,note-sale,100,52,5/12/2020
06EF42,conference-participant,100,50,5/12/2020
099C88,business-contract,100,69,5/12/2020
0F0693,public-offering,100,43,5/12/2020
102727,executive-appointment,100,54,5/12/2020
1065BC,note-sale,100,52,5/12/2020
131443,dividend,100,50,5/12/2020
133644,conference-participant,100,50,5/12/2020
1748F6,earnings,100,50,5/12/2020
17EDA5,investment-investor,100,55,5/12/2020
17EDA5,investment-investor,100,55,5/12/2020
1AC649,conference-participant,100,50,5/12/2020
1AE482,earnings,100,50,5/12/2020
1B6F77,conference-participant,100,50,5/12/2020
1DEBBE,credit-extension-recipient,100,69,5/12/2020
1F9258,revenues,100,50,5/12/2020
21153F,partnership,100,61,5/12/2020
223552,earnings,100,50,5/12/2020
228D42,business-contract,100,69,5/12/2020
232053,conference-participant,100,50,5/12/2020
249B39,dividend,100,50,5/12/2020
24FA23,board-meeting,100,51,5/12/2020
26F99F,earnings,100,50,5/12/2020
2A1009,conference-participant,100,50,5/12/2020
2A6DBE,earnings,100,50,5/12/2020
2ABF77,conference-participant,100,50,5/12/2020
2B7A40,conference-participant,100,50,5/12/2020
2CB4C9,earnings,100,50,5/12/2020
2E0445,earnings,100,50,5/12/2020
2E902B,conference-participant,100,50,5/12/2020
2EB04E,note-sale,100,52,5/12/2020
2EB88B,public-offering,100,43,5/12/2020
2F94A5,dividend,100,50,5/12/2020
2FEA66,dividend,100,50,5/12/2020
315EB0,public-offering,100,43,5/12/2020
32F943,conference-participant,100,50,5/12/2020
355B19,public-offering,100,43,5/12/2020
356B21,earnings,100,50,5/12/2020
356B21,earnings,100,50,5/12/2020
356B21,earnings,100,50,5/12/2020
356B21,earnings,100,50,5/12/2020
37020C,earnings,100,50,5/12/2020
3.73E+87,note-sale,100,52,5/12/2020
387541,conference-participant,100,50,5/12/2020
3AAEAE,earnings,100,50,5/12/2020
3C7F5F,note-sale,100,52,5/12/2020
3CCC90,executive-appointment,100,54,5/12/2020
3E15F6,dividend,100,50,5/12/2020
41ED98,dividend,100,50,5/12/2020
442769,conference-participant,100,50,5/12/2020
451D61,conference-participant,100,50,5/12/2020
458D2C,earnings,100,50,5/12/2020
45ABCC,conference-participant,100,50,5/12/2020
4A7C1F,legal-issues-defendant,100,22,5/12/2020
4DD09F,earnings-up,100,68,5/12/2020
4EE167,fraud-defendant,100,20,5/12/2020
50070E,conference-organizer,100,57,5/12/2020
50070E,conference-organizer,100,57,5/12/2020
50070E,conference-organizer,100,57,5/12/2020
50070E,conference-organizer,100,57,5/12/2020
50070E,conference-organizer,100,57,5/12/2020
520632,regulatory-product-approval-granted,100,81,5/12/2020
523039,earnings,100,50,5/12/2020
539F49,legal-issues-defendant,100,22,5/12/2020
543C77,earnings,100,50,5/12/2020
5480A7,dividend,100,50,5/12/2020
564F3E,dividend,100,50,5/12/2020
567F3D,conference-participant,100,50,5/12/2020
58CA9A,executive-appointment,100,54,5/12/2020
5A423F,public-offering,100,43,5/12/2020
5F3E74,public-offering,100,43,5/12/2020
616E3B,dividend,100,50,5/12/2020
619882,conference-organizer,100,57,5/12/2020
619882,conference-organizer,100,57,5/12/2020
619882,conference-organizer,100,57,5/12/2020
619882,conference-organizer,100,57,5/12/2020
619882,conference-organizer,100,57,5/12/2020
622DBE,note-sale,100,52,5/12/2020
622DBE,note-sale,100,52,5/12/2020
62B1C6,earnings,100,50,5/12/2020
657097,unit-acquisition-acquirer,100,49,5/12/2020
673C9A,earnings,100,50,5/12/2020
67529E,executive-appointment,100,54,5/12/2020
67B923,earnings,100,50,5/12/2020
6CBF41,earnings,100,50,5/12/2020
6CBF41,earnings,100,50,5/12/2020
71B0CF,earnings,100,50,5/12/2020
722D55,earnings,100,50,5/12/2020
724F84,earnings,100,50,5/12/2020
763DBE,conference-participant,100,50,5/12/2020
76F067,conference-participant,100,50,5/12/2020
7AF907,earnings,100,50,5/12/2020
7B9AFA,conference-participant,100,50,5/12/2020
7C790D,conference-participant,100,50,5/12/2020
7D85A9,note-sale,100,52,5/12/2020
7DD8CC,public-offering,100,43,5/12/2020
8A0368,conference-participant,100,50,5/12/2020
8D4486,partnership,100,61,5/12/2020
8E0E32,dividend,100,50,5/12/2020
8E10BF,earnings,100,50,5/12/2020
8EDACA,conference-call,100,50,5/12/2020
8F3BCC,conference-participant,100,50,5/12/2020
9196A2,regulatory-investigation,100,22,5/12/2020
934CC3,executive-appointment,100,54,5/12/2020
938D89,earnings,100,50,5/12/2020
938D89,business-contract,100,69,5/12/2020
93F143,executive-appointment,100,54,5/12/2020
944B2E,ownership-decrease-owner,100,46,5/12/2020
94637C,partnership,100,61,5/12/2020
94637C,partnership,100,61,5/12/2020
94983E,conference-participant,100,50,5/12/2020
94A326,earnings,100,50,5/12/2020
95C575,dividend,100,50,5/12/2020
968B00,dividend,100,50,5/12/2020
96BFF4,earnings,100,50,5/12/2020
96BFF4,earnings,100,50,5/12/2020
990AD0,conference-organizer,100,57,5/12/2020
990AD0,conference-organizer,100,57,5/12/2020
990AD0,conference-organizer,100,57,5/12/2020
99B61C,earnings,100,50,5/12/2020
9A2760,product-release,100,64,5/12/2020
9C8BC3,partnership,100,61,5/12/2020
A05C43,partnership,100,61,5/12/2020
A05C43,partnership,100,61,5/12/2020
A29DBD,earnings,100,50,5/12/2020
A3AAA5,dividend,100,50,5/12/2020
A79F7D,earnings,100,50,5/12/2020
A806FA,earnings,100,50,5/12/2020
A806FA,earnings,100,50,5/12/2020
A806FA,earnings,100,50,5/12/2020
A806FA,earnings,100,50,5/12/2020
AAEE21,note-sale,100,52,5/12/2020
AC7AAE,public-offering,100,43,5/12/2020
AC7C4F,business-contract,100,69,5/12/2020
AE0CCE,earnings,100,50,5/12/2020
AEF2C3,conference-participant,100,50,5/12/2020
B1DF3C,facility-open,100,65,5/12/2020
B2206F,earnings,100,50,5/12/2020
B33E77,conference-participant,100,50,5/12/2020
B33E77,legal-issues-defendant,100,22,5/12/2020
B33E77,legal-issues-defendant,100,22,5/12/2020
B508E5,executive-appointment,100,54,5/12/2020
B508E5,earnings,100,50,5/12/2020
B508E5,earnings,100,50,5/12/2020
B840EF,public-offering,100,43,5/12/2020
B9BDE8,earnings-up,100,68,5/12/2020
B9CD50,partnership,100,61,5/12/2020
BDF85E,executive-appointment,100,54,5/12/2020
BE14CF,note-sale,100,52,5/12/2020
BE14CF,note-sale,100,52,5/12/2020
C06EB6,clinical-trials-complete,100,56,5/12/2020
C38440,conference-participant,100,50,5/12/2020
C4A241,conference-participant,100,50,5/12/2020
C584BE,legal-issues-defendant,100,22,5/12/2020
CBFFDD,trading-resumed,100,58,5/12/2020
CC35BE,product-release,100,64,5/12/2020
CE5664,earnings,100,50,5/12/2020
CE5664,earnings,100,50,5/12/2020
CE5664,earnings,100,50,5/12/2020
CF073E,earnings,100,50,5/12/2020
D13F1C,executive-appointment,100,54,5/12/2020
D1588D,clinical-trials,100,56,5/12/2020
D33D8C,dividend,100,50,5/12/2020
D3FA2C,earnings,100,50,5/12/2020
D4C0CB,earnings,100,50,5/12/2020
D56D6D,dividend,100,50,5/12/2020
D5B13D,earnings,100,50,5/12/2020
D6489C,product-release,100,64,5/12/2020
D6EAA3,award,100,58,5/12/2020
DB23C8,conference-participant,100,50,5/12/2020
DB5CA5,earnings,100,50,5/12/2020
DC6EF3,board-meeting,100,51,5/12/2020
DEF058,partnership,100,61,5/12/2020
DFADDB,conference-participant,100,50,5/12/2020
E05026,earnings,100,50,5/12/2020
E06265,legal-issues-defendant,100,22,5/12/2020
E06265,legal-issues-defendant,100,22,5/12/2020
E09556,patent-awarded,100,72,5/12/2020
E0E4B7,public-offering,100,43,5/12/2020
E124EB,public-offering,100,43,5/12/2020
E21871,note-sale,100,52,5/12/2020
E259C7,dividend,100,50,5/12/2020
E598FB,earnings,100,50,5/12/2020
E5A3B6,conference-participant,100,50,5/12/2020
E829E8,award,100,58,5/12/2020
E8A49A,earnings,100,50,5/12/2020
E96E0B,executive-appointment,100,54,5/12/2020
EB1E1A,earnings,100,50,5/12/2020
ED1A74,earnings,100,50,5/12/2020
EDF5CA,legal-issues-defendant,100,22,5/12/2020
EE1E44,dividend,100,50,5/12/2020
EF5BED,public-offering,100,43,5/12/2020
F1529C,earnings,100,50,5/12/2020
F1529C,dividend,100,50,5/12/2020
F1EB39,government-contract,100,69,5/12/2020
F47871,conference-participant,100,50,5/12/2020
F509E2,fraud,100,44,5/12/2020
F5D410,investment-investor,100,55,5/12/2020
F5D410,investment-investor,100,55,5/12/2020
F5D499,earnings,100,50,5/12/2020
F6FA6A,executive-appointment,100,54,5/12/2020
F7ADEB,business-contract,100,69,5/12/2020
F8BA6C,conference-call,100,50,5/12/2020
F93C8A,dividend,100,50,5/12/2020
F9AA02,conference-participant,100,50,5/12/2020
FA840E,earnings,100,50,5/12/2020
FAAFA2,conference-call,100,50,5/12/2020
FC4550,dividend,100,50,5/12/2020
FCA54E,public-offering,100,43,5/12/2020
FD9526,dividend,100,50,5/12/2020
FEC475,dividend,100,50,5/12/2020
9397,facility-open,100,65,5/13/2020
0157B1,product-release,100,64,5/13/2020
0157B1,product-release,100,64,5/13/2020
0157B1,product-release,100,64,5/13/2020
01D03F,clinical-trials,100,56,5/13/2020
01D03F,clinical-trials,100,56,5/13/2020
053EFF,dividend,100,50,5/13/2020
98977,business-contract,100,69,5/13/2020
0B4D10,dividend,100,50,5/13/2020
0DBB81,regulatory-product-approval-granted,100,81,5/13/2020
0E499E,conference-participant,100,50,5/13/2020
0F2BC9,business-contract,100,69,5/13/2020
1065BC,board-meeting,100,51,5/13/2020
12DE76,earnings,100,50,5/13/2020
12DE76,earnings,100,50,5/13/2020
12DE76,earnings,100,50,5/13/2020
12DE76,earnings,100,50,5/13/2020
12DE76,earnings,100,50,5/13/2020
12E454,business-contract,100,69,5/13/2020
135B09,dividend,100,50,5/13/2020
136B26,earnings,100,50,5/13/2020
13D576,earnings,100,50,5/13/2020
1490F3,dividend,100,50,5/13/2020
16F4D8,earnings,100,50,5/13/2020
16F4D8,earnings,100,50,5/13/2020
16F4D8,earnings,100,50,5/13/2020
16F4D8,earnings,100,50,5/13/2020
1DA44F,dividend-suspended,100,13,5/13/2020
1EBF8D,unit-acquisition-acquirer,100,49,5/13/2020
1EBF8D,clinical-trials-positive,100,87,5/13/2020
24CB56,conference-participant,100,50,5/13/2020
26DC29,conference-call,100,50,5/13/2020
273BA3,executive-appointment,100,54,5/13/2020
2BC05E,product-release,100,64,5/13/2020
2C3348,product-release,100,64,5/13/2020
2CC60C,earnings,100,50,5/13/2020
2E61CC,partnership,100,61,5/13/2020
2EB04E,note-sale,100,52,5/13/2020
3159AA,facility-open,100,65,5/13/2020
34B97A,award,100,58,5/13/2020
355B19,public-offering,100,43,5/13/2020
35AE32,conference-participant,100,50,5/13/2020
384CD3,dividend,100,50,5/13/2020
39BFF6,executive-appointment,100,54,5/13/2020
39BFF6,executive-appointment,100,54,5/13/2020
39FB23,product-release,100,64,5/13/2020
3A6D90,executive-appointment,100,54,5/13/2020
3BB616,note-sale,100,52,5/13/2020
3C7F5F,partnership,100,61,5/13/2020
4017AD,conference-participant,100,50,5/13/2020
42978B,conference-call,100,50,5/13/2020
44A4FC,business-contract,100,69,5/13/2020
451D61,clinical-trials,100,56,5/13/2020
49A344,award,100,58,5/13/2020
4A2457,business-contract,100,69,5/13/2020
4A7C1F,legal-issues-defendant,100,22,5/13/2020
4B5054,partnership,100,61,5/13/2020
4BDCA7,conference-participant,100,50,5/13/2020
4BDCA7,clinical-trials,100,56,5/13/2020
4CDA2B,earnings,100,50,5/13/2020
4D72C8,public-offering,100,43,5/13/2020
4D72C8,public-offering,100,43,5/13/2020
4EC4C1,joint-venture,100,62,5/13/2020
519FE0,earnings,100,50,5/13/2020
519FE0,earnings,100,50,5/13/2020
519FE0,earnings,100,50,5/13/2020
519FE0,earnings,100,50,5/13/2020
51B442,earnings,100,50,5/13/2020
51F541,dividend,100,50,5/13/2020
539F49,legal-issues-defendant,100,22,5/13/2020
5.43E+08,clinical-trials,100,56,5/13/2020
553949,note-sale,100,52,5/13/2020
556F08,conference-participant,100,50,5/13/2020
589846,conference-call,100,50,5/13/2020
59872F,executive-appointment,100,54,5/13/2020
5A53BF,clinical-trials,100,56,5/13/2020
5B3415,note-sale,100,52,5/13/2020
5F3E74,public-offering,100,43,5/13/2020
6166D1,dividend,100,50,5/13/2020
619882,conference-organizer,100,57,5/13/2020
619882,conference-organizer,100,57,5/13/2020
6391C2,earnings,100,50,5/13/2020
676FFD,legal-issues-defendant,100,22,5/13/2020
676FFD,legal-issues-defendant,100,22,5/13/2020
676FFD,legal-issues-defendant,100,22,5/13/2020
676FFD,legal-issues-defendant,100,22,5/13/2020
676FFD,legal-issues-defendant,100,22,5/13/2020
68E3E0,dividend,100,50,5/13/2020
68E6E9,dividend,100,50,5/13/2020
6925EB,legal-issues-defendant,100,22,5/13/2020
6925EB,legal-issues-defendant,100,22,5/13/2020
6BBCBA,earnings,100,50,5/13/2020
6D9ECA,earnings,100,50,5/13/2020
6F22E7,earnings,100,50,5/13/2020
717DB4,conference-participant,100,50,5/13/2020
7255D2,note-sale,100,52,5/13/2020
7255D2,note-sale,100,52,5/13/2020
72CB93,executive-appointment,100,54,5/13/2020
769F40,earnings,100,50,5/13/2020
76E80F,conference-call,100,50,5/13/2020
7A0EC4,partnership,100,61,5/13/2020
7A0EC4,partnership,100,61,5/13/2020
7A10FF,dividend,100,50,5/13/2020
7B6EB1,note-sale,100,52,5/13/2020
7C4F43,clinical-trials,100,56,5/13/2020
803FED,board-meeting,100,51,5/13/2020
83A065,conference-call,100,50,5/13/2020
890FF4,conference-participant,100,50,5/13/2020
9004C4,earnings-positive,100,69,5/13/2020
9004C4,earnings-positive,100,69,5/13/2020
9004C4,earnings-positive,100,69,5/13/2020
9004C4,earnings-positive,100,69,5/13/2020
9004C4,earnings-positive,100,69,5/13/2020
9004C4,earnings-positive,100,69,5/13/2020
913437,earnings,100,50,5/13/2020
922F0C,dividend,100,50,5/13/2020
92D757,executive-appointment,100,54,5/13/2020
93965C,conference-participant,100,50,5/13/2020
94983E,dividend,100,50,5/13/2020
94A326,clinical-trials,100,56,5/13/2020
99ACAD,note-sale,100,52,5/13/2020
9A602D,acquisition-completed-acquirer,100,49,5/13/2020
9B71A7,executive-appointment,100,54,5/13/2020
9C3D3C,earnings,100,50,5/13/2020
A15C71,earnings,100,50,5/13/2020
A15C71,earnings,100,50,5/13/2020
A15C71,earnings,100,50,5/13/2020
A2C979,earnings,100,50,5/13/2020
A49498,earnings,100,50,5/13/2020
A49498,earnings,100,50,5/13/2020
A49498,earnings,100,50,5/13/2020
A60318,conference-participant,100,50,5/13/2020
A666C8,note-sale,100,52,5/13/2020
A666C8,note-sale,100,52,5/13/2020
A7A0C8,earnings,100,50,5/13/2020
AA98ED,business-contract,100,69,5/13/2020
AC775C,conference-participant,100,50,5/13/2020
ACDF88,conference-participant,100,50,5/13/2020
AD22F2,facility-open,100,65,5/13/2020
AECCA9,conference-call,100,50,5/13/2020
B076A1,dividend,100,50,5/13/2020
B076A1,buybacks,100,74,5/13/2020
B5767B,note-sale,100,52,5/13/2020
B7BBFF,earnings,100,50,5/13/2020
B8F71F,legal-issues-defendant,100,22,5/13/2020
BB127B,executive-appointment,100,54,5/13/2020
BB127B,executive-appointment,100,54,5/13/2020
BBAE2A,note-sale,100,52,5/13/2020
BCC13E,conference-participant,100,50,5/13/2020
BD682F,dividend,100,50,5/13/2020
BF5959,conference-call,100,50,5/13/2020
C06EB6,earnings-up,100,68,5/13/2020
C06EB6,earnings,100,50,5/13/2020
C06EB6,earnings,100,50,5/13/2020
C06EB6,earnings,100,50,5/13/2020
C0BA36,conference-participant,100,50,5/13/2020
C0F70B,conference-participant,100,50,5/13/2020
C2609A,conference-participant,100,50,5/13/2020
C36189,earnings,100,50,5/13/2020
C3BAE7,partnership,100,61,5/13/2020
C4C77F,conference-call,100,50,5/13/2020
C4F9C6,conference-participant,100,50,5/13/2020
C564E4,clinical-trials-positive,100,87,5/13/2020
C584BE,legal-issues-defendant,100,22,5/13/2020
C6C702,partnership,100,61,5/13/2020
C6C702,partnership,100,61,5/13/2020
C6C702,partnership,100,61,5/13/2020
C6C702,partnership,100,61,5/13/2020
C6C702,conference-participant,100,50,5/13/2020
C7863D,conference-call,100,50,5/13/2020
C83B88,dividend,100,50,5/13/2020
CA99D7,earnings,100,50,5/13/2020
CAC8D0,partnership,100,61,5/13/2020
CBDB4D,conference-participant,100,50,5/13/2020
CDC217,executive-resignation,100,44,5/13/2020
CE5C6E,conference-participant,100,50,5/13/2020
CFF97C,credit-rating-revision-enhancement-rater,20,50,5/13/2020
CFF97C,dividend,100,50,5/13/2020
CFF97C,credit-rating-outlook-negative-rater,20,50,5/13/2020
D0DE27,dividend,100,50,5/13/2020
D2C0B6,earnings,100,50,5/13/2020
D518D8,dividend,100,50,5/13/2020
D5938F,clinical-trials,100,56,5/13/2020
D5AF19,public-offering,100,43,5/13/2020
D76AEF,conference-call,100,50,5/13/2020
D90F43,note-sale,100,52,5/13/2020
DC0066,conference-participant,100,50,5/13/2020
DC2F77,conference-participant,100,50,5/13/2020
DF532D,partnership,100,61,5/13/2020
E06265,dividend,100,50,5/13/2020
E10D31,fundraising,100,64,5/13/2020
E3E68E,business-contract,100,69,5/13/2020
E3E68E,business-contract,100,69,5/13/2020
E592F0,conference-participant,100,50,5/13/2020
E72599,operating-earnings,100,50,5/13/2020
ED0402,unit-acquisition-acquirer,100,49,5/13/2020
ED0402,unit-acquisition-acquirer,100,49,5/13/2020
ED22DC,earnings,100,50,5/13/2020
ED9C04,executive-appointment,100,54,5/13/2020
EDF5CA,legal-issues-defendant,100,22,5/13/2020
F2BC3D,earnings,100,50,5/13/2020
F46EC9,partnership,100,61,5/13/2020
F47871,donation,100,54,5/13/2020
F4E882,product-release,100,64,5/13/2020
F4E992,conference-participant,100,50,5/13/2020
F57F6F,executive-appointment,100,54,5/13/2020
F58C23,earnings,100,50,5/13/2020
F58C23,earnings,100,50,5/13/2020
F6E248,business-contract,100,69,5/13/2020
F6E248,business-contract,100,69,5/13/2020
F6E248,business-contract,100,69,5/13/2020
F6E248,business-contract,100,69,5/13/2020
F6E248,business-contract,100,69,5/13/2020
F6E248,business-contract,100,69,5/13/2020
FAB97A,conference-participant,100,50,5/13/2020
FAE021,product-release,100,64,5/13/2020
FAE021,product-release,100,64,5/13/2020
FC9869,earnings,100,50,5/13/2020
FD554E,public-offering,100,43,5/13/2020
00326D,earnings,100,50,5/14/2020
00698D,conference-call,100,50,5/14/2020
00D6B5,unit-acquisition-acquirer,100,49,5/14/2020
01D03F,clinical-trials,100,56,5/14/2020
033B58,earnings,100,50,5/14/2020
03B8CF,revenues,100,50,5/14/2020
03B8CF,business-contract,100,69,5/14/2020
71860,partnership,100,61,5/14/2020
099C88,dividend,100,50,5/14/2020
0BD199,public-offering,100,43,5/14/2020
0D03C8,earnings,100,50,5/14/2020
0FABBD,conference-participant,100,50,5/14/2020
1201B5,earnings,100,50,5/14/2020
143C52,conference-call,100,50,5/14/2020
14ED2B,conference-participant,100,50,5/14/2020
152FA5,public-offering,100,43,5/14/2020
157CC1,earnings,100,50,5/14/2020
16B183,dividend,100,50,5/14/2020
1AB023,conference-call,100,50,5/14/2020
1AB023,conference-call,100,50,5/14/2020
1AB023,conference-call,100,50,5/14/2020
1AE9D5,revenue-up,100,65,5/14/2020
1AE9D5,revenue-up,100,65,5/14/2020
1B5FEA,earnings,100,50,5/14/2020
1B5FEA,earnings,100,50,5/14/2020
1B5FEA,earnings,100,50,5/14/2020
1BDB2A,dividend,100,50,5/14/2020
1EBF8D,conference-participant,100,50,5/14/2020
1F19C8,executive-appointment,100,54,5/14/2020
200D8B,earnings,100,50,5/14/2020
221AD7,product-release,100,64,5/14/2020
221AD7,product-release,100,64,5/14/2020
24CB56,earnings,100,50,5/14/2020
25102A,product-release,100,64,5/14/2020
251988,partnership,100,61,5/14/2020
267718,clinical-trials-positive,100,87,5/14/2020
275300,dividend,100,50,5/14/2020
28AC4E,earnings,100,50,5/14/2020
2DC88B,conference-call,100,50,5/14/2020
2EB88B,public-offering,100,43,5/14/2020
2EB88B,public-offering,100,43,5/14/2020
2F98A5,earnings,100,50,5/14/2020
30DE64,business-contract,100,69,5/14/2020
32DCB3,earnings,100,50,5/14/2020
339F20,dividend-up,100,81,5/14/2020
33AD83,conference-call,100,50,5/14/2020
3.50E+27,earnings,100,50,5/14/2020
36529A,clinical-trials-positive,100,87,5/14/2020
367434,clinical-trials,100,56,5/14/2020
367E1C,conference-participant,100,50,5/14/2020
36C09B,public-offering,100,43,5/14/2020
37E18B,earnings,100,50,5/14/2020
3C3B6B,conference-participant,100,50,5/14/2020
3CCC90,product-release,100,64,5/14/2020
3DD5E2,conference-participant,100,50,5/14/2020
416C55,conference-participant,100,50,5/14/2020
442587,executive-appointment,100,54,5/14/2020
467F2C,earnings,100,50,5/14/2020
4.60E+06,earnings,100,50,5/14/2020
47FCF2,unit-acquisition-acquiree,100,76,5/14/2020
4A6F00,partnership,100,61,5/14/2020
4A7C1F,legal-issues-defendant,100,22,5/14/2020
4AE584,revenue-up,100,69,5/14/2020
4AE584,revenue-up,100,69,5/14/2020
4B3676,conference-participant,100,50,5/14/2020
4BAF2E,earnings,100,50,5/14/2020
4D72C8,public-offering,100,43,5/14/2020
4D72C8,public-offering,100,43,5/14/2020
4ECD1A,earnings,100,50,5/14/2020
4ECD1A,earnings,100,50,5/14/2020
4ECD1A,earnings,100,50,5/14/2020
4F9926,product-release,100,64,5/14/2020
50070E,conference-organizer,100,57,5/14/2020
539F49,legal-issues-defendant,100,22,5/14/2020
53EF9E,dividend,100,50,5/14/2020
548AC0,asset-sale,100,62,5/14/2020
550D01,conference-participant,100,50,5/14/2020
562853,executive-appointment,100,54,5/14/2020
56765E,unit-acquisition-acquiree,100,76,5/14/2020
5A0FF1,conference-participant,100,50,5/14/2020
5B3415,note-sale,100,52,5/14/2020
5D0337,facility-open,100,65,5/14/2020
5E6959,partnership,100,61,5/14/2020
5F2FF7,conference-participant,100,50,5/14/2020
5FE4B6,dividend,100,50,5/14/2020
619882,conference-organizer,100,57,5/14/2020
64854A,executive-appointment,100,54,5/14/2020
665D7D,conference-participant,100,50,5/14/2020
676FFD,legal-issues-defendant,100,22,5/14/2020
676FFD,fraud-defendant,100,20,5/14/2020
69CE71,facility-open,100,65,5/14/2020
69CE71,facility-open,100,65,5/14/2020
69CE71,facility-open,100,65,5/14/2020
69CE71,facility-open,100,65,5/14/2020
69CE71,facility-open,100,65,5/14/2020
6B6375,executive-appointment,100,54,5/14/2020
6F6559,conference-call,100,50,5/14/2020
7032D0,dividend,100,50,5/14/2020
713810,partnership,100,61,5/14/2020
7255D2,note-sale,100,52,5/14/2020
7255D2,note-sale,100,52,5/14/2020
728737,dividend,100,50,5/14/2020
73A213,conference-participant,100,50,5/14/2020
747219,conference-participant,100,50,5/14/2020
76BECC,business-contract-terminated,100,31,5/14/2020
7A0EC4,earnings,100,50,5/14/2020
7ACFD4,executive-appointment,100,54,5/14/2020
7ACFD4,earnings,100,50,5/14/2020
7ACFD4,earnings,100,50,5/14/2020
7ACFD4,earnings,100,50,5/14/2020
7ACFD4,earnings,100,50,5/14/2020
7ACFD4,earnings,100,50,5/14/2020
7F7C87,earnings,100,50,5/14/2020
817ED9,board-meeting,100,51,5/14/2020
84920B,earnings-positive,100,69,5/14/2020
89F693,earnings-above-expectations,100,88,5/14/2020
8AB85C,earnings,100,50,5/14/2020
8B3B0E,dividend,100,50,5/14/2020
8D9993,executive-appointment,100,54,5/14/2020
8DBE73,investment-investor,100,55,5/14/2020
8DE74B,dividend-up,100,81,5/14/2020
8E10BF,patient-enrollment-complete,100,64,5/14/2020
92D757,earnings,100,50,5/14/2020
92D757,executive-appointment,100,54,5/14/2020
934029,regulatory-product-approval-granted,100,81,5/14/2020
934029,regulatory-product-approval-granted,100,81,5/14/2020
9.39E+69,clinical-trials,100,56,5/14/2020
9.39E+69,clinical-trials,100,56,5/14/2020
940C3D,dividend,100,50,5/14/2020
944B2E,business-contract,100,69,5/14/2020
9A2760,note-sale,100,52,5/14/2020
9B4066,unit-acquisition-acquirer,100,49,5/14/2020
9CA432,conference-participant,100,50,5/14/2020
9E98F2,partnership,100,61,5/14/2020
9E98F2,conference-participant,100,50,5/14/2020
A01200,public-offering,100,43,5/14/2020
A01200,executive-appointment,100,54,5/14/2020
A16DEA,dividend,100,50,5/14/2020
A4BCDE,earnings,100,50,5/14/2020
A631A3,earnings,100,50,5/14/2020
A63820,partnership,100,61,5/14/2020
A63820,partnership,100,61,5/14/2020
AA98ED,dividend,100,50,5/14/2020
ACDF88,conference-participant,100,50,5/14/2020
AD23DE,executive-appointment,100,54,5/14/2020
AD3008,public-offering,100,43,5/14/2020
AE7D16,partnership,100,61,5/14/2020
B08C51,earnings,100,50,5/14/2020
B1B10C,dividend,100,50,5/14/2020
B2206F,conference-participant,100,50,5/14/2020
B37FB4,dividend,100,50,5/14/2020
B48D6A,earnings,100,50,5/14/2020
B4B281,conference-call,100,50,5/14/2020
B4C673,dividend,100,50,5/14/2020
B5766D,executive-appointment,100,54,5/14/2020
B614F8,earnings,100,50,5/14/2020
B614F8,conference-call,100,50,5/14/2020
B6843B,revenue-up,100,68,5/14/2020
B6843B,revenue-up,100,68,5/14/2020
B6843B,revenue-up,100,68,5/14/2020
B6843B,revenue-up,100,68,5/14/2020
B6843B,revenue-up,100,68,5/14/2020
B76C82,earnings,100,50,5/14/2020
B803B1,dividend,100,50,5/14/2020
BC5680,acquisition-interest-acquiree,100,82,5/14/2020
BDD12C,partnership,100,61,5/14/2020
BDEC1E,conference-participant,100,50,5/14/2020
BE379D,rights-issue,100,43,5/14/2020
BFE02C,conference-participant,100,50,5/14/2020
C0030A,fundraising,100,64,5/14/2020
C1114B,conference-participant,100,50,5/14/2020
C16A8F,note-sale,100,52,5/14/2020
C3BAE7,product-release,100,64,5/14/2020
C45CE7,dividend,100,50,5/14/2020
C5E100,earnings,100,50,5/14/2020
C83B88,revenue-volume-up,100,69,5/14/2020
C941DC,partnership,100,61,5/14/2020
C94CFC,earnings,100,50,5/14/2020
C9739A,earnings,100,50,5/14/2020
C97B2D,note-sale,100,52,5/14/2020
CBFFDD,earnings,100,50,5/14/2020
CBFFDD,dividend,100,50,5/14/2020
CD4DA8,executive-appointment,100,54,5/14/2020
CDC217,earnings,100,50,5/14/2020
CF211D,conference-participant,100,50,5/14/2020
CF7292,conference-call,100,50,5/14/2020
D0DE27,executive-resignation,100,44,5/14/2020
D3F64D,earnings,100,50,5/14/2020
D60BB2,campaign-ad-release,100,59,5/14/2020
D6144F,partnership,100,61,5/14/2020
D6534D,dividend,100,50,5/14/2020
D78BF1,dividend,100,50,5/14/2020
D8F347,dividend,100,50,5/14/2020
D90F43,partnership,100,61,5/14/2020
D90F43,partnership,100,61,5/14/2020
D90F43,acquisition-interest-acquirer,100,46,5/14/2020
DA48E4,business-contract,100,69,5/14/2020
DA48E4,investment-investor,100,55,5/14/2020
E09E2B,partnership,100,61,5/14/2020
E13782,conference-participant,100,50,5/14/2020
E20392,board-meeting,100,51,5/14/2020
E261E9,earnings,100,50,5/14/2020
E28D9C,conference-participant,100,50,5/14/2020
E5752F,executive-appointment,100,54,5/14/2020
E5A3B6,earnings,100,50,5/14/2020
E5C910,earnings,100,50,5/14/2020
E74B55,executive-appointment,100,54,5/14/2020
E8846E,legal-issues-defendant,100,22,5/14/2020
ED9C04,partnership,100,61,5/14/2020
EFA7B2,earnings,100,50,5/14/2020
F209B4,earnings,100,50,5/14/2020
F209B4,earnings,100,50,5/14/2020
F46EC9,dividend,100,50,5/14/2020
F4CDA3,conference-participant,100,50,5/14/2020
FAAFA2,clinical-trials-start,100,64,5/14/2020
FAAFA2,earnings,100,50,5/14/2020
FAE021,dividend,100,50,5/14/2020
FAE021,dividend,100,50,5/14/2020
FD0CA4,unit-acquisition-completed-acquiree,100,67,5/14/2020
FD0CA4,acquisition-completed-acquiree,100,76,5/14/2020
FD0CA4,acquisition-completed-acquiree,100,76,5/14/2020
FD554E,public-offering,100,43,5/14/2020
FDF799,partnership,100,61,5/14/2020
FF227B,clinical-trials-start,100,64,5/14/2020
01D03F,product-release,100,64,5/15/2020
01D03F,product-release,100,64,5/15/2020
040DBB,executive-appointment,100,54,5/15/2020
43862,clinical-trials,100,56,5/15/2020
0968A5,conference-call,100,50,5/15/2020
0AAD90,earnings,100,50,5/15/2020
0B13E8,board-meeting,100,51,5/15/2020
0B57D7,dividend,100,50,5/15/2020
0C136E,settlement,100,56,5/15/2020
0C136E,dividend,100,50,5/15/2020
0E5223,business-contract-terminated,100,31,5/15/2020
0EF1AF,conference-participant,100,50,5/15/2020
0F65C9,conference-participant,100,50,5/15/2020
205AD5,partnership,100,61,5/15/2020
21F9CA,earnings,100,50,5/15/2020
227F04,legal-issues-defendant,100,22,5/15/2020
228D42,partnership,100,61,5/15/2020
228D42,partnership,100,61,5/15/2020
251988,partnership,100,61,5/15/2020
2.89E+11,dividend,100,50,5/15/2020
2AA6A8,clinical-trials,100,56,5/15/2020
2B9DBB,dividend,100,50,5/15/2020
36C09B,public-offering,100,43,5/15/2020
36C09B,clinical-trials,100,56,5/15/2020
3A113F,clinical-trials-positive,100,87,5/15/2020
3B9886,conference-call,100,50,5/15/2020
3DDE54,earnings,100,50,5/15/2020
3DDE54,earnings,100,50,5/15/2020
3DDE54,earnings,100,50,5/15/2020
3DDE54,earnings,100,50,5/15/2020
3DDE54,earnings,100,50,5/15/2020
3DDE54,earnings,100,50,5/15/2020
43A74A,conference-participant,100,50,5/15/2020
453282,conference-participant,100,50,5/15/2020
4649D5,earnings,100,50,5/15/2020
47FCF2,spin-off,100,58,5/15/2020
4A7C1F,legal-issues-defendant,100,22,5/15/2020
4AC91D,dividend,100,50,5/15/2020
4C31F3,conference-call,100,50,5/15/2020
4D203E,executive-appointment,100,54,5/15/2020
4DD09F,business-contract,100,69,5/15/2020
4FB770,dividend,100,50,5/15/2020
520632,legal-issues-defendant,100,22,5/15/2020
520632,legal-issues-defendant,100,22,5/15/2020
539F49,legal-issues-defendant,100,22,5/15/2020
53A226,earnings,100,50,5/15/2020
546A27,clinical-trials,100,56,5/15/2020
5487B1,legal-issues-defendant,100,22,5/15/2020
58CA9A,conference-participant,100,50,5/15/2020
5B6C11,merger-regulatory-approval,100,81,5/15/2020
5E1DF3,conference-participant,100,50,5/15/2020
5F3E74,public-offering,100,43,5/15/2020
619882,dividend,100,50,5/15/2020
619882,conference-organizer,100,57,5/15/2020
62A48D,earnings,100,50,5/15/2020
66667F,buybacks,100,74,5/15/2020
676FFD,legal-issues-defendant,100,22,5/15/2020
68586A,conference-participant,100,50,5/15/2020
6BDA0C,dividend,100,50,5/15/2020
6E705B,conference-participant,100,50,5/15/2020
726EEA,dividend,100,50,5/15/2020
76DD0C,clinical-trials,100,56,5/15/2020
7A51FE,dividend,100,50,5/15/2020
7B8CB5,dividend-up,100,60,5/15/2020
7E0EB0,executive-appointment,100,54,5/15/2020
7EA323,earnings,100,50,5/15/2020
7F7C87,earnings,100,50,5/15/2020
8.10E+32,dividend,100,50,5/15/2020
819492,earnings,100,50,5/15/2020
8.40E+120,clinical-trials,100,56,5/15/2020
8AA108,earnings,100,50,5/15/2020
8D0EEA,earnings,100,50,5/15/2020
8F8F2F,dividend,100,50,5/15/2020
93D207,conference-participant,100,50,5/15/2020
94637C,regulatory-product-approval-granted,100,81,5/15/2020
9978F1,clinical-trials,100,56,5/15/2020
9A2760,note-sale,100,52,5/15/2020
9C8BC3,note-sale,100,52,5/15/2020
9D4EC7,dividend,100,50,5/15/2020
A21649,conference-call,100,50,5/15/2020
A398F8,partnership,100,61,5/15/2020
A4B899,executive-appointment,100,54,5/15/2020
A4B899,dividend,100,50,5/15/2020
A94637,dividend-up,100,81,5/15/2020
A9ED24,conference-call,100,50,5/15/2020
B04426,clinical-trials,100,56,5/15/2020
B48D6A,clinical-trials,100,56,5/15/2020
C01737,clinical-trials,100,56,5/15/2020
C2609A,conference-participant,100,50,5/15/2020
C2609A,conference-participant,100,50,5/15/2020
C72B8F,conference-participant,100,50,5/15/2020
CBCC6A,buybacks,100,74,5/15/2020
CBCC6A,buybacks,100,74,5/15/2020
CE8A7B,earnings,100,50,5/15/2020
D1588D,earnings,100,50,5/15/2020
D5AF19,public-offering,100,43,5/15/2020
D6489C,executive-appointment,100,54,5/15/2020
D6534D,executive-appointment,100,54,5/15/2020
D78CCD,earnings,100,50,5/15/2020
DA48E4,partnership,100,61,5/15/2020
DDC415,product-release,100,64,5/15/2020
E06265,legal-issues-defendant,100,22,5/15/2020
E20392,conference-participant,100,50,5/15/2020
E71AE6,conference-participant,100,50,5/15/2020
E802CE,shareholder-rights-plan,100,43,5/15/2020
E8846E,conference-organizer,100,57,5/15/2020
E8846E,conference-organizer,100,57,5/15/2020
E8846E,dividend,100,50,5/15/2020
E8846E,dividend,100,50,5/15/2020
E8846E,dividend,100,50,5/15/2020
E90C84,dividend,100,50,5/15/2020
EE967B,dividend,100,50,5/15/2020
EF25A5,conference-participant,100,50,5/15/2020
F2BC3D,conference-participant,100,50,5/15/2020
F39E1E,legal-issues-defendant,100,22,5/15/2020
F43A11,fraud-defendant,100,20,5/15/2020
F43A11,legal-issues-defendant,100,22,5/15/2020
F43A11,legal-issues-defendant,100,22,5/15/2020
F43A11,legal-issues-defendant,100,22,5/15/2020
F6A392,earnings,100,50,5/15/2020
F6A392,earnings,100,50,5/15/2020
FCA54E,public-offering,100,43,5/15/2020
FF9FF6,drilling,100,68,5/15/2020
FF9FF6,drilling,100,68,5/15/2020
4A7C1F,legal-issues-defendant,100,22,5/16/2020
4ECD1A,dividend,100,50,5/16/2020
539F49,legal-issues-defendant,100,22,5/16/2020
76CEFB,conference-participant,100,50,5/16/2020
9C8BC3,note-sale,100,52,5/16/2020
539F49,legal-issues-defendant,100,22,5/17/2020
01D03F,partnership,100,61,5/18/2020
01D03F,regulatory-product-approval-granted,100,81,5/18/2020
01D03F,regulatory-product-approval-granted,100,81,5/18/2020
02FC1A,clinical-trials-start,100,64,5/18/2020
05D148,public-offering,100,43,5/18/2020
0624BE,earnings,100,50,5/18/2020
065D38,earnings,100,50,5/18/2020
070B45,executive-appointment,100,54,5/18/2020
0AAD90,conference-participant,100,50,5/18/2020
0BD199,public-offering,100,43,5/18/2020
0DC050,executive-appointment,100,54,5/18/2020
102727,executive-appointment,100,54,5/18/2020
1065BC,public-offering,100,43,5/18/2020
126F95,dividend,100,50,5/18/2020
159AE4,conference-call,100,50,5/18/2020
1B9535,conference-participant,100,50,5/18/2020
1DDEDA,conference-call,100,50,5/18/2020
228D42,partnership,100,61,5/18/2020
228D42,partnership,100,61,5/18/2020
26DC29,conference-participant,100,50,5/18/2020
28DCA8,conference-participant,100,50,5/18/2020
2E1322,partnership,100,61,5/18/2020
2F7A7E,note-sale,100,52,5/18/2020
309922,note-sale,100,52,5/18/2020
30E01D,executive-appointment,100,54,5/18/2020
32DCB3,clinical-trials,100,56,5/18/2020
36529A,public-offering,100,43,5/18/2020
37020C,conference-participant,100,50,5/18/2020
384CD3,note-sale,100,52,5/18/2020
3AAEAE,public-offering,100,43,5/18/2020
3B2311,public-offering,100,43,5/18/2020
3C6CCC,earnings,100,50,5/18/2020
3ED92D,note-sale,100,52,5/18/2020
3ED92D,note-sale,100,52,5/18/2020
41EC04,executive-appointment,100,54,5/18/2020
44A4FC,clinical-trials,100,56,5/18/2020
458D2C,revenue-volume,100,50,5/18/2020
4.60E+06,executive-appointment,100,54,5/18/2020
499C75,legal-issues-defendant,100,22,5/18/2020
49CC59,conference-call,100,50,5/18/2020
4A7C1F,legal-issues-defendant,100,22,5/18/2020
4B3DC9,conference-participant,100,50,5/18/2020
4B7006,earnings,100,50,5/18/2020
4C31F3,earnings,100,50,5/18/2020
4C31F3,earnings,100,50,5/18/2020
4E6F5A,executive-appointment,100,54,5/18/2020
51D876,conference-participant,100,50,5/18/2020
55C289,dividend,100,50,5/18/2020
5D16CF,dividend,100,50,5/18/2020
5D1956,acquisition-completed-acquirer,100,49,5/18/2020
5F9CE3,dividend,100,50,5/18/2020
60AC34,ipo,100,71,5/18/2020
619882,dividend,100,50,5/18/2020
67303E,public-offering,100,43,5/18/2020
673C9A,executive-appointment,100,54,5/18/2020
6844D2,partnership,100,61,5/18/2020
68E6E9,executive-resignation,100,44,5/18/2020
6BC6F9,product-resumed,100,52,5/18/2020
6BDA0C,public-offering,100,43,5/18/2020
6DBBBC,executive-appointment,100,54,5/18/2020
6DDA15,executive-appointment,100,54,5/18/2020
6E8864,public-offering,100,43,5/18/2020
756045,acquisition-completed-acquirer,100,49,5/18/2020
756BB4,earnings,100,50,5/18/2020
7CBC40,award,100,58,5/18/2020
7CD98F,dividend,100,50,5/18/2020
7E1D5D,partnership,100,61,5/18/2020
81222C,conference-participant,100,50,5/18/2020
817ED9,earnings,100,50,5/18/2020
880C0C,dividend,100,50,5/18/2020
88D80A,earnings,100,50,5/18/2020
89F693,note-acquisition,100,66,5/18/2020
8AB37F,conference-participant,100,50,5/18/2020
8B4A45,facility-open,100,65,5/18/2020
8D4486,partnership,100,61,5/18/2020
8D9993,conference-call,100,50,5/18/2020
8FCA78,acquisition-completed-acquirer,100,49,5/18/2020
97644E,legal-issues-defendant,100,22,5/18/2020
9810C0,conference-participant,100,50,5/18/2020
9978F1,executive-appointment,100,54,5/18/2020
9C3D3C,unit-acquisition-acquirer,100,49,5/18/2020
9F03CF,executive-appointment,100,54,5/18/2020
9F71E5,note-sale,100,52,5/18/2020
A47F2E,earnings,100,50,5/18/2020
A4BCDE,conference-participant,100,50,5/18/2020
A52B6B,conference-participant,100,50,5/18/2020
A75D43,conference-participant,100,50,5/18/2020
AE3113,conference-participant,100,50,5/18/2020
AE79CD,executive-appointment,100,54,5/18/2020
B08C51,conference-participant,100,50,5/18/2020
B1FC3B,business-contract,100,69,5/18/2020
B7EB38,conference-participant,100,50,5/18/2020
BB0587,dividend,100,50,5/18/2020
BE7BA4,conference-participant,100,50,5/18/2020
BF79F5,index-listing,100,76,5/18/2020
BFD0A7,conference-participant,100,50,5/18/2020
C03C8B,conference-participant,100,50,5/18/2020
C407A0,board-meeting,100,51,5/18/2020
C4A432,dividend,100,50,5/18/2020
C83B88,legal-issues-defendant,100,22,5/18/2020
C83B88,legal-issues-defendant,100,22,5/18/2020
C97B2D,note-sale,100,52,5/18/2020
CBDB4D,settlement,100,56,5/18/2020
CCB623,business-contract,100,69,5/18/2020
CDFCC9,product-release,100,64,5/18/2020
D1344A,exchange-noncompliance,100,24,5/18/2020
D1AE3B,conference-participant,100,50,5/18/2020
D58A11,business-contract,100,69,5/18/2020
D60BB2,dividend,100,50,5/18/2020
D6144F,conference-participant,100,50,5/18/2020
D697DE,conference-participant,100,50,5/18/2020
D9E036,award,100,58,5/18/2020
DBFB51,dividend,100,50,5/18/2020
E0207A,acquisition-completed-acquirer,100,49,5/18/2020
E114F4,conference-call,100,50,5/18/2020
E15736,note-sale,100,52,5/18/2020
E1E36F,dividend,100,50,5/18/2020
E4CE73,partnership,100,61,5/18/2020
E68733,executive-appointment,100,54,5/18/2020
E68733,executive-appointment,100,54,5/18/2020
E6D89E,settlement,100,56,5/18/2020
E70531,legal-issues-defendant,100,22,5/18/2020
E8846E,conference-organizer,100,57,5/18/2020
EAEA91,operating-earnings-up,100,68,5/18/2020
EB7D6C,earnings,100,50,5/18/2020
ED3CA8,executive-appointment,100,54,5/18/2020
EF5BED,executive-appointment,100,54,5/18/2020
F24FF0,conference-call,100,50,5/18/2020
F43A11,legal-issues-defendant,100,22,5/18/2020
F43A11,legal-issues-defendant,100,22,5/18/2020
FD9A97,earnings,100,50,5/18/2020
01D03F,regulatory-product-approval-granted,100,81,5/19/2020
01D03F,regulatory-product-approval-granted,100,81,5/19/2020
03FAA6,partnership,100,61,5/19/2020
04996E,unit-acquisition-acquirer,100,49,5/19/2020
04996E,earnings,100,50,5/19/2020
04996E,earnings,100,50,5/19/2020
05D148,public-offering,100,43,5/19/2020
06EF42,facility-open,100,65,5/19/2020
070B45,business-contract,100,69,5/19/2020
09DE1F,product-release,100,64,5/19/2020
0CE204,conference-participant,100,50,5/19/2020
0F0440,earnings,100,50,5/19/2020
0F0440,earnings,100,50,5/19/2020
11A49E,board-meeting,100,51,5/19/2020
12E454,settlement,100,56,5/19/2020
157D9F,facility-sale,100,52,5/19/2020
182BE7,legal-issues-defendant,100,22,5/19/2020
182BE7,legal-issues-defendant,100,22,5/19/2020
184988,conference-call,100,50,5/19/2020
1AB023,partnership,100,61,5/19/2020
1AB023,partnership,100,61,5/19/2020
1AB023,partnership,100,61,5/19/2020
1DEBBE,award,100,58,5/19/2020
228D42,copyright-infringement-defendant,100,27,5/19/2020
25102A,earnings,100,50,5/19/2020
267718,note-sale,100,52,5/19/2020
28F905,executive-appointment,100,54,5/19/2020
292A70,dividend,100,50,5/19/2020
2B5483,partnership,100,61,5/19/2020
2C35B5,regulatory-product-approval-granted,100,81,5/19/2020
2CBB58,earnings,100,50,5/19/2020
2D643C,executive-appointment,100,54,5/19/2020
326EDD,dividend,100,50,5/19/2020
355B19,dividend,100,50,5/19/2020
371C01,legal-issues-defendant,100,22,5/19/2020
3B318A,conference-call,100,50,5/19/2020
3B50FE,conference-call,100,50,5/19/2020
3C7F5F,dividend,100,50,5/19/2020
3C8A04,dividend,100,50,5/19/2020
408380,partnership,100,61,5/19/2020
46017C,note-sale,100,52,5/19/2020
46017C,note-sale,100,52,5/19/2020
499C75,legal-issues-defendant,100,22,5/19/2020
4BEB48,public-offering,100,43,5/19/2020
58EA22,earnings,100,50,5/19/2020
5B6C11,facility-upgrade,100,65,5/19/2020
5FE4B6,conference-participant,100,50,5/19/2020
619882,executive-resignation,100,44,5/19/2020
64E615,note-sale,100,52,5/19/2020
67303E,public-offering,100,43,5/19/2020
6925EB,legal-issues-defendant,100,22,5/19/2020
6A024C,executive-appointment,100,54,5/19/2020
6E8864,public-offering,100,43,5/19/2020
6ED519,dividend,100,50,5/19/2020
70CA28,conference-participant,100,50,5/19/2020
713810,same-store-sales-up,100,60,5/19/2020
7.45E+28,note-sale,100,52,5/19/2020
747219,conference-participant,100,50,5/19/2020
769F40,earnings,100,50,5/19/2020
791D59,award,100,58,5/19/2020
7C4168,note-sale,100,52,5/19/2020
7C75FD,earnings,100,50,5/19/2020
7D85A9,note-sale,100,52,5/19/2020
810FAD,executive-appointment,100,54,5/19/2020
8377DB,partnership,100,61,5/19/2020
85AD00,dividend,100,50,5/19/2020
85DE00,partnership,100,61,5/19/2020
873DB9,public-offering,100,43,5/19/2020
88193E,award,100,58,5/19/2020
8A0368,conference-participant,100,50,5/19/2020
8EDACA,earnings,100,50,5/19/2020
8EF425,dividend,100,50,5/19/2020
92D757,executive-appointment,100,54,5/19/2020
938D89,legal-issues-defendant,100,22,5/19/2020
9C5BA5,conference-participant,100,50,5/19/2020
9D5FA4,partnership,100,61,5/19/2020
9F37C5,dividend,100,50,5/19/2020
9F5997,conference-participant,100,50,5/19/2020
9F62D1,dividend,100,50,5/19/2020
9F71E5,earnings,100,50,5/19/2020
A11CF4,executive-appointment,100,54,5/19/2020
A1E3B3,partnership,100,61,5/19/2020
A247F5,legal-issues-defendant,100,22,5/19/2020
A495F7,product-release,100,64,5/19/2020
A631A3,legal-issues-defendant,100,22,5/19/2020
A6828A,legal-issues-defendant,100,22,5/19/2020
A8CBDA,conference-participant,100,50,5/19/2020
A94718,earnings,100,50,5/19/2020
AB4A7E,legal-issues-plaintiff,100,44,5/19/2020
AC3584,note-sale,100,52,5/19/2020
ACDF88,earnings,100,50,5/19/2020
ACDF88,earnings,100,50,5/19/2020
ACDF88,earnings,100,50,5/19/2020
AD1ACF,legal-issues-defendant,100,22,5/19/2020
B2206F,partnership,100,61,5/19/2020
B4528F,conference-call,100,50,5/19/2020
B48D6A,executive-appointment,100,54,5/19/2020
B54A74,note-sale,100,52,5/19/2020
B9764A,product-release,100,64,5/19/2020
B9764A,product-release,100,64,5/19/2020
B9CD50,product-release,100,64,5/19/2020
B9CD50,product-release,100,64,5/19/2020
BB88B6,product-release,100,64,5/19/2020
BB88B6,product-release,100,64,5/19/2020
BCC55F,business-contract,100,69,5/19/2020
BD15E8,dividend,100,50,5/19/2020
C22BE8,earnings,100,50,5/19/2020
C356AC,legal-issues-defendant,100,22,5/19/2020
C8A059,earnings,100,50,5/19/2020
D064D5,earnings,100,50,5/19/2020
D06755,conference-participant,100,50,5/19/2020
D1AE3B,dividend,100,50,5/19/2020
D7918D,legal-issues-defendant,100,22,5/19/2020
DB396B,dividend,100,50,5/19/2020
DB9829,dividend,100,50,5/19/2020
DD7A96,executive-appointment,100,54,5/19/2020
DF42A0,conference-call,100,50,5/19/2020
E0E4B7,public-offering,100,43,5/19/2020
E20BFE,earnings,100,50,5/19/2020
E20BFE,earnings,100,50,5/19/2020
E3A829,business-contract,100,69,5/19/2020
E4CE73,conference-participant,100,50,5/19/2020
E74B55,executive-appointment,100,54,5/19/2020
EB2F14,dividend,100,50,5/19/2020
ED0402,public-offering,100,43,5/19/2020
EDF5CA,legal-issues-defendant,100,22,5/19/2020
EE6F1C,unit-acquisition-completed-acquiree,100,67,5/19/2020
EF5BED,executive-appointment,100,54,5/19/2020
F1529C,acquisition-acquirer,100,49,5/19/2020
F1529C,acquisition-acquirer,100,49,5/19/2020
F24FF0,earnings,100,50,5/19/2020
F39E1E,earnings,100,50,5/19/2020
F4F46F,conference-participant,100,50,5/19/2020
F51DB0,public-offering,100,43,5/19/2020
F5349B,award,100,58,5/19/2020
F6DCE4,conference-call,100,50,5/19/2020
F8BA6C,conference-participant,100,50,5/19/2020
F9CAF8,earnings,100,50,5/19/2020
FB728F,earnings,100,50,5/19/2020
FB728F,executive-appointment,100,54,5/19/2020
FC1B7B,dividend-up,100,60,5/19/2020
FC80E6,dividend,100,50,5/19/2020
FCA54E,public-offering,100,43,5/19/2020
FE609F,public-offering,100,43,5/19/2020
00067A,business-contract,100,69,5/20/2020
00FC70,dividend,100,50,5/20/2020
01D03F,regulatory-product-approval-granted,100,81,5/20/2020
0BA8CE,executive-appointment,100,54,5/20/2020
0F2BC9,executive-appointment,100,54,5/20/2020
1151F4,dividend,100,50,5/20/2020
12DE76,partnership,100,61,5/20/2020
143C9C,earnings-up,100,68,5/20/2020
149301,dividend,100,50,5/20/2020
16B882,board-meeting,100,51,5/20/2020
197019,executive-appointment,100,54,5/20/2020
197612,dividend,100,50,5/20/2020
1AB023,earnings,100,50,5/20/2020
1AB023,earnings,100,50,5/20/2020
1AB023,earnings,100,50,5/20/2020
1D1B07,conference-participant,100,50,5/20/2020
1D1B07,conference-participant,100,50,5/20/2020
1D943E,executive-appointment,100,54,5/20/2020
1E83DE,earnings,100,50,5/20/2020
1E8A99,dividend,100,50,5/20/2020
1EBF8D,partnership,100,61,5/20/2020
200D8B,buybacks,100,74,5/20/2020
2031CE,dividend,100,50,5/20/2020
228D42,partnership,100,61,5/20/2020
24CB56,dividend,100,50,5/20/2020
25102A,business-contract,100,69,5/20/2020
2667B6,conference-participant,100,50,5/20/2020
279916,earnings,100,50,5/20/2020
292A70,partnership,100,61,5/20/2020
29A4CC,dividend,100,50,5/20/2020
2E902B,dividend,100,50,5/20/2020
2F5256,dividend,100,50,5/20/2020
37020C,product-release,100,64,5/20/2020
39692D,earnings,100,50,5/20/2020
3B2311,public-offering,100,43,5/20/2020
3B2311,public-offering,100,43,5/20/2020
3DD5E2,partnership,100,61,5/20/2020
3E70FC,executive-appointment,100,54,5/20/2020
4017AD,dividend,100,50,5/20/2020
4.03E+05,investment-investor,100,55,5/20/2020
43A060,executive-appointment,100,54,5/20/2020
43E8F5,conference-participant,100,50,5/20/2020
499C75,legal-issues-defendant,100,22,5/20/2020
49F4D0,dividend,100,50,5/20/2020
4A5C8D,earnings,100,50,5/20/2020
4A6F00,product-release,100,64,5/20/2020
4A6F00,partnership,100,61,5/20/2020
4BBA23,executive-appointment,100,54,5/20/2020
4E2D94,note-sale,100,52,5/20/2020
4EE167,legal-issues-defendant,100,22,5/20/2020
514067,conference-participant,100,50,5/20/2020
51B442,earnings,100,50,5/20/2020
520632,revenue-up,100,69,5/20/2020
5340D0,earnings,100,50,5/20/2020
5487B1,earnings,100,50,5/20/2020
553949,business-contract,100,69,5/20/2020
58CA9A,partnership,100,61,5/20/2020
5BC2F4,dividend,100,50,5/20/2020
5D02B7,dividend-suspended,100,13,5/20/2020
5D87DF,dividend,100,50,5/20/2020
5F9CE3,partnership,100,61,5/20/2020
6559D8,executive-appointment,100,54,5/20/2020
6925EB,legal-issues-defendant,100,22,5/20/2020
6925EB,legal-issues-defendant,100,22,5/20/2020
6925EB,legal-issues-defendant,100,22,5/20/2020
6A01DF,patent-infringement-defendant,100,26,5/20/2020
6BDA0C,public-offering,100,43,5/20/2020
6C6D73,fundraising,100,64,5/20/2020
6FCEF9,earnings,100,50,5/20/2020
71694D,executive-appointment,100,54,5/20/2020
719477,dividend-up,100,55,5/20/2020
73F70F,dividend,100,50,5/20/2020
7.45E+28,note-sale,100,52,5/20/2020
762A3E,award,100,58,5/20/2020
762A3E,award,100,58,5/20/2020
766047,dividend,100,50,5/20/2020
76E80F,revenues,100,50,5/20/2020
76E80F,revenues,100,50,5/20/2020
76E80F,revenues,100,50,5/20/2020
7771D7,executive-appointment,100,54,5/20/2020
7823A3,conference-participant,100,50,5/20/2020
78A1BB,dividend,100,50,5/20/2020
7A10FF,conference-participant,100,50,5/20/2020
7A2A49,conference-call,100,50,5/20/2020
7E1D5D,earnings,100,50,5/20/2020
7E1D5D,earnings,100,50,5/20/2020
7E1D5D,earnings,100,50,5/20/2020
7E1D5D,earnings,100,50,5/20/2020
7E3F8F,partnership,100,61,5/20/2020
7F2922,public-offering,100,43,5/20/2020
818A2F,dividend,100,50,5/20/2020
818A2F,dividend,100,50,5/20/2020
82FD6D,earnings,100,50,5/20/2020
850779,dividend,100,50,5/20/2020
85AD00,dividend,100,50,5/20/2020
8665BA,dividend,100,50,5/20/2020
88611B,dividend,100,50,5/20/2020
89F693,executive-appointment,100,54,5/20/2020
8B4A45,earnings,100,50,5/20/2020
8DA42F,executive-appointment,100,54,5/20/2020
8EEA28,earnings,100,50,5/20/2020
8FCA78,product-release,100,64,5/20/2020
8FF2EF,earnings,100,50,5/20/2020
9546A5,earnings,100,50,5/20/2020
954A47,dividend,100,50,5/20/2020
96F126,partnership,100,61,5/20/2020
97AAF6,investment-investor,100,55,5/20/2020
9810C0,dividend,100,50,5/20/2020
990AD0,conference-organizer,100,57,5/20/2020
990AD0,conference-organizer,100,57,5/20/2020
A01664,earnings,100,50,5/20/2020
A3230E,operating-earnings,100,50,5/20/2020
A350C1,business-contract,100,69,5/20/2020
A7CCF0,executive-appointment,100,54,5/20/2020
AD9F1D,fraud,100,44,5/20/2020
AD9F1D,legal-issues-defendant,100,22,5/20/2020
AD9F1D,legal-issues-defendant,100,22,5/20/2020
ADD9DC,earnings,100,50,5/20/2020
B0D41A,regulatory-product-approval-granted,100,81,5/20/2020
B37FB4,conference-participant,100,50,5/20/2020
B48D6A,conference-participant,100,50,5/20/2020
B54A74,note-sale,100,52,5/20/2020
B7BBFF,earnings,100,50,5/20/2020
BAD9EA,earnings,100,50,5/20/2020
C062D4,conference-participant,100,50,5/20/2020
C0F70B,product-release,100,64,5/20/2020
C2609A,product-release,100,64,5/20/2020
C4F9C6,public-offering,100,43,5/20/2020
C5D2AE,conference-participant,100,50,5/20/2020
C97B2D,public-offering,100,43,5/20/2020
CB7AB2,partnership,100,61,5/20/2020
CB88B3,conference-participant,100,50,5/20/2020
CC8F6E,regulatory-product-approval-granted,100,81,5/20/2020
CCBBAD,dividend,100,50,5/20/2020
CD2A4D,conference-participant,100,50,5/20/2020
CE5664,dividend,100,50,5/20/2020
D48275,dividend,100,50,5/20/2020
D56D6D,earnings,100,50,5/20/2020
D5B13D,public-offering,100,43,5/20/2020
D6489C,award,100,58,5/20/2020
D721C6,dividend,100,50,5/20/2020
D8DBA3,dividend,100,50,5/20/2020
D96202,executive-appointment,100,54,5/20/2020
DBB28E,partnership,100,61,5/20/2020
DC437D,dividend,100,50,5/20/2020
DC437D,earnings,100,50,5/20/2020
DD0099,dividend,100,50,5/20/2020
E0207A,dividend,100,50,5/20/2020
E114F4,credit-extension-recipient,100,69,5/20/2020
E68C3D,earnings,100,50,5/20/2020
E69BA5,dividend,100,50,5/20/2020
E6A53A,dividend,100,50,5/20/2020
E6A53A,dividend,100,50,5/20/2020
E8846E,conference-participant,100,50,5/20/2020
EB61C4,executive-resignation,100,44,5/20/2020
ED79D9,dividend,100,50,5/20/2020
ED9C04,patent-infringement-plaintiff,100,47,5/20/2020
EDF5CA,legal-issues-defendant,100,22,5/20/2020
EF5BED,executive-appointment,100,54,5/20/2020
F1529C,conference-participant,100,50,5/20/2020
F43A11,legal-issues-defendant,100,22,5/20/2020
F47871,regulatory-product-application,100,69,5/20/2020
F509E2,legal-issues-defendant,100,22,5/20/2020
F51DB0,public-offering,100,43,5/20/2020
F6581D,trading-halt,100,43,5/20/2020
F6A987,dividend,100,50,5/20/2020
F6DCE4,earnings,100,50,5/20/2020
F6DCE4,earnings,100,50,5/20/2020
F6DCE4,earnings,100,50,5/20/2020
F85CC0,dividend,100,50,5/20/2020
F85CC0,dividend,100,50,5/20/2020
F8BA6C,earnings,100,50,5/20/2020
FE609F,public-offering,100,43,5/20/2020
FE9C0D,clinical-trials-start,100,64,5/20/2020
FF6644,product-release,100,64,5/20/2020
00FC70,earnings,100,50,5/21/2020
0142B5,business-contract,100,69,5/21/2020
02870F,shareholder-rights-plan,100,43,5/21/2020
0624BE,executive-appointment,100,54,5/21/2020
070B45,conference-participant,100,50,5/21/2020
07EC43,conference-participant,100,50,5/21/2020
0A6824,conference-participant,100,50,5/21/2020
0A7650,dividend,100,50,5/21/2020
0BD4E8,government-contract,100,69,5/21/2020
0EC508,executive-appointment,100,54,5/21/2020
0F04E5,product-release,100,64,5/21/2020
119CB6,dividend,100,50,5/21/2020
1220D2,board-meeting,100,51,5/21/2020
147098,dividend,100,50,5/21/2020
152FA5,executive-appointment,100,54,5/21/2020
188394,product-release,100,64,5/21/2020
19BF16,executive-appointment,100,54,5/21/2020
1BDB2A,conference-participant,100,50,5/21/2020
1C2593,earnings-up,100,68,5/21/2020
1CD4B5,executive-appointment,100,54,5/21/2020
1F716B,donation,100,54,5/21/2020
1FCC00,earnings,100,50,5/21/2020
200D8B,earnings,100,50,5/21/2020
2093B1,dividend,100,50,5/21/2020
225CA2,dividend,100,50,5/21/2020
251988,partnership,100,61,5/21/2020
275300,conference-participant,100,50,5/21/2020
278C18,dividend,100,50,5/21/2020
27B191,dividend,100,50,5/21/2020
2920D5,dividend,100,50,5/21/2020
2BF36E,dividend,100,50,5/21/2020
2CB4C9,dividend,100,50,5/21/2020
2F9304,earnings,100,50,5/21/2020
2F98A5,executive-appointment,100,54,5/21/2020
2FF046,business-contract,100,69,5/21/2020
3461CF,product-release,100,64,5/21/2020
3461CF,conference-participant,100,50,5/21/2020
36E479,clinical-trials-start,100,64,5/21/2020
371B0A,earnings,100,50,5/21/2020
396D7C,legal-issues-defendant,100,22,5/21/2020
396D7C,legal-issues-defendant,100,22,5/21/2020
3A94DF,dividend,100,50,5/21/2020
3BB616,note-sale,100,52,5/21/2020
40B903,earnings,100,50,5/21/2020
40B903,earnings,100,50,5/21/2020
40B903,earnings,100,50,5/21/2020
40B903,earnings,100,50,5/21/2020
41785E,dividend,100,50,5/21/2020
417BF9,earnings,100,50,5/21/2020
41EC04,note-sale,100,52,5/21/2020
44A4FC,unit-acquisition-acquirer,100,49,5/21/2020
4649D5,award,100,58,5/21/2020
499C75,legal-issues-defendant,100,22,5/21/2020
4C7DB5,product-price-raise,100,57,5/21/2020
4E2D94,note-sale,100,52,5/21/2020
4F0A80,dividend,100,50,5/21/2020
504FE2,business-contract,100,69,5/21/2020
504FE2,conference-participant,100,50,5/21/2020
520632,clinical-trials,100,56,5/21/2020
5.43E+08,conference-call,100,50,5/21/2020
543900,earnings,100,50,5/21/2020
55C9B5,conference-participant,100,50,5/21/2020
55D0F3,earnings,100,50,5/21/2020
587D25,executive-appointment,100,54,5/21/2020
5B226B,dividend,100,50,5/21/2020
5D02B7,conference-call,100,50,5/21/2020
5DE5A5,conference-participant,100,50,5/21/2020
5E7E82,earnings,100,50,5/21/2020
5E7E82,earnings,100,50,5/21/2020
5E7E82,earnings,100,50,5/21/2020
5E7E82,earnings,100,50,5/21/2020
5E7E82,earnings,100,50,5/21/2020
5EAA43,conference-call,100,50,5/21/2020
64E615,note-sale,100,52,5/21/2020
6830FE,earnings,100,50,5/21/2020
68BA15,acquisition-acquirer,100,49,5/21/2020
6925EB,legal-issues-defendant,100,22,5/21/2020
69CE71,facility-open,100,65,5/21/2020
69CE71,facility-open,100,65,5/21/2020
69CE71,facility-open,100,65,5/21/2020
69CE71,facility-open,100,65,5/21/2020
69CE71,facility-open,100,65,5/21/2020
69CE71,facility-open,100,65,5/21/2020
69CE71,facility-open,100,65,5/21/2020
69CE71,facility-open,100,65,5/21/2020
69CE71,facility-open,100,65,5/21/2020
69FDFC,partnership,100,61,5/21/2020
6CC55E,conference-participant,100,50,5/21/2020
6DDA15,executive-appointment,100,54,5/21/2020
6F3FA8,dividend,100,50,5/21/2020
713810,conference-participant,100,50,5/21/2020
7239BB,conference-call,100,50,5/21/2020
7410C3,earnings,100,50,5/21/2020
756BB4,product-release,100,64,5/21/2020
75F982,partnership,100,61,5/21/2020
773A17,revenue-up,100,58,5/21/2020
773A17,revenue-up,100,69,5/21/2020
773A17,revenue-up,100,69,5/21/2020
773A17,revenue-up,100,69,5/21/2020
7740DE,earnings-negative,100,33,5/21/2020
787D14,award,100,58,5/21/2020
790C34,executive-appointment,100,54,5/21/2020
7E3F8F,product-release,100,64,5/21/2020
7F3669,conference-participant,100,50,5/21/2020
838ADD,conference-participant,100,50,5/21/2020
83A065,earnings,100,50,5/21/2020
859D62,earnings,100,50,5/21/2020
859D62,dividend,100,50,5/21/2020
896771,facility-open,100,65,5/21/2020
8C311A,conference-participant,100,50,5/21/2020
8C6C1B,earnings,100,50,5/21/2020
8C6C1B,earnings,100,50,5/21/2020
8D0EEA,public-offering,100,43,5/21/2020
901327,dividend,100,50,5/21/2020
901327,executive-appointment,100,54,5/21/2020
901327,executive-appointment,100,54,5/21/2020
905356,earnings-per-share-positive,100,69,5/21/2020
905356,earnings,100,50,5/21/2020
905356,earnings,100,50,5/21/2020
93D207,conference-participant,100,50,5/21/2020
949625,executive-appointment,100,54,5/21/2020
957A07,executive-appointment,100,54,5/21/2020
98A286,earnings,100,50,5/21/2020
990AD0,conference-organizer,100,57,5/21/2020
9934AD,product-release,100,64,5/21/2020
9.97E+09,dividend,100,50,5/21/2020
9B71A7,legal-issues-defendant,100,22,5/21/2020
9C5BA5,dividend,100,50,5/21/2020
9CA432,executive-appointment,100,54,5/21/2020
A03EE1,ipo-pricing,100,50,5/21/2020
A16DEA,conference-participant,100,50,5/21/2020
A1EAC8,conference-participant,100,50,5/21/2020
A403CF,earnings,100,50,5/21/2020
A403CF,dividend,100,50,5/21/2020
A43906,conference-participant,100,50,5/21/2020
A52B6B,earnings,100,50,5/21/2020
A60354,dividend,100,50,5/21/2020
A631A3,partnership,100,61,5/21/2020
A631A3,legal-issues-defendant,100,22,5/21/2020
A63820,product-release,100,64,5/21/2020
AC3584,note-sale,100,52,5/21/2020
AD1ACF,executive-appointment,100,54,5/21/2020
AD23DE,legal-issues-defendant,100,22,5/21/2020
AD23DE,loan-provider,100,57,5/21/2020
AD23DE,product-release,100,64,5/21/2020
AD9F1D,legal-issues-defendant,100,22,5/21/2020
AD9F1D,legal-issues-defendant,100,22,5/21/2020
AD9F1D,legal-issues-defendant,100,22,5/21/2020
AD9F1D,legal-issues-defendant,100,22,5/21/2020
AD9F1D,stock-loss,100,40,5/21/2020
AD9F1D,legal-issues-defendant,100,22,5/21/2020
AFF7B4,note-sale,100,52,5/21/2020
B1A85D,executive-appointment,100,54,5/21/2020
B37FB4,legal-issues-defendant,100,22,5/21/2020
B72BE9,dividend,100,50,5/21/2020
B934BF,dividend,100,50,5/21/2020
BB0787,conference-participant,100,50,5/21/2020
BCC55F,award,100,58,5/21/2020
BE14CF,conference-participant,100,50,5/21/2020
BF79F5,index-listing,100,76,5/21/2020
C0030A,facility-open,100,65,5/21/2020
C22BE8,dividend,100,50,5/21/2020
C4A432,earnings,100,50,5/21/2020
C4A432,earnings,100,50,5/21/2020
C4A432,earnings,100,50,5/21/2020
C4A432,earnings,100,50,5/21/2020
C4F9C6,public-offering,100,43,5/21/2020
C659EB,conference-participant,100,50,5/21/2020
C8A059,earnings,100,50,5/21/2020
C941DC,conference-participant,100,50,5/21/2020
C9739A,conference-participant,100,50,5/21/2020
CA99D7,dividend-up,100,81,5/21/2020
CD2A4D,executive-appointment,100,54,5/21/2020
CFF97C,partnership,100,61,5/21/2020
CFF97C,partnership,100,61,5/21/2020
D03C7A,dividend,100,50,5/21/2020
D36686,name-change,100,49,5/21/2020
D5AF19,dividend,100,50,5/21/2020
D5B13D,public-offering,100,43,5/21/2020
D697DE,conference-participant,100,50,5/21/2020
D8DA3D,dividend,100,50,5/21/2020
D90441,dividend,100,50,5/21/2020
D90441,dividend,100,50,5/21/2020
DA0A9E,conference-call,100,50,5/21/2020
DA48E4,dividend,100,50,5/21/2020
DBB28E,earnings,100,50,5/21/2020
DBB28E,earnings,100,50,5/21/2020
DBB28E,earnings,100,50,5/21/2020
DBB28E,earnings,100,50,5/21/2020
DBB28E,earnings,100,50,5/21/2020
DBB28E,earnings,100,50,5/21/2020
DBB28E,earnings,100,50,5/21/2020
DBB28E,earnings,100,50,5/21/2020
DD0F15,public-offering,100,43,5/21/2020
DF18E6,conference-call,100,50,5/21/2020
DF6FDD,dividend,100,50,5/21/2020
E09E2B,earnings,100,50,5/21/2020
E09E2B,earnings,100,50,5/21/2020
E09E2B,earnings,100,50,5/21/2020
E30B34,dividend,100,50,5/21/2020
E30B34,dividend,100,50,5/21/2020
E3E68E,note-sale,100,52,5/21/2020
E3E68E,note-sale,100,52,5/21/2020
E3E68E,note-sale,100,52,5/21/2020
E3E68E,note-sale,100,52,5/21/2020
E5C910,executive-appointment,100,54,5/21/2020
E68733,earnings,100,50,5/21/2020
E68733,earnings,100,50,5/21/2020
E6C8DC,executive-appointment,100,54,5/21/2020
E6EDED,dividend,100,50,5/21/2020
E9C7C0,product-release,100,64,5/21/2020
E9C7C0,earnings,100,50,5/21/2020
EB7FBF,conference-call,100,50,5/21/2020
ECDEB2,dividend,100,50,5/21/2020
ED79D9,earnings,100,50,5/21/2020
EDF5CA,legal-issues-defendant,100,22,5/21/2020
EF5BED,earnings,100,50,5/21/2020
F0A9DE,dividend,100,50,5/21/2020
F11638,revenue-down,100,42,5/21/2020
F11638,revenue-down,100,42,5/21/2020
F11638,revenue-down,100,42,5/21/2020
F11638,revenue-down,100,42,5/21/2020
F11638,revenue-down,100,42,5/21/2020
F1CD47,dividend,100,50,5/21/2020
F4E992,conference-participant,100,50,5/21/2020
F509E2,legal-issues-defendant,100,22,5/21/2020
F5C8AB,executive-appointment,100,54,5/21/2020
F66B58,conference-call,100,50,5/21/2020
F6DCE4,copyright-infringement-defendant,100,27,5/21/2020
F73DD1,dividend,100,50,5/21/2020
FC1B7B,conference-participant,100,50,5/21/2020
FD2565,public-offering,100,43,5/21/2020
FD6926,note-sale,100,52,5/21/2020
FD6926,note-sale,100,52,5/21/2020
FEE4B0,partnership,100,61,5/21/2020
01D03F,acquisition-acquirer,100,49,5/22/2020
02870F,dividend,100,50,5/22/2020
03B8CF,settlement,100,56,5/22/2020
05D148,public-offering,100,43,5/22/2020
0CE7F6,earnings,100,50,5/22/2020
20BEEA,dividend,100,50,5/22/2020
2DB344,dividend,100,50,5/22/2020
341759,board-meeting,100,51,5/22/2020
396D7C,legal-issues-defendant,100,22,5/22/2020
396D7C,legal-issues-defendant,100,22,5/22/2020
396D7C,legal-issues-defendant,100,22,5/22/2020
3B20AB,conference-participant,100,50,5/22/2020
3DE4D1,executive-appointment,100,54,5/22/2020
431B74,earnings-positive,100,69,5/22/2020
431B74,earnings-positive,100,69,5/22/2020
4676DF,dividend,100,50,5/22/2020
499C75,legal-issues-defendant,100,22,5/22/2020
4A3438,conference-participant,100,50,5/22/2020
4F71DC,earnings,100,50,5/22/2020
519FE0,facility-open,100,65,5/22/2020
53F491,dividend,100,50,5/22/2020
5E7E82,dividend,100,50,5/22/2020
61E975,conference-participant,100,50,5/22/2020
649CBD,clinical-trials,100,56,5/22/2020
64E615,executive-appointment,100,54,5/22/2020
66667F,partnership,100,61,5/22/2020
6830FE,partnership,100,61,5/22/2020
6925EB,legal-issues-defendant,100,22,5/22/2020
6DBBBC,investment-investor,100,55,5/22/2020
6DC1D7,dividend,100,50,5/22/2020
6E705B,conference-participant,100,50,5/22/2020
7.45E+28,note-sale,100,52,5/22/2020
75F665,dividend,100,50,5/22/2020
7A0EC4,conference-participant,100,50,5/22/2020
7B9212,earnings,100,50,5/22/2020
810FAD,dividend,100,50,5/22/2020
87B81A,conference-participant,100,50,5/22/2020
8A8E41,partnership,100,61,5/22/2020
8D0EEA,public-offering,100,43,5/22/2020
9196A2,conference-organizer,100,57,5/22/2020
91E5EE,dividend,100,50,5/22/2020
94637C,regulatory-product-approval-granted,100,81,5/22/2020
9.54E+32,dividend,100,50,5/22/2020
971334,dividend,100,50,5/22/2020
9.74E+08,dividend,100,50,5/22/2020
990AD0,conference-organizer,100,57,5/22/2020
9B71A7,facility-open,100,65,5/22/2020
9CA432,acquisition-failed-acquirer,100,41,5/22/2020
9CA432,business-contract-terminated,100,31,5/22/2020
9D2790,dividend,100,50,5/22/2020
A3BFAA,merger-completed,100,66,5/22/2020
A631A3,conference-participant,100,50,5/22/2020
AD9F1D,legal-issues-defendant,100,22,5/22/2020
AD9F1D,legal-issues-defendant,100,22,5/22/2020
AD9F1D,legal-issues-defendant,100,22,5/22/2020
B4C673,partnership,100,61,5/22/2020
BBF349,executive-appointment,100,54,5/22/2020
BD15E8,executive-appointment,100,54,5/22/2020
BFE02C,dividend,100,50,5/22/2020
C65004,conference-participant,100,50,5/22/2020
C97B2D,public-offering,100,43,5/22/2020
CFF97C,conference-participant,100,50,5/22/2020
D5AF19,conference-participant,100,50,5/22/2020
D7918D,legal-issues-defendant,100,22,5/22/2020
DAC66A,dividend,100,50,5/22/2020
DC0066,note-sale,100,52,5/22/2020
DF16DE,clinical-trials,100,56,5/22/2020
E06265,legal-issues-defendant,100,22,5/22/2020
E09E2B,dividend,100,50,5/22/2020
E68C3D,conference-participant,100,50,5/22/2020
E6A53A,executive-appointment,100,54,5/22/2020
E6A53A,executive-appointment,100,54,5/22/2020
E8F0E2,earnings,100,50,5/22/2020
EB7D6C,legal-issues-defendant,100,22,5/22/2020
EDF5CA,legal-issues-defendant,100,22,5/22/2020
EDF5CA,legal-issues-defendant,100,22,5/22/2020
F30508,partnership,100,61,5/22/2020
F43A11,fraud-defendant,100,20,5/22/2020
F509E2,legal-issues-defendant,100,22,5/22/2020
F5C8AB,executive-appointment,100,54,5/22/2020
F7902B,conference-participant,100,50,5/22/2020
FE609F,public-offering,100,43,5/22/2020
21D903,legal-issues-defendant,100,22,5/23/2020
EB7D6C,legal-issues-defendant,100,22,5/23/2020
3F4668,acquisition-acquiree,100,76,5/24/2020
896771,business-contract,100,69,5/24/2020
938D89,legal-issues-defendant,100,22,5/24/2020
2BF36E,conference-participant,100,50,5/25/2020
2C681C,clinical-trials-start,100,64,5/25/2020
2C681C,clinical-trials-start,100,64,5/25/2020
3F4668,legal-issues-defendant,100,22,5/25/2020
589803,public-offering,100,43,5/25/2020
589803,public-offering,100,43,5/25/2020
6925EB,legal-issues-defendant,100,22,5/25/2020
762A3E,conference-organizer,100,57,5/25/2020
BB127B,partnership,100,61,5/25/2020
CB89EA,conference-participant,100,50,5/25/2020
DD1BA1,acquisition-acquiree,100,76,5/25/2020
DD1BA1,acquisition-acquiree,100,76,5/25/2020
E06265,legal-issues-defendant,100,22,5/25/2020
E06265,legal-issues-defendant,100,22,5/25/2020
EB7D6C,legal-issues-defendant,100,22,5/25/2020
EDF5CA,legal-issues-defendant,100,22,5/25/2020
001F1B,facility-open,100,65,5/26/2020
13528,earnings,100,50,5/26/2020
01B8D6,public-offering,100,43,5/26/2020
01B8D6,public-offering,100,43,5/26/2020
20751,conference-participant,100,50,5/26/2020
033B58,conference-participant,100,50,5/26/2020
03FB17,dividend,100,50,5/26/2020
054E7E,executive-appointment,100,54,5/26/2020
75172,conference-participant,100,50,5/26/2020
0968A5,earnings,100,50,5/26/2020
0986B5,dividend,100,50,5/26/2020
0BC17A,conference-participant,100,50,5/26/2020
0BC853,note-sale,100,52,5/26/2020
0BF198,conference-participant,100,50,5/26/2020
0E2992,dividend,100,50,5/26/2020
0F0693,conference-participant,100,50,5/26/2020
11A49E,conference-participant,100,50,5/26/2020
12E454,product-release,100,64,5/26/2020
147C38,donation,100,54,5/26/2020
14BA06,conference-participant,100,50,5/26/2020
17EDA5,business-contract,100,69,5/26/2020
1B6F77,executive-appointment,100,54,5/26/2020
1D3A00,conference-call,100,50,5/26/2020
1DDEDA,earnings,100,50,5/26/2020
1EBF8D,partnership,100,61,5/26/2020
1EBF8D,partnership,100,61,5/26/2020
1EBF8D,acquisition-acquirer,100,49,5/26/2020
1EBF8D,dividend,100,50,5/26/2020
22C58E,conference-participant,100,50,5/26/2020
2.45E+15,facility-open,100,65,5/26/2020
25102A,conference-participant,100,50,5/26/2020
251988,product-release,100,64,5/26/2020
25A6CC,business-contract,100,69,5/26/2020
25A6CC,business-contract,100,69,5/26/2020
26008A,earnings,100,50,5/26/2020
263216,dividend,100,50,5/26/2020
27B191,conference-call,100,50,5/26/2020
27B191,conference-call,100,50,5/26/2020
2B49F4,conference-call,100,50,5/26/2020
2C35B5,conference-participant,100,50,5/26/2020
2D981A,conference-participant,100,50,5/26/2020
2E902B,conference-participant,100,50,5/26/2020
2FEA66,note-sale,100,52,5/26/2020
366A08,acquisition-completed-acquiree,100,76,5/26/2020
366A08,unit-acquisition-completed-acquiree,100,67,5/26/2020
367E1C,conference-participant,100,50,5/26/2020
385DD4,conference-participant,100,50,5/26/2020
389CFB,earnings-guidance-meet-expectations,100,59,5/26/2020
396D7C,conference-call,100,50,5/26/2020
396D7C,legal-issues-defendant,100,22,5/26/2020
3B318A,conference-participant,100,50,5/26/2020
3B9886,earnings,100,50,5/26/2020
3B9886,earnings,100,50,5/26/2020
3B9886,earnings,100,50,5/26/2020
3ED92D,note-sale,100,52,5/26/2020
3ED92D,business-contract,100,69,5/26/2020
3ED92D,business-contract,100,69,5/26/2020
3ED92D,business-contract,100,69,5/26/2020
3EE65E,earnings,100,50,5/26/2020
3F4668,fraud-defendant,100,20,5/26/2020
401072,conference-call,100,50,5/26/2020
41B53E,executive-appointment,100,54,5/26/2020
41ED98,product-release,100,64,5/26/2020
42AABD,conference-participant,100,50,5/26/2020
45ABCC,conference-participant,100,50,5/26/2020
45BC35,conference-participant,100,50,5/26/2020
4A3438,executive-appointment,100,54,5/26/2020
4A6F00,partnership,100,61,5/26/2020
4BDCA7,conference-participant,100,50,5/26/2020
4E6F5A,conference-participant,100,50,5/26/2020
4EE167,fraud-defendant,100,20,5/26/2020
4EE167,legal-issues-defendant,100,22,5/26/2020
4FCC78,board-meeting,100,51,5/26/2020
50070E,conference-organizer,100,57,5/26/2020
50070E,conference-organizer,100,57,5/26/2020
545272,conference-participant,100,50,5/26/2020
56AFF4,merger-failed,100,21,5/26/2020
56EA2B,conference-call,100,50,5/26/2020
56EFC7,earnings,100,50,5/26/2020
57356F,index-listing,100,76,5/26/2020
57DDB9,partnership,100,61,5/26/2020
589803,public-offering,100,43,5/26/2020
589803,public-offering,100,43,5/26/2020
58C2D4,conference-participant,100,50,5/26/2020
594402,conference-participant,100,50,5/26/2020
59DB8C,conference-participant,100,50,5/26/2020
5A0FF1,trading-listing,100,61,5/26/2020
5DE5A5,conference-participant,100,50,5/26/2020
5DE5A5,conference-participant,100,50,5/26/2020
5E9934,conference-call,100,50,5/26/2020
5EAA43,business-contract,100,69,5/26/2020
619882,conference-organizer,100,57,5/26/2020
61B81B,conference-participant,100,50,5/26/2020
62CDDE,conference-participant,100,50,5/26/2020
63F892,partnership,100,61,5/26/2020
63F892,partnership,100,61,5/26/2020
63F892,partnership,100,61,5/26/2020
657097,public-offering,100,43,5/26/2020
65D0AA,regulatory-product-approval-granted,100,81,5/26/2020
6634D9,conference-participant,100,50,5/26/2020
68BA15,acquisition-acquirer,100,49,5/26/2020
6925EB,legal-issues-defendant,100,22,5/26/2020
69345C,conference-participant,100,50,5/26/2020
6B6375,public-offering,100,43,5/26/2020
6CD55A,dividend,100,50,5/26/2020
6DBBBC,facility-open,100,65,5/26/2020
726DDF,conference-participant,100,50,5/26/2020
726DDF,conference-participant,100,50,5/26/2020
763DBE,conference-participant,100,50,5/26/2020
76DD0C,conference-participant,100,50,5/26/2020
773A17,executive-appointment,100,54,5/26/2020
7AB859,acquisition-acquirer,100,49,5/26/2020
7BC92D,conference-participant,100,50,5/26/2020
7D85A9,business-contract,100,69,5/26/2020
7DD8CC,executive-appointment,100,54,5/26/2020
819492,conference-participant,100,50,5/26/2020
850779,note-sale,100,52,5/26/2020
8665BA,partnership,100,61,5/26/2020
8665BA,partnership,100,61,5/26/2020
873DB9,conference-participant,100,50,5/26/2020
88193E,note-sale,100,52,5/26/2020
8CF6DD,executive-appointment,100,54,5/26/2020
8D0EEA,private-placement,100,56,5/26/2020
8D4486,settlement,100,56,5/26/2020
8DE74B,partnership,100,61,5/26/2020
8E93A4,merger-failed,100,21,5/26/2020
9196A2,conference-organizer,100,57,5/26/2020
9196A2,conference-organizer,100,57,5/26/2020
94637C,partnership,100,61,5/26/2020
9470CC,investment-investor,100,55,5/26/2020
954004,conference-call,100,50,5/26/2020
966DBE,legal-issues-plaintiff,100,44,5/26/2020
9A602D,conference-call,100,50,5/26/2020
9FB4B7,clinical-trials-positive,100,87,5/26/2020
A03EE1,ipo-completed,100,76,5/26/2020
A26C26,earnings,100,50,5/26/2020
A3230E,conference-participant,100,50,5/26/2020
A398B9,conference-participant,100,50,5/26/2020
A47F2E,conference-participant,100,50,5/26/2020
A49498,note-sale,100,52,5/26/2020
A4BCDE,note-sale,100,52,5/26/2020
A5195E,product-release,100,64,5/26/2020
A5E715,dividend,100,50,5/26/2020
A631A3,legal-issues-defendant,100,22,5/26/2020
A631A3,legal-issues-defendant,100,22,5/26/2020
A8B137,dividend,100,50,5/26/2020
A8CBDA,conference-participant,100,50,5/26/2020
A8E2FE,executive-appointment,100,54,5/26/2020
AD3C93,donation,100,54,5/26/2020
AD9F1D,legal-issues-defendant,100,22,5/26/2020
AE7D16,partnership,100,61,5/26/2020
AEEB76,conference-participant,100,50,5/26/2020
B1FC3B,acquisition-acquirer,100,49,5/26/2020
B37FB4,conference-participant,100,50,5/26/2020
B76C82,dividend,100,50,5/26/2020
B80AD1,regulatory-product-approval-granted,100,81,5/26/2020
B9CD50,conference-participant,100,50,5/26/2020
BA0442,public-offering,100,43,5/26/2020
BAD655,board-meeting,100,51,5/26/2020
BDF2BD,conference-participant,100,50,5/26/2020
BFCACF,conference-participant,100,50,5/26/2020
C06EB6,conference-participant,100,50,5/26/2020
C2609A,conference-participant,100,50,5/26/2020
C3F99F,conference-participant,100,50,5/26/2020
C50B26,note-sale,100,52,5/26/2020
C5C137,note-sale,100,52,5/26/2020
C66A8C,executive-appointment,100,54,5/26/2020
C81E00,note-sale,100,52,5/26/2020
C81E00,note-sale,100,52,5/26/2020
C8257F,award,100,58,5/26/2020
C85A72,partnership,100,61,5/26/2020
C85A72,investment-investor,100,55,5/26/2020
C9739A,conference-participant,100,50,5/26/2020
C97B2D,conference-participant,100,50,5/26/2020
CAB222,conference-participant,100,50,5/26/2020
CCB623,conference-participant,100,50,5/26/2020
CDD75E,clinical-trials-filed,100,60,5/26/2020
CDE51C,executive-appointment,100,54,5/26/2020
CDFCC9,note-sale,100,52,5/26/2020
CE5C6E,patient-enrollment-complete,100,64,5/26/2020
CE5C6E,patient-enrollment-complete,100,64,5/26/2020
D09938,conference-call,100,50,5/26/2020
D25249,conference-participant,100,50,5/26/2020
D29B44,conference-participant,100,50,5/26/2020
D33D8C,acquisition-completed-acquirer,100,49,5/26/2020
D598E7,earnings,100,50,5/26/2020
D90F43,partnership,100,61,5/26/2020
DA48E4,executive-appointment,100,54,5/26/2020
DB9829,earnings,100,50,5/26/2020
DD1BA1,acquisition-acquiree,100,76,5/26/2020
DD1BA1,acquisition-acquiree,100,76,5/26/2020
DF204B,conference-call,100,50,5/26/2020
E06265,legal-issues-defendant,100,22,5/26/2020
E06265,legal-issues-defendant,100,22,5/26/2020
E06265,legal-issues-defendant,100,22,5/26/2020
E13782,conference-participant,100,50,5/26/2020
E20392,conference-participant,100,50,5/26/2020
E4CE73,earnings,100,50,5/26/2020
E5A3B6,conference-participant,100,50,5/26/2020
EB1E1A,executive-appointment,100,54,5/26/2020
EB7D6C,legal-issues-defendant,100,22,5/26/2020
ECA300,conference-call,100,50,5/26/2020
ECF709,same-store-sales-down,100,49,5/26/2020
ECF709,same-store-sales-down,100,37,5/26/2020
ECF709,same-store-sales-down,100,37,5/26/2020
ED1A74,conference-participant,100,50,5/26/2020
ED22DC,conference-participant,100,50,5/26/2020
EDF5CA,legal-issues-defendant,100,22,5/26/2020
EFD406,note-sale,100,52,5/26/2020
EFD406,note-sale,100,52,5/26/2020
F30508,partnership,100,61,5/26/2020
F30508,partnership,100,61,5/26/2020
F30508,partnership,100,61,5/26/2020
F30508,partnership,100,61,5/26/2020
F3816D,conference-participant,100,50,5/26/2020
F47871,conference-call,100,50,5/26/2020
F47871,conference-call,100,50,5/26/2020
F48947,conference-participant,100,50,5/26/2020
F509E2,legal-issues-defendant,100,22,5/26/2020
F509E2,legal-issues-defendant,100,22,5/26/2020
F57F6F,board-meeting,100,51,5/26/2020
F5D410,donation,100,54,5/26/2020
F5D410,donation,100,54,5/26/2020
F6FA6A,product-release,100,64,5/26/2020
F93C8A,note-sale,100,52,5/26/2020
FBDA0F,executive-appointment,100,54,5/26/2020
FC1F9D,earnings-guidance,100,50,5/26/2020
FD4588,executive-appointment,100,54,5/26/2020
FDD3FC,business-contract,100,69,5/26/2020
00067A,conference-participant,100,50,5/27/2020
002A99,conference-participant,100,50,5/27/2020
9397,unit-acquisition-acquirer,100,49,5/27/2020
01478A,dividend,100,50,5/27/2020
0157B1,partnership,100,61,5/27/2020
01D03F,clinical-trials-positive,100,87,5/27/2020
01D03F,clinical-trials-positive,100,87,5/27/2020
054E7E,public-offering,100,43,5/27/2020
06A456,conference-call,100,50,5/27/2020
06EE79,index-listing,100,76,5/27/2020
07CA6A,business-contract,100,69,5/27/2020
07CA6A,business-contract,100,69,5/27/2020
07EC43,conference-participant,100,50,5/27/2020
0A59F8,partnership,100,61,5/27/2020
0CCCB7,executive-appointment,100,54,5/27/2020
0E499E,conference-participant,100,50,5/27/2020
10673F,dividend,100,50,5/27/2020
11A49E,executive-appointment,100,54,5/27/2020
12E454,partnership,100,61,5/27/2020
139303,conference-organizer,100,57,5/27/2020
13A782,conference-participant,100,50,5/27/2020
154272,conference-participant,100,50,5/27/2020
17EDA5,partnership,100,61,5/27/2020
182BE7,legal-issues-defendant,100,22,5/27/2020
184866,partnership,100,61,5/27/2020
1A6A94,earnings,100,50,5/27/2020
1CD4B5,conference-participant,100,50,5/27/2020
1E9A6D,award,100,58,5/27/2020
1F19C8,fundraising,100,64,5/27/2020
21F9CA,revenues,100,50,5/27/2020
223552,clinical-trials-start,100,64,5/27/2020
228D42,hirings,100,65,5/27/2020
228D42,partnership,100,61,5/27/2020
228D42,partnership,100,61,5/27/2020
24FA23,conference-participant,100,50,5/27/2020
2571FA,conference-participant,100,50,5/27/2020
26F99F,clinical-trials-start,100,64,5/27/2020
27B191,executive-appointment,100,54,5/27/2020
292388,note-sale,100,52,5/27/2020
2C3348,conference-participant,100,50,5/27/2020
2E0445,conference-participant,100,50,5/27/2020
31643A,earnings,100,50,5/27/2020
31643A,earnings,100,50,5/27/2020
31643A,earnings,100,50,5/27/2020
3390DE,shareholder-rights-plan,100,43,5/27/2020
33E9D5,earnings,100,50,5/27/2020
37B120,merger,100,66,5/27/2020
396D7C,legal-issues-defendant,100,22,5/27/2020
396D7C,legal-issues-defendant,100,22,5/27/2020
396D7C,legal-issues-defendant,100,22,5/27/2020
3BB616,facility-open,100,65,5/27/2020
3CBA2A,conference-participant,100,50,5/27/2020
3ED92D,conference-participant,100,50,5/27/2020
3F1C69,conference-participant,100,50,5/27/2020
3F4668,legal-issues-defendant,100,22,5/27/2020
3F4668,legal-issues-defendant,100,22,5/27/2020
401072,conference-participant,100,50,5/27/2020
429BFB,conference-participant,100,50,5/27/2020
42EFC7,executive-appointment,100,54,5/27/2020
431B74,dividend,100,50,5/27/2020
431B74,dividend,100,50,5/27/2020
448BF3,conference-participant,100,50,5/27/2020
448BF3,executive-appointment,100,54,5/27/2020
4885C8,partnership,100,61,5/27/2020
49A344,executive-appointment,100,54,5/27/2020
49BBBC,earnings,100,50,5/27/2020
4AC91D,earnings,100,50,5/27/2020
4AC91D,earnings,100,50,5/27/2020
4B7006,earnings,100,50,5/27/2020
4B7006,partnership,100,61,5/27/2020
4B7006,partnership,100,61,5/27/2020
4BF3D6,clinical-trials,100,56,5/27/2020
4C3FE9,conference-participant,100,50,5/27/2020
4FCC78,conference-participant,100,50,5/27/2020
50070E,conference-organizer,100,57,5/27/2020
543C77,conference-participant,100,50,5/27/2020
55C9B5,conference-participant,100,50,5/27/2020
56277A,conference-participant,100,50,5/27/2020
57634F,earnings,100,50,5/27/2020
586BD7,conference-participant,100,50,5/27/2020
589846,earnings,100,50,5/27/2020
59872F,earnings,100,50,5/27/2020
5B15E1,earnings,100,50,5/27/2020
5EF130,conference-call,100,50,5/27/2020
60AC34,ipo-completed,100,76,5/27/2020
64E346,earnings,100,50,5/27/2020
65D0AA,legal-issues-defendant,100,22,5/27/2020
65D0AA,legal-issues-defendant,100,22,5/27/2020
65D0AA,legal-issues-defendant,100,22,5/27/2020
65D0AA,legal-issues-defendant,100,22,5/27/2020
665D7D,clinical-trials-positive,100,87,5/27/2020
6830FE,product-release,100,64,5/27/2020
68BA15,conference-participant,100,50,5/27/2020
693ECD,executive-appointment,100,54,5/27/2020
6BC6F9,product-resumed,100,52,5/27/2020
701531,conference-participant,100,50,5/27/2020
726DDF,legal-issues-defendant,100,22,5/27/2020
726DDF,legal-issues-defendant,100,22,5/27/2020
726DDF,legal-issues-defendant,100,22,5/27/2020
726DDF,legal-issues-defendant,100,22,5/27/2020
726DDF,legal-issues-defendant,100,22,5/27/2020
762A3E,conference-organizer,100,57,5/27/2020
76D79A,dividend,100,50,5/27/2020
79340A,conference-participant,100,50,5/27/2020
7A5097,earnings,100,50,5/27/2020
7A51FE,partnership,100,61,5/27/2020
7AB859,partnership,100,61,5/27/2020
7B492C,donation,100,54,5/27/2020
7BEA98,conference-participant,100,50,5/27/2020
7F3FBC,dividend,100,50,5/27/2020
805CD8,conference-participant,100,50,5/27/2020
834152,conference-participant,100,50,5/27/2020
85DE00,conference-participant,100,50,5/27/2020
8614A2,conference-participant,100,50,5/27/2020
8665BA,partnership,100,61,5/27/2020
88923D,partnership,100,61,5/27/2020
88923D,partnership,100,61,5/27/2020
890FF4,conference-participant,100,50,5/27/2020
8D4486,partnership,100,61,5/27/2020
8D9993,earnings,100,50,5/27/2020
8D9993,earnings,100,50,5/27/2020
8D9993,earnings,100,50,5/27/2020
8D9993,earnings,100,50,5/27/2020
901327,product-release,100,64,5/27/2020
9196A2,conference-organizer,100,57,5/27/2020
9.31E+77,conference-participant,100,50,5/27/2020
934CC3,earnings,100,50,5/27/2020
938D89,legal-issues-defendant,100,22,5/27/2020
938D89,legal-issues-defendant,100,22,5/27/2020
93D207,executive-appointment,100,54,5/27/2020
94208D,conference-participant,100,50,5/27/2020
94637C,regulatory-product-approval-granted,100,81,5/27/2020
947B0B,conference-participant,100,50,5/27/2020
990AD0,conference-organizer,100,57,5/27/2020
990AD0,conference-organizer,100,57,5/27/2020
99B61C,executive-appointment,100,54,5/27/2020
99B61C,executive-appointment,100,54,5/27/2020
9A02C4,partnership,100,61,5/27/2020
9D307D,conference-participant,100,50,5/27/2020
9F03CF,note-sale,100,52,5/27/2020
A2C979,executive-appointment,100,54,5/27/2020
A49498,note-sale,100,52,5/27/2020
A5195E,public-offering,100,43,5/27/2020
A631A3,legal-issues-defendant,100,22,5/27/2020
A6FC89,executive-appointment,100,54,5/27/2020
AD1ACF,partnership,100,61,5/27/2020
B09B1F,conference-participant,100,50,5/27/2020
B1FC3B,business-contract,100,69,5/27/2020
B1FC3B,product-release,100,64,5/27/2020
B1FC3B,earnings,100,50,5/27/2020
B614F8,conference-participant,100,50,5/27/2020
B7FA9B,note-sale,100,52,5/27/2020
B7FA9B,note-sale,100,52,5/27/2020
B80AD1,conference-participant,100,50,5/27/2020
BB127B,partnership,100,61,5/27/2020
BB88B6,conference-participant,100,50,5/27/2020
BC3AD2,dividend,100,50,5/27/2020
BCE9DA,legal-issues-defendant,100,22,5/27/2020
BDE867,conference-participant,100,50,5/27/2020
C5C137,note-sale,100,52,5/27/2020
C941DC,conference-participant,100,50,5/27/2020
C94CFC,conference-participant,100,50,5/27/2020
C9A96E,conference-participant,100,50,5/27/2020
CDFCC9,note-sale,100,52,5/27/2020
CE1002,conference-participant,100,50,5/27/2020
CE5C6E,public-offering,100,43,5/27/2020
CF211D,earnings,100,50,5/27/2020
D15833,dividend,100,50,5/27/2020
D15833,dividend,100,50,5/27/2020
D2C0B6,earnings,100,50,5/27/2020
D4C0CB,conference-participant,100,50,5/27/2020
D56E4C,executive-appointment,100,54,5/27/2020
D56E4C,executive-resignation,100,44,5/27/2020
D5938F,conference-participant,100,50,5/27/2020
D5AF19,partnership,100,61,5/27/2020
D64C6D,executive-resignation,100,44,5/27/2020
D69D42,earnings,100,50,5/27/2020
D75910,earnings,100,50,5/27/2020
D75910,earnings,100,50,5/27/2020
D75910,earnings,100,50,5/27/2020
D75910,earnings,100,50,5/27/2020
D75910,earnings,100,50,5/27/2020
D76AEF,earnings,100,50,5/27/2020
D76AEF,dividend,100,50,5/27/2020
D7918D,legal-issues-defendant,100,22,5/27/2020
D81463,dividend,100,50,5/27/2020
D81463,dividend,100,50,5/27/2020
D95385,conference-participant,100,50,5/27/2020
DB9F70,conference-participant,100,50,5/27/2020
DC6EF3,public-offering,100,43,5/27/2020
DD0F15,public-offering,100,43,5/27/2020
DDEA6A,conference-participant,100,50,5/27/2020
DF42A0,dividend-up,100,81,5/27/2020
DF42A0,earnings,100,50,5/27/2020
DF42A0,earnings,100,50,5/27/2020
DF42A0,earnings,100,50,5/27/2020
DF42A0,earnings,100,50,5/27/2020
DF42A0,earnings,100,50,5/27/2020
DF532D,conference-participant,100,50,5/27/2020
E06265,legal-issues-defendant,100,22,5/27/2020
E1E093,partnership,100,61,5/27/2020
E71AE6,clinical-trials,100,56,5/27/2020
E866D2,business-contract,100,69,5/27/2020
E8846E,legal-issues-defendant,100,22,5/27/2020
EB5E78,conference-participant,100,50,5/27/2020
EB7D6C,legal-issues-defendant,100,22,5/27/2020
EBC84C,conference-participant,100,50,5/27/2020
EC4E82,conference-participant,100,50,5/27/2020
ED79D9,conference-participant,100,50,5/27/2020
F02170,revenue-up,100,63,5/27/2020
F02170,revenues,100,50,5/27/2020
F02170,revenues,100,50,5/27/2020
F02170,revenues,100,50,5/27/2020
F02170,revenues,100,50,5/27/2020
F02170,executive-appointment,100,54,5/27/2020
F04E05,note-sale,100,52,5/27/2020
F39E1E,legal-issues-defendant,100,22,5/27/2020
F4E992,index-listing,100,76,5/27/2020
F509E2,legal-issues-defendant,100,22,5/27/2020
F509E2,legal-issues-defendant,100,22,5/27/2020
F509E2,legal-issues-defendant,100,22,5/27/2020
F5349B,debt-extension-recipient,100,73,5/27/2020
F57F6F,conference-participant,100,50,5/27/2020
F6E248,partnership,100,61,5/27/2020
F7902B,note-sale,100,52,5/27/2020
F7ADEB,partnership,100,61,5/27/2020
F80389,union-pact,100,61,5/27/2020
FB728F,index-listing,100,76,5/27/2020
FD2565,public-offering,100,43,5/27/2020
FDD3FC,conference-participant,100,50,5/27/2020
00698D,earnings,100,50,5/28/2020
13528,partnership,100,61,5/28/2020
01D03F,clinical-trials-start,100,64,5/28/2020
01D03F,clinical-trials-start,100,64,5/28/2020
01D03F,clinical-trials-start,100,64,5/28/2020
03FAA6,product-release,100,64,5/28/2020
51332,executive-appointment,100,54,5/28/2020
0624BE,earnings,100,50,5/28/2020
68396,dividend,100,50,5/28/2020
95294,earnings,100,50,5/28/2020
09DE1F,partnership,100,61,5/28/2020
0BF528,earnings-up,100,68,5/28/2020
0BF528,earnings-up,100,68,5/28/2020
0BF528,earnings-up,100,68,5/28/2020
0BF528,earnings-up,100,68,5/28/2020
0C355F,conference-participant,100,50,5/28/2020
0CC62B,merger-regulatory-approval,100,81,5/28/2020
0F2BC9,business-contract,100,69,5/28/2020
12A3A3,conference-call,100,50,5/28/2020
12A3A3,conference-call,100,50,5/28/2020
12DE76,partnership,100,61,5/28/2020
12DE76,acquisition-interest-acquirer,100,46,5/28/2020
133644,conference-participant,100,50,5/28/2020
139303,conference-organizer,100,57,5/28/2020
139303,conference-organizer,100,57,5/28/2020
139303,conference-organizer,100,57,5/28/2020
143C52,earnings,100,50,5/28/2020
157D9F,conference-participant,100,50,5/28/2020
1866B2,dividend,100,50,5/28/2020
196D18,conference-participant,100,50,5/28/2020
1AC649,conference-participant,100,50,5/28/2020
1DB833,conference-participant,100,50,5/28/2020
1DB833,earnings,100,50,5/28/2020
1F716B,note-sale,100,52,5/28/2020
1F716B,note-sale,100,52,5/28/2020
228D42,partnership,100,61,5/28/2020
24A89A,conference-participant,100,50,5/28/2020
267718,business-contract,100,69,5/28/2020
267718,business-contract,100,69,5/28/2020
27A791,conference-participant,100,50,5/28/2020
2B8179,conference-participant,100,50,5/28/2020
2C19A4,conference-participant,100,50,5/28/2020
2CC71C,conference-participant,100,50,5/28/2020
2D5011,dividend,100,50,5/28/2020
2E2E6E,dividend,100,50,5/28/2020
2EB04E,executive-resignation,100,44,5/28/2020
2EB04E,partnership,100,61,5/28/2020
33AD83,conference-participant,100,50,5/28/2020
33AD83,earnings,100,50,5/28/2020
367434,conference-participant,100,50,5/28/2020
37E18B,conference-participant,100,50,5/28/2020
385DD4,partnership,100,61,5/28/2020
3C7F5F,executive-appointment,100,54,5/28/2020
3CCC90,partnership,100,61,5/28/2020
3F96D5,conference-participant,100,50,5/28/2020
414FFF,conference-call,100,50,5/28/2020
422CE3,earnings,100,50,5/28/2020
4290EF,partnership,100,61,5/28/2020
434F38,partnership,100,61,5/28/2020
44A4FC,conference-participant,100,50,5/28/2020
4E7C1F,business-contract,100,69,5/28/2020
4E7C1F,business-contract,100,69,5/28/2020
4EE167,conference-participant,100,50,5/28/2020
4EE167,legal-issues-defendant,100,22,5/28/2020
4EE167,business-contract,100,69,5/28/2020
539F49,conference-participant,100,50,5/28/2020
53A226,earnings,100,50,5/28/2020
55CD6F,dividend,100,50,5/28/2020
5D16CF,executive-resignation,100,44,5/28/2020
5EAA43,earnings,100,50,5/28/2020
5F2FF7,market-entry,100,57,5/28/2020
6559D8,conference-participant,100,50,5/28/2020
65D0AA,legal-issues-defendant,100,22,5/28/2020
67B052,conference-participant,100,50,5/28/2020
67B052,conference-participant,100,50,5/28/2020
69345C,conference-participant,100,50,5/28/2020
69CE71,facility-open,100,65,5/28/2020
69CE71,facility-open,100,65,5/28/2020
69CE71,facility-open,100,65,5/28/2020
69CE71,facility-open,100,65,5/28/2020
69CE71,facility-open,100,65,5/28/2020
69CE71,facility-open,100,65,5/28/2020
69CE71,facility-open,100,65,5/28/2020
69CE71,facility-open,100,65,5/28/2020
69CE71,facility-open,100,65,5/28/2020
69CE71,facility-open,100,65,5/28/2020
69CE71,facility-open,100,65,5/28/2020
69CE71,facility-open,100,65,5/28/2020
69CE71,facility-open,100,65,5/28/2020
69CE71,facility-open,100,65,5/28/2020
6AACDD,conference-participant,100,50,5/28/2020
6BBCBA,conference-participant,100,50,5/28/2020
6E8864,product-release,100,64,5/28/2020
709AED,expenses-down,100,61,5/28/2020
71694D,earnings,100,50,5/28/2020
72609A,earnings,100,50,5/28/2020
72609A,earnings,100,50,5/28/2020
72609A,earnings,100,50,5/28/2020
76E80F,dividend,100,50,5/28/2020
76F067,conference-participant,100,50,5/28/2020
7AB859,partnership,100,61,5/28/2020
7B0BA6,conference-participant,100,50,5/28/2020
7B9AFA,conference-participant,100,50,5/28/2020
7C790D,conference-participant,100,50,5/28/2020
82F088,conference-participant,100,50,5/28/2020
88193E,note-sale,100,52,5/28/2020
88923D,award,100,58,5/28/2020
890FF4,legal-issues-defendant,100,22,5/28/2020
890FF4,legal-issues-defendant,100,22,5/28/2020
8AA108,partnership,100,61,5/28/2020
8B1F37,public-offering,100,43,5/28/2020
8B3B0E,conference-participant,100,50,5/28/2020
8DCF18,conference-participant,100,50,5/28/2020
8E10BF,conference-participant,100,50,5/28/2020
8FE7A5,conference-participant,100,50,5/28/2020
9196A2,conference-organizer,100,57,5/28/2020
9196A2,conference-call,100,50,5/28/2020
92005C,conference-participant,100,50,5/28/2020
92D757,executive-appointment,100,54,5/28/2020
938D89,legal-issues-defendant,100,22,5/28/2020
938D89,legal-issues-defendant,100,22,5/28/2020
966ACE,public-offering,100,43,5/28/2020
96A6CD,conference-participant,100,50,5/28/2020
97693A,conference-call,100,50,5/28/2020
98A286,earnings,100,50,5/28/2020
98CEBB,partnership,100,61,5/28/2020
990AD0,conference-organizer,100,57,5/28/2020
990AD0,conference-organizer,100,57,5/28/2020
990AD0,conference-organizer,100,57,5/28/2020
990AD0,conference-organizer,100,57,5/28/2020
990AD0,conference-organizer,100,57,5/28/2020
997348,dividend,100,50,5/28/2020
9BB35A,merger,100,66,5/28/2020
9BF177,credit-extension-recipient,100,69,5/28/2020
9BF177,earnings,100,50,5/28/2020
9C5174,conference-participant,100,50,5/28/2020
9D56F2,conference-call,100,50,5/28/2020
9E0811,earnings,100,50,5/28/2020
9E98F2,partnership,100,61,5/28/2020
9F71E5,conference-participant,100,50,5/28/2020
9FB4B7,conference-participant,100,50,5/28/2020
A1E3B3,earnings,100,50,5/28/2020
A1E3B3,earnings,100,50,5/28/2020
A1E3B3,earnings,100,50,5/28/2020
A1E3B3,earnings,100,50,5/28/2020
A2A9BA,earnings,100,50,5/28/2020
A5195E,public-offering,100,43,5/28/2020
A5195E,conference-participant,100,50,5/28/2020
A5DD24,conference-participant,100,50,5/28/2020
A631A3,earnings,100,50,5/28/2020
A63387,conference-participant,100,50,5/28/2020
A6828A,conference-participant,100,50,5/28/2020
A72AB6,earnings,100,50,5/28/2020
A7A0BD,award,100,58,5/28/2020
A80FE0,conference-participant,100,50,5/28/2020
A868C9,conference-call,100,50,5/28/2020
A8E72A,conference-participant,100,50,5/28/2020
AD22F2,dividend,100,50,5/28/2020
AE79CD,conference-participant,100,50,5/28/2020
AEFC90,conference-participant,100,50,5/28/2020
AFDF2E,conference-participant,100,50,5/28/2020
B1DF3C,conference-participant,100,50,5/28/2020
B1FC3B,business-contract,100,69,5/28/2020
B1FC3B,business-contract,100,69,5/28/2020
B290A2,clinical-trials-start,100,64,5/28/2020
B48FC9,conference-participant,100,50,5/28/2020
B4B281,earnings,100,50,5/28/2020
B4B281,earnings,100,50,5/28/2020
B4B281,earnings,100,50,5/28/2020
B7BBFF,executive-appointment,100,54,5/28/2020
B85DCE,board-meeting,100,51,5/28/2020
B8EF97,earnings,100,50,5/28/2020
BA0442,public-offering,100,43,5/28/2020
BB127B,earnings-up,100,68,5/28/2020
BB5271,partnership,100,61,5/28/2020
BB5271,partnership,100,61,5/28/2020
BC5680,product-release,100,64,5/28/2020
BCE9DA,legal-issues-defendant,100,22,5/28/2020
BDD12C,campaign-ad-release,100,59,5/28/2020
C3DE7D,earnings,100,50,5/28/2020
C50B26,note-sale,100,52,5/28/2020
C564E4,conference-participant,100,50,5/28/2020
C66A8C,public-offering,100,43,5/28/2020
C66A8C,public-offering,100,43,5/28/2020
C6C702,public-offering,100,43,5/28/2020
C74887,conference-participant,100,50,5/28/2020
C8257F,dividend,100,50,5/28/2020
C9D65C,settlement,100,56,5/28/2020
CC0C78,conference-participant,100,50,5/28/2020
CC6F6E,earnings,100,50,5/28/2020
CC6F6E,earnings,100,50,5/28/2020
CC6F6E,earnings,100,50,5/28/2020
CC8F6E,executive-appointment,100,54,5/28/2020
CDC817,conference-participant,100,50,5/28/2020
CE5C6E,public-offering,100,43,5/28/2020
CF7292,earnings,100,50,5/28/2020
D2C0B6,conference-participant,100,50,5/28/2020
D518D8,partnership,100,61,5/28/2020
D5AF19,partnership,100,61,5/28/2020
D5B13D,conference-participant,100,50,5/28/2020
D64C6D,conference-call,100,50,5/28/2020
D7918D,legal-issues-defendant,100,22,5/28/2020
D7918D,legal-issues-defendant,100,22,5/28/2020
DC2B00,earnings,100,50,5/28/2020
DD0F15,earnings,100,50,5/28/2020
DF18E6,clinical-trials,100,56,5/28/2020
E06265,legal-issues-defendant,100,22,5/28/2020
E114F4,earnings,100,50,5/28/2020
E3656D,conference-participant,100,50,5/28/2020
E4CE73,conference-participant,100,50,5/28/2020
E598FB,conference-participant,100,50,5/28/2020
E67C2C,conference-participant,100,50,5/28/2020
E6C8DC,conference-participant,100,50,5/28/2020
E8F0E2,conference-participant,100,50,5/28/2020
EB7D6C,legal-issues-defendant,100,22,5/28/2020
EE6F1C,business-contract,100,69,5/28/2020
EF45B6,dividend,100,50,5/28/2020
F05B1B,regulatory-product-approval-granted,100,81,5/28/2020
F11638,conference-participant,100,50,5/28/2020
F1529C,conference-participant,100,50,5/28/2020
F18844,executive-appointment,100,54,5/28/2020
F39E1E,legal-issues-defendant,100,22,5/28/2020
F40EE2,business-contract,100,69,5/28/2020
F40EE2,business-contract,100,69,5/28/2020
F43A11,legal-issues-defendant,100,22,5/28/2020
F47871,clinical-trials-positive,100,87,5/28/2020
F47871,clinical-trials-positive,100,87,5/28/2020
F47871,clinical-trials-positive,100,87,5/28/2020
F4E992,award,100,58,5/28/2020
F509E2,legal-issues-defendant,100,22,5/28/2020
F748C7,earnings,100,50,5/28/2020
F748C7,dividend,100,50,5/28/2020
F7902B,note-sale,100,52,5/28/2020
FA36A4,earnings,100,50,5/28/2020
FD2565,conference-participant,100,50,5/28/2020
FD554E,dividend,100,50,5/28/2020
FDE409,earnings,100,50,5/28/2020
FDF1C0,dividend,100,50,5/28/2020
FDF799,conference-participant,100,50,5/28/2020
FE89E0,ownership-decrease-owner,100,46,5/28/2020
FF227B,public-offering,100,43,5/28/2020
FF227B,conference-participant,100,50,5/28/2020
01D03F,partnership,100,61,5/29/2020
01D03F,regulatory-product-approval-granted,100,81,5/29/2020
01D03F,regulatory-product-approval-granted,100,81,5/29/2020
0BC853,note-sale,100,52,5/29/2020
0BD970,buybacks,100,74,5/29/2020
0BF528,conference-participant,100,50,5/29/2020
1080C0,clinical-trials,100,56,5/29/2020
12DE76,partnership,100,61,5/29/2020
14391F,stake-acquirer,100,48,5/29/2020
190B91,conference-participant,100,50,5/29/2020
1F716B,business-contract,100,69,5/29/2020
1FCC00,dividend,100,50,5/29/2020
1FCC00,earnings,100,50,5/29/2020
1FCC00,earnings,100,50,5/29/2020
1FCC00,earnings,100,50,5/29/2020
223552,business-contract,100,69,5/29/2020
251988,executive-scandal,100,38,5/29/2020
253B2F,dividend,100,50,5/29/2020
26D8ED,executive-appointment,100,54,5/29/2020
28F905,executive-appointment,100,54,5/29/2020
292388,note-sale,100,52,5/29/2020
2A9C0A,note-sale,100,52,5/29/2020
2B5483,conference-participant,100,50,5/29/2020
2C35B5,board-meeting,100,51,5/29/2020
36C09B,clinical-trials,100,56,5/29/2020
37B120,merger,100,66,5/29/2020
3AAEAE,clinical-trials,100,56,5/29/2020
3C7F5F,partnership,100,61,5/29/2020
431B74,executive-appointment,100,54,5/29/2020
431B74,executive-appointment,100,54,5/29/2020
448BF3,clinical-trials,100,56,5/29/2020
451D61,clinical-trials,100,56,5/29/2020
4649D5,earnings,100,50,5/29/2020
4BBA23,conference-participant,100,50,5/29/2020
57A854,conference-participant,100,50,5/29/2020
589803,public-offering,100,43,5/29/2020
59B229,executive-appointment,100,54,5/29/2020
5E1DF3,demand-increase,100,83,5/29/2020
5F9CE3,partnership,100,61,5/29/2020
649CBD,conference-organizer,100,57,5/29/2020
665618,conference-participant,100,50,5/29/2020
69C99E,clinical-trials,100,56,5/29/2020
717DB4,conference-participant,100,50,5/29/2020
726DDF,legal-issues-defendant,100,22,5/29/2020
732A9B,clinical-trials,100,56,5/29/2020
752A70,conference-participant,100,50,5/29/2020
76F067,product-release,100,64,5/29/2020
7C4F43,clinical-trials,100,56,5/29/2020
804708,dividend,100,50,5/29/2020
81F4BE,note-sale,100,52,5/29/2020
8377DB,conference-participant,100,50,5/29/2020
8AB37F,conference-participant,100,50,5/29/2020
8B1F37,public-offering,100,43,5/29/2020
8C5519,conference-participant,100,50,5/29/2020
905356,headquarters-change,100,50,5/29/2020
9196A2,conference-organizer,100,57,5/29/2020
9196A2,conference-organizer,100,57,5/29/2020
938D89,clinical-trials,100,56,5/29/2020
938D89,legal-issues-defendant,100,22,5/29/2020
94208D,acquisition-completed-acquirer,100,49,5/29/2020
94637C,business-contract,100,69,5/29/2020
966ACE,public-offering,100,43,5/29/2020
9981C6,dividend,100,50,5/29/2020
9B71A7,legal-issues-defendant,100,22,5/29/2020
9F5CBB,dividend,100,50,5/29/2020
A1BB98,dividend,100,50,5/29/2020
A2C979,conference-participant,100,50,5/29/2020
A37D68,earnings,100,50,5/29/2020
A398F8,conference-participant,100,50,5/29/2020
A5A4F5,legal-issues-defendant,100,22,5/29/2020
A631A3,conference-participant,100,50,5/29/2020
A70BF5,dividend,100,50,5/29/2020
A8E2FE,conference-participant,100,50,5/29/2020
A96867,dividend,100,50,5/29/2020
ABB493,conference-participant,100,50,5/29/2020
AC642C,conference-participant,100,50,5/29/2020
AC642C,conference-participant,100,50,5/29/2020
AD9F1D,legal-issues-defendant,100,22,5/29/2020
AD9F1D,legal-issues-defendant,100,22,5/29/2020
AE0CCE,conference-participant,100,50,5/29/2020
B5DE80,conference-participant,100,50,5/29/2020
BB127B,conference-participant,100,50,5/29/2020
BCC55F,conference-participant,100,50,5/29/2020
BFE02C,conference-participant,100,50,5/29/2020
C01737,conference-participant,100,50,5/29/2020
C3BAE7,conference-participant,100,50,5/29/2020
C624A1,conference-participant,100,50,5/29/2020
C9B932,partnership,100,61,5/29/2020
C9E04B,conference-call,100,50,5/29/2020
CA212F,dividend,100,50,5/29/2020
CBFFDD,conference-participant,100,50,5/29/2020
CEDFD5,business-contract,100,69,5/29/2020
D36B23,clinical-trials,100,56,5/29/2020
D437C3,conference-participant,100,50,5/29/2020
D63B0F,conference-participant,100,50,5/29/2020
D7918D,legal-issues-defendant,100,22,5/29/2020
D88EF3,partnership,100,61,5/29/2020
DE5611,dividend,100,50,5/29/2020
E20392,executive-appointment,100,54,5/29/2020
E68C3D,conference-participant,100,50,5/29/2020
E7BF32,clinical-trials,100,56,5/29/2020
E7BF32,clinical-trials,100,56,5/29/2020
E96E0B,conference-participant,100,50,5/29/2020
EB61C4,conference-participant,100,50,5/29/2020
EEB5F9,conference-participant,100,50,5/29/2020
EF77A3,executive-appointment,100,54,5/29/2020
F05B1B,conference-participant,100,50,5/29/2020
F509E2,legal-issues-defendant,100,22,5/29/2020
F509E2,legal-issues-defendant,100,22,5/29/2020
F7935D,clinical-trials,100,56,5/29/2020
FDD3FC,clinical-trials,100,56,5/29/2020
FDD3FC,clinical-trials,100,56,5/29/2020
FF227B,public-offering,100,43,5/29/2020
FF6644,conference-participant,100,50,5/29/2020
3B2311,conference-participant,100,50,5/30/2020
AD9F1D,executive-firing,100,36,5/30/2020
F30508,regulatory-product-approval-granted,100,81,5/30/2020
4C1FA1,legal-issues-defendant,100,22,5/31/2020
938D89,legal-issues-defendant,100,22,5/31/2020
9934AD,business-contract,100,69,5/31/2020
D7918D,legal-issues-defendant,100,22,5/31/2020
F509E2,legal-issues-defendant,100,22,5/31/2020
00067A,conference-participant,100,50,6/1/2020
43862,executive-appointment,100,54,6/1/2020
0490C6,conference-participant,100,50,6/1/2020
04EB2F,credit-extension-recipient,100,69,6/1/2020
091B6C,executive-appointment,100,54,6/1/2020
091B6C,executive-appointment,100,54,6/1/2020
091B6C,executive-appointment,100,54,6/1/2020
095A04,public-offering,100,43,6/1/2020
0B400D,earnings,100,50,6/1/2020
0BC853,partnership,100,61,6/1/2020
0C136E,business-contract,100,69,6/1/2020
0CE204,merger-completed,100,66,6/1/2020
0E439E,acquisition-completed-acquirer,100,49,6/1/2020
12F98C,executive-appointment,100,54,6/1/2020
15901B,fundraising,100,64,6/1/2020
159739,dividend,100,50,6/1/2020
159739,dividend,100,50,6/1/2020
159739,conference-call,100,50,6/1/2020
159739,conference-call,100,50,6/1/2020
159AE4,conference-participant,100,50,6/1/2020
1748F6,earnings,100,50,6/1/2020
1834C0,conference-participant,100,50,6/1/2020
1880C5,conference-participant,100,50,6/1/2020
1A6A94,conference-participant,100,50,6/1/2020
1AB808,executive-appointment,100,54,6/1/2020
1D9E55,conference-participant,100,50,6/1/2020
1EBF8D,regulatory-product-review-positive,100,73,6/1/2020
1FE7F0,conference-participant,100,50,6/1/2020
227F04,acquisition-acquirer,100,49,6/1/2020
227F04,acquisition-acquirer,100,49,6/1/2020
227F04,acquisition-acquirer,100,49,6/1/2020
251988,executive-appointment,100,54,6/1/2020
270B78,conference-participant,100,50,6/1/2020
279916,conference-participant,100,50,6/1/2020
27B191,earnings,100,50,6/1/2020
284289,executive-appointment,100,54,6/1/2020
28F905,executive-appointment,100,54,6/1/2020
2C3348,regulatory-product-approval-granted,100,81,6/1/2020
2F9304,conference-participant,100,50,6/1/2020
2F9304,note-sale,100,52,6/1/2020
31803E,conference-participant,100,50,6/1/2020
3461CF,conference-participant,100,50,6/1/2020
370C50,business-contract,100,69,6/1/2020
3AAEAE,conference-participant,100,50,6/1/2020
3ED92D,conference-participant,100,50,6/1/2020
3F4668,legal-issues-defendant,100,22,6/1/2020
416C55,conference-participant,100,50,6/1/2020
41ED98,executive-appointment,100,54,6/1/2020
4676DF,earnings,100,50,6/1/2020
4676DF,earnings,100,50,6/1/2020
4676DF,earnings,100,50,6/1/2020
4676DF,earnings,100,50,6/1/2020
4676DF,earnings,100,50,6/1/2020
4676DF,earnings,100,50,6/1/2020
4676DF,earnings,100,50,6/1/2020
4676DF,earnings,100,50,6/1/2020
4676DF,earnings,100,50,6/1/2020
467F2C,executive-appointment,100,54,6/1/2020
4.91E+58,executive-appointment,100,54,6/1/2020
494EB9,executive-appointment,100,54,6/1/2020
4C1FA1,legal-issues-defendant,100,22,6/1/2020
4C350A,executive-appointment,100,54,6/1/2020
4C92B9,executive-appointment,100,54,6/1/2020
4D8313,private-placement,100,56,6/1/2020
4E7C1F,executive-appointment,100,54,6/1/2020
50070E,conference-organizer,100,57,6/1/2020
50070E,conference-organizer,100,57,6/1/2020
50070E,conference-organizer,100,57,6/1/2020
50070E,conference-organizer,100,57,6/1/2020
514067,executive-resignation,100,44,6/1/2020
523039,patient-enrollment-complete,100,64,6/1/2020
53E575,earnings,100,50,6/1/2020
5.47E+28,conference-participant,100,50,6/1/2020
54A713,unit-acquisition-acquiree,100,76,6/1/2020
54DF47,dividend,100,50,6/1/2020
56EA2B,dividend,100,50,6/1/2020
589803,partnership,100,61,6/1/2020
58CA9A,conference-organizer,100,57,6/1/2020
5968F9,executive-appointment,100,54,6/1/2020
59F0B0,conference-participant,100,50,6/1/2020
5D1329,partnership,100,61,6/1/2020
5D1329,public-offering,100,43,6/1/2020
5EF130,earnings,100,50,6/1/2020
601785,conference-participant,100,50,6/1/2020
665D7D,partnership,100,61,6/1/2020
66A667,business-contract,100,69,6/1/2020
66A667,business-contract,100,69,6/1/2020
69CE71,conference-participant,100,50,6/1/2020
6B236C,public-offering,100,43,6/1/2020
6C6D73,conference-call,100,50,6/1/2020
6DBBBC,acquisition-acquirer,100,49,6/1/2020
6F0096,dividend,100,50,6/1/2020
726DDF,legal-issues-defendant,100,22,6/1/2020
729368,conference-participant,100,50,6/1/2020
72EF75,note-sale,100,52,6/1/2020
73F70F,conference-participant,100,50,6/1/2020
741937,facility-open,100,65,6/1/2020
765913,acquisition-completed-acquirer,100,49,6/1/2020
7.83E+79,merger-completed,100,66,6/1/2020
7999F3,conference-participant,100,50,6/1/2020
7B8CB5,conference-participant,100,50,6/1/2020
803FED,conference-participant,100,50,6/1/2020
81EAD4,executive-appointment,100,54,6/1/2020
8.40E+120,partnership,100,61,6/1/2020
855DF7,conference-participant,100,50,6/1/2020
873DB9,conference-participant,100,50,6/1/2020
8BAA15,conference-call,100,50,6/1/2020
8EDACA,conference-participant,100,50,6/1/2020
8EF425,dividend,100,50,6/1/2020
938D89,legal-issues-defendant,100,22,6/1/2020
94637C,campaign-ad-release,100,59,6/1/2020
9.74E+08,executive-appointment,100,54,6/1/2020
979451,conference-participant,100,50,6/1/2020
97FE80,board-meeting,100,51,6/1/2020
990AD0,conference-organizer,100,57,6/1/2020
99B61C,executive-appointment,100,54,6/1/2020
9B71A7,executive-appointment,100,54,6/1/2020
9BB35A,acquisition-completed-acquirer,100,49,6/1/2020
9D6A24,note-sale,100,52,6/1/2020
9F6B1A,clinical-trials-start,100,64,6/1/2020
9FF5F1,conference-participant,100,50,6/1/2020
A05C43,reverse-stock-splits,100,51,6/1/2020
A072C4,partnership,100,61,6/1/2020
A23747,conference-participant,100,50,6/1/2020
A29DBD,executive-appointment,100,54,6/1/2020
A63387,business-contract,100,69,6/1/2020
A72FD9,conference-call,100,50,6/1/2020
A80FE0,note-sale,100,52,6/1/2020
AC642C,note-sale,100,52,6/1/2020
AC642C,note-sale,100,52,6/1/2020
AC642C,conference-participant,100,50,6/1/2020
AC642C,conference-participant,100,50,6/1/2020
AD375D,conference-participant,100,50,6/1/2020
AE3113,conference-participant,100,50,6/1/2020
AED6CF,conference-participant,100,50,6/1/2020
B05000,executive-appointment,100,54,6/1/2020
B1FC3B,business-contract,100,69,6/1/2020
B2206F,conference-participant,100,50,6/1/2020
B3CB74,executive-appointment,100,54,6/1/2020
B7FA9B,conference-participant,100,50,6/1/2020
BA0442,conference-participant,100,50,6/1/2020
BB0587,conference-participant,100,50,6/1/2020
BBBB41,conference-participant,100,50,6/1/2020
BDEF34,dividend,100,50,6/1/2020
C0F70B,conference-participant,100,50,6/1/2020
C27E19,conference-participant,100,50,6/1/2020
C7859D,dividend,100,50,6/1/2020
C8FAC7,facility-sale,100,52,6/1/2020
C9D866,conference-participant,100,50,6/1/2020
CAB222,acquisition-completed-acquirer,100,49,6/1/2020
CD051C,conference-participant,100,50,6/1/2020
CE5C6E,public-offering,100,43,6/1/2020
D1C0B9,conference-participant,100,50,6/1/2020
D1CFC8,conference-participant,100,50,6/1/2020
D7918D,legal-issues-defendant,100,22,6/1/2020
DB88A1,earnings,100,50,6/1/2020
DB9F70,executive-appointment,100,54,6/1/2020
DC1405,conference-participant,100,50,6/1/2020
DF11D9,executive-appointment,100,54,6/1/2020
E1E093,partnership,100,61,6/1/2020
E20392,public-offering,100,43,6/1/2020
E28D9C,conference-participant,100,50,6/1/2020
E2F130,conference-participant,100,50,6/1/2020
E35610,conference-participant,100,50,6/1/2020
E4CE73,conference-participant,100,50,6/1/2020
E70531,executive-resignation,100,44,6/1/2020
E71AE6,clinical-trials,100,56,6/1/2020
E7BF32,conference-call,100,50,6/1/2020
E7BF32,conference-call,100,50,6/1/2020
EAEBF3,executive-appointment,100,54,6/1/2020
ECE814,conference-participant,100,50,6/1/2020
ED79D9,product-release,100,64,6/1/2020
ED79D9,note-sale,100,52,6/1/2020
ED79D9,note-sale,100,52,6/1/2020
F18844,legal-issues-defendant,100,22,6/1/2020
F18844,legal-issues-defendant,100,22,6/1/2020
F2BC3D,acquisition-acquirer,100,49,6/1/2020
F2BC3D,acquisition-acquirer,100,49,6/1/2020
F2BC3D,partnership,100,61,6/1/2020
F2BC3D,partnership,100,61,6/1/2020
F32F88,conference-participant,100,50,6/1/2020
F509E2,legal-issues-defendant,100,22,6/1/2020
F6E248,clinical-trials,100,56,6/1/2020
F6E248,clinical-trials,100,56,6/1/2020
FA36A4,conference-participant,100,50,6/1/2020
FAAFA2,public-offering,100,43,6/1/2020
0157B1,partnership,100,61,6/2/2020
01D03F,regulatory-product-approval-granted,100,81,6/2/2020
01D03F,regulatory-product-approval-granted,100,81,6/2/2020
03FAA6,acquisition-acquirer,100,49,6/2/2020
03FAA6,executive-appointment,100,54,6/2/2020
04EB2F,executive-appointment,100,54,6/2/2020
095A04,public-offering,100,43,6/2/2020
0A9D0A,conference-participant,100,50,6/2/2020
0C6293,conference-call,100,50,6/2/2020
0E5619,conference-participant,100,50,6/2/2020
139303,conference-organizer,100,57,6/2/2020
184988,merger,100,66,6/2/2020
1E68B3,public-offering,100,43,6/2/2020
1F716B,note-sale,100,52,6/2/2020
1FAF22,conference-participant,100,50,6/2/2020
228D42,partnership,100,61,6/2/2020
25AB8E,earnings,100,50,6/2/2020
26E3BA,conference-participant,100,50,6/2/2020
2AE625,conference-participant,100,50,6/2/2020
2CC71C,conference-participant,100,50,6/2/2020
2D981A,clinical-trials-positive,100,87,6/2/2020
2F98A5,executive-appointment,100,54,6/2/2020
32F943,partnership,100,61,6/2/2020
32F943,conference-participant,100,50,6/2/2020
3461CF,award,100,58,6/2/2020
36C09B,conference-participant,100,50,6/2/2020
37B120,conference-participant,100,50,6/2/2020
38C46F,dividend,100,50,6/2/2020
3B50FE,earnings,100,50,6/2/2020
3C6CCC,earnings,100,50,6/2/2020
3C6CCC,earnings,100,50,6/2/2020
3C6CCC,earnings,100,50,6/2/2020
3C6CCC,earnings,100,50,6/2/2020
3C6CCC,earnings,100,50,6/2/2020
3C7F5F,product-release,100,64,6/2/2020
3ED92D,executive-appointment,100,54,6/2/2020
4017AD,conference-participant,100,50,6/2/2020
41785E,executive-appointment,100,54,6/2/2020
427F32,dividend,100,50,6/2/2020
4398A2,regulatory-product-approval-granted,100,81,6/2/2020
43A74A,note-sale,100,52,6/2/2020
43A74A,note-sale,100,52,6/2/2020
449A26,executive-appointment,100,54,6/2/2020
44A4FC,executive-appointment,100,54,6/2/2020
4C1FA1,legal-issues-defendant,100,22,6/2/2020
4C2F17,partnership,100,61,6/2/2020
50070E,conference-organizer,100,57,6/2/2020
50070E,conference-organizer,100,57,6/2/2020
50070E,conference-organizer,100,57,6/2/2020
50070E,conference-organizer,100,57,6/2/2020
50070E,conference-organizer,100,57,6/2/2020
50070E,conference-organizer,100,57,6/2/2020
50070E,conference-organizer,100,57,6/2/2020
50070E,conference-organizer,100,57,6/2/2020
50070E,conference-organizer,100,57,6/2/2020
50070E,conference-organizer,100,57,6/2/2020
504FE2,award,100,58,6/2/2020
587D25,conference-participant,100,50,6/2/2020
5AF08A,expenses-guidance-down,100,61,6/2/2020
5BFE94,unit-acquisition-acquiree,100,76,6/2/2020
609208,conference-call,100,50,6/2/2020
639BD6,revenues,100,50,6/2/2020
64E346,conference-participant,100,50,6/2/2020
66A667,earnings,100,50,6/2/2020
66A667,earnings,100,50,6/2/2020
69FDFC,partnership,100,61,6/2/2020
6B236C,public-offering,100,43,6/2/2020
6F6559,award,100,58,6/2/2020
70CA28,executive-appointment,100,54,6/2/2020
71553E,conference-participant,100,50,6/2/2020
731675,revenues,100,50,6/2/2020
7.45E+28,conference-participant,100,50,6/2/2020
747219,asset-sale,100,62,6/2/2020
75768D,conference-call,100,50,6/2/2020
762A3E,executive-appointment,100,54,6/2/2020
773A17,business-contract,100,69,6/2/2020
7A2A49,earnings,100,50,6/2/2020
7C790D,conference-participant,100,50,6/2/2020
855DF7,note-sale,100,52,6/2/2020
8614A2,conference-participant,100,50,6/2/2020
890FF4,legal-issues-defendant,100,22,6/2/2020
89E771,earnings,100,50,6/2/2020
89F693,product-release,100,64,6/2/2020
8E82A6,conference-participant,100,50,6/2/2020
9196A2,conference-organizer,100,57,6/2/2020
91C82E,conference-call,100,50,6/2/2020
938D89,legal-issues-defendant,100,22,6/2/2020
938D89,legal-issues-defendant,100,22,6/2/2020
954004,earnings,100,50,6/2/2020
966ACE,public-offering,100,43,6/2/2020
9810C0,market-entry,100,57,6/2/2020
98CAED,executive-appointment,100,54,6/2/2020
9A02C4,partnership,100,61,6/2/2020
9A602D,conference-call,100,50,6/2/2020
9E0811,public-offering,100,43,6/2/2020
9E575E,conference-participant,100,50,6/2/2020
A1DBF0,conference-participant,100,50,6/2/2020
A49498,conference-participant,100,50,6/2/2020
A631A3,executive-appointment,100,54,6/2/2020
A631A3,product-release,100,64,6/2/2020
A631A3,conference-participant,100,50,6/2/2020
A63820,earnings,100,50,6/2/2020
A6FB29,earnings,100,50,6/2/2020
AC642C,conference-participant,100,50,6/2/2020
AC642C,conference-participant,100,50,6/2/2020
AECCA9,dividend,100,50,6/2/2020
AED61E,earnings,100,50,6/2/2020
B01111,earnings,100,50,6/2/2020
B37FB4,conference-participant,100,50,6/2/2020
BBF349,sponsorship,100,57,6/2/2020
BDE867,executive-appointment,100,54,6/2/2020
BF5959,executive-appointment,100,54,6/2/2020
C3CF29,investment-investor,100,55,6/2/2020
C425AE,conference-participant,100,50,6/2/2020
C6C702,conference-participant,100,50,6/2/2020
C83B88,executive-appointment,100,54,6/2/2020
C9E107,conference-participant,100,50,6/2/2020
C9E4EC,conference-participant,100,50,6/2/2020
CCB623,campaign-ad-release,100,59,6/2/2020
CDAF5B,dividend,100,50,6/2/2020
CDFCC9,earnings-guidance,100,50,6/2/2020
CE4FD9,conference-participant,100,50,6/2/2020
CFF97C,conference-participant,100,50,6/2/2020
CFF97C,conference-participant,100,50,6/2/2020
D0909F,dividend,100,50,6/2/2020
D7918D,legal-issues-defendant,100,22,6/2/2020
D81D54,trading-resumed,100,58,6/2/2020
DA48E4,conference-participant,100,50,6/2/2020
DBCA3F,partnership,100,61,6/2/2020
DC6EF3,public-offering,100,43,6/2/2020
DD7A96,conference-participant,100,50,6/2/2020
DE5611,earnings,100,50,6/2/2020
E0207A,conference-participant,100,50,6/2/2020
E30B34,executive-appointment,100,54,6/2/2020
E38906,public-offering,100,43,6/2/2020
E610CD,conference-participant,100,50,6/2/2020
E845D9,earnings,100,50,6/2/2020
EB1E1A,conference-participant,100,50,6/2/2020
F18844,legal-issues-defendant,100,22,6/2/2020
F1EB39,executive-appointment,100,54,6/2/2020
F43A11,conference-call,100,50,6/2/2020
FA40E2,earnings,100,50,6/2/2020
FAAFA2,public-offering,100,43,6/2/2020
FC1A6E,partnership,100,61,6/2/2020
FD6926,patient-enrollment-start,100,58,6/2/2020
FEE4B0,conference-participant,100,50,6/2/2020
FF227B,public-offering,100,43,6/2/2020
00326E,note-sale,100,52,6/3/2020
13528,executive-appointment,100,54,6/3/2020
0157B1,business-contract,100,69,6/3/2020
03B8CF,executive-appointment,100,54,6/3/2020
054E7E,conference-participant,100,50,6/3/2020
06A456,earnings,100,50,6/3/2020
06A456,earnings,100,50,6/3/2020
06A456,earnings,100,50,6/3/2020
06EE79,conference-participant,100,50,6/3/2020
75172,conference-participant,100,50,6/3/2020
0AAD90,patient-enrollment-complete,100,64,6/3/2020
0AAD90,patient-enrollment-complete,100,64,6/3/2020
0BD199,conference-participant,100,50,6/3/2020
0CC62B,merger-completed,100,66,6/3/2020
139303,conference-organizer,100,57,6/3/2020
143C9C,executive-appointment,100,54,6/3/2020
14BA06,dividend,100,50,6/3/2020
14BA33,dividend,100,50,6/3/2020
157D9F,earnings,100,50,6/3/2020
15A388,conference-participant,100,50,6/3/2020
168A5D,product-release,100,64,6/3/2020
190BE6,earnings,100,50,6/3/2020
1B6F77,conference-participant,100,50,6/3/2020
1D1B07,earnings,100,50,6/3/2020
1D1B07,earnings,100,50,6/3/2020
1D5C51,executive-appointment,100,54,6/3/2020
1DEBBE,award,100,58,6/3/2020
1E68B3,public-offering,100,43,6/3/2020
1FA886,business-contract,100,69,6/3/2020
1FA886,business-contract,100,69,6/3/2020
21153F,business-contract,100,69,6/3/2020
21245F,earnings,100,50,6/3/2020
253604,patient-enrollment-start,100,58,6/3/2020
267718,executive-appointment,100,54,6/3/2020
279916,earnings,100,50,6/3/2020
2A6DBE,conference-participant,100,50,6/3/2020
2B7A40,conference-participant,100,50,6/3/2020
2CC60C,earnings,100,50,6/3/2020
31553A,executive-appointment,100,54,6/3/2020
3461CF,credit-rating-confirmation-rater,20,50,6/3/2020
3461CF,product-release,100,64,6/3/2020
384CD3,conference-participant,100,50,6/3/2020
3A1C46,conference-participant,100,50,6/3/2020
3C3B6B,conference-participant,100,50,6/3/2020
416C55,dividend,100,50,6/3/2020
417BF9,partnership,100,61,6/3/2020
42978B,dividend,100,50,6/3/2020
42978B,dividend,100,50,6/3/2020
4591D3,stake-acquirer,100,48,6/3/2020
479930,conference-participant,100,50,6/3/2020
4A6F00,business-contract,100,69,6/3/2020
4A6F00,business-contract,100,69,6/3/2020
4BF3D6,conference-participant,100,50,6/3/2020
4C1FA1,legal-issues-defendant,100,22,6/3/2020
4CDA2B,conference-participant,100,50,6/3/2020
4D8124,executive-appointment,100,54,6/3/2020
4DD09F,conference-participant,100,50,6/3/2020
4EE167,legal-issues-defendant,100,22,6/3/2020
4EE167,legal-issues-defendant,100,22,6/3/2020
50070E,conference-organizer,100,57,6/3/2020
50070E,conference-organizer,100,57,6/3/2020
50070E,conference-organizer,100,57,6/3/2020
50070E,conference-organizer,100,57,6/3/2020
50070E,conference-organizer,100,57,6/3/2020
50070E,conference-organizer,100,57,6/3/2020
504FE2,conference-participant,100,50,6/3/2020
520632,partnership,100,61,6/3/2020
5225A4,conference-participant,100,50,6/3/2020
52BF94,conference-call,100,50,6/3/2020
53E575,conference-participant,100,50,6/3/2020
543900,earnings,100,50,6/3/2020
543900,earnings,100,50,6/3/2020
543900,earnings,100,50,6/3/2020
543900,earnings,100,50,6/3/2020
543900,earnings,100,50,6/3/2020
543900,earnings,100,50,6/3/2020
543900,earnings,100,50,6/3/2020
543900,earnings,100,50,6/3/2020
543900,earnings,100,50,6/3/2020
57CAAB,executive-appointment,100,54,6/3/2020
589846,conference-participant,100,50,6/3/2020
58CA9A,conference-participant,100,50,6/3/2020
59DB8C,public-offering,100,43,6/3/2020
5D1329,public-offering,100,43,6/3/2020
5D41E4,conference-participant,100,50,6/3/2020
5DE5A5,conference-participant,100,50,6/3/2020
60DD84,conference-participant,100,50,6/3/2020
61A586,executive-resignation,100,44,6/3/2020
636BBF,earnings,100,50,6/3/2020
665D7D,conference-participant,100,50,6/3/2020
68E3E0,revenues,100,50,6/3/2020
6A6BDC,partnership,100,61,6/3/2020
6CC55E,conference-participant,100,50,6/3/2020
6F3936,conference-call,100,50,6/3/2020
7122EB,ipo-pricing,100,50,6/3/2020
71694D,conference-participant,100,50,6/3/2020
73A213,conference-participant,100,50,6/3/2020
73A213,conference-participant,100,50,6/3/2020
787D14,executive-appointment,100,54,6/3/2020
7E1D5D,product-release,100,64,6/3/2020
7FC386,dividend-up,100,81,6/3/2020
826FD6,earnings,100,50,6/3/2020
82FD6D,conference-participant,100,50,6/3/2020
8377DB,legal-issues-defendant,100,22,6/3/2020
8377DB,legal-issues-defendant,100,22,6/3/2020
855DF7,note-sale,100,52,6/3/2020
8A8E41,earnings,100,50,6/3/2020
8B8656,earnings,100,50,6/3/2020
8BAA15,executive-appointment,100,54,6/3/2020
8D4486,business-contract,100,69,6/3/2020
8DBE73,legal-issues-defendant,100,22,6/3/2020
8DBE73,legal-issues-defendant,100,22,6/3/2020
8E9CD8,public-offering,100,43,6/3/2020
9196A2,conference-organizer,100,57,6/3/2020
9196A2,conference-organizer,100,57,6/3/2020
9196A2,conference-organizer,100,57,6/3/2020
9196A2,conference-organizer,100,57,6/3/2020
92D3A0,conference-participant,100,50,6/3/2020
934029,conference-participant,100,50,6/3/2020
947B0B,executive-appointment,100,54,6/3/2020
96B4FF,clinical-trials,100,56,6/3/2020
96B4FF,earnings,100,50,6/3/2020
971F7B,conference-participant,100,50,6/3/2020
990AD0,conference-organizer,100,57,6/3/2020
9.92E+94,dividend,100,50,6/3/2020
9A2760,conference-participant,100,50,6/3/2020
9A602D,business-contract,100,69,6/3/2020
9A602D,merger-completed,100,66,6/3/2020
9CA619,conference-call,100,50,6/3/2020
9E0811,public-offering,100,43,6/3/2020
9F5CBB,executive-appointment,100,54,6/3/2020
A1DBF0,executive-appointment,100,54,6/3/2020
A3800A,facility-open,100,65,6/3/2020
A631A3,partnership,100,61,6/3/2020
A6FC89,earnings,100,50,6/3/2020
A6FC89,earnings,100,50,6/3/2020
A6FC89,earnings,100,50,6/3/2020
A6FC89,earnings,100,50,6/3/2020
A868C9,business-contract,100,69,6/3/2020
AA3AB8,earnings,100,50,6/3/2020
ACF0B4,partnership,100,61,6/3/2020
AD23DE,partnership,100,61,6/3/2020
AD6141,conference-participant,100,50,6/3/2020
AECCA9,earnings,100,50,6/3/2020
AECCA9,earnings,100,50,6/3/2020
AECCA9,earnings,100,50,6/3/2020
AECCA9,earnings,100,50,6/3/2020
AECCA9,earnings,100,50,6/3/2020
AECCA9,earnings,100,50,6/3/2020
B09B1F,conference-participant,100,50,6/3/2020
B1FC3B,business-contract,100,69,6/3/2020
B1FC3B,dividend,100,50,6/3/2020
B3CB74,conference-organizer,100,57,6/3/2020
B508E5,conference-participant,100,50,6/3/2020
B66928,conference-participant,100,50,6/3/2020
B8EF97,revenues,100,50,6/3/2020
BA0442,partnership,100,61,6/3/2020
BD8517,conference-participant,100,50,6/3/2020
BDF85E,earnings,100,50,6/3/2020
BF5959,conference-participant,100,50,6/3/2020
BF5959,conference-participant,100,50,6/3/2020
C83B88,executive-appointment,100,54,6/3/2020
C8FAC7,partnership,100,61,6/3/2020
C9732E,patient-enrollment-start,100,58,6/3/2020
C9E04B,earnings,100,50,6/3/2020
CA212F,legal-issues-defendant,100,22,6/3/2020
CB89EA,conference-participant,100,50,6/3/2020
CBB77B,dividend,100,50,6/3/2020
CE2791,award,100,58,6/3/2020
CF7292,conference-participant,100,50,6/3/2020
D1C26F,partnership,100,61,6/3/2020
D27FAB,conference-call,100,50,6/3/2020
D33D8C,product-release,100,64,6/3/2020
D58A11,partnership,100,61,6/3/2020
D58A11,conference-participant,100,50,6/3/2020
D88EF3,acquisition-acquirer,100,49,6/3/2020
DC1405,product-release,100,64,6/3/2020
DCD97F,dividend,100,50,6/3/2020
DD1BA1,conference-organizer,100,57,6/3/2020
DF204B,earnings,100,50,6/3/2020
E09556,earnings,100,50,6/3/2020
E09E2B,product-release,100,64,6/3/2020
E20392,public-offering,100,43,6/3/2020
E30A8F,partnership,100,61,6/3/2020
E3A829,conference-participant,100,50,6/3/2020
E8846E,conference-participant,100,50,6/3/2020
F0B877,note-sale,100,52,6/3/2020
F0B877,note-sale,100,52,6/3/2020
F179ED,partnership,100,61,6/3/2020
F4FBD8,executive-appointment,100,54,6/3/2020
FD6926,conference-participant,100,50,6/3/2020
0157B1,partnership,100,61,6/4/2020
02FC1A,clinical-trials,100,56,6/4/2020
070B45,conference-participant,100,50,6/4/2020
09DE1F,earnings,100,50,6/4/2020
0B73A7,earnings,100,50,6/4/2020
0B73A7,earnings,100,50,6/4/2020
0CCCB7,partnership,100,61,6/4/2020
152E1D,conference-participant,100,50,6/4/2020
1AD9CC,earnings,100,50,6/4/2020
1B4F31,executive-appointment,100,54,6/4/2020
1E1125,conference-organizer,100,57,6/4/2020
1E68B3,note-sale,100,52,6/4/2020
205AD5,investment-investor,100,55,6/4/2020
228D42,partnership,100,61,6/4/2020
241AF7,dividend,100,50,6/4/2020
250BEE,award,100,58,6/4/2020
26DC29,earnings,100,50,6/4/2020
275300,note-sale,100,52,6/4/2020
275300,note-sale,100,52,6/4/2020
279916,business-contract,100,69,6/4/2020
2CF9D3,conference-participant,100,50,6/4/2020
2D981A,public-offering,100,43,6/4/2020
2E89AE,executive-appointment,100,54,6/4/2020
2F98A5,earnings,100,50,6/4/2020
306623,partnership,100,61,6/4/2020
3159AA,facility-open,100,65,6/4/2020
367E1C,conference-participant,100,50,6/4/2020
384CD3,conference-participant,100,50,6/4/2020
3A1C46,supply-guidance-increase,100,74,6/4/2020
3A1C46,supply-guidance-increase,100,74,6/4/2020
3F4668,legal-issues-defendant,100,22,6/4/2020
3F4668,legal-issues-defendant,100,22,6/4/2020
4A5C8D,executive-appointment,100,54,6/4/2020
4A6F00,partnership,100,61,6/4/2020
4AC91D,partnership,100,61,6/4/2020
4AC91D,partnership,100,61,6/4/2020
4C1FA1,legal-issues-defendant,100,22,6/4/2020
4EE167,legal-issues-defendant,100,22,6/4/2020
4EE167,legal-issues-defendant,100,22,6/4/2020
50070E,conference-organizer,100,57,6/4/2020
50070E,conference-organizer,100,57,6/4/2020
50070E,conference-organizer,100,57,6/4/2020
50070E,conference-organizer,100,57,6/4/2020
50070E,conference-organizer,100,57,6/4/2020
50070E,conference-organizer,100,57,6/4/2020
50070E,conference-organizer,100,57,6/4/2020
52B567,earnings,100,50,6/4/2020
548AC0,asset-sale,100,62,6/4/2020
55438C,partnership,100,61,6/4/2020
589846,product-release,100,64,6/4/2020
59872F,executive-appointment,100,54,6/4/2020
5B6C11,dividend,100,50,6/4/2020
6391C2,executive-appointment,100,54,6/4/2020
65D0AA,legal-issues-defendant,100,22,6/4/2020
6830FE,earnings,100,50,6/4/2020
69C99E,conference-participant,100,50,6/4/2020
6AACDD,fundraising,100,64,6/4/2020
6D156D,executive-appointment,100,54,6/4/2020
6F0096,stake-acquirer,100,48,6/4/2020
7239BB,earnings,100,50,6/4/2020
73529F,executive-resignation,100,44,6/4/2020
73F70F,earnings,100,50,6/4/2020
747219,conference-participant,100,50,6/4/2020
756BB4,earnings,100,50,6/4/2020
7A0EC4,earnings,100,50,6/4/2020
7ADE57,conference-call,100,50,6/4/2020
7ADE57,partnership,100,61,6/4/2020
7B9212,revenues,100,50,6/4/2020
7CBC40,award,100,58,6/4/2020
7DD584,conference-participant,100,50,6/4/2020
7FEEE1,conference-participant,100,50,6/4/2020
817ED9,earnings,100,50,6/4/2020
817ED9,earnings,100,50,6/4/2020
817ED9,earnings,100,50,6/4/2020
817ED9,earnings,100,50,6/4/2020
8377DB,legal-issues-defendant,100,22,6/4/2020
863350,earnings,100,50,6/4/2020
86BAC7,board-meeting,100,51,6/4/2020
8A8E41,dividend,100,50,6/4/2020
8BAA15,dividend,100,50,6/4/2020
8D4486,partnership,100,61,6/4/2020
8D4486,partnership,100,61,6/4/2020
8D4486,partnership,100,61,6/4/2020
8D4486,partnership,100,61,6/4/2020
8D4486,partnership,100,61,6/4/2020
8D4486,partnership,100,61,6/4/2020
8D4486,partnership,100,61,6/4/2020
8DBE73,legal-issues-defendant,100,22,6/4/2020
8DBE73,legal-issues-defendant,100,22,6/4/2020
902670,partnership,100,61,6/4/2020
9196A2,conference-organizer,100,57,6/4/2020
9196A2,conference-organizer,100,57,6/4/2020
923D93,executive-appointment,100,54,6/4/2020
923D93,executive-appointment,100,54,6/4/2020
94637C,conference-participant,100,50,6/4/2020
95DC1F,conference-call,100,50,6/4/2020
95F59E,conference-participant,100,50,6/4/2020
972356,revenue-guidance,100,50,6/4/2020
9.82E+06,reorganization-unit,100,53,6/4/2020
9.82E+06,earnings,100,50,6/4/2020
986AF6,dividend,100,50,6/4/2020
9B71A7,legal-issues-defendant,100,22,6/4/2020
9BBFA5,conference-call,100,50,6/4/2020
9CDA4F,conference-participant,100,50,6/4/2020
9E575E,conference-participant,100,50,6/4/2020
A37D68,earnings,100,50,6/4/2020
A52B6B,note-sale,100,52,6/4/2020
A666C8,conference-participant,100,50,6/4/2020
A6828A,business-contract,100,69,6/4/2020
A6FB29,earnings,100,50,6/4/2020
A761FE,conference-call,100,50,6/4/2020
A8AC4C,conference-participant,100,50,6/4/2020
A8B137,business-contract,100,69,6/4/2020
AC7C4F,business-contract,100,69,6/4/2020
AD22F2,earnings,100,50,6/4/2020
AD22F2,earnings,100,50,6/4/2020
AD22F2,earnings,100,50,6/4/2020
AD22F2,earnings,100,50,6/4/2020
AD9F1D,partnership,100,61,6/4/2020
AD9F1D,legal-issues-defendant,100,22,6/4/2020
AD9F1D,product-release,100,64,6/4/2020
ADD9DC,earnings,100,50,6/4/2020
AE7D16,partnership,100,61,6/4/2020
B05118,donation,100,54,6/4/2020
B290A2,conference-participant,100,50,6/4/2020
B33E77,partnership,100,61,6/4/2020
B7FA9B,conference-participant,100,50,6/4/2020
B8F71F,executive-appointment,100,54,6/4/2020
BB127B,board-meeting,100,51,6/4/2020
C5F463,partnership,100,61,6/4/2020
C83B88,conference-participant,100,50,6/4/2020
C9739A,executive-appointment,100,54,6/4/2020
C9881C,conference-call,100,50,6/4/2020
CA212F,legal-issues-defendant,100,22,6/4/2020
CFF97C,conference-participant,100,50,6/4/2020
D1588D,executive-appointment,100,54,6/4/2020
D1C26F,product-release,100,64,6/4/2020
D33D8C,acquisition-completed-acquirer,100,49,6/4/2020
D33D8C,merger-regulatory-approval,100,81,6/4/2020
D33D8C,acquisition-regulatory-approval-acquirer,100,54,6/4/2020
D42DBA,earnings,100,50,6/4/2020
DA48E4,executive-appointment,100,54,6/4/2020
DB06B0,product-release,100,64,6/4/2020
DB9829,earnings,100,50,6/4/2020
DE5611,conference-participant,100,50,6/4/2020
DF18E6,conference-participant,100,50,6/4/2020
E22FDE,private-placement,100,56,6/4/2020
E68C3D,conference-participant,100,50,6/4/2020
E9C7C0,conference-participant,100,50,6/4/2020
EE04F0,executive-appointment,100,54,6/4/2020
F0B335,product-release,100,64,6/4/2020
F1EB39,conference-participant,100,50,6/4/2020
F4D241,conference-participant,100,50,6/4/2020
F66B58,earnings,100,50,6/4/2020
F92DBC,partnership,100,61,6/4/2020
FC4550,dividend,100,50,6/4/2020
FC8733,revenue-up,100,91,6/4/2020
FC8733,revenue-up,100,91,6/4/2020
FC8733,revenue-up,100,91,6/4/2020
FC8733,revenue-up,100,91,6/4/2020
001F1B,revenues,100,50,6/5/2020
16C544,dividend,100,50,6/5/2020
1EBF8D,regulatory-product-approval-granted,100,81,6/5/2020
1EBF8D,regulatory-product-approval-granted,100,81,6/5/2020
1F19C8,executive-appointment,100,54,6/5/2020
20BEEA,note-sale,100,52,6/5/2020
21D903,legal-issues-defendant,100,22,6/5/2020
26CC63,earnings,100,50,6/5/2020
2BA977,donation,100,54,6/5/2020
2C681C,government-contract,100,69,6/5/2020
2C681C,government-contract,100,69,6/5/2020
30CBF9,partnership,100,61,6/5/2020
31F25C,merger-completed,100,66,6/5/2020
3BBD10,conference-participant,100,50,6/5/2020
3F4668,legal-issues-defendant,100,22,6/5/2020
442587,conference-organizer,100,57,6/5/2020
4A6F00,product-release,100,64,6/5/2020
4B3555,note-sale,100,52,6/5/2020
4C1FA1,legal-issues-defendant,100,22,6/5/2020
4EE167,legal-issues-defendant,100,22,6/5/2020
4EE167,legal-issues-defendant,100,22,6/5/2020
50070E,conference-organizer,100,57,6/5/2020
50070E,conference-organizer,100,57,6/5/2020
50070E,conference-organizer,100,57,6/5/2020
50070E,conference-organizer,100,57,6/5/2020
5.43E+08,orphan-drug-designation,100,76,6/5/2020
594402,legal-issues-plaintiff,100,44,6/5/2020
59872F,conference-participant,100,50,6/5/2020
5CCDAD,conference-participant,100,50,6/5/2020
5D1329,public-offering,100,43,6/5/2020
636931,merger-completed,100,66,6/5/2020
6D0CAB,conference-participant,100,50,6/5/2020
7122EB,ipo-completed,100,76,6/5/2020
726DDF,legal-issues-defendant,100,22,6/5/2020
726DDF,legal-issues-defendant,100,22,6/5/2020
7448A3,conference-participant,100,50,6/5/2020
769F40,earnings,100,50,6/5/2020
76F067,conference-participant,100,50,6/5/2020
834152,fundraising,100,64,6/5/2020
8377DB,legal-issues-defendant,100,22,6/5/2020
8.79E+06,unit-acquisition-acquirer,100,49,6/5/2020
89E771,executive-resignation,100,44,6/5/2020
925759,conference-participant,100,50,6/5/2020
9978F1,conference-participant,100,50,6/5/2020
9B71A7,legal-issues-defendant,100,22,6/5/2020
9F5997,conference-participant,100,50,6/5/2020
A5A4F5,transportation-disruption,100,36,6/5/2020
A5A4F5,transportation-disruption,100,36,6/5/2020
AA7FE0,conference-call,100,50,6/5/2020
AA98ED,conference-participant,100,50,6/5/2020
AE79CD,legal-issues-defendant,100,22,6/5/2020
B7FA9B,note-sale,100,52,6/5/2020
BDF2BD,conference-participant,100,50,6/5/2020
C50B26,merger-regulatory-approval,100,81,6/5/2020
CA1620,dividend,100,50,6/5/2020
CF351E,dividend,100,50,6/5/2020
D1C26F,earnings,100,50,6/5/2020
DA48E4,conference-participant,100,50,6/5/2020
DB88A1,award,100,58,6/5/2020
DCD97F,unit-acquisition-acquiree,100,76,6/5/2020
DDB002,conference-participant,100,50,6/5/2020
E8846E,legal-issues-defendant,100,22,6/5/2020
E8846E,legal-issues-defendant,100,22,6/5/2020
FE7A63,dividend,100,50,6/5/2020
FF6644,legal-issues-defendant,100,22,6/5/2020
0B400D,legal-issues-defendant,100,22,6/6/2020
0BD4E8,legal-issues-defendant,100,22,6/6/2020
21D903,legal-issues-defendant,100,22,6/6/2020
25A6CC,legal-issues-defendant,100,22,6/6/2020
4.00E+163,legal-issues-defendant,100,22,6/6/2020
665D7D,product-release,100,64,6/6/2020
665D7D,product-release,100,64,6/6/2020
665D7D,product-release,100,64,6/6/2020
6F39FC,dividend,100,50,6/6/2020
726DDF,legal-issues-defendant,100,22,6/6/2020
979451,legal-issues-defendant,100,22,6/6/2020
CDFCC9,legal-issues-defendant,100,22,6/6/2020
2C7505,clinical-trials-positive,100,87,6/7/2020
2C7505,clinical-trials-positive,100,87,6/7/2020
2C7505,clinical-trials-positive,100,87,6/7/2020
3F4668,legal-issues-defendant,100,22,6/7/2020
4EE167,legal-issues-defendant,100,22,6/7/2020
8377DB,legal-issues-defendant,100,22,6/7/2020
002A99,patient-enrollment-start,100,58,6/8/2020
002A99,product-release,100,64,6/8/2020
002A99,product-release,100,64,6/8/2020
0157B1,partnership,100,61,6/8/2020
036C6F,dividend,100,50,6/8/2020
040DBB,dividend,100,50,6/8/2020
078D52,public-offering,100,43,6/8/2020
95294,executive-appointment,100,54,6/8/2020
0BF528,note-sale,100,52,6/8/2020
0BF528,private-placement,100,56,6/8/2020
0C466B,conference-participant,100,50,6/8/2020
0F04E5,conference-participant,100,50,6/8/2020
1201B5,index-listing,100,76,6/8/2020
12F98C,earnings,100,50,6/8/2020
143C52,partnership,100,61,6/8/2020
184866,conference-participant,100,50,6/8/2020
1B9535,executive-appointment,100,54,6/8/2020
1E83DE,earnings,100,50,6/8/2020
1FCC00,partnership,100,61,6/8/2020
228D42,partnership,100,61,6/8/2020
2667B6,dividend,100,50,6/8/2020
267718,partnership,100,61,6/8/2020
267718,partnership,100,61,6/8/2020
26DC29,conference-participant,100,50,6/8/2020
26E3BA,clinical-trials-filed,100,60,6/8/2020
2BC05E,conference-participant,100,50,6/8/2020
30AB63,note-sale,100,52,6/8/2020
356B21,legal-issues-defendant,100,22,6/8/2020
356B21,legal-issues-defendant,100,22,6/8/2020
356B21,legal-issues-defendant,100,22,6/8/2020
36529A,conference-participant,100,50,6/8/2020
367434,conference-call,100,50,6/8/2020
367E1C,clinical-trials-positive,100,87,6/8/2020
3B318A,earnings,100,50,6/8/2020
3EE65E,executive-appointment,100,54,6/8/2020
3F4668,legal-issues-defendant,100,22,6/8/2020
416C55,partnership,100,61,6/8/2020
451D61,orphan-drug-designation,100,76,6/8/2020
4A6F00,partnership,100,61,6/8/2020
4A6F00,legal-issues-defendant,100,22,6/8/2020
4C6C63,partnership,100,61,6/8/2020
4C6C63,note-sale,100,52,6/8/2020
4E6F5A,executive-appointment,100,54,6/8/2020
4EE167,legal-issues-defendant,100,22,6/8/2020
4F71DC,earnings,100,50,6/8/2020
50070E,conference-organizer,100,57,6/8/2020
50702E,earnings,100,50,6/8/2020
54B889,conference-participant,100,50,6/8/2020
587D25,executive-appointment,100,54,6/8/2020
59DB8C,public-offering,100,43,6/8/2020
5B226B,merger-failed,100,21,6/8/2020
5D1956,index-listing,100,76,6/8/2020
5E6959,public-offering,100,43,6/8/2020
64854A,regulatory-product-approval-granted,100,81,6/8/2020
64E615,conference-participant,100,50,6/8/2020
673C9A,index-listing,100,76,6/8/2020
6C6D73,conference-call,100,50,6/8/2020
6D9B53,conference-participant,100,50,6/8/2020
701531,public-offering,100,43,6/8/2020
722D55,conference-participant,100,50,6/8/2020
72CB93,executive-appointment,100,54,6/8/2020
76D79A,public-offering,100,43,6/8/2020
790C34,shareholder-rights-plan,100,43,6/8/2020
7AF907,clinical-trials,100,56,6/8/2020
7BFF81,partnership,100,61,6/8/2020
819492,clinical-trials-start,100,64,6/8/2020
82E58A,partnership,100,61,6/8/2020
8377DB,legal-issues-defendant,100,22,6/8/2020
8BAA15,executive-appointment,100,54,6/8/2020
8D4486,partnership,100,61,6/8/2020
9196A2,conference-organizer,100,57,6/8/2020
95C392,partnership,100,61,6/8/2020
96B4FF,public-offering,100,43,6/8/2020
972356,note-sale,100,52,6/8/2020
97644E,partnership,100,61,6/8/2020
990AD0,conference-organizer,100,57,6/8/2020
9.97E+09,executive-appointment,100,54,6/8/2020
9B71A7,legal-issues-defendant,100,22,6/8/2020
A204A7,conference-participant,100,50,6/8/2020
A4BCDE,executive-appointment,100,54,6/8/2020
AADE0B,unit-acquisition-acquirer,100,49,6/8/2020
ADD9DC,conference-participant,100,50,6/8/2020
B0D41A,public-offering,100,43,6/8/2020
B3CB74,conference-organizer,100,57,6/8/2020
B5766D,credit-extension-provider,100,57,6/8/2020
B762D3,earnings,100,50,6/8/2020
B762D3,earnings,100,50,6/8/2020
B762D3,earnings,100,50,6/8/2020
B9BDE8,index-listing,100,76,6/8/2020
BCC55F,executive-appointment,100,54,6/8/2020
BCC55F,executive-appointment,100,54,6/8/2020
BCC55F,partnership,100,61,6/8/2020
BE379D,rights-issue,100,43,6/8/2020
C03C8B,conference-participant,100,50,6/8/2020
C4A912,partnership,100,61,6/8/2020
C83B88,partnership,100,61,6/8/2020
CC6FF5,executive-appointment,100,54,6/8/2020
CCB623,regulatory-product-approval-granted,100,81,6/8/2020
CCBBAD,index-listing,100,76,6/8/2020
CE4E6D,product-release,100,64,6/8/2020
D064D5,earnings,100,50,6/8/2020
D139BC,public-offering,100,43,6/8/2020
D296C6,dividend,100,50,6/8/2020
D437C3,partnership,100,61,6/8/2020
D48275,conference-participant,100,50,6/8/2020
D622D5,dividend,100,50,6/8/2020
D622D5,operating-earnings,100,50,6/8/2020
DC1405,executive-appointment,100,54,6/8/2020
DE4924,note-sale,100,52,6/8/2020
E09556,earnings,100,50,6/8/2020
E19A99,note-sale,100,52,6/8/2020
E1E093,business-contract,100,69,6/8/2020
E21871,acquisition-acquiree,100,76,6/8/2020
E2CFD2,conference-participant,100,50,6/8/2020
E8846E,legal-issues-defendant,100,22,6/8/2020
E8846E,legal-issues-defendant,100,22,6/8/2020
E8A49A,business-contract,100,69,6/8/2020
E8A49A,business-contract,100,69,6/8/2020
EAA0A7,conference-participant,100,50,6/8/2020
ECF4F8,conference-participant,100,50,6/8/2020
EEB5F9,executive-appointment,100,54,6/8/2020
F05B1B,public-offering,100,43,6/8/2020
F0B335,conference-participant,100,50,6/8/2020
F1529C,product-release,100,64,6/8/2020
F30508,clinical-trials-start,100,64,6/8/2020
F3FCC3,earnings-guidance,100,50,6/8/2020
F3FCC3,earnings-guidance,100,50,6/8/2020
F4E882,partnership,100,61,6/8/2020
F569FD,public-offering,100,43,6/8/2020
F5D499,index-listing,100,76,6/8/2020
FAAFA2,board-meeting,100,51,6/8/2020
FDF799,board-meeting,100,51,6/8/2020
0358AF,dividend,100,50,6/9/2020
054B55,dividend,100,50,6/9/2020
0BA2EF,earnings,100,50,6/9/2020
0BA2EF,earnings,100,50,6/9/2020
0D03C8,index-listing,100,76,6/9/2020
0E5619,regulatory-product-approval-granted,100,81,6/9/2020
0FDE97,note-sale,100,52,6/9/2020
11074E,public-offering,100,43,6/9/2020
112694,clinical-trials,100,56,6/9/2020
138DDE,earnings,100,50,6/9/2020
152B9E,executive-resignation,100,44,6/9/2020
152FA5,product-release,100,64,6/9/2020
17EDA5,partnership,100,61,6/9/2020
196D18,product-release,100,64,6/9/2020
1AE482,executive-appointment,100,54,6/9/2020
1EBF8D,partnership,100,61,6/9/2020
1F08A6,dividend,100,50,6/9/2020
200D8B,award,100,58,6/9/2020
228D42,partnership,100,61,6/9/2020
26008A,dividend,100,50,6/9/2020
26DC29,executive-appointment,100,54,6/9/2020
2C3348,clinical-trials-positive,100,87,6/9/2020
2E902B,conference-participant,100,50,6/9/2020
2EBC0B,dividend,100,50,6/9/2020
315EB0,note-sale,100,52,6/9/2020
32DCB3,clinical-trials,100,56,6/9/2020
33E9D5,earnings,100,50,6/9/2020
36C09B,conference-participant,100,50,6/9/2020
382EAE,executive-appointment,100,54,6/9/2020
3A3948,public-offering,100,43,6/9/2020
3B2311,conference-participant,100,50,6/9/2020
3F4668,legal-issues-defendant,100,22,6/9/2020
3F6A9C,executive-appointment,100,54,6/9/2020
40F7DE,earnings,100,50,6/9/2020
41B0E2,legal-issues-defendant,100,22,6/9/2020
43A060,business-contract,100,69,6/9/2020
458D2C,revenue-volume,100,50,6/9/2020
490D4B,executive-resignation,100,44,6/9/2020
4A2457,executive-appointment,100,54,6/9/2020
4A6F00,campaign-ad-release,100,59,6/9/2020
4AC91D,note-sale,100,52,6/9/2020
4AC91D,note-sale,100,52,6/9/2020
50070E,conference-organizer,100,57,6/9/2020
50070E,conference-organizer,100,57,6/9/2020
50070E,investment-investor,100,55,6/9/2020
587D25,executive-appointment,100,54,6/9/2020
59DB8C,partnership,100,61,6/9/2020
5B51D6,executive-appointment,100,54,6/9/2020
5DD486,facility-open,100,65,6/9/2020
5E9934,earnings-up,100,68,6/9/2020
5EAA43,business-contract,100,69,6/9/2020
5F9CE3,partnership,100,61,6/9/2020
64636E,public-offering,100,43,6/9/2020
65CF8E,award,100,58,6/9/2020
701531,public-offering,100,43,6/9/2020
76D79A,public-offering,100,43,6/9/2020
7A0EC4,partnership,100,61,6/9/2020
7A2A49,partnership,100,61,6/9/2020
7BC92D,business-contract,100,69,6/9/2020
7CD98F,executive-appointment,100,54,6/9/2020
7E3F8F,note-sale,100,52,6/9/2020
8.10E+32,donation,100,54,6/9/2020
859D62,earnings,100,50,6/9/2020
859D62,earnings,100,50,6/9/2020
859D62,earnings,100,50,6/9/2020
859D62,earnings,100,50,6/9/2020
859D62,earnings,100,50,6/9/2020
859D62,earnings,100,50,6/9/2020
895D56,partnership,100,61,6/9/2020
8F8F2F,conference-participant,100,50,6/9/2020
9196A2,conference-organizer,100,57,6/9/2020
9.31E+77,unit-acquisition-completed-acquirer,100,49,6/9/2020
93965C,acquisition-acquirer,100,49,6/9/2020
94208D,revenues,100,50,6/9/2020
94637C,partnership,100,61,6/9/2020
950CDB,dividend-up,100,81,6/9/2020
957A07,legal-issues-defendant,100,22,6/9/2020
957A07,legal-issues-defendant,100,22,6/9/2020
957A07,legal-issues-defendant,100,22,6/9/2020
96A2D3,public-offering,100,43,6/9/2020
96B4FF,public-offering,100,43,6/9/2020
98CEBB,product-release,100,64,6/9/2020
9B71A7,legal-issues-defendant,100,22,6/9/2020
A11CF4,patent-awarded,100,72,6/9/2020
A1E3B3,product-release,100,64,6/9/2020
A1E3B3,product-release,100,64,6/9/2020
A26C26,earnings,100,50,6/9/2020
A3230E,executive-appointment,100,54,6/9/2020
A3800A,earnings,100,50,6/9/2020
A4B899,note-sale,100,52,6/9/2020
A4B899,note-sale,100,52,6/9/2020
A65325,executive-appointment,100,54,6/9/2020
A761FE,earnings,100,50,6/9/2020
A868C9,revenue-up,100,68,6/9/2020
A868C9,revenue-up,100,68,6/9/2020
A868C9,revenue-up,100,68,6/9/2020
A868C9,revenue-up,100,68,6/9/2020
A8E2FE,conference-participant,100,50,6/9/2020
ADF092,partnership,100,61,6/9/2020
ADF092,partnership,100,61,6/9/2020
B0D41A,public-offering,100,43,6/9/2020
B2206F,executive-appointment,100,54,6/9/2020
B614F8,index-listing,100,76,6/9/2020
B98EFA,business-contract,100,69,6/9/2020
B9C913,government-contract,100,69,6/9/2020
BE14CF,conference-participant,100,50,6/9/2020
C83B88,partnership,100,61,6/9/2020
CB6A9C,partnership,100,61,6/9/2020
CBA475,index-listing,100,76,6/9/2020
CC339B,dividend,100,50,6/9/2020
CC35BE,partnership,100,61,6/9/2020
CEC08B,partnership,100,61,6/9/2020
CF211D,earnings,100,50,6/9/2020
CF7292,conference-participant,100,50,6/9/2020
D139BC,public-offering,100,43,6/9/2020
D1C0B9,partnership,100,61,6/9/2020
D3CEDF,conference-participant,100,50,6/9/2020
D42DBA,earnings,100,50,6/9/2020
D42DBA,earnings,100,50,6/9/2020
D42DBA,earnings,100,50,6/9/2020
D42DBA,earnings,100,50,6/9/2020
D54E62,partnership,100,61,6/9/2020
D57D99,product-release,100,64,6/9/2020
D77F7E,executive-appointment,100,54,6/9/2020
D77F7E,executive-appointment,100,54,6/9/2020
D9E036,note-sale,100,52,6/9/2020
D9E036,note-sale,100,52,6/9/2020
DB23C8,note-sale,100,52,6/9/2020
DB23C8,conference-participant,100,50,6/9/2020
DB88A1,earnings,100,50,6/9/2020
DB88A1,earnings,100,50,6/9/2020
DB88A1,earnings,100,50,6/9/2020
DB88A1,earnings,100,50,6/9/2020
DB88A1,earnings,100,50,6/9/2020
DB88A1,earnings,100,50,6/9/2020
DB88A1,earnings,100,50,6/9/2020
DB88A1,earnings,100,50,6/9/2020
DB88A1,earnings,100,50,6/9/2020
DD7A96,dividend,100,50,6/9/2020
DD9E41,conference-participant,100,50,6/9/2020
E0207A,conference-participant,100,50,6/9/2020
E0207A,legal-issues-defendant,100,22,6/9/2020
E19A99,note-sale,100,52,6/9/2020
E19A99,conference-participant,100,50,6/9/2020
E72599,public-offering,100,43,6/9/2020
E8846E,legal-issues-defendant,100,22,6/9/2020
ECA300,earnings,100,50,6/9/2020
EDD234,earnings,100,50,6/9/2020
F1EB39,earnings,100,50,6/9/2020
F43A11,earnings,100,50,6/9/2020
F47871,clinical-trials-start,100,64,6/9/2020
F48947,regulatory-product-approval-granted,100,81,6/9/2020
F569FD,public-offering,100,43,6/9/2020
F5D499,fundraising,100,64,6/9/2020
FB7724,executive-resignation,100,44,6/9/2020
FD2565,patient-enrollment-complete,100,64,6/9/2020
FD9A97,dividend,100,50,6/9/2020
FDF799,public-offering,100,43,6/9/2020
FE89E0,conference-call,100,50,6/9/2020
FEBFE1,earnings,100,50,6/9/2020
099C88,award,100,58,6/10/2020
0A77DB,product-release,100,64,6/10/2020
0B4D10,dividend,100,50,6/10/2020
0B7375,public-offering,100,43,6/10/2020
0BF528,note-sale,100,52,6/10/2020
0C6293,earnings,100,50,6/10/2020
0C6293,earnings,100,50,6/10/2020
0C6293,earnings,100,50,6/10/2020
0FC848,partnership,100,61,6/10/2020
0FDE97,note-sale,100,52,6/10/2020
0FDE97,public-offering,100,43,6/10/2020
11074E,public-offering,100,43,6/10/2020
12DE76,dividend,100,50,6/10/2020
14391F,public-offering,100,43,6/10/2020
149301,dividend,100,50,6/10/2020
154272,executive-appointment,100,54,6/10/2020
16F4D8,conference-participant,100,50,6/10/2020
1748F6,earnings,100,50,6/10/2020
182BE7,insider-sell,100,40,6/10/2020
1866B2,acquisition-acquirer,100,49,6/10/2020
1866B2,acquisition-acquirer,100,49,6/10/2020
1D3A00,earnings,100,50,6/10/2020
1D3A00,earnings,100,50,6/10/2020
1D3A00,earnings,100,50,6/10/2020
1D3A00,earnings,100,50,6/10/2020
1E1125,conference-organizer,100,57,6/10/2020
1E1125,conference-organizer,100,57,6/10/2020
1EBF8D,partnership,100,61,6/10/2020
2262BD,executive-appointment,100,54,6/10/2020
25AB8E,reverse-stock-splits,100,51,6/10/2020
2667B6,executive-appointment,100,54,6/10/2020
292A70,earnings,100,50,6/10/2020
2C7505,clinical-trials,100,56,6/10/2020
2CD1E0,donation,100,54,6/10/2020
2F9304,conference-participant,100,50,6/10/2020
328250,note-sale,100,52,6/10/2020
356B21,legal-issues-defendant,100,22,6/10/2020
356B21,legal-issues-defendant,100,22,6/10/2020
37B618,dividend,100,50,6/10/2020
3A3948,public-offering,100,43,6/10/2020
3D7971,dividend,100,50,6/10/2020
3FACA7,earnings,100,50,6/10/2020
40F7DE,conference-participant,100,50,6/10/2020
416C55,conference-participant,100,50,6/10/2020
44A4FC,partnership,100,61,6/10/2020
44A4FC,public-offering,100,43,6/10/2020
49A344,award,100,58,6/10/2020
4A6F00,partnership,100,61,6/10/2020
4AC91D,note-sale,100,52,6/10/2020
4AC91D,note-sale,100,52,6/10/2020
4AC91D,fundraising,100,64,6/10/2020
4AC91D,fundraising,100,64,6/10/2020
4AE584,public-offering,100,43,6/10/2020
4B49CF,earnings,100,50,6/10/2020
4C2F17,partnership,100,61,6/10/2020
50070E,conference-organizer,100,57,6/10/2020
52BF94,conference-participant,100,50,6/10/2020
57DDB9,conference-participant,100,50,6/10/2020
5B6C11,executive-appointment,100,54,6/10/2020
5DE5A5,conference-participant,100,50,6/10/2020
5E6959,dividend,100,50,6/10/2020
619882,conference-organizer,100,57,6/10/2020
619882,conference-organizer,100,57,6/10/2020
619882,conference-organizer,100,57,6/10/2020
657097,unit-acquisition-acquirer,100,49,6/10/2020
665D7D,partnership,100,61,6/10/2020
665D7D,partnership,100,61,6/10/2020
665D7D,partnership,100,61,6/10/2020
665D7D,clinical-trials,100,56,6/10/2020
67529E,conference-participant,100,50,6/10/2020
6A01DF,executive-resignation,100,44,6/10/2020
6DBBBC,partnership,100,61,6/10/2020
6F3936,earnings,100,50,6/10/2020
6F3936,earnings,100,50,6/10/2020
6F3936,earnings,100,50,6/10/2020
6F3936,earnings,100,50,6/10/2020
6F3936,earnings,100,50,6/10/2020
6F92A9,buybacks,100,74,6/10/2020
726DDF,legal-issues-defendant,100,22,6/10/2020
72FCA3,earnings,100,50,6/10/2020
765913,note-sale,100,52,6/10/2020
767F86,dividend,100,50,6/10/2020
775439,earnings,100,50,6/10/2020
775439,note-sale,100,52,6/10/2020
7823A3,partnership,100,61,6/10/2020
7823A3,note-sale,100,52,6/10/2020
7A10FF,conference-participant,100,50,6/10/2020
7A975D,earnings,100,50,6/10/2020
7E1D5D,acquisition-acquirer,100,49,6/10/2020
7E3F8F,note-sale,100,52,6/10/2020
855DF7,earnings,100,50,6/10/2020
855DF7,earnings,100,50,6/10/2020
8614A2,public-offering,100,43,6/10/2020
8665BA,business-contract,100,69,6/10/2020
88923D,partnership,100,61,6/10/2020
89E771,earnings,100,50,6/10/2020
8AC740,dividend,100,50,6/10/2020
8DA42F,note-sale,100,52,6/10/2020
900356,business-contract-terminated,100,31,6/10/2020
957A07,legal-issues-defendant,100,22,6/10/2020
957A07,legal-issues-defendant,100,22,6/10/2020
957A07,legal-issues-defendant,100,22,6/10/2020
99B61C,conference-participant,100,50,6/10/2020
9B71A7,legal-issues-defendant,100,22,6/10/2020
9B71A7,legal-issues-defendant,100,22,6/10/2020
9B71A7,earnings,100,50,6/10/2020
9B730A,conference-participant,100,50,6/10/2020
9FA83B,conference-participant,100,50,6/10/2020
A01983,dividend,100,50,6/10/2020
A3AAA5,dividend,100,50,6/10/2020
A6213D,business-contract,100,69,6/10/2020
A6213D,business-contract,100,69,6/10/2020
A631A3,partnership,100,61,6/10/2020
A6828A,clinical-trials,100,56,6/10/2020
A6D095,fundraising,100,64,6/10/2020
A790A5,conference-call,100,50,6/10/2020
A79D88,index-listing,100,76,6/10/2020
A7A0C8,private-placement,100,56,6/10/2020
AE4EEB,dividend,100,50,6/10/2020
B1FC3B,business-contract,100,69,6/10/2020
B290A2,conference-call,100,50,6/10/2020
B3CB74,conference-organizer,100,57,6/10/2020
B508E5,product-release,100,64,6/10/2020
B5734D,conference-call,100,50,6/10/2020
B642E8,partnership,100,61,6/10/2020
B9CD50,product-release,100,64,6/10/2020
BB88B6,award,100,58,6/10/2020
BDCC11,note-sale,100,52,6/10/2020
BE379D,rights-issue,100,43,6/10/2020
BE645B,public-offering,100,43,6/10/2020
C062D4,product-release,100,64,6/10/2020
C07E05,earnings,100,50,6/10/2020
C48574,index-listing,100,76,6/10/2020
C54140,partnership,100,61,6/10/2020
C5F463,facility-open,100,65,6/10/2020
C66B44,partnership,100,61,6/10/2020
C83B88,facility-open,100,65,6/10/2020
CAB222,product-release,100,64,6/10/2020
CD4DA8,conference-organizer,100,57,6/10/2020
CDD75E,executive-appointment,100,54,6/10/2020
CFF97C,credit-rating-confirmation-rater,20,50,6/10/2020
D1CFC8,conference-call,100,50,6/10/2020
D4AC65,product-release,100,64,6/10/2020
D90F43,partnership,100,61,6/10/2020
E06265,fraud-defendant,100,20,6/10/2020
E124EB,business-contract,100,69,6/10/2020
E20392,fundraising,100,64,6/10/2020
E20392,fundraising,100,64,6/10/2020
E3656D,public-offering,100,43,6/10/2020
E72599,public-offering,100,43,6/10/2020
E8846E,legal-issues-defendant,100,22,6/10/2020
E8846E,legal-issues-defendant,100,22,6/10/2020
ED22DC,executive-appointment,100,54,6/10/2020
EEB5F9,conference-participant,100,50,6/10/2020
EF1AD9,executive-appointment,100,54,6/10/2020
F1529C,buybacks,100,74,6/10/2020
F43A11,legal-issues-defendant,100,22,6/10/2020
F5A214,note-sale,100,52,6/10/2020
FC1A6E,note-sale,100,52,6/10/2020
FC1A6E,note-sale,100,52,6/10/2020
FC1B7B,executive-appointment,100,54,6/10/2020
FD4BBE,conference-participant,100,50,6/10/2020
FD9A97,earnings,100,50,6/10/2020
FF6644,product-release,100,64,6/10/2020
FF6644,partnership,100,61,6/10/2020
9397,product-release,100,64,6/11/2020
31025,executive-appointment,100,54,6/11/2020
03FAA6,partnership,100,61,6/11/2020
48590,executive-appointment,100,54,6/11/2020
75172,conference-participant,100,50,6/11/2020
09F623,public-offering,100,43,6/11/2020
09F623,public-offering,100,43,6/11/2020
0B7375,public-offering,100,43,6/11/2020
0BD4E8,dividend,100,50,6/11/2020
0C28D1,business-contract,100,69,6/11/2020
0C28D1,business-contract,100,69,6/11/2020
0F2BC9,business-contract,100,69,6/11/2020
106394,dividend,100,50,6/11/2020
11074E,conference-participant,100,50,6/11/2020
14391F,public-offering,100,43,6/11/2020
1748F6,conference-participant,100,50,6/11/2020
1921DD,product-release,100,64,6/11/2020
1DF15D,dividend,100,50,6/11/2020
1F43A1,dividend-up,100,81,6/11/2020
214051,earnings,100,50,6/11/2020
214051,earnings,100,50,6/11/2020
2158DF,partnership,100,61,6/11/2020
274B8A,conference-call,100,50,6/11/2020
29B702,dividend,100,50,6/11/2020
2A1009,business-contract,100,69,6/11/2020
2ABF77,conference-participant,100,50,6/11/2020
2BAE5F,public-offering,100,43,6/11/2020
2BAE5F,public-offering,100,43,6/11/2020
2FDEE3,business-contract,100,69,6/11/2020
31AA84,award,100,58,6/11/2020
3390DE,conference-participant,100,50,6/11/2020
33E9D5,conference-participant,100,50,6/11/2020
367434,executive-appointment,100,54,6/11/2020
3.73E+87,conference-participant,100,50,6/11/2020
397A8F,earnings,100,50,6/11/2020
39FB23,award,100,58,6/11/2020
3B318A,conference-participant,100,50,6/11/2020
3C7F5F,executive-appointment,100,54,6/11/2020
3C7F5F,product-release,100,64,6/11/2020
3CCC90,product-release,100,64,6/11/2020
414FFF,earnings,100,50,6/11/2020
414FFF,earnings,100,50,6/11/2020
414FFF,earnings,100,50,6/11/2020
414FFF,earnings,100,50,6/11/2020
414FFF,earnings,100,50,6/11/2020
414FFF,earnings,100,50,6/11/2020
414FFF,earnings,100,50,6/11/2020
414FFF,earnings,100,50,6/11/2020
42EFC7,patient-enrollment-start,100,58,6/11/2020
44A4FC,public-offering,100,43,6/11/2020
468DD4,conference-participant,100,50,6/11/2020
49BBBC,donation,100,54,6/11/2020
4A6F00,partnership,100,61,6/11/2020
4AE584,index-listing,100,76,6/11/2020
4D8313,dividend,100,50,6/11/2020
5065B1,dividend,100,50,6/11/2020
56277A,dividend,100,50,6/11/2020
57DDB9,conference-participant,100,50,6/11/2020
589803,clinical-trials-start,100,64,6/11/2020
589803,clinical-trials-start,100,64,6/11/2020
619882,partnership,100,61,6/11/2020
619882,partnership,100,61,6/11/2020
619882,conference-organizer,100,57,6/11/2020
61B81B,conference-call,100,50,6/11/2020
620381,partnership,100,61,6/11/2020
63F892,conference-participant,100,50,6/11/2020
641F17,earnings,100,50,6/11/2020
67529E,executive-appointment,100,54,6/11/2020
693ECD,conference-participant,100,50,6/11/2020
698FF9,public-offering,100,43,6/11/2020
69CE71,facility-open,100,65,6/11/2020
6D9ECA,clinical-trials-start,100,64,6/11/2020
6-Dec-05,conference-participant,100,50,6/11/2020
6EE648,business-contract,100,69,6/11/2020
6EE648,business-contract,100,69,6/11/2020
6EE648,business-contract,100,69,6/11/2020
70CA28,business-contract,100,69,6/11/2020
70FCEF,executive-appointment,100,54,6/11/2020
732A9B,executive-appointment,100,54,6/11/2020
7732C2,executive-appointment,100,54,6/11/2020
7ACFD4,executive-appointment,100,54,6/11/2020
7ADE57,earnings,100,50,6/11/2020
7BFF81,conference-participant,100,50,6/11/2020
7E3F8F,note-sale,100,52,6/11/2020
834152,conference-participant,100,50,6/11/2020
859D62,partnership,100,61,6/11/2020
85DE00,partnership,100,61,6/11/2020
8614A2,public-offering,100,43,6/11/2020
8665BA,partnership,100,61,6/11/2020
896771,facility-open,100,65,6/11/2020
8B1F37,dividend-up,100,81,6/11/2020
8DA42F,note-sale,100,52,6/11/2020
8E10BF,patient-enrollment-start,100,58,6/11/2020
92005C,conference-participant,100,50,6/11/2020
942633,dividend,100,50,6/11/2020
944B2E,executive-appointment,100,54,6/11/2020
94637C,dividend,100,50,6/11/2020
96A2D3,public-offering,100,43,6/11/2020
97693A,earnings,100,50,6/11/2020
990AD0,dividend,100,50,6/11/2020
9B4066,facility-sale,100,52,6/11/2020
9B71A7,legal-issues-defendant,100,22,6/11/2020
9C5BA5,revenues,100,50,6/11/2020
9DDE1B,dividend,100,50,6/11/2020
A05C43,merger-completed,100,66,6/11/2020
A05C43,merger-completed,100,66,6/11/2020
A4BCDE,dividend,100,50,6/11/2020
A72FD9,earnings,100,50,6/11/2020
AD9F1D,legal-issues-defendant,100,22,6/11/2020
B0D41A,public-offering,100,43,6/11/2020
B0FE08,executive-appointment,100,54,6/11/2020
B3CB74,conference-organizer,100,57,6/11/2020
B3CB74,conference-organizer,100,57,6/11/2020
B3CB74,conference-organizer,100,57,6/11/2020
B3CB74,conference-organizer,100,57,6/11/2020
B3CB74,conference-organizer,100,57,6/11/2020
B3CB74,conference-organizer,100,57,6/11/2020
B3CB74,conference-organizer,100,57,6/11/2020
B3CB74,conference-organizer,100,57,6/11/2020
B3CB74,conference-organizer,100,57,6/11/2020
B3CB74,conference-organizer,100,57,6/11/2020
B3CB74,conference-organizer,100,57,6/11/2020
B3CB74,conference-organizer,100,57,6/11/2020
B3CB74,conference-organizer,100,57,6/11/2020
B614F8,index-listing,100,76,6/11/2020
B642E8,dividend,100,50,6/11/2020
BC5680,business-combination,100,54,6/11/2020
BC5680,acquisition-regulatory-scrutiny-acquiree,100,38,6/11/2020
BDCC11,note-sale,100,52,6/11/2020
BDF85E,earnings,100,50,6/11/2020
BE645B,public-offering,100,43,6/11/2020
C2609A,business-contract,100,69,6/11/2020
C36189,conference-participant,100,50,6/11/2020
C9881C,revenue-up,100,69,6/11/2020
C9881C,revenue-up,100,69,6/11/2020
C9881C,revenue-up,100,69,6/11/2020
C9F39B,executive-appointment,100,54,6/11/2020
CA1620,conference-participant,100,50,6/11/2020
CA1620,executive-appointment,100,54,6/11/2020
CFF57D,conference-call,100,50,6/11/2020
D0909F,conference-participant,100,50,6/11/2020
D139BC,public-offering,100,43,6/11/2020
D6853F,acquisition-acquiree,100,76,6/11/2020
D88EF3,investment-investor,100,55,6/11/2020
DAFED3,supply-increase,100,74,6/11/2020
DB5CA5,investment-investor,100,55,6/11/2020
DDEA6A,conference-participant,100,50,6/11/2020
E0207A,legal-issues-defendant,100,22,6/11/2020
E26FC3,executive-resignation,100,44,6/11/2020
E28D9C,executive-appointment,100,54,6/11/2020
E3656D,public-offering,100,43,6/11/2020
E8846E,conference-organizer,100,57,6/11/2020
E8846E,conference-organizer,100,57,6/11/2020
EA4E68,dividend,100,50,6/11/2020
EB6965,dividend,100,50,6/11/2020
F05B1B,public-offering,100,43,6/11/2020
F1529C,conference-call,100,50,6/11/2020
F6DCE4,dividend-up,100,53,6/11/2020
F6DCE4,earnings,100,50,6/11/2020
FDD3FC,conference-participant,100,50,6/11/2020
FDF799,public-offering,100,43,6/11/2020
FF6644,partnership,100,61,6/11/2020
00E601,earnings,100,50,6/12/2020
01D03F,acquisition-acquirer,100,49,6/12/2020
71860,partnership,100,61,6/12/2020
0AAD90,clinical-trials,100,56,6/12/2020
0AAD90,clinical-trials-positive,100,87,6/12/2020
0E5619,conference-participant,100,50,6/12/2020
0FABBD,conference-participant,100,50,6/12/2020
112694,clinical-trials,100,56,6/12/2020
1E1125,conference-organizer,100,57,6/12/2020
1EBF8D,regulatory-product-approval-granted,100,81,6/12/2020
1EBF8D,regulatory-product-approval-granted,100,81,6/12/2020
228D42,partnership,100,61,6/12/2020
2.90E+62,note-sale,100,52,6/12/2020
2AA6A8,clinical-trials,100,56,6/12/2020
2D2D43,earnings,100,50,6/12/2020
2F1299,partnership,100,61,6/12/2020
2F960F,dividend,100,50,6/12/2020
356B21,legal-issues-defendant,100,22,6/12/2020
367434,clinical-trials-positive,100,87,6/12/2020
38FB49,dividend,100,50,6/12/2020
3BB7D3,ipo-pricing,100,50,6/12/2020
3BB7D3,ipo-pricing,100,50,6/12/2020
3DDE54,earnings,100,50,6/12/2020
42978B,earnings,100,50,6/12/2020
451D61,business-contract,100,69,6/12/2020
468DD4,conference-participant,100,50,6/12/2020
50070E,price-target-upgrade-rater,20,50,6/12/2020
520632,dividend,100,50,6/12/2020
54DF47,dividend,100,50,6/12/2020
5C7601,dividend,100,50,6/12/2020
6A6BDC,earnings,100,50,6/12/2020
6D3B7B,dividend,100,50,6/12/2020
71B0CF,executive-appointment,100,54,6/12/2020
726DDF,conference-participant,100,50,6/12/2020
728737,dividend,100,50,6/12/2020
728737,dividend,100,50,6/12/2020
7.44E+09,note-sale,100,52,6/12/2020
7823A3,note-sale,100,52,6/12/2020
7A5097,dividend,100,50,6/12/2020
7B0BA6,executive-appointment,100,54,6/12/2020
826FD6,dividend,100,50,6/12/2020
838ADD,credit-extension-recipient,100,69,6/12/2020
918D6D,clinical-trials-positive,100,87,6/12/2020
918D6D,clinical-trials-positive,100,87,6/12/2020
918D6D,clinical-trials-positive,100,87,6/12/2020
94208D,executive-appointment,100,54,6/12/2020
9B71A7,legal-issues-defendant,100,22,6/12/2020
9B71A7,legal-issues-defendant,100,22,6/12/2020
9D30A8,index-listing,100,76,6/12/2020
9D5FA4,index-listing,100,76,6/12/2020
A80FE0,conference-participant,100,50,6/12/2020
B01111,dividend,100,50,6/12/2020
B1B10C,conference-call,100,50,6/12/2020
B3CB74,conference-organizer,100,57,6/12/2020
B3CB74,conference-organizer,100,57,6/12/2020
B5734D,earnings,100,50,6/12/2020
B762D3,dividend,100,50,6/12/2020
B8F71F,dividend-up,100,81,6/12/2020
BD9668,note-sale,100,52,6/12/2020
BFF98A,ipo-pricing,100,50,6/12/2020
D42DBA,executive-appointment,100,54,6/12/2020
D76AEF,conference-participant,100,50,6/12/2020
D9E036,note-sale,100,52,6/12/2020
DA9443,conference-participant,100,50,6/12/2020
DD1BA1,conference-participant,100,50,6/12/2020
E1C16B,executive-appointment,100,54,6/12/2020
E8846E,legal-issues-defendant,100,22,6/12/2020
E8846E,legal-issues-defendant,100,22,6/12/2020
E8846E,conference-organizer,100,57,6/12/2020
EF7163,dividend,100,50,6/12/2020
EF77A3,earnings,100,50,6/12/2020
F0027C,clinical-trials,100,56,6/12/2020
F294DD,dividend,100,50,6/12/2020
F30508,partnership,100,61,6/12/2020
F30508,product-release,100,64,6/12/2020
F5D410,earnings-up,100,68,6/12/2020
F5D499,revenue-up,100,60,6/12/2020
F6E248,regulatory-product-approval-granted,100,81,6/12/2020
586BD7,clinical-trials,100,56,6/13/2020
622DBE,settlement,100,56,6/13/2020
65D0AA,legal-issues-defendant,100,22,6/13/2020
7A0EC4,index-listing,100,76,6/13/2020
E8846E,legal-issues-defendant,100,22,6/13/2020
F6E248,business-contract,100,69,6/13/2020
9B71A7,legal-issues-defendant,100,22,6/14/2020
00067A,product-release,100,64,6/15/2020
00067A,conference-participant,100,50,6/15/2020
01D03F,executive-appointment,100,54,6/15/2020
03596A,executive-appointment,100,54,6/15/2020
03596A,executive-appointment,100,54,6/15/2020
03B8CF,revenues,100,50,6/15/2020
06EE79,executive-appointment,100,54,6/15/2020
091B6C,clinical-trials,100,56,6/15/2020
091B6C,clinical-trials,100,56,6/15/2020
099C88,government-contract,100,69,6/15/2020
0B7375,public-offering,100,43,6/15/2020
0CC01F,dividend,100,50,6/15/2020
106394,business-contract,100,69,6/15/2020
106394,public-offering,100,43,6/15/2020
131443,executive-appointment,100,54,6/15/2020
1348C9,executive-appointment,100,54,6/15/2020
1921DD,executive-appointment,100,54,6/15/2020
1E83DE,executive-appointment,100,54,6/15/2020
20D00A,business-contract,100,69,6/15/2020
228D42,partnership,100,61,6/15/2020
228D42,partnership,100,61,6/15/2020
251988,partnership,100,61,6/15/2020
25D3CE,conference-participant,100,50,6/15/2020
2A6DBE,executive-appointment,100,54,6/15/2020
2C681C,private-placement,100,56,6/15/2020
2C681C,fundraising,100,64,6/15/2020
30DE64,clinical-trials-positive,100,87,6/15/2020
32DCB3,clinical-trials-positive,100,87,6/15/2020
34A959,public-offering,100,43,6/15/2020
34A959,business-contract,100,69,6/15/2020
34A959,business-contract,100,69,6/15/2020
367E1C,conference-participant,100,50,6/15/2020
385DD4,note-sale,100,52,6/15/2020
385DD4,note-sale,100,52,6/15/2020
3C7F5F,executive-appointment,100,54,6/15/2020
3C7F5F,executive-appointment,100,54,6/15/2020
40F7DE,earnings,100,50,6/15/2020
448215,dividend,100,50,6/15/2020
448BF3,executive-appointment,100,54,6/15/2020
44A4FC,business-contract,100,69,6/15/2020
4A6F00,partnership,100,61,6/15/2020
4C5CC9,acquisition-completed-acquirer,100,49,6/15/2020
50070E,partnership,100,61,6/15/2020
50702E,patient-enrollment-start,100,58,6/15/2020
50702E,patient-enrollment-start,100,58,6/15/2020
546A9C,earnings,100,50,6/15/2020
54F1D2,executive-appointment,100,54,6/15/2020
55ACCB,partnership,100,61,6/15/2020
564F3E,facility-open,100,65,6/15/2020
5675EB,dividend,100,50,6/15/2020
5704AC,dividend,100,50,6/15/2020
5D41E4,award,100,58,6/15/2020
5DD486,conference-call,100,50,6/15/2020
5F3D91,public-offering,100,43,6/15/2020
619882,partnership,100,61,6/15/2020
619882,conference-organizer,100,57,6/15/2020
619882,dividend,100,50,6/15/2020
619882,conference-organizer,100,57,6/15/2020
619882,conference-organizer,100,57,6/15/2020
620381,partnership,100,61,6/15/2020
657097,dividend,100,50,6/15/2020
66ECFD,earnings,100,50,6/15/2020
6844D2,dividend,100,50,6/15/2020
68AB62,executive-appointment,100,54,6/15/2020
6CF43C,dividend,100,50,6/15/2020
6DDA15,executive-appointment,100,54,6/15/2020
6F0A63,business-contract,100,69,6/15/2020
6FCEF9,dividend,100,50,6/15/2020
75D689,clinical-trials-positive,100,87,6/15/2020
7DD8CC,dividend,100,50,6/15/2020
7F3A5F,executive-appointment,100,54,6/15/2020
82C202,partnership,100,61,6/15/2020
83A065,dividend,100,50,6/15/2020
8.40E+120,clinical-trials,100,56,6/15/2020
85AD00,merger-completed,100,66,6/15/2020
85AD00,conference-call,100,50,6/15/2020
877734,conference-call,100,50,6/15/2020
8AA108,clinical-trials,100,56,6/15/2020
8C84DF,executive-appointment,100,54,6/15/2020
8D0EEA,executive-appointment,100,54,6/15/2020
8D4486,unit-acquisition-acquirer,100,49,6/15/2020
8DA42F,note-sale,100,52,6/15/2020
8DBBE6,product-release,100,64,6/15/2020
9196A2,dividend,100,50,6/15/2020
91C82E,earnings,100,50,6/15/2020
91C82E,earnings-per-share-positive,100,69,6/15/2020
91C82E,earnings-per-share-positive,100,69,6/15/2020
91C82E,earnings-per-share-positive,100,69,6/15/2020
91C82E,earnings-per-share-positive,100,69,6/15/2020
9.36E+10,fundraising,100,64,6/15/2020
94C0B5,conference-call,100,50,6/15/2020
966ACE,executive-appointment,100,54,6/15/2020
990AD0,conference-organizer,100,57,6/15/2020
9B71A7,legal-issues-defendant,100,22,6/15/2020
9D2790,product-release,100,64,6/15/2020
A4BCDE,executive-appointment,100,54,6/15/2020
A52533,facility-open,100,65,6/15/2020
A9ED24,dividend,100,50,6/15/2020
AA1EAA,dividend,100,50,6/15/2020
AC642C,note-sale,100,52,6/15/2020
AC642C,note-sale,100,52,6/15/2020
AC7C4F,earnings,100,50,6/15/2020
AD9F1D,legal-issues-defendant,100,22,6/15/2020
B3CB74,conference-organizer,100,57,6/15/2020
B3CB74,conference-organizer,100,57,6/15/2020
BC5680,legal-issues-defendant,100,22,6/15/2020
C83B88,executive-appointment,100,54,6/15/2020
CAC8D0,earnings,100,50,6/15/2020
CC6FF5,partnership,100,61,6/15/2020
CD06A2,merger-regulatory-approval,100,81,6/15/2020
CE5C6E,executive-appointment,100,54,6/15/2020
D139BC,dividend,100,50,6/15/2020
D15833,unit-acquisition-acquirer,100,49,6/15/2020
D15833,unit-acquisition-acquirer,100,49,6/15/2020
D15833,acquisition-acquirer,100,49,6/15/2020
D1AE3B,conference-call,100,50,6/15/2020
D3FA2C,dividend,100,50,6/15/2020
D63B0F,dividend,100,50,6/15/2020
D65A13,executive-appointment,100,54,6/15/2020
D69D42,executive-appointment,100,54,6/15/2020
D77F7E,business-contract,100,69,6/15/2020
D8C09D,bankruptcy,100,7,6/15/2020
D8ECA1,executive-appointment,100,54,6/15/2020
D9B1C9,executive-appointment,100,54,6/15/2020
DA9443,clinical-trials,100,56,6/15/2020
DA9443,executive-appointment,100,54,6/15/2020
DB2E4E,conference-participant,100,50,6/15/2020
DC5299,dividend,100,50,6/15/2020
DF5F14,dividend,100,50,6/15/2020
E0339F,legal-verdict-disfavored,100,22,6/15/2020
E3E68E,stock-gain,100,63,6/15/2020
E3E68E,stock-gain,100,63,6/15/2020
E8846E,legal-issues-defendant,100,22,6/15/2020
ECD263,earnings,100,50,6/15/2020
ED1A74,partnership,100,61,6/15/2020
ED7F13,dividend,100,50,6/15/2020
EEB5F9,public-offering,100,43,6/15/2020
EEEA9F,executive-appointment,100,54,6/15/2020
F0EEFB,conference-call,100,50,6/15/2020
F1C04C,conference-participant,100,50,6/15/2020
F30508,clinical-trials-start,100,64,6/15/2020
F30508,clinical-trials-start,100,64,6/15/2020
F3816D,conference-participant,100,50,6/15/2020
F6581D,credit-extension-recipient,100,69,6/15/2020
F6581D,credit-extension-recipient,100,69,6/15/2020
F6581D,conference-participant,100,50,6/15/2020
F80389,dividend,100,50,6/15/2020
FDF799,public-offering,100,43,6/15/2020
00326D,dividend,100,50,6/16/2020
0142B5,business-contract,100,69,6/16/2020
01D03F,partnership,100,61,6/16/2020
02ACBD,conference-participant,100,50,6/16/2020
054B55,earnings,100,50,6/16/2020
0A59F8,partnership,100,61,6/16/2020
0A77DB,index-listing,100,76,6/16/2020
0A9D0A,public-offering,100,43,6/16/2020
0C2A0D,note-sale,100,52,6/16/2020
0C2A0D,note-sale,100,52,6/16/2020
0E499E,conference-participant,100,50,6/16/2020
106394,public-offering,100,43,6/16/2020
10AE08,note-sale,100,52,6/16/2020
12DE76,product-release,100,64,6/16/2020
1.79E+10,note-sale,100,52,6/16/2020
1.79E+10,note-sale,100,52,6/16/2020
1A3E1B,conference-call,100,50,6/16/2020
1B637E,partnership,100,61,6/16/2020
1CD4B5,conference-participant,100,50,6/16/2020
1E9A6D,note-sale,100,52,6/16/2020
1E9A6D,note-sale,100,52,6/16/2020
21245F,credit-extension-recipient,100,69,6/16/2020
21D903,legal-issues-defendant,100,22,6/16/2020
228D42,partnership,100,61,6/16/2020
25AB8E,earnings,100,50,6/16/2020
25DD05,dividend,100,50,6/16/2020
25DD05,dividend,100,50,6/16/2020
275300,donation,100,54,6/16/2020
2A1009,conference-participant,100,50,6/16/2020
2C681C,executive-appointment,100,54,6/16/2020
2C681C,executive-appointment,100,54,6/16/2020
2D485F,executive-appointment,100,54,6/16/2020
3.14E+47,dividend,100,50,6/16/2020
339F20,dividend,100,50,6/16/2020
3.30E+34,index-listing,100,76,6/16/2020
34A959,public-offering,100,43,6/16/2020
367E1C,partnership,100,61,6/16/2020
36C09B,conference-participant,100,50,6/16/2020
39FB23,partnership,100,61,6/16/2020
3A4BDB,note-sale,100,52,6/16/2020
3BB7D3,ipo-completed,100,76,6/16/2020
3C7F5F,business-contract,100,69,6/16/2020
3C8A04,conference-call,100,50,6/16/2020
3DD5E2,product-release,100,64,6/16/2020
3F4497,earnings-guidance,100,50,6/16/2020
415188,partnership,100,61,6/16/2020
42AABD,public-offering,100,43,6/16/2020
43E8F5,merger,100,66,6/16/2020
43E8F5,merger-regulatory-approval,100,81,6/16/2020
4A2457,award,100,58,6/16/2020
4A2457,acquisition-acquirer,100,49,6/16/2020
4A6F00,partnership,100,61,6/16/2020
4B3676,executive-appointment,100,54,6/16/2020
4C2F17,conference-participant,100,50,6/16/2020
4D72C8,note-sale,100,52,6/16/2020
4D72C8,note-sale,100,52,6/16/2020
4D72C8,note-sale,100,52,6/16/2020
4D72C8,note-sale,100,52,6/16/2020
4EE167,business-contract,100,69,6/16/2020
4F71DC,partnership,100,61,6/16/2020
5.43E+08,executive-appointment,100,54,6/16/2020
543C77,conference-participant,100,50,6/16/2020
55C9B5,earnings,100,50,6/16/2020
56EFC7,earnings,100,50,6/16/2020
56EFC7,earnings,100,50,6/16/2020
56EFC7,earnings,100,50,6/16/2020
58CA9A,conference-call,100,50,6/16/2020
5B97B2,dividend,100,50,6/16/2020
5C2A47,conference-participant,100,50,6/16/2020
6166D1,dividend,100,50,6/16/2020
6166D1,dividend,100,50,6/16/2020
6284B5,partnership,100,61,6/16/2020
63F892,partnership,100,61,6/16/2020
651C85,index-listing,100,76,6/16/2020
6559D8,public-offering,100,43,6/16/2020
67B052,conference-participant,100,50,6/16/2020
67B052,conference-participant,100,50,6/16/2020
68E6E9,earnings,100,50,6/16/2020
694749,credit-extension-recipient,100,69,6/16/2020
69FDFC,partnership,100,61,6/16/2020
6A024C,executive-appointment,100,54,6/16/2020
6BBCBA,conference-participant,100,50,6/16/2020
7A3633,executive-appointment,100,54,6/16/2020
7C790D,conference-participant,100,50,6/16/2020
80B32C,business-contract,100,69,6/16/2020
8377DB,dividend,100,50,6/16/2020
8A8E41,product-release,100,64,6/16/2020
8AB85C,conference-participant,100,50,6/16/2020
8C5519,note-sale,100,52,6/16/2020
8C5519,note-sale,100,52,6/16/2020
8C5519,note-sale,100,52,6/16/2020
8E10BF,executive-appointment,100,54,6/16/2020
8FCA78,executive-appointment,100,54,6/16/2020
96A2D3,public-offering,100,43,6/16/2020
9934AD,executive-appointment,100,54,6/16/2020
9B5968,partnership,100,61,6/16/2020
A16DEA,partnership,100,61,6/16/2020
A350C1,conference-call,100,50,6/16/2020
A868C9,business-contract,100,69,6/16/2020
AAC8B6,public-offering,100,43,6/16/2020
AAC8B6,public-offering,100,43,6/16/2020
ABE7DC,executive-appointment,100,54,6/16/2020
AD9F1D,partnership,100,61,6/16/2020
AEBB80,dividend,100,50,6/16/2020
B01111,dividend,100,50,6/16/2020
B1A85D,business-contract,100,69,6/16/2020
B290A2,conference-participant,100,50,6/16/2020
B3CB74,conference-organizer,100,57,6/16/2020
B3ED62,conference-call,100,50,6/16/2020
B614F8,legal-issues-defendant,100,22,6/16/2020
B614F8,legal-issues-defendant,100,22,6/16/2020
B803B1,rights-issue,100,43,6/16/2020
B840EF,partnership,100,61,6/16/2020
B8A51F,conference-participant,100,50,6/16/2020
BA218A,executive-appointment,100,54,6/16/2020
BAD9EA,index-listing,100,76,6/16/2020
BB127B,conference-participant,100,50,6/16/2020
BCC55F,partnership,100,61,6/16/2020
BD682F,dividend,100,50,6/16/2020
BFD0A7,conference-participant,100,50,6/16/2020
BFF98A,ipo-completed,100,76,6/16/2020
C4F9C6,conference-participant,100,50,6/16/2020
C66B44,executive-appointment,100,54,6/16/2020
CDE51C,executive-appointment,100,54,6/16/2020
CE2791,dividend,100,50,6/16/2020
CF073E,partnership,100,61,6/16/2020
CF073E,public-offering,100,43,6/16/2020
CF7292,partnership,100,61,6/16/2020
D11C1C,dividend,100,50,6/16/2020
D1AE3B,executive-appointment,100,54,6/16/2020
D2E553,dividend,100,50,6/16/2020
D6489C,partnership,100,61,6/16/2020
D6489C,partnership,100,61,6/16/2020
D6489C,award,100,58,6/16/2020
D6489C,earnings,100,50,6/16/2020
D75910,dividend,100,50,6/16/2020
D7AC6E,executive-appointment,100,54,6/16/2020
D854F3,product-release,100,64,6/16/2020
D90F43,partnership,100,61,6/16/2020
DBCA3F,executive-appointment,100,54,6/16/2020
DDCB34,conference-participant,100,50,6/16/2020
E68733,partnership,100,61,6/16/2020
E802CE,dividend,100,50,6/16/2020
E8B21D,dividend,100,50,6/16/2020
EB7FBF,dividend,100,50,6/16/2020
EEEA9F,public-offering,100,43,6/16/2020
F3D2EB,dividend,100,50,6/16/2020
F58C23,conference-participant,100,50,6/16/2020
F5D410,conference-participant,100,50,6/16/2020
F6E1B5,conference-participant,100,50,6/16/2020
F6E248,executive-appointment,100,54,6/16/2020
FA840E,public-offering,100,43,6/16/2020
FBD92D,revenue-guidance-up,100,83,6/16/2020
FF6644,product-release,100,64,6/16/2020
0157B1,partnership,100,61,6/17/2020
03596A,note-sale,100,52,6/17/2020
0624BE,note-sale,100,52,6/17/2020
07CA6A,executive-appointment,100,54,6/17/2020
07CA6A,executive-appointment,100,54,6/17/2020
0A1D77,executive-appointment,100,54,6/17/2020
0A6824,note-sale,100,52,6/17/2020
108A2B,dividend,100,50,6/17/2020
10AE08,note-sale,100,52,6/17/2020
1216D1,note-sale,100,52,6/17/2020
138DDE,dividend,100,50,6/17/2020
139303,conference-organizer,100,57,6/17/2020
147C38,executive-appointment,100,54,6/17/2020
168A5D,executive-appointment,100,54,6/17/2020
168A5D,executive-appointment,100,54,6/17/2020
17EDA5,executive-appointment,100,54,6/17/2020
1EBF8D,note-sale,100,52,6/17/2020
1EBF8D,acquisition-completed-acquirer,100,49,6/17/2020
1F43A1,public-offering,100,43,6/17/2020
228D42,dividend,100,50,6/17/2020
25AB8E,legal-issues-defendant,100,22,6/17/2020
25AB8E,legal-issues-defendant,100,22,6/17/2020
282C18,dividend,100,50,6/17/2020
2BBE62,legal-issues-defendant,100,22,6/17/2020
342218,dividend,100,50,6/17/2020
3.50E+27,dividend,100,50,6/17/2020
3798B9,partnership,100,61,6/17/2020
3D9999,product-release,100,64,6/17/2020
417BF9,index-listing,100,76,6/17/2020
42AABD,public-offering,100,43,6/17/2020
4455C4,credit-extension-recipient,100,69,6/17/2020
451D61,conference-participant,100,50,6/17/2020
47FCF2,fundraising,100,64,6/17/2020
4A2457,public-offering,100,43,6/17/2020
4AE584,unit-acquisition-acquirer,100,49,6/17/2020
4E2D94,earnings-guidance,100,50,6/17/2020
4E2D94,public-offering,100,43,6/17/2020
5065B1,earnings,100,50,6/17/2020
5487B1,fraud-defendant,100,20,6/17/2020
5487B1,legal-issues-defendant,100,22,6/17/2020
5487B1,legal-issues-defendant,100,22,6/17/2020
57DDB9,executive-appointment,100,54,6/17/2020
58B46F,conference-call,100,50,6/17/2020
60EA12,conference-participant,100,50,6/17/2020
6166D1,conference-call,100,50,6/17/2020
6284B5,note-sale,100,52,6/17/2020
665D7D,dividend,100,50,6/17/2020
6810DE,conference-participant,100,50,6/17/2020
6B6375,patient-enrollment-start,100,58,6/17/2020
6F0A63,note-sale,100,52,6/17/2020
73C521,earnings,100,50,6/17/2020
766047,executive-appointment,100,54,6/17/2020
775439,dividend,100,50,6/17/2020
7ADE57,partnership,100,61,6/17/2020
7E1D5D,partnership,100,61,6/17/2020
7E2DE6,earnings,100,50,6/17/2020
805CD8,public-offering,100,43,6/17/2020
84AB66,dividend,100,50,6/17/2020
855DF7,note-sale,100,52,6/17/2020
877734,earnings,100,50,6/17/2020
877734,earnings,100,50,6/17/2020
877734,earnings,100,50,6/17/2020
877734,earnings,100,50,6/17/2020
890FF4,partnership,100,61,6/17/2020
8D0EEA,clinical-trials,100,56,6/17/2020
8D4486,partnership,100,61,6/17/2020
8D4486,partnership,100,61,6/17/2020
8D4486,partnership,100,61,6/17/2020
8D4486,product-release,100,64,6/17/2020
8DCF18,conference-participant,100,50,6/17/2020
8E93A4,index-listing,100,76,6/17/2020
8FE7A5,index-listing,100,76,6/17/2020
8FF2EF,earnings,100,50,6/17/2020
901327,partnership,100,61,6/17/2020
911ACB,dividend,100,50,6/17/2020
93633B,dividend,100,50,6/17/2020
945DE6,note-sale,100,52,6/17/2020
9592FB,public-offering,100,43,6/17/2020
95DC1F,award,100,58,6/17/2020
9.65E+09,public-offering,100,43,6/17/2020
96B4FF,conference-participant,100,50,6/17/2020
990AD0,conference-organizer,100,57,6/17/2020
990AD0,conference-organizer,100,57,6/17/2020
9BF177,executive-appointment,100,54,6/17/2020
9BF177,earnings,100,50,6/17/2020
9C8BC3,note-sale,100,52,6/17/2020
9E5C2C,note-sale,100,52,6/17/2020
A1EAC8,business-contract,100,69,6/17/2020
A26C26,joint-venture,100,62,6/17/2020
A29DBD,partnership,100,61,6/17/2020
A29DBD,partnership,100,61,6/17/2020
A49498,partnership,100,61,6/17/2020
AE3113,partnership,100,61,6/17/2020
B1A85D,note-sale,100,52,6/17/2020
B1A85D,note-sale,100,52,6/17/2020
B2DAF6,product-release,100,64,6/17/2020
B3CB74,conference-organizer,100,57,6/17/2020
B3CB74,conference-organizer,100,57,6/17/2020
B5766D,executive-appointment,100,54,6/17/2020
B614F8,legal-issues-defendant,100,22,6/17/2020
B73395,conference-participant,100,50,6/17/2020
BCC55F,partnership,100,61,6/17/2020
BE379D,rights-issue,100,43,6/17/2020
C501B6,patent-infringement-defendant,100,26,6/17/2020
C62AA4,dividend-suspended,100,13,6/17/2020
C62AA4,dividend-suspended,100,13,6/17/2020
CBDB4D,patent-infringement-plaintiff,100,47,6/17/2020
D1173F,note-sale,100,52,6/17/2020
D17F7E,executive-appointment,100,54,6/17/2020
D6489C,stake-acquirer,100,48,6/17/2020
D96202,conference-call,100,50,6/17/2020
DA9443,public-offering,100,43,6/17/2020
E1BD05,business-contract,100,69,6/17/2020
E3A829,government-contract,100,69,6/17/2020
E5A3B6,conference-participant,100,50,6/17/2020
E6D89E,acquisition-acquirer,100,49,6/17/2020
E8E899,executive-appointment,100,54,6/17/2020
E959F3,conference-call,100,50,6/17/2020
EC99D0,conference-call,100,50,6/17/2020
ED22DC,clinical-trials-start,100,64,6/17/2020
EEB5F9,public-offering,100,43,6/17/2020
EEEA9F,public-offering,100,43,6/17/2020
F6DCE4,workforce-salary-increase,100,44,6/17/2020
FA840E,public-offering,100,43,6/17/2020
FD4588,acquisition-acquirer,100,49,6/17/2020
00E601,dividend,100,50,6/18/2020
0157B1,partnership,100,61,6/18/2020
0157B1,product-release,100,64,6/18/2020
02ACBD,clinical-trials,100,56,6/18/2020
03D5F9,reorganization-unit,100,53,6/18/2020
03D5F9,reorganization-unit,100,53,6/18/2020
054B55,earnings,100,50,6/18/2020
0624BE,note-sale,100,52,6/18/2020
0919B1,dividend-suspended,100,13,6/18/2020
0A6824,note-sale,100,52,6/18/2020
0A77DB,public-offering,100,43,6/18/2020
0C28D1,business-contract,100,69,6/18/2020
0C2A0D,note-sale,100,52,6/18/2020
0E3436,earnings,100,50,6/18/2020
0E3436,earnings,100,50,6/18/2020
0F0693,executive-appointment,100,54,6/18/2020
14ED2B,executive-appointment,100,54,6/18/2020
17EDA5,partnership,100,61,6/18/2020
1F43A1,public-offering,100,43,6/18/2020
20BEEA,earnings-guidance,100,50,6/18/2020
214051,earnings,100,50,6/18/2020
214051,earnings,100,50,6/18/2020
214051,earnings,100,50,6/18/2020
214051,earnings,100,50,6/18/2020
214051,earnings,100,50,6/18/2020
214051,earnings,100,50,6/18/2020
214051,earnings,100,50,6/18/2020
221AD7,partnership,100,61,6/18/2020
228D42,business-contract,100,69,6/18/2020
2A02DC,sponsorship,100,57,6/18/2020
2A1009,investment-investor,100,55,6/18/2020
2B8179,orphan-drug-designation,100,76,6/18/2020
2BC05E,product-release,100,64,6/18/2020
2F24A5,earnings,100,50,6/18/2020
306623,conference-participant,100,50,6/18/2020
32F943,business-contract,100,69,6/18/2020
32F943,business-contract,100,69,6/18/2020
341759,executive-appointment,100,54,6/18/2020
346BF2,public-offering,100,43,6/18/2020
346BF2,index-listing,100,76,6/18/2020
349DA4,note-sale,100,52,6/18/2020
37727A,dividend,100,50,6/18/2020
39D9DA,conference-call,100,50,6/18/2020
3A3447,trading-halt,100,43,6/18/2020
43A060,business-contract,100,69,6/18/2020
47752F,dividend,100,50,6/18/2020
4.91E+58,facility-open,100,65,6/18/2020
4BAF2E,executive-appointment,100,54,6/18/2020
4E2D94,public-offering,100,43,6/18/2020
4E4E75,conference-call,100,50,6/18/2020
52D936,business-contract,100,69,6/18/2020
545272,dividend,100,50,6/18/2020
5487B1,legal-issues-defendant,100,22,6/18/2020
55438C,executive-appointment,100,54,6/18/2020
55C9B5,partnership,100,61,6/18/2020
57DDB9,note-sale,100,52,6/18/2020
59872F,product-release,100,64,6/18/2020
5A0FF1,executive-resignation,100,44,6/18/2020
5B3FA2,conference-participant,100,50,6/18/2020
5B6C11,executive-appointment,100,54,6/18/2020
6166D1,executive-appointment,100,54,6/18/2020
665D7D,business-contract,100,69,6/18/2020
694749,executive-appointment,100,54,6/18/2020
6D2BF6,conference-participant,100,50,6/18/2020
6D9ECA,partnership,100,61,6/18/2020
6D9ECA,partnership,100,61,6/18/2020
6DBBBC,investment-investor,100,55,6/18/2020
7273FF,acquisition-acquirer,100,49,6/18/2020
73C521,facility-close,100,47,6/18/2020
73F7F9,earnings,100,50,6/18/2020
762A3E,conference-organizer,100,57,6/18/2020
76F067,conference-participant,100,50,6/18/2020
7AC86E,dividend,100,50,6/18/2020
805CD8,public-offering,100,43,6/18/2020
8.10E+32,business-contract,100,69,6/18/2020
810FAD,partnership,100,61,6/18/2020
838ADD,note-sale,100,52,6/18/2020
84A6B9,dividend,100,50,6/18/2020
863350,earnings,100,50,6/18/2020
868808,dividend,100,50,6/18/2020
89E771,business-contract,100,69,6/18/2020
8A8E41,partnership,100,61,6/18/2020
8AB85C,patient-enrollment-complete,100,64,6/18/2020
8E4250,earnings,100,50,6/18/2020
934029,clinical-trials-start,100,64,6/18/2020
934CC3,note-sale,100,52,6/18/2020
94637C,earnings,100,50,6/18/2020
94637C,partnership,100,61,6/18/2020
958938,clinical-trials,100,56,6/18/2020
958938,clinical-trials,100,56,6/18/2020
95DC1F,earnings,100,50,6/18/2020
95DC1F,earnings,100,50,6/18/2020
95DC1F,earnings,100,50,6/18/2020
95DC1F,earnings,100,50,6/18/2020
986AF6,earnings-guidance,100,50,6/18/2020
9A602D,conference-call,100,50,6/18/2020
9CE4C7,executive-appointment,100,54,6/18/2020
9CE4C7,dividend,100,50,6/18/2020
9F71E5,executive-appointment,100,54,6/18/2020
9FF5F1,partnership,100,61,6/18/2020
A16DEA,partnership,100,61,6/18/2020
A1DBF0,regulatory-product-application,100,69,6/18/2020
AB7726,executive-appointment,100,54,6/18/2020
AD1ACF,executive-appointment,100,54,6/18/2020
B05000,executive-appointment,100,54,6/18/2020
B08C51,index-listing,100,76,6/18/2020
B48D6A,conference-participant,100,50,6/18/2020
B614F8,legal-issues-defendant,100,22,6/18/2020
B614F8,legal-issues-defendant,100,22,6/18/2020
B614F8,legal-issues-defendant,100,22,6/18/2020
B66928,executive-appointment,100,54,6/18/2020
BB127B,product-release,100,64,6/18/2020
C05839,dividend,100,50,6/18/2020
C062D4,partnership,100,61,6/18/2020
C11C46,executive-appointment,100,54,6/18/2020
C2DD02,dividend,100,50,6/18/2020
C2E120,dividend,100,50,6/18/2020
C8257F,partnership,100,61,6/18/2020
C83B88,conference-call,100,50,6/18/2020
C83B88,product-release,100,64,6/18/2020
C8A248,award,100,58,6/18/2020
CCB623,legal-issues-defendant,100,22,6/18/2020
CCB623,legal-issues-defendant,100,22,6/18/2020
CCB623,legal-issues-defendant,100,22,6/18/2020
CF073E,public-offering,100,43,6/18/2020
D1173F,note-sale,100,52,6/18/2020
D1C26F,earnings-up,100,68,6/18/2020
D1C26F,earnings-up,100,68,6/18/2020
D1C26F,earnings-up,100,68,6/18/2020
D1C26F,earnings-up,100,68,6/18/2020
D29F43,executive-appointment,100,54,6/18/2020
D598E7,conference-call,100,50,6/18/2020
D6489C,product-release,100,64,6/18/2020
D6489C,product-release,100,64,6/18/2020
D7AC6E,conference-call,100,50,6/18/2020
DA0CB8,dividend,100,50,6/18/2020
DA9443,public-offering,100,43,6/18/2020
DAFED3,executive-appointment,100,54,6/18/2020
DD1BA1,partnership,100,61,6/18/2020
E30A8F,executive-appointment,100,54,6/18/2020
E5A3B6,executive-appointment,100,54,6/18/2020
E67C2C,executive-appointment,100,54,6/18/2020
E68733,partnership,100,61,6/18/2020
E68733,partnership,100,61,6/18/2020
E74FED,note-sale,100,52,6/18/2020
E74FED,note-sale,100,52,6/18/2020
E74FED,note-sale,100,52,6/18/2020
E8846E,legal-issues-defendant,100,22,6/18/2020
E8B315,dividend,100,50,6/18/2020
EB7FBF,earnings,100,50,6/18/2020
ECDEB2,dividend,100,50,6/18/2020
F30508,clinical-trials-start,100,64,6/18/2020
F3816D,business-contract,100,69,6/18/2020
F3816D,business-contract,100,69,6/18/2020
F43A11,legal-issues-defendant,100,22,6/18/2020
F57F6F,note-sale,100,52,6/18/2020
F6581D,conference-call,100,50,6/18/2020
F82D37,conference-call,100,50,6/18/2020
FA918D,executive-appointment,100,54,6/18/2020
FC1F9D,executive-appointment,100,54,6/18/2020
FE1A1D,executive-appointment,100,54,6/18/2020
FF4343,executive-appointment,100,54,6/18/2020
01D03F,regulatory-product-approval-granted,100,81,6/19/2020
033B58,executive-resignation,100,44,6/19/2020
07CA6A,partnership,100,61,6/19/2020
07CA6A,partnership,100,61,6/19/2020
099C88,business-contract,100,69,6/19/2020
0A77DB,public-offering,100,43,6/19/2020
0A9D0A,note-sale,100,52,6/19/2020
0E5619,conference-participant,100,50,6/19/2020
0FABBD,conference-participant,100,50,6/19/2020
106394,public-offering,100,43,6/19/2020
112694,ipo-pricing,100,50,6/19/2020
14391F,stake-acquirer,100,48,6/19/2020
1921DD,dividend,100,50,6/19/2020
1EBF8D,acquisition-completed-acquirer,100,49,6/19/2020
250BEE,executive-appointment,100,54,6/19/2020
250BEE,executive-appointment,100,54,6/19/2020
250BEE,executive-appointment,100,54,6/19/2020
26CC63,earnings,100,50,6/19/2020
26CC63,earnings,100,50,6/19/2020
26CC63,earnings,100,50,6/19/2020
2DDB22,dividend,100,50,6/19/2020
346BF2,public-offering,100,43,6/19/2020
349DA4,note-sale,100,52,6/19/2020
356B21,legal-issues-defendant,100,22,6/19/2020
3F4497,dividend,100,50,6/19/2020
420168,dividend,100,50,6/19/2020
42978B,executive-appointment,100,54,6/19/2020
442769,index-listing,100,76,6/19/2020
49F4D0,dividend,100,50,6/19/2020
4A2457,public-offering,100,43,6/19/2020
53F491,dividend,100,50,6/19/2020
5487B1,legal-issues-defendant,100,22,6/19/2020
5487B1,legal-issues-defendant,100,22,6/19/2020
5F3D91,public-offering,100,43,6/19/2020
63E8D5,dividend,100,50,6/19/2020
641F17,executive-appointment,100,54,6/19/2020
676FFD,legal-issues-defendant,100,22,6/19/2020
6BF593,dividend-suspended,100,13,6/19/2020
6EA292,dividend,100,50,6/19/2020
6F30F9,dividend,100,50,6/19/2020
701531,conference-participant,100,50,6/19/2020
7999F3,dividend,100,50,6/19/2020
7999F3,dividend,100,50,6/19/2020
7ACBA4,dividend,100,50,6/19/2020
7E1D5D,buybacks,100,74,6/19/2020
8817D5,conference-call,100,50,6/19/2020
9196A2,conference-organizer,100,57,6/19/2020
92B047,conference-call,100,50,6/19/2020
9548BB,acquisition-failed-acquirer,100,41,6/19/2020
A631A3,product-release,100,64,6/19/2020
A631A3,conference-participant,100,50,6/19/2020
A6828A,product-release,100,64,6/19/2020
A6FE1C,acquisition-acquirer,100,49,6/19/2020
AA09AD,partnership,100,61,6/19/2020
AA7FE0,earnings,100,50,6/19/2020
AA7FE0,earnings,100,50,6/19/2020
AA7FE0,earnings,100,50,6/19/2020
AA7FE0,earnings,100,50,6/19/2020
AA7FE0,earnings,100,50,6/19/2020
AC1952,note-sale,100,52,6/19/2020
BDF2BD,conference-participant,100,50,6/19/2020
C06EB6,patient-enrollment-start,100,58,6/19/2020
C06EB6,patient-enrollment-start,100,58,6/19/2020
C501B6,ipo-pricing,100,50,6/19/2020
C66B44,settlement,100,56,6/19/2020
CAC8D0,facility-open,100,65,6/19/2020
CCB623,legal-issues-defendant,100,22,6/19/2020
D1AE3B,executive-appointment,100,54,6/19/2020
D6489C,product-release,100,64,6/19/2020
EC1AF3,dividend,100,50,6/19/2020
F4CDA3,dividend,100,50,6/19/2020
FD2565,clinical-trials-start,100,64,6/19/2020
356B21,legal-issues-defendant,100,22,6/20/2020
13C3E0,public-offering,100,43,6/21/2020
13C3E0,note-sale,100,52,6/21/2020
002A99,executive-appointment,100,54,6/22/2020
43862,clinical-trials,100,56,6/22/2020
55018,conference-call,100,50,6/22/2020
091B6C,clinical-trials,100,56,6/22/2020
091B6C,clinical-trials,100,56,6/22/2020
0BC853,merger-completed,100,66,6/22/2020
1272B3,executive-appointment,100,54,6/22/2020
129DC8,executive-appointment,100,54,6/22/2020
138DDE,earnings,100,50,6/22/2020
147C38,executive-appointment,100,54,6/22/2020
152FA5,clinical-trials,100,56,6/22/2020
152FA5,clinical-trials,100,56,6/22/2020
1921DD,dividend,100,50,6/22/2020
1921DD,auditor-appointment,100,50,6/22/2020
1F43A1,public-offering,100,43,6/22/2020
228D42,partnership,100,61,6/22/2020
251988,partnership,100,61,6/22/2020
251988,executive-appointment,100,54,6/22/2020
25AB8E,legal-issues-defendant,100,22,6/22/2020
25AB8E,legal-issues-defendant,100,22,6/22/2020
267718,clinical-trials-start,100,64,6/22/2020
29B702,note-sale,100,52,6/22/2020
2AE625,executive-appointment,100,54,6/22/2020
2CC71C,executive-appointment,100,54,6/22/2020
2EC172,executive-appointment,100,54,6/22/2020
2F94A5,award,100,58,6/22/2020
32F943,partnership,100,61,6/22/2020
356B21,legal-issues-defendant,100,22,6/22/2020
35B907,earnings,100,50,6/22/2020
35B907,earnings,100,50,6/22/2020
36C09B,clinical-trials,100,56,6/22/2020
371C01,executive-appointment,100,54,6/22/2020
396D7C,clinical-trials,100,56,6/22/2020
3B8484,acquisition-acquirer,100,49,6/22/2020
408089,revenue-guidance-up,100,83,6/22/2020
43E8F5,merger-completed,100,66,6/22/2020
448BF3,patient-enrollment-complete,100,64,6/22/2020
44A4FC,partnership,100,61,6/22/2020
44A4FC,partnership,100,61,6/22/2020
4.91E+58,executive-appointment,100,54,6/22/2020
4BAF2E,clinical-trials-start,100,64,6/22/2020
4C37C5,conference-call,100,50,6/22/2020
4E4E75,dividend,100,50,6/22/2020
504FE2,partnership,100,61,6/22/2020
50702E,clinical-trials,100,56,6/22/2020
50702E,earnings,100,50,6/22/2020
50702E,earnings,100,50,6/22/2020
50702E,earnings,100,50,6/22/2020
54512F,partnership,100,61,6/22/2020
5480A7,index-listing,100,76,6/22/2020
5487B1,legal-issues-defendant,100,22,6/22/2020
5487B1,legal-issues-defendant,100,22,6/22/2020
5BFE94,asset-sale,100,62,6/22/2020
64636E,index-listing,100,76,6/22/2020
64636E,index-listing,100,76,6/22/2020
6.52E+64,fundraising,100,64,6/22/2020
6.52E+64,public-offering,100,43,6/22/2020
6559D8,public-offering,100,43,6/22/2020
66667F,partnership,100,61,6/22/2020
6810DE,business-contract,100,69,6/22/2020
69CE71,partnership,100,61,6/22/2020
6A171E,conference-participant,100,50,6/22/2020
6C6D73,partnership,100,61,6/22/2020
6C6D73,partnership,100,61,6/22/2020
723548,dividend,100,50,6/22/2020
746373,conference-call,100,50,6/22/2020
748EB6,public-offering,100,43,6/22/2020
771985,bought-deal,100,43,6/22/2020
771985,acquisition-acquiree,100,76,6/22/2020
7B9AFA,acquisition-acquirer,100,49,6/22/2020
805CD8,public-offering,100,43,6/22/2020
838ADD,note-sale,100,52,6/22/2020
8.40E+120,partnership,100,61,6/22/2020
8E82A6,earnings,100,50,6/22/2020
92D9C9,dividend,100,50,6/22/2020
957A07,earnings,100,50,6/22/2020
9592FB,public-offering,100,43,6/22/2020
966ACE,conference-participant,100,50,6/22/2020
96A6CD,executive-appointment,100,54,6/22/2020
9E3224,dividend,100,50,6/22/2020
9F37C5,dividend-up,100,81,6/22/2020
9F71E5,executive-appointment,100,54,6/22/2020
A3230E,clinical-trials,100,56,6/22/2020
A49498,public-offering,100,43,6/22/2020
A63387,partnership,100,61,6/22/2020
AA09AD,earnings,100,50,6/22/2020
AA09AD,earnings,100,50,6/22/2020
ACDCFA,executive-appointment,100,54,6/22/2020
AE0CCE,index-listing,100,76,6/22/2020
AFBEB4,partnership,100,61,6/22/2020
B04426,clinical-trials,100,56,6/22/2020
B614F8,legal-issues-defendant,100,22,6/22/2020
B8F71F,executive-appointment,100,54,6/22/2020
BB88B6,acquisition-acquirer,100,49,6/22/2020
C45C1F,business-contract,100,69,6/22/2020
C8257F,executive-appointment,100,54,6/22/2020
CBFFDD,product-release,100,64,6/22/2020
CCB623,legal-issues-defendant,100,22,6/22/2020
CCB623,legal-issues-defendant,100,22,6/22/2020
CFD4B6,executive-appointment,100,54,6/22/2020
D4AC65,product-release,100,64,6/22/2020
D8442A,product-release,100,64,6/22/2020
D8442A,product-release,100,64,6/22/2020
D8442A,product-release,100,64,6/22/2020
D8442A,product-release,100,64,6/22/2020
DA9443,executive-appointment,100,54,6/22/2020
DA9443,public-offering,100,43,6/22/2020
DB9F70,clinical-trials,100,56,6/22/2020
E09E2B,product-release,100,64,6/22/2020
E13782,conference-participant,100,50,6/22/2020
E22FDE,partnership,100,61,6/22/2020
E22FDE,partnership,100,61,6/22/2020
E2F130,conference-call,100,50,6/22/2020
E6D89E,partnership,100,61,6/22/2020
E6D89E,partnership,100,61,6/22/2020
EC8116,dividend,100,50,6/22/2020
ED9C04,note-sale,100,52,6/22/2020
ED9C04,note-sale,100,52,6/22/2020
F0B335,business-contract,100,69,6/22/2020
F0EEFB,earnings,100,50,6/22/2020
F0EEFB,earnings,100,50,6/22/2020
F0EEFB,earnings,100,50,6/22/2020
F0EEFB,earnings,100,50,6/22/2020
F2BC3D,public-offering,100,43,6/22/2020
F4E882,donation,100,54,6/22/2020
F50BAB,note-sale,100,52,6/22/2020
F6581D,earnings,100,50,6/22/2020
F6FF0D,note-sale,100,52,6/22/2020
F7935D,loan-recipient,100,59,6/22/2020
F7ADEB,executive-appointment,100,54,6/22/2020
F8BA6C,clinical-trials,100,56,6/22/2020
F8BA6C,clinical-trials,100,56,6/22/2020
FC9A88,executive-appointment,100,54,6/22/2020
FDE409,earnings,100,50,6/22/2020
FF227B,clinical-trials,100,56,6/22/2020
002A99,patient-enrollment-start,100,58,6/23/2020
13528,partnership,100,61,6/23/2020
0142B5,note-sale,100,52,6/23/2020
0157B1,product-release,100,64,6/23/2020
0157B1,product-release,100,64,6/23/2020
0157B1,product-release,100,64,6/23/2020
0157B1,product-release,100,64,6/23/2020
03B8CF,partnership,100,61,6/23/2020
03D5F9,executive-appointment,100,54,6/23/2020
03D5F9,executive-appointment,100,54,6/23/2020
06EE79,public-offering,100,43,6/23/2020
06EF42,earnings,100,50,6/23/2020
070B45,product-release,100,64,6/23/2020
083F72,executive-appointment,100,54,6/23/2020
08A40F,executive-appointment,100,54,6/23/2020
10AE08,note-sale,100,52,6/23/2020
112694,ipo-completed,100,76,6/23/2020
131443,joint-venture,100,62,6/23/2020
14BA06,conference-call,100,50,6/23/2020
157D9F,executive-appointment,100,54,6/23/2020
15A388,earnings,100,50,6/23/2020
1880C5,executive-appointment,100,54,6/23/2020
1AC649,partnership,100,61,6/23/2020
1AC649,partnership,100,61,6/23/2020
1AC649,partnership,100,61,6/23/2020
1AC649,partnership,100,61,6/23/2020
1F9D90,product-release,100,64,6/23/2020
21153F,executive-appointment,100,54,6/23/2020
21153F,executive-appointment,100,54,6/23/2020
2.45E+15,executive-appointment,100,54,6/23/2020
25102A,conference-call,100,50,6/23/2020
251988,earnings,100,50,6/23/2020
251988,product-release,100,64,6/23/2020
25AB8E,legal-issues-defendant,100,22,6/23/2020
267718,executive-appointment,100,54,6/23/2020
2AA6A8,public-offering,100,43,6/23/2020
30E01D,partnership,100,61,6/23/2020
33FD66,earnings,100,50,6/23/2020
387541,conference-participant,100,50,6/23/2020
3.88E+02,legal-issues-defendant,100,22,6/23/2020
3.88E+02,legal-issues-defendant,100,22,6/23/2020
39692D,product-discontinued,100,48,6/23/2020
422A82,earnings,100,50,6/23/2020
422A82,earnings,100,50,6/23/2020
422A82,earnings,100,50,6/23/2020
449A26,conference-call,100,50,6/23/2020
4AC91D,partnership,100,61,6/23/2020
4F9926,award,100,58,6/23/2020
50070E,conference-organizer,100,57,6/23/2020
50070E,conference-organizer,100,57,6/23/2020
520632,partnership,100,61,6/23/2020
520632,conference-call,100,50,6/23/2020
58CA9A,earnings,100,50,6/23/2020
5B6C11,facility-upgrade,100,65,6/23/2020
5BC2F4,partnership,100,61,6/23/2020
5F9CE3,market-entry,100,57,6/23/2020
61BCA7,note-sale,100,52,6/23/2020
627186,earnings,100,50,6/23/2020
636931,index-listing,100,76,6/23/2020
676FFD,legal-issues-defendant,100,22,6/23/2020
693ECD,index-listing,100,76,6/23/2020
6BBCBA,partnership,100,61,6/23/2020
6E705B,note-sale,100,52,6/23/2020
6E7060,dividend,100,50,6/23/2020
6F6559,earnings,100,50,6/23/2020
7255D2,acquisition-completed-acquirer,100,49,6/23/2020
7255D2,acquisition-completed-acquirer,100,49,6/23/2020
7255D2,acquisition-completed-acquirer,100,49,6/23/2020
7255D2,conference-call,100,50,6/23/2020
762B8D,unit-acquisition-acquirer,100,49,6/23/2020
76E80F,executive-appointment,100,54,6/23/2020
771985,bought-deal,100,43,6/23/2020
77B8E9,award,100,58,6/23/2020
7ADE57,business-contract,100,69,6/23/2020
7AF907,public-offering,100,43,6/23/2020
7B8CB5,conference-participant,100,50,6/23/2020
8.10E+205,conference-participant,100,50,6/23/2020
830BDB,conference-participant,100,50,6/23/2020
834152,clinical-trials-start,100,64,6/23/2020
8665BA,partnership,100,61,6/23/2020
8E10BF,executive-appointment,100,54,6/23/2020
8F8F2F,executive-health,100,41,6/23/2020
9196A2,conference-organizer,100,57,6/23/2020
98CAED,earnings,100,50,6/23/2020
990AD0,conference-call,100,50,6/23/2020
9D56F2,dividend,100,50,6/23/2020
A072C4,partnership,100,61,6/23/2020
A26C26,joint-venture,100,62,6/23/2020
A43906,conference-call,100,50,6/23/2020
A52B6B,executive-appointment,100,54,6/23/2020
A631A3,conference-participant,100,50,6/23/2020
A6FE1C,unit-acquisition-acquirer,100,49,6/23/2020
A790A5,earnings,100,50,6/23/2020
A868C9,executive-appointment,100,54,6/23/2020
AD1ACF,executive-appointment,100,54,6/23/2020
AE0CCE,public-offering,100,43,6/23/2020
AE7D16,partnership,100,61,6/23/2020
B0FE08,executive-appointment,100,54,6/23/2020
B33E77,government-contract,100,69,6/23/2020
B33E77,government-contract,100,69,6/23/2020
B4528F,executive-appointment,100,54,6/23/2020
B83BCE,conference-participant,100,50,6/23/2020
BB0787,partnership,100,61,6/23/2020
BB127B,partnership,100,61,6/23/2020
BFAEB4,donation,100,54,6/23/2020
C2609A,executive-appointment,100,54,6/23/2020
C4A432,executive-appointment,100,54,6/23/2020
C83B88,business-contract,100,69,6/23/2020
C9E107,earnings,100,50,6/23/2020
CBB77B,executive-appointment,100,54,6/23/2020
CBB77B,earnings,100,50,6/23/2020
CBFFDD,acquisition-interest-acquirer,100,46,6/23/2020
CCB623,legal-issues-defendant,100,22,6/23/2020
CFF97C,credit-rating-affirmation-rater,20,50,6/23/2020
CFF97C,dividend,100,50,6/23/2020
D33D8C,acquisition-completed-acquirer,100,49,6/23/2020
D6144F,conference-participant,100,50,6/23/2020
D88EF3,executive-appointment,100,54,6/23/2020
DB2E4E,executive-appointment,100,54,6/23/2020
DBB28E,product-release,100,64,6/23/2020
DD0099,earnings,100,50,6/23/2020
DF11D9,equity-shelf-registration,100,43,6/23/2020
E07573,earnings,100,50,6/23/2020
E09556,patent-awarded,100,72,6/23/2020
E829E8,conference-call,100,50,6/23/2020
EC99D0,product-release,100,64,6/23/2020
EC99D0,executive-appointment,100,54,6/23/2020
F1EB39,earnings,100,50,6/23/2020
F6E248,acquisition-completed-acquirer,100,49,6/23/2020
F6FF0D,note-sale,100,52,6/23/2020
F7935D,executive-appointment,100,54,6/23/2020
001F1B,facility-open,100,65,6/24/2020
0142B5,note-sale,100,52,6/24/2020
03F5A4,dividend,100,50,6/24/2020
05AF14,dividend-up,100,81,6/24/2020
06EE79,public-offering,100,43,6/24/2020
075CF7,executive-resignation,100,44,6/24/2020
08A40F,donation,100,54,6/24/2020
0BA2EF,buybacks,100,74,6/24/2020
0C355F,facility-open,100,65,6/24/2020
0CADBC,dividend,100,50,6/24/2020
0DBB81,clinical-trials-positive,100,87,6/24/2020
0E2992,conference-call,100,50,6/24/2020
1151F4,executive-appointment,100,54,6/24/2020
12A3A3,executive-appointment,100,54,6/24/2020
12A3A3,executive-appointment,100,54,6/24/2020
1.79E+10,conference-call,100,50,6/24/2020
184988,clinical-trials-start,100,64,6/24/2020
1AC649,public-offering,100,43,6/24/2020
1EBF8D,regulatory-product-approval-granted,100,81,6/24/2020
1EBF8D,regulatory-product-approval-granted,100,81,6/24/2020
1EBF8D,regulatory-product-approval-granted,100,81,6/24/2020
1EBF8D,regulatory-product-approval-granted,100,81,6/24/2020
1EBF8D,regulatory-product-approval-granted,100,81,6/24/2020
21245F,earnings,100,50,6/24/2020
21F9CA,partnership,100,61,6/24/2020
25AB8E,legal-issues-defendant,100,22,6/24/2020
275300,dividend,100,50,6/24/2020
292A70,earnings,100,50,6/24/2020
2A6DBE,index-listing,100,76,6/24/2020
2BC05E,executive-appointment,100,54,6/24/2020
2BF36E,legal-verdict-favored,100,78,6/24/2020
2D485F,executive-appointment,100,54,6/24/2020
2F7474,dividend,100,50,6/24/2020
30AB63,earnings-guidance,100,50,6/24/2020
339F20,executive-appointment,100,54,6/24/2020
3461CF,award,100,58,6/24/2020
3C7F5F,business-contract,100,69,6/24/2020
3CBA2A,dividend,100,50,6/24/2020
4135F7,conference-call,100,50,6/24/2020
4AC91D,dividend,100,50,6/24/2020
4B49CF,earnings,100,50,6/24/2020
4BBA23,business-contract,100,69,6/24/2020
4E4E75,earnings,100,50,6/24/2020
4F9487,conference-call,100,50,6/24/2020
510EA1,acquisition-acquirer,100,49,6/24/2020
510EA1,acquisition-acquirer,100,49,6/24/2020
51D876,executive-appointment,100,54,6/24/2020
53F491,earnings,100,50,6/24/2020
543900,dividend,100,50,6/24/2020
545272,executive-appointment,100,54,6/24/2020
5487B1,legal-issues-defendant,100,22,6/24/2020
57DDB9,public-offering,100,43,6/24/2020
57DDB9,public-offering,100,43,6/24/2020
616E3B,business-contract,100,69,6/24/2020
67B052,public-offering,100,43,6/24/2020
67B052,public-offering,100,43,6/24/2020
67B052,public-offering,100,43,6/24/2020
67B052,public-offering,100,43,6/24/2020
68BA15,conference-call,100,50,6/24/2020
69CE71,business-contract,100,69,6/24/2020
6ACFBF,merger-regulatory-approval,100,81,6/24/2020
6D9ECA,executive-appointment,100,54,6/24/2020
70FCEF,earnings,100,50,6/24/2020
72FCA3,earnings,100,50,6/24/2020
72FCA3,earnings,100,50,6/24/2020
72FCA3,earnings,100,50,6/24/2020
72FCA3,earnings,100,50,6/24/2020
72FCA3,earnings,100,50,6/24/2020
7C62A3,award,100,58,6/24/2020
7F3FBC,acquisition-acquirer,100,49,6/24/2020
7FDE1C,note-sale,100,52,6/24/2020
7FEEE1,clinical-trials,100,56,6/24/2020
88923D,executive-appointment,100,54,6/24/2020
89B2E7,dividend,100,50,6/24/2020
8A8E41,partnership,100,61,6/24/2020
8DE74B,award,100,58,6/24/2020
8EEA28,index-listing,100,76,6/24/2020
918D6D,orphan-drug-designation,100,76,6/24/2020
9196A2,executive-health,100,41,6/24/2020
92D757,note-sale,100,52,6/24/2020
93AD2E,earnings,100,50,6/24/2020
93D207,partnership,100,61,6/24/2020
93D207,partnership,100,61,6/24/2020
93D207,partnership,100,61,6/24/2020
949625,conference-call,100,50,6/24/2020
95A92E,partnership,100,61,6/24/2020
9934AD,executive-appointment,100,54,6/24/2020
9A602D,partnership,100,61,6/24/2020
AC642C,merger-regulatory-approval,100,81,6/24/2020
AC642C,merger-regulatory-approval,100,81,6/24/2020
ADF092,partnership,100,61,6/24/2020
AFDF2E,earnings-revision,100,29,6/24/2020
B05000,executive-appointment,100,54,6/24/2020
B614F8,legal-issues-defendant,100,22,6/24/2020
B98EFA,campaign-ad-release,100,59,6/24/2020
BA218A,dividend,100,50,6/24/2020
BE14CF,conference-call,100,50,6/24/2020
BEA527,business-contract,100,69,6/24/2020
C4FBDC,partnership,100,61,6/24/2020
C4FBDC,partnership,100,61,6/24/2020
CCB623,legal-issues-defendant,100,22,6/24/2020
CF211D,index-listing,100,76,6/24/2020
D08D2C,conference-call,100,50,6/24/2020
D21D8A,dividend,100,50,6/24/2020
D33270,business-contract,100,69,6/24/2020
D48275,index-listing,100,76,6/24/2020
D5AF19,earnings,100,50,6/24/2020
D6489C,revenue-up,100,69,6/24/2020
D6489C,revenue-up,100,69,6/24/2020
D93A25,conference-call,100,50,6/24/2020
DB06B0,partnership,100,61,6/24/2020
DDCB34,conference-participant,100,50,6/24/2020
E8A49A,award,100,58,6/24/2020
E99180,dividend,100,50,6/24/2020
ED0402,note-sale,100,52,6/24/2020
ED0402,unit-acquisition-completed-acquirer,100,49,6/24/2020
ED0402,note-sale,100,52,6/24/2020
F30508,product-release,100,64,6/24/2020
F47871,partnership,100,61,6/24/2020
F58C23,index-listing,100,76,6/24/2020
F80389,conference-call,100,50,6/24/2020
0358AF,earnings,100,50,6/25/2020
04996E,executive-appointment,100,54,6/25/2020
054B55,public-offering,100,43,6/25/2020
0560D8,dividend-up,100,54,6/25/2020
05AF14,earnings,100,50,6/25/2020
71860,partnership,100,61,6/25/2020
11A49E,clinical-trials-start,100,64,6/25/2020
129DC8,executive-appointment,100,54,6/25/2020
12A3A3,earnings,100,50,6/25/2020
12A3A3,earnings,100,50,6/25/2020
12A3A3,earnings,100,50,6/25/2020
12A3A3,earnings,100,50,6/25/2020
12DE76,partnership,100,61,6/25/2020
12DE76,partnership,100,61,6/25/2020
13C3E0,note-sale,100,52,6/25/2020
143C52,partnership,100,61,6/25/2020
14ED2B,executive-appointment,100,54,6/25/2020
1.79E+10,business-contract,100,69,6/25/2020
1.79E+10,acquisition-acquirer,100,49,6/25/2020
17EDA5,product-release,100,64,6/25/2020
1A9DE1,dividend,100,50,6/25/2020
1AE482,index-listing,100,76,6/25/2020
1DB833,index-listing,100,76,6/25/2020
1F19C8,acquisition-acquirer,100,49,6/25/2020
21D903,earnings,100,50,6/25/2020
228D42,product-release,100,64,6/25/2020
228D42,partnership,100,61,6/25/2020
228D42,partnership,100,61,6/25/2020
228D42,partnership,100,61,6/25/2020
228D42,partnership,100,61,6/25/2020
25AB8E,legal-issues-defendant,100,22,6/25/2020
267718,dividend,100,50,6/25/2020
27BFA1,conference-call,100,50,6/25/2020
27C10F,fraud-defendant,100,20,6/25/2020
27C10F,legal-issues-defendant,100,22,6/25/2020
292388,partnership,100,61,6/25/2020
2A6DBE,business-contract,100,69,6/25/2020
2D2D43,executive-appointment,100,54,6/25/2020
2D485F,earnings,100,50,6/25/2020
31F25C,conference-call,100,50,6/25/2020
32DCB3,public-offering,100,43,6/25/2020
337024,index-listing,100,76,6/25/2020
33A0F1,executive-appointment,100,54,6/25/2020
3461CF,award,100,58,6/25/2020
34B97A,partnership,100,61,6/25/2020
387375,earnings,100,50,6/25/2020
3A3948,partnership,100,61,6/25/2020
3A3948,partnership,100,61,6/25/2020
3B37F7,executive-appointment,100,54,6/25/2020
3CCC90,conference-call,100,50,6/25/2020
3D9999,partnership,100,61,6/25/2020
3F4497,conference-call,100,50,6/25/2020
448BF3,business-contract,100,69,6/25/2020
44A4FC,partnership,100,61,6/25/2020
44A4FC,partnership,100,61,6/25/2020
44A4FC,partnership,100,61,6/25/2020
44A4FC,partnership,100,61,6/25/2020
453282,conference-call,100,50,6/25/2020
48F795,executive-appointment,100,54,6/25/2020
4D371E,executive-appointment,100,54,6/25/2020
4F9487,note-sale,100,52,6/25/2020
51D876,executive-appointment,100,54,6/25/2020
524CE4,facility-open,100,65,6/25/2020
5487B1,legal-issues-defendant,100,22,6/25/2020
5487B1,legal-issues-defendant,100,22,6/25/2020
550D01,facility-open,100,65,6/25/2020
55D0F3,conference-participant,100,50,6/25/2020
579E8F,ipo-pricing,100,50,6/25/2020
59872F,executive-appointment,100,54,6/25/2020
5C7601,earnings,100,50,6/25/2020
6166D1,regulatory-stress-test,100,50,6/25/2020
620381,public-offering,100,43,6/25/2020
633054,partnership,100,61,6/25/2020
66A667,dividend,100,50,6/25/2020
66A667,dividend,100,50,6/25/2020
6BC6F9,partnership,100,61,6/25/2020
756045,index-listing,100,76,6/25/2020
75768D,earnings,100,50,6/25/2020
7771D7,earnings,100,50,6/25/2020
7ACFD4,dividend,100,50,6/25/2020
7ADE57,dividend-up,100,81,6/25/2020
7B0BA6,partnership,100,61,6/25/2020
7D5FD6,earnings,100,50,6/25/2020
7E1D5D,business-contract,100,69,6/25/2020
900356,merger-regulatory-approval,100,81,6/25/2020
91C82E,dividend,100,50,6/25/2020
92D757,note-sale,100,52,6/25/2020
9368BE,executive-appointment,100,54,6/25/2020
95C392,award,100,58,6/25/2020
95DC1F,dividend-up,100,63,6/25/2020
96F126,dividend,100,50,6/25/2020
986AF6,award,100,58,6/25/2020
98CEBB,business-contract,100,69,6/25/2020
9BBFA5,earnings,100,50,6/25/2020
9D56F2,revenues,100,50,6/25/2020
9D56F2,revenues,100,50,6/25/2020
9D56F2,revenues,100,50,6/25/2020
9D56F2,revenues,100,50,6/25/2020
9F03CF,earnings,100,50,6/25/2020
9F6B1A,product-release,100,64,6/25/2020
9F6B1A,product-release,100,64,6/25/2020
A247F5,partnership,100,61,6/25/2020
A26C26,dividend,100,50,6/25/2020
A49498,public-offering,100,43,6/25/2020
A495F7,product-release,100,64,6/25/2020
A8B137,earnings,100,50,6/25/2020
ADF092,earnings,100,50,6/25/2020
AE0CCE,public-offering,100,43,6/25/2020
AE7D16,partnership,100,61,6/25/2020
B66928,donation,100,54,6/25/2020
BA0442,partnership,100,61,6/25/2020
BB88B6,facility-upgrade,100,65,6/25/2020
BCE9DA,dividend,100,50,6/25/2020
BCE9DA,dividend,100,50,6/25/2020
BE86A1,dividend,100,50,6/25/2020
BF5959,public-offering,100,43,6/25/2020
BFAEB4,award,100,58,6/25/2020
BFE02C,investment-investor,100,55,6/25/2020
C4A241,conference-call,100,50,6/25/2020
C4C77F,executive-appointment,100,54,6/25/2020
C5C137,reorganization,100,53,6/25/2020
C81E00,conference-call,100,50,6/25/2020
C81E00,conference-call,100,50,6/25/2020
C8A248,dividend,100,50,6/25/2020
CAC8D0,earnings,100,50,6/25/2020
CBBFBF,partnership,100,61,6/25/2020
CBBFBF,partnership,100,61,6/25/2020
CCB623,fraud-defendant,100,20,6/25/2020
CDAF5B,index-listing,100,76,6/25/2020
CFF57D,earnings,100,50,6/25/2020
D15833,dividend,100,50,6/25/2020
D15833,dividend,100,50,6/25/2020
D27FAB,earnings,100,50,6/25/2020
D64C6D,earnings,100,50,6/25/2020
D650A7,award,100,58,6/25/2020
D78BF1,earnings,100,50,6/25/2020
D88EF3,executive-appointment,100,54,6/25/2020
DB88A1,partnership,100,61,6/25/2020
DBB28E,partnership,100,61,6/25/2020
DC2B00,partnership,100,61,6/25/2020
DF18E6,executive-appointment,100,54,6/25/2020
E10D31,dividend,100,50,6/25/2020
E1E093,clinical-trials-start,100,64,6/25/2020
E866D2,donation,100,54,6/25/2020
E8E899,earnings,100,50,6/25/2020
EEA6B3,earnings,100,50,6/25/2020
EF5BED,product-release,100,64,6/25/2020
EF77A3,dividend,100,50,6/25/2020
EFA7B2,earnings,100,50,6/25/2020
F11638,note-sale,100,52,6/25/2020
F2BC3D,public-offering,100,43,6/25/2020
F4F46F,partnership,100,61,6/25/2020
F5D059,earnings,100,50,6/25/2020
F5D499,partnership,100,61,6/25/2020
FBD92D,index-listing,100,76,6/25/2020
FE9C0D,fundraising,100,64,6/25/2020
FE9C0D,fundraising,100,64,6/25/2020
FF4343,executive-appointment,100,54,6/25/2020
FF4BA4,earnings,100,50,6/25/2020
054B55,public-offering,100,43,6/26/2020
0C8D82,conference-call,100,50,6/26/2020
14ED2B,executive-appointment,100,54,6/26/2020
1921DD,partnership,100,61,6/26/2020
1AC649,public-offering,100,43,6/26/2020
1AF7E2,credit-extension-recipient,100,69,6/26/2020
228D42,business-contract,100,69,6/26/2020
251988,dividend,100,50,6/26/2020
251988,dividend,100,50,6/26/2020
25AB8E,legal-issues-defendant,100,22,6/26/2020
2667B6,supply-decrease,100,28,6/26/2020
27C10F,legal-issues-defendant,100,22,6/26/2020
27C10F,legal-issues-defendant,100,22,6/26/2020
27C10F,legal-issues-defendant,100,22,6/26/2020
27C10F,legal-issues-defendant,100,22,6/26/2020
27C10F,legal-issues-defendant,100,22,6/26/2020
2AA6A8,public-offering,100,43,6/26/2020
2CF9D3,index-listing,100,76,6/26/2020
31643A,product-release,100,64,6/26/2020
32DCB3,public-offering,100,43,6/26/2020
34A959,merger-regulatory-approval,100,81,6/26/2020
3587B4,executive-appointment,100,54,6/26/2020
3BB616,facility-open,100,65,6/26/2020
434F38,partnership,100,61,6/26/2020
47B4CC,partnership,100,61,6/26/2020
47B4CC,partnership,100,61,6/26/2020
49914B,conference-call,100,50,6/26/2020
4AC91D,shareholder-rights-plan-suspended,100,57,6/26/2020
4B3555,dividend,100,50,6/26/2020
4FCC78,conference-call,100,50,6/26/2020
5088A5,unit-acquisition-acquiree,100,76,6/26/2020
5487B1,legal-issues-defendant,100,22,6/26/2020
55D0F3,board-meeting,100,51,6/26/2020
56632F,earnings,100,50,6/26/2020
5BE42C,public-offering,100,43,6/26/2020
616E3B,conference-call,100,50,6/26/2020
6.52E+64,public-offering,100,43,6/26/2020
65D0AA,legal-issues-defendant,100,22,6/26/2020
676FFD,legal-issues-defendant,100,22,6/26/2020
6E705B,product-resumed,100,52,6/26/2020
713810,partnership,100,61,6/26/2020
741937,earnings,100,50,6/26/2020
747219,reorganization-approval,100,74,6/26/2020
789ADD,earnings,100,50,6/26/2020
7AF907,public-offering,100,43,6/26/2020
86478F,dividend,100,50,6/26/2020
890FF4,legal-issues-defendant,100,22,6/26/2020
890FF4,legal-issues-defendant,100,22,6/26/2020
896771,facility-open,100,65,6/26/2020
8AB85C,index-listing,100,76,6/26/2020
92D3A0,conference-call,100,50,6/26/2020
9.31E+77,patent-infringement-plaintiff,100,47,6/26/2020
9.86E+03,business-combination,100,54,6/26/2020
A3AAA5,dividend,100,50,6/26/2020
A433A5,index-listing,100,76,6/26/2020
A6FE1C,unit-acquisition-acquirer,100,49,6/26/2020
A7F0A5,rights-issue,100,43,6/26/2020
AD9F1D,legal-issues-defendant,100,22,6/26/2020
AED61E,executive-appointment,100,54,6/26/2020
B5734D,index-listing,100,76,6/26/2020
B66928,reverse-stock-splits,100,51,6/26/2020
B6CD92,dividend,100,50,6/26/2020
BD9668,conference-call,100,50,6/26/2020
C03C8B,conference-call,100,50,6/26/2020
CCB623,legal-issues-defendant,100,22,6/26/2020
CDEDFE,index-listing,100,76,6/26/2020
D6489C,business-contract,100,69,6/26/2020
D88EF3,conference-call,100,50,6/26/2020
D90F43,legal-issues-defendant,100,22,6/26/2020
DC2F77,earnings,100,50,6/26/2020
E41190,executive-resignation,100,44,6/26/2020
E8846E,regulatory-stress-test,100,50,6/26/2020
E8F0E2,index-listing,100,76,6/26/2020
EF77A3,earnings,100,50,6/26/2020
EFA7B2,index-listing,100,76,6/26/2020
F5D410,executive-appointment,100,54,6/26/2020
4D8313,executive-resignation,100,44,6/27/2020
4D8313,executive-resignation,100,44,6/27/2020
A6FC89,legal-issues-defendant,100,22,6/27/2020
CCB623,fraud-defendant,100,20,6/27/2020
66CB62,bankruptcy,100,7,6/28/2020
01D03F,regulatory-product-approval-granted,100,81,6/29/2020
04CCCD,dividend,100,50,6/29/2020
55018,regulatory-stress-test,100,50,6/29/2020
05D148,index-listing,100,76,6/29/2020
06CB5B,executive-appointment,100,54,6/29/2020
71860,partnership,100,61,6/29/2020
07C69F,conference-call,100,50,6/29/2020
08A40F,executive-appointment,100,54,6/29/2020
099C88,business-contract,100,69,6/29/2020
0A7650,index-listing,100,76,6/29/2020
0A9D0A,business-contract,100,69,6/29/2020
0AAD90,executive-appointment,100,54,6/29/2020
0BC29E,business-contract,100,69,6/29/2020
0C136E,earnings,100,50,6/29/2020
0CC01F,earnings,100,50,6/29/2020
0F0693,regulatory-product-approval-granted,100,81,6/29/2020
0F2BC9,business-contract,100,69,6/29/2020
10C19B,conference-call,100,50,6/29/2020
147C38,executive-resignation,100,44,6/29/2020
15A388,executive-appointment,100,54,6/29/2020
188394,partnership,100,61,6/29/2020
18D9FA,index-listing,100,76,6/29/2020
1AE9D5,index-listing,100,76,6/29/2020
1B5FEA,index-listing,100,76,6/29/2020
1DB6A6,executive-appointment,100,54,6/29/2020
1EBF8D,regulatory-product-approval-granted,100,81,6/29/2020
1EBF8D,regulatory-product-approval-granted,100,81,6/29/2020
1EBF8D,regulatory-product-approval-granted,100,81,6/29/2020
1EBF8D,regulatory-product-approval-granted,100,81,6/29/2020
1EBF8D,regulatory-product-approval-granted,100,81,6/29/2020
1F08A6,joint-venture,100,62,6/29/2020
21245F,index-listing,100,76,6/29/2020
23207A,index-listing,100,76,6/29/2020
25AB8E,legal-issues-defendant,100,22,6/29/2020
25AB8E,legal-issues-defendant,100,22,6/29/2020
25D3CE,index-listing,100,76,6/29/2020
272704,earnings,100,50,6/29/2020
27C10F,legal-issues-defendant,100,22,6/29/2020
28AC4E,public-offering,100,43,6/29/2020
3.73E+87,earnings-guidance,100,50,6/29/2020
3.73E+87,earnings-guidance,100,50,6/29/2020
3E39A5,index-listing,100,76,6/29/2020
42312F,earnings,100,50,6/29/2020
4.91E+58,executive-appointment,100,54,6/29/2020
49A344,earnings,100,50,6/29/2020
49BBBC,earnings,100,50,6/29/2020
4A5C8D,business-contract,100,69,6/29/2020
4A6F00,partnership,100,61,6/29/2020
4C31F3,conference-participant,100,50,6/29/2020
520632,business-contract,100,69,6/29/2020
525A1C,partnership,100,61,6/29/2020
553949,executive-appointment,100,54,6/29/2020
5546DA,note-sale,100,52,6/29/2020
56277A,conference-call,100,50,6/29/2020
59F0B0,conference-call,100,50,6/29/2020
5D41E4,index-listing,100,76,6/29/2020
609208,earnings,100,50,6/29/2020
615B6D,earnings,100,50,6/29/2020
615B6D,earnings,100,50,6/29/2020
6166D1,executive-appointment,100,54,6/29/2020
657097,public-offering,100,43,6/29/2020
66667F,index-listing,100,76,6/29/2020
6C6D73,fundraising,100,64,6/29/2020
6CC55E,regulatory-product-approval-granted,100,81,6/29/2020
6D9B53,index-listing,100,76,6/29/2020
6-Dec-05,index-listing,100,76,6/29/2020
71B0CF,index-listing,100,76,6/29/2020
732A9B,executive-appointment,100,54,6/29/2020
756045,acquisition-completed-acquirer,100,49,6/29/2020
78F776,earnings,100,50,6/29/2020
7AF907,index-listing,100,76,6/29/2020
7E1D5D,partnership,100,61,6/29/2020
8.10E+205,index-listing,100,76,6/29/2020
830BDB,executive-appointment,100,54,6/29/2020
83B1C8,legal-issues-defendant,100,22,6/29/2020
83B1C8,legal-issues-defendant,100,22,6/29/2020
83E0AC,business-contract,100,69,6/29/2020
877734,conference-participant,100,50,6/29/2020
88D80A,index-listing,100,76,6/29/2020
890FF4,legal-issues-defendant,100,22,6/29/2020
890FF4,legal-issues-defendant,100,22,6/29/2020
890FF4,legal-issues-defendant,100,22,6/29/2020
890FF4,legal-issues-defendant,100,22,6/29/2020
8C5519,earnings,100,50,6/29/2020
8F3231,conference-call,100,50,6/29/2020
9196A2,earnings,100,50,6/29/2020
934029,clinical-trials-positive,100,87,6/29/2020
9.39E+69,executive-appointment,100,54,6/29/2020
968103,insider-buy,100,61,6/29/2020
97693A,acquisition-acquirer,100,49,6/29/2020
9810C0,conference-call,100,50,6/29/2020
990AD0,business-contract,100,69,6/29/2020
9C5174,earnings,100,50,6/29/2020
9FB4B7,index-listing,100,76,6/29/2020
A21649,capital-increase-completed,100,61,6/29/2020
A247F5,patent-awarded,100,72,6/29/2020
A63820,partnership,100,61,6/29/2020
A6828A,business-contract,100,69,6/29/2020
A72FD9,index-listing,100,76,6/29/2020
A79F7D,clinical-trials,100,56,6/29/2020
A7CCF0,conference-call,100,50,6/29/2020
A871B0,index-listing,100,76,6/29/2020
A8FDE8,business-contract,100,69,6/29/2020
AA98ED,conference-call,100,50,6/29/2020
AD1ACF,legal-issues-defendant,100,22,6/29/2020
ADFB3A,index-listing,100,76,6/29/2020
AE3113,partnership,100,61,6/29/2020
AE79CD,public-offering,100,43,6/29/2020
B01215,index-listing,100,76,6/29/2020
B1A85D,executive-appointment,100,54,6/29/2020
B1FC3B,business-contract,100,69,6/29/2020
B3ED62,business-contract,100,69,6/29/2020
B48D6A,index-listing,100,76,6/29/2020
B6CD92,dividend,100,50,6/29/2020
B8A51F,clinical-trials-filed,100,60,6/29/2020
B8A51F,clinical-trials-filed,100,60,6/29/2020
BAD655,board-meeting,100,51,6/29/2020
BC5680,partnership,100,61,6/29/2020
BDEC1E,clinical-trials-positive,100,87,6/29/2020
BF5959,index-listing,100,76,6/29/2020
BFCACF,index-listing,100,76,6/29/2020
C2E39B,index-listing,100,76,6/29/2020
C36189,index-listing,100,76,6/29/2020
C4FBDC,dividend,100,50,6/29/2020
C5E100,index-listing,100,76,6/29/2020
CC3EC4,index-listing,100,76,6/29/2020
CFF97C,credit-rating-affirmation-rater,20,50,6/29/2020
D1CFC8,partnership,100,61,6/29/2020
D6489C,partnership,100,61,6/29/2020
D697DE,government-contract,100,69,6/29/2020
D854F3,conference-call,100,50,6/29/2020
D8ECA1,business-contract,100,69,6/29/2020
DA199F,earnings,100,50,6/29/2020
DA9443,index-listing,100,76,6/29/2020
DB5CA5,business-contract,100,69,6/29/2020
DF11D9,conference-call,100,50,6/29/2020
DF532D,executive-appointment,100,54,6/29/2020
E074A0,executive-appointment,100,54,6/29/2020
E261E9,index-listing,100,76,6/29/2020
E68E62,regulatory-product-approval-granted,100,81,6/29/2020
E6C8DC,public-offering,100,43,6/29/2020
EBD89A,business-contract,100,69,6/29/2020
EDD234,index-listing,100,76,6/29/2020
EF1AD9,conference-call,100,50,6/29/2020
F18844,partnership,100,61,6/29/2020
F209B4,index-listing,100,76,6/29/2020
F2E253,product-release,100,64,6/29/2020
F2E253,product-release,100,64,6/29/2020
F2E253,product-release,100,64,6/29/2020
F2E253,product-release,100,64,6/29/2020
F57F6F,partnership,100,61,6/29/2020
F769E9,index-listing,100,76,6/29/2020
F7ADEB,index-listing,100,76,6/29/2020
FD9A97,conference-participant,100,50,6/29/2020
FEE4B0,partnership,100,61,6/29/2020
01D03F,business-contract,100,69,6/30/2020
0A7650,note-sale,100,52,6/30/2020
0C28D1,unit-acquisition-acquiree,100,76,6/30/2020
0E439E,earnings,100,50,6/30/2020
1348C9,conference-call,100,50,6/30/2020
1490F3,conference-call,100,50,6/30/2020
154272,legal-issues-defendant,100,22,6/30/2020
154272,legal-issues-defendant,100,22,6/30/2020
165B86,product-release,100,64,6/30/2020
18D9FA,fundraising,100,64,6/30/2020
1921DD,executive-appointment,100,54,6/30/2020
21153F,executive-appointment,100,54,6/30/2020
228D42,business-contract,100,69,6/30/2020
251988,business-contract,100,69,6/30/2020
267718,orphan-drug-designation,100,76,6/30/2020
26CC63,product-release,100,64,6/30/2020
27C10F,legal-issues-defendant,100,22,6/30/2020
2AE625,conference-call,100,50,6/30/2020
31553A,earnings,100,50,6/30/2020
31643A,unit-acquisition-acquirer,100,49,6/30/2020
32F943,executive-resignation,100,44,6/30/2020
3461CF,credit-rating-confirmation-rater,20,50,6/30/2020
39FB23,earnings,100,50,6/30/2020
3BCF24,dividend,100,50,6/30/2020
3C7F5F,business-contract,100,69,6/30/2020
3D9999,earnings,100,50,6/30/2020
408089,earnings,100,50,6/30/2020
442587,business-contract,100,69,6/30/2020
442587,business-contract,100,69,6/30/2020
453282,unit-acquisition-acquiree,100,76,6/30/2020
467F2C,public-offering,100,43,6/30/2020
4A2457,business-contract,100,69,6/30/2020
4A6F00,donation,100,54,6/30/2020
4BAF2E,product-release,100,64,6/30/2020
4E6F5A,clinical-trials-filed,100,60,6/30/2020
4EEB00,facility-open,100,65,6/30/2020
4F9487,note-sale,100,52,6/30/2020
51888A,unit-acquisition-acquiree,100,76,6/30/2020
5480A7,executive-appointment,100,54,6/30/2020
579E8F,ipo-completed,100,76,6/30/2020
57DDB9,business-contract,100,69,6/30/2020
58B46F,executive-appointment,100,54,6/30/2020
58B46F,executive-appointment,100,54,6/30/2020
58CA9A,campaign-ad-release,100,59,6/30/2020
5B6C11,dividend,100,50,6/30/2020
5BC2F4,earnings,100,50,6/30/2020
5F9CE3,partnership,100,61,6/30/2020
5FF95F,note-sale,100,52,6/30/2020
620381,public-offering,100,43,6/30/2020
66A667,earnings,100,50,6/30/2020
66A667,executive-appointment,100,54,6/30/2020
66A667,executive-appointment,100,54,6/30/2020
6844D2,earnings,100,50,6/30/2020
713810,partnership,100,61,6/30/2020
726EEA,executive-appointment,100,54,6/30/2020
7.40E+289,dividend,100,50,6/30/2020
75F982,dividend,100,50,6/30/2020
765913,earnings,100,50,6/30/2020
766047,executive-appointment,100,54,6/30/2020
76DD0C,clinical-trials,100,56,6/30/2020
771985,bought-deal,100,43,6/30/2020
79340A,earnings,100,50,6/30/2020
793C11,partnership,100,61,6/30/2020
7F3FBC,acquisition-acquirer,100,49,6/30/2020
8.10E+32,partnership,100,61,6/30/2020
885758,executive-appointment,100,54,6/30/2020
88923D,award,100,58,6/30/2020
890FF4,legal-issues-defendant,100,22,6/30/2020
8A8E41,product-release,100,64,6/30/2020
8C84DF,earnings,100,50,6/30/2020
8F3BCC,earnings,100,50,6/30/2020
8FF57A,business-contract,100,69,6/30/2020
9C8BC3,unit-acquisition-acquiree,100,76,6/30/2020
9C8BC3,partnership,100,61,6/30/2020
9CA619,dividend,100,50,6/30/2020
9E575E,clinical-trials-positive,100,87,6/30/2020
9F5CBB,dividend,100,50,6/30/2020
9F6B1A,partnership,100,61,6/30/2020
A1EAC8,business-contract,100,69,6/30/2020
A28C54,business-contract,100,69,6/30/2020
A5628C,earnings,100,50,6/30/2020
A6213D,facility-open,100,65,6/30/2020
A6FE1C,unit-acquisition-acquirer,100,49,6/30/2020
ABEE43,legal-issues-defendant,100,22,6/30/2020
AE0CCE,public-offering,100,43,6/30/2020
AE79CD,public-offering,100,43,6/30/2020
AE79CD,conference-call,100,50,6/30/2020
AFBEB4,index-listing,100,76,6/30/2020
AFF7B4,conference-call,100,50,6/30/2020
B1A85D,partnership,100,61,6/30/2020
B1FC3B,award,100,58,6/30/2020
B2F431,executive-appointment,100,54,6/30/2020
B33E77,clinical-trials-positive,100,87,6/30/2020
B33E77,clinical-trials-positive,100,87,6/30/2020
B37FB4,earnings,100,50,6/30/2020
B381D8,clinical-trials-start,100,64,6/30/2020
B6082A,conference-call,100,50,6/30/2020
B66928,reverse-stock-splits,100,51,6/30/2020
B77F14,product-release,100,64,6/30/2020
B803B1,dividend,100,50,6/30/2020
B840EF,earnings,100,50,6/30/2020
B8F71F,earnings,100,50,6/30/2020
B9CD50,partnership,100,61,6/30/2020
B9CD50,partnership,100,61,6/30/2020
BCC13E,clinical-trials-filed,100,60,6/30/2020
BEB756,conference-call,100,50,6/30/2020
BF5959,public-offering,100,43,6/30/2020
BFD0A7,board-meeting,100,51,6/30/2020
BFE02C,conference-call,100,50,6/30/2020
C11C46,partnership,100,61,6/30/2020
C230FE,earnings,100,50,6/30/2020
C3BAE7,legal-issues-defendant,100,22,6/30/2020
C3BAE7,legal-issues-defendant,100,22,6/30/2020
C3BAE7,legal-issues-defendant,100,22,6/30/2020
C3BAE7,legal-issues-defendant,100,22,6/30/2020
C3CF29,government-contract,100,69,6/30/2020
C45C1F,business-contract,100,69,6/30/2020
C4FBDC,conference-call,100,50,6/30/2020
C58D71,public-offering,100,43,6/30/2020
C598D7,conference-call,100,50,6/30/2020
C5D2AE,product-release,100,64,6/30/2020
C7859D,conference-call,100,50,6/30/2020
C8A248,executive-appointment,100,54,6/30/2020
C93C44,clinical-trials-start,100,64,6/30/2020
C93C44,clinical-trials-start,100,64,6/30/2020
C97B2D,conference-call,100,50,6/30/2020
C9B932,partnership,100,61,6/30/2020
C9B932,partnership,100,61,6/30/2020
C9F39B,conference-call,100,50,6/30/2020
CBA33B,earnings,100,50,6/30/2020
CBB77B,earnings,100,50,6/30/2020
CBB77B,earnings,100,50,6/30/2020
CBB77B,earnings,100,50,6/30/2020
CC176E,earnings,100,50,6/30/2020
CCB623,legal-issues-defendant,100,22,6/30/2020
CD06A2,earnings,100,50,6/30/2020
CDAB24,executive-resignation,100,44,6/30/2020
CDAB24,executive-resignation,100,44,6/30/2020
CDC217,index-listing,100,76,6/30/2020
CF073E,executive-appointment,100,54,6/30/2020
CFF97C,business-contract,100,69,6/30/2020
D1C26F,partnership,100,61,6/30/2020
D1CFC8,earnings,100,50,6/30/2020
D54E62,acquisition-completed-acquirer,100,49,6/30/2020
D6489C,legal-issues-defendant,100,22,6/30/2020
D8DA3D,conference-call,100,50,6/30/2020
DD1BA1,ipo,100,71,6/30/2020
DD1BA1,ipo,100,71,6/30/2020
DD1BA1,ipo,100,71,6/30/2020
DD1BA1,earnings,100,50,6/30/2020
E0647D,revenues,100,50,6/30/2020
E0647D,note-sale,100,52,6/30/2020
E10D31,conference-call,100,50,6/30/2020
E15736,conference-call,100,50,6/30/2020
E15736,conference-call,100,50,6/30/2020
E15736,conference-call,100,50,6/30/2020
E16133,executive-appointment,100,54,6/30/2020
E49AA3,executive-appointment,100,54,6/30/2020
E49AA3,executive-appointment,100,54,6/30/2020
E8A49A,business-contract,100,69,6/30/2020
EAEA91,dividend,100,50,6/30/2020
F0B877,conference-call,100,50,6/30/2020
F5349B,business-contract,100,69,6/30/2020
FA40E2,earnings,100,50,6/30/2020
FA40E2,earnings,100,50,6/30/2020
FA40E2,earnings,100,50,6/30/2020
FA40E2,earnings,100,50,6/30/2020
FA40E2,earnings,100,50,6/30/2020
FA40E2,earnings,100,50,6/30/2020
FA40E2,earnings,100,50,6/30/2020
FA40E2,earnings,100,50,6/30/2020
FA40E2,earnings,100,50,6/30/2020
FC1B7B,conference-call,100,50,6/30/2020
FC4550,conference-call,100,50,6/30/2020
FDE409,earnings,100,50,6/30/2020
FE7A63,earnings,100,50,6/30/2020
075CF7,executive-appointment,100,54,7/1/2020
0A6824,note-sale,100,52,7/1/2020
0AB700,dividend,100,50,7/1/2020
108FDA,dividend,100,50,7/1/2020
10C19B,dividend-up,100,81,7/1/2020
10C19B,unit-acquisition-acquiree,100,76,7/1/2020
12E454,earnings,100,50,7/1/2020
19CAC7,conference-call,100,50,7/1/2020
1D1B07,unit-acquisition-acquirer,100,49,7/1/2020
1D1B07,acquisition-acquirer,100,49,7/1/2020
1D1B07,earnings,100,50,7/1/2020
1D1B07,earnings,100,50,7/1/2020
1EBF8D,conference-call,100,50,7/1/2020
1EBF8D,business-contract,100,69,7/1/2020
1F716B,unit-acquisition-completed-acquirer,100,49,7/1/2020
21022F,earnings,100,50,7/1/2020
221AD7,earnings,100,50,7/1/2020
228D42,partnership,100,61,7/1/2020
249B39,earnings,100,50,7/1/2020
267718,business-contract,100,69,7/1/2020
267718,business-contract,100,69,7/1/2020
28AC4E,public-offering,100,43,7/1/2020
2A9C0A,conference-call,100,50,7/1/2020
2D643C,conference-call,100,50,7/1/2020
2F7474,conference-call,100,50,7/1/2020
2F9304,partnership,100,61,7/1/2020
2FDEE3,dividend,100,50,7/1/2020
338544,conference-call,100,50,7/1/2020
34B411,earnings,100,50,7/1/2020
35AE32,unit-acquisition-completed-acquirer,100,49,7/1/2020
36E479,clinical-trials-start,100,64,7/1/2020
39BFF6,conference-call,100,50,7/1/2020
3C7F5F,executive-appointment,100,54,7/1/2020
3C7F5F,business-contract,100,69,7/1/2020
401072,clinical-trials-filed,100,60,7/1/2020
41B53E,dividend,100,50,7/1/2020
44A4FC,unit-acquisition-completed-acquirer,100,49,7/1/2020
4.60E+06,public-offering,100,43,7/1/2020
4.60E+06,revenues,100,50,7/1/2020
4885C8,earnings,100,50,7/1/2020
4D8313,conference-call,100,50,7/1/2020
4EC4C1,conference-call,100,50,7/1/2020
4FCC78,dividend,100,50,7/1/2020
52FB2F,executive-appointment,100,54,7/1/2020
5487B1,conference-call,100,50,7/1/2020
5546DA,merger-completed,100,66,7/1/2020
57DDB9,business-contract,100,69,7/1/2020
58C2D4,legal-issues-defendant,100,22,7/1/2020
59B229,earnings,100,50,7/1/2020
59C539,conference-call,100,50,7/1/2020
5D41E4,conference-call,100,50,7/1/2020
60EA12,revenues,100,50,7/1/2020
622DBE,executive-appointment,100,54,7/1/2020
6284B5,partnership,100,61,7/1/2020
6.52E+64,bankruptcy-exit,100,59,7/1/2020
6.52E+64,bankruptcy-exit,100,59,7/1/2020
657097,unit-acquisition-acquirer,100,49,7/1/2020
65D0AA,legal-issues-defendant,100,22,7/1/2020
665618,dividend,100,50,7/1/2020
67B052,clinical-trials,100,56,7/1/2020
67B052,clinical-trials,100,56,7/1/2020
68BA15,dividend,100,50,7/1/2020
6ACFBF,acquisition-completed-acquirer,100,49,7/1/2020
6C6D73,executive-appointment,100,54,7/1/2020
6E1E61,conference-call,100,50,7/1/2020
6E705B,product-release,100,64,7/1/2020
6F0A63,conference-call,100,50,7/1/2020
719477,conference-call,100,50,7/1/2020
723548,dividend,100,50,7/1/2020
73C9E2,executive-appointment,100,54,7/1/2020
762A3E,conference-call,100,50,7/1/2020
79167B,conference-call,100,50,7/1/2020
7A975D,earnings,100,50,7/1/2020
7A975D,earnings,100,50,7/1/2020
7A975D,earnings,100,50,7/1/2020
7C790D,acquisition-acquirer,100,49,7/1/2020
7FDE1C,business-contract,100,69,7/1/2020
7FDE1C,market-entry,100,57,7/1/2020
810FAD,conference-call,100,50,7/1/2020
82FD6D,executive-appointment,100,54,7/1/2020
8.40E+120,executive-appointment,100,54,7/1/2020
890FF4,legal-issues-defendant,100,22,7/1/2020
8D4486,partnership,100,61,7/1/2020
8D4486,partnership,100,61,7/1/2020
8DE74B,executive-appointment,100,54,7/1/2020
942633,acquisition-completed-acquiree,100,76,7/1/2020
95DC1F,partnership,100,61,7/1/2020
96F126,earnings,100,50,7/1/2020
9C3D3C,unit-acquisition-acquirer,100,49,7/1/2020
9CA432,conference-call,100,50,7/1/2020
9CA619,earnings,100,50,7/1/2020
9CA619,earnings,100,50,7/1/2020
9CA619,earnings,100,50,7/1/2020
9CA619,earnings,100,50,7/1/2020
9CA619,earnings,100,50,7/1/2020
9CA619,earnings,100,50,7/1/2020
9CA619,earnings,100,50,7/1/2020
9CA619,earnings,100,50,7/1/2020
9CA619,earnings,100,50,7/1/2020
9CA619,earnings,100,50,7/1/2020
9CA619,earnings,100,50,7/1/2020
9CA619,partnership,100,61,7/1/2020
9D6A24,conference-call,100,50,7/1/2020
9E5C2C,conference-call,100,50,7/1/2020
9F37C5,dividend,100,50,7/1/2020
A16DEA,executive-appointment,100,54,7/1/2020
A1DBF0,partnership,100,61,7/1/2020
A5B913,earnings,100,50,7/1/2020
A70BF5,earnings,100,50,7/1/2020
A753BB,business-contract,100,69,7/1/2020
A8CBDA,earnings,100,50,7/1/2020
AB7F05,earnings,100,50,7/1/2020
ACDF88,partnership,100,61,7/1/2020
AD9F1D,conference-call,100,50,7/1/2020
AD9F1D,legal-issues-defendant,100,22,7/1/2020
B1A85D,note-sale,100,52,7/1/2020
B508E5,product-release,100,64,7/1/2020
B5DE80,conference-call,100,50,7/1/2020
B604DF,conference-call,100,50,7/1/2020
BBAE2A,conference-call,100,50,7/1/2020
BD9668,unit-acquisition-acquirer,100,49,7/1/2020
BFCACF,executive-appointment,100,54,7/1/2020
C0200F,earnings,100,50,7/1/2020
C3BAE7,legal-issues-defendant,100,22,7/1/2020
C3EE99,earnings,100,50,7/1/2020
C4C77F,business-contract,100,69,7/1/2020
C58D71,public-offering,100,43,7/1/2020
C5C137,earnings,100,50,7/1/2020
C5C137,earnings,100,50,7/1/2020
C5C137,earnings,100,50,7/1/2020
C7AE14,dividend,100,50,7/1/2020
C83B88,business-contract,100,69,7/1/2020
C83B88,unit-acquisition-acquiree,100,76,7/1/2020
C9D866,conference-call,100,50,7/1/2020
CBFFDD,acquisition-completed-acquirer,100,49,7/1/2020
CBFFDD,executive-appointment,100,54,7/1/2020
CC8F6E,product-release,100,64,7/1/2020
CF211D,credit-extension-recipient,100,69,7/1/2020
CF6A5A,earnings,100,50,7/1/2020
D1C26F,acquisition-completed-acquirer,100,49,7/1/2020
D33D8C,acquisition-completed-acquirer,100,49,7/1/2020
D57D99,product-release,100,64,7/1/2020
D6EAA3,conference-call,100,50,7/1/2020
D9E036,business-contract,100,69,7/1/2020
DB9F70,public-offering,100,43,7/1/2020
DC0D18,earnings,100,50,7/1/2020
DD0F15,regulatory-product-review-positive,100,73,7/1/2020
DD7A96,conference-call,100,50,7/1/2020
DF1F7A,conference-call,100,50,7/1/2020
E0207A,executive-appointment,100,54,7/1/2020
E0339F,earnings,100,50,7/1/2020
E12A6E,earnings,100,50,7/1/2020
E6C8DC,public-offering,100,43,7/1/2020
E6EDED,conference-call,100,50,7/1/2020
E84500,conference-call,100,50,7/1/2020
E959F3,earnings,100,50,7/1/2020
EC8116,dividend,100,50,7/1/2020
ECA300,executive-appointment,100,54,7/1/2020
ED0402,earnings,100,50,7/1/2020
F1529C,acquisition-rumor-acquiree,100,73,7/1/2020
F1529C,acquisition-rumor-acquiree,100,73,7/1/2020
F1CD47,earnings,100,50,7/1/2020
F31B13,executive-resignation,100,44,7/1/2020
F5D499,executive-appointment,100,54,7/1/2020
F82D37,executive-resignation,100,44,7/1/2020
F85CC0,acquisition-completed-acquirer,100,49,7/1/2020
F85CC0,acquisition-completed-acquirer,100,49,7/1/2020
F85CC0,acquisition-completed-acquirer,100,49,7/1/2020
F85CC0,acquisition-completed-acquirer,100,49,7/1/2020
FA36A4,conference-call,100,50,7/1/2020
FA40E2,partnership,100,61,7/1/2020
FFCD0E,stake-acquirer,100,48,7/1/2020
0624BE,note-sale,100,52,7/2/2020
0E499E,business-contract,100,69,7/2/2020
105D00,conference-call,100,50,7/2/2020
119CB6,conference-call,100,50,7/2/2020
16C544,partnership,100,61,7/2/2020
16C7F0,conference-call,100,50,7/2/2020
1A5957,revenues,100,50,7/2/2020
1A6A94,conference-call,100,50,7/2/2020
1EBF8D,acquisition-completed-acquirer,100,49,7/2/2020
1F08A6,conference-call,100,50,7/2/2020
1F716B,conference-call,100,50,7/2/2020
205AD5,earnings,100,50,7/2/2020
227F04,acquisition-completed-acquirer,100,49,7/2/2020
279916,award,100,58,7/2/2020
2B9DBB,conference-call,100,50,7/2/2020
30DFD3,conference-call,100,50,7/2/2020
317EC6,ipo-pricing,100,50,7/2/2020
32F943,business-contract,100,69,7/2/2020
32F943,business-contract,100,69,7/2/2020
32F943,business-contract,100,69,7/2/2020
342218,conference-call,100,50,7/2/2020
3471C0,conference-call,100,50,7/2/2020
3.88E+02,conference-call,100,50,7/2/2020
38C46F,dividend,100,50,7/2/2020
3B37F7,acquisition-acquirer,100,49,7/2/2020
46CF27,earnings,100,50,7/2/2020
4A2457,business-contract,100,69,7/2/2020
4A6F00,partnership,100,61,7/2/2020
504FE2,conference-call,100,50,7/2/2020
5088A5,unit-acquisition-acquiree,100,76,7/2/2020
51888A,executive-appointment,100,54,7/2/2020
519FE0,acquisition-completed-acquirer,100,49,7/2/2020
5487B1,legal-issues-defendant,100,22,7/2/2020
56B7C1,dividend,100,50,7/2/2020
57356F,conference-call,100,50,7/2/2020
58C2D4,legal-issues-defendant,100,22,7/2/2020
5AF08A,earnings,100,50,7/2/2020
5BFE94,conference-call,100,50,7/2/2020
63F892,earnings,100,50,7/2/2020
6.52E+64,partnership,100,61,7/2/2020
65D0AA,legal-issues-defendant,100,22,7/2/2020
67529E,conference-call,100,50,7/2/2020
6E705B,note-sale,100,52,7/2/2020
70FCEF,earnings,100,50,7/2/2020
713810,fundraising,100,64,7/2/2020
7262F2,business-contract,100,69,7/2/2020
763724,dividend,100,50,7/2/2020
769F40,executive-appointment,100,54,7/2/2020
773A17,product-release,100,64,7/2/2020
7D7716,earnings,100,50,7/2/2020
7DA412,earnings,100,50,7/2/2020
868808,executive-appointment,100,54,7/2/2020
873DB9,conference-call,100,50,7/2/2020
890FF4,legal-issues-defendant,100,22,7/2/2020
890FF4,legal-issues-defendant,100,22,7/2/2020
890FF4,legal-issues-defendant,100,22,7/2/2020
90D6A5,conference-call,100,50,7/2/2020
922F0C,earnings,100,50,7/2/2020
9CA4C6,conference-call,100,50,7/2/2020
9EED50,conference-call,100,50,7/2/2020
A350C1,executive-resignation,100,44,7/2/2020
A6213D,business-contract,100,69,7/2/2020
A6828A,business-contract,100,69,7/2/2020
A6FE1C,unit-acquisition-acquirer,100,49,7/2/2020
AE79CD,public-offering,100,43,7/2/2020
AFDF2E,dividend,100,50,7/2/2020
B290A2,patient-enrollment-complete,100,64,7/2/2020
B4703C,conference-call,100,50,7/2/2020
B5766D,conference-call,100,50,7/2/2020
BB5142,conference-call,100,50,7/2/2020
BCC55F,executive-appointment,100,54,7/2/2020
C0BA36,award,100,58,7/2/2020
C32A39,conference-call,100,50,7/2/2020
C951A2,earnings,100,50,7/2/2020
CC35BE,patent-awarded,100,72,7/2/2020
CC6FF5,earnings,100,50,7/2/2020
CD06A2,merger-completed,100,66,7/2/2020
CD06A2,merger-completed,100,66,7/2/2020
CEC5B9,executive-appointment,100,54,7/2/2020
CFF97C,conference-call,100,50,7/2/2020
D1C26F,partnership,100,61,7/2/2020
D5938F,clinical-trials-suspended,100,24,7/2/2020
D5938F,clinical-trials-suspended,100,24,7/2/2020
DD682D,executive-appointment,100,54,7/2/2020
DF16DE,executive-appointment,100,54,7/2/2020
E16133,conference-call,100,50,7/2/2020
E2F130,earnings,100,50,7/2/2020
E70531,partnership,100,61,7/2/2020
E8846E,earnings,100,50,7/2/2020
F18844,executive-appointment,100,54,7/2/2020
F2BC3D,executive-appointment,100,54,7/2/2020
F4E882,earnings,100,50,7/2/2020
F4E992,conference-call,100,50,7/2/2020
F5349B,earnings,100,50,7/2/2020
F5D059,dividend,100,50,7/2/2020
FB728F,credit-extension-recipient,100,69,7/2/2020
FC4550,dividend,100,50,7/2/2020
FEE4B0,earnings,100,50,7/2/2020
227F04,acquisition-completed-acquirer,100,49,7/3/2020
2F98A5,product-recall,100,29,7/3/2020
676FFD,legal-issues-defendant,100,22,7/3/2020
873DB9,government-contract,100,69,7/3/2020
873DB9,trading-resumed,100,58,7/3/2020
979451,legal-issues-defendant,100,22,7/3/2020
B614F8,legal-issues-defendant,100,22,7/3/2020
977A1E,unit-acquisition-acquiree,100,76,7/5/2020
A94718,executive-death,100,31,7/5/2020
00067A,earnings,100,50,7/6/2020
00326D,conference-call,100,50,7/6/2020
31025,earnings,100,50,7/6/2020
51332,legal-issues-defendant,100,22,7/6/2020
078D52,dividend,100,50,7/6/2020
95294,cyber-attacks,100,26,7/6/2020
099A92,conference-call,100,50,7/6/2020
09DE1F,note-sale,100,52,7/6/2020
0C136E,acquisition-completed-acquirer,100,49,7/6/2020
0C136E,acquisition-completed-acquirer,100,49,7/6/2020
0CBC4D,earnings,100,50,7/6/2020
0E499E,revenues,100,50,7/6/2020
0F2BC9,executive-appointment,100,54,7/6/2020
15A388,business-contract,100,69,7/6/2020
165B86,acquisition-acquirer,100,49,7/6/2020
1AB808,executive-appointment,100,54,7/6/2020
221445,dividend,100,50,7/6/2020
223552,public-offering,100,43,7/6/2020
2571FA,conference-call,100,50,7/6/2020
267718,acquisition-acquiree,100,76,7/6/2020
29A4CC,conference-call,100,50,7/6/2020
2A1009,business-contract,100,69,7/6/2020
315EB0,conference-call,100,50,7/6/2020
326EDD,conference-call,100,50,7/6/2020
3.50E+27,conference-call,100,50,7/6/2020
370C50,conference-call,100,50,7/6/2020
37727A,conference-call,100,50,7/6/2020
37B618,asset-sale,100,62,7/6/2020
3C7F5F,business-contract,100,69,7/6/2020
414FFF,note-sale,100,52,7/6/2020
414FFF,note-sale,100,52,7/6/2020
41785E,earnings,100,50,7/6/2020
467F2C,partnership,100,61,7/6/2020
492117,acquisition-acquirer,100,49,7/6/2020
492117,acquisition-acquirer,100,49,7/6/2020
4A3438,executive-appointment,100,54,7/6/2020
4A5C8D,earnings,100,50,7/6/2020
4BAF2E,public-offering,100,43,7/6/2020
4C6C63,earnings,100,50,7/6/2020
4E7C1F,award,100,58,7/6/2020
51D876,earnings,100,50,7/6/2020
520632,regulatory-product-approval-granted,100,81,7/6/2020
546A9C,stake-acquirer,100,48,7/6/2020
546A9C,conference-call,100,50,7/6/2020
5487B1,legal-issues-defendant,100,22,7/6/2020
54B889,credit-extension-recipient,100,69,7/6/2020
550D01,earnings,100,50,7/6/2020
56EA2B,public-offering,100,43,7/6/2020
57DDB9,business-contract,100,69,7/6/2020
587EDF,executive-appointment,100,54,7/6/2020
58C2D4,legal-issues-defendant,100,22,7/6/2020
5B6C11,dividend,100,50,7/6/2020
5BE42C,conference-call,100,50,7/6/2020
5C7601,executive-appointment,100,54,7/6/2020
5CC29D,earnings,100,50,7/6/2020
5E6959,conference-call,100,50,7/6/2020
5F6D73,executive-resignation,100,44,7/6/2020
6391C2,public-offering,100,43,7/6/2020
66749D,earnings,100,50,7/6/2020
676FFD,legal-issues-defendant,100,22,7/6/2020
676FFD,legal-issues-defendant,100,22,7/6/2020
6CB7F9,conference-call,100,50,7/6/2020
6D6B40,earnings,100,50,7/6/2020
70FCEF,partnership,100,61,7/6/2020
726DDF,legal-issues-defendant,100,22,7/6/2020
76CEFB,earnings,100,50,7/6/2020
790C34,business-contract,100,69,7/6/2020
7A5D58,executive-appointment,100,54,7/6/2020
7BC92D,executive-appointment,100,54,7/6/2020
7CD98F,earnings,100,50,7/6/2020
7FDE1C,business-contract,100,69,7/6/2020
8BE916,earnings,100,50,7/6/2020
8E93A4,conference-call,100,50,7/6/2020
900356,note-sale,100,52,7/6/2020
902670,conference-call,100,50,7/6/2020
911AB8,conference-call,100,50,7/6/2020
92005C,executive-appointment,100,54,7/6/2020
9.36E+10,business-contract,100,69,7/6/2020
9368BE,conference-call,100,50,7/6/2020
944B2E,board-meeting,100,51,7/6/2020
94637C,partnership,100,61,7/6/2020
94637C,partnership,100,61,7/6/2020
94637C,partnership,100,61,7/6/2020
97FE80,earnings,100,50,7/6/2020
97FE80,earnings,100,50,7/6/2020
9934AD,executive-appointment,100,54,7/6/2020
9C8BC3,conference-call,100,50,7/6/2020
9F6B1A,earnings,100,50,7/6/2020
A01200,public-offering,100,43,7/6/2020
A01664,earnings,100,50,7/6/2020
A41450,dividend,100,50,7/6/2020
A60318,earnings,100,50,7/6/2020
A6FE1C,unit-acquisition-acquirer,100,49,7/6/2020
AD1ACF,conference-call,100,50,7/6/2020
B1FC3B,business-contract,100,69,7/6/2020
B446B8,earnings,100,50,7/6/2020
B614F8,legal-issues-defendant,100,22,7/6/2020
BB02FB,conference-call,100,50,7/6/2020
BD15E8,conference-call,100,50,7/6/2020
BFAEB4,facility-close,100,47,7/6/2020
C5D2AE,earnings,100,50,7/6/2020
C7859D,dividend,100,50,7/6/2020
C83B88,facility-open,100,65,7/6/2020
CC8F6E,partnership,100,61,7/6/2020
CCB623,government-contract,100,69,7/6/2020
CD06A2,dividend,100,50,7/6/2020
CDC217,conference-participant,100,50,7/6/2020
CE4E6D,product-release,100,64,7/6/2020
D07B07,facility-open,100,65,7/6/2020
D29F43,executive-appointment,100,54,7/6/2020
D501DC,dividend,100,50,7/6/2020
D64EDF,executive-appointment,100,54,7/6/2020
D77F7E,earnings,100,50,7/6/2020
D8760C,conference-call,100,50,7/6/2020
D88EF3,note-sale,100,52,7/6/2020
D90F43,acquisition-acquirer,100,49,7/6/2020
D90F43,acquisition-acquirer,100,49,7/6/2020
D90F43,acquisition-acquirer,100,49,7/6/2020
D9C07E,acquisition-acquirer,100,49,7/6/2020
D9E036,executive-appointment,100,54,7/6/2020
DA0A9E,reorganization,100,53,7/6/2020
DA0CB8,conference-call,100,50,7/6/2020
DA48E4,partnership,100,61,7/6/2020
DB5CA5,dividend,100,50,7/6/2020
DC5299,conference-call,100,50,7/6/2020
DD1BA1,product-release,100,64,7/6/2020
DD1BA1,acquisition-completed-acquirer,100,49,7/6/2020
DD1BA1,acquisition-completed-acquirer,100,49,7/6/2020
E2F130,dividend,100,50,7/6/2020
E30A8F,earnings,100,50,7/6/2020
E8B315,conference-call,100,50,7/6/2020
ECE814,earnings,100,50,7/6/2020
ED22DC,public-offering,100,43,7/6/2020
ED9576,earnings,100,50,7/6/2020
EE967B,earnings,100,50,7/6/2020
F5349B,executive-appointment,100,54,7/6/2020
F5D410,conference-call,100,50,7/6/2020
F6581D,executive-appointment,100,54,7/6/2020
F6FA6A,earnings,100,50,7/6/2020
F8084B,earnings,100,50,7/6/2020
F83279,earnings,100,50,7/6/2020
FA044A,conference-call,100,50,7/6/2020
FAB97A,earnings,100,50,7/6/2020
FD0CA4,conference-call,100,50,7/6/2020
00326D,executive-appointment,100,54,7/7/2020
00D6B5,conference-call,100,50,7/7/2020
13528,executive-appointment,100,54,7/7/2020
03B8CF,investment-investor,100,55,7/7/2020
48590,earnings,100,50,7/7/2020
51332,credit-rating-affirmation,100,51,7/7/2020
054E7E,executive-appointment,100,54,7/7/2020
081AB9,conference-call,100,50,7/7/2020
09F623,conference-call,100,50,7/7/2020
0DE3D5,conference-call,100,50,7/7/2020
1151F4,conference-call,100,50,7/7/2020
1A3E1B,partnership,100,61,7/7/2020
1CDD1C,conference-call,100,50,7/7/2020
1DE526,conference-call,100,50,7/7/2020
1E7785,credit-rating-affirmation,100,54,7/7/2020
20BEEA,business-contract,100,69,7/7/2020
20BEEA,business-contract,100,69,7/7/2020
20BEEA,business-contract,100,69,7/7/2020
20BEEA,business-contract,100,69,7/7/2020
228D42,partnership,100,61,7/7/2020
228D42,business-contract,100,69,7/7/2020
25DD05,conference-call,100,50,7/7/2020
2667B6,earnings,100,50,7/7/2020
28DCA8,earnings-guidance,100,50,7/7/2020
2C681C,fundraising,100,64,7/7/2020
2C681C,fundraising,100,64,7/7/2020
2E902B,conference-call,100,50,7/7/2020
2F5256,conference-call,100,50,7/7/2020
317EC6,ipo-completed,100,76,7/7/2020
34E9F9,dividend,100,50,7/7/2020
387541,conference-call,100,50,7/7/2020
39692D,note-sale,100,52,7/7/2020
39692D,note-sale,100,52,7/7/2020
3AAEAE,business-contract,100,69,7/7/2020
3AAEAE,business-contract,100,69,7/7/2020
3C7F5F,business-contract,100,69,7/7/2020
3C7F5F,business-contract,100,69,7/7/2020
3DC887,earnings,100,50,7/7/2020
42AABD,partnership,100,61,7/7/2020
442587,business-contract,100,69,7/7/2020
442587,business-contract,100,69,7/7/2020
448215,executive-appointment,100,54,7/7/2020
45444E,conference-call,100,50,7/7/2020
467F2C,conference-call,100,50,7/7/2020
4.60E+06,public-offering,100,43,7/7/2020
4A6F00,partnership,100,61,7/7/2020
4A6F00,partnership,100,61,7/7/2020
4A6F00,partnership,100,61,7/7/2020
4A6F00,partnership,100,61,7/7/2020
4B6EF9,earnings,100,50,7/7/2020
4EE14A,earnings,100,50,7/7/2020
4EE14A,earnings,100,50,7/7/2020
4FB770,conference-call,100,50,7/7/2020
51E682,conference-call,100,50,7/7/2020
5487B1,legal-issues-defendant,100,22,7/7/2020
56EA2B,public-offering,100,43,7/7/2020
589803,business-contract,100,69,7/7/2020
589803,business-contract,100,69,7/7/2020
5A423F,earnings,100,50,7/7/2020
5A9F54,earnings,100,50,7/7/2020
5B7739,acquisition-acquirer,100,49,7/7/2020
5BC2F4,partnership,100,61,7/7/2020
5D1956,earnings,100,50,7/7/2020
5F2FF7,earnings,100,50,7/7/2020
601785,earnings,100,50,7/7/2020
60DD84,conference-call,100,50,7/7/2020
61B81B,executive-appointment,100,54,7/7/2020
61BCA7,earnings,100,50,7/7/2020
62CDDE,executive-appointment,100,54,7/7/2020
665D7D,conference-call,100,50,7/7/2020
676FFD,legal-issues-defendant,100,22,7/7/2020
6A024C,executive-appointment,100,54,7/7/2020
6E705B,conference-call,100,50,7/7/2020
6F6559,earnings,100,50,7/7/2020
7032D0,partnership,100,61,7/7/2020
713810,partnership,100,61,7/7/2020
726DDF,partnership,100,61,7/7/2020
7.44E+09,conference-call,100,50,7/7/2020
747219,earnings,100,50,7/7/2020
762A3E,executive-appointment,100,54,7/7/2020
7712CB,earnings,100,50,7/7/2020
771985,conference-call,100,50,7/7/2020
7999F3,executive-appointment,100,54,7/7/2020
7A975D,dividend,100,50,7/7/2020
7B0BA6,earnings,100,50,7/7/2020
810FAD,business-contract,100,69,7/7/2020
8303CD,conference-call,100,50,7/7/2020
8802B4,conference-call,100,50,7/7/2020
8B1F37,executive-appointment,100,54,7/7/2020
8B2C4A,conference-call,100,50,7/7/2020
8D4486,executive-appointment,100,54,7/7/2020
8D5145,earnings,100,50,7/7/2020
8DBE73,legal-issues-defendant,100,22,7/7/2020
8DDA23,note-sale,100,52,7/7/2020
9196A2,conference-call,100,50,7/7/2020
9.36E+10,business-contract,100,69,7/7/2020
93D207,earnings,100,50,7/7/2020
93F143,executive-appointment,100,54,7/7/2020
9548BB,earnings,100,50,7/7/2020
95C392,conference-call,100,50,7/7/2020
9.62E+76,earnings,100,50,7/7/2020
965360,earnings,100,50,7/7/2020
96A2D3,earnings,100,50,7/7/2020
986AF6,conference-call,100,50,7/7/2020
9C8664,conference-call,100,50,7/7/2020
9D3360,conference-call,100,50,7/7/2020
9D65C1,executive-appointment,100,54,7/7/2020
9F6B1A,product-release,100,64,7/7/2020
9F71E5,partnership,100,61,7/7/2020
A398B9,earnings,100,50,7/7/2020
A3F598,conference-call,100,50,7/7/2020
A433A5,product-release,100,64,7/7/2020
A5151E,earnings,100,50,7/7/2020
A63387,business-contract,100,69,7/7/2020
A7CCF0,executive-appointment,100,54,7/7/2020
A87CD6,earnings,100,50,7/7/2020
A8E72A,product-release,100,64,7/7/2020
AC775C,conference-call,100,50,7/7/2020
AC7AAE,executive-appointment,100,54,7/7/2020
B01111,partnership,100,61,7/7/2020
B1FC3B,business-contract,100,69,7/7/2020
B2256A,conference-call,100,50,7/7/2020
B290A2,patient-enrollment-complete,100,64,7/7/2020
B290A2,patient-enrollment-complete,100,64,7/7/2020
B83BCE,earnings-guidance-up,100,83,7/7/2020
B96637,conference-call,100,50,7/7/2020
B96637,conference-call,100,50,7/7/2020
BA218A,conference-call,100,50,7/7/2020
BB88B6,executive-appointment,100,54,7/7/2020
BB88B6,partnership,100,61,7/7/2020
BBF349,business-contract,100,69,7/7/2020
C03C8B,business-contract,100,69,7/7/2020
C2609A,executive-appointment,100,54,7/7/2020
C3BAE7,earnings,100,50,7/7/2020
C4706C,dividend,100,50,7/7/2020
C48574,revenue-up,100,78,7/7/2020
C48574,revenue-up,100,78,7/7/2020
C48574,revenue-up,100,78,7/7/2020
C48574,revenue-up,100,78,7/7/2020
C7863D,conference-call,100,50,7/7/2020
C7FC95,executive-appointment,100,54,7/7/2020
C7FC95,business-contract,100,69,7/7/2020
C9B932,partnership,100,61,7/7/2020
CA3CB9,conference-call,100,50,7/7/2020
CCB623,legal-issues-defendant,100,22,7/7/2020
CDC217,clinical-trials-start,100,64,7/7/2020
CDE51C,executive-appointment,100,54,7/7/2020
CFF15D,partnership,100,61,7/7/2020
CFF15D,partnership,100,61,7/7/2020
CFF15D,partnership,100,61,7/7/2020
CFF15D,business-contract,100,69,7/7/2020
CFF15D,business-contract,100,69,7/7/2020
D1C26F,partnership,100,61,7/7/2020
D25249,conference-call,100,50,7/7/2020
D36B23,clinical-trials-start,100,64,7/7/2020
D3FA2C,conference-call,100,50,7/7/2020
D501DC,conference-call,100,50,7/7/2020
D60BB2,award,100,58,7/7/2020
D6853F,business-contract,100,69,7/7/2020
D70365,conference-call,100,50,7/7/2020
D82EF3,note-sale,100,52,7/7/2020
D90F43,acquisition-acquirer,100,49,7/7/2020
DA48E4,business-contract,100,69,7/7/2020
DA48E4,business-contract,100,69,7/7/2020
DA48E4,conference-call,100,50,7/7/2020
DA48E4,business-contract,100,69,7/7/2020
DB5CA5,earnings,100,50,7/7/2020
DC0998,conference-call,100,50,7/7/2020
DC1405,earnings,100,50,7/7/2020
DD1BA1,reorganization-unit,100,53,7/7/2020
DD682D,earnings,100,50,7/7/2020
DEF058,earnings,100,50,7/7/2020
DF532D,conference-call,100,50,7/7/2020
E15736,note-sale,100,52,7/7/2020
E1E093,business-contract,100,69,7/7/2020
E259C7,partnership,100,61,7/7/2020
E2F130,acquisition-acquirer,100,49,7/7/2020
E30A8F,partnership,100,61,7/7/2020
E30B34,earnings,100,50,7/7/2020
E30B34,earnings,100,50,7/7/2020
E82A2D,conference-call,100,50,7/7/2020
E8846E,legal-issues-defendant,100,22,7/7/2020
E94704,conference-call,100,50,7/7/2020
E9FF33,earnings,100,50,7/7/2020
EA4E68,acquisition-completed-acquirer,100,49,7/7/2020
EB61C4,conference-call,100,50,7/7/2020
EC99D0,award,100,58,7/7/2020
EF5BED,executive-resignation,100,44,7/7/2020
F3EDB4,earnings,100,50,7/7/2020
F43A11,legal-issues-defendant,100,22,7/7/2020
F80389,conference-call,100,50,7/7/2020
FB7724,earnings,100,50,7/7/2020
FC8733,index-listing,100,76,7/7/2020
FD9526,earnings,100,50,7/7/2020
FDC7E6,conference-call,100,50,7/7/2020
FDF28E,earnings,100,50,7/7/2020
01478A,conference-call,100,50,7/8/2020
0157B1,partnership,100,61,7/8/2020
51332,earnings,100,50,7/8/2020
0B57D7,conference-call,100,50,7/8/2020
0BD4E8,business-contract,100,69,7/8/2020
0C4131,conference-call,100,50,7/8/2020
1216D1,conference-call,100,50,7/8/2020
157D9F,conference-call,100,50,7/8/2020
16F4D8,conference-call,100,50,7/8/2020
16FC89,earnings,100,50,7/8/2020
1748B3,conference-call,100,50,7/8/2020
1866B2,public-offering,100,43,7/8/2020
1866B2,earnings,100,50,7/8/2020
188394,conference-call,100,50,7/8/2020
1921DD,executive-appointment,100,54,7/8/2020
1BC12C,conference-call,100,50,7/8/2020
1E9A6D,earnings,100,50,7/8/2020
1EBF8D,partnership,100,61,7/8/2020
1EBF8D,partnership,100,61,7/8/2020
1F19C8,fundraising,100,64,7/8/2020
206852,conference-call,100,50,7/8/2020
21153F,executive-appointment,100,54,7/8/2020
223552,public-offering,100,43,7/8/2020
228D42,partnership,100,61,7/8/2020
24CB56,dividend,100,50,7/8/2020
251988,executive-appointment,100,54,7/8/2020
278C18,buybacks,100,74,7/8/2020
2950FF,earnings,100,50,7/8/2020
2950FF,earnings,100,50,7/8/2020
29B702,earnings,100,50,7/8/2020
2A1009,partnership,100,61,7/8/2020
2B7A40,conference-call,100,50,7/8/2020
2C7505,partnership,100,61,7/8/2020
2CA60F,partnership,100,61,7/8/2020
2CBB58,conference-call,100,50,7/8/2020
2D76CE,earnings,100,50,7/8/2020
2DC88B,executive-appointment,100,54,7/8/2020
346BF2,executive-appointment,100,54,7/8/2020
34A959,acquisition-regulatory-approval-acquirer,100,54,7/8/2020
384CD3,earnings,100,50,7/8/2020
3B37F7,dividend,100,50,7/8/2020
3BE00F,earnings,100,50,7/8/2020
3DD5E2,conference-call,100,50,7/8/2020
3E15F6,conference-call,100,50,7/8/2020
3ED92D,earnings-guidance,100,50,7/8/2020
3FACA7,dividend,100,50,7/8/2020
3FACA7,executive-appointment,100,54,7/8/2020
42EFC7,orphan-drug-designation,100,76,7/8/2020
47752F,earnings,100,50,7/8/2020
4B49CF,dividend,100,50,7/8/2020
4B5054,conference-call,100,50,7/8/2020
4B7006,award,100,58,7/8/2020
4BDCA7,partnership,100,61,7/8/2020
4BDCA7,partnership,100,61,7/8/2020
4C7DB5,earnings,100,50,7/8/2020
52015A,dividend,100,50,7/8/2020
532D47,conference-call,100,50,7/8/2020
55438C,earnings,100,50,7/8/2020
55C9B5,partnership,100,61,7/8/2020
562853,conference-call,100,50,7/8/2020
57DDB9,hirings,100,65,7/8/2020
57F3DA,unit-acquisition-acquirer,100,49,7/8/2020
589803,earnings,100,50,7/8/2020
59DB8C,partnership,100,61,7/8/2020
5B97B2,earnings,100,50,7/8/2020
5C7601,partnership,100,61,7/8/2020
605F40,conference-call,100,50,7/8/2020
6391C2,public-offering,100,43,7/8/2020
639BD6,earnings,100,50,7/8/2020
6474BA,earnings,100,50,7/8/2020
64E346,partnership,100,61,7/8/2020
676FFD,legal-issues-defendant,100,22,7/8/2020
69CE71,product-release,100,64,7/8/2020
69CE71,dividend,100,50,7/8/2020
69E8E1,conference-call,100,50,7/8/2020
69E8E1,conference-call,100,50,7/8/2020
6C6D73,partnership,100,61,7/8/2020
6C6D73,partnership,100,61,7/8/2020
6F0096,conference-call,100,50,7/8/2020
6F39FC,dividend,100,50,7/8/2020
71E2EF,earnings,100,50,7/8/2020
726DDF,conference-participant,100,50,7/8/2020
731675,revenues,100,50,7/8/2020
731675,note-sale,100,52,7/8/2020
73BCBA,conference-call,100,50,7/8/2020
7.40E+289,earnings,100,50,7/8/2020
7.40E+289,earnings,100,50,7/8/2020
791EC1,conference-call,100,50,7/8/2020
7A3633,earnings,100,50,7/8/2020
7E2DE6,earnings,100,50,7/8/2020
7E3F8F,earnings,100,50,7/8/2020
8.10E+32,dividend,100,50,7/8/2020
8.10E+32,conference-call,100,50,7/8/2020
8.22E+27,conference-call,100,50,7/8/2020
8665BA,business-contract,100,69,7/8/2020
873DB9,partnership,100,61,7/8/2020
87486A,conference-call,100,50,7/8/2020
877C0C,earnings,100,50,7/8/2020
89F693,executive-appointment,100,54,7/8/2020
89FBB1,dividend,100,50,7/8/2020
8A0368,business-contract,100,69,7/8/2020
8BAA15,earnings,100,50,7/8/2020
8DBBE6,conference-call,100,50,7/8/2020
8DBE73,legal-issues-defendant,100,22,7/8/2020
8F3231,partnership,100,61,7/8/2020
9043FE,note-sale,100,52,7/8/2020
9043FE,note-sale,100,52,7/8/2020
9043FE,note-sale,100,52,7/8/2020
9043FE,note-sale,100,52,7/8/2020
915E7B,facility-sale,100,52,7/8/2020
934CC3,partnership,100,61,7/8/2020
95DC1F,partnership,100,61,7/8/2020
977A1E,conference-call,100,50,7/8/2020
9B71A7,earnings,100,50,7/8/2020
9B71A7,earnings,100,50,7/8/2020
9B71A7,earnings,100,50,7/8/2020
9C25FF,partnership,100,61,7/8/2020
9CE4C7,earnings,100,50,7/8/2020
9D65C1,earnings,100,50,7/8/2020
A4A612,conference-call,100,50,7/8/2020
A63387,business-contract,100,69,7/8/2020
A65325,conference-call,100,50,7/8/2020
A6828A,unit-acquisition-acquiree,100,76,7/8/2020
A8CBDA,partnership,100,61,7/8/2020
AA5C8E,earnings,100,50,7/8/2020
AD9F1D,legal-issues-defendant,100,22,7/8/2020
AED61E,public-offering,100,43,7/8/2020
AFDF2E,executive-appointment,100,54,7/8/2020
AFF43F,earnings,100,50,7/8/2020
AFF7B4,partnership,100,61,7/8/2020
B1FC3B,fundraising,100,64,7/8/2020
B1FC3B,legal-issues-plaintiff,100,44,7/8/2020
B2E6B5,conference-call,100,50,7/8/2020
B8EF97,revenues,100,50,7/8/2020
B96637,product-release,100,64,7/8/2020
BB127B,conference-participant,100,50,7/8/2020
BB88B6,partnership,100,61,7/8/2020
BB88B6,earnings,100,50,7/8/2020
BBBB41,conference-call,100,50,7/8/2020
C41C25,earnings,100,50,7/8/2020
CAB222,clinical-trials-start,100,64,7/8/2020
CB7AB2,conference-call,100,50,7/8/2020
CD4DA8,conference-call,100,50,7/8/2020
D06755,earnings,100,50,7/8/2020
D0909F,earnings-guidance,100,50,7/8/2020
D1173F,conference-call,100,50,7/8/2020
D33270,partnership,100,61,7/8/2020
D437C3,earnings,100,50,7/8/2020
D54E62,conference-call,100,50,7/8/2020
D6534D,conference-call,100,50,7/8/2020
D7A953,earnings,100,50,7/8/2020
D82EF3,note-sale,100,52,7/8/2020
D93A25,earnings,100,50,7/8/2020
D93A25,note-sale,100,52,7/8/2020
D93A25,note-sale,100,52,7/8/2020
D96202,donation,100,54,7/8/2020
DB7FA7,conference-call,100,50,7/8/2020
DBB28E,partnership,100,61,7/8/2020
DCD97F,conference-call,100,50,7/8/2020
DD1BA1,partnership,100,61,7/8/2020
DD1BA1,partnership,100,61,7/8/2020
DF01B1,conference-call,100,50,7/8/2020
DF532D,facility-open,100,65,7/8/2020
E11C41,conference-call,100,50,7/8/2020
E1C16B,acquisition-acquirer,100,49,7/8/2020
E1C16B,acquisition-acquirer,100,49,7/8/2020
E26FC3,dividend,100,50,7/8/2020
E26FC3,executive-appointment,100,54,7/8/2020
E3A829,earnings,100,50,7/8/2020
E3E68E,conference-call,100,50,7/8/2020
E3E68E,conference-call,100,50,7/8/2020
E5C910,partnership,100,61,7/8/2020
E5C910,partnership,100,61,7/8/2020
E6EDED,executive-appointment,100,54,7/8/2020
E71AE6,executive-appointment,100,54,7/8/2020
E74B55,conference-call,100,50,7/8/2020
E8E899,executive-appointment,100,54,7/8/2020
E9E6FD,conference-call,100,50,7/8/2020
EBC84C,earnings,100,50,7/8/2020
ED0D7C,conference-call,100,50,7/8/2020
ED22DC,public-offering,100,43,7/8/2020
ED5171,earnings,100,50,7/8/2020
EF5BED,partnership,100,61,7/8/2020
F1EB39,business-contract,100,69,7/8/2020
F24FF0,asset-sale,100,62,7/8/2020
F30508,partnership,100,61,7/8/2020
F43A11,legal-issues-defendant,100,22,7/8/2020
F50BAB,conference-call,100,50,7/8/2020
F5D499,acquisition-completed-acquirer,100,49,7/8/2020
FD2565,partnership,100,61,7/8/2020
FD4E8D,earnings,100,50,7/8/2020
FE89E0,dividend,100,50,7/8/2020
FEC475,conference-call,100,50,7/8/2020
001F1B,operating-earnings,100,50,7/9/2020
00326D,earnings,100,50,7/9/2020
00326D,earnings,100,50,7/9/2020
0157B1,partnership,100,61,7/9/2020
048B70,conference-call,100,50,7/9/2020
58828,dividend,100,50,7/9/2020
71860,earnings,100,50,7/9/2020
07CA6A,conference-call,100,50,7/9/2020
07CA6A,conference-call,100,50,7/9/2020
07EC43,conference-call,100,50,7/9/2020
0B7375,regulatory-product-application,100,69,7/9/2020
0BC17A,conference-call,100,50,7/9/2020
0BC29E,earnings-guidance,100,50,7/9/2020
0C2A0D,earnings,100,50,7/9/2020
0CCCB7,regulatory-product-approval-granted,100,81,7/9/2020
0DC050,earnings,100,50,7/9/2020
0F04E5,earnings,100,50,7/9/2020
0F2BC9,conference-call,100,50,7/9/2020
11A49E,fast-track-designation,100,81,7/9/2020
13C3E0,earnings,100,50,7/9/2020
147C38,earnings,100,50,7/9/2020
1866B2,public-offering,100,43,7/9/2020
188394,partnership,100,61,7/9/2020
1B637E,partnership,100,61,7/9/2020
1DF15D,conference-call,100,50,7/9/2020
1E9A6D,executive-appointment,100,54,7/9/2020
1FAF22,conference-call,100,50,7/9/2020
227D48,conference-call,100,50,7/9/2020
24A89A,executive-appointment,100,54,7/9/2020
24C48B,executive-appointment,100,54,7/9/2020
253604,partnership,100,61,7/9/2020
26F31D,executive-appointment,100,54,7/9/2020
273BA3,product-release,100,64,7/9/2020
2.90E+62,earnings,100,50,7/9/2020
2A17B1,note-sale,100,52,7/9/2020
2DA92D,conference-call,100,50,7/9/2020
2DB344,earnings,100,50,7/9/2020
2E0496,product-release,100,64,7/9/2020
2E0496,product-release,100,64,7/9/2020
3461CF,credit-rating-set-rater,20,50,7/9/2020
3461CF,credit-rating-set-rater,20,50,7/9/2020
34B97A,conference-call,100,50,7/9/2020
3A113F,revenues,100,50,7/9/2020
3A3948,conference-call,100,50,7/9/2020
3C7F5F,earnings,100,50,7/9/2020
3DE4D1,conference-call,100,50,7/9/2020
408380,earnings,100,50,7/9/2020
415188,conference-call,100,50,7/9/2020
448BF3,clinical-trials-start,100,64,7/9/2020
458D2C,revenue-volume,100,50,7/9/2020
479930,earnings,100,50,7/9/2020
4806CE,conference-call,100,50,7/9/2020
4.91E+58,conference-call,100,50,7/9/2020
4A6F00,partnership,100,61,7/9/2020
4D8124,earnings,100,50,7/9/2020
4EE167,earnings,100,50,7/9/2020
4F9926,stake-acquirer,100,48,7/9/2020
51527B,conference-call,100,50,7/9/2020
564F3E,earnings,100,50,7/9/2020
56EA2B,public-offering,100,43,7/9/2020
57B174,conference-call,100,50,7/9/2020
5A64D5,note-sale,100,52,7/9/2020
5C2A47,conference-call,100,50,7/9/2020
5D63F1,note-sale,100,52,7/9/2020
6137BF,conference-call,100,50,7/9/2020
676FFD,legal-issues-defendant,100,22,7/9/2020
6B236C,conference-call,100,50,7/9/2020
6F6559,dividend,100,50,7/9/2020
728737,dividend,100,50,7/9/2020
72CB93,earnings,100,50,7/9/2020
72FCA3,dividend,100,50,7/9/2020
73C9E2,conference-call,100,50,7/9/2020
76D79A,conference-call,100,50,7/9/2020
7771D7,earnings,100,50,7/9/2020
791D59,earnings,100,50,7/9/2020
7A10FF,earnings,100,50,7/9/2020
7AC86E,facility-maintenance,100,49,7/9/2020
7B0BA6,facility-open,100,65,7/9/2020
7B9212,revenues,100,50,7/9/2020
7F2922,executive-resignation,100,44,7/9/2020
837C04,conference-call,100,50,7/9/2020
8665BA,dividend,100,50,7/9/2020
86A1B9,earnings,100,50,7/9/2020
86F123,executive-appointment,100,54,7/9/2020
885758,earnings,100,50,7/9/2020
88923D,partnership,100,61,7/9/2020
896771,facility-open,100,65,7/9/2020
8A0368,conference-call,100,50,7/9/2020
8A8E41,business-contract,100,69,7/9/2020
8DBE73,legal-issues-defendant,100,22,7/9/2020
8DBE73,conference-call,100,50,7/9/2020
8DBE73,legal-issues-defendant,100,22,7/9/2020
8DE74B,conference-call,100,50,7/9/2020
8FE7A5,earnings,100,50,7/9/2020
92D9C9,conference-call,100,50,7/9/2020
934029,conference-call,100,50,7/9/2020
93633B,conference-call,100,50,7/9/2020
94756D,earnings,100,50,7/9/2020
9507FF,executive-appointment,100,54,7/9/2020
95F59E,earnings,100,50,7/9/2020
967D92,conference-call,100,50,7/9/2020
971F7B,earnings,100,50,7/9/2020
97FE80,executive-appointment,100,54,7/9/2020
990AD0,executive-appointment,100,54,7/9/2020
990AD0,earnings,100,50,7/9/2020
A02FB1,conference-call,100,50,7/9/2020
A1EAC8,conference-call,100,50,7/9/2020
A6828A,business-contract,100,69,7/9/2020
A75D43,conference-call,100,50,7/9/2020
A80FE0,conference-call,100,50,7/9/2020
A9ED24,conference-call,100,50,7/9/2020
AA09AD,note-sale,100,52,7/9/2020
AD9F1D,dividend,100,50,7/9/2020
AE0CCE,clinical-trials,100,56,7/9/2020
AE3113,conference-organizer,100,57,7/9/2020
AF210D,earnings,100,50,7/9/2020
AFDF2E,earnings,100,50,7/9/2020
AFDF2E,earnings,100,50,7/9/2020
B0D41A,regulatory-product-approval-granted,100,81,7/9/2020
B0D41A,regulatory-product-approval-granted,100,81,7/9/2020
B1DF3C,earnings,100,50,7/9/2020
B2206F,partnership,100,61,7/9/2020
B2206F,partnership,100,61,7/9/2020
B7BBFF,dividend,100,50,7/9/2020
B934BF,conference-call,100,50,7/9/2020
BAAA60,conference-call,100,50,7/9/2020
BB0587,conference-call,100,50,7/9/2020
BB5271,conference-call,100,50,7/9/2020
BBBB41,dividend,100,50,7/9/2020
BCC13E,earnings,100,50,7/9/2020
BCC55F,partnership,100,61,7/9/2020
BF79F5,conference-call,100,50,7/9/2020
BFAEB4,conference-call,100,50,7/9/2020
C0F70B,earnings,100,50,7/9/2020
C27E19,earnings,100,50,7/9/2020
C2F597,partnership,100,61,7/9/2020
C356AC,earnings,100,50,7/9/2020
C3BAE7,legal-issues-defendant,100,22,7/9/2020
C3BAE7,fraud-defendant,100,20,7/9/2020
C3BAE7,legal-issues-defendant,100,22,7/9/2020
C3BAE7,legal-issues-defendant,100,22,7/9/2020
C4452A,dividend,100,50,7/9/2020
C5C0E9,conference-call,100,50,7/9/2020
C66B44,executive-appointment,100,54,7/9/2020
C7FC95,business-contract,100,69,7/9/2020
C8FAC7,product-release,100,64,7/9/2020
C8FAC7,partnership,100,61,7/9/2020
CA212F,earnings,100,50,7/9/2020
CA99D7,facility-close,100,47,7/9/2020
CCB623,legal-issues-defendant,100,22,7/9/2020
CD051C,conference-call,100,50,7/9/2020
CDAA0E,earnings,100,50,7/9/2020
CDC817,executive-appointment,100,54,7/9/2020
CDE51C,earnings,100,50,7/9/2020
CFF97C,partnership,100,61,7/9/2020
D1C26F,partnership,100,61,7/9/2020
D1C26F,partnership,100,61,7/9/2020
D2C0B6,award,100,58,7/9/2020
D56E4C,conference-call,100,50,7/9/2020
D56E4C,conference-call,100,50,7/9/2020
D57D99,executive-appointment,100,54,7/9/2020
D6489C,government-contract,100,69,7/9/2020
D7AC6E,earnings,100,50,7/9/2020
D90F43,partnership,100,61,7/9/2020
DB06B0,earnings,100,50,7/9/2020
DC1405,executive-appointment,100,54,7/9/2020
DD3BB1,earnings,100,50,7/9/2020
DD682D,dividend,100,50,7/9/2020
DF1F7A,business-contract,100,69,7/9/2020
E05DC8,earnings,100,50,7/9/2020
E12A6E,dividend,100,50,7/9/2020
E15736,note-sale,100,52,7/9/2020
E35610,conference-call,100,50,7/9/2020
E3E68E,award,100,58,7/9/2020
E3E68E,award,100,58,7/9/2020
E68733,business-contract,100,69,7/9/2020
EA62FC,conference-call,100,50,7/9/2020
EB5E78,conference-call,100,50,7/9/2020
EBD89A,acquisition-acquirer,100,49,7/9/2020
ED3CA8,conference-call,100,50,7/9/2020
EDD234,conference-call,100,50,7/9/2020
EE6F1C,earnings,100,50,7/9/2020
EF7163,conference-call,100,50,7/9/2020
F43A11,legal-issues-defendant,100,22,7/9/2020
F43A11,legal-issues-defendant,100,22,7/9/2020
F43A11,legal-issues-defendant,100,22,7/9/2020
F4E992,earnings,100,50,7/9/2020
F51DB0,conference-call,100,50,7/9/2020
F6FA6A,executive-appointment,100,54,7/9/2020
F85CC0,executive-appointment,100,54,7/9/2020
F85CC0,executive-appointment,100,54,7/9/2020
FACF19,earnings,100,50,7/9/2020
FAE021,partnership,100,61,7/9/2020
FB728F,conference-call,100,50,7/9/2020
FC9A88,conference-call,100,50,7/9/2020
FE9C0D,ipo-pricing,100,50,7/9/2020
FF5413,earnings,100,50,7/9/2020
083F72,conference-call,100,50,7/10/2020
0A0D9E,conference-call,100,50,7/10/2020
0A7650,conference-call,100,50,7/10/2020
0ED415,conference-call,100,50,7/10/2020
10AE08,earnings,100,50,7/10/2020
1201B5,partnership,100,61,7/10/2020
1AF7E2,conference-call,100,50,7/10/2020
1D9E55,earnings,100,50,7/10/2020
20BEEA,conference-call,100,50,7/10/2020
223552,public-offering,100,43,7/10/2020
223552,executive-appointment,100,54,7/10/2020
28DCF3,earnings,100,50,7/10/2020
2BBE62,earnings,100,50,7/10/2020
2CB4C9,earnings,100,50,7/10/2020
2E902B,executive-appointment,100,54,7/10/2020
2EB88B,facility-open,100,65,7/10/2020
2EBA55,dividend,100,50,7/10/2020
32C8CD,earnings,100,50,7/10/2020
34A959,acquisition-regulatory-approval-acquirer,100,54,7/10/2020
3F6A9C,conference-call,100,50,7/10/2020
425BDC,conference-call,100,50,7/10/2020
458D2C,conference-call,100,50,7/10/2020
4B3555,earnings,100,50,7/10/2020
4EC4C1,executive-resignation,100,44,7/10/2020
4EC4C1,earnings,100,50,7/10/2020
513A86,earnings,100,50,7/10/2020
546A9C,earnings,100,50,7/10/2020
5546DA,conference-call,100,50,7/10/2020
5675EB,earnings,100,50,7/10/2020
56B7C1,conference-call,100,50,7/10/2020
57B174,dividend,100,50,7/10/2020
5D43A7,executive-appointment,100,54,7/10/2020
5FF95F,earnings,100,50,7/10/2020
61E975,dividend,100,50,7/10/2020
63E8D5,earnings,100,50,7/10/2020
676FFD,legal-issues-defendant,100,22,7/10/2020
698FF9,earnings,100,50,7/10/2020
6C6D73,regulatory-product-application,100,69,7/10/2020
6D0CAB,operating-earnings,100,50,7/10/2020
6D0CAB,dividend,100,50,7/10/2020
6D3B7B,earnings-up,100,68,7/10/2020
726DDF,legal-issues-defendant,100,22,7/10/2020
73A71F,conference-call,100,50,7/10/2020
752A70,earnings,100,50,7/10/2020
762B8D,dividend,100,50,7/10/2020
7B6EB1,earnings,100,50,7/10/2020
7B9AFA,earnings,100,50,7/10/2020
855DF7,conference-call,100,50,7/10/2020
877C0C,product-release,100,64,7/10/2020
88611B,earnings,100,50,7/10/2020
890FF4,legal-issues-defendant,100,22,7/10/2020
8E0E32,earnings,100,50,7/10/2020
8E9CD8,earnings,100,50,7/10/2020
915E7B,conference-call,100,50,7/10/2020
9.36E+10,business-contract,100,69,7/10/2020
93F143,earnings,100,50,7/10/2020
94983E,partnership,100,61,7/10/2020
97AF94,dividend,100,50,7/10/2020
980C14,conference-call,100,50,7/10/2020
9E298A,conference-call,100,50,7/10/2020
A1A317,conference-call,100,50,7/10/2020
A28C54,business-contract,100,69,7/10/2020
A28C54,business-contract,100,69,7/10/2020
A6213D,earnings,100,50,7/10/2020
A74F6F,conference-call,100,50,7/10/2020
A8AC4C,conference-call,100,50,7/10/2020
AA1EAA,conference-call,100,50,7/10/2020
AD9F1D,legal-issues-defendant,100,22,7/10/2020
BC5680,partnership,100,61,7/10/2020
BE14CF,unit-acquisition-acquirer,100,49,7/10/2020
C3BAE7,legal-issues-defendant,100,22,7/10/2020
C3BAE7,legal-issues-defendant,100,22,7/10/2020
C564E4,partnership,100,61,7/10/2020
C65004,revenues,100,50,7/10/2020
CB88B3,earnings,100,50,7/10/2020
CE5664,earnings,100,50,7/10/2020
D47D56,ipo-pricing,100,50,7/10/2020
D5B13D,executive-appointment,100,54,7/10/2020
D78CCD,conference-call,100,50,7/10/2020
E1E093,facility-open,100,65,7/10/2020
E4158B,earnings,100,50,7/10/2020
E592F0,earnings,100,50,7/10/2020
ED22DC,public-offering,100,43,7/10/2020
EDF5CA,conference-call,100,50,7/10/2020
EE74E1,earnings,100,50,7/10/2020
F02D0A,earnings,100,50,7/10/2020
F294DD,earnings,100,50,7/10/2020
F2BC3D,earnings,100,50,7/10/2020
F43A11,legal-issues-defendant,100,22,7/10/2020
F43A11,legal-issues-defendant,100,22,7/10/2020
F6A945,earnings,100,50,7/10/2020
F6FA6A,executive-appointment,100,54,7/10/2020
F7902B,earnings,100,50,7/10/2020
F93C8A,dividend,100,50,7/10/2020
FD2565,partnership,100,61,7/10/2020
FE9C0D,ipo-pricing,100,50,7/10/2020
FF6644,conference-call,100,50,7/10/2020
7448A3,settlement,100,56,7/11/2020
01D03F,clinical-trials,100,56,7/12/2020
676FFD,legal-issues-defendant,100,22,7/12/2020
00326E,conference-call,100,50,7/13/2020
0142B5,conference-call,100,50,7/13/2020
01D03F,clinical-trials,100,56,7/13/2020
01D03F,clinical-trials,100,56,7/13/2020
01D03F,clinical-trials,100,56,7/13/2020
01D03F,clinical-trials,100,56,7/13/2020
01D03F,partnership,100,61,7/13/2020
03FAA6,partnership,100,61,7/13/2020
05D148,clinical-trials-start,100,64,7/13/2020
0C6293,credit-extension-recipient,100,69,7/13/2020
0C6861,conference-call,100,50,7/13/2020
0F65C9,conference-call,100,50,7/13/2020
10943B,product-release,100,64,7/13/2020
129DC8,conference-call,100,50,7/13/2020
1782D5,conference-call,100,50,7/13/2020
1BDB2A,conference-call,100,50,7/13/2020
1EBF8D,partnership,100,61,7/13/2020
2158DF,earnings,100,50,7/13/2020
228D42,partnership,100,61,7/13/2020
228D42,partnership,100,61,7/13/2020
228D42,partnership,100,61,7/13/2020
228D42,partnership,100,61,7/13/2020
22C58E,revenues,100,50,7/13/2020
251988,award,100,58,7/13/2020
267718,business-contract,100,69,7/13/2020
284289,earnings,100,50,7/13/2020
2E0496,earnings,100,50,7/13/2020
2E0496,earnings,100,50,7/13/2020
2F7A7E,conference-call,100,50,7/13/2020
309922,conference-call,100,50,7/13/2020
3390DE,conference-call,100,50,7/13/2020
34A959,acquisition-regulatory-approval-acquirer,100,54,7/13/2020
356B21,legal-issues-defendant,100,22,7/13/2020
35F4B5,conference-call,100,50,7/13/2020
366A08,conference-call,100,50,7/13/2020
367E1C,earnings,100,50,7/13/2020
396D7C,legal-issues-defendant,100,22,7/13/2020
3A3447,executive-appointment,100,54,7/13/2020
3AAEAE,executive-appointment,100,54,7/13/2020
3BCF24,earnings,100,50,7/13/2020
3F4668,product-release,100,64,7/13/2020
450ECB,conference-call,100,50,7/13/2020
4BAF2E,public-offering,100,43,7/13/2020
4C3FE9,clinical-trials-start,100,64,7/13/2020
4C6C63,unit-acquisition-acquirer,100,49,7/13/2020
56765E,earnings,100,50,7/13/2020
58CA9A,partnership,100,61,7/13/2020
5C8D61,earnings,100,50,7/13/2020
5DD486,partnership,100,61,7/13/2020
5DD486,partnership,100,61,7/13/2020
5F9CE3,earnings,100,50,7/13/2020
610D47,conference-call,100,50,7/13/2020
61A586,earnings,100,50,7/13/2020
62B20A,executive-appointment,100,54,7/13/2020
62B20A,executive-appointment,100,54,7/13/2020
62CDDE,conference-participant,100,50,7/13/2020
6391C2,public-offering,100,43,7/13/2020
662682,conference-call,100,50,7/13/2020
676FFD,legal-issues-defendant,100,22,7/13/2020
676FFD,legal-issues-defendant,100,22,7/13/2020
676FFD,legal-issues-defendant,100,22,7/13/2020
6B0E45,conference-call,100,50,7/13/2020
6BD606,note-sale,100,52,7/13/2020
6BD606,note-sale,100,52,7/13/2020
6F3FA8,earnings,100,50,7/13/2020
7032D0,earnings,100,50,7/13/2020
723548,fundraising,100,64,7/13/2020
72609A,conference-call,100,50,7/13/2020
729368,earnings,100,50,7/13/2020
7448A3,settlement,100,56,7/13/2020
76F067,stake-acquirer,100,48,7/13/2020
7710F3,conference-call,100,50,7/13/2020
78F9ED,conference-call,100,50,7/13/2020
7CBC40,earnings,100,50,7/13/2020
7D35D8,earnings,100,50,7/13/2020
7E1542,earnings,100,50,7/13/2020
7F3A5F,earnings,100,50,7/13/2020
80D744,conference-call,100,50,7/13/2020
810FAD,award,100,58,7/13/2020
850779,earnings,100,50,7/13/2020
85DE00,conference-call,100,50,7/13/2020
8665BA,partnership,100,61,7/13/2020
88350F,conference-call,100,50,7/13/2020
8B3B0E,conference-call,100,50,7/13/2020
8D4AE6,earnings,100,50,7/13/2020
8DCBBB,conference-call,100,50,7/13/2020
9043FE,note-sale,100,52,7/13/2020
9043FE,note-sale,100,52,7/13/2020
92D3A0,dividend,100,50,7/13/2020
934CC3,acquisition-completed-acquirer,100,49,7/13/2020
94A326,patient-enrollment-complete,100,64,7/13/2020
990AD0,dividend,100,50,7/13/2020
99ACAD,earnings,100,50,7/13/2020
99B61C,patient-enrollment-start,100,58,7/13/2020
9B4066,unit-acquisition-acquirer,100,49,7/13/2020
9F048E,earnings,100,50,7/13/2020
9F5997,conference-call,100,50,7/13/2020
A01983,dividend,100,50,7/13/2020
A3AAA5,dividend,100,50,7/13/2020
A48593,conference-call,100,50,7/13/2020
A58224,conference-call,100,50,7/13/2020
A746F6,conference-call,100,50,7/13/2020
ABBAD1,legal-issues-defendant,100,22,7/13/2020
AD23DE,conference-call,100,50,7/13/2020
AD3008,earnings,100,50,7/13/2020
AD9F1D,legal-issues-defendant,100,22,7/13/2020
ADFB3A,business-contract,100,69,7/13/2020
ADFB3A,business-contract,100,69,7/13/2020
ADFB3A,business-contract,100,69,7/13/2020
ADFB3A,business-contract,100,69,7/13/2020
AED61E,public-offering,100,43,7/13/2020
AFEC35,earnings,100,50,7/13/2020
B1FC3B,business-contract,100,69,7/13/2020
B4703C,executive-resignation,100,44,7/13/2020
B4703C,dividend,100,50,7/13/2020
B72D2E,partnership,100,61,7/13/2020
B803B1,conference-call,100,50,7/13/2020
BBF349,earnings,100,50,7/13/2020
BC948D,conference-call,100,50,7/13/2020
BDE867,unit-acquisition-acquiree,100,76,7/13/2020
BE7BA4,conference-call,100,50,7/13/2020
C062D4,earnings-guidance,100,50,7/13/2020
C188F8,reorganization-costs,100,47,7/13/2020
C32A39,dividend,100,50,7/13/2020
C3BAE7,legal-issues-defendant,100,22,7/13/2020
C5E100,business-contract,100,69,7/13/2020
CA1620,campaign-ad-release,100,59,7/13/2020
CE2791,conference-call,100,50,7/13/2020
CE96E7,earnings,100,50,7/13/2020
D13F1C,earnings,100,50,7/13/2020
D2B9E5,earnings,100,50,7/13/2020
D3C794,earnings,100,50,7/13/2020
D4463B,note-sale,100,52,7/13/2020
D4463B,note-acquisition,100,66,7/13/2020
D4463B,acquisition-interest-acquirer,100,46,7/13/2020
D64EDF,earnings,100,50,7/13/2020
D697DE,executive-appointment,100,54,7/13/2020
D721C6,loan-provider,100,57,7/13/2020
D721C6,loan-provider,100,57,7/13/2020
D8DBA3,acquisition-completed-acquirer,100,49,7/13/2020
D93A25,note-sale,100,52,7/13/2020
DBB28E,acquisition-acquirer,100,49,7/13/2020
DC486E,earnings,100,50,7/13/2020
DC486E,earnings,100,50,7/13/2020
E0207A,earnings,100,50,7/13/2020
E09556,regulatory-product-approval-granted,100,81,7/13/2020
E09E2B,executive-appointment,100,54,7/13/2020
E0D3BA,earnings,100,50,7/13/2020
E124EB,conference-call,100,50,7/13/2020
E598FB,executive-appointment,100,54,7/13/2020
E68C3D,earnings-guidance-up,100,83,7/13/2020
E68E62,clinical-trials-start,100,64,7/13/2020
E8846E,executive-appointment,100,54,7/13/2020
E8846E,grant-recipient,100,63,7/13/2020
F3016C,earnings,100,50,7/13/2020
F43A11,legal-issues-defendant,100,22,7/13/2020
F509E2,business-contract,100,69,7/13/2020
F6E248,partnership,100,61,7/13/2020
F85CC0,earnings,100,50,7/13/2020
F88A04,earnings,100,50,7/13/2020
FAE021,executive-appointment,100,54,7/13/2020
FAE021,executive-appointment,100,54,7/13/2020
FD1312,earnings,100,50,7/13/2020
FD4588,conference-call,100,50,7/13/2020
FD554E,executive-appointment,100,54,7/13/2020
01D03F,partnership,100,61,7/14/2020
01D03F,partnership,100,61,7/14/2020
01D03F,partnership,100,61,7/14/2020
20751,patient-enrollment-start,100,58,7/14/2020
20751,patient-enrollment-start,100,58,7/14/2020
03596A,earnings,100,50,7/14/2020
070B45,earnings,100,50,7/14/2020
71860,partnership,100,61,7/14/2020
099A92,executive-appointment,100,54,7/14/2020
099C88,business-contract,100,69,7/14/2020
0BD970,acquisition-completed-acquirer,100,49,7/14/2020
0C355F,conference-call,100,50,7/14/2020
11074E,conference-call,100,50,7/14/2020
1220D2,earnings,100,50,7/14/2020
12E454,partnership,100,61,7/14/2020
131443,dividend,100,50,7/14/2020
1348C9,dividend,100,50,7/14/2020
154272,fraud-defendant,100,20,7/14/2020
154272,fraud-defendant,100,20,7/14/2020
154272,legal-issues-defendant,100,22,7/14/2020
1834C0,conference-call,100,50,7/14/2020
1866B2,conference-call,100,50,7/14/2020
190B91,earnings,100,50,7/14/2020
1A5D5D,legal-issues-defendant,100,22,7/14/2020
1B16C1,executive-appointment,100,54,7/14/2020
1B9535,earnings,100,50,7/14/2020
1CD4B5,executive-appointment,100,54,7/14/2020
1FAF22,dividend,100,50,7/14/2020
1FE3CB,conference-call,100,50,7/14/2020
21268E,conference-call,100,50,7/14/2020
221445,conference-call,100,50,7/14/2020
222BF9,conference-call,100,50,7/14/2020
228D42,partnership,100,61,7/14/2020
228D42,partnership,100,61,7/14/2020
228D42,partnership,100,61,7/14/2020
228D42,product-release,100,64,7/14/2020
22C58E,legal-issues-defendant,100,22,7/14/2020
24D81E,business-contract,100,69,7/14/2020
250BEE,conference-call,100,50,7/14/2020
25AB8E,revenue-up,100,70,7/14/2020
26F31D,earnings,100,50,7/14/2020
29CEBF,earnings-guidance,100,50,7/14/2020
2BA977,conference-call,100,50,7/14/2020
2C19A4,conference-call,100,50,7/14/2020
2E61CC,dividend,100,50,7/14/2020
2EBA55,conference-call,100,50,7/14/2020
2F1299,conference-call,100,50,7/14/2020
34B411,executive-appointment,100,54,7/14/2020
371B0A,conference-call,100,50,7/14/2020
373B06,earnings,100,50,7/14/2020
3798B9,earnings,100,50,7/14/2020
382EAE,conference-call,100,50,7/14/2020
387541,dividend,100,50,7/14/2020
396D7C,legal-issues-defendant,100,22,7/14/2020
3A4BDB,conference-call,100,50,7/14/2020
3CBA2A,conference-call,100,50,7/14/2020
401072,partnership,100,61,7/14/2020
401072,partnership,100,61,7/14/2020
416C55,executive-appointment,100,54,7/14/2020
43A74A,earnings,100,50,7/14/2020
442769,conference-call,100,50,7/14/2020
46A16E,conference-call,100,50,7/14/2020
4A6F00,partnership,100,61,7/14/2020
4A6F00,partnership,100,61,7/14/2020
4C3FE9,executive-appointment,100,54,7/14/2020
4C6C63,dividend,100,50,7/14/2020
4C6C63,executive-appointment,100,54,7/14/2020
4D971D,conference-call,100,50,7/14/2020
4F9926,business-contract,100,69,7/14/2020
524CE4,credit-extension-recipient,100,69,7/14/2020
54DF47,conference-call,100,50,7/14/2020
553949,executive-appointment,100,54,7/14/2020
55C9B5,conference-call,100,50,7/14/2020
567F3D,conference-call,100,50,7/14/2020
58CA9A,earnings,100,50,7/14/2020
5B3415,conference-call,100,50,7/14/2020
5B35C7,earnings-up,100,68,7/14/2020
5F2FF7,earnings,100,50,7/14/2020
5FC507,executive-appointment,100,54,7/14/2020
619882,earnings,100,50,7/14/2020
6284B5,conference-call,100,50,7/14/2020
62B20A,conference-call,100,50,7/14/2020
62F41C,executive-appointment,100,54,7/14/2020
63F892,product-release,100,64,7/14/2020
63F892,product-release,100,64,7/14/2020
657097,unit-acquisition-acquirer,100,49,7/14/2020
665618,conference-call,100,50,7/14/2020
67A658,business-contract,100,69,7/14/2020
67B923,conference-call,100,50,7/14/2020
6B494E,dividend,100,50,7/14/2020
6BF593,conference-call,100,50,7/14/2020
726EEA,earnings,100,50,7/14/2020
7448A3,settlement,100,56,7/14/2020
773A17,earnings,100,50,7/14/2020
787D14,executive-appointment,100,54,7/14/2020
7A51FE,conference-call,100,50,7/14/2020
7AC86E,earnings,100,50,7/14/2020
7BFF81,partnership,100,61,7/14/2020
7E3F8F,partnership,100,61,7/14/2020
7E62B5,conference-call,100,50,7/14/2020
804708,conference-call,100,50,7/14/2020
80B32C,earnings,100,50,7/14/2020
82E58A,dividend,100,50,7/14/2020
859281,earnings,100,50,7/14/2020
860AB6,conference-call,100,50,7/14/2020
880C0C,conference-call,100,50,7/14/2020
881190,conference-call,100,50,7/14/2020
88350F,business-contract,100,69,7/14/2020
8A8E41,partnership,100,61,7/14/2020
8A8E41,partnership,100,61,7/14/2020
8AC65D,conference-call,100,50,7/14/2020
8B6E7E,conference-call,100,50,7/14/2020
8D4486,business-contract,100,69,7/14/2020
8E0E32,dividend,100,50,7/14/2020
8E3F58,earnings,100,50,7/14/2020
8E82A6,dividend,100,50,7/14/2020
900356,partnership,100,61,7/14/2020
92D3A0,earnings,100,50,7/14/2020
94637C,partnership,100,61,7/14/2020
95DC1F,partnership,100,61,7/14/2020
968966,executive-appointment,100,54,7/14/2020
96F126,earnings,100,50,7/14/2020
9C5BA5,earnings,100,50,7/14/2020
9E0811,earnings,100,50,7/14/2020
9EBAFA,dividend,100,50,7/14/2020
9FD2D9,conference-call,100,50,7/14/2020
A4386C,earnings,100,50,7/14/2020
A4B899,regulatory-investigation,100,22,7/14/2020
A60318,earnings,100,50,7/14/2020
A60354,revenues,100,50,7/14/2020
A63387,business-contract,100,69,7/14/2020
A6FE1C,acquisition-acquirer,100,49,7/14/2020
A75D43,executive-appointment,100,54,7/14/2020
A79D88,public-offering,100,43,7/14/2020
A806FA,conference-call,100,50,7/14/2020
A868C9,business-contract,100,69,7/14/2020
AADE0B,conference-call,100,50,7/14/2020
AAEE21,conference-call,100,50,7/14/2020
ABBAD1,legal-issues-defendant,100,22,7/14/2020
ABBAD1,legal-issues-defendant,100,22,7/14/2020
ABBAD1,legal-issues-defendant,100,22,7/14/2020
ABBAD1,legal-issues-defendant,100,22,7/14/2020
ABEE43,legal-issues-defendant,100,22,7/14/2020
ACF77B,dividend,100,50,7/14/2020
AD9F1D,legal-issues-defendant,100,22,7/14/2020
AEF2C3,conference-call,100,50,7/14/2020
B0D41A,business-contract,100,69,7/14/2020
B13B68,conference-call,100,50,7/14/2020
B1FC3B,business-contract,100,69,7/14/2020
B2206F,award,100,58,7/14/2020
B3ED62,business-contract,100,69,7/14/2020
B54A74,earnings,100,50,7/14/2020
B66928,donation,100,54,7/14/2020
B72BE9,conference-call,100,50,7/14/2020
B7BDA3,conference-call,100,50,7/14/2020
BCC55F,business-contract,100,69,7/14/2020
BCE9DA,earnings,100,50,7/14/2020
BCE9DA,earnings,100,50,7/14/2020
C15DB3,executive-resignation,100,44,7/14/2020
C16A8F,conference-call,100,50,7/14/2020
C22BE8,government-contract,100,69,7/14/2020
C2F597,product-release,100,64,7/14/2020
C3BCD5,product-release,100,64,7/14/2020
C48574,executive-appointment,100,54,7/14/2020
C659EB,partnership,100,61,7/14/2020
C659EB,conference-call,100,50,7/14/2020
C66B44,conference-call,100,50,7/14/2020
C7859D,earnings,100,50,7/14/2020
C7859D,earnings,100,50,7/14/2020
C7AE14,conference-call,100,50,7/14/2020
C83B88,business-contract,100,69,7/14/2020
CA1620,conference-call,100,50,7/14/2020
CB22CD,conference-call,100,50,7/14/2020
CB9E13,conference-call,100,50,7/14/2020
CBCC6A,executive-appointment,100,54,7/14/2020
CE1002,dividend-up,100,81,7/14/2020
CE1002,dividend,100,50,7/14/2020
CFF97C,partnership,100,61,7/14/2020
D04D9F,conference-call,100,50,7/14/2020
D17C1B,earnings,100,50,7/14/2020
D1C26F,partnership,100,61,7/14/2020
D437C3,award,100,58,7/14/2020
D47D56,ipo-completed,100,76,7/14/2020
D6489C,product-release,100,64,7/14/2020
D697DE,executive-appointment,100,54,7/14/2020
DE4924,conference-participant,100,50,7/14/2020
DE5611,donation,100,54,7/14/2020
E06265,legal-issues-defendant,100,22,7/14/2020
E074A0,earnings,100,50,7/14/2020
E21871,earnings,100,50,7/14/2020
E67C2C,earnings,100,50,7/14/2020
E6C8DC,note-sale,100,52,7/14/2020
E87676,conference-call,100,50,7/14/2020
E8846E,earnings,100,50,7/14/2020
E8A49A,earnings,100,50,7/14/2020
EB36DE,conference-call,100,50,7/14/2020
ED2A5E,conference-call,100,50,7/14/2020
F1C04C,conference-call,100,50,7/14/2020
F3EDB4,executive-appointment,100,54,7/14/2020
F43A11,legal-issues-defendant,100,22,7/14/2020
F46EC9,earnings,100,50,7/14/2020
F5C78B,conference-call,100,50,7/14/2020
F88A04,partnership,100,61,7/14/2020
F8C5D7,conference-call,100,50,7/14/2020
F9CAF8,conference-call,100,50,7/14/2020
FA35C6,earnings,100,50,7/14/2020
FD2565,clinical-trials-start,100,64,7/14/2020
13528,dividend,100,50,7/15/2020
0142B5,dividend,100,50,7/15/2020
0157B1,partnership,100,61,7/15/2020
018C11,conference-call,100,50,7/15/2020
03F5A4,earnings-positive,100,69,7/15/2020
0A9D0A,earnings,100,50,7/15/2020
0AB700,note-sale,100,52,7/15/2020
0B4D10,earnings,100,50,7/15/2020
0C6861,dividend,100,50,7/15/2020
0FDE97,conference-call,100,50,7/15/2020
108A2B,conference-call,100,50,7/15/2020
10C19B,unit-acquisition-acquiree,100,76,7/15/2020
1272B3,partnership,100,61,7/15/2020
135B09,conference-call,100,50,7/15/2020
16B183,conference-call,100,50,7/15/2020
182BE7,earnings,100,50,7/15/2020
184866,public-offering,100,43,7/15/2020
1B16C1,conference-call,100,50,7/15/2020
1D5C51,conference-call,100,50,7/15/2020
1EBF8D,partnership,100,61,7/15/2020
1F9D90,executive-appointment,100,54,7/15/2020
1F9D90,executive-appointment,100,54,7/15/2020
1F9D90,conference-call,100,50,7/15/2020
228D42,partnership,100,61,7/15/2020
232053,legal-issues-defendant,100,22,7/15/2020
2.45E+15,earnings,100,50,7/15/2020
249674,conference-call,100,50,7/15/2020
2571FA,business-contract,100,69,7/15/2020
2720AB,conference-call,100,50,7/15/2020
27B191,partnership,100,61,7/15/2020
27B191,partnership,100,61,7/15/2020
295F9F,conference-call,100,50,7/15/2020
2A17B1,conference-call,100,50,7/15/2020
2B0AF4,conference-call,100,50,7/15/2020
2B7A40,legal-issues-defendant,100,22,7/15/2020
2E1322,earnings,100,50,7/15/2020
2EB88B,earnings,100,50,7/15/2020
2F960F,earnings,100,50,7/15/2020
306623,conference-call,100,50,7/15/2020
30E01D,earnings,100,50,7/15/2020
31643A,facility-open,100,65,7/15/2020
31666F,dividend,100,50,7/15/2020
31A7CC,earnings,100,50,7/15/2020
31A7CC,earnings,100,50,7/15/2020
31A7CC,earnings,100,50,7/15/2020
31A7CC,earnings,100,50,7/15/2020
32CB22,conference-call,100,50,7/15/2020
32DCB3,regulatory-product-approval-granted,100,81,7/15/2020
32F943,product-release,100,64,7/15/2020
3461CF,award,100,58,7/15/2020
3461CF,award,100,58,7/15/2020
3696BF,conference-call,100,50,7/15/2020
37020C,earnings,100,50,7/15/2020
370C50,dividend,100,50,7/15/2020
396D7C,legal-issues-defendant,100,22,7/15/2020
3B20AB,dividend,100,50,7/15/2020
3B2311,earnings,100,50,7/15/2020
3BB616,note-sale,100,52,7/15/2020
3BBD10,earnings,100,50,7/15/2020
416C55,earnings,100,50,7/15/2020
420168,earnings,100,50,7/15/2020
434F38,earnings,100,50,7/15/2020
444CC8,conference-call,100,50,7/15/2020
449A26,executive-appointment,100,54,7/15/2020
44ED36,earnings,100,50,7/15/2020
4591D3,hirings,100,65,7/15/2020
47BA98,conference-call,100,50,7/15/2020
47FCF2,spin-off,100,58,7/15/2020
47FCF2,spin-off,100,58,7/15/2020
499C75,unit-acquisition-regulatory-approval-acquiree,100,70,7/15/2020
4A6F00,partnership,100,61,7/15/2020
4AC91D,product-release,100,64,7/15/2020
4C5CC9,conference-call,100,50,7/15/2020
4EE167,partnership,100,61,7/15/2020
50070E,executive-appointment,100,54,7/15/2020
514067,conference-call,100,50,7/15/2020
5225A4,conference-organizer,100,57,7/15/2020
524CE4,earnings,100,50,7/15/2020
525A1C,earnings,100,50,7/15/2020
53A226,earnings,100,50,7/15/2020
53C421,conference-call,100,50,7/15/2020
5487B1,legal-issues-defendant,100,22,7/15/2020
5487B1,legal-issues-defendant,100,22,7/15/2020
58CA9A,dividend,100,50,7/15/2020
5B7739,acquisition-acquirer,100,49,7/15/2020
5C7601,product-release,100,64,7/15/2020
5D63F1,earnings,100,50,7/15/2020
5EC388,earnings,100,50,7/15/2020
5F60CE,earnings,100,50,7/15/2020
6137BF,executive-appointment,100,54,7/15/2020
6166D1,earnings,100,50,7/15/2020
619882,executive-appointment,100,54,7/15/2020
619882,dividend,100,50,7/15/2020
61B81B,earnings-positive,100,69,7/15/2020
61B81B,earnings,100,50,7/15/2020
61B81B,earnings,100,50,7/15/2020
61B81B,earnings,100,50,7/15/2020
61B81B,earnings,100,50,7/15/2020
61B81B,earnings,100,50,7/15/2020
61B81B,earnings,100,50,7/15/2020
61B81B,earnings,100,50,7/15/2020
622DBE,conference-call,100,50,7/15/2020
62CDDE,conference-call,100,50,7/15/2020
6.52E+64,legal-issues-defendant,100,22,7/15/2020
68B03F,earnings,100,50,7/15/2020
68E3E0,executive-appointment,100,54,7/15/2020
69345C,earnings,100,50,7/15/2020
6ABCB8,earnings,100,50,7/15/2020
6ED519,conference-call,100,50,7/15/2020
71B0CF,conference-participant,100,50,7/15/2020
722D55,earnings,100,50,7/15/2020
726DDF,note-sale,100,52,7/15/2020
72C2CE,conference-call,100,50,7/15/2020
766047,earnings,100,50,7/15/2020
7823A3,earnings,100,50,7/15/2020
78F776,revenues,100,50,7/15/2020
7A5097,partnership,100,61,7/15/2020
7BAAE7,executive-appointment,100,54,7/15/2020
7C62A3,conference-call,100,50,7/15/2020
7D5384,conference-call,100,50,7/15/2020
7E1542,executive-appointment,100,54,7/15/2020
81A88D,earnings,100,50,7/15/2020
838ADD,earnings,100,50,7/15/2020
85DA04,earnings,100,50,7/15/2020
88350F,product-release,100,64,7/15/2020
88923D,conference-call,100,50,7/15/2020
8A8E41,partnership,100,61,7/15/2020
8C6C1B,legal-issues-defendant,100,22,7/15/2020
8FF2EF,earnings,100,50,7/15/2020
901327,earnings,100,50,7/15/2020
942165,earnings,100,50,7/15/2020
942165,dividend,100,50,7/15/2020
942165,dividend,100,50,7/15/2020
9470CC,earnings,100,50,7/15/2020
950AB7,earnings,100,50,7/15/2020
950CDB,executive-death,100,31,7/15/2020
968103,earnings,100,50,7/15/2020
9.74E+08,earnings,100,50,7/15/2020
9.92E+94,earnings,100,50,7/15/2020
9A02C4,conference-call,100,50,7/15/2020
9B5968,dividend,100,50,7/15/2020
9B5968,dividend,100,50,7/15/2020
9D30A8,earnings,100,50,7/15/2020
9D5D35,earnings,100,50,7/15/2020
A16DEA,dividend,100,50,7/15/2020
A23747,product-release,100,64,7/15/2020
A495F7,earnings,100,50,7/15/2020
A6FE1C,unit-acquisition-acquirer,100,49,7/15/2020
A7102F,business-contract,100,69,7/15/2020
A79D88,public-offering,100,43,7/15/2020
AAC8B6,conference-call,100,50,7/15/2020
AAC8B6,conference-call,100,50,7/15/2020
AB7F05,earnings,100,50,7/15/2020
AB7F05,earnings,100,50,7/15/2020
AD9F1D,legal-issues-defendant,100,22,7/15/2020
AE3113,earnings,100,50,7/15/2020
AE7D16,earnings,100,50,7/15/2020
AFBEB4,earnings,100,50,7/15/2020
AFD1CA,conference-call,100,50,7/15/2020
B1A85D,earnings,100,50,7/15/2020
B2206F,earnings,100,50,7/15/2020
B53C12,conference-call,100,50,7/15/2020
B642E8,earnings,100,50,7/15/2020
B8A51F,earnings,100,50,7/15/2020
B8EF97,dividend,100,50,7/15/2020
B9764A,partnership,100,61,7/15/2020
BB58FF,conference-organizer,100,57,7/15/2020
BD682F,earnings,100,50,7/15/2020
BDE867,operating-earnings,100,50,7/15/2020
BF79F5,dividend,100,50,7/15/2020
C0030A,earnings,100,50,7/15/2020
C3EE99,award,100,58,7/15/2020
C4C77F,dividend,100,50,7/15/2020
C9B932,earnings,100,50,7/15/2020
CBBFBF,earnings,100,50,7/15/2020
CBBFBF,dividend,100,50,7/15/2020
CDAF5B,conference-call,100,50,7/15/2020
CEC5B9,conference-call,100,50,7/15/2020
CEC5B9,conference-call,100,50,7/15/2020
CFF15D,dividend,100,50,7/15/2020
D139BC,conference-call,100,50,7/15/2020
D27FAB,conference-call,100,50,7/15/2020
D5AF19,dividend,100,50,7/15/2020
D63B0F,conference-call,100,50,7/15/2020
D6489C,acquisition-completed-acquiree,100,76,7/15/2020
D721C6,dividend,100,50,7/15/2020
D854F3,dividend,100,50,7/15/2020
D93A25,earnings,100,50,7/15/2020
DB396B,credit-extension-recipient,100,69,7/15/2020
DB88A1,partnership,100,61,7/15/2020
DD1BA1,partnership,100,61,7/15/2020
DD682D,executive-appointment,100,54,7/15/2020
E06265,legal-issues-defendant,100,22,7/15/2020
E0647D,earnings,100,50,7/15/2020
E09E2B,partnership,100,61,7/15/2020
E124EB,executive-appointment,100,54,7/15/2020
E1E36F,earnings,100,50,7/15/2020
E3656D,conference-call,100,50,7/15/2020
E5752F,earnings,100,50,7/15/2020
E5C910,public-offering,100,43,7/15/2020
E68733,acquisition-acquirer,100,49,7/15/2020
E68733,acquisition-acquirer,100,49,7/15/2020
E68733,acquisition-acquirer,100,49,7/15/2020
E8846E,legal-issues-defendant,100,22,7/15/2020
E90C84,conference-call,100,50,7/15/2020
EF5BED,dividend,100,50,7/15/2020
EF5BED,earnings-positive,100,69,7/15/2020
EF5BED,earnings,100,50,7/15/2020
EF5BED,earnings,100,50,7/15/2020
EF5BED,earnings,100,50,7/15/2020
EFD406,conference-call,100,50,7/15/2020
F179ED,earnings,100,50,7/15/2020
F30508,dividend,100,50,7/15/2020
F3FCC3,earnings,100,50,7/15/2020
F40EE2,partnership,100,61,7/15/2020
F40EE2,partnership,100,61,7/15/2020
F40EE2,dividend,100,50,7/15/2020
F40EE2,dividend,100,50,7/15/2020
F702CA,dividend,100,50,7/15/2020
F721A7,earnings,100,50,7/15/2020
F721A7,earnings,100,50,7/15/2020
FAE021,product-release,100,64,7/15/2020
FAE021,product-release,100,64,7/15/2020
FD4BBE,earnings,100,50,7/15/2020
FDC08C,dividend,100,50,7/15/2020
FFAB4A,earnings,100,50,7/15/2020
00698D,dividend,100,50,7/16/2020
0157B1,conference-call,100,50,7/16/2020
01D03F,partnership,100,61,7/16/2020
02FC1A,clinical-trials-start,100,64,7/16/2020
03B431,conference-call,100,50,7/16/2020
03D5F9,earnings,100,50,7/16/2020
040DBB,earnings,100,50,7/16/2020
43862,conference-call,100,50,7/16/2020
04EB2F,earnings,100,50,7/16/2020
0624BE,partnership,100,61,7/16/2020
07C907,earnings,100,50,7/16/2020
07C907,earnings,100,50,7/16/2020
07C907,earnings,100,50,7/16/2020
083F72,dividend,100,50,7/16/2020
09062E,earnings,100,50,7/16/2020
099C88,conference-call,100,50,7/16/2020
09DE1F,partnership,100,61,7/16/2020
09DE1F,partnership,100,61,7/16/2020
09DE1F,partnership,100,61,7/16/2020
0A0CF0,earnings,100,50,7/16/2020
0AAD90,clinical-trials,100,56,7/16/2020
0BB9E5,earnings,100,50,7/16/2020
0BC29E,earnings,100,50,7/16/2020
0BC853,conference-call,100,50,7/16/2020
0DBB81,clinical-trials,100,56,7/16/2020
0E5223,conference-call,100,50,7/16/2020
0F91FC,conference-call,100,50,7/16/2020
1272B3,earnings,100,50,7/16/2020
13C3E0,partnership,100,61,7/16/2020
13C3E0,partnership,100,61,7/16/2020
154272,legal-issues-defendant,100,22,7/16/2020
154272,legal-issues-defendant,100,22,7/16/2020
168A5D,executive-appointment,100,54,7/16/2020
17EDA5,dividend,100,50,7/16/2020
17EDA5,partnership,100,61,7/16/2020
180DA0,conference-call,100,50,7/16/2020
182B8C,conference-call,100,50,7/16/2020
1866B2,merger-completed,100,66,7/16/2020
19C105,earnings,100,50,7/16/2020
19CAC7,earnings,100,50,7/16/2020
19CAC7,earnings,100,50,7/16/2020
1A2D9F,earnings,100,50,7/16/2020
1A3E1B,earnings,100,50,7/16/2020
1A3E1B,earnings,100,50,7/16/2020
1A3E1B,earnings,100,50,7/16/2020
1A3E1B,earnings,100,50,7/16/2020
1A3E1B,earnings,100,50,7/16/2020
1A3E1B,earnings,100,50,7/16/2020
1A3E1B,earnings,100,50,7/16/2020
1A3E1B,earnings,100,50,7/16/2020
1A3E1B,earnings,100,50,7/16/2020
1A3E1B,earnings,100,50,7/16/2020
1A3E1B,earnings,100,50,7/16/2020
1A3E1B,earnings,100,50,7/16/2020
1A3E1B,earnings,100,50,7/16/2020
1A3E1B,earnings,100,50,7/16/2020
1A3E1B,earnings,100,50,7/16/2020
1A6A94,dividend,100,50,7/16/2020
1B4F31,earnings,100,50,7/16/2020
1CD4B5,executive-appointment,100,54,7/16/2020
1DEBBE,earnings,100,50,7/16/2020
1EBF8D,partnership,100,61,7/16/2020
1FA886,business-contract,100,69,7/16/2020
219B21,conference-call,100,50,7/16/2020
221783,earnings,100,50,7/16/2020
227F04,executive-appointment,100,54,7/16/2020
228D42,partnership,100,61,7/16/2020
228D42,business-contract,100,69,7/16/2020
239106,conference-call,100,50,7/16/2020
24C48B,conference-call,100,50,7/16/2020
24D81E,earnings,100,50,7/16/2020
24D81E,executive-resignation,100,44,7/16/2020
26CC63,dividend,100,50,7/16/2020
26D8ED,conference-call,100,50,7/16/2020
26F99F,clinical-trials-start,100,64,7/16/2020
275300,conference-call,100,50,7/16/2020
2920D5,earnings,100,50,7/16/2020
2A1009,conference-call,100,50,7/16/2020
2D485F,executive-resignation,100,44,7/16/2020
2F1299,award,100,58,7/16/2020
314D88,earnings,100,50,7/16/2020
3.14E+47,earnings,100,50,7/16/2020
315EB0,facility-open,100,65,7/16/2020
31DB20,earnings,100,50,7/16/2020
328250,conference-call,100,50,7/16/2020
32F24A,conference-call,100,50,7/16/2020
3.30E+34,dividend,100,50,7/16/2020
343996,dividend,100,50,7/16/2020
343996,dividend,100,50,7/16/2020
3461CF,executive-appointment,100,54,7/16/2020
34B411,donation,100,54,7/16/2020
367434,earnings,100,50,7/16/2020
372037,conference-call,100,50,7/16/2020
37426C,earnings,100,50,7/16/2020
396D7C,legal-issues-defendant,100,22,7/16/2020
39FB23,earnings,100,50,7/16/2020
39FB23,earnings,100,50,7/16/2020
39FB23,earnings,100,50,7/16/2020
3B2311,earnings,100,50,7/16/2020
3BB616,earnings,100,50,7/16/2020
3BC360,conference-call,100,50,7/16/2020
3C3B6B,earnings,100,50,7/16/2020
3C8A04,earnings,100,50,7/16/2020
3E149C,investment-investor,100,55,7/16/2020
3F4668,earnings,100,50,7/16/2020
3FBC9B,earnings,100,50,7/16/2020
416291,conference-call,100,50,7/16/2020
427F32,conference-call,100,50,7/16/2020
44A4FC,partnership,100,61,7/16/2020
44A4FC,partnership,100,61,7/16/2020
44A4FC,partnership,100,61,7/16/2020
44A4FC,partnership,100,61,7/16/2020
451D61,conference-call,100,50,7/16/2020
4591D3,product-release,100,64,7/16/2020
45ABCC,earnings,100,50,7/16/2020
47BA98,dividend,100,50,7/16/2020
485445,legal-issues-defendant,100,22,7/16/2020
48F795,earnings,100,50,7/16/2020
490D4B,conference-call,100,50,7/16/2020
4A5C8D,award,100,58,7/16/2020
4BBA23,conference-call,100,50,7/16/2020
4BEB48,earnings,100,50,7/16/2020
4C2F17,executive-appointment,100,54,7/16/2020
4EEE7E,earnings,100,50,7/16/2020
4F9926,business-contract,100,69,7/16/2020
510EA6,acquisition-interest-acquirer,100,46,7/16/2020
520632,earnings-above-expectations,100,88,7/16/2020
520632,earnings,100,50,7/16/2020
520632,earnings,100,50,7/16/2020
520632,earnings,100,50,7/16/2020
520632,earnings,100,50,7/16/2020
53E575,conference-call,100,50,7/16/2020
5403F8,same-store-sales,100,50,7/16/2020
54512F,partnership,100,61,7/16/2020
545272,conference-call,100,50,7/16/2020
55ACCB,earnings,100,50,7/16/2020
57CAAB,earnings,100,50,7/16/2020
57DDB9,product-release,100,64,7/16/2020
57DDB9,product-release,100,64,7/16/2020
57F3DA,earnings,100,50,7/16/2020
583553,ipo-pricing,100,50,7/16/2020
58C2D4,earnings,100,50,7/16/2020
59DB8C,partnership,100,61,7/16/2020
5BC2F4,dividend,100,50,7/16/2020
5BFE94,dividend,100,50,7/16/2020
5CCDAD,earnings,100,50,7/16/2020
5D0337,earnings,100,50,7/16/2020
5D16CF,conference-call,100,50,7/16/2020
5D43A7,dividend,100,50,7/16/2020
5F1B7B,earnings,100,50,7/16/2020
6137BF,business-contract,100,69,7/16/2020
622037,earnings,100,50,7/16/2020
6251A3,clinical-trials-start,100,64,7/16/2020
6251A3,partnership,100,61,7/16/2020
627186,earnings,100,50,7/16/2020
641F17,dividend,100,50,7/16/2020
65D0AA,legal-issues-defendant,100,22,7/16/2020
6A024C,business-contract,100,69,7/16/2020
6B0784,conference-call,100,50,7/16/2020
6B0784,conference-call,100,50,7/16/2020
6BBD2D,ipo-pricing,100,50,7/16/2020
6C4D2F,conference-call,100,50,7/16/2020
6CC55E,earnings,100,50,7/16/2020
6D3B7B,earnings,100,50,7/16/2020
6E8349,earnings,100,50,7/16/2020
701531,earnings,100,50,7/16/2020
719477,partnership,100,61,7/16/2020
7255D2,product-release,100,64,7/16/2020
72DF04,earnings,100,50,7/16/2020
731675,conference-call,100,50,7/16/2020
74404C,conference-call,100,50,7/16/2020
75D689,executive-appointment,100,54,7/16/2020
766047,dividend,100,50,7/16/2020
789A7D,conference-call,100,50,7/16/2020
790C34,earnings,100,50,7/16/2020
7A5097,conference-participant,100,50,7/16/2020
7A5097,conference-call,100,50,7/16/2020
7ACD98,conference-call,100,50,7/16/2020
7ACFD4,executive-appointment,100,54,7/16/2020
7BAAE7,dividend,100,50,7/16/2020
7D97DE,conference-call,100,50,7/16/2020
7DD8CC,conference-call,100,50,7/16/2020
803FED,conference-call,100,50,7/16/2020
82C202,earnings,100,50,7/16/2020
8377DB,partnership,100,61,7/16/2020
855DF7,dividend,100,50,7/16/2020
868808,executive-appointment,100,54,7/16/2020
896771,conference-call,100,50,7/16/2020
89B2E7,earnings,100,50,7/16/2020
89FBB1,conference-call,100,50,7/16/2020
8A8E41,partnership,100,61,7/16/2020
8D4486,partnership,100,61,7/16/2020
8D9993,conference-call,100,50,7/16/2020
9043FE,earnings,100,50,7/16/2020
9043FE,earnings,100,50,7/16/2020
9196A2,earnings,100,50,7/16/2020
9196A2,earnings,100,50,7/16/2020
9196A2,earnings,100,50,7/16/2020
9196A2,earnings,100,50,7/16/2020
9196A2,earnings,100,50,7/16/2020
94208D,conference-call,100,50,7/16/2020
968B00,earnings,100,50,7/16/2020
971F7B,executive-appointment,100,54,7/16/2020
97AAF6,dividend,100,50,7/16/2020
9.86E+03,earnings,100,50,7/16/2020
98CEBB,earnings,100,50,7/16/2020
98D33E,dividend,100,50,7/16/2020
990AD0,earnings,100,50,7/16/2020
9A2760,acquisition-regulatory-approval-acquirer,100,54,7/16/2020
9ABD30,earnings,100,50,7/16/2020
9D5FA4,earnings,100,50,7/16/2020
9E98F2,earnings,100,50,7/16/2020
9EA947,conference-call,100,50,7/16/2020
9F5CBB,conference-call,100,50,7/16/2020
A01200,conference-call,100,50,7/16/2020
A3800A,executive-appointment,100,54,7/16/2020
A3800A,executive-appointment,100,54,7/16/2020
A4D173,conference-call,100,50,7/16/2020
A4D173,conference-call,100,50,7/16/2020
A52533,earnings,100,50,7/16/2020
A63387,earnings,100,50,7/16/2020
A65325,executive-appointment,100,54,7/16/2020
A6828A,earnings,100,50,7/16/2020
A79F7D,business-contract,100,69,7/16/2020
A868C9,executive-appointment,100,54,7/16/2020
AA247D,earnings,100,50,7/16/2020
AA847A,conference-call,100,50,7/16/2020
AD23DE,product-release,100,64,7/16/2020
AD9F1D,legal-issues-defendant,100,22,7/16/2020
AD9F1D,legal-issues-defendant,100,22,7/16/2020
AE4125,executive-appointment,100,54,7/16/2020
AEEB76,earnings,100,50,7/16/2020
B01111,executive-appointment,100,54,7/16/2020
B01111,executive-appointment,100,54,7/16/2020
B09B1F,conference-call,100,50,7/16/2020
B1B10C,dividend,100,50,7/16/2020
B2DAF6,earnings,100,50,7/16/2020
B614F8,legal-issues-defendant,100,22,7/16/2020
B6843B,earnings,100,50,7/16/2020
B77F14,business-contract,100,69,7/16/2020
B8DD94,award,100,58,7/16/2020
BCC55F,executive-appointment,100,54,7/16/2020
BCC55F,conference-call,100,50,7/16/2020
BD8517,earnings,100,50,7/16/2020
BDD12C,earnings,100,50,7/16/2020
BDF2BD,conference-call,100,50,7/16/2020
C2F597,earnings,100,50,7/16/2020
C32A39,earnings-per-share-positive,100,69,7/16/2020
C38440,earnings,100,50,7/16/2020
C4A912,conference-call,100,50,7/16/2020
C66A8C,earnings,100,50,7/16/2020
C6C702,conference-call,100,50,7/16/2020
C941DC,earnings,100,50,7/16/2020
C98CDB,earnings,100,50,7/16/2020
C99CC8,partnership,100,61,7/16/2020
CAD7D9,credit-extension-recipient,100,69,7/16/2020
CB6A9C,conference-call,100,50,7/16/2020
CE1002,partnership,100,61,7/16/2020
CEC08B,earnings,100,50,7/16/2020
D17C1B,partnership,100,61,7/16/2020
D17C1B,partnership,100,61,7/16/2020
D17F7E,executive-appointment,100,54,7/16/2020
D33D8C,earnings-per-share-positive,100,69,7/16/2020
D33D8C,earnings-per-share-positive,100,69,7/16/2020
D33D8C,earnings-per-share-positive,100,69,7/16/2020
D33D8C,earnings-per-share-positive,100,69,7/16/2020
D33D8C,earnings-per-share-positive,100,69,7/16/2020
D33D8C,earnings-per-share-positive,100,69,7/16/2020
D33D8C,earnings-per-share-positive,100,69,7/16/2020
D33D8C,earnings-per-share-positive,100,69,7/16/2020
D518D8,conference-call,100,50,7/16/2020
D65A13,conference-call,100,50,7/16/2020
D7918D,earnings,100,50,7/16/2020
DA48E4,dividend,100,50,7/16/2020
DDC415,earnings,100,50,7/16/2020
DF6FDD,earnings,100,50,7/16/2020
E06265,legal-issues-defendant,100,22,7/16/2020
E0647D,note-sale,100,52,7/16/2020
E1C16B,dividend,100,50,7/16/2020
E2CB7B,product-release,100,64,7/16/2020
E5C910,public-offering,100,43,7/16/2020
E6D89E,earnings,100,50,7/16/2020
E84500,dividend,100,50,7/16/2020
E8846E,legal-issues-defendant,100,22,7/16/2020
E8846E,legal-issues-defendant,100,22,7/16/2020
EAEBF3,earnings,100,50,7/16/2020
ECD263,earnings,100,50,7/16/2020
ED9C04,earnings,100,50,7/16/2020
EEA6B3,dividend,100,50,7/16/2020
EF5BED,executive-appointment,100,54,7/16/2020
EFA7B2,revenues,100,50,7/16/2020
F2BC3D,acquisition-acquirer,100,49,7/16/2020
F32F88,conference-call,100,50,7/16/2020
F44EA2,executive-appointment,100,54,7/16/2020
F4F46F,conference-call,100,50,7/16/2020
F6E248,business-contract,100,69,7/16/2020
F6E248,earnings,100,50,7/16/2020
F702CA,earnings,100,50,7/16/2020
F702CA,earnings,100,50,7/16/2020
F702CA,earnings,100,50,7/16/2020
F702CA,earnings,100,50,7/16/2020
F702CA,earnings,100,50,7/16/2020
F702CA,earnings,100,50,7/16/2020
FA36A4,dividend,100,50,7/16/2020
FA918D,conference-call,100,50,7/16/2020
FACF19,partnership,100,61,7/16/2020
FAE021,earnings,100,50,7/16/2020
FAE021,earnings,100,50,7/16/2020
FB728F,dividend,100,50,7/16/2020
FD2565,partnership,100,61,7/16/2020
FD2565,partnership,100,61,7/16/2020
FD9A97,earnings,100,50,7/16/2020
FDF799,earnings,100,50,7/16/2020
FE9C0D,executive-appointment,100,54,7/16/2020
FE9C0D,executive-appointment,100,54,7/16/2020
FF6644,facility-open,100,65,7/16/2020
FFE543,earnings,100,50,7/16/2020
0A59F8,earnings,100,50,7/17/2020
0BC853,shareholder-rights-plan,100,43,7/17/2020
10943B,conference-call,100,50,7/17/2020
154272,legal-issues-defendant,100,22,7/17/2020
154272,legal-issues-defendant,100,22,7/17/2020
184866,public-offering,100,43,7/17/2020
188394,dividend,100,50,7/17/2020
1D943E,earnings,100,50,7/17/2020
1DA44F,conference-call,100,50,7/17/2020
1E9A6D,dividend,100,50,7/17/2020
1F43A1,earnings,100,50,7/17/2020
1F716B,unit-acquisition-acquirer,100,49,7/17/2020
1F716B,unit-acquisition-acquirer,100,49,7/17/2020
25A6CC,earnings,100,50,7/17/2020
2B5483,legal-issues-defendant,100,22,7/17/2020
2DB344,executive-appointment,100,54,7/17/2020
2DC88B,earnings,100,50,7/17/2020
34A959,acquisition-regulatory-approval-acquirer,100,54,7/17/2020
355B19,dividend-up,100,81,7/17/2020
396D7C,legal-issues-defendant,100,22,7/17/2020
3A6D90,executive-appointment,100,54,7/17/2020
3B20AB,earnings,100,50,7/17/2020
3DCECC,conference-call,100,50,7/17/2020
3DCECC,executive-resignation,100,44,7/17/2020
41EC04,conference-call,100,50,7/17/2020
4C31F3,legal-issues-defendant,100,22,7/17/2020
52FB2F,earnings,100,50,7/17/2020
5876DC,dividend,100,50,7/17/2020
5B6C11,acquisition-completed-acquirer,100,49,7/17/2020
5B6C11,earnings,100,50,7/17/2020
5BC2F4,earnings,100,50,7/17/2020
5BFE94,earnings,100,50,7/17/2020
6166D1,dividend,100,50,7/17/2020
619882,conference-organizer,100,57,7/17/2020
633043,earnings,100,50,7/17/2020
647143,dividend,100,50,7/17/2020
6CDFC6,conference-call,100,50,7/17/2020
6DBBBC,business-contract,100,69,7/17/2020
726DDF,note-sale,100,52,7/17/2020
73529F,conference-call,100,50,7/17/2020
73C521,earnings-negative,100,33,7/17/2020
73C521,earnings-negative,100,33,7/17/2020
73C521,earnings-negative,100,33,7/17/2020
73C521,earnings-negative,100,33,7/17/2020
73C521,earnings-negative,100,33,7/17/2020
73C521,earnings-negative,100,33,7/17/2020
767F86,earnings,100,50,7/17/2020
76B926,conference-call,100,50,7/17/2020
76BECC,conference-call,100,50,7/17/2020
7AB859,conference-call,100,50,7/17/2020
7DC1C4,earnings,100,50,7/17/2020
838ADD,dividend,100,50,7/17/2020
83A065,conference-call,100,50,7/17/2020
850779,note-sale,100,52,7/17/2020
8D4486,partnership,100,61,7/17/2020
8D4486,partnership,100,61,7/17/2020
8D4486,partnership,100,61,7/17/2020
8D4486,partnership,100,61,7/17/2020
8EEA28,note-sale,100,52,7/17/2020
9004C4,conference-call,100,50,7/17/2020
911ACB,earnings,100,50,7/17/2020
9196A2,merger-regulatory-approval,100,81,7/17/2020
93965C,earnings,100,50,7/17/2020
94637C,regulatory-product-approval-granted,100,81,7/17/2020
966DBE,earnings,100,50,7/17/2020
989E2F,earnings,100,50,7/17/2020
989E2F,earnings,100,50,7/17/2020
989E2F,earnings,100,50,7/17/2020
989E2F,earnings,100,50,7/17/2020
9C8664,equity-shelf-registration,100,43,7/17/2020
9CF9B1,earnings,100,50,7/17/2020
9E9147,settlement,100,56,7/17/2020
A11CF4,ipo-pricing,100,50,7/17/2020
ABE7DC,unit-acquisition-acquirer,100,49,7/17/2020
AD9F1D,legal-issues-defendant,100,22,7/17/2020
AFF7B4,dividend,100,50,7/17/2020
B303A6,settlement,100,56,7/17/2020
BEB756,dividend,100,50,7/17/2020
BFE02C,earnings-positive,100,69,7/17/2020
C54140,earnings,100,50,7/17/2020
C94CFC,private-placement,100,56,7/17/2020
C9E107,earnings,100,50,7/17/2020
CCB623,legal-issues-defendant,100,22,7/17/2020
CD06A2,earnings-per-share-positive,100,69,7/17/2020
CE96E7,executive-appointment,100,54,7/17/2020
CF9054,earnings,100,50,7/17/2020
D29B44,earnings,100,50,7/17/2020
D598E7,award,100,58,7/17/2020
D5AF19,earnings,100,50,7/17/2020
D721C6,earnings-positive,100,69,7/17/2020
D8DA3D,dividend,100,50,7/17/2020
DA0A9E,dividend,100,50,7/17/2020
DB396B,conference-call,100,50,7/17/2020
E05026,earnings,100,50,7/17/2020
E06265,legal-issues-defendant,100,22,7/17/2020
E2F66E,conference-call,100,50,7/17/2020
E6E012,earnings,100,50,7/17/2020
E6E012,earnings,100,50,7/17/2020
E8D221,dividend,100,50,7/17/2020
EB6965,conference-call,100,50,7/17/2020
F30508,conference-call,100,50,7/17/2020
F47871,partnership,100,61,7/17/2020
F47871,partnership,100,61,7/17/2020
F4D241,fundraising,100,64,7/17/2020
F82D37,earnings,100,50,7/17/2020
FC01C0,conference-call,100,50,7/17/2020
FD39EB,dividend,100,50,7/17/2020
5F9CE3,regulatory-product-approval-granted,100,81,7/18/2020
CCB623,legal-issues-defendant,100,22,7/18/2020
20751,product-release,100,64,7/20/2020
20751,product-release,100,64,7/20/2020
43862,executive-appointment,100,54,7/20/2020
065D38,earnings,100,50,7/20/2020
95294,earnings,100,50,7/20/2020
0CC01F,earnings,100,50,7/20/2020
0CC62B,conference-call,100,50,7/20/2020
0DBB81,executive-appointment,100,54,7/20/2020
106394,acquisition-completed-acquirer,100,49,7/20/2020
11A49E,partnership,100,61,7/20/2020
126F95,earnings,100,50,7/20/2020
126F95,earnings,100,50,7/20/2020
126F95,earnings,100,50,7/20/2020
126F95,earnings,100,50,7/20/2020
138DDE,earnings,100,50,7/20/2020
147C38,dividend,100,50,7/20/2020
152AB9,earnings,100,50,7/20/2020
152AB9,public-offering,100,43,7/20/2020
15789A,earnings,100,50,7/20/2020
15B10D,conference-call,100,50,7/20/2020
1748B3,earnings,100,50,7/20/2020
1748B3,earnings,100,50,7/20/2020
1748B3,earnings,100,50,7/20/2020
1748B3,earnings,100,50,7/20/2020
1748B3,earnings,100,50,7/20/2020
1748B3,earnings,100,50,7/20/2020
1A3E1B,unit-acquisition-acquiree,100,76,7/20/2020
1AC649,business-contract,100,69,7/20/2020
1C599A,earnings,100,50,7/20/2020
1D943E,product-release,100,64,7/20/2020
1F19C8,earnings,100,50,7/20/2020
1F19C8,executive-appointment,100,54,7/20/2020
1FCC00,executive-appointment,100,54,7/20/2020
20BEEA,earnings,100,50,7/20/2020
20BEEA,earnings,100,50,7/20/2020
228D42,business-contract,100,69,7/20/2020
267718,business-contract,100,69,7/20/2020
267718,business-contract,100,69,7/20/2020
267718,business-contract,100,69,7/20/2020
267718,business-contract,100,69,7/20/2020
267718,business-contract,100,69,7/20/2020
2720AB,unit-acquisition-acquiree,100,76,7/20/2020
2720AB,earnings,100,50,7/20/2020
282C18,earnings,100,50,7/20/2020
297DA8,earnings,100,50,7/20/2020
2A1009,index-listing,100,76,7/20/2020
2B49F4,earnings,100,50,7/20/2020
2B49F4,earnings,100,50,7/20/2020
2B49F4,earnings,100,50,7/20/2020
2B49F4,earnings,100,50,7/20/2020
2B49F4,earnings,100,50,7/20/2020
2E902B,earnings-guidance-up,100,83,7/20/2020
309922,earnings,100,50,7/20/2020
31553A,earnings,100,50,7/20/2020
33E8C7,earnings,100,50,7/20/2020
33FD66,executive-appointment,100,54,7/20/2020
34A959,merger-completed,100,66,7/20/2020
34B411,earnings,100,50,7/20/2020
36529A,executive-appointment,100,54,7/20/2020
38FB49,earnings,100,50,7/20/2020
38FB49,earnings,100,50,7/20/2020
38FB49,earnings,100,50,7/20/2020
38FB49,earnings,100,50,7/20/2020
38FB49,earnings,100,50,7/20/2020
38FB49,earnings,100,50,7/20/2020
38FB49,earnings,100,50,7/20/2020
396D7C,legal-issues-defendant,100,22,7/20/2020
396D7C,legal-issues-defendant,100,22,7/20/2020
3A3447,earnings,100,50,7/20/2020
3B9886,revenue-up,100,69,7/20/2020
3B9886,revenue-up,100,69,7/20/2020
3F868D,conference-call,100,50,7/20/2020
4017AD,earnings,100,50,7/20/2020
42AABD,conference-call,100,50,7/20/2020
42DC93,earnings,100,50,7/20/2020
435ACE,conference-call,100,50,7/20/2020
4455C4,conference-call,100,50,7/20/2020
44740A,conference-call,100,50,7/20/2020
4595EF,conference-call,100,50,7/20/2020
468DD4,product-recall,100,29,7/20/2020
4885C8,partnership,100,61,7/20/2020
499C75,asset-sale,100,62,7/20/2020
4A6F00,partnership,100,61,7/20/2020
4BEB48,award,100,58,7/20/2020
4C92B9,dividend-up,100,62,7/20/2020
4D371E,earnings,100,50,7/20/2020
4D72C8,conference-call,100,50,7/20/2020
4D72C8,conference-call,100,50,7/20/2020
4F9926,partnership,100,61,7/20/2020
5088A5,earnings,100,50,7/20/2020
51F541,conference-call,100,50,7/20/2020
52015A,conference-call,100,50,7/20/2020
53EF9E,conference-call,100,50,7/20/2020
53F491,dividend,100,50,7/20/2020
5487B1,legal-issues-defendant,100,22,7/20/2020
55438C,partnership,100,61,7/20/2020
57DDB9,conference-call,100,50,7/20/2020
5A64D5,conference-call,100,50,7/20/2020
5B7739,conference-call,100,50,7/20/2020
5D1329,partnership,100,61,7/20/2020
5D1329,partnership,100,61,7/20/2020
5D87DF,earnings,100,50,7/20/2020
5FDBD0,conference-call,100,50,7/20/2020
5FE4B6,conference-call,100,50,7/20/2020
647143,earnings,100,50,7/20/2020
647143,earnings,100,50,7/20/2020
647143,earnings,100,50,7/20/2020
647143,earnings,100,50,7/20/2020
647143,earnings,100,50,7/20/2020
647143,earnings,100,50,7/20/2020
6.52E+64,conference-call,100,50,7/20/2020
657097,unit-acquisition-acquirer,100,49,7/20/2020
65D0AA,legal-issues-defendant,100,22,7/20/2020
665440,conference-call,100,50,7/20/2020
6A024C,executive-appointment,100,54,7/20/2020
6BBD2D,ipo-completed,100,76,7/20/2020
6D1ADF,conference-call,100,50,7/20/2020
6D3F35,conference-call,100,50,7/20/2020
6EB9DA,earnings-up,100,68,7/20/2020
71694D,conference-call,100,50,7/20/2020
717DB4,earnings,100,50,7/20/2020
726DDF,legal-issues-defendant,100,22,7/20/2020
726DDF,legal-issues-defendant,100,22,7/20/2020
726DDF,conference-call,100,50,7/20/2020
75F665,earnings,100,50,7/20/2020
75F665,earnings,100,50,7/20/2020
75F665,earnings,100,50,7/20/2020
76D79A,conference-call,100,50,7/20/2020
775439,earnings,100,50,7/20/2020
7823A3,partnership,100,61,7/20/2020
797C20,conference-call,100,50,7/20/2020
7BAAE7,earnings,100,50,7/20/2020
7C75FD,conference-call,100,50,7/20/2020
7D7716,award,100,58,7/20/2020
7E3F8F,partnership,100,61,7/20/2020
7F3669,earnings,100,50,7/20/2020
82E58A,conference-call,100,50,7/20/2020
82FD6D,conference-call,100,50,7/20/2020
83066C,conference-call,100,50,7/20/2020
8377DB,executive-appointment,100,54,7/20/2020
860AB6,earnings,100,50,7/20/2020
86A1B9,business-contract,100,69,7/20/2020
8802B4,dividend,100,50,7/20/2020
8D4486,earnings,100,50,7/20/2020
8D4486,earnings,100,50,7/20/2020
8D4486,earnings,100,50,7/20/2020
8D4486,earnings,100,50,7/20/2020
8D4486,earnings,100,50,7/20/2020
8D9993,dividend,100,50,7/20/2020
8DBE73,legal-issues-defendant,100,22,7/20/2020
8DBE73,legal-issues-defendant,100,22,7/20/2020
8DE56F,executive-appointment,100,54,7/20/2020
8DE56F,executive-appointment,100,54,7/20/2020
8F8F2F,conference-call,100,50,7/20/2020
903AB4,earnings-up,100,68,7/20/2020
9043FE,partnership,100,61,7/20/2020
9087B9,conference-call,100,50,7/20/2020
91E5EE,regulatory-product-approval-granted,100,81,7/20/2020
91E5EE,earnings,100,50,7/20/2020
92B047,earnings,100,50,7/20/2020
92B625,executive-appointment,100,54,7/20/2020
94C0B5,earnings,100,50,7/20/2020
954A47,earnings-positive,100,69,7/20/2020
979451,earnings,100,50,7/20/2020
9BB35A,conference-call,100,50,7/20/2020
9C8BC3,dividend,100,50,7/20/2020
9D4EC7,conference-call,100,50,7/20/2020
9D4EC7,conference-call,100,50,7/20/2020
9F62D1,acquisition-completed-acquirer,100,49,7/20/2020
9FF5F1,earnings,100,50,7/20/2020
A247F5,award,100,58,7/20/2020
A37D68,partnership,100,61,7/20/2020
A403CF,earnings,100,50,7/20/2020
A49498,conference-call,100,50,7/20/2020
A5628C,earnings-positive,100,69,7/20/2020
A6213D,executive-appointment,100,54,7/20/2020
A63820,product-release,100,64,7/20/2020
A6828A,dividend,100,50,7/20/2020
A79F7D,earnings,100,50,7/20/2020
A871B0,earnings,100,50,7/20/2020
AA09AD,note-sale,100,52,7/20/2020
AC775C,conference-participant,100,50,7/20/2020
AD23DE,dividend,100,50,7/20/2020
AD9F1D,legal-issues-defendant,100,22,7/20/2020
AD9F1D,legal-issues-defendant,100,22,7/20/2020
AEBB80,executive-appointment,100,54,7/20/2020
B2F431,earnings-positive,100,69,7/20/2020
B7EB38,earnings,100,50,7/20/2020
B7FA9B,conference-call,100,50,7/20/2020
C0200F,earnings,100,50,7/20/2020
C0200F,earnings,100,50,7/20/2020
C0200F,earnings,100,50,7/20/2020
C0F4D0,executive-appointment,100,54,7/20/2020
C11C46,earnings,100,50,7/20/2020
C2E39B,executive-appointment,100,54,7/20/2020
C3CF29,earnings,100,50,7/20/2020
C4706C,business-contract,100,69,7/20/2020
C99CC8,product-release,100,64,7/20/2020
CAB222,stake-acquiree,100,62,7/20/2020
CC35BE,product-release,100,64,7/20/2020
CC6FF5,earnings,100,50,7/20/2020
CD06A2,unit-acquisition-acquirer,100,49,7/20/2020
CEC08B,award,100,58,7/20/2020
CFF15D,conference-call,100,50,7/20/2020
D1CFC8,partnership,100,61,7/20/2020
D3FD6D,conference-call,100,50,7/20/2020
D54E62,acquisition-acquirer,100,49,7/20/2020
D57D99,earnings,100,50,7/20/2020
D82EF3,conference-call,100,50,7/20/2020
D8760C,earnings-positive,100,69,7/20/2020
D8760C,earnings,100,50,7/20/2020
D8760C,earnings,100,50,7/20/2020
D8760C,earnings,100,50,7/20/2020
D8760C,earnings,100,50,7/20/2020
D8760C,earnings,100,50,7/20/2020
DC0066,fundraising,100,64,7/20/2020
DD1BA1,acquisition-acquirer,100,49,7/20/2020
DDEA6A,executive-appointment,100,54,7/20/2020
E06265,legal-issues-defendant,100,22,7/20/2020
E19A99,earnings,100,50,7/20/2020
E2CB7B,executive-appointment,100,54,7/20/2020
E2F66E,note-sale,100,52,7/20/2020
E802CE,conference-call,100,50,7/20/2020
E8846E,legal-issues-defendant,100,22,7/20/2020
E8846E,legal-issues-defendant,100,22,7/20/2020
E8846E,executive-appointment,100,54,7/20/2020
E93A40,earnings,100,50,7/20/2020
E96E0B,earnings,100,50,7/20/2020
EB36DE,settlement,100,56,7/20/2020
EC1AF3,conference-call,100,50,7/20/2020
ECDEB2,earnings,100,50,7/20/2020
ED7F13,earnings,100,50,7/20/2020
EEA6B3,executive-appointment,100,54,7/20/2020
EEEA9F,earnings,100,50,7/20/2020
EF5BED,executive-appointment,100,54,7/20/2020
EF5BED,executive-appointment,100,54,7/20/2020
F24FF0,conference-call,100,50,7/20/2020
F31B13,earnings-up,100,83,7/20/2020
F44EA2,earnings,100,50,7/20/2020
F47871,regulatory-product-approval-granted,100,81,7/20/2020
F509E2,conference-call,100,50,7/20/2020
F5C78B,earnings,100,50,7/20/2020
FA840E,executive-appointment,100,54,7/20/2020
FC1F9D,partnership,100,61,7/20/2020
FD1312,earnings,100,50,7/20/2020
FD6926,conference-call,100,50,7/20/2020
02870F,legal-issues-defendant,100,22,7/21/2020
02870F,legal-issues-defendant,100,22,7/21/2020
03FAA6,earnings,100,50,7/21/2020
03FB17,earnings,100,50,7/21/2020
55018,earnings-negative,100,33,7/21/2020
55018,earnings-negative,100,33,7/21/2020
55018,earnings-negative,100,33,7/21/2020
55018,earnings-negative,100,33,7/21/2020
55018,earnings-negative,100,33,7/21/2020
55018,earnings-negative,100,33,7/21/2020
55018,earnings-negative,100,33,7/21/2020
55018,earnings-negative,100,33,7/21/2020
55018,earnings-negative,100,33,7/21/2020
55018,earnings-negative,100,33,7/21/2020
070B45,product-release,100,64,7/21/2020
07CA6A,dividend,100,50,7/21/2020
07CA6A,dividend,100,50,7/21/2020
0BC29E,headquarters-change,100,50,7/21/2020
0C4131,earnings,100,50,7/21/2020
0FABBD,conference-call,100,50,7/21/2020
10100E,earnings,100,50,7/21/2020
1065BC,conference-call,100,50,7/21/2020
1348C9,earnings,100,50,7/21/2020
1348C9,earnings,100,50,7/21/2020
1348C9,earnings,100,50,7/21/2020
149301,earnings,100,50,7/21/2020
152B9E,conference-call,100,50,7/21/2020
15A388,partnership,100,61,7/21/2020
184866,public-offering,100,43,7/21/2020
18EC17,earnings,100,50,7/21/2020
18EC17,earnings,100,50,7/21/2020
18EC17,earnings,100,50,7/21/2020
18EC17,earnings,100,50,7/21/2020
1CD09C,partnership,100,61,7/21/2020
1E04A5,earnings,100,50,7/21/2020
1E9A6D,earnings,100,50,7/21/2020
1EBF8D,partnership,100,61,7/21/2020
1EBF8D,partnership,100,61,7/21/2020
1FA8F7,earnings-per-share-positive,100,69,7/21/2020
20BEEA,conference-call,100,50,7/21/2020
21F9CA,earnings,100,50,7/21/2020
225CA2,conference-call,100,50,7/21/2020
228D42,partnership,100,61,7/21/2020
228D42,partnership,100,61,7/21/2020
241AF7,conference-call,100,50,7/21/2020
251988,product-release,100,64,7/21/2020
26E3BA,public-offering,100,43,7/21/2020
270305,earnings,100,50,7/21/2020
272704,earnings-positive,100,69,7/21/2020
297DA8,business-contract,100,69,7/21/2020
2CBB58,operating-earnings-positive,100,69,7/21/2020
2CBB58,operating-earnings-positive,100,69,7/21/2020
2CBB58,operating-earnings-positive,100,69,7/21/2020
2CBB58,operating-earnings-positive,100,69,7/21/2020
2E2E6E,earnings,100,50,7/21/2020
2EBC0B,public-offering,100,43,7/21/2020
2EBC0B,public-offering,100,43,7/21/2020
2F1299,partnership,100,61,7/21/2020
2F5256,earnings,100,50,7/21/2020
2F6782,conference-call,100,50,7/21/2020
2F98A5,dividend-up,100,81,7/21/2020
3.14E+47,earnings,100,50,7/21/2020
3.14E+47,earnings,100,50,7/21/2020
31803E,earnings,100,50,7/21/2020
33AD83,conference-call,100,50,7/21/2020
349DA4,earnings,100,50,7/21/2020
356B21,legal-issues-defendant,100,22,7/21/2020
389CFB,conference-call,100,50,7/21/2020
39BFF6,earnings,100,50,7/21/2020
39BFF6,earnings,100,50,7/21/2020
39BFF6,earnings,100,50,7/21/2020
3A1C46,earnings,100,50,7/21/2020
3CCC90,dividend,100,50,7/21/2020
3D9999,earnings-positive,100,69,7/21/2020
3D9999,earnings,100,50,7/21/2020
3D9999,earnings,100,50,7/21/2020
3D9999,earnings,100,50,7/21/2020
3D9999,earnings,100,50,7/21/2020
3D9999,earnings,100,50,7/21/2020
3E39A5,earnings,100,50,7/21/2020
3F4668,product-release,100,64,7/21/2020
4.03E+05,conference-call,100,50,7/21/2020
4.00E+163,legal-issues-defendant,100,22,7/21/2020
41785E,earnings,100,50,7/21/2020
423279,earnings-per-share-positive,100,69,7/21/2020
429BFB,earnings,100,50,7/21/2020
448215,earnings,100,50,7/21/2020
45444E,acquisition-completed-acquirer,100,49,7/21/2020
46017C,conference-call,100,50,7/21/2020
4C1FA1,earnings,100,50,7/21/2020
4C7DB5,product-price-raise,100,57,7/21/2020
4DD09F,earnings,100,50,7/21/2020
510EA6,earnings,100,50,7/21/2020
510EA6,earnings,100,50,7/21/2020
5225A4,earnings,100,50,7/21/2020
5225A4,earnings,100,50,7/21/2020
545272,business-contract-terminated,100,31,7/21/2020
54A646,earnings-positive,100,69,7/21/2020
54A646,earnings-positive,100,69,7/21/2020
54A646,earnings-positive,100,69,7/21/2020
54A646,earnings-positive,100,69,7/21/2020
54B889,conference-call,100,50,7/21/2020
583553,ipo-completed,100,76,7/21/2020
583A75,conference-call,100,50,7/21/2020
5876DC,earnings,100,50,7/21/2020
596116,earnings,100,50,7/21/2020
5B15E1,conference-call,100,50,7/21/2020
5DA8B3,executive-appointment,100,54,7/21/2020
5FF95F,earnings,100,50,7/21/2020
60DD84,executive-appointment,100,54,7/21/2020
64E615,conference-call,100,50,7/21/2020
651C85,conference-call,100,50,7/21/2020
65D0AA,legal-issues-defendant,100,22,7/21/2020
65D0AA,legal-issues-defendant,100,22,7/21/2020
694749,earnings,100,50,7/21/2020
6BC6F9,earnings,100,50,7/21/2020
6BD606,conference-call,100,50,7/21/2020
6D156D,earnings,100,50,7/21/2020
6D3F35,business-contract,100,69,7/21/2020
6D3F35,business-contract,100,69,7/21/2020
6E705B,legal-issues-defendant,100,22,7/21/2020
6F39FC,conference-call,100,50,7/21/2020
726DDF,legal-issues-defendant,100,22,7/21/2020
7448A3,conference-call,100,50,7/21/2020
75F665,earnings,100,50,7/21/2020
75F665,earnings,100,50,7/21/2020
75F665,earnings,100,50,7/21/2020
75F665,earnings,100,50,7/21/2020
75F665,earnings,100,50,7/21/2020
75F665,earnings,100,50,7/21/2020
75F665,earnings,100,50,7/21/2020
75F665,earnings,100,50,7/21/2020
75F665,earnings,100,50,7/21/2020
75F665,earnings,100,50,7/21/2020
75F665,earnings,100,50,7/21/2020
75F665,dividend,100,50,7/21/2020
75F982,business-contract,100,69,7/21/2020
7823A3,partnership,100,61,7/21/2020
7823A3,partnership,100,61,7/21/2020
7AB859,executive-appointment,100,54,7/21/2020
7B1E50,dividend,100,50,7/21/2020
7D35D8,earnings,100,50,7/21/2020
7E3F8F,executive-appointment,100,54,7/21/2020
7F0372,executive-appointment,100,54,7/21/2020
804708,conference-call,100,50,7/21/2020
82B57E,earnings,100,50,7/21/2020
82F088,conference-call,100,50,7/21/2020
830BDB,conference-call,100,50,7/21/2020
8377DB,merger,100,66,7/21/2020
850779,earnings,100,50,7/21/2020
85DA04,partnership,100,61,7/21/2020
85DA04,partnership,100,61,7/21/2020
86F123,earnings,100,50,7/21/2020
87B81A,executive-appointment,100,54,7/21/2020
8AB37F,executive-appointment,100,54,7/21/2020
8AC740,conference-call,100,50,7/21/2020
8C1238,buybacks,100,74,7/21/2020
8C311A,earnings,100,50,7/21/2020
8C5519,earnings,100,50,7/21/2020
8C5519,earnings,100,50,7/21/2020
8C5519,earnings,100,50,7/21/2020
8C5519,earnings,100,50,7/21/2020
8C5519,earnings,100,50,7/21/2020
8C5519,earnings,100,50,7/21/2020
8CF6DD,earnings,100,50,7/21/2020
8D4486,earnings,100,50,7/21/2020
8D4486,business-contract,100,69,7/21/2020
8D4486,partnership,100,61,7/21/2020
8DAAB9,earnings,100,50,7/21/2020
8DBE73,legal-issues-defendant,100,22,7/21/2020
8DCBBB,earnings,100,50,7/21/2020
8DDA23,dividend,100,50,7/21/2020
93633B,earnings,100,50,7/21/2020
93633B,earnings,100,50,7/21/2020
93633B,earnings,100,50,7/21/2020
93633B,earnings,100,50,7/21/2020
93633B,earnings,100,50,7/21/2020
93F143,earnings,100,50,7/21/2020
93F143,earnings,100,50,7/21/2020
93F143,earnings,100,50,7/21/2020
93F143,earnings,100,50,7/21/2020
93F143,earnings,100,50,7/21/2020
93F143,earnings,100,50,7/21/2020
94563D,earnings,100,50,7/21/2020
9548BB,earnings-per-share-positive,100,69,7/21/2020
9.54E+32,dividend,100,50,7/21/2020
96F126,earnings,100,50,7/21/2020
972356,acquisition-acquiree,100,76,7/21/2020
972356,acquisition-acquiree,100,76,7/21/2020
97AF94,earnings,100,50,7/21/2020
9934AD,conference-call,100,50,7/21/2020
9B71A7,business-contract,100,69,7/21/2020
9CA4C6,dividend,100,50,7/21/2020
9CA4C6,earnings,100,50,7/21/2020
9EF4CF,earnings,100,50,7/21/2020
9F37C5,conference-call,100,50,7/21/2020
9F62D1,earnings-per-share-down,100,34,7/21/2020
A017F4,executive-appointment,100,54,7/21/2020
A01983,conference-call,100,50,7/21/2020
A0F146,conference-call,100,50,7/21/2020
A16DEA,earnings,100,50,7/21/2020
A21649,conference-call,100,50,7/21/2020
A23747,earnings,100,50,7/21/2020
A3AAA5,conference-call,100,50,7/21/2020
A4CD53,earnings,100,50,7/21/2020
A60354,conference-call,100,50,7/21/2020
A63820,executive-appointment,100,54,7/21/2020
A666C8,earnings,100,50,7/21/2020
A7102F,conference-call,100,50,7/21/2020
A746F6,earnings-per-share-positive,100,69,7/21/2020
A746F6,earnings-per-share-positive,100,69,7/21/2020
A746F6,earnings-per-share-positive,100,69,7/21/2020
A746F6,earnings-per-share-positive,100,69,7/21/2020
A746F6,earnings-per-share-positive,100,69,7/21/2020
A746F6,earnings-per-share-positive,100,69,7/21/2020
A746F6,earnings-per-share-positive,100,69,7/21/2020
A746F6,earnings-per-share-positive,100,69,7/21/2020
A746F6,earnings-per-share-positive,100,69,7/21/2020
A746F6,earnings-per-share-positive,100,69,7/21/2020
A746F6,earnings-per-share-positive,100,69,7/21/2020
A746F6,earnings-per-share-positive,100,69,7/21/2020
A7A0C8,partnership,100,61,7/21/2020
A7A0C8,partnership,100,61,7/21/2020
A7F0A5,earnings,100,50,7/21/2020
A868C9,conference-call,100,50,7/21/2020
A8CBDA,dividend,100,50,7/21/2020
AB7726,earnings,100,50,7/21/2020
ACC7D3,earnings,100,50,7/21/2020
ACD9A4,earnings,100,50,7/21/2020
AD3C93,earnings,100,50,7/21/2020
AFDF2E,asset-sale,100,62,7/21/2020
AFF43F,earnings,100,50,7/21/2020
B05118,earnings,100,50,7/21/2020
B0FE08,dividend,100,50,7/21/2020
B48FC9,earnings,100,50,7/21/2020
B560AF,dividend,100,50,7/21/2020
B5766D,dividend,100,50,7/21/2020
B7202A,conference-call,100,50,7/21/2020
B8F71F,earnings,100,50,7/21/2020
B96DF5,earnings,100,50,7/21/2020
BB5142,earnings,100,50,7/21/2020
BC5680,business-contract,100,69,7/21/2020
BD15E8,earnings,100,50,7/21/2020
BD9668,earnings,100,50,7/21/2020
BE14CF,dividend,100,50,7/21/2020
BFEA04,conference-call,100,50,7/21/2020
C11C46,executive-appointment,100,54,7/21/2020
C2609A,conference-call,100,50,7/21/2020
C3BAE7,conference-participant,100,50,7/21/2020
C45CE7,earnings,100,50,7/21/2020
C72B8F,conference-call,100,50,7/21/2020
C97B2D,regulatory-product-approval-granted,100,81,7/21/2020
C9881C,partnership,100,61,7/21/2020
C99CC8,earnings,100,50,7/21/2020
CAD7D9,conference-call,100,50,7/21/2020
CB9E13,earnings,100,50,7/21/2020
CDC817,earnings,100,50,7/21/2020
CDE118,earnings,100,50,7/21/2020
CDFCC9,legal-issues-defendant,100,22,7/21/2020
CEDFD5,clinical-trials-start,100,64,7/21/2020
CEDFD5,clinical-trials-start,100,64,7/21/2020
CEDFD5,clinical-trials-start,100,64,7/21/2020
CEDFD5,executive-appointment,100,54,7/21/2020
CEDFD5,executive-appointment,100,54,7/21/2020
CFE5BE,earnings,100,50,7/21/2020
CFE5BE,earnings,100,50,7/21/2020
CFE5BE,earnings,100,50,7/21/2020
CFE5BE,earnings,100,50,7/21/2020
CFE5BE,earnings,100,50,7/21/2020
CFE5BE,earnings,100,50,7/21/2020
CFE5BE,earnings,100,50,7/21/2020
CFE5BE,earnings,100,50,7/21/2020
CFE5BE,earnings,100,50,7/21/2020
D1C0B9,business-contract,100,69,7/21/2020
D2B9E5,business-contract,100,69,7/21/2020
D3CEDF,conference-call,100,50,7/21/2020
D6853F,business-contract,100,69,7/21/2020
D697DE,earnings,100,50,7/21/2020
D8DA3D,executive-appointment,100,54,7/21/2020
D9164D,earnings,100,50,7/21/2020
D9B1C9,dividend,100,50,7/21/2020
DBFB51,conference-call,100,50,7/21/2020
DDCB34,conference-call,100,50,7/21/2020
DDEA6A,product-release,100,64,7/21/2020
DF11D9,earnings,100,50,7/21/2020
DF18E6,executive-appointment,100,54,7/21/2020
DF532D,earnings,100,50,7/21/2020
DF532D,earnings,100,50,7/21/2020
E06265,legal-issues-defendant,100,22,7/21/2020
E114F4,conference-call,100,50,7/21/2020
E8846E,executive-appointment,100,54,7/21/2020
E90C84,conference-call,100,50,7/21/2020
EB7FBF,unit-acquisition-acquirer,100,49,7/21/2020
EC4E82,conference-participant,100,50,7/21/2020
ECDEB2,earnings,100,50,7/21/2020
ECE19E,executive-appointment,100,54,7/21/2020
EEA6B3,earnings,100,50,7/21/2020
EEA6B3,earnings,100,50,7/21/2020
EEA6B3,earnings,100,50,7/21/2020
F04E05,dividend,100,50,7/21/2020
F05B1B,patient-enrollment-start,100,58,7/21/2020
F0A9DE,earnings,100,50,7/21/2020
F3D2EB,buybacks,100,74,7/21/2020
F3EDB4,earnings,100,50,7/21/2020
F46EC9,executive-resignation,100,44,7/21/2020
F4F46F,partnership,100,61,7/21/2020
F57F6F,earnings,100,50,7/21/2020
F8BA6C,conference-participant,100,50,7/21/2020
F8DE55,earnings,100,50,7/21/2020
FA35C6,earnings,100,50,7/21/2020
FA840E,earnings,100,50,7/21/2020
FADF1A,conference-call,100,50,7/21/2020
FC9A88,dividend,100,50,7/21/2020
FD0CA4,earnings,100,50,7/21/2020
FD2565,executive-appointment,100,54,7/21/2020
FE7A63,earnings,100,50,7/21/2020
FE7A63,earnings,100,50,7/21/2020
FE7A63,earnings,100,50,7/21/2020
FE7A63,earnings,100,50,7/21/2020
FE7A63,earnings,100,50,7/21/2020
FE7A63,earnings,100,50,7/21/2020
FE7A63,earnings,100,50,7/21/2020
FEE4B0,business-contract,100,69,7/21/2020
FF4343,conference-call,100,50,7/21/2020
FF6644,business-contract,100,69,7/21/2020
0157B1,facility-open,100,65,7/22/2020
0157B1,partnership,100,61,7/22/2020
02870F,legal-issues-defendant,100,22,7/22/2020
02870F,legal-issues-defendant,100,22,7/22/2020
02870F,legal-issues-defendant,100,22,7/22/2020
02870F,legal-issues-defendant,100,22,7/22/2020
02870F,legal-issues-defendant,100,22,7/22/2020
02870F,legal-issues-defendant,100,22,7/22/2020
02870F,legal-issues-defendant,100,22,7/22/2020
03D5F9,executive-appointment,100,54,7/22/2020
03D5F9,executive-appointment,100,54,7/22/2020
099A02,earnings,100,50,7/22/2020
099A02,earnings,100,50,7/22/2020
09F623,dividend,100,50,7/22/2020
0A0CF0,dividend,100,50,7/22/2020
0A1D77,earnings,100,50,7/22/2020
0A59F8,partnership,100,61,7/22/2020
0B400D,earnings,100,50,7/22/2020
0C466B,earnings-up,100,68,7/22/2020
0CBC4D,earnings,100,50,7/22/2020
0E6027,earnings-positive,100,69,7/22/2020
0E6027,earnings,100,50,7/22/2020
1096C6,executive-appointment,100,54,7/22/2020
1279ED,conference-call,100,50,7/22/2020
139303,conference-call,100,50,7/22/2020
15789A,earnings,100,50,7/22/2020
159739,earnings,100,50,7/22/2020
159739,earnings,100,50,7/22/2020
165B3A,earnings-positive,100,69,7/22/2020
165B3A,earnings-positive,100,69,7/22/2020
165B3A,earnings-positive,100,69,7/22/2020
165B3A,earnings-positive,100,69,7/22/2020
165B3A,earnings-positive,100,69,7/22/2020
165B3A,earnings-positive,100,69,7/22/2020
19BF16,earnings,100,50,7/22/2020
1A9DE1,earnings-up,100,53,7/22/2020
1AB808,earnings,100,50,7/22/2020
1B637E,partnership,100,61,7/22/2020
1C2593,facility-open,100,65,7/22/2020
1CD708,earnings,100,50,7/22/2020
1E5786,dividend,100,50,7/22/2020
2031CE,earnings-positive,100,69,7/22/2020
2096DE,earnings,100,50,7/22/2020
221AD7,earnings,100,50,7/22/2020
228D42,partnership,100,61,7/22/2020
228D42,legal-issues-defendant,100,22,7/22/2020
2.45E+15,earnings,100,50,7/22/2020
24CB56,earnings-positive,100,69,7/22/2020
24CB56,earnings,100,50,7/22/2020
24CB56,earnings,100,50,7/22/2020
24CB56,earnings,100,50,7/22/2020
24CB56,earnings,100,50,7/22/2020
24CB56,earnings,100,50,7/22/2020
24CB56,earnings,100,50,7/22/2020
24CB56,earnings,100,50,7/22/2020
24CB56,earnings,100,50,7/22/2020
24CB56,earnings,100,50,7/22/2020
24FA23,earnings,100,50,7/22/2020
25102A,dividend,100,50,7/22/2020
25102A,earnings,100,50,7/22/2020
25102A,earnings,100,50,7/22/2020
25102A,earnings,100,50,7/22/2020
25102A,earnings,100,50,7/22/2020
25102A,earnings,100,50,7/22/2020
264EB3,earnings,100,50,7/22/2020
264EB3,earnings,100,50,7/22/2020
267718,business-contract,100,69,7/22/2020
267718,business-contract,100,69,7/22/2020
267718,business-contract,100,69,7/22/2020
267718,business-contract,100,69,7/22/2020
267718,business-contract,100,69,7/22/2020
26FA41,earnings,100,50,7/22/2020
27B191,conference-call,100,50,7/22/2020
27BFA1,earnings,100,50,7/22/2020
27BFA1,earnings,100,50,7/22/2020
27BFA1,earnings,100,50,7/22/2020
27BFA1,earnings,100,50,7/22/2020
27BFA1,earnings,100,50,7/22/2020
27BFA1,earnings,100,50,7/22/2020
27BFA1,earnings,100,50,7/22/2020
27BFA1,earnings,100,50,7/22/2020
28B730,earnings,100,50,7/22/2020
29A4CC,earnings,100,50,7/22/2020
2BF36E,conference-call,100,50,7/22/2020
30CBF9,unit-acquisition-acquiree,100,76,7/22/2020
31553A,note-sale,100,52,7/22/2020
319BE2,conference-call,100,50,7/22/2020
31DB20,earnings,100,50,7/22/2020
31F25C,earnings,100,50,7/22/2020
339F20,earnings,100,50,7/22/2020
33AD83,partnership,100,61,7/22/2020
34B411,dividend,100,50,7/22/2020
34B97A,earnings,100,50,7/22/2020
34B97A,earnings,100,50,7/22/2020
36A1CB,conference-call,100,50,7/22/2020
387541,earnings,100,50,7/22/2020
39692D,legal-issues-defendant,100,22,7/22/2020
3ACF46,earnings,100,50,7/22/2020
3CBA2A,legal-verdict-disfavored,100,22,7/22/2020
3CBA2A,legal-issues-defendant,100,22,7/22/2020
3CCC90,earnings,100,50,7/22/2020
3D9999,executive-appointment,100,54,7/22/2020
3D9999,dividend,100,50,7/22/2020
3F96D5,earnings,100,50,7/22/2020
407878,conference-call,100,50,7/22/2020
408089,dividend,100,50,7/22/2020
442587,business-contract,100,69,7/22/2020
448BF3,executive-appointment,100,54,7/22/2020
468DD4,earnings,100,50,7/22/2020
47FCF2,earnings,100,50,7/22/2020
485445,earnings,100,50,7/22/2020
49A344,government-contract,100,69,7/22/2020
4A6F00,partnership,100,61,7/22/2020
4A6F00,partnership,100,61,7/22/2020
4B6EF9,dividend,100,50,7/22/2020
4B6EF9,earnings,100,50,7/22/2020
4C37C5,dividend,100,50,7/22/2020
4D203E,earnings,100,50,7/22/2020
4D7BD8,revenues,100,50,7/22/2020
4D7BD8,revenues,100,50,7/22/2020
4D7BD8,revenues,100,50,7/22/2020
4D7BD8,revenues,100,50,7/22/2020
4D7BD8,revenues,100,50,7/22/2020
4D7BD8,revenues,100,50,7/22/2020
4D7BD8,revenues,100,50,7/22/2020
4D7BD8,revenues,100,50,7/22/2020
4D8313,earnings,100,50,7/22/2020
4D8313,earnings,100,50,7/22/2020
4D8313,earnings,100,50,7/22/2020
4D971D,earnings,100,50,7/22/2020
4D971D,earnings,100,50,7/22/2020
4D971D,earnings,100,50,7/22/2020
4D971D,earnings,100,50,7/22/2020
4D971D,earnings,100,50,7/22/2020
4D971D,earnings,100,50,7/22/2020
4D971D,dividend,100,50,7/22/2020
4E4E75,legal-issues-defendant,100,22,7/22/2020
4F9487,earnings-positive,100,69,7/22/2020
4F9487,earnings-positive,100,69,7/22/2020
4F9487,earnings-positive,100,69,7/22/2020
4F9487,earnings-positive,100,69,7/22/2020
4F9487,earnings-positive,100,69,7/22/2020
4F9487,earnings-positive,100,69,7/22/2020
4F9487,earnings-positive,100,69,7/22/2020
4F9487,earnings-positive,100,69,7/22/2020
4F9487,earnings-positive,100,69,7/22/2020
53F491,earnings-per-share-positive,100,69,7/22/2020
5480A7,earnings,100,50,7/22/2020
5487B1,legal-issues-defendant,100,22,7/22/2020
55C289,earnings,100,50,7/22/2020
562853,earnings,100,50,7/22/2020
5675EB,earnings,100,50,7/22/2020
5675EB,dividend,100,50,7/22/2020
56AFF4,operating-earnings,100,50,7/22/2020
589F5A,dividend,100,50,7/22/2020
594402,earnings,100,50,7/22/2020
59A832,conference-call,100,50,7/22/2020
5A9F54,earnings-up,100,68,7/22/2020
5A9F54,earnings-up,100,68,7/22/2020
5A9F54,earnings-up,100,68,7/22/2020
5A9F54,earnings-up,100,68,7/22/2020
5A9F54,earnings-up,100,68,7/22/2020
5AA3B1,earnings,100,50,7/22/2020
5AAE17,conference-call,100,50,7/22/2020
5B97B2,earnings,100,50,7/22/2020
5D41E4,conference-call,100,50,7/22/2020
5DD48B,earnings,100,50,7/22/2020
5F3E74,earnings,100,50,7/22/2020
5F6D73,earnings,100,50,7/22/2020
5F6D73,earnings,100,50,7/22/2020
5F6D73,earnings,100,50,7/22/2020
5F6D73,earnings,100,50,7/22/2020
5F6D73,earnings,100,50,7/22/2020
5F6D73,earnings,100,50,7/22/2020
60DD84,revenue-up,100,69,7/22/2020
62B1C6,dividend,100,50,7/22/2020
62EFEE,earnings,100,50,7/22/2020
636639,earnings,100,50,7/22/2020
636639,earnings,100,50,7/22/2020
636639,earnings,100,50,7/22/2020
636639,earnings,100,50,7/22/2020
636639,earnings,100,50,7/22/2020
64E346,acquisition-acquirer,100,49,7/22/2020
657097,earnings,100,50,7/22/2020
65CF8E,earnings,100,50,7/22/2020
65D0AA,legal-issues-defendant,100,22,7/22/2020
662682,dividend,100,50,7/22/2020
67529E,earnings-positive,100,69,7/22/2020
68AB62,conference-call,100,50,7/22/2020
69E8E1,legal-issues-defendant,100,22,7/22/2020
6ACFBF,earnings,100,50,7/22/2020
6CB7F9,earnings,100,50,7/22/2020
6CD55A,earnings,100,50,7/22/2020
6CF43C,earnings,100,50,7/22/2020
6D4636,conference-call,100,50,7/22/2020
6DC1D7,conference-call,100,50,7/22/2020
6DD6BA,earnings,100,50,7/22/2020
6DD6BA,earnings,100,50,7/22/2020
6DD6BA,earnings,100,50,7/22/2020
6E7060,earnings,100,50,7/22/2020
6F0096,earnings,100,50,7/22/2020
6F0096,earnings,100,50,7/22/2020
6F0096,earnings,100,50,7/22/2020
6F0096,earnings,100,50,7/22/2020
6F3FA8,conference-call,100,50,7/22/2020
704B78,earnings,100,50,7/22/2020
7262F2,earnings,100,50,7/22/2020
726DDF,legal-issues-defendant,100,22,7/22/2020
726DDF,legal-issues-defendant,100,22,7/22/2020
73BCBA,earnings,100,50,7/22/2020
73BCBA,earnings,100,50,7/22/2020
73BCBA,earnings,100,50,7/22/2020
73BCBA,earnings,100,50,7/22/2020
73C521,dividend,100,50,7/22/2020
763724,conference-call,100,50,7/22/2020
7A2A49,conference-call,100,50,7/22/2020
7B1E50,legal-issues-defendant,100,22,7/22/2020
7B1E50,legal-issues-defendant,100,22,7/22/2020
7B1E50,legal-issues-defendant,100,22,7/22/2020
7B1E50,legal-issues-defendant,100,22,7/22/2020
7B4B91,conference-call,100,50,7/22/2020
7C75FD,dividend,100,50,7/22/2020
7E0EB0,conference-call,100,50,7/22/2020
7E3F8F,earnings-guidance-up,100,83,7/22/2020
7E3F8F,earnings,100,50,7/22/2020
7E3F8F,earnings,100,50,7/22/2020
7E3F8F,earnings,100,50,7/22/2020
7F0372,earnings,100,50,7/22/2020
7F3FBC,operating-earnings,100,50,7/22/2020
7F3FBC,dividend,100,50,7/22/2020
7FD8B9,conference-call,100,50,7/22/2020
8275FE,earnings,100,50,7/22/2020
845533,earnings,100,50,7/22/2020
845655,conference-call,100,50,7/22/2020
845655,conference-call,100,50,7/22/2020
84A6B9,earnings,100,50,7/22/2020
85AD00,earnings-per-share-positive,100,69,7/22/2020
863350,earnings,100,50,7/22/2020
8665BA,earnings,100,50,7/22/2020
873DB9,regulatory-product-approval-granted,100,81,7/22/2020
87B81A,earnings,100,50,7/22/2020
881190,earnings,100,50,7/22/2020
881190,earnings,100,50,7/22/2020
881190,earnings,100,50,7/22/2020
881190,earnings,100,50,7/22/2020
895D56,conference-call,100,50,7/22/2020
8CF6DD,investment-investor,100,55,7/22/2020
8D4486,partnership,100,61,7/22/2020
8DE56F,business-contract,100,69,7/22/2020
902255,earnings,100,50,7/22/2020
911ACB,executive-appointment,100,54,7/22/2020
92D9C9,earnings,100,50,7/22/2020
93D207,dividend,100,50,7/22/2020
940C3D,earnings,100,50,7/22/2020
94C0B5,partnership,100,61,7/22/2020
95F59E,donation,100,54,7/22/2020
9.62E+76,earnings,100,50,7/22/2020
9.62E+76,earnings,100,50,7/22/2020
9.62E+76,earnings,100,50,7/22/2020
9.65E+09,conference-call,100,50,7/22/2020
968966,executive-appointment,100,54,7/22/2020
96B4FF,executive-appointment,100,54,7/22/2020
986AF6,conference-call,100,50,7/22/2020
98CAED,dividend,100,50,7/22/2020
98CAED,earnings-up,100,68,7/22/2020
98CAED,earnings-up,100,68,7/22/2020
98CAED,earnings-up,100,68,7/22/2020
98CAED,earnings-up,100,68,7/22/2020
990AD0,dividend,100,50,7/22/2020
9.92E+94,earnings,100,50,7/22/2020
9.92E+94,earnings,100,50,7/22/2020
9.92E+94,earnings,100,50,7/22/2020
99DC8D,conference-call,100,50,7/22/2020
9CE4C7,earnings,100,50,7/22/2020
9D30A8,earnings,100,50,7/22/2020
9EF4CF,partnership,100,61,7/22/2020
9F37C5,dividend,100,50,7/22/2020
A247F5,earnings,100,50,7/22/2020
A29DBD,earnings,100,50,7/22/2020
A2CAF7,earnings,100,50,7/22/2020
A398F8,earnings,100,50,7/22/2020
A433A5,conference-call,100,50,7/22/2020
A63820,earnings,100,50,7/22/2020
A63820,earnings,100,50,7/22/2020
A63820,earnings,100,50,7/22/2020
A63820,earnings,100,50,7/22/2020
A6828A,product-release,100,64,7/22/2020
A8AC4C,earnings,100,50,7/22/2020
A8CBDA,earnings-negative,100,33,7/22/2020
AA5C8E,dividend,100,50,7/22/2020
AABEA0,dividend-up,100,81,7/22/2020
AD23DE,earnings,100,50,7/22/2020
AD23DE,earnings,100,50,7/22/2020
AD23DE,earnings,100,50,7/22/2020
AD23DE,earnings,100,50,7/22/2020
AD23DE,earnings,100,50,7/22/2020
AD23DE,earnings,100,50,7/22/2020
ADF1B0,conference-call,100,50,7/22/2020
AEBB80,earnings,100,50,7/22/2020
B1B10C,earnings,100,50,7/22/2020
B1B10C,earnings,100,50,7/22/2020
B1B10C,earnings,100,50,7/22/2020
B1B10C,earnings,100,50,7/22/2020
B3ED62,legal-issues-defendant,100,22,7/22/2020
B3ED62,legal-issues-defendant,100,22,7/22/2020
B3ED62,legal-issues-defendant,100,22,7/22/2020
B4F5F4,conference-call,100,50,7/22/2020
B66928,earnings,100,50,7/22/2020
B96637,conference-call,100,50,7/22/2020
BA0442,earnings,100,50,7/22/2020
BA218A,earnings-positive,100,69,7/22/2020
BA218A,earnings,100,50,7/22/2020
BA218A,earnings,100,50,7/22/2020
BA218A,earnings,100,50,7/22/2020
BA218A,earnings,100,50,7/22/2020
BA218A,earnings,100,50,7/22/2020
BA218A,earnings,100,50,7/22/2020
BA218A,earnings,100,50,7/22/2020
BCC13E,earnings,100,50,7/22/2020
BDD12C,earnings,100,50,7/22/2020
BFF98A,executive-appointment,100,54,7/22/2020
C0F4D0,executive-appointment,100,54,7/22/2020
C29715,earnings,100,50,7/22/2020
C29715,earnings,100,50,7/22/2020
C45C1F,business-contract,100,69,7/22/2020
C564E4,campaign-ad-release,100,59,7/22/2020
C598D7,dividend,100,50,7/22/2020
C6C702,partnership,100,61,7/22/2020
C7FC95,partnership,100,61,7/22/2020
C9B932,earnings,100,50,7/22/2020
C9F39B,earnings,100,50,7/22/2020
C9F39B,earnings,100,50,7/22/2020
C9F39B,earnings,100,50,7/22/2020
C9F39B,earnings,100,50,7/22/2020
C9F39B,earnings,100,50,7/22/2020
C9F39B,earnings,100,50,7/22/2020
C9F39B,earnings,100,50,7/22/2020
C9F39B,earnings,100,50,7/22/2020
CAB222,conference-call,100,50,7/22/2020
CB88B3,earnings,100,50,7/22/2020
CB89EA,earnings,100,50,7/22/2020
CC8F6E,executive-resignation,100,44,7/22/2020
CD4DA8,earnings,100,50,7/22/2020
CD4DA8,earnings,100,50,7/22/2020
CD4DA8,earnings,100,50,7/22/2020
CD4DA8,earnings,100,50,7/22/2020
CD4DA8,earnings,100,50,7/22/2020
CD4DA8,earnings,100,50,7/22/2020
CD4DA8,earnings,100,50,7/22/2020
CD4DA8,earnings,100,50,7/22/2020
CD4DA8,earnings,100,50,7/22/2020
CD4DA8,earnings,100,50,7/22/2020
CD4DA8,earnings,100,50,7/22/2020
CD4DA8,earnings,100,50,7/22/2020
CDC817,campaign-ad-release,100,59,7/22/2020
D06755,award,100,58,7/22/2020
D21D8A,earnings,100,50,7/22/2020
D21D8A,earnings,100,50,7/22/2020
D21D8A,earnings,100,50,7/22/2020
D21D8A,earnings,100,50,7/22/2020
D21D8A,earnings,100,50,7/22/2020
D21D8A,earnings,100,50,7/22/2020
D21D8A,earnings,100,50,7/22/2020
D21D8A,earnings,100,50,7/22/2020
D29F43,conference-call,100,50,7/22/2020
D33270,business-contract,100,69,7/22/2020
D393DF,earnings,100,50,7/22/2020
D393DF,earnings,100,50,7/22/2020
D45285,conference-call,100,50,7/22/2020
D48275,earnings,100,50,7/22/2020
D4AC65,conference-call,100,50,7/22/2020
D58A11,earnings,100,50,7/22/2020
D6EAA3,dividend,100,50,7/22/2020
D721C6,partnership,100,61,7/22/2020
D77F7E,executive-appointment,100,54,7/22/2020
D7A953,earnings,100,50,7/22/2020
D88EF3,note-sale,100,52,7/22/2020
D93A25,supply-decrease,100,28,7/22/2020
DA90E1,dividend,100,50,7/22/2020
DB2E4E,public-offering,100,43,7/22/2020
DC0998,earnings,100,50,7/22/2020
DC0998,earnings,100,50,7/22/2020
DC0998,earnings,100,50,7/22/2020
DC0998,earnings,100,50,7/22/2020
DD3BB1,earnings,100,50,7/22/2020
DDB002,conference-call,100,50,7/22/2020
E1BD05,earnings,100,50,7/22/2020
E20392,conference-call,100,50,7/22/2020
E26FC3,earnings,100,50,7/22/2020
E28D9C,conference-call,100,50,7/22/2020
E49AA3,product-release,100,64,7/22/2020
E5F0A8,earnings-positive,100,69,7/22/2020
E5F0A8,earnings,100,50,7/22/2020
E5F0A8,earnings,100,50,7/22/2020
E5F0A8,earnings,100,50,7/22/2020
E5F0A8,earnings,100,50,7/22/2020
E68C3D,legal-issues-defendant,100,22,7/22/2020
E754F0,earnings,100,50,7/22/2020
E829E8,earnings,100,50,7/22/2020
E829E8,earnings,100,50,7/22/2020
E829E8,earnings,100,50,7/22/2020
E829E8,earnings,100,50,7/22/2020
E8846E,product-release,100,64,7/22/2020
E90C84,earnings,100,50,7/22/2020
EA4E68,earnings,100,50,7/22/2020
EB2F14,dividend,100,50,7/22/2020
ED0D7C,dividend,100,50,7/22/2020
ED5171,earnings,100,50,7/22/2020
ED9576,earnings,100,50,7/22/2020
EE6F1C,business-contract,100,69,7/22/2020
EF25A5,partnership,100,61,7/22/2020
F0B2B5,conference-call,100,50,7/22/2020
F24FF0,conference-call,100,50,7/22/2020
F48947,earnings,100,50,7/22/2020
F4E882,executive-appointment,100,54,7/22/2020
F4E882,executive-appointment,100,54,7/22/2020
F8D759,earnings,100,50,7/22/2020
F8D759,earnings,100,50,7/22/2020
F8D759,earnings,100,50,7/22/2020
F8D759,earnings,100,50,7/22/2020
F8D759,earnings,100,50,7/22/2020
F8D759,earnings,100,50,7/22/2020
F8D759,earnings,100,50,7/22/2020
F8D759,earnings,100,50,7/22/2020
F8D759,earnings,100,50,7/22/2020
F8D759,earnings,100,50,7/22/2020
F8D759,earnings,100,50,7/22/2020
F8D759,earnings,100,50,7/22/2020
F8D759,earnings,100,50,7/22/2020
F8D759,earnings,100,50,7/22/2020
F8D759,earnings,100,50,7/22/2020
F8D759,earnings,100,50,7/22/2020
F8D759,earnings,100,50,7/22/2020
F8D759,earnings,100,50,7/22/2020
F8D759,earnings,100,50,7/22/2020
F8D759,earnings,100,50,7/22/2020
F8D759,earnings,100,50,7/22/2020
F8D759,earnings,100,50,7/22/2020
F8D759,earnings,100,50,7/22/2020
F8D759,earnings,100,50,7/22/2020
F8D759,earnings,100,50,7/22/2020
F8D759,earnings,100,50,7/22/2020
FAEABE,earnings-per-share-positive,100,69,7/22/2020
FAEABE,earnings,100,50,7/22/2020
FAEABE,earnings,100,50,7/22/2020
FC1736,earnings,100,50,7/22/2020
FC1F9D,donation,100,54,7/22/2020
FD4E8D,revenues,100,50,7/22/2020
FD4E8D,revenues,100,50,7/22/2020
FD4E8D,revenues,100,50,7/22/2020
FE89E0,business-contract,100,69,7/22/2020
FEE4B0,business-contract,100,69,7/22/2020
FEE4B0,business-contract,100,69,7/22/2020
FF4BA4,product-release,100,64,7/22/2020
FF6644,legal-issues-defendant,100,22,7/22/2020
FFAB4A,dividend,100,50,7/22/2020
FFCD0E,revenues,100,50,7/22/2020
002A99,earnings,100,50,7/23/2020
01B8D6,earnings,100,50,7/23/2020
02870F,fraud-defendant,100,20,7/23/2020
02870F,legal-issues-defendant,100,22,7/23/2020
02870F,conference-call,100,50,7/23/2020
02870F,legal-issues-defendant,100,22,7/23/2020
31025,earnings,100,50,7/23/2020
51332,dividend,100,50,7/23/2020
61366,earnings,100,50,7/23/2020
061A3B,earnings,100,50,7/23/2020
68396,earnings,100,50,7/23/2020
06EE79,earnings,100,50,7/23/2020
71860,earnings,100,50,7/23/2020
07EC43,legal-issues-defendant,100,22,7/23/2020
08A40F,earnings-negative,100,33,7/23/2020
08A40F,earnings-negative,100,33,7/23/2020
08A40F,earnings-negative,100,33,7/23/2020
08A40F,earnings-negative,100,33,7/23/2020
08A40F,earnings-negative,100,33,7/23/2020
08A40F,earnings-negative,100,33,7/23/2020
08A40F,earnings-negative,100,33,7/23/2020
08A40F,earnings-negative,100,33,7/23/2020
95294,business-contract,100,69,7/23/2020
09DE1F,unit-acquisition-completed-acquiree,100,67,7/23/2020
0A0CF0,earnings,100,50,7/23/2020
0A0CF0,earnings,100,50,7/23/2020
0A0CF0,earnings,100,50,7/23/2020
0A0CF0,earnings,100,50,7/23/2020
0A0CF0,earnings,100,50,7/23/2020
0A7650,earnings,100,50,7/23/2020
0B13E8,conference-call,100,50,7/23/2020
0B2071,dividend,100,50,7/23/2020
0B9E6F,earnings-up,100,68,7/23/2020
0B9E6F,earnings-up,100,68,7/23/2020
0C8D82,earnings,100,50,7/23/2020
102F04,earnings,100,50,7/23/2020
105D00,earnings,100,50,7/23/2020
10673F,earnings,100,50,7/23/2020
10673F,earnings,100,50,7/23/2020
108FDA,earnings,100,50,7/23/2020
1096C6,earnings,100,50,7/23/2020
10C19B,earnings,100,50,7/23/2020
10C19B,earnings,100,50,7/23/2020
10C19B,earnings,100,50,7/23/2020
10C19B,earnings,100,50,7/23/2020
10C19B,earnings,100,50,7/23/2020
10C19B,earnings,100,50,7/23/2020
10C19B,earnings,100,50,7/23/2020
10C19B,earnings,100,50,7/23/2020
119CB6,dividend,100,50,7/23/2020
12731D,conference-call,100,50,7/23/2020
12731D,conference-call,100,50,7/23/2020
129DC8,conference-participant,100,50,7/23/2020
17EDA5,legal-issues-defendant,100,22,7/23/2020
182B8C,earnings,100,50,7/23/2020
184866,earnings,100,50,7/23/2020
1AF7E2,earnings,100,50,7/23/2020
1CD09C,conference-call,100,50,7/23/2020
1DB6A6,earnings,100,50,7/23/2020
20DC4E,earnings,100,50,7/23/2020
21245F,conference-call,100,50,7/23/2020
225CA2,dividend,100,50,7/23/2020
228D42,partnership,100,61,7/23/2020
2491BC,earnings,100,50,7/23/2020
2491BC,earnings,100,50,7/23/2020
2491BC,earnings,100,50,7/23/2020
2491BC,earnings,100,50,7/23/2020
2491BC,earnings,100,50,7/23/2020
251988,earnings,100,50,7/23/2020
251988,earnings,100,50,7/23/2020
251988,earnings,100,50,7/23/2020
251988,earnings,100,50,7/23/2020
251988,earnings,100,50,7/23/2020
251988,earnings,100,50,7/23/2020
253B2F,conference-call,100,50,7/23/2020
25AB8E,earnings,100,50,7/23/2020
272472,earnings,100,50,7/23/2020
272704,dividend,100,50,7/23/2020
278C18,earnings,100,50,7/23/2020
27B191,product-release,100,64,7/23/2020
28DCF3,earnings,100,50,7/23/2020
28F905,conference-call,100,50,7/23/2020
29B702,earnings,100,50,7/23/2020
29B702,executive-appointment,100,54,7/23/2020
2AA6A8,conference-call,100,50,7/23/2020
2B9DBB,earnings,100,50,7/23/2020
2BBE62,executive-appointment,100,54,7/23/2020
2DA92D,earnings,100,50,7/23/2020
2E6514,earnings-positive,100,69,7/23/2020
2E902B,note-sale,100,52,7/23/2020
2EC172,conference-call,100,50,7/23/2020
2F5256,dividend,100,50,7/23/2020
2F7474,earnings,100,50,7/23/2020
301493,conference-call,100,50,7/23/2020
31553A,note-sale,100,52,7/23/2020
31553A,public-offering,100,43,7/23/2020
3159AA,conference-call,100,50,7/23/2020
31666F,earnings,100,50,7/23/2020
3471C0,earnings,100,50,7/23/2020
34E9F9,conference-call,100,50,7/23/2020
37020C,dividend,100,50,7/23/2020
37B120,public-offering,100,43,7/23/2020
37E18B,conference-call,100,50,7/23/2020
3A3447,dividend,100,50,7/23/2020
3A3948,earnings,100,50,7/23/2020
3B37F7,conference-call,100,50,7/23/2020
3BE00F,conference-participant,100,50,7/23/2020
3C75D6,executive-appointment,100,54,7/23/2020
3C7F5F,partnership,100,61,7/23/2020
3CCC90,partnership,100,61,7/23/2020
3CCC90,partnership,100,61,7/23/2020
3DE4D1,earnings,100,50,7/23/2020
3E39A5,dividend,100,50,7/23/2020
3ED92D,partnership,100,61,7/23/2020
401072,earnings,100,50,7/23/2020
408380,earnings,100,50,7/23/2020
43E8F5,conference-call,100,50,7/23/2020
442769,business-contract,100,69,7/23/2020
449217,earnings-positive,100,69,7/23/2020
449217,earnings,100,50,7/23/2020
449217,earnings,100,50,7/23/2020
449217,earnings,100,50,7/23/2020
449217,earnings,100,50,7/23/2020
449217,earnings,100,50,7/23/2020
449A26,earnings-positive,100,69,7/23/2020
449A26,dividend,100,50,7/23/2020
453282,earnings-per-share-positive,100,69,7/23/2020
46CF27,earnings,100,50,7/23/2020
46CF27,earnings,100,50,7/23/2020
46CF27,earnings,100,50,7/23/2020
46CF27,earnings,100,50,7/23/2020
46CF27,earnings,100,50,7/23/2020
46CF27,earnings,100,50,7/23/2020
46CF27,earnings,100,50,7/23/2020
46CF27,earnings,100,50,7/23/2020
46CF27,earnings,100,50,7/23/2020
47B4CC,conference-call,100,50,7/23/2020
487B7A,dividend,100,50,7/23/2020
4A6F00,partnership,100,61,7/23/2020
4B3676,earnings,100,50,7/23/2020
4B3DC9,loan-provider,100,57,7/23/2020
4C2F17,earnings,100,50,7/23/2020
4C6C63,product-release,100,64,7/23/2020
4DD203,conference-call,100,50,7/23/2020
4E913D,earnings,100,50,7/23/2020
4EE167,earnings,100,50,7/23/2020
4F783B,fundraising,100,64,7/23/2020
5065B1,earnings,100,50,7/23/2020
50702E,earnings,100,50,7/23/2020
520632,regulatory-product-approval-granted,100,81,7/23/2020
5.43E+08,earnings,100,50,7/23/2020
5487B1,legal-issues-defendant,100,22,7/23/2020
5546DA,earnings,100,50,7/23/2020
556A57,dividend,100,50,7/23/2020
556F08,earnings,100,50,7/23/2020
55C9B5,partnership,100,61,7/23/2020
56632F,partnership,100,61,7/23/2020
57356F,earnings,100,50,7/23/2020
57356F,earnings,100,50,7/23/2020
57356F,earnings,100,50,7/23/2020
57356F,earnings,100,50,7/23/2020
57EF50,conference-call,100,50,7/23/2020
586BD7,conference-call,100,50,7/23/2020
587D25,conference-call,100,50,7/23/2020
589803,legal-issues-defendant,100,22,7/23/2020
58CA9A,dividend,100,50,7/23/2020
59DB8C,executive-appointment,100,54,7/23/2020
5B3FA2,earnings,100,50,7/23/2020
5BE42C,dividend,100,50,7/23/2020
5BE42C,dividend,100,50,7/23/2020
5CC29D,dividend,100,50,7/23/2020
5D1956,earnings,100,50,7/23/2020
5DAF89,conference-call,100,50,7/23/2020
5DE5A5,earnings-up,100,68,7/23/2020
5DE5A5,earnings,100,50,7/23/2020
5DE5A5,earnings,100,50,7/23/2020
5DE5A5,earnings,100,50,7/23/2020
5EAA43,conference-call,100,50,7/23/2020
5F9CE3,earnings,100,50,7/23/2020
6137BF,earnings,100,50,7/23/2020
619882,conference-organizer,100,57,7/23/2020
622037,dividend,100,50,7/23/2020
622037,buybacks,100,74,7/23/2020
62B1C6,dividend,100,50,7/23/2020
6474BA,earnings-positive,100,69,7/23/2020
6474BA,earnings,100,50,7/23/2020
6474BA,earnings,100,50,7/23/2020
6474BA,earnings,100,50,7/23/2020
6474BA,earnings,100,50,7/23/2020
6474BA,earnings,100,50,7/23/2020
6474BA,earnings,100,50,7/23/2020
6474BA,earnings,100,50,7/23/2020
6474BA,earnings,100,50,7/23/2020
6474BA,earnings,100,50,7/23/2020
6474BA,earnings,100,50,7/23/2020
6474BA,earnings,100,50,7/23/2020
64FF65,conference-call,100,50,7/23/2020
65AB30,ipo-pricing,100,50,7/23/2020
65D0AA,legal-issues-defendant,100,22,7/23/2020
65D0AA,legal-issues-defendant,100,22,7/23/2020
665618,earnings-up,100,68,7/23/2020
665618,earnings-up,100,68,7/23/2020
67B052,earnings,100,50,7/23/2020
67B052,earnings,100,50,7/23/2020
68586A,conference-call,100,50,7/23/2020
693ECD,clinical-trials,100,56,7/23/2020
6A3C35,executive-resignation,100,44,7/23/2020
6BDA0C,conference-call,100,50,7/23/2020
6C987C,earnings-positive,100,69,7/23/2020
6D2BF6,earnings,100,50,7/23/2020
6DBBBC,conference-call,100,50,7/23/2020
6-Dec-05,business-contract,100,69,7/23/2020
6.00E+19,conference-call,100,50,7/23/2020
6E8864,conference-call,100,50,7/23/2020
6EB9DA,earnings,100,50,7/23/2020
6EB9DA,earnings,100,50,7/23/2020
6EB9DA,earnings,100,50,7/23/2020
726DDF,legal-issues-defendant,100,22,7/23/2020
7273FF,earnings,100,50,7/23/2020
7410C3,earnings,100,50,7/23/2020
7520CC,earnings,100,50,7/23/2020
76F067,executive-appointment,100,54,7/23/2020
76F067,dividend,100,50,7/23/2020
76F067,earnings,100,50,7/23/2020
78A1BB,earnings,100,50,7/23/2020
78A1BB,earnings,100,50,7/23/2020
78A1BB,earnings,100,50,7/23/2020
78A1BB,earnings,100,50,7/23/2020
78A1BB,earnings,100,50,7/23/2020
7B0BA6,dividend,100,50,7/23/2020
7B1156,conference-call,100,50,7/23/2020
7B1E50,legal-issues-defendant,100,22,7/23/2020
7B1E50,earnings,100,50,7/23/2020
7B9AFA,earnings,100,50,7/23/2020
7D5FD6,earnings,100,50,7/23/2020
7F3665,earnings,100,50,7/23/2020
7FD8B9,conference-participant,100,50,7/23/2020
80D744,earnings,100,50,7/23/2020
8.10E+205,earnings,100,50,7/23/2020
8.22E+27,earnings,100,50,7/23/2020
83598E,dividend,100,50,7/23/2020
8377DB,earnings,100,50,7/23/2020
8377DB,earnings,100,50,7/23/2020
8377DB,earnings,100,50,7/23/2020
8377DB,earnings,100,50,7/23/2020
8377DB,earnings,100,50,7/23/2020
8377DB,merger,100,66,7/23/2020
8377DB,legal-issues-defendant,100,22,7/23/2020
8377DB,legal-issues-defendant,100,22,7/23/2020
859D62,dividend,100,50,7/23/2020
862941,business-contract,100,69,7/23/2020
862941,business-contract,100,69,7/23/2020
862941,business-contract,100,69,7/23/2020
862941,business-contract,100,69,7/23/2020
86478F,earnings,100,50,7/23/2020
8817D5,earnings,100,50,7/23/2020
8A8E41,earnings,100,50,7/23/2020
8AB37F,conference-call,100,50,7/23/2020
8BFE9A,conference-call,100,50,7/23/2020
8C311A,conference-participant,100,50,7/23/2020
8C84DF,earnings,100,50,7/23/2020
8D4AE6,earnings,100,50,7/23/2020
8D4AE6,earnings,100,50,7/23/2020
8D4AE6,earnings,100,50,7/23/2020
8D4AE6,earnings,100,50,7/23/2020
8D4AE6,earnings,100,50,7/23/2020
8D5145,earnings,100,50,7/23/2020
8DE74B,earnings,100,50,7/23/2020
8F3231,earnings,100,50,7/23/2020
8F3BCC,earnings-per-share-positive,100,69,7/23/2020
907ED2,earnings,100,50,7/23/2020
911AB8,dividend,100,50,7/23/2020
922F0C,earnings-per-share,100,50,7/23/2020
92D6A5,dividend,100,50,7/23/2020
943239,earnings,100,50,7/23/2020
949D62,earnings,100,50,7/23/2020
9507FF,earnings,100,50,7/23/2020
9592FB,earnings,100,50,7/23/2020
965360,earnings,100,50,7/23/2020
9.74E+08,partnership,100,61,7/23/2020
986AF6,earnings,100,50,7/23/2020
986AF6,earnings,100,50,7/23/2020
986AF6,earnings,100,50,7/23/2020
9.97E+09,earnings,100,50,7/23/2020
9A2760,earnings,100,50,7/23/2020
9DDE1B,earnings,100,50,7/23/2020
9E298A,dividend,100,50,7/23/2020
9F03CF,earnings,100,50,7/23/2020
9F03CF,dividend,100,50,7/23/2020
A02FB1,earnings,100,50,7/23/2020
A15C71,conference-call,100,50,7/23/2020
A204A7,earnings,100,50,7/23/2020
A37D68,partnership,100,61,7/23/2020
A3800A,facility-open,100,65,7/23/2020
A41450,earnings,100,50,7/23/2020
A433A5,partnership,100,61,7/23/2020
A4B899,conference-call,100,50,7/23/2020
A4D173,earnings,100,50,7/23/2020
A4D173,earnings,100,50,7/23/2020
A5195E,earnings,100,50,7/23/2020
A5B913,earnings,100,50,7/23/2020
A5B913,earnings,100,50,7/23/2020
A6828A,executive-appointment,100,54,7/23/2020
A7F0A5,rights-issue,100,43,7/23/2020
A868C9,conference-participant,100,50,7/23/2020
A94718,conference-call,100,50,7/23/2020
AB4A7E,conference-call,100,50,7/23/2020
AD23DE,partnership,100,61,7/23/2020
AD375D,earnings,100,50,7/23/2020
ADFB3A,partnership,100,61,7/23/2020
AE0CCE,conference-call,100,50,7/23/2020
AFD1CA,earnings,100,50,7/23/2020
B076A1,conference-call,100,50,7/23/2020
B0B969,conference-call,100,50,7/23/2020
B1A85D,earnings-above-expectations,100,88,7/23/2020
B1FC3B,business-contract,100,69,7/23/2020
B381D8,patient-enrollment-complete,100,64,7/23/2020
B3ED62,legal-issues-defendant,100,22,7/23/2020
B3ED62,legal-issues-defendant,100,22,7/23/2020
B3ED62,legal-issues-defendant,100,22,7/23/2020
B3ED62,legal-issues-defendant,100,22,7/23/2020
B3ED62,legal-issues-defendant,100,22,7/23/2020
B3ED62,legal-issues-defendant,100,22,7/23/2020
B5766D,earnings-per-share-positive,100,69,7/23/2020
B5766D,earnings,100,50,7/23/2020
B5766D,earnings,100,50,7/23/2020
B5766D,earnings,100,50,7/23/2020
B5766D,earnings,100,50,7/23/2020
B5766D,earnings,100,50,7/23/2020
B83BCE,earnings,100,50,7/23/2020
B840EF,partnership,100,61,7/23/2020
B96637,earnings-positive,100,69,7/23/2020
B96637,earnings-positive,100,69,7/23/2020
B9CD50,earnings,100,50,7/23/2020
BA0442,acquisition-acquirer,100,49,7/23/2020
BA0442,acquisition-acquirer,100,49,7/23/2020
BB88B6,partnership,100,61,7/23/2020
BBF349,unit-acquisition-completed-acquirer,100,49,7/23/2020
BC3AD2,earnings,100,50,7/23/2020
BC3AD2,earnings,100,50,7/23/2020
BC3AD2,earnings,100,50,7/23/2020
BC3AD2,earnings,100,50,7/23/2020
BC3AD2,earnings,100,50,7/23/2020
BC3AD2,earnings,100,50,7/23/2020
BC3AD2,earnings,100,50,7/23/2020
BC3AD2,earnings,100,50,7/23/2020
BC5680,earnings,100,50,7/23/2020
BDE867,executive-appointment,100,54,7/23/2020
BEB756,earnings,100,50,7/23/2020
BF79F5,earnings,100,50,7/23/2020
BF79F5,earnings,100,50,7/23/2020
BF79F5,earnings,100,50,7/23/2020
BFAEB4,earnings,100,50,7/23/2020
C062D4,dividend,100,50,7/23/2020
C1114B,conference-call,100,50,7/23/2020
C188F8,product-release,100,64,7/23/2020
C1CBA4,earnings-positive,100,69,7/23/2020
C1CBA4,earnings-positive,100,69,7/23/2020
C1CBA4,earnings-positive,100,69,7/23/2020
C1CBA4,earnings-positive,100,69,7/23/2020
C1CBA4,earnings-positive,100,69,7/23/2020
C1CBA4,earnings-positive,100,69,7/23/2020
C1CBA4,earnings-positive,100,69,7/23/2020
C1CBA4,earnings-positive,100,69,7/23/2020
C1CBA4,earnings-positive,100,69,7/23/2020
C41C25,earnings,100,50,7/23/2020
C4452A,dividend,100,50,7/23/2020
C4706C,conference-call,100,50,7/23/2020
C501B6,settlement,100,56,7/23/2020
C5E840,ipo-pricing,100,50,7/23/2020
C62AA4,conference-call,100,50,7/23/2020
C83B88,partnership,100,61,7/23/2020
C8923A,earnings,100,50,7/23/2020
C9E107,earnings,100,50,7/23/2020
C9E107,dividend,100,50,7/23/2020
CBFFDD,conference-participant,100,50,7/23/2020
CC35BE,earnings,100,50,7/23/2020
CCB623,earnings,100,50,7/23/2020
CD4DA8,partnership,100,61,7/23/2020
CF6A5A,earnings,100,50,7/23/2020
CFD4B6,conference-call,100,50,7/23/2020
D1344A,earnings,100,50,7/23/2020
D1AE3B,earnings,100,50,7/23/2020
D33D8C,dividend,100,50,7/23/2020
D4463B,earnings,100,50,7/23/2020
D58A11,executive-appointment,100,54,7/23/2020
D650A7,earnings,100,50,7/23/2020
D8ECA1,earnings,100,50,7/23/2020
D8F347,earnings,100,50,7/23/2020
D8F347,earnings,100,50,7/23/2020
D8F347,earnings,100,50,7/23/2020
D8F347,earnings,100,50,7/23/2020
D9C07E,earnings,100,50,7/23/2020
DA48E4,earnings-per-share,100,50,7/23/2020
DA90E1,earnings,100,50,7/23/2020
DBCA3F,earnings,100,50,7/23/2020
DD0099,earnings-up,100,72,7/23/2020
DE4924,conference-call,100,50,7/23/2020
E05DC8,earnings,100,50,7/23/2020
E09E2B,product-release,100,64,7/23/2020
E124EB,earnings,100,50,7/23/2020
E124EB,earnings,100,50,7/23/2020
E124EB,earnings,100,50,7/23/2020
E124EB,earnings,100,50,7/23/2020
E22FDE,conference-call,100,50,7/23/2020
E2CB7B,earnings,100,50,7/23/2020
E2CFD2,conference-call,100,50,7/23/2020
E38906,earnings,100,50,7/23/2020
E393B0,earnings,100,50,7/23/2020
E40FB6,earnings,100,50,7/23/2020
E40FB6,earnings,100,50,7/23/2020
E40FB6,earnings,100,50,7/23/2020
E40FB6,earnings,100,50,7/23/2020
E40FB6,earnings,100,50,7/23/2020
E49AA3,earnings,100,50,7/23/2020
E68C3D,earnings,100,50,7/23/2020
E72599,conference-call,100,50,7/23/2020
E866D2,earnings,100,50,7/23/2020
E866D2,earnings,100,50,7/23/2020
E866D2,earnings,100,50,7/23/2020
E866D2,earnings,100,50,7/23/2020
E866D2,earnings,100,50,7/23/2020
E866D2,earnings,100,50,7/23/2020
E866D2,earnings,100,50,7/23/2020
E8B21D,earnings,100,50,7/23/2020
E8B21D,earnings,100,50,7/23/2020
E8B21D,earnings,100,50,7/23/2020
E8B21D,earnings,100,50,7/23/2020
E8B21D,earnings,100,50,7/23/2020
E8B21D,earnings,100,50,7/23/2020
E8B315,earnings-positive,100,69,7/23/2020
E93A40,earnings,100,50,7/23/2020
E99180,earnings,100,50,7/23/2020
EB2F14,earnings,100,50,7/23/2020
EB5E78,earnings,100,50,7/23/2020
EB5E78,earnings,100,50,7/23/2020
EB5E78,earnings,100,50,7/23/2020
EB5E78,earnings,100,50,7/23/2020
EB61C4,dividend,100,50,7/23/2020
ED8676,earnings-positive,100,69,7/23/2020
ED8676,earnings-positive,100,69,7/23/2020
ED8676,earnings-positive,100,69,7/23/2020
ED8676,earnings-positive,100,69,7/23/2020
ED8676,earnings-positive,100,69,7/23/2020
ED8676,earnings-positive,100,69,7/23/2020
ED8676,earnings-positive,100,69,7/23/2020
ED8676,earnings-positive,100,69,7/23/2020
ED8676,earnings-positive,100,69,7/23/2020
ED8676,earnings-positive,100,69,7/23/2020
ED8676,earnings-positive,100,69,7/23/2020
ED8676,dividend,100,50,7/23/2020
EF1AD9,dividend,100,50,7/23/2020
EF1AD9,earnings,100,50,7/23/2020
EF1AD9,earnings,100,50,7/23/2020
EF1AD9,earnings,100,50,7/23/2020
EF1AD9,earnings,100,50,7/23/2020
EF25A5,earnings,100,50,7/23/2020
EF5BED,executive-appointment,100,54,7/23/2020
EF76C8,dividend,100,50,7/23/2020
F02170,partnership,100,61,7/23/2020
F179ED,executive-appointment,100,54,7/23/2020
F294DD,earnings,100,50,7/23/2020
F294DD,earnings,100,50,7/23/2020
F294DD,earnings,100,50,7/23/2020
F294DD,earnings,100,50,7/23/2020
F4E882,earnings,100,50,7/23/2020
F5349B,executive-appointment,100,54,7/23/2020
F793FA,earnings,100,50,7/23/2020
F793FA,earnings,100,50,7/23/2020
F793FA,earnings,100,50,7/23/2020
F793FA,earnings,100,50,7/23/2020
F793FA,earnings,100,50,7/23/2020
F793FA,earnings,100,50,7/23/2020
F8084B,earnings,100,50,7/23/2020
F93C8A,conference-call,100,50,7/23/2020
FAAFA2,clinical-trials-start,100,64,7/23/2020
FACCF6,earnings,100,50,7/23/2020
FBD92D,earnings,100,50,7/23/2020
FC1F9D,revenue-up,100,69,7/23/2020
FC1F9D,revenue-up,100,69,7/23/2020
FC1F9D,revenue-up,100,69,7/23/2020
FC1F9D,revenue-up,100,69,7/23/2020
FC4550,earnings,100,50,7/23/2020
FC80E6,conference-call,100,50,7/23/2020
FC9A88,earnings-up,100,68,7/23/2020
FD2565,partnership,100,61,7/23/2020
FF6644,legal-issues-defendant,100,22,7/23/2020
FFE543,earnings,100,50,7/23/2020
02870F,legal-issues-defendant,100,22,7/24/2020
02870F,legal-issues-defendant,100,22,7/24/2020
02870F,legal-issues-defendant,100,22,7/24/2020
56045,ipo-pricing,100,50,7/24/2020
091B6C,ipo-pricing,100,50,7/24/2020
091B6C,ipo-pricing,100,50,7/24/2020
95294,partnership,100,61,7/24/2020
108BD2,earnings,100,50,7/24/2020
10AE08,earnings,100,50,7/24/2020
129DC8,trading-halt,100,43,7/24/2020
129DC8,trading-resumed,100,58,7/24/2020
152B9E,dividend,100,50,7/24/2020
156A99,earnings,100,50,7/24/2020
17EDA5,legal-issues-defendant,100,22,7/24/2020
17EDA5,legal-issues-defendant,100,22,7/24/2020
17EDA5,legal-issues-defendant,100,22,7/24/2020
17EDA5,legal-issues-defendant,100,22,7/24/2020
19C105,earnings,100,50,7/24/2020
19C105,earnings,100,50,7/24/2020
19C105,earnings,100,50,7/24/2020
19C105,dividend,100,50,7/24/2020
1A5957,earnings,100,50,7/24/2020
1DB833,earnings,100,50,7/24/2020
1DDEDA,conference-call,100,50,7/24/2020
1FAF22,partnership,100,61,7/24/2020
223216,revenue-up,100,52,7/24/2020
272472,dividend,100,50,7/24/2020
27C10F,earnings,100,50,7/24/2020
2CB4C9,earnings,100,50,7/24/2020
2CD1E0,acquisition-acquiree,100,76,7/24/2020
2CD1E0,acquisition-acquiree,100,76,7/24/2020
32F943,fast-track-designation,100,81,7/24/2020
34E9F9,legal-issues-defendant,100,22,7/24/2020
3C3B6B,acquisition-acquirer,100,49,7/24/2020
3C3B6B,earnings,100,50,7/24/2020
41A93D,earnings,100,50,7/24/2020
41B53E,earnings,100,50,7/24/2020
4649D5,earnings,100,50,7/24/2020
4A2457,government-contract,100,69,7/24/2020
4C37C5,partnership,100,61,7/24/2020
4C37C5,revenues,100,50,7/24/2020
4C37C5,revenues,100,50,7/24/2020
4C37C5,revenues,100,50,7/24/2020
4FCC78,acquisition-completed-acquirer,100,49,7/24/2020
553949,conference-call,100,50,7/24/2020
65D0AA,acquisition-acquirer,100,49,7/24/2020
65D0AA,legal-issues-defendant,100,22,7/24/2020
69CE71,conference-call,100,50,7/24/2020
6A01DF,earnings,100,50,7/24/2020
6A3C35,earnings,100,50,7/24/2020
6B236C,dividend,100,50,7/24/2020
6DDA15,earnings,100,50,7/24/2020
6E705B,executive-appointment,100,54,7/24/2020
6E8349,earnings,100,50,7/24/2020
7032D0,earnings,100,50,7/24/2020
726DDF,legal-issues-defendant,100,22,7/24/2020
72F0FC,dividend,100,50,7/24/2020
72F0FC,earnings-up,100,68,7/24/2020
742AAB,conference-call,100,50,7/24/2020
76BD96,conference-call,100,50,7/24/2020
76CEFB,earnings,100,50,7/24/2020
7ACD98,award,100,58,7/24/2020
7BC92D,earnings,100,50,7/24/2020
859281,dividend,100,50,7/24/2020
8C1238,conference-call,100,50,7/24/2020
8F3231,dividend,100,50,7/24/2020
92005C,earnings,100,50,7/24/2020
965360,dividend,100,50,7/24/2020
997348,earnings,100,50,7/24/2020
997348,earnings,100,50,7/24/2020
9AF3DC,dividend,100,50,7/24/2020
9B4066,asset-sale,100,62,7/24/2020
9D307D,earnings,100,50,7/24/2020
A403CF,executive-appointment,100,54,7/24/2020
A806FA,dividend,100,50,7/24/2020
ABE7DC,ipo-pricing,100,50,7/24/2020
AD23DE,credit-extension-recipient,100,69,7/24/2020
B5BA39,earnings,100,50,7/24/2020
BB88B6,partnership,100,61,7/24/2020
BDCC11,earnings,100,50,7/24/2020
C01737,earnings,100,50,7/24/2020
C1CBA4,dividend,100,50,7/24/2020
C564E4,conference-call,100,50,7/24/2020
C8257F,conference-call,100,50,7/24/2020
C83B88,business-contract,100,69,7/24/2020
C8A059,earnings,100,50,7/24/2020
C8A248,partnership,100,61,7/24/2020
CC339B,earnings,100,50,7/24/2020
CCB623,legal-issues-defendant,100,22,7/24/2020
CE4E6D,product-release,100,64,7/24/2020
CFF15D,executive-appointment,100,54,7/24/2020
D0DFE5,earnings,100,50,7/24/2020
D6853F,executive-appointment,100,54,7/24/2020
D7F569,earnings,100,50,7/24/2020
D7F569,dividend,100,50,7/24/2020
DBEF02,earnings,100,50,7/24/2020
DF204B,conference-call,100,50,7/24/2020
DFADDB,earnings,100,50,7/24/2020
E6E012,dividend,100,50,7/24/2020
E6E012,dividend,100,50,7/24/2020
EA79C7,executive-appointment,100,54,7/24/2020
EAA0A7,earnings,100,50,7/24/2020
ED0D7C,earnings,100,50,7/24/2020
ED0D7C,earnings,100,50,7/24/2020
ED0D7C,earnings,100,50,7/24/2020
ED0D7C,earnings,100,50,7/24/2020
ED0D7C,earnings,100,50,7/24/2020
ED2EFD,dividend,100,50,7/24/2020
EE1E44,earnings,100,50,7/24/2020
EE1E44,earnings,100,50,7/24/2020
EE1E44,earnings,100,50,7/24/2020
EE1E44,earnings,100,50,7/24/2020
EE1E44,earnings,100,50,7/24/2020
EE1E44,earnings,100,50,7/24/2020
F0B877,earnings,100,50,7/24/2020
F2E253,conference-call,100,50,7/24/2020
F5349B,business-contract,100,69,7/24/2020
FA40E2,dividend,100,50,7/24/2020
FD39EB,acquisition-acquirer,100,49,7/24/2020
FD39EB,acquisition-acquirer,100,49,7/24/2020
FDC08C,earnings,100,50,7/24/2020
FDC08C,earnings,100,50,7/24/2020
FDC08C,earnings,100,50,7/24/2020
FDC08C,earnings,100,50,7/24/2020
FDC08C,earnings,100,50,7/24/2020
FDC08C,earnings,100,50,7/24/2020
FF6644,earnings-per-share-positive,100,69,7/24/2020
FF6644,earnings-per-share-positive,100,69,7/24/2020
FF6644,earnings-per-share-positive,100,69,7/24/2020
FF6644,earnings-per-share-positive,100,69,7/24/2020
FF6644,earnings-per-share-positive,100,69,7/24/2020
FF6644,earnings-per-share-positive,100,69,7/24/2020
FF6644,earnings-per-share-positive,100,69,7/24/2020
FF6644,earnings-per-share-positive,100,69,7/24/2020
FF6644,earnings-per-share-positive,100,69,7/24/2020
02870F,legal-issues-defendant,100,22,7/25/2020
02870F,legal-issues-defendant,100,22,7/25/2020
279916,fraud-defendant,100,20,7/25/2020
B3ED62,legal-issues-defendant,100,22,7/25/2020
FF6644,legal-issues-defendant,100,22,7/25/2020
00326E,executive-appointment,100,54,7/27/2020
13528,partnership,100,61,7/27/2020
04996E,earnings,100,50,7/27/2020
091B6C,ipo-pricing,100,50,7/27/2020
0A6824,dividend,100,50,7/27/2020
0A7650,earnings,100,50,7/27/2020
0AB700,earnings,100,50,7/27/2020
0BF198,conference-call,100,50,7/27/2020
0CE204,earnings,100,50,7/27/2020
0D26E0,earnings-positive,100,69,7/27/2020
0DBB81,executive-appointment,100,54,7/27/2020
0DE3D5,award,100,58,7/27/2020
12E454,conference-call,100,50,7/27/2020
14833D,earnings,100,50,7/27/2020
152E1D,conference-call,100,50,7/27/2020
157CC1,regulatory-product-application,100,69,7/27/2020
168A5D,executive-appointment,100,54,7/27/2020
1782D5,capex,100,50,7/27/2020
17EDA5,legal-issues-defendant,100,22,7/27/2020
180DA0,business-contract,100,69,7/27/2020
1AF7E2,executive-appointment,100,54,7/27/2020
1DF15D,earnings,100,50,7/27/2020
1DF15D,earnings,100,50,7/27/2020
1DF15D,earnings,100,50,7/27/2020
206852,earnings,100,50,7/27/2020
2082EA,clinical-trials-positive,100,87,7/27/2020
20DC4E,dividend,100,50,7/27/2020
228D42,partnership,100,61,7/27/2020
238302,conference-call,100,50,7/27/2020
2720AB,note-sale,100,52,7/27/2020
279916,legal-issues-defendant,100,22,7/27/2020
279916,legal-issues-defendant,100,22,7/27/2020
279916,legal-issues-defendant,100,22,7/27/2020
279916,legal-issues-defendant,100,22,7/27/2020
279916,legal-issues-defendant,100,22,7/27/2020
27A791,earnings,100,50,7/27/2020
28DCF3,earnings,100,50,7/27/2020
2A1009,business-contract,100,69,7/27/2020
2A6DBE,legal-issues-defendant,100,22,7/27/2020
2A6DBE,legal-issues-defendant,100,22,7/27/2020
2A6DBE,legal-issues-defendant,100,22,7/27/2020
2A6DBE,legal-issues-defendant,100,22,7/27/2020
2A6DBE,legal-issues-defendant,100,22,7/27/2020
2A9C0A,earnings-positive,100,69,7/27/2020
2A9C0A,earnings,100,50,7/27/2020
2A9C0A,earnings,100,50,7/27/2020
2A9C0A,earnings,100,50,7/27/2020
2A9C0A,earnings,100,50,7/27/2020
2A9C0A,earnings,100,50,7/27/2020
2AA6A8,executive-appointment,100,54,7/27/2020
2C3348,earnings,100,50,7/27/2020
2D643C,executive-resignation,100,44,7/27/2020
2DB344,earnings,100,50,7/27/2020
2DDB22,earnings-guidance,100,50,7/27/2020
2EB04E,earnings,100,50,7/27/2020
2FDEE3,executive-appointment,100,54,7/27/2020
317EC6,earnings,100,50,7/27/2020
319BE2,dividend,100,50,7/27/2020
319BE2,earnings,100,50,7/27/2020
3.20E+263,clinical-trials,100,56,7/27/2020
339F20,earnings,100,50,7/27/2020
33A0F1,partnership,100,61,7/27/2020
346BF2,conference-call,100,50,7/27/2020
356B21,legal-issues-defendant,100,22,7/27/2020
35AE32,earnings,100,50,7/27/2020
366A08,earnings,100,50,7/27/2020
366A08,earnings,100,50,7/27/2020
366A08,earnings,100,50,7/27/2020
366A08,earnings,100,50,7/27/2020
366A08,earnings,100,50,7/27/2020
366A08,earnings,100,50,7/27/2020
37E18B,conference-participant,100,50,7/27/2020
3A4BDB,earnings-positive,100,69,7/27/2020
3A6D90,dividend,100,50,7/27/2020
3AAEAE,executive-appointment,100,54,7/27/2020
3AF7FD,dividend,100,50,7/27/2020
3BA1BF,conference-call,100,50,7/27/2020
3BB7D3,executive-appointment,100,54,7/27/2020
3DB18B,earnings,100,50,7/27/2020
42AABD,acquisition-acquirer,100,49,7/27/2020
453282,dividend,100,50,7/27/2020
49914B,earnings,100,50,7/27/2020
49914B,earnings,100,50,7/27/2020
49914B,earnings,100,50,7/27/2020
49CC59,earnings,100,50,7/27/2020
4A2457,conference-call,100,50,7/27/2020
4B3DC9,earnings,100,50,7/27/2020
4B3DC9,earnings,100,50,7/27/2020
4B3DC9,earnings,100,50,7/27/2020
4B3DC9,earnings,100,50,7/27/2020
4B3DC9,earnings,100,50,7/27/2020
4B3DC9,earnings,100,50,7/27/2020
4B3DC9,earnings,100,50,7/27/2020
4B3DC9,earnings,100,50,7/27/2020
4B3DC9,earnings,100,50,7/27/2020
4B3DC9,earnings,100,50,7/27/2020
4B3DC9,earnings,100,50,7/27/2020
4B3DC9,earnings,100,50,7/27/2020
4B3DC9,earnings,100,50,7/27/2020
4BBA23,conference-call,100,50,7/27/2020
4C5CC9,dividend,100,50,7/27/2020
4D8E5E,earnings,100,50,7/27/2020
51E682,earnings,100,50,7/27/2020
56EA2B,revenue-up,100,67,7/27/2020
57A854,earnings,100,50,7/27/2020
59B229,earnings,100,50,7/27/2020
59B229,earnings,100,50,7/27/2020
5BE42C,earnings,100,50,7/27/2020
5C8D61,earnings,100,50,7/27/2020
5C8D61,earnings,100,50,7/27/2020
5C8D61,earnings,100,50,7/27/2020
5D02B7,earnings,100,50,7/27/2020
61E975,conference-call,100,50,7/27/2020
622DBE,executive-appointment,100,54,7/27/2020
636931,earnings,100,50,7/27/2020
63F892,partnership,100,61,7/27/2020
64636E,patient-enrollment-start,100,58,7/27/2020
64636E,patient-enrollment-start,100,58,7/27/2020
64636E,patient-enrollment-start,100,58,7/27/2020
65D0AA,legal-issues-defendant,100,22,7/27/2020
662682,earnings,100,50,7/27/2020
68B03F,earnings,100,50,7/27/2020
693ECD,earnings,100,50,7/27/2020
6B494E,earnings,100,50,7/27/2020
6BD606,note-sale,100,52,7/27/2020
6C4D2F,earnings,100,50,7/27/2020
6C4D2F,earnings,100,50,7/27/2020
6C4D2F,earnings,100,50,7/27/2020
6C4D2F,earnings,100,50,7/27/2020
6C4D2F,earnings,100,50,7/27/2020
6C4D2F,earnings,100,50,7/27/2020
6C4D2F,earnings,100,50,7/27/2020
6C4D2F,earnings,100,50,7/27/2020
6C4D2F,earnings,100,50,7/27/2020
6C4D2F,executive-appointment,100,54,7/27/2020
71553E,earnings,100,50,7/27/2020
71B0CF,earnings,100,50,7/27/2020
726DDF,legal-issues-defendant,100,22,7/27/2020
726DDF,legal-issues-defendant,100,22,7/27/2020
728737,earnings,100,50,7/27/2020
735388,earnings,100,50,7/27/2020
7.44E+09,dividend,100,50,7/27/2020
7448A3,earnings,100,50,7/27/2020
748EB6,conference-call,100,50,7/27/2020
751C8D,ipo,100,71,7/27/2020
765913,dividend,100,50,7/27/2020
769F40,earnings,100,50,7/27/2020
76E80F,partnership,100,61,7/27/2020
791D59,earnings,100,50,7/27/2020
79340A,earnings,100,50,7/27/2020
7B1E50,legal-issues-defendant,100,22,7/27/2020
7B6C88,conference-call,100,50,7/27/2020
7CBC40,earnings,100,50,7/27/2020
7CBC40,earnings,100,50,7/27/2020
7CBC40,earnings,100,50,7/27/2020
7CBC40,earnings,100,50,7/27/2020
7E1542,earnings,100,50,7/27/2020
7F2922,earnings,100,50,7/27/2020
7FC386,earnings,100,50,7/27/2020
80C400,conference-call,100,50,7/27/2020
824CCA,earnings,100,50,7/27/2020
859281,earnings,100,50,7/27/2020
859281,earnings,100,50,7/27/2020
859281,earnings,100,50,7/27/2020
859281,earnings,100,50,7/27/2020
859281,earnings,100,50,7/27/2020
859281,earnings,100,50,7/27/2020
859281,earnings,100,50,7/27/2020
85AD00,earnings,100,50,7/27/2020
85DA04,executive-appointment,100,54,7/27/2020
85DA04,partnership,100,61,7/27/2020
862941,earnings,100,50,7/27/2020
873DB9,dividend,100,50,7/27/2020
8802B4,earnings,100,50,7/27/2020
890FF4,earnings,100,50,7/27/2020
893904,earnings,100,50,7/27/2020
8AA108,partnership,100,61,7/27/2020
8AA108,public-offering,100,43,7/27/2020
8B2C4A,earnings,100,50,7/27/2020
8B2C4A,earnings,100,50,7/27/2020
8B2C4A,earnings,100,50,7/27/2020
8B2C4A,earnings,100,50,7/27/2020
8B2C4A,earnings,100,50,7/27/2020
8B2C4A,earnings,100,50,7/27/2020
8B2C4A,earnings,100,50,7/27/2020
8B2C4A,earnings,100,50,7/27/2020
8BE916,earnings,100,50,7/27/2020
8DA42F,conference-call,100,50,7/27/2020
8DDA23,earnings-positive,100,69,7/27/2020
8E10BF,public-offering,100,43,7/27/2020
8E93A4,earnings,100,50,7/27/2020
8F8F2F,earnings,100,50,7/27/2020
8FE7A5,earnings,100,50,7/27/2020
92D6A5,earnings,100,50,7/27/2020
944B2E,earnings,100,50,7/27/2020
950AB7,earnings,100,50,7/27/2020
95DE39,earnings-positive,100,69,7/27/2020
95DE39,earnings-positive,100,69,7/27/2020
95DE39,earnings-positive,100,69,7/27/2020
95DE39,earnings-positive,100,69,7/27/2020
95DE39,earnings-positive,100,69,7/27/2020
9673BD,conference-call,100,50,7/27/2020
97644E,earnings,100,50,7/27/2020
97AAF6,business-contract,100,69,7/27/2020
97AAF6,business-contract,100,69,7/27/2020
97B027,conference-call,100,50,7/27/2020
99B61C,executive-appointment,100,54,7/27/2020
9BB35A,dividend,100,50,7/27/2020
9C8664,earnings,100,50,7/27/2020
9D5D35,earnings,100,50,7/27/2020
9D5D35,earnings,100,50,7/27/2020
9D5D35,earnings,100,50,7/27/2020
9D5D35,executive-appointment,100,54,7/27/2020
9F18FA,earnings,100,50,7/27/2020
9F18FA,earnings,100,50,7/27/2020
A247F5,award,100,58,7/27/2020
A29A46,conference-call,100,50,7/27/2020
A350C1,operating-earnings,100,50,7/27/2020
A350C1,operating-earnings,100,50,7/27/2020
A350C1,operating-earnings,100,50,7/27/2020
A350C1,operating-earnings,100,50,7/27/2020
A350C1,operating-earnings,100,50,7/27/2020
A350C1,operating-earnings,100,50,7/27/2020
A350C1,operating-earnings,100,50,7/27/2020
A3BFAA,earnings,100,50,7/27/2020
A47A7D,earnings,100,50,7/27/2020
A47F2E,earnings,100,50,7/27/2020
A8B137,product-release,100,64,7/27/2020
A96867,earnings-positive,100,69,7/27/2020
A96867,earnings-positive,100,69,7/27/2020
A96867,earnings-positive,100,69,7/27/2020
A96867,earnings-positive,100,69,7/27/2020
A96867,earnings-positive,100,69,7/27/2020
A96867,earnings-positive,100,69,7/27/2020
A96867,earnings-positive,100,69,7/27/2020
A96867,earnings-positive,100,69,7/27/2020
AA98ED,earnings,100,50,7/27/2020
AAEE21,earnings,100,50,7/27/2020
AC7C4F,award,100,58,7/27/2020
AD6141,executive-appointment,100,54,7/27/2020
ADF1B0,earnings,100,50,7/27/2020
ADF1B0,earnings,100,50,7/27/2020
B1FC3B,government-contract,100,69,7/27/2020
B33E77,earnings,100,50,7/27/2020
B3A166,conference-call,100,50,7/27/2020
B604DF,earnings,100,50,7/27/2020
B604DF,earnings,100,50,7/27/2020
B604DF,earnings,100,50,7/27/2020
B604DF,earnings,100,50,7/27/2020
B604DF,earnings,100,50,7/27/2020
B619CB,earnings-positive,100,69,7/27/2020
B72BE9,revenues,100,50,7/27/2020
B72BE9,revenues,100,50,7/27/2020
B72BE9,revenues,100,50,7/27/2020
BBAE2A,earnings,100,50,7/27/2020
BD15E8,dividend,100,50,7/27/2020
BE14CF,earnings,100,50,7/27/2020
BE379D,conference-call,100,50,7/27/2020
C0BA36,award,100,58,7/27/2020
C11C46,executive-appointment,100,54,7/27/2020
C188F8,product-release,100,64,7/27/2020
C598D7,revenue-up,100,54,7/27/2020
C598D7,revenues,100,50,7/27/2020
C598D7,revenues,100,50,7/27/2020
C8257F,partnership,100,61,7/27/2020
C941DC,executive-appointment,100,54,7/27/2020
CB9E13,note-sale,100,52,7/27/2020
CB9E13,note-sale,100,52,7/27/2020
CC3EC4,earnings,100,50,7/27/2020
CCBBAD,earnings,100,50,7/27/2020
CDE51C,sponsorship,100,57,7/27/2020
CE4E6D,product-release,100,64,7/27/2020
CE8A7B,asset-sale,100,62,7/27/2020
D06996,earnings,100,50,7/27/2020
D0DFE5,earnings,100,50,7/27/2020
D15833,dividend,100,50,7/27/2020
D15833,dividend,100,50,7/27/2020
D296C6,earnings,100,50,7/27/2020
D33D8C,executive-appointment,100,54,7/27/2020
D3C794,earnings,100,50,7/27/2020
D4463B,note-sale,100,52,7/27/2020
D6144F,conference-call,100,50,7/27/2020
D721C6,executive-appointment,100,54,7/27/2020
DAC66A,earnings,100,50,7/27/2020
DC2F77,dividend,100,50,7/27/2020
DD1BA1,earnings,100,50,7/27/2020
DD9E41,partnership,100,61,7/27/2020
DF46C5,dividend,100,50,7/27/2020
DF46C5,earnings,100,50,7/27/2020
DF46C5,earnings,100,50,7/27/2020
DF46C5,earnings,100,50,7/27/2020
DF46C5,earnings,100,50,7/27/2020
DF46C5,earnings,100,50,7/27/2020
E0339F,dividend,100,50,7/27/2020
E0647D,earnings,100,50,7/27/2020
E0647D,earnings,100,50,7/27/2020
E0647D,earnings,100,50,7/27/2020
E0647D,earnings,100,50,7/27/2020
E0647D,earnings,100,50,7/27/2020
E09997,conference-call,100,50,7/27/2020
E1E36F,dividend,100,50,7/27/2020
E22FDE,partnership,100,61,7/27/2020
E68C3D,unit-acquisition-acquirer,100,49,7/27/2020
E70531,earnings,100,50,7/27/2020
E7BF32,earnings,100,50,7/27/2020
E7BF32,earnings,100,50,7/27/2020
E84500,earnings,100,50,7/27/2020
E87676,dividend,100,50,7/27/2020
E8846E,legal-issues-defendant,100,22,7/27/2020
E8846E,legal-issues-defendant,100,22,7/27/2020
EA62FC,dividend,100,50,7/27/2020
EB61C4,earnings,100,50,7/27/2020
EBD89A,business-contract,100,69,7/27/2020
EC70EC,stake-acquirer,100,48,7/27/2020
EC8116,fundraising,100,64,7/27/2020
ECF4F8,conference-call,100,50,7/27/2020
ED79D9,conference-call,100,50,7/27/2020
F2526D,earnings,100,50,7/27/2020
F2E253,hirings,100,65,7/27/2020
F30508,partnership,100,61,7/27/2020
F32F88,dividend,100,50,7/27/2020
F3EDB4,business-contract,100,69,7/27/2020
F5D059,earnings,100,50,7/27/2020
F5D059,earnings,100,50,7/27/2020
F5D059,earnings,100,50,7/27/2020
F5D059,earnings,100,50,7/27/2020
F5D059,earnings,100,50,7/27/2020
F5D059,earnings,100,50,7/27/2020
F72E4B,earnings,100,50,7/27/2020
F7935D,earnings,100,50,7/27/2020
F88147,public-offering,100,43,7/27/2020
F95726,earnings,100,50,7/27/2020
FC1736,revenues,100,50,7/27/2020
FC1736,revenues,100,50,7/27/2020
FC1736,revenues,100,50,7/27/2020
FEC475,executive-resignation,100,44,7/27/2020
FF6644,conference-participant,100,50,7/27/2020
0157B1,revenue-up,100,69,7/28/2020
01B8D6,conference-participant,100,50,7/28/2020
036C6F,conference-call,100,50,7/28/2020
03B8CF,earnings,100,50,7/28/2020
03B8CF,earnings,100,50,7/28/2020
03B8CF,earnings,100,50,7/28/2020
03B8CF,earnings,100,50,7/28/2020
03B8CF,earnings,100,50,7/28/2020
03B8CF,earnings,100,50,7/28/2020
03B8CF,earnings,100,50,7/28/2020
0490C6,earnings,100,50,7/28/2020
053EFF,conference-call,100,50,7/28/2020
054E7E,conference-participant,100,50,7/28/2020
56045,ipo-completed,100,76,7/28/2020
05AF14,conference-participant,100,50,7/28/2020
065D38,earnings,100,50,7/28/2020
070B45,earnings,100,50,7/28/2020
95294,partnership,100,61,7/28/2020
095A04,earnings,100,50,7/28/2020
09F623,earnings,100,50,7/28/2020
09F623,earnings,100,50,7/28/2020
09F623,earnings,100,50,7/28/2020
0F65C9,executive-appointment,100,54,7/28/2020
102727,earnings,100,50,7/28/2020
1220D2,earnings,100,50,7/28/2020
131443,earnings,100,50,7/28/2020
131443,earnings,100,50,7/28/2020
131443,earnings,100,50,7/28/2020
131443,earnings,100,50,7/28/2020
131443,earnings,100,50,7/28/2020
131443,earnings,100,50,7/28/2020
1866B2,earnings,100,50,7/28/2020
1A2D9F,earnings,100,50,7/28/2020
1A2D9F,earnings,100,50,7/28/2020
1A3E1B,dividend,100,50,7/28/2020
1BDB2A,dividend,100,50,7/28/2020
1DE526,earnings,100,50,7/28/2020
1EBF8D,dividend,100,50,7/28/2020
1F9D90,earnings,100,50,7/28/2020
1FA886,partnership,100,61,7/28/2020
1FA886,partnership,100,61,7/28/2020
1FE3CB,dividend,100,50,7/28/2020
1FE3CB,operating-earnings,100,50,7/28/2020
2093B1,earnings-up,100,68,7/28/2020
2093B1,earnings,100,50,7/28/2020
2093B1,earnings,100,50,7/28/2020
2093B1,earnings,100,50,7/28/2020
222BF9,earnings,100,50,7/28/2020
223552,earnings,100,50,7/28/2020
225CA2,earnings,100,50,7/28/2020
225CA2,earnings,100,50,7/28/2020
225CA2,earnings,100,50,7/28/2020
225CA2,earnings,100,50,7/28/2020
225CA2,earnings,100,50,7/28/2020
225CA2,earnings,100,50,7/28/2020
225CA2,earnings,100,50,7/28/2020
225CA2,earnings,100,50,7/28/2020
225CA2,earnings,100,50,7/28/2020
225CA2,earnings,100,50,7/28/2020
225CA2,earnings,100,50,7/28/2020
228D42,partnership,100,61,7/28/2020
228D42,partnership,100,61,7/28/2020
22C58E,earnings,100,50,7/28/2020
249B39,earnings-positive,100,69,7/28/2020
24FA23,conference-participant,100,50,7/28/2020
2667B6,earnings,100,50,7/28/2020
267718,earnings,100,50,7/28/2020
267718,earnings,100,50,7/28/2020
267718,earnings,100,50,7/28/2020
267718,earnings,100,50,7/28/2020
267718,earnings,100,50,7/28/2020
267718,earnings,100,50,7/28/2020
267718,earnings,100,50,7/28/2020
267718,earnings,100,50,7/28/2020
267718,earnings,100,50,7/28/2020
267718,earnings,100,50,7/28/2020
270305,dividend,100,50,7/28/2020
270305,earnings,100,50,7/28/2020
270305,earnings,100,50,7/28/2020
270305,earnings,100,50,7/28/2020
270305,earnings,100,50,7/28/2020
279916,legal-issues-defendant,100,22,7/28/2020
279916,legal-issues-defendant,100,22,7/28/2020
279916,legal-issues-defendant,100,22,7/28/2020
27B191,partnership,100,61,7/28/2020
2A6DBE,legal-issues-defendant,100,22,7/28/2020
2ABF77,conference-call,100,50,7/28/2020
2BA977,earnings,100,50,7/28/2020
2CC71C,earnings,100,50,7/28/2020
2D643C,dividend,100,50,7/28/2020
2D981A,earnings,100,50,7/28/2020
2DC88B,earnings,100,50,7/28/2020
2EC172,earnings,100,50,7/28/2020
2EC172,earnings,100,50,7/28/2020
2EC172,earnings,100,50,7/28/2020
2EC172,earnings,100,50,7/28/2020
2EC172,earnings,100,50,7/28/2020
2EC172,earnings,100,50,7/28/2020
2F24A5,earnings,100,50,7/28/2020
332F87,earnings,100,50,7/28/2020
343996,earnings,100,50,7/28/2020
36529A,clinical-trials-start,100,64,7/28/2020
37020C,earnings,100,50,7/28/2020
370C50,earnings,100,50,7/28/2020
371C01,conference-call,100,50,7/28/2020
373B06,earnings,100,50,7/28/2020
37727A,earnings,100,50,7/28/2020
37727A,earnings,100,50,7/28/2020
37727A,earnings,100,50,7/28/2020
37727A,earnings,100,50,7/28/2020
37727A,earnings,100,50,7/28/2020
37727A,earnings,100,50,7/28/2020
37727A,earnings,100,50,7/28/2020
37727A,earnings,100,50,7/28/2020
383ADA,earnings,100,50,7/28/2020
384CD3,business-contract,100,69,7/28/2020
396D7C,earnings,100,50,7/28/2020
3BB616,earnings,100,50,7/28/2020
3BB616,earnings,100,50,7/28/2020
3BB616,earnings,100,50,7/28/2020
3BCF24,earnings,100,50,7/28/2020
3C6CCC,earnings,100,50,7/28/2020
3CBA2A,earnings,100,50,7/28/2020
3CBA2A,earnings,100,50,7/28/2020
3CBA2A,earnings,100,50,7/28/2020
3CBA2A,earnings,100,50,7/28/2020
3CBA2A,earnings,100,50,7/28/2020
3CBA2A,earnings,100,50,7/28/2020
3CBA2A,earnings,100,50,7/28/2020
3ED92D,earnings,100,50,7/28/2020
3ED92D,earnings,100,50,7/28/2020
3ED92D,earnings,100,50,7/28/2020
3ED92D,earnings,100,50,7/28/2020
3ED92D,earnings,100,50,7/28/2020
3ED92D,earnings,100,50,7/28/2020
3ED92D,earnings,100,50,7/28/2020
3ED92D,earnings,100,50,7/28/2020
3F6A9C,dividend,100,50,7/28/2020
408089,earnings,100,50,7/28/2020
416C55,earnings,100,50,7/28/2020
417BF9,conference-call,100,50,7/28/2020
41ED98,conference-call,100,50,7/28/2020
420168,earnings,100,50,7/28/2020
43A060,earnings,100,50,7/28/2020
44209A,earnings,100,50,7/28/2020
442769,business-contract,100,69,7/28/2020
447FC6,conference-call,100,50,7/28/2020
448BF3,earnings,100,50,7/28/2020
4591D3,conference-call,100,50,7/28/2020
467F2C,earnings,100,50,7/28/2020
487B7A,executive-appointment,100,54,7/28/2020
4885C8,dividend,100,50,7/28/2020
492117,earnings-up,100,68,7/28/2020
4A2457,conference-participant,100,50,7/28/2020
4A6F00,business-contract,100,69,7/28/2020
4A6F00,partnership,100,61,7/28/2020
4A6F00,partnership,100,61,7/28/2020
4A6F00,partnership,100,61,7/28/2020
4BBA23,executive-appointment,100,54,7/28/2020
4BDCA7,conference-call,100,50,7/28/2020
4BF3D6,partnership,100,61,7/28/2020
4C3FE9,earnings,100,50,7/28/2020
4F71DC,executive-appointment,100,54,7/28/2020
504FE2,conference-participant,100,50,7/28/2020
510EA1,acquisition-completed-acquirer,100,49,7/28/2020
510EA1,executive-appointment,100,54,7/28/2020
51B442,earnings,100,50,7/28/2020
52B567,conference-call,100,50,7/28/2020
52BF94,earnings,100,50,7/28/2020
52BF94,earnings,100,50,7/28/2020
52BF94,earnings,100,50,7/28/2020
52BF94,earnings,100,50,7/28/2020
52BF94,earnings,100,50,7/28/2020
52D936,partnership,100,61,7/28/2020
543C77,fast-track-designation,100,81,7/28/2020
5487B1,legal-issues-defendant,100,22,7/28/2020
548AC0,conference-call,100,50,7/28/2020
55C9B5,partnership,100,61,7/28/2020
564F3E,earnings,100,50,7/28/2020
56632F,business-contract,100,69,7/28/2020
567F3D,earnings,100,50,7/28/2020
567F3D,earnings,100,50,7/28/2020
567F3D,earnings,100,50,7/28/2020
567F3D,earnings,100,50,7/28/2020
56AFF4,dividend,100,50,7/28/2020
583A75,executive-appointment,100,54,7/28/2020
583A75,executive-appointment,100,54,7/28/2020
583A75,executive-appointment,100,54,7/28/2020
583A75,executive-appointment,100,54,7/28/2020
589F5A,earnings,100,50,7/28/2020
596116,earnings,100,50,7/28/2020
59C539,dividend,100,50,7/28/2020
59DB8C,product-release,100,64,7/28/2020
5A423F,earnings,100,50,7/28/2020
5A53BF,earnings,100,50,7/28/2020
5B6C11,earnings,100,50,7/28/2020
5CC29D,earnings,100,50,7/28/2020
5E6959,earnings,100,50,7/28/2020
5EC388,earnings,100,50,7/28/2020
601785,dividend,100,50,7/28/2020
60AC34,earnings,100,50,7/28/2020
62B1C6,earnings,100,50,7/28/2020
62B20A,earnings,100,50,7/28/2020
64854A,conference-call,100,50,7/28/2020
649CBD,earnings,100,50,7/28/2020
66E3C0,equity-shelf-registration,100,43,7/28/2020
67B923,earnings,100,50,7/28/2020
6810DE,business-contract,100,69,7/28/2020
68E3E0,dividend,100,50,7/28/2020
69345C,earnings,100,50,7/28/2020
69345C,earnings,100,50,7/28/2020
69345C,earnings,100,50,7/28/2020
69345C,earnings,100,50,7/28/2020
69494C,conference-call,100,50,7/28/2020
69E8E1,conference-call,100,50,7/28/2020
69E8E1,conference-call,100,50,7/28/2020
6ABCB8,earnings,100,50,7/28/2020
6B0E45,dividend,100,50,7/28/2020
6BBCBA,partnership,100,61,7/28/2020
6BBCBA,partnership,100,61,7/28/2020
6BC6F9,product-release,100,64,7/28/2020
6-Dec-05,public-offering,100,43,7/28/2020
6F0A63,executive-resignation,100,44,7/28/2020
724F84,earnings,100,50,7/28/2020
762A3E,earnings,100,50,7/28/2020
762A3E,earnings,100,50,7/28/2020
762A3E,earnings,100,50,7/28/2020
762A3E,earnings,100,50,7/28/2020
762A3E,earnings,100,50,7/28/2020
762A3E,earnings,100,50,7/28/2020
762A3E,dividend,100,50,7/28/2020
766047,donation,100,54,7/28/2020
76F067,earnings,100,50,7/28/2020
7732C2,fundraising,100,64,7/28/2020
7732C2,fundraising,100,64,7/28/2020
773A17,revenues,100,50,7/28/2020
782B46,earnings,100,50,7/28/2020
7.83E+79,operating-earnings,100,50,7/28/2020
7A10FF,earnings,100,50,7/28/2020
7A5D58,note-sale,100,52,7/28/2020
7AC86E,earnings-up,100,68,7/28/2020
7AC86E,earnings,100,50,7/28/2020
7AC86E,earnings,100,50,7/28/2020
7C75FD,earnings-up,100,68,7/28/2020
7F9E16,conference-call,100,50,7/28/2020
804708,executive-appointment,100,54,7/28/2020
81F4BE,earnings,100,50,7/28/2020
81F4BE,earnings,100,50,7/28/2020
8303CD,earnings,100,50,7/28/2020
8377DB,earnings,100,50,7/28/2020
8377DB,earnings,100,50,7/28/2020
859281,earnings,100,50,7/28/2020
859281,earnings,100,50,7/28/2020
859281,earnings,100,50,7/28/2020
859281,earnings,100,50,7/28/2020
859281,earnings,100,50,7/28/2020
859281,earnings,100,50,7/28/2020
859281,earnings,100,50,7/28/2020
8665BA,partnership,100,61,7/28/2020
885758,earnings,100,50,7/28/2020
890FF4,legal-issues-defendant,100,22,7/28/2020
8A0368,business-contract,100,69,7/28/2020
8AC65D,earnings,100,50,7/28/2020
8C311A,public-offering,100,43,7/28/2020
8CF6DD,investment-investor,100,55,7/28/2020
8CF6DD,dividend,100,50,7/28/2020
8D4486,partnership,100,61,7/28/2020
8D4486,dividend,100,50,7/28/2020
8D4486,dividend,100,50,7/28/2020
8E4250,earnings,100,50,7/28/2020
8E4250,earnings,100,50,7/28/2020
8E4250,earnings,100,50,7/28/2020
8E4250,earnings,100,50,7/28/2020
8E4250,earnings,100,50,7/28/2020
8FCA78,earnings,100,50,7/28/2020
8FCA78,earnings,100,50,7/28/2020
8FCA78,earnings,100,50,7/28/2020
8FCA78,earnings,100,50,7/28/2020
93D207,earnings,100,50,7/28/2020
94563D,earnings,100,50,7/28/2020
94563D,earnings,100,50,7/28/2020
94563D,earnings,100,50,7/28/2020
94563D,earnings,100,50,7/28/2020
94563D,earnings,100,50,7/28/2020
945DE6,earnings-guidance,100,50,7/28/2020
945DE6,earnings,100,50,7/28/2020
945DE6,earnings,100,50,7/28/2020
945DE6,earnings,100,50,7/28/2020
945DE6,earnings-guidance,100,50,7/28/2020
9.54E+32,earnings,100,50,7/28/2020
9.54E+32,earnings,100,50,7/28/2020
972356,earnings-above-expectations,100,88,7/28/2020
97AAF6,earnings,100,50,7/28/2020
9.82E+06,note-sale,100,52,7/28/2020
9934AD,product-release,100,64,7/28/2020
9B71A7,executive-appointment,100,54,7/28/2020
9D2790,earnings,100,50,7/28/2020
9D307D,product-release,100,64,7/28/2020
9E4A5F,earnings,100,50,7/28/2020
9F6B1A,earnings,100,50,7/28/2020
9F6B1A,earnings,100,50,7/28/2020
9F6B1A,earnings,100,50,7/28/2020
9F6B1A,earnings,100,50,7/28/2020
9F6B1A,earnings,100,50,7/28/2020
9FB4B7,earnings,100,50,7/28/2020
A01200,partnership,100,61,7/28/2020
A01200,executive-appointment,100,54,7/28/2020
A16DEA,market-entry,100,57,7/28/2020
A1A317,earnings,100,50,7/28/2020
A1A317,earnings,100,50,7/28/2020
A1A317,earnings,100,50,7/28/2020
A1A317,earnings,100,50,7/28/2020
A3800A,business-contract,100,69,7/28/2020
A398B9,earnings,100,50,7/28/2020
A398B9,earnings,100,50,7/28/2020
A398B9,earnings,100,50,7/28/2020
A429A5,operating-earnings,100,50,7/28/2020
A4F67C,earnings,100,50,7/28/2020
A65325,dividend,100,50,7/28/2020
A65325,earnings-positive,100,69,7/28/2020
A70BF5,earnings,100,50,7/28/2020
A70BF5,earnings,100,50,7/28/2020
A70BF5,earnings,100,50,7/28/2020
A70BF5,earnings,100,50,7/28/2020
A70BF5,earnings,100,50,7/28/2020
A70BF5,earnings,100,50,7/28/2020
A79D88,earnings,100,50,7/28/2020
A79D88,earnings,100,50,7/28/2020
A87CD6,earnings-per-share-down,100,12,7/28/2020
A87CD6,earnings-per-share-positive,100,69,7/28/2020
A87CD6,earnings-per-share-positive,100,69,7/28/2020
A87CD6,earnings-per-share-positive,100,69,7/28/2020
A87CD6,earnings-per-share-positive,100,69,7/28/2020
A87CD6,earnings-per-share-positive,100,69,7/28/2020
A87CD6,earnings-per-share-positive,100,69,7/28/2020
A8B137,earnings,100,50,7/28/2020
A8B137,earnings,100,50,7/28/2020
A8B137,earnings,100,50,7/28/2020
A8B137,earnings,100,50,7/28/2020
A8B137,earnings,100,50,7/28/2020
ABBAD1,legal-issues-defendant,100,22,7/28/2020
ACC7D3,conference-participant,100,50,7/28/2020
AD3C93,earnings,100,50,7/28/2020
AE4EEB,earnings,100,50,7/28/2020
AEEB76,earnings,100,50,7/28/2020
AEEB76,earnings,100,50,7/28/2020
AEF2C3,earnings,100,50,7/28/2020
AFF7B4,earnings,100,50,7/28/2020
AFF7B4,earnings,100,50,7/28/2020
AFF7B4,earnings,100,50,7/28/2020
B05000,earnings,100,50,7/28/2020
B076A1,earnings,100,50,7/28/2020
B076A1,earnings,100,50,7/28/2020
B076A1,earnings,100,50,7/28/2020
B076A1,earnings,100,50,7/28/2020
B0998E,earnings,100,50,7/28/2020
B106FA,earnings,100,50,7/28/2020
B303A6,dividend,100,50,7/28/2020
B303A6,executive-appointment,100,54,7/28/2020
B37FB4,earnings,100,50,7/28/2020
B37FB4,earnings,100,50,7/28/2020
B37FB4,earnings,100,50,7/28/2020
B37FB4,earnings,100,50,7/28/2020
B37FB4,earnings,100,50,7/28/2020
B37FB4,earnings,100,50,7/28/2020
B37FB4,earnings,100,50,7/28/2020
B381D8,clinical-trials-start,100,64,7/28/2020
B381D8,earnings,100,50,7/28/2020
B6082A,earnings,100,50,7/28/2020
B77F14,conference-call,100,50,7/28/2020
B840EF,earnings,100,50,7/28/2020
B8A51F,conference-participant,100,50,7/28/2020
B9764A,earnings,100,50,7/28/2020
B98EFA,operating-earnings,100,50,7/28/2020
BA218A,executive-appointment,100,54,7/28/2020
BB5271,earnings,100,50,7/28/2020
BB88B6,award,100,58,7/28/2020
BB88B6,award,100,58,7/28/2020
BBC05B,operating-earnings,100,50,7/28/2020
BDEF34,earnings,100,50,7/28/2020
BDEF34,earnings,100,50,7/28/2020
BDEF34,earnings,100,50,7/28/2020
BDEF34,earnings,100,50,7/28/2020
BDEF34,earnings,100,50,7/28/2020
BDEF34,earnings,100,50,7/28/2020
BDEF34,earnings,100,50,7/28/2020
BDEF34,earnings,100,50,7/28/2020
BDEF34,earnings,100,50,7/28/2020
C062D4,earnings,100,50,7/28/2020
C062D4,earnings,100,50,7/28/2020
C062D4,earnings,100,50,7/28/2020
C062D4,earnings,100,50,7/28/2020
C062D4,earnings,100,50,7/28/2020
C062D4,earnings,100,50,7/28/2020
C062D4,earnings,100,50,7/28/2020
C07E05,earnings,100,50,7/28/2020
C0BA36,conference-call,100,50,7/28/2020
C0BA36,conference-call,100,50,7/28/2020
C2E39B,earnings,100,50,7/28/2020
C2E426,earnings,100,50,7/28/2020
C3CF29,earnings,100,50,7/28/2020
C3CF29,earnings,100,50,7/28/2020
C3CF29,earnings,100,50,7/28/2020
C3CF29,earnings,100,50,7/28/2020
C3F99F,earnings,100,50,7/28/2020
C41C25,dividend,100,50,7/28/2020
C45CE7,earnings,100,50,7/28/2020
C4A241,earnings-up,100,68,7/28/2020
C4A241,earnings,100,50,7/28/2020
C4A241,earnings,100,50,7/28/2020
C4A241,earnings,100,50,7/28/2020
C659EB,earnings,100,50,7/28/2020
C659EB,earnings,100,50,7/28/2020
C659EB,earnings,100,50,7/28/2020
C659EB,earnings,100,50,7/28/2020
C72B8F,earnings,100,50,7/28/2020
C7FC95,partnership,100,61,7/28/2020
C7FC95,partnership,100,61,7/28/2020
C8257F,earnings,100,50,7/28/2020
C85A72,revenues,100,50,7/28/2020
C85A72,revenues,100,50,7/28/2020
C85A72,revenues,100,50,7/28/2020
CBA33B,dividend,100,50,7/28/2020
CBA475,earnings,100,50,7/28/2020
CBA475,earnings,100,50,7/28/2020
CBA475,earnings,100,50,7/28/2020
CBA475,earnings,100,50,7/28/2020
CBBFBF,business-contract,100,69,7/28/2020
CC0C78,earnings,100,50,7/28/2020
CC176E,earnings,100,50,7/28/2020
CC35BE,business-contract,100,69,7/28/2020
CD06A2,dividend,100,50,7/28/2020
CDAF5B,operating-earnings,100,50,7/28/2020
CEC5B9,partnership,100,61,7/28/2020
CFE5BE,dividend,100,50,7/28/2020
CFF97C,revenue-up,100,64,7/28/2020
CFF97C,revenue-up,100,64,7/28/2020
CFF97C,revenue-up,100,64,7/28/2020
CFF97C,revenue-up,100,64,7/28/2020
CFF97C,revenue-up,100,64,7/28/2020
D04D9F,earnings,100,50,7/28/2020
D04D9F,executive-appointment,100,54,7/28/2020
D09938,earnings,100,50,7/28/2020
D17C1B,earnings,100,50,7/28/2020
D17C1B,earnings,100,50,7/28/2020
D17C1B,earnings,100,50,7/28/2020
D20C8F,earnings,100,50,7/28/2020
D29F43,dividend,100,50,7/28/2020
D33270,business-contract,100,69,7/28/2020
D33270,business-contract,100,69,7/28/2020
D501DC,earnings,100,50,7/28/2020
D56E4C,earnings,100,50,7/28/2020
D56E4C,earnings,100,50,7/28/2020
D6534D,earnings,100,50,7/28/2020
D69D42,executive-appointment,100,54,7/28/2020
D7918D,operating-earnings,100,50,7/28/2020
D854DD,conference-call,100,50,7/28/2020
D854F3,partnership,100,61,7/28/2020
D9B1C9,legal-issues-defendant,100,22,7/28/2020
D9B1C9,legal-issues-defendant,100,22,7/28/2020
DA0A9E,earnings,100,50,7/28/2020
DB7FA7,earnings-positive,100,69,7/28/2020
DC2F77,earnings,100,50,7/28/2020
DC437D,earnings,100,50,7/28/2020
DD1BA1,product-price-cut,100,49,7/28/2020
DDC415,earnings,100,50,7/28/2020
DDC415,earnings,100,50,7/28/2020
E0207A,earnings,100,50,7/28/2020
E0207A,earnings,100,50,7/28/2020
E0207A,earnings,100,50,7/28/2020
E0207A,earnings,100,50,7/28/2020
E05DC8,note-sale,100,52,7/28/2020
E07573,dividend-guidance,100,50,7/28/2020
E10D31,earnings,100,50,7/28/2020
E12A6E,earnings,100,50,7/28/2020
E30A8F,earnings,100,50,7/28/2020
E30A8F,earnings,100,50,7/28/2020
E30A8F,earnings,100,50,7/28/2020
E30A8F,earnings,100,50,7/28/2020
E3E68E,executive-appointment,100,54,7/28/2020
E3E68E,executive-appointment,100,54,7/28/2020
E69BA5,conference-call,100,50,7/28/2020
E6A53A,earnings,100,50,7/28/2020
E6A53A,earnings,100,50,7/28/2020
E6EDED,earnings,100,50,7/28/2020
E866D2,award,100,58,7/28/2020
E87676,revenues,100,50,7/28/2020
E8846E,legal-issues-defendant,100,22,7/28/2020
E8846E,dividend,100,50,7/28/2020
E8846E,legal-issues-defendant,100,22,7/28/2020
E8A49A,earnings,100,50,7/28/2020
E8D221,earnings,100,50,7/28/2020
E9E6FD,earnings,100,50,7/28/2020
E9FF33,earnings,100,50,7/28/2020
EBD89A,business-contract,100,69,7/28/2020
EC99D0,earnings,100,50,7/28/2020
ED0402,revenue-up,100,66,7/28/2020
ED0402,revenues,100,50,7/28/2020
ED0402,revenues,100,50,7/28/2020
ED0402,revenues,100,50,7/28/2020
EDF5CA,earnings,100,50,7/28/2020
EDF5CA,earnings,100,50,7/28/2020
EDF5CA,earnings,100,50,7/28/2020
EDF5CA,earnings,100,50,7/28/2020
EDF5CA,earnings,100,50,7/28/2020
EDF5CA,earnings,100,50,7/28/2020
EDF5CA,earnings,100,50,7/28/2020
EDF5CA,earnings,100,50,7/28/2020
EE04F0,conference-call,100,50,7/28/2020
EF25A5,partnership,100,61,7/28/2020
EF45B6,earnings,100,50,7/28/2020
F04E05,earnings,100,50,7/28/2020
F0B2B5,earnings,100,50,7/28/2020
F209B4,executive-appointment,100,54,7/28/2020
F294DD,earnings,100,50,7/28/2020
F294DD,earnings,100,50,7/28/2020
F294DD,earnings,100,50,7/28/2020
F294DD,earnings,100,50,7/28/2020
F294DD,earnings,100,50,7/28/2020
F294DD,earnings,100,50,7/28/2020
F294DD,earnings,100,50,7/28/2020
F294DD,earnings,100,50,7/28/2020
F294DD,earnings,100,50,7/28/2020
F294DD,earnings,100,50,7/28/2020
F294DD,earnings,100,50,7/28/2020
F294DD,earnings,100,50,7/28/2020
F294DD,earnings,100,50,7/28/2020
F294DD,earnings,100,50,7/28/2020
F294DD,earnings,100,50,7/28/2020
F294DD,earnings,100,50,7/28/2020
F294DD,earnings,100,50,7/28/2020
F294DD,earnings,100,50,7/28/2020
F294DD,acquisition-regulatory-approval-acquirer,100,54,7/28/2020
F30508,partnership,100,61,7/28/2020
F30508,partnership,100,61,7/28/2020
F40EE2,earnings,100,50,7/28/2020
F40EE2,earnings,100,50,7/28/2020
F40EE2,earnings,100,50,7/28/2020
F47871,earnings,100,50,7/28/2020
F4D241,earnings,100,50,7/28/2020
F5D059,executive-appointment,100,54,7/28/2020
F5D410,earnings,100,50,7/28/2020
F6E1B5,earnings,100,50,7/28/2020
FA044A,earnings,100,50,7/28/2020
FAE021,executive-appointment,100,54,7/28/2020
FAE021,executive-appointment,100,54,7/28/2020
FAEABE,dividend,100,50,7/28/2020
FD4BBE,earnings,100,50,7/28/2020
FD4BBE,earnings,100,50,7/28/2020
FD4BBE,earnings,100,50,7/28/2020
FFAB4A,earnings,100,50,7/28/2020
00067A,partnership,100,61,7/29/2020
00326E,earnings,100,50,7/29/2020
9397,partnership,100,61,7/29/2020
00D6B5,earnings,100,50,7/29/2020
01478A,earnings,100,50,7/29/2020
0157B1,partnership,100,61,7/29/2020
018C11,earnings,100,50,7/29/2020
01D03F,partnership,100,61,7/29/2020
01D03F,partnership,100,61,7/29/2020
03542C,earnings,100,50,7/29/2020
03CF95,earnings,100,50,7/29/2020
61366,executive-resignation,100,44,7/29/2020
61366,executive-resignation,100,44,7/29/2020
07C69F,earnings,100,50,7/29/2020
07EC43,earnings,100,50,7/29/2020
07EC43,earnings,100,50,7/29/2020
07EC43,earnings,100,50,7/29/2020
07EC43,earnings,100,50,7/29/2020
07EC43,executive-appointment,100,54,7/29/2020
081AB9,earnings,100,50,7/29/2020
0919B1,conference-call,100,50,7/29/2020
0986B5,earnings,100,50,7/29/2020
98977,earnings,100,50,7/29/2020
099A92,earnings,100,50,7/29/2020
0A9D0A,dividend,100,50,7/29/2020
0B2071,earnings,100,50,7/29/2020
0B4D10,earnings,100,50,7/29/2020
0B57D7,earnings,100,50,7/29/2020
0C136E,earnings,100,50,7/29/2020
0CCCB7,conference-call,100,50,7/29/2020
0DC050,earnings,100,50,7/29/2020
0DC050,earnings,100,50,7/29/2020
0DC050,earnings,100,50,7/29/2020
0DC050,earnings,100,50,7/29/2020
0E2992,earnings-per-share-positive,100,69,7/29/2020
0EC508,earnings,100,50,7/29/2020
106394,earnings,100,50,7/29/2020
108A2B,executive-appointment,100,54,7/29/2020
108A2B,operating-earnings,100,50,7/29/2020
1216D1,earnings,100,50,7/29/2020
12DE76,conference-call,100,50,7/29/2020
14BA33,earnings,100,50,7/29/2020
168A5D,executive-appointment,100,54,7/29/2020
16B183,resource-discovery,100,88,7/29/2020
16B183,operating-earnings,100,50,7/29/2020
16F4D8,earnings,100,50,7/29/2020
16F4D8,earnings,100,50,7/29/2020
16F4D8,earnings,100,50,7/29/2020
16F4D8,earnings,100,50,7/29/2020
16F4D8,earnings,100,50,7/29/2020
16F4D8,earnings,100,50,7/29/2020
1.79E+10,conference-call,100,50,7/29/2020
17EDA5,fraud-defendant,100,20,7/29/2020
17EDA5,fraud-defendant,100,20,7/29/2020
17EDA5,legal-issues-defendant,100,22,7/29/2020
17EDA5,legal-issues-defendant,100,22,7/29/2020
180DA0,dividend,100,50,7/29/2020
180DA0,earnings,100,50,7/29/2020
197019,dividend,100,50,7/29/2020
1AE9D5,conference-call,100,50,7/29/2020
1B9535,earnings,100,50,7/29/2020
1BC12C,earnings,100,50,7/29/2020
1BDB2A,earnings,100,50,7/29/2020
1CB9D3,conference-call,100,50,7/29/2020
1D5C51,earnings,100,50,7/29/2020
1DA44F,earnings,100,50,7/29/2020
1E8A99,earnings,100,50,7/29/2020
1EC3E8,earnings,100,50,7/29/2020
1EC3E8,earnings,100,50,7/29/2020
1F3CFB,earnings,100,50,7/29/2020
1FAF22,partnership,100,61,7/29/2020
2003A5,earnings,100,50,7/29/2020
202E5A,conference-call,100,50,7/29/2020
202E5A,conference-participant,100,50,7/29/2020
20D00A,earnings,100,50,7/29/2020
21022F,earnings,100,50,7/29/2020
221445,earnings,100,50,7/29/2020
2262BD,credit-extension-recipient,100,69,7/29/2020
24FA23,earnings,100,50,7/29/2020
250BEE,dividend,100,50,7/29/2020
25A6CC,earnings,100,50,7/29/2020
25A6CC,earnings,100,50,7/29/2020
25A6CC,earnings,100,50,7/29/2020
25A6CC,earnings,100,50,7/29/2020
25A6CC,earnings,100,50,7/29/2020
26F31D,earnings,100,50,7/29/2020
26F31D,earnings,100,50,7/29/2020
26F31D,earnings,100,50,7/29/2020
26F31D,earnings,100,50,7/29/2020
275300,earnings,100,50,7/29/2020
275300,earnings,100,50,7/29/2020
275300,earnings,100,50,7/29/2020
275300,earnings,100,50,7/29/2020
275300,earnings,100,50,7/29/2020
275300,earnings,100,50,7/29/2020
275300,earnings,100,50,7/29/2020
275300,earnings,100,50,7/29/2020
275300,earnings,100,50,7/29/2020
279916,legal-issues-defendant,100,22,7/29/2020
28AC4E,earnings,100,50,7/29/2020
28DCA8,earnings-positive,100,69,7/29/2020
28DCA8,earnings,100,50,7/29/2020
28DCA8,earnings,100,50,7/29/2020
2950FF,earnings,100,50,7/29/2020
2950FF,earnings,100,50,7/29/2020
29CEBF,earnings,100,50,7/29/2020
29CEBF,earnings,100,50,7/29/2020
29CEBF,earnings,100,50,7/29/2020
29CEBF,earnings,100,50,7/29/2020
2A17B1,earnings,100,50,7/29/2020
2A17B1,earnings,100,50,7/29/2020
2A17B1,earnings,100,50,7/29/2020
2A6DBE,legal-issues-defendant,100,22,7/29/2020
2AA6A8,partnership,100,61,7/29/2020
2AA6A8,partnership,100,61,7/29/2020
2B0AF4,earnings,100,50,7/29/2020
2B7A40,earnings-per-share-positive,100,69,7/29/2020
2B7A40,earnings-positive,100,69,7/29/2020
2B7A40,earnings-positive,100,69,7/29/2020
2B7A40,earnings-positive,100,69,7/29/2020
2BC05E,earnings,100,50,7/29/2020
2BC05E,earnings,100,50,7/29/2020
2BC05E,earnings,100,50,7/29/2020
2BC05E,earnings,100,50,7/29/2020
2BF36E,dividend,100,50,7/29/2020
2CBB58,executive-appointment,100,54,7/29/2020
2D2D43,dividend,100,50,7/29/2020
2D5011,earnings,100,50,7/29/2020
2D643C,earnings,100,50,7/29/2020
2EBC0B,award,100,58,7/29/2020
2F6782,dividend,100,50,7/29/2020
2F94A5,earnings,100,50,7/29/2020
2FEA66,operating-earnings,100,50,7/29/2020
306623,conference-participant,100,50,7/29/2020
315EB0,earnings,100,50,7/29/2020
315EB0,earnings,100,50,7/29/2020
315EB0,earnings,100,50,7/29/2020
315EB0,earnings,100,50,7/29/2020
315EB0,earnings,100,50,7/29/2020
315EB0,earnings,100,50,7/29/2020
315EB0,earnings,100,50,7/29/2020
315EB0,dividend,100,50,7/29/2020
31A7CC,dividend,100,50,7/29/2020
3224CC,earnings,100,50,7/29/2020
326EDD,earnings,100,50,7/29/2020
32CB22,earnings,100,50,7/29/2020
32DCB3,earnings,100,50,7/29/2020
32F943,earnings,100,50,7/29/2020
33A0F1,executive-appointment,100,54,7/29/2020
33AD83,settlement,100,56,7/29/2020
33E8C7,earnings,100,50,7/29/2020
33E8C7,earnings,100,50,7/29/2020
33FD66,earnings,100,50,7/29/2020
33FD66,earnings,100,50,7/29/2020
33FD66,earnings,100,50,7/29/2020
33FD66,earnings,100,50,7/29/2020
33FD66,earnings,100,50,7/29/2020
33FD66,earnings,100,50,7/29/2020
33FD66,earnings,100,50,7/29/2020
3.50E+27,earnings,100,50,7/29/2020
3696BF,earnings,100,50,7/29/2020
3.88E+02,dividend,100,50,7/29/2020
3BC360,earnings,100,50,7/29/2020
3BC360,earnings,100,50,7/29/2020
3BC360,earnings,100,50,7/29/2020
3BC360,earnings,100,50,7/29/2020
3C6CCC,product-release,100,64,7/29/2020
3C7F5F,award,100,58,7/29/2020
3DC887,product-release,100,64,7/29/2020
3E15F6,dividend,100,50,7/29/2020
3ED92D,business-contract,100,69,7/29/2020
3ED92D,business-contract,100,69,7/29/2020
3ED92D,business-contract,100,69,7/29/2020
3ED92D,business-contract,100,69,7/29/2020
4135F7,earnings,100,50,7/29/2020
4135F7,unit-acquisition-acquirer,100,49,7/29/2020
4135F7,business-contract,100,69,7/29/2020
415188,donation,100,54,7/29/2020
41D61C,earnings,100,50,7/29/2020
425BDC,earnings,100,50,7/29/2020
429BFB,conference-participant,100,50,7/29/2020
43A060,business-contract,100,69,7/29/2020
43F4A8,earnings,100,50,7/29/2020
442769,earnings,100,50,7/29/2020
442769,earnings,100,50,7/29/2020
442769,earnings,100,50,7/29/2020
442769,earnings,100,50,7/29/2020
4455C4,earnings,100,50,7/29/2020
4455C4,earnings,100,50,7/29/2020
4455C4,earnings,100,50,7/29/2020
4455C4,earnings,100,50,7/29/2020
44A4FC,partnership,100,61,7/29/2020
44A4FC,partnership,100,61,7/29/2020
458D2C,earnings,100,50,7/29/2020
47752F,earnings,100,50,7/29/2020
47752F,earnings,100,50,7/29/2020
47752F,earnings,100,50,7/29/2020
47752F,earnings,100,50,7/29/2020
47BA98,earnings,100,50,7/29/2020
4806CE,dividend,100,50,7/29/2020
49A344,earnings,100,50,7/29/2020
49A344,earnings,100,50,7/29/2020
49A344,earnings,100,50,7/29/2020
4A5C8D,dividend,100,50,7/29/2020
4AE584,earnings,100,50,7/29/2020
4B3555,earnings,100,50,7/29/2020
4BEB48,award,100,58,7/29/2020
4C5CC9,earnings,100,50,7/29/2020
4C5CC9,earnings,100,50,7/29/2020
4C5CC9,earnings,100,50,7/29/2020
4C5CC9,earnings,100,50,7/29/2020
4C6C63,product-release,100,64,7/29/2020
4C6C63,product-release,100,64,7/29/2020
4D8313,executive-appointment,100,54,7/29/2020
4DD203,executive-appointment,100,54,7/29/2020
50070E,partnership,100,61,7/29/2020
50070E,partnership,100,61,7/29/2020
50070E,partnership,100,61,7/29/2020
514067,conference-participant,100,50,7/29/2020
51888A,earnings-positive,100,69,7/29/2020
51888A,dividend-up,100,83,7/29/2020
519FE0,earnings,100,50,7/29/2020
51F541,earnings,100,50,7/29/2020
532D47,earnings-positive,100,69,7/29/2020
532D47,earnings,100,50,7/29/2020
532D47,earnings,100,50,7/29/2020
5340D0,earnings,100,50,7/29/2020
53A226,earnings,100,50,7/29/2020
53EF9E,earnings,100,50,7/29/2020
5.47E+28,earnings,100,50,7/29/2020
54F271,earnings,100,50,7/29/2020
553949,earnings,100,50,7/29/2020
553949,earnings,100,50,7/29/2020
553949,earnings,100,50,7/29/2020
553949,earnings,100,50,7/29/2020
553949,earnings,100,50,7/29/2020
553949,earnings,100,50,7/29/2020
55438C,earnings,100,50,7/29/2020
55438C,earnings,100,50,7/29/2020
55438C,earnings,100,50,7/29/2020
55438C,earnings,100,50,7/29/2020
55438C,earnings,100,50,7/29/2020
55C289,note-sale,100,52,7/29/2020
56EA2B,note-sale,100,52,7/29/2020
56EA2B,note-sale,100,52,7/29/2020
583A75,public-offering,100,43,7/29/2020
58B46F,dividend,100,50,7/29/2020
58C2D4,business-contract,100,69,7/29/2020
594402,earnings,100,50,7/29/2020
5968F9,earnings,100,50,7/29/2020
59872F,award,100,58,7/29/2020
59F0B0,earnings,100,50,7/29/2020
59F0B0,earnings,100,50,7/29/2020
59F0B0,earnings,100,50,7/29/2020
59F0B0,earnings,100,50,7/29/2020
5A423F,conference-participant,100,50,7/29/2020
5AAE17,earnings,100,50,7/29/2020
5AF08A,earnings,100,50,7/29/2020
5B6C11,executive-appointment,100,54,7/29/2020
5DA8B3,earnings,100,50,7/29/2020
5DD486,earnings,100,50,7/29/2020
5DE5A5,conference-participant,100,50,7/29/2020
5F1B7B,earnings,100,50,7/29/2020
605F40,earnings,100,50,7/29/2020
60AC34,conference-participant,100,50,7/29/2020
61BCA7,earnings,100,50,7/29/2020
62F41C,executive-appointment,100,54,7/29/2020
62F41C,hirings,100,65,7/29/2020
63E8D5,earnings,100,50,7/29/2020
64636E,conference-participant,100,50,7/29/2020
64636E,conference-participant,100,50,7/29/2020
665D7D,clinical-trials-positive,100,87,7/29/2020
665D7D,clinical-trials-positive,100,87,7/29/2020
66E3C0,earnings-up,100,68,7/29/2020
66E3C0,earnings,100,50,7/29/2020
66ECFD,earnings,100,50,7/29/2020
67303E,clinical-trials-filed,100,60,7/29/2020
6ACFBF,executive-resignation,100,44,7/29/2020
6B5379,earnings,100,50,7/29/2020
6B6375,earnings,100,50,7/29/2020
6D156D,conference-participant,100,50,7/29/2020
6D4636,earnings,100,50,7/29/2020
6D4636,earnings,100,50,7/29/2020
6D4636,earnings,100,50,7/29/2020
6DBBBC,dividend,100,50,7/29/2020
6E1E61,earnings,100,50,7/29/2020
6E7060,earnings,100,50,7/29/2020
6E7060,earnings,100,50,7/29/2020
6E7060,earnings,100,50,7/29/2020
6E7060,earnings,100,50,7/29/2020
6E7060,earnings,100,50,7/29/2020
6E7060,earnings,100,50,7/29/2020
6E7060,earnings,100,50,7/29/2020
6E7060,earnings,100,50,7/29/2020
6E7060,earnings,100,50,7/29/2020
6E7060,earnings,100,50,7/29/2020
6E7060,earnings,100,50,7/29/2020
6E7060,earnings,100,50,7/29/2020
6EB9DA,dividend-up,100,56,7/29/2020
6F22E7,conference-call,100,50,7/29/2020
709AED,dividend,100,50,7/29/2020
713810,business-contract,100,69,7/29/2020
71553E,conference-participant,100,50,7/29/2020
722D55,earnings,100,50,7/29/2020
722DE3,earnings,100,50,7/29/2020
722DE3,earnings,100,50,7/29/2020
72609A,earnings,100,50,7/29/2020
72609A,earnings,100,50,7/29/2020
729368,earnings,100,50,7/29/2020
73A71F,dividend,100,50,7/29/2020
7.45E+28,earnings,100,50,7/29/2020
763724,earnings,100,50,7/29/2020
763724,earnings,100,50,7/29/2020
763724,earnings,100,50,7/29/2020
76BECC,earnings,100,50,7/29/2020
76BECC,earnings,100,50,7/29/2020
76BECC,earnings,100,50,7/29/2020
76BECC,earnings,100,50,7/29/2020
771985,earnings,100,50,7/29/2020
771985,earnings,100,50,7/29/2020
771985,earnings,100,50,7/29/2020
771985,earnings,100,50,7/29/2020
771985,earnings,100,50,7/29/2020
771985,earnings,100,50,7/29/2020
771985,earnings,100,50,7/29/2020
771985,earnings,100,50,7/29/2020
771985,earnings,100,50,7/29/2020
787D14,conference-call,100,50,7/29/2020
789ADD,dividend,100,50,7/29/2020
7AB859,earnings,100,50,7/29/2020
7AB859,earnings,100,50,7/29/2020
7AB859,earnings,100,50,7/29/2020
7AB859,earnings,100,50,7/29/2020
7AB859,earnings,100,50,7/29/2020
7AB859,earnings,100,50,7/29/2020
7AF5B8,clinical-trials,100,56,7/29/2020
7B1E50,legal-issues-defendant,100,22,7/29/2020
7B1E50,legal-issues-defendant,100,22,7/29/2020
7B1E50,legal-issues-defendant,100,22,7/29/2020
7B1E50,stock-loss,100,40,7/29/2020
7B1E50,legal-issues-defendant,100,22,7/29/2020
7B9AFA,conference-participant,100,50,7/29/2020
7C62A3,earnings,100,50,7/29/2020
7D7716,earnings,100,50,7/29/2020
7D7716,earnings,100,50,7/29/2020
7D7716,earnings,100,50,7/29/2020
7D7716,earnings,100,50,7/29/2020
7D7716,earnings,100,50,7/29/2020
7E62B5,earnings,100,50,7/29/2020
805CD8,conference-call,100,50,7/29/2020
80C400,earnings,100,50,7/29/2020
81222C,earnings,100,50,7/29/2020
837C04,dividend,100,50,7/29/2020
837C04,earnings,100,50,7/29/2020
837C04,earnings,100,50,7/29/2020
837C04,earnings,100,50,7/29/2020
837C04,earnings,100,50,7/29/2020
837C04,earnings,100,50,7/29/2020
837C04,earnings,100,50,7/29/2020
837C04,earnings,100,50,7/29/2020
838ADD,earnings,100,50,7/29/2020
838ADD,earnings,100,50,7/29/2020
838ADD,earnings,100,50,7/29/2020
838ADD,earnings,100,50,7/29/2020
838ADD,earnings,100,50,7/29/2020
838ADD,earnings,100,50,7/29/2020
84A6B9,earnings,100,50,7/29/2020
84A6B9,earnings,100,50,7/29/2020
84A6B9,earnings,100,50,7/29/2020
84A6B9,earnings,100,50,7/29/2020
84A6B9,earnings,100,50,7/29/2020
84A6B9,earnings,100,50,7/29/2020
84A6B9,earnings,100,50,7/29/2020
84A6B9,earnings,100,50,7/29/2020
84AB66,earnings-positive,100,69,7/29/2020
858942,note-sale,100,52,7/29/2020
858942,earnings,100,50,7/29/2020
85CDC9,earnings,100,50,7/29/2020
8.79E+06,earnings,100,50,7/29/2020
896771,earnings,100,50,7/29/2020
8A0368,product-release,100,64,7/29/2020
8AC65D,public-offering,100,43,7/29/2020
8B1E11,earnings,100,50,7/29/2020
8B9B3B,earnings,100,50,7/29/2020
8C1238,earnings-up,100,68,7/29/2020
8C1238,earnings,100,50,7/29/2020
8C1238,earnings,100,50,7/29/2020
8C1238,earnings,100,50,7/29/2020
8C1238,earnings,100,50,7/29/2020
8C1238,earnings,100,50,7/29/2020
8DBE73,revenues,100,50,7/29/2020
8DBE73,revenues,100,50,7/29/2020
8DBE73,revenues,100,50,7/29/2020
8DBE73,revenues,100,50,7/29/2020
8DCF18,conference-call,100,50,7/29/2020
8DE56F,earnings,100,50,7/29/2020
8DE56F,earnings,100,50,7/29/2020
8E10BF,public-offering,100,43,7/29/2020
8E8E6E,executive-appointment,100,54,7/29/2020
8E93A4,dividend,100,50,7/29/2020
8EF425,earnings,100,50,7/29/2020
8EF425,earnings,100,50,7/29/2020
8EF425,earnings,100,50,7/29/2020
8EF425,earnings,100,50,7/29/2020
8EF425,earnings,100,50,7/29/2020
8EF425,earnings,100,50,7/29/2020
8FF2EF,conference-call,100,50,7/29/2020
901327,earnings,100,50,7/29/2020
901327,earnings,100,50,7/29/2020
901327,earnings,100,50,7/29/2020
901327,earnings,100,50,7/29/2020
92005C,earnings,100,50,7/29/2020
92B625,conference-call,100,50,7/29/2020
945DE6,equity-shelf-registration,100,43,7/29/2020
945DE6,dividend,100,50,7/29/2020
94637C,clinical-trials-filed,100,60,7/29/2020
947B0B,public-offering,100,43,7/29/2020
94C0B5,dividend,100,50,7/29/2020
958938,conference-call,100,50,7/29/2020
966ACE,executive-appointment,100,54,7/29/2020
9673BD,dividend,100,50,7/29/2020
9.74E+08,earnings,100,50,7/29/2020
9934AD,earnings,100,50,7/29/2020
9A02C4,earnings,100,50,7/29/2020
9A02C4,dividend,100,50,7/29/2020
9C25FF,conference-call,100,50,7/29/2020
9C8BC3,stake-acquirer,100,48,7/29/2020
9D65C1,earnings,100,50,7/29/2020
9FA83B,conference-call,100,50,7/29/2020
A01664,partnership,100,61,7/29/2020
A23747,conference-participant,100,50,7/29/2020
A247F5,buybacks,100,74,7/29/2020
A247F5,earnings-per-share-positive,100,69,7/29/2020
A247F5,earnings-per-share-positive,100,69,7/29/2020
A2CA3F,earnings,100,50,7/29/2020
A350C1,dividend,100,50,7/29/2020
A3AAA5,earnings,100,50,7/29/2020
A4A612,earnings,100,50,7/29/2020
A6ABE9,earnings,100,50,7/29/2020
A79F7D,earnings,100,50,7/29/2020
AA1EAA,earnings,100,50,7/29/2020
AA847A,earnings,100,50,7/29/2020
AA98ED,dividend,100,50,7/29/2020
AADE0B,dividend,100,50,7/29/2020
AD3008,earnings,100,50,7/29/2020
AD9F1D,earnings,100,50,7/29/2020
AD9F1D,earnings,100,50,7/29/2020
AD9F1D,earnings,100,50,7/29/2020
AD9F1D,earnings,100,50,7/29/2020
AD9F1D,earnings,100,50,7/29/2020
AD9F1D,earnings,100,50,7/29/2020
AD9F1D,earnings,100,50,7/29/2020
AD9F1D,earnings,100,50,7/29/2020
AD9F1D,earnings,100,50,7/29/2020
AD9F1D,earnings,100,50,7/29/2020
AFD7DD,conference-call,100,50,7/29/2020
B08954,earnings,100,50,7/29/2020
B09B1F,earnings,100,50,7/29/2020
B09B1F,earnings,100,50,7/29/2020
B09B1F,earnings,100,50,7/29/2020
B0D41A,earnings,100,50,7/29/2020
B1FC3B,conference-participant,100,50,7/29/2020
B33E77,orphan-drug-designation,100,76,7/29/2020
B33E77,orphan-drug-designation,100,76,7/29/2020
B508E5,conference-call,100,50,7/29/2020
B8DD94,conference-call,100,50,7/29/2020
BA218A,investment-investor,100,55,7/29/2020
BAAA60,earnings,100,50,7/29/2020
BB88B6,earnings,100,50,7/29/2020
BC4876,dividend,100,50,7/29/2020
BFD0A7,conference-call,100,50,7/29/2020
C05839,earnings,100,50,7/29/2020
C05839,earnings,100,50,7/29/2020
C05839,earnings,100,50,7/29/2020
C05839,earnings,100,50,7/29/2020
C230FE,earnings,100,50,7/29/2020
C230FE,earnings,100,50,7/29/2020
C8257F,dividend,100,50,7/29/2020
C8FAC7,partnership,100,61,7/29/2020
C951A2,earnings,100,50,7/29/2020
C951A2,earnings,100,50,7/29/2020
C951A2,earnings,100,50,7/29/2020
C951A2,earnings,100,50,7/29/2020
C951A2,earnings,100,50,7/29/2020
C951A2,earnings,100,50,7/29/2020
C97B2D,earnings,100,50,7/29/2020
C9D866,earnings,100,50,7/29/2020
C9D866,earnings,100,50,7/29/2020
C9D866,earnings,100,50,7/29/2020
C9D866,earnings,100,50,7/29/2020
C9D866,earnings,100,50,7/29/2020
C9D866,earnings,100,50,7/29/2020
C9D866,earnings,100,50,7/29/2020
C9D866,earnings,100,50,7/29/2020
C9D866,earnings,100,50,7/29/2020
C9D866,earnings,100,50,7/29/2020
C9D866,earnings,100,50,7/29/2020
C9D866,earnings,100,50,7/29/2020
C9D866,earnings,100,50,7/29/2020
C9E04B,conference-call,100,50,7/29/2020
C9E04B,conference-call,100,50,7/29/2020
CAC8D0,facility-open,100,65,7/29/2020
CBA33B,earnings,100,50,7/29/2020
CBA33B,earnings,100,50,7/29/2020
CBDB4D,conference-call,100,50,7/29/2020
CBFFDD,dividend,100,50,7/29/2020
CC8F6E,product-release,100,64,7/29/2020
CDC817,executive-resignation,100,44,7/29/2020
CDE51C,unit-acquisition-acquirer,100,49,7/29/2020
CE4E6D,conference-call,100,50,7/29/2020
CE5C6E,earnings,100,50,7/29/2020
CFF15D,earnings,100,50,7/29/2020
CFF15D,earnings,100,50,7/29/2020
D06755,earnings,100,50,7/29/2020
D06755,earnings,100,50,7/29/2020
D06755,earnings,100,50,7/29/2020
D06755,earnings,100,50,7/29/2020
D07B07,earnings,100,50,7/29/2020
D0909F,earnings,100,50,7/29/2020
D0DFE5,hirings,100,65,7/29/2020
D139BC,earnings,100,50,7/29/2020
D17C1B,product-release,100,64,7/29/2020
D1AE3B,partnership,100,61,7/29/2020
D1C26F,earnings,100,50,7/29/2020
D25249,earnings,100,50,7/29/2020
D33D8C,product-release,100,64,7/29/2020
D437C3,earnings,100,50,7/29/2020
D437C3,earnings,100,50,7/29/2020
D437C3,earnings,100,50,7/29/2020
D437C3,earnings,100,50,7/29/2020
D518D8,revenues,100,50,7/29/2020
D518D8,revenues,100,50,7/29/2020
D518D8,revenues,100,50,7/29/2020
D518D8,revenues,100,50,7/29/2020
D518D8,revenues,100,50,7/29/2020
D54E62,dividend,100,50,7/29/2020
D6489C,product-release,100,64,7/29/2020
D6489C,unit-acquisition-acquiree,100,76,7/29/2020
D64EDF,dividend,100,50,7/29/2020
D78BF1,earnings,100,50,7/29/2020
D96202,dividend-up,100,81,7/29/2020
DAC66A,index-listing,100,76,7/29/2020
DB88A1,award,100,58,7/29/2020
DCD97F,earnings,100,50,7/29/2020
DD1BA1,unit-acquisition-acquirer,100,49,7/29/2020
DD7A96,earnings,100,50,7/29/2020
DEF058,earnings-up,100,68,7/29/2020
DEF058,earnings-up,100,68,7/29/2020
DEF058,earnings-up,100,68,7/29/2020
DEF058,earnings-up,100,68,7/29/2020
DF18E6,conference-call,100,50,7/29/2020
DF42A0,conference-call,100,50,7/29/2020
E00373,earnings,100,50,7/29/2020
E13782,executive-appointment,100,54,7/29/2020
E16133,unit-acquisition-acquiree,100,76,7/29/2020
E16133,business-contract,100,69,7/29/2020
E21871,dividend,100,50,7/29/2020
E22FDE,legal-issues-defendant,100,22,7/29/2020
E22FDE,legal-issues-defendant,100,22,7/29/2020
E30B34,earnings,100,50,7/29/2020
E30B34,earnings,100,50,7/29/2020
E5752F,partnership,100,61,7/29/2020
E592F0,product-release,100,64,7/29/2020
E5D914,earnings,100,50,7/29/2020
E5D914,earnings,100,50,7/29/2020
E6BC2C,name-change,100,49,7/29/2020
E70531,dividend,100,50,7/29/2020
E8846E,legal-issues-defendant,100,22,7/29/2020
E93A40,award,100,58,7/29/2020
E93A40,earnings,100,50,7/29/2020
E96E0B,conference-participant,100,50,7/29/2020
EB36DE,earnings,100,50,7/29/2020
EBC84C,earnings,100,50,7/29/2020
EBC84C,earnings,100,50,7/29/2020
EBC84C,earnings,100,50,7/29/2020
EBC84C,earnings,100,50,7/29/2020
EBC84C,earnings,100,50,7/29/2020
EBC84C,earnings,100,50,7/29/2020
EBC84C,earnings,100,50,7/29/2020
EC70EC,legal-issues-defendant,100,22,7/29/2020
ED2A5E,earnings,100,50,7/29/2020
ED2A5E,earnings,100,50,7/29/2020
ED2A5E,earnings,100,50,7/29/2020
ED2A5E,earnings,100,50,7/29/2020
ED2A5E,earnings,100,50,7/29/2020
ED2A5E,earnings,100,50,7/29/2020
ED2A5E,earnings,100,50,7/29/2020
EDF5CA,dividend,100,50,7/29/2020
EE74E1,earnings,100,50,7/29/2020
EE74E1,earnings,100,50,7/29/2020
EE74E1,earnings,100,50,7/29/2020
EE967B,business-contract,100,69,7/29/2020
EE967B,earnings,100,50,7/29/2020
EEA6B3,partnership,100,61,7/29/2020
EEBCEF,dividend,100,50,7/29/2020
EF5BED,executive-appointment,100,54,7/29/2020
EF76C8,earnings,100,50,7/29/2020
F11638,product-release,100,64,7/29/2020
F11638,product-release,100,64,7/29/2020
F1C04C,operating-earnings,100,50,7/29/2020
F1CD47,earnings,100,50,7/29/2020
F3016C,conference-participant,100,50,7/29/2020
F3FCC3,earnings,100,50,7/29/2020
F50BAB,earnings,100,50,7/29/2020
F50BAB,earnings,100,50,7/29/2020
F50BAB,earnings,100,50,7/29/2020
F50BAB,earnings,100,50,7/29/2020
F569FD,earnings,100,50,7/29/2020
F5D410,unit-acquisition-acquiree,100,76,7/29/2020
F7902B,earnings,100,50,7/29/2020
F7902B,earnings,100,50,7/29/2020
F7FCA4,dividend,100,50,7/29/2020
F80389,asset-sale,100,62,7/29/2020
FA36A4,earnings,100,50,7/29/2020
FA918D,dividend,100,50,7/29/2020
FBDA0F,earnings,100,50,7/29/2020
FD4588,executive-appointment,100,54,7/29/2020
FDC7E6,dividend,100,50,7/29/2020
FDC7E6,earnings,100,50,7/29/2020
FDD3FC,earnings,100,50,7/29/2020
FE1A1D,operating-earnings,100,50,7/29/2020
FEE4B0,dividend,100,50,7/29/2020
9397,earnings,100,50,7/30/2020
0142B5,earnings-per-share-positive,100,69,7/30/2020
0157B1,earnings,100,50,7/30/2020
0157B1,earnings,100,50,7/30/2020
0157B1,earnings,100,50,7/30/2020
0157B1,earnings,100,50,7/30/2020
0157B1,earnings,100,50,7/30/2020
0157B1,earnings,100,50,7/30/2020
0157B1,earnings,100,50,7/30/2020
01D03F,regulatory-product-approval-granted,100,81,7/30/2020
01D03F,regulatory-product-approval-granted,100,81,7/30/2020
01D03F,regulatory-product-approval-granted,100,81,7/30/2020
01D03F,regulatory-product-approval-granted,100,81,7/30/2020
20751,earnings,100,50,7/30/2020
20751,conference-participant,100,50,7/30/2020
02870F,award,100,58,7/30/2020
02870F,legal-issues-defendant,100,22,7/30/2020
03B8CF,partnership,100,61,7/30/2020
03FAA6,earnings,100,50,7/30/2020
03FAA6,earnings,100,50,7/30/2020
03FAA6,earnings,100,50,7/30/2020
03FAA6,earnings,100,50,7/30/2020
03FAA6,earnings,100,50,7/30/2020
56045,executive-appointment,100,54,7/30/2020
68396,earnings,100,50,7/30/2020
06EF42,business-contract,100,69,7/30/2020
06EF42,partnership,100,61,7/30/2020
07CA6A,earnings,100,50,7/30/2020
07CA6A,earnings,100,50,7/30/2020
0A77DB,earnings,100,50,7/30/2020
0BC17A,dividend,100,50,7/30/2020
0BC17A,earnings,100,50,7/30/2020
0C2A0D,earnings,100,50,7/30/2020
0C355F,earnings,100,50,7/30/2020
0E499E,earnings,100,50,7/30/2020
0E5619,conference-call,100,50,7/30/2020
0ED415,earnings,100,50,7/30/2020
0ED415,earnings,100,50,7/30/2020
0ED415,earnings,100,50,7/30/2020
0ED415,earnings,100,50,7/30/2020
0F04E5,earnings,100,50,7/30/2020
0F04E5,earnings,100,50,7/30/2020
0F04E5,earnings,100,50,7/30/2020
0F91FC,earnings,100,50,7/30/2020
10100E,conference-participant,100,50,7/30/2020
105D00,dividend,100,50,7/30/2020
1080C0,earnings,100,50,7/30/2020
10943B,earnings,100,50,7/30/2020
112694,executive-appointment,100,54,7/30/2020
1151F4,earnings,100,50,7/30/2020
1151F4,earnings,100,50,7/30/2020
1151F4,earnings,100,50,7/30/2020
1151F4,earnings,100,50,7/30/2020
1151F4,earnings,100,50,7/30/2020
1151F4,earnings,100,50,7/30/2020
1151F4,earnings,100,50,7/30/2020
1151F4,earnings,100,50,7/30/2020
119CB6,earnings-per-share-positive,100,69,7/30/2020
12E454,earnings,100,50,7/30/2020
12E454,earnings,100,50,7/30/2020
12E454,earnings,100,50,7/30/2020
147C38,earnings,100,50,7/30/2020
1490F3,earnings,100,50,7/30/2020
1490F3,earnings,100,50,7/30/2020
157CC1,regulatory-product-application,100,69,7/30/2020
15901B,executive-appointment,100,54,7/30/2020
15901B,earnings,100,50,7/30/2020
15A388,conference-participant,100,50,7/30/2020
165B86,conference-call,100,50,7/30/2020
16B882,earnings,100,50,7/30/2020
1.79E+10,dividend,100,50,7/30/2020
17EDA5,conference-call,100,50,7/30/2020
17EDA5,legal-issues-defendant,100,22,7/30/2020
17EDA5,legal-issues-defendant,100,22,7/30/2020
1834C0,dividend,100,50,7/30/2020
18D9FA,conference-call,100,50,7/30/2020
1A3E1B,earnings,100,50,7/30/2020
1A6A94,earnings,100,50,7/30/2020
1AF7E2,executive-appointment,100,54,7/30/2020
1B5FEA,earnings,100,50,7/30/2020
1DDEDA,earnings,100,50,7/30/2020
1DEBBE,earnings,100,50,7/30/2020
1DEBBE,executive-appointment,100,54,7/30/2020
1E04A5,business-contract,100,69,7/30/2020
1F08A6,earnings,100,50,7/30/2020
1F716B,earnings,100,50,7/30/2020
1F9258,earnings,100,50,7/30/2020
1FAF22,earnings,100,50,7/30/2020
1FAF22,earnings,100,50,7/30/2020
1FAF22,earnings,100,50,7/30/2020
1FAF22,earnings,100,50,7/30/2020
1FAF22,earnings,100,50,7/30/2020
1FAF22,earnings,100,50,7/30/2020
1FAF22,earnings,100,50,7/30/2020
2082EA,conference-call,100,50,7/30/2020
219B21,earnings,100,50,7/30/2020
219B21,earnings,100,50,7/30/2020
219B21,earnings,100,50,7/30/2020
219B21,earnings,100,50,7/30/2020
219B21,earnings,100,50,7/30/2020
219B21,earnings,100,50,7/30/2020
227D48,earnings,100,50,7/30/2020
227D48,earnings,100,50,7/30/2020
239106,earnings,100,50,7/30/2020
239106,earnings,100,50,7/30/2020
239106,earnings,100,50,7/30/2020
249674,earnings,100,50,7/30/2020
25DD05,earnings,100,50,7/30/2020
2667B6,business-contract,100,69,7/30/2020
26D8ED,earnings,100,50,7/30/2020
279916,legal-issues-defendant,100,22,7/30/2020
279916,legal-issues-defendant,100,22,7/30/2020
284289,earnings,100,50,7/30/2020
292388,earnings,100,50,7/30/2020
2.90E+62,earnings,100,50,7/30/2020
2.90E+62,earnings,100,50,7/30/2020
2.90E+62,earnings,100,50,7/30/2020
2.90E+62,earnings,100,50,7/30/2020
2.90E+62,earnings,100,50,7/30/2020
2.90E+62,earnings,100,50,7/30/2020
2.90E+62,dividend,100,50,7/30/2020
2A02DC,private-placement,100,56,7/30/2020
2A1009,earnings,100,50,7/30/2020
2A1009,earnings,100,50,7/30/2020
2A1009,earnings,100,50,7/30/2020
2A1009,earnings,100,50,7/30/2020
2A1009,earnings,100,50,7/30/2020
2BAE5F,earnings,100,50,7/30/2020
2BAE5F,earnings,100,50,7/30/2020
2C3348,earnings,100,50,7/30/2020
2CA60F,earnings,100,50,7/30/2020
2CA60F,earnings,100,50,7/30/2020
2CA60F,earnings,100,50,7/30/2020
2CB4C9,dividend,100,50,7/30/2020
2E61CC,earnings,100,50,7/30/2020
2EB04E,partnership,100,61,7/30/2020
30DFD3,earnings,100,50,7/30/2020
314D88,earnings,100,50,7/30/2020
31803E,conference-participant,100,50,7/30/2020
328250,earnings,100,50,7/30/2020
3.30E+30,ipo-pricing,100,50,7/30/2020
338544,earnings,100,50,7/30/2020
3461CF,earnings,100,50,7/30/2020
349DA4,earnings,100,50,7/30/2020
35557B,earnings,100,50,7/30/2020
356B21,conference-call,100,50,7/30/2020
36529A,conference-participant,100,50,7/30/2020
367434,earnings,100,50,7/30/2020
371C01,earnings,100,50,7/30/2020
371C01,earnings,100,50,7/30/2020
372037,dividend,100,50,7/30/2020
372037,earnings,100,50,7/30/2020
3.73E+87,earnings,100,50,7/30/2020
3798B9,earnings,100,50,7/30/2020
385DD4,legal-issues-defendant,100,22,7/30/2020
387375,earnings,100,50,7/30/2020
3.88E+02,earnings,100,50,7/30/2020
39692D,earnings,100,50,7/30/2020
3A94DF,earnings,100,50,7/30/2020
3B2311,earnings,100,50,7/30/2020
3B37F7,earnings,100,50,7/30/2020
3B8484,earnings,100,50,7/30/2020
3F4497,earnings,100,50,7/30/2020
3F4668,partnership,100,61,7/30/2020
3F6A9C,earnings,100,50,7/30/2020
3F868D,earnings,100,50,7/30/2020
401072,earnings,100,50,7/30/2020
4017AD,earnings,100,50,7/30/2020
41B53E,earnings,100,50,7/30/2020
41B53E,earnings,100,50,7/30/2020
41B53E,earnings,100,50,7/30/2020
427F32,earnings,100,50,7/30/2020
435ACE,dividend,100,50,7/30/2020
43E8F5,earnings,100,50,7/30/2020
444CC8,settlement,100,56,7/30/2020
44A4FC,revenues,100,50,7/30/2020
451D61,earnings,100,50,7/30/2020
4595EF,earnings,100,50,7/30/2020
45ABCC,revenue-up,100,58,7/30/2020
45ABCC,revenue-up,100,58,7/30/2020
45ABCC,revenue-up,100,58,7/30/2020
45BC35,earnings,100,50,7/30/2020
4.60E+06,earnings,100,50,7/30/2020
479930,earnings,100,50,7/30/2020
47B4CC,earnings,100,50,7/30/2020
47B4CC,earnings,100,50,7/30/2020
4806CE,earnings,100,50,7/30/2020
4885C8,earnings,100,50,7/30/2020
4A2457,product-release,100,64,7/30/2020
4A6F00,partnership,100,61,7/30/2020
4B5054,dividend,100,50,7/30/2020
4BD6DB,earnings,100,50,7/30/2020
4BF3D6,conference-participant,100,50,7/30/2020
4C6C63,earnings,100,50,7/30/2020
4C6C63,earnings,100,50,7/30/2020
4C6C63,earnings,100,50,7/30/2020
4C6C63,earnings,100,50,7/30/2020
4C6C63,earnings,100,50,7/30/2020
4C6C63,earnings,100,50,7/30/2020
4C6C63,earnings,100,50,7/30/2020
4C6C63,earnings,100,50,7/30/2020
4C6C63,earnings,100,50,7/30/2020
4C6C63,earnings,100,50,7/30/2020
4C7DB5,earnings,100,50,7/30/2020
4E2D94,earnings,100,50,7/30/2020
4E2D94,dividend,100,50,7/30/2020
4EEE7E,earnings,100,50,7/30/2020
4F0A80,earnings,100,50,7/30/2020
4F783B,dividend,100,50,7/30/2020
524CE4,earnings,100,50,7/30/2020
525A1C,earnings,100,50,7/30/2020
53E575,earnings,100,50,7/30/2020
54A646,dividend,100,50,7/30/2020
54A713,dividend,100,50,7/30/2020
54B889,conference-participant,100,50,7/30/2020
55438C,legal-issues-defendant,100,22,7/30/2020
55C9B5,earnings,100,50,7/30/2020
55D0F3,earnings,100,50,7/30/2020
56632F,earnings,100,50,7/30/2020
56632F,earnings,100,50,7/30/2020
56632F,earnings,100,50,7/30/2020
57634F,earnings,100,50,7/30/2020
57CAAB,earnings,100,50,7/30/2020
57F3DA,earnings,100,50,7/30/2020
586BD7,earnings,100,50,7/30/2020
586BD7,business-contract,100,69,7/30/2020
58C2D4,conference-participant,100,50,7/30/2020
59C539,earnings,100,50,7/30/2020
59DB8C,earnings,100,50,7/30/2020
5A64D5,earnings,100,50,7/30/2020
5CCDAD,earnings,100,50,7/30/2020
5D0337,earnings,100,50,7/30/2020
5D1329,conference-call,100,50,7/30/2020
5D16CF,earnings,100,50,7/30/2020
5D43A7,earnings,100,50,7/30/2020
5D43A7,earnings,100,50,7/30/2020
5D43A7,earnings,100,50,7/30/2020
5D43A7,earnings,100,50,7/30/2020
5D43A7,earnings,100,50,7/30/2020
5EAA43,business-contract,100,69,7/30/2020
5EF130,conference-call,100,50,7/30/2020
5FC507,ipo-pricing,100,50,7/30/2020
616E3B,earnings,100,50,7/30/2020
616E3B,earnings,100,50,7/30/2020
641F17,earnings,100,50,7/30/2020
641F17,earnings,100,50,7/30/2020
641F17,earnings,100,50,7/30/2020
641F17,earnings,100,50,7/30/2020
641F17,earnings,100,50,7/30/2020
641F17,earnings,100,50,7/30/2020
641F17,earnings,100,50,7/30/2020
641F17,earnings,100,50,7/30/2020
641F17,earnings,100,50,7/30/2020
64636E,earnings,100,50,7/30/2020
64636E,earnings,100,50,7/30/2020
6.52E+64,earnings,100,50,7/30/2020
6559D8,conference-call,100,50,7/30/2020
66ECFD,award,100,58,7/30/2020
67B052,earnings,100,50,7/30/2020
67B052,earnings,100,50,7/30/2020
68E3E0,revenue-up,100,69,7/30/2020
68E3E0,revenue-up,100,69,7/30/2020
68E3E0,revenue-up,100,69,7/30/2020
68E3E0,revenue-up,100,69,7/30/2020
68E3E0,revenue-up,100,69,7/30/2020
694749,earnings,100,50,7/30/2020
694749,earnings,100,50,7/30/2020
694749,earnings,100,50,7/30/2020
694749,earnings,100,50,7/30/2020
69494C,earnings,100,50,7/30/2020
69C99E,earnings,100,50,7/30/2020
6A3C35,earnings,100,50,7/30/2020
6A3C35,earnings,100,50,7/30/2020
6A3C35,earnings,100,50,7/30/2020
6A3C35,earnings,100,50,7/30/2020
6A3C35,earnings,100,50,7/30/2020
6B0784,earnings,100,50,7/30/2020
6BD606,dividend,100,50,7/30/2020
6BF593,earnings,100,50,7/30/2020
6C6D73,conference-participant,100,50,7/30/2020
6CDFC6,earnings,100,50,7/30/2020
6DC1D7,unit-acquisition-acquiree,100,76,7/30/2020
6DC1D7,earnings,100,50,7/30/2020
6F0A63,earnings,100,50,7/30/2020
6F22E7,executive-resignation,100,44,7/30/2020
6F3936,award,100,58,7/30/2020
701531,earnings,100,50,7/30/2020
717DB4,earnings,100,50,7/30/2020
717DB4,earnings,100,50,7/30/2020
717DB4,earnings,100,50,7/30/2020
717DB4,earnings,100,50,7/30/2020
717DB4,earnings,100,50,7/30/2020
7255D2,earnings,100,50,7/30/2020
72CB93,earnings,100,50,7/30/2020
731675,earnings,100,50,7/30/2020
731675,product-release,100,64,7/30/2020
732449,executive-appointment,100,54,7/30/2020
73529F,earnings,100,50,7/30/2020
73A71F,earnings,100,50,7/30/2020
73C9E2,earnings,100,50,7/30/2020
742AAB,earnings,100,50,7/30/2020
746373,earnings,100,50,7/30/2020
746373,earnings,100,50,7/30/2020
747219,conference-participant,100,50,7/30/2020
762A3E,executive-appointment,100,54,7/30/2020
766047,earnings,100,50,7/30/2020
76B926,earnings,100,50,7/30/2020
76F067,business-contract,100,69,7/30/2020
7710F3,earnings,100,50,7/30/2020
7710F3,earnings,100,50,7/30/2020
7823A3,earnings,100,50,7/30/2020
7823A3,earnings,100,50,7/30/2020
7823A3,earnings,100,50,7/30/2020
7823A3,earnings,100,50,7/30/2020
7823A3,earnings,100,50,7/30/2020
7823A3,earnings,100,50,7/30/2020
782B46,dividend,100,50,7/30/2020
78F9ED,earnings,100,50,7/30/2020
78F9ED,earnings,100,50,7/30/2020
78F9ED,earnings,100,50,7/30/2020
78F9ED,earnings,100,50,7/30/2020
78F9ED,earnings,100,50,7/30/2020
78F9ED,earnings,100,50,7/30/2020
78F9ED,earnings,100,50,7/30/2020
78F9ED,earnings,100,50,7/30/2020
79167B,earnings,100,50,7/30/2020
79167B,earnings,100,50,7/30/2020
79167B,earnings,100,50,7/30/2020
79167B,earnings,100,50,7/30/2020
79167B,earnings,100,50,7/30/2020
7A10FF,partnership,100,61,7/30/2020
7A5D58,earnings,100,50,7/30/2020
7B1E50,legal-issues-defendant,100,22,7/30/2020
7B1E50,legal-issues-defendant,100,22,7/30/2020
7B1E50,legal-issues-defendant,100,22,7/30/2020
7B1E50,legal-issues-defendant,100,22,7/30/2020
7B4B91,earnings,100,50,7/30/2020
7BEA98,earnings,100,50,7/30/2020
7C4F43,earnings,100,50,7/30/2020
7D5384,earnings,100,50,7/30/2020
7D5384,earnings,100,50,7/30/2020
7D5384,earnings,100,50,7/30/2020
7D5384,earnings,100,50,7/30/2020
7D5384,earnings,100,50,7/30/2020
7DC1C4,earnings,100,50,7/30/2020
7E0EB0,earnings,100,50,7/30/2020
7F3669,executive-appointment,100,54,7/30/2020
81A88D,earnings,100,50,7/30/2020
84920B,earnings,100,50,7/30/2020
858942,note-sale,100,52,7/30/2020
859D62,executive-appointment,100,54,7/30/2020
859D62,donation,100,54,7/30/2020
860AB6,dividend,100,50,7/30/2020
860AB6,dividend,100,50,7/30/2020
862941,partnership,100,61,7/30/2020
86AA9C,conference-call,100,50,7/30/2020
86BAC7,earnings,100,50,7/30/2020
877734,conference-call,100,50,7/30/2020
880C0C,earnings,100,50,7/30/2020
8A0368,earnings,100,50,7/30/2020
8A0368,earnings,100,50,7/30/2020
8A0368,earnings,100,50,7/30/2020
8A0368,earnings,100,50,7/30/2020
8AB85C,earnings,100,50,7/30/2020
8B3B0E,earnings,100,50,7/30/2020
8B6E7E,earnings-up,100,68,7/30/2020
8B6E7E,earnings,100,50,7/30/2020
8B6E7E,earnings,100,50,7/30/2020
8B6E7E,earnings,100,50,7/30/2020
8BAA15,patent-infringement-plaintiff,100,47,7/30/2020
8BFAA4,conference-call,100,50,7/30/2020
8BFE9A,earnings,100,50,7/30/2020
8C311A,public-offering,100,43,7/30/2020
8D4486,partnership,100,61,7/30/2020
8D9993,earnings,100,50,7/30/2020
8D9993,earnings,100,50,7/30/2020
8D9993,earnings,100,50,7/30/2020
8D9993,earnings,100,50,7/30/2020
8E0E32,earnings,100,50,7/30/2020
8E8E6E,earnings,100,50,7/30/2020
9043FE,earnings,100,50,7/30/2020
9043FE,earnings,100,50,7/30/2020
9087B9,dividend,100,50,7/30/2020
911AB8,earnings-positive,100,69,7/30/2020
913437,earnings,100,50,7/30/2020
934029,earnings,100,50,7/30/2020
93965C,earnings,100,50,7/30/2020
93C130,earnings,100,50,7/30/2020
93C130,dividend,100,50,7/30/2020
940C3D,dividend,100,50,7/30/2020
94756D,earnings,100,50,7/30/2020
947B0B,public-offering,100,43,7/30/2020
94A326,conference-participant,100,50,7/30/2020
958938,partnership,100,61,7/30/2020
95A92E,product-release,100,64,7/30/2020
95C575,earnings,100,50,7/30/2020
967D92,earnings,100,50,7/30/2020
968966,earnings,100,50,7/30/2020
971F7B,earnings,100,50,7/30/2020
971F7B,earnings,100,50,7/30/2020
971F7B,earnings,100,50,7/30/2020
971F7B,earnings,100,50,7/30/2020
9.74E+08,partnership,100,61,7/30/2020
977A1E,dividend,100,50,7/30/2020
9810C0,earnings,100,50,7/30/2020
9.82E+06,note-sale,100,52,7/30/2020
9.86E+03,business-contract,100,69,7/30/2020
9.86E+03,business-contract,100,69,7/30/2020
98CEBB,conference-participant,100,50,7/30/2020
9.97E+09,earnings,100,50,7/30/2020
9AF3DC,earnings-up,100,68,7/30/2020
9AF3DC,earnings,100,50,7/30/2020
9AF3DC,earnings,100,50,7/30/2020
9AF3DC,earnings,100,50,7/30/2020
9AF3DC,earnings,100,50,7/30/2020
9AF3DC,earnings,100,50,7/30/2020
9AF3DC,earnings,100,50,7/30/2020
9AF3DC,earnings,100,50,7/30/2020
9AF3DC,earnings,100,50,7/30/2020
9B5968,earnings,100,50,7/30/2020
9B5968,earnings,100,50,7/30/2020
9B730A,conference-call,100,50,7/30/2020
9BF177,executive-appointment,100,54,7/30/2020
9CF9B1,earnings,100,50,7/30/2020
9D307D,conference-participant,100,50,7/30/2020
9D5FA4,earnings,100,50,7/30/2020
9D6A24,dividend,100,50,7/30/2020
9DDE1B,earnings,100,50,7/30/2020
9E298A,earnings,100,50,7/30/2020
9E298A,earnings,100,50,7/30/2020
9E298A,earnings,100,50,7/30/2020
9E298A,earnings,100,50,7/30/2020
9E3224,earnings,100,50,7/30/2020
9E4A5F,partnership,100,61,7/30/2020
9E575E,earnings,100,50,7/30/2020
9EED50,earnings,100,50,7/30/2020
9F71E5,earnings,100,50,7/30/2020
9F71E5,dividend,100,50,7/30/2020
A072C4,conference-call,100,50,7/30/2020
A204A7,earnings,100,50,7/30/2020
A28C54,business-contract,100,69,7/30/2020
A2CA3F,dividend,100,50,7/30/2020
A4D173,dividend,100,50,7/30/2020
A4D173,dividend,100,50,7/30/2020
A5151E,earnings,100,50,7/30/2020
A52533,earnings,100,50,7/30/2020
A63387,business-contract,100,69,7/30/2020
A6828A,regulatory-product-approval-granted,100,81,7/30/2020
A7CCF0,earnings,100,50,7/30/2020
A80FE0,earnings,100,50,7/30/2020
A8B137,dividend,100,50,7/30/2020
A94637,revenues,100,50,7/30/2020
A99576,earnings,100,50,7/30/2020
AA09AD,earnings,100,50,7/30/2020
AADE0B,earnings,100,50,7/30/2020
ABBAD1,earnings,100,50,7/30/2020
ABE7DC,ipo-completed,100,76,7/30/2020
ABEE43,earnings-per-share,100,50,7/30/2020
ABEE43,earnings-per-share,100,50,7/30/2020
ABEE43,earnings-per-share,100,50,7/30/2020
ABEE43,earnings-per-share,100,50,7/30/2020
AC1952,earnings,100,50,7/30/2020
AC7AAE,earnings,100,50,7/30/2020
ACDCFA,earnings,100,50,7/30/2020
ACF0B4,conference-call,100,50,7/30/2020
AE0CCE,conference-participant,100,50,7/30/2020
AECCA9,conference-call,100,50,7/30/2020
AEEB76,conference-participant,100,50,7/30/2020
AF93DE,conference-call,100,50,7/30/2020
AFF43F,earnings,100,50,7/30/2020
AFF43F,dividend,100,50,7/30/2020
B01215,conference-call,100,50,7/30/2020
B05118,earnings,100,50,7/30/2020
B0B969,earnings,100,50,7/30/2020
B2206F,earnings,100,50,7/30/2020
B2256A,earnings,100,50,7/30/2020
B3ED62,earnings,100,50,7/30/2020
B4703C,earnings,100,50,7/30/2020
B4C673,earnings,100,50,7/30/2020
B4C673,earnings,100,50,7/30/2020
B4C673,earnings,100,50,7/30/2020
B4C673,earnings,100,50,7/30/2020
B4C673,earnings,100,50,7/30/2020
B4C673,earnings,100,50,7/30/2020
B5BA39,earnings,100,50,7/30/2020
B6CD92,earnings,100,50,7/30/2020
B6CD92,earnings,100,50,7/30/2020
B6CD92,earnings,100,50,7/30/2020
B6CD92,earnings,100,50,7/30/2020
B6CD92,earnings,100,50,7/30/2020
B6CD92,earnings,100,50,7/30/2020
B73395,conference-call,100,50,7/30/2020
B80AD1,earnings,100,50,7/30/2020
BB07E4,dividend,100,50,7/30/2020
BBBB41,earnings,100,50,7/30/2020
BBBB41,earnings,100,50,7/30/2020
BBBB41,earnings,100,50,7/30/2020
BBBB41,earnings,100,50,7/30/2020
BBBB41,earnings,100,50,7/30/2020
BBBB41,earnings,100,50,7/30/2020
BBBB41,earnings,100,50,7/30/2020
BC5680,earnings,100,50,7/30/2020
BC5680,earnings,100,50,7/30/2020
BC5680,earnings,100,50,7/30/2020
BD682F,earnings,100,50,7/30/2020
BD8517,earnings,100,50,7/30/2020
BDF2BD,earnings,100,50,7/30/2020
BDF2BD,earnings,100,50,7/30/2020
BDF2BD,earnings,100,50,7/30/2020
BDF2BD,earnings,100,50,7/30/2020
BDF2BD,earnings,100,50,7/30/2020
BDF2BD,earnings,100,50,7/30/2020
BE7BA4,conference-participant,100,50,7/30/2020
BE86A1,earnings,100,50,7/30/2020
C0030A,earnings,100,50,7/30/2020
C0030A,earnings,100,50,7/30/2020
C0030A,earnings,100,50,7/30/2020
C0030A,earnings,100,50,7/30/2020
C0030A,earnings,100,50,7/30/2020
C05839,conference-participant,100,50,7/30/2020
C06EB6,earnings,100,50,7/30/2020
C15DB3,earnings,100,50,7/30/2020
C16A8F,dividend,100,50,7/30/2020
C2609A,dividend,100,50,7/30/2020
C356AC,dividend,100,50,7/30/2020
C356AC,earnings,100,50,7/30/2020
C356AC,earnings,100,50,7/30/2020
C356AC,earnings,100,50,7/30/2020
C356AC,earnings,100,50,7/30/2020
C356AC,earnings,100,50,7/30/2020
C356AC,earnings,100,50,7/30/2020
C38440,earnings,100,50,7/30/2020
C4F9C6,earnings,100,50,7/30/2020
C564E4,earnings,100,50,7/30/2020
C5D2AE,earnings,100,50,7/30/2020
C5E100,conference-call,100,50,7/30/2020
C624A1,earnings,100,50,7/30/2020
C624A1,earnings,100,50,7/30/2020
C65004,conference-participant,100,50,7/30/2020
C7FC95,earnings,100,50,7/30/2020
C7FC95,earnings,100,50,7/30/2020
C81E00,operating-earnings,100,50,7/30/2020
C81E00,operating-earnings,100,50,7/30/2020
C83B88,business-contract,100,69,7/30/2020
C83B88,earnings,100,50,7/30/2020
C83B88,earnings,100,50,7/30/2020
C83B88,earnings,100,50,7/30/2020
C83B88,earnings,100,50,7/30/2020
C83B88,earnings,100,50,7/30/2020
C83B88,earnings,100,50,7/30/2020
C83B88,dividend,100,50,7/30/2020
C83B88,business-contract,100,69,7/30/2020
C83B88,business-contract,100,69,7/30/2020
C8A248,earnings,100,50,7/30/2020
C8A248,earnings,100,50,7/30/2020
C8A248,earnings,100,50,7/30/2020
C8A248,earnings,100,50,7/30/2020
C8A248,earnings,100,50,7/30/2020
C8A248,earnings,100,50,7/30/2020
C8A248,earnings,100,50,7/30/2020
C8A248,earnings,100,50,7/30/2020
C8FAC7,earnings,100,50,7/30/2020
C941DC,earnings,100,50,7/30/2020
CBCC6A,earnings,100,50,7/30/2020
CBCC6A,earnings,100,50,7/30/2020
CDC217,earnings,100,50,7/30/2020
CDEDFE,earnings,100,50,7/30/2020
CE1002,earnings,100,50,7/30/2020
CE1002,earnings,100,50,7/30/2020
CE1002,earnings,100,50,7/30/2020
CE1002,earnings,100,50,7/30/2020
CE1002,earnings,100,50,7/30/2020
CE8251,earnings,100,50,7/30/2020
CFB6CA,executive-resignation,100,44,7/30/2020
D03C7A,earnings,100,50,7/30/2020
D0DE27,earnings,100,50,7/30/2020
D17C1B,business-contract,100,69,7/30/2020
D1AE3B,executive-appointment,100,54,7/30/2020
D1C26F,business-contract,100,69,7/30/2020
D296C6,earnings,100,50,7/30/2020
D3DE34,reverse-stock-splits,100,51,7/30/2020
D3DE34,reverse-stock-splits,100,51,7/30/2020
D4070C,dividend,100,50,7/30/2020
D54E62,business-contract,100,69,7/30/2020
D54E62,business-contract,100,69,7/30/2020
D56D6D,earnings,100,50,7/30/2020
D5A350,dividend,100,50,7/30/2020
D8442A,earnings,100,50,7/30/2020
D8442A,earnings,100,50,7/30/2020
D8442A,earnings,100,50,7/30/2020
D8760C,dividend,100,50,7/30/2020
D8DBA3,earnings,100,50,7/30/2020
D8ECA1,earnings,100,50,7/30/2020
D8ECA1,earnings,100,50,7/30/2020
D8ECA1,earnings,100,50,7/30/2020
D8F347,dividend,100,50,7/30/2020
D96202,executive-appointment,100,54,7/30/2020
D9B1C9,conference-call,100,50,7/30/2020
D9B1C9,legal-issues-defendant,100,22,7/30/2020
DB06B0,earnings,100,50,7/30/2020
DB06B0,earnings,100,50,7/30/2020
DB06B0,earnings,100,50,7/30/2020
DB06B0,earnings,100,50,7/30/2020
DB06B0,earnings,100,50,7/30/2020
DB5CA5,partnership,100,61,7/30/2020
DC437D,dividend,100,50,7/30/2020
DC5299,operating-earnings,100,50,7/30/2020
DD0F15,earnings,100,50,7/30/2020
DD1BA1,revenues,100,50,7/30/2020
DD1BA1,revenues,100,50,7/30/2020
DD1BA1,revenues,100,50,7/30/2020
DD1BA1,revenues,100,50,7/30/2020
DDCB34,dividend,100,50,7/30/2020
DDCB34,earnings,100,50,7/30/2020
DDEA6A,operating-earnings,100,50,7/30/2020
DE4924,dividend,100,50,7/30/2020
DE4924,earnings,100,50,7/30/2020
DE5611,award,100,58,7/30/2020
E0339F,earnings,100,50,7/30/2020
E0339F,earnings,100,50,7/30/2020
E0339F,earnings,100,50,7/30/2020
E0339F,earnings,100,50,7/30/2020
E09E2B,conference-call,100,50,7/30/2020
E13782,earnings,100,50,7/30/2020
E1BD05,revenue-up,100,69,7/30/2020
E1BD05,revenue-up,100,69,7/30/2020
E2F66E,earnings-above-expectations,100,88,7/30/2020
E3E68E,executive-appointment,100,54,7/30/2020
E3E68E,executive-appointment,100,54,7/30/2020
E3E68E,earnings,100,50,7/30/2020
E3E68E,earnings,100,50,7/30/2020
E4CE73,conference-call,100,50,7/30/2020
E5752F,partnership,100,61,7/30/2020
E67C2C,earnings,100,50,7/30/2020
E6C8DC,executive-appointment,100,54,7/30/2020
E6C8DC,conference-call,100,50,7/30/2020
E6E012,earnings,100,50,7/30/2020
E6E012,earnings,100,50,7/30/2020
E6E012,earnings,100,50,7/30/2020
E6E012,earnings,100,50,7/30/2020
E6E012,earnings,100,50,7/30/2020
E71AE6,earnings,100,50,7/30/2020
E8846E,legal-issues-defendant,100,22,7/30/2020
E8C557,earnings,100,50,7/30/2020
EC70EC,earnings,100,50,7/30/2020
EC70EC,earnings,100,50,7/30/2020
EC70EC,earnings,100,50,7/30/2020
EC70EC,earnings,100,50,7/30/2020
EC70EC,earnings,100,50,7/30/2020
EC70EC,earnings,100,50,7/30/2020
EC70EC,earnings,100,50,7/30/2020
ED1A74,conference-participant,100,50,7/30/2020
ED4560,earnings,100,50,7/30/2020
EFD406,earnings,100,50,7/30/2020
EFD406,earnings,100,50,7/30/2020
EFD406,earnings,100,50,7/30/2020
EFD406,earnings,100,50,7/30/2020
EFD406,earnings,100,50,7/30/2020
EFD406,earnings,100,50,7/30/2020
EFD406,earnings,100,50,7/30/2020
F0027C,earnings,100,50,7/30/2020
F02D0A,dividend,100,50,7/30/2020
F11638,earnings,100,50,7/30/2020
F1D7E1,earnings,100,50,7/30/2020
F209B4,conference-participant,100,50,7/30/2020
F30508,earnings,100,50,7/30/2020
F30508,earnings,100,50,7/30/2020
F30508,earnings,100,50,7/30/2020
F30508,earnings,100,50,7/30/2020
F30508,earnings,100,50,7/30/2020
F30508,earnings,100,50,7/30/2020
F3816D,conference-call,100,50,7/30/2020
F44EA2,dividend-up,100,60,7/30/2020
F46EC9,earnings,100,50,7/30/2020
F46EC9,earnings,100,50,7/30/2020
F46EC9,earnings,100,50,7/30/2020
F46EC9,earnings,100,50,7/30/2020
F46EC9,earnings,100,50,7/30/2020
F4F46F,earnings,100,50,7/30/2020
F51DB0,earnings,100,50,7/30/2020
F6A945,earnings,100,50,7/30/2020
F6E248,earnings,100,50,7/30/2020
F6E248,dividend,100,50,7/30/2020
F7D8AE,earnings,100,50,7/30/2020
F7FCA4,earnings,100,50,7/30/2020
F7FCA4,earnings,100,50,7/30/2020
F7FCA4,earnings,100,50,7/30/2020
F7FCA4,earnings,100,50,7/30/2020
F80389,earnings,100,50,7/30/2020
F88A04,earnings,100,50,7/30/2020
F88A04,earnings,100,50,7/30/2020
F88A04,earnings,100,50,7/30/2020
F88A04,earnings,100,50,7/30/2020
F92DBC,earnings,100,50,7/30/2020
F92DBC,earnings,100,50,7/30/2020
F92DBC,earnings,100,50,7/30/2020
F92DBC,earnings,100,50,7/30/2020
F92DBC,earnings,100,50,7/30/2020
F92DBC,earnings,100,50,7/30/2020
F92DBC,earnings,100,50,7/30/2020
F92DBC,earnings,100,50,7/30/2020
F92DBC,earnings,100,50,7/30/2020
F92DBC,earnings,100,50,7/30/2020
F92DBC,earnings,100,50,7/30/2020
F92DBC,earnings,100,50,7/30/2020
F9CAF8,earnings-up,100,68,7/30/2020
F9CAF8,earnings,100,50,7/30/2020
F9CAF8,earnings,100,50,7/30/2020
F9CAF8,earnings,100,50,7/30/2020
FA35C6,earnings,100,50,7/30/2020
FA840E,conference-participant,100,50,7/30/2020
FA918D,earnings,100,50,7/30/2020
FA918D,earnings,100,50,7/30/2020
FA918D,earnings,100,50,7/30/2020
FAE021,earnings,100,50,7/30/2020
FAE021,earnings,100,50,7/30/2020
FAE021,earnings,100,50,7/30/2020
FAE021,earnings,100,50,7/30/2020
FC1B7B,earnings,100,50,7/30/2020
FC1B7B,award,100,58,7/30/2020
FC9869,earnings,100,50,7/30/2020
FD2565,conference-call,100,50,7/30/2020
FD4588,earnings,100,50,7/30/2020
FD4588,earnings,100,50,7/30/2020
FD4588,earnings,100,50,7/30/2020
FD554E,conference-call,100,50,7/30/2020
FD6926,earnings,100,50,7/30/2020
FD6926,earnings,100,50,7/30/2020
FD6926,earnings,100,50,7/30/2020
FD6926,earnings,100,50,7/30/2020
FD6926,earnings,100,50,7/30/2020
FD6926,dividend,100,50,7/30/2020
FD9526,earnings,100,50,7/30/2020
FD9A97,earnings,100,50,7/30/2020
FDF799,conference-participant,100,50,7/30/2020
FE89E0,earnings,100,50,7/30/2020
FE89E0,earnings,100,50,7/30/2020
FF4343,earnings-up,100,68,7/30/2020
FF4343,earnings,100,50,7/30/2020
FF4343,earnings,100,50,7/30/2020
FF4343,earnings,100,50,7/30/2020
FF4343,earnings,100,50,7/30/2020
FF4343,earnings,100,50,7/30/2020
FF4343,earnings,100,50,7/30/2020
FF4343,earnings,100,50,7/30/2020
FF4343,earnings,100,50,7/30/2020
FF4343,earnings,100,50,7/30/2020
FF4343,earnings,100,50,7/30/2020
FF4343,earnings,100,50,7/30/2020
FF4343,earnings,100,50,7/30/2020
FF4343,earnings,100,50,7/30/2020
FF5413,earnings,100,50,7/30/2020
FFCD0E,conference-call,100,50,7/30/2020
01D03F,regulatory-product-approval-granted,100,81,7/31/2020
01D03F,regulatory-product-approval-granted,100,81,7/31/2020
43862,earnings,100,50,7/31/2020
55018,dividend,100,50,7/31/2020
0624BE,earnings,100,50,7/31/2020
09DE1F,debt-extension-recipient,100,73,7/31/2020
0BD970,unit-acquisition-acquiree,100,76,7/31/2020
0BD970,earnings,100,50,7/31/2020
0D03C8,earnings,100,50,7/31/2020
0FDE97,earnings,100,50,7/31/2020
0FDE97,earnings,100,50,7/31/2020
0FDE97,earnings,100,50,7/31/2020
0FDE97,earnings,100,50,7/31/2020
0FDE97,earnings,100,50,7/31/2020
0FDE97,earnings,100,50,7/31/2020
0FDE97,earnings,100,50,7/31/2020
139303,earnings,100,50,7/31/2020
147C38,product-release,100,64,7/31/2020
17EDA5,legal-issues-defendant,100,22,7/31/2020
1AB023,conference-call,100,50,7/31/2020
1AB023,conference-call,100,50,7/31/2020
1AB023,conference-call,100,50,7/31/2020
1CF3A8,conference-call,100,50,7/31/2020
1EBF8D,earnings,100,50,7/31/2020
1F43A1,earnings,100,50,7/31/2020
25102A,business-contract,100,69,7/31/2020
251988,facility-open,100,65,7/31/2020
297DA8,earnings,100,50,7/31/2020
2AE625,earnings,100,50,7/31/2020
32CB22,note-sale,100,52,7/31/2020
32CB22,note-sale,100,52,7/31/2020
353DBB,earnings,100,50,7/31/2020
353DBB,earnings,100,50,7/31/2020
356B21,legal-issues-defendant,100,22,7/31/2020
39692D,earnings,100,50,7/31/2020
3DDE54,earnings,100,50,7/31/2020
3DDE54,earnings,100,50,7/31/2020
3DDE54,earnings,100,50,7/31/2020
3DDE54,earnings,100,50,7/31/2020
3DDE54,earnings,100,50,7/31/2020
3DDE54,earnings,100,50,7/31/2020
3FACA7,earnings,100,50,7/31/2020
41EC04,earnings,100,50,7/31/2020
41EC04,earnings,100,50,7/31/2020
41EC04,earnings,100,50,7/31/2020
423279,dividend,100,50,7/31/2020
44DDBD,conference-call,100,50,7/31/2020
460C93,earnings,100,50,7/31/2020
4B5054,earnings,100,50,7/31/2020
4D371E,dividend,100,50,7/31/2020
504FE2,dividend,100,50,7/31/2020
51D876,earnings,100,50,7/31/2020
54512F,earnings,100,50,7/31/2020
589803,partnership,100,61,7/31/2020
589803,partnership,100,61,7/31/2020
5B6C11,acquisition-acquirer,100,49,7/31/2020
5B6C11,acquisition-completed-acquirer,100,49,7/31/2020
5DE5A5,dividend,100,50,7/31/2020
5FE4B6,earnings,100,50,7/31/2020
5FE4B6,earnings,100,50,7/31/2020
665D7D,earnings,100,50,7/31/2020
6925EB,executive-appointment,100,54,7/31/2020
6B67BD,earnings,100,50,7/31/2020
6BD606,earnings,100,50,7/31/2020
6D9B53,conference-participant,100,50,7/31/2020
6-Dec-05,public-offering,100,43,7/31/2020
6E705B,product-resumed,100,52,7/31/2020
6E7060,dividend,100,50,7/31/2020
705636,earnings,100,50,7/31/2020
705636,dividend,100,50,7/31/2020
717DB4,conference-participant,100,50,7/31/2020
726EEA,earnings,100,50,7/31/2020
726EEA,earnings,100,50,7/31/2020
726EEA,earnings,100,50,7/31/2020
726EEA,earnings,100,50,7/31/2020
726EEA,earnings,100,50,7/31/2020
72EF75,dividend,100,50,7/31/2020
72EF75,earnings,100,50,7/31/2020
743C70,unit-acquisition-acquirer,100,49,7/31/2020
75768D,dividend,100,50,7/31/2020
767F86,earnings,100,50,7/31/2020
767F86,earnings,100,50,7/31/2020
767F86,earnings,100,50,7/31/2020
767F86,earnings,100,50,7/31/2020
767F86,earnings,100,50,7/31/2020
767F86,earnings,100,50,7/31/2020
767F86,earnings,100,50,7/31/2020
767F86,earnings,100,50,7/31/2020
767F86,earnings,100,50,7/31/2020
767F86,earnings,100,50,7/31/2020
767F86,earnings,100,50,7/31/2020
76BD96,dividend-up,100,81,7/31/2020
76D79A,earnings,100,50,7/31/2020
789ADD,earnings,100,50,7/31/2020
789ADD,earnings,100,50,7/31/2020
789ADD,earnings,100,50,7/31/2020
789ADD,earnings,100,50,7/31/2020
7B1E50,legal-issues-defendant,100,22,7/31/2020
81EAD4,conference-call,100,50,7/31/2020
82F088,conference-participant,100,50,7/31/2020
83E0AC,conference-call,100,50,7/31/2020
87486A,conference-call,100,50,7/31/2020
8AC65D,public-offering,100,43,7/31/2020
8B1F37,acquisition-completed-acquirer,100,49,7/31/2020
8F6995,conference-call,100,50,7/31/2020
902255,dividend,100,50,7/31/2020
92005C,earnings,100,50,7/31/2020
949D62,conference-participant,100,50,7/31/2020
977A1E,earnings,100,50,7/31/2020
977A1E,earnings,100,50,7/31/2020
977A1E,earnings,100,50,7/31/2020
977A1E,executive-appointment,100,54,7/31/2020
97B027,dividend,100,50,7/31/2020
9981C6,earnings,100,50,7/31/2020
9CDA4F,earnings,100,50,7/31/2020
9F5CBB,dividend,100,50,7/31/2020
A2C979,conference-participant,100,50,7/31/2020
A4BCDE,earnings,100,50,7/31/2020
A6FE1C,unit-acquisition-acquirer,100,49,7/31/2020
A7A0BD,conference-call,100,50,7/31/2020
ACD9A4,dividend,100,50,7/31/2020
AD6141,dividend,100,50,7/31/2020
AE7D16,earnings,100,50,7/31/2020
B04426,conference-call,100,50,7/31/2020
B290A2,earnings,100,50,7/31/2020
B2AA0A,earnings-positive,100,69,7/31/2020
B560AF,earnings,100,50,7/31/2020
B560AF,earnings,100,50,7/31/2020
B560AF,earnings,100,50,7/31/2020
B560AF,earnings,100,50,7/31/2020
B560AF,earnings,100,50,7/31/2020
B5767B,conference-call,100,50,7/31/2020
B60366,ipo-pricing,100,50,7/31/2020
B60366,ipo-pricing,100,50,7/31/2020
B72D2E,earnings,100,50,7/31/2020
B77F14,earnings,100,50,7/31/2020
B77F14,earnings,100,50,7/31/2020
B7EB38,earnings,100,50,7/31/2020
B98EFA,business-contract,100,69,7/31/2020
BBBB41,conference-participant,100,50,7/31/2020
BBF349,acquisition-completed-acquirer,100,49,7/31/2020
C01737,earnings,100,50,7/31/2020
C32A39,earnings,100,50,7/31/2020
C3BCD5,earnings,100,50,7/31/2020
C50B26,acquisition-completed-acquirer,100,49,7/31/2020
C9C62A,earnings,100,50,7/31/2020
CA3CB9,earnings-up,100,68,7/31/2020
CF351E,earnings,100,50,7/31/2020
CF351E,earnings,100,50,7/31/2020
CF351E,earnings,100,50,7/31/2020
D1344A,buybacks,100,74,7/31/2020
D17F7E,earnings,100,50,7/31/2020
D33270,unit-acquisition-completed-acquirer,100,49,7/31/2020
D3FD6D,revenue-up,100,69,7/31/2020
D3FD6D,earnings,100,50,7/31/2020
D3FD6D,earnings,100,50,7/31/2020
D3FD6D,earnings,100,50,7/31/2020
D54E62,earnings,100,50,7/31/2020
D54E62,earnings,100,50,7/31/2020
D54E62,earnings,100,50,7/31/2020
D54E62,earnings,100,50,7/31/2020
D54E62,earnings,100,50,7/31/2020
D598E7,earnings,100,50,7/31/2020
D76AEF,conference-call,100,50,7/31/2020
D78CCD,earnings,100,50,7/31/2020
D78CCD,earnings,100,50,7/31/2020
D78CCD,earnings,100,50,7/31/2020
D78CCD,earnings,100,50,7/31/2020
D78CCD,earnings,100,50,7/31/2020
D854F3,earnings,100,50,7/31/2020
D854F3,earnings,100,50,7/31/2020
D854F3,earnings,100,50,7/31/2020
D854F3,earnings,100,50,7/31/2020
D88EF3,earnings,100,50,7/31/2020
D88EF3,earnings,100,50,7/31/2020
D88EF3,earnings,100,50,7/31/2020
D88EF3,earnings,100,50,7/31/2020
D88EF3,earnings,100,50,7/31/2020
D88EF3,earnings,100,50,7/31/2020
D88EF3,earnings,100,50,7/31/2020
DB23C8,earnings,100,50,7/31/2020
DB23C8,earnings,100,50,7/31/2020
DB23C8,earnings,100,50,7/31/2020
DD1BA1,partnership,100,61,7/31/2020
DD1BA1,partnership,100,61,7/31/2020
DE5611,dividend,100,50,7/31/2020
DF5F14,earnings,100,50,7/31/2020
E0E4B7,earnings,100,50,7/31/2020
E70531,earnings,100,50,7/31/2020
E70531,earnings,100,50,7/31/2020
E70531,earnings,100,50,7/31/2020
E70531,earnings,100,50,7/31/2020
E70531,earnings,100,50,7/31/2020
E70531,earnings,100,50,7/31/2020
E8846E,legal-issues-defendant,100,22,7/31/2020
E94704,earnings,100,50,7/31/2020
E94704,earnings,100,50,7/31/2020
E94704,earnings,100,50,7/31/2020
E94704,earnings,100,50,7/31/2020
E94704,earnings,100,50,7/31/2020
E959F3,dividend,100,50,7/31/2020
EB6965,earnings,100,50,7/31/2020
EB6965,earnings,100,50,7/31/2020
EB6965,earnings,100,50,7/31/2020
EB6965,earnings,100,50,7/31/2020
EB6965,earnings,100,50,7/31/2020
EB6965,earnings,100,50,7/31/2020
ECDEB2,earnings,100,50,7/31/2020
ED2EFD,earnings,100,50,7/31/2020
ED9576,dividend,100,50,7/31/2020
EE6F1C,earnings,100,50,7/31/2020
EE6F1C,earnings,100,50,7/31/2020
EE6F1C,earnings,100,50,7/31/2020
EE6F1C,earnings,100,50,7/31/2020
EEB5F9,conference-call,100,50,7/31/2020
EF5914,earnings,100,50,7/31/2020
F02D0A,executive-appointment,100,54,7/31/2020
F0EEFB,conference-call,100,50,7/31/2020
F1529C,earnings,100,50,7/31/2020
F1529C,earnings,100,50,7/31/2020
F294DD,dividend,100,50,7/31/2020
F2E253,dividend,100,50,7/31/2020
F31B13,dividend,100,50,7/31/2020
F4CDA3,conference-call,100,50,7/31/2020
F6DE54,earnings,100,50,7/31/2020
FD0CA4,dividend,100,50,7/31/2020
FF227B,earnings,100,50,7/31/2020
FF4BA4,earnings,100,50,7/31/2020
FF4BA4,earnings,100,50,7/31/2020
FF4BA4,earnings,100,50,7/31/2020
FF4BA4,earnings,100,50,7/31/2020
FF4BA4,earnings,100,50,7/31/2020
FF4BA4,earnings,100,50,7/31/2020
FF6644,dividend,100,50,7/31/2020
27C10F,legal-issues-defendant,100,22,8/1/2020
705636,earnings,100,50,8/1/2020
4E7C1F,acquisition-acquiree,100,76,8/2/2020
4E7C1F,business-combination,100,54,8/2/2020
4E7C1F,business-combination,100,54,8/2/2020
4E7C1F,earnings,100,50,8/2/2020
4E7C1F,earnings,100,50,8/2/2020
4E7C1F,earnings,100,50,8/2/2020
4E7C1F,acquisition-regulatory-approval-acquiree,100,81,8/2/2020
003B70,operating-earnings,100,50,8/3/2020
0157B1,partnership,100,61,8/3/2020
0157B1,partnership,100,61,8/3/2020
02870F,earnings,100,50,8/3/2020
02870F,earnings,100,50,8/3/2020
02870F,earnings,100,50,8/3/2020
02870F,earnings,100,50,8/3/2020
02ACBD,conference-call,100,50,8/3/2020
0325B7,conference-call,100,50,8/3/2020
03B8CF,business-contract,100,69,8/3/2020
054B55,executive-appointment,100,54,8/3/2020
06C826,conference-call,100,50,8/3/2020
09DE1F,earnings,100,50,8/3/2020
0B7375,conference-call,100,50,8/3/2020
0BC29E,earnings,100,50,8/3/2020
0BC29E,earnings,100,50,8/3/2020
0BC29E,earnings,100,50,8/3/2020
0BC29E,earnings,100,50,8/3/2020
0BC29E,earnings,100,50,8/3/2020
0BC29E,earnings,100,50,8/3/2020
0BC29E,earnings,100,50,8/3/2020
0BC29E,earnings,100,50,8/3/2020
0BC29E,earnings,100,50,8/3/2020
0BC29E,earnings,100,50,8/3/2020
0BC29E,dividend,100,50,8/3/2020
0BD199,conference-call,100,50,8/3/2020
0BF528,earnings,100,50,8/3/2020
0CCCB7,acquisition-completed-acquirer,100,49,8/3/2020
0DBB81,earnings,100,50,8/3/2020
0E5223,earnings,100,50,8/3/2020
0F0693,earnings,100,50,8/3/2020
0FC848,earnings,100,50,8/3/2020
10100E,earnings,100,50,8/3/2020
1272B3,earnings,100,50,8/3/2020
12731D,conference-call,100,50,8/3/2020
12731D,conference-call,100,50,8/3/2020
13A782,earnings,100,50,8/3/2020
157D9F,product-release,100,64,8/3/2020
15A388,award,100,58,8/3/2020
15B10D,earnings,100,50,8/3/2020
15B10D,earnings,100,50,8/3/2020
15B10D,earnings,100,50,8/3/2020
165B86,executive-appointment,100,54,8/3/2020
16B183,note-sale,100,52,8/3/2020
1748F6,union-pact,100,61,8/3/2020
1782D5,earnings,100,50,8/3/2020
17EDA5,partnership,100,61,8/3/2020
184988,earnings,100,50,8/3/2020
1866B2,equity-shelf-registration,100,43,8/3/2020
1880C5,conference-call,100,50,8/3/2020
1BC12C,trading-listing,100,61,8/3/2020
1BC12C,legal-issues-defendant,100,22,8/3/2020
1CD4B5,earnings,100,50,8/3/2020
1D9E55,partnership,100,61,8/3/2020
1D9E55,earnings,100,50,8/3/2020
1D9E55,business-contract,100,69,8/3/2020
1EBF8D,acquisition-completed-acquirer,100,49,8/3/2020
1EBF8D,business-contract,100,69,8/3/2020
1F08A6,joint-venture,100,62,8/3/2020
20BEEA,acquisition-completed-acquirer,100,49,8/3/2020
225CA2,note-sale,100,52,8/3/2020
241AF7,earnings,100,50,8/3/2020
250BEE,earnings,100,50,8/3/2020
250BEE,earnings,100,50,8/3/2020
250BEE,earnings,100,50,8/3/2020
250BEE,earnings,100,50,8/3/2020
250BEE,earnings,100,50,8/3/2020
267718,business-contract,100,69,8/3/2020
26E3BA,earnings,100,50,8/3/2020
26F99F,conference-participant,100,50,8/3/2020
275300,conference-participant,100,50,8/3/2020
27A791,conference-participant,100,50,8/3/2020
27BFA1,dividend,100,50,8/3/2020
284289,note-sale,100,52,8/3/2020
2A02DC,earnings,100,50,8/3/2020
2ABF77,conference-participant,100,50,8/3/2020
2B5483,earnings,100,50,8/3/2020
2C35B5,conference-participant,100,50,8/3/2020
2C7505,clinical-trials-filed,100,60,8/3/2020
2C7505,clinical-trials-filed,100,60,8/3/2020
2D2D43,earnings,100,50,8/3/2020
2E0445,conference-participant,100,50,8/3/2020
2F94A5,dividend,100,50,8/3/2020
2FDEE3,earnings,100,50,8/3/2020
306623,earnings,100,50,8/3/2020
30AB63,earnings,100,50,8/3/2020
30DE64,earnings,100,50,8/3/2020
30E01D,executive-resignation,100,44,8/3/2020
30E01D,executive-appointment,100,54,8/3/2020
3224CC,public-offering,100,43,8/3/2020
3.20E+263,earnings,100,50,8/3/2020
338544,merger-completed,100,66,8/3/2020
3390DE,earnings,100,50,8/3/2020
3461CF,credit-rating-confirmation-rater,20,50,8/3/2020
35557B,note-sale,100,52,8/3/2020
367E1C,earnings,100,50,8/3/2020
383ADA,earnings,100,50,8/3/2020
384CD3,earnings,100,50,8/3/2020
3A3447,earnings,100,50,8/3/2020
3A3447,earnings,100,50,8/3/2020
3A3447,earnings,100,50,8/3/2020
3A3447,earnings,100,50,8/3/2020
3A3447,earnings,100,50,8/3/2020
3AF7FD,conference-call,100,50,8/3/2020
3C7F5F,dividend,100,50,8/3/2020
3DE4D1,dividend,100,50,8/3/2020
3F1C69,earnings,100,50,8/3/2020
427F32,dividend,100,50,8/3/2020
4290EF,earnings,100,50,8/3/2020
43A74A,earnings,100,50,8/3/2020
43A74A,earnings,100,50,8/3/2020
43A74A,earnings,100,50,8/3/2020
43A74A,earnings,100,50,8/3/2020
43A74A,earnings,100,50,8/3/2020
43A74A,earnings,100,50,8/3/2020
43A74A,earnings,100,50,8/3/2020
43A74A,earnings,100,50,8/3/2020
45BC35,conference-participant,100,50,8/3/2020
490D4B,earnings,100,50,8/3/2020
4A5C8D,earnings,100,50,8/3/2020
4A5C8D,earnings,100,50,8/3/2020
4A6F00,partnership,100,61,8/3/2020
4A6F00,partnership,100,61,8/3/2020
4A6F00,partnership,100,61,8/3/2020
4A6F00,partnership,100,61,8/3/2020
4AC91D,executive-appointment,100,54,8/3/2020
4BF3D6,clinical-trials,100,56,8/3/2020
4C1FA1,earnings,100,50,8/3/2020
4C1FA1,earnings,100,50,8/3/2020
4C1FA1,earnings,100,50,8/3/2020
4C1FA1,earnings,100,50,8/3/2020
4C1FA1,earnings,100,50,8/3/2020
4D229C,earnings,100,50,8/3/2020
4E7C1F,acquisition-regulatory-scrutiny-acquiree,100,38,8/3/2020
504FE2,executive-appointment,100,54,8/3/2020
507AE7,earnings,100,50,8/3/2020
5088A5,earnings,100,50,8/3/2020
510EA6,unit-acquisition-acquirer,100,49,8/3/2020
51F541,note-sale,100,52,8/3/2020
51F541,note-sale,100,52,8/3/2020
52015A,earnings,100,50,8/3/2020
546A27,earnings,100,50,8/3/2020
5487B1,legal-issues-defendant,100,22,8/3/2020
56FB7C,dividend-up,100,81,8/3/2020
579E8F,conference-participant,100,50,8/3/2020
586BD7,acquisition-acquiree,100,76,8/3/2020
587EDF,earnings,100,50,8/3/2020
58C2D4,executive-appointment,100,54,8/3/2020
5B3415,earnings,100,50,8/3/2020
5D1329,conference-participant,100,50,8/3/2020
5D16CF,acquisition-completed-acquirer,100,49,8/3/2020
5EAA43,unit-acquisition-acquiree,100,76,8/3/2020
5F9CE3,acquisition-completed-acquirer,100,49,8/3/2020
5FC507,ipo-completed,100,76,8/3/2020
5FDBD0,conference-call,100,50,8/3/2020
5FDBD0,operating-earnings,100,50,8/3/2020
619882,conference-organizer,100,57,8/3/2020
61A586,executive-appointment,100,54,8/3/2020
61A586,earnings,100,50,8/3/2020
62EFEE,dividend,100,50,8/3/2020
62EFEE,earnings,100,50,8/3/2020
6391C2,conference-participant,100,50,8/3/2020
64636E,public-offering,100,43,8/3/2020
6559D8,executive-appointment,100,54,8/3/2020
665440,conference-participant,100,50,8/3/2020
66749D,earnings,100,50,8/3/2020
66749D,earnings,100,50,8/3/2020
66749D,earnings,100,50,8/3/2020
66749D,earnings,100,50,8/3/2020
66749D,earnings,100,50,8/3/2020
6A01DF,partnership,100,61,8/3/2020
6A01DF,partnership,100,61,8/3/2020
6A01DF,earnings,100,50,8/3/2020
6A171E,earnings,100,50,8/3/2020
6B236C,earnings,100,50,8/3/2020
6BBCBA,conference-call,100,50,8/3/2020
6C6D73,award,100,58,8/3/2020
6D6B40,earnings,100,50,8/3/2020
6DBBBC,business-contract,100,69,8/3/2020
701531,conference-participant,100,50,8/3/2020
704B78,conference-participant,100,50,8/3/2020
70CA28,conference-participant,100,50,8/3/2020
719477,earnings,100,50,8/3/2020
719477,earnings,100,50,8/3/2020
719477,earnings,100,50,8/3/2020
719477,earnings,100,50,8/3/2020
72CB93,executive-appointment,100,54,8/3/2020
73C521,executive-appointment,100,54,8/3/2020
7.44E+09,earnings,100,50,8/3/2020
762A3E,conference-organizer,100,57,8/3/2020
76DD0C,earnings,100,50,8/3/2020
7712CB,earnings,100,50,8/3/2020
7712CB,earnings,100,50,8/3/2020
7712CB,earnings,100,50,8/3/2020
7712CB,earnings,100,50,8/3/2020
7712CB,earnings,100,50,8/3/2020
797C20,earnings,100,50,8/3/2020
7ACD98,product-release,100,64,8/3/2020
7B6C88,earnings,100,50,8/3/2020
7BAAE7,earnings-per-share-positive,100,69,8/3/2020
7BAAE7,earnings,100,50,8/3/2020
7C4168,earnings,100,50,8/3/2020
7F3669,earnings,100,50,8/3/2020
7F3A5F,note-sale,100,52,8/3/2020
7FDE1C,partnership,100,61,8/3/2020
7FDE1C,partnership,100,61,8/3/2020
7FEEE1,conference-participant,100,50,8/3/2020
819492,earnings,100,50,8/3/2020
81EAD4,product-release,100,64,8/3/2020
824CCA,partnership,100,61,8/3/2020
824CCA,partnership,100,61,8/3/2020
82C202,earnings,100,50,8/3/2020
83066C,earnings,100,50,8/3/2020
83066C,earnings,100,50,8/3/2020
835C86,dividend,100,50,8/3/2020
83B1C8,earnings,100,50,8/3/2020
85DA04,earnings,100,50,8/3/2020
85DA04,earnings,100,50,8/3/2020
85DA04,earnings,100,50,8/3/2020
85DA04,earnings,100,50,8/3/2020
85DA04,earnings,100,50,8/3/2020
85DE00,executive-appointment,100,54,8/3/2020
860AB6,earnings,100,50,8/3/2020
8665BA,acquisition-interest-acquirer,100,46,8/3/2020
881190,dividend,100,50,8/3/2020
8DE74B,dividend,100,50,8/3/2020
8E4F9A,earnings,100,50,8/3/2020
8E4F9A,earnings,100,50,8/3/2020
8EF425,note-sale,100,52,8/3/2020
8F6995,earnings,100,50,8/3/2020
900356,conference-call,100,50,8/3/2020
905356,conference-call,100,50,8/3/2020
92D757,partnership,100,61,8/3/2020
9368BE,earnings,100,50,8/3/2020
947B0B,earnings,100,50,8/3/2020
94983E,earnings,100,50,8/3/2020
9546A5,conference-call,100,50,8/3/2020
957A07,earnings,100,50,8/3/2020
95DC1F,partnership,100,61,8/3/2020
968103,earnings,100,50,8/3/2020
968966,business-contract,100,69,8/3/2020
968966,dividend,100,50,8/3/2020
968B00,earnings-negative,100,33,8/3/2020
968B00,earnings-negative,100,33,8/3/2020
96A6CD,earnings,100,50,8/3/2020
972356,partnership,100,61,8/3/2020
97644E,partnership,100,61,8/3/2020
979451,earnings,100,50,8/3/2020
98CEBB,earnings,100,50,8/3/2020
98D33E,earnings,100,50,8/3/2020
9A2760,unit-acquisition-completed-acquirer,100,49,8/3/2020
9ABD30,executive-appointment,100,54,8/3/2020
9B71A7,facility-close,100,47,8/3/2020
9C5BA5,earnings,100,50,8/3/2020
9D4EC7,earnings,100,50,8/3/2020
9D4EC7,earnings,100,50,8/3/2020
9D4EC7,earnings,100,50,8/3/2020
9D4EC7,earnings,100,50,8/3/2020
9F5997,conference-participant,100,50,8/3/2020
9FB4B7,earnings,100,50,8/3/2020
A01664,earnings,100,50,8/3/2020
A1BB98,earnings,100,50,8/3/2020
A28675,earnings,100,50,8/3/2020
A3800A,earnings,100,50,8/3/2020
A5195E,fast-track-designation,100,81,8/3/2020
A6213D,product-release,100,64,8/3/2020
A63387,business-contract,100,69,8/3/2020
A7F0A5,earnings,100,50,8/3/2020
A8FDE8,earnings,100,50,8/3/2020
A8FDE8,earnings,100,50,8/3/2020
A8FDE8,dividend,100,50,8/3/2020
AC3584,earnings,100,50,8/3/2020
AD1ACF,earnings,100,50,8/3/2020
AD1ACF,earnings,100,50,8/3/2020
AD1ACF,earnings,100,50,8/3/2020
AD1ACF,earnings,100,50,8/3/2020
AD1ACF,earnings,100,50,8/3/2020
AD1ACF,executive-appointment,100,54,8/3/2020
AD23DE,product-release,100,64,8/3/2020
AE79CD,earnings,100,50,8/3/2020
AED6CF,earnings,100,50,8/3/2020
AEEB76,partnership,100,61,8/3/2020
AEF2C3,partnership,100,61,8/3/2020
B01111,earnings,100,50,8/3/2020
B09B1F,conference-participant,100,50,8/3/2020
B0FE08,earnings-up,100,68,8/3/2020
B0FE08,earnings-up,100,68,8/3/2020
B0FE08,earnings-up,100,68,8/3/2020
B0FE08,earnings-up,100,68,8/3/2020
B2D492,earnings,100,50,8/3/2020
B5DE80,earnings,100,50,8/3/2020
B7BBFF,earnings,100,50,8/3/2020
B83BCE,acquisition-completed-acquirer,100,49,8/3/2020
B9BDE8,earnings,100,50,8/3/2020
BB0787,product-release,100,64,8/3/2020
BB58FF,earnings,100,50,8/3/2020
BC4876,earnings,100,50,8/3/2020
BD8517,conference-participant,100,50,8/3/2020
BE7BA4,earnings,100,50,8/3/2020
BE7BA4,executive-appointment,100,54,8/3/2020
C037A8,executive-appointment,100,54,8/3/2020
C0F70B,earnings,100,50,8/3/2020
C188F8,product-release,100,64,8/3/2020
C2DD02,conference-call,100,50,8/3/2020
C3EE99,partnership,100,61,8/3/2020
C45C1F,business-contract,100,69,8/3/2020
C4706C,award,100,58,8/3/2020
C48574,conference-participant,100,50,8/3/2020
C58D71,earnings,100,50,8/3/2020
C74887,conference-participant,100,50,8/3/2020
C941DC,public-offering,100,43,8/3/2020
C9C62A,executive-appointment,100,54,8/3/2020
CDAB24,conference-call,100,50,8/3/2020
CDC817,executive-appointment,100,54,8/3/2020
CDD75E,conference-call,100,50,8/3/2020
CF3FF9,earnings,100,50,8/3/2020
D03C7A,public-offering,100,43,8/3/2020
D06996,earnings,100,50,8/3/2020
D11C1C,conference-call,100,50,8/3/2020
D15833,conference-call,100,50,8/3/2020
D15833,conference-call,100,50,8/3/2020
D2B9E5,earnings,100,50,8/3/2020
D2B9E5,earnings,100,50,8/3/2020
D2B9E5,earnings,100,50,8/3/2020
D4070C,earnings,100,50,8/3/2020
D57D99,earnings,100,50,8/3/2020
D63B0F,conference-call,100,50,8/3/2020
D78CCD,executive-appointment,100,54,8/3/2020
D9E036,earnings-up,100,68,8/3/2020
D9E036,earnings,100,50,8/3/2020
DA91AE,earnings,100,50,8/3/2020
DBFB51,dividend-up,100,81,8/3/2020
DBFB51,earnings,100,50,8/3/2020
DC0D18,earnings,100,50,8/3/2020
DC0D18,earnings,100,50,8/3/2020
DC0D18,earnings,100,50,8/3/2020
DC0D18,earnings,100,50,8/3/2020
DC0D18,earnings,100,50,8/3/2020
DD9E41,earnings,100,50,8/3/2020
DD9E41,earnings,100,50,8/3/2020
DD9E41,earnings,100,50,8/3/2020
DD9E41,earnings,100,50,8/3/2020
DD9E41,earnings,100,50,8/3/2020
DD9E41,earnings,100,50,8/3/2020
DDB002,acquisition-acquirer,100,49,8/3/2020
DF6FDD,executive-appointment,100,54,8/3/2020
E06265,conference-call,100,50,8/3/2020
E074A0,earnings,100,50,8/3/2020
E07573,earnings,100,50,8/3/2020
E07573,earnings,100,50,8/3/2020
E07573,earnings,100,50,8/3/2020
E15736,earnings,100,50,8/3/2020
E15736,earnings,100,50,8/3/2020
E1E093,partnership,100,61,8/3/2020
E21871,earnings,100,50,8/3/2020
E28D9C,joint-venture,100,62,8/3/2020
E49AA3,acquisition-acquirer,100,49,8/3/2020
E61888,conference-call,100,50,8/3/2020
E68C3D,partnership,100,61,8/3/2020
E71AE6,conference-participant,100,50,8/3/2020
E7BF32,earnings,100,50,8/3/2020
E7BF32,earnings,100,50,8/3/2020
E8846E,legal-issues-defendant,100,22,8/3/2020
E8E899,executive-appointment,100,54,8/3/2020
E96E0B,earnings,100,50,8/3/2020
EA62FC,earnings,100,50,8/3/2020
EA79C7,earnings,100,50,8/3/2020
ED1A74,business-contract,100,69,8/3/2020
ED1A74,business-contract,100,69,8/3/2020
ED5171,dividend,100,50,8/3/2020
ED7F13,earnings,100,50,8/3/2020
EE04F0,earnings,100,50,8/3/2020
EE04F0,earnings,100,50,8/3/2020
EE04F0,earnings,100,50,8/3/2020
EE04F0,earnings,100,50,8/3/2020
EEA734,earnings,100,50,8/3/2020
EEEA9F,earnings,100,50,8/3/2020
EEEA9F,earnings,100,50,8/3/2020
EF5BED,executive-appointment,100,54,8/3/2020
F05B1B,orphan-drug-designation,100,76,8/3/2020
F0B335,earnings,100,50,8/3/2020
F1529C,conference-participant,100,50,8/3/2020
F32F88,earnings,100,50,8/3/2020
F3816D,conference-participant,100,50,8/3/2020
F3816D,executive-appointment,100,54,8/3/2020
F44EA2,earnings,100,50,8/3/2020
F702CA,acquisition-acquirer,100,49,8/3/2020
F88147,earnings,100,50,8/3/2020
F9AA02,earnings,100,50,8/3/2020
FF4343,partnership,100,61,8/3/2020
01D03F,partnership,100,61,8/4/2020
033B58,earnings,100,50,8/4/2020
03596A,earnings,100,50,8/4/2020
03B431,earnings,100,50,8/4/2020
03D5F9,partnership,100,61,8/4/2020
03FB17,earnings,100,50,8/4/2020
48590,earnings-up,100,68,8/4/2020
06EE79,earnings,100,50,8/4/2020
09062E,earnings,100,50,8/4/2020
09062E,earnings,100,50,8/4/2020
0A77DB,partnership,100,61,8/4/2020
0AD2E3,earnings,100,50,8/4/2020
0AD2E3,earnings,100,50,8/4/2020
0B400D,earnings,100,50,8/4/2020
0B400D,earnings,100,50,8/4/2020
0B400D,earnings,100,50,8/4/2020
0B7375,conference-participant,100,50,8/4/2020
0C6293,conference-call,100,50,8/4/2020
0E499E,regulatory-product-approval-granted,100,81,8/4/2020
0F65C9,earnings,100,50,8/4/2020
0F65C9,dividend,100,50,8/4/2020
0FABBD,earnings,100,50,8/4/2020
0FABBD,earnings,100,50,8/4/2020
0FABBD,earnings,100,50,8/4/2020
0FABBD,earnings,100,50,8/4/2020
0FABBD,earnings,100,50,8/4/2020
0FABBD,earnings,100,50,8/4/2020
0FE3A6,conference-call,100,50,8/4/2020
1080C0,conference-participant,100,50,8/4/2020
11074E,earnings,100,50,8/4/2020
129DC8,earnings,100,50,8/4/2020
129DC8,earnings,100,50,8/4/2020
129DC8,earnings,100,50,8/4/2020
133644,conference-participant,100,50,8/4/2020
135B09,earnings-up,100,83,8/4/2020
14BA06,operating-earnings,100,50,8/4/2020
152AB9,earnings,100,50,8/4/2020
152AB9,earnings,100,50,8/4/2020
152E1D,operating-earnings,100,50,8/4/2020
152E1D,operating-earnings,100,50,8/4/2020
152E1D,operating-earnings,100,50,8/4/2020
152E1D,operating-earnings,100,50,8/4/2020
152E1D,operating-earnings,100,50,8/4/2020
152E1D,operating-earnings,100,50,8/4/2020
152E1D,operating-earnings,100,50,8/4/2020
154272,fraud,100,44,8/4/2020
157CC1,earnings,100,50,8/4/2020
17EDA5,legal-issues-defendant,100,22,8/4/2020
17EDA5,legal-issues-defendant,100,22,8/4/2020
1834C0,earnings,100,50,8/4/2020
1834C0,partnership,100,61,8/4/2020
188394,earnings-guidance-up,100,83,8/4/2020
188394,earnings-guidance-up,100,83,8/4/2020
188394,earnings-guidance-up,100,83,8/4/2020
188394,earnings-guidance-up,100,83,8/4/2020
1A5D5D,earnings,100,50,8/4/2020
1B16C1,earnings,100,50,8/4/2020
1CDD1C,earnings,100,50,8/4/2020
1DA44F,note-sale,100,52,8/4/2020
1DA44F,note-sale,100,52,8/4/2020
1DB833,conference-participant,100,50,8/4/2020
1E04A5,earnings,100,50,8/4/2020
1E68B3,earnings,100,50,8/4/2020
1EBF8D,business-contract,100,69,8/4/2020
21F9CA,revenues,100,50,8/4/2020
225CA2,note-sale,100,52,8/4/2020
228D42,partnership,100,61,8/4/2020
2571FA,earnings,100,50,8/4/2020
2571FA,earnings,100,50,8/4/2020
2571FA,earnings,100,50,8/4/2020
2571FA,earnings,100,50,8/4/2020
28B730,earnings,100,50,8/4/2020
28F905,earnings,100,50,8/4/2020
2920D5,earnings,100,50,8/4/2020
292388,earnings,100,50,8/4/2020
292388,earnings,100,50,8/4/2020
292388,earnings,100,50,8/4/2020
292388,earnings,100,50,8/4/2020
295F9F,earnings,100,50,8/4/2020
2A1009,note-sale,100,52,8/4/2020
2ABF77,earnings,100,50,8/4/2020
2ABF77,earnings,100,50,8/4/2020
2C681C,clinical-trials-positive,100,87,8/4/2020
2C681C,clinical-trials-positive,100,87,8/4/2020
2E0496,earnings,100,50,8/4/2020
2E0496,earnings,100,50,8/4/2020
2E61CC,partnership,100,61,8/4/2020
2E61CC,partnership,100,61,8/4/2020
2F1299,earnings,100,50,8/4/2020
2F1299,earnings,100,50,8/4/2020
2F1299,earnings,100,50,8/4/2020
2F1299,earnings,100,50,8/4/2020
2F1299,earnings,100,50,8/4/2020
2F1299,earnings,100,50,8/4/2020
2F1299,earnings,100,50,8/4/2020
2F1299,earnings,100,50,8/4/2020
2F6782,earnings,100,50,8/4/2020
2F9304,earnings,100,50,8/4/2020
2F98A5,earnings,100,50,8/4/2020
31DB20,earnings,100,50,8/4/2020
3224CC,public-offering,100,43,8/4/2020
32C8CD,earnings,100,50,8/4/2020
32F24A,earnings,100,50,8/4/2020
337024,earnings,100,50,8/4/2020
337024,earnings,100,50,8/4/2020
337024,earnings,100,50,8/4/2020
337024,earnings,100,50,8/4/2020
343996,earnings,100,50,8/4/2020
343996,earnings,100,50,8/4/2020
346BF2,earnings,100,50,8/4/2020
35F4B5,earnings,100,50,8/4/2020
35F4B5,earnings,100,50,8/4/2020
36A1CB,earnings,100,50,8/4/2020
36A1CB,earnings,100,50,8/4/2020
36E479,earnings,100,50,8/4/2020
371B0A,board-meeting,100,51,8/4/2020
3798B9,partnership,100,61,8/4/2020
3798B9,partnership-terminated,100,36,8/4/2020
389CFB,earnings,100,50,8/4/2020
38C46F,dividend,100,50,8/4/2020
396D7C,conference-participant,100,50,8/4/2020
3A1C46,earnings,100,50,8/4/2020
3BE00F,earnings,100,50,8/4/2020
3BE00F,earnings,100,50,8/4/2020
3BE00F,earnings,100,50,8/4/2020
3BE00F,earnings,100,50,8/4/2020
3C6CCC,earnings,100,50,8/4/2020
3C6CCC,earnings,100,50,8/4/2020
3C6CCC,earnings,100,50,8/4/2020
3C6CCC,earnings,100,50,8/4/2020
3C6CCC,earnings,100,50,8/4/2020
3D7971,dividend,100,50,8/4/2020
3DC887,earnings,100,50,8/4/2020
3E70FC,earnings,100,50,8/4/2020
4.03E+05,earnings-guidance-up,100,83,8/4/2020
4.03E+05,earnings,100,50,8/4/2020
4.03E+05,earnings,100,50,8/4/2020
4.03E+05,earnings,100,50,8/4/2020
4.03E+05,dividend,100,50,8/4/2020
4.00E+163,earnings,100,50,8/4/2020
40F7DE,conference-call,100,50,8/4/2020
429BFB,earnings,100,50,8/4/2020
4398A2,earnings,100,50,8/4/2020
45444E,earnings,100,50,8/4/2020
46A16E,earnings,100,50,8/4/2020
49BBBC,executive-appointment,100,54,8/4/2020
4A2457,earnings,100,50,8/4/2020
4A6F00,partnership,100,61,8/4/2020
4BDCA7,earnings,100,50,8/4/2020
4C31F3,conference-call,100,50,8/4/2020
4CDA2B,conference-participant,100,50,8/4/2020
4E7C1F,legal-issues-defendant,100,22,8/4/2020
4F783B,earnings,100,50,8/4/2020
4F783B,earnings,100,50,8/4/2020
4F783B,earnings,100,50,8/4/2020
4F783B,earnings,100,50,8/4/2020
4F783B,earnings,100,50,8/4/2020
4FB770,earnings,100,50,8/4/2020
504FE2,earnings,100,50,8/4/2020
50D1EC,partnership,100,61,8/4/2020
51B442,earnings,100,50,8/4/2020
53EF9E,dividend,100,50,8/4/2020
543C77,executive-appointment,100,54,8/4/2020
5487B1,legal-issues-defendant,100,22,8/4/2020
54A713,earnings,100,50,8/4/2020
54B889,earnings,100,50,8/4/2020
54F1D2,earnings,100,50,8/4/2020
550D01,earnings,100,50,8/4/2020
550D01,earnings,100,50,8/4/2020
550D01,earnings,100,50,8/4/2020
56277A,earnings,100,50,8/4/2020
56FB7C,earnings,100,50,8/4/2020
577033,earnings,100,50,8/4/2020
57B174,earnings,100,50,8/4/2020
57B174,earnings,100,50,8/4/2020
57B174,earnings,100,50,8/4/2020
57B174,earnings,100,50,8/4/2020
57DDB9,rights-issue,100,43,8/4/2020
57EF50,earnings,100,50,8/4/2020
57EF50,earnings,100,50,8/4/2020
57EF50,earnings,100,50,8/4/2020
583223,earnings,100,50,8/4/2020
583223,note-sale,100,52,8/4/2020
583223,note-sale,100,52,8/4/2020
5876DC,earnings,100,50,8/4/2020
587EDF,earnings,100,50,8/4/2020
58B46F,executive-appointment,100,54,8/4/2020
58C2D4,earnings,100,50,8/4/2020
59A832,earnings,100,50,8/4/2020
59DB8C,partnership,100,61,8/4/2020
5A53BF,earnings,100,50,8/4/2020
5A9F54,fundraising,100,64,8/4/2020
5B15E1,earnings,100,50,8/4/2020
5B6C11,dividend,100,50,8/4/2020
5E1DF3,earnings-up,100,68,8/4/2020
5EAA43,earnings,100,50,8/4/2020
5EAA43,note-sale,100,52,8/4/2020
619882,conference-organizer,100,57,8/4/2020
622DBE,earnings,100,50,8/4/2020
62CDDE,earnings,100,50,8/4/2020
636BBF,executive-appointment,100,54,8/4/2020
64E615,earnings,100,50,8/4/2020
64E615,earnings,100,50,8/4/2020
64E615,earnings,100,50,8/4/2020
64E615,earnings,100,50,8/4/2020
64E615,earnings,100,50,8/4/2020
6.52E+64,product-release,100,64,8/4/2020
65CF8E,earnings,100,50,8/4/2020
65CF8E,earnings,100,50,8/4/2020
6634D9,earnings,100,50,8/4/2020
676FFD,earnings,100,50,8/4/2020
68BA15,earnings,100,50,8/4/2020
6B236C,earnings,100,50,8/4/2020
6BDA0C,dividend-up,100,81,8/4/2020
6CC55E,earnings,100,50,8/4/2020
6CDFC6,product-release,100,64,8/4/2020
6DDA15,earnings,100,50,8/4/2020
6DDA15,earnings,100,50,8/4/2020
6DDA15,earnings,100,50,8/4/2020
6DDA15,earnings,100,50,8/4/2020
6DDA15,earnings,100,50,8/4/2020
6DDA15,earnings,100,50,8/4/2020
6-Dec-05,earnings,100,50,8/4/2020
704B78,earnings,100,50,8/4/2020
70CA28,conference-participant,100,50,8/4/2020
713810,partnership,100,61,8/4/2020
722DE3,earnings,100,50,8/4/2020
7273FF,product-release,100,64,8/4/2020
732A9B,earnings,100,50,8/4/2020
747219,dividend,100,50,8/4/2020
752A70,earnings,100,50,8/4/2020
767F86,business-contract,100,69,8/4/2020
77B8E9,conference-participant,100,50,8/4/2020
787D14,earnings,100,50,8/4/2020
7A3633,earnings,100,50,8/4/2020
7B0BA6,earnings,100,50,8/4/2020
7B0BA6,earnings,100,50,8/4/2020
7B0BA6,earnings,100,50,8/4/2020
7B0BA6,earnings,100,50,8/4/2020
7B0BA6,earnings,100,50,8/4/2020
7B492C,conference-call,100,50,8/4/2020
7B6EB1,earnings,100,50,8/4/2020
7BC92D,conference-participant,100,50,8/4/2020
7BFF81,earnings-positive,100,69,8/4/2020
7BFF81,earnings,100,50,8/4/2020
7BFF81,earnings,100,50,8/4/2020
7BFF81,earnings,100,50,8/4/2020
7F3A5F,note-sale,100,52,8/4/2020
7F9984,earnings,100,50,8/4/2020
7F9BE2,dividend,100,50,8/4/2020
7FDE1C,conference-call,100,50,8/4/2020
805CD8,conference-participant,100,50,8/4/2020
810FAD,conference-participant,100,50,8/4/2020
82B57E,earnings,100,50,8/4/2020
82F088,earnings,100,50,8/4/2020
830BDB,revenue-up,100,61,8/4/2020
85DE00,earnings,100,50,8/4/2020
85DE00,dividend,100,50,8/4/2020
8665BA,acquisition-interest-acquirer,100,46,8/4/2020
86F123,earnings,100,50,8/4/2020
877734,earnings,100,50,8/4/2020
877734,earnings,100,50,8/4/2020
877734,earnings,100,50,8/4/2020
877734,earnings,100,50,8/4/2020
88193E,earnings,100,50,8/4/2020
895D56,earnings,100,50,8/4/2020
8AB85C,conference-participant,100,50,8/4/2020
8AC740,earnings,100,50,8/4/2020
8D4486,partnership,100,61,8/4/2020
8D4AE6,dividend,100,50,8/4/2020
8D5145,dividend,100,50,8/4/2020
8DA42F,executive-appointment,100,54,8/4/2020
8DCF18,conference-participant,100,50,8/4/2020
8E3F58,earnings-up,100,68,8/4/2020
8E3F58,earnings,100,50,8/4/2020
8E4F9A,operating-earnings,100,50,8/4/2020
8EEA28,earnings,100,50,8/4/2020
902255,earnings,100,50,8/4/2020
902255,earnings,100,50,8/4/2020
902255,earnings,100,50,8/4/2020
902255,earnings,100,50,8/4/2020
915E7B,earnings,100,50,8/4/2020
91E5EE,earnings,100,50,8/4/2020
91E5EE,executive-resignation,100,44,8/4/2020
92005C,note-sale,100,52,8/4/2020
92D230,conference-call,100,50,8/4/2020
9.65E+07,conference-call,100,50,8/4/2020
968966,partnership,100,61,8/4/2020
968B00,dividend,100,50,8/4/2020
968B00,note-sale,100,52,8/4/2020
96B4FF,conference-participant,100,50,8/4/2020
96BFF4,legal-issues-defendant,100,22,8/4/2020
97AF94,earnings,100,50,8/4/2020
9.86E+03,earnings,100,50,8/4/2020
994468,dividend,100,50,8/4/2020
99B61C,executive-appointment,100,54,8/4/2020
99DC8D,dividend,100,50,8/4/2020
99DC8D,earnings,100,50,8/4/2020
9B730A,clinical-trials-positive,100,87,8/4/2020
9BB35A,operating-earnings-positive,100,69,8/4/2020
9BB35A,earnings-per-share,100,50,8/4/2020
9BB35A,earnings-per-share,100,50,8/4/2020
9BB35A,earnings-per-share,100,50,8/4/2020
9BB35A,earnings-per-share,100,50,8/4/2020
9CA432,earnings,100,50,8/4/2020
9D307D,product-release,100,64,8/4/2020
9D6A24,earnings,100,50,8/4/2020
9D6A24,earnings,100,50,8/4/2020
9E0811,earnings,100,50,8/4/2020
9E91C6,earnings,100,50,8/4/2020
9EA947,earnings,100,50,8/4/2020
9EF4CF,earnings,100,50,8/4/2020
9F18FA,earnings,100,50,8/4/2020
9F18FA,earnings,100,50,8/4/2020
9FF5F1,earnings,100,50,8/4/2020
A16DEA,earnings,100,50,8/4/2020
A16DEA,earnings,100,50,8/4/2020
A16DEA,earnings,100,50,8/4/2020
A16DEA,earnings,100,50,8/4/2020
A16DEA,earnings,100,50,8/4/2020
A16DEA,earnings,100,50,8/4/2020
A16DEA,earnings,100,50,8/4/2020
A16DEA,earnings,100,50,8/4/2020
A16DEA,earnings,100,50,8/4/2020
A1EAC8,dividend,100,50,8/4/2020
A23747,earnings,100,50,8/4/2020
A3230E,conference-call,100,50,8/4/2020
A41450,earnings,100,50,8/4/2020
A4386C,dividend,100,50,8/4/2020
A4386C,earnings,100,50,8/4/2020
A4CD53,earnings,100,50,8/4/2020
A4CD53,earnings,100,50,8/4/2020
A4CD53,earnings,100,50,8/4/2020
A52B6B,earnings,100,50,8/4/2020
A5DD24,earnings,100,50,8/4/2020
A60354,earnings,100,50,8/4/2020
A60354,earnings,100,50,8/4/2020
A60354,earnings,100,50,8/4/2020
A60354,earnings,100,50,8/4/2020
A6213D,conference-call,100,50,8/4/2020
A6213D,executive-resignation,100,44,8/4/2020
A63387,dividend,100,50,8/4/2020
A6828A,business-contract,100,69,8/4/2020
A6FC89,conference-participant,100,50,8/4/2020
A7102F,earnings,100,50,8/4/2020
A74F6F,revenues,100,50,8/4/2020
A74F6F,revenues,100,50,8/4/2020
A868C9,revenue-up,100,61,8/4/2020
A868C9,revenue-up,100,61,8/4/2020
A868C9,revenue-up,100,61,8/4/2020
A94718,earnings,100,50,8/4/2020
AA3AB8,earnings,100,50,8/4/2020
ABEE43,executive-appointment,100,54,8/4/2020
AC3584,partnership,100,61,8/4/2020
AC775C,earnings,100,50,8/4/2020
AC775C,earnings,100,50,8/4/2020
AC775C,earnings,100,50,8/4/2020
AC775C,earnings,100,50,8/4/2020
ACC7D3,orphan-drug-designation,100,76,8/4/2020
ACDF88,conference-call,100,50,8/4/2020
ACDF88,facility-open,100,65,8/4/2020
AD6141,earnings,100,50,8/4/2020
AD9F1D,legal-issues-defendant,100,22,8/4/2020
AE3113,executive-appointment,100,54,8/4/2020
AE3113,earnings,100,50,8/4/2020
AFEC35,executive-appointment,100,54,8/4/2020
B08C51,earnings,100,50,8/4/2020
B0D41A,conference-participant,100,50,8/4/2020
B303A6,award,100,58,8/4/2020
B303A6,earnings,100,50,8/4/2020
B303A6,earnings,100,50,8/4/2020
B303A6,earnings,100,50,8/4/2020
B303A6,earnings,100,50,8/4/2020
B303A6,legal-issues-defendant,100,22,8/4/2020
B381D8,earnings,100,50,8/4/2020
B3A166,conference-call,100,50,8/4/2020
B3CB74,executive-appointment,100,54,8/4/2020
B3ED62,fraud,100,44,8/4/2020
B446B8,conference-call,100,50,8/4/2020
B48FC9,revenues,100,50,8/4/2020
B48FC9,revenues,100,50,8/4/2020
B48FC9,revenues,100,50,8/4/2020
B53C12,earnings,100,50,8/4/2020
B54A74,earnings,100,50,8/4/2020
B5767B,earnings,100,50,8/4/2020
B5767B,earnings,100,50,8/4/2020
B5767B,earnings,100,50,8/4/2020
B5767B,earnings,100,50,8/4/2020
B5767B,earnings,100,50,8/4/2020
B5767B,earnings,100,50,8/4/2020
B60366,ipo-completed,100,76,8/4/2020
B80AD1,conference-participant,100,50,8/4/2020
B8A51F,earnings,100,50,8/4/2020
B8F71F,dividend,100,50,8/4/2020
B98EFA,earnings-up,100,68,8/4/2020
B98EFA,earnings,100,50,8/4/2020
B98EFA,earnings,100,50,8/4/2020
B98EFA,earnings,100,50,8/4/2020
BB0587,earnings,100,50,8/4/2020
BB127B,conference-call,100,50,8/4/2020
BBC05B,operating-earnings,100,50,8/4/2020
BCE9DA,earnings,100,50,8/4/2020
BCE9DA,earnings,100,50,8/4/2020
BDA775,earnings,100,50,8/4/2020
BDEC1E,conference-call,100,50,8/4/2020
BFD0A7,facility-open,100,65,8/4/2020
BFEA04,earnings,100,50,8/4/2020
BFEA04,earnings,100,50,8/4/2020
BFEA04,earnings,100,50,8/4/2020
BFEA04,earnings,100,50,8/4/2020
C11C46,earnings,100,50,8/4/2020
C15F8F,earnings,100,50,8/4/2020
C2E39B,earnings,100,50,8/4/2020
C2E39B,earnings,100,50,8/4/2020
C2E39B,earnings,100,50,8/4/2020
C2E39B,earnings,100,50,8/4/2020
C36189,conference-participant,100,50,8/4/2020
C3BAE7,legal-issues-defendant,100,22,8/4/2020
C3BAE7,fraud,100,44,8/4/2020
C3DE7D,earnings,100,50,8/4/2020
C3EE99,award,100,58,8/4/2020
C3F99F,earnings,100,50,8/4/2020
C407A0,executive-appointment,100,54,8/4/2020
C4A912,earnings,100,50,8/4/2020
C4A912,earnings,100,50,8/4/2020
C4A912,earnings,100,50,8/4/2020
C54140,earnings,100,50,8/4/2020
C564E4,conference-participant,100,50,8/4/2020
C5C0E9,earnings,100,50,8/4/2020
C5D2AE,partnership,100,61,8/4/2020
C7AE14,earnings,100,50,8/4/2020
C8257F,executive-appointment,100,54,8/4/2020
C83B88,partnership-terminated,100,36,8/4/2020
C8923A,earnings-up,100,68,8/4/2020
C941DC,public-offering,100,43,8/4/2020
C99CC8,earnings,100,50,8/4/2020
C99CC8,earnings,100,50,8/4/2020
C99CC8,earnings,100,50,8/4/2020
C99CC8,earnings,100,50,8/4/2020
C99CC8,earnings,100,50,8/4/2020
CB22CD,earnings,100,50,8/4/2020
CB7AB2,earnings,100,50,8/4/2020
CBBFBF,earnings,100,50,8/4/2020
CDC817,executive-appointment,100,54,8/4/2020
CDC817,earnings,100,50,8/4/2020
CDFCC9,product-release,100,64,8/4/2020
CDFCC9,dividend,100,50,8/4/2020
CDFCC9,earnings,100,50,8/4/2020
CDFCC9,earnings,100,50,8/4/2020
CDFCC9,earnings,100,50,8/4/2020
CDFCC9,earnings,100,50,8/4/2020
CE5664,earnings,100,50,8/4/2020
CE5664,earnings,100,50,8/4/2020
CE5664,earnings,100,50,8/4/2020
D03C7A,public-offering,100,43,8/4/2020
D09938,earnings,100,50,8/4/2020
D1173F,earnings,100,50,8/4/2020
D1173F,earnings,100,50,8/4/2020
D1173F,earnings,100,50,8/4/2020
D1173F,earnings,100,50,8/4/2020
D1173F,earnings,100,50,8/4/2020
D15833,earnings,100,50,8/4/2020
D15833,earnings,100,50,8/4/2020
D1588D,conference-participant,100,50,8/4/2020
D3CEDF,earnings,100,50,8/4/2020
D3CEDF,earnings,100,50,8/4/2020
D3CEDF,earnings,100,50,8/4/2020
D3CEDF,earnings,100,50,8/4/2020
D3CEDF,earnings,100,50,8/4/2020
D3CEDF,earnings,100,50,8/4/2020
D3F64D,conference-call,100,50,8/4/2020
D45285,earnings,100,50,8/4/2020
D57D99,dividend,100,50,8/4/2020
D5938F,conference-participant,100,50,8/4/2020
D60BB2,partnership,100,61,8/4/2020
D64EDF,business-contract,100,69,8/4/2020
D69D42,earnings,100,50,8/4/2020
D81463,earnings,100,50,8/4/2020
D81463,earnings,100,50,8/4/2020
D81463,dividend,100,50,8/4/2020
D81463,dividend,100,50,8/4/2020
D82EF3,partnership,100,61,8/4/2020
D82EF3,partnership,100,61,8/4/2020
D9FC89,earnings,100,50,8/4/2020
D9FC89,earnings,100,50,8/4/2020
D9FC89,earnings,100,50,8/4/2020
D9FC89,earnings,100,50,8/4/2020
D9FC89,earnings,100,50,8/4/2020
DAFED3,earnings,100,50,8/4/2020
DAFED3,earnings,100,50,8/4/2020
DAFED3,earnings,100,50,8/4/2020
DAFED3,earnings,100,50,8/4/2020
DC1405,earnings,100,50,8/4/2020
DC486E,executive-appointment,100,54,8/4/2020
DC486E,executive-appointment,100,54,8/4/2020
DD0F15,conference-participant,100,50,8/4/2020
DD682D,earnings,100,50,8/4/2020
DF204B,earnings,100,50,8/4/2020
DF8855,earnings,100,50,8/4/2020
E06265,legal-issues-defendant,100,22,8/4/2020
E114F4,executive-appointment,100,54,8/4/2020
E114F4,earnings,100,50,8/4/2020
E114F4,earnings,100,50,8/4/2020
E114F4,earnings,100,50,8/4/2020
E114F4,earnings,100,50,8/4/2020
E13782,earnings,100,50,8/4/2020
E1BD05,business-contract,100,69,8/4/2020
E38906,earnings,100,50,8/4/2020
E592F0,product-release,100,64,8/4/2020
E5D914,earnings,100,50,8/4/2020
E5D914,earnings,100,50,8/4/2020
E5D914,earnings,100,50,8/4/2020
E5D914,earnings,100,50,8/4/2020
E69BA5,earnings,100,50,8/4/2020
E6C8DC,earnings,100,50,8/4/2020
E8E899,business-contract,100,69,8/4/2020
EB1E1A,conference-participant,100,50,8/4/2020
EC1AF3,earnings,100,50,8/4/2020
ED3CA8,facility-open,100,65,8/4/2020
EF5BED,earnings,100,50,8/4/2020
F1529C,acquisition-completed-acquirer,100,49,8/4/2020
F179ED,earnings,100,50,8/4/2020
F179ED,earnings,100,50,8/4/2020
F179ED,earnings,100,50,8/4/2020
F179ED,earnings,100,50,8/4/2020
F3016C,earnings,100,50,8/4/2020
F3016C,earnings,100,50,8/4/2020
F3016C,earnings,100,50,8/4/2020
F3016C,earnings,100,50,8/4/2020
F39E1E,earnings,100,50,8/4/2020
F47871,earnings,100,50,8/4/2020
F48947,earnings,100,50,8/4/2020
F4D241,conference-participant,100,50,8/4/2020
F4E992,public-offering,100,43,8/4/2020
F57F6F,earnings,100,50,8/4/2020
F58C23,conference-participant,100,50,8/4/2020
F5C8AB,earnings-per-share-positive,100,69,8/4/2020
F5C8AB,earnings-per-share,100,50,8/4/2020
F5C8AB,earnings-per-share,100,50,8/4/2020
F5C8AB,earnings-per-share,100,50,8/4/2020
F6A987,earnings-up,100,68,8/4/2020
F85CC0,earnings,100,50,8/4/2020
F85CC0,earnings,100,50,8/4/2020
F8C5D7,operating-earnings,100,50,8/4/2020
F90EE5,earnings,100,50,8/4/2020
FAAFA2,earnings,100,50,8/4/2020
FB7724,earnings,100,50,8/4/2020
FC1A6E,earnings,100,50,8/4/2020
FC4550,dividend,100,50,8/4/2020
FC80E6,earnings,100,50,8/4/2020
FDD3FC,earnings,100,50,8/4/2020
FDF28E,earnings,100,50,8/4/2020
FDF799,earnings,100,50,8/4/2020
FDF799,earnings,100,50,8/4/2020
FDF799,earnings,100,50,8/4/2020
FEC475,earnings,100,50,8/4/2020
FF227B,conference-participant,100,50,8/4/2020
00067A,earnings,100,50,8/5/2020
00E601,operating-earnings,100,50,8/5/2020
01B8D6,earnings,100,50,8/5/2020
02FC1A,earnings,100,50,8/5/2020
02FC1A,earnings,100,50,8/5/2020
02FC1A,earnings,100,50,8/5/2020
0358AF,revenue-up,100,69,8/5/2020
03B8CF,acquisition-acquiree,100,76,8/5/2020
03B8CF,business-contract,100,69,8/5/2020
03D5F9,earnings,100,50,8/5/2020
48590,note-sale,100,52,8/5/2020
048B70,earnings,100,50,8/5/2020
048B70,earnings,100,50,8/5/2020
048B70,earnings,100,50,8/5/2020
048B70,earnings,100,50,8/5/2020
053EFF,earnings,100,50,8/5/2020
054B55,earnings,100,50,8/5/2020
0560D8,earnings,100,50,8/5/2020
0560D8,earnings,100,50,8/5/2020
05D148,clinical-trials,100,56,8/5/2020
05D148,clinical-trials,100,56,8/5/2020
06C826,earnings,100,50,8/5/2020
0919B1,earnings,100,50,8/5/2020
095A04,earnings,100,50,8/5/2020
98977,earnings,100,50,8/5/2020
0A0D9E,earnings,100,50,8/5/2020
0A0D9E,earnings,100,50,8/5/2020
0A0D9E,earnings,100,50,8/5/2020
0A1D77,executive-appointment,100,54,8/5/2020
0A6824,earnings,100,50,8/5/2020
0A748B,earnings,100,50,8/5/2020
0A9D0A,earnings,100,50,8/5/2020
0BA8CE,earnings,100,50,8/5/2020
0C2A0D,conference-participant,100,50,8/5/2020
0CADBC,earnings,100,50,8/5/2020
0CC62B,earnings,100,50,8/5/2020
0CC62B,earnings,100,50,8/5/2020
0CC62B,earnings,100,50,8/5/2020
0CC62B,earnings,100,50,8/5/2020
0CC62B,earnings,100,50,8/5/2020
0CC62B,earnings,100,50,8/5/2020
0CC62B,earnings,100,50,8/5/2020
0CCCB7,dividend,100,50,8/5/2020
0CCCB7,earnings,100,50,8/5/2020
0DE3D5,earnings,100,50,8/5/2020
0DE3D5,earnings,100,50,8/5/2020
0DE3D5,earnings,100,50,8/5/2020
0DE3D5,earnings,100,50,8/5/2020
0DE3D5,earnings,100,50,8/5/2020
0E439E,dividend,100,50,8/5/2020
0E499E,clinical-trials,100,56,8/5/2020
0E499E,conference-participant,100,50,8/5/2020
0F04E5,conference-participant,100,50,8/5/2020
0F2BC9,earnings-up,100,68,8/5/2020
0F2BC9,earnings-up,100,68,8/5/2020
0F2BC9,earnings-up,100,68,8/5/2020
0FE3A6,earnings,100,50,8/5/2020
11A49E,earnings,100,50,8/5/2020
12731D,earnings,100,50,8/5/2020
12731D,earnings,100,50,8/5/2020
12731D,earnings,100,50,8/5/2020
12731D,earnings,100,50,8/5/2020
12731D,earnings,100,50,8/5/2020
12731D,earnings,100,50,8/5/2020
12731D,earnings,100,50,8/5/2020
136B26,earnings,100,50,8/5/2020
149301,earnings,100,50,8/5/2020
154272,business-contract,100,69,8/5/2020
154272,earnings,100,50,8/5/2020
15B10D,executive-appointment,100,54,8/5/2020
16FC89,earnings,100,50,8/5/2020
17EDA5,partnership,100,61,8/5/2020
190B91,earnings,100,50,8/5/2020
190B91,earnings,100,50,8/5/2020
190B91,earnings,100,50,8/5/2020
190B91,earnings,100,50,8/5/2020
190B91,earnings,100,50,8/5/2020
190B91,earnings,100,50,8/5/2020
190B91,earnings,100,50,8/5/2020
19BF16,earnings-up,100,68,8/5/2020
19BF16,earnings,100,50,8/5/2020
19BF16,earnings,100,50,8/5/2020
19BF16,earnings,100,50,8/5/2020
19BF16,earnings,100,50,8/5/2020
1AB808,earnings,100,50,8/5/2020
1AB808,earnings,100,50,8/5/2020
1B637E,earnings,100,50,8/5/2020
1C599A,earnings,100,50,8/5/2020
1CB9D3,earnings,100,50,8/5/2020
1CD4B5,conference-participant,100,50,8/5/2020
1D943E,earnings,100,50,8/5/2020
1DB6A6,dividend,100,50,8/5/2020
1DB833,earnings,100,50,8/5/2020
1E7785,earnings,100,50,8/5/2020
1E7785,earnings,100,50,8/5/2020
1E7785,earnings,100,50,8/5/2020
1E7785,earnings,100,50,8/5/2020
1E7785,earnings,100,50,8/5/2020
1E7785,earnings,100,50,8/5/2020
1EBF8D,acquisition-completed-acquirer,100,49,8/5/2020
1F19C8,revenue-up,100,69,8/5/2020
1F19C8,revenue-up,100,69,8/5/2020
1F19C8,revenue-up,100,69,8/5/2020
1F19C8,revenue-up,100,69,8/5/2020
1F19C8,revenue-up,100,69,8/5/2020
1F19C8,revenue-up,100,69,8/5/2020
2003A5,earnings,100,50,8/5/2020
200D8B,earnings,100,50,8/5/2020
200D8B,earnings,100,50,8/5/2020
200D8B,earnings,100,50,8/5/2020
2096DE,earnings,100,50,8/5/2020
21245F,earnings,100,50,8/5/2020
2158DF,earnings,100,50,8/5/2020
2158DF,earnings,100,50,8/5/2020
2158DF,earnings,100,50,8/5/2020
2158DF,earnings,100,50,8/5/2020
221783,earnings,100,50,8/5/2020
221783,earnings,100,50,8/5/2020
221783,earnings,100,50,8/5/2020
221783,earnings,100,50,8/5/2020
221783,earnings,100,50,8/5/2020
221783,earnings,100,50,8/5/2020
222BF9,dividend,100,50,8/5/2020
227F04,earnings,100,50,8/5/2020
227F04,acquisition-acquirer,100,49,8/5/2020
249B39,dividend,100,50,8/5/2020
24D81E,facility-open,100,65,8/5/2020
26008A,conference-call,100,50,8/5/2020
263216,earnings,100,50,8/5/2020
27C10F,legal-issues-defendant,100,22,8/5/2020
27C10F,earnings,100,50,8/5/2020
27C10F,earnings,100,50,8/5/2020
27C10F,earnings,100,50,8/5/2020
27C10F,earnings,100,50,8/5/2020
27C10F,earnings,100,50,8/5/2020
2950FF,note-sale,100,52,8/5/2020
2950FF,note-sale,100,52,8/5/2020
2B7A40,dividend,100,50,8/5/2020
2CA60F,public-offering,100,43,8/5/2020
2D485F,earnings,100,50,8/5/2020
2D485F,earnings,100,50,8/5/2020
2D485F,earnings,100,50,8/5/2020
2D485F,earnings,100,50,8/5/2020
2E89AE,earnings,100,50,8/5/2020
2F7A7E,earnings,100,50,8/5/2020
2F960F,earnings,100,50,8/5/2020
30E01D,executive-appointment,100,54,8/5/2020
31643A,earnings,100,50,8/5/2020
3224CC,conference-participant,100,50,8/5/2020
32C8CD,earnings,100,50,8/5/2020
32F943,earnings,100,50,8/5/2020
33A0F1,partnership,100,61,8/5/2020
3461CF,conference-participant,100,50,8/5/2020
35579D,earnings,100,50,8/5/2020
35AE32,earnings,100,50,8/5/2020
35AE32,earnings,100,50,8/5/2020
35AE32,earnings,100,50,8/5/2020
35AE32,earnings,100,50,8/5/2020
39692D,legal-issues-defendant,100,22,8/5/2020
39FB23,partnership,100,61,8/5/2020
3D6933,pretax-earnings-positive,100,69,8/5/2020
3D6933,pretax-earnings-positive,100,69,8/5/2020
3DC887,partnership,100,61,8/5/2020
3DCECC,earnings,100,50,8/5/2020
407878,earnings,100,50,8/5/2020
40B903,earnings,100,50,8/5/2020
4135F7,public-offering,100,43,8/5/2020
434F38,earnings,100,50,8/5/2020
435ACE,earnings,100,50,8/5/2020
444CC8,earnings,100,50,8/5/2020
44740A,earnings,100,50,8/5/2020
447FC6,earnings,100,50,8/5/2020
448215,earnings,100,50,8/5/2020
44ED36,earnings,100,50,8/5/2020
44ED36,earnings,100,50,8/5/2020
44ED36,earnings,100,50,8/5/2020
44ED36,earnings,100,50,8/5/2020
44ED36,earnings,100,50,8/5/2020
468DD4,earnings,100,50,8/5/2020
47FCF2,earnings,100,50,8/5/2020
47FCF2,earnings,100,50,8/5/2020
47FCF2,earnings,100,50,8/5/2020
47FCF2,earnings,100,50,8/5/2020
47FCF2,earnings,100,50,8/5/2020
47FCF2,earnings,100,50,8/5/2020
47FCF2,earnings,100,50,8/5/2020
47FCF2,earnings,100,50,8/5/2020
47FCF2,earnings,100,50,8/5/2020
47FCF2,earnings,100,50,8/5/2020
49BBBC,executive-appointment,100,54,8/5/2020
49CC59,earnings,100,50,8/5/2020
4A6F00,partnership,100,61,8/5/2020
4BDCA7,conference-participant,100,50,8/5/2020
4BEB48,earnings,100,50,8/5/2020
4BEB48,earnings,100,50,8/5/2020
4BEB48,earnings,100,50,8/5/2020
4BEB48,earnings,100,50,8/5/2020
4BEB48,earnings,100,50,8/5/2020
4BF3D6,earnings,100,50,8/5/2020
4C31F3,earnings,100,50,8/5/2020
4C350A,earnings,100,50,8/5/2020
4C350A,earnings,100,50,8/5/2020
4C92B9,earnings,100,50,8/5/2020
4D72C8,earnings,100,50,8/5/2020
4D72C8,earnings,100,50,8/5/2020
4D8124,partnership,100,61,8/5/2020
4D8124,dividend,100,50,8/5/2020
4D8124,executive-appointment,100,54,8/5/2020
4E3D15,operating-earnings,100,50,8/5/2020
4E913D,executive-appointment,100,54,8/5/2020
4EE14A,operating-earnings,100,50,8/5/2020
4EE14A,operating-earnings,100,50,8/5/2020
4FCC78,earnings,100,50,8/5/2020
513A86,earnings,100,50,8/5/2020
514067,earnings,100,50,8/5/2020
5403F8,earnings,100,50,8/5/2020
5.43E+08,conference-participant,100,50,8/5/2020
543C77,conference-participant,100,50,8/5/2020
545272,earnings,100,50,8/5/2020
5487B1,legal-issues-defendant,100,22,8/5/2020
54F271,earnings,100,50,8/5/2020
54F271,earnings,100,50,8/5/2020
54F271,earnings,100,50,8/5/2020
54F271,earnings,100,50,8/5/2020
553949,dividend,100,50,8/5/2020
556F08,earnings,100,50,8/5/2020
567F3D,dividend,100,50,8/5/2020
5704AC,operating-earnings,100,50,8/5/2020
579E8F,executive-appointment,100,54,8/5/2020
57A854,earnings-up,100,68,8/5/2020
57A854,earnings,100,50,8/5/2020
57A854,earnings,100,50,8/5/2020
589803,earnings,100,50,8/5/2020
594402,conference-participant,100,50,8/5/2020
5C7601,earnings,100,50,8/5/2020
5CEE02,earnings,100,50,8/5/2020
5D41E4,earnings,100,50,8/5/2020
5EAA43,note-sale,100,52,8/5/2020
5F1B7B,product-release,100,64,8/5/2020
5F3E74,earnings,100,50,8/5/2020
5F3E74,earnings,100,50,8/5/2020
60EA12,dividend,100,50,8/5/2020
60EA12,earnings-guidance-up,100,83,8/5/2020
60FE03,earnings,100,50,8/5/2020
619882,conference-organizer,100,57,8/5/2020
619882,conference-organizer,100,57,8/5/2020
619882,conference-organizer,100,57,8/5/2020
619882,conference-organizer,100,57,8/5/2020
61E975,earnings-positive,100,69,8/5/2020
62CDDE,conference-participant,100,50,8/5/2020
633043,earnings,100,50,8/5/2020
64854A,earnings,100,50,8/5/2020
657097,earnings,100,50,8/5/2020
665440,earnings,100,50,8/5/2020
66E04A,executive-appointment,100,54,8/5/2020
66ECFD,dividend,100,50,8/5/2020
67303E,earnings,100,50,8/5/2020
6925EB,conference-participant,100,50,8/5/2020
693ECD,earnings,100,50,8/5/2020
693ECD,earnings,100,50,8/5/2020
698FF9,earnings,100,50,8/5/2020
698FF9,dividend,100,50,8/5/2020
69CE71,earnings,100,50,8/5/2020
69CE71,earnings,100,50,8/5/2020
69CE71,earnings,100,50,8/5/2020
69CE71,earnings,100,50,8/5/2020
69CE71,earnings,100,50,8/5/2020
69CE71,earnings,100,50,8/5/2020
69CE71,earnings,100,50,8/5/2020
69CE71,earnings,100,50,8/5/2020
6B0E45,earnings,100,50,8/5/2020
6B6375,earnings,100,50,8/5/2020
6BDA0C,executive-appointment,100,54,8/5/2020
6CBF41,earnings,100,50,8/5/2020
6D3F35,earnings,100,50,8/5/2020
6D3F35,earnings,100,50,8/5/2020
6D3F35,earnings,100,50,8/5/2020
6D3F35,earnings,100,50,8/5/2020
6D3F35,earnings,100,50,8/5/2020
6DBBBC,earnings,100,50,8/5/2020
6DBBBC,earnings,100,50,8/5/2020
6E8864,patient-enrollment-start,100,58,8/5/2020
6ED519,earnings,100,50,8/5/2020
6ED519,earnings,100,50,8/5/2020
6ED519,earnings,100,50,8/5/2020
6F22E7,earnings,100,50,8/5/2020
6F3FA8,earnings,100,50,8/5/2020
6F3FA8,earnings,100,50,8/5/2020
6F3FA8,earnings,100,50,8/5/2020
6F3FA8,earnings,100,50,8/5/2020
6F3FA8,earnings,100,50,8/5/2020
71B0CF,conference-participant,100,50,8/5/2020
71E2EF,earnings,100,50,8/5/2020
723548,earnings,100,50,8/5/2020
7262F2,earnings,100,50,8/5/2020
72C2CE,earnings,100,50,8/5/2020
72FCA3,product-release,100,64,8/5/2020
7410C3,earnings,100,50,8/5/2020
742AAB,partnership,100,61,8/5/2020
7.45E+28,earnings,100,50,8/5/2020
748EB6,conference-participant,100,50,8/5/2020
751C8D,ipo-pricing,100,50,8/5/2020
76959C,earnings,100,50,8/5/2020
769F40,earnings,100,50,8/5/2020
7A2A49,earnings,100,50,8/5/2020
7AB859,partnership,100,61,8/5/2020
7ACD98,acquisition-acquirer,100,49,8/5/2020
7ACD98,earnings-up,100,68,8/5/2020
7B1156,earnings,100,50,8/5/2020
7B8CB5,dividend,100,50,8/5/2020
7BEA98,conference-participant,100,50,8/5/2020
7C4F43,conference-participant,100,50,8/5/2020
7CBC40,executive-resignation,100,44,8/5/2020
7D85A9,earnings,100,50,8/5/2020
7E1D5D,earnings,100,50,8/5/2020
7F9BE2,earnings,100,50,8/5/2020
7FD8B9,earnings,100,50,8/5/2020
7FEEE1,earnings,100,50,8/5/2020
803FED,earnings,100,50,8/5/2020
805CD8,earnings,100,50,8/5/2020
8.10E+32,earnings,100,50,8/5/2020
8.10E+32,earnings,100,50,8/5/2020
8.10E+32,earnings,100,50,8/5/2020
8.10E+32,earnings,100,50,8/5/2020
8.10E+32,earnings,100,50,8/5/2020
8.10E+32,earnings,100,50,8/5/2020
8.10E+32,earnings,100,50,8/5/2020
8.10E+32,earnings,100,50,8/5/2020
8.10E+32,earnings,100,50,8/5/2020
8.10E+32,earnings,100,50,8/5/2020
810FAD,earnings,100,50,8/5/2020
818A2F,earnings,100,50,8/5/2020
818A2F,earnings,100,50,8/5/2020
818A2F,dividend,100,50,8/5/2020
818A2F,dividend,100,50,8/5/2020
8.10E+205,product-release,100,64,8/5/2020
83A065,earnings,100,50,8/5/2020
845533,earnings,100,50,8/5/2020
8614A2,earnings,100,50,8/5/2020
86BAC7,dividend,100,50,8/5/2020
87486A,dividend,100,50,8/5/2020
87486A,executive-appointment,100,54,8/5/2020
87B81A,earnings,100,50,8/5/2020
87B81A,earnings,100,50,8/5/2020
87B81A,earnings,100,50,8/5/2020
87B81A,earnings,100,50,8/5/2020
87B81A,dividend,100,50,8/5/2020
88350F,conference-participant,100,50,8/5/2020
88611B,earnings,100,50,8/5/2020
890FF4,award,100,58,8/5/2020
89FBB1,facility-sale,100,52,8/5/2020
8A8E41,partnership,100,61,8/5/2020
8AB37F,revenue-up,100,72,8/5/2020
8AB37F,revenue-up,100,69,8/5/2020
8AB37F,revenue-up,100,69,8/5/2020
8B3B0E,conference-participant,100,50,8/5/2020
8B9B3B,earnings,100,50,8/5/2020
8DAAB9,dividend,100,50,8/5/2020
8DBE73,legal-issues-defendant,100,22,8/5/2020
8DBE73,legal-issues-defendant,100,22,8/5/2020
8E82A6,earnings,100,50,8/5/2020
8E82A6,earnings,100,50,8/5/2020
8E82A6,earnings,100,50,8/5/2020
8E82A6,earnings,100,50,8/5/2020
8E82A6,earnings,100,50,8/5/2020
8E9CD8,earnings,100,50,8/5/2020
8FCA78,dividend,100,50,8/5/2020
902670,earnings,100,50,8/5/2020
902670,earnings,100,50,8/5/2020
902670,earnings,100,50,8/5/2020
9087B9,earnings,100,50,8/5/2020
90D6A5,earnings,100,50,8/5/2020
90D6A5,earnings,100,50,8/5/2020
90D6A5,earnings,100,50,8/5/2020
90D6A5,earnings,100,50,8/5/2020
925759,earnings,100,50,8/5/2020
92B625,earnings,100,50,8/5/2020
9.39E+69,conference-participant,100,50,8/5/2020
94208D,earnings,100,50,8/5/2020
94208D,earnings,100,50,8/5/2020
94208D,earnings,100,50,8/5/2020
94208D,earnings,100,50,8/5/2020
94208D,earnings,100,50,8/5/2020
94208D,earnings,100,50,8/5/2020
94208D,earnings,100,50,8/5/2020
9470CC,earnings,100,50,8/5/2020
949625,dividend,100,50,8/5/2020
9507FF,earnings,100,50,8/5/2020
957A07,conference-participant,100,50,8/5/2020
958938,earnings,100,50,8/5/2020
9592FB,earnings,100,50,8/5/2020
9.65E+09,executive-appointment,100,54,8/5/2020
9.65E+09,earnings,100,50,8/5/2020
96A2D3,earnings,100,50,8/5/2020
96BFF4,legal-issues-defendant,100,22,8/5/2020
972356,partnership,100,61,8/5/2020
97644E,earnings,100,50,8/5/2020
97644E,earnings,100,50,8/5/2020
97644E,earnings,100,50,8/5/2020
97644E,earnings,100,50,8/5/2020
97644E,earnings,100,50,8/5/2020
980C14,earnings,100,50,8/5/2020
9810C0,conference-participant,100,50,8/5/2020
99ACAD,earnings,100,50,8/5/2020
99ACAD,earnings,100,50,8/5/2020
9B0C9C,earnings,100,50,8/5/2020
9B4066,dividend-up,100,81,8/5/2020
9C009A,earnings,100,50,8/5/2020
9C25FF,earnings,100,50,8/5/2020
9EBAFA,earnings,100,50,8/5/2020
9F048E,earnings,100,50,8/5/2020
9F048E,earnings,100,50,8/5/2020
9F048E,earnings,100,50,8/5/2020
9F048E,earnings,100,50,8/5/2020
9F048E,earnings,100,50,8/5/2020
9F048E,earnings,100,50,8/5/2020
9F5997,earnings,100,50,8/5/2020
9F5CBB,earnings,100,50,8/5/2020
9FB4B7,conference-participant,100,50,8/5/2020
A26EF7,conference-participant,100,50,8/5/2020
A29DBD,earnings,100,50,8/5/2020
A398F8,earnings,100,50,8/5/2020
A3F598,earnings,100,50,8/5/2020
A3F598,earnings,100,50,8/5/2020
A3F598,earnings,100,50,8/5/2020
A3F598,earnings,100,50,8/5/2020
A433A5,earnings,100,50,8/5/2020
A631A3,partnership,100,61,8/5/2020
A63387,earnings,100,50,8/5/2020
A6828A,business-contract,100,69,8/5/2020
A6828A,business-contract,100,69,8/5/2020
A6828A,business-contract,100,69,8/5/2020
A7A0C8,conference-call,100,50,8/5/2020
A80FE0,conference-participant,100,50,8/5/2020
A80FE0,conference-participant,100,50,8/5/2020
A871B0,earnings,100,50,8/5/2020
A9ED24,earnings,100,50,8/5/2020
A9ED24,earnings,100,50,8/5/2020
AAC8B6,earnings,100,50,8/5/2020
AAC8B6,earnings,100,50,8/5/2020
AAC8B6,earnings,100,50,8/5/2020
AAC8B6,earnings,100,50,8/5/2020
AAC8B6,earnings,100,50,8/5/2020
AAC8B6,earnings,100,50,8/5/2020
AAC8B6,earnings,100,50,8/5/2020
ACF0B4,earnings,100,50,8/5/2020
ADF092,earnings,100,50,8/5/2020
AE79CD,conference-participant,100,50,8/5/2020
AEBB80,earnings,100,50,8/5/2020
AEFC90,earnings,100,50,8/5/2020
AF93DE,earnings,100,50,8/5/2020
AFD7DD,earnings,100,50,8/5/2020
AFD7DD,earnings,100,50,8/5/2020
B05000,earnings-up,100,68,8/5/2020
B05000,earnings,100,50,8/5/2020
B0D41A,earnings,100,50,8/5/2020
B13B68,earnings,100,50,8/5/2020
B2E6B5,dividend,100,50,8/5/2020
B2E6B5,earnings,100,50,8/5/2020
B2E6B5,earnings,100,50,8/5/2020
B2E6B5,earnings,100,50,8/5/2020
B48D6A,conference-participant,100,50,8/5/2020
B642E8,earnings,100,50,8/5/2020
B66928,earnings,100,50,8/5/2020
B7202A,earnings-positive,100,69,8/5/2020
B7202A,earnings-positive,100,69,8/5/2020
B73395,earnings,100,50,8/5/2020
B73395,earnings,100,50,8/5/2020
B73395,earnings,100,50,8/5/2020
B73395,earnings,100,50,8/5/2020
B8EF97,revenues,100,50,8/5/2020
B8F71F,executive-appointment,100,54,8/5/2020
BA0442,conference-participant,100,50,8/5/2020
BBF349,earnings,100,50,8/5/2020
BCC13E,earnings,100,50,8/5/2020
BCC55F,executive-appointment,100,54,8/5/2020
BCC55F,conference-participant,100,50,8/5/2020
BD9668,dividend,100,50,8/5/2020
BE14CF,conference-participant,100,50,8/5/2020
BFCACF,conference-call,100,50,8/5/2020
BFF98A,conference-participant,100,50,8/5/2020
C16A8F,earnings,100,50,8/5/2020
C16A8F,earnings,100,50,8/5/2020
C16A8F,earnings,100,50,8/5/2020
C16A8F,earnings,100,50,8/5/2020
C2609A,conference-participant,100,50,8/5/2020
C2609A,earnings,100,50,8/5/2020
C27E19,operating-earnings,100,50,8/5/2020
C38440,executive-appointment,100,54,8/5/2020
C3EE99,conference-call,100,50,8/5/2020
C407A0,earnings,100,50,8/5/2020
C4F9C6,earnings,100,50,8/5/2020
C4FBDC,earnings,100,50,8/5/2020
C62AA4,earnings,100,50,8/5/2020
C66B44,earnings,100,50,8/5/2020
C9739A,conference-call,100,50,8/5/2020
C9739A,conference-participant,100,50,8/5/2020
C99CC8,earnings,100,50,8/5/2020
C99CC8,earnings,100,50,8/5/2020
C99CC8,earnings,100,50,8/5/2020
C99CC8,earnings,100,50,8/5/2020
C99CC8,earnings,100,50,8/5/2020
C99CC8,earnings,100,50,8/5/2020
CA14CC,earnings,100,50,8/5/2020
CA14CC,earnings,100,50,8/5/2020
CA14CC,earnings,100,50,8/5/2020
CAB222,earnings,100,50,8/5/2020
CAC8D0,executive-appointment,100,54,8/5/2020
CB6A9C,earnings,100,50,8/5/2020
CB6A9C,earnings,100,50,8/5/2020
CB6A9C,earnings,100,50,8/5/2020
CB6A9C,earnings,100,50,8/5/2020
CB6A9C,earnings,100,50,8/5/2020
CB6A9C,earnings,100,50,8/5/2020
CB6A9C,earnings,100,50,8/5/2020
CB89EA,earnings,100,50,8/5/2020
CBDB4D,earnings,100,50,8/5/2020
CBFFDD,earnings,100,50,8/5/2020
CBFFDD,trading-halt,100,43,8/5/2020
CC0C78,conference-participant,100,50,8/5/2020
CD051C,earnings,100,50,8/5/2020
CD2A4D,earnings,100,50,8/5/2020
CD4DA8,conference-participant,100,50,8/5/2020
CE2791,earnings,100,50,8/5/2020
CE4E6D,earnings,100,50,8/5/2020
CE4E6D,earnings,100,50,8/5/2020
CE4E6D,earnings,100,50,8/5/2020
CE4E6D,earnings,100,50,8/5/2020
CE4E6D,earnings,100,50,8/5/2020
CE4FD9,earnings,100,50,8/5/2020
CE4FD9,earnings,100,50,8/5/2020
CE4FD9,earnings,100,50,8/5/2020
CE4FD9,earnings,100,50,8/5/2020
CE5C6E,earnings,100,50,8/5/2020
CE5C6E,earnings,100,50,8/5/2020
CE96E7,earnings,100,50,8/5/2020
CFB6CA,earnings,100,50,8/5/2020
CFB6CA,earnings,100,50,8/5/2020
D07B07,earnings,100,50,8/5/2020
D08D2C,earnings,100,50,8/5/2020
D08D2C,earnings,100,50,8/5/2020
D08D2C,earnings,100,50,8/5/2020
D08D2C,earnings,100,50,8/5/2020
D08D2C,earnings,100,50,8/5/2020
D08D2C,earnings,100,50,8/5/2020
D0DE27,earnings,100,50,8/5/2020
D0DE27,earnings,100,50,8/5/2020
D0DE27,earnings,100,50,8/5/2020
D0DE27,earnings,100,50,8/5/2020
D0DE27,earnings,100,50,8/5/2020
D0DE27,earnings,100,50,8/5/2020
D17F7E,earnings,100,50,8/5/2020
D17F7E,earnings,100,50,8/5/2020
D17F7E,earnings,100,50,8/5/2020
D17F7E,earnings,100,50,8/5/2020
D17F7E,earnings,100,50,8/5/2020
D29F43,earnings,100,50,8/5/2020
D36B23,conference-participant,100,50,8/5/2020
D4AC65,earnings,100,50,8/5/2020
D4AC65,earnings,100,50,8/5/2020
D4AC65,earnings,100,50,8/5/2020
D4AC65,earnings,100,50,8/5/2020
D4AC65,earnings,100,50,8/5/2020
D64EDF,earnings-above-expectations,100,88,8/5/2020
D64EDF,earnings,100,50,8/5/2020
D64EDF,earnings,100,50,8/5/2020
D64EDF,earnings,100,50,8/5/2020
D650A7,dividend,100,50,8/5/2020
D650A7,earnings,100,50,8/5/2020
D650A7,earnings,100,50,8/5/2020
D650A7,earnings,100,50,8/5/2020
D650A7,earnings,100,50,8/5/2020
D697DE,earnings,100,50,8/5/2020
D70365,earnings,100,50,8/5/2020
D854DD,executive-appointment,100,54,8/5/2020
D854DD,earnings,100,50,8/5/2020
D8ECA1,executive-appointment,100,54,8/5/2020
D90441,earnings,100,50,8/5/2020
D90441,earnings,100,50,8/5/2020
D90441,earnings,100,50,8/5/2020
D90441,dividend,100,50,8/5/2020
D90441,dividend,100,50,8/5/2020
DB2E4E,earnings,100,50,8/5/2020
DB7014,operating-earnings,100,50,8/5/2020
DB9F70,conference-call,100,50,8/5/2020
DCD97F,dividend,100,50,8/5/2020
DDB002,earnings,100,50,8/5/2020
DDB002,earnings,100,50,8/5/2020
DDB002,earnings,100,50,8/5/2020
DE5611,patent-awarded,100,72,8/5/2020
DF16DE,earnings,100,50,8/5/2020
DF42A0,dividend,100,50,8/5/2020
DF42A0,earnings,100,50,8/5/2020
DF6FDD,dividend,100,50,8/5/2020
DFADDB,executive-appointment,100,54,8/5/2020
E06265,earnings,100,50,8/5/2020
E0E4B7,earnings,100,50,8/5/2020
E15736,earnings,100,50,8/5/2020
E1E36F,earnings,100,50,8/5/2020
E1E36F,earnings,100,50,8/5/2020
E1E36F,earnings,100,50,8/5/2020
E1E36F,earnings,100,50,8/5/2020
E1E36F,earnings,100,50,8/5/2020
E1E36F,earnings,100,50,8/5/2020
E1E36F,earnings,100,50,8/5/2020
E1E36F,earnings,100,50,8/5/2020
E1F30A,ipo,100,71,8/5/2020
E20392,earnings,100,50,8/5/2020
E28D9C,earnings,100,50,8/5/2020
E35610,earnings,100,50,8/5/2020
E35610,earnings,100,50,8/5/2020
E35610,earnings,100,50,8/5/2020
E35610,earnings,100,50,8/5/2020
E5752F,earnings,100,50,8/5/2020
E5752F,earnings,100,50,8/5/2020
E5752F,earnings,100,50,8/5/2020
E5752F,earnings,100,50,8/5/2020
E5A3B6,executive-appointment,100,54,8/5/2020
E5C910,conference-participant,100,50,8/5/2020
E610CD,earnings,100,50,8/5/2020
E610CD,earnings,100,50,8/5/2020
E68E62,earnings,100,50,8/5/2020
E71AE6,patient-enrollment-complete,100,64,8/5/2020
E71AE6,patient-enrollment-complete,100,64,8/5/2020
E74B55,earnings,100,50,8/5/2020
E74FED,earnings,100,50,8/5/2020
E802CE,earnings,100,50,8/5/2020
E82A2D,earnings,100,50,8/5/2020
EC8116,earnings,100,50,8/5/2020
ECE814,earnings,100,50,8/5/2020
EEB5F9,earnings,100,50,8/5/2020
EEBCEF,earnings,100,50,8/5/2020
F02170,earnings,100,50,8/5/2020
F02D0A,earnings,100,50,8/5/2020
F02D0A,earnings,100,50,8/5/2020
F05B1B,conference-participant,100,50,8/5/2020
F0EEFB,earnings,100,50,8/5/2020
F0EEFB,earnings,100,50,8/5/2020
F15E41,earnings,100,50,8/5/2020
F15E41,earnings,100,50,8/5/2020
F15E41,earnings,100,50,8/5/2020
F15E41,earnings,100,50,8/5/2020
F15E41,earnings,100,50,8/5/2020
F4CDA3,earnings,100,50,8/5/2020
F4CDA3,earnings,100,50,8/5/2020
F4CDA3,earnings,100,50,8/5/2020
F4CDA3,earnings,100,50,8/5/2020
F4CDA3,earnings,100,50,8/5/2020
F4CDA3,earnings,100,50,8/5/2020
F4E882,partnership,100,61,8/5/2020
F5349B,earnings,100,50,8/5/2020
F5349B,dividend,100,50,8/5/2020
F569FD,earnings,100,50,8/5/2020
F5C78B,dividend,100,50,8/5/2020
FAAFA2,conference-participant,100,50,8/5/2020
FC1F9D,donation,100,54,8/5/2020
FD554E,earnings,100,50,8/5/2020
FF4343,executive-appointment,100,54,8/5/2020
002A99,earnings,100,50,8/6/2020
0157B1,business-contract,100,69,8/6/2020
01D03F,clinical-trials,100,56,8/6/2020
01D03F,clinical-trials,100,56,8/6/2020
01D03F,clinical-trials,100,56,8/6/2020
20751,earnings,100,50,8/6/2020
20751,earnings,100,50,8/6/2020
02870F,legal-issues-defendant,100,22,8/6/2020
02870F,legal-issues-defendant,100,22,8/6/2020
02ACBD,earnings,100,50,8/6/2020
03542C,earnings,100,50,8/6/2020
03FB17,dividend,100,50,8/6/2020
0490C6,partnership,100,61,8/6/2020
04CCCD,earnings,100,50,8/6/2020
04EB2F,earnings,100,50,8/6/2020
054E7E,earnings,100,50,8/6/2020
61366,earnings,100,50,8/6/2020
61366,business-contract,100,69,8/6/2020
061A3B,earnings,100,50,8/6/2020
061A3B,earnings,100,50,8/6/2020
061A3B,earnings,100,50,8/6/2020
061A3B,earnings,100,50,8/6/2020
06C826,earnings,100,50,8/6/2020
078D52,earnings,100,50,8/6/2020
078D52,earnings,100,50,8/6/2020
84625,earnings,100,50,8/6/2020
84625,earnings,100,50,8/6/2020
95294,earnings,100,50,8/6/2020
099C88,earnings,100,50,8/6/2020
099C88,earnings,100,50,8/6/2020
099C88,earnings,100,50,8/6/2020
099C88,earnings,100,50,8/6/2020
0A59F8,earnings,100,50,8/6/2020
0A59F8,earnings,100,50,8/6/2020
0A59F8,earnings,100,50,8/6/2020
0A59F8,earnings,100,50,8/6/2020
0A59F8,earnings,100,50,8/6/2020
0A59F8,earnings,100,50,8/6/2020
0A59F8,earnings,100,50,8/6/2020
0A59F8,earnings,100,50,8/6/2020
0B13E8,earnings,100,50,8/6/2020
0BC29E,conference-participant,100,50,8/6/2020
0BC853,business-contract,100,69,8/6/2020
0BF198,earnings,100,50,8/6/2020
0E499E,earnings,100,50,8/6/2020
0E5619,earnings,100,50,8/6/2020
0E64D4,earnings,100,50,8/6/2020
0E64D4,earnings,100,50,8/6/2020
0E64D4,earnings,100,50,8/6/2020
0E64D4,earnings,100,50,8/6/2020
0E64D4,earnings,100,50,8/6/2020
0E64D4,earnings,100,50,8/6/2020
0E64D4,earnings,100,50,8/6/2020
0E64D4,earnings,100,50,8/6/2020
0E64D4,earnings,100,50,8/6/2020
102F04,earnings,100,50,8/6/2020
102F04,executive-appointment,100,54,8/6/2020
1080C0,earnings,100,50,8/6/2020
1096C6,earnings,100,50,8/6/2020
11AEDE,ipo-pricing,100,50,8/6/2020
1279ED,earnings,100,50,8/6/2020
133644,earnings,100,50,8/6/2020
138DDE,earnings,100,50,8/6/2020
13D576,acquisition-completed-acquirer,100,49,8/6/2020
147098,earnings,100,50,8/6/2020
152FA5,earnings,100,50,8/6/2020
165B86,executive-appointment,100,54,8/6/2020
165B86,earnings,100,50,8/6/2020
16C544,earnings,100,50,8/6/2020
17EDA5,earnings,100,50,8/6/2020
17EDA5,partnership,100,61,8/6/2020
184866,earnings,100,50,8/6/2020
197019,earnings,100,50,8/6/2020
1A3E1B,earnings,100,50,8/6/2020
1A5957,earnings,100,50,8/6/2020
1A5957,earnings,100,50,8/6/2020
1A5957,earnings,100,50,8/6/2020
1A5957,earnings,100,50,8/6/2020
1A5957,earnings,100,50,8/6/2020
1AC649,earnings,100,50,8/6/2020
1B4F31,earnings,100,50,8/6/2020
1BC12C,partnership,100,61,8/6/2020
1C2593,conference-call,100,50,8/6/2020
1CD09C,earnings,100,50,8/6/2020
1CDD1C,supply-increase,100,74,8/6/2020
1F464F,executive-appointment,100,54,8/6/2020
1F464F,earnings,100,50,8/6/2020
1F9258,revenues,100,50,8/6/2020
1FA886,legal-issues-defendant,100,22,8/6/2020
1FC422,earnings,100,50,8/6/2020
202E5A,earnings,100,50,8/6/2020
20403D,earnings,100,50,8/6/2020
2082EA,earnings,100,50,8/6/2020
2.45E+15,dividend,100,50,8/6/2020
24D81E,executive-appointment,100,54,8/6/2020
253B2F,earnings,100,50,8/6/2020
253B2F,buybacks,100,74,8/6/2020
25529C,earnings,100,50,8/6/2020
25AB8E,earnings,100,50,8/6/2020
270B78,earnings,100,50,8/6/2020
270B78,executive-appointment,100,54,8/6/2020
275300,dividend,100,50,8/6/2020
27A791,earnings,100,50,8/6/2020
27A791,earnings,100,50,8/6/2020
27A791,earnings,100,50,8/6/2020
27A791,earnings,100,50,8/6/2020
284289,conference-participant,100,50,8/6/2020
2920D5,note-sale,100,52,8/6/2020
2A6DBE,earnings,100,50,8/6/2020
2A6DBE,earnings,100,50,8/6/2020
2AA6A8,earnings,100,50,8/6/2020
2B8179,earnings,100,50,8/6/2020
2BBE62,earnings,100,50,8/6/2020
2BBE62,earnings,100,50,8/6/2020
2BBE62,earnings,100,50,8/6/2020
2BBE62,earnings,100,50,8/6/2020
2BF36E,earnings,100,50,8/6/2020
2C19A4,earnings,100,50,8/6/2020
2C19A4,earnings,100,50,8/6/2020
2C19A4,earnings,100,50,8/6/2020
2C19A4,earnings,100,50,8/6/2020
2C19A4,earnings,100,50,8/6/2020
2C35B5,earnings,100,50,8/6/2020
2C681C,conference-call,100,50,8/6/2020
2C681C,conference-call,100,50,8/6/2020
2C681C,partnership,100,61,8/6/2020
2C681C,partnership,100,61,8/6/2020
2C7505,earnings,100,50,8/6/2020
2D981A,earnings,100,50,8/6/2020
2DDB22,earnings,100,50,8/6/2020
2E0445,earnings,100,50,8/6/2020
2E1322,earnings,100,50,8/6/2020
2E36AD,earnings,100,50,8/6/2020
2E36AD,earnings,100,50,8/6/2020
2FF046,earnings,100,50,8/6/2020
2FF046,earnings,100,50,8/6/2020
2FF046,earnings,100,50,8/6/2020
2FF046,earnings,100,50,8/6/2020
301493,earnings,100,50,8/6/2020
3159AA,earnings,100,50,8/6/2020
3159AA,dividend,100,50,8/6/2020
342218,earnings,100,50,8/6/2020
342218,earnings,100,50,8/6/2020
34A959,earnings,100,50,8/6/2020
34E9F9,earnings,100,50,8/6/2020
34E9F9,earnings,100,50,8/6/2020
34E9F9,earnings,100,50,8/6/2020
34E9F9,earnings,100,50,8/6/2020
34E9F9,earnings,100,50,8/6/2020
355B19,earnings,100,50,8/6/2020
356B21,legal-issues-defendant,100,22,8/6/2020
3587B4,earnings,100,50,8/6/2020
35F4B5,dividend,100,50,8/6/2020
36C09B,conference-call,100,50,8/6/2020
36E479,earnings,100,50,8/6/2020
371B0A,earnings,100,50,8/6/2020
37426C,earnings,100,50,8/6/2020
37426C,earnings,100,50,8/6/2020
37B618,earnings,100,50,8/6/2020
37E18B,earnings,100,50,8/6/2020
382EAE,operating-earnings,100,50,8/6/2020
382EAE,operating-earnings,100,50,8/6/2020
382EAE,operating-earnings,100,50,8/6/2020
382EAE,operating-earnings,100,50,8/6/2020
387375,conference-participant,100,50,8/6/2020
396D7C,earnings,100,50,8/6/2020
3A1C46,conference-participant,100,50,8/6/2020
3ACF46,earnings,100,50,8/6/2020
3ACF46,government-contract,100,69,8/6/2020
3B8484,earnings-up,100,68,8/6/2020
3C3B6B,earnings,100,50,8/6/2020
3C75D6,earnings-positive,100,69,8/6/2020
3C75D6,earnings,100,50,8/6/2020
3C75D6,earnings,100,50,8/6/2020
3C75D6,earnings,100,50,8/6/2020
3C7F5F,earnings,100,50,8/6/2020
3C7F5F,earnings,100,50,8/6/2020
3C7F5F,earnings,100,50,8/6/2020
3C7F5F,earnings,100,50,8/6/2020
3C7F5F,earnings,100,50,8/6/2020
3C7F5F,earnings,100,50,8/6/2020
3E15F6,earnings,100,50,8/6/2020
3E15F6,earnings,100,50,8/6/2020
3E15F6,earnings,100,50,8/6/2020
3E15F6,earnings,100,50,8/6/2020
3E39A5,earnings,100,50,8/6/2020
3E39A5,earnings,100,50,8/6/2020
3E39A5,earnings,100,50,8/6/2020
3F1C69,conference-participant,100,50,8/6/2020
3F4668,revenues,100,50,8/6/2020
3F4668,executive-appointment,100,54,8/6/2020
3F96D5,earnings,100,50,8/6/2020
4.03E+05,investment-investor,100,55,8/6/2020
4.00E+163,public-offering,100,43,8/6/2020
4135F7,public-offering,100,43,8/6/2020
415188,dividend,100,50,8/6/2020
415188,earnings,100,50,8/6/2020
416291,earnings,100,50,8/6/2020
417BF9,fundraising,100,64,8/6/2020
41A93D,earnings,100,50,8/6/2020
41C36B,earnings,100,50,8/6/2020
41C528,earnings,100,50,8/6/2020
41ED98,dividend,100,50,8/6/2020
4398A2,earnings,100,50,8/6/2020
448BF3,earnings,100,50,8/6/2020
44DDBD,earnings,100,50,8/6/2020
451D61,conference-participant,100,50,8/6/2020
46017C,earnings,100,50,8/6/2020
468DD4,investment-investor,100,55,8/6/2020
4.60E+06,earnings,100,50,8/6/2020
47752F,executive-appointment,100,54,8/6/2020
48F795,earnings,100,50,8/6/2020
4.91E+58,earnings,100,50,8/6/2020
4.91E+58,earnings,100,50,8/6/2020
4.91E+58,earnings,100,50,8/6/2020
4.91E+58,earnings,100,50,8/6/2020
4.91E+58,earnings,100,50,8/6/2020
4.91E+58,earnings,100,50,8/6/2020
4.91E+58,earnings,100,50,8/6/2020
49F4D0,earnings,100,50,8/6/2020
4A6F00,partnership,100,61,8/6/2020
4AC91D,earnings,100,50,8/6/2020
4B7006,earnings,100,50,8/6/2020
4BEB48,award,100,58,8/6/2020
4C2F17,earnings,100,50,8/6/2020
4D8124,earnings,100,50,8/6/2020
4DD203,earnings,100,50,8/6/2020
4E6F5A,earnings,100,50,8/6/2020
50702E,earnings,100,50,8/6/2020
507AE7,dividend,100,50,8/6/2020
50D1EC,earnings,100,50,8/6/2020
510EA1,earnings,100,50,8/6/2020
519FE0,product-release,100,64,8/6/2020
523039,patient-enrollment-start,100,58,8/6/2020
52FB2F,earnings,100,50,8/6/2020
52FB2F,earnings,100,50,8/6/2020
52FB2F,earnings,100,50,8/6/2020
52FB2F,earnings,100,50,8/6/2020
53C421,earnings,100,50,8/6/2020
5.47E+28,operating-earnings,100,50,8/6/2020
5487B1,fraud,100,44,8/6/2020
548AC0,earnings,100,50,8/6/2020
54DF47,earnings,100,50,8/6/2020
55ACCB,earnings,100,50,8/6/2020
55ACCB,earnings,100,50,8/6/2020
55ACCB,earnings,100,50,8/6/2020
55D0F3,earnings,100,50,8/6/2020
562853,dividend,100,50,8/6/2020
56765E,earnings,100,50,8/6/2020
567F3D,executive-appointment,100,54,8/6/2020
56B7C1,earnings,100,50,8/6/2020
56B7C1,earnings,100,50,8/6/2020
56B7C1,earnings,100,50,8/6/2020
56B7C1,earnings,100,50,8/6/2020
57DDB9,conference-participant,100,50,8/6/2020
587D25,earnings,100,50,8/6/2020
58B46F,earnings-per-share-positive,100,69,8/6/2020
58B46F,earnings,100,50,8/6/2020
58B46F,earnings,100,50,8/6/2020
58B46F,earnings,100,50,8/6/2020
58B46F,earnings,100,50,8/6/2020
58B46F,earnings,100,50,8/6/2020
58B46F,earnings,100,50,8/6/2020
58B46F,earnings,100,50,8/6/2020
5968F9,earnings,100,50,8/6/2020
59872F,conference-call,100,50,8/6/2020
59DB8C,earnings,100,50,8/6/2020
5B3FA2,earnings,100,50,8/6/2020
5D1329,earnings,100,50,8/6/2020
5D63F1,earnings,100,50,8/6/2020
5DAF89,earnings,100,50,8/6/2020
5DD486,dividend,100,50,8/6/2020
5EF130,earnings,100,50,8/6/2020
5EF130,earnings,100,50,8/6/2020
5EF130,earnings,100,50,8/6/2020
5F1B7B,product-release,100,64,8/6/2020
619882,conference-organizer,100,57,8/6/2020
619882,conference-organizer,100,57,8/6/2020
620381,earnings,100,50,8/6/2020
6284B5,earnings,100,50,8/6/2020
6284B5,earnings,100,50,8/6/2020
6284B5,earnings,100,50,8/6/2020
6284B5,earnings,100,50,8/6/2020
636639,dividend-up,100,81,8/6/2020
63F892,earnings,100,50,8/6/2020
649CBD,earnings,100,50,8/6/2020
64E615,conference-participant,100,50,8/6/2020
6559D8,earnings,100,50,8/6/2020
66E04A,earnings,100,50,8/6/2020
66E04A,earnings,100,50,8/6/2020
66E04A,earnings,100,50,8/6/2020
66E04A,earnings,100,50,8/6/2020
66E04A,earnings,100,50,8/6/2020
66E04A,earnings,100,50,8/6/2020
68586A,earnings,100,50,8/6/2020
68E6E9,earnings,100,50,8/6/2020
69E8E1,earnings,100,50,8/6/2020
69E8E1,earnings,100,50,8/6/2020
69E8E1,earnings,100,50,8/6/2020
69E8E1,earnings,100,50,8/6/2020
69E8E1,earnings,100,50,8/6/2020
6B5379,earnings,100,50,8/6/2020
6BC6F9,earnings,100,50,8/6/2020
6BDA0C,earnings,100,50,8/6/2020
6BDA0C,earnings,100,50,8/6/2020
6BDA0C,earnings,100,50,8/6/2020
6BDA0C,earnings,100,50,8/6/2020
6BDA0C,earnings,100,50,8/6/2020
6D0CAB,earnings,100,50,8/6/2020
6D156D,earnings,100,50,8/6/2020
6D156D,earnings,100,50,8/6/2020
6D1ADF,earnings,100,50,8/6/2020
6D2BF6,earnings,100,50,8/6/2020
6-Dec-05,executive-appointment,100,54,8/6/2020
6.00E+19,earnings,100,50,8/6/2020
6E705B,business-contract,100,69,8/6/2020
6E8864,operating-earnings,100,50,8/6/2020
6EA292,earnings,100,50,8/6/2020
6F30F9,earnings,100,50,8/6/2020
6F39FC,earnings,100,50,8/6/2020
6F92A9,earnings,100,50,8/6/2020
6FCEF9,earnings,100,50,8/6/2020
705636,reorganization,100,53,8/6/2020
7255D2,earnings,100,50,8/6/2020
7273FF,earnings,100,50,8/6/2020
72C2CE,acquisition-acquirer,100,49,8/6/2020
73A213,conference-participant,100,50,8/6/2020
741937,earnings,100,50,8/6/2020
741937,earnings,100,50,8/6/2020
741937,earnings,100,50,8/6/2020
743C70,earnings,100,50,8/6/2020
743C70,earnings,100,50,8/6/2020
74404C,earnings,100,50,8/6/2020
74404C,earnings,100,50,8/6/2020
747219,earnings,100,50,8/6/2020
756045,earnings,100,50,8/6/2020
77B8E9,clinical-trials-positive,100,87,8/6/2020
7823A3,conference-participant,100,50,8/6/2020
789A7D,earnings,100,50,8/6/2020
789A7D,earnings,100,50,8/6/2020
789A7D,earnings,100,50,8/6/2020
789A7D,earnings,100,50,8/6/2020
790D0D,earnings,100,50,8/6/2020
793C11,earnings,100,50,8/6/2020
7A51FE,earnings,100,50,8/6/2020
7ACBA4,earnings,100,50,8/6/2020
7AF5B8,partnership,100,61,8/6/2020
7AF5B8,partnership,100,61,8/6/2020
7AF5B8,partnership,100,61,8/6/2020
7AF5B8,partnership,100,61,8/6/2020
7B4B91,dividend,100,50,8/6/2020
7B8CB5,earnings,100,50,8/6/2020
7B9212,revenues,100,50,8/6/2020
7BAAE7,dividend,100,50,8/6/2020
7BC92D,partnership,100,61,8/6/2020
7BEA98,earnings,100,50,8/6/2020
7C4F43,earnings,100,50,8/6/2020
7C790D,conference-call,100,50,8/6/2020
7CD98F,earnings,100,50,8/6/2020
7DA412,earnings,100,50,8/6/2020
7DD8CC,earnings,100,50,8/6/2020
7F3665,earnings,100,50,8/6/2020
7F9E16,executive-appointment,100,54,8/6/2020
81222C,earnings,100,50,8/6/2020
81222C,executive-appointment,100,54,8/6/2020
8.10E+205,earnings,100,50,8/6/2020
81EAD4,earnings,100,50,8/6/2020
81EAD4,earnings,100,50,8/6/2020
81EAD4,earnings,100,50,8/6/2020
824CCA,earnings,100,50,8/6/2020
824CCA,earnings,100,50,8/6/2020
824CCA,earnings,100,50,8/6/2020
824CCA,earnings,100,50,8/6/2020
82FD6D,earnings,100,50,8/6/2020
834152,earnings,100,50,8/6/2020
83E0AC,earnings,100,50,8/6/2020
848C0B,earnings,100,50,8/6/2020
85CDC9,earnings,100,50,8/6/2020
86AA9C,revenue-up,100,69,8/6/2020
86AA9C,revenue-up,100,69,8/6/2020
86AA9C,revenue-up,100,69,8/6/2020
86AA9C,revenue-up,100,69,8/6/2020
86AA9C,revenue-up,100,69,8/6/2020
86AA9C,revenue-up,100,69,8/6/2020
86AA9C,revenue-up,100,69,8/6/2020
86AA9C,revenue-up,100,69,8/6/2020
86AA9C,revenue-up,100,69,8/6/2020
86AA9C,revenue-up,100,69,8/6/2020
86AA9C,revenue-up,100,69,8/6/2020
86AA9C,revenue-up,100,69,8/6/2020
86AA9C,revenue-up,100,69,8/6/2020
86AA9C,revenue-up,100,69,8/6/2020
873DB9,earnings,100,50,8/6/2020
873DB9,earnings,100,50,8/6/2020
873DB9,earnings,100,50,8/6/2020
873DB9,earnings,100,50,8/6/2020
873DB9,earnings,100,50,8/6/2020
87486A,earnings,100,50,8/6/2020
87486A,earnings,100,50,8/6/2020
87486A,earnings,100,50,8/6/2020
87486A,earnings,100,50,8/6/2020
877C0C,earnings,100,50,8/6/2020
885758,note-sale,100,52,8/6/2020
88923D,earnings,100,50,8/6/2020
88923D,earnings,100,50,8/6/2020
88923D,earnings,100,50,8/6/2020
88923D,earnings,100,50,8/6/2020
88923D,earnings,100,50,8/6/2020
88923D,earnings,100,50,8/6/2020
890FF4,fraud,100,44,8/6/2020
89FBB1,earnings,100,50,8/6/2020
89FBB1,earnings,100,50,8/6/2020
89FBB1,earnings,100,50,8/6/2020
8AC65D,conference-participant,100,50,8/6/2020
8B1F37,earnings,100,50,8/6/2020
8B1F37,earnings,100,50,8/6/2020
8B1F37,earnings,100,50,8/6/2020
8B1F37,earnings,100,50,8/6/2020
8B1F37,earnings,100,50,8/6/2020
8B1F37,earnings,100,50,8/6/2020
8B1F37,earnings,100,50,8/6/2020
8B1F37,earnings,100,50,8/6/2020
8B1F37,earnings,100,50,8/6/2020
8B1F37,earnings,100,50,8/6/2020
8B1F37,earnings,100,50,8/6/2020
8BAA15,earnings,100,50,8/6/2020
8BAA15,earnings,100,50,8/6/2020
8BFAA4,earnings,100,50,8/6/2020
8BFAA4,earnings,100,50,8/6/2020
8BFAA4,earnings,100,50,8/6/2020
8BFAA4,earnings,100,50,8/6/2020
8C6C1B,conference-call,100,50,8/6/2020
8D4486,partnership,100,61,8/6/2020
8DA42F,earnings,100,50,8/6/2020
8DA42F,earnings,100,50,8/6/2020
8DBBE6,earnings,100,50,8/6/2020
8DE56F,earnings,100,50,8/6/2020
8DE56F,earnings,100,50,8/6/2020
8E10BF,conference-participant,100,50,8/6/2020
8E4F9A,public-offering,100,43,8/6/2020
9004C4,earnings,100,50,8/6/2020
922F0C,dividend,100,50,8/6/2020
92B73F,dividend,100,50,8/6/2020
92D230,earnings,100,50,8/6/2020
92D230,earnings,100,50,8/6/2020
92D230,earnings,100,50,8/6/2020
92D230,earnings,100,50,8/6/2020
92D230,earnings,100,50,8/6/2020
92D230,earnings,100,50,8/6/2020
92D230,earnings,100,50,8/6/2020
92D230,earnings,100,50,8/6/2020
9.39E+69,earnings,100,50,8/6/2020
93AD2E,earnings,100,50,8/6/2020
94208D,executive-appointment,100,54,8/6/2020
94208D,executive-appointment,100,54,8/6/2020
943239,earnings,100,50,8/6/2020
943239,earnings,100,50,8/6/2020
94637C,earnings,100,50,8/6/2020
949625,operating-earnings,100,50,8/6/2020
9548BB,dividend-up,100,55,8/6/2020
95A92E,earnings,100,50,8/6/2020
95C392,earnings,100,50,8/6/2020
9.65E+07,earnings,100,50,8/6/2020
9.65E+07,earnings,100,50,8/6/2020
9.65E+07,earnings,100,50,8/6/2020
966ACE,earnings,100,50,8/6/2020
966DBE,earnings,100,50,8/6/2020
966DBE,earnings,100,50,8/6/2020
966DBE,earnings,100,50,8/6/2020
966DBE,earnings,100,50,8/6/2020
966DBE,earnings,100,50,8/6/2020
971334,earnings,100,50,8/6/2020
971334,earnings,100,50,8/6/2020
971334,earnings,100,50,8/6/2020
971334,earnings,100,50,8/6/2020
97644E,note-sale,100,52,8/6/2020
97AAF6,earnings,100,50,8/6/2020
97AAF6,earnings,100,50,8/6/2020
97AAF6,earnings,100,50,8/6/2020
97FE80,earnings,100,50,8/6/2020
97FE80,earnings,100,50,8/6/2020
97FE80,earnings,100,50,8/6/2020
99028D,conference-call,100,50,8/6/2020
9978F1,earnings,100,50,8/6/2020
9A2760,earnings-up,100,68,8/6/2020
9A2760,earnings,100,50,8/6/2020
9A2760,earnings,100,50,8/6/2020
9A2760,earnings,100,50,8/6/2020
9A602D,dividend,100,50,8/6/2020
9ABD30,earnings,100,50,8/6/2020
9B730A,earnings,100,50,8/6/2020
9C3D3C,earnings,100,50,8/6/2020
9C5174,revenue-up,100,73,8/6/2020
9C5174,revenues,100,50,8/6/2020
9C5174,revenues,100,50,8/6/2020
9D307D,earnings,100,50,8/6/2020
9E4A5F,earnings,100,50,8/6/2020
9E575E,earnings,100,50,8/6/2020
9E5C2C,earnings,100,50,8/6/2020
9E98F2,earnings,100,50,8/6/2020
9E98F2,earnings,100,50,8/6/2020
9E98F2,earnings,100,50,8/6/2020
9F71E5,acquisition-acquirer,100,49,8/6/2020
9FD2D9,earnings,100,50,8/6/2020
9FD2D9,earnings,100,50,8/6/2020
9FD2D9,earnings,100,50,8/6/2020
A05C43,earnings,100,50,8/6/2020
A072C4,earnings,100,50,8/6/2020
A1EAC8,earnings,100,50,8/6/2020
A21649,earnings,100,50,8/6/2020
A26EF7,earnings,100,50,8/6/2020
A26EF7,earnings,100,50,8/6/2020
A3800A,earnings,100,50,8/6/2020
A403CF,earnings,100,50,8/6/2020
A403CF,dividend,100,50,8/6/2020
A43906,earnings,100,50,8/6/2020
A43906,earnings,100,50,8/6/2020
A43906,earnings,100,50,8/6/2020
A43906,earnings,100,50,8/6/2020
A43906,earnings,100,50,8/6/2020
A43906,earnings,100,50,8/6/2020
A43906,earnings,100,50,8/6/2020
A43906,earnings,100,50,8/6/2020
A43906,earnings,100,50,8/6/2020
A43906,earnings,100,50,8/6/2020
A43906,earnings,100,50,8/6/2020
A48593,earnings,100,50,8/6/2020
A4B899,earnings,100,50,8/6/2020
A5195E,earnings,100,50,8/6/2020
A63387,conference-participant,100,50,8/6/2020
A75D43,earnings,100,50,8/6/2020
A790A5,conference-call,100,50,8/6/2020
A7A0BD,earnings,100,50,8/6/2020
A7A0C8,conference-participant,100,50,8/6/2020
A87CD6,dividend,100,50,8/6/2020
A94637,earnings,100,50,8/6/2020
A94637,earnings,100,50,8/6/2020
AB4A7E,earnings,100,50,8/6/2020
ABB493,earnings,100,50,8/6/2020
AC3584,earnings,100,50,8/6/2020
AC3584,earnings,100,50,8/6/2020
AC3584,earnings,100,50,8/6/2020
AC7AAE,earnings,100,50,8/6/2020
ACC7D3,earnings,100,50,8/6/2020
ACDCFA,operating-earnings,100,50,8/6/2020
AD1ACF,dividend,100,50,8/6/2020
AFBEB4,earnings,100,50,8/6/2020
B01215,earnings,100,50,8/6/2020
B106FA,earnings,100,50,8/6/2020
B1DF3C,earnings,100,50,8/6/2020
B37FB4,dividend,100,50,8/6/2020
B4B281,conference-call,100,50,8/6/2020
B6843B,earnings,100,50,8/6/2020
B7BDA3,earnings,100,50,8/6/2020
B80AD1,earnings,100,50,8/6/2020
B83D67,earnings,100,50,8/6/2020
B934BF,earnings,100,50,8/6/2020
B9BDE8,earnings-above-expectations,100,88,8/6/2020
B9CD50,earnings,100,50,8/6/2020
BAAA60,dividend,100,50,8/6/2020
BB58FF,conference-participant,100,50,8/6/2020
BB88B6,partnership,100,61,8/6/2020
BB88B6,note-sale,100,52,8/6/2020
BCC55F,earnings,100,50,8/6/2020
BDCC11,earnings,100,50,8/6/2020
BDCC11,executive-appointment,100,54,8/6/2020
BE379D,executive-appointment,100,54,8/6/2020
BE5935,earnings,100,50,8/6/2020
C03C8B,earnings,100,50,8/6/2020
C03C8B,earnings,100,50,8/6/2020
C03C8B,earnings,100,50,8/6/2020
C03C8B,earnings,100,50,8/6/2020
C03C8B,earnings,100,50,8/6/2020
C03C8B,earnings,100,50,8/6/2020
C0F70B,conference-participant,100,50,8/6/2020
C1114B,earnings,100,50,8/6/2020
C1114B,earnings,100,50,8/6/2020
C1114B,earnings,100,50,8/6/2020
C1114B,earnings,100,50,8/6/2020
C2F597,earnings,100,50,8/6/2020
C3BCD5,dividend,100,50,8/6/2020
C4706C,earnings,100,50,8/6/2020
C490F9,public-offering,100,43,8/6/2020
C490F9,public-offering,100,43,8/6/2020
C490F9,public-offering,100,43,8/6/2020
C501B6,earnings,100,50,8/6/2020
C50B26,earnings,100,50,8/6/2020
C584BE,earnings,100,50,8/6/2020
C5E100,earnings,100,50,8/6/2020
C65004,earnings,100,50,8/6/2020
C659EB,dividend,100,50,8/6/2020
C66A8C,earnings,100,50,8/6/2020
C66A8C,earnings,100,50,8/6/2020
C66A8C,earnings,100,50,8/6/2020
C66A8C,earnings,100,50,8/6/2020
C6C702,earnings,100,50,8/6/2020
C8A059,earnings,100,50,8/6/2020
C951A2,partnership,100,61,8/6/2020
C9A96E,earnings,100,50,8/6/2020
C9D866,conference-participant,100,50,8/6/2020
C9E4EC,earnings,100,50,8/6/2020
CA99D7,earnings,100,50,8/6/2020
CB89EA,executive-appointment,100,54,8/6/2020
CB89EA,conference-participant,100,50,8/6/2020
CBB77B,business-contract,100,69,8/6/2020
CBFFDD,trading-resumed,100,58,8/6/2020
CC35BE,earnings-above-expectations,100,88,8/6/2020
CC8F6E,earnings,100,50,8/6/2020
CCB623,earnings,100,50,8/6/2020
CDAA0E,earnings,100,50,8/6/2020
CE4FD9,conference-call,100,50,8/6/2020
CEC08B,earnings,100,50,8/6/2020
CEC08B,earnings,100,50,8/6/2020
CEC08B,earnings,100,50,8/6/2020
CEC08B,earnings,100,50,8/6/2020
CEC08B,earnings,100,50,8/6/2020
CEC5B9,earnings,100,50,8/6/2020
CEC5B9,earnings,100,50,8/6/2020
CEC5B9,earnings,100,50,8/6/2020
CEDFD5,partnership,100,61,8/6/2020
CEDFD5,partnership,100,61,8/6/2020
CEDFD5,partnership,100,61,8/6/2020
CEDFD5,partnership,100,61,8/6/2020
CF6A5A,partnership,100,61,8/6/2020
CFD4B6,earnings,100,50,8/6/2020
CFD4B6,earnings,100,50,8/6/2020
CFD4B6,earnings,100,50,8/6/2020
CFD4B6,dividend,100,50,8/6/2020
D11C1C,operating-earnings,100,50,8/6/2020
D13F1C,earnings,100,50,8/6/2020
D13F1C,earnings,100,50,8/6/2020
D13F1C,earnings,100,50,8/6/2020
D13F1C,earnings,100,50,8/6/2020
D13F1C,earnings,100,50,8/6/2020
D13F1C,earnings,100,50,8/6/2020
D1C26F,earnings-up,100,68,8/6/2020
D1C26F,earnings-up,100,68,8/6/2020
D1C26F,earnings-up,100,68,8/6/2020
D29B44,earnings,100,50,8/6/2020
D29B44,executive-appointment,100,54,8/6/2020
D36B23,earnings,100,50,8/6/2020
D3F64D,earnings,100,50,8/6/2020
D3F64D,earnings,100,50,8/6/2020
D3F64D,earnings,100,50,8/6/2020
D3F64D,earnings,100,50,8/6/2020
D3F64D,earnings,100,50,8/6/2020
D3F64D,earnings,100,50,8/6/2020
D3FA2C,earnings,100,50,8/6/2020
D518D8,dividend,100,50,8/6/2020
D6489C,product-release,100,64,8/6/2020
D6489C,product-release,100,64,8/6/2020
D64C6D,dividend,100,50,8/6/2020
D65A13,revenues,100,50,8/6/2020
D65A13,revenues,100,50,8/6/2020
D65A13,revenues,100,50,8/6/2020
D77F7E,earnings,100,50,8/6/2020
D77F7E,earnings,100,50,8/6/2020
D77F7E,earnings,100,50,8/6/2020
D77F7E,earnings,100,50,8/6/2020
D77F7E,earnings,100,50,8/6/2020
D8DA3D,earnings,100,50,8/6/2020
D8DA3D,earnings,100,50,8/6/2020
D8DA3D,earnings,100,50,8/6/2020
D8DA3D,earnings,100,50,8/6/2020
D8DA3D,earnings,100,50,8/6/2020
D8DA3D,earnings,100,50,8/6/2020
D90F43,product-release,100,64,8/6/2020
D90F43,earnings,100,50,8/6/2020
D90F43,earnings,100,50,8/6/2020
D90F43,earnings,100,50,8/6/2020
D90F43,earnings,100,50,8/6/2020
D90F43,earnings,100,50,8/6/2020
D90F43,earnings,100,50,8/6/2020
D90F43,earnings,100,50,8/6/2020
D90F43,earnings,100,50,8/6/2020
D9164D,earnings-up,100,68,8/6/2020
D96202,earnings,100,50,8/6/2020
D9B1C9,earnings,100,50,8/6/2020
D9B1C9,earnings,100,50,8/6/2020
D9B1C9,earnings,100,50,8/6/2020
DA0CB8,earnings,100,50,8/6/2020
DA9443,earnings,100,50,8/6/2020
DB06B0,partnership,100,61,8/6/2020
DB7EC3,earnings-up,100,68,8/6/2020
DB7EC3,earnings-up,100,68,8/6/2020
DB9F70,conference-participant,100,50,8/6/2020
DBB28E,partnership,100,61,8/6/2020
DC0066,earnings,100,50,8/6/2020
DC2B00,conference-call,100,50,8/6/2020
DD0F15,earnings,100,50,8/6/2020
DD1BA1,earnings,100,50,8/6/2020
DDEA6A,earnings,100,50,8/6/2020
DDEA6A,earnings,100,50,8/6/2020
DE20DF,operating-earnings,100,50,8/6/2020
DE5611,conference-call,100,50,8/6/2020
DF1F7A,earnings,100,50,8/6/2020
DF5F14,earnings,100,50,8/6/2020
DF6FDD,earnings,100,50,8/6/2020
DFADDB,earnings,100,50,8/6/2020
E0D3BA,earnings,100,50,8/6/2020
E11C41,earnings,100,50,8/6/2020
E16133,earnings,100,50,8/6/2020
E19A99,earnings,100,50,8/6/2020
E22FDE,earnings,100,50,8/6/2020
E22FDE,earnings,100,50,8/6/2020
E22FDE,earnings,100,50,8/6/2020
E22FDE,earnings,100,50,8/6/2020
E259C7,earnings,100,50,8/6/2020
E2CB7B,earnings,100,50,8/6/2020
E2CFD2,earnings,100,50,8/6/2020
E3A829,earnings,100,50,8/6/2020
E3A829,earnings,100,50,8/6/2020
E3A829,earnings,100,50,8/6/2020
E3A829,earnings,100,50,8/6/2020
E3A829,earnings,100,50,8/6/2020
E41190,earnings,100,50,8/6/2020
E41190,earnings,100,50,8/6/2020
E41190,earnings,100,50,8/6/2020
E41190,earnings,100,50,8/6/2020
E41190,earnings,100,50,8/6/2020
E49AA3,earnings,100,50,8/6/2020
E598FB,earnings,100,50,8/6/2020
E5F0A8,note-sale,100,52,8/6/2020
E6D89E,earnings,100,50,8/6/2020
E6D89E,earnings,100,50,8/6/2020
E6D89E,earnings,100,50,8/6/2020
E6D89E,earnings,100,50,8/6/2020
E71AE6,earnings,100,50,8/6/2020
E754F0,earnings,100,50,8/6/2020
E8846E,legal-issues-defendant,100,22,8/6/2020
E8C557,earnings,100,50,8/6/2020
E94704,dividend,100,50,8/6/2020
EAA0A7,earnings,100,50,8/6/2020
EAA0A7,earnings,100,50,8/6/2020
EAA0A7,earnings,100,50,8/6/2020
EAA0A7,earnings,100,50,8/6/2020
EAA0A7,earnings,100,50,8/6/2020
EAA0A7,earnings,100,50,8/6/2020
EAEBF3,earnings,100,50,8/6/2020
EBC84C,dividend,100,50,8/6/2020
ED2EFD,facility-upgrade,100,65,8/6/2020
ED3CA8,earnings,100,50,8/6/2020
ED9C04,earnings,100,50,8/6/2020
ED9C04,earnings,100,50,8/6/2020
ED9C04,earnings,100,50,8/6/2020
EDD234,earnings,100,50,8/6/2020
EF25A5,earnings,100,50,8/6/2020
EF25A5,earnings,100,50,8/6/2020
EF25A5,earnings,100,50,8/6/2020
EF25A5,earnings,100,50,8/6/2020
EF5914,earnings,100,50,8/6/2020
EF7163,earnings,100,50,8/6/2020
EFD406,note-sale,100,52,8/6/2020
EFD406,note-sale,100,52,8/6/2020
F0027C,earnings,100,50,8/6/2020
F05B1B,earnings,100,50,8/6/2020
F11638,partnership,100,61,8/6/2020
F1C04C,partnership,100,61,8/6/2020
F2E253,earnings,100,50,8/6/2020
F2E253,earnings,100,50,8/6/2020
F2E253,earnings,100,50,8/6/2020
F2E253,earnings,100,50,8/6/2020
F2E253,earnings,100,50,8/6/2020
F2E253,earnings,100,50,8/6/2020
F3816D,earnings,100,50,8/6/2020
F6E1B5,earnings,100,50,8/6/2020
F6FA6A,earnings,100,50,8/6/2020
F6FA6A,earnings,100,50,8/6/2020
F6FA6A,earnings,100,50,8/6/2020
F6FA6A,earnings,100,50,8/6/2020
F6FA6A,earnings,100,50,8/6/2020
F6FA6A,earnings,100,50,8/6/2020
F6FA6A,earnings,100,50,8/6/2020
F6FA6A,earnings,100,50,8/6/2020
F6FA6A,earnings,100,50,8/6/2020
F6FF0D,earnings,100,50,8/6/2020
F6FF0D,earnings,100,50,8/6/2020
F6FF0D,earnings,100,50,8/6/2020
F721A7,earnings,100,50,8/6/2020
F72E4B,earnings,100,50,8/6/2020
F73DD1,earnings,100,50,8/6/2020
F73DD1,earnings,100,50,8/6/2020
F73DD1,earnings,100,50,8/6/2020
F73DD1,earnings,100,50,8/6/2020
F73DD1,earnings,100,50,8/6/2020
F73DD1,earnings,100,50,8/6/2020
F73DD1,earnings,100,50,8/6/2020
F73DD1,dividend,100,50,8/6/2020
F7935D,earnings,100,50,8/6/2020
F7935D,revenues,100,50,8/6/2020
F83279,earnings,100,50,8/6/2020
F83279,earnings,100,50,8/6/2020
F83279,earnings,100,50,8/6/2020
F83279,executive-appointment,100,54,8/6/2020
F93C8A,earnings,100,50,8/6/2020
FAB97A,earnings,100,50,8/6/2020
FB728F,earnings,100,50,8/6/2020
FBD92D,earnings-up,100,68,8/6/2020
FBD92D,earnings,100,50,8/6/2020
FBD92D,earnings,100,50,8/6/2020
FC1F9D,dividend-up,100,81,8/6/2020
FCA54E,earnings,100,50,8/6/2020
FD2565,earnings,100,50,8/6/2020
FD39EB,earnings,100,50,8/6/2020
FDD3FC,conference-participant,100,50,8/6/2020
FEE4B0,earnings,100,50,8/6/2020
FEE4B0,earnings,100,50,8/6/2020
FEE4B0,earnings,100,50,8/6/2020
FEE4B0,earnings,100,50,8/6/2020
FEE4B0,earnings,100,50,8/6/2020
00D6B5,dividend,100,50,8/7/2020
06CB5B,earnings,100,50,8/7/2020
083F72,earnings,100,50,8/7/2020
84625,dividend,100,50,8/7/2020
0A1D77,executive-appointment,100,54,8/7/2020
1065BC,earnings,100,50,8/7/2020
12DE76,acquisition-completed-acquirer,100,49,8/7/2020
13D576,executive-resignation,100,44,8/7/2020
14391F,earnings,100,50,8/7/2020
14391F,earnings,100,50,8/7/2020
14391F,earnings,100,50,8/7/2020
14391F,earnings,100,50,8/7/2020
157D9F,earnings,100,50,8/7/2020
157D9F,earnings,100,50,8/7/2020
157D9F,earnings,100,50,8/7/2020
157D9F,earnings,100,50,8/7/2020
157D9F,earnings,100,50,8/7/2020
159AE4,earnings,100,50,8/7/2020
159AE4,earnings,100,50,8/7/2020
16B882,earnings,100,50,8/7/2020
19CAC7,dividend-up,100,81,8/7/2020
1AB023,earnings,100,50,8/7/2020
1AB023,earnings,100,50,8/7/2020
1AB023,earnings,100,50,8/7/2020
1B16C1,executive-appointment,100,54,8/7/2020
1CD4B5,earnings,100,50,8/7/2020
1FA886,legal-issues-defendant,100,22,8/7/2020
1FA886,legal-issues-defendant,100,22,8/7/2020
1FA886,legal-issues-defendant,100,22,8/7/2020
1FA886,legal-issues-defendant,100,22,8/7/2020
1FA886,legal-issues-defendant,100,22,8/7/2020
1FE7F0,earnings,100,50,8/7/2020
1FE7F0,earnings,100,50,8/7/2020
1FE7F0,earnings,100,50,8/7/2020
1FE7F0,earnings,100,50,8/7/2020
1FE7F0,earnings,100,50,8/7/2020
1FE7F0,earnings,100,50,8/7/2020
2571FA,conference-participant,100,50,8/7/2020
267718,regulatory-investigation,100,22,8/7/2020
267718,business-contract,100,69,8/7/2020
26F31D,executive-appointment,100,54,8/7/2020
2C681C,partnership,100,61,8/7/2020
2C681C,partnership,100,61,8/7/2020
2C681C,partnership,100,61,8/7/2020
2C681C,partnership,100,61,8/7/2020
2C681C,partnership,100,61,8/7/2020
2CF9D3,earnings,100,50,8/7/2020
2E89AE,conference-participant,100,50,8/7/2020
353DBB,dividend,100,50,8/7/2020
3EE65E,earnings,100,50,8/7/2020
4.00E+163,public-offering,100,43,8/7/2020
41785E,dividend,100,50,8/7/2020
42EFC7,earnings,100,50,8/7/2020
4649D5,earnings,100,50,8/7/2020
4A2457,conference-participant,100,50,8/7/2020
4BBA23,operating-earnings,100,50,8/7/2020
4C350A,conference-call,100,50,8/7/2020
4D203E,conference-participant,100,50,8/7/2020
52B567,earnings,100,50,8/7/2020
54512F,earnings,100,50,8/7/2020
589803,public-offering,100,43,8/7/2020
589803,public-offering,100,43,8/7/2020
5AA3B1,earnings,100,50,8/7/2020
5C2A47,earnings,100,50,8/7/2020
5D41E4,conference-participant,100,50,8/7/2020
619882,conference-organizer,100,57,8/7/2020
619882,conference-participant,100,50,8/7/2020
66667F,revenue-up,100,82,8/7/2020
66749D,dividend,100,50,8/7/2020
6A01DF,executive-appointment,100,54,8/7/2020
6A6BDC,earnings,100,50,8/7/2020
6B67BD,earnings,100,50,8/7/2020
6F0A63,dividend,100,50,8/7/2020
726DDF,earnings,100,50,8/7/2020
732A9B,conference-participant,100,50,8/7/2020
73F70F,earnings,100,50,8/7/2020
7999F3,earnings,100,50,8/7/2020
7999F3,earnings,100,50,8/7/2020
7999F3,earnings,100,50,8/7/2020
7999F3,earnings,100,50,8/7/2020
7999F3,earnings,100,50,8/7/2020
7999F3,earnings,100,50,8/7/2020
7999F3,earnings,100,50,8/7/2020
7999F3,earnings,100,50,8/7/2020
7999F3,earnings,100,50,8/7/2020
7999F3,earnings,100,50,8/7/2020
7999F3,earnings,100,50,8/7/2020
7AF5B8,earnings,100,50,8/7/2020
7DD584,conference-participant,100,50,8/7/2020
7FDE1C,earnings,100,50,8/7/2020
81222C,conference-participant,100,50,8/7/2020
82E58A,earnings,100,50,8/7/2020
83E0AC,conference-call,100,50,8/7/2020
855DF7,earnings,100,50,8/7/2020
873DB9,product-recall,100,29,8/7/2020
8E10BF,conference-call,100,50,8/7/2020
8E4F9A,public-offering,100,43,8/7/2020
8FF2EF,dividend,100,50,8/7/2020
918D6D,conference-call,100,50,8/7/2020
92D757,earnings,100,50,8/7/2020
94983E,partnership,100,61,8/7/2020
94983E,dividend,100,50,8/7/2020
95F59E,earnings,100,50,8/7/2020
95F59E,earnings,100,50,8/7/2020
95F59E,earnings,100,50,8/7/2020
95F59E,earnings,100,50,8/7/2020
96B4FF,earnings,100,50,8/7/2020
A47A7D,executive-appointment,100,54,8/7/2020
A6D095,ipo-pricing,100,50,8/7/2020
A6FC89,conference-call,100,50,8/7/2020
ABB493,conference-participant,100,50,8/7/2020
AFF7B4,conference-participant,100,50,8/7/2020
B04426,earnings,100,50,8/7/2020
BB88B6,note-sale,100,52,8/7/2020
BD44C9,earnings,100,50,8/7/2020
BDE867,earnings,100,50,8/7/2020
BDE867,earnings,100,50,8/7/2020
BDE867,earnings,100,50,8/7/2020
BDE867,earnings,100,50,8/7/2020
BDE867,dividend,100,50,8/7/2020
BFD0A7,earnings-up,100,68,8/7/2020
BFD0A7,earnings-up,100,68,8/7/2020
BFD0A7,earnings-up,100,68,8/7/2020
C941DC,public-offering,100,43,8/7/2020
C9C62A,earnings,100,50,8/7/2020
CBCC6A,conference-organizer,100,57,8/7/2020
CBDB4D,legal-issues-plaintiff,100,44,8/7/2020
CDE118,earnings,100,50,8/7/2020
CEDFD5,regulatory-product-approval-granted,100,81,8/7/2020
CEDFD5,regulatory-product-approval-granted,100,81,8/7/2020
CEDFD5,regulatory-product-approval-granted,100,81,8/7/2020
CEDFD5,regulatory-product-approval-granted,100,81,8/7/2020
D4463B,executive-appointment,100,54,8/7/2020
D6144F,earnings,100,50,8/7/2020
DB23C8,conference-participant,100,50,8/7/2020
DB396B,earnings,100,50,8/7/2020
DB396B,earnings,100,50,8/7/2020
DB396B,earnings,100,50,8/7/2020
DC6EF3,earnings,100,50,8/7/2020
E3656D,earnings,100,50,8/7/2020
E3656D,executive-appointment,100,54,8/7/2020
ECE814,conference-participant,100,50,8/7/2020
EF25A5,conference-participant,100,50,8/7/2020
F00285,earnings,100,50,8/7/2020
F6DA75,earnings,100,50,8/7/2020
F6DE54,executive-resignation,100,44,8/7/2020
F6E248,business-contract,100,69,8/7/2020
F80FF9,conference-call,100,50,8/7/2020
FACCF6,executive-appointment,100,54,8/7/2020
FF227B,earnings,100,50,8/7/2020
6F39FC,dividend,100,50,8/8/2020
790C34,earnings,100,50,8/8/2020
CCB623,legal-issues-defendant,100,22,8/8/2020
F30508,clinical-trials,100,56,8/8/2020
F30508,clinical-trials,100,56,8/8/2020
B7FA9B,earnings,100,50,8/9/2020
E8846E,legal-issues-defendant,100,22,8/9/2020
01D03F,clinical-trials,100,56,8/10/2020
01D03F,clinical-trials,100,56,8/10/2020
01D03F,partnership,100,61,8/10/2020
02870F,legal-issues-defendant,100,22,8/10/2020
0325B7,earnings,100,50,8/10/2020
036C6F,earnings,100,50,8/10/2020
036C6F,earnings,100,50,8/10/2020
036C6F,earnings,100,50,8/10/2020
036C6F,earnings,100,50,8/10/2020
03FAA6,executive-appointment,100,54,8/10/2020
48590,executive-appointment,100,54,8/10/2020
0490C6,earnings,100,50,8/10/2020
0490C6,earnings,100,50,8/10/2020
0490C6,earnings,100,50,8/10/2020
0490C6,earnings,100,50,8/10/2020
04996E,earnings,100,50,8/10/2020
04996E,earnings,100,50,8/10/2020
04996E,earnings,100,50,8/10/2020
0A77DB,conference-participant,100,50,8/10/2020
0B7375,earnings,100,50,8/10/2020
0C6293,earnings,100,50,8/10/2020
0C6861,earnings,100,50,8/10/2020
0CE204,earnings,100,50,8/10/2020
0F0693,earnings,100,50,8/10/2020
0FC848,conference-participant,100,50,8/10/2020
0FC848,earnings,100,50,8/10/2020
1096C6,conference-participant,100,50,8/10/2020
11AEDE,ipo-completed,100,76,8/10/2020
12A3A3,conference-participant,100,50,8/10/2020
12A3A3,conference-participant,100,50,8/10/2020
131443,business-contract,100,69,8/10/2020
14833D,earnings,100,50,8/10/2020
152FA5,conference-participant,100,50,8/10/2020
15789A,earnings,100,50,8/10/2020
15789A,earnings,100,50,8/10/2020
15789A,earnings,100,50,8/10/2020
15789A,earnings,100,50,8/10/2020
157D9F,executive-appointment,100,54,8/10/2020
182BE7,earnings,100,50,8/10/2020
1880C5,earnings,100,50,8/10/2020
18D9FA,earnings,100,50,8/10/2020
196D18,partnership,100,61,8/10/2020
196D18,earnings,100,50,8/10/2020
1CF3A8,earnings,100,50,8/10/2020
1D3A00,conference-call,100,50,8/10/2020
1E4FB9,earnings,100,50,8/10/2020
1E9A6D,fundraising,100,64,8/10/2020
1FA886,legal-issues-defendant,100,22,8/10/2020
21D903,earnings,100,50,8/10/2020
232053,earnings,100,50,8/10/2020
238302,earnings,100,50,8/10/2020
24A89A,earnings,100,50,8/10/2020
24A89A,earnings,100,50,8/10/2020
25102A,conference-participant,100,50,8/10/2020
25D3CE,earnings,100,50,8/10/2020
26E3BA,earnings,100,50,8/10/2020
2B49F4,partnership,100,61,8/10/2020
2B49F4,dividend,100,50,8/10/2020
2B7A40,business-contract,100,69,8/10/2020
2BDC1C,business-contract,100,69,8/10/2020
2BDC1C,business-contract,100,69,8/10/2020
2BDC1C,earnings,100,50,8/10/2020
2C681C,operating-earnings,100,50,8/10/2020
2C681C,operating-earnings,100,50,8/10/2020
2C681C,partnership,100,61,8/10/2020
2C681C,partnership,100,61,8/10/2020
2D485F,public-offering,100,43,8/10/2020
2E0496,product-release,100,64,8/10/2020
2E0496,product-release,100,64,8/10/2020
2E0496,product-release,100,64,8/10/2020
2E0496,product-release,100,64,8/10/2020
2EBA55,earnings,100,50,8/10/2020
30DE64,earnings,100,50,8/10/2020
315EB0,market-entry,100,57,8/10/2020
315EB0,market-entry,100,57,8/10/2020
31803E,earnings,100,50,8/10/2020
32F24A,note-sale,100,52,8/10/2020
346BF2,conference-participant,100,50,8/10/2020
35557B,executive-appointment,100,54,8/10/2020
36529A,earnings,100,50,8/10/2020
36C09B,earnings,100,50,8/10/2020
37B120,earnings,100,50,8/10/2020
385DD4,earnings,100,50,8/10/2020
385DD4,legal-issues-defendant,100,22,8/10/2020
3A113F,earnings,100,50,8/10/2020
3AAEAE,earnings,100,50,8/10/2020
3B8484,unit-acquisition-acquirer,100,49,8/10/2020
3BB7D3,earnings,100,50,8/10/2020
3D7971,earnings,100,50,8/10/2020
3D7971,earnings,100,50,8/10/2020
3D7971,earnings,100,50,8/10/2020
3D7971,earnings,100,50,8/10/2020
3D7971,earnings,100,50,8/10/2020
3D7971,earnings,100,50,8/10/2020
3DD5E2,operating-earnings,100,50,8/10/2020
3DED49,conference-call,100,50,8/10/2020
3F1C69,earnings,100,50,8/10/2020
42AABD,earnings,100,50,8/10/2020
43A060,earnings,100,50,8/10/2020
43A060,earnings,100,50,8/10/2020
43A060,earnings,100,50,8/10/2020
43F4A8,earnings,100,50,8/10/2020
43F4A8,earnings,100,50,8/10/2020
43F4A8,earnings,100,50,8/10/2020
43F4A8,earnings,100,50,8/10/2020
43F4A8,earnings,100,50,8/10/2020
450ECB,revenues,100,50,8/10/2020
485445,earnings,100,50,8/10/2020
485445,earnings,100,50,8/10/2020
485445,earnings,100,50,8/10/2020
485445,earnings,100,50,8/10/2020
485445,earnings,100,50,8/10/2020
485445,earnings,100,50,8/10/2020
485445,earnings,100,50,8/10/2020
4A5C8D,executive-appointment,100,54,8/10/2020
4A5C8D,executive-appointment,100,54,8/10/2020
4A6F00,partnership,100,61,8/10/2020
4A6F00,product-release,100,64,8/10/2020
4B3676,stake-acquirer,100,48,8/10/2020
4B3676,stake-acquirer,100,48,8/10/2020
4BAF2E,earnings,100,50,8/10/2020
4C3FE9,earnings,100,50,8/10/2020
4E5784,earnings,100,50,8/10/2020
4EEB00,operating-earnings,100,50,8/10/2020
50070E,earnings-guidance-up,100,83,8/10/2020
5065B1,earnings,100,50,8/10/2020
51D876,conference-participant,100,50,8/10/2020
51F541,note-sale,100,52,8/10/2020
539F49,earnings,100,50,8/10/2020
53E575,conference-participant,100,50,8/10/2020
546A27,clinical-trials-positive,100,87,8/10/2020
546A27,earnings,100,50,8/10/2020
5487B1,legal-issues-defendant,100,22,8/10/2020
5487B1,earnings,100,50,8/10/2020
5487B1,earnings,100,50,8/10/2020
5487B1,earnings,100,50,8/10/2020
5487B1,earnings,100,50,8/10/2020
5487B1,earnings,100,50,8/10/2020
5487B1,earnings,100,50,8/10/2020
5487B1,earnings,100,50,8/10/2020
564F3E,note-sale,100,52,8/10/2020
57F3DA,executive-appointment,100,54,8/10/2020
583223,acquisition-acquirer,100,49,8/10/2020
58B46F,conference-call,100,50,8/10/2020
5A9A82,earnings,100,50,8/10/2020
5B3FA2,public-offering,100,43,8/10/2020
5B7739,earnings,100,50,8/10/2020
5C2A47,earnings,100,50,8/10/2020
5F3D91,reorganization,100,53,8/10/2020
5F3D91,earnings,100,50,8/10/2020
619882,conference-organizer,100,57,8/10/2020
6284B5,conference-participant,100,50,8/10/2020
6284B5,note-sale,100,52,8/10/2020
6284B5,note-sale,100,52,8/10/2020
62B1C6,earnings,100,50,8/10/2020
64636E,public-offering,100,43,8/10/2020
64FF65,earnings,100,50,8/10/2020
6634D9,earnings,100,50,8/10/2020
68AB62,earnings,100,50,8/10/2020
6925EB,clinical-trials,100,56,8/10/2020
6925EB,earnings,100,50,8/10/2020
693ECD,conference-participant,100,50,8/10/2020
69C99E,clinical-trials-negative,100,18,8/10/2020
69C99E,earnings,100,50,8/10/2020
69FDFC,earnings,100,50,8/10/2020
6BBCBA,earnings,100,50,8/10/2020
6BBCBA,public-offering,100,43,8/10/2020
6CDFC6,note-sale,100,52,8/10/2020
6-Dec-05,earnings,100,50,8/10/2020
713810,conference-call,100,50,8/10/2020
71553E,earnings,100,50,8/10/2020
71694D,earnings,100,50,8/10/2020
71B0CF,earnings,100,50,8/10/2020
729368,conference-participant,100,50,8/10/2020
741937,executive-appointment,100,54,8/10/2020
747219,earnings,100,50,8/10/2020
748EB6,earnings,100,50,8/10/2020
763DBE,earnings,100,50,8/10/2020
76DD0C,earnings,100,50,8/10/2020
78F776,earnings,100,50,8/10/2020
791EC1,earnings,100,50,8/10/2020
7AF907,earnings,100,50,8/10/2020
7B1E50,legal-issues-defendant,100,22,8/10/2020
7B1E50,legal-issues-defendant,100,22,8/10/2020
7BC92D,earnings,100,50,8/10/2020
7C790D,earnings,100,50,8/10/2020
7EA323,earnings,100,50,8/10/2020
8.10E+32,partnership,100,61,8/10/2020
817ED9,earnings,100,50,8/10/2020
82C202,acquisition-acquirer,100,49,8/10/2020
82C202,acquisition-acquirer,100,49,8/10/2020
83B1C8,earnings,100,50,8/10/2020
845655,earnings,100,50,8/10/2020
845655,earnings,100,50,8/10/2020
845655,earnings,100,50,8/10/2020
845655,earnings,100,50,8/10/2020
845655,earnings,100,50,8/10/2020
858942,earnings,100,50,8/10/2020
862941,executive-appointment,100,54,8/10/2020
862941,operating-earnings,100,50,8/10/2020
8.79E+06,earnings,100,50,8/10/2020
87B81A,note-sale,100,52,8/10/2020
87B81A,note-sale,100,52,8/10/2020
890FF4,earnings,100,50,8/10/2020
890FF4,earnings,100,50,8/10/2020
890FF4,earnings,100,50,8/10/2020
890FF4,earnings,100,50,8/10/2020
890FF4,earnings,100,50,8/10/2020
893904,earnings,100,50,8/10/2020
893904,earnings,100,50,8/10/2020
8BFE9A,executive-appointment,100,54,8/10/2020
8DBBE6,note-sale,100,52,8/10/2020
8E8E6E,stake-acquiree,100,62,8/10/2020
8E8E6E,stake-acquiree,100,62,8/10/2020
900356,earnings,100,50,8/10/2020
911CA9,earnings,100,50,8/10/2020
911CA9,earnings,100,50,8/10/2020
931AE7,earnings,100,50,8/10/2020
944B2E,earnings,100,50,8/10/2020
944B2E,earnings,100,50,8/10/2020
944B2E,earnings,100,50,8/10/2020
944B2E,earnings,100,50,8/10/2020
944B2E,earnings,100,50,8/10/2020
944B2E,earnings,100,50,8/10/2020
947B0B,earnings,100,50,8/10/2020
94A326,earnings,100,50,8/10/2020
9546A5,earnings,100,50,8/10/2020
9.54E+32,legal-issues-defendant,100,22,8/10/2020
958938,conference-participant,100,50,8/10/2020
9592FB,conference-participant,100,50,8/10/2020
967D92,note-sale,100,52,8/10/2020
96A6CD,earnings,100,50,8/10/2020
96BFF4,legal-issues-defendant,100,22,8/10/2020
97B027,earnings,100,50,8/10/2020
97B027,earnings,100,50,8/10/2020
97B027,earnings,100,50,8/10/2020
9.86E+03,conference-participant,100,50,8/10/2020
99B61C,conference-participant,100,50,8/10/2020
9B0C9C,conference-participant,100,50,8/10/2020
A017F4,earnings,100,50,8/10/2020
A01983,earnings,100,50,8/10/2020
A01983,dividend,100,50,8/10/2020
A1BB98,earnings,100,50,8/10/2020
A1BB98,earnings,100,50,8/10/2020
A1BB98,earnings,100,50,8/10/2020
A1BB98,earnings,100,50,8/10/2020
A1BB98,earnings,100,50,8/10/2020
A1BB98,earnings,100,50,8/10/2020
A28675,earnings,100,50,8/10/2020
A3AAA5,dividend,100,50,8/10/2020
A48593,conference-participant,100,50,8/10/2020
A495F7,earnings,100,50,8/10/2020
A52B6B,award,100,58,8/10/2020
A6213D,executive-appointment,100,54,8/10/2020
A65325,public-offering,100,43,8/10/2020
A65325,public-offering,100,43,8/10/2020
A8E72A,earnings,100,50,8/10/2020
AB7726,dividend,100,50,8/10/2020
ABAA03,executive-appointment,100,54,8/10/2020
ADFB3A,earnings,100,50,8/10/2020
AE3113,conference-participant,100,50,8/10/2020
AE79CD,earnings,100,50,8/10/2020
B0998E,earnings,100,50,8/10/2020
B2206F,conference-participant,100,50,8/10/2020
B2D492,earnings,100,50,8/10/2020
B2D799,earnings,100,50,8/10/2020
B33E77,earnings,100,50,8/10/2020
B3A166,earnings,100,50,8/10/2020
B4F5F4,earnings,100,50,8/10/2020
B508E5,conference-participant,100,50,8/10/2020
B614F8,legal-issues-defendant,100,22,8/10/2020
B803B1,earnings,100,50,8/10/2020
B8A51F,fast-track-designation,100,81,8/10/2020
B8A51F,fast-track-designation,100,81,8/10/2020
B9CD50,conference-participant,100,50,8/10/2020
BA0442,earnings,100,50,8/10/2020
BB5142,executive-appointment,100,54,8/10/2020
BDEC1E,earnings,100,50,8/10/2020
BDEF34,grant-recipient,100,63,8/10/2020
BDEF34,grant-recipient,100,63,8/10/2020
BE379D,earnings,100,50,8/10/2020
BE645B,earnings,100,50,8/10/2020
C1114B,executive-appointment,100,54,8/10/2020
C2DD02,earnings,100,50,8/10/2020
C2E120,earnings,100,50,8/10/2020
C3BAE7,executive-appointment,100,54,8/10/2020
C3BAE7,earnings,100,50,8/10/2020
C3BAE7,earnings,100,50,8/10/2020
C3BAE7,earnings,100,50,8/10/2020
C3BAE7,earnings,100,50,8/10/2020
C3BAE7,earnings,100,50,8/10/2020
C3BAE7,earnings,100,50,8/10/2020
C3BAE7,earnings,100,50,8/10/2020
C490F9,public-offering,100,43,8/10/2020
C490F9,public-offering,100,43,8/10/2020
C490F9,public-offering,100,43,8/10/2020
C584BE,earnings,100,50,8/10/2020
C58D71,earnings,100,50,8/10/2020
C58D71,earnings,100,50,8/10/2020
C598D7,acquisition-acquirer,100,49,8/10/2020
C93C44,earnings,100,50,8/10/2020
C93C44,earnings,100,50,8/10/2020
C9732E,earnings,100,50,8/10/2020
C98CDB,earnings,100,50,8/10/2020
C99CC8,award,100,58,8/10/2020
C9F39B,dividend,100,50,8/10/2020
CA212F,earnings,100,50,8/10/2020
CC0C78,revenues,100,50,8/10/2020
CC176E,public-offering,100,43,8/10/2020
CCB623,legal-issues-defendant,100,22,8/10/2020
CDE51C,earnings,100,50,8/10/2020
CDFCC9,conference-participant,100,50,8/10/2020
CDFCC9,conference-participant,100,50,8/10/2020
CED4D0,earnings,100,50,8/10/2020
CF3FF9,earnings,100,50,8/10/2020
CFE5BE,executive-appointment,100,54,8/10/2020
CFF97C,note-sale,100,52,8/10/2020
CFF97C,conference-participant,100,50,8/10/2020
CFF97C,note-sale,100,52,8/10/2020
D1588D,earnings,100,50,8/10/2020
D27FAB,earnings,100,50,8/10/2020
D5938F,legal-issues-defendant,100,22,8/10/2020
D63B0F,earnings,100,50,8/10/2020
D63B0F,earnings,100,50,8/10/2020
D63B0F,earnings,100,50,8/10/2020
D6EAA3,earnings,100,50,8/10/2020
D6EAA3,earnings,100,50,8/10/2020
D6EAA3,earnings,100,50,8/10/2020
D6EAA3,earnings,100,50,8/10/2020
D6EAA3,earnings,100,50,8/10/2020
D6EAA3,earnings,100,50,8/10/2020
D95385,earnings,100,50,8/10/2020
D96202,partnership,100,61,8/10/2020
DB5CA5,earnings,100,50,8/10/2020
DDEA6A,executive-appointment,100,54,8/10/2020
DE5611,conference-participant,100,50,8/10/2020
DF532D,regulatory-investigation,100,22,8/10/2020
E09997,earnings,100,50,8/10/2020
E21871,executive-appointment,100,54,8/10/2020
E35610,note-sale,100,52,8/10/2020
E5F0A8,note-sale,100,52,8/10/2020
E61888,earnings,100,50,8/10/2020
E6C8DC,conference-participant,100,50,8/10/2020
E70531,executive-resignation,100,44,8/10/2020
E8846E,legal-issues-defendant,100,22,8/10/2020
E9C7C0,earnings,100,50,8/10/2020
E9C7C0,earnings,100,50,8/10/2020
E9C7C0,earnings,100,50,8/10/2020
E9C7C0,earnings,100,50,8/10/2020
E9C7C0,earnings,100,50,8/10/2020
E9C7C0,earnings,100,50,8/10/2020
EB43F4,earnings,100,50,8/10/2020
EB7D6C,earnings,100,50,8/10/2020
ECE814,public-offering,100,43,8/10/2020
ECF4F8,earnings,100,50,8/10/2020
ED9C04,patent-infringement-plaintiff,100,47,8/10/2020
EEA734,earnings,100,50,8/10/2020
EF25A5,executive-appointment,100,54,8/10/2020
F0B335,earnings,100,50,8/10/2020
F24FF0,earnings,100,50,8/10/2020
F3016C,executive-appointment,100,54,8/10/2020
F30508,partnership,100,61,8/10/2020
F47871,legal-issues-defendant,100,22,8/10/2020
F4D241,earnings,100,50,8/10/2020
F4E992,public-offering,100,43,8/10/2020
F509E2,earnings,100,50,8/10/2020
F51DB0,public-offering,100,43,8/10/2020
F6E248,regulatory-product-application,100,69,8/10/2020
F7902B,conference-participant,100,50,8/10/2020
F7ADEB,earnings,100,50,8/10/2020
F7ADEB,earnings,100,50,8/10/2020
F7ADEB,earnings,100,50,8/10/2020
F7ADEB,earnings,100,50,8/10/2020
F88147,earnings,100,50,8/10/2020
FADF1A,earnings,100,50,8/10/2020
FD4588,note-sale,100,52,8/10/2020
FE609F,conference-call,100,50,8/10/2020
FEE4B0,note-sale,100,52,8/10/2020
FEE4B0,note-sale,100,52,8/10/2020
FF6644,partnership,100,61,8/10/2020
FFCD0E,earnings,100,50,8/10/2020
00067A,partnership,100,61,8/11/2020
002A99,patient-enrollment-start,100,58,8/11/2020
00698D,conference-call,100,50,8/11/2020
0157B1,market-entry,100,57,8/11/2020
05D148,executive-appointment,100,54,8/11/2020
75172,earnings,100,50,8/11/2020
0A77DB,earnings,100,50,8/11/2020
0A9D0A,unit-acquisition-acquirer,100,49,8/11/2020
0AAD90,earnings,100,50,8/11/2020
0BC29E,conference-participant,100,50,8/11/2020
0FDE97,note-sale,100,52,8/11/2020
1490F3,dividend,100,50,8/11/2020
152FA5,executive-appointment,100,54,8/11/2020
156A99,executive-appointment,100,54,8/11/2020
157CC1,regulatory-investigation,100,22,8/11/2020
17EDA5,legal-issues-defendant,100,22,8/11/2020
1A3E1B,executive-appointment,100,54,8/11/2020
1B6F77,earnings,100,50,8/11/2020
1BC12C,executive-appointment,100,54,8/11/2020
1E1125,executive-appointment,100,54,8/11/2020
1FAF22,product-release,100,64,8/11/2020
20D00A,business-contract,100,69,8/11/2020
21268E,earnings,100,50,8/11/2020
223552,earnings,100,50,8/11/2020
228D42,partnership,100,61,8/11/2020
24C48B,earnings,100,50,8/11/2020
24C48B,earnings,100,50,8/11/2020
24C48B,earnings,100,50,8/11/2020
24C48B,earnings,100,50,8/11/2020
24C48B,earnings,100,50,8/11/2020
26F31D,product-release,100,64,8/11/2020
26F99F,earnings,100,50,8/11/2020
2B7A40,business-contract,100,69,8/11/2020
2CC71C,public-offering,100,43,8/11/2020
2D485F,public-offering,100,43,8/11/2020
32DCB3,earnings,100,50,8/11/2020
32F24A,note-sale,100,52,8/11/2020
32F943,partnership,100,61,8/11/2020
3.30E+30,conference-call,100,50,8/11/2020
33E8C7,executive-appointment,100,54,8/11/2020
3461CF,stake-acquirer,100,48,8/11/2020
356B21,earnings,100,50,8/11/2020
356B21,earnings,100,50,8/11/2020
356B21,earnings,100,50,8/11/2020
356B21,earnings,100,50,8/11/2020
385DD4,product-release,100,64,8/11/2020
39FB23,revenue-up,100,69,8/11/2020
42AABD,note-sale,100,52,8/11/2020
435ACE,conference-participant,100,50,8/11/2020
458D2C,revenue-volume,100,50,8/11/2020
4591D3,revenues,100,50,8/11/2020
4591D3,earnings,100,50,8/11/2020
4591D3,earnings,100,50,8/11/2020
4591D3,earnings,100,50,8/11/2020
490D4B,note-sale,100,52,8/11/2020
4C2F17,public-offering,100,43,8/11/2020
4C37C5,partnership,100,61,8/11/2020
4CDA2B,earnings,100,50,8/11/2020
4D229C,earnings,100,50,8/11/2020
4DD09F,earnings,100,50,8/11/2020
4DD09F,earnings,100,50,8/11/2020
4DD09F,earnings,100,50,8/11/2020
4DD09F,earnings,100,50,8/11/2020
4F9926,business-contract,100,69,8/11/2020
519FE0,earnings,100,50,8/11/2020
519FE0,earnings,100,50,8/11/2020
519FE0,earnings,100,50,8/11/2020
519FE0,earnings,100,50,8/11/2020
519FE0,earnings,100,50,8/11/2020
52FB2F,note-sale,100,52,8/11/2020
543C77,earnings,100,50,8/11/2020
5480A7,dividend,100,50,8/11/2020
59872F,product-release,100,64,8/11/2020
5D02B7,conference-call,100,50,8/11/2020
60AC34,earnings,100,50,8/11/2020
6166D1,executive-appointment,100,54,8/11/2020
619882,conference-organizer,100,57,8/11/2020
62A48D,conference-call,100,50,8/11/2020
63F892,partnership,100,61,8/11/2020
651C85,earnings,100,50,8/11/2020
67303E,executive-appointment,100,54,8/11/2020
6A01DF,public-offering,100,43,8/11/2020
6A6BDC,partnership,100,61,8/11/2020
6BF593,note-sale,100,52,8/11/2020
6D9ECA,market-entry,100,57,8/11/2020
6D9ECA,earnings,100,50,8/11/2020
6DBBBC,investment-investor,100,55,8/11/2020
6ED519,dividend,100,50,8/11/2020
6F5DD2,earnings,100,50,8/11/2020
7122EB,earnings,100,50,8/11/2020
7255D2,public-offering,100,43,8/11/2020
75D689,executive-appointment,100,54,8/11/2020
7734AC,dividend,100,50,8/11/2020
791EC1,conference-call,100,50,8/11/2020
7ACFD4,earnings,100,50,8/11/2020
7ACFD4,earnings,100,50,8/11/2020
7ACFD4,earnings,100,50,8/11/2020
7ACFD4,earnings,100,50,8/11/2020
7ACFD4,earnings,100,50,8/11/2020
7DD584,earnings,100,50,8/11/2020
810FAD,partnership,100,61,8/11/2020
8.10E+205,conference-participant,100,50,8/11/2020
81EAD4,note-sale,100,52,8/11/2020
8A8E41,business-contract,100,69,8/11/2020
8B3B0E,note-sale,100,52,8/11/2020
8B3B0E,note-sale,100,52,8/11/2020
8C311A,revenue-up,100,69,8/11/2020
8D4486,business-contract,100,69,8/11/2020
8D4486,business-contract,100,69,8/11/2020
8E4F9A,conference-participant,100,50,8/11/2020
8E4F9A,public-offering,100,43,8/11/2020
9.31E+77,revenues,100,50,8/11/2020
938D89,earnings,100,50,8/11/2020
95C575,dividend,100,50,8/11/2020
95DC1F,partnership,100,61,8/11/2020
95F59E,conference-participant,100,50,8/11/2020
9673BD,partnership,100,61,8/11/2020
9673BD,executive-appointment,100,54,8/11/2020
967D92,note-sale,100,52,8/11/2020
96BFF4,legal-issues-defendant,100,22,8/11/2020
96BFF4,earnings,100,50,8/11/2020
99B61C,earnings,100,50,8/11/2020
9C3D3C,earnings,100,50,8/11/2020
9C3D3C,earnings,100,50,8/11/2020
9C3D3C,earnings,100,50,8/11/2020
9C3D3C,earnings,100,50,8/11/2020
9C3D3C,earnings,100,50,8/11/2020
9CDA4F,earnings,100,50,8/11/2020
9D2790,earnings,100,50,8/11/2020
9E5C2C,note-sale,100,52,8/11/2020
9F62D1,dividend,100,50,8/11/2020
A350C1,conference-participant,100,50,8/11/2020
A7A0C8,clinical-trials,100,56,8/11/2020
A7A0C8,earnings,100,50,8/11/2020
A806FA,earnings,100,50,8/11/2020
A806FA,earnings,100,50,8/11/2020
A806FA,earnings,100,50,8/11/2020
A806FA,earnings,100,50,8/11/2020
A868C9,business-contract,100,69,8/11/2020
AEFC90,clinical-trials-start,100,64,8/11/2020
B1DF3C,award,100,58,8/11/2020
B446B8,earnings,100,50,8/11/2020
B446B8,earnings,100,50,8/11/2020
B446B8,earnings,100,50,8/11/2020
B446B8,earnings,100,50,8/11/2020
B508E5,earnings,100,50,8/11/2020
B9764A,dividend,100,50,8/11/2020
BAD9EA,earnings,100,50,8/11/2020
BB0787,partnership,100,61,8/11/2020
BFAEB4,award,100,58,8/11/2020
BFEA04,award,100,58,8/11/2020
BFF98A,earnings,100,50,8/11/2020
C07E05,earnings,100,50,8/11/2020
C5C137,earnings,100,50,8/11/2020
C5F463,partnership,100,61,8/11/2020
C62AA4,index-listing,100,76,8/11/2020
C6C702,conference-participant,100,50,8/11/2020
C72B8F,public-offering,100,43,8/11/2020
C7863D,acquisition-acquirer,100,49,8/11/2020
C9739A,earnings,100,50,8/11/2020
CAD7D9,earnings,100,50,8/11/2020
CEC5B9,note-sale,100,52,8/11/2020
CEC5B9,note-sale,100,52,8/11/2020
D33270,facility-upgrade,100,65,8/11/2020
D5938F,legal-issues-defendant,100,22,8/11/2020
D5938F,legal-issues-defendant,100,22,8/11/2020
D5938F,legal-issues-defendant,100,22,8/11/2020
D5938F,legal-issues-defendant,100,22,8/11/2020
D6144F,conference-participant,100,50,8/11/2020
D6489C,partnership,100,61,8/11/2020
D75910,conference-call,100,50,8/11/2020
D8DA3D,stake-acquirer,100,48,8/11/2020
D8ECA1,public-offering,100,43,8/11/2020
D90F43,partnership,100,61,8/11/2020
DBB28E,conference-call,100,50,8/11/2020
DD1BA1,partnership,100,61,8/11/2020
DD1BA1,partnership,100,61,8/11/2020
DE4924,public-offering,100,43,8/11/2020
DF18E6,public-offering,100,43,8/11/2020
E0207A,conference-participant,100,50,8/11/2020
E05026,earnings,100,50,8/11/2020
E56A0D,earnings,100,50,8/11/2020
E592F0,earnings,100,50,8/11/2020
E68733,acquisition-acquirer,100,49,8/11/2020
E68733,acquisition-acquirer,100,49,8/11/2020
E68733,earnings,100,50,8/11/2020
E68733,earnings,100,50,8/11/2020
E70531,business-contract,100,69,8/11/2020
EAEBF3,note-sale,100,52,8/11/2020
EAEBF3,note-sale,100,52,8/11/2020
EBD89A,conference-call,100,50,8/11/2020
F51DB0,public-offering,100,43,8/11/2020
F5349B,executive-appointment,100,54,8/11/2020
F5C78B,index-listing,100,76,8/11/2020
F6A987,dividend,100,50,8/11/2020
F82D37,dividend,100,50,8/11/2020
F90EE5,dividend,100,50,8/11/2020
FA840E,earnings,100,50,8/11/2020
FC80E6,dividend,100,50,8/11/2020
FD9A97,dividend,100,50,8/11/2020
FEC475,dividend,100,50,8/11/2020
FF227B,fast-track-designation,100,81,8/11/2020
58828,conference-call,100,50,8/12/2020
06A456,partnership,100,61,8/12/2020
0C6861,note-sale,100,52,8/12/2020
1065BC,dividend,100,50,8/12/2020
125212,earnings,100,50,8/12/2020
12DE76,earnings,100,50,8/12/2020
12DE76,executive-appointment,100,54,8/12/2020
157CC1,earnings,100,50,8/12/2020
182546,earnings,100,50,8/12/2020
1AB808,legal-issues-defendant,100,22,8/12/2020
1AE9D5,revenue-up,100,69,8/12/2020
1AE9D5,revenue-up,100,69,8/12/2020
1FA886,legal-issues-defendant,100,22,8/12/2020
228D42,partnership,100,61,8/12/2020
27B191,earnings,100,50,8/12/2020
27B191,earnings,100,50,8/12/2020
27B191,earnings,100,50,8/12/2020
27B191,dividend,100,50,8/12/2020
28AF37,earnings,100,50,8/12/2020
2A4131,earnings,100,50,8/12/2020
2B5483,earnings,100,50,8/12/2020
2B9DBB,dividend,100,50,8/12/2020
2E61CC,executive-appointment,100,54,8/12/2020
2EB04E,earnings,100,50,8/12/2020
2EB04E,earnings,100,50,8/12/2020
2EB04E,earnings,100,50,8/12/2020
2EB04E,earnings,100,50,8/12/2020
366A08,note-sale,100,52,8/12/2020
3C3B6B,executive-appointment,100,54,8/12/2020
3CCC90,partnership,100,61,8/12/2020
3FACA7,facility-upgrade,100,65,8/12/2020
414FFF,executive-appointment,100,54,8/12/2020
4AC91D,executive-appointment,100,54,8/12/2020
4B7006,partnership,100,61,8/12/2020
4B7006,partnership,100,61,8/12/2020
4C2F17,public-offering,100,43,8/12/2020
51F541,dividend,100,50,8/12/2020
520632,partnership,100,61,8/12/2020
523039,earnings,100,50,8/12/2020
5487B1,legal-issues-defendant,100,22,8/12/2020
589803,regulatory-product-approval-granted,100,81,8/12/2020
589846,conference-call,100,50,8/12/2020
596116,facility-open,100,65,8/12/2020
5A64D5,dividend,100,50,8/12/2020
5B3FA2,public-offering,100,43,8/12/2020
615B6D,earnings,100,50,8/12/2020
649CBD,clinical-trials-start,100,64,8/12/2020
6A01DF,public-offering,100,43,8/12/2020
6DD6BA,note-sale,100,52,8/12/2020
6ED519,note-sale,100,52,8/12/2020
7255D2,public-offering,100,43,8/12/2020
726EEA,dividend,100,50,8/12/2020
732449,earnings-guidance,100,50,8/12/2020
73529F,acquisition-acquirer,100,49,8/12/2020
73529F,public-offering,100,43,8/12/2020
76B926,dividend,100,50,8/12/2020
76E80F,conference-call,100,50,8/12/2020
7E1D5D,product-release,100,64,8/12/2020
84920B,earnings,100,50,8/12/2020
84920B,earnings,100,50,8/12/2020
84920B,earnings,100,50,8/12/2020
84920B,earnings,100,50,8/12/2020
86478F,earnings,100,50,8/12/2020
86A1B9,executive-appointment,100,54,8/12/2020
89E771,partnership,100,61,8/12/2020
8D4486,partnership,100,61,8/12/2020
8D4486,partnership,100,61,8/12/2020
8DBE73,legal-issues-defendant,100,22,8/12/2020
8DCBBB,fundraising,100,64,8/12/2020
8DCBBB,fundraising,100,64,8/12/2020
8FF57A,earnings,100,50,8/12/2020
903AB4,note-sale,100,52,8/12/2020
913437,earnings,100,50,8/12/2020
94563D,unit-acquisition-acquirer,100,49,8/12/2020
971334,dividend,100,50,8/12/2020
9FA83B,earnings,100,50,8/12/2020
A01200,earnings,100,50,8/12/2020
A15C71,earnings,100,50,8/12/2020
A15C71,earnings,100,50,8/12/2020
A15C71,earnings,100,50,8/12/2020
A1EAC8,executive-appointment,100,54,8/12/2020
A21649,dividend,100,50,8/12/2020
A2C979,earnings,100,50,8/12/2020
A49498,earnings,100,50,8/12/2020
A49498,earnings,100,50,8/12/2020
A49498,earnings,100,50,8/12/2020
A49498,earnings,100,50,8/12/2020
A5151E,executive-appointment,100,54,8/12/2020
A63387,government-contract,100,69,8/12/2020
A6FE1C,business-contract,100,69,8/12/2020
AD22F2,earnings,100,50,8/12/2020
AE0CCE,earnings,100,50,8/12/2020
B1A85D,partnership,100,61,8/12/2020
B446B8,legal-issues-defendant,100,22,8/12/2020
B446B8,legal-issues-defendant,100,22,8/12/2020
B48D6A,earnings,100,50,8/12/2020
B508E5,partnership,100,61,8/12/2020
B560AF,executive-appointment,100,54,8/12/2020
B614F8,legal-issues-defendant,100,22,8/12/2020
B840EF,executive-appointment,100,54,8/12/2020
BAD655,merger,100,66,8/12/2020
BAD655,earnings,100,50,8/12/2020
BFE02C,conference-participant,100,50,8/12/2020
C037A8,conference-call,100,50,8/12/2020
C3DE7D,partnership,100,61,8/12/2020
C3DE7D,partnership,100,61,8/12/2020
C4A432,conference-call,100,50,8/12/2020
C94CFC,earnings,100,50,8/12/2020
C9E04B,earnings,100,50,8/12/2020
C9E107,partnership,100,61,8/12/2020
CC176E,public-offering,100,43,8/12/2020
CCB623,legal-issues-defendant,100,22,8/12/2020
CCB623,legal-issues-defendant,100,22,8/12/2020
CF073E,earnings,100,50,8/12/2020
D33270,business-contract,100,69,8/12/2020
D36686,earnings,100,50,8/12/2020
D36686,earnings,100,50,8/12/2020
D4070C,joint-venture,100,62,8/12/2020
D54E62,stake-acquirer,100,48,8/12/2020
D58A11,earnings,100,50,8/12/2020
D58A11,earnings,100,50,8/12/2020
D58A11,earnings,100,50,8/12/2020
D58A11,earnings,100,50,8/12/2020
D58A11,facility-open,100,65,8/12/2020
D5938F,legal-issues-defendant,100,22,8/12/2020
D598E7,note-sale,100,52,8/12/2020
D598E7,note-sale,100,52,8/12/2020
D76AEF,earnings,100,50,8/12/2020
D8ECA1,public-offering,100,43,8/12/2020
DB9F70,earnings,100,50,8/12/2020
DD0099,dividend,100,50,8/12/2020
DD682D,executive-appointment,100,54,8/12/2020
E35610,note-sale,100,52,8/12/2020
E35610,public-offering,100,43,8/12/2020
E5C910,earnings,100,50,8/12/2020
E69BA5,dividend,100,50,8/12/2020
E6A53A,dividend,100,50,8/12/2020
E72599,executive-appointment,100,54,8/12/2020
E72599,operating-earnings,100,50,8/12/2020
E845D9,earnings,100,50,8/12/2020
E8846E,legal-issues-defendant,100,22,8/12/2020
E8C557,settlement,100,56,8/12/2020
EB1E1A,earnings,100,50,8/12/2020
EB2F14,executive-appointment,100,54,8/12/2020
ECE814,public-offering,100,43,8/12/2020
ED22DC,earnings,100,50,8/12/2020
F40EE2,business-contract,100,69,8/12/2020
FAE021,dividend,100,50,8/12/2020
FAE021,dividend,100,50,8/12/2020
FC1B7B,executive-appointment,100,54,8/12/2020
FD9526,dividend,100,50,8/12/2020
0157B1,facility-open,100,65,8/13/2020
033B58,earnings,100,50,8/13/2020
03B8CF,revenues,100,50,8/13/2020
03B8CF,dividend,100,50,8/13/2020
07EC43,executive-appointment,100,54,8/13/2020
0BC29E,executive-appointment,100,54,8/13/2020
0BC853,earnings,100,50,8/13/2020
0C6861,note-sale,100,52,8/13/2020
0D03C8,earnings,100,50,8/13/2020
112694,earnings,100,50,8/13/2020
135B09,dividend,100,50,8/13/2020
143C52,conference-call,100,50,8/13/2020
190B91,business-contract,100,69,8/13/2020
1AB808,legal-issues-defendant,100,22,8/13/2020
1B5FEA,earnings,100,50,8/13/2020
1B5FEA,earnings,100,50,8/13/2020
1B5FEA,earnings,100,50,8/13/2020
1EBF8D,partnership,100,61,8/13/2020
1EBF8D,partnership,100,61,8/13/2020
1FA886,legal-issues-defendant,100,22,8/13/2020
21153F,earnings,100,50,8/13/2020
21153F,earnings,100,50,8/13/2020
21153F,earnings,100,50,8/13/2020
21153F,earnings,100,50,8/13/2020
21153F,earnings,100,50,8/13/2020
21153F,earnings,100,50,8/13/2020
21153F,earnings,100,50,8/13/2020
21153F,earnings,100,50,8/13/2020
21153F,earnings,100,50,8/13/2020
21153F,earnings,100,50,8/13/2020
21153F,earnings,100,50,8/13/2020
21153F,earnings,100,50,8/13/2020
21153F,earnings,100,50,8/13/2020
21153F,earnings,100,50,8/13/2020
228D42,partnership,100,61,8/13/2020
26DC29,conference-call,100,50,8/13/2020
275300,executive-appointment,100,54,8/13/2020
28AC4E,public-offering,100,43,8/13/2020
28AC4E,public-offering,100,43,8/13/2020
2B8179,executive-appointment,100,54,8/13/2020
2C681C,partnership,100,61,8/13/2020
2C681C,partnership,100,61,8/13/2020
2CC71C,public-offering,100,43,8/13/2020
2CF9D3,earnings,100,50,8/13/2020
317EC6,earnings,100,50,8/13/2020
317EC6,earnings,100,50,8/13/2020
317EC6,earnings,100,50,8/13/2020
33AD83,conference-call,100,50,8/13/2020
36C09B,regulatory-product-approval-granted,100,81,8/13/2020
3.88E+02,legal-issues-defendant,100,22,8/13/2020
3.88E+02,legal-issues-defendant,100,22,8/13/2020
4.03E+05,executive-resignation,100,44,8/13/2020
448215,executive-resignation,100,44,8/13/2020
4A7C1F,earnings,100,50,8/13/2020
4AE584,earnings,100,50,8/13/2020
4AE584,earnings,100,50,8/13/2020
4BF3D6,executive-appointment,100,54,8/13/2020
4ECD1A,earnings,100,50,8/13/2020
4ECD1A,earnings,100,50,8/13/2020
4ECD1A,earnings,100,50,8/13/2020
4F71DC,partnership,100,61,8/13/2020
50070E,executive-appointment,100,54,8/13/2020
52FB2F,note-sale,100,52,8/13/2020
5487B1,legal-issues-defendant,100,22,8/13/2020
5487B1,legal-issues-defendant,100,22,8/13/2020
54A713,public-offering,100,43,8/13/2020
54A713,public-offering,100,43,8/13/2020
579E8F,earnings,100,50,8/13/2020
586FFD,conference-call,100,50,8/13/2020
589846,product-release,100,64,8/13/2020
5E6959,acquisition-acquirer,100,49,8/13/2020
5E6959,acquisition-acquirer,100,49,8/13/2020
6391C2,earnings,100,50,8/13/2020
673C9A,conference-call,100,50,8/13/2020
69CE71,hirings,100,65,8/13/2020
69E8E1,legal-issues-defendant,100,22,8/13/2020
6B0784,partnership,100,61,8/13/2020
6B5379,partnership-terminated,100,36,8/13/2020
6B5379,dividend,100,50,8/13/2020
6BBCBA,public-offering,100,43,8/13/2020
6CDFC6,note-sale,100,52,8/13/2020
713810,partnership,100,61,8/13/2020
713810,partnership,100,61,8/13/2020
728737,dividend,100,50,8/13/2020
751C8D,earnings,100,50,8/13/2020
762B8D,earnings,100,50,8/13/2020
762B8D,earnings,100,50,8/13/2020
7A0EC4,earnings,100,50,8/13/2020
7ACD98,executive-appointment,100,54,8/13/2020
7CBC40,executive-appointment,100,54,8/13/2020
7F3A5F,executive-appointment,100,54,8/13/2020
819492,earnings,100,50,8/13/2020
834152,executive-appointment,100,54,8/13/2020
863350,note-sale,100,52,8/13/2020
863350,note-sale,100,52,8/13/2020
8665BA,acquisition-interest-acquirer,100,46,8/13/2020
8665BA,acquisition-interest-acquirer,100,46,8/13/2020
873DB9,conference-participant,100,50,8/13/2020
8AA108,earnings,100,50,8/13/2020
8AB85C,earnings,100,50,8/13/2020
8B4A45,facility-open,100,65,8/13/2020
8F8F2F,dividend,100,50,8/13/2020
918D6D,clinical-trials-start,100,64,8/13/2020
92D757,earnings,100,50,8/13/2020
9.97E+09,dividend,100,50,8/13/2020
9C5BA5,revenues,100,50,8/13/2020
9C5BA5,dividend,100,50,8/13/2020
A2A9BA,earnings,100,50,8/13/2020
A2CAF7,buybacks,100,74,8/13/2020
A4BCDE,earnings,100,50,8/13/2020
A631A3,earnings,100,50,8/13/2020
B08C51,earnings,100,50,8/13/2020
B2DAF6,earnings,100,50,8/13/2020
B446B8,legal-issues-defendant,100,22,8/13/2020
B446B8,legal-issues-defendant,100,22,8/13/2020
B4C673,dividend,100,50,8/13/2020
B614F8,legal-issues-defendant,100,22,8/13/2020
B614F8,legal-issues-defendant,100,22,8/13/2020
B614F8,earnings,100,50,8/13/2020
B614F8,earnings,100,50,8/13/2020
BAD655,legal-issues-defendant,100,22,8/13/2020
BAD655,acquisition-regulatory-scrutiny-acquiree,100,38,8/13/2020
BB0787,earnings,100,50,8/13/2020
BF5959,conference-call,100,50,8/13/2020
C06EB6,revenue-up,100,69,8/13/2020
C06EB6,revenue-up,100,69,8/13/2020
C06EB6,revenue-up,100,69,8/13/2020
C0BA36,earnings,100,50,8/13/2020
C356AC,executive-appointment,100,54,8/13/2020
C36189,earnings,100,50,8/13/2020
C501B6,earnings,100,50,8/13/2020
C5E840,conference-call,100,50,8/13/2020
C72B8F,legal-issues-defendant,100,22,8/13/2020
C83B88,product-release,100,64,8/13/2020
CBFFDD,executive-appointment,100,54,8/13/2020
CC8F6E,earnings,100,50,8/13/2020
CC8F6E,executive-appointment,100,54,8/13/2020
CCB623,legal-issues-defendant,100,22,8/13/2020
CCB623,legal-issues-defendant,100,22,8/13/2020
CDC217,earnings,100,50,8/13/2020
CF7292,conference-call,100,50,8/13/2020
D064D5,earnings,100,50,8/13/2020
D064D5,executive-appointment,100,54,8/13/2020
D2C0B6,earnings,100,50,8/13/2020
D33270,business-contract,100,69,8/13/2020
D5938F,legal-issues-defendant,100,22,8/13/2020
D5B13D,earnings,100,50,8/13/2020
D6489C,business-contract,100,69,8/13/2020
D6534D,dividend-up,100,81,8/13/2020
D697DE,public-offering,100,43,8/13/2020
D9C07E,acquisition-completed-acquirer,100,49,8/13/2020
DF18E6,public-offering,100,43,8/13/2020
E13782,public-offering,100,43,8/13/2020
E1F30A,ipo-pricing,100,50,8/13/2020
E30B34,dividend,100,50,8/13/2020
E30B34,dividend,100,50,8/13/2020
E3E68E,partnership,100,61,8/13/2020
E3E68E,partnership,100,61,8/13/2020
E5A3B6,earnings,100,50,8/13/2020
E7BF32,conference-participant,100,50,8/13/2020
E7BF32,conference-participant,100,50,8/13/2020
E8846E,executive-appointment,100,54,8/13/2020
E8F0E2,earnings,100,50,8/13/2020
EFA7B2,earnings,100,50,8/13/2020
F1CD47,dividend,100,50,8/13/2020
F209B4,earnings,100,50,8/13/2020
F2BC3D,earnings,100,50,8/13/2020
F32F88,conference-participant,100,50,8/13/2020
F39E1E,executive-appointment,100,54,8/13/2020
F46EC9,dividend,100,50,8/13/2020
F80FF9,earnings,100,50,8/13/2020
F93C8A,dividend,100,50,8/13/2020
FCA54E,earnings-up,100,68,8/13/2020
FCA54E,earnings,100,50,8/13/2020
FCA54E,earnings,100,50,8/13/2020
FE609F,earnings,100,50,8/13/2020
9397,executive-resignation,100,44,8/14/2020
0968A5,conference-call,100,50,8/14/2020
0D03C8,earnings,100,50,8/14/2020
12A3A3,dividend,100,50,8/14/2020
12A3A3,dividend,100,50,8/14/2020
143C9C,earnings-up,100,68,8/14/2020
143C9C,earnings-up,100,68,8/14/2020
17EDA5,acquisition-acquiree,100,76,8/14/2020
1A3E1B,executive-appointment,100,54,8/14/2020
1AB808,legal-issues-defendant,100,22,8/14/2020
1FAF22,regulatory-product-approval-granted,100,81,8/14/2020
24CB56,conference-participant,100,50,8/14/2020
2.89E+11,dividend,100,50,8/14/2020
2C681C,partnership,100,61,8/14/2020
2C681C,partnership,100,61,8/14/2020
2F5256,note-sale,100,52,8/14/2020
2F5256,note-sale,100,52,8/14/2020
3.88E+02,legal-issues-defendant,100,22,8/14/2020
3.88E+02,legal-issues-defendant,100,22,8/14/2020
3.88E+02,legal-issues-defendant,100,22,8/14/2020
3B9886,conference-call,100,50,8/14/2020
3C75D6,conference-participant,100,50,8/14/2020
4017AD,dividend,100,50,8/14/2020
4017AD,executive-appointment,100,54,8/14/2020
4017AD,executive-appointment,100,54,8/14/2020
42978B,conference-call,100,50,8/14/2020
4B3555,executive-appointment,100,54,8/14/2020
4BBA23,earnings,100,50,8/14/2020
4D371E,executive-appointment,100,54,8/14/2020
51B442,executive-appointment,100,54,8/14/2020
51E682,dividend,100,50,8/14/2020
5487B1,legal-issues-defendant,100,22,8/14/2020
619882,dividend,100,50,8/14/2020
62A48D,earnings,100,50,8/14/2020
6844D2,dividend,100,50,8/14/2020
6BC6F9,partnership,100,61,8/14/2020
6F3936,executive-appointment,100,54,8/14/2020
719B43,ownership-decrease-owner,100,46,8/14/2020
719B43,ownership-decrease-owner,100,46,8/14/2020
73529F,public-offering,100,43,8/14/2020
7.49E+07,earnings,100,50,8/14/2020
752A70,executive-resignation,100,44,8/14/2020
789A7D,dividend,100,50,8/14/2020
7C62A3,debt-extension-recipient,100,73,8/14/2020
7DD8CC,note-sale,100,52,8/14/2020
7F7C87,earnings,100,50,8/14/2020
82F088,note-sale,100,52,8/14/2020
86DFBD,earnings,100,50,8/14/2020
8D0EEA,earnings,100,50,8/14/2020
8DBE73,legal-issues-defendant,100,22,8/14/2020
8E10BF,earnings,100,50,8/14/2020
9043FE,executive-appointment,100,54,8/14/2020
9043FE,executive-appointment,100,54,8/14/2020
918D6D,earnings,100,50,8/14/2020
96BFF4,fraud-defendant,100,20,8/14/2020
96BFF4,legal-issues-defendant,100,22,8/14/2020
96BFF4,legal-issues-defendant,100,22,8/14/2020
96BFF4,legal-issues-defendant,100,22,8/14/2020
96BFF4,legal-issues-defendant,100,22,8/14/2020
9D3360,acquisition-acquirer,100,49,8/14/2020
9EA947,dividend,100,50,8/14/2020
A38F30,executive-appointment,100,54,8/14/2020
A4B899,dividend,100,50,8/14/2020
AC7C4F,business-contract,100,69,8/14/2020
ADD9DC,facility-open,100,65,8/14/2020
B0998E,award,100,58,8/14/2020
B614F8,legal-issues-defendant,100,22,8/14/2020
BAD655,legal-issues-defendant,100,22,8/14/2020
BAD655,legal-issues-defendant,100,22,8/14/2020
BB88B6,award,100,58,8/14/2020
C45CE7,dividend,100,50,8/14/2020
CA99D7,dividend,100,50,8/14/2020
CCB623,legal-issues-defendant,100,22,8/14/2020
CCB623,legal-issues-defendant,100,22,8/14/2020
CCBBAD,executive-appointment,100,54,8/14/2020
CE8A7B,earnings,100,50,8/14/2020
D2B9E5,acquisition-acquiree,100,76,8/14/2020
D56D6D,dividend-up,100,53,8/14/2020
D697DE,public-offering,100,43,8/14/2020
DF1F7A,dividend,100,50,8/14/2020
DF204B,facility-open,100,65,8/14/2020
E13782,public-offering,100,43,8/14/2020
E22FDE,executive-appointment,100,54,8/14/2020
E261E9,earnings,100,50,8/14/2020
E2CFD2,conference-participant,100,50,8/14/2020
E61888,business-contract-terminated,100,31,8/14/2020
E61888,business-contract,100,69,8/14/2020
E8846E,dividend,100,50,8/14/2020
EBD89A,business-contract,100,69,8/14/2020
F1529C,dividend-up,100,81,8/14/2020
F6581D,earnings,100,50,8/14/2020
F6A392,earnings,100,50,8/14/2020
F6A392,earnings,100,50,8/14/2020
168A5D,partnership,100,61,8/15/2020
3.88E+02,legal-issues-defendant,100,22,8/15/2020
6A6BDC,partnership,100,61,8/15/2020
7BFF81,legal-issues-defendant,100,22,8/15/2020
96BFF4,fraud-defendant,100,20,8/15/2020
96BFF4,legal-issues-defendant,100,22,8/15/2020
B0B969,legal-issues-defendant,100,22,8/15/2020
D5938F,legal-issues-defendant,100,22,8/15/2020
5487B1,legal-issues-defendant,100,22,8/16/2020
890FF4,legal-issues-defendant,100,22,8/16/2020
96BFF4,acquisition-acquiree,100,76,8/16/2020
B614F8,legal-issues-defendant,100,22,8/16/2020
CCB623,legal-issues-defendant,100,22,8/16/2020
00FC70,conference-call,100,50,8/17/2020
01D03F,product-release,100,64,8/17/2020
02870F,legal-issues-defendant,100,22,8/17/2020
1096C6,note-sale,100,52,8/17/2020
126F95,dividend,100,50,8/17/2020
15A388,note-sale,100,52,8/17/2020
17EDA5,legal-issues-defendant,100,22,8/17/2020
1AB808,legal-issues-defendant,100,22,8/17/2020
225CA2,note-sale,100,52,8/17/2020
24D81E,hirings,100,65,8/17/2020
25D3CE,conference-organizer,100,57,8/17/2020
2C7505,fundraising,100,64,8/17/2020
2DA92D,dividend,100,50,8/17/2020
2EC172,note-sale,100,52,8/17/2020
2EC172,note-sale,100,52,8/17/2020
2F24A5,executive-appointment,100,54,8/17/2020
30AB63,note-sale,100,52,8/17/2020
3159AA,facility-open,100,65,8/17/2020
3.88E+02,legal-issues-defendant,100,22,8/17/2020
42DC93,public-offering,100,43,8/17/2020
444CC8,executive-appointment,100,54,8/17/2020
46CF27,executive-appointment,100,54,8/17/2020
499C75,executive-appointment,100,54,8/17/2020
4A3438,legal-issues-defendant,100,22,8/17/2020
4BBA23,earnings,100,50,8/17/2020
4C37C5,acquisition-acquirer,100,49,8/17/2020
504FE2,executive-appointment,100,54,8/17/2020
546A27,clinical-trials-start,100,64,8/17/2020
5487B1,legal-issues-defendant,100,22,8/17/2020
594402,regulatory-product-approval-granted,100,81,8/17/2020
5D16CF,dividend,100,50,8/17/2020
5D41E4,executive-appointment,100,54,8/17/2020
5F9CE3,partnership,100,61,8/17/2020
60FE03,conference-participant,100,50,8/17/2020
6166D1,dividend,100,50,8/17/2020
627186,patient-enrollment-start,100,58,8/17/2020
64E346,acquisition-completed-acquirer,100,49,8/17/2020
67303E,clinical-trials,100,56,8/17/2020
67A658,reorganization-unit,100,53,8/17/2020
6BBCBA,public-offering,100,43,8/17/2020
6C4D2F,dividend,100,50,8/17/2020
6D3B7B,dividend,100,50,8/17/2020
790C34,note-sale,100,52,8/17/2020
7A51FE,dividend,100,50,8/17/2020
7AB859,partnership,100,61,8/17/2020
7EA323,earnings,100,50,8/17/2020
7F3669,conference-participant,100,50,8/17/2020
8.10E+32,dividend,100,50,8/17/2020
8665BA,business-contract,100,69,8/17/2020
88D80A,earnings,100,50,8/17/2020
8EEA28,earnings,100,50,8/17/2020
903AB4,executive-appointment,100,54,8/17/2020
905356,earnings-per-share-positive,100,69,8/17/2020
905356,earnings,100,50,8/17/2020
911AB8,partnership,100,61,8/17/2020
911AB8,business-contract,100,69,8/17/2020
94563D,partnership,100,61,8/17/2020
9.62E+76,executive-appointment,100,54,8/17/2020
9673BD,partnership,100,61,8/17/2020
972356,partnership,100,61,8/17/2020
977A1E,acquisition-acquirer,100,49,8/17/2020
9F71E5,note-sale,100,52,8/17/2020
A6213D,product-release,100,64,8/17/2020
AC7C4F,executive-appointment,100,54,8/17/2020
ACF0B4,note-sale,100,52,8/17/2020
B01215,executive-appointment,100,54,8/17/2020
B37FB4,acquisition-acquirer,100,49,8/17/2020
B4F5F4,executive-resignation,100,44,8/17/2020
B614F8,legal-issues-defendant,100,22,8/17/2020
B73395,conference-participant,100,50,8/17/2020
B9CD50,award,100,58,8/17/2020
BB5142,product-release,100,64,8/17/2020
BE645B,conference-participant,100,50,8/17/2020
C037A8,unit-acquisition-acquirer,100,49,8/17/2020
C15DB3,dividend,100,50,8/17/2020
C188F8,business-contract,100,69,8/17/2020
C3BAE7,legal-issues-defendant,100,22,8/17/2020
C62AA4,business-contract,100,69,8/17/2020
C8A248,note-sale,100,52,8/17/2020
C9B932,partnership,100,61,8/17/2020
CCB623,legal-issues-defendant,100,22,8/17/2020
CFF97C,product-release,100,64,8/17/2020
D1588D,executive-appointment,100,54,8/17/2020
D4C0CB,earnings,100,50,8/17/2020
D64EDF,partnership,100,61,8/17/2020
D6853F,asset-sale,100,62,8/17/2020
D78BF1,dividend,100,50,8/17/2020
DB9829,earnings,100,50,8/17/2020
DD682D,acquisition-acquirer,100,49,8/17/2020
DF204B,note-sale,100,52,8/17/2020
E261E9,earnings,100,50,8/17/2020
E41190,executive-appointment,100,54,8/17/2020
E754F0,executive-resignation,100,44,8/17/2020
ECE814,public-offering,100,43,8/17/2020
ED3CA8,public-offering,100,43,8/17/2020
ED3CA8,public-offering,100,43,8/17/2020
F11638,partnership,100,61,8/17/2020
F1C04C,conference-participant,100,50,8/17/2020
F5349B,award,100,58,8/17/2020
F5C78B,merger-completed,100,66,8/17/2020
FF4343,dividend,100,50,8/17/2020
9397,partnership,100,61,8/18/2020
9397,unit-acquisition-completed-acquirer,100,49,8/18/2020
0157B1,hirings,100,65,8/18/2020
070B45,executive-appointment,100,54,8/18/2020
08A40F,executive-appointment,100,54,8/18/2020
0B4D10,dividend,100,50,8/18/2020
0F0440,earnings,100,50,8/18/2020
0F0440,earnings,100,50,8/18/2020
10673F,dividend,100,50,8/18/2020
1096C6,note-sale,100,52,8/18/2020
1151F4,executive-appointment,100,54,8/18/2020
12E454,legal-issues-defendant,100,22,8/18/2020
14391F,stake-acquirer,100,48,8/18/2020
15A388,note-sale,100,52,8/18/2020
168A5D,unit-acquisition-acquirer,100,49,8/18/2020
16C544,note-sale,100,52,8/18/2020
1782D5,note-sale,100,52,8/18/2020
184866,partnership,100,61,8/18/2020
190B91,public-offering,100,43,8/18/2020
190BE6,executive-appointment,100,54,8/18/2020
1AB808,legal-issues-defendant,100,22,8/18/2020
1FA886,legal-issues-defendant,100,22,8/18/2020
20D00A,note-sale,100,52,8/18/2020
228D42,partnership,100,61,8/18/2020
228D42,partnership,100,61,8/18/2020
26F31D,executive-appointment,100,54,8/18/2020
27C10F,legal-issues-defendant,100,22,8/18/2020
2A1009,conference-participant,100,50,8/18/2020
2A1009,executive-appointment,100,54,8/18/2020
2A17B1,dividend,100,50,8/18/2020
3.30E+30,revenue-up,100,76,8/18/2020
3.88E+02,legal-issues-defendant,100,22,8/18/2020
39BFF6,executive-appointment,100,54,8/18/2020
3B318A,conference-call,100,50,8/18/2020
3C8A04,dividend,100,50,8/18/2020
417BF9,earnings,100,50,8/18/2020
51E682,conference-participant,100,50,8/18/2020
53A226,dividend,100,50,8/18/2020
583223,note-sale,100,52,8/18/2020
5E6959,public-offering,100,43,8/18/2020
5E6959,public-offering,100,43,8/18/2020
5F9CE3,dividend,100,50,8/18/2020
616E3B,dividend,100,50,8/18/2020
6.18E+08,earnings,100,50,8/18/2020
6.18E+08,earnings,100,50,8/18/2020
6.18E+08,earnings,100,50,8/18/2020
619882,partnership,100,61,8/18/2020
636BBF,partnership,100,61,8/18/2020
63F892,partnership,100,61,8/18/2020
63F892,partnership,100,61,8/18/2020
6A961B,dividend,100,50,8/18/2020
6D156D,public-offering,100,43,8/18/2020
6-Dec-05,business-contract,100,69,8/18/2020
713810,same-store-sales-up,100,59,8/18/2020
719477,conference-call,100,50,8/18/2020
722DE3,government-contract,100,69,8/18/2020
7239BB,conference-call,100,50,8/18/2020
72CB93,partnership,100,61,8/18/2020
73529F,note-sale,100,52,8/18/2020
73529F,public-offering,100,43,8/18/2020
73529F,note-sale,100,52,8/18/2020
7B492C,earnings,100,50,8/18/2020
7B8CB5,note-sale,100,52,8/18/2020
7B8CB5,note-sale,100,52,8/18/2020
7E62B5,executive-appointment,100,54,8/18/2020
804708,executive-appointment,100,54,8/18/2020
890FF4,legal-issues-defendant,100,22,8/18/2020
8D4486,partnership,100,61,8/18/2020
8D4486,partnership,100,61,8/18/2020
8DE56F,executive-appointment,100,54,8/18/2020
8DE56F,executive-appointment,100,54,8/18/2020
8E82A6,conference-participant,100,50,8/18/2020
8EEA28,note-sale,100,52,8/18/2020
925759,clinical-trials,100,56,8/18/2020
9.31E+77,earnings,100,50,8/18/2020
934029,executive-appointment,100,54,8/18/2020
96BFF4,legal-issues-defendant,100,22,8/18/2020
96BFF4,legal-issues-defendant,100,22,8/18/2020
98CEBB,award,100,58,8/18/2020
9CA619,product-recall,100,29,8/18/2020
9D307D,partnership,100,61,8/18/2020
9F5997,executive-appointment,100,54,8/18/2020
A631A3,reorganization-unit,100,53,8/18/2020
A790A5,earnings,100,50,8/18/2020
A790A5,earnings,100,50,8/18/2020
AAC8B6,executive-appointment,100,54,8/18/2020
AAC8B6,executive-appointment,100,54,8/18/2020
ACDF88,dividend,100,50,8/18/2020
ACDF88,earnings,100,50,8/18/2020
ACDF88,dividend,100,50,8/18/2020
ADD9DC,earnings,100,50,8/18/2020
AEFC90,conference-participant,100,50,8/18/2020
BAD655,legal-issues-defendant,100,22,8/18/2020
BCC55F,partnership,100,61,8/18/2020
BCC55F,partnership,100,61,8/18/2020
BDD12C,dividend,100,50,8/18/2020
BE5935,regulatory-product-approval-granted,100,81,8/18/2020
C06EB6,business-contract,100,69,8/18/2020
C06EB6,business-contract,100,69,8/18/2020
CA99D7,executive-appointment,100,54,8/18/2020
CDAB24,earnings,100,50,8/18/2020
CE5664,dividend,100,50,8/18/2020
CFF97C,credit-rating-upgrade-rater,20,50,8/18/2020
D13F1C,executive-appointment,100,54,8/18/2020
D1AE3B,dividend,100,50,8/18/2020
D5938F,legal-issues-defendant,100,22,8/18/2020
D60BB2,earnings,100,50,8/18/2020
D697DE,public-offering,100,43,8/18/2020
D8442A,partnership,100,61,8/18/2020
DB396B,dividend,100,50,8/18/2020
DBCA3F,partnership,100,61,8/18/2020
DD3BB1,partnership,100,61,8/18/2020
DE4924,public-offering,100,43,8/18/2020
DF18E6,public-offering,100,43,8/18/2020
DF8855,earnings,100,50,8/18/2020
DF8855,earnings,100,50,8/18/2020
DF8855,earnings,100,50,8/18/2020
DF8855,earnings,100,50,8/18/2020
DF8855,earnings,100,50,8/18/2020
DF8855,earnings,100,50,8/18/2020
E06265,conference-participant,100,50,8/18/2020
E1F30A,dividend,100,50,8/18/2020
E68C3D,executive-appointment,100,54,8/18/2020
EC99D0,business-contract,100,69,8/18/2020
ED79D9,earnings,100,50,8/18/2020
F0027C,conference-participant,100,50,8/18/2020
F30508,business-contract,100,69,8/18/2020
F39E1E,earnings,100,50,8/18/2020
F6DCE4,conference-call,100,50,8/18/2020
FC4550,dividend,100,50,8/18/2020
0157B1,partnership,100,61,8/19/2020
0157B1,partnership,100,61,8/19/2020
0157B1,partnership,100,61,8/19/2020
0157B1,partnership,100,61,8/19/2020
01D03F,partnership,100,61,8/19/2020
01D03F,partnership,100,61,8/19/2020
01D03F,partnership,100,61,8/19/2020
01D03F,partnership,100,61,8/19/2020
03B8CF,legal-issues-dismissed-plaintiff,100,44,8/19/2020
03FAA6,partnership,100,61,8/19/2020
053EFF,dividend,100,50,8/19/2020
58828,earnings-per-share-positive,100,69,8/19/2020
06A456,conference-call,100,50,8/19/2020
0A7650,dividend,100,50,8/19/2020
0C2A0D,partnership,100,61,8/19/2020
1151F4,dividend,100,50,8/19/2020
12DE76,partnership,100,61,8/19/2020
12DE76,partnership,100,61,8/19/2020
12DE76,partnership,100,61,8/19/2020
12F98C,conference-call,100,50,8/19/2020
17EDA5,partnership,100,61,8/19/2020
1866B2,executive-resignation,100,44,8/19/2020
1AB808,legal-issues-defendant,100,22,8/19/2020
1AB808,legal-issues-defendant,100,22,8/19/2020
1B6F77,legal-issues-defendant,100,22,8/19/2020
1B6F77,legal-issues-defendant,100,22,8/19/2020
1E7785,conference-participant,100,50,8/19/2020
1FAF22,conference-participant,100,50,8/19/2020
2031CE,dividend,100,50,8/19/2020
221445,executive-appointment,100,54,8/19/2020
263216,dividend,100,50,8/19/2020
274B8A,conference-call,100,50,8/19/2020
278C18,dividend,100,50,8/19/2020
279916,earnings,100,50,8/19/2020
27C10F,legal-issues-defendant,100,22,8/19/2020
28AC4E,partnership,100,61,8/19/2020
292388,conference-participant,100,50,8/19/2020
292A70,dividend-up,100,59,8/19/2020
2CB4C9,earnings,100,50,8/19/2020
2CC60C,earnings,100,50,8/19/2020
40B903,earnings,100,50,8/19/2020
40B903,earnings,100,50,8/19/2020
40B903,earnings,100,50,8/19/2020
414FFF,conference-call,100,50,8/19/2020
416C55,executive-appointment,100,54,8/19/2020
45ABCC,executive-appointment,100,54,8/19/2020
4A6F00,partnership,100,61,8/19/2020
4A6F00,partnership,100,61,8/19/2020
4A6F00,partnership,100,61,8/19/2020
55ACCB,conference-participant,100,50,8/19/2020
564F3E,dividend,100,50,8/19/2020
56EFC7,dividend,100,50,8/19/2020
589803,partnership,100,61,8/19/2020
589803,partnership,100,61,8/19/2020
589803,partnership,100,61,8/19/2020
589803,partnership,100,61,8/19/2020
589803,partnership,100,61,8/19/2020
59872F,partnership,100,61,8/19/2020
5D02B7,note-sale,100,52,8/19/2020
5D87DF,dividend,100,50,8/19/2020
6A024C,executive-appointment,100,54,8/19/2020
6D156D,public-offering,100,43,8/19/2020
713810,conference-participant,100,50,8/19/2020
73BCBA,executive-appointment,100,54,8/19/2020
73BCBA,conference-participant,100,50,8/19/2020
7520CC,executive-appointment,100,54,8/19/2020
76E80F,revenues,100,50,8/19/2020
76E80F,revenues,100,50,8/19/2020
76E80F,revenues,100,50,8/19/2020
76E80F,product-release,100,64,8/19/2020
78A1BB,dividend,100,50,8/19/2020
790C34,note-sale,100,52,8/19/2020
791D59,acquisition-acquirer,100,49,8/19/2020
7E1D5D,earnings,100,50,8/19/2020
7E1D5D,earnings,100,50,8/19/2020
7E1D5D,earnings,100,50,8/19/2020
7E1D5D,earnings,100,50,8/19/2020
7E1D5D,executive-appointment,100,54,8/19/2020
7F7464,ipo-pricing,100,50,8/19/2020
859D62,earnings,100,50,8/19/2020
85AD00,dividend-up,100,81,8/19/2020
863350,earnings,100,50,8/19/2020
890FF4,legal-issues-defendant,100,22,8/19/2020
8EDACA,conference-call,100,50,8/19/2020
8FF2EF,earnings,100,50,8/19/2020
901327,dividend,100,50,8/19/2020
92D3A0,executive-appointment,100,54,8/19/2020
954004,conference-call,100,50,8/19/2020
981656,ipo-pricing,100,50,8/19/2020
98A286,earnings,100,50,8/19/2020
A03EE1,earnings,100,50,8/19/2020
A6828A,acquisition-acquirer,100,49,8/19/2020
A6828A,acquisition-acquirer,100,49,8/19/2020
A6828A,business-contract,100,69,8/19/2020
A70BF5,note-sale,100,52,8/19/2020
A94A7B,business-contract,100,69,8/19/2020
AD1ACF,partnership,100,61,8/19/2020
B0D41A,executive-appointment,100,54,8/19/2020
B1B10C,partnership,100,61,8/19/2020
B1B10C,partnership,100,61,8/19/2020
B37FB4,executive-appointment,100,54,8/19/2020
B3CB74,conference-organizer,100,57,8/19/2020
BB127B,product-release,100,64,8/19/2020
BD682F,dividend,100,50,8/19/2020
BFCACF,earnings,100,50,8/19/2020
C062D4,conference-participant,100,50,8/19/2020
C188F8,conference-call,100,50,8/19/2020
C4C77F,conference-call,100,50,8/19/2020
C4F9C6,executive-appointment,100,54,8/19/2020
CA212F,facility-sale,100,52,8/19/2020
CCBBAD,dividend,100,50,8/19/2020
CE8251,executive-appointment,100,54,8/19/2020
CE8251,executive-appointment,100,54,8/19/2020
CF7292,facility-close,100,47,8/19/2020
D03C7A,dividend,100,50,8/19/2020
D56D6D,earnings,100,50,8/19/2020
D8DBA3,dividend,100,50,8/19/2020
DF1F7A,partnership,100,61,8/19/2020
DF204B,note-sale,100,52,8/19/2020
E06265,dividend-up,100,56,8/19/2020
E09E2B,earnings,100,50,8/19/2020
E09E2B,earnings,100,50,8/19/2020
E09E2B,earnings,100,50,8/19/2020
E68C3D,earnings,100,50,8/19/2020
E8846E,conference-organizer,100,57,8/19/2020
EB36DE,note-sale,100,52,8/19/2020
EB36DE,note-sale,100,52,8/19/2020
EE6F1C,partnership,100,61,8/19/2020
F6581D,earnings,100,50,8/19/2020
F66B58,conference-call,100,50,8/19/2020
F6DCE4,earnings,100,50,8/19/2020
F6DCE4,earnings,100,50,8/19/2020
F82D37,award,100,58,8/19/2020
F8BA6C,executive-appointment,100,54,8/19/2020
FC1B7B,dividend,100,50,8/19/2020
FCA54E,executive-resignation,100,44,8/19/2020
FD39EB,executive-appointment,100,54,8/19/2020
FDF28E,product-release,100,64,8/19/2020
9397,unit-acquisition-completed-acquirer,100,49,8/20/2020
0157B1,partnership,100,61,8/20/2020
02870F,legal-issues-defendant,100,22,8/20/2020
1096C6,note-sale,100,52,8/20/2020
12E454,stock-gain,100,63,8/20/2020
12E454,stock-gain,100,63,8/20/2020
147098,dividend-up,100,63,8/20/2020
14ED2B,dividend,100,50,8/20/2020
14ED2B,earnings,100,50,8/20/2020
188394,partnership,100,61,8/20/2020
190BE6,earnings,100,50,8/20/2020
1AB808,legal-issues-defendant,100,22,8/20/2020
1AB808,legal-issues-defendant,100,22,8/20/2020
1AB808,legal-issues-defendant,100,22,8/20/2020
1AB808,legal-issues-defendant,100,22,8/20/2020
1B6F77,legal-issues-defendant,100,22,8/20/2020
1B6F77,legal-issues-defendant,100,22,8/20/2020
1BC12C,executive-appointment,100,54,8/20/2020
1C2593,earnings-up,100,68,8/20/2020
1E83DE,earnings,100,50,8/20/2020
1F9258,investment-investor,100,55,8/20/2020
1F9258,investment-investor,100,55,8/20/2020
1FAF22,conference-participant,100,50,8/20/2020
1FCC00,earnings,100,50,8/20/2020
205AD5,partnership,100,61,8/20/2020
2093B1,dividend,100,50,8/20/2020
223552,clinical-trials,100,56,8/20/2020
228D42,product-release,100,64,8/20/2020
24FA23,clinical-trials,100,56,8/20/2020
25529C,buybacks,100,74,8/20/2020
26DC29,executive-appointment,100,54,8/20/2020
27C10F,legal-issues-defendant,100,22,8/20/2020
2920D5,dividend,100,50,8/20/2020
2DB344,dividend,100,50,8/20/2020
30DE64,executive-appointment,100,54,8/20/2020
34E9F9,legal-issues-defendant,100,22,8/20/2020
3.50E+27,dividend,100,50,8/20/2020
37E18B,executive-appointment,100,54,8/20/2020
3B20AB,conference-participant,100,50,8/20/2020
3DB18B,partnership,100,61,8/20/2020
42312F,earnings,100,50,8/20/2020
42DC93,public-offering,100,43,8/20/2020
49F4D0,dividend,100,50,8/20/2020
4ECD1A,dividend,100,50,8/20/2020
4FCC78,credit-extension-recipient,100,69,8/20/2020
519FE0,partnership,100,61,8/20/2020
53F491,dividend,100,50,8/20/2020
543900,earnings,100,50,8/20/2020
55C9B5,partnership,100,61,8/20/2020
5675EB,partnership,100,61,8/20/2020
583553,earnings,100,50,8/20/2020
589846,partnership,100,61,8/20/2020
59B229,executive-appointment,100,54,8/20/2020
5B15E1,executive-resignation,100,44,8/20/2020
5B226B,business-contract,100,69,8/20/2020
5C7601,dividend,100,50,8/20/2020
5FE4B6,dividend,100,50,8/20/2020
636639,acquisition-acquirer,100,49,8/20/2020
65D0AA,merger,100,66,8/20/2020
65D0AA,merger,100,66,8/20/2020
66667F,executive-appointment,100,54,8/20/2020
6830FE,earnings,100,50,8/20/2020
7273FF,product-release,100,64,8/20/2020
73F70F,dividend,100,50,8/20/2020
7740DE,earnings-negative,100,33,8/20/2020
7740DE,earnings-negative,100,33,8/20/2020
7A51FE,executive-appointment,100,54,8/20/2020
7B1E50,legal-issues-defendant,100,22,8/20/2020
7BC92D,conference-participant,100,50,8/20/2020
7D5384,executive-appointment,100,54,8/20/2020
7FD8B9,conference-participant,100,50,8/20/2020
804708,executive-appointment,100,54,8/20/2020
8.10E+32,partnership,100,61,8/20/2020
810FAD,dividend,100,50,8/20/2020
830BDB,regulatory-product-application,100,69,8/20/2020
890FF4,legal-issues-defendant,100,22,8/20/2020
8C6C1B,earnings,100,50,8/20/2020
8C6C1B,earnings,100,50,8/20/2020
8D4486,partnership,100,61,8/20/2020
913437,business-contract,100,69,8/20/2020
9196A2,conference-organizer,100,57,8/20/2020
93F143,dividend,100,50,8/20/2020
954A47,dividend,100,50,8/20/2020
96BFF4,legal-issues-defendant,100,22,8/20/2020
96BFF4,legal-issues-defendant,100,22,8/20/2020
96BFF4,legal-issues-defendant,100,22,8/20/2020
9CDA4F,conference-participant,100,50,8/20/2020
A02FB1,note-sale,100,52,8/20/2020
A47A7D,executive-appointment,100,54,8/20/2020
A5628C,executive-appointment,100,54,8/20/2020
A761FE,conference-call,100,50,8/20/2020
A868C9,business-contract,100,69,8/20/2020
ADD9DC,facility-open,100,65,8/20/2020
AE79CD,executive-appointment,100,54,8/20/2020
AE7D16,partnership,100,61,8/20/2020
B3CB74,conference-organizer,100,57,8/20/2020
B3ED62,legal-issues-defendant,100,22,8/20/2020
B4B281,earnings-up,100,68,8/20/2020
B619CB,note-sale,100,52,8/20/2020
B83BCE,conference-participant,100,50,8/20/2020
B8A51F,clinical-trials-start,100,64,8/20/2020
B8DD94,earnings,100,50,8/20/2020
B934BF,dividend-up,100,81,8/20/2020
BAD655,legal-issues-defendant,100,22,8/20/2020
BB0587,dividend,100,50,8/20/2020
C0BA36,product-release,100,64,8/20/2020
C15F8F,executive-resignation,100,44,8/20/2020
C501B6,legal-issues-defendant,100,22,8/20/2020
C6C702,award,100,58,8/20/2020
C6C702,award,100,58,8/20/2020
C83B88,product-release,100,64,8/20/2020
CBB77B,business-contract,100,69,8/20/2020
CFF57D,conference-call,100,50,8/20/2020
D2E553,executive-appointment,100,54,8/20/2020
D47D56,earnings,100,50,8/20/2020
D78CCD,partnership,100,61,8/20/2020
D9B1C9,legal-issues-defendant,100,22,8/20/2020
D9B1C9,legal-issues-defendant,100,22,8/20/2020
DCD97F,legal-issues-defendant,100,22,8/20/2020
DCD97F,legal-issues-defendant,100,22,8/20/2020
E11C41,public-offering,100,43,8/20/2020
E124EB,product-release,100,64,8/20/2020
E4CE73,earnings,100,50,8/20/2020
EB5E78,conference-participant,100,50,8/20/2020
EBD89A,earnings,100,50,8/20/2020
ECA300,conference-call,100,50,8/20/2020
F0B2B5,executive-appointment,100,54,8/20/2020
F0B2B5,executive-appointment,100,54,8/20/2020
F0B2B5,executive-appointment,100,54,8/20/2020
F179ED,partnership,100,61,8/20/2020
F1EB39,conference-participant,100,50,8/20/2020
F57F6F,conference-participant,100,50,8/20/2020
F5D499,business-contract,100,69,8/20/2020
FDE409,earnings,100,50,8/20/2020
FE9C0D,earnings,100,50,8/20/2020
0968A5,executive-appointment,100,54,8/21/2020
0C6861,dividend,100,50,8/21/2020
0CE7F6,earnings,100,50,8/21/2020
14391F,ipo-completed,100,76,8/21/2020
147C38,executive-appointment,100,54,8/21/2020
17EDA5,fraud-defendant,100,20,8/21/2020
17EDA5,legal-issues-defendant,100,22,8/21/2020
197612,dividend,100,50,8/21/2020
1AB808,legal-issues-defendant,100,22,8/21/2020
1AB808,fraud,100,44,8/21/2020
1AB808,legal-issues-defendant,100,22,8/21/2020
1B6F77,legal-issues-defendant,100,22,8/21/2020
20BEEA,dividend,100,50,8/21/2020
228D42,partnership,100,61,8/21/2020
24CB56,earnings,100,50,8/21/2020
253604,ipo-pricing,100,50,8/21/2020
27C10F,legal-issues-defendant,100,22,8/21/2020
31643A,dividend,100,50,8/21/2020
33FD66,facility-open,100,65,8/21/2020
3B2311,conference-participant,100,50,8/21/2020
431B74,earnings-positive,100,69,8/21/2020
431B74,earnings-positive,100,69,8/21/2020
431B74,earnings-positive,100,69,8/21/2020
431B74,earnings-positive,100,69,8/21/2020
431B74,earnings-positive,100,69,8/21/2020
431B74,earnings-positive,100,69,8/21/2020
431B74,earnings-positive,100,69,8/21/2020
431B74,earnings,100,50,8/21/2020
431B74,earnings,100,50,8/21/2020
431B74,earnings,100,50,8/21/2020
431B74,earnings,100,50,8/21/2020
431B74,earnings,100,50,8/21/2020
468DD4,product-recall,100,29,8/21/2020
46CF27,acquisition-completed-acquirer,100,49,8/21/2020
46CF27,acquisition-completed-acquirer,100,49,8/21/2020
485445,executive-appointment,100,54,8/21/2020
485445,executive-appointment,100,54,8/21/2020
4A3438,legal-issues-defendant,100,22,8/21/2020
4C5CC9,conference-participant,100,50,8/21/2020
4F0A80,dividend,100,50,8/21/2020
4FB770,dividend,100,50,8/21/2020
58C2D4,conference-participant,100,50,8/21/2020
5B226B,dividend,100,50,8/21/2020
68AB62,conference-participant,100,50,8/21/2020
6A171E,executive-appointment,100,54,8/21/2020
6D156D,public-offering,100,43,8/21/2020
75F665,dividend,100,50,8/21/2020
76E80F,dividend-up,100,59,8/21/2020
78A1BB,executive-appointment,100,54,8/21/2020
7B9212,earnings,100,50,8/21/2020
7B9212,earnings,100,50,8/21/2020
7F7464,ipo-completed,100,76,8/21/2020
835C86,earnings,100,50,8/21/2020
883D82,earnings,100,50,8/21/2020
88611B,dividend,100,50,8/21/2020
890FF4,legal-issues-defendant,100,22,8/21/2020
9.62E+76,dividend,100,50,8/21/2020
96BFF4,legal-issues-defendant,100,22,8/21/2020
96BFF4,fraud-defendant,100,20,8/21/2020
981656,public-offering,100,43,8/21/2020
99028D,settlement,100,56,8/21/2020
9D2790,dividend,100,50,8/21/2020
A52B6B,conference-participant,100,50,8/21/2020
AC3584,business-contract,100,69,8/21/2020
B1FC3B,conference-participant,100,50,8/21/2020
B3CB74,conference-organizer,100,57,8/21/2020
B446B8,legal-issues-defendant,100,22,8/21/2020
B446B8,legal-issues-defendant,100,22,8/21/2020
B446B8,legal-issues-defendant,100,22,8/21/2020
B446B8,legal-issues-defendant,100,22,8/21/2020
B446B8,legal-issues-defendant,100,22,8/21/2020
BCE9DA,dividend,100,50,8/21/2020
BCE9DA,dividend,100,50,8/21/2020
BD15E8,dividend,100,50,8/21/2020
C0BA36,conference-participant,100,50,8/21/2020
C3BAE7,legal-issues-defendant,100,22,8/21/2020
C3BAE7,legal-issues-defendant,100,22,8/21/2020
C624A1,conference-call,100,50,8/21/2020
D9B1C9,legal-issues-defendant,100,22,8/21/2020
D9B1C9,legal-issues-defendant,100,22,8/21/2020
D9B1C9,legal-issues-defendant,100,22,8/21/2020
D9B1C9,legal-issues-defendant,100,22,8/21/2020
E68C3D,conference-participant,100,50,8/21/2020
E8846E,executive-appointment,100,54,8/21/2020
E90C84,dividend,100,50,8/21/2020
EB36DE,note-sale,100,52,8/21/2020
F04E05,executive-appointment,100,54,8/21/2020
F4E882,executive-appointment,100,54,8/21/2020
F8BA6C,conference-participant,100,50,8/21/2020
F8C5D7,executive-appointment,100,54,8/21/2020
FF6644,conference-call,100,50,8/21/2020
7B1E50,legal-issues-defendant,100,22,8/22/2020
D9B1C9,legal-issues-defendant,100,22,8/22/2020
27C10F,legal-issues-defendant,100,22,8/23/2020
890FF4,legal-issues-defendant,100,22,8/23/2020
02870F,legal-issues-defendant,100,22,8/24/2020
09062E,executive-appointment,100,54,8/24/2020
0CC62B,executive-appointment,100,54,8/24/2020
0CCCB7,partnership,100,61,8/24/2020
0E2992,dividend,100,50,8/24/2020
159AE4,conference-call,100,50,8/24/2020
168A5D,executive-appointment,100,54,8/24/2020
1A3E1B,unit-acquisition-acquiree,100,76,8/24/2020
1AB808,legal-issues-defendant,100,22,8/24/2020
223552,partnership,100,61,8/24/2020
228D42,partnership,100,61,8/24/2020
24D81E,product-release,100,64,8/24/2020
27C10F,legal-issues-defendant,100,22,8/24/2020
2.89E+11,executive-appointment,100,54,8/24/2020
28AF37,earnings,100,50,8/24/2020
2A6DBE,legal-issues-defendant,100,22,8/24/2020
2B49F4,conference-call,100,50,8/24/2020
2C681C,clinical-trials-start,100,64,8/24/2020
2C681C,clinical-trials-start,100,64,8/24/2020
31643A,facility-close,100,47,8/24/2020
34E9F9,legal-issues-defendant,100,22,8/24/2020
3DED49,ipo-considered,100,60,8/24/2020
44A4FC,business-contract,100,69,8/24/2020
492117,acquisition-completed-acquirer,100,49,8/24/2020
4A6F00,partnership,100,61,8/24/2020
4AC91D,acquisition-acquirer,100,49,8/24/2020
4F71DC,executive-appointment,100,54,8/24/2020
50070E,conference-call,100,50,8/24/2020
55C289,dividend,100,50,8/24/2020
58CA9A,conference-participant,100,50,8/24/2020
58EA22,conference-participant,100,50,8/24/2020
5AF08A,executive-appointment,100,54,8/24/2020
5D41E4,conference-participant,100,50,8/24/2020
609208,executive-appointment,100,54,8/24/2020
615B6D,executive-appointment,100,54,8/24/2020
6844D2,partnership,100,61,8/24/2020
70CA28,earnings,100,50,8/24/2020
722D55,executive-appointment,100,54,8/24/2020
73F7F9,spin-off,100,58,8/24/2020
73F7F9,executive-appointment,100,54,8/24/2020
73F7F9,conference-call,100,50,8/24/2020
75F665,executive-resignation,100,44,8/24/2020
76F067,index-listing,100,76,8/24/2020
78F776,executive-appointment,100,54,8/24/2020
7A0EC4,executive-appointment,100,54,8/24/2020
7AB859,business-contract,100,69,8/24/2020
7D5384,product-release,100,64,8/24/2020
7D5FD6,revenue-up,100,69,8/24/2020
83598E,earnings,100,50,8/24/2020
85CDC9,clinical-trials-filed,100,60,8/24/2020
8876D6,partnership,100,61,8/24/2020
890FF4,legal-issues-defendant,100,22,8/24/2020
8A0368,award,100,58,8/24/2020
8AB37F,conference-participant,100,50,8/24/2020
8BFAA4,unit-acquisition-acquiree,100,76,8/24/2020
8BFAA4,unit-acquisition-acquiree,100,76,8/24/2020
8FF57A,business-contract,100,69,8/24/2020
9004C4,board-meeting,100,51,8/24/2020
925759,clinical-trials,100,56,8/24/2020
93D207,business-contract,100,69,8/24/2020
94637C,acquisition-acquirer,100,49,8/24/2020
9470CC,executive-appointment,100,54,8/24/2020
950CDB,patent-awarded,100,72,8/24/2020
950CDB,patent-awarded,100,72,8/24/2020
9C5174,conference-participant,100,50,8/24/2020
A1DBF0,regulatory-product-application,100,69,8/24/2020
A52B6B,acquisition-interest-acquirer,100,46,8/24/2020
A52B6B,earnings,100,50,8/24/2020
AE4EEB,executive-appointment,100,54,8/24/2020
B1B10C,executive-appointment,100,54,8/24/2020
B446B8,legal-issues-defendant,100,22,8/24/2020
B642E8,executive-appointment,100,54,8/24/2020
B98EFA,partnership,100,61,8/24/2020
BCC55F,award,100,58,8/24/2020
BE5935,executive-appointment,100,54,8/24/2020
BFAEB4,donation,100,54,8/24/2020
C3BAE7,legal-issues-defendant,100,22,8/24/2020
C624A1,clinical-trials-positive,100,87,8/24/2020
C99CC8,partnership,100,61,8/24/2020
CA1620,executive-appointment,100,54,8/24/2020
CAD7D9,executive-appointment,100,54,8/24/2020
CAD7D9,executive-appointment,100,54,8/24/2020
CDC217,clinical-trials-start,100,64,8/24/2020
CDFCC9,conference-participant,100,50,8/24/2020
CF211D,conference-participant,100,50,8/24/2020
CFF57D,executive-appointment,100,54,8/24/2020
D1C0B9,credit-extension-recipient,100,69,8/24/2020
D33270,business-contract,100,69,8/24/2020
D4AC65,partnership,100,61,8/24/2020
D4AC65,executive-appointment,100,54,8/24/2020
D60BB2,dividend,100,50,8/24/2020
D76AEF,dividend,100,50,8/24/2020
D9B1C9,legal-issues-defendant,100,22,8/24/2020
E3A829,partnership,100,61,8/24/2020
E3E68E,award,100,58,8/24/2020
E3E68E,award,100,58,8/24/2020
E49AA3,note-sale,100,52,8/24/2020
E4CE73,conference-participant,100,50,8/24/2020
E68733,dividend,100,50,8/24/2020
E68733,dividend,100,50,8/24/2020
E6E012,executive-appointment,100,54,8/24/2020
E6E012,executive-appointment,100,54,8/24/2020
ED9C04,partnership,100,61,8/24/2020
EE74E1,partnership,100,61,8/24/2020
EF5BED,executive-appointment,100,54,8/24/2020
F0B2B5,executive-appointment,100,54,8/24/2020
F0B2B5,executive-appointment,100,54,8/24/2020
F0B2B5,executive-appointment,100,54,8/24/2020
F4F46F,business-contract,100,69,8/24/2020
F88A04,executive-appointment,100,54,8/24/2020
FAB97A,partnership,100,61,8/24/2020
FEBFE1,conference-participant,100,50,8/24/2020
FF6644,legal-issues-defendant,100,22,8/24/2020
FF6644,index-listing,100,76,8/24/2020
01478A,dividend,100,50,8/25/2020
02870F,legal-issues-defendant,100,22,8/25/2020
75172,earnings,100,50,8/25/2020
07EC43,acquisition-acquirer,100,49,8/25/2020
0968A5,earnings,100,50,8/25/2020
0986B5,dividend,100,50,8/25/2020
099C88,dividend,100,50,8/25/2020
0A9D0A,conference-participant,100,50,8/25/2020
0C8D82,business-contract,100,69,8/25/2020
0C8D82,business-contract,100,69,8/25/2020
0C8D82,business-contract,100,69,8/25/2020
0C8D82,acquisition-acquiree,100,76,8/25/2020
0C8D82,acquisition-acquiree,100,76,8/25/2020
0CE204,partnership,100,61,8/25/2020
0CE204,partnership,100,61,8/25/2020
1080C0,executive-appointment,100,54,8/25/2020
12DE76,acquisition-interest-acquirer,100,46,8/25/2020
12E454,partnership,100,61,8/25/2020
147C38,executive-appointment,100,54,8/25/2020
168A5D,partnership,100,61,8/25/2020
16F4D8,partnership,100,61,8/25/2020
1.79E+10,executive-appointment,100,54,8/25/2020
1866B2,dividend,100,50,8/25/2020
1AE9D5,conference-participant,100,50,8/25/2020
1DB6A6,note-sale,100,52,8/25/2020
205AD5,executive-appointment,100,54,8/25/2020
2158DF,regulatory-product-approval-granted,100,81,8/25/2020
253604,ipo-completed,100,76,8/25/2020
2A6DBE,legal-issues-defendant,100,22,8/25/2020
2A6DBE,legal-issues-defendant,100,22,8/25/2020
2A6DBE,legal-issues-defendant,100,22,8/25/2020
2A6DBE,legal-issues-defendant,100,22,8/25/2020
2A6DBE,legal-issues-defendant,100,22,8/25/2020
2B5483,partnership,100,61,8/25/2020
2E0496,regulatory-product-approval-granted,100,81,8/25/2020
2E0496,regulatory-product-approval-granted,100,81,8/25/2020
2F98A5,earnings,100,50,8/25/2020
30A565,regulatory-investigation,100,22,8/25/2020
34B97A,conference-participant,100,50,8/25/2020
3587B4,business-contract,100,69,8/25/2020
3587B4,business-contract,100,69,8/25/2020
3587B4,legal-issues-defendant,100,22,8/25/2020
36529A,clinical-trials-start,100,64,8/25/2020
385DD4,partnership,100,61,8/25/2020
397A8F,earnings,100,50,8/25/2020
3EE65E,earnings,100,50,8/25/2020
422CE3,earnings,100,50,8/25/2020
450ECB,partnership,100,61,8/25/2020
4591D3,note-sale,100,52,8/25/2020
4AC91D,award,100,58,8/25/2020
4B5054,legal-issues-defendant,100,22,8/25/2020
4B5054,legal-issues-defendant,100,22,8/25/2020
4B5054,legal-issues-defendant,100,22,8/25/2020
4B5054,legal-issues-defendant,100,22,8/25/2020
50070E,conference-organizer,100,57,8/25/2020
519FE0,partnership,100,61,8/25/2020
553949,executive-appointment,100,54,8/25/2020
55C9B5,product-release,100,64,8/25/2020
55C9B5,product-release,100,64,8/25/2020
5675EB,partnership,100,61,8/25/2020
56EA2B,conference-call,100,50,8/25/2020
58CA9A,product-release,100,64,8/25/2020
5A9F54,index-listing,100,76,8/25/2020
5B51D6,fast-track-designation,100,81,8/25/2020
5D41E4,auditor-appointment,100,50,8/25/2020
5E7E82,earnings,100,50,8/25/2020
5E7E82,earnings,100,50,8/25/2020
5E7E82,earnings,100,50,8/25/2020
5E7E82,earnings,100,50,8/25/2020
5E7E82,earnings,100,50,8/25/2020
5F3E74,conference-participant,100,50,8/25/2020
5FC507,conference-participant,100,50,8/25/2020
615B6D,clinical-trials-positive,100,87,8/25/2020
615B6D,clinical-trials-positive,100,87,8/25/2020
64E346,earnings,100,50,8/25/2020
64FF65,unit-acquisition-acquiree,100,76,8/25/2020
64FF65,unit-acquisition-acquiree,100,76,8/25/2020
665440,conference-participant,100,50,8/25/2020
665D7D,regulatory-product-application,100,69,8/25/2020
665D7D,regulatory-product-application,100,69,8/25/2020
673C9A,earnings,100,50,8/25/2020
6C6D73,conference-participant,100,50,8/25/2020
6C6D73,conference-participant,100,50,8/25/2020
6CD55A,dividend,100,50,8/25/2020
71553E,regulatory-product-approval-granted,100,81,8/25/2020
717DB4,conference-participant,100,50,8/25/2020
722DE3,business-contract,100,69,8/25/2020
726DDF,conference-participant,100,50,8/25/2020
726DDF,conference-participant,100,50,8/25/2020
73C9E2,business-contract,100,69,8/25/2020
73F7F9,spin-off,100,58,8/25/2020
73F7F9,conference-call,100,50,8/25/2020
789A7D,award,100,58,8/25/2020
791D59,conference-participant,100,50,8/25/2020
7DD584,earnings,100,50,8/25/2020
7E1D5D,partnership,100,61,8/25/2020
80D744,dividend,100,50,8/25/2020
82F088,conference-participant,100,50,8/25/2020
855DF7,facility-relocation,100,50,8/25/2020
8D0EEA,business-contract,100,69,8/25/2020
8E8E6E,partnership,100,61,8/25/2020
918D6D,orphan-drug-designation,100,76,8/25/2020
9196A2,conference-organizer,100,57,8/25/2020
9196A2,conference-organizer,100,57,8/25/2020
93AD2E,note-sale,100,52,8/25/2020
94208D,public-offering,100,43,8/25/2020
95DC1F,partnership,100,61,8/25/2020
95F59E,conference-participant,100,50,8/25/2020
97693A,conference-call,100,50,8/25/2020
990AD0,conference-organizer,100,57,8/25/2020
9D30A8,government-contract,100,69,8/25/2020
A01664,conference-participant,100,50,8/25/2020
A350C1,partnership,100,61,8/25/2020
A5E715,dividend,100,50,8/25/2020
A60354,dividend,100,50,8/25/2020
A63387,product-release,100,64,8/25/2020
A6FC89,partnership,100,61,8/25/2020
A72FD9,conference-call,100,50,8/25/2020
A72FD9,conference-call,100,50,8/25/2020
A8CBDA,conference-participant,100,50,8/25/2020
AA98ED,partnership,100,61,8/25/2020
AC3584,acquisition-acquirer,100,49,8/25/2020
AC3584,acquisition-acquirer,100,49,8/25/2020
AECCA9,dividend,100,50,8/25/2020
B05118,award,100,58,8/25/2020
B3ED62,award,100,58,8/25/2020
B446B8,legal-issues-defendant,100,22,8/25/2020
B6082A,dividend,100,50,8/25/2020
B619CB,note-sale,100,52,8/25/2020
B642E8,donation,100,54,8/25/2020
B9764A,earnings,100,50,8/25/2020
BB127B,earnings-up,100,68,8/25/2020
BDD12C,executive-appointment,100,54,8/25/2020
C0030A,unit-acquisition-acquirer,100,49,8/25/2020
C3DE7D,earnings,100,50,8/25/2020
C4A432,earnings,100,50,8/25/2020
C4A432,earnings,100,50,8/25/2020
C4A432,earnings,100,50,8/25/2020
C951A2,acquisition-acquirer,100,49,8/25/2020
C951A2,acquisition-acquirer,100,49,8/25/2020
CBB77B,earnings,100,50,8/25/2020
CDC217,public-offering,100,43,8/25/2020
D2C0B6,conference-participant,100,50,8/25/2020
D63B0F,conference-participant,100,50,8/25/2020
D6489C,partnership,100,61,8/25/2020
D75910,earnings,100,50,8/25/2020
D75910,earnings,100,50,8/25/2020
D75910,earnings,100,50,8/25/2020
D75910,earnings,100,50,8/25/2020
DBB28E,earnings,100,50,8/25/2020
DBB28E,earnings,100,50,8/25/2020
DBB28E,earnings,100,50,8/25/2020
DBB28E,earnings,100,50,8/25/2020
DBB28E,earnings,100,50,8/25/2020
DBB28E,earnings,100,50,8/25/2020
DBB28E,earnings,100,50,8/25/2020
DBB28E,earnings,100,50,8/25/2020
E074A0,dividend,100,50,8/25/2020
E20BFE,earnings-up,100,68,8/25/2020
E20BFE,earnings-up,100,68,8/25/2020
E20BFE,earnings-up,100,68,8/25/2020
E68733,earnings,100,50,8/25/2020
E68733,earnings,100,50,8/25/2020
E68733,earnings,100,50,8/25/2020
E6D89E,executive-appointment,100,54,8/25/2020
E6D89E,partnership,100,61,8/25/2020
ED9C04,conference-participant,100,50,8/25/2020
EF5BED,executive-appointment,100,54,8/25/2020
F11638,revenue-up,100,63,8/25/2020
F11638,revenue-up,100,63,8/25/2020
F11638,revenue-up,100,63,8/25/2020
F11638,revenue-up,100,63,8/25/2020
F11638,revenue-up,100,63,8/25/2020
F4F46F,conference-participant,100,50,8/25/2020
FF6644,legal-issues-defendant,100,22,8/25/2020
00E601,earnings,100,50,8/26/2020
13528,earnings,100,50,8/26/2020
01D03F,regulatory-product-approval-granted,100,81,8/26/2020
06A456,earnings,100,50,8/26/2020
06A456,earnings,100,50,8/26/2020
06A456,earnings,100,50,8/26/2020
06A456,earnings,100,50,8/26/2020
081AB9,executive-appointment,100,54,8/26/2020
0CE7F6,facility-open,100,65,8/26/2020
1.79E+10,regulatory-investigation,100,22,8/26/2020
184866,partnership,100,61,8/26/2020
1D3A00,earnings,100,50,8/26/2020
1D3A00,earnings,100,50,8/26/2020
1D3A00,earnings,100,50,8/26/2020
1D3A00,earnings,100,50,8/26/2020
1E8A99,dividend,100,50,8/26/2020
221783,partnership,100,61,8/26/2020
228D42,partnership,100,61,8/26/2020
228D42,partnership,100,61,8/26/2020
2A1009,executive-appointment,100,54,8/26/2020
2B7A40,capital-increase-completed,100,61,8/26/2020
2F9304,executive-appointment,100,54,8/26/2020
2F9304,earnings,100,50,8/26/2020
326EDD,dividend-up,100,53,8/26/2020
32C8CD,executive-appointment,100,54,8/26/2020
33E9D5,earnings,100,50,8/26/2020
356B21,executive-appointment,100,54,8/26/2020
372037,executive-appointment,100,54,8/26/2020
3AF7FD,earnings,100,50,8/26/2020
3B9886,facility-open,100,65,8/26/2020
4.03E+05,executive-appointment,100,54,8/26/2020
41C36B,clinical-trials,100,56,8/26/2020
431B74,dividend,100,50,8/26/2020
431B74,dividend,100,50,8/26/2020
45ABCC,conference-participant,100,50,8/26/2020
4C37C5,product-release,100,64,8/26/2020
4C37C5,conference-participant,100,50,8/26/2020
4F9926,campaign-ad-release,100,59,8/26/2020
50070E,conference-organizer,100,57,8/26/2020
50070E,conference-organizer,100,57,8/26/2020
55ACCB,conference-participant,100,50,8/26/2020
5704AC,conference-participant,100,50,8/26/2020
589846,earnings,100,50,8/26/2020
5E7E82,dividend,100,50,8/26/2020
5E9934,conference-call,100,50,8/26/2020
639BD6,conference-participant,100,50,8/26/2020
673C9A,conference-participant,100,50,8/26/2020
67B923,executive-appointment,100,54,8/26/2020
6D9B53,conference-participant,100,50,8/26/2020
6D9B53,conference-participant,100,50,8/26/2020
6F3936,conference-call,100,50,8/26/2020
73F70F,earnings,100,50,8/26/2020
756BB4,earnings,100,50,8/26/2020
7A5097,earnings,100,50,8/26/2020
7D5384,executive-appointment,100,54,8/26/2020
82BB33,earnings,100,50,8/26/2020
838ADD,buybacks,100,74,8/26/2020
89E771,earnings,100,50,8/26/2020
8A8E41,business-contract,100,69,8/26/2020
8EDACA,earnings,100,50,8/26/2020
8EDACA,buybacks,100,74,8/26/2020
934CC3,earnings,100,50,8/26/2020
93D207,conference-participant,100,50,8/26/2020
94208D,public-offering,100,43,8/26/2020
945DE6,executive-appointment,100,54,8/26/2020
9810C0,executive-appointment,100,54,8/26/2020
98A286,earnings,100,50,8/26/2020
98A286,earnings,100,50,8/26/2020
9BF177,earnings,100,50,8/26/2020
9F37C5,dividend,100,50,8/26/2020
A26C26,earnings,100,50,8/26/2020
A350C1,conference-participant,100,50,8/26/2020
A4CD53,conference-participant,100,50,8/26/2020
A631A3,conference-participant,100,50,8/26/2020
AECCA9,earnings,100,50,8/26/2020
AECCA9,earnings,100,50,8/26/2020
AECCA9,earnings,100,50,8/26/2020
AECCA9,earnings,100,50,8/26/2020
AECCA9,earnings,100,50,8/26/2020
AECCA9,earnings,100,50,8/26/2020
B01111,earnings,100,50,8/26/2020
B01111,earnings,100,50,8/26/2020
B01111,earnings,100,50,8/26/2020
B01111,earnings,100,50,8/26/2020
B05118,investment-investor,100,55,8/26/2020
B3ED62,legal-issues-defendant,100,22,8/26/2020
B446B8,legal-issues-defendant,100,22,8/26/2020
BAD655,trading-listing,100,61,8/26/2020
BAD655,legal-issues-defendant,100,22,8/26/2020
BC3AD2,dividend,100,50,8/26/2020
BDD12C,partnership,100,61,8/26/2020
C0BA36,dividend,100,50,8/26/2020
C188F8,earnings,100,50,8/26/2020
C22BE8,earnings,100,50,8/26/2020
C624A1,public-offering,100,43,8/26/2020
C83B88,conference-participant,100,50,8/26/2020
CBA33B,executive-appointment,100,54,8/26/2020
CBB77B,business-contract,100,69,8/26/2020
CBCC6A,executive-appointment,100,54,8/26/2020
D15833,dividend,100,50,8/26/2020
D15833,dividend,100,50,8/26/2020
D2B9E5,note-sale,100,52,8/26/2020
D8442A,partnership,100,61,8/26/2020
DEF058,conference-participant,100,50,8/26/2020
DF16DE,executive-appointment,100,54,8/26/2020
E74B55,executive-appointment,100,54,8/26/2020
E8846E,conference-organizer,100,57,8/26/2020
E8846E,conference-organizer,100,57,8/26/2020
E8E899,executive-appointment,100,54,8/26/2020
E96E0B,conference-participant,100,50,8/26/2020
ED0402,donation,100,54,8/26/2020
F02170,revenue-up,100,61,8/26/2020
F02170,revenues,100,50,8/26/2020
F02170,revenues,100,50,8/26/2020
F02170,revenues,100,50,8/26/2020
F02170,revenues,100,50,8/26/2020
F1EB39,conference-call,100,50,8/26/2020
F5349B,executive-appointment,100,54,8/26/2020
F6DCE4,executive-appointment,100,54,8/26/2020
F6E1B5,conference-participant,100,50,8/26/2020
F748C7,earnings,100,50,8/26/2020
F748C7,dividend,100,50,8/26/2020
FA840E,conference-participant,100,50,8/26/2020
FD6926,conference-participant,100,50,8/26/2020
FDC7E6,executive-appointment,100,54,8/26/2020
FF6644,legal-issues-defendant,100,22,8/26/2020
00698D,earnings,100,50,8/27/2020
0157B1,partnership,100,61,8/27/2020
0157B1,partnership,100,61,8/27/2020
0157B1,partnership,100,61,8/27/2020
0157B1,partnership,100,61,8/27/2020
02870F,dividend,100,50,8/27/2020
31025,partnership,100,61,8/27/2020
054E7E,conference-participant,100,50,8/27/2020
0624BE,earnings,100,50,8/27/2020
0B57D7,dividend-up,100,63,8/27/2020
0BF528,earnings-up,100,68,8/27/2020
0BF528,earnings-up,100,68,8/27/2020
0BF528,earnings-up,100,68,8/27/2020
0BF528,earnings-up,100,68,8/27/2020
0C355F,conference-participant,100,50,8/27/2020
0FABBD,partnership,100,61,8/27/2020
11A49E,partnership,100,61,8/27/2020
129DC8,conference-participant,100,50,8/27/2020
129DC8,trading-halt,100,43,8/27/2020
129DC8,trading-resumed,100,58,8/27/2020
12A3A3,conference-call,100,50,8/27/2020
12A3A3,conference-call,100,50,8/27/2020
13D576,partnership,100,61,8/27/2020
143C52,earnings,100,50,8/27/2020
1CD4B5,patent-awarded,100,72,8/27/2020
1D943E,conference-participant,100,50,8/27/2020
214051,earnings,100,50,8/27/2020
2262BD,earnings,100,50,8/27/2020
22C58E,product-release,100,64,8/27/2020
253604,executive-appointment,100,54,8/27/2020
253B2F,dividend,100,50,8/27/2020
267718,partnership,100,61,8/27/2020
29A4CC,dividend,100,50,8/27/2020
2A6DBE,fraud-defendant,100,20,8/27/2020
2A6DBE,executive-appointment,100,54,8/27/2020
2CA60F,partnership,100,61,8/27/2020
2D5011,buybacks,100,74,8/27/2020
2D643C,conference-participant,100,50,8/27/2020
2E2E6E,dividend,100,50,8/27/2020
314D88,executive-appointment,100,54,8/27/2020
33AD83,earnings,100,50,8/27/2020
35AE32,executive-appointment,100,54,8/27/2020
372037,executive-appointment,100,54,8/27/2020
4.03E+05,business-contract,100,69,8/27/2020
417BF9,conference-participant,100,50,8/27/2020
4290EF,dividend,100,50,8/27/2020
449A26,executive-appointment,100,54,8/27/2020
451D61,conference-participant,100,50,8/27/2020
4591D3,note-sale,100,52,8/27/2020
485445,merger-regulatory-approval,100,81,8/27/2020
485445,merger-regulatory-approval,100,81,8/27/2020
4AC91D,earnings,100,50,8/27/2020
4AC91D,earnings,100,50,8/27/2020
4AC91D,earnings,100,50,8/27/2020
4AC91D,earnings,100,50,8/27/2020
4AC91D,earnings,100,50,8/27/2020
4AC91D,earnings,100,50,8/27/2020
4B7006,executive-appointment,100,54,8/27/2020
4B7006,earnings,100,50,8/27/2020
4E4E75,conference-call,100,50,8/27/2020
50070E,conference-organizer,100,57,8/27/2020
54A646,dividend,100,50,8/27/2020
55ACCB,product-release,100,64,8/27/2020
583553,earnings,100,50,8/27/2020
586FFD,earnings,100,50,8/27/2020
59872F,investment-investor,100,55,8/27/2020
59872F,investment-investor,100,55,8/27/2020
59872F,earnings,100,50,8/27/2020
60AC34,conference-participant,100,50,8/27/2020
6.18E+08,conference-participant,100,50,8/27/2020
636BBF,legal-issues-defendant,100,22,8/27/2020
6830FE,product-release,100,64,8/27/2020
6BBD2D,earnings,100,50,8/27/2020
6C987C,dividend,100,50,8/27/2020
6F3FA8,conference-participant,100,50,8/27/2020
704B78,conference-participant,100,50,8/27/2020
70FCEF,earnings,100,50,8/27/2020
726DDF,note-sale,100,52,8/27/2020
73529F,note-sale,100,52,8/27/2020
7A0EC4,conference-participant,100,50,8/27/2020
7ACD98,award,100,58,8/27/2020
7ADE57,conference-call,100,50,8/27/2020
7B1E50,legal-issues-defendant,100,22,8/27/2020
7CD98F,dividend,100,50,8/27/2020
817ED9,earnings,100,50,8/27/2020
817ED9,earnings,100,50,8/27/2020
817ED9,earnings,100,50,8/27/2020
817ED9,earnings,100,50,8/27/2020
850779,dividend,100,50,8/27/2020
88923D,award,100,58,8/27/2020
896771,business-contract,100,69,8/27/2020
8E8E6E,facility-open,100,65,8/27/2020
9196A2,partnership,100,61,8/27/2020
9196A2,conference-organizer,100,57,8/27/2020
9196A2,conference-organizer,100,57,8/27/2020
92D9C9,executive-appointment,100,54,8/27/2020
95DC1F,conference-call,100,50,8/27/2020
9.74E+08,partnership,100,61,8/27/2020
99028D,earnings,100,50,8/27/2020
997348,dividend,100,50,8/27/2020
9BBFA5,conference-call,100,50,8/27/2020
9CA4C6,executive-appointment,100,54,8/27/2020
A1BB98,dividend,100,50,8/27/2020
A1E3B3,earnings,100,50,8/27/2020
A1E3B3,earnings,100,50,8/27/2020
A47F2E,conference-participant,100,50,8/27/2020
A631A3,earnings,100,50,8/27/2020
A63387,market-entry,100,57,8/27/2020
A70BF5,conference-participant,100,50,8/27/2020
A72AB6,earnings,100,50,8/27/2020
A761FE,earnings,100,50,8/27/2020
A761FE,business-contract,100,69,8/27/2020
AA5C8E,campaign-ad-release,100,59,8/27/2020
ACDF88,conference-participant,100,50,8/27/2020
AD22F2,dividend,100,50,8/27/2020
AFD7DD,executive-resignation,100,44,8/27/2020
B2256A,business-combination,100,54,8/27/2020
B2256A,business-combination,100,54,8/27/2020
B2256A,business-combination,100,54,8/27/2020
B2D492,fundraising,100,64,8/27/2020
B446B8,legal-issues-defendant,100,22,8/27/2020
B446B8,fraud-defendant,100,20,8/27/2020
B446B8,legal-issues-defendant,100,22,8/27/2020
B60366,earnings,100,50,8/27/2020
B73395,conference-participant,100,50,8/27/2020
BB88B6,award,100,58,8/27/2020
BC948D,note-sale,100,52,8/27/2020
BDF85E,earnings,100,50,8/27/2020
BF5959,conference-participant,100,50,8/27/2020
C29E71,earnings,100,50,8/27/2020
C2E39B,conference-participant,100,50,8/27/2020
C3DE7D,executive-appointment,100,54,8/27/2020
C501B6,legal-issues-defendant,100,22,8/27/2020
C501B6,legal-issues-defendant,100,22,8/27/2020
C501B6,legal-issues-defendant,100,22,8/27/2020
C624A1,public-offering,100,43,8/27/2020
C8A248,merger-regulatory-approval,100,81,8/27/2020
C8A248,merger-regulatory-approval,100,81,8/27/2020
CAC8D0,executive-appointment,100,54,8/27/2020
CBDB4D,partnership,100,61,8/27/2020
CC6F6E,earnings,100,50,8/27/2020
CC6F6E,earnings,100,50,8/27/2020
CC6F6E,earnings,100,50,8/27/2020
CD2A4D,conference-participant,100,50,8/27/2020
CF3FF9,clinical-trials-positive,100,87,8/27/2020
CF6A5A,product-release,100,64,8/27/2020
CF7292,earnings,100,50,8/27/2020
D1C0B9,revenue-up,100,69,8/27/2020
D1C0B9,revenue-up,100,69,8/27/2020
D1C0B9,revenue-up,100,69,8/27/2020
D1C0B9,revenue-up,100,69,8/27/2020
D1C0B9,revenue-up,100,69,8/27/2020
D1C0B9,partnership,100,61,8/27/2020
D1C26F,conference-participant,100,50,8/27/2020
D2C0B6,earnings,100,50,8/27/2020
D60BB2,partnership,100,61,8/27/2020
D64C6D,conference-call,100,50,8/27/2020
D77F7E,award,100,58,8/27/2020
D854DD,dividend,100,50,8/27/2020
D8F347,executive-appointment,100,54,8/27/2020
DB88A1,award,100,58,8/27/2020
DBB28E,donation,100,54,8/27/2020
DC2B00,earnings,100,50,8/27/2020
DC2B00,executive-appointment,100,54,8/27/2020
DD7A96,dividend,100,50,8/27/2020
E10D31,dividend,100,50,8/27/2020
E1C16B,dividend,100,50,8/27/2020
E20392,conference-participant,100,50,8/27/2020
E259C7,partnership,100,61,8/27/2020
E49AA3,dividend,100,50,8/27/2020
E56A0D,clinical-trials-start,100,64,8/27/2020
E592F0,partnership,100,61,8/27/2020
E68E62,fast-track-designation,100,81,8/27/2020
E6EDED,dividend-up,100,81,8/27/2020
E802CE,conference-participant,100,50,8/27/2020
E8846E,conference-organizer,100,57,8/27/2020
E99180,buybacks,100,74,8/27/2020
ECF709,executive-appointment,100,54,8/27/2020
EE967B,dividend,100,50,8/27/2020
EEA6B3,donation,100,54,8/27/2020
EF45B6,dividend,100,50,8/27/2020
EF5BED,executive-appointment,100,54,8/27/2020
F0A9DE,dividend,100,50,8/27/2020
F18844,earnings,100,50,8/27/2020
F43A11,conference-call,100,50,8/27/2020
FC01C0,conference-participant,100,50,8/27/2020
FD554E,dividend,100,50,8/27/2020
FDF1C0,dividend,100,50,8/27/2020
15901B,conference-participant,100,50,8/28/2020
16C544,donation,100,54,8/28/2020
1A3E1B,trading-halt,100,43,8/28/2020
1AD9CC,earnings,100,50,8/28/2020
1FCC00,earnings-up,100,68,8/28/2020
1FCC00,earnings-up,100,68,8/28/2020
1FCC00,earnings-up,100,68,8/28/2020
24FA23,clinical-trials,100,56,8/28/2020
25D3CE,loan-recipient,100,59,8/28/2020
275300,conference-participant,100,50,8/28/2020
28F905,executive-appointment,100,54,8/28/2020
34E9F9,legal-issues-defendant,100,22,8/28/2020
3A94DF,dividend,100,50,8/28/2020
3B9886,earnings,100,50,8/28/2020
3B9886,earnings,100,50,8/28/2020
3B9886,earnings,100,50,8/28/2020
3B9886,earnings,100,50,8/28/2020
422A82,partnership,100,61,8/28/2020
4D371E,conference-participant,100,50,8/28/2020
55C9B5,product-release,100,64,8/28/2020
58CA9A,conference-organizer,100,57,8/28/2020
5B6C11,dividend,100,50,8/28/2020
5D16CF,acquisition-completed-acquirer,100,49,8/28/2020
5DE5A5,executive-resignation,100,44,8/28/2020
69C99E,clinical-trials,100,56,8/28/2020
6D2BF6,conference-participant,100,50,8/28/2020
7.45E+28,legal-issues-defendant,100,22,8/28/2020
7823A3,conference-participant,100,50,8/28/2020
880C0C,dividend,100,50,8/28/2020
8D5145,unit-acquisition-acquiree,100,76,8/28/2020
8DBE73,legal-issues-defendant,100,22,8/28/2020
8DBE73,legal-issues-defendant,100,22,8/28/2020
8E8E6E,business-contract,100,69,8/28/2020
90D6A5,dividend,100,50,8/28/2020
93AD2E,product-recall,100,29,8/28/2020
96BFF4,legal-issues-defendant,100,22,8/28/2020
990AD0,conference-organizer,100,57,8/28/2020
9E9147,earnings,100,50,8/28/2020
9E9147,earnings,100,50,8/28/2020
9E9147,earnings,100,50,8/28/2020
9E9147,earnings,100,50,8/28/2020
9E9147,earnings,100,50,8/28/2020
9E9147,earnings,100,50,8/28/2020
9E9147,earnings,100,50,8/28/2020
9E9147,earnings,100,50,8/28/2020
9E9147,earnings,100,50,8/28/2020
9E9147,earnings,100,50,8/28/2020
9E9147,earnings,100,50,8/28/2020
9E9147,earnings,100,50,8/28/2020
9E9147,earnings,100,50,8/28/2020
9E9147,earnings,100,50,8/28/2020
9E9147,earnings,100,50,8/28/2020
9E9147,earnings,100,50,8/28/2020
A6213D,donation,100,54,8/28/2020
A96867,dividend,100,50,8/28/2020
B446B8,legal-issues-defendant,100,22,8/28/2020
C0F4D0,executive-appointment,100,54,8/28/2020
C9E107,note-sale,100,52,8/28/2020
CDC217,public-offering,100,43,8/28/2020
D8F347,executive-appointment,100,54,8/28/2020
DBCA3F,executive-appointment,100,54,8/28/2020
DD9E41,conference-participant,100,50,8/28/2020
E1C16B,executive-appointment,100,54,8/28/2020
E8C557,note-acquisition,100,66,8/28/2020
ECF709,earnings,100,50,8/28/2020
EE6F1C,dividend,100,50,8/28/2020
F6E248,regulatory-product-approval-granted,100,81,8/28/2020
F82D37,executive-appointment,100,54,8/28/2020
FF6644,legal-issues-defendant,100,22,8/28/2020
67303E,clinical-trials,100,56,8/29/2020
7.45E+28,legal-issues-defendant,100,22,8/29/2020
76F067,clinical-trials-positive,100,87,8/29/2020
76F067,clinical-trials-positive,100,87,8/29/2020
76F067,clinical-trials-positive,100,87,8/29/2020
A2C979,clinical-trials,100,56,8/29/2020
C501B6,legal-issues-defendant,100,22,8/29/2020
168A5D,partnership,100,61,8/30/2020
96BFF4,legal-issues-defendant,100,22,8/30/2020
0142B5,executive-appointment,100,54,8/31/2020
02870F,legal-issues-defendant,100,22,8/31/2020
03FB17,product-release,100,64,8/31/2020
0490C6,credit-extension-recipient,100,69,8/31/2020
68396,dividend,100,50,8/31/2020
099C88,business-contract,100,69,8/31/2020
102727,buybacks,100,74,8/31/2020
13D576,executive-appointment,100,54,8/31/2020
157CC1,executive-appointment,100,54,8/31/2020
159739,dividend,100,50,8/31/2020
159739,dividend,100,50,8/31/2020
159739,conference-call,100,50,8/31/2020
159739,conference-call,100,50,8/31/2020
15B10D,conference-participant,100,50,8/31/2020
1748B3,dividend,100,50,8/31/2020
18D9FA,business-contract,100,69,8/31/2020
1A3E1B,trading-resumed,100,58,8/31/2020
1AB808,legal-issues-defendant,100,22,8/31/2020
1AB808,legal-issues-defendant,100,22,8/31/2020
21D903,conference-participant,100,50,8/31/2020
223552,clinical-trials-start,100,64,8/31/2020
2667B6,business-contract,100,69,8/31/2020
279916,legal-issues-defendant,100,22,8/31/2020
28AF37,earnings,100,50,8/31/2020
28DCA8,conference-participant,100,50,8/31/2020
2A1009,partnership,100,61,8/31/2020
2A6DBE,legal-issues-defendant,100,22,8/31/2020
2C681C,business-contract,100,69,8/31/2020
2C681C,business-contract,100,69,8/31/2020
3587B4,executive-appointment,100,54,8/31/2020
382EAE,executive-appointment,100,54,8/31/2020
385DD4,trading-delisting,100,36,8/31/2020
3B8484,acquisition-acquirer,100,49,8/31/2020
43A060,partnership,100,61,8/31/2020
43A74A,conference-participant,100,50,8/31/2020
44740A,executive-appointment,100,54,8/31/2020
44A4FC,earnings,100,50,8/31/2020
49BBBC,earnings,100,50,8/31/2020
4C37C5,executive-appointment,100,54,8/31/2020
504FE2,conference-participant,100,50,8/31/2020
514067,conference-participant,100,50,8/31/2020
5.47E+28,regulatory-product-approval-granted,100,81,8/31/2020
55C9B5,partnership,100,61,8/31/2020
56EFC7,executive-appointment,100,54,8/31/2020
58EA22,earnings,100,50,8/31/2020
58EA22,earnings,100,50,8/31/2020
5DAF89,conference-participant,100,50,8/31/2020
5DD48B,note-sale,100,52,8/31/2020
619882,conference-organizer,100,57,8/31/2020
6810DE,executive-appointment,100,54,8/31/2020
698FF9,conference-participant,100,50,8/31/2020
6BF593,executive-appointment,100,54,8/31/2020
6DBBBC,expenses-guidance-down,100,61,8/31/2020
6F0096,dividend,100,50,8/31/2020
6F5DD2,conference-participant,100,50,8/31/2020
735388,executive-appointment,100,54,8/31/2020
747219,conference-participant,100,50,8/31/2020
751C8D,earnings,100,50,8/31/2020
76D79A,dividend,100,50,8/31/2020
79340A,conference-participant,100,50,8/31/2020
7B6EB1,conference-participant,100,50,8/31/2020
7B9AFA,conference-participant,100,50,8/31/2020
804708,dividend,100,50,8/31/2020
810FAD,executive-appointment,100,54,8/31/2020
85AD00,acquisition-acquirer,100,49,8/31/2020
873DB9,conference-participant,100,50,8/31/2020
88193E,conference-participant,100,50,8/31/2020
896771,facility-open,100,65,8/31/2020
89E771,partnership,100,61,8/31/2020
8DBE73,legal-issues-defendant,100,22,8/31/2020
8DBE73,legal-issues-defendant,100,22,8/31/2020
8E4250,earnings,100,50,8/31/2020
92005C,executive-appointment,100,54,8/31/2020
925759,stake-acquirer,100,48,8/31/2020
92B625,executive-appointment,100,54,8/31/2020
96A2D3,revenue-guidance-up,100,83,8/31/2020
990AD0,conference-organizer,100,57,8/31/2020
9C8BC3,government-contract,100,69,8/31/2020
9D307D,conference-participant,100,50,8/31/2020
9F5CBB,dividend,100,50,8/31/2020
A11CF4,earnings,100,50,8/31/2020
A4BCDE,dividend,100,50,8/31/2020
A5195E,orphan-drug-designation,100,76,8/31/2020
A5DD24,executive-appointment,100,54,8/31/2020
A631A3,award,100,58,8/31/2020
A70BF5,dividend,100,50,8/31/2020
AAC8B6,dividend,100,50,8/31/2020
AAC8B6,dividend,100,50,8/31/2020
AC7C4F,business-contract,100,69,8/31/2020
AE3113,conference-participant,100,50,8/31/2020
AEFC90,clinical-trials,100,56,8/31/2020
B642E8,dividend,100,50,8/31/2020
B6843B,conference-participant,100,50,8/31/2020
B8F71F,conference-participant,100,50,8/31/2020
BA0442,partnership,100,61,8/31/2020
BB127B,conference-participant,100,50,8/31/2020
C0F70B,conference-participant,100,50,8/31/2020
C3BAE7,conference-participant,100,50,8/31/2020
C490F9,earnings,100,50,8/31/2020
C501B6,legal-issues-defendant,100,22,8/31/2020
C501B6,legal-issues-defendant,100,22,8/31/2020
C501B6,legal-issues-defendant,100,22,8/31/2020
C501B6,legal-issues-defendant,100,22,8/31/2020
C58D71,campaign-ad-release,100,59,8/31/2020
C5D2AE,buybacks,100,74,8/31/2020
C5E840,earnings,100,50,8/31/2020
CA99D7,executive-appointment,100,54,8/31/2020
CBB77B,dividend,100,50,8/31/2020
CBCC6A,product-release,100,64,8/31/2020
CC339B,dividend,100,50,8/31/2020
CDAB24,executive-appointment,100,54,8/31/2020
CF073E,conference-participant,100,50,8/31/2020
CF211D,earnings,100,50,8/31/2020
D25249,conference-participant,100,50,8/31/2020
D57D99,partnership,100,61,8/31/2020
D598E7,government-contract,100,69,8/31/2020
D90F43,conference-participant,100,50,8/31/2020
E11C41,executive-appointment,100,54,8/31/2020
E49AA3,acquisition-acquirer,100,49,8/31/2020
E8C557,asset-sale,100,62,8/31/2020
ECE19E,clinical-trials-start,100,64,8/31/2020
EE1E44,dividend,100,50,8/31/2020
EEA6B3,partnership,100,61,8/31/2020
EF1AD9,product-release,100,64,8/31/2020
EF5BED,executive-appointment,100,54,8/31/2020
F3EDB4,unit-acquisition-acquiree,100,76,8/31/2020
F47871,executive-appointment,100,54,8/31/2020
F4E992,conference-participant,100,50,8/31/2020
F5C78B,note-sale,100,52,8/31/2020
FACF19,executive-appointment,100,54,8/31/2020
FD2565,conference-participant,100,50,8/31/2020
FEC475,conference-participant,100,50,8/31/2020
FF227B,executive-appointment,100,54,8/31/2020
FF6644,legal-issues-defendant,100,22,8/31/2020
FF6644,legal-issues-defendant,100,22,8/31/2020
002A99,conference-participant,100,50,9/1/2020
0157B1,partnership,100,61,9/1/2020
01B8D6,conference-participant,100,50,9/1/2020
01D03F,product-release,100,64,9/1/2020
02870F,award,100,58,9/1/2020
03D5F9,partnership,100,61,9/1/2020
03D5F9,partnership,100,61,9/1/2020
06EE79,executive-appointment,100,54,9/1/2020
091B6C,earnings,100,50,9/1/2020
091B6C,earnings,100,50,9/1/2020
09DE1F,product-release,100,64,9/1/2020
10100E,conference-participant,100,50,9/1/2020
10AE08,executive-appointment,100,54,9/1/2020
129DC8,trading-halt,100,43,9/1/2020
129DC8,trading-resumed,100,58,9/1/2020
159AE4,dividend,100,50,9/1/2020
17EDA5,executive-appointment,100,54,9/1/2020
1921DD,partnership,100,61,9/1/2020
19BF16,executive-resignation,100,44,9/1/2020
1A3E1B,conference-participant,100,50,9/1/2020
1D5C51,conference-participant,100,50,9/1/2020
1D5C51,conference-participant,100,50,9/1/2020
1D9E55,business-contract,100,69,9/1/2020
1E1125,conference-organizer,100,57,9/1/2020
1E9A6D,asset-sale,100,62,9/1/2020
1F716B,acquisition-completed-acquirer,100,49,9/1/2020
1F9258,conference-participant,100,50,9/1/2020
1FA886,fraud,100,44,9/1/2020
1FA886,partnership,100,61,9/1/2020
2158DF,conference-participant,100,50,9/1/2020
223552,executive-appointment,100,54,9/1/2020
232053,conference-participant,100,50,9/1/2020
25102A,conference-participant,100,50,9/1/2020
2667B6,acquisition-completed-acquiree,100,76,9/1/2020
2667B6,acquisition-completed-acquiree,100,76,9/1/2020
267718,facility-sale,100,52,9/1/2020
2E89AE,conference-participant,100,50,9/1/2020
30AB63,conference-participant,100,50,9/1/2020
315EB0,partnership,100,61,9/1/2020
317EC6,conference-participant,100,50,9/1/2020
31803E,conference-participant,100,50,9/1/2020
34E9F9,legal-issues-defendant,100,22,9/1/2020
371C01,executive-appointment,100,54,9/1/2020
3AAEAE,conference-participant,100,50,9/1/2020
3B37F7,public-offering,100,43,9/1/2020
3B50FE,conference-call,100,50,9/1/2020
3C7F5F,executive-appointment,100,54,9/1/2020
3FFA78,executive-appointment,100,54,9/1/2020
401072,executive-appointment,100,54,9/1/2020
431B74,acquisition-completed-acquirer,100,49,9/1/2020
431B74,acquisition-completed-acquirer,100,49,9/1/2020
43A74A,note-sale,100,52,9/1/2020
43A74A,note-sale,100,52,9/1/2020
45BC35,conference-participant,100,50,9/1/2020
4D8124,business-contract,100,69,9/1/2020
532D47,business-contract,100,69,9/1/2020
54DF47,dividend,100,50,9/1/2020
55C9B5,partnership,100,61,9/1/2020
55CD6F,dividend,100,50,9/1/2020
56EA2B,dividend,100,50,9/1/2020
56EFC7,earnings,100,50,9/1/2020
57356F,conference-participant,100,50,9/1/2020
57CAAB,regulatory-product-approval-granted,100,81,9/1/2020
59F0B0,conference-call,100,50,9/1/2020
5A423F,conference-participant,100,50,9/1/2020
5E1DF3,demand-increase,100,83,9/1/2020
5EAA43,partnership,100,61,9/1/2020
61B81B,conference-participant,100,50,9/1/2020
636639,acquisition-acquirer,100,49,9/1/2020
6.52E+64,executive-appointment,100,54,9/1/2020
657097,unit-acquisition-acquirer,100,49,9/1/2020
6634D9,unit-acquisition-acquiree,100,76,9/1/2020
69CE71,partnership,100,61,9/1/2020
6CC55E,conference-participant,100,50,9/1/2020
6D156D,conference-participant,100,50,9/1/2020
6FCEF9,earnings,100,50,9/1/2020
713810,partnership,100,61,9/1/2020
722DE3,government-contract,100,69,9/1/2020
7410C3,executive-appointment,100,54,9/1/2020
751C8D,conference-participant,100,50,9/1/2020
75768D,conference-call,100,50,9/1/2020
7ACFD4,executive-appointment,100,54,9/1/2020
7BFF81,conference-participant,100,50,9/1/2020
7CD98F,conference-participant,100,50,9/1/2020
7FD8B9,conference-participant,100,50,9/1/2020
863350,earnings,100,50,9/1/2020
86AA9C,dividend-up,100,81,9/1/2020
8.73E+09,executive-resignation,100,44,9/1/2020
88350F,donation,100,54,9/1/2020
8AA108,executive-appointment,100,54,9/1/2020
8DBE73,legal-issues-defendant,100,22,9/1/2020
8DBE73,legal-issues-defendant,100,22,9/1/2020
8EF425,dividend,100,50,9/1/2020
9196A2,conference-organizer,100,57,9/1/2020
9196A2,conference-organizer,100,57,9/1/2020
9196A2,conference-organizer,100,57,9/1/2020
9196A2,conference-organizer,100,57,9/1/2020
9196A2,conference-organizer,100,57,9/1/2020
9196A2,conference-organizer,100,57,9/1/2020
9196A2,conference-organizer,100,57,9/1/2020
9196A2,conference-organizer,100,57,9/1/2020
94563D,conference-participant,100,50,9/1/2020
95C392,executive-appointment,100,54,9/1/2020
965360,conference-participant,100,50,9/1/2020
990AD0,facility-open,100,65,9/1/2020
9D56F2,conference-call,100,50,9/1/2020
9E0811,public-offering,100,43,9/1/2020
9F03CF,executive-appointment,100,54,9/1/2020
A03EE1,partnership,100,61,9/1/2020
A38F30,reorganization-complete,100,74,9/1/2020
A38F30,reorganization-complete,100,74,9/1/2020
A52B6B,partnership,100,61,9/1/2020
A63820,earnings,100,50,9/1/2020
A6FE1C,unit-acquisition-acquirer,100,49,9/1/2020
A70BF5,executive-appointment,100,54,9/1/2020
A79F7D,conference-participant,100,50,9/1/2020
A868C9,business-contract,100,69,9/1/2020
AAC8B6,executive-appointment,100,54,9/1/2020
AAC8B6,executive-appointment,100,54,9/1/2020
AD22F2,earnings,100,50,9/1/2020
AD22F2,earnings,100,50,9/1/2020
AD22F2,earnings,100,50,9/1/2020
AD22F2,earnings,100,50,9/1/2020
AD22F2,earnings,100,50,9/1/2020
AED6CF,asset-sale,100,62,9/1/2020
B04426,business-contract,100,69,9/1/2020
B04426,business-contract,100,69,9/1/2020
B33E77,conference-participant,100,50,9/1/2020
B8EF97,business-contract,100,69,9/1/2020
B8F71F,note-sale,100,52,9/1/2020
B9764A,partnership,100,61,9/1/2020
BAD655,legal-issues-defendant,100,22,9/1/2020
BDD12C,executive-appointment,100,54,9/1/2020
BDEF34,dividend,100,50,9/1/2020
BF5959,executive-appointment,100,54,9/1/2020
BFD0A7,conference-participant,100,50,9/1/2020
C3BAE7,legal-issues-defendant,100,22,9/1/2020
C501B6,legal-issues-defendant,100,22,9/1/2020
C501B6,legal-issues-defendant,100,22,9/1/2020
C5D2AE,conference-participant,100,50,9/1/2020
CBB77B,earnings,100,50,9/1/2020
CBB77B,earnings,100,50,9/1/2020
CC35BE,executive-appointment,100,54,9/1/2020
CD4DA8,conference-organizer,100,57,9/1/2020
CDAF5B,dividend,100,50,9/1/2020
CE5C6E,clinical-trials-start,100,64,9/1/2020
CE96E7,conference-participant,100,50,9/1/2020
D1CFC8,workforce-salary-decrease,100,53,9/1/2020
D29B44,product-release,100,64,9/1/2020
D56E4C,joint-venture-terminated,100,38,9/1/2020
D56E4C,joint-venture-terminated,100,38,9/1/2020
D6489C,executive-appointment,100,54,9/1/2020
D6489C,executive-appointment,100,54,9/1/2020
D697DE,conference-participant,100,50,9/1/2020
D854F3,conference-participant,100,50,9/1/2020
DB88A1,earnings,100,50,9/1/2020
E0207A,executive-appointment,100,54,9/1/2020
E124EB,executive-appointment,100,54,9/1/2020
E8846E,business-contract,100,69,9/1/2020
EAEBF3,conference-participant,100,50,9/1/2020
EBD89A,business-contract,100,69,9/1/2020
ECE19E,conference-participant,100,50,9/1/2020
EF5BED,business-contract,100,69,9/1/2020
F294DD,acquisition-completed-acquirer,100,49,9/1/2020
F2E253,partnership,100,61,9/1/2020
F3816D,fundraising,100,64,9/1/2020
F40EE2,business-contract,100,69,9/1/2020
F40EE2,business-contract,100,69,9/1/2020
F6E248,business-contract,100,69,9/1/2020
F6E248,business-contract,100,69,9/1/2020
FA40E2,earnings,100,50,9/1/2020
FE609F,conference-participant,100,50,9/1/2020
FEE4B0,acquisition-completed-acquirer,100,49,9/1/2020
FF6644,legal-issues-defendant,100,22,9/1/2020
00067A,conference-participant,100,50,9/2/2020
9397,executive-appointment,100,54,9/2/2020
9397,conference-participant,100,50,9/2/2020
0157B1,product-release,100,64,9/2/2020
0157B1,partnership,100,61,9/2/2020
03D5F9,partnership,100,61,9/2/2020
03D5F9,partnership,100,61,9/2/2020
070B45,acquisition-completed-acquirer,100,49,9/2/2020
07EC43,conference-participant,100,50,9/2/2020
09DE1F,product-release,100,64,9/2/2020
0C6293,conference-participant,100,50,9/2/2020
0E5223,conference-participant,100,50,9/2/2020
10100E,conference-participant,100,50,9/2/2020
133644,conference-participant,100,50,9/2/2020
13C3E0,conference-participant,100,50,9/2/2020
16F4D8,conference-participant,100,50,9/2/2020
17EDA5,product-release,100,64,9/2/2020
17EDA5,product-release,100,64,9/2/2020
184866,conference-participant,100,50,9/2/2020
1A3E1B,conference-call,100,50,9/2/2020
1AB808,conference-participant,100,50,9/2/2020
1B637E,settlement,100,56,9/2/2020
1B6F77,conference-participant,100,50,9/2/2020
1BDB2A,conference-participant,100,50,9/2/2020
1CD4B5,conference-participant,100,50,9/2/2020
1EBF8D,partnership,100,61,9/2/2020
1F19C8,executive-appointment,100,54,9/2/2020
221783,conference-participant,100,50,9/2/2020
228D42,partnership,100,61,9/2/2020
24FA23,conference-participant,100,50,9/2/2020
270B78,conference-participant,100,50,9/2/2020
279916,earnings,100,50,9/2/2020
2B7A40,conference-participant,100,50,9/2/2020
2C3348,conference-participant,100,50,9/2/2020
2D981A,name-change,100,49,9/2/2020
2F6782,asset-sale,100,62,9/2/2020
3.30E+30,executive-appointment,100,54,9/2/2020
349DA4,acquisition-acquirer,100,49,9/2/2020
349DA4,acquisition-acquirer,100,49,9/2/2020
34E9F9,legal-issues-defendant,100,22,9/2/2020
367434,clinical-trials,100,56,9/2/2020
367E1C,conference-participant,100,50,9/2/2020
38C46F,dividend,100,50,9/2/2020
3AF7FD,conference-participant,100,50,9/2/2020
3C3B6B,conference-participant,100,50,9/2/2020
3C7F5F,conference-participant,100,50,9/2/2020
3E15F6,product-release,100,64,9/2/2020
3E70FC,executive-appointment,100,54,9/2/2020
3F4668,unit-acquisition-acquiree,100,76,9/2/2020
408380,conference-participant,100,50,9/2/2020
414FFF,earnings,100,50,9/2/2020
414FFF,earnings,100,50,9/2/2020
414FFF,earnings,100,50,9/2/2020
414FFF,earnings,100,50,9/2/2020
414FFF,earnings,100,50,9/2/2020
414FFF,earnings,100,50,9/2/2020
414FFF,earnings,100,50,9/2/2020
414FFF,earnings,100,50,9/2/2020
414FFF,earnings,100,50,9/2/2020
41785E,conference-participant,100,50,9/2/2020
47FCF2,sponsorship,100,57,9/2/2020
4C2F17,conference-participant,100,50,9/2/2020
4DD203,conference-participant,100,50,9/2/2020
4F71DC,partnership,100,61,9/2/2020
50070E,conference-organizer,100,57,9/2/2020
50070E,conference-organizer,100,57,9/2/2020
5487B1,dividend,100,50,9/2/2020
57634F,award,100,58,9/2/2020
5D1329,conference-participant,100,50,9/2/2020
5F2FF7,conference-participant,100,50,9/2/2020
5F9CE3,conference-participant,100,50,9/2/2020
5FC507,earnings,100,50,9/2/2020
615B6D,public-offering,100,43,9/2/2020
620381,executive-appointment,100,54,9/2/2020
6284B5,partnership,100,61,9/2/2020
636BBF,earnings,100,50,9/2/2020
64E346,conference-participant,100,50,9/2/2020
65D0AA,acquisition-completed-acquirer,100,49,9/2/2020
693ECD,executive-appointment,100,54,9/2/2020
69CE71,conference-participant,100,50,9/2/2020
69FDFC,executive-appointment,100,54,9/2/2020
6C6D73,conference-call,100,50,9/2/2020
6CF43C,business-contract,100,69,9/2/2020
6D9B53,executive-appointment,100,54,9/2/2020
6DBBBC,award,100,58,9/2/2020
6F3936,earnings,100,50,9/2/2020
6F3936,earnings,100,50,9/2/2020
6F3936,earnings,100,50,9/2/2020
6F3936,earnings,100,50,9/2/2020
6F3936,earnings,100,50,9/2/2020
6F3936,earnings,100,50,9/2/2020
70CA28,executive-appointment,100,54,9/2/2020
7239BB,earnings,100,50,9/2/2020
726DDF,conference-participant,100,50,9/2/2020
729368,conference-participant,100,50,9/2/2020
73A213,earnings,100,50,9/2/2020
76E80F,conference-participant,100,50,9/2/2020
7712CB,conference-participant,100,50,9/2/2020
7ACD98,award,100,58,9/2/2020
7B0BA6,conference-participant,100,50,9/2/2020
7BFF81,executive-appointment,100,54,9/2/2020
7DD584,revenue-up,100,75,9/2/2020
7DD584,revenue-up,100,75,9/2/2020
7DD584,revenue-up,100,75,9/2/2020
7E1D5D,executive-appointment,100,54,9/2/2020
7E1D5D,conference-participant,100,50,9/2/2020
7FC386,dividend,100,50,9/2/2020
803FED,conference-participant,100,50,9/2/2020
819492,conference-participant,100,50,9/2/2020
8.10E+205,conference-participant,100,50,9/2/2020
82E58A,note-sale,100,52,9/2/2020
834152,conference-participant,100,50,9/2/2020
859D62,earnings-positive,100,69,9/2/2020
859D62,earnings-positive,100,69,9/2/2020
859D62,earnings-positive,100,69,9/2/2020
859D62,earnings-positive,100,69,9/2/2020
859D62,earnings-positive,100,69,9/2/2020
862941,conference-participant,100,50,9/2/2020
86A1B9,legal-issues-defendant,100,22,9/2/2020
8A8E41,partnership,100,61,9/2/2020
8B4A45,earnings,100,50,9/2/2020
8B8656,earnings,100,50,9/2/2020
8BAA15,earnings-guidance,100,50,9/2/2020
8DBE73,legal-issues-defendant,100,22,9/2/2020
8DCBBB,conference-participant,100,50,9/2/2020
8DCF18,conference-participant,100,50,9/2/2020
8E82A6,business-contract,100,69,9/2/2020
918D6D,conference-participant,100,50,9/2/2020
9196A2,conference-organizer,100,57,9/2/2020
9196A2,conference-organizer,100,57,9/2/2020
9196A2,conference-organizer,100,57,9/2/2020
91C82E,conference-call,100,50,9/2/2020
931AE7,conference-participant,100,50,9/2/2020
9.31E+77,conference-participant,100,50,9/2/2020
94637C,conference-participant,100,50,9/2/2020
954004,earnings,100,50,9/2/2020
972356,partnership,100,61,9/2/2020
9.74E+08,executive-appointment,100,54,9/2/2020
9810C0,dividend,100,50,9/2/2020
990AD0,conference-organizer,100,57,9/2/2020
9A602D,award,100,58,9/2/2020
9B0C9C,unit-acquisition-acquiree,100,76,9/2/2020
9B730A,conference-participant,100,50,9/2/2020
9E0811,public-offering,100,43,9/2/2020
9E91C6,partnership,100,61,9/2/2020
A05C43,conference-participant,100,50,9/2/2020
A26C26,unit-acquisition-acquiree,100,76,9/2/2020
A26EF7,conference-participant,100,50,9/2/2020
A3230E,conference-participant,100,50,9/2/2020
A43906,conference-participant,100,50,9/2/2020
A47F2E,earnings,100,50,9/2/2020
A631A3,partnership,100,61,9/2/2020
A6FB29,earnings,100,50,9/2/2020
A6FC89,earnings,100,50,9/2/2020
A6FC89,earnings,100,50,9/2/2020
A6FC89,earnings,100,50,9/2/2020
A6FC89,earnings,100,50,9/2/2020
A80FE0,note-sale,100,52,9/2/2020
A8E72A,conference-participant,100,50,9/2/2020
AD3C93,conference-participant,100,50,9/2/2020
B1A85D,partnership,100,61,9/2/2020
B290A2,conference-participant,100,50,9/2/2020
B642E8,executive-appointment,100,54,9/2/2020
B83D67,conference-participant,100,50,9/2/2020
B8EF97,revenues,100,50,9/2/2020
B96637,product-release,100,64,9/2/2020
BAD9EA,executive-appointment,100,54,9/2/2020
BFCACF,conference-participant,100,50,9/2/2020
BFD0A7,conference-participant,100,50,9/2/2020
C1114B,executive-appointment,100,54,9/2/2020
C36189,conference-participant,100,50,9/2/2020
C3BAE7,legal-issues-defendant,100,22,9/2/2020
C3BAE7,legal-issues-defendant,100,22,9/2/2020
C3F99F,conference-participant,100,50,9/2/2020
C425AE,earnings,100,50,9/2/2020
C45C1F,conference-participant,100,50,9/2/2020
C490F9,drilling,100,68,9/2/2020
C490F9,drilling,100,68,9/2/2020
C564E4,executive-appointment,100,54,9/2/2020
C598D7,acquisition-acquirer,100,49,9/2/2020
C5C137,earnings,100,50,9/2/2020
C5C137,earnings,100,50,9/2/2020
C5C137,earnings,100,50,9/2/2020
C5C137,earnings,100,50,9/2/2020
C7859D,dividend,100,50,9/2/2020
C81E00,conference-participant,100,50,9/2/2020
C81E00,conference-participant,100,50,9/2/2020
C8A059,conference-participant,100,50,9/2/2020
C93C44,executive-appointment,100,54,9/2/2020
C9739A,conference-participant,100,50,9/2/2020
C9B932,partnership,100,61,9/2/2020
C9D866,executive-appointment,100,54,9/2/2020
CBFFDD,conference-participant,100,50,9/2/2020
CD051C,conference-participant,100,50,9/2/2020
CE4E6D,business-contract,100,69,9/2/2020
CE4E6D,executive-appointment,100,54,9/2/2020
CE8251,partnership,100,61,9/2/2020
D07B07,conference-participant,100,50,9/2/2020
D0909F,dividend,100,50,9/2/2020
D11C1C,market-entry,100,57,9/2/2020
D1CFC8,conference-call,100,50,9/2/2020
D296C6,dividend,100,50,9/2/2020
D5938F,earnings,100,50,9/2/2020
DAFED3,award,100,58,9/2/2020
DC1405,conference-participant,100,50,9/2/2020
DDCB34,conference-participant,100,50,9/2/2020
DF204B,conference-participant,100,50,9/2/2020
DFADDB,conference-participant,100,50,9/2/2020
E35610,conference-participant,100,50,9/2/2020
E5D914,hirings,100,65,9/2/2020
E67C2C,conference-participant,100,50,9/2/2020
E754F0,conference-participant,100,50,9/2/2020
E7BF32,conference-participant,100,50,9/2/2020
E7BF32,conference-participant,100,50,9/2/2020
E8846E,conference-organizer,100,57,9/2/2020
E8846E,conference-participant,100,50,9/2/2020
E8846E,conference-organizer,100,57,9/2/2020
E8846E,conference-organizer,100,57,9/2/2020
E8846E,conference-organizer,100,57,9/2/2020
E8846E,conference-organizer,100,57,9/2/2020
E8846E,conference-organizer,100,57,9/2/2020
E8846E,conference-organizer,100,57,9/2/2020
EB5E78,conference-participant,100,50,9/2/2020
EF25A5,executive-appointment,100,54,9/2/2020
F0B2B5,executive-appointment,100,54,9/2/2020
F0B2B5,executive-appointment,100,54,9/2/2020
F0B2B5,executive-appointment,100,54,9/2/2020
F11638,conference-participant,100,50,9/2/2020
F179ED,conference-participant,100,50,9/2/2020
F6DCE4,executive-appointment,100,54,9/2/2020
F769E9,credit-extension-recipient,100,69,9/2/2020
F8BA6C,conference-participant,100,50,9/2/2020
F95726,note-sale,100,52,9/2/2020
FAB97A,conference-participant,100,50,9/2/2020
FAE021,partnership,100,61,9/2/2020
FD6926,conference-participant,100,50,9/2/2020
FEC475,conference-participant,100,50,9/2/2020
FEE4B0,facility-open,100,65,9/2/2020
FF4BA4,executive-appointment,100,54,9/2/2020
FF6644,legal-issues-defendant,100,22,9/2/2020
FF6644,legal-issues-defendant,100,22,9/2/2020
03596A,business-contract,100,69,9/3/2020
036C6F,dividend,100,50,9/3/2020
09DE1F,earnings,100,50,9/3/2020
0AAD90,conference-participant,100,50,9/3/2020
0BC853,dividend,100,50,9/3/2020
0BF528,conference-participant,100,50,9/3/2020
0BF528,executive-appointment,100,54,9/3/2020
0CC62B,conference-participant,100,50,9/3/2020
0E3436,earnings,100,50,9/3/2020
0E3436,earnings,100,50,9/3/2020
0E5619,conference-participant,100,50,9/3/2020
0F04E5,conference-participant,100,50,9/3/2020
108FDA,buybacks,100,74,9/3/2020
11AEDE,earnings,100,50,9/3/2020
125212,patent-awarded,100,72,9/3/2020
129DC8,trading-halt,100,43,9/3/2020
129DC8,trading-resumed,100,58,9/3/2020
12DE76,partnership,100,61,9/3/2020
136B26,conference-participant,100,50,9/3/2020
147C38,executive-appointment,100,54,9/3/2020
149301,dividend,100,50,9/3/2020
152FA5,conference-participant,100,50,9/3/2020
1.79E+10,partnership,100,61,9/3/2020
1921DD,dividend,100,50,9/3/2020
196D18,conference-participant,100,50,9/3/2020
1A9DE1,unit-acquisition-acquirer,100,49,9/3/2020
1AC649,conference-participant,100,50,9/3/2020
1BC12C,business-contract,100,69,9/3/2020
1D1B07,earnings,100,50,9/3/2020
1D1B07,earnings,100,50,9/3/2020
1F08A6,conference-participant,100,50,9/3/2020
200D8B,partnership,100,61,9/3/2020
227D48,dividend,100,50,9/3/2020
228D42,partnership,100,61,9/3/2020
228D42,partnership,100,61,9/3/2020
241AF7,dividend,100,50,9/3/2020
26DC29,earnings,100,50,9/3/2020
279916,conference-participant,100,50,9/3/2020
2A6DBE,conference-participant,100,50,9/3/2020
2ABF77,conference-participant,100,50,9/3/2020
2CF9D3,conference-participant,100,50,9/3/2020
2DC88B,executive-appointment,100,54,9/3/2020
2F1299,conference-participant,100,50,9/3/2020
2F6782,executive-appointment,100,54,9/3/2020
2F960F,dividend,100,50,9/3/2020
32F943,conference-participant,100,50,9/3/2020
367434,conference-participant,100,50,9/3/2020
3.73E+87,conference-participant,100,50,9/3/2020
3B2311,partnership,100,61,9/3/2020
3BB7D3,conference-participant,100,50,9/3/2020
3DD5E2,conference-participant,100,50,9/3/2020
3E70FC,acquisition-completed-acquirer,100,49,9/3/2020
4017AD,executive-appointment,100,54,9/3/2020
42978B,earnings-up,100,68,9/3/2020
42978B,earnings-up,100,68,9/3/2020
42978B,earnings-up,100,68,9/3/2020
42978B,earnings-up,100,68,9/3/2020
42EFC7,executive-appointment,100,54,9/3/2020
42EFC7,conference-participant,100,50,9/3/2020
43E8F5,conference-participant,100,50,9/3/2020
442769,conference-participant,100,50,9/3/2020
44A4FC,conference-participant,100,50,9/3/2020
49A344,executive-appointment,100,54,9/3/2020
4A2457,product-release,100,64,9/3/2020
4A6F00,legal-issues-defendant,100,22,9/3/2020
4B5054,fraud-defendant,100,20,9/3/2020
4BDCA7,partnership,100,61,9/3/2020
4BF3D6,conference-participant,100,50,9/3/2020
4CDA2B,conference-participant,100,50,9/3/2020
4E4E75,operating-earnings,100,50,9/3/2020
4E7C1F,partnership,100,61,9/3/2020
4E7C1F,partnership,100,61,9/3/2020
50070E,conference-organizer,100,57,9/3/2020
50070E,conference-organizer,100,57,9/3/2020
523039,conference-participant,100,50,9/3/2020
52BF94,conference-call,100,50,9/3/2020
5.43E+08,conference-participant,100,50,9/3/2020
543900,earnings,100,50,9/3/2020
55C9B5,conference-participant,100,50,9/3/2020
56277A,conference-participant,100,50,9/3/2020
57A854,conference-participant,100,50,9/3/2020
57DDB9,product-release,100,64,9/3/2020
586BD7,conference-participant,100,50,9/3/2020
58C2D4,executive-appointment,100,54,9/3/2020
58EA22,conference-participant,100,50,9/3/2020
59872F,conference-participant,100,50,9/3/2020
59DB8C,conference-participant,100,50,9/3/2020
5E6959,acquisition-completed-acquirer,100,49,9/3/2020
665D7D,conference-participant,100,50,9/3/2020
6830FE,earnings,100,50,9/3/2020
693ECD,conference-participant,100,50,9/3/2020
69C99E,conference-participant,100,50,9/3/2020
70FCEF,earnings,100,50,9/3/2020
713810,product-release,100,64,9/3/2020
713810,partnership,100,61,9/3/2020
731675,revenue-up,100,69,9/3/2020
73F7F9,earnings,100,50,9/3/2020
73F7F9,earnings,100,50,9/3/2020
7448A3,conference-participant,100,50,9/3/2020
747219,conference-participant,100,50,9/3/2020
747219,conference-participant,100,50,9/3/2020
775439,earnings,100,50,9/3/2020
78F776,conference-participant,100,50,9/3/2020
7A0EC4,earnings,100,50,9/3/2020
7A0EC4,executive-appointment,100,54,9/3/2020
7AB859,executive-appointment,100,54,9/3/2020
7ADE57,earnings,100,50,9/3/2020
7ADE57,earnings,100,50,9/3/2020
7ADE57,earnings,100,50,9/3/2020
7ADE57,earnings,100,50,9/3/2020
7ADE57,earnings,100,50,9/3/2020
7B0BA6,partnership,100,61,9/3/2020
7B9212,revenues,100,50,9/3/2020
7C790D,conference-participant,100,50,9/3/2020
7E1D5D,partnership,100,61,9/3/2020
7E1D5D,partnership,100,61,9/3/2020
805CD8,conference-participant,100,50,9/3/2020
83B1C8,conference-participant,100,50,9/3/2020
85DE00,conference-participant,100,50,9/3/2020
8A8E41,dividend-up,100,81,9/3/2020
8AB85C,conference-participant,100,50,9/3/2020
8DA42F,conference-participant,100,50,9/3/2020
8DBE73,legal-issues-defendant,100,22,9/3/2020
9196A2,conference-organizer,100,57,9/3/2020
9196A2,conference-organizer,100,57,9/3/2020
9196A2,conference-organizer,100,57,9/3/2020
9196A2,conference-organizer,100,57,9/3/2020
925759,conference-participant,100,50,9/3/2020
934029,conference-participant,100,50,9/3/2020
9.39E+69,conference-participant,100,50,9/3/2020
9.54E+32,partnership,100,61,9/3/2020
990AD0,conference-organizer,100,57,9/3/2020
9934AD,executive-appointment,100,54,9/3/2020
9978F1,conference-participant,100,50,9/3/2020
9A602D,donation,100,54,9/3/2020
9B71A7,earnings,100,50,9/3/2020
9EF4CF,partnership,100,61,9/3/2020
A47A7D,conference-participant,100,50,9/3/2020
A47A7D,conference-participant,100,50,9/3/2020
A52B6B,partnership,100,61,9/3/2020
A5DD24,clinical-trials,100,56,9/3/2020
A6213D,partnership,100,61,9/3/2020
A631A3,conference-participant,100,50,9/3/2020
A6FE1C,unit-acquisition-acquirer,100,49,9/3/2020
A79F7D,partnership,100,61,9/3/2020
AA3AB8,operating-earnings,100,50,9/3/2020
ABE7DC,earnings,100,50,9/3/2020
AC642C,conference-participant,100,50,9/3/2020
AC642C,conference-participant,100,50,9/3/2020
AD1ACF,executive-appointment,100,54,9/3/2020
ADD9DC,earnings,100,50,9/3/2020
AEEB76,conference-participant,100,50,9/3/2020
B9764A,conference-participant,100,50,9/3/2020
BB88B6,partnership,100,61,9/3/2020
C29715,note-sale,100,52,9/3/2020
C3BAE7,legal-issues-defendant,100,22,9/3/2020
C3BAE7,legal-issues-defendant,100,22,9/3/2020
C4F9C6,conference-participant,100,50,9/3/2020
C564E4,conference-participant,100,50,9/3/2020
C5D2AE,partnership,100,61,9/3/2020
C65004,earnings,100,50,9/3/2020
C72B8F,conference-participant,100,50,9/3/2020
C9E107,conference-participant,100,50,9/3/2020
CA212F,dividend,100,50,9/3/2020
CAB222,conference-participant,100,50,9/3/2020
CDC217,conference-participant,100,50,9/3/2020
CE5C6E,conference-participant,100,50,9/3/2020
CF3FF9,conference-participant,100,50,9/3/2020
CF7292,conference-participant,100,50,9/3/2020
CFF57D,earnings,100,50,9/3/2020
CFF57D,earnings,100,50,9/3/2020
CFF57D,earnings,100,50,9/3/2020
CFF57D,earnings,100,50,9/3/2020
D437C3,conference-participant,100,50,9/3/2020
D518D8,product-release,100,64,9/3/2020
D60BB2,partnership,100,61,9/3/2020
DB9829,earnings,100,50,9/3/2020
DBB28E,business-contract,100,69,9/3/2020
DC0066,conference-participant,100,50,9/3/2020
DD1BA1,acquisition-acquiree,100,76,9/3/2020
DE5611,earnings,100,50,9/3/2020
E0207A,partnership,100,61,9/3/2020
E2CB7B,business-contract,100,69,9/3/2020
E2CFD2,conference-participant,100,50,9/3/2020
E3A829,conference-participant,100,50,9/3/2020
E41190,conference-participant,100,50,9/3/2020
E5A3B6,conference-participant,100,50,9/3/2020
E5C910,conference-participant,100,50,9/3/2020
E8846E,conference-organizer,100,57,9/3/2020
E8846E,conference-organizer,100,57,9/3/2020
E8846E,conference-organizer,100,57,9/3/2020
E8846E,conference-organizer,100,57,9/3/2020
E8846E,conference-organizer,100,57,9/3/2020
E8846E,conference-organizer,100,57,9/3/2020
E8846E,conference-organizer,100,57,9/3/2020
E8846E,conference-organizer,100,57,9/3/2020
E8846E,conference-organizer,100,57,9/3/2020
E8846E,conference-organizer,100,57,9/3/2020
E8A49A,partnership,100,61,9/3/2020
E96E0B,conference-participant,100,50,9/3/2020
EBD89A,business-contract,100,69,9/3/2020
ECA300,earnings,100,50,9/3/2020
EEA6B3,executive-appointment,100,54,9/3/2020
EF77A3,earnings,100,50,9/3/2020
F1CD47,conference-participant,100,50,9/3/2020
F2BC3D,conference-participant,100,50,9/3/2020
F43A11,earnings,100,50,9/3/2020
F4D241,conference-participant,100,50,9/3/2020
F66B58,earnings,100,50,9/3/2020
F6E248,partnership,100,61,9/3/2020
FCA54E,credit-extension-recipient,100,69,9/3/2020
FD4E8D,conference-participant,100,50,9/3/2020
FDE409,earnings,100,50,9/3/2020
FF227B,conference-participant,100,50,9/3/2020
FF6644,legal-issues-defendant,100,22,9/3/2020
FF6644,legal-issues-defendant,100,22,9/3/2020
01D03F,regulatory-product-approval-granted,100,81,9/4/2020
02870F,legal-issues-defendant,100,22,9/4/2020
054B55,dividend,100,50,9/4/2020
71860,conference-participant,100,50,9/4/2020
14ED2B,executive-appointment,100,54,9/4/2020
15901B,conference-participant,100,50,9/4/2020
18A98C,executive-appointment,100,54,9/4/2020
1921DD,dividend,100,50,9/4/2020
1EBF8D,conference-participant,100,50,9/4/2020
1F3CFB,conference-participant,100,50,9/4/2020
200D8B,award,100,58,9/4/2020
275300,conference-participant,100,50,9/4/2020
279916,legal-issues-defendant,100,22,9/4/2020
2A02DC,conference-participant,100,50,9/4/2020
2A6DBE,legal-issues-defendant,100,22,9/4/2020
2AA6A8,conference-participant,100,50,9/4/2020
2BF36E,conference-participant,100,50,9/4/2020
2CD1E0,unit-acquisition-acquirer,100,49,9/4/2020
3A3447,partnership,100,61,9/4/2020
41EC04,facility-close,100,47,9/4/2020
43A060,business-contract,100,69,9/4/2020
44A4FC,index-listing,100,76,9/4/2020
499C75,conference-participant,100,50,9/4/2020
4A3438,legal-issues-defendant,100,22,9/4/2020
4B5054,legal-issues-defendant,100,22,9/4/2020
4B5054,legal-issues-defendant,100,22,9/4/2020
50070E,conference-organizer,100,57,9/4/2020
586BD7,clinical-trials-start,100,64,9/4/2020
609208,conference-call,100,50,9/4/2020
615B6D,public-offering,100,43,9/4/2020
665D7D,partnership,100,61,9/4/2020
665D7D,partnership,100,61,9/4/2020
6E705B,executive-appointment,100,54,9/4/2020
6F3FA8,award,100,58,9/4/2020
732A9B,conference-participant,100,50,9/4/2020
7.45E+28,legal-issues-defendant,100,22,9/4/2020
748EB6,conference-participant,100,50,9/4/2020
76F067,conference-participant,100,50,9/4/2020
790C34,executive-resignation,100,44,9/4/2020
7B1E50,legal-issues-defendant,100,22,9/4/2020
7E0EB0,conference-participant,100,50,9/4/2020
8377DB,conference-participant,100,50,9/4/2020
89FBB1,conference-participant,100,50,9/4/2020
8B8656,conference-participant,100,50,9/4/2020
8C5519,dividend,100,50,9/4/2020
8DBE73,legal-issues-defendant,100,22,9/4/2020
8DBE73,legal-issues-defendant,100,22,9/4/2020
8E3F58,conference-participant,100,50,9/4/2020
9196A2,conference-organizer,100,57,9/4/2020
92005C,conference-participant,100,50,9/4/2020
93F143,index-listing,100,76,9/4/2020
94983E,conference-participant,100,50,9/4/2020
9507FF,conference-participant,100,50,9/4/2020
95F59E,conference-participant,100,50,9/4/2020
990AD0,conference-organizer,100,57,9/4/2020
990AD0,conference-organizer,100,57,9/4/2020
9F71E5,unit-acquisition-completed-acquirer,100,49,9/4/2020
A5DD24,conference-participant,100,50,9/4/2020
A631A3,conference-participant,100,50,9/4/2020
AD6141,conference-participant,100,50,9/4/2020
B3ED62,legal-issues-defendant,100,22,9/4/2020
B446B8,legal-issues-defendant,100,22,9/4/2020
B5734D,conference-call,100,50,9/4/2020
B762D3,earnings,100,50,9/4/2020
BCC13E,conference-participant,100,50,9/4/2020
C062D4,conference-participant,100,50,9/4/2020
C2609A,conference-participant,100,50,9/4/2020
C3BAE7,legal-issues-defendant,100,22,9/4/2020
C501B6,legal-issues-defendant,100,22,9/4/2020
C941DC,conference-participant,100,50,9/4/2020
D1AE3B,conference-call,100,50,9/4/2020
D5938F,conference-participant,100,50,9/4/2020
D9B1C9,legal-issues-defendant,100,22,9/4/2020
DAFED3,conference-participant,100,50,9/4/2020
E0339F,business-contract,100,69,9/4/2020
E0339F,business-contract,100,69,9/4/2020
E0339F,business-contract,100,69,9/4/2020
E30B34,conference-participant,100,50,9/4/2020
E30B34,conference-participant,100,50,9/4/2020
E68C3D,conference-participant,100,50,9/4/2020
E8846E,conference-organizer,100,57,9/4/2020
E8846E,conference-organizer,100,57,9/4/2020
F6E248,regulatory-product-application,100,69,9/4/2020
F6E248,clinical-trials-filed,100,60,9/4/2020
FC1A6E,conference-participant,100,50,9/4/2020
FC4550,dividend,100,50,9/4/2020
FE7A63,dividend,100,50,9/4/2020
FF6644,legal-issues-defendant,100,22,9/4/2020
1AB808,legal-issues-defendant,100,22,9/5/2020
1FA886,legal-issues-defendant,100,22,9/5/2020
34E9F9,legal-issues-defendant,100,22,9/5/2020
4.00E+163,legal-issues-defendant,100,22,9/5/2020
4B5054,fraud-defendant,100,20,9/5/2020
4E4E75,legal-issues-defendant,100,22,9/5/2020
589803,legal-issues-defendant,100,22,9/5/2020
69E8E1,legal-issues-defendant,100,22,9/5/2020
96BFF4,legal-issues-defendant,100,22,9/5/2020
CDFCC9,legal-issues-defendant,100,22,9/5/2020
D5938F,legal-issues-defendant,100,22,9/5/2020
F18844,legal-issues-defendant,100,22,9/5/2020
FAB97A,legal-issues-defendant,100,22,9/5/2020
20751,clinical-trials,100,56,9/7/2020
1AB808,legal-issues-defendant,100,22,9/7/2020
B4C673,product-release,100,64,9/7/2020
C3BAE7,legal-issues-defendant,100,22,9/7/2020
C8A248,product-release,100,64,9/7/2020
00067A,executive-appointment,100,54,9/8/2020
001F1B,conference-call,100,50,9/8/2020
002A99,executive-appointment,100,54,9/8/2020
0157B1,partnership,100,61,9/8/2020
01D03F,regulatory-product-approval-granted,100,81,9/8/2020
20751,public-offering,100,43,9/8/2020
02870F,legal-issues-defendant,100,22,9/8/2020
03FAA6,conference-participant,100,50,9/8/2020
56045,earnings,100,50,9/8/2020
07CA6A,buybacks,100,74,9/8/2020
07CA6A,buybacks,100,74,9/8/2020
091B6C,conference-participant,100,50,9/8/2020
091B6C,conference-participant,100,50,9/8/2020
099C88,partnership,100,61,9/8/2020
0B7375,conference-participant,100,50,9/8/2020
0BD199,conference-participant,100,50,9/8/2020
0D03C8,conference-participant,100,50,9/8/2020
0F0440,product-release,100,64,9/8/2020
12F98C,partnership,100,61,9/8/2020
12F98C,earnings-up,100,68,9/8/2020
136B26,executive-appointment,100,54,9/8/2020
14833D,executive-appointment,100,54,9/8/2020
154272,legal-issues-defendant,100,22,9/8/2020
182BE7,conference-participant,100,50,9/8/2020
1AB808,legal-issues-defendant,100,22,9/8/2020
1AC649,patient-enrollment-start,100,58,9/8/2020
1C599A,note-sale,100,52,9/8/2020
1CD09C,conference-participant,100,50,9/8/2020
1F08A6,dividend,100,50,9/8/2020
1FC422,note-sale,100,52,9/8/2020
206852,conference-participant,100,50,9/8/2020
223552,conference-participant,100,50,9/8/2020
227F04,conference-participant,100,50,9/8/2020
228D42,partnership,100,61,9/8/2020
24A89A,conference-participant,100,50,9/8/2020
2E0445,conference-participant,100,50,9/8/2020
2F9304,conference-participant,100,50,9/8/2020
306623,loan-recipient,100,59,9/8/2020
30AB63,conference-participant,100,50,9/8/2020
30DE64,conference-participant,100,50,9/8/2020
30DFD3,conference-participant,100,50,9/8/2020
32DCB3,conference-participant,100,50,9/8/2020
33AD83,conference-participant,100,50,9/8/2020
349DA4,conference-participant,100,50,9/8/2020
367E1C,conference-participant,100,50,9/8/2020
36E479,conference-participant,100,50,9/8/2020
3BA1BF,executive-appointment,100,54,9/8/2020
3D7971,business-contract,100,69,9/8/2020
3DED49,ipo,100,71,9/8/2020
3EE65E,conference-participant,100,50,9/8/2020
3F6A9C,executive-appointment,100,54,9/8/2020
417BF9,conference-participant,100,50,9/8/2020
43A060,business-contract,100,69,9/8/2020
448215,dividend,100,50,9/8/2020
44A4FC,partnership,100,61,9/8/2020
44A4FC,partnership,100,61,9/8/2020
451D61,executive-appointment,100,54,9/8/2020
4A2457,government-contract,100,69,9/8/2020
4A6F00,partnership,100,61,9/8/2020
4A6F00,partnership,100,61,9/8/2020
4BAF2E,conference-participant,100,50,9/8/2020
4D8313,drilling,100,68,9/8/2020
4F71DC,earnings,100,50,9/8/2020
4F9926,product-release,100,64,9/8/2020
50070E,conference-organizer,100,57,9/8/2020
50070E,conference-organizer,100,57,9/8/2020
50070E,conference-organizer,100,57,9/8/2020
5065B1,dividend,100,50,9/8/2020
51888A,executive-appointment,100,54,9/8/2020
53E575,conference-participant,100,50,9/8/2020
543C77,executive-appointment,100,54,9/8/2020
54512F,award,100,58,9/8/2020
545272,conference-participant,100,50,9/8/2020
546A27,conference-participant,100,50,9/8/2020
5.47E+28,clinical-trials-positive,100,87,9/8/2020
55C9B5,partnership,100,61,9/8/2020
55C9B5,partnership,100,61,9/8/2020
56277A,conference-participant,100,50,9/8/2020
56EFC7,executive-appointment,100,54,9/8/2020
577033,ipo,100,71,9/8/2020
579E8F,conference-participant,100,50,9/8/2020
57F3DA,executive-appointment,100,54,9/8/2020
59872F,product-release,100,64,9/8/2020
59872F,partnership,100,61,9/8/2020
59872F,executive-appointment,100,54,9/8/2020
5A53BF,conference-participant,100,50,9/8/2020
5DE5A5,conference-participant,100,50,9/8/2020
5E6959,conference-participant,100,50,9/8/2020
5F1B7B,product-release,100,64,9/8/2020
5F9CE3,award,100,58,9/8/2020
5FC507,executive-appointment,100,54,9/8/2020
6.18E+08,executive-appointment,100,54,9/8/2020
641F17,note-sale,100,52,9/8/2020
6559D8,conference-participant,100,50,9/8/2020
67B052,conference-participant,100,50,9/8/2020
67B052,conference-participant,100,50,9/8/2020
69345C,conference-participant,100,50,9/8/2020
69C99E,conference-participant,100,50,9/8/2020
69FDFC,note-sale,100,52,9/8/2020
6B6375,regulatory-product-approval-granted,100,81,9/8/2020
6BBCBA,conference-participant,100,50,9/8/2020
6D3F35,conference-participant,100,50,9/8/2020
6-Dec-05,conference-participant,100,50,9/8/2020
6E8864,conference-participant,100,50,9/8/2020
713810,business-contract,100,69,9/8/2020
71B0CF,conference-participant,100,50,9/8/2020
722D55,conference-participant,100,50,9/8/2020
72FCA3,earnings,100,50,9/8/2020
73A213,earnings,100,50,9/8/2020
73A71F,executive-appointment,100,54,9/8/2020
73BCBA,conference-participant,100,50,9/8/2020
7448A3,executive-resignation,100,44,9/8/2020
751C8D,partnership,100,61,9/8/2020
763DBE,conference-participant,100,50,9/8/2020
76DD0C,conference-participant,100,50,9/8/2020
79340A,buybacks,100,74,9/8/2020
7F3FBC,executive-appointment,100,54,9/8/2020
834152,orphan-drug-designation,100,76,9/8/2020
84A6B9,dividend,100,50,9/8/2020
85CDC9,partnership,100,61,9/8/2020
85CDC9,partnership,100,61,9/8/2020
85CDC9,partnership,100,61,9/8/2020
85DE00,partnership,100,61,9/8/2020
8D4486,partnership,100,61,9/8/2020
8D4486,partnership,100,61,9/8/2020
8D4486,partnership,100,61,9/8/2020
8D4486,partnership,100,61,9/8/2020
8D4486,partnership,100,61,9/8/2020
8EEA28,dividend,100,50,9/8/2020
9196A2,conference-organizer,100,57,9/8/2020
9196A2,conference-organizer,100,57,9/8/2020
9196A2,conference-organizer,100,57,9/8/2020
9196A2,conference-organizer,100,57,9/8/2020
9196A2,conference-organizer,100,57,9/8/2020
9196A2,conference-organizer,100,57,9/8/2020
9196A2,conference-organizer,100,57,9/8/2020
943239,conference-participant,100,50,9/8/2020
9470CC,executive-appointment,100,54,9/8/2020
947B0B,conference-participant,100,50,9/8/2020
94983E,executive-appointment,100,54,9/8/2020
949D62,conference-participant,100,50,9/8/2020
9592FB,conference-participant,100,50,9/8/2020
97644E,conference-participant,100,50,9/8/2020
97693A,earnings,100,50,9/8/2020
990AD0,conference-organizer,100,57,9/8/2020
9BF177,earnings,100,50,9/8/2020
9E575E,conference-participant,100,50,9/8/2020
9E98F2,product-release,100,64,9/8/2020
9F6B1A,product-release,100,64,9/8/2020
A01983,executive-appointment,100,54,9/8/2020
A072C4,conference-participant,100,50,9/8/2020
A28C54,executive-appointment,100,54,9/8/2020
A29DBD,business-contract,100,69,9/8/2020
A3800A,facility-open,100,65,9/8/2020
A3800A,facility-open,100,65,9/8/2020
A5195E,conference-participant,100,50,9/8/2020
A72FD9,earnings,100,50,9/8/2020
A7A0C8,conference-participant,100,50,9/8/2020
A868C9,product-release,100,64,9/8/2020
AAEE21,conference-participant,100,50,9/8/2020
AD6141,executive-appointment,100,54,9/8/2020
AED61E,earnings,100,50,9/8/2020
AED61E,earnings,100,50,9/8/2020
AED61E,earnings,100,50,9/8/2020
AED61E,earnings,100,50,9/8/2020
AEFC90,executive-appointment,100,54,9/8/2020
AEFC90,conference-participant,100,50,9/8/2020
B0FE08,executive-appointment,100,54,9/8/2020
B13B68,conference-participant,100,50,9/8/2020
B3ED62,legal-issues-defendant,100,22,9/8/2020
B46E12,dividend,100,50,9/8/2020
B614F8,partnership,100,61,9/8/2020
B614F8,business-contract,100,69,9/8/2020
B80AD1,conference-participant,100,50,9/8/2020
B8F71F,executive-appointment,100,54,9/8/2020
BA0442,partnership,100,61,9/8/2020
BB5142,executive-appointment,100,54,9/8/2020
BB88B6,executive-appointment,100,54,9/8/2020
BB88B6,conference-participant,100,50,9/8/2020
BD8517,partnership,100,61,9/8/2020
BFE02C,dividend,100,50,9/8/2020
C01737,conference-participant,100,50,9/8/2020
C38440,executive-appointment,100,54,9/8/2020
C3BAE7,legal-issues-defendant,100,22,9/8/2020
C3BAE7,legal-issues-defendant,100,22,9/8/2020
C58D71,conference-participant,100,50,9/8/2020
C94CFC,conference-participant,100,50,9/8/2020
CAC8D0,earnings,100,50,9/8/2020
CB7AB2,conference-participant,100,50,9/8/2020
CDD75E,conference-participant,100,50,9/8/2020
CDFCC9,conference-participant,100,50,9/8/2020
CEC08B,executive-appointment,100,54,9/8/2020
CFF97C,executive-appointment,100,54,9/8/2020
D064D5,earnings,100,50,9/8/2020
D064D5,executive-appointment,100,54,9/8/2020
D0909F,resource-discovery,100,88,9/8/2020
D1C0B9,hirings,100,65,9/8/2020
D36B23,conference-participant,100,50,9/8/2020
D45285,note-sale,100,52,9/8/2020
D622D5,dividend,100,50,9/8/2020
D622D5,operating-earnings,100,50,9/8/2020
D6EAA3,note-sale,100,52,9/8/2020
D6EAA3,note-sale,100,52,9/8/2020
D90F43,partnership,100,61,9/8/2020
DDEA6A,conference-participant,100,50,9/8/2020
E0207A,product-release,100,64,9/8/2020
E22FDE,conference-participant,100,50,9/8/2020
E28D9C,conference-participant,100,50,9/8/2020
E2CB7B,conference-organizer,100,57,9/8/2020
E38906,campaign-ad-release,100,59,9/8/2020
E3E68E,executive-appointment,100,54,9/8/2020
E3E68E,executive-appointment,100,54,9/8/2020
E4CE73,business-contract,100,69,9/8/2020
E71AE6,clinical-trials,100,56,9/8/2020
E8846E,conference-organizer,100,57,9/8/2020
EC70EC,note-sale,100,52,9/8/2020
EC70EC,note-sale,100,52,9/8/2020
ED9C04,partnership,100,61,9/8/2020
EEA6B3,partnership,100,61,9/8/2020
EF25A5,conference-participant,100,50,9/8/2020
EF5BED,executive-appointment,100,54,9/8/2020
F0027C,conference-participant,100,50,9/8/2020
F18844,legal-issues-defendant,100,22,9/8/2020
F18844,legal-issues-defendant,100,22,9/8/2020
F18844,legal-issues-defendant,100,22,9/8/2020
F18844,legal-issues-defendant,100,22,9/8/2020
F209B4,conference-participant,100,50,9/8/2020
F3816D,conference-participant,100,50,9/8/2020
F5D410,business-contract,100,69,9/8/2020
F7935D,public-offering,100,43,9/8/2020
FA35C6,partnership,100,61,9/8/2020
FA35C6,partnership,100,61,9/8/2020
FC1736,earnings,100,50,9/8/2020
FD0CA4,conference-participant,100,50,9/8/2020
FE89E0,executive-appointment,100,54,9/8/2020
0157B1,partnership,100,61,9/9/2020
0157B1,partnership,100,61,9/9/2020
0157B1,hirings,100,65,9/9/2020
0157B1,product-release,100,64,9/9/2020
033B58,conference-participant,100,50,9/9/2020
0A7650,conference-participant,100,50,9/9/2020
0BA2EF,earnings,100,50,9/9/2020
0BA2EF,earnings,100,50,9/9/2020
0BD4E8,facility-open,100,65,9/9/2020
0BF198,conference-participant,100,50,9/9/2020
0C136E,executive-resignation,100,44,9/9/2020
0DBB81,conference-participant,100,50,9/9/2020
112694,executive-appointment,100,54,9/9/2020
125212,conference-participant,100,50,9/9/2020
1272B3,partnership,100,61,9/9/2020
12DE76,dividend,100,50,9/9/2020
154272,legal-issues-defendant,100,22,9/9/2020
190B91,conference-participant,100,50,9/9/2020
1AB808,legal-issues-defendant,100,22,9/9/2020
1C2593,conference-participant,100,50,9/9/2020
1C599A,legal-issues-defendant,100,22,9/9/2020
1CF3A8,public-offering,100,43,9/9/2020
1E68B3,executive-appointment,100,54,9/9/2020
1E83DE,earnings,100,50,9/9/2020
1FAF22,conference-call,100,50,9/9/2020
1FAF22,conference-call,100,50,9/9/2020
1FCC00,conference-participant,100,50,9/9/2020
200D8B,product-release,100,64,9/9/2020
202E5A,conference-participant,100,50,9/9/2020
223552,conference-participant,100,50,9/9/2020
23207A,conference-call,100,50,9/9/2020
24FA23,clinical-trials-start,100,64,9/9/2020
253604,executive-appointment,100,54,9/9/2020
2571FA,executive-appointment,100,54,9/9/2020
26DC29,conference-participant,100,50,9/9/2020
26F99F,conference-participant,100,50,9/9/2020
292388,conference-participant,100,50,9/9/2020
29B702,dividend,100,50,9/9/2020
2A6DBE,fraud,100,44,9/9/2020
2AE625,conference-participant,100,50,9/9/2020
2B49F4,partnership,100,61,9/9/2020
2B49F4,partnership,100,61,9/9/2020
2B7A40,conference-participant,100,50,9/9/2020
2CC60C,executive-appointment,100,54,9/9/2020
2CC60C,earnings,100,50,9/9/2020
2D981A,conference-participant,100,50,9/9/2020
2DC88B,executive-appointment,100,54,9/9/2020
2EC172,award,100,58,9/9/2020
2F1299,donation,100,54,9/9/2020
326EDD,conference-participant,100,50,9/9/2020
3.30E+30,executive-appointment,100,54,9/9/2020
33E9D5,earnings,100,50,9/9/2020
35557B,conference-participant,100,50,9/9/2020
36529A,conference-participant,100,50,9/9/2020
36C09B,conference-participant,100,50,9/9/2020
37B618,dividend,100,50,9/9/2020
37E18B,acquisition-acquiree,100,76,9/9/2020
3.88E+02,legal-issues-defendant,100,22,9/9/2020
3C7F5F,partnership,100,61,9/9/2020
3DD5E2,conference-participant,100,50,9/9/2020
401072,conference-participant,100,50,9/9/2020
415188,product-release,100,64,9/9/2020
416C55,conference-participant,100,50,9/9/2020
42AABD,business-contract,100,69,9/9/2020
434F38,partnership,100,61,9/9/2020
44A4FC,investment-investor,100,55,9/9/2020
458D2C,revenue-volume,100,50,9/9/2020
487B7A,business-contract,100,69,9/9/2020
49F4D0,conference-participant,100,50,9/9/2020
4AC91D,executive-appointment,100,54,9/9/2020
4B49CF,earnings,100,50,9/9/2020
4B5054,legal-issues-defendant,100,22,9/9/2020
4B5054,legal-issues-defendant,100,22,9/9/2020
4B5054,fraud-defendant,100,20,9/9/2020
4BAF2E,conference-participant,100,50,9/9/2020
4BDCA7,clinical-trials,100,56,9/9/2020
4BDCA7,conference-participant,100,50,9/9/2020
50070E,conference-organizer,100,57,9/9/2020
50070E,conference-organizer,100,57,9/9/2020
50070E,conference-organizer,100,57,9/9/2020
504FE2,conference-participant,100,50,9/9/2020
51E682,executive-resignation,100,44,9/9/2020
53F491,conference-participant,100,50,9/9/2020
5.47E+28,public-offering,100,43,9/9/2020
556A57,buybacks,100,74,9/9/2020
56B7C1,note-sale,100,52,9/9/2020
583223,earnings-guidance-up,100,83,9/9/2020
5B6C11,name-change,100,49,9/9/2020
5C8D61,conference-participant,100,50,9/9/2020
5E9934,earnings,100,50,9/9/2020
619882,conference-organizer,100,57,9/9/2020
63E8D5,buybacks,100,74,9/9/2020
651C85,conference-participant,100,50,9/9/2020
6A961B,earnings,100,50,9/9/2020
6C6D73,conference-call,100,50,9/9/2020
6CBF41,executive-appointment,100,54,9/9/2020
6F39FC,dividend,100,50,9/9/2020
6F92A9,conference-participant,100,50,9/9/2020
70B3D6,ipo-considered,100,60,9/9/2020
713810,partnership,100,61,9/9/2020
724F84,executive-appointment,100,54,9/9/2020
73F70F,conference-participant,100,50,9/9/2020
756BB4,acquisition-acquirer,100,49,9/9/2020
756BB4,earnings,100,50,9/9/2020
75F982,legal-issues-defendant,100,22,9/9/2020
75F982,legal-issues-defendant,100,22,9/9/2020
762B8D,earnings,100,50,9/9/2020
7AC86E,earnings-up,100,68,9/9/2020
7B1E50,legal-issues-defendant,100,22,9/9/2020
7BEA98,conference-participant,100,50,9/9/2020
7C4F43,executive-appointment,100,54,9/9/2020
7D5FD6,dividend,100,50,9/9/2020
804708,campaign-ad-release,100,59,9/9/2020
80D744,executive-appointment,100,54,9/9/2020
819492,fast-track-designation,100,81,9/9/2020
82E58A,dividend-up,100,56,9/9/2020
82F088,conference-participant,100,50,9/9/2020
83066C,debt-reduction,100,74,9/9/2020
85DA04,note-sale,100,52,9/9/2020
8665BA,facility-open,100,65,9/9/2020
895D56,executive-appointment,100,54,9/9/2020
8AB37F,conference-participant,100,50,9/9/2020
8D0EEA,conference-participant,100,50,9/9/2020
8DAAB9,executive-appointment,100,54,9/9/2020
8DCF18,conference-participant,100,50,9/9/2020
8E10BF,conference-participant,100,50,9/9/2020
8EDACA,conference-participant,100,50,9/9/2020
903AB4,dividend,100,50,9/9/2020
90D6A5,dividend,100,50,9/9/2020
9196A2,conference-organizer,100,57,9/9/2020
9196A2,conference-organizer,100,57,9/9/2020
9196A2,conference-organizer,100,57,9/9/2020
9196A2,conference-organizer,100,57,9/9/2020
9196A2,conference-organizer,100,57,9/9/2020
9196A2,conference-organizer,100,57,9/9/2020
9196A2,partnership,100,61,9/9/2020
9196A2,conference-organizer,100,57,9/9/2020
9196A2,conference-organizer,100,57,9/9/2020
9196A2,conference-organizer,100,57,9/9/2020
9196A2,conference-organizer,100,57,9/9/2020
9196A2,conference-organizer,100,57,9/9/2020
9196A2,conference-organizer,100,57,9/9/2020
9196A2,conference-organizer,100,57,9/9/2020
9196A2,conference-organizer,100,57,9/9/2020
92D9C9,note-sale,100,52,9/9/2020
9.31E+77,conference-participant,100,50,9/9/2020
93965C,executive-appointment,100,54,9/9/2020
944B2E,rights-issue,100,43,9/9/2020
95DC1F,product-release,100,64,9/9/2020
96BFF4,legal-issues-defendant,100,22,9/9/2020
96F126,business-contract,100,69,9/9/2020
9810C0,business-contract,100,69,9/9/2020
9.82E+06,earnings,100,50,9/9/2020
990AD0,conference-organizer,100,57,9/9/2020
990AD0,conference-organizer,100,57,9/9/2020
9D307D,conference-participant,100,50,9/9/2020
9F71E5,public-offering,100,43,9/9/2020
A03EE1,earnings,100,50,9/9/2020
A16DEA,conference-participant,100,50,9/9/2020
A247F5,conference-participant,100,50,9/9/2020
A26C26,earnings,100,50,9/9/2020
A631A3,award,100,58,9/9/2020
A631A3,conference-participant,100,50,9/9/2020
A63820,investment-investor,100,55,9/9/2020
A666C8,conference-participant,100,50,9/9/2020
A6FB29,earnings-up,100,68,9/9/2020
A80FE0,conference-participant,100,50,9/9/2020
A80FE0,conference-participant,100,50,9/9/2020
ACDCFA,business-contract,100,69,9/9/2020
AD23DE,executive-appointment,100,54,9/9/2020
AD6141,conference-participant,100,50,9/9/2020
AFD1CA,conference-participant,100,50,9/9/2020
AFDF2E,conference-participant,100,50,9/9/2020
B37FB4,conference-participant,100,50,9/9/2020
B446B8,fraud,100,44,9/9/2020
B4C673,note-sale,100,52,9/9/2020
B508E5,conference-participant,100,50,9/9/2020
B8DD94,conference-participant,100,50,9/9/2020
B9CD50,partnership,100,61,9/9/2020
B9CD50,partnership,100,61,9/9/2020
BA0442,public-offering,100,43,9/9/2020
BBC05B,unit-acquisition-acquiree,100,76,9/9/2020
BCC13E,conference-participant,100,50,9/9/2020
BDEC1E,public-offering,100,43,9/9/2020
BFEA04,buybacks,100,74,9/9/2020
C037A8,earnings,100,50,9/9/2020
C15F8F,conference-participant,100,50,9/9/2020
C3F99F,conference-participant,100,50,9/9/2020
C4F9C6,conference-participant,100,50,9/9/2020
C501B6,legal-issues-defendant,100,22,9/9/2020
C65004,conference-participant,100,50,9/9/2020
C83B88,executive-appointment,100,54,9/9/2020
C8A248,note-sale,100,52,9/9/2020
C97B2D,product-release,100,64,9/9/2020
C9D866,conference-participant,100,50,9/9/2020
CA1620,dividend-up,100,53,9/9/2020
CC0C78,conference-participant,100,50,9/9/2020
CDD75E,conference-call,100,50,9/9/2020
CDD75E,business-contract,100,69,9/9/2020
CDFCC9,earnings-guidance-down,100,19,9/9/2020
CE1002,conference-participant,100,50,9/9/2020
CF211D,earnings,100,50,9/9/2020
CFF97C,partnership,100,61,9/9/2020
D1588D,conference-participant,100,50,9/9/2020
D29B44,conference-participant,100,50,9/9/2020
D36686,conference-participant,100,50,9/9/2020
D42DBA,earnings,100,50,9/9/2020
D42DBA,earnings,100,50,9/9/2020
D42DBA,earnings,100,50,9/9/2020
D42DBA,earnings,100,50,9/9/2020
D42DBA,earnings,100,50,9/9/2020
D45285,note-sale,100,52,9/9/2020
D4C0CB,conference-participant,100,50,9/9/2020
D5938F,earnings,100,50,9/9/2020
D5938F,earnings,100,50,9/9/2020
D8442A,business-contract,100,69,9/9/2020
D8442A,business-contract,100,69,9/9/2020
D88EF3,legal-issues-defendant,100,22,9/9/2020
D9B1C9,fraud,100,44,9/9/2020
DB88A1,award,100,58,9/9/2020
DB88A1,earnings,100,50,9/9/2020
DB88A1,earnings,100,50,9/9/2020
DB88A1,earnings,100,50,9/9/2020
DB88A1,earnings,100,50,9/9/2020
DB88A1,earnings,100,50,9/9/2020
DB88A1,earnings,100,50,9/9/2020
DB88A1,earnings,100,50,9/9/2020
DB88A1,earnings,100,50,9/9/2020
DB88A1,earnings,100,50,9/9/2020
DB88A1,earnings,100,50,9/9/2020
DB9F70,conference-participant,100,50,9/9/2020
DD0F15,conference-participant,100,50,9/9/2020
E05026,note-sale,100,52,9/9/2020
E261E9,conference-participant,100,50,9/9/2020
E261E9,conference-participant,100,50,9/9/2020
E2CFD2,conference-participant,100,50,9/9/2020
E35610,executive-appointment,100,54,9/9/2020
E598FB,conference-participant,100,50,9/9/2020
E68C3D,partnership,100,61,9/9/2020
E68C3D,product-release,100,64,9/9/2020
E7BF32,conference-participant,100,50,9/9/2020
E8846E,conference-organizer,100,57,9/9/2020
E94704,conference-participant,100,50,9/9/2020
ED22DC,conference-participant,100,50,9/9/2020
F02170,conference-participant,100,50,9/9/2020
F18844,legal-issues-defendant,100,22,9/9/2020
F1EB39,earnings,100,50,9/9/2020
F5D059,earnings,100,50,9/9/2020
F88147,conference-participant,100,50,9/9/2020
F8BA6C,conference-participant,100,50,9/9/2020
F92DBC,partnership,100,61,9/9/2020
F92DBC,partnership,100,61,9/9/2020
FAAFA2,conference-participant,100,50,9/9/2020
FCA54E,public-offering,100,43,9/9/2020
FFCD0E,earnings-guidance,100,50,9/9/2020
0157B1,partnership,100,61,9/10/2020
20751,public-offering,100,43,9/10/2020
03CF95,partnership,100,61,9/10/2020
03D5F9,product-release,100,64,9/10/2020
55018,product-release,100,64,9/10/2020
95294,executive-appointment,100,54,9/10/2020
09DE1F,conference-participant,100,50,9/10/2020
0B4D10,dividend,100,50,9/10/2020
0BC29E,executive-appointment,100,54,9/10/2020
0BD4E8,dividend,100,50,9/10/2020
0DE3D5,note-sale,100,52,9/10/2020
106394,dividend-up,100,61,9/10/2020
12DE76,partnership,100,61,9/10/2020
138DDE,dividend,100,50,9/10/2020
139303,conference-organizer,100,57,9/10/2020
139303,executive-appointment,100,54,9/10/2020
147C38,award,100,58,9/10/2020
154272,legal-issues-defendant,100,22,9/10/2020
15A388,conference-participant,100,50,9/10/2020
1A5D5D,donation,100,54,9/10/2020
1AB808,legal-issues-defendant,100,22,9/10/2020
1AD9CC,earnings,100,50,9/10/2020
1B637E,dividend,100,50,9/10/2020
1B637E,buybacks,100,74,9/10/2020
1C599A,note-sale,100,52,9/10/2020
1CD708,dividend,100,50,9/10/2020
1DB833,clinical-trials,100,56,9/10/2020
1DB833,clinical-trials,100,56,9/10/2020
1E1125,conference-organizer,100,57,9/10/2020
1E1125,conference-organizer,100,57,9/10/2020
1E1125,conference-organizer,100,57,9/10/2020
1E1125,conference-organizer,100,57,9/10/2020
1EBF8D,conference-participant,100,50,9/10/2020
2262BD,earnings,100,50,9/10/2020
228D42,partnership,100,61,9/10/2020
239106,acquisition-acquiree,100,76,9/10/2020
2571FA,business-contract,100,69,9/10/2020
25D3CE,conference-participant,100,50,9/10/2020
26DC29,conference-participant,100,50,9/10/2020
2.90E+62,conference-participant,100,50,9/10/2020
2B8179,conference-participant,100,50,9/10/2020
2C681C,conference-participant,100,50,9/10/2020
2C681C,conference-participant,100,50,9/10/2020
2CA60F,partnership,100,61,9/10/2020
2CBB58,executive-appointment,100,54,9/10/2020
2D485F,executive-appointment,100,54,9/10/2020
32DCB3,business-contract,100,69,9/10/2020
3461CF,conference-participant,100,50,9/10/2020
3461CF,award,100,58,9/10/2020
370C50,conference-participant,100,50,9/10/2020
37727A,conference-participant,100,50,9/10/2020
37B120,conference-participant,100,50,9/10/2020
385DD4,conference-participant,100,50,9/10/2020
38FB49,dividend,100,50,9/10/2020
3FBC9B,conference-participant,100,50,9/10/2020
40F7DE,conference-participant,100,50,9/10/2020
453282,conference-participant,100,50,9/10/2020
47FCF2,earnings-guidance,100,50,9/10/2020
4806CE,award,100,58,9/10/2020
499C75,conference-participant,100,50,9/10/2020
4B5054,legal-issues-defendant,100,22,9/10/2020
4B5054,fraud-defendant,100,20,9/10/2020
4C37C5,executive-appointment,100,54,9/10/2020
50070E,conference-organizer,100,57,9/10/2020
50070E,conference-organizer,100,57,9/10/2020
50070E,conference-organizer,100,57,9/10/2020
504FE2,executive-appointment,100,54,9/10/2020
523039,clinical-trials,100,56,9/10/2020
543C77,conference-participant,100,50,9/10/2020
55C9B5,partnership,100,61,9/10/2020
56277A,dividend,100,50,9/10/2020
567F3D,conference-participant,100,50,9/10/2020
567F3D,conference-participant,100,50,9/10/2020
57CAAB,donation,100,54,9/10/2020
57CAAB,clinical-trials-positive,100,87,9/10/2020
57CAAB,clinical-trials-positive,100,87,9/10/2020
58CA9A,executive-resignation,100,44,9/10/2020
5E6959,partnership,100,61,9/10/2020
5F2FF7,conference-participant,100,50,9/10/2020
60FE03,conference-participant,100,50,9/10/2020
619882,conference-organizer,100,57,9/10/2020
64FF65,executive-resignation,100,44,9/10/2020
66A667,earnings,100,50,9/10/2020
66A667,earnings,100,50,9/10/2020
713810,partnership,100,61,9/10/2020
72CB93,note-sale,100,52,9/10/2020
7448A3,note-sale,100,52,9/10/2020
7448A3,note-sale,100,52,9/10/2020
76E80F,product-release,100,64,9/10/2020
7A5097,dividend,100,50,9/10/2020
7BC92D,conference-participant,100,50,9/10/2020
7C4F43,conference-participant,100,50,9/10/2020
80C400,product-release,100,64,9/10/2020
837C04,executive-appointment,100,54,9/10/2020
84920B,supply-increase,100,74,9/10/2020
85DA04,partnership,100,61,9/10/2020
8AC740,dividend,100,50,9/10/2020
8B1F37,dividend,100,50,9/10/2020
8B9B3B,clinical-trials-positive,100,87,9/10/2020
8BAA15,dividend,100,50,9/10/2020
8CF6DD,donation,100,54,9/10/2020
8D4486,partnership,100,61,9/10/2020
8E93A4,note-sale,100,52,9/10/2020
9196A2,conference-organizer,100,57,9/10/2020
9196A2,conference-organizer,100,57,9/10/2020
9196A2,conference-organizer,100,57,9/10/2020
9196A2,conference-organizer,100,57,9/10/2020
9196A2,conference-organizer,100,57,9/10/2020
9196A2,conference-organizer,100,57,9/10/2020
9196A2,conference-organizer,100,57,9/10/2020
9196A2,conference-organizer,100,57,9/10/2020
9196A2,conference-organizer,100,57,9/10/2020
9196A2,conference-organizer,100,57,9/10/2020
9196A2,conference-organizer,100,57,9/10/2020
9196A2,conference-organizer,100,57,9/10/2020
93D207,partnership,100,61,9/10/2020
94637C,conference-participant,100,50,9/10/2020
94637C,dividend,100,50,9/10/2020
96A6CD,conference-participant,100,50,9/10/2020
96F126,business-contract,100,69,9/10/2020
972356,executive-appointment,100,54,9/10/2020
9.74E+08,partnership,100,61,9/10/2020
9.74E+08,dividend,100,50,9/10/2020
986AF6,dividend,100,50,9/10/2020
990AD0,conference-organizer,100,57,9/10/2020
9E5C2C,conference-participant,100,50,9/10/2020
9F71E5,public-offering,100,43,9/10/2020
9FB4B7,conference-participant,100,50,9/10/2020
A01983,dividend,100,50,9/10/2020
A11CF4,conference-participant,100,50,9/10/2020
A247F5,partnership,100,61,9/10/2020
A350C1,award,100,58,9/10/2020
A41450,business-contract,100,69,9/10/2020
A49498,conference-participant,100,50,9/10/2020
A65325,executive-appointment,100,54,9/10/2020
AA7FE0,conference-call,100,50,9/10/2020
AEBB80,dividend,100,50,9/10/2020
B2DAF6,conference-participant,100,50,9/10/2020
B37FB4,conference-participant,100,50,9/10/2020
B381D8,clinical-trials-start,100,64,9/10/2020
B48D6A,conference-participant,100,50,9/10/2020
B5734D,earnings,100,50,9/10/2020
B60366,earnings,100,50,9/10/2020
BB127B,conference-participant,100,50,9/10/2020
BCC55F,executive-appointment,100,54,9/10/2020
BDF85E,earnings,100,50,9/10/2020
BE645B,conference-participant,100,50,9/10/2020
C03C8B,conference-participant,100,50,9/10/2020
C05839,conference-participant,100,50,9/10/2020
C27E19,conference-participant,100,50,9/10/2020
C93C44,conference-participant,100,50,9/10/2020
C9739A,executive-appointment,100,54,9/10/2020
C9881C,conference-call,100,50,9/10/2020
CA1620,conference-participant,100,50,9/10/2020
CBB77B,conference-participant,100,50,9/10/2020
CBCC6A,note-sale,100,52,9/10/2020
CBCC6A,note-sale,100,52,9/10/2020
CBDB4D,conference-participant,100,50,9/10/2020
CDC217,conference-participant,100,50,9/10/2020
CF7292,conference-participant,100,50,9/10/2020
CFF97C,conference-participant,100,50,9/10/2020
D518D8,revenue-guidance-up,100,83,9/10/2020
D6489C,earnings,100,50,9/10/2020
D6EAA3,executive-appointment,100,54,9/10/2020
D6EAA3,note-sale,100,52,9/10/2020
D8ECA1,conference-participant,100,50,9/10/2020
DB7014,conference-participant,100,50,9/10/2020
DB9F70,executive-appointment,100,54,9/10/2020
DBB28E,partnership,100,61,9/10/2020
DD1BA1,conference-participant,100,50,9/10/2020
DF6FDD,product-release,100,64,9/10/2020
E0207A,partnership,100,61,9/10/2020
E05026,note-sale,100,52,9/10/2020
E22FDE,legal-issues-defendant,100,22,9/10/2020
E22FDE,legal-issues-defendant,100,22,9/10/2020
E3E68E,partnership,100,61,9/10/2020
E3E68E,partnership,100,61,9/10/2020
E72599,public-offering,100,43,9/10/2020
E72599,public-offering,100,43,9/10/2020
E8C557,spin-off,100,58,9/10/2020
E8C557,spin-off,100,58,9/10/2020
EA4E68,dividend,100,50,9/10/2020
EB6965,dividend,100,50,9/10/2020
ED3CA8,conference-participant,100,50,9/10/2020
ED7F13,conference-participant,100,50,9/10/2020
EE6F1C,government-contract,100,69,9/10/2020
F05B1B,conference-participant,100,50,9/10/2020
F18844,legal-issues-defendant,100,22,9/10/2020
F18844,legal-issues-defendant,100,22,9/10/2020
F3EDB4,earnings,100,50,9/10/2020
F4F46F,business-contract,100,69,9/10/2020
F569FD,conference-participant,100,50,9/10/2020
F5D410,conference-participant,100,50,9/10/2020
F769E9,earnings,100,50,9/10/2020
FAB97A,legal-issues-defendant,100,22,9/10/2020
FAE021,executive-appointment,100,54,9/10/2020
FAE021,executive-appointment,100,54,9/10/2020
FBDA0F,buybacks,100,74,9/10/2020
FCA54E,public-offering,100,43,9/10/2020
FD4BBE,executive-appointment,100,54,9/10/2020
02870F,legal-issues-defendant,100,22,9/11/2020
02FC1A,conference-participant,100,50,9/11/2020
0C355F,revenue-guidance,100,50,9/11/2020
0E499E,conference-participant,100,50,9/11/2020
125212,conference-call,100,50,9/11/2020
154272,legal-issues-defendant,100,22,9/11/2020
1C599A,legal-issues-defendant,100,22,9/11/2020
1C599A,legal-issues-defendant,100,22,9/11/2020
1CF3A8,public-offering,100,43,9/11/2020
1E7785,conference-participant,100,50,9/11/2020
1E83DE,conference-participant,100,50,9/11/2020
225CA2,executive-resignation,100,44,9/11/2020
263216,trading-halt,100,43,9/11/2020
263216,trading-resumed,100,58,9/11/2020
26E3BA,conference-participant,100,50,9/11/2020
2BC05E,conference-participant,100,50,9/11/2020
2E0496,acquisition-acquirer,100,49,9/11/2020
2E902B,conference-participant,100,50,9/11/2020
2EBA55,dividend,100,50,9/11/2020
2EBC0B,dividend,100,50,9/11/2020
2FF046,facility-sale,100,52,9/11/2020
3461CF,conference-participant,100,50,9/11/2020
3461CF,credit-rating-set-rater,20,50,9/11/2020
3DDE54,executive-resignation,100,44,9/11/2020
4017AD,conference-participant,100,50,9/11/2020
416291,legal-issues-defendant,100,22,9/11/2020
416291,legal-issues-defendant,100,22,9/11/2020
4A6F00,partnership,100,61,9/11/2020
4AE584,conference-participant,100,50,9/11/2020
4B3676,conference-participant,100,50,9/11/2020
4B5054,legal-issues-defendant,100,22,9/11/2020
4B5054,fraud-defendant,100,20,9/11/2020
4B5054,legal-issues-defendant,100,22,9/11/2020
4D203E,unit-acquisition-acquiree,100,76,9/11/2020
50070E,conference-organizer,100,57,9/11/2020
50702E,conference-participant,100,50,9/11/2020
5704AC,executive-appointment,100,54,9/11/2020
594402,executive-appointment,100,54,9/11/2020
59F0B0,conference-participant,100,50,9/11/2020
61B81B,conference-call,100,50,9/11/2020
61E975,conference-participant,100,50,9/11/2020
665D7D,dividend,100,50,9/11/2020
6925EB,conference-participant,100,50,9/11/2020
6CF43C,dividend,100,50,9/11/2020
6D3B7B,dividend,100,50,9/11/2020
6DC1D7,dividend,100,50,9/11/2020
6F5DD2,conference-participant,100,50,9/11/2020
70CA28,conference-participant,100,50,9/11/2020
713810,partnership,100,61,9/11/2020
728737,dividend,100,50,9/11/2020
728737,dividend,100,50,9/11/2020
72CB93,note-sale,100,52,9/11/2020
73A213,conference-participant,100,50,9/11/2020
76F067,conference-participant,100,50,9/11/2020
7B492C,acquisition-acquirer,100,49,9/11/2020
7B8CB5,conference-participant,100,50,9/11/2020
7BEA98,executive-appointment,100,54,9/11/2020
7EA323,executive-appointment,100,54,9/11/2020
826FD6,dividend,100,50,9/11/2020
890FF4,award,100,58,9/11/2020
89F693,conference-organizer,100,57,9/11/2020
9196A2,conference-organizer,100,57,9/11/2020
9196A2,conference-organizer,100,57,9/11/2020
9196A2,conference-organizer,100,57,9/11/2020
9196A2,conference-organizer,100,57,9/11/2020
9196A2,conference-organizer,100,57,9/11/2020
9196A2,conference-organizer,100,57,9/11/2020
9196A2,conference-organizer,100,57,9/11/2020
94983E,acquisition-acquirer,100,49,9/11/2020
958938,executive-appointment,100,54,9/11/2020
95DC1F,earnings,100,50,9/11/2020
95DC1F,earnings,100,50,9/11/2020
95DC1F,earnings,100,50,9/11/2020
95DC1F,earnings,100,50,9/11/2020
990AD0,dividend,100,50,9/11/2020
990AD0,conference-organizer,100,57,9/11/2020
9DDE1B,dividend-up,100,81,9/11/2020
A60354,conference-participant,100,50,9/11/2020
ABB493,conference-participant,100,50,9/11/2020
AD375D,conference-participant,100,50,9/11/2020
ADFB3A,conference-participant,100,50,9/11/2020
AE3113,conference-participant,100,50,9/11/2020
B3CB74,conference-organizer,100,57,9/11/2020
B3CB74,conference-organizer,100,57,9/11/2020
B446B8,legal-issues-defendant,100,22,9/11/2020
B48FC9,executive-appointment,100,54,9/11/2020
B8A51F,clinical-trials-start,100,64,9/11/2020
BAD655,legal-issues-defendant,100,22,9/11/2020
BB58FF,conference-participant,100,50,9/11/2020
BBBB41,conference-participant,100,50,9/11/2020
BDEC1E,public-offering,100,43,9/11/2020
BDF85E,earnings,100,50,9/11/2020
C3BCD5,executive-appointment,100,54,9/11/2020
C74887,conference-participant,100,50,9/11/2020
CBCC6A,conference-organizer,100,57,9/11/2020
CBDB4D,public-offering,100,43,9/11/2020
CFF57D,conference-participant,100,50,9/11/2020
DA0CB8,conference-participant,100,50,9/11/2020
DB23C8,conference-participant,100,50,9/11/2020
DB23C8,conference-participant,100,50,9/11/2020
E0207A,conference-participant,100,50,9/11/2020
E0E4B7,conference-participant,100,50,9/11/2020
E16133,acquisition-acquiree,100,76,9/11/2020
E35610,partnership,100,61,9/11/2020
E3A829,conference-participant,100,50,9/11/2020
E8D221,earnings,100,50,9/11/2020
EB43F4,conference-participant,100,50,9/11/2020
ECA300,conference-participant,100,50,9/11/2020
ECF4F8,executive-appointment,100,54,9/11/2020
ED3CA8,executive-appointment,100,54,9/11/2020
F18844,legal-issues-defendant,100,22,9/11/2020
F18844,legal-issues-defendant,100,22,9/11/2020
1E1125,conference-organizer,100,57,9/13/2020
6391C2,clinical-trials,100,56,9/13/2020
B3ED62,legal-issues-defendant,100,22,9/13/2020
E09E2B,unit-acquisition-acquirer,100,49,9/13/2020
E09E2B,unit-acquisition-acquirer,100,49,9/13/2020
E16133,unit-acquisition-acquiree,100,76,9/13/2020
F6E248,acquisition-acquirer,100,49,9/13/2020
F6E248,acquisition-acquirer,100,49,9/13/2020
F6E248,acquisition-acquirer,100,49,9/13/2020
00326D,dividend,100,50,9/14/2020
00E601,dividend,100,50,9/14/2020
0157B1,hirings,100,65,9/14/2020
02870F,legal-issues-defendant,100,22,9/14/2020
03596A,executive-appointment,100,54,9/14/2020
036C6F,executive-appointment,100,54,9/14/2020
03D5F9,executive-appointment,100,54,9/14/2020
05D148,conference-participant,100,50,9/14/2020
0B13E8,executive-appointment,100,54,9/14/2020
0C355F,executive-appointment,100,54,9/14/2020
0DBB81,executive-appointment,100,54,9/14/2020
0E3436,conference-participant,100,50,9/14/2020
0F04E5,conference-participant,100,50,9/14/2020
1220D2,conference-participant,100,50,9/14/2020
125212,clinical-trials,100,56,9/14/2020
131443,executive-appointment,100,54,9/14/2020
168A5D,executive-appointment,100,54,9/14/2020
168A5D,executive-appointment,100,54,9/14/2020
1748F6,earnings,100,50,9/14/2020
1AB808,patient-enrollment-complete,100,64,9/14/2020
1B5FEA,conference-participant,100,50,9/14/2020
1BC12C,partnership,100,61,9/14/2020
1EBF8D,partnership,100,61,9/14/2020
1FA886,legal-issues-defendant,100,22,9/14/2020
21153F,executive-appointment,100,54,9/14/2020
21153F,executive-appointment,100,54,9/14/2020
228D42,partnership,100,61,9/14/2020
253604,conference-participant,100,50,9/14/2020
25D3CE,clinical-trials-start,100,64,9/14/2020
27A791,executive-appointment,100,54,9/14/2020
292388,conference-participant,100,50,9/14/2020
2A6DBE,regulatory-product-approval-granted,100,81,9/14/2020
2ABF77,clinical-trials-start,100,64,9/14/2020
2BDC1C,conference-call,100,50,9/14/2020
2CB4C9,conference-participant,100,50,9/14/2020
2CC71C,conference-participant,100,50,9/14/2020
2F7A7E,note-sale,100,52,9/14/2020
2FDEE3,conference-participant,100,50,9/14/2020
33E9D5,conference-participant,100,50,9/14/2020
34A959,business-contract,100,69,9/14/2020
34A959,business-contract,100,69,9/14/2020
34B411,donation,100,54,9/14/2020
3A3447,acquisition-acquirer,100,49,9/14/2020
3C7F5F,unit-acquisition-acquiree,100,76,9/14/2020
4017AD,note-sale,100,52,9/14/2020
4017AD,note-sale,100,52,9/14/2020
407878,product-release,100,64,9/14/2020
431B74,acquisition-acquiree,100,76,9/14/2020
435ACE,conference-participant,100,50,9/14/2020
467F2C,conference-participant,100,50,9/14/2020
492117,note-sale,100,52,9/14/2020
4B5054,fraud-defendant,100,20,9/14/2020
4B5054,legal-issues-defendant,100,22,9/14/2020
4BBA23,product-release,100,64,9/14/2020
4C6C63,partnership,100,61,9/14/2020
4D8313,fundraising,100,64,9/14/2020
4E7C1F,executive-appointment,100,54,9/14/2020
4FB770,conference-participant,100,50,9/14/2020
50070E,conference-organizer,100,57,9/14/2020
50070E,conference-organizer,100,57,9/14/2020
50070E,conference-organizer,100,57,9/14/2020
50070E,partnership,100,61,9/14/2020
5675EB,dividend,100,50,9/14/2020
56B7C1,conference-participant,100,50,9/14/2020
57DDB9,conference-participant,100,50,9/14/2020
59F0B0,dividend,100,50,9/14/2020
5AAE17,business-contract,100,69,9/14/2020
5CC29D,conference-call,100,50,9/14/2020
5F2FF7,note-sale,100,52,9/14/2020
5FE4B6,conference-participant,100,50,9/14/2020
6391C2,clinical-trials-positive,100,87,9/14/2020
6391C2,public-offering,100,43,9/14/2020
66ECFD,executive-appointment,100,54,9/14/2020
67B052,executive-appointment,100,54,9/14/2020
67B052,executive-appointment,100,54,9/14/2020
69C99E,clinical-trials,100,56,9/14/2020
6A01DF,executive-appointment,100,54,9/14/2020
6ABCB8,earnings-guidance-up,100,83,9/14/2020
6B6375,clinical-trials,100,56,9/14/2020
6B6375,clinical-trials,100,56,9/14/2020
6C6D73,conference-call,100,50,9/14/2020
7239BB,market-entry,100,57,9/14/2020
73A213,conference-participant,100,50,9/14/2020
76F067,conference-participant,100,50,9/14/2020
7999F3,conference-participant,100,50,9/14/2020
7A5097,conference-participant,100,50,9/14/2020
7ACD98,award,100,58,9/14/2020
7FDE1C,business-contract,100,69,9/14/2020
83A065,dividend,100,50,9/14/2020
8665BA,partnership,100,61,9/14/2020
8665BA,conference-participant,100,50,9/14/2020
895D56,partnership,100,61,9/14/2020
8A8E41,acquisition-acquirer,100,49,9/14/2020
8A8E41,executive-appointment,100,54,9/14/2020
8BE916,note-sale,100,52,9/14/2020
8C6C1B,facility-open,100,65,9/14/2020
8D4486,partnership,100,61,9/14/2020
8E8E6E,partnership,100,61,9/14/2020
8EF425,conference-participant,100,50,9/14/2020
9196A2,conference-organizer,100,57,9/14/2020
9196A2,conference-organizer,100,57,9/14/2020
9196A2,conference-organizer,100,57,9/14/2020
9196A2,conference-organizer,100,57,9/14/2020
9196A2,conference-organizer,100,57,9/14/2020
91C82E,earnings-per-share-positive,100,69,9/14/2020
91C82E,earnings-per-share-positive,100,69,9/14/2020
91C82E,earnings-per-share-positive,100,69,9/14/2020
91C82E,earnings-per-share-positive,100,69,9/14/2020
92D9C9,note-sale,100,52,9/14/2020
9.31E+77,regulatory-product-application,100,69,9/14/2020
934029,partnership,100,61,9/14/2020
93D207,partnership,100,61,9/14/2020
94A326,conference-participant,100,50,9/14/2020
966ACE,government-contract,100,69,9/14/2020
990AD0,conference-organizer,100,57,9/14/2020
990AD0,conference-organizer,100,57,9/14/2020
990AD0,conference-organizer,100,57,9/14/2020
990AD0,conference-organizer,100,57,9/14/2020
990AD0,conference-organizer,100,57,9/14/2020
9A29F4,ipo,100,71,9/14/2020
9B71A7,executive-appointment,100,54,9/14/2020
9C5BA5,revenues,100,50,9/14/2020
9E298A,executive-appointment,100,54,9/14/2020
A0F146,conference-participant,100,50,9/14/2020
A3AAA5,dividend,100,50,9/14/2020
A79F7D,conference-participant,100,50,9/14/2020
ABAA03,executive-appointment,100,54,9/14/2020
ACF77B,dividend,100,50,9/14/2020
ADF092,earnings,100,50,9/14/2020
AFDF2E,conference-participant,100,50,9/14/2020
B08C51,conference-participant,100,50,9/14/2020
B1FC3B,business-contract,100,69,9/14/2020
B2256A,legal-issues-defendant,100,22,9/14/2020
B3ED62,legal-issues-defendant,100,22,9/14/2020
B446B8,executive-resignation,100,44,9/14/2020
B7BDA3,note-sale,100,52,9/14/2020
BB88B6,acquisition-acquiree,100,76,9/14/2020
BB88B6,acquisition-acquiree,100,76,9/14/2020
BB88B6,acquisition-acquiree,100,76,9/14/2020
BBBB41,conference-participant,100,50,9/14/2020
BD8517,conference-participant,100,50,9/14/2020
BDCC11,executive-appointment,100,54,9/14/2020
BDEC1E,conference-participant,100,50,9/14/2020
C74887,earnings,100,50,9/14/2020
C941DC,executive-appointment,100,54,9/14/2020
C951A2,note-sale,100,52,9/14/2020
C951A2,note-sale,100,52,9/14/2020
CBCC6A,conference-organizer,100,57,9/14/2020
CD4DA8,conference-organizer,100,57,9/14/2020
CEDFD5,investment-investor,100,55,9/14/2020
CEDFD5,investment-investor,100,55,9/14/2020
CEDFD5,investment-investor,100,55,9/14/2020
CEDFD5,investment-investor,100,55,9/14/2020
D2C0B6,buybacks,100,74,9/14/2020
D36B23,executive-appointment,100,54,9/14/2020
D54E62,donation,100,54,9/14/2020
D76AEF,executive-appointment,100,54,9/14/2020
D90F43,note-sale,100,52,9/14/2020
D90F43,note-sale,100,52,9/14/2020
DA199F,partnership,100,61,9/14/2020
DD682D,executive-appointment,100,54,9/14/2020
DE5611,conference-participant,100,50,9/14/2020
E0647D,public-offering,100,43,9/14/2020
E09E2B,unit-acquisition-acquirer,100,49,9/14/2020
E11C41,dividend,100,50,9/14/2020
E13782,conference-participant,100,50,9/14/2020
E30B34,conference-participant,100,50,9/14/2020
E30B34,conference-participant,100,50,9/14/2020
E38906,clinical-trials,100,56,9/14/2020
E49AA3,partnership,100,61,9/14/2020
E6EDED,conference-call,100,50,9/14/2020
E8F0E2,conference-participant,100,50,9/14/2020
EB1E1A,partnership,100,61,9/14/2020
ECF4F8,conference-participant,100,50,9/14/2020
EEA6B3,note-sale,100,52,9/14/2020
EEA6B3,note-sale,100,52,9/14/2020
EEA6B3,note-sale,100,52,9/14/2020
EEA6B3,note-sale,100,52,9/14/2020
EEA734,executive-appointment,100,54,9/14/2020
EF5BED,executive-appointment,100,54,9/14/2020
F18844,legal-issues-defendant,100,22,9/14/2020
F18844,legal-issues-defendant,100,22,9/14/2020
F3FCC3,revenue-guidance,100,50,9/14/2020
F57F6F,note-sale,100,52,9/14/2020
F5D410,partnership,100,61,9/14/2020
F5D410,partnership,100,61,9/14/2020
F7D8AE,public-offering,100,43,9/14/2020
F8BA6C,conference-participant,100,50,9/14/2020
FAE021,facility-open,100,65,9/14/2020
FAE021,facility-open,100,65,9/14/2020
FC1736,revenue-up,100,69,9/14/2020
FC1736,earnings,100,50,9/14/2020
FD2565,business-contract,100,69,9/14/2020
FD2565,business-contract,100,69,9/14/2020
FD2565,business-contract,100,69,9/14/2020
FEE4B0,business-contract,100,69,9/14/2020
00FC70,dividend-up,100,81,9/15/2020
02870F,legal-issues-defendant,100,22,9/15/2020
02870F,legal-issues-defendant,100,22,9/15/2020
31025,partnership,100,61,9/15/2020
03B8CF,revenues,100,50,9/15/2020
099C88,note-sale,100,52,9/15/2020
0BC29E,executive-appointment,100,54,9/15/2020
0E499E,partnership,100,61,9/15/2020
108A2B,dividend,100,50,9/15/2020
112694,executive-appointment,100,54,9/15/2020
149301,dividend,100,50,9/15/2020
1921DD,partnership,100,61,9/15/2020
1C599A,legal-issues-defendant,100,22,9/15/2020
1EBF8D,conference-participant,100,50,9/15/2020
21F9CA,award,100,58,9/15/2020
228D42,partnership,100,61,9/15/2020
228D42,partnership,100,61,9/15/2020
228D42,dividend-up,100,81,9/15/2020
22C58E,legal-issues-defendant,100,22,9/15/2020
270B78,conference-participant,100,50,9/15/2020
279916,legal-issues-defendant,100,22,9/15/2020
284289,conference-participant,100,50,9/15/2020
2BBE62,partnership,100,61,9/15/2020
2C3348,clinical-trials-start,100,64,9/15/2020
2CBB58,conference-participant,100,50,9/15/2020
2D485F,partnership,100,61,9/15/2020
2D485F,partnership,100,61,9/15/2020
2E0496,product-release,100,64,9/15/2020
2E0496,product-release,100,64,9/15/2020
2F24A5,dividend,100,50,9/15/2020
3.20E+263,executive-appointment,100,54,9/15/2020
3A3447,facility-open,100,65,9/15/2020
3A3948,business-contract,100,69,9/15/2020
3B50FE,earnings,100,50,9/15/2020
3CCC90,product-release,100,64,9/15/2020
408380,executive-appointment,100,54,9/15/2020
41EC04,partnership,100,61,9/15/2020
42AABD,acquisition-completed-acquirer,100,49,9/15/2020
42AABD,acquisition-completed-acquirer,100,49,9/15/2020
4.91E+58,product-release,100,64,9/15/2020
4C2F17,campaign-ad-release,100,59,9/15/2020
4F9926,product-release,100,64,9/15/2020
4F9926,product-release,100,64,9/15/2020
5.47E+28,conference-participant,100,50,9/15/2020
54DF47,dividend,100,50,9/15/2020
5704AC,dividend-up,100,53,9/15/2020
57DDB9,business-contract,100,69,9/15/2020
5C61CC,executive-resignation,100,44,9/15/2020
6166D1,dividend,100,50,9/15/2020
616E3B,award,100,58,9/15/2020
616E3B,award,100,58,9/15/2020
619882,executive-appointment,100,54,9/15/2020
619882,dividend,100,50,9/15/2020
619882,dividend,100,50,9/15/2020
657097,dividend,100,50,9/15/2020
66ECFD,award,100,58,9/15/2020
6844D2,earnings-up,100,68,9/15/2020
6844D2,earnings-up,100,68,9/15/2020
68BA15,acquisition-acquirer,100,49,9/15/2020
68E6E9,note-sale,100,52,9/15/2020
6A024C,executive-appointment,100,54,9/15/2020
6ABCB8,dividend,100,50,9/15/2020
6CB7F9,stock-splits,100,49,9/15/2020
6D3F35,product-release,100,64,9/15/2020
6D3F35,product-release,100,64,9/15/2020
6DBBBC,product-release,100,64,9/15/2020
762A3E,unit-acquisition-acquirer,100,49,9/15/2020
76959C,unit-acquisition-completed-acquiree,100,67,9/15/2020
773A17,partnership,100,61,9/15/2020
78F9ED,joint-venture,100,62,9/15/2020
78F9ED,joint-venture,100,62,9/15/2020
79340A,conference-participant,100,50,9/15/2020
7AF907,conference-participant,100,50,9/15/2020
7B1E50,dividend,100,50,9/15/2020
7B9212,dividend,100,50,9/15/2020
7C62A3,note-sale,100,52,9/15/2020
7C62A3,note-sale,100,52,9/15/2020
7DA412,executive-appointment,100,54,9/15/2020
7DA412,executive-appointment,100,54,9/15/2020
7DD8CC,dividend,100,50,9/15/2020
8A0368,executive-appointment,100,54,9/15/2020
8C6C1B,facility-open,100,65,9/15/2020
8EDACA,conference-participant,100,50,9/15/2020
911AB8,business-contract,100,69,9/15/2020
9196A2,conference-organizer,100,57,9/15/2020
9196A2,dividend,100,50,9/15/2020
91E5EE,dividend,100,50,9/15/2020
93F143,executive-appointment,100,54,9/15/2020
9470CC,executive-appointment,100,54,9/15/2020
990AD0,conference-organizer,100,57,9/15/2020
99B61C,conference-participant,100,50,9/15/2020
9B5968,executive-appointment,100,54,9/15/2020
9D5D35,executive-appointment,100,54,9/15/2020
A1E3B3,business-contract,100,69,9/15/2020
A1E3B3,business-contract,100,69,9/15/2020
A5DD24,executive-appointment,100,54,9/15/2020
A80FE0,business-contract,100,69,9/15/2020
AA1EAA,dividend,100,50,9/15/2020
AC7C4F,business-contract,100,69,9/15/2020
AD22F2,conference-participant,100,50,9/15/2020
AD375D,dividend,100,50,9/15/2020
AE4EEB,dividend,100,50,9/15/2020
B01111,partnership,100,61,9/15/2020
B3ED62,legal-issues-defendant,100,22,9/15/2020
BCC55F,partnership,100,61,9/15/2020
BDEC1E,conference-participant,100,50,9/15/2020
C1114B,conference-participant,100,50,9/15/2020
C22BE8,product-release,100,64,9/15/2020
C29715,note-sale,100,52,9/15/2020
C356AC,unit-acquisition-acquiree,100,76,9/15/2020
C356AC,unit-acquisition-acquiree,100,76,9/15/2020
C54140,executive-resignation,100,44,9/15/2020
C62AA4,business-contract,100,69,9/15/2020
C941DC,conference-participant,100,50,9/15/2020
C9881C,revenue-up,100,69,9/15/2020
C9881C,revenue-up,100,69,9/15/2020
C9881C,revenue-up,100,69,9/15/2020
C9D866,public-offering,100,43,9/15/2020
CA1620,partnership,100,61,9/15/2020
CAD7D9,conference-call,100,50,9/15/2020
CBB77B,board-meeting,100,51,9/15/2020
CBCC6A,conference-organizer,100,57,9/15/2020
CD4DA8,partnership,100,61,9/15/2020
CDD75E,executive-appointment,100,54,9/15/2020
CE4FD9,conference-participant,100,50,9/15/2020
CFF97C,credit-rating-upgrade-rater,20,50,9/15/2020
CFF97C,credit-rating-upgrade-rater,20,50,9/15/2020
CFF97C,credit-rating-upgrade-rater,20,50,9/15/2020
D11C1C,dividend,100,50,9/15/2020
D139BC,dividend,100,50,9/15/2020
D3FA2C,dividend,100,50,9/15/2020
D3FD6D,conference-participant,100,50,9/15/2020
D48275,conference-call,100,50,9/15/2020
D5938F,executive-appointment,100,54,9/15/2020
D63B0F,dividend,100,50,9/15/2020
D82EF3,campaign-ad-release,100,59,9/15/2020
D8442A,partnership,100,61,9/15/2020
D8442A,product-release,100,64,9/15/2020
D8442A,product-release,100,64,9/15/2020
D9164D,note-sale,100,52,9/15/2020
DB7FA7,note-sale,100,52,9/15/2020
DB9829,dividend,100,50,9/15/2020
DC5299,dividend,100,50,9/15/2020
DCD97F,business-contract,100,69,9/15/2020
DD7A96,conference-participant,100,50,9/15/2020
DDCB34,partnership,100,61,9/15/2020
DF18E6,executive-appointment,100,54,9/15/2020
DF5F14,dividend,100,50,9/15/2020
E05026,conference-participant,100,50,9/15/2020
E124EB,dividend,100,50,9/15/2020
E1E093,business-contract,100,69,9/15/2020
E261E9,conference-participant,100,50,9/15/2020
E4CE73,product-release,100,64,9/15/2020
EB7FBF,conference-call,100,50,9/15/2020
EBD89A,business-contract,100,69,9/15/2020
ECD263,earnings,100,50,9/15/2020
ED7F13,dividend,100,50,9/15/2020
EEA734,executive-appointment,100,54,9/15/2020
EF7163,dividend,100,50,9/15/2020
F294DD,dividend,100,50,9/15/2020
F30508,fast-track-designation,100,81,9/15/2020
F48947,acquisition-acquirer,100,49,9/15/2020
F4F46F,business-contract,100,69,9/15/2020
F4FBD8,ipo-pricing,100,50,9/15/2020
F80389,dividend,100,50,9/15/2020
F88A04,conference-participant,100,50,9/15/2020
F9AA02,executive-appointment,100,54,9/15/2020
FCA54E,public-offering,100,43,9/15/2020
00FC70,earnings,100,50,9/16/2020
0157B1,business-contract,100,69,9/16/2020
02870F,legal-issues-defendant,100,22,9/16/2020
02FC1A,clinical-trials,100,56,9/16/2020
033B58,conference-participant,100,50,9/16/2020
054B55,public-offering,100,43,9/16/2020
61366,public-offering,100,43,9/16/2020
07C69F,dividend,100,50,9/16/2020
099C88,note-sale,100,52,9/16/2020
0A6824,note-sale,100,52,9/16/2020
0A6824,note-sale,100,52,9/16/2020
0C466B,conference-call,100,50,9/16/2020
10943B,acquisition-acquirer,100,49,9/16/2020
1201B5,earnings,100,50,9/16/2020
12E454,partnership,100,61,9/16/2020
147C38,executive-appointment,100,54,9/16/2020
14BA06,dividend,100,50,9/16/2020
157CC1,regulatory-investigation,100,22,9/16/2020
16B183,dividend,100,50,9/16/2020
17EDA5,legal-issues-defendant,100,22,9/16/2020
17EDA5,legal-issues-defendant,100,22,9/16/2020
1921DD,business-contract,100,69,9/16/2020
197612,executive-appointment,100,54,9/16/2020
1DEBBE,partnership,100,61,9/16/2020
1EBF8D,legal-issues-defendant,100,22,9/16/2020
1FAF22,business-contract,100,69,9/16/2020
228D42,award,100,58,9/16/2020
228D42,partnership,100,61,9/16/2020
23699B,ipo-pricing,100,50,9/16/2020
251988,partnership,100,61,9/16/2020
2571FA,conference-participant,100,50,9/16/2020
25DD05,dividend,100,50,9/16/2020
26CC63,executive-appointment,100,54,9/16/2020
26DC29,partnership,100,61,9/16/2020
282C18,dividend,100,50,9/16/2020
2BF36E,executive-appointment,100,54,9/16/2020
2CB4C9,unit-acquisition-acquiree,100,76,9/16/2020
2CB4C9,unit-acquisition-acquiree,100,76,9/16/2020
2DDB22,dividend,100,50,9/16/2020
2EC172,partnership,100,61,9/16/2020
2FEA66,dividend,100,50,9/16/2020
3.20E+263,clinical-trials-positive,100,87,9/16/2020
36A1CB,executive-appointment,100,54,9/16/2020
372037,award,100,58,9/16/2020
384CD3,dividend,100,50,9/16/2020
3DE4D1,executive-appointment,100,54,9/16/2020
3ED92D,product-release,100,64,9/16/2020
43A060,patent-awarded,100,72,9/16/2020
4A6F00,partnership,100,61,9/16/2020
4AC91D,product-release,100,64,9/16/2020
4B5054,fraud-defendant,100,20,9/16/2020
4C6C63,partnership,100,61,9/16/2020
4E4E75,dividend,100,50,9/16/2020
548AC0,executive-appointment,100,54,9/16/2020
594402,conference-participant,100,50,9/16/2020
596116,conference-participant,100,50,9/16/2020
5B3FA2,product-release,100,64,9/16/2020
5B51D6,ipo-pricing,100,50,9/16/2020
5C2A47,partnership,100,61,9/16/2020
5CCDAD,conference-participant,100,50,9/16/2020
609208,earnings,100,50,9/16/2020
60DD84,acquisition-acquirer,100,49,9/16/2020
6166D1,conference-call,100,50,9/16/2020
6166D1,dividend,100,50,9/16/2020
62CDDE,conference-participant,100,50,9/16/2020
63E8D5,dividend,100,50,9/16/2020
641F17,earnings,100,50,9/16/2020
6830FE,executive-appointment,100,54,9/16/2020
693ECD,patent-awarded,100,72,9/16/2020
69CE71,investment-investor,100,55,9/16/2020
75F982,partnership,100,61,9/16/2020
75F982,partnership,100,61,9/16/2020
75F982,partnership,100,61,9/16/2020
767F86,executive-appointment,100,54,9/16/2020
771985,conference-participant,100,50,9/16/2020
775439,dividend,100,50,9/16/2020
7ACBA4,dividend,100,50,9/16/2020
7B1E50,legal-issues-defendant,100,22,9/16/2020
8.10E+32,executive-appointment,100,54,9/16/2020
84AB66,dividend,100,50,9/16/2020
896771,facility-open,100,65,9/16/2020
8A8E41,product-release,100,64,9/16/2020
8A8E41,product-release,100,64,9/16/2020
8C6C1B,facility-open,100,65,9/16/2020
911ACB,dividend,100,50,9/16/2020
9196A2,conference-organizer,100,57,9/16/2020
9196A2,conference-organizer,100,57,9/16/2020
93633B,dividend,100,50,9/16/2020
942633,dividend,100,50,9/16/2020
96BFF4,legal-issues-defendant,100,22,9/16/2020
990AD0,legal-issues-defendant,100,22,9/16/2020
99B61C,patient-enrollment-complete,100,64,9/16/2020
9C3D3C,unit-acquisition-acquirer,100,49,9/16/2020
9F6B1A,partnership,100,61,9/16/2020
A05C43,executive-appointment,100,54,9/16/2020
A38F30,earnings-guidance,100,50,9/16/2020
A52B6B,product-release,100,64,9/16/2020
A6213D,partnership,100,61,9/16/2020
B3ED62,legal-issues-defendant,100,22,9/16/2020
B48D6A,clinical-trials,100,56,9/16/2020
B72D2E,partnership,100,61,9/16/2020
B762D3,dividend,100,50,9/16/2020
B8F71F,note-sale,100,52,9/16/2020
BAD655,legal-issues-defendant,100,22,9/16/2020
BAD655,legal-issues-defendant,100,22,9/16/2020
BCC13E,regulatory-product-approval-granted,100,81,9/16/2020
BCC55F,award,100,58,9/16/2020
BCC55F,award,100,58,9/16/2020
BD682F,dividend,100,50,9/16/2020
C425AE,conference-participant,100,50,9/16/2020
C83B88,partnership,100,61,9/16/2020
C8A248,partnership,100,61,9/16/2020
CD06A2,donation,100,54,9/16/2020
CDC817,note-sale,100,52,9/16/2020
CE2791,dividend,100,50,9/16/2020
D0DE27,dividend-up,100,53,9/16/2020
D6489C,partnership,100,61,9/16/2020
D697DE,award,100,58,9/16/2020
D76AEF,executive-appointment,100,54,9/16/2020
D78BF1,business-contract,100,69,9/16/2020
D8442A,product-release,100,64,9/16/2020
DA0A9E,business-contract,100,69,9/16/2020
DDB002,conference-participant,100,50,9/16/2020
DEF058,note-sale,100,52,9/16/2020
DFADDB,executive-appointment,100,54,9/16/2020
E074A0,conference-participant,100,50,9/16/2020
E1F30A,ipo-completed,100,76,9/16/2020
E8846E,conference-organizer,100,57,9/16/2020
EB1E1A,partnership,100,61,9/16/2020
ED79D9,dividend,100,50,9/16/2020
F5D499,partnership,100,61,9/16/2020
F85CC0,dividend,100,50,9/16/2020
F85CC0,dividend,100,50,9/16/2020
FDF28E,conference-participant,100,50,9/16/2020
00067A,business-contract,100,69,9/17/2020
13528,facility-open,100,65,9/17/2020
0142B5,conference-participant,100,50,9/17/2020
02870F,legal-issues-defendant,100,22,9/17/2020
61366,public-offering,100,43,9/17/2020
07C69F,executive-appointment,100,54,9/17/2020
0A9D0A,product-recall,100,29,9/17/2020
0C28D1,product-release,100,64,9/17/2020
0C28D1,product-release,100,64,9/17/2020
11AEDE,earnings,100,50,9/17/2020
1.79E+10,conference-call,100,50,9/17/2020
188394,conference-call,100,50,9/17/2020
1B5FEA,partnership,100,61,9/17/2020
1B5FEA,partnership,100,61,9/17/2020
1E1125,partnership,100,61,9/17/2020
1E1125,partnership,100,61,9/17/2020
1EBF8D,partnership,100,61,9/17/2020
1F43A1,dividend-up,100,81,9/17/2020
20BEEA,earnings-guidance,100,50,9/17/2020
21153F,dividend,100,50,9/17/2020
21153F,dividend,100,50,9/17/2020
2491BC,partnership,100,61,9/17/2020
253B2F,note-sale,100,52,9/17/2020
273BA3,ipo-pricing,100,50,9/17/2020
273BA3,ipo-pricing,100,50,9/17/2020
279916,legal-issues-defendant,100,22,9/17/2020
2CA60F,executive-appointment,100,54,9/17/2020
372037,executive-appointment,100,54,9/17/2020
37727A,dividend,100,50,9/17/2020
3AF7FD,executive-appointment,100,54,9/17/2020
3DED49,ipo-pricing,100,50,9/17/2020
401072,clinical-trials,100,56,9/17/2020
416291,legal-issues-defendant,100,22,9/17/2020
448215,public-offering,100,43,9/17/2020
449217,buybacks,100,74,9/17/2020
47752F,executive-appointment,100,54,9/17/2020
47752F,dividend,100,50,9/17/2020
4A6F00,partnership,100,61,9/17/2020
4A6F00,partnership,100,61,9/17/2020
4C92B9,dividend-up,100,86,9/17/2020
4EEB00,conference-participant,100,50,9/17/2020
520632,dividend,100,50,9/17/2020
53EF9E,conference-participant,100,50,9/17/2020
53F491,dividend,100,50,9/17/2020
53F491,earnings,100,50,9/17/2020
543900,executive-appointment,100,54,9/17/2020
55438C,executive-appointment,100,54,9/17/2020
55C9B5,partnership,100,61,9/17/2020
55C9B5,partnership,100,61,9/17/2020
55C9B5,partnership,100,61,9/17/2020
55C9B5,partnership,100,61,9/17/2020
577033,ipo-pricing,100,50,9/17/2020
58B46F,executive-appointment,100,54,9/17/2020
5BC2F4,dividend,100,50,9/17/2020
5DD48B,partnership,100,61,9/17/2020
5DD48B,private-placement,100,56,9/17/2020
60AC34,executive-appointment,100,54,9/17/2020
60FE03,bought-deal,100,43,9/17/2020
627186,earnings,100,50,9/17/2020
62A48D,business-contract,100,69,9/17/2020
6391C2,public-offering,100,43,9/17/2020
65D0AA,regulatory-product-approval-granted,100,81,9/17/2020
6CC55E,conference-organizer,100,57,9/17/2020
6CC55E,conference-organizer,100,57,9/17/2020
6CC55E,conference-organizer,100,57,9/17/2020
6DBBBC,business-contract,100,69,9/17/2020
6EA292,dividend,100,50,9/17/2020
6FCEF9,dividend,100,50,9/17/2020
76F067,partnership,100,61,9/17/2020
7BEA98,executive-appointment,100,54,9/17/2020
7F9984,executive-appointment,100,54,9/17/2020
8.10E+32,acquisition-acquirer,100,49,9/17/2020
810FAD,conference-participant,100,50,9/17/2020
819492,partnership,100,61,9/17/2020
819492,partnership,100,61,9/17/2020
8B3B0E,dividend,100,50,9/17/2020
8BAA15,conference-participant,100,50,9/17/2020
8C6C1B,facility-open,100,65,9/17/2020
8DCF18,clinical-trials,100,56,9/17/2020
8E8E6E,executive-appointment,100,54,9/17/2020
8FF2EF,earnings,100,50,9/17/2020
9196A2,conference-organizer,100,57,9/17/2020
9196A2,conference-organizer,100,57,9/17/2020
94208D,executive-appointment,100,54,9/17/2020
94208D,executive-appointment,100,54,9/17/2020
94637C,settlement,100,56,9/17/2020
94637C,earnings,100,50,9/17/2020
95DC1F,dividend,100,50,9/17/2020
96BFF4,legal-issues-defendant,100,22,9/17/2020
97AAF6,executive-appointment,100,54,9/17/2020
986AF6,earnings-guidance,100,50,9/17/2020
98CAED,acquisition-completed-acquirer,100,49,9/17/2020
990AD0,executive-appointment,100,54,9/17/2020
9978F1,partnership,100,61,9/17/2020
9978F1,partnership,100,61,9/17/2020
99ACAD,unit-acquisition-acquiree,100,76,9/17/2020
9B71A7,partnership,100,61,9/17/2020
A16DEA,partnership,100,61,9/17/2020
A247F5,award,100,58,9/17/2020
A350C1,conference-call,100,50,9/17/2020
A52B6B,acquisition-completed-acquirer,100,49,9/17/2020
A6FE1C,acquisition-acquirer,100,49,9/17/2020
A70BF5,earnings,100,50,9/17/2020
A868C9,business-contract,100,69,9/17/2020
A9ED24,dividend,100,50,9/17/2020
AC775C,conference-participant,100,50,9/17/2020
B076A1,dividend,100,50,9/17/2020
B3ED62,legal-issues-defendant,100,22,9/17/2020
B446B8,executive-appointment,100,54,9/17/2020
B66928,partnership,100,61,9/17/2020
B72BE9,executive-appointment,100,54,9/17/2020
B77F14,executive-appointment,100,54,9/17/2020
B8F71F,partnership,100,61,9/17/2020
BB127B,partnership,100,61,9/17/2020
BCC55F,partnership,100,61,9/17/2020
C05839,dividend,100,50,9/17/2020
C29E71,index-listing,100,76,9/17/2020
C2DD02,dividend,100,50,9/17/2020
C425AE,conference-participant,100,50,9/17/2020
C501B6,legal-issues-defendant,100,22,9/17/2020
C624A1,legal-issues-defendant,100,22,9/17/2020
C624A1,legal-issues-defendant,100,22,9/17/2020
C624A1,legal-issues-defendant,100,22,9/17/2020
CB22CD,note-sale,100,52,9/17/2020
CBCC6A,note-sale,100,52,9/17/2020
CBCC6A,note-sale,100,52,9/17/2020
CBFFDD,business-contract,100,69,9/17/2020
CC6FF5,award,100,58,9/17/2020
CD4DA8,conference-organizer,100,57,9/17/2020
D1C26F,fundraising,100,64,9/17/2020
D6853F,business-contract,100,69,9/17/2020
D75910,acquisition-acquirer,100,49,9/17/2020
D75910,acquisition-acquirer,100,49,9/17/2020
D7A953,executive-appointment,100,54,9/17/2020
D8442A,partnership,100,61,9/17/2020
DA0A9E,conference-call,100,50,9/17/2020
DDCB34,conference-participant,100,50,9/17/2020
DE4924,conference-participant,100,50,9/17/2020
E0647D,public-offering,100,43,9/17/2020
E0647D,public-offering,100,43,9/17/2020
E30A8F,partnership,100,61,9/17/2020
E8846E,legal-issues-defendant,100,22,9/17/2020
E8B315,dividend,100,50,9/17/2020
EBC84C,executive-appointment,100,54,9/17/2020
EC99D0,conference-call,100,50,9/17/2020
ECDEB2,dividend,100,50,9/17/2020
EF1AD9,note-sale,100,52,9/17/2020
EF77A3,earnings,100,50,9/17/2020
EF77A3,executive-resignation,100,44,9/17/2020
F209B4,conference-participant,100,50,9/17/2020
F30508,partnership,100,61,9/17/2020
F4FBD8,ipo-completed,100,76,9/17/2020
F5349B,award,100,58,9/17/2020
F5D410,conference-call,100,50,9/17/2020
F5D499,conference-call,100,50,9/17/2020
F7ADEB,government-contract,100,69,9/17/2020
F88147,executive-appointment,100,54,9/17/2020
F9AA02,executive-appointment,100,54,9/17/2020
FE7A63,executive-appointment,100,54,9/17/2020
FE89E0,conference-call,100,50,9/17/2020
FEC475,executive-appointment,100,54,9/17/2020
01D03F,product-release,100,64,9/18/2020
01D03F,partnership,100,61,9/18/2020
01D03F,regulatory-product-review-positive,100,73,9/18/2020
02870F,legal-issues-defendant,100,22,9/18/2020
02870F,legal-issues-defendant,100,22,9/18/2020
054B55,public-offering,100,43,9/18/2020
0AAD90,executive-appointment,100,54,9/18/2020
0E499E,regulatory-product-review-positive,100,73,9/18/2020
14BA33,dividend,100,50,9/18/2020
17EDA5,dividend,100,50,9/18/2020
1DF15D,dividend,100,50,9/18/2020
1F43A1,executive-appointment,100,54,9/18/2020
279916,legal-issues-defendant,100,22,9/18/2020
2E902B,dividend,100,50,9/18/2020
301493,acquisition-acquiree,100,76,9/18/2020
339F20,dividend-up,100,56,9/18/2020
3.88E+02,legal-issues-defendant,100,22,9/18/2020
3F4497,dividend,100,50,9/18/2020
40B903,executive-appointment,100,54,9/18/2020
420168,dividend,100,50,9/18/2020
427F32,executive-appointment,100,54,9/18/2020
4A6F00,partnership,100,61,9/18/2020
4B5054,fraud-defendant,100,20,9/18/2020
4C31F3,conference-participant,100,50,9/18/2020
4D8313,dividend,100,50,9/18/2020
4E2D94,earnings-guidance,100,50,9/18/2020
56EA2B,partnership,100,61,9/18/2020
5DE5A5,conference-participant,100,50,9/18/2020
5E6959,dividend,100,50,9/18/2020
6AACDD,ipo-pricing,100,50,9/18/2020
6CC55E,clinical-trials,100,56,9/18/2020
6E7060,dividend,100,50,9/18/2020
6F5DD2,patent-awarded,100,72,9/18/2020
7.44E+09,executive-appointment,100,54,9/18/2020
756BB4,award,100,58,9/18/2020
756BB4,award,100,58,9/18/2020
75F982,business-contract,100,69,9/18/2020
7999F3,dividend,100,50,9/18/2020
7AB859,business-contract,100,69,9/18/2020
7DA412,partnership,100,61,9/18/2020
7DA412,partnership,100,61,9/18/2020
7F9BE2,note-sale,100,52,9/18/2020
8817D5,conference-call,100,50,9/18/2020
8C6C1B,facility-open,100,65,9/18/2020
8DCBBB,donation,100,54,9/18/2020
94637C,regulatory-product-approval-granted,100,81,9/18/2020
96BFF4,legal-issues-defendant,100,22,9/18/2020
9978F1,clinical-trials,100,56,9/18/2020
A6D095,earnings,100,50,9/18/2020
B05118,note-sale,100,52,9/18/2020
B2D799,settlement,100,56,9/18/2020
B3ED62,legal-issues-defendant,100,22,9/18/2020
B72BE9,dividend,100,50,9/18/2020
C06EB6,clinical-trials-positive,100,87,9/18/2020
C27E19,earnings,100,50,9/18/2020
C501B6,index-listing,100,76,9/18/2020
C584BE,conference-participant,100,50,9/18/2020
C624A1,legal-issues-defendant,100,22,9/18/2020
C624A1,legal-issues-defendant,100,22,9/18/2020
C624A1,legal-issues-defendant,100,22,9/18/2020
C9739A,conference-participant,100,50,9/18/2020
C9B932,legal-issues-defendant,100,22,9/18/2020
CB22CD,note-sale,100,52,9/18/2020
CDC817,note-sale,100,52,9/18/2020
CE5C6E,conference-participant,100,50,9/18/2020
CF351E,dividend,100,50,9/18/2020
D598E7,conference-call,100,50,9/18/2020
D96202,conference-call,100,50,9/18/2020
DA0CB8,dividend,100,50,9/18/2020
DD1BA1,executive-appointment,100,54,9/18/2020
DD1BA1,revenue-up,100,91,9/18/2020
E8E899,award,100,58,9/18/2020
EB1E1A,business-contract,100,69,9/18/2020
EE1E44,executive-appointment,100,54,9/18/2020
EEA6B3,note-sale,100,52,9/18/2020
F30508,regulatory-product-approval-granted,100,81,9/18/2020
F30508,regulatory-product-approval-granted,100,81,9/18/2020
F4CDA3,dividend,100,50,9/18/2020
F7D8AE,public-offering,100,43,9/18/2020
F82D37,conference-call,100,50,9/18/2020
F9CAF8,acquisition-completed-acquiree,100,76,9/18/2020
FA044A,trading-listing,100,61,9/18/2020
FF9FF6,public-offering,100,43,9/18/2020
FF9FF6,public-offering,100,43,9/18/2020
01D03F,clinical-trials,100,56,9/19/2020
01D03F,clinical-trials,100,56,9/19/2020
02870F,legal-issues-defendant,100,22,9/20/2020
B3ED62,legal-issues-defendant,100,22,9/20/2020
F18844,legal-issues-defendant,100,22,9/20/2020
0157B1,partnership,100,61,9/21/2020
01D03F,acquisition-acquirer,100,49,9/21/2020
02870F,legal-issues-defendant,100,22,9/21/2020
06C826,credit-extension-recipient,100,69,9/21/2020
06EF42,business-contract,100,69,9/21/2020
06EF42,business-contract,100,69,9/21/2020
0A7650,conference-participant,100,50,9/21/2020
0BD4E8,award,100,58,9/21/2020
0CC01F,dividend,100,50,9/21/2020
0CE204,product-release,100,64,9/21/2020
0EF1AF,conference-participant,100,50,9/21/2020
1834C0,unit-acquisition-acquirer,100,49,9/21/2020
1A3E1B,product-release,100,64,9/21/2020
1E9A6D,credit-extension-provider,100,57,9/21/2020
1E9A6D,credit-extension-provider,100,57,9/21/2020
1EBF8D,regulatory-product-review-positive,100,73,9/21/2020
1EC3E8,executive-appointment,100,54,9/21/2020
1EC3E8,executive-appointment,100,54,9/21/2020
1F19C8,executive-appointment,100,54,9/21/2020
228D42,product-release,100,64,9/21/2020
228D42,acquisition-acquirer,100,49,9/21/2020
23699B,ipo-completed,100,76,9/21/2020
267718,partnership,100,61,9/21/2020
279916,legal-issues-defendant,100,22,9/21/2020
30AB63,earnings-guidance,100,50,9/21/2020
315EB0,partnership,100,61,9/21/2020
33A0F1,executive-appointment,100,54,9/21/2020
33FD66,earnings,100,50,9/21/2020
34B411,donation,100,54,9/21/2020
353DBB,business-contract,100,69,9/21/2020
39692D,product-release,100,64,9/21/2020
3BB616,partnership,100,61,9/21/2020
450ECB,executive-appointment,100,54,9/21/2020
4B6EF9,executive-appointment,100,54,9/21/2020
4D8124,earnings-guidance,100,50,9/21/2020
4FCC78,acquisition-completed-acquirer,100,49,9/21/2020
507AE7,executive-appointment,100,54,9/21/2020
520632,conference-call,100,50,9/21/2020
5.43E+08,partnership,100,61,9/21/2020
545272,dividend,100,50,9/21/2020
5546DA,executive-appointment,100,54,9/21/2020
577033,ipo-completed,100,76,9/21/2020
589846,partnership,100,61,9/21/2020
5B97B2,dividend,100,50,9/21/2020
619882,legal-issues-defendant,100,22,9/21/2020
619882,legal-issues-defendant,100,22,9/21/2020
61E975,conference-call,100,50,9/21/2020
627186,product-release,100,64,9/21/2020
657097,unit-acquisition-acquirer,100,49,9/21/2020
6AACDD,ipo-pricing,100,50,9/21/2020
6C6D73,conference-call,100,50,9/21/2020
6CC55E,partnership,100,61,9/21/2020
6D9B53,executive-appointment,100,54,9/21/2020
6D9ECA,clinical-trials-start,100,64,9/21/2020
6F0096,executive-appointment,100,54,9/21/2020
6F30F9,dividend,100,50,9/21/2020
6F92A9,note-sale,100,52,9/21/2020
719477,executive-appointment,100,54,9/21/2020
71B0CF,executive-appointment,100,54,9/21/2020
73C521,earnings,100,50,9/21/2020
741937,executive-appointment,100,54,9/21/2020
746373,conference-call,100,50,9/21/2020
75F982,legal-issues-defendant,100,22,9/21/2020
76D79A,conference-call,100,50,9/21/2020
7B1E50,legal-issues-defendant,100,22,9/21/2020
7F3FBC,acquisition-acquirer,100,49,9/21/2020
819492,partnership,100,61,9/21/2020
845533,executive-appointment,100,54,9/21/2020
85DA04,facility-open,100,65,9/21/2020
85DA04,facility-open,100,65,9/21/2020
8B9B3B,executive-appointment,100,54,9/21/2020
8C6C1B,facility-open,100,65,9/21/2020
8E3F58,index-listing,100,76,9/21/2020
911AB8,asset-sale,100,62,9/21/2020
911AB8,unit-acquisition-acquiree,100,76,9/21/2020
911AB8,unit-acquisition-acquiree,100,76,9/21/2020
92B047,conference-call,100,50,9/21/2020
9368BE,executive-appointment,100,54,9/21/2020
94637C,acquisition-completed-acquirer,100,49,9/21/2020
97644E,stake-acquirer,100,48,9/21/2020
9D5D35,conference-participant,100,50,9/21/2020
9E3224,dividend,100,50,9/21/2020
A3AAA5,dividend,100,50,9/21/2020
A495F7,partnership,100,61,9/21/2020
A631A3,partnership,100,61,9/21/2020
A63387,shareholder-rights-plan,100,43,9/21/2020
A94637,conference-participant,100,50,9/21/2020
ACDCFA,public-offering,100,43,9/21/2020
AEBB80,executive-appointment,100,54,9/21/2020
B05118,partnership,100,61,9/21/2020
B3ED62,legal-issues-defendant,100,22,9/21/2020
B3ED62,legal-issues-defendant,100,22,9/21/2020
BFE02C,conference-call,100,50,9/21/2020
C2609A,business-contract,100,69,9/21/2020
C624A1,legal-issues-defendant,100,22,9/21/2020
C624A1,legal-issues-defendant,100,22,9/21/2020
C65004,business-contract,100,69,9/21/2020
C9B932,legal-issues-defendant,100,22,9/21/2020
C9B932,legal-issues-defendant,100,22,9/21/2020
C9B932,legal-issues-defendant,100,22,9/21/2020
CAC8D0,executive-appointment,100,54,9/21/2020
CBCC6A,conference-organizer,100,57,9/21/2020
CC35BE,partnership,100,61,9/21/2020
CFF97C,product-release,100,64,9/21/2020
D8ECA1,executive-appointment,100,54,9/21/2020
DBB28E,acquisition-completed-acquirer,100,49,9/21/2020
DC486E,executive-appointment,100,54,9/21/2020
DC486E,executive-appointment,100,54,9/21/2020
DD1BA1,patent-infringement-plaintiff,100,47,9/21/2020
E4CE73,reorganization-unit,100,53,9/21/2020
E6C8DC,executive-appointment,100,54,9/21/2020
E70531,business-contract,100,69,9/21/2020
EB1E1A,partnership,100,61,9/21/2020
EEA6B3,note-sale,100,52,9/21/2020
EEEA9F,grant-recipient,100,63,9/21/2020
F1529C,conference-call,100,50,9/21/2020
F30508,product-release,100,64,9/21/2020
F40EE2,patent-infringement-defendant,100,26,9/21/2020
F6FA6A,executive-appointment,100,54,9/21/2020
FAB97A,legal-issues-defendant,100,22,9/21/2020
FC9A88,executive-appointment,100,54,9/21/2020
13528,partnership,100,61,9/22/2020
036C6F,regulatory-investigation-completed,100,50,9/22/2020
0490C6,conference-participant,100,50,9/22/2020
55018,conference-call,100,50,9/22/2020
07EC43,award,100,58,9/22/2020
0A59F8,partnership,100,61,9/22/2020
0B73A7,partnership,100,61,9/22/2020
17EDA5,legal-issues-defendant,100,22,9/22/2020
17EDA5,executive-appointment,100,54,9/22/2020
180DA0,executive-appointment,100,54,9/22/2020
1BDB2A,award,100,58,9/22/2020
1E7785,conference-participant,100,50,9/22/2020
1EBF8D,partnership,100,61,9/22/2020
200D8B,award,100,58,9/22/2020
228D42,partnership,100,61,9/22/2020
228D42,partnership,100,61,9/22/2020
228D42,partnership,100,61,9/22/2020
251988,partnership,100,61,9/22/2020
251988,partnership,100,61,9/22/2020
251988,earnings,100,50,9/22/2020
253B2F,note-sale,100,52,9/22/2020
272704,conference-participant,100,50,9/22/2020
279916,legal-issues-defendant,100,22,9/22/2020
27A791,partnership,100,61,9/22/2020
2CC71C,conference-participant,100,50,9/22/2020
3.14E+47,dividend,100,50,9/22/2020
337024,buybacks,100,74,9/22/2020
371B0A,executive-appointment,100,54,9/22/2020
3.73E+87,partnership,100,61,9/22/2020
3.73E+87,partnership,100,61,9/22/2020
37B120,government-contract,100,69,9/22/2020
3.88E+02,legal-issues-defendant,100,22,9/22/2020
39D9DA,conference-call,100,50,9/22/2020
3B20AB,partnership,100,61,9/22/2020
3B318A,earnings,100,50,9/22/2020
3C8A04,conference-call,100,50,9/22/2020
3DDE54,earnings,100,50,9/22/2020
448215,public-offering,100,43,9/22/2020
448BF3,executive-appointment,100,54,9/22/2020
449A26,unit-acquisition-acquiree,100,76,9/22/2020
450ECB,legal-issues-defendant,100,22,9/22/2020
450ECB,legal-issues-defendant,100,22,9/22/2020
450ECB,legal-issues-defendant,100,22,9/22/2020
47FCF2,fundraising,100,64,9/22/2020
4806CE,product-release,100,64,9/22/2020
494EB9,executive-appointment,100,54,9/22/2020
4A2457,partnership,100,61,9/22/2020
4A6F00,partnership,100,61,9/22/2020
4A6F00,partnership,100,61,9/22/2020
4A6F00,partnership,100,61,9/22/2020
4AC91D,partnership,100,61,9/22/2020
4C37C5,conference-call,100,50,9/22/2020
4F9487,executive-resignation,100,44,9/22/2020
5088A5,unit-acquisition-acquiree,100,76,9/22/2020
510EA6,earnings,100,50,9/22/2020
510EA6,earnings,100,50,9/22/2020
520632,partnership,100,61,9/22/2020
55C9B5,dividend,100,50,9/22/2020
56EFC7,partnership,100,61,9/22/2020
57DDB9,note-sale,100,52,9/22/2020
58CA9A,earnings,100,50,9/22/2020
5A0FF1,executive-appointment,100,54,9/22/2020
5A9F54,market-entry,100,57,9/22/2020
62F41C,executive-appointment,100,54,9/22/2020
633043,dividend,100,50,9/22/2020
651C85,conference-participant,100,50,9/22/2020
6559D8,partnership,100,61,9/22/2020
65D0AA,clinical-trials-positive,100,87,9/22/2020
69345C,product-release,100,64,9/22/2020
6AACDD,ipo-completed,100,76,9/22/2020
6F6559,earnings,100,50,9/22/2020
719477,dividend,100,50,9/22/2020
72FCA3,earnings,100,50,9/22/2020
72FCA3,earnings,100,50,9/22/2020
72FCA3,earnings,100,50,9/22/2020
72FCA3,earnings,100,50,9/22/2020
73BCBA,partnership,100,61,9/22/2020
756BB4,acquisition-completed-acquirer,100,49,9/22/2020
756BB4,acquisition-completed-acquirer,100,49,9/22/2020
7A975D,earnings,100,50,9/22/2020
7B1E50,legal-issues-defendant,100,22,9/22/2020
7FDE1C,business-contract,100,69,9/22/2020
83598E,conference-participant,100,50,9/22/2020
8377DB,dividend,100,50,9/22/2020
85AD00,conference-call,100,50,9/22/2020
868808,dividend,100,50,9/22/2020
8B9B3B,executive-appointment,100,54,9/22/2020
8B9B3B,note-sale,100,52,9/22/2020
8C6C1B,facility-open,100,65,9/22/2020
8CF6DD,executive-appointment,100,54,9/22/2020
8E82A6,earnings,100,50,9/22/2020
913437,partnership,100,61,9/22/2020
944B2E,rights-issue,100,43,9/22/2020
94563D,note-sale,100,52,9/22/2020
94637C,partnership,100,61,9/22/2020
966ACE,reverse-stock-splits,100,51,9/22/2020
977A1E,partnership,100,61,9/22/2020
9A602D,conference-call,100,50,9/22/2020
9D30A8,product-release,100,64,9/22/2020
9D30A8,product-release,100,64,9/22/2020
9D56F2,dividend,100,50,9/22/2020
A4386C,earnings,100,50,9/22/2020
A43906,conference-call,100,50,9/22/2020
A6FE1C,unit-acquisition-acquirer,100,49,9/22/2020
B01111,executive-appointment,100,54,9/22/2020
B05000,executive-appointment,100,54,9/22/2020
B37FB4,executive-appointment,100,54,9/22/2020
B66928,conference-participant,100,50,9/22/2020
B8F71F,executive-appointment,100,54,9/22/2020
B934BF,public-offering,100,43,9/22/2020
BA0442,public-offering,100,43,9/22/2020
BB5271,partnership,100,61,9/22/2020
C29E71,partnership,100,61,9/22/2020
C83B88,conference-call,100,50,9/22/2020
C93C44,conference-call,100,50,9/22/2020
C94CFC,patient-enrollment-complete,100,64,9/22/2020
D08D2C,conference-call,100,50,9/22/2020
D1CFC8,executive-appointment,100,54,9/22/2020
D1CFC8,earnings,100,50,9/22/2020
D27FAB,shareholder-rights-plan,100,43,9/22/2020
D36B23,legal-issues-defendant,100,22,9/22/2020
D36B23,legal-issues-defendant,100,22,9/22/2020
D36B23,legal-issues-defendant,100,22,9/22/2020
D36B23,legal-issues-defendant,100,22,9/22/2020
D36B23,legal-issues-defendant,100,22,9/22/2020
D64C6D,earnings,100,50,9/22/2020
D6853F,conference-organizer,100,57,9/22/2020
D75910,dividend,100,50,9/22/2020
D8760C,executive-appointment,100,54,9/22/2020
D9164D,dividend,100,50,9/22/2020
DC0998,product-release,100,64,9/22/2020
DD1BA1,business-contract,100,69,9/22/2020
E05026,executive-appointment,100,54,9/22/2020
E30A8F,product-release,100,64,9/22/2020
E56A0D,conference-participant,100,50,9/22/2020
E68C3D,partnership,100,61,9/22/2020
E754F0,conference-participant,100,50,9/22/2020
E802CE,dividend,100,50,9/22/2020
EC70EC,note-sale,100,52,9/22/2020
ECF709,same-store-sales-up,100,71,9/22/2020
ECF709,same-store-sales-up,100,62,9/22/2020
ECF709,same-store-sales-up,100,62,9/22/2020
EF5BED,executive-appointment,100,54,9/22/2020
F18844,legal-issues-defendant,100,22,9/22/2020
F3D2EB,dividend,100,50,9/22/2020
F4E992,partnership,100,61,9/22/2020
F4F46F,business-contract,100,69,9/22/2020
F5349B,executive-appointment,100,54,9/22/2020
FAB97A,fraud-defendant,100,20,9/22/2020
FE7A63,earnings,100,50,9/22/2020
00326E,executive-appointment,100,54,9/23/2020
003B70,public-offering,100,43,9/23/2020
0157B1,partnership,100,61,9/23/2020
03F5A4,dividend,100,50,9/23/2020
05AF14,earnings,100,50,9/23/2020
05AF14,dividend,100,50,9/23/2020
0A0CF0,dividend,100,50,9/23/2020
0AB700,dividend,100,50,9/23/2020
0C136E,conference-organizer,100,57,9/23/2020
0C136E,conference-organizer,100,57,9/23/2020
1201B5,conference-call,100,50,9/23/2020
12A3A3,award,100,58,9/23/2020
12A3A3,award,100,58,9/23/2020
157D9F,earnings,100,50,9/23/2020
15901B,legal-issues-defendant,100,22,9/23/2020
15901B,legal-issues-defendant,100,22,9/23/2020
17EDA5,partnership,100,61,9/23/2020
17EDA5,legal-issues-defendant,100,22,9/23/2020
17EDA5,product-release,100,64,9/23/2020
17EDA5,product-release,100,64,9/23/2020
184866,clinical-trials-start,100,64,9/23/2020
1A3E1B,donation,100,54,9/23/2020
1FA886,business-contract,100,69,9/23/2020
228D42,product-release,100,64,9/23/2020
228D42,partnership,100,61,9/23/2020
22C58E,business-contract,100,69,9/23/2020
2.45E+15,executive-appointment,100,54,9/23/2020
24C48B,conference-participant,100,50,9/23/2020
267718,business-contract,100,69,9/23/2020
270B78,conference-participant,100,50,9/23/2020
279916,legal-issues-defendant,100,22,9/23/2020
279916,legal-issues-defendant,100,22,9/23/2020
28DCA8,executive-appointment,100,54,9/23/2020
2A6DBE,legal-issues-defendant,100,22,9/23/2020
315EB0,partnership,100,61,9/23/2020
3.20E+263,clinical-trials-positive,100,87,9/23/2020
3.73E+87,partnership,100,61,9/23/2020
3BE00F,dividend,100,50,9/23/2020
3CCC90,conference-call,100,50,9/23/2020
416291,legal-issues-defendant,100,22,9/23/2020
449A26,conference-call,100,50,9/23/2020
49F4D0,dividend,100,50,9/23/2020
4B49CF,earnings,100,50,9/23/2020
4B5054,legal-issues-defendant,100,22,9/23/2020
50070E,partnership,100,61,9/23/2020
504FE2,conference-call,100,50,9/23/2020
543900,dividend,100,50,9/23/2020
5675EB,revenue-volume,100,50,9/23/2020
57356F,conference-call,100,50,9/23/2020
5B7739,partnership,100,61,9/23/2020
5E1DF3,executive-appointment,100,54,9/23/2020
5EAA43,business-contract,100,69,9/23/2020
60DD84,executive-appointment,100,54,9/23/2020
616E3B,conference-call,100,50,9/23/2020
6284B5,award,100,58,9/23/2020
6.52E+64,product-release,100,64,9/23/2020
6634D9,shareholder-rights-plan,100,43,9/23/2020
6830FE,product-release,100,64,9/23/2020
6A3C35,dividend,100,50,9/23/2020
6E7060,partnership,100,61,9/23/2020
6F0A63,conference-call,100,50,9/23/2020
7255D2,partnership,100,61,9/23/2020
7410C3,executive-appointment,100,54,9/23/2020
762A3E,executive-appointment,100,54,9/23/2020
7999F3,note-sale,100,52,9/23/2020
7B1E50,legal-issues-defendant,100,22,9/23/2020
7DA412,partnership,100,61,9/23/2020
8665BA,partnership,100,61,9/23/2020
8665BA,partnership,100,61,9/23/2020
88350F,executive-appointment,100,54,9/23/2020
89B2E7,dividend,100,50,9/23/2020
8A8E41,earnings,100,50,9/23/2020
8B2C4A,note-sale,100,52,9/23/2020
8C6C1B,facility-open,100,65,9/23/2020
913437,unit-acquisition-completed-acquiree,100,67,9/23/2020
91E5EE,award,100,58,9/23/2020
92D9C9,dividend,100,50,9/23/2020
934CC3,product-release,100,64,9/23/2020
96BFF4,legal-issues-defendant,100,22,9/23/2020
98CAED,earnings,100,50,9/23/2020
9A29F4,ipo-pricing,100,50,9/23/2020
9B5968,product-release,100,64,9/23/2020
9B5968,dividend,100,50,9/23/2020
9B5968,dividend,100,50,9/23/2020
9B71A7,executive-appointment,100,54,9/23/2020
9CA619,earnings-up,100,68,9/23/2020
9CA619,earnings,100,50,9/23/2020
9CA619,earnings,100,50,9/23/2020
9CA619,earnings,100,50,9/23/2020
9CA619,earnings,100,50,9/23/2020
9CA619,earnings,100,50,9/23/2020
9E0811,executive-appointment,100,54,9/23/2020
9F37C5,dividend,100,50,9/23/2020
9FF5F1,facility-open,100,65,9/23/2020
A03EE1,executive-appointment,100,54,9/23/2020
A350C1,note-sale,100,52,9/23/2020
A43906,executive-appointment,100,54,9/23/2020
A6828A,clinical-trials-start,100,64,9/23/2020
A6828A,clinical-trials-start,100,64,9/23/2020
A6828A,clinical-trials-start,100,64,9/23/2020
A6FE1C,unit-acquisition-acquirer,100,49,9/23/2020
A80FE0,note-sale,100,52,9/23/2020
AEEB76,executive-appointment,100,54,9/23/2020
B8F71F,earnings,100,50,9/23/2020
B934BF,public-offering,100,43,9/23/2020
BFAEB4,earnings,100,50,9/23/2020
BFEA04,partnership,100,61,9/23/2020
C624A1,legal-issues-defendant,100,22,9/23/2020
C9B932,legal-issues-defendant,100,22,9/23/2020
CDD75E,public-offering,100,43,9/23/2020
D0DFE5,executive-appointment,100,54,9/23/2020
D36B23,legal-issues-defendant,100,22,9/23/2020
D3FD6D,conference-participant,100,50,9/23/2020
D45285,note-sale,100,52,9/23/2020
D6489C,legal-verdict-favored,100,78,9/23/2020
D6853F,executive-appointment,100,54,9/23/2020
D93A25,conference-call,100,50,9/23/2020
DA199F,earnings,100,50,9/23/2020
DF11D9,conference-call,100,50,9/23/2020
E1BD05,partnership,100,61,9/23/2020
E802CE,conference-call,100,50,9/23/2020
E8B21D,dividend,100,50,9/23/2020
E99180,dividend,100,50,9/23/2020
EEA6B3,earnings,100,50,9/23/2020
F11638,product-release,100,64,9/23/2020
F24FF0,earnings-guidance,100,50,9/23/2020
F5D410,note-sale,100,52,9/23/2020
F5D410,note-sale,100,52,9/23/2020
F5D410,public-offering,100,43,9/23/2020
F5D499,earnings,100,50,9/23/2020
F5D499,earnings,100,50,9/23/2020
F5D499,earnings,100,50,9/23/2020
F7935D,regulatory-product-approval-granted,100,81,9/23/2020
F80389,conference-call,100,50,9/23/2020
FAB97A,legal-issues-defendant,100,22,9/23/2020
00698D,dividend-up,100,81,9/24/2020
01D03F,regulatory-product-approval-granted,100,81,9/24/2020
040DBB,dividend,100,50,9/24/2020
0A0CF0,earnings,100,50,9/24/2020
0A7650,note-sale,100,52,9/24/2020
0B73A7,earnings,100,50,9/24/2020
0B73A7,earnings,100,50,9/24/2020
0C355F,executive-appointment,100,54,9/24/2020
12A3A3,earnings-up,100,68,9/24/2020
12A3A3,earnings-up,100,68,9/24/2020
12A3A3,earnings-up,100,68,9/24/2020
12A3A3,earnings-up,100,68,9/24/2020
12A3A3,earnings-up,100,68,9/24/2020
12E454,partnership,100,61,9/24/2020
15901B,legal-issues-defendant,100,22,9/24/2020
15901B,legal-issues-defendant,100,22,9/24/2020
15901B,legal-issues-defendant,100,22,9/24/2020
15901B,legal-issues-defendant,100,22,9/24/2020
15A388,earnings,100,50,9/24/2020
15A388,business-contract,100,69,9/24/2020
17EDA5,legal-issues-defendant,100,22,9/24/2020
1A9DE1,dividend,100,50,9/24/2020
1BC12C,partnership,100,61,9/24/2020
1EBF8D,product-release,100,64,9/24/2020
223552,product-release,100,64,9/24/2020
251988,settlement,100,56,9/24/2020
267718,clinical-trials,100,56,9/24/2020
267718,dividend,100,50,9/24/2020
26CC63,earnings-positive,100,69,9/24/2020
26CC63,earnings-positive,100,69,9/24/2020
26CC63,earnings-positive,100,69,9/24/2020
2720AB,dividend,100,50,9/24/2020
275300,business-contract,100,69,9/24/2020
2A6DBE,legal-issues-defendant,100,22,9/24/2020
2A6DBE,legal-issues-defendant,100,22,9/24/2020
2C681C,clinical-trials-start,100,64,9/24/2020
2C681C,clinical-trials-start,100,64,9/24/2020
2EB88B,public-offering,100,43,9/24/2020
2EB88B,public-offering,100,43,9/24/2020
2F9304,executive-appointment,100,54,9/24/2020
3159AA,product-release,100,64,9/24/2020
315EB0,note-sale,100,52,9/24/2020
315EB0,award,100,58,9/24/2020
317EC6,earnings,100,50,9/24/2020
36529A,conference-participant,100,50,9/24/2020
384CD3,acquisition-acquirer,100,49,9/24/2020
3.88E+02,legal-issues-defendant,100,22,9/24/2020
3FACA7,earnings,100,50,9/24/2020
423279,partnership,100,61,9/24/2020
43A060,business-contract,100,69,9/24/2020
44A4FC,unit-acquisition-acquirer,100,49,9/24/2020
4A6F00,partnership,100,61,9/24/2020
4B5054,legal-issues-defendant,100,22,9/24/2020
4C3FE9,clinical-trials-start,100,64,9/24/2020
4E7C1F,legal-issues-defendant,100,22,9/24/2020
579E8F,conference-participant,100,50,9/24/2020
57DDB9,facility-open,100,65,9/24/2020
59B229,executive-appointment,100,54,9/24/2020
5BC2F4,earnings,100,50,9/24/2020
5C7601,earnings,100,50,9/24/2020
5CC29D,dividend,100,50,9/24/2020
6830FE,award,100,58,9/24/2020
68E6E9,earnings,100,50,9/24/2020
69C99E,clinical-trials,100,56,9/24/2020
6F6559,product-release,100,64,9/24/2020
6F92A9,note-sale,100,52,9/24/2020
70B3D6,ipo,100,71,9/24/2020
717DB4,conference-participant,100,50,9/24/2020
7239BB,unit-acquisition-acquirer,100,49,9/24/2020
7255D2,business-contract,100,69,9/24/2020
77B8E9,clinical-trials-positive,100,87,9/24/2020
77B8E9,clinical-trials-positive,100,87,9/24/2020
7A3633,investment-investor,100,55,9/24/2020
7AB859,acquisition-completed-acquirer,100,49,9/24/2020
7AB859,fundraising,100,64,9/24/2020
7AC86E,executive-appointment,100,54,9/24/2020
7ADE57,dividend,100,50,9/24/2020
7B0BA6,partnership,100,61,9/24/2020
7B1E50,legal-issues-defendant,100,22,9/24/2020
7BAAE7,market-entry,100,57,9/24/2020
7D5FD6,earnings,100,50,9/24/2020
7E1D5D,partnership,100,61,9/24/2020
7E1D5D,partnership,100,61,9/24/2020
7F3FBC,acquisition-acquirer,100,49,9/24/2020
81F4BE,executive-appointment,100,54,9/24/2020
82B57E,earnings-guidance,100,50,9/24/2020
83E0AC,dividend,100,50,9/24/2020
893904,legal-issues-defendant,100,22,9/24/2020
8A8E41,settlement,100,56,9/24/2020
8B9B3B,note-sale,100,52,9/24/2020
8C311A,product-release,100,64,9/24/2020
8C6C1B,market-entry,100,57,9/24/2020
8EF425,executive-appointment,100,54,9/24/2020
8EF425,dividend,100,50,9/24/2020
8F3231,executive-appointment,100,54,9/24/2020
8F8F2F,executive-appointment,100,54,9/24/2020
91E5EE,award,100,58,9/24/2020
92D757,executive-appointment,100,54,9/24/2020
93AD2E,earnings,100,50,9/24/2020
9470CC,executive-appointment,100,54,9/24/2020
94C0B5,conference-call,100,50,9/24/2020
95DC1F,partnership,100,61,9/24/2020
990AD0,executive-appointment,100,54,9/24/2020
9BBFA5,earnings,100,50,9/24/2020
A11CF4,conference-participant,100,50,9/24/2020
A350C1,award,100,58,9/24/2020
A6FE1C,unit-acquisition-acquirer,100,49,9/24/2020
AA7FE0,earnings-up,100,68,9/24/2020
AA7FE0,earnings,100,50,9/24/2020
AA7FE0,earnings,100,50,9/24/2020
AA7FE0,earnings,100,50,9/24/2020
ACDCFA,public-offering,100,43,9/24/2020
B290A2,conference-participant,100,50,9/24/2020
B8EF97,earnings,100,50,9/24/2020
BA218A,dividend,100,50,9/24/2020
BB5271,award,100,58,9/24/2020
BB88B6,partnership,100,61,9/24/2020
BE14CF,conference-call,100,50,9/24/2020
BFF98A,conference-participant,100,50,9/24/2020
C2E120,dividend,100,50,9/24/2020
C3CF29,partnership,100,61,9/24/2020
C4FBDC,dividend,100,50,9/24/2020
C501B6,legal-issues-defendant,100,22,9/24/2020
C83B88,business-contract,100,69,9/24/2020
CAB222,conference-participant,100,50,9/24/2020
CAC8D0,earnings,100,50,9/24/2020
CC6FF5,partnership,100,61,9/24/2020
CD051C,executive-appointment,100,54,9/24/2020
CF073E,clinical-trials,100,56,9/24/2020
CFF15D,partnership,100,61,9/24/2020
CFF15D,partnership,100,61,9/24/2020
CFF15D,partnership,100,61,9/24/2020
D21D8A,dividend,100,50,9/24/2020
D33270,campaign-ad-retired,100,48,9/24/2020
D36B23,legal-issues-defendant,100,22,9/24/2020
D36B23,legal-issues-plaintiff,100,44,9/24/2020
D4AC65,product-release,100,64,9/24/2020
D64C6D,revenue-up,100,69,9/24/2020
D8442A,product-release,100,64,9/24/2020
D8442A,product-release,100,64,9/24/2020
DC1405,earnings,100,50,9/24/2020
DD0099,earnings,100,50,9/24/2020
E68733,note-sale,100,52,9/24/2020
E8E899,earnings,100,50,9/24/2020
EBD89A,business-contract,100,69,9/24/2020
ED5171,earnings,100,50,9/24/2020
EE74E1,product-release,100,64,9/24/2020
EEA6B3,partnership,100,61,9/24/2020
EF5BED,partnership,100,61,9/24/2020
F3816D,conference-participant,100,50,9/24/2020
F3EDB4,earnings,100,50,9/24/2020
F3EDB4,earnings,100,50,9/24/2020
F3EDB4,earnings,100,50,9/24/2020
F6DCE4,dividend,100,50,9/24/2020
F6E248,note-sale,100,52,9/24/2020
FAB97A,legal-issues-defendant,100,22,9/24/2020
FAB97A,legal-issues-defendant,100,22,9/24/2020
FD2565,executive-appointment,100,54,9/24/2020
FDE409,revenue-guidance,100,50,9/24/2020
FF4BA4,earnings,100,50,9/24/2020
FF9FF6,public-offering,100,43,9/24/2020
FF9FF6,public-offering,100,43,9/24/2020
0BF528,executive-appointment,100,54,9/25/2020
0C136E,conference-organizer,100,57,9/25/2020
0CADBC,dividend,100,50,9/25/2020
0CCCB7,index-listing,100,76,9/25/2020
15901B,legal-issues-defendant,100,22,9/25/2020
15901B,legal-issues-defendant,100,22,9/25/2020
15901B,legal-issues-defendant,100,22,9/25/2020
17EDA5,legal-issues-defendant,100,22,9/25/2020
18A98C,ipo-pricing,100,50,9/25/2020
18A98C,executive-appointment,100,54,9/25/2020
1AB808,legal-issues-defendant,100,22,9/25/2020
251988,dividend,100,50,9/25/2020
251988,dividend,100,50,9/25/2020
28DCF3,note-sale,100,52,9/25/2020
2A6DBE,legal-issues-defendant,100,22,9/25/2020
2CF9D3,conference-participant,100,50,9/25/2020
2D2D43,earnings,100,50,9/25/2020
2E0445,conference-participant,100,50,9/25/2020
2EB88B,public-offering,100,43,9/25/2020
2EB88B,public-offering,100,43,9/25/2020
31F25C,conference-call,100,50,9/25/2020
3D9999,earnings,100,50,9/25/2020
3ED92D,executive-appointment,100,54,9/25/2020
416291,legal-issues-defendant,100,22,9/25/2020
43A74A,earnings,100,50,9/25/2020
4A2457,government-contract,100,69,9/25/2020
4E7C1F,legal-issues-defendant,100,22,9/25/2020
4FCC78,conference-call,100,50,9/25/2020
514067,conference-participant,100,50,9/25/2020
5288FC,ipo-pricing,100,50,9/25/2020
539F49,conference-participant,100,50,9/25/2020
5DA8B3,executive-appointment,100,54,9/25/2020
5DAF89,partnership,100,61,9/25/2020
5DD486,conference-call,100,50,9/25/2020
619882,legal-issues-defendant,100,22,9/25/2020
66ECFD,earnings,100,50,9/25/2020
69FDFC,note-sale,100,52,9/25/2020
719477,business-contract,100,69,9/25/2020
723548,dividend,100,50,9/25/2020
75F665,conference-call,100,50,9/25/2020
7B1E50,legal-issues-defendant,100,22,9/25/2020
7B1E50,legal-issues-defendant,100,22,9/25/2020
8A8E41,executive-appointment,100,54,9/25/2020
8C6C1B,facility-open,100,65,9/25/2020
9.39E+69,conference-participant,100,50,9/25/2020
96BFF4,legal-issues-defendant,100,22,9/25/2020
96F126,dividend,100,50,9/25/2020
97B027,fundraising,100,64,9/25/2020
9981C6,dividend-up,100,81,9/25/2020
9B730A,conference-participant,100,50,9/25/2020
A1A317,grant-recipient,100,63,9/25/2020
A63387,product-release,100,64,9/25/2020
A6828A,partnership,100,61,9/25/2020
A8B137,earnings,100,50,9/25/2020
B1FC3B,earnings,100,50,9/25/2020
B6082A,conference-call,100,50,9/25/2020
B6CD92,dividend,100,50,9/25/2020
B7202A,executive-appointment,100,54,9/25/2020
B803B1,executive-appointment,100,54,9/25/2020
BE86A1,dividend-up,100,56,9/25/2020
C564E4,conference-participant,100,50,9/25/2020
C8A248,award,100,58,9/25/2020
C94CFC,executive-appointment,100,54,9/25/2020
C9739A,conference-participant,100,50,9/25/2020
C9E4EC,executive-appointment,100,54,9/25/2020
CD06A2,earnings,100,50,9/25/2020
CDEDFE,acquisition-regulatory-scrutiny-acquiree,100,38,9/25/2020
CDEDFE,legal-issues-defendant,100,22,9/25/2020
D36B23,legal-issues-defendant,100,22,9/25/2020
D36B23,legal-issues-defendant,100,22,9/25/2020
D36B23,legal-issues-defendant,100,22,9/25/2020
D6853F,earnings,100,50,9/25/2020
D6853F,earnings,100,50,9/25/2020
D6853F,earnings,100,50,9/25/2020
DA9443,conference-participant,100,50,9/25/2020
DC2B00,executive-appointment,100,54,9/25/2020
E0207A,conference-participant,100,50,9/25/2020
E15736,conference-call,100,50,9/25/2020
E15736,conference-call,100,50,9/25/2020
E15736,conference-call,100,50,9/25/2020
EC8116,dividend,100,50,9/25/2020
FAB97A,legal-issues-defendant,100,22,9/25/2020
FAB97A,legal-issues-defendant,100,22,9/25/2020
FAB97A,legal-issues-defendant,100,22,9/25/2020
FF6644,dividend-guidance-up,100,83,9/25/2020
0CC01F,earnings,100,50,9/26/2020
830BDB,legal-issues-defendant,100,22,9/26/2020
0157B1,hirings,100,65,9/28/2020
0157B1,partnership,100,61,9/28/2020
0157B1,legal-issues-defendant,100,22,9/28/2020
02FC1A,regulatory-product-approval-granted,100,81,9/28/2020
03CF95,partnership,100,61,9/28/2020
04CCCD,dividend,100,50,9/28/2020
0BA8CE,executive-appointment,100,54,9/28/2020
0BD4E8,executive-appointment,100,54,9/28/2020
0E439E,earnings,100,50,9/28/2020
10943B,product-release,100,64,9/28/2020
1272B3,partnership,100,61,9/28/2020
14BA06,business-combination,100,54,9/28/2020
14BA06,business-combination,100,54,9/28/2020
14BA06,business-combination,100,54,9/28/2020
14BA06,business-combination,100,54,9/28/2020
14BA06,business-combination,100,54,9/28/2020
14BA06,business-combination,100,54,9/28/2020
1748F6,earnings,100,50,9/28/2020
17EDA5,legal-issues-defendant,100,22,9/28/2020
1921DD,regulatory-product-approval-granted,100,81,9/28/2020
1AE482,earnings,100,50,9/28/2020
1AE482,earnings,100,50,9/28/2020
1AE482,earnings,100,50,9/28/2020
1BC12C,investment-investor,100,55,9/28/2020
1F716B,conference-call,100,50,9/28/2020
1FA886,legal-issues-defendant,100,22,9/28/2020
205AD5,earnings,100,50,9/28/2020
23207A,revenue-up,100,71,9/28/2020
23207A,revenue-up,100,71,9/28/2020
238302,fundraising,100,64,9/28/2020
238302,dividend,100,50,9/28/2020
24D81E,product-release,100,64,9/28/2020
251988,product-release,100,64,9/28/2020
2571FA,business-contract,100,69,9/28/2020
267718,regulatory-product-approval-granted,100,81,9/28/2020
267718,regulatory-product-approval-granted,100,81,9/28/2020
267718,regulatory-product-approval-granted,100,81,9/28/2020
2ABF77,conference-participant,100,50,9/28/2020
3A4BDB,executive-appointment,100,54,9/28/2020
3A94DF,acquisition-acquirer,100,49,9/28/2020
3DC887,acquisition-acquirer,100,49,9/28/2020
3E149C,business-contract,100,69,9/28/2020
3ED92D,executive-appointment,100,54,9/28/2020
42DC93,earnings,100,50,9/28/2020
434F38,product-release,100,64,9/28/2020
444CC8,partnership,100,61,9/28/2020
49A344,conference-call,100,50,9/28/2020
4BEB48,award,100,58,9/28/2020
4C7DB5,acquisition-acquirer,100,49,9/28/2020
4C7DB5,acquisition-acquirer,100,49,9/28/2020
50070E,reorganization-complete,100,74,9/28/2020
51888A,revenue-volume,100,50,9/28/2020
5D1329,conference-participant,100,50,9/28/2020
5D16CF,acquisition-completed-acquirer,100,49,9/28/2020
619882,product-release,100,64,9/28/2020
622DBE,executive-appointment,100,54,9/28/2020
629F0F,earnings,100,50,9/28/2020
62A48D,business-contract,100,69,9/28/2020
6391C2,conference-participant,100,50,9/28/2020
6474BA,earnings,100,50,9/28/2020
65D0AA,clinical-trials-positive,100,87,9/28/2020
65D0AA,clinical-trials-positive,100,87,9/28/2020
65D0AA,clinical-trials-positive,100,87,9/28/2020
65D0AA,clinical-trials-positive,100,87,9/28/2020
65D0AA,clinical-trials-positive,100,87,9/28/2020
65D0AA,clinical-trials-positive,100,87,9/28/2020
65D0AA,clinical-trials-positive,100,87,9/28/2020
65D0AA,clinical-trials-positive,100,87,9/28/2020
65D0AA,clinical-trials-positive,100,87,9/28/2020
65D0AA,clinical-trials-positive,100,87,9/28/2020
65D0AA,clinical-trials-positive,100,87,9/28/2020
65D0AA,clinical-trials-positive,100,87,9/28/2020
65D0AA,clinical-trials-positive,100,87,9/28/2020
65D0AA,clinical-trials-positive,100,87,9/28/2020
65D0AA,clinical-trials-positive,100,87,9/28/2020
65D0AA,clinical-trials-positive,100,87,9/28/2020
65D0AA,clinical-trials-positive,100,87,9/28/2020
65D0AA,clinical-trials-positive,100,87,9/28/2020
65D0AA,clinical-trials-positive,100,87,9/28/2020
65D0AA,clinical-trials-positive,100,87,9/28/2020
65D0AA,clinical-trials-positive,100,87,9/28/2020
65D0AA,clinical-trials-positive,100,87,9/28/2020
65D0AA,clinical-trials-positive,100,87,9/28/2020
65D0AA,clinical-trials-positive,100,87,9/28/2020
65D0AA,clinical-trials-positive,100,87,9/28/2020
65D0AA,clinical-trials-positive,100,87,9/28/2020
67303E,conference-participant,100,50,9/28/2020
698FF9,partnership,100,61,9/28/2020
6BD606,unit-acquisition-acquirer,100,49,9/28/2020
6BD606,dividend,100,50,9/28/2020
6BDA0C,partnership,100,61,9/28/2020
747219,conference-participant,100,50,9/28/2020
76DD0C,executive-appointment,100,54,9/28/2020
79340A,earnings,100,50,9/28/2020
7ACD98,dividend,100,50,9/28/2020
7B1E50,legal-issues-defendant,100,22,9/28/2020
7D5384,conference-call,100,50,9/28/2020
7F3FBC,asset-sale,100,62,9/28/2020
819492,conference-participant,100,50,9/28/2020
82E58A,award,100,58,9/28/2020
830BDB,legal-issues-defendant,100,22,9/28/2020
830BDB,legal-issues-defendant,100,22,9/28/2020
8B2C4A,note-sale,100,52,9/28/2020
8C5519,earnings,100,50,9/28/2020
8C6C1B,facility-open,100,65,9/28/2020
8C84DF,earnings,100,50,9/28/2020
8F6995,dividend,100,50,9/28/2020
92D3A0,conference-call,100,50,9/28/2020
9.39E+69,orphan-drug-designation,100,76,9/28/2020
9B71A7,executive-appointment,100,54,9/28/2020
9D3360,conference-call,100,50,9/28/2020
9F03CF,conference-call,100,50,9/28/2020
9F6B1A,business-contract,100,69,9/28/2020
9F6B1A,business-contract,100,69,9/28/2020
9F6B1A,business-contract,100,69,9/28/2020
9F6B1A,earnings,100,50,9/28/2020
AA98ED,conference-call,100,50,9/28/2020
B05118,conference-participant,100,50,9/28/2020
B33E77,clinical-trials-suspended,100,24,9/28/2020
B3ED62,conference-call,100,50,9/28/2020
C659EB,executive-appointment,100,54,9/28/2020
C7AE14,executive-death,100,31,9/28/2020
C81E00,conference-call,100,50,9/28/2020
C81E00,conference-call,100,50,9/28/2020
C97B2D,product-release,100,64,9/28/2020
CC176E,earnings,100,50,9/28/2020
D15833,dividend,100,50,9/28/2020
D15833,dividend,100,50,9/28/2020
D17C1B,partnership,100,61,9/28/2020
D2E553,revenue-up,100,69,9/28/2020
D2E553,revenue-up,100,69,9/28/2020
D2E553,revenue-up,100,69,9/28/2020
D9B1C9,executive-appointment,100,54,9/28/2020
DD3BB1,business-contract,100,69,9/28/2020
DFADDB,conference-participant,100,50,9/28/2020
E6D89E,earnings,100,50,9/28/2020
EC70EC,merger-completed,100,66,9/28/2020
EC99D0,acquisition-interest-acquirer,100,46,9/28/2020
EC99D0,acquisition-interest-acquirer,100,46,9/28/2020
EC99D0,acquisition-interest-acquirer,100,46,9/28/2020
EC99D0,acquisition-interest-acquirer,100,46,9/28/2020
EC99D0,acquisition-interest-acquirer,100,46,9/28/2020
EC99D0,acquisition-interest-acquirer,100,46,9/28/2020
EC99D0,acquisition-interest-acquirer,100,46,9/28/2020
EC99D0,acquisition-interest-acquirer,100,46,9/28/2020
EC99D0,acquisition-interest-acquirer,100,46,9/28/2020
EC99D0,acquisition-interest-acquirer,100,46,9/28/2020
EC99D0,acquisition-interest-acquirer,100,46,9/28/2020
EC99D0,acquisition-interest-acquirer,100,46,9/28/2020
EC99D0,acquisition-interest-acquirer,100,46,9/28/2020
ED1A74,public-offering,100,43,9/28/2020
ED22DC,conference-participant,100,50,9/28/2020
F209B4,conference-participant,100,50,9/28/2020
F83279,dividend-up,100,54,9/28/2020
FAB97A,legal-issues-defendant,100,22,9/28/2020
FD4588,conference-call,100,50,9/28/2020
00067A,business-contract,100,69,9/29/2020
0157B1,partnership,100,61,9/29/2020
0AAD90,executive-appointment,100,54,9/29/2020
0C136E,earnings,100,50,9/29/2020
0D26E0,executive-appointment,100,54,9/29/2020
12731D,supply-increase,100,74,9/29/2020
12731D,supply-increase,100,74,9/29/2020
1348C9,conference-call,100,50,9/29/2020
157CC1,regulatory-product-approval-granted,100,81,9/29/2020
15901B,legal-issues-defendant,100,22,9/29/2020
159739,acquisition-acquirer,100,49,9/29/2020
159739,acquisition-acquirer,100,49,9/29/2020
159739,business-contract,100,69,9/29/2020
16C7F0,conference-call,100,50,9/29/2020
16F4D8,government-contract,100,69,9/29/2020
1AB808,legal-issues-defendant,100,22,9/29/2020
1AC649,conference-participant,100,50,9/29/2020
1C599A,earnings,100,50,9/29/2020
1D5C51,stake-acquiree,100,62,9/29/2020
1D5C51,stake-acquiree,100,62,9/29/2020
1E9A6D,product-release,100,64,9/29/2020
1FA886,legal-issues-defendant,100,22,9/29/2020
221AD7,legal-issues-defendant,100,22,9/29/2020
25102A,conference-call,100,50,9/29/2020
26E3BA,partnership,100,61,9/29/2020
272704,earnings,100,50,9/29/2020
2B7A40,conference-call,100,50,9/29/2020
2CB4C9,acquisition-acquirer,100,49,9/29/2020
2D643C,award,100,58,9/29/2020
2E0496,executive-appointment,100,54,9/29/2020
2E0496,executive-appointment,100,54,9/29/2020
2EB88B,public-offering,100,43,9/29/2020
2EB88B,public-offering,100,43,9/29/2020
2EB88B,public-offering,100,43,9/29/2020
32C8CD,public-offering,100,43,9/29/2020
3.88E+02,legal-issues-defendant,100,22,9/29/2020
3A113F,asset-sale,100,62,9/29/2020
3BCF24,dividend,100,50,9/29/2020
3F4497,conference-call,100,50,9/29/2020
408089,revenue-guidance-up,100,83,9/29/2020
435ACE,conference-participant,100,50,9/29/2020
43A74A,expenses-guidance-down,100,61,9/29/2020
453282,conference-call,100,50,9/29/2020
458D2C,partnership,100,61,9/29/2020
47BA98,private-placement,100,56,9/29/2020
49BBBC,earnings,100,50,9/29/2020
4A6F00,partnership,100,61,9/29/2020
4A6F00,partnership,100,61,9/29/2020
4A6F00,partnership,100,61,9/29/2020
4A6F00,partnership,100,61,9/29/2020
4B5054,legal-issues-defendant,100,22,9/29/2020
4C37C5,dividend,100,50,9/29/2020
4C6C63,partnership,100,61,9/29/2020
4C6C63,earnings,100,50,9/29/2020
4F9926,partnership,100,61,9/29/2020
5288FC,ipo-completed,100,76,9/29/2020
543C77,executive-appointment,100,54,9/29/2020
55C9B5,partnership,100,61,9/29/2020
58C2D4,executive-appointment,100,54,9/29/2020
5A0FF1,campaign-ad-release,100,59,9/29/2020
5A9F54,earnings,100,50,9/29/2020
5A9F54,public-offering,100,43,9/29/2020
5A9F54,note-sale,100,52,9/29/2020
5D1329,clinical-trials,100,56,9/29/2020
627186,earnings,100,50,9/29/2020
63F892,award,100,58,9/29/2020
63F892,award,100,58,9/29/2020
65D0AA,clinical-trials,100,56,9/29/2020
66667F,acquisition-acquirer,100,49,9/29/2020
66667F,acquisition-acquirer,100,49,9/29/2020
693ECD,executive-appointment,100,54,9/29/2020
69C99E,loan-recipient,100,59,9/29/2020
6F3FA8,award,100,58,9/29/2020
722DE3,acquisition-acquirer,100,49,9/29/2020
75F982,legal-issues-plaintiff,100,44,9/29/2020
76DD0C,conference-participant,100,50,9/29/2020
789ADD,earnings,100,50,9/29/2020
78F9ED,business-contract,100,69,9/29/2020
793C11,executive-appointment,100,54,9/29/2020
7C62A3,note-sale,100,52,9/29/2020
803FED,conference-call,100,50,9/29/2020
82B57E,public-offering,100,43,9/29/2020
830BDB,legal-issues-defendant,100,22,9/29/2020
830BDB,legal-issues-defendant,100,22,9/29/2020
835C86,executive-appointment,100,54,9/29/2020
8377DB,product-release,100,64,9/29/2020
8A8E41,product-release,100,64,9/29/2020
8C6C1B,facility-open,100,65,9/29/2020
900356,dividend,100,50,9/29/2020
902670,conference-call,100,50,9/29/2020
911AB8,joint-venture,100,62,9/29/2020
922F0C,executive-resignation,100,44,9/29/2020
94563D,earnings,100,50,9/29/2020
957A07,legal-issues-defendant,100,22,9/29/2020
95DC1F,executive-appointment,100,54,9/29/2020
9.62E+76,earnings,100,50,9/29/2020
9673BD,partnership,100,61,9/29/2020
967D92,conference-call,100,50,9/29/2020
99B61C,clinical-trials-positive,100,87,9/29/2020
99B61C,public-offering,100,43,9/29/2020
9A02C4,buybacks,100,74,9/29/2020
9B5968,executive-appointment,100,54,9/29/2020
9D56F2,earnings-up,100,68,9/29/2020
9D56F2,earnings-up,100,68,9/29/2020
9D56F2,earnings-up,100,68,9/29/2020
9D56F2,earnings-up,100,68,9/29/2020
9D56F2,earnings-up,100,68,9/29/2020
9F6B1A,partnership,100,61,9/29/2020
A16DEA,business-contract,100,69,9/29/2020
A398B9,earnings,100,50,9/29/2020
A52533,product-release,100,64,9/29/2020
A631A3,partnership,100,61,9/29/2020
A631A3,partnership,100,61,9/29/2020
A631A3,partnership,100,61,9/29/2020
A631A3,partnership,100,61,9/29/2020
A6FE1C,unit-acquisition-acquirer,100,49,9/29/2020
A868C9,business-contract,100,69,9/29/2020
A8B137,partnership,100,61,9/29/2020
AC7C4F,business-contract,100,69,9/29/2020
AECCA9,executive-appointment,100,54,9/29/2020
AEEB76,business-contract,100,69,9/29/2020
B1FC3B,earnings,100,50,9/29/2020
B1FC3B,dividend,100,50,9/29/2020
B1FC3B,buybacks,100,74,9/29/2020
B381D8,legal-issues-defendant,100,22,9/29/2020
B4C673,partnership,100,61,9/29/2020
BC5680,merger,100,66,9/29/2020
BCC55F,partnership,100,61,9/29/2020
C062D4,partnership,100,61,9/29/2020
C062D4,partnership,100,61,9/29/2020
C06EB6,patient-enrollment-complete,100,64,9/29/2020
C06EB6,patient-enrollment-complete,100,64,9/29/2020
C2609A,business-contract,100,69,9/29/2020
C3BAE7,acquisition-acquirer,100,49,9/29/2020
C3DE7D,partnership,100,61,9/29/2020
C490F9,public-offering,100,43,9/29/2020
C4A432,dividend,100,50,9/29/2020
C5D2AE,award,100,58,9/29/2020
C7859D,conference-call,100,50,9/29/2020
C83B88,partnership,100,61,9/29/2020
C93C44,conference-call,100,50,9/29/2020
CBBFBF,note-sale,100,52,9/29/2020
CDC217,conference-participant,100,50,9/29/2020
D17F7E,legal-issues-defendant,100,22,9/29/2020
D17F7E,legal-issues-defendant,100,22,9/29/2020
D17F7E,legal-issues-defendant,100,22,9/29/2020
D17F7E,legal-issues-defendant,100,22,9/29/2020
D17F7E,legal-issues-defendant,100,22,9/29/2020
D17F7E,legal-issues-defendant,100,22,9/29/2020
D17F7E,legal-issues-defendant,100,22,9/29/2020
D36B23,legal-issues-defendant,100,22,9/29/2020
D4AC65,executive-appointment,100,54,9/29/2020
D5AF19,earnings,100,50,9/29/2020
D6EAA3,conference-call,100,50,9/29/2020
D70365,conference-call,100,50,9/29/2020
D78BF1,earnings,100,50,9/29/2020
D7AC6E,conference-call,100,50,9/29/2020
DB396B,legal-issues-defendant,100,22,9/29/2020
DB5CA5,commodity-offer,100,54,9/29/2020
DB5CA5,investment-investor,100,55,9/29/2020
DC0D18,earnings,100,50,9/29/2020
DC2F77,earnings,100,50,9/29/2020
DE4924,business-contract,100,69,9/29/2020
E0339F,earnings,100,50,9/29/2020
E2F66E,partnership,100,61,9/29/2020
E2F66E,partnership,100,61,9/29/2020
E4158B,investment-investor,100,55,9/29/2020
E4CE73,product-release,100,64,9/29/2020
E592F0,product-release,100,64,9/29/2020
E68733,public-offering,100,43,9/29/2020
E68733,note-sale,100,52,9/29/2020
E96E0B,conference-call,100,50,9/29/2020
EE6F1C,earnings,100,50,9/29/2020
EEA6B3,business-contract,100,69,9/29/2020
EF25A5,partnership,100,61,9/29/2020
EF5BED,executive-appointment,100,54,9/29/2020
F0027C,patient-enrollment-complete,100,64,9/29/2020
F0B877,conference-call,100,50,9/29/2020
F1EB39,partnership,100,61,9/29/2020
F2526D,award,100,58,9/29/2020
F4E992,partnership,100,61,9/29/2020
F7902B,executive-appointment,100,54,9/29/2020
FAAFA2,clinical-trials-start,100,64,9/29/2020
FADF1A,business-contract,100,69,9/29/2020
FC1A6E,note-sale,100,52,9/29/2020
FC1A6E,note-sale,100,52,9/29/2020
FF6644,partnership,100,61,9/29/2020
00067A,business-contract,100,69,9/30/2020
03FAA6,business-contract,100,69,9/30/2020
07C69F,conference-call,100,50,9/30/2020
0A6824,note-sale,100,52,9/30/2020
0B57D7,conference-call,100,50,9/30/2020
0C28D1,acquisition-acquiree,100,76,9/30/2020
0E2992,conference-call,100,50,9/30/2020
0F2BC9,business-contract,100,69,9/30/2020
10C19B,conference-call,100,50,9/30/2020
133644,clinical-trials-start,100,64,9/30/2020
138DDE,dividend,100,50,9/30/2020
1490F3,conference-call,100,50,9/30/2020
159739,public-offering,100,43,9/30/2020
159739,public-offering,100,43,9/30/2020
16FC89,earnings,100,50,9/30/2020
180DA0,executive-resignation,100,44,9/30/2020
1921DD,product-release,100,64,9/30/2020
1F08A6,conference-call,100,50,9/30/2020
1FE3CB,note-sale,100,52,9/30/2020
228D42,business-contract,100,69,9/30/2020
228D42,partnership,100,61,9/30/2020
251988,sponsorship,100,57,9/30/2020
2571FA,conference-call,100,50,9/30/2020
263216,ownership-decrease-owner,100,46,9/30/2020
27BFA1,conference-call,100,50,9/30/2020
2AE625,conference-call,100,50,9/30/2020
2C7505,clinical-trials-positive,100,87,9/30/2020
2CC60C,executive-appointment,100,54,9/30/2020
2D485F,earnings,100,50,9/30/2020
2D643C,conference-call,100,50,9/30/2020
2F5256,conference-call,100,50,9/30/2020
2FDEE3,dividend-suspended,100,13,9/30/2020
32C8CD,public-offering,100,43,9/30/2020
3390DE,conference-call,100,50,9/30/2020
342218,conference-call,100,50,9/30/2020
3461CF,award,100,58,9/30/2020
34A959,acquisition-acquirer,100,49,9/30/2020
34A959,acquisition-acquirer,100,49,9/30/2020
37727A,conference-call,100,50,9/30/2020
384CD3,partnership,100,61,9/30/2020
384CD3,earnings,100,50,9/30/2020
3.88E+02,legal-issues-defendant,100,22,9/30/2020
3C75D6,conference-participant,100,50,9/30/2020
3CBA2A,dividend-up,100,60,9/30/2020
43E8F5,regulatory-product-application,100,69,9/30/2020
458D2C,note-sale,100,52,9/30/2020
46A16E,conference-call,100,50,9/30/2020
4885C8,earnings,100,50,9/30/2020
4A5C8D,partnership,100,61,9/30/2020
4A6F00,business-contract,100,69,9/30/2020
4A6F00,antitrust-suit-defendant,100,21,9/30/2020
4AC91D,regulatory-investigation,100,22,9/30/2020
4B3555,dividend,100,50,9/30/2020
4B5054,conference-call,100,50,9/30/2020
4D8313,fundraising,100,64,9/30/2020
50D1EC,index-listing,100,76,9/30/2020
513A86,executive-appointment,100,54,9/30/2020
514067,executive-appointment,100,54,9/30/2020
5288FC,clinical-trials-start,100,64,9/30/2020
539F49,public-offering,100,43,9/30/2020
556A57,executive-appointment,100,54,9/30/2020
65D0AA,business-contract,100,69,9/30/2020
65D0AA,business-contract,100,69,9/30/2020
66E04A,executive-appointment,100,54,9/30/2020
6ABCB8,patent-infringement-plaintiff,100,47,9/30/2020
6ABCB8,patent-infringement-plaintiff,100,47,9/30/2020
6C6D73,business-contract,100,69,9/30/2020
6C6D73,business-contract,100,69,9/30/2020
6D0CAB,business-contract,100,69,9/30/2020
6D0CAB,business-contract,100,69,9/30/2020
6DC1D7,asset-sale,100,62,9/30/2020
72CB93,award,100,58,9/30/2020
75768D,earnings,100,50,9/30/2020
765913,earnings,100,50,9/30/2020
7A0EC4,business-contract,100,69,9/30/2020
7AF907,clinical-trials,100,56,9/30/2020
7D5FD6,facility-upgrade,100,65,9/30/2020
7E1D5D,product-release,100,64,9/30/2020
7E2DE6,earnings,100,50,9/30/2020
7F3FBC,unit-acquisition-acquirer,100,49,9/30/2020
8303CD,award,100,58,9/30/2020
834152,clinical-trials-filed,100,60,9/30/2020
850779,earnings,100,50,9/30/2020
895D56,partnership,100,61,9/30/2020
8C6C1B,facility-open,100,65,9/30/2020
8E3F58,partnership,100,61,9/30/2020
9196A2,partnership,100,61,9/30/2020
9196A2,conference-call,100,50,9/30/2020
9196A2,acquisition-regulatory-approval-acquirer,100,54,9/30/2020
925759,orphan-drug-designation,100,76,9/30/2020
94983E,acquisition-acquirer,100,49,9/30/2020
957A07,legal-issues-defendant,100,22,9/30/2020
957A07,legal-issues-defendant,100,22,9/30/2020
957A07,legal-issues-defendant,100,22,9/30/2020
957A07,legal-issues-defendant,100,22,9/30/2020
95DC1F,campaign-ad-release,100,59,9/30/2020
9BB35A,business-contract,100,69,9/30/2020
9CA4C6,conference-call,100,50,9/30/2020
9D2790,executive-appointment,100,54,9/30/2020
9E98F2,business-contract,100,69,9/30/2020
9F5CBB,dividend,100,50,9/30/2020
9FB4B7,conference-participant,100,50,9/30/2020
A49498,partnership,100,61,9/30/2020
A631A3,partnership,100,61,9/30/2020
A6FE1C,unit-acquisition-acquirer,100,49,9/30/2020
A790A5,award,100,58,9/30/2020
A8AC4C,conference-call,100,50,9/30/2020
AA09AD,partnership,100,61,9/30/2020
AEFC90,conference-participant,100,50,9/30/2020
B0D41A,conference-participant,100,50,9/30/2020
B1A85D,partnership,100,61,9/30/2020
B2206F,partnership,100,61,9/30/2020
B7202A,settlement,100,56,9/30/2020
B803B1,dividend,100,50,9/30/2020
B96637,award,100,58,9/30/2020
B96637,award,100,58,9/30/2020
BE14CF,note-sale,100,52,9/30/2020
BE14CF,note-sale,100,52,9/30/2020
C03C8B,conference-call,100,50,9/30/2020
C3EE99,earnings,100,50,9/30/2020
C4C77F,executive-appointment,100,54,9/30/2020
C598D7,conference-call,100,50,9/30/2020
C8257F,executive-appointment,100,54,9/30/2020
C83B88,investment-investor,100,55,9/30/2020
C83B88,facility-open,100,65,9/30/2020
C8FAC7,partnership,100,61,9/30/2020
C97B2D,product-release,100,64,9/30/2020
C9D866,conference-call,100,50,9/30/2020
CBA475,note-sale,100,52,9/30/2020
CBBFBF,note-sale,100,52,9/30/2020
CC3EC4,executive-appointment,100,54,9/30/2020
CDFCC9,product-release,100,64,9/30/2020
CFF97C,executive-appointment,100,54,9/30/2020
CFF97C,dividend,100,50,9/30/2020
D17F7E,legal-issues-defendant,100,22,9/30/2020
D17F7E,legal-issues-defendant,100,22,9/30/2020
D6144F,public-offering,100,43,9/30/2020
D78CCD,conference-call,100,50,9/30/2020
D88EF3,conference-call,100,50,9/30/2020
DB396B,legal-issues-defendant,100,22,9/30/2020
DB396B,legal-issues-defendant,100,22,9/30/2020
DB396B,legal-issues-defendant,100,22,9/30/2020
DD1BA1,executive-appointment,100,54,9/30/2020
DD1BA1,earnings,100,50,9/30/2020
E11C41,conference-call,100,50,9/30/2020
E124EB,note-sale,100,52,9/30/2020
E124EB,partnership,100,61,9/30/2020
E124EB,partnership,100,61,9/30/2020
E2CFD2,partnership,100,61,9/30/2020
E3E68E,award,100,58,9/30/2020
E3E68E,award,100,58,9/30/2020
E68733,acquisition-acquirer,100,49,9/30/2020
E68733,acquisition-acquirer,100,49,9/30/2020
E829E8,conference-call,100,50,9/30/2020
E9C7C0,partnership,100,61,9/30/2020
E9FF33,earnings,100,50,9/30/2020
EAEA91,dividend,100,50,9/30/2020
ED22DC,patient-enrollment-complete,100,64,9/30/2020
ED9576,earnings,100,50,9/30/2020
F18844,legal-issues-defendant,100,22,9/30/2020
F6E248,award,100,58,9/30/2020
FA36A4,conference-call,100,50,9/30/2020
FC4550,conference-call,100,50,9/30/2020
00067A,earnings,100,50,10/1/2020
036C6F,legal-issues-defendant,100,22,10/1/2020
078D52,dividend,100,50,10/1/2020
0A59F8,executive-appointment,100,54,10/1/2020
0C28D1,unit-acquisition-completed-acquiree,100,67,10/1/2020
0C8D82,business-contract,100,69,10/1/2020
0FC848,executive-appointment,100,54,10/1/2020
105D00,conference-call,100,50,10/1/2020
108FDA,dividend,100,50,10/1/2020
10C19B,dividend-up,100,81,10/1/2020
12DE76,acquisition-completed-acquirer,100,49,10/1/2020
12F98C,product-release,100,64,10/1/2020
184988,merger-regulatory-approval,100,81,10/1/2020
1921DD,partnership,100,61,10/1/2020
19CAC7,conference-call,100,50,10/1/2020
1AB808,fraud,100,44,10/1/2020
1D1B07,earnings,100,50,10/1/2020
1D1B07,earnings,100,50,10/1/2020
1D943E,executive-appointment,100,54,10/1/2020
1EBF8D,conference-call,100,50,10/1/2020
1FA886,legal-issues-defendant,100,22,10/1/2020
2158DF,product-release,100,64,10/1/2020
21D903,earnings,100,50,10/1/2020
221AD7,earnings,100,50,10/1/2020
228D42,partnership,100,61,10/1/2020
228D42,business-contract,100,69,10/1/2020
228D42,partnership,100,61,10/1/2020
249B39,earnings,100,50,10/1/2020
267718,fast-track-designation,100,81,10/1/2020
26DC29,conference-participant,100,50,10/1/2020
2A9C0A,conference-call,100,50,10/1/2020
2AA6A8,conference-participant,100,50,10/1/2020
2E61CC,partnership,100,61,10/1/2020
2EB04E,partnership,100,61,10/1/2020
2EB04E,partnership,100,61,10/1/2020
2F7474,dividend-up,100,81,10/1/2020
315EB0,acquisition-completed-acquirer,100,49,10/1/2020
315EB0,acquisition-completed-acquirer,100,49,10/1/2020
31803E,executive-appointment,100,54,10/1/2020
33AD83,donation,100,54,10/1/2020
3461CF,analyst-ratings-change-positive-rater,20,50,10/1/2020
3471C0,conference-call,100,50,10/1/2020
34B411,earnings,100,50,10/1/2020
387375,conference-call,100,50,10/1/2020
3.88E+02,conference-call,100,50,10/1/2020
39FB23,earnings,100,50,10/1/2020
3A4BDB,conference-call,100,50,10/1/2020
3AF7FD,conference-call,100,50,10/1/2020
3DE4D1,acquisition-completed-acquirer,100,49,10/1/2020
3F1C69,executive-appointment,100,54,10/1/2020
3F4668,asset-sale,100,62,10/1/2020
3F4668,unit-acquisition-acquiree,100,76,10/1/2020
4.03E+05,business-contract,100,69,10/1/2020
4.03E+05,acquisition-completed-acquirer,100,49,10/1/2020
408089,earnings,100,50,10/1/2020
408380,earnings,100,50,10/1/2020
4135F7,conference-call,100,50,10/1/2020
415188,conference-call,100,50,10/1/2020
41B53E,dividend,100,50,10/1/2020
43A74A,expenses-guidance-down,100,61,10/1/2020
44A4FC,product-release,100,64,10/1/2020
4.60E+06,acquisition-completed-acquirer,100,49,10/1/2020
479930,donation,100,54,10/1/2020
49914B,executive-appointment,100,54,10/1/2020
4A5C8D,partnership,100,61,10/1/2020
4A6F00,partnership,100,61,10/1/2020
4A6F00,partnership,100,61,10/1/2020
4AC91D,legal-issues-defendant,100,22,10/1/2020
4B49CF,dividend,100,50,10/1/2020
4D8313,conference-call,100,50,10/1/2020
4FCC78,dividend,100,50,10/1/2020
510EA6,index-listing,100,76,10/1/2020
5225A4,note-sale,100,52,10/1/2020
539F49,public-offering,100,43,10/1/2020
539F49,public-offering,100,43,10/1/2020
54F271,note-sale,100,52,10/1/2020
54F271,note-sale,100,52,10/1/2020
56B7C1,dividend,100,50,10/1/2020
589846,executive-appointment,100,54,10/1/2020
58B46F,note-sale,100,52,10/1/2020
59C539,conference-call,100,50,10/1/2020
5A9F54,public-offering,100,43,10/1/2020
5AF08A,earnings,100,50,10/1/2020
5B51D6,product-release,100,64,10/1/2020
5F9CE3,earnings,100,50,10/1/2020
601785,earnings,100,50,10/1/2020
60EA12,revenues,100,50,10/1/2020
619882,business-contract,100,69,10/1/2020
61B81B,executive-appointment,100,54,10/1/2020
6251A3,ipo-pricing,100,50,10/1/2020
63E8D5,earnings,100,50,10/1/2020
63F892,earnings,100,50,10/1/2020
657097,partnership,100,61,10/1/2020
665618,dividend,100,50,10/1/2020
68BA15,dividend,100,50,10/1/2020
68E6E9,executive-appointment,100,54,10/1/2020
6AACDD,clinical-trials-start,100,64,10/1/2020
6-Dec-05,conference-participant,100,50,10/1/2020
6E1E61,conference-call,100,50,10/1/2020
70B3D6,ipo-pricing,100,50,10/1/2020
70B3D6,ipo-pricing,100,50,10/1/2020
713810,partnership,100,61,10/1/2020
723548,dividend,100,50,10/1/2020
763724,dividend,100,50,10/1/2020
7D97DE,conference-call,100,50,10/1/2020
7DC1C4,conference-participant,100,50,10/1/2020
80D744,conference-call,100,50,10/1/2020
810FAD,conference-call,100,50,10/1/2020
82C202,acquisition-completed-acquirer,100,49,10/1/2020
82C202,acquisition-completed-acquirer,100,49,10/1/2020
830BDB,legal-issues-defendant,100,22,10/1/2020
830BDB,legal-issues-defendant,100,22,10/1/2020
830BDB,legal-issues-defendant,100,22,10/1/2020
8.40E+120,clinical-trials-start,100,64,10/1/2020
85AD00,acquisition-completed-acquirer,100,49,10/1/2020
85DE00,facility-open,100,65,10/1/2020
8B2C4A,conference-call,100,50,10/1/2020
8C6C1B,facility-open,100,65,10/1/2020
911AB8,conference-call,100,50,10/1/2020
91C82E,dividend-up,100,81,10/1/2020
940C3D,unit-acquisition-completed-acquiree,100,67,10/1/2020
94563D,acquisition-completed-acquirer,100,49,10/1/2020
9507FF,executive-appointment,100,54,10/1/2020
957A07,legal-issues-defendant,100,22,10/1/2020
957A07,fraud-defendant,100,20,10/1/2020
957A07,legal-issues-defendant,100,22,10/1/2020
957A07,legal-issues-defendant,100,22,10/1/2020
957A07,earnings,100,50,10/1/2020
96B4FF,conference-participant,100,50,10/1/2020
96F126,earnings,100,50,10/1/2020
9810C0,partnership,100,61,10/1/2020
9B5968,partnership,100,61,10/1/2020
9B71A7,earnings,100,50,10/1/2020
9B71A7,earnings,100,50,10/1/2020
9B71A7,earnings,100,50,10/1/2020
9B71A7,earnings,100,50,10/1/2020
9C3D3C,joint-venture,100,62,10/1/2020
9E5C2C,conference-call,100,50,10/1/2020
9EA947,award,100,58,10/1/2020
9F37C5,dividend,100,50,10/1/2020
A05C43,conference-participant,100,50,10/1/2020
A26C26,dividend,100,50,10/1/2020
A350C1,facility-open,100,65,10/1/2020
A5151E,earnings,100,50,10/1/2020
A5628C,campaign-ad-release,100,59,10/1/2020
A5B913,earnings,100,50,10/1/2020
A63387,business-contract,100,69,10/1/2020
A6828A,acquisition-completed-acquirer,100,49,10/1/2020
A806FA,conference-call,100,50,10/1/2020
A8CBDA,earnings,100,50,10/1/2020
AB7F05,earnings,100,50,10/1/2020
AC3584,acquisition-completed-acquirer,100,49,10/1/2020
AC3584,acquisition-completed-acquirer,100,49,10/1/2020
AD9F1D,conference-call,100,50,10/1/2020
AD9F1D,dividend,100,50,10/1/2020
ADD9DC,facility-open,100,65,10/1/2020
B0FE08,unit-acquisition-acquiree,100,76,10/1/2020
B5766D,conference-call,100,50,10/1/2020
B5DE80,conference-call,100,50,10/1/2020
B604DF,conference-call,100,50,10/1/2020
B840EF,conference-call,100,50,10/1/2020
BDEC1E,executive-appointment,100,54,10/1/2020
BE645B,clinical-trials-start,100,64,10/1/2020
BE645B,conference-participant,100,50,10/1/2020
BEB756,conference-call,100,50,10/1/2020
C3BAE7,note-sale,100,52,10/1/2020
C4A241,conference-call,100,50,10/1/2020
C7AE14,dividend,100,50,10/1/2020
C97B2D,conference-call,100,50,10/1/2020
C9E107,earnings,100,50,10/1/2020
C9F39B,conference-call,100,50,10/1/2020
CA212F,asset-sale,100,62,10/1/2020
CB89EA,executive-appointment,100,54,10/1/2020
CBA33B,earnings,100,50,10/1/2020
CBFFDD,legal-issues-defendant,100,22,10/1/2020
CC176E,executive-appointment,100,54,10/1/2020
CDEDFE,merger,100,66,10/1/2020
CE5664,acquisition-acquirer,100,49,10/1/2020
CE5C6E,patient-enrollment-complete,100,64,10/1/2020
CF3FF9,clinical-trials,100,56,10/1/2020
CF6A5A,earnings,100,50,10/1/2020
CFF97C,conference-call,100,50,10/1/2020
CFF97C,partnership,100,61,10/1/2020
D1173F,conference-call,100,50,10/1/2020
D2B9E5,facility-open,100,65,10/1/2020
D33270,government-contract,100,69,10/1/2020
D3C794,index-listing,100,76,10/1/2020
D6144F,public-offering,100,43,10/1/2020
D697DE,executive-appointment,100,54,10/1/2020
D9B1C9,legal-issues-defendant,100,22,10/1/2020
DA91AE,business-contract,100,69,10/1/2020
DC5299,conference-call,100,50,10/1/2020
DC6AA0,earnings,100,50,10/1/2020
DCD97F,business-contract,100,69,10/1/2020
DCD97F,business-contract,100,69,10/1/2020
DD0F15,loan-recipient,100,59,10/1/2020
DDEA6A,business-contract,100,69,10/1/2020
DF1F7A,conference-call,100,50,10/1/2020
DF42A0,acquisition-completed-acquirer,100,49,10/1/2020
E0647D,analyst-ratings-change-positive,100,78,10/1/2020
E12A6E,earnings,100,50,10/1/2020
E1C16B,partnership,100,61,10/1/2020
E28D9C,business-contract,100,69,10/1/2020
E2CFD2,reorganization,100,53,10/1/2020
E30B34,executive-appointment,100,54,10/1/2020
E4CE73,executive-appointment,100,54,10/1/2020
E70531,executive-resignation,100,44,10/1/2020
E84500,conference-call,100,50,10/1/2020
E94704,conference-call,100,50,10/1/2020
E959F3,conference-call,100,50,10/1/2020
EB36DE,business-contract,100,69,10/1/2020
EBD89A,business-contract,100,69,10/1/2020
ED0402,earnings,100,50,10/1/2020
ED1A74,public-offering,100,43,10/1/2020
EE04F0,executive-appointment,100,54,10/1/2020
F1CD47,earnings,100,50,10/1/2020
F24FF0,conference-call,100,50,10/1/2020
F4E882,earnings,100,50,10/1/2020
F5349B,award,100,58,10/1/2020
F88A04,partnership,100,61,10/1/2020
FA40E2,dividend-up,100,73,10/1/2020
FA40E2,earnings-up,100,68,10/1/2020
FA40E2,earnings,100,50,10/1/2020
FA40E2,earnings,100,50,10/1/2020
FA40E2,earnings,100,50,10/1/2020
FA40E2,earnings,100,50,10/1/2020
FA40E2,earnings,100,50,10/1/2020
FAAFA2,executive-appointment,100,54,10/1/2020
FC1B7B,conference-call,100,50,10/1/2020
FC4550,dividend,100,50,10/1/2020
FD9526,earnings,100,50,10/1/2020
FDC7E6,buybacks,100,74,10/1/2020
0157B1,partnership,100,61,10/2/2020
03596A,buybacks,100,74,10/2/2020
07EC43,conference-call,100,50,10/2/2020
0A748B,buybacks,100,74,10/2/2020
0A7650,conference-call,100,50,10/2/2020
0C136E,dividend,100,50,10/2/2020
0C8D82,conference-call,100,50,10/2/2020
14BA06,asset-sale,100,62,10/2/2020
1.79E+10,acquisition-completed-acquirer,100,49,10/2/2020
1.79E+10,executive-appointment,100,54,10/2/2020
1A6A94,conference-call,100,50,10/2/2020
1AB808,legal-issues-defendant,100,22,10/2/2020
1D1B07,executive-appointment,100,54,10/2/2020
1D1B07,executive-appointment,100,54,10/2/2020
1EBF8D,executive-appointment,100,54,10/2/2020
1EBF8D,executive-appointment,100,54,10/2/2020
1FA886,legal-issues-defendant,100,22,10/2/2020
227F04,acquisition-completed-acquirer,100,49,10/2/2020
2A6DBE,legal-issues-defendant,100,22,10/2/2020
2B9DBB,conference-call,100,50,10/2/2020
3.14E+47,legal-issues-defendant,100,22,10/2/2020
338544,conference-call,100,50,10/2/2020
341759,conference-participant,100,50,10/2/2020
370C50,conference-call,100,50,10/2/2020
3.88E+02,legal-issues-defendant,100,22,10/2/2020
38C46F,dividend,100,50,10/2/2020
39BFF6,conference-call,100,50,10/2/2020
3A3447,acquisition-acquirer,100,49,10/2/2020
3A6D90,executive-appointment,100,54,10/2/2020
44740A,executive-appointment,100,54,10/2/2020
4B5054,legal-issues-defendant,100,22,10/2/2020
4B6EF9,earnings,100,50,10/2/2020
4BDCA7,clinical-trials,100,56,10/2/2020
4EE167,product-release,100,64,10/2/2020
4FB770,conference-call,100,50,10/2/2020
546A27,legal-issues-defendant,100,22,10/2/2020
546A27,legal-issues-defendant,100,22,10/2/2020
546A27,legal-issues-defendant,100,22,10/2/2020
546A27,legal-issues-defendant,100,22,10/2/2020
57634F,fraud-defendant,100,20,10/2/2020
583553,acquisition-completed-acquirer,100,49,10/2/2020
5BFE94,conference-call,100,50,10/2/2020
67529E,conference-call,100,50,10/2/2020
693ECD,earnings,100,50,10/2/2020
75F982,legal-issues-plaintiff,100,44,10/2/2020
76CEFB,earnings,100,50,10/2/2020
830BDB,legal-issues-defendant,100,22,10/2/2020
873DB9,conference-call,100,50,10/2/2020
8876D6,partnership,100,61,10/2/2020
8A8E41,executive-appointment,100,54,10/2/2020
8C6C1B,facility-open,100,65,10/2/2020
8DCBBB,conference-call,100,50,10/2/2020
9196A2,acquisition-completed-acquirer,100,49,10/2/2020
949625,conference-call,100,50,10/2/2020
957A07,legal-issues-defendant,100,22,10/2/2020
95C392,acquisition-acquirer,100,49,10/2/2020
95C392,conference-call,100,50,10/2/2020
99B61C,public-offering,100,43,10/2/2020
9C3D3C,unit-acquisition-acquirer,100,49,10/2/2020
9EED50,conference-call,100,50,10/2/2020
9F6B1A,regulatory-product-approval-granted,100,81,10/2/2020
A6213D,revenue-up,100,69,10/2/2020
A65325,conference-call,100,50,10/2/2020
A99576,conference-call,100,50,10/2/2020
AA1EAA,conference-call,100,50,10/2/2020
ACDF88,executive-appointment,100,54,10/2/2020
ACDF88,executive-appointment,100,54,10/2/2020
AF210D,earnings,100,50,10/2/2020
AFDF2E,earnings-revision,100,29,10/2/2020
AFF7B4,conference-call,100,50,10/2/2020
B1B10C,executive-appointment,100,54,10/2/2020
B5734D,public-offering,100,43,10/2/2020
B76C82,settlement,100,56,10/2/2020
BB02FB,conference-call,100,50,10/2/2020
BBAE2A,conference-call,100,50,10/2/2020
BC5680,merger,100,66,10/2/2020
BD15E8,conference-call,100,50,10/2/2020
BEA527,business-contract,100,69,10/2/2020
C83B88,partnership,100,61,10/2/2020
CBDB4D,clinical-trials,100,56,10/2/2020
CC6FF5,earnings,100,50,10/2/2020
CCB623,regulatory-product-approval-granted,100,81,10/2/2020
D17F7E,legal-issues-defendant,100,22,10/2/2020
D17F7E,legal-issues-defendant,100,22,10/2/2020
D36B23,legal-issues-defendant,100,22,10/2/2020
D54E62,merger-regulatory-approval,100,81,10/2/2020
D5938F,clinical-trials-start,100,64,10/2/2020
D5938F,legal-issues-defendant,100,22,10/2/2020
D598E7,conference-participant,100,50,10/2/2020
D64EDF,donation,100,54,10/2/2020
D64EDF,donation,100,54,10/2/2020
D90F43,fundraising,100,64,10/2/2020
DA199F,board-meeting,100,51,10/2/2020
DB5CA5,earnings,100,50,10/2/2020
DCD97F,award,100,58,10/2/2020
E09E2B,conference-organizer,100,57,10/2/2020
E10D31,conference-call,100,50,10/2/2020
E68733,merger,100,66,10/2/2020
E8C557,spin-off,100,58,10/2/2020
ED1A74,conference-participant,100,50,10/2/2020
F48947,acquisition-completed-acquirer,100,49,10/2/2020
FAB97A,legal-issues-defendant,100,22,10/2/2020
12E454,earnings,100,50,10/3/2020
546A27,legal-issues-defendant,100,22,10/3/2020
57634F,legal-issues-defendant,100,22,10/3/2020
6E705B,product-resumed,100,52,10/4/2020
76F067,partnership,100,61,10/4/2020
76F067,partnership,100,61,10/4/2020
96BFF4,legal-issues-defendant,100,22,10/4/2020
00067A,business-contract,100,69,10/5/2020
00067A,business-contract,100,69,10/5/2020
00326D,conference-call,100,50,10/5/2020
31025,earnings,100,50,10/5/2020
06EF42,earnings,100,50,10/5/2020
0919B1,conference-call,100,50,10/5/2020
96930,ipo-pricing,100,50,10/5/2020
0C355F,conference-call,100,50,10/5/2020
0CBC4D,executive-appointment,100,54,10/5/2020
10943B,acquisition-acquirer,100,49,10/5/2020
1201B5,earnings,100,50,10/5/2020
13D576,executive-appointment,100,54,10/5/2020
143C52,hirings,100,65,10/5/2020
184988,merger-completed,100,66,10/5/2020
1AB808,legal-issues-defendant,100,22,10/5/2020
1CDD1C,product-release,100,64,10/5/2020
1D9E55,earnings,100,50,10/5/2020
1F43A1,investment-investor,100,55,10/5/2020
1FA886,legal-issues-defendant,100,22,10/5/2020
20BEEA,conference-call,100,50,10/5/2020
214051,executive-appointment,100,54,10/5/2020
228D42,executive-appointment,100,54,10/5/2020
22C58E,earnings,100,50,10/5/2020
24C48B,partnership,100,61,10/5/2020
251988,partnership,100,61,10/5/2020
267718,partnership,100,61,10/5/2020
29A4CC,conference-call,100,50,10/5/2020
2E902B,conference-call,100,50,10/5/2020
2F7474,conference-call,100,50,10/5/2020
306623,executive-appointment,100,54,10/5/2020
315EB0,conference-call,100,50,10/5/2020
326EDD,conference-call,100,50,10/5/2020
34B97A,partnership,100,61,10/5/2020
3.50E+27,conference-call,100,50,10/5/2020
3.88E+02,legal-issues-defendant,100,22,10/5/2020
38C46F,dividend,100,50,10/5/2020
3DC887,earnings,100,50,10/5/2020
3DD5E2,conference-call,100,50,10/5/2020
43A060,partnership,100,61,10/5/2020
46CF27,earnings,100,50,10/5/2020
49914B,conference-call,100,50,10/5/2020
4A5C8D,earnings,100,50,10/5/2020
4C37C5,facility-open,100,65,10/5/2020
4DD09F,business-contract,100,69,10/5/2020
4EE14A,earnings,100,50,10/5/2020
4EE14A,earnings,100,50,10/5/2020
504FE2,note-sale,100,52,10/5/2020
504FE2,note-sale,100,52,10/5/2020
51D876,earnings,100,50,10/5/2020
51D876,earnings,100,50,10/5/2020
52015A,dividend,100,50,10/5/2020
520632,patent-awarded,100,72,10/5/2020
524CE4,conference-call,100,50,10/5/2020
539F49,public-offering,100,43,10/5/2020
5403F8,same-store-sales,100,50,10/5/2020
546A27,legal-issues-defendant,100,22,10/5/2020
54DF47,conference-call,100,50,10/5/2020
550D01,earnings,100,50,10/5/2020
553949,executive-appointment,100,54,10/5/2020
55438C,business-contract,100,69,10/5/2020
567F3D,earnings,100,50,10/5/2020
57634F,legal-issues-defendant,100,22,10/5/2020
59B229,earnings,100,50,10/5/2020
5D1329,executive-appointment,100,54,10/5/2020
5E6959,conference-call,100,50,10/5/2020
5F9CE3,partnership,100,61,10/5/2020
619882,conference-participant,100,50,10/5/2020
619882,conference-participant,100,50,10/5/2020
6B236C,conference-call,100,50,10/5/2020
6CC55E,partnership,100,61,10/5/2020
6CC55E,partnership,100,61,10/5/2020
6D9ECA,merger,100,66,10/5/2020
70FCEF,executive-appointment,100,54,10/5/2020
7122EB,executive-appointment,100,54,10/5/2020
729368,earnings,100,50,10/5/2020
73C9E2,conference-call,100,50,10/5/2020
741937,earnings,100,50,10/5/2020
747219,product-release,100,64,10/5/2020
767F86,acquisition-acquirer,100,49,10/5/2020
76F067,clinical-trials-positive,100,87,10/5/2020
76F067,clinical-trials-positive,100,87,10/5/2020
7712CB,facility-close,100,47,10/5/2020
7AD81E,ipo-completed,100,76,10/5/2020
830BDB,executive-appointment,100,54,10/5/2020
830BDB,legal-issues-defendant,100,22,10/5/2020
835C86,facility-upgrade,100,65,10/5/2020
8665BA,conference-call,100,50,10/5/2020
87486A,conference-call,100,50,10/5/2020
881190,conference-call,100,50,10/5/2020
8C6C1B,facility-open,100,65,10/5/2020
8DBBE6,executive-appointment,100,54,10/5/2020
8DBBE6,note-sale,100,52,10/5/2020
8DBBE6,note-sale,100,52,10/5/2020
8DE56F,partnership,100,61,10/5/2020
8E4250,note-sale,100,52,10/5/2020
8F3BCC,earnings,100,50,10/5/2020
9043FE,earnings,100,50,10/5/2020
9043FE,earnings,100,50,10/5/2020
90D6A5,conference-call,100,50,10/5/2020
915E7B,conference-call,100,50,10/5/2020
9196A2,award,100,58,10/5/2020
9.31E+77,executive-appointment,100,54,10/5/2020
94637C,acquisition-acquirer,100,49,10/5/2020
94637C,acquisition-acquirer,100,49,10/5/2020
94637C,acquisition-acquirer,100,49,10/5/2020
957A07,legal-issues-defendant,100,22,10/5/2020
957A07,fraud-defendant,100,20,10/5/2020
957A07,legal-issues-defendant,100,22,10/5/2020
96BFF4,legal-issues-defendant,100,22,10/5/2020
9810C0,conference-call,100,50,10/5/2020
990AD0,conference-organizer,100,57,10/5/2020
9C5174,earnings,100,50,10/5/2020
9C8664,conference-call,100,50,10/5/2020
9E91C6,business-contract,100,69,10/5/2020
A16DEA,earnings,100,50,10/5/2020
A2CAF7,campaign-ad-release,100,59,10/5/2020
A75D43,partnership,100,61,10/5/2020
A7A0C8,clinical-trials-start,100,64,10/5/2020
A7F0A5,buybacks,100,74,10/5/2020
A87CD6,earnings,100,50,10/5/2020
A8E72A,clinical-trials-start,100,64,10/5/2020
AE79CD,executive-appointment,100,54,10/5/2020
AEF2C3,executive-appointment,100,54,10/5/2020
B05118,earnings,100,50,10/5/2020
B1FC3B,merger-failed,100,21,10/5/2020
B1FC3B,merger-failed,100,21,10/5/2020
B48FC9,business-contract,100,69,10/5/2020
B7EB38,earnings,100,50,10/5/2020
B96637,conference-call,100,50,10/5/2020
B9BDE8,acquisition-acquirer,100,49,10/5/2020
BB5142,conference-call,100,50,10/5/2020
BB88B6,award,100,58,10/5/2020
C0200F,earnings,100,50,10/5/2020
C32A39,conference-call,100,50,10/5/2020
C356AC,partnership,100,61,10/5/2020
C356AC,partnership,100,61,10/5/2020
C356AC,earnings,100,50,10/5/2020
C5D2AE,earnings,100,50,10/5/2020
C6C702,award,100,58,10/5/2020
C7859D,dividend,100,50,10/5/2020
C8A248,partnership,100,61,10/5/2020
C9881C,executive-appointment,100,54,10/5/2020
C9C62A,executive-appointment,100,54,10/5/2020
CBBFBF,note-sale,100,52,10/5/2020
CC339B,partnership,100,61,10/5/2020
CDC217,conference-participant,100,50,10/5/2020
CE4FD9,executive-appointment,100,54,10/5/2020
CE4FD9,executive-appointment,100,54,10/5/2020
CFF97C,credit-rating-upgrade-rater,20,50,10/5/2020
CFF97C,analyst-ratings-change-positive-rater,20,50,10/5/2020
D0909F,ownership-decrease-owner,100,46,10/5/2020
D139BC,conference-call,100,50,10/5/2020
D1AE3B,product-release,100,64,10/5/2020
D1AE3B,executive-appointment,100,54,10/5/2020
D3FA2C,conference-call,100,50,10/5/2020
D54E62,acquisition-completed-acquirer,100,49,10/5/2020
D5938F,legal-issues-defendant,100,22,10/5/2020
D7AC6E,dividend,100,50,10/5/2020
D8760C,conference-call,100,50,10/5/2020
D8DA3D,conference-call,100,50,10/5/2020
DD1BA1,executive-appointment,100,54,10/5/2020
DD1BA1,partnership,100,61,10/5/2020
DF01B1,conference-call,100,50,10/5/2020
E0647D,analyst-ratings-change-positive,100,78,10/5/2020
E074A0,executive-appointment,100,54,10/5/2020
E09E2B,partnership,100,61,10/5/2020
E30A8F,earnings,100,50,10/5/2020
E30B34,earnings,100,50,10/5/2020
E30B34,earnings,100,50,10/5/2020
E845D9,acquisition-acquirer,100,49,10/5/2020
E8B315,conference-call,100,50,10/5/2020
EAEBF3,buybacks,100,74,10/5/2020
EB1E1A,partnership,100,61,10/5/2020
EF25A5,partnership,100,61,10/5/2020
F179ED,earnings,100,50,10/5/2020
F2E253,executive-appointment,100,54,10/5/2020
F50BAB,conference-call,100,50,10/5/2020
F83279,earnings,100,50,10/5/2020
F92DBC,unit-acquisition-acquirer,100,49,10/5/2020
F92DBC,stake-acquirer,100,48,10/5/2020
F92DBC,stake-acquirer,100,48,10/5/2020
FADF1A,acquisition-completed-acquirer,100,49,10/5/2020
FD0CA4,conference-call,100,50,10/5/2020
FD39EB,executive-appointment,100,54,10/5/2020
01D03F,partnership,100,61,10/6/2020
01D03F,partnership,100,61,10/6/2020
48590,product-release,100,64,10/6/2020
07CA6A,executive-appointment,100,54,10/6/2020
07CA6A,executive-appointment,100,54,10/6/2020
96930,ipo-completed,100,76,10/6/2020
09F623,conference-call,100,50,10/6/2020
0E5619,regulatory-product-approval-granted,100,81,10/6/2020
119CB6,conference-call,100,50,10/6/2020
1201B5,revenues,100,50,10/6/2020
1220D2,earnings,100,50,10/6/2020
1272B3,earnings,100,50,10/6/2020
129DC8,conference-call,100,50,10/6/2020
131443,business-contract,100,69,10/6/2020
147C38,earnings,100,50,10/6/2020
157CC1,regulatory-product-application,100,69,10/6/2020
15901B,fraud,100,44,10/6/2020
1880C5,patent-awarded,100,72,10/6/2020
1EC3E8,executive-appointment,100,54,10/6/2020
1EC3E8,executive-appointment,100,54,10/6/2020
1F43A1,note-sale,100,52,10/6/2020
1FA886,partnership,100,61,10/6/2020
206852,conference-call,100,50,10/6/2020
21022F,revenues,100,50,10/6/2020
221783,earnings,100,50,10/6/2020
227D48,conference-call,100,50,10/6/2020
228D42,partnership,100,61,10/6/2020
228D42,partnership,100,61,10/6/2020
228D42,product-release,100,64,10/6/2020
228D42,partnership,100,61,10/6/2020
273BA3,conference-organizer,100,57,10/6/2020
27C10F,partnership,100,61,10/6/2020
284289,earnings,100,50,10/6/2020
28AF37,executive-appointment,100,54,10/6/2020
28DCA8,earnings-guidance,100,50,10/6/2020
2EB04E,partnership,100,61,10/6/2020
2F7474,executive-appointment,100,54,10/6/2020
2F7A7E,conference-call,100,50,10/6/2020
30DFD3,conference-call,100,50,10/6/2020
31553A,earnings,100,50,10/6/2020
3461CF,award,100,58,10/6/2020
34E9F9,dividend,100,50,10/6/2020
367E1C,earnings,100,50,10/6/2020
370C50,product-price-raise,100,57,10/6/2020
3.88E+02,legal-issues-defendant,100,22,10/6/2020
396D7C,executive-resignation,100,44,10/6/2020
397A8F,loan-recipient,100,59,10/6/2020
397A8F,executive-appointment,100,54,10/6/2020
3A113F,revenues,100,50,10/6/2020
3C7F5F,executive-appointment,100,54,10/6/2020
3C7F5F,earnings,100,50,10/6/2020
3DD5E2,public-offering,100,43,10/6/2020
3ED92D,earnings-guidance,100,50,10/6/2020
3F96D5,partnership,100,61,10/6/2020
4.03E+05,executive-appointment,100,54,10/6/2020
416C55,partnership,100,61,10/6/2020
41785E,executive-appointment,100,54,10/6/2020
41785E,earnings,100,50,10/6/2020
420168,earnings,100,50,10/6/2020
467F2C,conference-call,100,50,10/6/2020
467F2C,executive-appointment,100,54,10/6/2020
47752F,earnings,100,50,10/6/2020
4A6F00,partnership,100,61,10/6/2020
4B49CF,note-sale,100,52,10/6/2020
4B5054,fraud,100,44,10/6/2020
4BBA23,trading-halt,100,43,10/6/2020
4C6C63,dividend-up,100,60,10/6/2020
4C7DB5,earnings,100,50,10/6/2020
4F9487,conference-call,100,50,10/6/2020
519FE0,note-sale,100,52,10/6/2020
519FE0,note-sale,100,52,10/6/2020
5225A4,note-sale,100,52,10/6/2020
546A27,legal-issues-defendant,100,22,10/6/2020
546A27,legal-issues-defendant,100,22,10/6/2020
546A9C,conference-call,100,50,10/6/2020
56277A,conference-call,100,50,10/6/2020
56632F,earnings,100,50,10/6/2020
56EFC7,executive-appointment,100,54,10/6/2020
589803,earnings,100,50,10/6/2020
59872F,product-release,100,64,10/6/2020
5F2FF7,earnings,100,50,10/6/2020
619882,partnership,100,61,10/6/2020
6.52E+64,partnership,100,61,10/6/2020
6.52E+64,partnership,100,61,10/6/2020
65AB30,conference-participant,100,50,10/6/2020
665D7D,conference-call,100,50,10/6/2020
66A667,dividend,100,50,10/6/2020
66A667,dividend,100,50,10/6/2020
69E8E1,conference-call,100,50,10/6/2020
69E8E1,conference-call,100,50,10/6/2020
6BF593,executive-appointment,100,54,10/6/2020
6D6B40,earnings,100,50,10/6/2020
6-Dec-05,business-contract,100,69,10/6/2020
6E705B,partnership,100,61,10/6/2020
6F6559,earnings,100,50,10/6/2020
6F6559,earnings,100,50,10/6/2020
6F6559,earnings,100,50,10/6/2020
6F6559,earnings,100,50,10/6/2020
732A9B,conference-participant,100,50,10/6/2020
7.44E+09,conference-call,100,50,10/6/2020
752A70,earnings,100,50,10/6/2020
762A3E,conference-call,100,50,10/6/2020
773A17,partnership,100,61,10/6/2020
78F9ED,partnership,100,61,10/6/2020
7B0BA6,product-release,100,64,10/6/2020
7D7716,earnings,100,50,10/6/2020
7DA412,business-contract,100,69,10/6/2020
7DA412,business-contract,100,69,10/6/2020
86478F,earnings,100,50,10/6/2020
8A8E41,partnership,100,61,10/6/2020
8A8E41,executive-appointment,100,54,10/6/2020
8A8E41,partnership,100,61,10/6/2020
8BFAA4,asset-sale,100,62,10/6/2020
8C6C1B,facility-open,100,65,10/6/2020
8D4486,product-release,100,64,10/6/2020
8D5145,earnings,100,50,10/6/2020
8E8E6E,partnership,100,61,10/6/2020
8E93A4,conference-call,100,50,10/6/2020
8F3231,conference-call,100,50,10/6/2020
925759,partnership,100,61,10/6/2020
944B2E,unit-acquisition-acquiree,100,76,10/6/2020
944B2E,unit-acquisition-acquiree,100,76,10/6/2020
9548BB,earnings,100,50,10/6/2020
9.54E+32,partnership,100,61,10/6/2020
965360,earnings,100,50,10/6/2020
96A2D3,earnings,100,50,10/6/2020
977A1E,conference-call,100,50,10/6/2020
986AF6,conference-call,100,50,10/6/2020
99B61C,public-offering,100,43,10/6/2020
9C8BC3,conference-call,100,50,10/6/2020
9CA432,conference-call,100,50,10/6/2020
9D6A24,conference-call,100,50,10/6/2020
A02FB1,conference-call,100,50,10/6/2020
A1EAC8,executive-appointment,100,54,10/6/2020
A3F598,conference-call,100,50,10/6/2020
A4A612,conference-call,100,50,10/6/2020
A5628C,earnings,100,50,10/6/2020
A6828A,regulatory-product-approval-granted,100,81,10/6/2020
A94718,conference-call,100,50,10/6/2020
AC775C,conference-call,100,50,10/6/2020
AFF43F,earnings,100,50,10/6/2020
B2D799,legal-issues-defendant,100,22,10/6/2020
B446B8,earnings,100,50,10/6/2020
B48FC9,partnership,100,61,10/6/2020
B5734D,fraud,100,44,10/6/2020
B619CB,executive-appointment,100,54,10/6/2020
B9B6B8,product-release,100,64,10/6/2020
BA218A,conference-call,100,50,10/6/2020
BC5680,partnership,100,61,10/6/2020
C3BAE7,acquisition-completed-acquirer,100,49,10/6/2020
C4706C,dividend,100,50,10/6/2020
C5C137,partnership,100,61,10/6/2020
C5C137,partnership,100,61,10/6/2020
C5C137,partnership,100,61,10/6/2020
C65004,revenues,100,50,10/6/2020
C8FAC7,partnership,100,61,10/6/2020
CA1620,award,100,58,10/6/2020
CAD7D9,earnings,100,50,10/6/2020
CEDFD5,partnership,100,61,10/6/2020
D17F7E,legal-issues-defendant,100,22,10/6/2020
D18AFC,partnership,100,61,10/6/2020
D25249,conference-call,100,50,10/6/2020
D33D8C,acquisition-completed-acquirer,100,49,10/6/2020
D33D8C,acquisition-completed-acquirer,100,49,10/6/2020
D36B23,legal-issues-defendant,100,22,10/6/2020
D437C3,earnings,100,50,10/6/2020
D54E62,conference-call,100,50,10/6/2020
D58A11,product-release,100,64,10/6/2020
D5938F,legal-issues-defendant,100,22,10/6/2020
D6144F,product-release,100,64,10/6/2020
DCD97F,business-contract,100,69,10/6/2020
DD1BA1,business-contract,100,69,10/6/2020
DD1BA1,partnership,100,61,10/6/2020
DEF058,earnings,100,50,10/6/2020
DF532D,conference-call,100,50,10/6/2020
E0207A,partnership,100,61,10/6/2020
E09556,earnings,100,50,10/6/2020
E124EB,product-release,100,64,10/6/2020
E2F130,conference-call,100,50,10/6/2020
E4CE73,clinical-trials,100,56,10/6/2020
E68733,executive-resignation,100,44,10/6/2020
E68733,executive-resignation,100,44,10/6/2020
E71AE6,clinical-trials,100,56,10/6/2020
E74B55,executive-appointment,100,54,10/6/2020
EA62FC,conference-call,100,50,10/6/2020
EB1E1A,public-offering,100,43,10/6/2020
EE967B,earnings,100,50,10/6/2020
EEA6B3,partnership,100,61,10/6/2020
EF1AD9,conference-call,100,50,10/6/2020
F5349B,executive-appointment,100,54,10/6/2020
F5349B,earnings,100,50,10/6/2020
F748C7,facility-close,100,47,10/6/2020
F8084B,earnings,100,50,10/6/2020
FA044A,conference-call,100,50,10/6/2020
FA40E2,executive-resignation,100,44,10/6/2020
FAB97A,fraud,100,44,10/6/2020
FAB97A,earnings,100,50,10/6/2020
FEE4B0,earnings,100,50,10/6/2020
01478A,note-sale,100,52,10/7/2020
0157B1,partnership,100,61,10/7/2020
51332,earnings,100,50,10/7/2020
081AB9,conference-call,100,50,10/7/2020
0AAD90,clinical-trials-start,100,64,10/7/2020
0AAD90,regulatory-product-approval-granted,100,81,10/7/2020
0BC853,conference-call,100,50,10/7/2020
0BF528,partnership,100,61,10/7/2020
0BF528,product-release,100,64,10/7/2020
0CBC4D,earnings,100,50,10/7/2020
0CCCB7,conference-call,100,50,10/7/2020
0DE3D5,conference-call,100,50,10/7/2020
0ED415,conference-call,100,50,10/7/2020
0F04E5,earnings,100,50,10/7/2020
105D00,executive-appointment,100,54,10/7/2020
1151F4,conference-call,100,50,10/7/2020
1216D1,conference-call,100,50,10/7/2020
12E454,partnership,100,61,10/7/2020
16F4D8,conference-call,100,50,10/7/2020
1748F6,business-contract,100,69,10/7/2020
1748F6,business-contract,100,69,10/7/2020
17EDA5,product-release,100,64,10/7/2020
1A5957,earnings,100,50,10/7/2020
1CDD1C,conference-call,100,50,10/7/2020
1F9258,earnings-up,100,68,10/7/2020
228D42,partnership,100,61,10/7/2020
228D42,partnership,100,61,10/7/2020
228D42,partnership,100,61,10/7/2020
228D42,business-combination,100,54,10/7/2020
228D42,business-combination,100,54,10/7/2020
228D42,partnership,100,61,10/7/2020
24D81E,hirings,100,65,10/7/2020
251988,product-release,100,64,10/7/2020
25DD05,conference-call,100,50,10/7/2020
2667B6,earnings,100,50,10/7/2020
267718,business-contract,100,69,10/7/2020
279916,buybacks,100,74,10/7/2020
2920D5,executive-appointment,100,54,10/7/2020
2.90E+62,earnings,100,50,10/7/2020
2A6DBE,legal-issues-defendant,100,22,10/7/2020
2CB4C9,earnings,100,50,10/7/2020
2E0496,earnings,100,50,10/7/2020
2E0496,earnings,100,50,10/7/2020
3.14E+47,legal-issues-defendant,100,22,10/7/2020
3.14E+47,legal-issues-defendant,100,22,10/7/2020
31643A,partnership,100,61,10/7/2020
382EAE,conference-call,100,50,10/7/2020
385DD4,business-contract-terminated,100,31,10/7/2020
387541,conference-call,100,50,10/7/2020
3.88E+02,legal-issues-defendant,100,22,10/7/2020
3.88E+02,legal-issues-defendant,100,22,10/7/2020
3B20AB,dividend,100,50,10/7/2020
3DD5E2,public-offering,100,43,10/7/2020
3DE4D1,executive-appointment,100,54,10/7/2020
3E15F6,conference-call,100,50,10/7/2020
44ED36,note-sale,100,52,10/7/2020
458D2C,note-sale,100,52,10/7/2020
4A6F00,partnership,100,61,10/7/2020
4B3555,earnings,100,50,10/7/2020
4B49CF,note-sale,100,52,10/7/2020
4BBA23,trading-resumed,100,58,10/7/2020
4BBA23,product-release,100,64,10/7/2020
4EE14A,earnings-guidance,100,50,10/7/2020
4EE14A,earnings-guidance,100,50,10/7/2020
4F9926,partnership,100,61,10/7/2020
507AE7,earnings,100,50,10/7/2020
5088A5,earnings,100,50,10/7/2020
520632,product-release,100,64,10/7/2020
532D47,conference-call,100,50,10/7/2020
546A27,legal-issues-defendant,100,22,10/7/2020
546A27,legal-issues-defendant,100,22,10/7/2020
546A27,legal-issues-defendant,100,22,10/7/2020
5487B1,conference-call,100,50,10/7/2020
55438C,earnings,100,50,10/7/2020
5704AC,earnings,100,50,10/7/2020
5AF08A,executive-appointment,100,54,10/7/2020
5B3415,conference-call,100,50,10/7/2020
5B97B2,earnings,100,50,10/7/2020
5BE42C,conference-call,100,50,10/7/2020
5CC29D,earnings,100,50,10/7/2020
5D1956,earnings,100,50,10/7/2020
5EC388,earnings,100,50,10/7/2020
605F40,conference-call,100,50,10/7/2020
609208,product-release,100,64,10/7/2020
6137BF,conference-call,100,50,10/7/2020
62A48D,executive-appointment,100,54,10/7/2020
62B20A,conference-call,100,50,10/7/2020
633054,partnership,100,61,10/7/2020
6559D8,partnership,100,61,10/7/2020
69CE71,dividend,100,50,10/7/2020
69FDFC,award,100,58,10/7/2020
6B0E45,conference-call,100,50,10/7/2020
6BF593,conference-call,100,50,10/7/2020
6D6B40,hirings,100,65,10/7/2020
6.00E+19,conference-call,100,50,10/7/2020
6F39FC,dividend,100,50,10/7/2020
726EEA,dividend,100,50,10/7/2020
73BCBA,conference-call,100,50,10/7/2020
76E80F,note-sale,100,52,10/7/2020
771985,conference-call,100,50,10/7/2020
790C34,product-release,100,64,10/7/2020
7A3633,earnings,100,50,10/7/2020
7B0BA6,earnings,100,50,10/7/2020
7B6EB1,earnings,100,50,10/7/2020
7BFF81,business-contract,100,69,10/7/2020
7DA412,earnings,100,50,10/7/2020
7E3F8F,earnings,100,50,10/7/2020
8.10E+32,conference-call,100,50,10/7/2020
826FD6,earnings,100,50,10/7/2020
8377DB,partnership,100,61,10/7/2020
855DF7,business-contract-terminated,100,31,10/7/2020
88350F,conference-call,100,50,10/7/2020
88923D,conference-call,100,50,10/7/2020
8AC65D,partnership,100,61,10/7/2020
8BAA15,earnings,100,50,10/7/2020
8C6C1B,facility-open,100,65,10/7/2020
922F0C,earnings,100,50,10/7/2020
93633B,conference-call,100,50,10/7/2020
93D207,earnings,100,50,10/7/2020
944B2E,rights-issue,100,43,10/7/2020
94637C,regulatory-product-approval-granted,100,81,10/7/2020
94756D,earnings,100,50,10/7/2020
949625,dividend,100,50,10/7/2020
9.54E+32,partnership,100,61,10/7/2020
96BFF4,legal-issues-defendant,100,22,10/7/2020
990AD0,earnings,100,50,10/7/2020
9B0C9C,partnership,100,61,10/7/2020
9C5BA5,earnings,100,50,10/7/2020
9CE4C7,earnings,100,50,10/7/2020
9EBAFA,public-offering,100,43,10/7/2020
A01200,product-release,100,64,10/7/2020
A3AAA5,conference-call,100,50,10/7/2020
A746F6,conference-call,100,50,10/7/2020
AA5C8E,earnings,100,50,10/7/2020
AA98ED,executive-resignation,100,44,10/7/2020
AD23DE,conference-call,100,50,10/7/2020
B37FB4,earnings,100,50,10/7/2020
B4703C,conference-call,100,50,10/7/2020
B840EF,partnership,100,61,10/7/2020
B840EF,partnership,100,61,10/7/2020
B8EF97,revenues,100,50,10/7/2020
BAAA60,conference-call,100,50,10/7/2020
BB127B,partnership,100,61,10/7/2020
BB5271,conference-call,100,50,10/7/2020
BB88B6,earnings,100,50,10/7/2020
BD9668,conference-call,100,50,10/7/2020
BE379D,clinical-trials-start,100,64,10/7/2020
C03C8B,dividend,100,50,10/7/2020
C062D4,product-release,100,64,10/7/2020
C230FE,earnings,100,50,10/7/2020
C41C25,earnings,100,50,10/7/2020
C659EB,conference-call,100,50,10/7/2020
C7AE14,conference-call,100,50,10/7/2020
C83B88,executive-appointment,100,54,10/7/2020
C941DC,earnings,100,50,10/7/2020
C951A2,earnings,100,50,10/7/2020
C9E107,partnership,100,61,10/7/2020
CD051C,conference-call,100,50,10/7/2020
CD4DA8,conference-call,100,50,10/7/2020
CDFCC9,revenue-up,100,69,10/7/2020
D06755,earnings,100,50,10/7/2020
D0909F,earnings-guidance,100,50,10/7/2020
D0DFE5,executive-appointment,100,54,10/7/2020
D1C26F,partnership,100,61,10/7/2020
D2B9E5,earnings,100,50,10/7/2020
D45285,conference-call,100,50,10/7/2020
D501DC,conference-call,100,50,10/7/2020
D5938F,legal-issues-defendant,100,22,10/7/2020
D7A953,earnings,100,50,10/7/2020
DA0CB8,conference-call,100,50,10/7/2020
DB7FA7,conference-call,100,50,10/7/2020
DC0998,conference-call,100,50,10/7/2020
DD1BA1,business-contract,100,69,10/7/2020
DD1BA1,product-release,100,64,10/7/2020
DD7A96,conference-call,100,50,10/7/2020
E0D3BA,earnings,100,50,10/7/2020
E124EB,conference-call,100,50,10/7/2020
E8846E,earnings,100,50,10/7/2020
ED5171,earnings,100,50,10/7/2020
EE74E1,business-contract,100,69,10/7/2020
EF5BED,executive-appointment,100,54,10/7/2020
EF77A3,dividend,100,50,10/7/2020
F18844,legal-issues-defendant,100,22,10/7/2020
F30508,partnership,100,61,10/7/2020
F30508,partnership,100,61,10/7/2020
F30508,partnership,100,61,10/7/2020
F40EE2,dividend,100,50,10/7/2020
F40EE2,dividend,100,50,10/7/2020
F5D059,earnings,100,50,10/7/2020
F5D059,earnings,100,50,10/7/2020
F5D059,earnings,100,50,10/7/2020
F5D059,earnings,100,50,10/7/2020
F5D059,earnings,100,50,10/7/2020
F721A7,earnings,100,50,10/7/2020
F721A7,earnings,100,50,10/7/2020
FAE021,earnings,100,50,10/7/2020
FAE021,earnings,100,50,10/7/2020
FD4E8D,earnings,100,50,10/7/2020
FDC7E6,conference-call,100,50,10/7/2020
FDF799,revenues,100,50,10/7/2020
FEC475,conference-call,100,50,10/7/2020
00067A,market-entry,100,57,10/8/2020
00326D,earnings,100,50,10/8/2020
01478A,conference-call,100,50,10/8/2020
0157B1,partnership,100,61,10/8/2020
018C11,conference-call,100,50,10/8/2020
01D03F,partnership,100,61,10/8/2020
03542C,acquisition-acquirer,100,49,10/8/2020
48590,earnings,100,50,10/8/2020
07CA6A,conference-call,100,50,10/8/2020
07CA6A,conference-call,100,50,10/8/2020
083F72,executive-appointment,100,54,10/8/2020
099A92,conference-call,100,50,10/8/2020
0A0D9E,product-release,100,64,10/8/2020
0BC17A,conference-call,100,50,10/8/2020
0C4131,conference-call,100,50,10/8/2020
0C6861,product-release,100,64,10/8/2020
0C6861,conference-call,100,50,10/8/2020
10100E,revenues,100,50,10/8/2020
13A782,executive-appointment,100,54,10/8/2020
13C3E0,earnings,100,50,10/8/2020
13C3E0,executive-appointment,100,54,10/8/2020
190B91,earnings,100,50,10/8/2020
1B9535,earnings,100,50,10/8/2020
1EBF8D,clinical-trials,100,56,10/8/2020
1EBF8D,clinical-trials,100,56,10/8/2020
1EBF8D,clinical-trials,100,56,10/8/2020
1EBF8D,business-contract,100,69,10/8/2020
1F9258,earnings-up,100,68,10/8/2020
1FE3CB,conference-call,100,50,10/8/2020
21268E,conference-call,100,50,10/8/2020
228D42,partnership,100,61,10/8/2020
24D81E,earnings,100,50,10/8/2020
251988,legal-issues-defendant,100,22,10/8/2020
251988,executive-appointment,100,54,10/8/2020
26D8ED,conference-call,100,50,10/8/2020
275300,conference-call,100,50,10/8/2020
2920D5,earnings,100,50,10/8/2020
292388,partnership,100,61,10/8/2020
2DA92D,conference-call,100,50,10/8/2020
2DB344,earnings,100,50,10/8/2020
2EB88B,earnings,100,50,10/8/2020
3.14E+47,earnings,100,50,10/8/2020
34B97A,earnings,100,50,10/8/2020
34B97A,earnings,100,50,10/8/2020
36529A,clinical-trials,100,56,10/8/2020
367434,fast-track-designation,100,81,10/8/2020
367E1C,partnership,100,61,10/8/2020
382EAE,note-sale,100,52,10/8/2020
3.88E+02,legal-issues-defendant,100,22,10/8/2020
39FB23,earnings-guidance,100,50,10/8/2020
3B37F7,dividend,100,50,10/8/2020
3BB616,earnings,100,50,10/8/2020
3BCF24,earnings,100,50,10/8/2020
3C6CCC,earnings,100,50,10/8/2020
3DCECC,award,100,58,10/8/2020
3DE4D1,conference-call,100,50,10/8/2020
434F38,earnings,100,50,10/8/2020
458D2C,revenue-volume,100,50,10/8/2020
4.91E+58,conference-call,100,50,10/8/2020
4B7006,award,100,58,10/8/2020
4B7006,award,100,58,10/8/2020
4EE167,earnings,100,50,10/8/2020
514067,conference-call,100,50,10/8/2020
53E575,conference-call,100,50,10/8/2020
546A27,legal-issues-defendant,100,22,10/8/2020
54DF47,credit-extension-recipient,100,69,10/8/2020
55C9B5,partnership,100,61,10/8/2020
564F3E,earnings,100,50,10/8/2020
56B7C1,conference-call,100,50,10/8/2020
57DDB9,product-release,100,64,10/8/2020
57DDB9,product-release,100,64,10/8/2020
5B7739,acquisition-completed-acquirer,100,49,10/8/2020
5C2A47,conference-call,100,50,10/8/2020
5D0337,partnership,100,61,10/8/2020
5D0337,partnership,100,61,10/8/2020
5D0337,partnership,100,61,10/8/2020
5DAF89,acquisition-acquirer,100,49,10/8/2020
61BCA7,earnings,100,50,10/8/2020
6.52E+64,conference-call,100,50,10/8/2020
66749D,earnings,100,50,10/8/2020
66A667,earnings,100,50,10/8/2020
68BA15,conference-call,100,50,10/8/2020
6D0CAB,operating-earnings,100,50,10/8/2020
728737,dividend,100,50,10/8/2020
72CB93,earnings,100,50,10/8/2020
72FCA3,dividend-up,100,81,10/8/2020
74404C,conference-call,100,50,10/8/2020
766047,executive-appointment,100,54,10/8/2020
789A7D,earnings,100,50,10/8/2020
79167B,conference-call,100,50,10/8/2020
7A3633,investment-investor,100,55,10/8/2020
7B9212,revenues,100,50,10/8/2020
8.22E+27,conference-call,100,50,10/8/2020
885758,earnings,100,50,10/8/2020
88923D,award,100,58,10/8/2020
89F693,earnings,100,50,10/8/2020
8A0368,conference-call,100,50,10/8/2020
8B3B0E,conference-call,100,50,10/8/2020
8C6C1B,facility-open,100,65,10/8/2020
8DBBE6,conference-call,100,50,10/8/2020
8DBE73,conference-call,100,50,10/8/2020
8DE74B,conference-call,100,50,10/8/2020
8E8E6E,note-sale,100,52,10/8/2020
8E8E6E,note-sale,100,52,10/8/2020
8E9CD8,earnings,100,50,10/8/2020
8FE7A5,earnings,100,50,10/8/2020
9043FE,debt-extension-recipient,100,73,10/8/2020
9043FE,debt-extension-recipient,100,73,10/8/2020
9196A2,acquisition-acquirer,100,49,10/8/2020
9196A2,acquisition-acquirer,100,49,10/8/2020
934029,name-change,100,49,10/8/2020
9368BE,conference-call,100,50,10/8/2020
9.54E+32,revenue-up,100,69,10/8/2020
957A07,fraud,100,44,10/8/2020
957A07,legal-issues-defendant,100,22,10/8/2020
95DC1F,partnership,100,61,10/8/2020
95F59E,earnings,100,50,10/8/2020
968103,earnings,100,50,10/8/2020
96BFF4,legal-issues-defendant,100,22,10/8/2020
971F7B,earnings,100,50,10/8/2020
980C14,conference-call,100,50,10/8/2020
990AD0,dividend,100,50,10/8/2020
9D65C1,earnings,100,50,10/8/2020
9EBAFA,public-offering,100,43,10/8/2020
9EF4CF,product-release,100,64,10/8/2020
A01664,earnings,100,50,10/8/2020
A1EAC8,conference-call,100,50,10/8/2020
A58224,conference-call,100,50,10/8/2020
A5A4F5,earnings,100,50,10/8/2020
A5A4F5,earnings,100,50,10/8/2020
A5A4F5,earnings,100,50,10/8/2020
A5A4F5,earnings,100,50,10/8/2020
A5A4F5,earnings,100,50,10/8/2020
A5A4F5,earnings,100,50,10/8/2020
A5A4F5,earnings,100,50,10/8/2020
A5A4F5,earnings,100,50,10/8/2020
A5A4F5,earnings,100,50,10/8/2020
A5A4F5,earnings,100,50,10/8/2020
A5A4F5,earnings,100,50,10/8/2020
A5A4F5,earnings,100,50,10/8/2020
A5A4F5,earnings,100,50,10/8/2020
A5A4F5,earnings,100,50,10/8/2020
A5A4F5,earnings,100,50,10/8/2020
A5A4F5,earnings,100,50,10/8/2020
A5A4F5,earnings,100,50,10/8/2020
A5A4F5,earnings,100,50,10/8/2020
A5A4F5,earnings,100,50,10/8/2020
A5A4F5,earnings,100,50,10/8/2020
A5A4F5,earnings,100,50,10/8/2020
AE3113,product-release,100,64,10/8/2020
AE7D16,earnings,100,50,10/8/2020
AEFC90,partnership,100,61,10/8/2020
AEFC90,partnership,100,61,10/8/2020
AFDF2E,dividend,100,50,10/8/2020
AFEC35,earnings,100,50,10/8/2020
B01111,hirings,100,65,10/8/2020
B0B969,conference-call,100,50,10/8/2020
B1DF3C,earnings,100,50,10/8/2020
B2256A,conference-call,100,50,10/8/2020
B2D799,legal-issues-defendant,100,22,10/8/2020
B2E6B5,conference-call,100,50,10/8/2020
B54A74,earnings,100,50,10/8/2020
B7BBFF,dividend,100,50,10/8/2020
B803B1,conference-call,100,50,10/8/2020
B934BF,conference-call,100,50,10/8/2020
BB0587,conference-call,100,50,10/8/2020
BB127B,conference-participant,100,50,10/8/2020
BBF349,earnings,100,50,10/8/2020
BC948D,conference-call,100,50,10/8/2020
BF79F5,conference-call,100,50,10/8/2020
C0F70B,earnings,100,50,10/8/2020
C4C77F,acquisition-acquiree,100,76,10/8/2020
C4C77F,acquisition-acquiree,100,76,10/8/2020
C6C702,award,100,58,10/8/2020
C9D866,executive-appointment,100,54,10/8/2020
CB88B3,earnings,100,50,10/8/2020
CDE51C,earnings,100,50,10/8/2020
CE2791,conference-call,100,50,10/8/2020
D17F7E,fraud,100,44,10/8/2020
D2E553,executive-appointment,100,54,10/8/2020
D42DBA,partnership,100,61,10/8/2020
D5938F,legal-issues-defendant,100,22,10/8/2020
D6534D,conference-call,100,50,10/8/2020
D65A13,conference-call,100,50,10/8/2020
D77F7E,business-contract,100,69,10/8/2020
D77F7E,earnings,100,50,10/8/2020
D7918D,legal-issues-defendant,100,22,10/8/2020
D854F3,conference-call,100,50,10/8/2020
D88EF3,note-sale,100,52,10/8/2020
DB88A1,executive-appointment,100,54,10/8/2020
DB9829,award,100,58,10/8/2020
DCD97F,conference-call,100,50,10/8/2020
DD1BA1,executive-appointment,100,54,10/8/2020
DD1BA1,executive-appointment,100,54,10/8/2020
DD3BB1,earnings,100,50,10/8/2020
DDC415,earnings,100,50,10/8/2020
E0207A,earnings,100,50,10/8/2020
E05DC8,earnings,100,50,10/8/2020
E1E36F,earnings,100,50,10/8/2020
E22FDE,legal-issues-defendant,100,22,10/8/2020
E26FC3,executive-appointment,100,54,10/8/2020
E26FC3,dividend,100,50,10/8/2020
E2CB7B,unit-acquisition-acquirer,100,49,10/8/2020
E3E68E,executive-appointment,100,54,10/8/2020
E3E68E,executive-appointment,100,54,10/8/2020
E67C2C,earnings,100,50,10/8/2020
E71AE6,reorganization,100,53,10/8/2020
E74B55,earnings,100,50,10/8/2020
E866D2,product-release,100,64,10/8/2020
E866D2,product-release,100,64,10/8/2020
E9E6FD,conference-call,100,50,10/8/2020
EB1E1A,public-offering,100,43,10/8/2020
ECE19E,ipo-pricing,100,50,10/8/2020
ECE814,earnings,100,50,10/8/2020
EDD234,conference-call,100,50,10/8/2020
EF5BED,executive-appointment,100,54,10/8/2020
EF7163,conference-call,100,50,10/8/2020
F179ED,executive-appointment,100,54,10/8/2020
F30508,conference-call,100,50,10/8/2020
F51DB0,conference-call,100,50,10/8/2020
F58C23,conference-participant,100,50,10/8/2020
F5D059,dividend-up,100,81,10/8/2020
F66B58,executive-appointment,100,54,10/8/2020
F6E248,business-contract,100,69,10/8/2020
F7ADEB,executive-appointment,100,54,10/8/2020
F7ADEB,conference-call,100,50,10/8/2020
F88147,conference-participant,100,50,10/8/2020
FB728F,conference-call,100,50,10/8/2020
FC9A88,conference-call,100,50,10/8/2020
FF6644,partnership,100,61,10/8/2020
FFE543,earnings,100,50,10/8/2020
48590,partnership,100,61,10/9/2020
48590,partnership,100,61,10/9/2020
48590,partnership,100,61,10/9/2020
065D38,earnings,100,50,10/9/2020
71860,earnings,100,50,10/9/2020
0C2A0D,earnings,100,50,10/9/2020
0F65C9,conference-call,100,50,10/9/2020
10AE08,earnings,100,50,10/9/2020
1DEBBE,award,100,58,10/9/2020
1E9A6D,earnings,100,50,10/9/2020
20BEEA,note-sale,100,52,10/9/2020
227F04,partnership,100,61,10/9/2020
25A6CC,earnings,100,50,10/9/2020
28DCF3,earnings,100,50,10/9/2020
29B702,earnings,100,50,10/9/2020
2BBE62,earnings,100,50,10/9/2020
2C3348,product-release,100,64,10/9/2020
2EBA55,dividend,100,50,10/9/2020
306623,conference-call,100,50,10/9/2020
309922,conference-call,100,50,10/9/2020
356B21,earnings,100,50,10/9/2020
371B0A,conference-call,100,50,10/9/2020
3.88E+02,legal-issues-defendant,100,22,10/9/2020
3.88E+02,legal-issues-defendant,100,22,10/9/2020
3A3948,conference-call,100,50,10/9/2020
3FACA7,executive-appointment,100,54,10/9/2020
3FACA7,dividend,100,50,10/9/2020
44ED36,earnings,100,50,10/9/2020
458D2C,conference-call,100,50,10/9/2020
45BC35,conference-call,100,50,10/9/2020
4A3438,legal-issues-defendant,100,22,10/9/2020
4C92B9,business-contract,100,69,10/9/2020
4D971D,conference-call,100,50,10/9/2020
546A27,legal-issues-defendant,100,22,10/9/2020
55C9B5,conference-call,100,50,10/9/2020
562853,conference-call,100,50,10/9/2020
5675EB,earnings,100,50,10/9/2020
567F3D,spin-off,100,58,10/9/2020
57634F,legal-issues-defendant,100,22,10/9/2020
57634F,legal-issues-defendant,100,22,10/9/2020
57B174,dividend,100,50,10/9/2020
5B6C11,earnings,100,50,10/9/2020
61BCA7,acquisition-acquirer,100,49,10/9/2020
61BCA7,acquisition-acquirer,100,49,10/9/2020
633043,earnings,100,50,10/9/2020
6.52E+64,partnership,100,61,10/9/2020
68AB62,conference-call,100,50,10/9/2020
6A024C,ipo-pricing,100,50,10/9/2020
6CB7F9,conference-call,100,50,10/9/2020
713810,hirings,100,65,10/9/2020
7.83E+79,earnings,100,50,10/9/2020
789A7D,dividend-up,100,81,10/9/2020
78F9ED,conference-call,100,50,10/9/2020
791EC1,conference-call,100,50,10/9/2020
7B9AFA,earnings,100,50,10/9/2020
7C4F43,clinical-trials,100,56,10/9/2020
82FD6D,conference-call,100,50,10/9/2020
8303CD,conference-call,100,50,10/9/2020
855DF7,conference-call,100,50,10/9/2020
8C311A,partnership,100,61,10/9/2020
8C6C1B,facility-open,100,65,10/9/2020
8E0E32,earnings,100,50,10/9/2020
90DD65,ipo-pricing,100,50,10/9/2020
93F143,earnings,100,50,10/9/2020
957A07,legal-issues-defendant,100,22,10/9/2020
96BFF4,legal-issues-defendant,100,22,10/9/2020
97AF94,dividend,100,50,10/9/2020
9CF9B1,earnings,100,50,10/9/2020
A15C71,conference-call,100,50,10/9/2020
A1A317,conference-call,100,50,10/9/2020
A41450,dividend,100,50,10/9/2020
A75D43,earnings,100,50,10/9/2020
AD23DE,executive-appointment,100,54,10/9/2020
B2D799,legal-issues-defendant,100,22,10/9/2020
B83BCE,earnings,100,50,10/9/2020
BAD655,merger,100,66,10/9/2020
BB88B6,award,100,58,10/9/2020
BBBB41,conference-call,100,50,10/9/2020
C3F99F,patient-enrollment-start,100,58,10/9/2020
C5C0E9,conference-call,100,50,10/9/2020
CA1620,executive-appointment,100,54,10/9/2020
CDEDFE,merger,100,66,10/9/2020
CE1002,award,100,58,10/9/2020
D2E553,dividend-up,100,52,10/9/2020
D501DC,dividend,100,50,10/9/2020
D5938F,legal-issues-defendant,100,22,10/9/2020
D63B0F,conference-call,100,50,10/9/2020
D9B1C9,legal-issues-defendant,100,22,10/9/2020
DA199F,ipo-pricing,100,50,10/9/2020
DE5611,donation,100,54,10/9/2020
E12A6E,dividend,100,50,10/9/2020
E1E093,ownership-increase-owner,100,56,10/9/2020
E22FDE,legal-issues-defendant,100,22,10/9/2020
E35610,conference-call,100,50,10/9/2020
E3E68E,conference-call,100,50,10/9/2020
E3E68E,conference-call,100,50,10/9/2020
E4158B,earnings,100,50,10/9/2020
E592F0,earnings,100,50,10/9/2020
ED0D7C,conference-call,100,50,10/9/2020
ED3CA8,conference-call,100,50,10/9/2020
F48947,earnings,100,50,10/9/2020
F7902B,earnings,100,50,10/9/2020
FE89E0,dividend-up,100,81,10/9/2020
FF5413,earnings,100,50,10/9/2020
94637C,clinical-trials-positive,100,87,10/10/2020
C9E107,executive-appointment,100,54,10/10/2020
12E454,partnership,100,61,10/11/2020
58CA9A,legal-issues-defendant,100,22,10/11/2020
5FF95F,earnings,100,50,10/11/2020
BDE867,award,100,58,10/11/2020
D9B1C9,legal-issues-defendant,100,22,10/11/2020
9397,executive-appointment,100,54,10/12/2020
0142B5,conference-call,100,50,10/12/2020
040DBB,unit-acquisition-acquirer,100,49,10/12/2020
040DBB,business-contract,100,69,10/12/2020
43862,fundraising,100,64,10/12/2020
083F72,executive-resignation,100,44,10/12/2020
0A59F8,partnership,100,61,10/12/2020
0BD4E8,business-contract,100,69,10/12/2020
0F2BC9,government-contract,100,69,10/12/2020
168A5D,executive-appointment,100,54,10/12/2020
18D9FA,fundraising,100,64,10/12/2020
1921DD,regulatory-product-approval-granted,100,81,10/12/2020
1A6A94,executive-appointment,100,54,10/12/2020
1AB023,partnership,100,61,10/12/2020
1AB023,partnership,100,61,10/12/2020
1AB023,partnership,100,61,10/12/2020
1AB808,fraud,100,44,10/12/2020
1AB808,legal-issues-defendant,100,22,10/12/2020
1AB808,legal-issues-defendant,100,22,10/12/2020
1AF7E2,conference-call,100,50,10/12/2020
1BDB2A,conference-call,100,50,10/12/2020
1F9D90,conference-call,100,50,10/12/2020
227D48,acquisition-acquirer,100,49,10/12/2020
249674,conference-call,100,50,10/12/2020
270305,earnings,100,50,10/12/2020
2BF36E,conference-call,100,50,10/12/2020
2DC88B,earnings,100,50,10/12/2020
366A08,conference-call,100,50,10/12/2020
371C01,conference-call,100,50,10/12/2020
37727A,executive-appointment,100,54,10/12/2020
3798B9,earnings,100,50,10/12/2020
3.88E+02,legal-issues-defendant,100,22,10/12/2020
45444E,conference-call,100,50,10/12/2020
4591D3,conference-call,100,50,10/12/2020
50070E,merger-completed,100,66,10/12/2020
519FE0,earnings,100,50,10/12/2020
543C77,clinical-trials,100,56,10/12/2020
546A27,legal-issues-defendant,100,22,10/12/2020
56765E,earnings,100,50,10/12/2020
567F3D,conference-call,100,50,10/12/2020
57634F,legal-issues-defendant,100,22,10/12/2020
5A0FF1,earnings,100,50,10/12/2020
5B7739,conference-call,100,50,10/12/2020
5BC2F4,partnership,100,61,10/12/2020
5C8D61,earnings,100,50,10/12/2020
5FDBD0,conference-call,100,50,10/12/2020
610D47,conference-call,100,50,10/12/2020
61A586,earnings,100,50,10/12/2020
61BCA7,earnings,100,50,10/12/2020
665618,conference-call,100,50,10/12/2020
66A667,business-contract,100,69,10/12/2020
66A667,business-contract,100,69,10/12/2020
6D6B40,product-release,100,64,10/12/2020
6D6B40,product-release,100,64,10/12/2020
6ED519,conference-call,100,50,10/12/2020
6F0096,conference-call,100,50,10/12/2020
6F3FA8,product-release,100,64,10/12/2020
7032D0,earnings,100,50,10/12/2020
722DE3,conference-participant,100,50,10/12/2020
7239BB,facility-open,100,65,10/12/2020
7273FF,executive-appointment,100,54,10/12/2020
73529F,conference-call,100,50,10/12/2020
747219,earnings,100,50,10/12/2020
762B8D,dividend,100,50,10/12/2020
7823A3,earnings,100,50,10/12/2020
7AB859,conference-call,100,50,10/12/2020
7C790D,conference-call,100,50,10/12/2020
7CBC40,earnings,100,50,10/12/2020
7D35D8,earnings,100,50,10/12/2020
7DC1C4,conference-participant,100,50,10/12/2020
7DD8CC,conference-call,100,50,10/12/2020
7E1D5D,executive-appointment,100,54,10/12/2020
7E62B5,conference-call,100,50,10/12/2020
82C202,acquisition-acquiree,100,76,10/12/2020
82C202,spin-off,100,58,10/12/2020
837C04,conference-call,100,50,10/12/2020
8C6C1B,facility-open,100,65,10/12/2020
8D4AE6,earnings,100,50,10/12/2020
92005C,clinical-trials-start,100,64,10/12/2020
925759,acquisition-completed-acquirer,100,49,10/12/2020
92D3A0,dividend,100,50,10/12/2020
92D757,earnings,100,50,10/12/2020
96BFF4,legal-issues-defendant,100,22,10/12/2020
96BFF4,legal-issues-defendant,100,22,10/12/2020
96BFF4,legal-issues-defendant,100,22,10/12/2020
9.86E+03,earnings,100,50,10/12/2020
99ACAD,earnings,100,50,10/12/2020
9D5D35,earnings,100,50,10/12/2020
9F5997,conference-call,100,50,10/12/2020
A6828A,earnings,100,50,10/12/2020
A6828A,earnings,100,50,10/12/2020
A6828A,earnings,100,50,10/12/2020
A6828A,earnings,100,50,10/12/2020
A80FE0,conference-call,100,50,10/12/2020
AAEE21,conference-call,100,50,10/12/2020
AD3008,earnings,100,50,10/12/2020
B1B10C,conference-call,100,50,10/12/2020
B446B8,conference-call,100,50,10/12/2020
B446B8,legal-issues-defendant,100,22,10/12/2020
B4703C,dividend-up,100,81,10/12/2020
B4C673,executive-appointment,100,54,10/12/2020
B7FA9B,conference-call,100,50,10/12/2020
C062D4,earnings-guidance,100,50,10/12/2020
C062D4,earnings-guidance,100,50,10/12/2020
C3BAE7,executive-appointment,100,54,10/12/2020
C598D7,business-contract,100,69,10/12/2020
CA212F,earnings,100,50,10/12/2020
CAC8D0,executive-appointment,100,54,10/12/2020
CDE51C,market-entry,100,57,10/12/2020
CED4D0,legal-issues-defendant,100,22,10/12/2020
D1C0B9,earnings,100,50,10/12/2020
D3C794,earnings,100,50,10/12/2020
D64EDF,donation,100,54,10/12/2020
D8F347,executive-appointment,100,54,10/12/2020
D90F43,conference-call,100,50,10/12/2020
D9B1C9,legal-issues-defendant,100,22,10/12/2020
DA91AE,award,100,58,10/12/2020
DB396B,legal-issues-defendant,100,22,10/12/2020
DC486E,earnings,100,50,10/12/2020
DC486E,earnings,100,50,10/12/2020
DD9E41,product-release,100,64,10/12/2020
E05026,earnings,100,50,10/12/2020
E1E36F,donation,100,54,10/12/2020
E21871,earnings,100,50,10/12/2020
E866D2,partnership,100,61,10/12/2020
EBC84C,earnings,100,50,10/12/2020
EC1AF3,conference-call,100,50,10/12/2020
ED7F13,earnings,100,50,10/12/2020
EF25A5,business-contract,100,69,10/12/2020
F05B1B,executive-appointment,100,54,10/12/2020
F748C7,dividend-up,100,60,10/12/2020
F85CC0,earnings,100,50,10/12/2020
F85CC0,earnings,100,50,10/12/2020
FDF28E,earnings,100,50,10/12/2020
FF6644,business-contract,100,69,10/12/2020
00326D,executive-appointment,100,54,10/13/2020
003B70,executive-appointment,100,54,10/13/2020
00D6B5,conference-call,100,50,10/13/2020
01D03F,product-release,100,64,10/13/2020
03FAA6,unit-acquisition-acquiree,100,76,10/13/2020
05AF14,unit-acquisition-acquiree,100,76,10/13/2020
61366,earnings,100,50,10/13/2020
099C88,dividend,100,50,10/13/2020
0C8D82,partnership,100,61,10/13/2020
0C8D82,unit-acquisition-acquirer,100,49,10/13/2020
0DC050,revenues,100,50,10/13/2020
0ED415,conference-call,100,50,10/13/2020
0EF1AF,product-release,100,64,10/13/2020
0F2BC9,conference-call,100,50,10/13/2020
0FDE97,conference-call,100,50,10/13/2020
131443,executive-appointment,100,54,10/13/2020
14BA06,conference-call,100,50,10/13/2020
152AB9,earnings,100,50,10/13/2020
157CC1,public-offering,100,43,10/13/2020
1748B3,conference-call,100,50,10/13/2020
17EDA5,asset-sale,100,62,10/13/2020
1834C0,conference-call,100,50,10/13/2020
1866B2,conference-call,100,50,10/13/2020
1921DD,partnership,100,61,10/13/2020
1A2D9F,earnings,100,50,10/13/2020
1AB808,legal-issues-defendant,100,22,10/13/2020
1B4F31,partnership,100,61,10/13/2020
1DF15D,conference-call,100,50,10/13/2020
1F19C8,earnings,100,50,10/13/2020
2158DF,earnings,100,50,10/13/2020
221445,conference-call,100,50,10/13/2020
228D42,partnership,100,61,10/13/2020
25102A,partnership,100,61,10/13/2020
25102A,partnership,100,61,10/13/2020
2720AB,conference-call,100,50,10/13/2020
282C18,conference-call,100,50,10/13/2020
284289,earnings,100,50,10/13/2020
2A6DBE,clinical-trials-start,100,64,10/13/2020
2C3348,earnings,100,50,10/13/2020
2E0496,partnership,100,61,10/13/2020
2E0496,partnership,100,61,10/13/2020
2E1322,earnings,100,50,10/13/2020
2E61CC,dividend,100,50,10/13/2020
2E61CC,note-sale,100,52,10/13/2020
30A565,conference-call,100,50,10/13/2020
30E01D,earnings,100,50,10/13/2020
34A959,unit-acquisition-acquiree,100,76,10/13/2020
34E9F9,conference-call,100,50,10/13/2020
37020C,earnings,100,50,10/13/2020
373B06,earnings,100,50,10/13/2020
387541,dividend,100,50,10/13/2020
3.88E+02,legal-issues-defendant,100,22,10/13/2020
389CFB,conference-call,100,50,10/13/2020
3AF7FD,conference-participant,100,50,10/13/2020
3DD5E2,public-offering,100,43,10/13/2020
3FBC9B,acquisition-completed-acquirer,100,49,10/13/2020
416C55,conference-organizer,100,57,10/13/2020
425BDC,conference-call,100,50,10/13/2020
468DD4,executive-appointment,100,54,10/13/2020
47BA98,conference-call,100,50,10/13/2020
4B5054,legal-issues-defendant,100,22,10/13/2020
4C37C5,partnership,100,61,10/13/2020
4C37C5,conference-organizer,100,57,10/13/2020
519FE0,unit-acquisition-acquirer,100,49,10/13/2020
546A9C,earnings,100,50,10/13/2020
57DDB9,conference-call,100,50,10/13/2020
58CA9A,earnings,100,50,10/13/2020
59DB8C,partnership,100,61,10/13/2020
59DB8C,sponsorship,100,57,10/13/2020
5A423F,earnings,100,50,10/13/2020
5A64D5,conference-call,100,50,10/13/2020
5B35C7,earnings-up,100,68,10/13/2020
5B35C7,earnings-up,100,68,10/13/2020
5B35C7,earnings-up,100,68,10/13/2020
5D63F1,earnings,100,50,10/13/2020
5F2FF7,earnings,100,50,10/13/2020
619882,earnings,100,50,10/13/2020
62CDDE,conference-call,100,50,10/13/2020
665440,conference-call,100,50,10/13/2020
67B052,clinical-trials-start,100,64,10/13/2020
67B052,clinical-trials-start,100,64,10/13/2020
67B923,conference-call,100,50,10/13/2020
6810DE,executive-appointment,100,54,10/13/2020
68B03F,earnings,100,50,10/13/2020
6925EB,clinical-trials-positive,100,87,10/13/2020
6B494E,dividend,100,50,10/13/2020
6C4D2F,conference-call,100,50,10/13/2020
6DBBBC,executive-appointment,100,54,10/13/2020
6.00E+19,partnership,100,61,10/13/2020
722DE3,business-contract,100,69,10/13/2020
72609A,conference-call,100,50,10/13/2020
726EEA,earnings,100,50,10/13/2020
726EEA,partnership,100,61,10/13/2020
72FCA3,executive-appointment,100,54,10/13/2020
72FCA3,executive-appointment,100,54,10/13/2020
73C9E2,partnership,100,61,10/13/2020
75768D,business-contract,100,69,10/13/2020
767F86,earnings,100,50,10/13/2020
7712CB,earnings,100,50,10/13/2020
773A17,earnings,100,50,10/13/2020
797C20,conference-call,100,50,10/13/2020
7A10FF,earnings,100,50,10/13/2020
7A51FE,conference-call,100,50,10/13/2020
7AB859,fundraising,100,64,10/13/2020
7AF5B8,business-contract,100,69,10/13/2020
7AF5B8,business-contract,100,69,10/13/2020
7CD98F,earnings,100,50,10/13/2020
7E1542,earnings,100,50,10/13/2020
7F3A5F,product-release,100,64,10/13/2020
7F3A5F,earnings,100,50,10/13/2020
8.40E+120,ipo-pricing,100,50,10/13/2020
859281,earnings,100,50,10/13/2020
85DE00,conference-call,100,50,10/13/2020
8665BA,sponsorship,100,57,10/13/2020
8802B4,conference-call,100,50,10/13/2020
8AB37F,revenue-guidance-up,100,83,10/13/2020
8AC65D,conference-call,100,50,10/13/2020
8C6C1B,facility-open,100,65,10/13/2020
8E0E32,dividend,100,50,10/13/2020
8E8E6E,product-release,100,64,10/13/2020
8E8E6E,note-sale,100,52,10/13/2020
901327,earnings,100,50,10/13/2020
92D3A0,earnings,100,50,10/13/2020
938D89,clinical-trials,100,56,10/13/2020
95DC1F,executive-appointment,100,54,10/13/2020
96BFF4,legal-issues-defendant,100,22,10/13/2020
96BFF4,legal-issues-defendant,100,22,10/13/2020
96F126,earnings,100,50,10/13/2020
9E98F2,earnings,100,50,10/13/2020
9EBAFA,dividend,100,50,10/13/2020
A017F4,legal-issues-defendant,100,22,10/13/2020
A017F4,legal-issues-defendant,100,22,10/13/2020
A017F4,legal-issues-defendant,100,22,10/13/2020
A01983,dividend,100,50,10/13/2020
A3800A,facility-open,100,65,10/13/2020
A3800A,facility-open,100,65,10/13/2020
A3AAA5,dividend,100,50,10/13/2020
A43906,unit-acquisition-acquiree,100,76,10/13/2020
A43906,unit-acquisition-acquiree,100,76,10/13/2020
A43906,unit-acquisition-acquiree,100,76,10/13/2020
A495F7,earnings,100,50,10/13/2020
A6213D,partnership,100,61,10/13/2020
A6213D,partnership,100,61,10/13/2020
A6213D,earnings,100,50,10/13/2020
A631A3,award,100,58,10/13/2020
A6828A,earnings,100,50,10/13/2020
A70BF5,earnings-guidance,100,50,10/13/2020
A761FE,product-release,100,64,10/13/2020
ABE7DC,executive-appointment,100,54,10/13/2020
AD1ACF,conference-call,100,50,10/13/2020
AD22F2,unit-acquisition-acquiree,100,76,10/13/2020
AD23DE,product-release,100,64,10/13/2020
AEF2C3,conference-call,100,50,10/13/2020
AFD1CA,conference-call,100,50,10/13/2020
AFDF2E,executive-appointment,100,54,10/13/2020
AFDF2E,earnings,100,50,10/13/2020
B13B68,conference-call,100,50,10/13/2020
B1FC3B,fundraising,100,64,10/13/2020
B446B8,legal-issues-defendant,100,22,10/13/2020
B840EF,executive-appointment,100,54,10/13/2020
B9764A,conference-call,100,50,10/13/2020
BB58FF,conference-organizer,100,57,10/13/2020
BCE9DA,earnings,100,50,10/13/2020
BCE9DA,earnings,100,50,10/13/2020
BDE867,operating-earnings,100,50,10/13/2020
BE7BA4,conference-call,100,50,10/13/2020
BEA527,earnings,100,50,10/13/2020
BEA527,earnings,100,50,10/13/2020
BF5959,business-contract,100,69,10/13/2020
BFCACF,conference-call,100,50,10/13/2020
BFE02C,conference-participant,100,50,10/13/2020
C2609A,product-release,100,64,10/13/2020
C4A912,conference-call,100,50,10/13/2020
C501B6,legal-issues-defendant,100,22,10/13/2020
C6C702,conference-call,100,50,10/13/2020
C7859D,earnings,100,50,10/13/2020
C7859D,earnings,100,50,10/13/2020
C7859D,earnings,100,50,10/13/2020
C7859D,earnings,100,50,10/13/2020
C7859D,earnings,100,50,10/13/2020
C7859D,earnings,100,50,10/13/2020
C7859D,earnings,100,50,10/13/2020
C99CC8,earnings,100,50,10/13/2020
CB22CD,conference-call,100,50,10/13/2020
CBFFDD,business-contract,100,69,10/13/2020
CDAF5B,conference-call,100,50,10/13/2020
CE1002,dividend,100,50,10/13/2020
CE1002,dividend,100,50,10/13/2020
D17C1B,product-release,100,64,10/13/2020
D17C1B,earnings,100,50,10/13/2020
D33270,product-release,100,64,10/13/2020
D3CEDF,conference-call,100,50,10/13/2020
D56E4C,facility-open,100,65,10/13/2020
D56E4C,facility-open,100,65,10/13/2020
D5AF19,earnings,100,50,10/13/2020
D78CCD,executive-appointment,100,54,10/13/2020
D8442A,product-release,100,64,10/13/2020
D8442A,product-release,100,64,10/13/2020
D8442A,product-release,100,64,10/13/2020
D8442A,product-release,100,64,10/13/2020
D8442A,product-release,100,64,10/13/2020
D9B1C9,legal-issues-defendant,100,22,10/13/2020
DB88A1,business-contract,100,69,10/13/2020
DCD97F,business-contract,100,69,10/13/2020
DCD97F,business-contract,100,69,10/13/2020
DD682D,earnings,100,50,10/13/2020
DDC415,joint-venture-terminated,100,38,10/13/2020
DDCB34,conference-call,100,50,10/13/2020
E0647D,earnings,100,50,10/13/2020
E074A0,earnings,100,50,10/13/2020
E09556,earnings,100,50,10/13/2020
E09E2B,partnership,100,61,10/13/2020
E20BFE,executive-appointment,100,54,10/13/2020
E393B0,note-sale,100,52,10/13/2020
E3A829,earnings,100,50,10/13/2020
E6E012,earnings,100,50,10/13/2020
E6E012,earnings,100,50,10/13/2020
E87676,conference-call,100,50,10/13/2020
E8A49A,earnings,100,50,10/13/2020
EB1E1A,public-offering,100,43,10/13/2020
ECE814,partnership,100,61,10/13/2020
EE74E1,earnings,100,50,10/13/2020
EF5BED,executive-appointment,100,54,10/13/2020
F3016C,earnings,100,50,10/13/2020
F4E992,dividend,100,50,10/13/2020
F5C78B,conference-call,100,50,10/13/2020
F8BA6C,conference-participant,100,50,10/13/2020
F8BDCE,earnings,100,50,10/13/2020
F92DBC,executive-appointment,100,54,10/13/2020
F93C8A,dividend,100,50,10/13/2020
F9CAF8,conference-call,100,50,10/13/2020
FA35C6,earnings,100,50,10/13/2020
FD4BBE,acquisition-completed-acquirer,100,49,10/13/2020
FD4BBE,earnings,100,50,10/13/2020
0157B1,partnership,100,61,10/14/2020
01D03F,partnership,100,61,10/14/2020
03D5F9,business-contract,100,69,10/14/2020
03D5F9,business-contract,100,69,10/14/2020
96930,conference-participant,100,50,10/14/2020
0A9D0A,earnings,100,50,10/14/2020
0AAD90,product-release,100,64,10/14/2020
0B4D10,earnings,100,50,10/14/2020
0CC62B,conference-call,100,50,10/14/2020
0E5223,conference-call,100,50,10/14/2020
0FABBD,partnership,100,61,10/14/2020
10100E,public-offering,100,43,10/14/2020
135B09,conference-call,100,50,10/14/2020
14ED2B,partnership,100,61,10/14/2020
157CC1,public-offering,100,43,10/14/2020
15B10D,conference-call,100,50,10/14/2020
16B183,conference-call,100,50,10/14/2020
180DA0,executive-appointment,100,54,10/14/2020
1921DD,product-release,100,64,10/14/2020
1921DD,partnership,100,61,10/14/2020
1AB808,legal-issues-defendant,100,22,10/14/2020
1AB808,legal-issues-defendant,100,22,10/14/2020
1D5C51,conference-call,100,50,10/14/2020
1DA44F,dividend,100,50,10/14/2020
1E04A5,product-release,100,64,10/14/2020
21245F,conference-call,100,50,10/14/2020
222BF9,earnings,100,50,10/14/2020
222BF9,executive-resignation,100,44,10/14/2020
228D42,partnership,100,61,10/14/2020
2.45E+15,earnings,100,50,10/14/2020
250BEE,conference-call,100,50,10/14/2020
2667B6,dividend,100,50,10/14/2020
27B191,partnership,100,61,10/14/2020
295F9F,conference-call,100,50,10/14/2020
2B0AF4,conference-call,100,50,10/14/2020
2CBB58,conference-call,100,50,10/14/2020
2EC172,conference-call,100,50,10/14/2020
30A565,partnership,100,61,10/14/2020
31666F,dividend,100,50,10/14/2020
317EC6,earnings,100,50,10/14/2020
317EC6,earnings,100,50,10/14/2020
317EC6,earnings,100,50,10/14/2020
32C8CD,executive-appointment,100,54,10/14/2020
32C8CD,earnings,100,50,10/14/2020
33A0F1,executive-appointment,100,54,10/14/2020
33E8C7,earnings,100,50,10/14/2020
3461CF,credit-extension-recipient,100,69,10/14/2020
3461CF,credit-rating-upgrade-rater,20,50,10/14/2020
35F4B5,conference-call,100,50,10/14/2020
3696BF,conference-call,100,50,10/14/2020
370C50,dividend,100,50,10/14/2020
370C50,executive-appointment,100,54,10/14/2020
37426C,earnings,100,50,10/14/2020
3BE00F,earnings,100,50,10/14/2020
3CCC90,partnership,100,61,10/14/2020
429BFB,earnings,100,50,10/14/2020
4398A2,regulatory-product-approval-granted,100,81,10/14/2020
45ABCC,note-sale,100,52,10/14/2020
46017C,conference-call,100,50,10/14/2020
479930,earnings,100,50,10/14/2020
4A6F00,partnership,100,61,10/14/2020
4A6F00,partnership,100,61,10/14/2020
4AC91D,product-release,100,64,10/14/2020
4AC91D,product-release,100,64,10/14/2020
4B3676,earnings,100,50,10/14/2020
4BDCA7,clinical-trials,100,56,10/14/2020
4F9926,product-release,100,64,10/14/2020
51527B,conference-call,100,50,10/14/2020
525A1C,earnings,100,50,10/14/2020
53A226,earnings,100,50,10/14/2020
55438C,business-contract,100,69,10/14/2020
57634F,legal-issues-defendant,100,22,10/14/2020
57B174,conference-call,100,50,10/14/2020
57F3DA,earnings,100,50,10/14/2020
5B6C11,note-sale,100,52,10/14/2020
5BC2F4,dividend,100,50,10/14/2020
5EAA43,business-contract,100,69,10/14/2020
5F60CE,earnings,100,50,10/14/2020
5F9CE3,award,100,58,10/14/2020
6166D1,earnings,100,50,10/14/2020
619882,investment-investor,100,55,10/14/2020
619882,investment-investor,100,55,10/14/2020
61B81B,earnings-positive,100,69,10/14/2020
61B81B,earnings-positive,100,69,10/14/2020
61B81B,earnings-positive,100,69,10/14/2020
61B81B,earnings-positive,100,69,10/14/2020
61B81B,earnings-positive,100,69,10/14/2020
61B81B,earnings-positive,100,69,10/14/2020
61B81B,earnings-positive,100,69,10/14/2020
61B81B,earnings-positive,100,69,10/14/2020
62F41C,business-combination,100,54,10/14/2020
65AB30,earnings,100,50,10/14/2020
665440,executive-appointment,100,54,10/14/2020
67B052,patient-enrollment-complete,100,64,10/14/2020
67B052,patient-enrollment-complete,100,64,10/14/2020
6A024C,ipo-completed,100,76,10/14/2020
6D3B7B,earnings,100,50,10/14/2020
6F92A9,note-sale,100,52,10/14/2020
71694D,conference-call,100,50,10/14/2020
71E2EF,earnings,100,50,10/14/2020
722D55,earnings,100,50,10/14/2020
731675,conference-call,100,50,10/14/2020
73A71F,conference-call,100,50,10/14/2020
767F86,dividend,100,50,10/14/2020
78F776,earnings,100,50,10/14/2020
790C34,earnings,100,50,10/14/2020
7A5097,conference-call,100,50,10/14/2020
7E1D5D,partnership,100,61,10/14/2020
804708,conference-call,100,50,10/14/2020
8.10E+32,partnership,100,61,10/14/2020
819492,executive-appointment,100,54,10/14/2020
81A88D,earnings,100,50,10/14/2020
8303CD,award,100,58,10/14/2020
84A6B9,earnings,100,50,10/14/2020
85DA04,earnings,100,50,10/14/2020
868808,note-sale,100,52,10/14/2020
88611B,earnings,100,50,10/14/2020
896771,conference-call,100,50,10/14/2020
8BAA15,partnership,100,61,10/14/2020
8BAA15,partnership,100,61,10/14/2020
8C6C1B,facility-open,100,65,10/14/2020
8DBE73,business-contract,100,69,10/14/2020
8FF2EF,earnings,100,50,10/14/2020
90DD65,ipo-completed,100,76,10/14/2020
92D9C9,conference-call,100,50,10/14/2020
9368BE,conference-call,100,50,10/14/2020
942165,earnings,100,50,10/14/2020
942165,dividend,100,50,10/14/2020
950AB7,earnings,100,50,10/14/2020
950CDB,executive-appointment,100,54,10/14/2020
95DC1F,partnership,100,61,10/14/2020
95DC1F,conference-call,100,50,10/14/2020
967D92,note-sale,100,52,10/14/2020
9.74E+08,earnings,100,50,10/14/2020
990AD0,earnings,100,50,10/14/2020
990AD0,earnings,100,50,10/14/2020
9.92E+94,earnings,100,50,10/14/2020
9A02C4,conference-call,100,50,10/14/2020
9C5BA5,dividend,100,50,10/14/2020
9D30A8,earnings,100,50,10/14/2020
9E0811,earnings,100,50,10/14/2020
9E575E,clinical-trials-positive,100,87,10/14/2020
9EA947,conference-call,100,50,10/14/2020
9FD2D9,conference-call,100,50,10/14/2020
A01664,acquisition-acquirer,100,49,10/14/2020
A16DEA,partnership,100,61,10/14/2020
A21649,conference-call,100,50,10/14/2020
A60354,executive-appointment,100,54,10/14/2020
A6FE1C,unit-acquisition-acquirer,100,49,10/14/2020
A7CCF0,conference-call,100,50,10/14/2020
A8AC4C,earnings,100,50,10/14/2020
AAC8B6,conference-call,100,50,10/14/2020
AAC8B6,conference-call,100,50,10/14/2020
AADE0B,conference-call,100,50,10/14/2020
AB7F05,earnings-up,100,68,10/14/2020
B1B10C,dividend-up,100,81,10/14/2020
B1FC3B,business-contract,100,69,10/14/2020
B2206F,earnings,100,50,10/14/2020
B446B8,legal-issues-defendant,100,22,10/14/2020
B4C673,partnership,100,61,10/14/2020
B5766D,executive-appointment,100,54,10/14/2020
B642E8,award,100,58,10/14/2020
B66928,business-contract,100,69,10/14/2020
B66928,business-contract,100,69,10/14/2020
B8A51F,earnings,100,50,10/14/2020
B8DD94,conference-call,100,50,10/14/2020
B8EF97,dividend,100,50,10/14/2020
B9B6B8,product-release,100,64,10/14/2020
BAD655,merger,100,66,10/14/2020
BC5680,earnings,100,50,10/14/2020
BCC13E,revenues,100,50,10/14/2020
BDD12C,earnings,100,50,10/14/2020
BE7BA4,executive-appointment,100,54,10/14/2020
BEA527,executive-appointment,100,54,10/14/2020
BFE02C,partnership,100,61,10/14/2020
C11C46,earnings,100,50,10/14/2020
C32A39,dividend,100,50,10/14/2020
C4C77F,executive-resignation,100,44,10/14/2020
C4C77F,legal-issues-defendant,100,22,10/14/2020
C5C137,executive-appointment,100,54,10/14/2020
C7FC95,partnership,100,61,10/14/2020
C8257F,executive-resignation,100,44,10/14/2020
C83B88,investment-investor,100,55,10/14/2020
C8A248,dividend,100,50,10/14/2020
C8FAC7,partnership,100,61,10/14/2020
C9B932,earnings,100,50,10/14/2020
CB6A9C,conference-call,100,50,10/14/2020
CB7AB2,conference-call,100,50,10/14/2020
CB9E13,conference-call,100,50,10/14/2020
CD051C,executive-appointment,100,54,10/14/2020
CDAA0E,partnership,100,61,10/14/2020
CDEDFE,legal-issues-defendant,100,22,10/14/2020
CE5664,earnings-guidance-up,100,83,10/14/2020
CE96E7,earnings,100,50,10/14/2020
CFF15D,dividend,100,50,10/14/2020
D27FAB,conference-call,100,50,10/14/2020
D3FD6D,conference-call,100,50,10/14/2020
D56E4C,conference-call,100,50,10/14/2020
D56E4C,conference-call,100,50,10/14/2020
D64EDF,earnings,100,50,10/14/2020
D78BF1,executive-appointment,100,54,10/14/2020
D7918D,earnings,100,50,10/14/2020
D8442A,product-release,100,64,10/14/2020
D90F43,legal-issues-defendant,100,22,10/14/2020
D9164D,earnings,100,50,10/14/2020
D93A25,earnings,100,50,10/14/2020
D9B1C9,legal-issues-defendant,100,22,10/14/2020
DA199F,board-meeting,100,51,10/14/2020
DA199F,ipo-completed,100,76,10/14/2020
DA48E4,product-release,100,64,10/14/2020
DA9443,patent-awarded,100,72,10/14/2020
DD1BA1,partnership,100,61,10/14/2020
DDC415,executive-appointment,100,54,10/14/2020
E16133,conference-call,100,50,10/14/2020
E28D9C,conference-call,100,50,10/14/2020
E5D914,earnings,100,50,10/14/2020
E5D914,earnings,100,50,10/14/2020
E68733,partnership,100,61,10/14/2020
E68733,partnership,100,61,10/14/2020
E754F0,earnings,100,50,10/14/2020
E8846E,earnings,100,50,10/14/2020
E93A40,earnings,100,50,10/14/2020
EB7FBF,dividend,100,50,10/14/2020
ECE19E,ipo-completed,100,76,10/14/2020
ED2A5E,conference-call,100,50,10/14/2020
F02D0A,earnings,100,50,10/14/2020
F0B2B5,partnership,100,61,10/14/2020
F18844,legal-issues-defendant,100,22,10/14/2020
F30508,legal-issues-defendant,100,22,10/14/2020
F30508,legal-issues-defendant,100,22,10/14/2020
F30508,legal-issues-defendant,100,22,10/14/2020
F46EC9,earnings,100,50,10/14/2020
F6E248,earnings,100,50,10/14/2020
F7ADEB,business-contract,100,69,10/14/2020
F88A04,earnings,100,50,10/14/2020
F93C8A,executive-appointment,100,54,10/14/2020
FAEABE,earnings-per-share-positive,100,69,10/14/2020
FAEABE,earnings-per-share,100,50,10/14/2020
FAEABE,earnings-per-share,100,50,10/14/2020
FB7724,earnings,100,50,10/14/2020
FD9A97,earnings,100,50,10/14/2020
FF227B,clinical-trials,100,56,10/14/2020
FFAB4A,earnings,100,50,10/14/2020
00326E,conference-call,100,50,10/15/2020
0157B1,conference-call,100,50,10/15/2020
0358AF,earnings,100,50,10/15/2020
03B431,conference-call,100,50,10/15/2020
03F5A4,earnings-positive,100,69,10/15/2020
03FB17,earnings,100,50,10/15/2020
04EB2F,earnings,100,50,10/15/2020
07C907,earnings,100,50,10/15/2020
07C907,earnings,100,50,10/15/2020
07C907,earnings,100,50,10/15/2020
07CA6A,executive-appointment,100,54,10/15/2020
07CA6A,executive-appointment,100,54,10/15/2020
083F72,dividend,100,50,10/15/2020
09062E,earnings,100,50,10/15/2020
095A04,partnership,100,61,10/15/2020
0A0D9E,conference-call,100,50,10/15/2020
0BB9E5,earnings,100,50,10/15/2020
0FABBD,conference-call,100,50,10/15/2020
10100E,public-offering,100,43,10/15/2020
15901B,fraud-defendant,100,20,10/15/2020
1782D5,conference-call,100,50,10/15/2020
180DA0,conference-call,100,50,10/15/2020
182BE7,earnings,100,50,10/15/2020
18EC17,earnings,100,50,10/15/2020
18EC17,earnings,100,50,10/15/2020
18EC17,earnings,100,50,10/15/2020
18EC17,earnings,100,50,10/15/2020
1A3E1B,earnings,100,50,10/15/2020
1A3E1B,earnings,100,50,10/15/2020
1A3E1B,earnings,100,50,10/15/2020
1A3E1B,earnings,100,50,10/15/2020
1A3E1B,earnings,100,50,10/15/2020
1A3E1B,earnings,100,50,10/15/2020
1A3E1B,earnings,100,50,10/15/2020
1A3E1B,earnings,100,50,10/15/2020
1A3E1B,earnings,100,50,10/15/2020
1A3E1B,earnings,100,50,10/15/2020
1A3E1B,earnings,100,50,10/15/2020
1A3E1B,earnings,100,50,10/15/2020
1A3E1B,earnings,100,50,10/15/2020
1A3E1B,earnings,100,50,10/15/2020
1A3E1B,earnings,100,50,10/15/2020
1A3E1B,earnings,100,50,10/15/2020
1A6A94,dividend,100,50,10/15/2020
1AB808,legal-issues-defendant,100,22,10/15/2020
1B4F31,earnings,100,50,10/15/2020
1BC12C,conference-call,100,50,10/15/2020
1CD09C,partnership,100,61,10/15/2020
1DA44F,conference-organizer,100,57,10/15/2020
1DEBBE,earnings,100,50,10/15/2020
1E1125,conference-organizer,100,57,10/15/2020
1E9A6D,dividend,100,50,10/15/2020
1FAF22,conference-participant,100,50,10/15/2020
2158DF,partnership,100,61,10/15/2020
219B21,conference-call,100,50,10/15/2020
253B2F,conference-call,100,50,10/15/2020
26CC63,dividend,100,50,10/15/2020
270B78,earnings,100,50,10/15/2020
27C10F,earnings,100,50,10/15/2020
28F905,earnings,100,50,10/15/2020
2950FF,earnings,100,50,10/15/2020
2950FF,earnings,100,50,10/15/2020
29CEBF,conference-call,100,50,10/15/2020
2A1009,conference-call,100,50,10/15/2020
2A6DBE,legal-issues-defendant,100,22,10/15/2020
2B0AF4,patent-awarded,100,72,10/15/2020
2BBE62,partnership,100,61,10/15/2020
2D2D43,regulatory-investigation,100,22,10/15/2020
2EB04E,earnings,100,50,10/15/2020
314D88,earnings,100,50,10/15/2020
328250,conference-call,100,50,10/15/2020
32CB22,conference-call,100,50,10/15/2020
33A0F1,patent-awarded,100,72,10/15/2020
343996,dividend,100,50,10/15/2020
343996,dividend,100,50,10/15/2020
36E479,clinical-trials-positive,100,87,10/15/2020
370C50,product-price-raise,100,57,10/15/2020
372037,conference-call,100,50,10/15/2020
39FB23,dividend,100,50,10/15/2020
3ACF46,earnings,100,50,10/15/2020
3BC360,conference-call,100,50,10/15/2020
3C3B6B,earnings,100,50,10/15/2020
3C7F5F,partnership,100,61,10/15/2020
3CBA2A,conference-call,100,50,10/15/2020
3DCECC,conference-call,100,50,10/15/2020
3E149C,partnership,100,61,10/15/2020
3F6A9C,conference-call,100,50,10/15/2020
3FBC9B,earnings,100,50,10/15/2020
407878,product-release,100,64,10/15/2020
408380,earnings,100,50,10/15/2020
416291,conference-call,100,50,10/15/2020
422CE3,product-release,100,64,10/15/2020
427F32,conference-call,100,50,10/15/2020
448215,earnings,100,50,10/15/2020
47FCF2,earnings,100,50,10/15/2020
4806CE,conference-call,100,50,10/15/2020
48F795,earnings,100,50,10/15/2020
4B3676,executive-appointment,100,54,10/15/2020
4C5CC9,conference-call,100,50,10/15/2020
4D203E,earnings,100,50,10/15/2020
4D203E,earnings,100,50,10/15/2020
4E7C1F,business-combination,100,54,10/15/2020
4EC4C1,conference-call,100,50,10/15/2020
50070E,price-target-upgrade-rater,20,50,10/15/2020
513A86,earnings,100,50,10/15/2020
52015A,conference-call,100,50,10/15/2020
5225A4,conference-organizer,100,57,10/15/2020
52FB2F,earnings,100,50,10/15/2020
545272,conference-call,100,50,10/15/2020
5546DA,conference-call,100,50,10/15/2020
55ACCB,earnings,100,50,10/15/2020
55C9B5,partnership,100,61,10/15/2020
594402,product-release,100,64,10/15/2020
594402,product-release,100,64,10/15/2020
5A64D5,dividend,100,50,10/15/2020
5BFE94,dividend,100,50,10/15/2020
5CCDAD,acquisition-acquirer,100,49,10/15/2020
5D0337,earnings,100,50,10/15/2020
5D16CF,conference-call,100,50,10/15/2020
5D43A7,dividend,100,50,10/15/2020
5D63F1,partnership,100,61,10/15/2020
5DAF89,conference-call,100,50,10/15/2020
5F3E74,earnings,100,50,10/15/2020
601785,dividend,100,50,10/15/2020
619882,partnership,100,61,10/15/2020
619882,dividend,100,50,10/15/2020
622037,earnings,100,50,10/15/2020
6284B5,conference-call,100,50,10/15/2020
64FF65,conference-call,100,50,10/15/2020
66ECFD,award,100,58,10/15/2020
69345C,earnings,100,50,10/15/2020
693ECD,earnings,100,50,10/15/2020
693ECD,earnings,100,50,10/15/2020
6A01DF,partnership,100,61,10/15/2020
6B0784,conference-call,100,50,10/15/2020
6B0784,conference-call,100,50,10/15/2020
6BC6F9,executive-appointment,100,54,10/15/2020
6D1ADF,conference-call,100,50,10/15/2020
6D3F35,conference-call,100,50,10/15/2020
6D6B40,product-release,100,64,10/15/2020
6DC1D7,conference-call,100,50,10/15/2020
6F3FA8,conference-call,100,50,10/15/2020
6F6559,dividend,100,50,10/15/2020
717DB4,earnings,100,50,10/15/2020
726DDF,conference-call,100,50,10/15/2020
72C2CE,conference-call,100,50,10/15/2020
73C521,dividend,100,50,10/15/2020
762B8D,earnings,100,50,10/15/2020
76B926,conference-call,100,50,10/15/2020
76DD0C,clinical-trials,100,56,10/15/2020
7710F3,conference-call,100,50,10/15/2020
787D14,stake-acquirer,100,48,10/15/2020
791D59,earnings,100,50,10/15/2020
79340A,embargo-lifted-issuer,100,56,10/15/2020
7A2A49,conference-call,100,50,10/15/2020
7ACD98,earnings,100,50,10/15/2020
7BAAE7,dividend,100,50,10/15/2020
7BAAE7,earnings,100,50,10/15/2020
7DC1C4,earnings,100,50,10/15/2020
81222C,earnings,100,50,10/15/2020
82B57E,earnings,100,50,10/15/2020
838ADD,earnings,100,50,10/15/2020
855DF7,dividend,100,50,10/15/2020
860AB6,conference-call,100,50,10/15/2020
86A1B9,earnings,100,50,10/15/2020
877C0C,earnings,100,50,10/15/2020
89B2E7,earnings,100,50,10/15/2020
8A0368,partnership,100,61,10/15/2020
8C6C1B,facility-open,100,65,10/15/2020
8D9993,conference-call,100,50,10/15/2020
8F8F2F,conference-call,100,50,10/15/2020
9196A2,earnings,100,50,10/15/2020
9196A2,earnings,100,50,10/15/2020
9196A2,earnings,100,50,10/15/2020
9196A2,earnings,100,50,10/15/2020
9196A2,earnings,100,50,10/15/2020
93965C,earnings,100,50,10/15/2020
945DE6,dividend,100,50,10/15/2020
9470CC,earnings,100,50,10/15/2020
98CEBB,earnings,100,50,10/15/2020
9EBAFA,executive-appointment,100,54,10/15/2020
9FF5F1,earnings,100,50,10/15/2020
A49498,conference-call,100,50,10/15/2020
A4D173,conference-call,100,50,10/15/2020
A4D173,conference-call,100,50,10/15/2020
A52533,earnings,100,50,10/15/2020
A9ED24,conference-call,100,50,10/15/2020
AA847A,conference-call,100,50,10/15/2020
ABB493,partnership,100,61,10/15/2020
ABB493,partnership,100,61,10/15/2020
ACC7D3,earnings,100,50,10/15/2020
AD22F2,executive-appointment,100,54,10/15/2020
AE3113,earnings,100,50,10/15/2020
AFBEB4,earnings,100,50,10/15/2020
AFD7DD,conference-call,100,50,10/15/2020
B09B1F,conference-call,100,50,10/15/2020
B1FC3B,award,100,58,10/15/2020
B2AA0A,dividend-guidance,100,50,10/15/2020
B2D799,legal-issues-defendant,100,22,10/15/2020
B2DAF6,earnings,100,50,10/15/2020
B446B8,legal-issues-defendant,100,22,10/15/2020
B5BA39,earnings,100,50,10/15/2020
B642E8,earnings,100,50,10/15/2020
B9764A,government-contract,100,69,10/15/2020
BB127B,acquisition-acquiree,100,76,10/15/2020
BB127B,acquisition-acquiree,100,76,10/15/2020
BCC55F,conference-call,100,50,10/15/2020
BD8517,earnings,100,50,10/15/2020
BEA527,executive-appointment,100,54,10/15/2020
C0030A,earnings,100,50,10/15/2020
C3BAE7,partnership,100,61,10/15/2020
C3CF29,earnings,100,50,10/15/2020
C4C77F,dividend,100,50,10/15/2020
C4FBDC,conference-call,100,50,10/15/2020
C66A8C,earnings,100,50,10/15/2020
C7FC95,partnership,100,61,10/15/2020
C83B88,product-release,100,64,10/15/2020
CA3CB9,earnings,100,50,10/15/2020
CAB222,conference-call,100,50,10/15/2020
CCB623,regulatory-product-application,100,69,10/15/2020
CDC217,conference-participant,100,50,10/15/2020
D04D9F,conference-call,100,50,10/15/2020
D33270,product-release,100,64,10/15/2020
D33D8C,earnings-per-share-positive,100,69,10/15/2020
D33D8C,earnings-per-share-positive,100,69,10/15/2020
D33D8C,earnings-per-share-positive,100,69,10/15/2020
D33D8C,earnings-per-share-positive,100,69,10/15/2020
D33D8C,earnings-per-share-positive,100,69,10/15/2020
D33D8C,earnings-per-share-positive,100,69,10/15/2020
D33D8C,earnings-per-share-positive,100,69,10/15/2020
D33D8C,earnings-per-share-positive,100,69,10/15/2020
D3F64D,conference-call,100,50,10/15/2020
D518D8,conference-call,100,50,10/15/2020
D57D99,earnings,100,50,10/15/2020
D9B1C9,legal-issues-defendant,100,22,10/15/2020
DB06B0,earnings,100,50,10/15/2020
DB396B,conference-call,100,50,10/15/2020
DC0998,executive-appointment,100,54,10/15/2020
DF6FDD,earnings,100,50,10/15/2020
E19A99,earnings,100,50,10/15/2020
E28D9C,joint-venture,100,62,10/15/2020
E30A8F,award,100,58,10/15/2020
E38906,investment-recipient,100,73,10/15/2020
E49AA3,earnings,100,50,10/15/2020
E592F0,partnership,100,61,10/15/2020
E6D89E,product-release,100,64,10/15/2020
E84500,dividend,100,50,10/15/2020
E90C84,conference-call,100,50,10/15/2020
EAEBF3,dividend,100,50,10/15/2020
EB5E78,conference-call,100,50,10/15/2020
EB7FBF,earnings,100,50,10/15/2020
EC70EC,earnings,100,50,10/15/2020
ED9C04,earnings,100,50,10/15/2020
EEA6B3,dividend,100,50,10/15/2020
EF5BED,executive-appointment,100,54,10/15/2020
EFA7B2,earnings,100,50,10/15/2020
EFD406,conference-call,100,50,10/15/2020
F18844,executive-appointment,100,54,10/15/2020
F1EB39,partnership,100,61,10/15/2020
F2BC3D,earnings,100,50,10/15/2020
F32F88,conference-call,100,50,10/15/2020
F46EC9,dividend,100,50,10/15/2020
F48947,revenue-guidance,100,50,10/15/2020
F4F46F,conference-call,100,50,10/15/2020
F5349B,unit-acquisition-acquirer,100,49,10/15/2020
F569FD,conference-participant,100,50,10/15/2020
F7D8AE,executive-appointment,100,54,10/15/2020
F8DE55,earnings,100,50,10/15/2020
FA36A4,dividend,100,50,10/15/2020
FA918D,conference-call,100,50,10/15/2020
FACF19,earnings,100,50,10/15/2020
FB728F,dividend,100,50,10/15/2020
FDF799,earnings,100,50,10/15/2020
FF6644,business-contract,100,69,10/15/2020
FF6644,unit-acquisition-acquirer,100,49,10/15/2020
FF6644,unit-acquisition-acquirer,100,49,10/15/2020
0157B1,partnership,100,61,10/16/2020
0157B1,partnership,100,61,10/16/2020
0157B1,partnership,100,61,10/16/2020
0157B1,facility-open,100,65,10/16/2020
03596A,unit-acquisition-acquiree,100,76,10/16/2020
03D5F9,earnings,100,50,10/16/2020
061A3B,earnings,100,50,10/16/2020
0BC29E,earnings,100,50,10/16/2020
0D26E0,dividend,100,50,10/16/2020
0F91FC,conference-call,100,50,10/16/2020
10943B,conference-call,100,50,10/16/2020
152B9E,conference-call,100,50,10/16/2020
157CC1,public-offering,100,43,10/16/2020
168A5D,award,100,58,10/16/2020
18D9FA,fundraising,100,64,10/16/2020
19CAC7,earnings,100,50,10/16/2020
19CAC7,earnings,100,50,10/16/2020
1AB808,legal-issues-defendant,100,22,10/16/2020
1E9A6D,partnership,100,61,10/16/2020
1E9A6D,partnership,100,61,10/16/2020
1E9A6D,earnings,100,50,10/16/2020
1E9A6D,legal-issues-defendant,100,22,10/16/2020
1E9A6D,acquisition-regulatory-scrutiny-acquiree,100,38,10/16/2020
1F43A1,earnings,100,50,10/16/2020
24C48B,conference-call,100,50,10/16/2020
26F31D,earnings,100,50,10/16/2020
270305,partnership,100,61,10/16/2020
270305,partnership,100,61,10/16/2020
270305,earnings,100,50,10/16/2020
270305,earnings,100,50,10/16/2020
270305,earnings,100,50,10/16/2020
270305,earnings,100,50,10/16/2020
270305,earnings,100,50,10/16/2020
2A6DBE,legal-issues-defendant,100,22,10/16/2020
2C7505,regulatory-product-review-positive,100,73,10/16/2020
2CB4C9,dividend,100,50,10/16/2020
2DDB22,earnings-guidance,100,50,10/16/2020
34A959,earnings,100,50,10/16/2020
355B19,dividend,100,50,10/16/2020
36529A,executive-resignation,100,44,10/16/2020
39FB23,executive-appointment,100,54,10/16/2020
3A3447,earnings,100,50,10/16/2020
3B20AB,earnings,100,50,10/16/2020
41EC04,conference-call,100,50,10/16/2020
44A4FC,earnings,100,50,10/16/2020
45ABCC,note-sale,100,52,10/16/2020
4B5054,legal-issues-defendant,100,22,10/16/2020
4B5054,legal-issues-defendant,100,22,10/16/2020
4EEE7E,earnings,100,50,10/16/2020
51F541,conference-call,100,50,10/16/2020
589803,regulatory-product-approval-granted,100,81,10/16/2020
589803,regulatory-product-approval-granted,100,81,10/16/2020
589803,regulatory-product-approval-granted,100,81,10/16/2020
589803,regulatory-product-approval-granted,100,81,10/16/2020
589803,regulatory-product-approval-granted,100,81,10/16/2020
589803,regulatory-product-approval-granted,100,81,10/16/2020
5BC2F4,earnings,100,50,10/16/2020
5BFE94,earnings,100,50,10/16/2020
6166D1,dividend,100,50,10/16/2020
647143,dividend,100,50,10/16/2020
665440,public-offering,100,43,10/16/2020
665440,public-offering,100,43,10/16/2020
665440,public-offering,100,43,10/16/2020
69CE71,partnership,100,61,10/16/2020
6CDFC6,conference-call,100,50,10/16/2020
6D3B7B,earnings,100,50,10/16/2020
726EEA,business-contract,100,69,10/16/2020
72DF04,earnings,100,50,10/16/2020
75D689,ipo-pricing,100,50,10/16/2020
7732C2,ipo-pricing,100,50,10/16/2020
7AC86E,earnings,100,50,10/16/2020
7E62B5,conference-call,100,50,10/16/2020
893904,legal-issues-defendant,100,22,10/16/2020
89FBB1,conference-call,100,50,10/16/2020
8A8E41,unit-acquisition-acquiree,100,76,10/16/2020
8B9B3B,regulatory-product-review-positive,100,73,10/16/2020
8C6C1B,facility-open,100,65,10/16/2020
8D4AE6,executive-appointment,100,54,10/16/2020
911ACB,earnings,100,50,10/16/2020
911ACB,earnings,100,50,10/16/2020
918D6D,clinical-trials-start,100,64,10/16/2020
966DBE,earnings,100,50,10/16/2020
979451,earnings,100,50,10/16/2020
99028D,conference-call,100,50,10/16/2020
9C8BC3,dividend,100,50,10/16/2020
9DDE1B,conference-call,100,50,10/16/2020
9F5CBB,conference-call,100,50,10/16/2020
A03EE1,earnings,100,50,10/16/2020
A1DBF0,ipo-pricing,100,50,10/16/2020
A23747,earnings,100,50,10/16/2020
A63387,business-contract,100,69,10/16/2020
A6FE1C,unit-acquisition-acquirer,100,49,10/16/2020
A6FE1C,unit-acquisition-acquirer,100,49,10/16/2020
A74F6F,conference-call,100,50,10/16/2020
AFF7B4,dividend,100,50,10/16/2020
B13B68,executive-appointment,100,54,10/16/2020
B446B8,legal-issues-defendant,100,22,10/16/2020
B7BDA3,conference-call,100,50,10/16/2020
BEB756,dividend,100,50,10/16/2020
BEB756,earnings,100,50,10/16/2020
BFE02C,earnings-positive,100,69,10/16/2020
C501B6,legal-issues-defendant,100,22,10/16/2020
C62AA4,conference-call,100,50,10/16/2020
CF6A5A,executive-appointment,100,54,10/16/2020
CF9054,earnings,100,50,10/16/2020
D13F1C,earnings,100,50,10/16/2020
D721C6,earnings-up,100,61,10/16/2020
D78CCD,earnings,100,50,10/16/2020
D78CCD,earnings,100,50,10/16/2020
D78CCD,earnings,100,50,10/16/2020
D78CCD,earnings,100,50,10/16/2020
D78CCD,earnings,100,50,10/16/2020
D78CCD,earnings,100,50,10/16/2020
D9B1C9,legal-issues-defendant,100,22,10/16/2020
D9B1C9,legal-issues-defendant,100,22,10/16/2020
DA0A9E,dividend,100,50,10/16/2020
E2F66E,conference-call,100,50,10/16/2020
E8D221,dividend,100,50,10/16/2020
EB6965,conference-call,100,50,10/16/2020
EDF5CA,conference-call,100,50,10/16/2020
EF5BED,earnings-positive,100,69,10/16/2020
EF5BED,earnings,100,50,10/16/2020
EF5BED,earnings,100,50,10/16/2020
EF5BED,earnings,100,50,10/16/2020
EF5BED,dividend,100,50,10/16/2020
F1529C,acquisition-acquirer,100,49,10/16/2020
F1529C,acquisition-acquirer,100,49,10/16/2020
F1529C,acquisition-acquirer,100,49,10/16/2020
F1529C,acquisition-acquirer,100,49,10/16/2020
F6E248,regulatory-product-review-positive,100,73,10/16/2020
F6FA6A,conference-call,100,50,10/16/2020
F82D37,earnings,100,50,10/16/2020
F82D37,earnings,100,50,10/16/2020
FD39EB,earnings,100,50,10/16/2020
FDF28E,executive-appointment,100,54,10/16/2020
FF6644,conference-call,100,50,10/16/2020
131443,product-release,100,64,10/18/2020
1AB808,legal-issues-defendant,100,22,10/18/2020
698FF9,partnership,100,61,10/18/2020
698FF9,partnership,100,61,10/18/2020
698FF9,partnership,100,61,10/18/2020
B446B8,legal-issues-defendant,100,22,10/18/2020
D9B1C9,legal-issues-defendant,100,22,10/18/2020
E68733,business-contract,100,69,10/18/2020
E68733,business-contract,100,69,10/18/2020
13528,partnership,100,61,10/19/2020
033B58,executive-appointment,100,54,10/19/2020
03596A,unit-acquisition-completed-acquiree,100,67,10/19/2020
03596A,headquarters-change,100,50,10/19/2020
03B8CF,partnership,100,61,10/19/2020
040DBB,earnings,100,50,10/19/2020
43862,partnership,100,61,10/19/2020
58828,operating-earnings,100,50,10/19/2020
06EF42,unit-acquisition-acquirer,100,49,10/19/2020
95294,earnings,100,50,10/19/2020
0CC01F,earnings,100,50,10/19/2020
0E6027,executive-appointment,100,54,10/19/2020
10100E,earnings,100,50,10/19/2020
102F04,business-contract,100,69,10/19/2020
147C38,dividend,100,50,10/19/2020
147C38,product-release,100,64,10/19/2020
15789A,earnings,100,50,10/19/2020
168A5D,product-release,100,64,10/19/2020
1748B3,earnings,100,50,10/19/2020
1748B3,earnings,100,50,10/19/2020
1748B3,earnings,100,50,10/19/2020
1748B3,earnings,100,50,10/19/2020
1748B3,earnings,100,50,10/19/2020
1748B3,earnings,100,50,10/19/2020
1748B3,earnings,100,50,10/19/2020
1880C5,patent-filing,100,64,10/19/2020
19BF16,unit-acquisition-acquiree,100,76,10/19/2020
19BF16,unit-acquisition-acquiree,100,76,10/19/2020
19BF16,acquisition-acquiree,100,76,10/19/2020
19CAC7,executive-appointment,100,54,10/19/2020
1AB808,legal-issues-defendant,100,22,10/19/2020
1AB808,legal-issues-defendant,100,22,10/19/2020
1CD4B5,credit-extension-provider,100,57,10/19/2020
1E9A6D,merger,100,66,10/19/2020
20BEEA,conference-call,100,50,10/19/2020
20BEEA,earnings,100,50,10/19/2020
20BEEA,earnings,100,50,10/19/2020
20BEEA,earnings,100,50,10/19/2020
20F5E2,earnings,100,50,10/19/2020
20F5E2,earnings,100,50,10/19/2020
20F5E2,earnings,100,50,10/19/2020
20F5E2,earnings,100,50,10/19/2020
221AD7,legal-issues-plaintiff,100,44,10/19/2020
228D42,partnership,100,61,10/19/2020
228D42,partnership,100,61,10/19/2020
228D42,partnership,100,61,10/19/2020
241AF7,conference-call,100,50,10/19/2020
2491BC,partnership,100,61,10/19/2020
264EB3,executive-appointment,100,54,10/19/2020
282C18,earnings,100,50,10/19/2020
297DA8,earnings,100,50,10/19/2020
2A17B1,conference-call,100,50,10/19/2020
2A6DBE,legal-issues-defendant,100,22,10/19/2020
2B49F4,earnings,100,50,10/19/2020
2B49F4,earnings,100,50,10/19/2020
2B49F4,earnings,100,50,10/19/2020
2B49F4,earnings,100,50,10/19/2020
2B49F4,earnings,100,50,10/19/2020
2E902B,revenues,100,50,10/19/2020
2E902B,earnings,100,50,10/19/2020
2E902B,earnings,100,50,10/19/2020
2E902B,earnings,100,50,10/19/2020
2E902B,earnings,100,50,10/19/2020
2F5256,award,100,58,10/19/2020
2F94A5,executive-appointment,100,54,10/19/2020
2F960F,earnings,100,50,10/19/2020
309922,earnings,100,50,10/19/2020
315EB0,partnership,100,61,10/19/2020
317EC6,public-offering,100,43,10/19/2020
31803E,earnings,100,50,10/19/2020
34B411,earnings,100,50,10/19/2020
34B97A,conference-call,100,50,10/19/2020
3798B9,partnership,100,61,10/19/2020
382EAE,note-sale,100,52,10/19/2020
38FB49,earnings,100,50,10/19/2020
38FB49,earnings,100,50,10/19/2020
38FB49,earnings,100,50,10/19/2020
38FB49,earnings,100,50,10/19/2020
38FB49,earnings,100,50,10/19/2020
38FB49,earnings,100,50,10/19/2020
38FB49,earnings,100,50,10/19/2020
38FB49,earnings,100,50,10/19/2020
39FB23,earnings-up,100,68,10/19/2020
39FB23,earnings,100,50,10/19/2020
39FB23,earnings,100,50,10/19/2020
3BBD10,earnings,100,50,10/19/2020
3D9999,partnership,100,61,10/19/2020
3E39A5,earnings,100,50,10/19/2020
407878,conference-call,100,50,10/19/2020
416C55,executive-appointment,100,54,10/19/2020
42AABD,conference-call,100,50,10/19/2020
435ACE,earnings,100,50,10/19/2020
4455C4,conference-call,100,50,10/19/2020
4595EF,conference-call,100,50,10/19/2020
494EB9,earnings,100,50,10/19/2020
4A6F00,partnership,100,61,10/19/2020
4B5054,legal-issues-defendant,100,22,10/19/2020
4C37C5,partnership,100,61,10/19/2020
4C37C5,dividend,100,50,10/19/2020
4C6C63,acquisition-completed-acquirer,100,49,10/19/2020
4C6C63,acquisition-completed-acquirer,100,49,10/19/2020
4C6C63,unit-acquisition-acquirer,100,49,10/19/2020
4D371E,earnings,100,50,10/19/2020
4F71DC,public-offering,100,43,10/19/2020
520632,executive-appointment,100,54,10/19/2020
524CE4,patent-awarded,100,72,10/19/2020
54B889,conference-call,100,50,10/19/2020
57634F,legal-issues-defendant,100,22,10/19/2020
57CAAB,earnings,100,50,10/19/2020
57DDB9,note-sale,100,52,10/19/2020
5876DC,dividend,100,50,10/19/2020
589846,partnership,100,61,10/19/2020
59B229,award,100,58,10/19/2020
5CCDAD,earnings,100,50,10/19/2020
5D1329,clinical-trials-start,100,64,10/19/2020
5E7E82,partnership,100,61,10/19/2020
5EAA43,conference-call,100,50,10/19/2020
5F3D91,executive-appointment,100,54,10/19/2020
5FE4B6,conference-call,100,50,10/19/2020
60DD84,conference-call,100,50,10/19/2020
619882,legal-issues-defendant,100,22,10/19/2020
61E975,executive-appointment,100,54,10/19/2020
622DBE,conference-call,100,50,10/19/2020
62EFEE,earnings,100,50,10/19/2020
647143,earnings-up,100,68,10/19/2020
647143,earnings-up,100,68,10/19/2020
665D7D,legal-issues-defendant,100,22,10/19/2020
66667F,acquisition-completed-acquirer,100,49,10/19/2020
69CE71,hirings,100,65,10/19/2020
6A01DF,earnings,100,50,10/19/2020
6ABCB8,earnings,100,50,10/19/2020
6E8349,earnings,100,50,10/19/2020
6F39FC,conference-call,100,50,10/19/2020
713810,partnership,100,61,10/19/2020
71E2EF,executive-appointment,100,54,10/19/2020
75D689,ipo-pricing,100,50,10/19/2020
769F40,earnings,100,50,10/19/2020
7C75FD,conference-call,100,50,10/19/2020
7D5384,executive-appointment,100,54,10/19/2020
7F0372,earnings,100,50,10/19/2020
7F2922,earnings,100,50,10/19/2020
7F3669,earnings,100,50,10/19/2020
82C202,earnings,100,50,10/19/2020
838ADD,dividend,100,50,10/19/2020
873DB9,trading-halt,100,43,10/19/2020
87B81A,earnings,100,50,10/19/2020
881190,earnings,100,50,10/19/2020
881190,earnings,100,50,10/19/2020
881190,earnings,100,50,10/19/2020
881190,earnings,100,50,10/19/2020
88193E,conference-call,100,50,10/19/2020
893904,legal-issues-defendant,100,22,10/19/2020
893904,legal-issues-defendant,100,22,10/19/2020
8A8E41,acquisition-acquirer,100,49,10/19/2020
8A8E41,partnership,100,61,10/19/2020
8AB85C,clinical-trials-positive,100,87,10/19/2020
8AC740,conference-call,100,50,10/19/2020
8C6C1B,facility-open,100,65,10/19/2020
8D4486,earnings,100,50,10/19/2020
8D4486,earnings,100,50,10/19/2020
8D4486,earnings,100,50,10/19/2020
8D4486,earnings,100,50,10/19/2020
8D4486,earnings,100,50,10/19/2020
8D9993,dividend,100,50,10/19/2020
900356,conference-call,100,50,10/19/2020
903AB4,earnings,100,50,10/19/2020
9087B9,conference-call,100,50,10/19/2020
92B047,earnings,100,50,10/19/2020
93633B,earnings,100,50,10/19/2020
93633B,earnings,100,50,10/19/2020
93633B,earnings,100,50,10/19/2020
93633B,earnings,100,50,10/19/2020
93633B,earnings,100,50,10/19/2020
94983E,product-release,100,64,10/19/2020
954A47,earnings-positive,100,69,10/19/2020
96B4FF,executive-appointment,100,54,10/19/2020
97B027,dividend,100,50,10/19/2020
989E2F,buybacks,100,74,10/19/2020
9B0C9C,earnings,100,50,10/19/2020
9B5968,executive-appointment,100,54,10/19/2020
9D4EC7,conference-call,100,50,10/19/2020
9D4EC7,conference-call,100,50,10/19/2020
9D5FA4,earnings,100,50,10/19/2020
9E91C6,executive-appointment,100,54,10/19/2020
A01200,executive-appointment,100,54,10/19/2020
A60354,conference-call,100,50,10/19/2020
A7102F,conference-call,100,50,10/19/2020
AE4125,conference-call,100,50,10/19/2020
B1FC3B,business-contract,100,69,10/19/2020
B290A2,clinical-trials,100,56,10/19/2020
B2DAF6,executive-appointment,100,54,10/19/2020
B37FB4,partnership,100,61,10/19/2020
B446B8,legal-issues-defendant,100,22,10/19/2020
B53C12,conference-call,100,50,10/19/2020
B604DF,earnings,100,50,10/19/2020
B604DF,earnings,100,50,10/19/2020
B604DF,earnings,100,50,10/19/2020
B604DF,earnings,100,50,10/19/2020
B604DF,earnings,100,50,10/19/2020
B6843B,earnings,100,50,10/19/2020
B9CD50,earnings,100,50,10/19/2020
BBBB41,executive-appointment,100,54,10/19/2020
BD682F,earnings,100,50,10/19/2020
BDD12C,dividend-up,100,81,10/19/2020
BDE867,unit-acquisition-acquiree,100,76,10/19/2020
BDF85E,note-sale,100,52,10/19/2020
C32A39,dividend,100,50,10/19/2020
C32A39,earnings-per-share-positive,100,69,10/19/2020
C81E00,product-release,100,64,10/19/2020
C8923A,earnings,100,50,10/19/2020
C951A2,executive-appointment,100,54,10/19/2020
C951A2,executive-appointment,100,54,10/19/2020
CC6FF5,earnings,100,50,10/19/2020
CDAA0E,earnings,100,50,10/19/2020
CDC817,earnings,100,50,10/19/2020
CDEDFE,merger,100,66,10/19/2020
CF6A5A,product-release,100,64,10/19/2020
CFE5BE,earnings,100,50,10/19/2020
CFE5BE,earnings,100,50,10/19/2020
CFE5BE,earnings,100,50,10/19/2020
CFE5BE,earnings,100,50,10/19/2020
CFE5BE,earnings,100,50,10/19/2020
CFE5BE,earnings,100,50,10/19/2020
CFE5BE,earnings,100,50,10/19/2020
CFE5BE,earnings,100,50,10/19/2020
CFE5BE,earnings,100,50,10/19/2020
D36B23,legal-issues-defendant,100,22,10/19/2020
D82EF3,conference-call,100,50,10/19/2020
D8442A,partnership,100,61,10/19/2020
D8760C,earnings-positive,100,69,10/19/2020
D8760C,earnings,100,50,10/19/2020
D8760C,earnings,100,50,10/19/2020
D8760C,earnings,100,50,10/19/2020
D8760C,earnings,100,50,10/19/2020
D8760C,earnings,100,50,10/19/2020
D9B1C9,legal-issues-defendant,100,22,10/19/2020
D9B1C9,legal-issues-defendant,100,22,10/19/2020
E10D31,business-contract,100,69,10/19/2020
E1E36F,dividend,100,50,10/19/2020
E26FC3,executive-appointment,100,54,10/19/2020
E61888,acquisition-acquiree,100,76,10/19/2020
E61888,legal-issues-defendant,100,22,10/19/2020
E61888,acquisition-regulatory-scrutiny-acquiree,100,38,10/19/2020
EC99D0,acquisition-interest-acquirer,100,46,10/19/2020
ECDEB2,earnings,100,50,10/19/2020
EEA6B3,trading-resumed,100,58,10/19/2020
EEB5F9,conference-call,100,50,10/19/2020
F0B335,earnings,100,50,10/19/2020
F1C04C,conference-call,100,50,10/19/2020
F30508,dividend,100,50,10/19/2020
F702CA,executive-appointment,100,54,10/19/2020
F702CA,dividend,100,50,10/19/2020
FCA54E,partnership,100,61,10/19/2020
FD1312,earnings,100,50,10/19/2020
FD6926,conference-call,100,50,10/19/2020
FE89E0,acquisition-acquirer,100,49,10/19/2020
FE89E0,acquisition-acquirer,100,49,10/19/2020
FE89E0,acquisition-acquirer,100,49,10/19/2020
0157B1,product-release,100,64,10/20/2020
03B8CF,product-release,100,64,10/20/2020
03B8CF,legal-issues-defendant,100,22,10/20/2020
03FAA6,acquisition-acquirer,100,49,10/20/2020
03FAA6,earnings,100,50,10/20/2020
070B45,earnings,100,50,10/20/2020
71860,partnership,100,61,10/20/2020
71860,partnership,100,61,10/20/2020
75172,conference-call,100,50,10/20/2020
07CA6A,dividend-up,100,81,10/20/2020
07CA6A,dividend-up,100,81,10/20/2020
0A59F8,earnings,100,50,10/20/2020
0A77DB,earnings,100,50,10/20/2020
0BF198,conference-call,100,50,10/20/2020
0C4131,earnings,100,50,10/20/2020
0E499E,earnings,100,50,10/20/2020
0FDE97,partnership,100,61,10/20/2020
1151F4,index-listing,100,76,10/20/2020
11A49E,executive-appointment,100,54,10/20/2020
1220D2,earnings,100,50,10/20/2020
126F95,earnings,100,50,10/20/2020
126F95,earnings,100,50,10/20/2020
126F95,earnings,100,50,10/20/2020
126F95,earnings,100,50,10/20/2020
1279ED,conference-call,100,50,10/20/2020
129DC8,conference-participant,100,50,10/20/2020
12A3A3,acquisition-acquirer,100,49,10/20/2020
12A3A3,acquisition-acquirer,100,49,10/20/2020
1348C9,earnings,100,50,10/20/2020
1348C9,earnings,100,50,10/20/2020
1348C9,earnings,100,50,10/20/2020
139303,conference-call,100,50,10/20/2020
149301,earnings,100,50,10/20/2020
17EDA5,acquisition-acquiree,100,76,10/20/2020
17EDA5,acquisition-acquiree,100,76,10/20/2020
17EDA5,acquisition-acquiree,100,76,10/20/2020
1B16C1,conference-call,100,50,10/20/2020
1BC12C,investment-investor,100,55,10/20/2020
1D943E,earnings,100,50,10/20/2020
1E1125,executive-appointment,100,54,10/20/2020
1FA886,business-contract,100,69,10/20/2020
1FA8F7,earnings,100,50,10/20/2020
205AD5,partnership,100,61,10/20/2020
239106,conference-call,100,50,10/20/2020
25102A,business-contract,100,69,10/20/2020
2720AB,earnings,100,50,10/20/2020
28B730,earnings,100,50,10/20/2020
2920D5,acquisition-acquirer,100,49,10/20/2020
2A6DBE,legal-issues-defendant,100,22,10/20/2020
2A6DBE,legal-issues-defendant,100,22,10/20/2020
2C19A4,conference-call,100,50,10/20/2020
2C681C,clinical-trials,100,56,10/20/2020
2C681C,clinical-trials,100,56,10/20/2020
2E61CC,earnings,100,50,10/20/2020
2F1299,conference-call,100,50,10/20/2020
2F5256,earnings,100,50,10/20/2020
2F6782,conference-call,100,50,10/20/2020
30DE64,fast-track-designation,100,81,10/20/2020
3.14E+47,earnings,100,50,10/20/2020
3.14E+47,earnings,100,50,10/20/2020
3.14E+47,earnings,100,50,10/20/2020
3.14E+47,earnings,100,50,10/20/2020
3.14E+47,earnings,100,50,10/20/2020
3.14E+47,earnings,100,50,10/20/2020
3.14E+47,earnings,100,50,10/20/2020
3.14E+47,earnings,100,50,10/20/2020
319BE2,conference-call,100,50,10/20/2020
31AA84,award,100,58,10/20/2020
31DB20,earnings,100,50,10/20/2020
32F24A,conference-call,100,50,10/20/2020
3696BF,note-sale,100,52,10/20/2020
384CD3,executive-appointment,100,54,10/20/2020
39BFF6,earnings,100,50,10/20/2020
39BFF6,earnings,100,50,10/20/2020
39BFF6,earnings,100,50,10/20/2020
3CCC90,dividend,100,50,10/20/2020
3D9999,earnings-positive,100,69,10/20/2020
3D9999,earnings,100,50,10/20/2020
3D9999,earnings,100,50,10/20/2020
3D9999,earnings,100,50,10/20/2020
3D9999,earnings,100,50,10/20/2020
3D9999,earnings,100,50,10/20/2020
3F1C69,business-contract,100,69,10/20/2020
3F1C69,business-contract,100,69,10/20/2020
3F868D,conference-call,100,50,10/20/2020
4.03E+05,conference-call,100,50,10/20/2020
41785E,earnings,100,50,10/20/2020
41A93D,earnings,100,50,10/20/2020
423279,earnings-per-share-positive,100,69,10/20/2020
43A74A,earnings,100,50,10/20/2020
43A74A,earnings,100,50,10/20/2020
43A74A,earnings,100,50,10/20/2020
43A74A,earnings,100,50,10/20/2020
43A74A,earnings,100,50,10/20/2020
43A74A,earnings,100,50,10/20/2020
43A74A,earnings,100,50,10/20/2020
43A74A,earnings,100,50,10/20/2020
44740A,conference-call,100,50,10/20/2020
447FC6,conference-call,100,50,10/20/2020
47B4CC,partnership,100,61,10/20/2020
490D4B,conference-call,100,50,10/20/2020
4A2457,product-release,100,64,10/20/2020
4A6F00,partnership,100,61,10/20/2020
4A6F00,executive-appointment,100,54,10/20/2020
4B5054,legal-issues-defendant,100,22,10/20/2020
4BBA23,conference-call,100,50,10/20/2020
4BEB48,earnings,100,50,10/20/2020
4C1FA1,earnings,100,50,10/20/2020
51B442,earnings,100,50,10/20/2020
5225A4,earnings,100,50,10/20/2020
5225A4,earnings,100,50,10/20/2020
5225A4,earnings,100,50,10/20/2020
5225A4,earnings,100,50,10/20/2020
5225A4,earnings,100,50,10/20/2020
5225A4,earnings,100,50,10/20/2020
53EF9E,conference-call,100,50,10/20/2020
53F491,dividend,100,50,10/20/2020
583A75,conference-call,100,50,10/20/2020
58C2D4,earnings,100,50,10/20/2020
596116,earnings,100,50,10/20/2020
59C539,dividend,100,50,10/20/2020
5AF08A,earnings,100,50,10/20/2020
5AF08A,note-sale,100,52,10/20/2020
5AF08A,note-sale,100,52,10/20/2020
5EC388,earnings,100,50,10/20/2020
5FF95F,earnings,100,50,10/20/2020
6.18E+08,earnings,100,50,10/20/2020
62B20A,earnings,100,50,10/20/2020
636639,earnings,100,50,10/20/2020
636639,earnings,100,50,10/20/2020
636639,earnings,100,50,10/20/2020
636639,earnings,100,50,10/20/2020
636639,earnings,100,50,10/20/2020
64E615,conference-call,100,50,10/20/2020
665440,public-offering,100,43,10/20/2020
67B923,product-release,100,64,10/20/2020
67B923,earnings,100,50,10/20/2020
6810DE,earnings,100,50,10/20/2020
6844D2,partnership,100,61,10/20/2020
6A3C35,earnings,100,50,10/20/2020
6BC6F9,earnings,100,50,10/20/2020
6BD606,conference-call,100,50,10/20/2020
6CC55E,earnings,100,50,10/20/2020
6E8864,conference-call,100,50,10/20/2020
6F0A63,conference-call,100,50,10/20/2020
70B3D6,partnership,100,61,10/20/2020
70B3D6,partnership,100,61,10/20/2020
71553E,earnings,100,50,10/20/2020
722DE3,business-contract,100,69,10/20/2020
73C521,earnings-positive,100,69,10/20/2020
73C521,earnings,100,50,10/20/2020
73C521,earnings,100,50,10/20/2020
73C521,earnings,100,50,10/20/2020
73C521,earnings,100,50,10/20/2020
73C521,earnings,100,50,10/20/2020
7.40E+289,dividend,100,50,10/20/2020
75D689,ipo-completed,100,76,10/20/2020
75F665,earnings,100,50,10/20/2020
75F665,earnings,100,50,10/20/2020
75F665,earnings,100,50,10/20/2020
75F665,earnings,100,50,10/20/2020
75F665,earnings,100,50,10/20/2020
75F665,earnings,100,50,10/20/2020
75F665,earnings,100,50,10/20/2020
75F665,earnings,100,50,10/20/2020
75F665,earnings,100,50,10/20/2020
75F665,earnings,100,50,10/20/2020
75F665,earnings,100,50,10/20/2020
75F665,dividend,100,50,10/20/2020
762B8D,note-sale,100,52,10/20/2020
767F86,executive-resignation,100,44,10/20/2020
7732C2,ipo-completed,100,76,10/20/2020
773A17,business-contract,100,69,10/20/2020
7.83E+79,earnings,100,50,10/20/2020
7B0BA6,market-entry,100,57,10/20/2020
7BFF81,business-contract,100,69,10/20/2020
7D35D8,earnings,100,50,10/20/2020
7E3F8F,earnings,100,50,10/20/2020
7E3F8F,earnings,100,50,10/20/2020
7E3F8F,earnings,100,50,10/20/2020
7E3F8F,earnings,100,50,10/20/2020
7FDE1C,business-contract,100,69,10/20/2020
8.10E+32,dividend,100,50,10/20/2020
850779,earnings-per-share-positive,100,69,10/20/2020
850779,earnings-per-share,100,50,10/20/2020
850779,earnings-per-share,100,50,10/20/2020
850779,earnings-per-share,100,50,10/20/2020
860AB6,earnings,100,50,10/20/2020
862941,earnings,100,50,10/20/2020
873DB9,trading-resumed,100,58,10/20/2020
893904,legal-issues-defendant,100,22,10/20/2020
893904,legal-issues-defendant,100,22,10/20/2020
893904,legal-issues-defendant,100,22,10/20/2020
8A8E41,earnings,100,50,10/20/2020
8A8E41,partnership,100,61,10/20/2020
8AB37F,conference-participant,100,50,10/20/2020
8AB85C,public-offering,100,43,10/20/2020
8C311A,earnings,100,50,10/20/2020
8C5519,earnings,100,50,10/20/2020
8C5519,earnings,100,50,10/20/2020
8C5519,earnings,100,50,10/20/2020
8C5519,earnings,100,50,10/20/2020
8C5519,earnings,100,50,10/20/2020
8C5519,earnings,100,50,10/20/2020
8C6C1B,note-sale,100,52,10/20/2020
8C6C1B,facility-open,100,65,10/20/2020
8C84DF,earnings,100,50,10/20/2020
8CF6DD,earnings,100,50,10/20/2020
8D4486,earnings,100,50,10/20/2020
8DAAB9,earnings-up,100,68,10/20/2020
8DDA23,dividend,100,50,10/20/2020
8E9CD8,business-contract,100,69,10/20/2020
8F3231,dividend,100,50,10/20/2020
93F143,earnings,100,50,10/20/2020
93F143,earnings,100,50,10/20/2020
93F143,earnings,100,50,10/20/2020
93F143,earnings,100,50,10/20/2020
93F143,earnings,100,50,10/20/2020
93F143,earnings,100,50,10/20/2020
9507FF,earnings,100,50,10/20/2020
9548BB,earnings-per-share-positive,100,69,10/20/2020
966ACE,earnings,100,50,10/20/2020
968B00,earnings,100,50,10/20/2020
96B4FF,public-offering,100,43,10/20/2020
96F126,partnership,100,61,10/20/2020
96F126,earnings,100,50,10/20/2020
96F126,earnings,100,50,10/20/2020
97AF94,earnings,100,50,10/20/2020
9994DA,ipo-completed,100,76,10/20/2020
9BB35A,conference-call,100,50,10/20/2020
9C5174,executive-appointment,100,54,10/20/2020
9CA4C6,dividend,100,50,10/20/2020
9CA4C6,earnings,100,50,10/20/2020
9D2790,earnings,100,50,10/20/2020
9D30A8,executive-appointment,100,54,10/20/2020
9F048E,earnings,100,50,10/20/2020
9F62D1,earnings-per-share-down,100,26,10/20/2020
A0F146,conference-call,100,50,10/20/2020
A29DBD,product-release,100,64,10/20/2020
A29DBD,product-release,100,64,10/20/2020
A29DBD,product-release,100,64,10/20/2020
A398B9,earnings,100,50,10/20/2020
A398B9,earnings,100,50,10/20/2020
A398B9,earnings,100,50,10/20/2020
A403CF,earnings,100,50,10/20/2020
A47A7D,business-contract,100,69,10/20/2020
A4B899,conference-call,100,50,10/20/2020
A4CD53,earnings,100,50,10/20/2020
A666C8,earnings,100,50,10/20/2020
A6FE1C,unit-acquisition-acquirer,100,49,10/20/2020
A746F6,earnings-per-share-positive,100,69,10/20/2020
A746F6,earnings-per-share-positive,100,69,10/20/2020
A746F6,earnings-per-share-positive,100,69,10/20/2020
A746F6,earnings-per-share-positive,100,69,10/20/2020
A746F6,earnings-per-share-positive,100,69,10/20/2020
A7F0A5,earnings,100,50,10/20/2020
A746F6,earnings-per-share-positive,100,69,10/20/2020
A746F6,earnings-per-share-positive,100,69,10/20/2020
A746F6,earnings-per-share-positive,100,69,10/20/2020
A746F6,earnings-per-share-positive,100,69,10/20/2020
A746F6,earnings-per-share-positive,100,69,10/20/2020
A746F6,earnings-per-share-positive,100,69,10/20/2020
A746F6,earnings-per-share-positive,100,69,10/20/2020
A868C9,conference-call,100,50,10/20/2020
A871B0,earnings,100,50,10/20/2020
A8CBDA,dividend,100,50,10/20/2020
AB7726,earnings,100,50,10/20/2020
ACD9A4,earnings,100,50,10/20/2020
AD3C93,earnings,100,50,10/20/2020
ADF1B0,conference-call,100,50,10/20/2020
AE3113,partnership,100,61,10/20/2020
AE3113,partnership,100,61,10/20/2020
AEBB80,earnings,100,50,10/20/2020
AFF43F,earnings,100,50,10/20/2020
AFF43F,dividend,100,50,10/20/2020
B1A85D,earnings,100,50,10/20/2020
B2D492,earnings,100,50,10/20/2020
B2E6B5,index-listing,100,76,10/20/2020
B60366,earnings,100,50,10/20/2020
B8F71F,earnings,100,50,10/20/2020
B96DF5,earnings,100,50,10/20/2020
BB5142,earnings-up,100,68,10/20/2020
BD15E8,earnings,100,50,10/20/2020
BD9668,earnings,100,50,10/20/2020
BDF2BD,conference-call,100,50,10/20/2020
BDF85E,note-sale,100,52,10/20/2020
BE14CF,dividend,100,50,10/20/2020
BE7BA4,public-offering,100,43,10/20/2020
C0200F,earnings,100,50,10/20/2020
C0200F,earnings,100,50,10/20/2020
C0200F,earnings,100,50,10/20/2020
C29715,earnings,100,50,10/20/2020
C29715,earnings,100,50,10/20/2020
C2E39B,business-contract,100,69,10/20/2020
C3BAE7,earnings,100,50,10/20/2020
C45CE7,earnings,100,50,10/20/2020
C4A432,executive-appointment,100,54,10/20/2020
C4C77F,legal-issues-defendant,100,22,10/20/2020
C598D7,partnership,100,61,10/20/2020
C598D7,dividend-up,100,59,10/20/2020
C65004,earnings,100,50,10/20/2020
C72B8F,conference-call,100,50,10/20/2020
C8257F,conference-call,100,50,10/20/2020
C98CDB,earnings,100,50,10/20/2020
C9E107,note-sale,100,52,10/20/2020
CA1620,earnings-per-share-up,100,70,10/20/2020
CBBFBF,earnings,100,50,10/20/2020
CC176E,product-release,100,64,10/20/2020
CEC08B,earnings,100,50,10/20/2020
D17C1B,product-release,100,64,10/20/2020
D393DF,earnings,100,50,10/20/2020
D393DF,earnings,100,50,10/20/2020
D4AC65,partnership,100,61,10/20/2020
D60BB2,executive-appointment,100,54,10/20/2020
D69D42,executive-appointment,100,54,10/20/2020
D7AC6E,earnings,100,50,10/20/2020
D8ECA1,earnings,100,50,10/20/2020
D9B1C9,dividend-up,100,81,10/20/2020
D9B1C9,award,100,58,10/20/2020
DB9F70,executive-appointment,100,54,10/20/2020
DBFB51,conference-call,100,50,10/20/2020
DDB002,conference-call,100,50,10/20/2020
DF18E6,clinical-trials,100,56,10/20/2020
DF532D,earnings,100,50,10/20/2020
DF532D,earnings,100,50,10/20/2020
E09997,facility-close,100,47,10/20/2020
E22FDE,partnership,100,61,10/20/2020
E38906,patient-enrollment-start,100,58,10/20/2020
E3A829,credit-extension-recipient,100,69,10/20/2020
E3E68E,hirings,100,65,10/20/2020
E3E68E,hirings,100,65,10/20/2020
E8F0E2,clinical-trials-start,100,64,10/20/2020
E90C84,conference-call,100,50,10/20/2020
EB61C4,dividend-up,100,81,10/20/2020
EB61C4,executive-appointment,100,54,10/20/2020
EBD89A,conference-call,100,50,10/20/2020
ECD263,earnings,100,50,10/20/2020
ECDEB2,earnings,100,50,10/20/2020
ECF4F8,conference-call,100,50,10/20/2020
ED0D7C,executive-appointment,100,54,10/20/2020
ED0D7C,executive-appointment,100,54,10/20/2020
ED79D9,partnership,100,61,10/20/2020
EF76C8,dividend,100,50,10/20/2020
F04E05,dividend,100,50,10/20/2020
F11638,executive-appointment,100,54,10/20/2020
F5349B,executive-appointment,100,54,10/20/2020
F57F6F,earnings,100,50,10/20/2020
F7ADEB,product-release,100,64,10/20/2020
F93C8A,conference-call,100,50,10/20/2020
FACCF6,earnings,100,50,10/20/2020
FD0CA4,earnings,100,50,10/20/2020
FE7A63,earnings,100,50,10/20/2020
FE7A63,earnings,100,50,10/20/2020
FE7A63,earnings,100,50,10/20/2020
FE7A63,earnings,100,50,10/20/2020
FE7A63,earnings,100,50,10/20/2020
FE7A63,earnings,100,50,10/20/2020
FE7A63,earnings,100,50,10/20/2020
FF6644,product-release,100,64,10/20/2020
00067A,business-contract,100,69,10/21/2020
13528,conference-organizer,100,57,10/21/2020
0142B5,dividend,100,50,10/21/2020
0157B1,partnership,100,61,10/21/2020
0157B1,facility-upgrade,100,65,10/21/2020
01B8D6,earnings,100,50,10/21/2020
01D03F,partnership,100,61,10/21/2020
03CF95,product-release,100,64,10/21/2020
03CF95,executive-appointment,100,54,10/21/2020
61366,acquisition-acquiree,100,76,10/21/2020
98977,earnings,100,50,10/21/2020
099A02,earnings,100,50,10/21/2020
099A02,earnings,100,50,10/21/2020
099C88,conference-call,100,50,10/21/2020
09F623,dividend,100,50,10/21/2020
0A1D77,earnings,100,50,10/21/2020
0B13E8,conference-call,100,50,10/21/2020
0B57D7,earnings,100,50,10/21/2020
0C466B,earnings,100,50,10/21/2020
0C466B,earnings,100,50,10/21/2020
0C466B,earnings,100,50,10/21/2020
0CE204,earnings,100,50,10/21/2020
0D26E0,earnings-positive,100,69,10/21/2020
0E6027,earnings-positive,100,69,10/21/2020
0E6027,earnings,100,50,10/21/2020
1065BC,conference-call,100,50,10/21/2020
108A2B,conference-call,100,50,10/21/2020
108FDA,executive-appointment,100,54,10/21/2020
11074E,conference-call,100,50,10/21/2020
1348C9,merger,100,66,10/21/2020
1348C9,merger,100,66,10/21/2020
1348C9,business-combination,100,54,10/21/2020
1348C9,business-combination,100,54,10/21/2020
138DDE,earnings,100,50,10/21/2020
159739,earnings,100,50,10/21/2020
159739,earnings,100,50,10/21/2020
165B3A,earnings-positive,100,69,10/21/2020
165B3A,earnings-positive,100,69,10/21/2020
165B3A,earnings-positive,100,69,10/21/2020
165B3A,earnings-positive,100,69,10/21/2020
165B3A,earnings-positive,100,69,10/21/2020
165B3A,earnings-positive,100,69,10/21/2020
184866,earnings,100,50,10/21/2020
1921DD,investment-investor,100,55,10/21/2020
1A2D9F,earnings,100,50,10/21/2020
1A2D9F,earnings,100,50,10/21/2020
1A2D9F,earnings,100,50,10/21/2020
1A2D9F,earnings,100,50,10/21/2020
1A2D9F,earnings,100,50,10/21/2020
1A2D9F,earnings,100,50,10/21/2020
1A2D9F,earnings,100,50,10/21/2020
1A2D9F,earnings,100,50,10/21/2020
1A6A94,unit-acquisition-acquiree,100,76,10/21/2020
1A9DE1,earnings,100,50,10/21/2020
1A9DE1,earnings,100,50,10/21/2020
1A9DE1,earnings,100,50,10/21/2020
1A9DE1,earnings,100,50,10/21/2020
1AB808,earnings,100,50,10/21/2020
1AF7E2,executive-resignation,100,44,10/21/2020
1CD708,earnings,100,50,10/21/2020
1D1B07,donation,100,54,10/21/2020
1E1125,conference-organizer,100,57,10/21/2020
1E5786,dividend-up,100,81,10/21/2020
1E9A6D,acquisition-regulatory-scrutiny-acquiree,100,38,10/21/2020
2031CE,executive-appointment,100,54,10/21/2020
221AD7,earnings,100,50,10/21/2020
228D42,product-release,100,64,10/21/2020
2.45E+15,earnings,100,50,10/21/2020
24CB56,earnings-positive,100,69,10/21/2020
24CB56,earnings,100,50,10/21/2020
24CB56,earnings,100,50,10/21/2020
24CB56,earnings,100,50,10/21/2020
24CB56,earnings,100,50,10/21/2020
24CB56,earnings,100,50,10/21/2020
24CB56,earnings,100,50,10/21/2020
24CB56,earnings,100,50,10/21/2020
24CB56,earnings,100,50,10/21/2020
24CB56,earnings,100,50,10/21/2020
24FA23,earnings,100,50,10/21/2020
25102A,dividend,100,50,10/21/2020
25102A,earnings,100,50,10/21/2020
25102A,earnings,100,50,10/21/2020
25102A,earnings,100,50,10/21/2020
25102A,earnings,100,50,10/21/2020
25102A,earnings,100,50,10/21/2020
25102A,executive-resignation,100,44,10/21/2020
272704,earnings-positive,100,69,10/21/2020
272704,earnings,100,50,10/21/2020
272704,earnings,100,50,10/21/2020
272704,earnings,100,50,10/21/2020
272704,earnings,100,50,10/21/2020
272704,earnings,100,50,10/21/2020
272704,earnings,100,50,10/21/2020
272704,earnings,100,50,10/21/2020
275300,executive-appointment,100,54,10/21/2020
275300,earnings,100,50,10/21/2020
275300,earnings,100,50,10/21/2020
275300,earnings,100,50,10/21/2020
275300,earnings,100,50,10/21/2020
275300,earnings,100,50,10/21/2020
275300,earnings,100,50,10/21/2020
275300,earnings,100,50,10/21/2020
275300,earnings,100,50,10/21/2020
275300,earnings,100,50,10/21/2020
27B191,conference-call,100,50,10/21/2020
27BFA1,earnings,100,50,10/21/2020
27BFA1,earnings,100,50,10/21/2020
27BFA1,earnings,100,50,10/21/2020
27BFA1,earnings,100,50,10/21/2020
27BFA1,earnings,100,50,10/21/2020
27BFA1,earnings,100,50,10/21/2020
27BFA1,earnings,100,50,10/21/2020
27BFA1,earnings,100,50,10/21/2020
27BFA1,earnings,100,50,10/21/2020
28AF37,earnings,100,50,10/21/2020
292A70,earnings,100,50,10/21/2020
29A4CC,earnings,100,50,10/21/2020
2A6DBE,legal-issues-defendant,100,22,10/21/2020
2B8179,orphan-drug-designation,100,76,10/21/2020
2CB4C9,earnings,100,50,10/21/2020
31A7CC,earnings,100,50,10/21/2020
31A7CC,earnings,100,50,10/21/2020
31A7CC,earnings,100,50,10/21/2020
31A7CC,earnings,100,50,10/21/2020
31F25C,earnings,100,50,10/21/2020
339F20,earnings,100,50,10/21/2020
3.30E+34,earnings,100,50,10/21/2020
3.30E+34,earnings,100,50,10/21/2020
3.30E+34,earnings,100,50,10/21/2020
3461CF,unit-acquisition-acquirer,100,49,10/21/2020
349DA4,earnings,100,50,10/21/2020
36A1CB,conference-call,100,50,10/21/2020
36C09B,fast-track-designation,100,81,10/21/2020
3.73E+87,earnings,100,50,10/21/2020
387541,earnings,100,50,10/21/2020
3A1C46,earnings,100,50,10/21/2020
3C7F5F,dividend,100,50,10/21/2020
3CCC90,earnings,100,50,10/21/2020
3D9999,dividend,100,50,10/21/2020
3DED49,earnings,100,50,10/21/2020
3EE65E,business-contract,100,69,10/21/2020
3F4668,earnings,100,50,10/21/2020
408089,dividend,100,50,10/21/2020
41785E,legal-issues-defendant,100,22,10/21/2020
41785E,legal-issues-defendant,100,22,10/21/2020
435ACE,business-contract,100,69,10/21/2020
468DD4,earnings,100,50,10/21/2020
4A2457,conference-call,100,50,10/21/2020
4A6F00,partnership,100,61,10/21/2020
4B6EF9,earnings,100,50,10/21/2020
4B6EF9,dividend,100,50,10/21/2020
4D7BD8,earnings,100,50,10/21/2020
4D7BD8,earnings,100,50,10/21/2020
4D7BD8,earnings,100,50,10/21/2020
4D7BD8,earnings,100,50,10/21/2020
4D7BD8,earnings,100,50,10/21/2020
4D7BD8,earnings,100,50,10/21/2020
4D7BD8,earnings,100,50,10/21/2020
4D7BD8,earnings,100,50,10/21/2020
4D8313,revenue-up,100,69,10/21/2020
4D8313,revenue-up,100,69,10/21/2020
4D8313,revenue-up,100,69,10/21/2020
4F71DC,public-offering,100,43,10/21/2020
4F9487,earnings-positive,100,69,10/21/2020
4F9487,earnings-positive,100,69,10/21/2020
4F9487,earnings-positive,100,69,10/21/2020
4F9487,earnings-positive,100,69,10/21/2020
4F9487,earnings-positive,100,69,10/21/2020
4F9487,earnings-positive,100,69,10/21/2020
4F9487,earnings-positive,100,69,10/21/2020
4F9487,earnings-positive,100,69,10/21/2020
4F9487,earnings-positive,100,69,10/21/2020
50702E,clinical-trials-start,100,64,10/21/2020
520632,earnings,100,50,10/21/2020
520632,earnings,100,50,10/21/2020
520632,earnings,100,50,10/21/2020
520632,earnings,100,50,10/21/2020
520632,earnings,100,50,10/21/2020
53F491,earnings-per-share-positive,100,69,10/21/2020
5480A7,earnings,100,50,10/21/2020
54A646,earnings-positive,100,69,10/21/2020
54A646,earnings-positive,100,69,10/21/2020
54A646,earnings-positive,100,69,10/21/2020
54A646,earnings-positive,100,69,10/21/2020
553949,conference-call,100,50,10/21/2020
5675EB,dividend,100,50,10/21/2020
5675EB,earnings,100,50,10/21/2020
56AFF4,operating-earnings,100,50,10/21/2020
586FFD,conference-call,100,50,10/21/2020
5876DC,earnings,100,50,10/21/2020
594402,earnings,100,50,10/21/2020
5A9F54,earnings-up,100,68,10/21/2020
5A9F54,earnings-up,100,68,10/21/2020
5A9F54,earnings-up,100,68,10/21/2020
5A9F54,earnings-up,100,68,10/21/2020
5A9F54,earnings-up,100,68,10/21/2020
5AAE17,conference-call,100,50,10/21/2020
5B97B2,earnings,100,50,10/21/2020
6137BF,earnings,100,50,10/21/2020
6137BF,earnings,100,50,10/21/2020
639BD6,earnings,100,50,10/21/2020
662682,dividend-up,100,81,10/21/2020
662682,earnings,100,50,10/21/2020
67529E,earnings-up,100,68,10/21/2020
6844D2,expenses-guidance-down,100,61,10/21/2020
6A961B,conference-call,100,50,10/21/2020
6C987C,earnings-positive,100,69,10/21/2020
6CB7F9,earnings,100,50,10/21/2020
6D9ECA,partnership,100,61,10/21/2020
6DD6BA,earnings,100,50,10/21/2020
6DD6BA,earnings,100,50,10/21/2020
6DD6BA,earnings,100,50,10/21/2020
6E7060,earnings,100,50,10/21/2020
6F0096,earnings,100,50,10/21/2020
6F0096,earnings,100,50,10/21/2020
6F0096,earnings,100,50,10/21/2020
6F0096,earnings,100,50,10/21/2020
701531,earnings,100,50,10/21/2020
713810,partnership,100,61,10/21/2020
722DE3,conference-call,100,50,10/21/2020
7262F2,earnings,100,50,10/21/2020
73BCBA,earnings,100,50,10/21/2020
73BCBA,earnings,100,50,10/21/2020
73BCBA,earnings,100,50,10/21/2020
73BCBA,earnings,100,50,10/21/2020
751C8D,executive-appointment,100,54,10/21/2020
751C8D,executive-appointment,100,54,10/21/2020
762B8D,public-offering,100,43,10/21/2020
763724,conference-call,100,50,10/21/2020
766047,dividend,100,50,10/21/2020
76F067,dividend,100,50,10/21/2020
775439,earnings,100,50,10/21/2020
77B8E9,executive-appointment,100,54,10/21/2020
7A975D,earnings,100,50,10/21/2020
7A975D,earnings,100,50,10/21/2020
7A975D,earnings,100,50,10/21/2020
7B1156,conference-call,100,50,10/21/2020
7C62A3,conference-call,100,50,10/21/2020
7C75FD,dividend,100,50,10/21/2020
7DC1C4,conference-participant,100,50,10/21/2020
7E0EB0,earnings,100,50,10/21/2020
7F3FBC,dividend,100,50,10/21/2020
7F3FBC,operating-earnings,100,50,10/21/2020
7F9E16,conference-call,100,50,10/21/2020
7FD8B9,conference-call,100,50,10/21/2020
8.10E+32,conference-organizer,100,57,10/21/2020
817ED9,partnership,100,61,10/21/2020
8275FE,earnings,100,50,10/21/2020
8303CD,award,100,58,10/21/2020
845655,conference-call,100,50,10/21/2020
845655,conference-call,100,50,10/21/2020
84AB66,dividend,100,50,10/21/2020
8665BA,earnings,100,50,10/21/2020
86F123,earnings,100,50,10/21/2020
893904,legal-issues-defendant,100,22,10/21/2020
893904,legal-issues-defendant,100,22,10/21/2020
8A0368,award,100,58,10/21/2020
8A8E41,earnings,100,50,10/21/2020
8A8E41,earnings,100,50,10/21/2020
8B6E7E,conference-call,100,50,10/21/2020
8C6C1B,facility-open,100,65,10/21/2020
8CF6DD,donation,100,54,10/21/2020
9196A2,product-release,100,64,10/21/2020
9196A2,product-release,100,64,10/21/2020
92D6A5,dividend,100,50,10/21/2020
9.39E+69,executive-appointment,100,54,10/21/2020
940C3D,earnings,100,50,10/21/2020
94208D,earnings,100,50,10/21/2020
9592FB,earnings,100,50,10/21/2020
9.62E+76,earnings,100,50,10/21/2020
9.62E+76,earnings,100,50,10/21/2020
9.62E+76,earnings,100,50,10/21/2020
97644E,executive-appointment,100,54,10/21/2020
97AAF6,earnings,100,50,10/21/2020
97B027,earnings,100,50,10/21/2020
97B027,note-sale,100,52,10/21/2020
986AF6,conference-call,100,50,10/21/2020
98CAED,dividend-up,100,81,10/21/2020
98CAED,earnings-up,100,68,10/21/2020
98CAED,earnings-up,100,68,10/21/2020
98CAED,earnings-up,100,68,10/21/2020
98CAED,earnings-up,100,68,10/21/2020
990AD0,dividend,100,50,10/21/2020
9.92E+94,earnings,100,50,10/21/2020
9.92E+94,earnings,100,50,10/21/2020
9.92E+94,earnings,100,50,10/21/2020
9CE4C7,earnings,100,50,10/21/2020
9D30A8,earnings,100,50,10/21/2020
9F37C5,dividend,100,50,10/21/2020
9F37C5,earnings,100,50,10/21/2020
A01983,conference-call,100,50,10/21/2020
A398F8,earnings,100,50,10/21/2020
A433A5,conference-call,100,50,10/21/2020
A62FD6,partnership,100,61,10/21/2020
A62FD6,partnership,100,61,10/21/2020
A63820,earnings,100,50,10/21/2020
A63820,earnings,100,50,10/21/2020
A63820,earnings,100,50,10/21/2020
A63820,earnings,100,50,10/21/2020
A65325,dividend,100,50,10/21/2020
A65325,earnings-positive,100,69,10/21/2020
A8CBDA,product-release,100,64,10/21/2020
A8CBDA,earnings-positive,100,69,10/21/2020
AA5C8E,earnings,100,50,10/21/2020
AA5C8E,earnings,100,50,10/21/2020
AA5C8E,earnings,100,50,10/21/2020
AA5C8E,earnings,100,50,10/21/2020
AA5C8E,earnings,100,50,10/21/2020
AA5C8E,earnings,100,50,10/21/2020
AABEA0,dividend,100,50,10/21/2020
AC642C,earnings,100,50,10/21/2020
AC642C,earnings,100,50,10/21/2020
AD23DE,earnings,100,50,10/21/2020
AD23DE,earnings,100,50,10/21/2020
AD23DE,earnings,100,50,10/21/2020
AD23DE,earnings,100,50,10/21/2020
AD23DE,earnings,100,50,10/21/2020
AD23DE,earnings,100,50,10/21/2020
AE0CCE,conference-call,100,50,10/21/2020
B54A74,partnership,100,61,10/21/2020
B96637,conference-call,100,50,10/21/2020
B98EFA,operating-earnings,100,50,10/21/2020
B9B6B8,earnings,100,50,10/21/2020
BA218A,earnings,100,50,10/21/2020
BA218A,earnings-up,100,68,10/21/2020
BA218A,earnings-up,100,68,10/21/2020
BA218A,earnings-up,100,68,10/21/2020
BA218A,earnings-up,100,68,10/21/2020
BA218A,earnings-up,100,68,10/21/2020
BA218A,earnings-up,100,68,10/21/2020
BA218A,earnings-up,100,68,10/21/2020
BAD655,merger,100,66,10/21/2020
BDD12C,executive-appointment,100,54,10/21/2020
BDD12C,earnings,100,50,10/21/2020
BE7BA4,public-offering,100,43,10/21/2020
C2F597,earnings,100,50,10/21/2020
C4A432,executive-resignation,100,44,10/21/2020
C501B6,legal-issues-defendant,100,22,10/21/2020
C54140,earnings,100,50,10/21/2020
C564E4,conference-call,100,50,10/21/2020
C9732E,clinical-trials,100,56,10/21/2020
C99CC8,note-sale,100,52,10/21/2020
C9B932,earnings,100,50,10/21/2020
C9B932,earnings,100,50,10/21/2020
C9F39B,earnings,100,50,10/21/2020
C9F39B,earnings,100,50,10/21/2020
C9F39B,earnings,100,50,10/21/2020
C9F39B,earnings,100,50,10/21/2020
C9F39B,earnings,100,50,10/21/2020
C9F39B,earnings,100,50,10/21/2020
C9F39B,earnings,100,50,10/21/2020
C9F39B,earnings,100,50,10/21/2020
CBBFBF,dividend,100,50,10/21/2020
CD4DA8,dividend-up,100,81,10/21/2020
CD4DA8,earnings,100,50,10/21/2020
CD4DA8,earnings,100,50,10/21/2020
CD4DA8,earnings,100,50,10/21/2020
CD4DA8,earnings,100,50,10/21/2020
CD4DA8,earnings,100,50,10/21/2020
CD4DA8,earnings,100,50,10/21/2020
CD4DA8,earnings,100,50,10/21/2020
CD4DA8,earnings,100,50,10/21/2020
CD4DA8,earnings,100,50,10/21/2020
CD4DA8,earnings,100,50,10/21/2020
CD4DA8,earnings,100,50,10/21/2020
CDE118,earnings,100,50,10/21/2020
CDFCC9,acquisition-acquirer,100,49,10/21/2020
CF351E,merger,100,66,10/21/2020
CF351E,merger,100,66,10/21/2020
CF351E,business-combination,100,54,10/21/2020
CF351E,business-combination,100,54,10/21/2020
CF351E,acquisition-regulatory-scrutiny-acquiree,100,38,10/21/2020
CF351E,legal-issues-defendant,100,22,10/21/2020
D0DFE5,executive-appointment,100,54,10/21/2020
D1C26F,partnership,100,61,10/21/2020
D21D8A,earnings,100,50,10/21/2020
D21D8A,earnings,100,50,10/21/2020
D21D8A,earnings,100,50,10/21/2020
D21D8A,earnings,100,50,10/21/2020
D21D8A,earnings,100,50,10/21/2020
D21D8A,earnings,100,50,10/21/2020
D21D8A,earnings,100,50,10/21/2020
D21D8A,earnings,100,50,10/21/2020
D48275,earnings,100,50,10/21/2020
D4AC65,conference-call,100,50,10/21/2020
D501DC,legal-issues-defendant,100,22,10/21/2020
D64EDF,acquisition-acquirer,100,49,10/21/2020
D650A7,earnings,100,50,10/21/2020
D697DE,earnings,100,50,10/21/2020
D7A953,earnings,100,50,10/21/2020
D8DA3D,dividend,100,50,10/21/2020
DA0CB8,partnership,100,61,10/21/2020
DA199F,partnership,100,61,10/21/2020
DA90E1,dividend,100,50,10/21/2020
DBB28E,business-contract,100,69,10/21/2020
DC0998,earnings,100,50,10/21/2020
DC0998,earnings,100,50,10/21/2020
DC0998,earnings,100,50,10/21/2020
DC0998,earnings,100,50,10/21/2020
DC437D,earnings,100,50,10/21/2020
DC437D,dividend,100,50,10/21/2020
DD3BB1,earnings,100,50,10/21/2020
E20392,conference-call,100,50,10/21/2020
E26FC3,earnings,100,50,10/21/2020
E2F130,dividend,100,50,10/21/2020
E30B34,earnings,100,50,10/21/2020
E30B34,earnings,100,50,10/21/2020
E3E68E,executive-appointment,100,54,10/21/2020
E3E68E,executive-appointment,100,54,10/21/2020
E592F0,executive-resignation,100,44,10/21/2020
E61888,acquisition-regulatory-scrutiny-acquiree,100,38,10/21/2020
E6C8DC,conference-call,100,50,10/21/2020
E72599,conference-call,100,50,10/21/2020
E829E8,earnings,100,50,10/21/2020
E829E8,earnings,100,50,10/21/2020
E829E8,earnings,100,50,10/21/2020
E829E8,earnings,100,50,10/21/2020
E90C84,earnings,100,50,10/21/2020
E90C84,earnings,100,50,10/21/2020
EB36DE,conference-call,100,50,10/21/2020
EB61C4,executive-appointment,100,54,10/21/2020
EBC84C,executive-appointment,100,54,10/21/2020
ECE19E,conference-participant,100,50,10/21/2020
ED0D7C,dividend,100,50,10/21/2020
ED22DC,conference-participant,100,50,10/21/2020
ED2EFD,dividend-up,100,56,10/21/2020
ED9576,earnings,100,50,10/21/2020
EE6F1C,business-contract,100,69,10/21/2020
EEEA9F,earnings,100,50,10/21/2020
F0B2B5,conference-call,100,50,10/21/2020
F18844,legal-issues-defendant,100,22,10/21/2020
F294DD,earnings,100,50,10/21/2020
F7ADEB,partnership,100,61,10/21/2020
F8DE55,earnings,100,50,10/21/2020
FA044A,earnings,100,50,10/21/2020
FC80E6,conference-call,100,50,10/21/2020
FD4E8D,revenues,100,50,10/21/2020
FD4E8D,revenues,100,50,10/21/2020
FD4E8D,revenues,100,50,10/21/2020
FDC08C,dividend,100,50,10/21/2020
FE9C0D,partnership,100,61,10/21/2020
FF6644,business-contract,100,69,10/21/2020
FFAB4A,dividend-up,100,81,10/21/2020
00067A,partnership,100,61,10/22/2020
00698D,buybacks,100,74,10/22/2020
0157B1,partnership,100,61,10/22/2020
0157B1,partnership,100,61,10/22/2020
01D03F,partnership,100,61,10/22/2020
01D03F,partnership,100,61,10/22/2020
31025,earnings,100,50,10/22/2020
03D5F9,product-release,100,64,10/22/2020
43862,conference-call,100,50,10/22/2020
51332,dividend,100,50,10/22/2020
55018,earnings-positive,100,69,10/22/2020
55018,earnings,100,50,10/22/2020
55018,earnings,100,50,10/22/2020
55018,earnings,100,50,10/22/2020
55018,earnings,100,50,10/22/2020
55018,earnings,100,50,10/22/2020
55018,earnings,100,50,10/22/2020
55018,earnings,100,50,10/22/2020
55018,earnings,100,50,10/22/2020
55018,earnings,100,50,10/22/2020
55018,earnings,100,50,10/22/2020
0560D8,partnership,100,61,10/22/2020
68396,earnings,100,50,10/22/2020
71860,executive-appointment,100,54,10/22/2020
71860,earnings,100,50,10/22/2020
07CA6A,executive-appointment,100,54,10/22/2020
07CA6A,executive-appointment,100,54,10/22/2020
08A40F,earnings-per-share-positive,100,69,10/22/2020
08A40F,earnings-per-share-positive,100,69,10/22/2020
08A40F,earnings-per-share-positive,100,69,10/22/2020
08A40F,earnings-per-share-positive,100,69,10/22/2020
08A40F,earnings-per-share-positive,100,69,10/22/2020
08A40F,earnings-per-share-positive,100,69,10/22/2020
08A40F,earnings-per-share-positive,100,69,10/22/2020
08A40F,earnings-per-share-positive,100,69,10/22/2020
0A0D9E,partnership,100,61,10/22/2020
0A7650,earnings,100,50,10/22/2020
0A77DB,executive-appointment,100,54,10/22/2020
0A9D0A,dividend,100,50,10/22/2020
0AB700,earnings,100,50,10/22/2020
0B2071,dividend,100,50,10/22/2020
0C466B,earnings,100,50,10/22/2020
0C8D82,earnings,100,50,10/22/2020
0EF1AF,savings,100,74,10/22/2020
0F2BC9,business-contract,100,69,10/22/2020
105D00,earnings-up,100,68,10/22/2020
105D00,earnings,100,50,10/22/2020
105D00,earnings,100,50,10/22/2020
105D00,earnings,100,50,10/22/2020
105D00,earnings,100,50,10/22/2020
105D00,earnings,100,50,10/22/2020
105D00,earnings,100,50,10/22/2020
105D00,earnings,100,50,10/22/2020
10C19B,earnings,100,50,10/22/2020
10C19B,earnings,100,50,10/22/2020
10C19B,earnings,100,50,10/22/2020
10C19B,earnings,100,50,10/22/2020
10C19B,earnings,100,50,10/22/2020
10C19B,earnings,100,50,10/22/2020
10C19B,earnings,100,50,10/22/2020
10C19B,earnings,100,50,10/22/2020
12731D,conference-call,100,50,10/22/2020
12731D,conference-call,100,50,10/22/2020
13C3E0,earnings,100,50,10/22/2020
152B9E,dividend,100,50,10/22/2020
15789A,earnings,100,50,10/22/2020
1748F6,note-sale,100,52,10/22/2020
1.79E+10,partnership,100,61,10/22/2020
1.79E+10,conference-call,100,50,10/22/2020
19BF16,earnings,100,50,10/22/2020
1AF7E2,earnings,100,50,10/22/2020
1AF7E2,earnings,100,50,10/22/2020
1CD09C,conference-call,100,50,10/22/2020
1DB6A6,earnings,100,50,10/22/2020
1EBF8D,donation,100,54,10/22/2020
20DC4E,earnings,100,50,10/22/2020
225CA2,dividend,100,50,10/22/2020
228D42,partnership,100,61,10/22/2020
228D42,partnership,100,61,10/22/2020
228D42,partnership,100,61,10/22/2020
228D42,partnership,100,61,10/22/2020
228D42,partnership,100,61,10/22/2020
251988,earnings,100,50,10/22/2020
251988,earnings,100,50,10/22/2020
251988,earnings,100,50,10/22/2020
251988,earnings,100,50,10/22/2020
251988,earnings,100,50,10/22/2020
251988,earnings,100,50,10/22/2020
251988,partnership,100,61,10/22/2020
25AB8E,earnings,100,50,10/22/2020
267718,acquisition-acquirer,100,49,10/22/2020
272472,earnings,100,50,10/22/2020
275300,dividend,100,50,10/22/2020
278C18,earnings,100,50,10/22/2020
28DCF3,earnings,100,50,10/22/2020
29A4CC,dividend,100,50,10/22/2020
29B702,earnings,100,50,10/22/2020
2A6DBE,legal-issues-defendant,100,22,10/22/2020
2A6DBE,legal-issues-defendant,100,22,10/22/2020
2B7A40,conference-call,100,50,10/22/2020
2B9DBB,earnings,100,50,10/22/2020
2C7505,clinical-trials-positive,100,87,10/22/2020
2CC71C,executive-appointment,100,54,10/22/2020
2DA92D,earnings,100,50,10/22/2020
2DC88B,earnings,100,50,10/22/2020
2E89AE,earnings,100,50,10/22/2020
2EB04E,product-resumed,100,52,10/22/2020
2F7474,earnings,100,50,10/22/2020
2F7474,earnings,100,50,10/22/2020
301493,conference-call,100,50,10/22/2020
31553A,earnings,100,50,10/22/2020
31553A,earnings,100,50,10/22/2020
31553A,earnings,100,50,10/22/2020
31553A,earnings,100,50,10/22/2020
31666F,earnings,100,50,10/22/2020
317EC6,public-offering,100,43,10/22/2020
31DB20,earnings,100,50,10/22/2020
32DCB3,executive-appointment,100,54,10/22/2020
3.30E+34,dividend,100,50,10/22/2020
342218,dividend-up,100,81,10/22/2020
3461CF,debt-reduction,100,74,10/22/2020
3471C0,earnings,100,50,10/22/2020
366A08,earnings,100,50,10/22/2020
366A08,earnings,100,50,10/22/2020
366A08,earnings,100,50,10/22/2020
366A08,earnings,100,50,10/22/2020
366A08,earnings,100,50,10/22/2020
366A08,earnings,100,50,10/22/2020
367434,earnings,100,50,10/22/2020
37020C,dividend,100,50,10/22/2020
3A3948,earnings,100,50,10/22/2020
3A94DF,earnings-per-share-up,100,76,10/22/2020
3AAEAE,conference-call,100,50,10/22/2020
3B2311,earnings,100,50,10/22/2020
3B318A,executive-appointment,100,54,10/22/2020
3C8A04,earnings,100,50,10/22/2020
3DB18B,executive-appointment,100,54,10/22/2020
3DE4D1,earnings,100,50,10/22/2020
3E39A5,dividend,100,50,10/22/2020
3F96D5,earnings,100,50,10/22/2020
401072,earnings,100,50,10/22/2020
4017AD,earnings,100,50,10/22/2020
407878,conference-call,100,50,10/22/2020
41785E,legal-issues-defendant,100,22,10/22/2020
43E8F5,conference-call,100,50,10/22/2020
442769,conference-call,100,50,10/22/2020
449447,earnings,100,50,10/22/2020
449A26,earnings-positive,100,69,10/22/2020
449A26,dividend,100,50,10/22/2020
44A4FC,partnership,100,61,10/22/2020
44A4FC,partnership,100,61,10/22/2020
44ED36,dividend,100,50,10/22/2020
451D61,conference-call,100,50,10/22/2020
453282,earnings-per-share-positive,100,69,10/22/2020
45ABCC,earnings,100,50,10/22/2020
4649D5,earnings,100,50,10/22/2020
47B4CC,conference-call,100,50,10/22/2020
47BA98,dividend-up,100,81,10/22/2020
485445,facility-open,100,65,10/22/2020
487B7A,dividend,100,50,10/22/2020
49A344,business-contract,100,69,10/22/2020
4A6F00,business-contract,100,69,10/22/2020
4A6F00,business-contract,100,69,10/22/2020
4AE584,earnings,100,50,10/22/2020
4B3676,partnership,100,61,10/22/2020
4B5054,legal-issues-defendant,100,22,10/22/2020
4C2F17,earnings,100,50,10/22/2020
4C6C63,earnings,100,50,10/22/2020
4C6C63,earnings,100,50,10/22/2020
4C6C63,earnings,100,50,10/22/2020
4C6C63,earnings,100,50,10/22/2020
4C6C63,earnings,100,50,10/22/2020
4C6C63,earnings,100,50,10/22/2020
4C6C63,earnings,100,50,10/22/2020
4C6C63,earnings,100,50,10/22/2020
4C6C63,earnings,100,50,10/22/2020
4DD09F,earnings,100,50,10/22/2020
4E913D,earnings,100,50,10/22/2020
4EE167,earnings,100,50,10/22/2020
4EE167,earnings,100,50,10/22/2020
50070E,regulatory-investigation,100,22,10/22/2020
52B567,conference-call,100,50,10/22/2020
53E575,earnings,100,50,10/22/2020
53F491,conference-organizer,100,57,10/22/2020
5546DA,earnings,100,50,10/22/2020
556A57,dividend,100,50,10/22/2020
57356F,earnings,100,50,10/22/2020
57356F,earnings,100,50,10/22/2020
57356F,earnings,100,50,10/22/2020
589F5A,dividend,100,50,10/22/2020
58CA9A,dividend,100,50,10/22/2020
59C539,earnings,100,50,10/22/2020
5A64D5,earnings,100,50,10/22/2020
5B3FA2,earnings,100,50,10/22/2020
5BE42C,dividend,100,50,10/22/2020
5BE42C,dividend,100,50,10/22/2020
5D1956,earnings,100,50,10/22/2020
5DA8B3,earnings,100,50,10/22/2020
5DE5A5,earnings-up,100,68,10/22/2020
5DE5A5,earnings,100,50,10/22/2020
5DE5A5,earnings,100,50,10/22/2020
5DE5A5,earnings,100,50,10/22/2020
5F1B7B,earnings,100,50,10/22/2020
5F6D73,executive-appointment,100,54,10/22/2020
5F9CE3,earnings,100,50,10/22/2020
61E975,dividend,100,50,10/22/2020
622037,dividend,100,50,10/22/2020
62F41C,partnership,100,61,10/22/2020
641F17,earnings,100,50,10/22/2020
641F17,earnings,100,50,10/22/2020
641F17,earnings,100,50,10/22/2020
641F17,earnings,100,50,10/22/2020
641F17,earnings,100,50,10/22/2020
641F17,earnings,100,50,10/22/2020
641F17,earnings,100,50,10/22/2020
641F17,earnings,100,50,10/22/2020
641F17,earnings,100,50,10/22/2020
641F17,earnings,100,50,10/22/2020
6474BA,earnings-positive,100,69,10/22/2020
6474BA,earnings,100,50,10/22/2020
6474BA,earnings,100,50,10/22/2020
6474BA,earnings,100,50,10/22/2020
6474BA,earnings,100,50,10/22/2020
6474BA,earnings,100,50,10/22/2020
6474BA,earnings,100,50,10/22/2020
6474BA,earnings,100,50,10/22/2020
6474BA,earnings,100,50,10/22/2020
6474BA,earnings,100,50,10/22/2020
6474BA,earnings,100,50,10/22/2020
6474BA,earnings,100,50,10/22/2020
6474BA,earnings,100,50,10/22/2020
665618,earnings-per-share-up,100,72,10/22/2020
665618,earnings-per-share-up,100,72,10/22/2020
67B052,earnings,100,50,10/22/2020
67B052,earnings,100,50,10/22/2020
6830FE,executive-appointment,100,54,10/22/2020
68586A,conference-call,100,50,10/22/2020
693ECD,partnership,100,61,10/22/2020
693ECD,partnership,100,61,10/22/2020
6A01DF,partnership,100,61,10/22/2020
6B0E45,dividend,100,50,10/22/2020
6B494E,executive-appointment,100,54,10/22/2020
6BDA0C,conference-call,100,50,10/22/2020
6CF43C,earnings,100,50,10/22/2020
6D156D,earnings,100,50,10/22/2020
6DBBBC,conference-call,100,50,10/22/2020
6DDA15,earnings,100,50,10/22/2020
6EB9DA,earnings,100,50,10/22/2020
6EB9DA,earnings,100,50,10/22/2020
6EB9DA,earnings,100,50,10/22/2020
713810,legal-issues-plaintiff,100,44,10/22/2020
7273FF,earnings,100,50,10/22/2020
72DF04,dividend,100,50,10/22/2020
72FCA3,award,100,58,10/22/2020
7410C3,earnings,100,50,10/22/2020
7448A3,conference-call,100,50,10/22/2020
7.45E+28,partnership,100,61,10/22/2020
7520CC,earnings,100,50,10/22/2020
7520CC,earnings,100,50,10/22/2020
7520CC,earnings,100,50,10/22/2020
7520CC,earnings,100,50,10/22/2020
756045,acquisition-completed-acquirer,100,49,10/22/2020
75F982,dividend,100,50,10/22/2020
76B926,executive-appointment,100,54,10/22/2020
7771D7,earnings,100,50,10/22/2020
77B8E9,partnership,100,61,10/22/2020
787D14,conference-call,100,50,10/22/2020
7AD81E,earnings,100,50,10/22/2020
7B0BA6,dividend,100,50,10/22/2020
7B492C,conference-call,100,50,10/22/2020
7D5384,earnings,100,50,10/22/2020
7D5384,earnings,100,50,10/22/2020
7D5384,earnings,100,50,10/22/2020
7D5384,earnings,100,50,10/22/2020
7D5384,earnings,100,50,10/22/2020
7D5FD6,earnings,100,50,10/22/2020
7F3665,earnings,100,50,10/22/2020
80D744,earnings,100,50,10/22/2020
824CCA,earnings,100,50,10/22/2020
82F088,conference-call,100,50,10/22/2020
830BDB,conference-call,100,50,10/22/2020
83598E,dividend-up,100,59,10/22/2020
835C86,earnings,100,50,10/22/2020
8377DB,earnings,100,50,10/22/2020
8377DB,earnings,100,50,10/22/2020
8377DB,earnings,100,50,10/22/2020
8377DB,earnings,100,50,10/22/2020
8377DB,earnings,100,50,10/22/2020
83A065,conference-call,100,50,10/22/2020
83B1C8,legal-issues-defendant,100,22,10/22/2020
845533,earnings,100,50,10/22/2020
85CDC9,earnings,100,50,10/22/2020
863350,earnings,100,50,10/22/2020
8876D6,partnership,100,61,10/22/2020
893904,legal-issues-defendant,100,22,10/22/2020
893904,legal-issues-defendant,100,22,10/22/2020
893904,legal-issues-defendant,100,22,10/22/2020
893904,legal-issues-defendant,100,22,10/22/2020
895D56,conference-call,100,50,10/22/2020
89FBB1,dividend,100,50,10/22/2020
8A8E41,partnership,100,61,10/22/2020
8A8E41,partnership,100,61,10/22/2020
8AB85C,public-offering,100,43,10/22/2020
8B2C4A,earnings,100,50,10/22/2020
8B2C4A,earnings,100,50,10/22/2020
8B2C4A,earnings,100,50,10/22/2020
8B2C4A,earnings,100,50,10/22/2020
8B2C4A,earnings,100,50,10/22/2020
8B2C4A,earnings,100,50,10/22/2020
8B2C4A,earnings,100,50,10/22/2020
8B2C4A,earnings,100,50,10/22/2020
8C311A,partnership,100,61,10/22/2020
8C311A,conference-participant,100,50,10/22/2020
8C6C1B,facility-open,100,65,10/22/2020
8C6C1B,note-sale,100,52,10/22/2020
8D4486,partnership,100,61,10/22/2020
8D5145,earnings,100,50,10/22/2020
8DA42F,conference-call,100,50,10/22/2020
8DCF18,conference-call,100,50,10/22/2020
8DDA23,earnings,100,50,10/22/2020
8DE74B,earnings,100,50,10/22/2020
902255,earnings,100,50,10/22/2020
907ED2,earnings,100,50,10/22/2020
91E5EE,earnings,100,50,10/22/2020
943239,earnings,100,50,10/22/2020
94756D,conference-participant,100,50,10/22/2020
965360,earnings,100,50,10/22/2020
9673BD,conference-call,100,50,10/22/2020
96B4FF,public-offering,100,43,10/22/2020
96F126,partnership,100,61,10/22/2020
972356,facility-sale,100,52,10/22/2020
97644E,earnings,100,50,10/22/2020
97AAF6,dividend,100,50,10/22/2020
97FE80,partnership,100,61,10/22/2020
986AF6,earnings,100,50,10/22/2020
986AF6,earnings,100,50,10/22/2020
986AF6,earnings,100,50,10/22/2020
989E2F,earnings,100,50,10/22/2020
989E2F,earnings,100,50,10/22/2020
989E2F,earnings,100,50,10/22/2020
989E2F,earnings,100,50,10/22/2020
990AD0,executive-appointment,100,54,10/22/2020
9934AD,conference-call,100,50,10/22/2020
9.97E+09,earnings,100,50,10/22/2020
9A2760,earnings,100,50,10/22/2020
9ABD30,earnings,100,50,10/22/2020
9C25FF,conference-call,100,50,10/22/2020
9D307D,business-contract,100,69,10/22/2020
9D307D,earnings,100,50,10/22/2020
9E98F2,award,100,58,10/22/2020
A017F4,product-release,100,64,10/22/2020
A02FB1,earnings,100,50,10/22/2020
A204A7,earnings,100,50,10/22/2020
A29A46,conference-call,100,50,10/22/2020
A29DBD,earnings,100,50,10/22/2020
A350C1,facility-open,100,65,10/22/2020
A4BCDE,business-contract,100,69,10/22/2020
A4BCDE,business-contract,100,69,10/22/2020
A4D173,earnings,100,50,10/22/2020
A4D173,earnings,100,50,10/22/2020
A5195E,earnings,100,50,10/22/2020
A5628C,earnings-positive,100,69,10/22/2020
A5B913,earnings,100,50,10/22/2020
A5B913,earnings,100,50,10/22/2020
A65325,note-sale,100,52,10/22/2020
A6828A,dividend,100,50,10/22/2020
A94A7B,partnership,100,61,10/22/2020
A94A7B,partnership,100,61,10/22/2020
A94A7B,partnership,100,61,10/22/2020
AA247D,earnings,100,50,10/22/2020
AB4A7E,conference-call,100,50,10/22/2020
ABAA03,partnership,100,61,10/22/2020
ABAA03,partnership,100,61,10/22/2020
AC7C4F,business-contract,100,69,10/22/2020
AD375D,earnings,100,50,10/22/2020
AFD1CA,earnings,100,50,10/22/2020
AFD7DD,partnership,100,61,10/22/2020
B076A1,conference-call,100,50,10/22/2020
B0B969,earnings,100,50,10/22/2020
B1FC3B,business-contract,100,69,10/22/2020
B48FC9,partnership,100,61,10/22/2020
B5766D,earnings-per-share-positive,100,69,10/22/2020
B5766D,earnings,100,50,10/22/2020
B5766D,earnings,100,50,10/22/2020
B5766D,earnings,100,50,10/22/2020
B5766D,earnings,100,50,10/22/2020
B5766D,earnings,100,50,10/22/2020
B66928,earnings,100,50,10/22/2020
B7202A,conference-call,100,50,10/22/2020
B83BCE,earnings,100,50,10/22/2020
B96637,earnings-up,100,68,10/22/2020
B96637,earnings-up,100,68,10/22/2020
BA0442,earnings,100,50,10/22/2020
BAAA60,dividend,100,50,10/22/2020
BB88B6,partnership,100,61,10/22/2020
BC3AD2,earnings,100,50,10/22/2020
BC3AD2,earnings,100,50,10/22/2020
BC3AD2,earnings,100,50,10/22/2020
BC3AD2,earnings,100,50,10/22/2020
BC3AD2,earnings,100,50,10/22/2020
BC3AD2,earnings,100,50,10/22/2020
BC3AD2,earnings,100,50,10/22/2020
BC3AD2,earnings,100,50,10/22/2020
BCC13E,earnings,100,50,10/22/2020
BDCC11,earnings,100,50,10/22/2020
BEB756,earnings,100,50,10/22/2020
BF79F5,earnings,100,50,10/22/2020
BF79F5,earnings,100,50,10/22/2020
BF79F5,earnings,100,50,10/22/2020
C037A8,conference-call,100,50,10/22/2020
C062D4,dividend,100,50,10/22/2020
C07E05,earnings,100,50,10/22/2020
C0BA36,conference-call,100,50,10/22/2020
C0BA36,conference-call,100,50,10/22/2020
C1114B,conference-call,100,50,10/22/2020
C11C46,executive-appointment,100,54,10/22/2020
C15DB3,earnings,100,50,10/22/2020
C16A8F,dividend,100,50,10/22/2020
C38440,earnings,100,50,10/22/2020
C41C25,earnings,100,50,10/22/2020
C4452A,dividend,100,50,10/22/2020
C4A432,executive-appointment,100,54,10/22/2020
C8A059,earnings,100,50,10/22/2020
C98CDB,investment-investor,100,55,10/22/2020
C99CC8,note-sale,100,52,10/22/2020
C9E107,earnings,100,50,10/22/2020
C9E107,dividend,100,50,10/22/2020
C9E107,earnings-up,100,68,10/22/2020
C9E4EC,earnings,100,50,10/22/2020
CA99D7,conference-call,100,50,10/22/2020
CA99D7,conference-call,100,50,10/22/2020
CB89EA,earnings,100,50,10/22/2020
CDAB24,earnings,100,50,10/22/2020
CE96E7,reorganization-unit,100,53,10/22/2020
CF073E,partnership,100,61,10/22/2020
CF6A5A,partnership,100,61,10/22/2020
CF6A5A,partnership,100,61,10/22/2020
CF6A5A,partnership,100,61,10/22/2020
CF6A5A,earnings,100,50,10/22/2020
CFD4B6,conference-call,100,50,10/22/2020
CFE5BE,buybacks,100,74,10/22/2020
D1AE3B,earnings,100,50,10/22/2020
D29B44,earnings,100,50,10/22/2020
D29F43,conference-call,100,50,10/22/2020
D33D8C,investment-investor,100,55,10/22/2020
D33D8C,dividend,100,50,10/22/2020
D4463B,earnings,100,50,10/22/2020
D4AC65,business-contract,100,69,10/22/2020
D6489C,partnership,100,61,10/22/2020
D6853F,earnings,100,50,10/22/2020
D6853F,earnings,100,50,10/22/2020
D8F347,earnings,100,50,10/22/2020
D8F347,earnings,100,50,10/22/2020
D8F347,earnings,100,50,10/22/2020
D9B1C9,earnings,100,50,10/22/2020
D9B1C9,earnings,100,50,10/22/2020
D9B1C9,earnings,100,50,10/22/2020
DA90E1,earnings,100,50,10/22/2020
DBCA3F,executive-appointment,100,54,10/22/2020
DBCA3F,earnings,100,50,10/22/2020
DC1405,executive-appointment,100,54,10/22/2020
DD0099,earnings-up,100,72,10/22/2020
DDC415,earnings,100,50,10/22/2020
DDC415,earnings,100,50,10/22/2020
DDC415,earnings,100,50,10/22/2020
DDC415,earnings,100,50,10/22/2020
DDC415,earnings,100,50,10/22/2020
DDC415,earnings,100,50,10/22/2020
DDEA6A,earnings,100,50,10/22/2020
E05DC8,earnings,100,50,10/22/2020
E10D31,dividend,100,50,10/22/2020
E114F4,conference-call,100,50,10/22/2020
E124EB,earnings,100,50,10/22/2020
E124EB,earnings,100,50,10/22/2020
E124EB,earnings,100,50,10/22/2020
E124EB,earnings,100,50,10/22/2020
E13782,revenues,100,50,10/22/2020
E2CB7B,earnings,100,50,10/22/2020
E2CFD2,conference-call,100,50,10/22/2020
E2F130,earnings,100,50,10/22/2020
E393B0,earnings,100,50,10/22/2020
E40FB6,earnings,100,50,10/22/2020
E40FB6,earnings,100,50,10/22/2020
E40FB6,earnings,100,50,10/22/2020
E40FB6,earnings,100,50,10/22/2020
E40FB6,earnings,100,50,10/22/2020
E40FB6,earnings,100,50,10/22/2020
E5F0A8,earnings-positive,100,69,10/22/2020
E5F0A8,earnings,100,50,10/22/2020
E5F0A8,earnings,100,50,10/22/2020
E5F0A8,earnings,100,50,10/22/2020
E5F0A8,earnings,100,50,10/22/2020
E68C3D,partnership,100,61,10/22/2020
E82A2D,conference-call,100,50,10/22/2020
E866D2,earnings,100,50,10/22/2020
E866D2,earnings,100,50,10/22/2020
E866D2,earnings,100,50,10/22/2020
E866D2,earnings,100,50,10/22/2020
E866D2,earnings,100,50,10/22/2020
E866D2,earnings,100,50,10/22/2020
E866D2,earnings,100,50,10/22/2020
E866D2,earnings,100,50,10/22/2020
E8B315,earnings-positive,100,69,10/22/2020
E94704,earnings,100,50,10/22/2020
E94704,earnings,100,50,10/22/2020
E94704,earnings,100,50,10/22/2020
E94704,earnings,100,50,10/22/2020
E94704,earnings,100,50,10/22/2020
E959F3,earnings,100,50,10/22/2020
E99180,earnings,100,50,10/22/2020
EA62FC,dividend,100,50,10/22/2020
EAA0A7,earnings,100,50,10/22/2020
EB2F14,earnings,100,50,10/22/2020
ED8676,earnings-positive,100,69,10/22/2020
ED8676,earnings-positive,100,69,10/22/2020
ED8676,earnings-positive,100,69,10/22/2020
ED8676,earnings-positive,100,69,10/22/2020
ED8676,earnings-positive,100,69,10/22/2020
ED8676,earnings-positive,100,69,10/22/2020
ED8676,earnings-positive,100,69,10/22/2020
ED8676,earnings-positive,100,69,10/22/2020
ED8676,earnings-positive,100,69,10/22/2020
ED8676,earnings-positive,100,69,10/22/2020
ED8676,dividend,100,50,10/22/2020
EEA6B3,earnings,100,50,10/22/2020
EEA6B3,earnings,100,50,10/22/2020
EEA6B3,earnings,100,50,10/22/2020
F0B2B5,executive-appointment,100,54,10/22/2020
F0B877,earnings,100,50,10/22/2020
F2E253,conference-call,100,50,10/22/2020
F30508,fraud,100,44,10/22/2020
F3FCC3,earnings,100,50,10/22/2020
F40EE2,partnership,100,61,10/22/2020
F44EA2,earnings,100,50,10/22/2020
F4D241,earnings,100,50,10/22/2020
F4E882,earnings,100,50,10/22/2020
F4FBD8,earnings,100,50,10/22/2020
F6E248,executive-appointment,100,54,10/22/2020
F702CA,earnings,100,50,10/22/2020
F702CA,earnings,100,50,10/22/2020
F702CA,earnings,100,50,10/22/2020
F702CA,earnings,100,50,10/22/2020
F702CA,earnings,100,50,10/22/2020
F702CA,earnings,100,50,10/22/2020
F7935D,earnings,100,50,10/22/2020
FA840E,conference-call,100,50,10/22/2020
FBD92D,earnings,100,50,10/22/2020
FC1B7B,earnings,100,50,10/22/2020
FC1F9D,earnings-up,100,68,10/22/2020
FC9A88,earnings,100,50,10/22/2020
FD2565,conference-call,100,50,10/22/2020
FEE4B0,business-contract,100,69,10/22/2020
FEE4B0,business-contract,100,69,10/22/2020
FEE4B0,partnership,100,61,10/22/2020
FF6644,partnership,100,61,10/22/2020
0157B1,facility-open,100,65,10/23/2020
02870F,conference-call,100,50,10/23/2020
07CA6A,partnership,100,61,10/23/2020
07CA6A,partnership,100,61,10/23/2020
07EC43,legal-issues-defendant,100,22,10/23/2020
083F72,conference-call,100,50,10/23/2020
0A7650,earnings,100,50,10/23/2020
0C28D1,executive-appointment,100,54,10/23/2020
0EF1AF,earnings,100,50,10/23/2020
0FC848,earnings,100,50,10/23/2020
102F04,earnings,100,50,10/23/2020
10673F,earnings,100,50,10/23/2020
10673F,earnings,100,50,10/23/2020
108BD2,earnings,100,50,10/23/2020
1096C6,earnings,100,50,10/23/2020
119CB6,dividend,100,50,10/23/2020
156A99,earnings,100,50,10/23/2020
16B882,earnings,100,50,10/23/2020
1BC12C,business-combination,100,54,10/23/2020
1DDEDA,conference-call,100,50,10/23/2020
2096DE,earnings,100,50,10/23/2020
2158DF,award,100,58,10/23/2020
250BEE,dividend,100,50,10/23/2020
272472,dividend,100,50,10/23/2020
28AC4E,executive-appointment,100,54,10/23/2020
2A6DBE,legal-issues-defendant,100,22,10/23/2020
2F7A7E,executive-appointment,100,54,10/23/2020
2F98A5,dividend,100,50,10/23/2020
337024,earnings,100,50,10/23/2020
341759,partnership,100,61,10/23/2020
353DBB,earnings,100,50,10/23/2020
353DBB,earnings,100,50,10/23/2020
353DBB,earnings,100,50,10/23/2020
35AE32,earnings,100,50,10/23/2020
3A1C46,executive-appointment,100,54,10/23/2020
3B20AB,conference-participant,100,50,10/23/2020
3B37F7,conference-call,100,50,10/23/2020
3BB616,business-contract,100,69,10/23/2020
41B53E,earnings,100,50,10/23/2020
435ACE,dividend,100,50,10/23/2020
499C75,acquisition-completed-acquirer,100,49,10/23/2020
4B5054,legal-issues-defendant,100,22,10/23/2020
4C37C5,revenues,100,50,10/23/2020
4C37C5,revenues,100,50,10/23/2020
4C37C5,revenues,100,50,10/23/2020
4C7DB5,earnings,100,50,10/23/2020
4D371E,dividend,100,50,10/23/2020
4D72C8,conference-call,100,50,10/23/2020
4D72C8,conference-call,100,50,10/23/2020
4EC4C1,earnings,100,50,10/23/2020
4F71DC,public-offering,100,43,10/23/2020
50702E,conference-call,100,50,10/23/2020
562853,earnings,100,50,10/23/2020
57A854,earnings,100,50,10/23/2020
5AA3B1,earnings,100,50,10/23/2020
5AAE17,buybacks,100,74,10/23/2020
665D7D,legal-issues-defendant,100,22,10/23/2020
69CE71,conference-call,100,50,10/23/2020
6B236C,dividend,100,50,10/23/2020
6B67BD,earnings,100,50,10/23/2020
6E8349,earnings,100,50,10/23/2020
7032D0,earnings,100,50,10/23/2020
72F0FC,dividend,100,50,10/23/2020
72F0FC,earnings-up,100,68,10/23/2020
76BD96,conference-call,100,50,10/23/2020
76CEFB,earnings,100,50,10/23/2020
7AB859,partnership,100,61,10/23/2020
7B1E50,donation,100,54,10/23/2020
7B4B91,executive-appointment,100,54,10/23/2020
80D744,legal-issues-defendant,100,22,10/23/2020
80D744,legal-issues-defendant,100,22,10/23/2020
80D744,legal-issues-defendant,100,22,10/23/2020
80D744,legal-issues-defendant,100,22,10/23/2020
859281,dividend,100,50,10/23/2020
893904,legal-issues-defendant,100,22,10/23/2020
89FBB1,earnings-guidance-down,100,19,10/23/2020
8C6C1B,facility-open,100,65,10/23/2020
8DA42F,facility-open,100,65,10/23/2020
9004C4,conference-call,100,50,10/23/2020
94637C,business-contract,100,69,10/23/2020
94A326,clinical-trials-positive,100,87,10/23/2020
9AF3DC,dividend,100,50,10/23/2020
9E4A5F,earnings,100,50,10/23/2020
A79D88,executive-appointment,100,54,10/23/2020
A8B137,donation,100,54,10/23/2020
AABEA0,earnings,100,50,10/23/2020
AABEA0,earnings,100,50,10/23/2020
AABEA0,earnings,100,50,10/23/2020
B2D799,legal-issues-defendant,100,22,10/23/2020
B446B8,award,100,58,10/23/2020
B48FC9,earnings,100,50,10/23/2020
BB58FF,conference-participant,100,50,10/23/2020
C1CBA4,dividend,100,50,10/23/2020
C4A432,executive-resignation,100,44,10/23/2020
C501B6,legal-issues-defendant,100,22,10/23/2020
C501B6,legal-issues-defendant,100,22,10/23/2020
C564E4,partnership,100,61,10/23/2020
C9B932,legal-issues-defendant,100,22,10/23/2020
C9B932,legal-issues-defendant,100,22,10/23/2020
C9B932,legal-issues-defendant,100,22,10/23/2020
C9B932,legal-issues-defendant,100,22,10/23/2020
C9B932,legal-issues-defendant,100,22,10/23/2020
CC339B,earnings,100,50,10/23/2020
CCB623,earnings,100,50,10/23/2020
CD06A2,earnings,100,50,10/23/2020
CE4E6D,conference-call,100,50,10/23/2020
CED4D0,stake-acquirer,100,48,10/23/2020
CED4D0,legal-issues-defendant,100,22,10/23/2020
CFF15D,conference-call,100,50,10/23/2020
D0DFE5,earnings,100,50,10/23/2020
D1C26F,partnership,100,61,10/23/2020
D7F569,earnings,100,50,10/23/2020
D7F569,dividend-up,100,57,10/23/2020
DA0A9E,earnings,100,50,10/23/2020
DB5CA5,dividend,100,50,10/23/2020
DBEF02,earnings,100,50,10/23/2020
DF204B,conference-call,100,50,10/23/2020
DF8855,earnings,100,50,10/23/2020
E22FDE,conference-call,100,50,10/23/2020
E22FDE,legal-issues-defendant,100,22,10/23/2020
E3656D,earnings-guidance,100,50,10/23/2020
E6E012,dividend-up,100,58,10/23/2020
E6E012,dividend-up,100,58,10/23/2020
E71AE6,clinical-trials,100,56,10/23/2020
EA4E68,earnings,100,50,10/23/2020
ED0D7C,earnings,100,50,10/23/2020
ED0D7C,earnings,100,50,10/23/2020
ED0D7C,earnings,100,50,10/23/2020
ED0D7C,earnings,100,50,10/23/2020
ED0D7C,earnings,100,50,10/23/2020
EE1E44,earnings-up,100,68,10/23/2020
EE1E44,earnings-up,100,68,10/23/2020
EE1E44,earnings-up,100,68,10/23/2020
EE1E44,earnings-up,100,68,10/23/2020
EE1E44,earnings-up,100,68,10/23/2020
EE1E44,earnings-up,100,68,10/23/2020
EE6F1C,dividend,100,50,10/23/2020
EEA6B3,partnership,100,61,10/23/2020
EF25A5,executive-appointment,100,54,10/23/2020
F04E05,executive-appointment,100,54,10/23/2020
F4CDA3,conference-call,100,50,10/23/2020
F6E248,acquisition-completed-acquirer,100,49,10/23/2020
FD39EB,dividend,100,50,10/23/2020
FDC08C,earnings,100,50,10/23/2020
FDC08C,earnings,100,50,10/23/2020
FDC08C,earnings,100,50,10/23/2020
FDC08C,earnings,100,50,10/23/2020
FDC08C,earnings,100,50,10/23/2020
FF6644,legal-issues-defendant,100,22,10/23/2020
30A565,legal-issues-defendant,100,22,10/24/2020
3AAEAE,clinical-trials,100,56,10/24/2020
57634F,legal-issues-defendant,100,22,10/24/2020
619882,legal-issues-defendant,100,22,10/24/2020
619882,legal-issues-defendant,100,22,10/24/2020
7C4F43,clinical-trials,100,56,10/24/2020
80D744,legal-issues-defendant,100,22,10/24/2020
80D744,legal-issues-defendant,100,22,10/24/2020
C9B932,legal-issues-defendant,100,22,10/24/2020
370C50,earnings,100,50,10/25/2020
80D744,legal-issues-defendant,100,22,10/25/2020
C9B932,legal-issues-defendant,100,22,10/25/2020
EEA6B3,acquisition-interest-acquiree,100,82,10/25/2020
00FC70,conference-call,100,50,10/26/2020
0142B5,buybacks,100,74,10/26/2020
03596A,earnings,100,50,10/26/2020
04996E,earnings,100,50,10/26/2020
054B55,conference-call,100,50,10/26/2020
58828,earnings-per-share-positive,100,69,10/26/2020
06EE79,earnings,100,50,10/26/2020
07CA6A,executive-appointment,100,54,10/26/2020
07CA6A,executive-appointment,100,54,10/26/2020
98977,regulatory-product-approval-granted,100,81,10/26/2020
0B13E8,executive-appointment,100,54,10/26/2020
0B400D,earnings,100,50,10/26/2020
0B400D,executive-appointment,100,54,10/26/2020
0F0693,earnings,100,50,10/26/2020
10C19B,executive-appointment,100,54,10/26/2020
14833D,earnings,100,50,10/26/2020
152E1D,conference-call,100,50,10/26/2020
168A5D,partnership,100,61,10/26/2020
17EDA5,conference-call,100,50,10/26/2020
188394,executive-appointment,100,54,10/26/2020
18D9FA,conference-call,100,50,10/26/2020
1E04A5,earnings,100,50,10/26/2020
1E9A6D,merger,100,66,10/26/2020
1F19C8,fundraising,100,64,10/26/2020
1F2B5D,earnings,100,50,10/26/2020
1F2B5D,earnings,100,50,10/26/2020
1F2B5D,earnings,100,50,10/26/2020
1F2B5D,earnings,100,50,10/26/2020
1F2B5D,earnings,100,50,10/26/2020
1F2B5D,earnings,100,50,10/26/2020
1F2B5D,earnings,100,50,10/26/2020
206852,earnings,100,50,10/26/2020
20DC4E,dividend,100,50,10/26/2020
214051,earnings,100,50,10/26/2020
228D42,partnership,100,61,10/26/2020
25DD05,earnings,100,50,10/26/2020
2667B6,acquisition-acquiree,100,76,10/26/2020
28DCF3,earnings,100,50,10/26/2020
297DA8,business-contract,100,69,10/26/2020
2A9C0A,earnings-positive,100,69,10/26/2020
2A9C0A,earnings,100,50,10/26/2020
2A9C0A,earnings,100,50,10/26/2020
2A9C0A,earnings,100,50,10/26/2020
2A9C0A,earnings,100,50,10/26/2020
2A9C0A,earnings,100,50,10/26/2020
2A9C0A,earnings,100,50,10/26/2020
2B5483,earnings,100,50,10/26/2020
2CF9D3,orphan-drug-designation,100,76,10/26/2020
2DB344,earnings,100,50,10/26/2020
30A565,legal-issues-defendant,100,22,10/26/2020
317EC6,public-offering,100,43,10/26/2020
319BE2,dividend-up,100,81,10/26/2020
319BE2,earnings,100,50,10/26/2020
328250,unit-acquisition-acquiree,100,76,10/26/2020
339F20,earnings,100,50,10/26/2020
34B97A,earnings,100,50,10/26/2020
34B97A,earnings,100,50,10/26/2020
34B97A,earnings,100,50,10/26/2020
34B97A,earnings,100,50,10/26/2020
3A4BDB,earnings-positive,100,69,10/26/2020
3AAEAE,public-offering,100,43,10/26/2020
3B8484,acquisition-acquirer,100,49,10/26/2020
3BB616,earnings,100,50,10/26/2020
3BB616,earnings,100,50,10/26/2020
3BB616,earnings,100,50,10/26/2020
3DB18B,earnings,100,50,10/26/2020
416C55,earnings,100,50,10/26/2020
4398A2,regulatory-product-approval-granted,100,81,10/26/2020
449217,earnings-positive,100,69,10/26/2020
449217,earnings,100,50,10/26/2020
449217,earnings,100,50,10/26/2020
449217,earnings,100,50,10/26/2020
449217,earnings,100,50,10/26/2020
449217,earnings,100,50,10/26/2020
44DDBD,conference-call,100,50,10/26/2020
4591D3,revenue-up,100,78,10/26/2020
4591D3,revenues,100,50,10/26/2020
4591D3,revenues,100,50,10/26/2020
4591D3,revenues,100,50,10/26/2020
4591D3,revenues,100,50,10/26/2020
4591D3,revenues,100,50,10/26/2020
49914B,earnings,100,50,10/26/2020
49914B,earnings,100,50,10/26/2020
49914B,earnings,100,50,10/26/2020
49BBBC,partnership,100,61,10/26/2020
49CC59,earnings,100,50,10/26/2020
4B3DC9,executive-resignation,100,44,10/26/2020
4B3DC9,earnings,100,50,10/26/2020
4B3DC9,earnings,100,50,10/26/2020
4B3DC9,earnings,100,50,10/26/2020
4B3DC9,earnings,100,50,10/26/2020
4B3DC9,earnings,100,50,10/26/2020
4B3DC9,earnings,100,50,10/26/2020
4B3DC9,earnings,100,50,10/26/2020
4B3DC9,earnings,100,50,10/26/2020
4B3DC9,earnings,100,50,10/26/2020
4B3DC9,earnings,100,50,10/26/2020
4B3DC9,earnings,100,50,10/26/2020
4B3DC9,earnings,100,50,10/26/2020
4B3DC9,earnings,100,50,10/26/2020
4B5054,legal-issues-defendant,100,22,10/26/2020
4C37C5,executive-appointment,100,54,10/26/2020
4C37C5,partnership,100,61,10/26/2020
4D8E5E,earnings,100,50,10/26/2020
504FE2,business-contract,100,69,10/26/2020
5065B1,earnings,100,50,10/26/2020
51E682,earnings,100,50,10/26/2020
543C77,clinical-trials,100,56,10/26/2020
546A27,legal-issues-defendant,100,22,10/26/2020
55D0F3,earnings,100,50,10/26/2020
56AFF4,dividend,100,50,10/26/2020
56EA2B,earnings-per-share,100,50,10/26/2020
59B229,earnings,100,50,10/26/2020
59B229,earnings,100,50,10/26/2020
59B229,earnings,100,50,10/26/2020
59B229,earnings,100,50,10/26/2020
59B229,earnings,100,50,10/26/2020
5A423F,conference-participant,100,50,10/26/2020
5BE42C,earnings,100,50,10/26/2020
5C8D61,earnings,100,50,10/26/2020
5C8D61,earnings,100,50,10/26/2020
5C8D61,earnings,100,50,10/26/2020
5D02B7,earnings,100,50,10/26/2020
619882,legal-issues-defendant,100,22,10/26/2020
619882,legal-issues-defendant,100,22,10/26/2020
61B81B,conference-participant,100,50,10/26/2020
65AB30,executive-appointment,100,54,10/26/2020
665D7D,legal-issues-defendant,100,22,10/26/2020
68B03F,earnings,100,50,10/26/2020
693ECD,business-contract,100,69,10/26/2020
694749,note-sale,100,52,10/26/2020
698FF9,earnings,100,50,10/26/2020
6B5379,earnings,100,50,10/26/2020
6BDA0C,note-sale,100,52,10/26/2020
6BDA0C,note-sale,100,52,10/26/2020
6C987C,executive-appointment,100,54,10/26/2020
6CD55A,earnings,100,50,10/26/2020
6D2BF6,earnings,100,50,10/26/2020
6D9B53,executive-appointment,100,54,10/26/2020
6DBBBC,dividend,100,50,10/26/2020
70B3D6,note-sale,100,52,10/26/2020
728737,earnings,100,50,10/26/2020
748EB6,conference-call,100,50,10/26/2020
771985,stake-acquiree,100,62,10/26/2020
79340A,earnings,100,50,10/26/2020
7A975D,dividend,100,50,10/26/2020
7BC92D,earnings,100,50,10/26/2020
7CBC40,earnings,100,50,10/26/2020
7CBC40,earnings,100,50,10/26/2020
7CBC40,earnings,100,50,10/26/2020
7CBC40,earnings,100,50,10/26/2020
7E1542,earnings,100,50,10/26/2020
7E2DE6,earnings,100,50,10/26/2020
805CD8,conference-call,100,50,10/26/2020
80C400,conference-call,100,50,10/26/2020
80D744,legal-issues-defendant,100,22,10/26/2020
80D744,legal-issues-defendant,100,22,10/26/2020
83066C,conference-call,100,50,10/26/2020
835C86,dividend,100,50,10/26/2020
8377DB,executive-appointment,100,54,10/26/2020
84A6B9,earnings,100,50,10/26/2020
84A6B9,earnings,100,50,10/26/2020
84A6B9,earnings,100,50,10/26/2020
84A6B9,earnings,100,50,10/26/2020
84A6B9,earnings,100,50,10/26/2020
84A6B9,earnings,100,50,10/26/2020
84A6B9,earnings,100,50,10/26/2020
859281,earnings,100,50,10/26/2020
859281,earnings,100,50,10/26/2020
859281,earnings,100,50,10/26/2020
859281,earnings,100,50,10/26/2020
859281,earnings,100,50,10/26/2020
859281,earnings,100,50,10/26/2020
859281,earnings,100,50,10/26/2020
859281,earnings,100,50,10/26/2020
85AD00,earnings,100,50,10/26/2020
85CDC9,patient-enrollment-start,100,58,10/26/2020
85CDC9,patient-enrollment-start,100,58,10/26/2020
8.79E+06,earnings,100,50,10/26/2020
8AB37F,conference-call,100,50,10/26/2020
8AB85C,public-offering,100,43,10/26/2020
8B9B3B,earnings,100,50,10/26/2020
8C1238,conference-call,100,50,10/26/2020
8C6C1B,facility-open,100,65,10/26/2020
8D4AE6,earnings,100,50,10/26/2020
8D4AE6,earnings,100,50,10/26/2020
8D4AE6,earnings,100,50,10/26/2020
8D4AE6,earnings,100,50,10/26/2020
8D4AE6,earnings,100,50,10/26/2020
8DE56F,earnings,100,50,10/26/2020
8DE56F,earnings,100,50,10/26/2020
8E10BF,regulatory-product-approval-granted,100,81,10/26/2020
8E3F58,earnings,100,50,10/26/2020
8E93A4,earnings,100,50,10/26/2020
8FE7A5,earnings,100,50,10/26/2020
92D9C9,earnings,100,50,10/26/2020
93F143,executive-appointment,100,54,10/26/2020
942633,partnership,100,61,10/26/2020
944B2E,earnings,100,50,10/26/2020
945DE6,executive-appointment,100,54,10/26/2020
94C0B5,earnings,100,50,10/26/2020
950AB7,earnings,100,50,10/26/2020
95DE39,earnings-positive,100,69,10/26/2020
95DE39,earnings-positive,100,69,10/26/2020
95DE39,earnings-positive,100,69,10/26/2020
95DE39,earnings-positive,100,69,10/26/2020
95DE39,earnings-positive,100,69,10/26/2020
95DE39,earnings-positive,100,69,10/26/2020
990AD0,conference-organizer,100,57,10/26/2020
997348,earnings,100,50,10/26/2020
997348,earnings,100,50,10/26/2020
997348,earnings,100,50,10/26/2020
9978F1,public-offering,100,43,10/26/2020
99B61C,patient-enrollment-complete,100,64,10/26/2020
9B71A7,executive-appointment,100,54,10/26/2020
9BF177,executive-appointment,100,54,10/26/2020
9CA4C6,unit-acquisition-acquiree,100,76,10/26/2020
9CE4C7,note-sale,100,52,10/26/2020
9CE4C7,public-offering,100,43,10/26/2020
9D5D35,earnings,100,50,10/26/2020
9D5D35,earnings,100,50,10/26/2020
9D5D35,earnings,100,50,10/26/2020
9EBAFA,unit-acquisition-acquirer,100,49,10/26/2020
9F18FA,earnings,100,50,10/26/2020
9F18FA,earnings,100,50,10/26/2020
9FB4B7,conference-participant,100,50,10/26/2020
A350C1,operating-earnings,100,50,10/26/2020
A350C1,operating-earnings,100,50,10/26/2020
A350C1,operating-earnings,100,50,10/26/2020
A350C1,operating-earnings,100,50,10/26/2020
A350C1,operating-earnings,100,50,10/26/2020
A350C1,operating-earnings,100,50,10/26/2020
A350C1,operating-earnings,100,50,10/26/2020
A3BFAA,dividend,100,50,10/26/2020
A41450,earnings,100,50,10/26/2020
A47A7D,earnings,100,50,10/26/2020
A47F2E,earnings,100,50,10/26/2020
A4A612,earnings,100,50,10/26/2020
A63387,executive-appointment,100,54,10/26/2020
A6FE1C,acquisition-acquirer,100,49,10/26/2020
A70BF5,market-entry,100,57,10/26/2020
A96867,earnings-positive,100,69,10/26/2020
A96867,earnings-positive,100,69,10/26/2020
A96867,earnings-positive,100,69,10/26/2020
A96867,earnings-positive,100,69,10/26/2020
A96867,earnings-positive,100,69,10/26/2020
A96867,earnings-positive,100,69,10/26/2020
A96867,earnings-positive,100,69,10/26/2020
A96867,earnings-positive,100,69,10/26/2020
A96867,earnings-positive,100,69,10/26/2020
AA98ED,earnings,100,50,10/26/2020
AAEE21,earnings,100,50,10/26/2020
AC7AAE,earnings,100,50,10/26/2020
AD9F1D,product-release,100,64,10/26/2020
ADF1B0,earnings,100,50,10/26/2020
ADF1B0,earnings,100,50,10/26/2020
ADF1B0,earnings,100,50,10/26/2020
AFDF2E,asset-sale,100,62,10/26/2020
B2F431,earnings-positive,100,69,10/26/2020
B33E77,earnings,100,50,10/26/2020
B508E5,conference-call,100,50,10/26/2020
B5766D,executive-resignation,100,44,10/26/2020
B60366,executive-appointment,100,54,10/26/2020
B6082A,earnings,100,50,10/26/2020
B619CB,earnings-positive,100,69,10/26/2020
B77F14,conference-call,100,50,10/26/2020
B9764A,dividend,100,50,10/26/2020
BBAE2A,dividend-up,100,62,10/26/2020
BC4876,fundraising,100,64,10/26/2020
BDEF34,earnings,100,50,10/26/2020
BDEF34,earnings,100,50,10/26/2020
BDEF34,earnings,100,50,10/26/2020
BDEF34,earnings,100,50,10/26/2020
BDEF34,earnings,100,50,10/26/2020
BDEF34,earnings,100,50,10/26/2020
BDEF34,earnings,100,50,10/26/2020
BDEF34,earnings,100,50,10/26/2020
BDEF34,earnings,100,50,10/26/2020
BDEF34,earnings,100,50,10/26/2020
BDEF34,earnings,100,50,10/26/2020
BE7BA4,public-offering,100,43,10/26/2020
BFE02C,executive-appointment,100,54,10/26/2020
C03C8B,conference-participant,100,50,10/26/2020
C0F70B,earnings,100,50,10/26/2020
C501B6,legal-issues-defendant,100,22,10/26/2020
C564E4,clinical-trials-positive,100,87,10/26/2020
C598D7,revenue-up,100,59,10/26/2020
C598D7,revenues,100,50,10/26/2020
C598D7,revenues,100,50,10/26/2020
C5E100,conference-call,100,50,10/26/2020
C5E840,conference-call,100,50,10/26/2020
C6C702,partnership,100,61,10/26/2020
C9732E,clinical-trials,100,56,10/26/2020
C9881C,partnership,100,61,10/26/2020
C98CDB,executive-appointment,100,54,10/26/2020
C99CC8,earnings,100,50,10/26/2020
C99CC8,earnings,100,50,10/26/2020
C99CC8,earnings,100,50,10/26/2020
C99CC8,earnings,100,50,10/26/2020
C99CC8,earnings,100,50,10/26/2020
C9B932,legal-issues-defendant,100,22,10/26/2020
C9B932,legal-issues-defendant,100,22,10/26/2020
CAB222,clinical-trials-start,100,64,10/26/2020
CC35BE,earnings,100,50,10/26/2020
CE8251,executive-appointment,100,54,10/26/2020
CE96E7,partnership,100,61,10/26/2020
CF351E,merger,100,66,10/26/2020
CFE5BE,dividend,100,50,10/26/2020
D064D5,dividend-up,100,81,10/26/2020
D17F7E,executive-appointment,100,54,10/26/2020
D3C794,earnings,100,50,10/26/2020
D42DBA,partnership,100,61,10/26/2020
D90F43,partnership,100,61,10/26/2020
D9B1C9,business-contract,100,69,10/26/2020
DAC66A,earnings,100,50,10/26/2020
DCD97F,government-contract,100,69,10/26/2020
DD9E41,earnings,100,50,10/26/2020
DD9E41,earnings,100,50,10/26/2020
DD9E41,earnings,100,50,10/26/2020
DD9E41,earnings,100,50,10/26/2020
DD9E41,earnings,100,50,10/26/2020
DD9E41,earnings,100,50,10/26/2020
DF204B,facility-open,100,65,10/26/2020
DF42A0,conference-call,100,50,10/26/2020
DF46C5,dividend,100,50,10/26/2020
DF46C5,earnings,100,50,10/26/2020
DF46C5,earnings,100,50,10/26/2020
DF46C5,earnings,100,50,10/26/2020
DF46C5,earnings,100,50,10/26/2020
DF46C5,earnings,100,50,10/26/2020
E09997,conference-call,100,50,10/26/2020
E22FDE,legal-issues-defendant,100,22,10/26/2020
E68733,regulatory-product-approval-granted,100,81,10/26/2020
E70531,earnings,100,50,10/26/2020
E7BF32,earnings,100,50,10/26/2020
E7BF32,earnings,100,50,10/26/2020
E802CE,earnings,100,50,10/26/2020
E87676,dividend,100,50,10/26/2020
EB1E1A,business-contract,100,69,10/26/2020
EB1E1A,acquisition-acquiree,100,76,10/26/2020
EB1E1A,business-contract,100,69,10/26/2020
ED5171,dividend,100,50,10/26/2020
ED7F13,earnings,100,50,10/26/2020
EE74E1,product-release,100,64,10/26/2020
EF5BED,public-offering,100,43,10/26/2020
F179ED,earnings,100,50,10/26/2020
F179ED,earnings,100,50,10/26/2020
F179ED,earnings,100,50,10/26/2020
F179ED,earnings,100,50,10/26/2020
F24FF0,earnings,100,50,10/26/2020
F294DD,earnings,100,50,10/26/2020
F294DD,earnings,100,50,10/26/2020
F294DD,earnings,100,50,10/26/2020
F294DD,earnings,100,50,10/26/2020
F47871,earnings,100,50,10/26/2020
F5C78B,earnings,100,50,10/26/2020
F6581D,merger,100,66,10/26/2020
F6581D,capital-increase,100,43,10/26/2020
F6581D,capital-increase,100,43,10/26/2020
F6E248,business-contract,100,69,10/26/2020
F95726,earnings,100,50,10/26/2020
FB728F,asset-sale,100,62,10/26/2020
FC9A88,dividend,100,50,10/26/2020
FD1312,earnings,100,50,10/26/2020
FFAB4A,product-release,100,64,10/26/2020
0157B1,facility-open,100,65,10/27/2020
01D03F,partnership,100,61,10/27/2020
01D03F,partnership,100,61,10/27/2020
01D03F,partnership,100,61,10/27/2020
03B8CF,earnings,100,50,10/27/2020
03B8CF,earnings,100,50,10/27/2020
03B8CF,earnings,100,50,10/27/2020
03B8CF,earnings,100,50,10/27/2020
03B8CF,earnings,100,50,10/27/2020
03B8CF,earnings,100,50,10/27/2020
03B8CF,earnings,100,50,10/27/2020
053EFF,conference-call,100,50,10/27/2020
054B55,note-sale,100,52,10/27/2020
61366,earnings,100,50,10/27/2020
095A04,earnings,100,50,10/27/2020
0BA8CE,earnings,100,50,10/27/2020
0BC17A,executive-appointment,100,54,10/27/2020
0C355F,earnings-up,100,68,10/27/2020
0C355F,earnings-up,100,68,10/27/2020
0C355F,earnings-up,100,68,10/27/2020
0C355F,earnings-up,100,68,10/27/2020
0C4131,buybacks,100,74,10/27/2020
0F65C9,earnings,100,50,10/27/2020
0F65C9,dividend-up,100,59,10/27/2020
102727,earnings,100,50,10/27/2020
108FDA,earnings,100,50,10/27/2020
1096C6,product-release,100,64,10/27/2020
119CB6,earnings-per-share-positive,100,69,10/27/2020
1220D2,earnings,100,50,10/27/2020
131443,earnings,100,50,10/27/2020
131443,earnings,100,50,10/27/2020
131443,earnings,100,50,10/27/2020
131443,earnings,100,50,10/27/2020
131443,earnings,100,50,10/27/2020
131443,earnings,100,50,10/27/2020
131443,earnings,100,50,10/27/2020
136B26,earnings,100,50,10/27/2020
15901B,legal-issues-defendant,100,22,10/27/2020
1866B2,earnings,100,50,10/27/2020
190B91,earnings,100,50,10/27/2020
190B91,earnings,100,50,10/27/2020
190B91,earnings,100,50,10/27/2020
190B91,earnings,100,50,10/27/2020
190B91,earnings,100,50,10/27/2020
190B91,earnings,100,50,10/27/2020
190B91,earnings,100,50,10/27/2020
19BF16,conference-participant,100,50,10/27/2020
1A3E1B,dividend,100,50,10/27/2020
1BDB2A,dividend,100,50,10/27/2020
1BDB2A,earnings,100,50,10/27/2020
1CD4B5,public-offering,100,43,10/27/2020
1DE526,conference-call,100,50,10/27/2020
1E1125,conference-organizer,100,57,10/27/2020
1E1125,conference-organizer,100,57,10/27/2020
1EBF8D,earnings,100,50,10/27/2020
1F3CFB,partnership,100,61,10/27/2020
1F9258,earnings,100,50,10/27/2020
1F9D90,earnings,100,50,10/27/2020
1FE3CB,dividend,100,50,10/27/2020
1FE3CB,operating-earnings,100,50,10/27/2020
2082EA,conference-call,100,50,10/27/2020
221445,earnings,100,50,10/27/2020
223216,revenue-up,100,56,10/27/2020
223552,earnings,100,50,10/27/2020
225CA2,earnings,100,50,10/27/2020
225CA2,earnings,100,50,10/27/2020
225CA2,earnings,100,50,10/27/2020
225CA2,earnings,100,50,10/27/2020
225CA2,earnings,100,50,10/27/2020
225CA2,earnings,100,50,10/27/2020
225CA2,earnings,100,50,10/27/2020
225CA2,earnings,100,50,10/27/2020
225CA2,earnings,100,50,10/27/2020
225CA2,earnings,100,50,10/27/2020
225CA2,earnings,100,50,10/27/2020
225CA2,earnings,100,50,10/27/2020
228D42,partnership,100,61,10/27/2020
228D42,partnership,100,61,10/27/2020
22C58E,earnings,100,50,10/27/2020
238302,conference-call,100,50,10/27/2020
24A89A,executive-appointment,100,54,10/27/2020
2667B6,earnings,100,50,10/27/2020
267718,earnings,100,50,10/27/2020
267718,earnings,100,50,10/27/2020
267718,earnings,100,50,10/27/2020
267718,earnings,100,50,10/27/2020
267718,earnings,100,50,10/27/2020
267718,earnings,100,50,10/27/2020
267718,earnings,100,50,10/27/2020
267718,earnings,100,50,10/27/2020
267718,earnings,100,50,10/27/2020
270305,dividend,100,50,10/27/2020
27A791,conference-call,100,50,10/27/2020
2B9DBB,note-sale,100,52,10/27/2020
2CA60F,earnings,100,50,10/27/2020
2CA60F,earnings,100,50,10/27/2020
2CA60F,earnings,100,50,10/27/2020
2CA60F,earnings,100,50,10/27/2020
2CBB58,earnings,100,50,10/27/2020
2CBB58,earnings,100,50,10/27/2020
2CBB58,earnings,100,50,10/27/2020
2CBB58,earnings,100,50,10/27/2020
2D643C,dividend,100,50,10/27/2020
2E2E6E,earnings,100,50,10/27/2020
2E61CC,note-sale,100,52,10/27/2020
2E6514,earnings,100,50,10/27/2020
2E6514,earnings,100,50,10/27/2020
2E6514,earnings,100,50,10/27/2020
2E6514,earnings,100,50,10/27/2020
2E6514,earnings,100,50,10/27/2020
2E6514,earnings,100,50,10/27/2020
2EC172,earnings,100,50,10/27/2020
2EC172,earnings,100,50,10/27/2020
2EC172,earnings,100,50,10/27/2020
2EC172,earnings,100,50,10/27/2020
2EC172,earnings,100,50,10/27/2020
2EC172,earnings,100,50,10/27/2020
2F24A5,earnings,100,50,10/27/2020
2F9304,executive-appointment,100,54,10/27/2020
306623,partnership,100,61,10/27/2020
32DCB3,executive-appointment,100,54,10/27/2020
33A0F1,executive-appointment,100,54,10/27/2020
343996,earnings,100,50,10/27/2020
3461CF,award,100,58,10/27/2020
346BF2,conference-call,100,50,10/27/2020
366A08,acquisition-acquirer,100,49,10/27/2020
366A08,public-offering,100,43,10/27/2020
37020C,earnings,100,50,10/27/2020
373B06,earnings,100,50,10/27/2020
3.73E+87,acquisition-acquiree,100,76,10/27/2020
3.73E+87,acquisition-acquiree,100,76,10/27/2020
3.73E+87,legal-issues-defendant,100,22,10/27/2020
3.73E+87,acquisition-regulatory-scrutiny-acquiree,100,38,10/27/2020
384CD3,partnership,100,61,10/27/2020
3.88E+02,legal-issues-defendant,100,22,10/27/2020
3BCF24,earnings,100,50,10/27/2020
3E15F6,unit-acquisition-acquirer,100,49,10/27/2020
3ED92D,earnings,100,50,10/27/2020
3ED92D,earnings,100,50,10/27/2020
3ED92D,earnings,100,50,10/27/2020
3ED92D,earnings,100,50,10/27/2020
3ED92D,earnings,100,50,10/27/2020
3ED92D,earnings,100,50,10/27/2020
3ED92D,earnings,100,50,10/27/2020
3ED92D,earnings,100,50,10/27/2020
3F6A9C,dividend,100,50,10/27/2020
408089,earnings,100,50,10/27/2020
40B903,executive-appointment,100,54,10/27/2020
40F7DE,product-release,100,64,10/27/2020
416291,legal-issues-defendant,100,22,10/27/2020
420168,earnings,100,50,10/27/2020
427F32,dividend,100,50,10/27/2020
43F4A8,earnings,100,50,10/27/2020
44209A,revenue-up,100,57,10/27/2020
44209A,revenue-up,100,57,10/27/2020
44209A,revenue-up,100,57,10/27/2020
450ECB,earnings,100,50,10/27/2020
453282,dividend,100,50,10/27/2020
45BC35,acquisition-acquirer,100,49,10/27/2020
45BC35,acquisition-acquirer,100,49,10/27/2020
45BC35,earnings,100,50,10/27/2020
467F2C,earnings,100,50,10/27/2020
46CF27,earnings,100,50,10/27/2020
46CF27,earnings,100,50,10/27/2020
46CF27,earnings,100,50,10/27/2020
46CF27,earnings,100,50,10/27/2020
46CF27,earnings,100,50,10/27/2020
46CF27,earnings,100,50,10/27/2020
46CF27,earnings,100,50,10/27/2020
46CF27,earnings,100,50,10/27/2020
46CF27,earnings,100,50,10/27/2020
46CF27,earnings,100,50,10/27/2020
47BA98,earnings,100,50,10/27/2020
485445,earnings,100,50,10/27/2020
4885C8,dividend,100,50,10/27/2020
492117,earnings,100,50,10/27/2020
4A6F00,product-release,100,64,10/27/2020
4A6F00,product-release,100,64,10/27/2020
4A6F00,partnership,100,61,10/27/2020
4A6F00,partnership,100,61,10/27/2020
4B3DC9,earnings,100,50,10/27/2020
4B5054,legal-issues-defendant,100,22,10/27/2020
4B5054,legal-issues-defendant,100,22,10/27/2020
4C2F17,conference-participant,100,50,10/27/2020
4C5CC9,dividend,100,50,10/27/2020
4DD203,conference-call,100,50,10/27/2020
4E7C1F,earnings,100,50,10/27/2020
4E7C1F,earnings,100,50,10/27/2020
4E7C1F,earnings,100,50,10/27/2020
5340D0,earnings,100,50,10/27/2020
53EF9E,earnings,100,50,10/27/2020
553949,earnings,100,50,10/27/2020
553949,earnings,100,50,10/27/2020
553949,earnings,100,50,10/27/2020
553949,earnings,100,50,10/27/2020
553949,earnings,100,50,10/27/2020
553949,earnings,100,50,10/27/2020
56632F,earnings,100,50,10/27/2020
56632F,earnings,100,50,10/27/2020
56632F,earnings,100,50,10/27/2020
567F3D,earnings,100,50,10/27/2020
567F3D,earnings,100,50,10/27/2020
567F3D,earnings,100,50,10/27/2020
567F3D,earnings,100,50,10/27/2020
56AFF4,executive-appointment,100,54,10/27/2020
57634F,legal-issues-defendant,100,22,10/27/2020
583223,earnings,100,50,10/27/2020
583A75,earnings,100,50,10/27/2020
586BD7,conference-call,100,50,10/27/2020
589F5A,earnings,100,50,10/27/2020
596116,earnings-up,100,68,10/27/2020
596116,earnings,100,50,10/27/2020
596116,earnings,100,50,10/27/2020
59DB8C,partnership,100,61,10/27/2020
59DB8C,partnership,100,61,10/27/2020
5B3415,earnings,100,50,10/27/2020
5B3415,earnings,100,50,10/27/2020
5D41E4,earnings,100,50,10/27/2020
5DD48B,business-contract,100,69,10/27/2020
5E6959,earnings,100,50,10/27/2020
5E6959,earnings,100,50,10/27/2020
60DD84,revenues,100,50,10/27/2020
60DD84,revenues,100,50,10/27/2020
60DD84,revenues,100,50,10/27/2020
6166D1,executive-appointment,100,54,10/27/2020
619882,legal-issues-defendant,100,22,10/27/2020
619882,executive-appointment,100,54,10/27/2020
619882,partnership,100,61,10/27/2020
619882,legal-issues-defendant,100,22,10/27/2020
64854A,conference-call,100,50,10/27/2020
649CBD,clinical-trials,100,56,10/27/2020
6634D9,earnings,100,50,10/27/2020
665D7D,legal-issues-defendant,100,22,10/27/2020
66A667,note-sale,100,52,10/27/2020
66A667,note-sale,100,52,10/27/2020
66A667,note-sale,100,52,10/27/2020
66A667,note-sale,100,52,10/27/2020
673C9A,conference-call,100,50,10/27/2020
68E3E0,dividend,100,50,10/27/2020
69345C,earnings,100,50,10/27/2020
69345C,earnings,100,50,10/27/2020
69345C,earnings,100,50,10/27/2020
69345C,earnings,100,50,10/27/2020
69345C,acquisition-acquirer,100,49,10/27/2020
69345C,acquisition-acquirer,100,49,10/27/2020
6C4D2F,earnings,100,50,10/27/2020
6C4D2F,earnings,100,50,10/27/2020
6C4D2F,earnings,100,50,10/27/2020
6C4D2F,earnings,100,50,10/27/2020
6C4D2F,earnings,100,50,10/27/2020
6C4D2F,earnings,100,50,10/27/2020
6C4D2F,earnings,100,50,10/27/2020
6C4D2F,earnings,100,50,10/27/2020
6C4D2F,earnings,100,50,10/27/2020
6D9ECA,clinical-trials-start,100,64,10/27/2020
6DDA15,partnership,100,61,10/27/2020
6F0A63,earnings-up,100,68,10/27/2020
6F0A63,unit-acquisition-acquirer,100,49,10/27/2020
6F3FA8,award,100,58,10/27/2020
704B78,earnings,100,50,10/27/2020
70CA28,business-contract,100,69,10/27/2020
72609A,earnings,100,50,10/27/2020
72609A,earnings,100,50,10/27/2020
72609A,earnings,100,50,10/27/2020
72609A,earnings,100,50,10/27/2020
7.44E+09,dividend-up,100,56,10/27/2020
7.40E+289,earnings,100,50,10/27/2020
75F665,executive-resignation,100,44,10/27/2020
762A3E,earnings,100,50,10/27/2020
762A3E,earnings,100,50,10/27/2020
762A3E,earnings,100,50,10/27/2020
762A3E,earnings,100,50,10/27/2020
762A3E,earnings,100,50,10/27/2020
762A3E,earnings,100,50,10/27/2020
762A3E,dividend,100,50,10/27/2020
762B8D,public-offering,100,43,10/27/2020
765913,earnings,100,50,10/27/2020
767F86,earnings,100,50,10/27/2020
767F86,earnings,100,50,10/27/2020
767F86,earnings,100,50,10/27/2020
767F86,earnings,100,50,10/27/2020
767F86,earnings,100,50,10/27/2020
767F86,earnings,100,50,10/27/2020
767F86,earnings,100,50,10/27/2020
767F86,earnings,100,50,10/27/2020
767F86,earnings,100,50,10/27/2020
767F86,earnings,100,50,10/27/2020
76F067,earnings,100,50,10/27/2020
7734AC,earnings,100,50,10/27/2020
7734AC,earnings,100,50,10/27/2020
773A17,revenues,100,50,10/27/2020
78A1BB,earnings-up,100,68,10/27/2020
791D59,conference-participant,100,50,10/27/2020
7AC86E,earnings-up,100,68,10/27/2020
7AC86E,earnings,100,50,10/27/2020
7AC86E,earnings,100,50,10/27/2020
7B4B91,conference-call,100,50,10/27/2020
7BFF81,earnings-up,100,68,10/27/2020
7BFF81,earnings-up,100,68,10/27/2020
7C75FD,earnings-up,100,68,10/27/2020
7C75FD,dividend-up,100,81,10/27/2020
7DC1C4,executive-appointment,100,54,10/27/2020
80D744,legal-issues-defendant,100,22,10/27/2020
80D744,patent-awarded,100,72,10/27/2020
80D744,legal-issues-defendant,100,22,10/27/2020
81F4BE,earnings,100,50,10/27/2020
81F4BE,earnings,100,50,10/27/2020
81F4BE,earnings,100,50,10/27/2020
81F4BE,earnings,100,50,10/27/2020
81F4BE,earnings,100,50,10/27/2020
81F4BE,earnings,100,50,10/27/2020
8303CD,earnings,100,50,10/27/2020
8377DB,earnings,100,50,10/27/2020
8377DB,earnings,100,50,10/27/2020
88193E,conference-participant,100,50,10/27/2020
8AC65D,earnings,100,50,10/27/2020
8BE916,earnings-up,100,68,10/27/2020
8BFE9A,conference-call,100,50,10/27/2020
8D4486,dividend,100,50,10/27/2020
8D4486,dividend,100,50,10/27/2020
8E82A6,dividend,100,50,10/27/2020
8F8F2F,earnings,100,50,10/27/2020
8F8F2F,earnings,100,50,10/27/2020
92D6A5,earnings,100,50,10/27/2020
92D757,executive-appointment,100,54,10/27/2020
9.31E+77,conference-call,100,50,10/27/2020
94563D,earnings,100,50,10/27/2020
94563D,earnings,100,50,10/27/2020
94563D,earnings,100,50,10/27/2020
94563D,earnings,100,50,10/27/2020
94563D,earnings,100,50,10/27/2020
94A326,clinical-trials,100,56,10/27/2020
9.65E+09,conference-call,100,50,10/27/2020
9A29F4,conference-call,100,50,10/27/2020
9B4066,unit-acquisition-acquirer,100,49,10/27/2020
9EF4CF,earnings,100,50,10/27/2020
9F6B1A,earnings,100,50,10/27/2020
9F6B1A,earnings,100,50,10/27/2020
9F6B1A,earnings,100,50,10/27/2020
9F6B1A,earnings,100,50,10/27/2020
9FB4B7,earnings,100,50,10/27/2020
A1A317,earnings,100,50,10/27/2020
A1A317,earnings,100,50,10/27/2020
A1A317,earnings,100,50,10/27/2020
A1A317,earnings,100,50,10/27/2020
A26C26,executive-appointment,100,54,10/27/2020
A37D68,partnership,100,61,10/27/2020
A48593,conference-call,100,50,10/27/2020
A4F67C,earnings,100,50,10/27/2020
A5E715,earnings,100,50,10/27/2020
A631A3,partnership,100,61,10/27/2020
A70BF5,earnings,100,50,10/27/2020
A70BF5,earnings,100,50,10/27/2020
A70BF5,earnings,100,50,10/27/2020
A70BF5,earnings,100,50,10/27/2020
A70BF5,earnings,100,50,10/27/2020
A70BF5,earnings,100,50,10/27/2020
A79D88,earnings,100,50,10/27/2020
A79D88,earnings,100,50,10/27/2020
A868C9,business-contract,100,69,10/27/2020
A87CD6,earnings-per-share-down,100,27,10/27/2020
A87CD6,earnings-per-share-positive,100,69,10/27/2020
A87CD6,earnings-per-share-positive,100,69,10/27/2020
A87CD6,earnings-per-share-positive,100,69,10/27/2020
A87CD6,earnings-per-share-positive,100,69,10/27/2020
A87CD6,earnings-per-share-positive,100,69,10/27/2020
A87CD6,earnings-per-share-positive,100,69,10/27/2020
A8B137,earnings,100,50,10/27/2020
A8B137,earnings,100,50,10/27/2020
A8B137,earnings,100,50,10/27/2020
A8B137,earnings,100,50,10/27/2020
A8B137,earnings,100,50,10/27/2020
A94718,earnings,100,50,10/27/2020
AC642C,conference-participant,100,50,10/27/2020
AC642C,conference-participant,100,50,10/27/2020
ACF0B4,conference-call,100,50,10/27/2020
AD3C93,earnings,100,50,10/27/2020
AE4EEB,earnings,100,50,10/27/2020
AEEB76,earnings,100,50,10/27/2020
AEF2C3,earnings,100,50,10/27/2020
AF93DE,conference-call,100,50,10/27/2020
AFF7B4,earnings,100,50,10/27/2020
AFF7B4,earnings,100,50,10/27/2020
AFF7B4,earnings,100,50,10/27/2020
B076A1,earnings,100,50,10/27/2020
B076A1,earnings,100,50,10/27/2020
B076A1,earnings,100,50,10/27/2020
B0998E,earnings,100,50,10/27/2020
B106FA,earnings,100,50,10/27/2020
B290A2,partnership,100,61,10/27/2020
B290A2,partnership,100,61,10/27/2020
B290A2,partnership,100,61,10/27/2020
B290A2,partnership,100,61,10/27/2020
B37FB4,earnings,100,50,10/27/2020
B37FB4,earnings,100,50,10/27/2020
B37FB4,earnings,100,50,10/27/2020
B37FB4,earnings,100,50,10/27/2020
B37FB4,earnings,100,50,10/27/2020
B37FB4,earnings,100,50,10/27/2020
B37FB4,earnings,100,50,10/27/2020
B381D8,earnings,100,50,10/27/2020
B5766D,dividend,100,50,10/27/2020
B840EF,earnings,100,50,10/27/2020
BA218A,executive-appointment,100,54,10/27/2020
BB0787,executive-appointment,100,54,10/27/2020
BB5271,earnings,100,50,10/27/2020
BC5680,legal-issues-defendant,100,22,10/27/2020
BDF85E,note-sale,100,52,10/27/2020
BFAEB4,dividend-up,100,81,10/27/2020
BFCACF,earnings,100,50,10/27/2020
C0BA36,award,100,58,10/27/2020
C1CBA4,earnings-positive,100,69,10/27/2020
C1CBA4,earnings-positive,100,69,10/27/2020
C1CBA4,earnings-positive,100,69,10/27/2020
C1CBA4,earnings-positive,100,69,10/27/2020
C1CBA4,earnings-positive,100,69,10/27/2020
C1CBA4,earnings-positive,100,69,10/27/2020
C1CBA4,earnings-positive,100,69,10/27/2020
C1CBA4,earnings-positive,100,69,10/27/2020
C1CBA4,earnings-positive,100,69,10/27/2020
C2E426,earnings,100,50,10/27/2020
C3CF29,earnings,100,50,10/27/2020
C3CF29,earnings,100,50,10/27/2020
C3CF29,earnings,100,50,10/27/2020
C3CF29,earnings,100,50,10/27/2020
C41C25,dividend,100,50,10/27/2020
C45CE7,earnings,100,50,10/27/2020
C501B6,legal-issues-defendant,100,22,10/27/2020
C501B6,legal-issues-defendant,100,22,10/27/2020
C564E4,earnings,100,50,10/27/2020
C5C137,partnership,100,61,10/27/2020
C659EB,earnings,100,50,10/27/2020
C659EB,earnings,100,50,10/27/2020
C659EB,earnings,100,50,10/27/2020
C659EB,earnings,100,50,10/27/2020
C72B8F,earnings,100,50,10/27/2020
C7859D,conference-participant,100,50,10/27/2020
C8257F,earnings,100,50,10/27/2020
C85A72,revenue-up,100,70,10/27/2020
C85A72,revenue-up,100,70,10/27/2020
C85A72,revenue-up,100,70,10/27/2020
C85A72,revenue-up,100,70,10/27/2020
C9732E,public-offering,100,43,10/27/2020
C9739A,fast-track-designation,100,81,10/27/2020
C99CC8,earnings,100,50,10/27/2020
C99CC8,earnings,100,50,10/27/2020
C99CC8,earnings,100,50,10/27/2020
C99CC8,earnings,100,50,10/27/2020
C99CC8,earnings,100,50,10/27/2020
C99CC8,earnings,100,50,10/27/2020
CB9E13,earnings,100,50,10/27/2020
CBA33B,stock-splits,100,49,10/27/2020
CBA33B,executive-resignation,100,44,10/27/2020
CC0C78,earnings,100,50,10/27/2020
CC176E,earnings,100,50,10/27/2020
CC3EC4,earnings,100,50,10/27/2020
CD06A2,dividend,100,50,10/27/2020
CDAF5B,operating-earnings,100,50,10/27/2020
CDC217,conference-participant,100,50,10/27/2020
CDD75E,earnings,100,50,10/27/2020
CE1002,earnings-up,100,68,10/27/2020
CE1002,earnings,100,50,10/27/2020
CE1002,earnings,100,50,10/27/2020
CE1002,earnings,100,50,10/27/2020
CE1002,earnings,100,50,10/27/2020
CFF97C,revenue-up,100,59,10/27/2020
CFF97C,revenue-up,100,59,10/27/2020
CFF97C,revenue-up,100,59,10/27/2020
CFF97C,revenue-up,100,59,10/27/2020
CFF97C,revenue-up,100,59,10/27/2020
CFF97C,revenue-up,100,59,10/27/2020
CFF97C,credit-rating-confirmation-rater,20,50,10/27/2020
D04D9F,earnings,100,50,10/27/2020
D0DFE5,earnings-delayed,100,26,10/27/2020
D15833,dividend,100,50,10/27/2020
D15833,dividend,100,50,10/27/2020
D17C1B,earnings,100,50,10/27/2020
D17C1B,earnings,100,50,10/27/2020
D17C1B,earnings,100,50,10/27/2020
D17C1B,earnings,100,50,10/27/2020
D17C1B,product-release,100,64,10/27/2020
D17C1B,product-release,100,64,10/27/2020
D20C8F,earnings,100,50,10/27/2020
D501DC,earnings,100,50,10/27/2020
D54E62,acquisition-acquiree,100,76,10/27/2020
D6489C,award,100,58,10/27/2020
D6489C,award,100,58,10/27/2020
D6489C,award,100,58,10/27/2020
D64EDF,dividend,100,50,10/27/2020
D7918D,operating-earnings,100,50,10/27/2020
DA91AE,business-contract,100,69,10/27/2020
DB7FA7,earnings-positive,100,69,10/27/2020
DBCA3F,market-entry,100,57,10/27/2020
DBCA3F,market-entry,100,57,10/27/2020
DBFB51,business-contract,100,69,10/27/2020
DC1405,conference-participant,100,50,10/27/2020
DC486E,business-contract,100,69,10/27/2020
DC486E,business-contract,100,69,10/27/2020
DD1BA1,earnings,100,50,10/27/2020
DF11D9,earnings,100,50,10/27/2020
E0207A,partnership,100,61,10/27/2020
E07573,dividend-guidance,100,50,10/27/2020
E10D31,earnings,100,50,10/27/2020
E1BD05,earnings,100,50,10/27/2020
E21871,dividend,100,50,10/27/2020
E259C7,business-combination,100,54,10/27/2020
E30A8F,earnings,100,50,10/27/2020
E30A8F,earnings,100,50,10/27/2020
E30A8F,earnings,100,50,10/27/2020
E30A8F,earnings,100,50,10/27/2020
E38906,earnings,100,50,10/27/2020
E69BA5,conference-call,100,50,10/27/2020
E6E012,earnings,100,50,10/27/2020
E6E012,earnings,100,50,10/27/2020
E6E012,earnings,100,50,10/27/2020
E6E012,earnings,100,50,10/27/2020
E6E012,earnings,100,50,10/27/2020
E6E012,earnings,100,50,10/27/2020
E6EDED,earnings,100,50,10/27/2020
E87676,revenues,100,50,10/27/2020
E8846E,dividend,100,50,10/27/2020
E8A49A,earnings,100,50,10/27/2020
E8B21D,earnings,100,50,10/27/2020
E8B21D,earnings,100,50,10/27/2020
E8B21D,earnings,100,50,10/27/2020
E8B21D,earnings,100,50,10/27/2020
E8B21D,earnings,100,50,10/27/2020
E8B21D,earnings,100,50,10/27/2020
E9C7C0,partnership,100,61,10/27/2020
E9E6FD,earnings,100,50,10/27/2020
E9FF33,earnings,100,50,10/27/2020
EB61C4,earnings,100,50,10/27/2020
EC99D0,earnings,100,50,10/27/2020
ED0402,revenue-up,100,70,10/27/2020
ED0402,revenue-up,100,69,10/27/2020
ED0402,revenue-up,100,69,10/27/2020
ED0402,revenue-up,100,69,10/27/2020
ED0402,revenue-up,100,69,10/27/2020
ED4560,dividend,100,50,10/27/2020
EDF5CA,earnings,100,50,10/27/2020
EDF5CA,earnings,100,50,10/27/2020
EDF5CA,earnings,100,50,10/27/2020
EDF5CA,earnings,100,50,10/27/2020
EDF5CA,earnings,100,50,10/27/2020
EDF5CA,earnings,100,50,10/27/2020
EDF5CA,earnings,100,50,10/27/2020
EDF5CA,earnings,100,50,10/27/2020
EF25A5,partnership,100,61,10/27/2020
EF5914,earnings,100,50,10/27/2020
F04E05,earnings,100,50,10/27/2020
F0A9DE,earnings,100,50,10/27/2020
F0B2B5,earnings,100,50,10/27/2020
F2526D,earnings,100,50,10/27/2020
F30508,earnings,100,50,10/27/2020
F30508,earnings,100,50,10/27/2020
F30508,earnings,100,50,10/27/2020
F30508,earnings,100,50,10/27/2020
F30508,earnings,100,50,10/27/2020
F30508,earnings,100,50,10/27/2020
F39E1E,earnings,100,50,10/27/2020
F40EE2,earnings,100,50,10/27/2020
F40EE2,earnings,100,50,10/27/2020
F40EE2,earnings,100,50,10/27/2020
F5D410,earnings,100,50,10/27/2020
F88A04,product-release,100,64,10/27/2020
FAEABE,dividend,100,50,10/27/2020
FC01C0,conference-call,100,50,10/27/2020
FD4BBE,earnings,100,50,10/27/2020
FD4BBE,earnings,100,50,10/27/2020
FD4BBE,earnings,100,50,10/27/2020
FD9A97,dividend,100,50,10/27/2020
FFAB4A,earnings,100,50,10/27/2020
FFCD0E,revenues,100,50,10/27/2020
00D6B5,earnings,100,50,10/28/2020
00E601,operating-earnings,100,50,10/28/2020
13528,partnership,100,61,10/28/2020
03B8CF,earnings,100,50,10/28/2020
03B8CF,earnings,100,50,10/28/2020
03B8CF,earnings,100,50,10/28/2020
03B8CF,earnings,100,50,10/28/2020
03B8CF,earnings,100,50,10/28/2020
03B8CF,earnings,100,50,10/28/2020
03B8CF,earnings,100,50,10/28/2020
03B8CF,earnings,100,50,10/28/2020
03B8CF,earnings,100,50,10/28/2020
03B8CF,earnings,100,50,10/28/2020
03B8CF,earnings,100,50,10/28/2020
03B8CF,earnings,100,50,10/28/2020
03B8CF,earnings,100,50,10/28/2020
03B8CF,earnings,100,50,10/28/2020
03B8CF,earnings,100,50,10/28/2020
03B8CF,earnings,100,50,10/28/2020
03B8CF,earnings,100,50,10/28/2020
03B8CF,earnings,100,50,10/28/2020
03B8CF,earnings,100,50,10/28/2020
03B8CF,earnings,100,50,10/28/2020
03B8CF,earnings,100,50,10/28/2020
03B8CF,earnings,100,50,10/28/2020
03B8CF,earnings,100,50,10/28/2020
03B8CF,earnings,100,50,10/28/2020
03B8CF,earnings,100,50,10/28/2020
03B8CF,earnings,100,50,10/28/2020
03B8CF,earnings,100,50,10/28/2020
03B8CF,earnings,100,50,10/28/2020
03B8CF,earnings,100,50,10/28/2020
03B8CF,earnings,100,50,10/28/2020
03B8CF,earnings,100,50,10/28/2020
03B8CF,earnings,100,50,10/28/2020
03B8CF,earnings,100,50,10/28/2020
03B8CF,earnings,100,50,10/28/2020
03B8CF,earnings,100,50,10/28/2020
03B8CF,earnings,100,50,10/28/2020
03B8CF,earnings,100,50,10/28/2020
03B8CF,earnings,100,50,10/28/2020
03B8CF,earnings,100,50,10/28/2020
03B8CF,earnings,100,50,10/28/2020
03B8CF,earnings,100,50,10/28/2020
03B8CF,earnings,100,50,10/28/2020
03B8CF,earnings,100,50,10/28/2020
03B8CF,earnings,100,50,10/28/2020
03B8CF,earnings,100,50,10/28/2020
03CF95,investment-investor,100,55,10/28/2020
07C69F,earnings,100,50,10/28/2020
07CA6A,investment-investor,100,55,10/28/2020
07CA6A,investment-investor,100,55,10/28/2020
07EC43,earnings,100,50,10/28/2020
07EC43,earnings,100,50,10/28/2020
07EC43,earnings,100,50,10/28/2020
07EC43,earnings,100,50,10/28/2020
081AB9,earnings,100,50,10/28/2020
0986B5,earnings,100,50,10/28/2020
98977,earnings,100,50,10/28/2020
099A92,earnings,100,50,10/28/2020
0B2071,earnings,100,50,10/28/2020
0B4D10,earnings,100,50,10/28/2020
0B7375,clinical-trials-positive,100,87,10/28/2020
0B9E6F,earnings,100,50,10/28/2020
0B9E6F,earnings,100,50,10/28/2020
0C136E,earnings,100,50,10/28/2020
0C2A0D,earnings,100,50,10/28/2020
0CBC4D,revenue-up,100,69,10/28/2020
0CC62B,earnings,100,50,10/28/2020
0CC62B,earnings,100,50,10/28/2020
0CC62B,earnings,100,50,10/28/2020
0CC62B,earnings,100,50,10/28/2020
0CC62B,earnings,100,50,10/28/2020
0CC62B,earnings,100,50,10/28/2020
0CC62B,earnings,100,50,10/28/2020
0DBB81,executive-appointment,100,54,10/28/2020
0E2992,earnings-per-share-positive,100,69,10/28/2020
0EC508,earnings,100,50,10/28/2020
106394,earnings,100,50,10/28/2020
1216D1,earnings,100,50,10/28/2020
12DE76,product-release,100,64,10/28/2020
12DE76,product-release,100,64,10/28/2020
12F98C,partnership,100,61,10/28/2020
159AE4,dividend,100,50,10/28/2020
15B10D,earnings,100,50,10/28/2020
15B10D,earnings,100,50,10/28/2020
15B10D,earnings,100,50,10/28/2020
16F4D8,earnings,100,50,10/28/2020
16F4D8,earnings,100,50,10/28/2020
16F4D8,earnings,100,50,10/28/2020
16F4D8,earnings,100,50,10/28/2020
16F4D8,earnings,100,50,10/28/2020
16F4D8,earnings,100,50,10/28/2020
180DA0,earnings,100,50,10/28/2020
1834C0,dividend,100,50,10/28/2020
18D9FA,regulatory-product-application,100,69,10/28/2020
197019,dividend,100,50,10/28/2020
1A3E1B,executive-appointment,100,54,10/28/2020
1AE9D5,conference-call,100,50,10/28/2020
1B9535,earnings,100,50,10/28/2020
1D5C51,earnings,100,50,10/28/2020
1DB833,executive-appointment,100,54,10/28/2020
1E04A5,product-release,100,64,10/28/2020
1E1125,conference-organizer,100,57,10/28/2020
1E1125,conference-organizer,100,57,10/28/2020
1E8A99,earnings,100,50,10/28/2020
1EC3E8,earnings,100,50,10/28/2020
1EC3E8,earnings,100,50,10/28/2020
1F3CFB,earnings,100,50,10/28/2020
1F716B,earnings,100,50,10/28/2020
2003A5,earnings,100,50,10/28/2020
202E5A,conference-call,100,50,10/28/2020
2031CE,earnings,100,50,10/28/2020
2031CE,earnings,100,50,10/28/2020
2031CE,earnings,100,50,10/28/2020
2031CE,earnings,100,50,10/28/2020
2031CE,earnings,100,50,10/28/2020
2031CE,earnings,100,50,10/28/2020
2082EA,business-contract,100,69,10/28/2020
2093B1,earnings,100,50,10/28/2020
20D00A,operating-earnings,100,50,10/28/2020
21153F,buybacks,100,74,10/28/2020
21153F,buybacks,100,74,10/28/2020
21245F,earnings,100,50,10/28/2020
222BF9,earnings,100,50,10/28/2020
227D48,earnings,100,50,10/28/2020
227D48,earnings,100,50,10/28/2020
227D48,earnings,100,50,10/28/2020
227D48,earnings,100,50,10/28/2020
227D48,earnings,100,50,10/28/2020
228D42,business-contract,100,69,10/28/2020
228D42,partnership,100,61,10/28/2020
2.45E+15,executive-resignation,100,44,10/28/2020
2.45E+15,executive-resignation,100,44,10/28/2020
249674,earnings,100,50,10/28/2020
249B39,earnings-positive,100,69,10/28/2020
24FA23,earnings,100,50,10/28/2020
25A6CC,earnings,100,50,10/28/2020
25A6CC,earnings,100,50,10/28/2020
25A6CC,earnings,100,50,10/28/2020
25A6CC,earnings,100,50,10/28/2020
25A6CC,earnings,100,50,10/28/2020
264EB3,earnings,100,50,10/28/2020
264EB3,earnings,100,50,10/28/2020
264EB3,earnings,100,50,10/28/2020
264EB3,earnings,100,50,10/28/2020
264EB3,earnings,100,50,10/28/2020
264EB3,earnings,100,50,10/28/2020
267718,product-release,100,64,10/28/2020
26F31D,earnings,100,50,10/28/2020
26F31D,earnings,100,50,10/28/2020
26F31D,earnings,100,50,10/28/2020
26F31D,earnings,100,50,10/28/2020
28AC4E,earnings-up,100,68,10/28/2020
28AC4E,earnings,100,50,10/28/2020
28AC4E,earnings,100,50,10/28/2020
28AC4E,earnings,100,50,10/28/2020
28AC4E,earnings,100,50,10/28/2020
28DCA8,earnings-positive,100,69,10/28/2020
28DCA8,earnings,100,50,10/28/2020
28DCA8,earnings,100,50,10/28/2020
29CEBF,earnings,100,50,10/28/2020
29CEBF,earnings,100,50,10/28/2020
29CEBF,earnings,100,50,10/28/2020
29CEBF,earnings,100,50,10/28/2020
2.90E+62,earnings,100,50,10/28/2020
2.90E+62,earnings,100,50,10/28/2020
2.90E+62,earnings,100,50,10/28/2020
2.90E+62,earnings,100,50,10/28/2020
2.90E+62,earnings,100,50,10/28/2020
2.90E+62,earnings,100,50,10/28/2020
2.90E+62,dividend,100,50,10/28/2020
2B0AF4,revenues,100,50,10/28/2020
2B0AF4,revenues,100,50,10/28/2020
2B0AF4,revenues,100,50,10/28/2020
2B0AF4,revenues,100,50,10/28/2020
2BC05E,earnings,100,50,10/28/2020
2BC05E,earnings,100,50,10/28/2020
2BC05E,earnings,100,50,10/28/2020
2BC05E,earnings,100,50,10/28/2020
2BC05E,earnings,100,50,10/28/2020
2D2D43,dividend,100,50,10/28/2020
2D643C,earnings,100,50,10/28/2020
2E6514,executive-appointment,100,54,10/28/2020
2F6782,dividend,100,50,10/28/2020
2F94A5,dividend,100,50,10/28/2020
2FEA66,operating-earnings,100,50,10/28/2020
314D88,earnings,100,50,10/28/2020
315EB0,earnings,100,50,10/28/2020
315EB0,earnings,100,50,10/28/2020
315EB0,earnings,100,50,10/28/2020
315EB0,earnings,100,50,10/28/2020
315EB0,earnings,100,50,10/28/2020
315EB0,earnings,100,50,10/28/2020
315EB0,earnings,100,50,10/28/2020
315EB0,dividend,100,50,10/28/2020
317EC6,conference-participant,100,50,10/28/2020
3224CC,earnings,100,50,10/28/2020
326EDD,earnings,100,50,10/28/2020
32CB22,earnings-guidance-up,100,83,10/28/2020
33E8C7,earnings,100,50,10/28/2020
33E8C7,earnings,100,50,10/28/2020
33FD66,earnings,100,50,10/28/2020
33FD66,earnings,100,50,10/28/2020
33FD66,earnings,100,50,10/28/2020
33FD66,earnings,100,50,10/28/2020
33FD66,earnings,100,50,10/28/2020
33FD66,earnings,100,50,10/28/2020
34B411,dividend,100,50,10/28/2020
366A08,public-offering,100,43,10/28/2020
3696BF,earnings,100,50,10/28/2020
370C50,business-contract,100,69,10/28/2020
384CD3,earnings,100,50,10/28/2020
3.88E+02,dividend,100,50,10/28/2020
3A113F,earnings,100,50,10/28/2020
3A3447,earnings,100,50,10/28/2020
3A3447,earnings,100,50,10/28/2020
3A3447,earnings,100,50,10/28/2020
3A3447,earnings,100,50,10/28/2020
3A3447,earnings,100,50,10/28/2020
3A3447,earnings,100,50,10/28/2020
3C7F5F,executive-appointment,100,54,10/28/2020
3F4497,earnings,100,50,10/28/2020
416C55,partnership,100,61,10/28/2020
41D61C,earnings,100,50,10/28/2020
425BDC,earnings,100,50,10/28/2020
429BFB,earnings,100,50,10/28/2020
442769,conference-participant,100,50,10/28/2020
444CC8,conference-call,100,50,10/28/2020
458D2C,earnings,100,50,10/28/2020
47752F,earnings,100,50,10/28/2020
47752F,earnings,100,50,10/28/2020
47752F,earnings,100,50,10/28/2020
47752F,earnings,100,50,10/28/2020
479930,earnings,100,50,10/28/2020
47FCF2,earnings,100,50,10/28/2020
47FCF2,earnings,100,50,10/28/2020
47FCF2,earnings,100,50,10/28/2020
47FCF2,earnings,100,50,10/28/2020
47FCF2,earnings,100,50,10/28/2020
47FCF2,earnings,100,50,10/28/2020
47FCF2,earnings,100,50,10/28/2020
47FCF2,earnings,100,50,10/28/2020
47FCF2,earnings,100,50,10/28/2020
4806CE,dividend,100,50,10/28/2020
4885C8,executive-appointment,100,54,10/28/2020
4885C8,product-release,100,64,10/28/2020
494EB9,earnings,100,50,10/28/2020
4B3555,earnings,100,50,10/28/2020
4B5054,legal-issues-defendant,100,22,10/28/2020
4B5054,dividend,100,50,10/28/2020
4D971D,earnings,100,50,10/28/2020
4D971D,earnings,100,50,10/28/2020
4D971D,earnings,100,50,10/28/2020
4D971D,earnings,100,50,10/28/2020
4D971D,earnings,100,50,10/28/2020
4D971D,earnings,100,50,10/28/2020
4D971D,earnings,100,50,10/28/2020
4D971D,dividend,100,50,10/28/2020
507AE7,earnings,100,50,10/28/2020
5088A5,earnings,100,50,10/28/2020
51888A,dividend-up,100,91,10/28/2020
51888A,operating-earnings,100,50,10/28/2020
51B442,earnings,100,50,10/28/2020
51F541,earnings,100,50,10/28/2020
52BF94,earnings,100,50,10/28/2020
52BF94,earnings,100,50,10/28/2020
52BF94,earnings,100,50,10/28/2020
52BF94,earnings,100,50,10/28/2020
52BF94,earnings,100,50,10/28/2020
532D47,earnings,100,50,10/28/2020
53A226,earnings,100,50,10/28/2020
5.43E+08,earnings,100,50,10/28/2020
55438C,earnings,100,50,10/28/2020
55438C,earnings,100,50,10/28/2020
55438C,earnings,100,50,10/28/2020
55438C,earnings,100,50,10/28/2020
55438C,earnings,100,50,10/28/2020
55438C,earnings,100,50,10/28/2020
55438C,earnings,100,50,10/28/2020
55438C,earnings,100,50,10/28/2020
55438C,earnings,100,50,10/28/2020
55438C,earnings,100,50,10/28/2020
55438C,earnings,100,50,10/28/2020
55438C,earnings,100,50,10/28/2020
55438C,earnings,100,50,10/28/2020
55438C,earnings,100,50,10/28/2020
556F08,earnings,100,50,10/28/2020
55C289,earnings,100,50,10/28/2020
55C9B5,earnings,100,50,10/28/2020
564F3E,earnings,100,50,10/28/2020
5675EB,note-sale,100,52,10/28/2020
57EF50,conference-call,100,50,10/28/2020
594402,earnings,100,50,10/28/2020
5B6C11,facility-upgrade,100,65,10/28/2020
5DD486,earnings,100,50,10/28/2020
5DD48B,earnings,100,50,10/28/2020
5DD48B,earnings,100,50,10/28/2020
5EF130,conference-call,100,50,10/28/2020
5F6D73,earnings,100,50,10/28/2020
5F6D73,earnings,100,50,10/28/2020
5F6D73,earnings,100,50,10/28/2020
5F6D73,earnings,100,50,10/28/2020
5F6D73,earnings,100,50,10/28/2020
5F6D73,earnings,100,50,10/28/2020
605F40,earnings,100,50,10/28/2020
619882,executive-appointment,100,54,10/28/2020
619882,legal-issues-defendant,100,22,10/28/2020
63E8D5,earnings,100,50,10/28/2020
63E8D5,earnings,100,50,10/28/2020
641F17,dividend,100,50,10/28/2020
649CBD,earnings,100,50,10/28/2020
665D7D,legal-issues-defendant,100,22,10/28/2020
66A667,partnership,100,61,10/28/2020
66ECFD,earnings,100,50,10/28/2020
69345C,product-release,100,64,10/28/2020
69345C,product-release,100,64,10/28/2020
69345C,product-release,100,64,10/28/2020
694749,note-sale,100,52,10/28/2020
69C99E,earnings,100,50,10/28/2020
69FDFC,partnership,100,61,10/28/2020
6ACFBF,earnings,100,50,10/28/2020
6B0E45,earnings,100,50,10/28/2020
6B236C,earnings,100,50,10/28/2020
6B5379,dividend,100,50,10/28/2020
6E1E61,earnings,100,50,10/28/2020
6E705B,product-release,100,64,10/28/2020
6E7060,earnings,100,50,10/28/2020
6E7060,earnings,100,50,10/28/2020
6E7060,earnings,100,50,10/28/2020
6E7060,earnings,100,50,10/28/2020
6E7060,earnings,100,50,10/28/2020
6E7060,earnings,100,50,10/28/2020
6E7060,earnings,100,50,10/28/2020
6E7060,earnings,100,50,10/28/2020
6EB9DA,dividend,100,50,10/28/2020
6EB9DA,executive-appointment,100,54,10/28/2020
709AED,earnings,100,50,10/28/2020
709AED,dividend-up,100,81,10/28/2020
70B3D6,note-sale,100,52,10/28/2020
722D55,earnings,100,50,10/28/2020
729368,earnings,100,50,10/28/2020
731675,earnings,100,50,10/28/2020
732449,earnings,100,50,10/28/2020
73A213,earnings,100,50,10/28/2020
73A71F,dividend,100,50,10/28/2020
746373,earnings,100,50,10/28/2020
746373,earnings,100,50,10/28/2020
746373,earnings,100,50,10/28/2020
746373,dividend,100,50,10/28/2020
752A70,earnings,100,50,10/28/2020
763724,earnings,100,50,10/28/2020
763724,earnings,100,50,10/28/2020
763724,earnings,100,50,10/28/2020
766047,executive-appointment,100,54,10/28/2020
767F86,earnings,100,50,10/28/2020
76BECC,conference-call,100,50,10/28/2020
76DD0C,clinical-trials,100,56,10/28/2020
76F067,earnings,100,50,10/28/2020
76F067,earnings,100,50,10/28/2020
771985,earnings,100,50,10/28/2020
771985,earnings,100,50,10/28/2020
771985,earnings,100,50,10/28/2020
771985,earnings,100,50,10/28/2020
771985,earnings,100,50,10/28/2020
771985,earnings,100,50,10/28/2020
771985,earnings,100,50,10/28/2020
771985,earnings,100,50,10/28/2020
771985,earnings,100,50,10/28/2020
771985,earnings,100,50,10/28/2020
782B46,earnings,100,50,10/28/2020
789ADD,dividend,100,50,10/28/2020
7A5097,conference-participant,100,50,10/28/2020
7AB859,earnings,100,50,10/28/2020
7AB859,earnings,100,50,10/28/2020
7AB859,earnings,100,50,10/28/2020
7AB859,earnings,100,50,10/28/2020
7AB859,earnings,100,50,10/28/2020
7AB859,earnings,100,50,10/28/2020
7B0BA6,partnership,100,61,10/28/2020
7E62B5,earnings,100,50,10/28/2020
80C400,earnings,100,50,10/28/2020
818A2F,dividend,100,50,10/28/2020
818A2F,dividend,100,50,10/28/2020
82E58A,regulatory-product-approval-granted,100,81,10/28/2020
837C04,dividend,100,50,10/28/2020
837C04,earnings,100,50,10/28/2020
837C04,earnings,100,50,10/28/2020
837C04,earnings,100,50,10/28/2020
837C04,earnings,100,50,10/28/2020
837C04,earnings,100,50,10/28/2020
837C04,earnings,100,50,10/28/2020
837C04,earnings,100,50,10/28/2020
85AD00,earnings-per-share-positive,100,69,10/28/2020
86478F,earnings,100,50,10/28/2020
88350F,partnership,100,61,10/28/2020
893904,legal-issues-defendant,100,22,10/28/2020
896771,earnings,100,50,10/28/2020
8A0368,earnings,100,50,10/28/2020
8A0368,earnings,100,50,10/28/2020
8A0368,earnings,100,50,10/28/2020
8A0368,earnings,100,50,10/28/2020
8B1E11,earnings,100,50,10/28/2020
8C5519,asset-sale,100,62,10/28/2020
8DBE73,revenues,100,50,10/28/2020
8DBE73,revenues,100,50,10/28/2020
8DBE73,revenues,100,50,10/28/2020
8DBE73,revenues,100,50,10/28/2020
8DBE73,revenues,100,50,10/28/2020
8DCBBB,earnings,100,50,10/28/2020
8DCBBB,earnings,100,50,10/28/2020
8EDACA,executive-appointment,100,54,10/28/2020
8EF425,earnings,100,50,10/28/2020
8EF425,earnings,100,50,10/28/2020
8EF425,earnings,100,50,10/28/2020
8EF425,earnings,100,50,10/28/2020
8EF425,earnings,100,50,10/28/2020
8EF425,earnings,100,50,10/28/2020
8F8F2F,executive-appointment,100,54,10/28/2020
8FF2EF,conference-call,100,50,10/28/2020
901327,earnings,100,50,10/28/2020
901327,earnings,100,50,10/28/2020
901327,earnings,100,50,10/28/2020
901327,earnings,100,50,10/28/2020
901327,earnings,100,50,10/28/2020
9043FE,earnings,100,50,10/28/2020
9043FE,earnings,100,50,10/28/2020
911AB8,dividend-up,100,83,10/28/2020
922F0C,earnings-per-share,100,50,10/28/2020
92D9C9,executive-appointment,100,54,10/28/2020
94637C,partnership,100,61,10/28/2020
947B0B,earnings,100,50,10/28/2020
958938,conference-call,100,50,10/28/2020
96A2D3,market-entry,100,57,10/28/2020
972356,earnings-above-expectations,100,88,10/28/2020
9.74E+08,earnings-meet-expectations,100,59,10/28/2020
97B027,conference-call,100,50,10/28/2020
981656,earnings,100,50,10/28/2020
986AF6,unit-acquisition-acquirer,100,49,10/28/2020
990AD0,conference-organizer,100,57,10/28/2020
9978F1,public-offering,100,43,10/28/2020
9A02C4,earnings,100,50,10/28/2020
9A02C4,dividend,100,50,10/28/2020
9B0C9C,earnings,100,50,10/28/2020
9B71A7,buybacks,100,74,10/28/2020
9B730A,conference-call,100,50,10/28/2020
9BB35A,dividend-up,100,59,10/28/2020
9C8664,earnings,100,50,10/28/2020
9CDA4F,earnings,100,50,10/28/2020
9D65C1,earnings,100,50,10/28/2020
9EA947,earnings,100,50,10/28/2020
A05C43,earnings,100,50,10/28/2020
A1E3B3,business-contract,100,69,10/28/2020
A1E3B3,business-contract,100,69,10/28/2020
A2CA3F,earnings,100,50,10/28/2020
A2CAF7,earnings,100,50,10/28/2020
A3800A,earnings,100,50,10/28/2020
A3AAA5,earnings,100,50,10/28/2020
A429A5,operating-earnings,100,50,10/28/2020
A43906,conference-participant,100,50,10/28/2020
A4CD53,partnership,100,61,10/28/2020
A631A3,partnership,100,61,10/28/2020
A6ABE9,earnings,100,50,10/28/2020
A7102F,business-contract,100,69,10/28/2020
A8CBDA,executive-appointment,100,54,10/28/2020
AA09AD,earnings,100,50,10/28/2020
AA1EAA,earnings,100,50,10/28/2020
AA847A,earnings,100,50,10/28/2020
AADE0B,dividend,100,50,10/28/2020
AC1952,executive-appointment,100,54,10/28/2020
AD3008,earnings,100,50,10/28/2020
AD9F1D,earnings,100,50,10/28/2020
AD9F1D,earnings,100,50,10/28/2020
AD9F1D,earnings,100,50,10/28/2020
AD9F1D,earnings,100,50,10/28/2020
AD9F1D,earnings,100,50,10/28/2020
AD9F1D,earnings,100,50,10/28/2020
AD9F1D,earnings,100,50,10/28/2020
AD9F1D,earnings,100,50,10/28/2020
AD9F1D,earnings,100,50,10/28/2020
AD9F1D,earnings,100,50,10/28/2020
B01111,facility-open,100,65,10/28/2020
B08954,earnings,100,50,10/28/2020
B09B1F,earnings-up,100,68,10/28/2020
B09B1F,earnings,100,50,10/28/2020
B09B1F,earnings,100,50,10/28/2020
B0FE08,conference-call,100,50,10/28/2020
B2206F,business-contract,100,69,10/28/2020
B2206F,earnings,100,50,10/28/2020
B2DAF6,business-contract,100,69,10/28/2020
B72BE9,conference-call,100,50,10/28/2020
B8F71F,executive-appointment,100,54,10/28/2020
B9BDE8,earnings,100,50,10/28/2020
BAAA60,earnings,100,50,10/28/2020
BB88B6,executive-appointment,100,54,10/28/2020
BB88B6,partnership,100,61,10/28/2020
BB88B6,earnings,100,50,10/28/2020
BB88B6,executive-appointment,100,54,10/28/2020
BBC05B,operating-earnings,100,50,10/28/2020
BC4876,dividend,100,50,10/28/2020
BC5680,earnings,100,50,10/28/2020
BC5680,earnings,100,50,10/28/2020
BC5680,earnings,100,50,10/28/2020
BE14CF,earnings,100,50,10/28/2020
BE379D,conference-call,100,50,10/28/2020
BF79F5,dividend-up,100,81,10/28/2020
BFD0A7,conference-call,100,50,10/28/2020
BFEA04,conference-call,100,50,10/28/2020
C05839,earnings,100,50,10/28/2020
C05839,earnings,100,50,10/28/2020
C05839,earnings,100,50,10/28/2020
C05839,earnings,100,50,10/28/2020
C05839,earnings,100,50,10/28/2020
C062D4,earnings,100,50,10/28/2020
C062D4,earnings,100,50,10/28/2020
C062D4,earnings,100,50,10/28/2020
C062D4,earnings,100,50,10/28/2020
C062D4,earnings,100,50,10/28/2020
C062D4,earnings,100,50,10/28/2020
C062D4,earnings,100,50,10/28/2020
C15DB3,note-sale,100,52,10/28/2020
C188F8,earnings,100,50,10/28/2020
C2609A,business-contract,100,69,10/28/2020
C4A241,earnings-up,100,68,10/28/2020
C4A241,earnings,100,50,10/28/2020
C4A241,earnings,100,50,10/28/2020
C4A241,earnings,100,50,10/28/2020
C4FBDC,earnings,100,50,10/28/2020
C564E4,public-offering,100,43,10/28/2020
C564E4,public-offering,100,43,10/28/2020
C5C137,partnership,100,61,10/28/2020
C624A1,earnings,100,50,10/28/2020
C624A1,earnings,100,50,10/28/2020
C66B44,earnings,100,50,10/28/2020
C7AE14,earnings,100,50,10/28/2020
C97B2D,earnings,100,50,10/28/2020
C9D866,earnings,100,50,10/28/2020
C9D866,earnings,100,50,10/28/2020
C9D866,earnings,100,50,10/28/2020
C9D866,earnings,100,50,10/28/2020
C9D866,earnings,100,50,10/28/2020
C9D866,earnings,100,50,10/28/2020
C9D866,earnings,100,50,10/28/2020
C9D866,earnings,100,50,10/28/2020
C9D866,earnings,100,50,10/28/2020
C9D866,earnings,100,50,10/28/2020
C9D866,earnings,100,50,10/28/2020
C9D866,earnings,100,50,10/28/2020
C9D866,earnings,100,50,10/28/2020
C9D866,earnings,100,50,10/28/2020
C9E04B,conference-call,100,50,10/28/2020
C9E107,conference-participant,100,50,10/28/2020
CB22CD,unit-acquisition-acquiree,100,76,10/28/2020
CB88B3,earnings,100,50,10/28/2020
CBA33B,earnings,100,50,10/28/2020
CBFFDD,dividend,100,50,10/28/2020
CDE118,business-contract,100,69,10/28/2020
CE4E6D,product-release,100,64,10/28/2020
CE4FD9,earnings,100,50,10/28/2020
CE4FD9,earnings,100,50,10/28/2020
CE4FD9,earnings,100,50,10/28/2020
CE4FD9,earnings,100,50,10/28/2020
CE4FD9,earnings,100,50,10/28/2020
CE96E7,executive-appointment,100,54,10/28/2020
CE96E7,earnings,100,50,10/28/2020
CF351E,legal-issues-defendant,100,22,10/28/2020
D06755,earnings,100,50,10/28/2020
D06755,earnings,100,50,10/28/2020
D06755,earnings,100,50,10/28/2020
D06755,earnings,100,50,10/28/2020
D0909F,earnings,100,50,10/28/2020
D17F7E,legal-issues-defendant,100,22,10/28/2020
D1C0B9,product-release,100,64,10/28/2020
D3FD6D,revenue-up,100,69,10/28/2020
D3FD6D,earnings,100,50,10/28/2020
D3FD6D,earnings,100,50,10/28/2020
D3FD6D,earnings,100,50,10/28/2020
D437C3,earnings,100,50,10/28/2020
D437C3,partnership,100,61,10/28/2020
D54E62,dividend,100,50,10/28/2020
D56E4C,operating-earnings-positive,100,69,10/28/2020
D56E4C,earnings,100,50,10/28/2020
D56E4C,earnings,100,50,10/28/2020
D56E4C,earnings,100,50,10/28/2020
D56E4C,operating-earnings-positive,100,69,10/28/2020
D56E4C,earnings,100,50,10/28/2020
D56E4C,earnings,100,50,10/28/2020
D56E4C,earnings,100,50,10/28/2020
D5A350,dividend-up,100,57,10/28/2020
D6489C,executive-appointment,100,54,10/28/2020
D6489C,partnership,100,61,10/28/2020
D6EAA3,dividend,100,50,10/28/2020
D6EAA3,executive-appointment,100,54,10/28/2020
D76AEF,conference-call,100,50,10/28/2020
D78BF1,earnings,100,50,10/28/2020
D8DA3D,earnings,100,50,10/28/2020
D8DA3D,earnings,100,50,10/28/2020
D8DA3D,earnings,100,50,10/28/2020
D8DA3D,earnings,100,50,10/28/2020
D8DA3D,earnings,100,50,10/28/2020
D8DA3D,earnings,100,50,10/28/2020
D8DA3D,executive-resignation,100,44,10/28/2020
D90F43,partnership,100,61,10/28/2020
D90F43,partnership,100,61,10/28/2020
DB88A1,partnership,100,61,10/28/2020
DCD97F,earnings,100,50,10/28/2020
DD7A96,earnings,100,50,10/28/2020
DDC415,note-sale,100,52,10/28/2020
DF5F14,earnings,100,50,10/28/2020
DF6FDD,earnings,100,50,10/28/2020
E00373,earnings-above-expectations,100,88,10/28/2020
E00373,earnings,100,50,10/28/2020
E00373,earnings,100,50,10/28/2020
E00373,earnings,100,50,10/28/2020
E0207A,earnings,100,50,10/28/2020
E0339F,dividend,100,50,10/28/2020
E0647D,earnings,100,50,10/28/2020
E0647D,earnings,100,50,10/28/2020
E0647D,earnings,100,50,10/28/2020
E0647D,earnings,100,50,10/28/2020
E0647D,earnings,100,50,10/28/2020
E09E2B,conference-call,100,50,10/28/2020
E1E36F,earnings,100,50,10/28/2020
E1E36F,earnings,100,50,10/28/2020
E1E36F,earnings,100,50,10/28/2020
E1E36F,earnings,100,50,10/28/2020
E1E36F,earnings,100,50,10/28/2020
E1E36F,earnings,100,50,10/28/2020
E1E36F,earnings,100,50,10/28/2020
E1E36F,earnings,100,50,10/28/2020
E259C7,legal-issues-defendant,100,22,10/28/2020
E4CE73,conference-call,100,50,10/28/2020
E5752F,earnings,100,50,10/28/2020
E5D914,earnings,100,50,10/28/2020
E5D914,earnings,100,50,10/28/2020
E5D914,earnings,100,50,10/28/2020
E5D914,earnings,100,50,10/28/2020
E70531,dividend,100,50,10/28/2020
E754F0,earnings,100,50,10/28/2020
E84500,earnings,100,50,10/28/2020
E93A40,earnings,100,50,10/28/2020
E96E0B,earnings,100,50,10/28/2020
EA62FC,earnings,100,50,10/28/2020
EB43F4,conference-participant,100,50,10/28/2020
EBC84C,award,100,58,10/28/2020
ECA300,executive-appointment,100,54,10/28/2020
ECDEB2,earnings,100,50,10/28/2020
ED0D7C,conference-participant,100,50,10/28/2020
ED2A5E,earnings,100,50,10/28/2020
ED2A5E,earnings,100,50,10/28/2020
ED2A5E,earnings,100,50,10/28/2020
ED2A5E,earnings,100,50,10/28/2020
ED2A5E,earnings,100,50,10/28/2020
ED2A5E,earnings,100,50,10/28/2020
ED2A5E,earnings,100,50,10/28/2020
EE74E1,earnings,100,50,10/28/2020
EE74E1,earnings,100,50,10/28/2020
EE74E1,earnings,100,50,10/28/2020
EE967B,earnings,100,50,10/28/2020
EF25A5,earnings,100,50,10/28/2020
EF76C8,earnings,100,50,10/28/2020
F1529C,dividend,100,50,10/28/2020
F18844,legal-issues-defendant,100,22,10/28/2020
F1CD47,earnings,100,50,10/28/2020
F30508,business-contract,100,69,10/28/2020
F31B13,dividend,100,50,10/28/2020
F4CDA3,earnings,100,50,10/28/2020
F4CDA3,earnings,100,50,10/28/2020
F4CDA3,earnings,100,50,10/28/2020
F4CDA3,earnings,100,50,10/28/2020
F4CDA3,earnings,100,50,10/28/2020
F4CDA3,earnings,100,50,10/28/2020
F4CDA3,earnings,100,50,10/28/2020
F4F46F,business-contract,100,69,10/28/2020
F50BAB,earnings,100,50,10/28/2020
F50BAB,earnings,100,50,10/28/2020
F50BAB,earnings,100,50,10/28/2020
F50BAB,earnings,100,50,10/28/2020
F5D499,public-offering,100,43,10/28/2020
F6A945,executive-appointment,100,54,10/28/2020
F6E1B5,earnings,100,50,10/28/2020
F6E248,earnings,100,50,10/28/2020
F6E248,dividend,100,50,10/28/2020
F7902B,earnings,100,50,10/28/2020
F7902B,earnings,100,50,10/28/2020
F7902B,earnings,100,50,10/28/2020
FA35C6,earnings,100,50,10/28/2020
FA36A4,earnings,100,50,10/28/2020
FA918D,dividend,100,50,10/28/2020
FAE021,earnings,100,50,10/28/2020
FAE021,earnings,100,50,10/28/2020
FAE021,earnings,100,50,10/28/2020
FC1A6E,executive-appointment,100,54,10/28/2020
FC4550,earnings,100,50,10/28/2020
FC80E6,earnings,100,50,10/28/2020
FD554E,conference-call,100,50,10/28/2020
FD9A97,revenues,100,50,10/28/2020
FD9A97,revenue-up,100,69,10/28/2020
FD9A97,revenue-up,100,69,10/28/2020
FD9A97,revenue-up,100,69,10/28/2020
FDC7E6,dividend,100,50,10/28/2020
FDC7E6,earnings,100,50,10/28/2020
FDD3FC,earnings,100,50,10/28/2020
FE1A1D,operating-earnings,100,50,10/28/2020
FE1A1D,operating-earnings,100,50,10/28/2020
FE1A1D,operating-earnings,100,50,10/28/2020
FE1A1D,operating-earnings,100,50,10/28/2020
FE1A1D,operating-earnings,100,50,10/28/2020
FE1A1D,operating-earnings,100,50,10/28/2020
FE1A1D,operating-earnings,100,50,10/28/2020
FEE4B0,dividend,100,50,10/28/2020
FF4343,executive-appointment,100,54,10/28/2020
FF4343,earnings-up,100,68,10/28/2020
FF4343,earnings,100,50,10/28/2020
FF4343,earnings,100,50,10/28/2020
FF4343,earnings,100,50,10/28/2020
FF4343,earnings,100,50,10/28/2020
FF4343,earnings,100,50,10/28/2020
FF4343,earnings,100,50,10/28/2020
FF4343,earnings,100,50,10/28/2020
FF4343,earnings,100,50,10/28/2020
FF4343,earnings,100,50,10/28/2020
FF4343,earnings,100,50,10/28/2020
FF4343,earnings,100,50,10/28/2020
FF4343,earnings,100,50,10/28/2020
FF4343,earnings,100,50,10/28/2020
001F1B,earnings,100,50,10/29/2020
002A99,earnings,100,50,10/29/2020
9397,earnings,100,50,10/29/2020
9397,earnings,100,50,10/29/2020
0142B5,earnings-per-share-positive,100,69,10/29/2020
01478A,earnings,100,50,10/29/2020
0157B1,business-contract,100,69,10/29/2020
0157B1,partnership,100,61,10/29/2020
0157B1,earnings,100,50,10/29/2020
0157B1,earnings,100,50,10/29/2020
0157B1,earnings,100,50,10/29/2020
0157B1,earnings,100,50,10/29/2020
0157B1,earnings,100,50,10/29/2020
0157B1,earnings,100,50,10/29/2020
0157B1,earnings,100,50,10/29/2020
0157B1,earnings,100,50,10/29/2020
018C11,earnings,100,50,10/29/2020
033B58,clinical-trials-start,100,64,10/29/2020
03D5F9,earnings,100,50,10/29/2020
03FAA6,earnings,100,50,10/29/2020
03FAA6,earnings,100,50,10/29/2020
03FAA6,earnings,100,50,10/29/2020
03FAA6,earnings,100,50,10/29/2020
03FAA6,earnings,100,50,10/29/2020
48590,earnings-above-expectations,100,88,10/29/2020
55018,dividend,100,50,10/29/2020
0560D8,dividend,100,50,10/29/2020
061A3B,earnings,100,50,10/29/2020
061A3B,earnings,100,50,10/29/2020
061A3B,earnings,100,50,10/29/2020
061A3B,earnings,100,50,10/29/2020
065D38,earnings,100,50,10/29/2020
68396,earnings,100,50,10/29/2020
07CA6A,earnings,100,50,10/29/2020
07CA6A,earnings,100,50,10/29/2020
099C88,earnings,100,50,10/29/2020
099C88,earnings,100,50,10/29/2020
099C88,earnings,100,50,10/29/2020
099C88,earnings,100,50,10/29/2020
0A748B,earnings,100,50,10/29/2020
0A748B,earnings,100,50,10/29/2020
0A9D0A,conference-call,100,50,10/29/2020
0BC17A,dividend,100,50,10/29/2020
0BC17A,earnings,100,50,10/29/2020
0BD199,conference-call,100,50,10/29/2020
0BF198,earnings,100,50,10/29/2020
0DC050,earnings,100,50,10/29/2020
0DC050,earnings,100,50,10/29/2020
0DC050,earnings,100,50,10/29/2020
0DC050,earnings,100,50,10/29/2020
0E499E,earnings,100,50,10/29/2020
0E5619,conference-call,100,50,10/29/2020
0ED415,earnings,100,50,10/29/2020
0ED415,earnings,100,50,10/29/2020
0ED415,earnings,100,50,10/29/2020
0ED415,earnings,100,50,10/29/2020
0F04E5,earnings,100,50,10/29/2020
0F04E5,earnings,100,50,10/29/2020
0F04E5,earnings,100,50,10/29/2020
0F91FC,earnings,100,50,10/29/2020
0FABBD,earnings-up,100,68,10/29/2020
0FABBD,earnings-up,100,68,10/29/2020
0FABBD,earnings-up,100,68,10/29/2020
0FABBD,earnings-up,100,68,10/29/2020
0FABBD,earnings-up,100,68,10/29/2020
0FABBD,earnings-up,100,68,10/29/2020
0FC848,earnings,100,50,10/29/2020
105D00,dividend,100,50,10/29/2020
1080C0,earnings,100,50,10/29/2020
10943B,earnings,100,50,10/29/2020
10AE08,earnings,100,50,10/29/2020
10AE08,earnings,100,50,10/29/2020
1151F4,earnings,100,50,10/29/2020
1151F4,earnings,100,50,10/29/2020
1151F4,earnings,100,50,10/29/2020
1151F4,earnings,100,50,10/29/2020
1151F4,earnings,100,50,10/29/2020
1151F4,earnings,100,50,10/29/2020
1151F4,earnings,100,50,10/29/2020
1151F4,earnings,100,50,10/29/2020
11AEDE,earnings,100,50,10/29/2020
129DC8,earnings,100,50,10/29/2020
129DC8,earnings,100,50,10/29/2020
129DC8,earnings,100,50,10/29/2020
129DC8,earnings-delayed,100,26,10/29/2020
129DC8,earnings,100,50,10/29/2020
12DE76,conference-call,100,50,10/29/2020
12E454,earnings,100,50,10/29/2020
12E454,earnings,100,50,10/29/2020
12E454,earnings,100,50,10/29/2020
147C38,earnings,100,50,10/29/2020
147C38,executive-appointment,100,54,10/29/2020
1490F3,earnings,100,50,10/29/2020
1490F3,earnings,100,50,10/29/2020
1490F3,earnings,100,50,10/29/2020
1490F3,earnings,100,50,10/29/2020
1490F3,earnings,100,50,10/29/2020
1490F3,earnings,100,50,10/29/2020
1490F3,earnings,100,50,10/29/2020
14BA06,operating-earnings,100,50,10/29/2020
14BA33,earnings,100,50,10/29/2020
15901B,legal-issues-defendant,100,22,10/29/2020
15901B,earnings,100,50,10/29/2020
165B86,conference-call,100,50,10/29/2020
1782D5,earnings,100,50,10/29/2020
1.79E+10,revenue-up,100,69,10/29/2020
1.79E+10,revenues,100,50,10/29/2020
1.79E+10,revenues,100,50,10/29/2020
180DA0,conference-call,100,50,10/29/2020
180DA0,conference-call,100,50,10/29/2020
19C105,earnings,100,50,10/29/2020
1A3E1B,earnings,100,50,10/29/2020
1A3E1B,earnings,100,50,10/29/2020
1A3E1B,conference-participant,100,50,10/29/2020
1B5FEA,earnings,100,50,10/29/2020
1CD4B5,public-offering,100,43,10/29/2020
1D9E55,earnings,100,50,10/29/2020
1D9E55,earnings,100,50,10/29/2020
1DDEDA,earnings,100,50,10/29/2020
1DEBBE,earnings,100,50,10/29/2020
1DF15D,earnings,100,50,10/29/2020
1DF15D,earnings,100,50,10/29/2020
1DF15D,earnings,100,50,10/29/2020
1E1125,conference-organizer,100,57,10/29/2020
1F08A6,earnings,100,50,10/29/2020
1F19C8,earnings-up,100,70,10/29/2020
1F19C8,earnings-up,100,70,10/29/2020
1F19C8,earnings-up,100,70,10/29/2020
1F19C8,earnings-up,100,70,10/29/2020
1F19C8,earnings-up,100,70,10/29/2020
1F19C8,earnings-up,100,70,10/29/2020
1FAF22,earnings,100,50,10/29/2020
1FAF22,earnings,100,50,10/29/2020
1FAF22,earnings,100,50,10/29/2020
1FAF22,earnings,100,50,10/29/2020
1FAF22,earnings,100,50,10/29/2020
1FAF22,earnings,100,50,10/29/2020
1FAF22,earnings,100,50,10/29/2020
1FAF22,note-sale,100,52,10/29/2020
1FCC00,fundraising,100,64,10/29/2020
2082EA,clinical-trials-start,100,64,10/29/2020
2158DF,partnership,100,61,10/29/2020
219B21,earnings,100,50,10/29/2020
219B21,earnings,100,50,10/29/2020
219B21,earnings,100,50,10/29/2020
219B21,earnings,100,50,10/29/2020
219B21,earnings,100,50,10/29/2020
2262BD,earnings,100,50,10/29/2020
228D42,partnership,100,61,10/29/2020
228D42,partnership,100,61,10/29/2020
241AF7,executive-appointment,100,54,10/29/2020
2491BC,earnings,100,50,10/29/2020
2491BC,earnings,100,50,10/29/2020
2491BC,earnings,100,50,10/29/2020
2491BC,earnings,100,50,10/29/2020
2491BC,earnings,100,50,10/29/2020
24CB56,conference-participant,100,50,10/29/2020
250BEE,earnings,100,50,10/29/2020
250BEE,earnings,100,50,10/29/2020
250BEE,earnings,100,50,10/29/2020
250BEE,earnings,100,50,10/29/2020
250BEE,earnings,100,50,10/29/2020
250BEE,earnings,100,50,10/29/2020
253B2F,earnings,100,50,10/29/2020
253B2F,earnings,100,50,10/29/2020
25529C,earnings,100,50,10/29/2020
2667B6,fraud,100,44,10/29/2020
2667B6,legal-issues-defendant,100,22,10/29/2020
2667B6,legal-issues-defendant,100,22,10/29/2020
2667B6,legal-issues-defendant,100,22,10/29/2020
26F31D,earnings-revision,100,29,10/29/2020
26F31D,earnings,100,50,10/29/2020
26FA41,earnings,100,50,10/29/2020
270B78,earnings,100,50,10/29/2020
272704,dividend,100,50,10/29/2020
2950FF,earnings,100,50,10/29/2020
2950FF,earnings,100,50,10/29/2020
2A17B1,earnings,100,50,10/29/2020
2A17B1,earnings,100,50,10/29/2020
2A17B1,earnings,100,50,10/29/2020
2A17B1,earnings,100,50,10/29/2020
2AA6A8,conference-call,100,50,10/29/2020
2B7A40,earnings-per-share-positive,100,69,10/29/2020
2B7A40,earnings-positive,100,69,10/29/2020
2B7A40,earnings-positive,100,69,10/29/2020
2B7A40,earnings-positive,100,69,10/29/2020
2B7A40,earnings-positive,100,69,10/29/2020
2C3348,earnings,100,50,10/29/2020
2CA60F,partnership,100,61,10/29/2020
2D5011,earnings,100,50,10/29/2020
2DDB22,earnings,100,50,10/29/2020
2EB88B,revenues,100,50,10/29/2020
2F94A5,earnings,100,50,10/29/2020
30DFD3,earnings,100,50,10/29/2020
31A7CC,dividend,100,50,10/29/2020
328250,earnings,100,50,10/29/2020
32DCB3,earnings,100,50,10/29/2020
32F943,earnings,100,50,10/29/2020
3.30E+30,conference-call,100,50,10/29/2020
33AD83,product-release,100,64,10/29/2020
3461CF,earnings,100,50,10/29/2020
3461CF,credit-rating-upgrade-rater,20,50,10/29/2020
34B411,executive-appointment,100,54,10/29/2020
34E9F9,earnings,100,50,10/29/2020
34E9F9,earnings,100,50,10/29/2020
34E9F9,earnings,100,50,10/29/2020
34E9F9,earnings,100,50,10/29/2020
34E9F9,earnings,100,50,10/29/2020
35557B,earnings,100,50,10/29/2020
35F4B5,earnings,100,50,10/29/2020
35F4B5,earnings,100,50,10/29/2020
371C01,earnings,100,50,10/29/2020
371C01,earnings,100,50,10/29/2020
372037,dividend,100,50,10/29/2020
372037,earnings-up,100,68,10/29/2020
372037,earnings,100,50,10/29/2020
372037,earnings,100,50,10/29/2020
3.73E+87,legal-issues-defendant,100,22,10/29/2020
37727A,earnings,100,50,10/29/2020
37727A,earnings,100,50,10/29/2020
37727A,earnings,100,50,10/29/2020
37727A,earnings,100,50,10/29/2020
37727A,earnings,100,50,10/29/2020
37727A,earnings,100,50,10/29/2020
37727A,earnings,100,50,10/29/2020
37727A,earnings,100,50,10/29/2020
37727A,earnings,100,50,10/29/2020
3798B9,earnings,100,50,10/29/2020
387375,earnings,100,50,10/29/2020
3.88E+02,earnings,100,50,10/29/2020
396D7C,earnings,100,50,10/29/2020
3AAEAE,public-offering,100,43,10/29/2020
3B37F7,earnings-up,100,68,10/29/2020
3B37F7,earnings,100,50,10/29/2020
3B37F7,earnings,100,50,10/29/2020
3B37F7,earnings,100,50,10/29/2020
3B8484,earnings,100,50,10/29/2020
3BE00F,executive-appointment,100,54,10/29/2020
3CBA2A,earnings,100,50,10/29/2020
3CBA2A,earnings,100,50,10/29/2020
3CBA2A,earnings,100,50,10/29/2020
3CBA2A,earnings,100,50,10/29/2020
3CBA2A,earnings,100,50,10/29/2020
3CBA2A,earnings,100,50,10/29/2020
3CBA2A,earnings,100,50,10/29/2020
3CBA2A,earnings,100,50,10/29/2020
3F868D,earnings,100,50,10/29/2020
401072,earnings,100,50,10/29/2020
405762,earnings,100,50,10/29/2020
407878,earnings,100,50,10/29/2020
415188,dividend,100,50,10/29/2020
415188,earnings,100,50,10/29/2020
41785E,legal-issues-defendant,100,22,10/29/2020
41B53E,earnings,100,50,10/29/2020
41B53E,earnings,100,50,10/29/2020
41B53E,earnings,100,50,10/29/2020
41ED98,conference-call,100,50,10/29/2020
422CE3,hirings,100,65,10/29/2020
422CE3,hirings,100,65,10/29/2020
422CE3,hirings,100,65,10/29/2020
422CE3,hirings,100,65,10/29/2020
427F32,earnings,100,50,10/29/2020
4290EF,dividend,100,50,10/29/2020
42AABD,executive-appointment,100,54,10/29/2020
434F38,earnings,100,50,10/29/2020
4398A2,earnings,100,50,10/29/2020
43A060,earnings,100,50,10/29/2020
43E8F5,partnership,100,61,10/29/2020
4455C4,earnings,100,50,10/29/2020
4455C4,earnings,100,50,10/29/2020
4455C4,earnings,100,50,10/29/2020
4455C4,earnings,100,50,10/29/2020
448BF3,earnings,100,50,10/29/2020
44A4FC,business-contract,100,69,10/29/2020
44A4FC,unit-acquisition-acquirer,100,49,10/29/2020
44DDBD,earnings,100,50,10/29/2020
44ED36,earnings,100,50,10/29/2020
44ED36,earnings,100,50,10/29/2020
44ED36,earnings,100,50,10/29/2020
44ED36,earnings,100,50,10/29/2020
44ED36,earnings,100,50,10/29/2020
44ED36,earnings,100,50,10/29/2020
4595EF,earnings,100,50,10/29/2020
45BC35,partnership,100,61,10/29/2020
45BC35,partnership-terminated,100,36,10/29/2020
4.60E+06,earnings,100,50,10/29/2020
47B4CC,earnings,100,50,10/29/2020
47B4CC,earnings,100,50,10/29/2020
4806CE,acquisition-acquirer,100,49,10/29/2020
4885C8,earnings,100,50,10/29/2020
49A344,business-contract,100,69,10/29/2020
4A2457,earnings,100,50,10/29/2020
4A5C8D,dividend,100,50,10/29/2020
4A6F00,partnership,100,61,10/29/2020
4B5054,legal-issues-defendant,100,22,10/29/2020
4B5054,legal-issues-defendant,100,22,10/29/2020
4BD6DB,earnings,100,50,10/29/2020
4BDCA7,conference-call,100,50,10/29/2020
4C3FE9,earnings,100,50,10/29/2020
4C5CC9,earnings-guidance-up,100,83,10/29/2020
4C5CC9,earnings-guidance-up,100,83,10/29/2020
4C5CC9,earnings-guidance-up,100,83,10/29/2020
4C5CC9,earnings-guidance-up,100,83,10/29/2020
4E2D94,earnings,100,50,10/29/2020
4E2D94,dividend,100,50,10/29/2020
4EEE7E,earnings,100,50,10/29/2020
4F783B,dividend,100,50,10/29/2020
50070E,business-contract,100,69,10/29/2020
50070E,conference-organizer,100,57,10/29/2020
504FE2,business-contract,100,69,10/29/2020
513A86,earnings,100,50,10/29/2020
514067,earnings,100,50,10/29/2020
519FE0,earnings,100,50,10/29/2020
519FE0,earnings,100,50,10/29/2020
519FE0,earnings,100,50,10/29/2020
519FE0,earnings,100,50,10/29/2020
519FE0,earnings,100,50,10/29/2020
519FE0,partnership,100,61,10/29/2020
51D876,earnings,100,50,10/29/2020
51D876,conference-call,100,50,10/29/2020
51D876,conference-call,100,50,10/29/2020
52015A,earnings,100,50,10/29/2020
524CE4,earnings,100,50,10/29/2020
525A1C,earnings,100,50,10/29/2020
546A27,fraud-defendant,100,20,10/29/2020
5.47E+28,earnings,100,50,10/29/2020
54A646,dividend,100,50,10/29/2020
56277A,conference-participant,100,50,10/29/2020
57634F,earnings,100,50,10/29/2020
57CAAB,earnings,100,50,10/29/2020
57F3DA,earnings,100,50,10/29/2020
586BD7,earnings,100,50,10/29/2020
58B46F,dividend,100,50,10/29/2020
5968F9,earnings,100,50,10/29/2020
59F0B0,earnings,100,50,10/29/2020
59F0B0,earnings,100,50,10/29/2020
59F0B0,earnings,100,50,10/29/2020
59F0B0,earnings,100,50,10/29/2020
5C61CC,executive-appointment,100,54,10/29/2020
5D0337,earnings,100,50,10/29/2020
5D1329,conference-call,100,50,10/29/2020
5D16CF,earnings,100,50,10/29/2020
5D43A7,partnership,100,61,10/29/2020
5D43A7,earnings,100,50,10/29/2020
5D43A7,earnings,100,50,10/29/2020
5D43A7,earnings,100,50,10/29/2020
5D43A7,earnings,100,50,10/29/2020
5D43A7,earnings,100,50,10/29/2020
5E1DF3,earnings-up,100,68,10/29/2020
5F3E74,earnings,100,50,10/29/2020
5F3E74,earnings,100,50,10/29/2020
5FE4B6,earnings,100,50,10/29/2020
5FE4B6,earnings,100,50,10/29/2020
60AC34,earnings,100,50,10/29/2020
6166D1,executive-appointment,100,54,10/29/2020
619882,legal-issues-defendant,100,22,10/29/2020
619882,legal-issues-defendant,100,22,10/29/2020
619882,legal-issues-defendant,100,22,10/29/2020
619882,legal-issues-defendant,100,22,10/29/2020
619882,conference-participant,100,50,10/29/2020
61BCA7,earnings,100,50,10/29/2020
636931,earnings,100,50,10/29/2020
63F892,earnings,100,50,10/29/2020
649CBD,conference-organizer,100,57,10/29/2020
6.52E+64,earnings,100,50,10/29/2020
6559D8,conference-call,100,50,10/29/2020
65CF8E,earnings,100,50,10/29/2020
65CF8E,earnings,100,50,10/29/2020
665440,business-contract,100,69,10/29/2020
665D7D,legal-issues-defendant,100,22,10/29/2020
66749D,earnings,100,50,10/29/2020
66749D,earnings,100,50,10/29/2020
66749D,earnings,100,50,10/29/2020
66749D,earnings,100,50,10/29/2020
66749D,earnings,100,50,10/29/2020
67B052,earnings,100,50,10/29/2020
67B052,earnings,100,50,10/29/2020
69345C,legal-issues-defendant,100,22,10/29/2020
694749,earnings,100,50,10/29/2020
698FF9,earnings,100,50,10/29/2020
698FF9,earnings,100,50,10/29/2020
698FF9,partnership,100,61,10/29/2020
69E8E1,earnings,100,50,10/29/2020
69E8E1,earnings,100,50,10/29/2020
69E8E1,earnings,100,50,10/29/2020
69E8E1,earnings,100,50,10/29/2020
69E8E1,earnings,100,50,10/29/2020
6A3C35,earnings,100,50,10/29/2020
6A3C35,earnings,100,50,10/29/2020
6A3C35,earnings,100,50,10/29/2020
6A3C35,earnings,100,50,10/29/2020
6A3C35,earnings,100,50,10/29/2020
6ABCB8,earnings,100,50,10/29/2020
6B494E,facility-sale,100,52,10/29/2020
6B5379,executive-resignation,100,44,10/29/2020
6BD606,dividend,100,50,10/29/2020
6CDFC6,earnings,100,50,10/29/2020
6D4636,conference-call,100,50,10/29/2020
6DC1D7,earnings,100,50,10/29/2020
6F0A63,public-offering,100,43,10/29/2020
6F3FA8,earnings,100,50,10/29/2020
6F3FA8,earnings,100,50,10/29/2020
6F3FA8,earnings,100,50,10/29/2020
6F3FA8,earnings,100,50,10/29/2020
6F3FA8,earnings,100,50,10/29/2020
6F3FA8,earnings,100,50,10/29/2020
70CA28,business-contract,100,69,10/29/2020
70CA28,business-contract,100,69,10/29/2020
713810,product-release,100,64,10/29/2020
717DB4,earnings,100,50,10/29/2020
717DB4,earnings,100,50,10/29/2020
717DB4,earnings,100,50,10/29/2020
717DB4,earnings,100,50,10/29/2020
717DB4,earnings,100,50,10/29/2020
717DB4,conference-participant,100,50,10/29/2020
71E2EF,unit-acquisition-acquiree,100,76,10/29/2020
7239BB,facility-open,100,65,10/29/2020
724F84,earnings,100,50,10/29/2020
726DDF,conference-participant,100,50,10/29/2020
72CB93,earnings,100,50,10/29/2020
73529F,earnings,100,50,10/29/2020
735388,earnings,100,50,10/29/2020
73C9E2,earnings,100,50,10/29/2020
7.44E+09,conference-participant,100,50,10/29/2020
74404C,earnings,100,50,10/29/2020
74404C,conference-call,100,50,10/29/2020
7448A3,earnings,100,50,10/29/2020
766047,earnings,100,50,10/29/2020
76B926,earnings,100,50,10/29/2020
76B926,earnings,100,50,10/29/2020
76DD0C,earnings,100,50,10/29/2020
773A17,award,100,58,10/29/2020
7823A3,earnings,100,50,10/29/2020
7823A3,earnings,100,50,10/29/2020
7823A3,earnings,100,50,10/29/2020
7823A3,earnings,100,50,10/29/2020
7823A3,earnings,100,50,10/29/2020
7823A3,earnings,100,50,10/29/2020
782B46,dividend,100,50,10/29/2020
789ADD,earnings,100,50,10/29/2020
789ADD,earnings,100,50,10/29/2020
789ADD,earnings,100,50,10/29/2020
789ADD,earnings,100,50,10/29/2020
78F9ED,earnings,100,50,10/29/2020
78F9ED,earnings,100,50,10/29/2020
78F9ED,earnings,100,50,10/29/2020
78F9ED,earnings,100,50,10/29/2020
78F9ED,earnings,100,50,10/29/2020
78F9ED,earnings,100,50,10/29/2020
78F9ED,earnings,100,50,10/29/2020
78F9ED,earnings,100,50,10/29/2020
79167B,earnings,100,50,10/29/2020
79167B,earnings,100,50,10/29/2020
79167B,earnings,100,50,10/29/2020
79167B,earnings,100,50,10/29/2020
79167B,earnings,100,50,10/29/2020
791D59,earnings,100,50,10/29/2020
7A2A49,earnings,100,50,10/29/2020
7A5D58,earnings,100,50,10/29/2020
7B0BA6,earnings,100,50,10/29/2020
7B0BA6,earnings,100,50,10/29/2020
7B0BA6,earnings,100,50,10/29/2020
7B0BA6,earnings,100,50,10/29/2020
7B0BA6,earnings,100,50,10/29/2020
7B0BA6,earnings,100,50,10/29/2020
7B4B91,dividend-up,100,81,10/29/2020
7B9AFA,earnings,100,50,10/29/2020
7BAAE7,earnings-positive,100,69,10/29/2020
7BFF81,sponsorship,100,57,10/29/2020
7C4F43,earnings,100,50,10/29/2020
7C62A3,partnership,100,61,10/29/2020
7DC1C4,earnings,100,50,10/29/2020
7DD584,earnings,100,50,10/29/2020
7E0EB0,earnings,100,50,10/29/2020
7E3390,earnings,100,50,10/29/2020
7F3A5F,earnings,100,50,10/29/2020
7F3A5F,earnings,100,50,10/29/2020
7F3A5F,earnings,100,50,10/29/2020
7F3A5F,earnings,100,50,10/29/2020
7F3A5F,earnings,100,50,10/29/2020
7FC386,earnings,100,50,10/29/2020
80D744,legal-issues-defendant,100,22,10/29/2020
8.10E+32,business-contract,100,69,10/29/2020
81A88D,earnings,100,50,10/29/2020
8.22E+27,earnings,100,50,10/29/2020
83598E,earnings,100,50,10/29/2020
838ADD,earnings,100,50,10/29/2020
838ADD,earnings,100,50,10/29/2020
838ADD,earnings,100,50,10/29/2020
838ADD,earnings,100,50,10/29/2020
838ADD,earnings,100,50,10/29/2020
838ADD,earnings,100,50,10/29/2020
83B1C8,legal-issues-defendant,100,22,10/29/2020
83B1C8,legal-issues-defendant,100,22,10/29/2020
83B1C8,legal-issues-defendant,100,22,10/29/2020
860AB6,dividend,100,50,10/29/2020
860AB6,dividend,100,50,10/29/2020
8665BA,partnership,100,61,10/29/2020
86AA9C,conference-call,100,50,10/29/2020
877734,conference-call,100,50,10/29/2020
880C0C,earnings,100,50,10/29/2020
8817D5,earnings,100,50,10/29/2020
88193E,earnings,100,50,10/29/2020
885758,earnings,100,50,10/29/2020
893904,legal-issues-defendant,100,22,10/29/2020
893904,earnings,100,50,10/29/2020
893904,earnings,100,50,10/29/2020
893904,executive-appointment,100,54,10/29/2020
8AB85C,earnings,100,50,10/29/2020
8B3B0E,earnings,100,50,10/29/2020
8B9B3B,earnings,100,50,10/29/2020
8BFAA4,conference-call,100,50,10/29/2020
8C1238,earnings,100,50,10/29/2020
8C1238,earnings,100,50,10/29/2020
8C1238,earnings,100,50,10/29/2020
8C1238,earnings,100,50,10/29/2020
8C1238,earnings,100,50,10/29/2020
8C311A,product-release,100,64,10/29/2020
8D4486,business-contract,100,69,10/29/2020
8D9993,earnings,100,50,10/29/2020
8D9993,earnings,100,50,10/29/2020
8D9993,earnings,100,50,10/29/2020
8D9993,earnings,100,50,10/29/2020
8E0E32,earnings,100,50,10/29/2020
8E4250,earnings,100,50,10/29/2020
8E4250,earnings,100,50,10/29/2020
8E4250,earnings,100,50,10/29/2020
8E4250,earnings,100,50,10/29/2020
8E4250,earnings,100,50,10/29/2020
8E4F9A,earnings,100,50,10/29/2020
8E8E6E,product-release,100,64,10/29/2020
8E8E6E,earnings,100,50,10/29/2020
8F3231,earnings,100,50,10/29/2020
8FCA78,earnings-up,100,68,10/29/2020
8FCA78,earnings,100,50,10/29/2020
8FCA78,earnings,100,50,10/29/2020
8FCA78,earnings,100,50,10/29/2020
902255,dividend,100,50,10/29/2020
911AB8,earnings-up,100,68,10/29/2020
911AB8,unit-acquisition-completed-acquiree,100,67,10/29/2020
911AB8,unit-acquisition-completed-acquiree,100,67,10/29/2020
918D6D,conference-call,100,50,10/29/2020
92B625,conference-call,100,50,10/29/2020
934029,earnings,100,50,10/29/2020
9.39E+69,orphan-drug-designation,100,76,10/29/2020
93C130,earnings,100,50,10/29/2020
93C130,dividend,100,50,10/29/2020
940C3D,dividend,100,50,10/29/2020
945DE6,earnings,100,50,10/29/2020
945DE6,earnings,100,50,10/29/2020
945DE6,earnings,100,50,10/29/2020
945DE6,earnings,100,50,10/29/2020
945DE6,earnings,100,50,10/29/2020
94756D,earnings,100,50,10/29/2020
957A07,fraud-defendant,100,20,10/29/2020
9592FB,conference-participant,100,50,10/29/2020
95C392,earnings,100,50,10/29/2020
965360,dividend,100,50,10/29/2020
9673BD,dividend,100,50,10/29/2020
96A6CD,earnings,100,50,10/29/2020
971F7B,executive-appointment,100,54,10/29/2020
971F7B,earnings,100,50,10/29/2020
971F7B,earnings,100,50,10/29/2020
971F7B,earnings,100,50,10/29/2020
971F7B,earnings,100,50,10/29/2020
979451,earnings,100,50,10/29/2020
980C14,earnings,100,50,10/29/2020
9810C0,earnings,100,50,10/29/2020
9.86E+03,earnings,100,50,10/29/2020
98D33E,dividend,100,50,10/29/2020
990AD0,conference-organizer,100,57,10/29/2020
9934AD,earnings,100,50,10/29/2020
9934AD,conference-call,100,50,10/29/2020
9.97E+09,earnings,100,50,10/29/2020
9AF3DC,earnings,100,50,10/29/2020
9B5968,earnings,100,50,10/29/2020
9B5968,earnings,100,50,10/29/2020
9C8BC3,executive-appointment,100,54,10/29/2020
9C8BC3,executive-appointment,100,54,10/29/2020
9CF9B1,earnings,100,50,10/29/2020
9D5FA4,earnings,100,50,10/29/2020
9DDE1B,earnings,100,50,10/29/2020
9E0811,facility-open,100,65,10/29/2020
9E3224,earnings,100,50,10/29/2020
9EA947,conference-call,100,50,10/29/2020
9EA947,conference-call,100,50,10/29/2020
9EED50,earnings,100,50,10/29/2020
9F5CBB,dividend,100,50,10/29/2020
9F6B1A,partnership,100,61,10/29/2020
9F71E5,earnings,100,50,10/29/2020
9F71E5,dividend,100,50,10/29/2020
9FD2D9,earnings,100,50,10/29/2020
9FD2D9,earnings,100,50,10/29/2020
9FD2D9,earnings,100,50,10/29/2020
A072C4,conference-call,100,50,10/29/2020
A16DEA,earnings,100,50,10/29/2020
A16DEA,earnings,100,50,10/29/2020
A16DEA,earnings,100,50,10/29/2020
A16DEA,earnings,100,50,10/29/2020
A16DEA,earnings,100,50,10/29/2020
A16DEA,earnings,100,50,10/29/2020
A16DEA,earnings,100,50,10/29/2020
A16DEA,earnings,100,50,10/29/2020
A16DEA,earnings,100,50,10/29/2020
A204A7,earnings,100,50,10/29/2020
A247F5,earnings,100,50,10/29/2020
A2CA3F,dividend,100,50,10/29/2020
A47F2E,conference-participant,100,50,10/29/2020
A4D173,dividend,100,50,10/29/2020
A4D173,dividend,100,50,10/29/2020
A5151E,earnings,100,50,10/29/2020
A52533,earnings,100,50,10/29/2020
A52B6B,partnership,100,61,10/29/2020
A6FE1C,unit-acquisition-acquirer,100,49,10/29/2020
A7CCF0,earnings,100,50,10/29/2020
A7CCF0,earnings,100,50,10/29/2020
A806FA,dividend,100,50,10/29/2020
A80FE0,earnings,100,50,10/29/2020
A8B137,dividend,100,50,10/29/2020
A8E72A,partnership,100,61,10/29/2020
A94637,revenues,100,50,10/29/2020
A99576,earnings,100,50,10/29/2020
A99576,earnings,100,50,10/29/2020
AADE0B,earnings,100,50,10/29/2020
ABBAD1,earnings,100,50,10/29/2020
AC1952,earnings-positive,100,69,10/29/2020
AC3584,earnings,100,50,10/29/2020
ACDCFA,earnings,100,50,10/29/2020
AD22F2,earnings,100,50,10/29/2020
AD3C93,partnership,100,61,10/29/2020
ADF1B0,partnership,100,61,10/29/2020
B05118,earnings,100,50,10/29/2020
B13B68,earnings,100,50,10/29/2020
B2256A,earnings,100,50,10/29/2020
B2D492,earnings,100,50,10/29/2020
B2DAF6,earnings,100,50,10/29/2020
B3ED62,earnings,100,50,10/29/2020
B4703C,earnings-per-share-positive,100,69,10/29/2020
B4703C,earnings,100,50,10/29/2020
B4703C,earnings,100,50,10/29/2020
B4C673,earnings,100,50,10/29/2020
B5BA39,earnings,100,50,10/29/2020
B6CD92,earnings-positive,100,69,10/29/2020
B6CD92,earnings,100,50,10/29/2020
B6CD92,earnings,100,50,10/29/2020
B6CD92,earnings,100,50,10/29/2020
B6CD92,earnings,100,50,10/29/2020
B6CD92,earnings,100,50,10/29/2020
B77F14,earnings,100,50,10/29/2020
B77F14,earnings,100,50,10/29/2020
B77F14,earnings,100,50,10/29/2020
B77F14,earnings,100,50,10/29/2020
B7EB38,earnings,100,50,10/29/2020
B7EB38,earnings,100,50,10/29/2020
B80AD1,earnings,100,50,10/29/2020
B8DD94,earnings,100,50,10/29/2020
BB0787,earnings,100,50,10/29/2020
BB5271,partnership,100,61,10/29/2020
BBBB41,dividend,100,50,10/29/2020
BC5680,partnership,100,61,10/29/2020
BD682F,earnings,100,50,10/29/2020
BD8517,earnings,100,50,10/29/2020
BE7BA4,earnings-guidance-up,100,83,10/29/2020
BE86A1,earnings,100,50,10/29/2020
C0030A,earnings-up,100,68,10/29/2020
C0030A,earnings-up,100,68,10/29/2020
C0030A,earnings-up,100,68,10/29/2020
C0030A,earnings-up,100,68,10/29/2020
C0030A,earnings-up,100,68,10/29/2020
C062D4,regulatory-product-approval-granted,100,81,10/29/2020
C230FE,earnings-up,100,68,10/29/2020
C230FE,earnings-up,100,68,10/29/2020
C2609A,executive-appointment,100,54,10/29/2020
C2609A,dividend,100,50,10/29/2020
C2E39B,earnings,100,50,10/29/2020
C32A39,executive-resignation,100,44,10/29/2020
C32A39,earnings,100,50,10/29/2020
C356AC,dividend,100,50,10/29/2020
C356AC,earnings,100,50,10/29/2020
C356AC,earnings,100,50,10/29/2020
C356AC,earnings,100,50,10/29/2020
C356AC,earnings,100,50,10/29/2020
C356AC,earnings,100,50,10/29/2020
C356AC,earnings,100,50,10/29/2020
C3EE99,award,100,58,10/29/2020
C3F99F,earnings,100,50,10/29/2020
C4452A,investment-investor,100,55,10/29/2020
C4A912,earnings,100,50,10/29/2020
C4A912,earnings,100,50,10/29/2020
C4A912,earnings,100,50,10/29/2020
C4A912,partnership,100,61,10/29/2020
C4F9C6,earnings,100,50,10/29/2020
C58D71,earnings,100,50,10/29/2020
C5D2AE,earnings,100,50,10/29/2020
C659EB,product-release,100,64,10/29/2020
C81E00,operating-earnings,100,50,10/29/2020
C81E00,operating-earnings,100,50,10/29/2020
C83B88,earnings,100,50,10/29/2020
C83B88,earnings,100,50,10/29/2020
C83B88,earnings,100,50,10/29/2020
C83B88,earnings,100,50,10/29/2020
C83B88,earnings,100,50,10/29/2020
C83B88,earnings,100,50,10/29/2020
C83B88,earnings,100,50,10/29/2020
C83B88,dividend,100,50,10/29/2020
C83B88,facility-upgrade,100,65,10/29/2020
C8923A,earnings-up,100,68,10/29/2020
C8A248,earnings,100,50,10/29/2020
C8A248,earnings,100,50,10/29/2020
C8A248,earnings,100,50,10/29/2020
C8A248,earnings,100,50,10/29/2020
C8A248,earnings,100,50,10/29/2020
C8A248,earnings,100,50,10/29/2020
C8A248,earnings,100,50,10/29/2020
C8A248,earnings,100,50,10/29/2020
C8FAC7,earnings,100,50,10/29/2020
C94CFC,clinical-trials,100,56,10/29/2020
C9732E,public-offering,100,43,10/29/2020
C98CDB,earnings,100,50,10/29/2020
C99CC8,note-sale,100,52,10/29/2020
CAB222,earnings,100,50,10/29/2020
CBA475,earnings,100,50,10/29/2020
CBA475,earnings,100,50,10/29/2020
CBA475,earnings,100,50,10/29/2020
CBA475,earnings,100,50,10/29/2020
CBCC6A,earnings,100,50,10/29/2020
CBCC6A,earnings,100,50,10/29/2020
CBDB4D,conference-call,100,50,10/29/2020
CBFFDD,business-contract,100,69,10/29/2020
CD06A2,executive-appointment,100,54,10/29/2020
CDEDFE,earnings,100,50,10/29/2020
CE1002,note-sale,100,52,10/29/2020
CF6A5A,business-contract,100,69,10/29/2020
D03C7A,earnings,100,50,10/29/2020
D07B07,earnings,100,50,10/29/2020
D09938,earnings,100,50,10/29/2020
D0DE27,earnings,100,50,10/29/2020
D0DFE5,earnings,100,50,10/29/2020
D1173F,earnings,100,50,10/29/2020
D1173F,earnings,100,50,10/29/2020
D1173F,earnings,100,50,10/29/2020
D1173F,earnings,100,50,10/29/2020
D1173F,earnings,100,50,10/29/2020
D1344A,earnings,100,50,10/29/2020
D139BC,earnings,100,50,10/29/2020
D17C1B,partnership,100,61,10/29/2020
D17C1B,partnership,100,61,10/29/2020
D17F7E,partnership,100,61,10/29/2020
D17F7E,earnings,100,50,10/29/2020
D1C0B9,revenue-up,100,69,10/29/2020
D1C0B9,revenue-up,100,69,10/29/2020
D1C0B9,revenue-up,100,69,10/29/2020
D1C0B9,revenue-up,100,69,10/29/2020
D1C26F,partnership,100,61,10/29/2020
D3F64D,earnings,100,50,10/29/2020
D3F64D,earnings,100,50,10/29/2020
D3F64D,earnings,100,50,10/29/2020
D3F64D,earnings,100,50,10/29/2020
D3F64D,earnings,100,50,10/29/2020
D3F64D,earnings,100,50,10/29/2020
D3FD6D,conference-participant,100,50,10/29/2020
D4070C,earnings,100,50,10/29/2020
D45285,earnings,100,50,10/29/2020
D45285,earnings,100,50,10/29/2020
D57D99,earnings,100,50,10/29/2020
D57D99,dividend,100,50,10/29/2020
D6489C,product-release,100,64,10/29/2020
D6489C,facility-upgrade,100,65,10/29/2020
D6534D,earnings,100,50,10/29/2020
D6534D,earnings,100,50,10/29/2020
D65A13,revenue-up,100,72,10/29/2020
D65A13,revenues,100,50,10/29/2020
D69D42,earnings,100,50,10/29/2020
D8442A,earnings,100,50,10/29/2020
D8442A,earnings,100,50,10/29/2020
D8442A,earnings,100,50,10/29/2020
D8760C,dividend,100,50,10/29/2020
D8DBA3,earnings,100,50,10/29/2020
D8ECA1,earnings,100,50,10/29/2020
D8ECA1,earnings,100,50,10/29/2020
D8ECA1,earnings,100,50,10/29/2020
D90441,dividend,100,50,10/29/2020
D90441,dividend,100,50,10/29/2020
DC0D18,earnings,100,50,10/29/2020
DC0D18,earnings,100,50,10/29/2020
DC0D18,earnings,100,50,10/29/2020
DC0D18,earnings,100,50,10/29/2020
DC2F77,earnings,100,50,10/29/2020
DC5299,operating-earnings,100,50,10/29/2020
DC6AA0,legal-issues-defendant,100,22,10/29/2020
DD0F15,earnings,100,50,10/29/2020
DD1BA1,earnings,100,50,10/29/2020
DD1BA1,earnings,100,50,10/29/2020
DD1BA1,earnings,100,50,10/29/2020
DD1BA1,earnings,100,50,10/29/2020
DD1BA1,business-contract,100,69,10/29/2020
DDC415,partnership,100,61,10/29/2020
DDCB34,dividend-up,100,63,10/29/2020
DDCB34,earnings,100,50,10/29/2020
DEF058,earnings,100,50,10/29/2020
DFADDB,earnings,100,50,10/29/2020
E0339F,earnings,100,50,10/29/2020
E0339F,earnings,100,50,10/29/2020
E0339F,earnings,100,50,10/29/2020
E0339F,earnings,100,50,10/29/2020
E0E4B7,earnings,100,50,10/29/2020
E1C16B,executive-appointment,100,54,10/29/2020
E1F30A,earnings,100,50,10/29/2020
E20BFE,partnership,100,61,10/29/2020
E259C7,legal-issues-defendant,100,22,10/29/2020
E2F66E,earnings,100,50,10/29/2020
E49AA3,earnings,100,50,10/29/2020
E67C2C,earnings,100,50,10/29/2020
E68C3D,earnings,100,50,10/29/2020
E6D89E,earnings,100,50,10/29/2020
E6D89E,earnings,100,50,10/29/2020
E6D89E,earnings,100,50,10/29/2020
E6D89E,earnings,100,50,10/29/2020
E74FED,earnings,100,50,10/29/2020
E8C557,earnings,100,50,10/29/2020
E93A40,earnings,100,50,10/29/2020
EAA0A7,product-release,100,64,10/29/2020
EBC84C,earnings,100,50,10/29/2020
EBC84C,earnings,100,50,10/29/2020
EBC84C,earnings,100,50,10/29/2020
EBC84C,earnings,100,50,10/29/2020
EBC84C,earnings,100,50,10/29/2020
EBC84C,earnings,100,50,10/29/2020
EBC84C,earnings,100,50,10/29/2020
EBD89A,earnings,100,50,10/29/2020
EC70EC,earnings,100,50,10/29/2020
ECDEB2,buybacks,100,74,10/29/2020
ECE19E,conference-participant,100,50,10/29/2020
EE74E1,award,100,58,10/29/2020
EEB5F9,earnings,100,50,10/29/2020
EF1AD9,dividend,100,50,10/29/2020
EF1AD9,acquisition-acquirer,100,49,10/29/2020
EF1AD9,earnings,100,50,10/29/2020
EF1AD9,earnings,100,50,10/29/2020
EF1AD9,earnings,100,50,10/29/2020
EF1AD9,earnings,100,50,10/29/2020
EFD406,earnings,100,50,10/29/2020
EFD406,earnings,100,50,10/29/2020
EFD406,earnings,100,50,10/29/2020
EFD406,earnings,100,50,10/29/2020
EFD406,earnings,100,50,10/29/2020
EFD406,earnings,100,50,10/29/2020
EFD406,earnings,100,50,10/29/2020
F0027C,earnings,100,50,10/29/2020
F11638,earnings,100,50,10/29/2020
F18844,legal-issues-defendant,100,22,10/29/2020
F1C04C,operating-earnings,100,50,10/29/2020
F3816D,conference-call,100,50,10/29/2020
F46EC9,earnings,100,50,10/29/2020
F46EC9,earnings,100,50,10/29/2020
F46EC9,earnings,100,50,10/29/2020
F46EC9,earnings,100,50,10/29/2020
F46EC9,earnings,100,50,10/29/2020
F46EC9,earnings,100,50,10/29/2020
F4F46F,earnings,100,50,10/29/2020
F51DB0,earnings,100,50,10/29/2020
F51DB0,executive-appointment,100,54,10/29/2020
F6A945,earnings,100,50,10/29/2020
F6DE54,earnings,100,50,10/29/2020
F72E4B,earnings,100,50,10/29/2020
F793FA,earnings,100,50,10/29/2020
F7ADEB,business-contract,100,69,10/29/2020
F80389,earnings,100,50,10/29/2020
F80FF9,conference-call,100,50,10/29/2020
F88147,earnings,100,50,10/29/2020
F8DE55,acquisition-acquiree,100,76,10/29/2020
F9CAF8,earnings-up,100,68,10/29/2020
F9CAF8,earnings,100,50,10/29/2020
F9CAF8,earnings,100,50,10/29/2020
FA044A,acquisition-acquirer,100,49,10/29/2020
FA918D,earnings,100,50,10/29/2020
FA918D,earnings,100,50,10/29/2020
FA918D,earnings,100,50,10/29/2020
FACF19,dividend,100,50,10/29/2020
FBDA0F,earnings,100,50,10/29/2020
FC1A6E,earnings,100,50,10/29/2020
FD4588,earnings,100,50,10/29/2020
FD4588,earnings,100,50,10/29/2020
FD4588,earnings,100,50,10/29/2020
FD4588,earnings,100,50,10/29/2020
FD6926,earnings,100,50,10/29/2020
FD6926,earnings,100,50,10/29/2020
FD6926,earnings,100,50,10/29/2020
FD6926,earnings,100,50,10/29/2020
FD6926,earnings,100,50,10/29/2020
FD6926,dividend,100,50,10/29/2020
FD9526,earnings,100,50,10/29/2020
FD9526,earnings,100,50,10/29/2020
FDF799,earnings,100,50,10/29/2020
FDF799,earnings,100,50,10/29/2020
FDF799,executive-appointment,100,54,10/29/2020
FE89E0,earnings,100,50,10/29/2020
FE89E0,earnings,100,50,10/29/2020
FE89E0,earnings,100,50,10/29/2020
FE89E0,earnings,100,50,10/29/2020
FF5413,earnings-positive,100,69,10/29/2020
FF5413,earnings-positive,100,69,10/29/2020
FF6644,product-release,100,64,10/29/2020
FFE543,earnings,100,50,10/29/2020
0157B1,facility-open,100,65,10/30/2020
02ACBD,conference-call,100,50,10/30/2020
03542C,conference-call,100,50,10/30/2020
040DBB,debt-increase,100,26,10/30/2020
0490C6,earnings,100,50,10/30/2020
0624BE,earnings,100,50,10/30/2020
0DBB81,clinical-trials,100,56,10/30/2020
0FDE97,earnings,100,50,10/30/2020
0FDE97,earnings,100,50,10/30/2020
0FDE97,earnings,100,50,10/30/2020
0FDE97,earnings,100,50,10/30/2020
0FDE97,earnings,100,50,10/30/2020
0FDE97,earnings,100,50,10/30/2020
0FDE97,earnings,100,50,10/30/2020
12DE76,partnership,100,61,10/30/2020
139303,earnings,100,50,10/30/2020
159739,acquisition-completed-acquirer,100,49,10/30/2020
159739,acquisition-completed-acquirer,100,49,10/30/2020
168A5D,partnership,100,61,10/30/2020
1A1CB0,ipo-completed,100,76,10/30/2020
1A6A94,earnings,100,50,10/30/2020
1AB023,conference-call,100,50,10/30/2020
1AB023,conference-call,100,50,10/30/2020
1AB023,conference-call,100,50,10/30/2020
1BC12C,executive-appointment,100,54,10/30/2020
1E1125,conference-organizer,100,57,10/30/2020
1F43A1,earnings,100,50,10/30/2020
1FE7F0,earnings,100,50,10/30/2020
1FE7F0,earnings,100,50,10/30/2020
1FE7F0,earnings,100,50,10/30/2020
1FE7F0,earnings,100,50,10/30/2020
1FE7F0,earnings,100,50,10/30/2020
1FE7F0,earnings,100,50,10/30/2020
21153F,executive-appointment,100,54,10/30/2020
21153F,executive-appointment,100,54,10/30/2020
241252,ipo-pricing,100,50,10/30/2020
24C48B,earnings,100,50,10/30/2020
25102A,product-release,100,64,10/30/2020
2667B6,legal-issues-defendant,100,22,10/30/2020
2667B6,legal-issues-defendant,100,22,10/30/2020
2667B6,legal-issues-defendant,100,22,10/30/2020
2667B6,legal-issues-defendant,100,22,10/30/2020
26D8ED,earnings,100,50,10/30/2020
297DA8,earnings,100,50,10/30/2020
2AE625,earnings,100,50,10/30/2020
2BA977,earnings,100,50,10/30/2020
2BA977,executive-appointment,100,54,10/30/2020
2C7505,award,100,58,10/30/2020
332F87,earnings-up,100,68,10/30/2020
332F87,earnings-positive,100,69,10/30/2020
332F87,earnings-positive,100,69,10/30/2020
332F87,earnings-positive,100,69,10/30/2020
332F87,earnings-positive,100,69,10/30/2020
332F87,earnings-positive,100,69,10/30/2020
332F87,earnings-positive,100,69,10/30/2020
338544,earnings,100,50,10/30/2020
342218,earnings,100,50,10/30/2020
342218,earnings,100,50,10/30/2020
353DBB,dividend,100,50,10/30/2020
366A08,note-sale,100,52,10/30/2020
383ADA,earnings,100,50,10/30/2020
3C7F5F,unit-acquisition-completed-acquiree,100,67,10/30/2020
3FACA7,earnings,100,50,10/30/2020
41785E,legal-issues-defendant,100,22,10/30/2020
41EC04,earnings,100,50,10/30/2020
41EC04,earnings,100,50,10/30/2020
41EC04,earnings,100,50,10/30/2020
41EC04,earnings,100,50,10/30/2020
423279,dividend,100,50,10/30/2020
460C93,earnings,100,50,10/30/2020
499C75,conference-call,100,50,10/30/2020
4A6F00,earnings-above-expectations,100,88,10/30/2020
4B5054,executive-appointment,100,54,10/30/2020
4B5054,earnings,100,50,10/30/2020
4B5054,legal-issues-defendant,100,22,10/30/2020
4C350A,executive-resignation,100,44,10/30/2020
4C6C63,business-contract,100,69,10/30/2020
504FE2,dividend,100,50,10/30/2020
520632,award,100,58,10/30/2020
520632,award,100,58,10/30/2020
5675EB,note-sale,100,52,10/30/2020
5A53BF,earnings,100,50,10/30/2020
5D0337,legal-issues-defendant,100,22,10/30/2020
5DE5A5,dividend,100,50,10/30/2020
616E3B,acquisition-completed-acquirer,100,49,10/30/2020
62F41C,business-contract,100,69,10/30/2020
665D7D,earnings,100,50,10/30/2020
694749,note-sale,100,52,10/30/2020
6BD606,executive-appointment,100,54,10/30/2020
6BD606,earnings,100,50,10/30/2020
6D9B53,product-release,100,64,10/30/2020
6-Dec-05,earnings,100,50,10/30/2020
6E7060,dividend-up,100,81,10/30/2020
6F0A63,public-offering,100,43,10/30/2020
713810,partnership,100,61,10/30/2020
713810,facility-sale,100,52,10/30/2020
713810,partnership,100,61,10/30/2020
726EEA,earnings,100,50,10/30/2020
726EEA,earnings,100,50,10/30/2020
726EEA,earnings,100,50,10/30/2020
726EEA,earnings,100,50,10/30/2020
726EEA,earnings,100,50,10/30/2020
72EF75,dividend,100,50,10/30/2020
76BD96,dividend-up,100,81,10/30/2020
76E80F,executive-appointment,100,54,10/30/2020
7ACBA4,earnings,100,50,10/30/2020
7B4B91,earnings,100,50,10/30/2020
7F2922,earnings,100,50,10/30/2020
82C202,earnings,100,50,10/30/2020
82FD6D,earnings,100,50,10/30/2020
8377DB,earnings,100,50,10/30/2020
8377DB,conference-participant,100,50,10/30/2020
83E0AC,conference-call,100,50,10/30/2020
84AB66,earnings-positive,100,69,10/30/2020
86BAC7,earnings,100,50,10/30/2020
877734,conference-participant,100,50,10/30/2020
8D4486,award,100,58,10/30/2020
8E8E6E,partnership,100,61,10/30/2020
913437,earnings,100,50,10/30/2020
925759,award,100,58,10/30/2020
9546A5,conference-call,100,50,10/30/2020
95C575,earnings,100,50,10/30/2020
967D92,earnings,100,50,10/30/2020
968966,earnings,100,50,10/30/2020
971334,conference-call,100,50,10/30/2020
9978F1,public-offering,100,43,10/30/2020
99B61C,product-release,100,64,10/30/2020
9D6A24,dividend,100,50,10/30/2020
9E298A,conference-call,100,50,10/30/2020
A23747,earnings,100,50,10/30/2020
A4BCDE,earnings,100,50,10/30/2020
A5E715,acquisition-completed-acquirer,100,49,10/30/2020
A666C8,earnings,100,50,10/30/2020
A666C8,earnings,100,50,10/30/2020
A666C8,earnings,100,50,10/30/2020
A666C8,earnings,100,50,10/30/2020
A7A0BD,conference-call,100,50,10/30/2020
ABAA03,ipo-pricing,100,50,10/30/2020
AE79CD,earnings,100,50,10/30/2020
AE7D16,earnings,100,50,10/30/2020
B04426,conference-call,100,50,10/30/2020
B1DF3C,partnership,100,61,10/30/2020
B2D799,legal-issues-defendant,100,22,10/30/2020
B3A166,conference-call,100,50,10/30/2020
B560AF,earnings,100,50,10/30/2020
B560AF,earnings,100,50,10/30/2020
B560AF,earnings,100,50,10/30/2020
B560AF,earnings,100,50,10/30/2020
B560AF,earnings,100,50,10/30/2020
B73395,conference-call,100,50,10/30/2020
B7BBFF,earnings-up,100,68,10/30/2020
B9B6B8,partnership,100,61,10/30/2020
BAD655,legal-issues-defendant,100,22,10/30/2020
BDF2BD,earnings,100,50,10/30/2020
BDF2BD,earnings,100,50,10/30/2020
BDF2BD,earnings,100,50,10/30/2020
BDF2BD,earnings,100,50,10/30/2020
BDF2BD,earnings,100,50,10/30/2020
BDF2BD,earnings,100,50,10/30/2020
BE86A1,executive-appointment,100,54,10/30/2020
C01737,earnings,100,50,10/30/2020
C3BCD5,earnings,100,50,10/30/2020
C3BCD5,earnings,100,50,10/30/2020
C4C77F,legal-issues-defendant,100,22,10/30/2020
C951A2,government-contract,100,69,10/30/2020
CBBFBF,unit-acquisition-completed-acquirer,100,49,10/30/2020
CBBFBF,unit-acquisition-completed-acquirer,100,49,10/30/2020
CC35BE,award,100,58,10/30/2020
CDEDFE,legal-issues-defendant,100,22,10/30/2020
CEDFD5,regulatory-product-approval-granted,100,81,10/30/2020
CEDFD5,regulatory-product-approval-granted,100,81,10/30/2020
CF351E,earnings,100,50,10/30/2020
CF351E,earnings,100,50,10/30/2020
CF351E,earnings,100,50,10/30/2020
CF3FF9,earnings,100,50,10/30/2020
D09938,executive-appointment,100,54,10/30/2020
D13F1C,earnings-up,100,68,10/30/2020
D13F1C,earnings-up,100,68,10/30/2020
D13F1C,earnings-up,100,68,10/30/2020
D13F1C,earnings-up,100,68,10/30/2020
D13F1C,earnings-up,100,68,10/30/2020
D13F1C,earnings-up,100,68,10/30/2020
D15833,conference-call,100,50,10/30/2020
D15833,conference-call,100,50,10/30/2020
D17F7E,legal-issues-defendant,100,22,10/30/2020
D296C6,earnings,100,50,10/30/2020
D54E62,earnings,100,50,10/30/2020
D54E62,earnings,100,50,10/30/2020
D54E62,earnings,100,50,10/30/2020
D54E62,earnings,100,50,10/30/2020
D54E62,earnings,100,50,10/30/2020
D598E7,earnings,100,50,10/30/2020
D6144F,conference-call,100,50,10/30/2020
D88EF3,earnings,100,50,10/30/2020
D88EF3,earnings,100,50,10/30/2020
D88EF3,earnings,100,50,10/30/2020
D88EF3,earnings,100,50,10/30/2020
D88EF3,earnings,100,50,10/30/2020
D88EF3,earnings,100,50,10/30/2020
DAFED3,earnings,100,50,10/30/2020
DAFED3,earnings,100,50,10/30/2020
DAFED3,earnings,100,50,10/30/2020
DAFED3,earnings,100,50,10/30/2020
DB23C8,earnings,100,50,10/30/2020
DB23C8,earnings,100,50,10/30/2020
DB23C8,earnings,100,50,10/30/2020
DDC415,note-sale,100,52,10/30/2020
DF01B1,legal-issues-defendant,100,22,10/30/2020
E259C7,legal-issues-defendant,100,22,10/30/2020
E6A53A,earnings,100,50,10/30/2020
E6A53A,earnings,100,50,10/30/2020
E70531,earnings,100,50,10/30/2020
E70531,earnings,100,50,10/30/2020
E70531,earnings,100,50,10/30/2020
E70531,earnings,100,50,10/30/2020
E70531,earnings,100,50,10/30/2020
E70531,earnings,100,50,10/30/2020
EB6965,earnings,100,50,10/30/2020
EB6965,earnings,100,50,10/30/2020
EB6965,earnings,100,50,10/30/2020
EB6965,earnings,100,50,10/30/2020
EB6965,earnings,100,50,10/30/2020
EB6965,earnings,100,50,10/30/2020
EB6965,earnings,100,50,10/30/2020
EB6965,executive-appointment,100,54,10/30/2020
ED2EFD,earnings,100,50,10/30/2020
EE6F1C,earnings-up,100,68,10/30/2020
EEBCEF,dividend,100,50,10/30/2020
EF45B6,earnings,100,50,10/30/2020
F02D0A,dividend,100,50,10/30/2020
F1529C,earnings,100,50,10/30/2020
F1529C,earnings,100,50,10/30/2020
F18844,legal-issues-defendant,100,22,10/30/2020
F294DD,earnings,100,50,10/30/2020
F294DD,earnings,100,50,10/30/2020
F294DD,earnings,100,50,10/30/2020
F294DD,earnings,100,50,10/30/2020
F294DD,earnings,100,50,10/30/2020
F294DD,earnings,100,50,10/30/2020
F294DD,earnings,100,50,10/30/2020
F294DD,earnings,100,50,10/30/2020
F294DD,earnings,100,50,10/30/2020
F294DD,earnings,100,50,10/30/2020
F294DD,earnings,100,50,10/30/2020
F294DD,earnings,100,50,10/30/2020
F294DD,earnings,100,50,10/30/2020
F294DD,earnings,100,50,10/30/2020
F294DD,earnings,100,50,10/30/2020
F294DD,earnings,100,50,10/30/2020
F294DD,earnings,100,50,10/30/2020
F294DD,earnings,100,50,10/30/2020
F294DD,earnings,100,50,10/30/2020
F294DD,earnings,100,50,10/30/2020
F294DD,earnings,100,50,10/30/2020
F294DD,earnings,100,50,10/30/2020
F294DD,earnings,100,50,10/30/2020
F294DD,earnings,100,50,10/30/2020
F294DD,earnings,100,50,10/30/2020
F294DD,earnings,100,50,10/30/2020
F294DD,earnings,100,50,10/30/2020
F294DD,earnings,100,50,10/30/2020
F294DD,earnings,100,50,10/30/2020
F294DD,dividend,100,50,10/30/2020
F2E253,dividend,100,50,10/30/2020
F31B13,earnings-up,100,85,10/30/2020
F5C78B,dividend,100,50,10/30/2020
F5D499,public-offering,100,43,10/30/2020
F8C5D7,conference-call,100,50,10/30/2020
FACF19,executive-appointment,100,54,10/30/2020
FC1F9D,note-sale,100,52,10/30/2020
FCA54E,earnings,100,50,10/30/2020
FD0CA4,dividend,100,50,10/30/2020
FF4BA4,earnings,100,50,10/30/2020
FF4BA4,earnings,100,50,10/30/2020
FF4BA4,earnings,100,50,10/30/2020
FF4BA4,earnings,100,50,10/30/2020
FF4BA4,earnings,100,50,10/30/2020
FF4BA4,earnings,100,50,10/30/2020
FF4BA4,dividend,100,50,10/30/2020
FF6644,earnings-per-share-positive,100,69,10/30/2020
FF6644,earnings-per-share-positive,100,69,10/30/2020
FF6644,earnings-per-share-positive,100,69,10/30/2020
FF6644,earnings-per-share-positive,100,69,10/30/2020
FF6644,earnings-per-share-positive,100,69,10/30/2020
FF6644,earnings-per-share-positive,100,69,10/30/2020
FF6644,earnings-per-share-positive,100,69,10/30/2020
FF6644,earnings-per-share-positive,100,69,10/30/2020
FF6644,earnings-per-share-positive,100,69,10/30/2020
FF6644,earnings-per-share-positive,100,69,10/30/2020
FF6644,earnings-per-share-positive,100,69,10/30/2020
1A3E1B,earnings,100,50,10/31/2020
2667B6,legal-issues-defendant,100,22,10/31/2020
790C34,earnings,100,50,10/31/2020
AE79CD,earnings,100,50,10/31/2020
D11C1C,conference-call,100,50,10/31/2020
DF01B1,legal-issues-defendant,100,22,10/31/2020
E8846E,legal-issues-defendant,100,22,10/31/2020
F294DD,earnings,100,50,10/31/2020
